(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN intake)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (CC either) (NP (NN drug3)) (CC or) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (JJ Pharmacokinetic) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBD produced) (NP (NP (NP (DT a) (ADJP (CD 25) (NN %)) (NN increase)) (PP (IN in) (NP (NN AUC)))) (CC and) (NP (NP (DT a) (ADJP (CD 33) (NN %)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN Cmax)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN adjustment)) (PP (IN of) (NP (NN dosage)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN in) (NP (JJ such) (NNS patients)))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (PRP$ its) (JJ major) (NN metabolite) (CD drug2))) (VP (VBD were) (VP (VBN unaffected) (PP (VBG following) (NP (NP (NN co-administration)) (PP (IN with) (NP (NN drug3)))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (JJ concomitant) (NNS therapies)) (: :) (S (PP (IN In) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NP (DT the) (NN safety) (NN profile)) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NN drug1))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (NN drug5))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NN drug6)))))))) (VP (VBD was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NP (NNS subjects)) (VP (VBG taking) (NP (NN placebo)) (PP (IN with) (NP (DT these) (JJ concomitant) (NNS medications))))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NP (NN drug1)) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN drug2)))))) (ADVP (RBR more) (RB commonly)) (VP (VBD reported) (NP (CC both) (NP (NN weight) (NN gain)) (CC and) (NP (NN weight) (NN loss))) (, ,) (S (VP (VBN compared) (PP (IN with) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (DT either) (NN medication)) (ADVP (RB alone)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drugs))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB fully)) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NNS neutrophils)))))))) (, ,) (PP (JJ such) (IN as) (NP (NN drug1))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB augment) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ other) (NNS drug2))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN with) (NP (JJ other) (NN drug1)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NP (JJ human) (NN plasma) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN mean) (CD 99.2) (NN %)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)) (NP (DT The) (ADJP (FW in) (FW vitro)) (NN binding))) (PP (IN of) (NP (NN drug5))) (PP (TO to) (NP (NN plasma) (NNS proteins)))) (VP (VBZ is) (ADVP (RB only) (RB slightly)) (VP (VBN reduced) (PP (IN by) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (CD 99.5) (NN %) (NN control) (CC vs) (CD 99.3) (NN %)) (-RRB- -RRB-)))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug7) (NN plasma) (NNS concentrations)) (VP (VBP reach) (NP (CD 5) (ADJP (CD to10) (NN m)) (NN g/mL)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB alter) (NP (NN drug2) (NN protein) (NN binding))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (, ,) (PP (IN at) (NP (NP (JJ therapeutic) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 300) (NN m) (NN g/mL)) (-RRB- -RRB-)))))) (, ,) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN drug2)))) (VP (VBD was) (VP (VBN reduced) (PP (IN from) (NP (QP (RB approximately) (CD 99.2) (NN %) (TO to) (CD 97.5)) (NN %))) (, ,) (S (VP (VBG representing) (NP (NP (DT a) (JJ potential) (JJ twofold) (NN increase)) (PP (IN in) (NP (JJ unbound) (NN drug3) (NN plasma) (NNS levels)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Therapeutic) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7) (NN andtolbutamide))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NN drug8) (NN protein) (NN binding))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (NN study)) (VP (VBG involving) (NP (CD 12) (JJ adult) (NNS volunteers))))) (, ,) (NP (NN TORADOLORAL)) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (ADJP (CD 25) (NN mg)) (NN drug1))))) (, ,) (S (VP (VBG causing) (NP (NP (DT no) (JJ significant) (NNS changes)) (PP (IN in) (NP (NP (NP (NNS pharmacokinetics)) (CC or) (NP (NNS pharmacodynamics))) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT another) (NN study))) (, ,) (NP (NN TORADOLIV/IM)) (VP (VBD was) (VP (VBN given) (PP (IN with) (NP (NP (CD two) (NNS doses)) (PP (IN of) (NP (NP (CD 5000) (NN U)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (CD 11) (JJ healthy) (NNS volunteers))))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (NN mean) (NN template) (JJ bleeding) (NN time)) (PP (IN of) (NP (NP (CD 6.4) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.2) (TO to) (CD 11.4)) (NN min)) (-RRB- -RRB-)))))) (S (VP (VBN compared) (PP (TO to) (NP (DT a) (NN mean))) (PP (IN of) (NP (NP (NP (NP (NP (CD 6.0) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.4) (TO to) (CD 7.5)) (NN min)) (-RRB- -RRB-))) (PP (IN for) (NP (NN drug2)))) (ADVP (RB alone))) (CC and) (NP (NP (CD 5.1) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.5) (TO to) (CD 8.5)) (NN min)) (-RRB- -RRB-))))) (PP (IN for) (NP (NN placebo))))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (DT these) (NNS results)) (VP (VBP do) (RB not) (VP (VB indicate) (NP (NP (DT a) (JJ significant) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (CC or) (NP (NN drug3))))))))) (, ,) (S (S (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug4))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug5)))))) (VP (MD should) (VP (VB be) (VP (VBN done) (ADVP (RB extremely) (RB cautiously)))))) (, ,) (CC and) (S (NP (NNS patients)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2) (NN IV/IM)) (VP (VBD reduced) (NP (NP (DT the) (NN drug3) (NN response)) (PP (TO to) (NP (NN drug4))) (PP (IN in) (NP (JJ normovolemic) (JJ healthy) (NNS subjects)))) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %))) (PRN (-LRB- -LRB-) (S (NP (NP (JJ mean) (NN sodium)) (CC and) (NP (JJ urinary) (NN output))) (VP (VBD decreased) (NP (CD 17) (NN %)))) (-RRB- -RRB-)))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2) (JJ ORAL)) (CC and) (NP (NN drug3))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (VBN decreased) (NN clearance)) (PP (IN of) (NP (NN drug4)))) (CC and) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (NP (NN drug5) (NN plasma) (NNS levels)) (PRN (-LRB- -LRB-) (NP (NP (JJ total) (NN AUC)) (VP (VBD increased) (ADVP (RB approximately) (RB threefold)) (PP (IN from) (NP (ADJP (QP (CD 5.4) (TO to) (CD 17.8)) (NN m)) (NN g/h/mL))))) (-RRB- -RRB-))))))))) (CC and) (S (NP (JJ terminal) (NN half-life)) (VP (VBD increased) (ADVP (RB approximately) (RB twofold)) (PP (IN from) (NP (QP (CD 6.6) (TO to) (CD 15.1)) (NNS hours)))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (JJ renal) (NN drug2) (NN clearance)) (, ,) (VP (VBG leading) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN plasma) (NN drug3) (NN concentration)))))) (, ,)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (DT some) (NN prostaglandin) (JJ synthesis-inhibiting) (NNS drugs))))))) (. .))))
(S1 (S (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN plasma) (NNS drug2)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (, ,) (CC but) (S (NP (NP (NNS cases)) (PP (IN of) (NP (NP (VBN increased) (NN drug3) (NN plasma) (NNS levels)) (PP (IN during) (NP (NN drug4) (NN therapy)))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (DT some) (NN drug3))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NNS drug4))))))))) (, ,) (S (VP (VBG enhancing) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN drug5)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN drug2) (NN clearance)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NN postmarketing))) (VP (VBP experience) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (DT a) (JJ possible) (NN interaction)) (PP (IN between) (NP (NP (NN TORADOLIV/IM)) (CC and) (NP (NN drug2)))))) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (NN apnea)))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB formally)) (VP (VBN studied))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ renal) (NN impairment)))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (JJ volume-depleted) (NNS patients)))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Sporadic) (NNS cases)) (PP (IN of) (NP (NNS seizures)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (PRN (-LRB- -LRB-) (NP (NP (NN drug4)) (, ,) (NP (NN drug5))) (-RRB- -RRB-)))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NNS Hallucinations)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-)))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN TORADOLIV/IM)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2))) (PP (IN in) (NP (NP (JJ several) (JJ clinical) (NNS trials)) (PP (IN of) (NP (JJ postoperative) (NN pain))) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ adverse) (NNS interactions))))))))))) (. .))))
(S1 (S (S (VP (VBP Do) (RB not) (NP (NN mix) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (DT the) (JJ same) (NN syringe))))) (. .)))
(S1 (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (NN evidence)) (PP (IN in) (NP (ADJP (ADJP (JJ animal)) (CC or) (ADJP (JJ human))) (NNS studies))) (SBAR (IN that) (S (NP (NN drug1)) (VP (VP (VBZ induces)) (CC or) (VP (VBZ inhibits) (NP (NP (JJ hepatic) (NNS enzymes)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG metabolizing) (NP (NP (PRP itself)) (CC or) (NP (JJ other) (NNS drugs))))))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (NN Synergism)) (PP (IN between) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (JJ other) (NNS drug4))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (S (NP (DT This)) (VP (MD should) (VP (VB be) (VP (VBN considered) (ADVP (RB whenever)))))) (NP (DT these) (NNS agents)) (VP (VBP are) (VP (VBN prescribed) (ADVP (RB concomitantly))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ competes) (PP (IN for) (NP (JJ tubular) (NN secretion)))))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN plasma) (NN half-life)) (PP (IN of) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (JJ Few) (JJ systemic) (NNS data)) (VP (VBP have) (VP (VBN been) (VP (VBN collected) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug1))))) (PP (VBG following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (CC or) (, ,) (ADVP (RB alternatively)) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))))) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (JJ other) (NNS drugs)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB extensively)) (VP (VBN metabolized))))) (, ,) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (JJ other) (NNS drugs)))) (VP (MD may) (VP (VB affect) (NP (PRP$ its) (JJ clinical) (NN activity))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB primarily)) (VP (VBN metabolized) (PP (TO to) (NP (NN drug2))) (PP (IN by) (NP (DT the) (NN CYP2B6) (NN isoenzyme))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (DT the) (NN potential)) (VP (VBZ exists) (PP (IN for) (NP (NP (DT a) (NN drug) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP affect) (NP (NP (DT the) (NN CYP2B6) (NN isoenzyme)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ drug1) (NN metabolite)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB be) (VP (VBN produced) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NNS isoenzymes)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (PRP$ its) (JJ active) (NNS metabolites))))))) (VP (VBD were) (VP (VBN studied) (PP (IN in) (NP (CD 24) (JJ healthy) (JJ young) (JJ male) (NNS volunteers)))))) (. .)))
(S1 (S (S (PP (VBG Following) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (CD two) (NN 150-mg) (NN sustained-release) (NNS tablets)) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NP (CD 800) (NN mg)) (PP (IN of) (NP (NN drug1)))))))))) (, ,) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD were) (VP (VBN unaffected)))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (VBD were) (NP (NP (CD 16) (NN %)) (CC and) (NP (NP (ADJP (CD 32) (NN %)) (NNS increases)) (PP (IN in) (NP (DT the) (NP (NN AUC)) (CC and) (NP (NN Cmax))))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN of) (NP (NP (DT the) (JJ combined) (NNS moieties)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (SBAR (IN While) (VP (RB not) (ADVP (RB systematically)) (VBN studied))) (, ,) (NP (JJ certain) (NNS drugs)) (VP (MD may) (VP (VB induce) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NN Animal) (NNS data)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB be) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (NP (JJ drug-metabolizing) (NNS enzymes)) (PP (IN in) (NP (NNS humans)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (CD one) (NN study))) (, ,) (PP (VBG following) (NP (NP (JJ chronic) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (CD 100) (NN mg)) (ADJP (CD 3) (NNS times) (JJ daily) (PP (TO to) (NP (CD 8) (JJ healthy) (JJ male) (NNS volunteers))) (PP (IN for) (NP (CD 14) (NNS days))))))))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN induction)) (PP (IN of) (NP (PRP$ its) (JJ own) (NN metabolism)))))))) (. .)))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (NP (EX there)) (VP (MD may) (VP (VB be) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (ADJP (RB clinically) (JJ important)) (NNS alterations)) (PP (IN of) (NP (NP (NN blood) (NNS levels)) (PP (IN of) (NP (JJ coadministered) (NNS drugs))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NP (NP (NP (NN Cytochrome) (NN P450IID6)) (PRN (-LRB- -LRB-) (NP (NN CYP2D6)) (-RRB- -RRB-))) (: :) (JJ Many) (NNS drugs)) (, ,) (PP (VBG including) (NP (NP (NP (JJ most) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN SSRIs)) (, ,) (NP (JJ many) (NNS drug2))) (-RRB- -RRB-))) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))))))) (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN CYP2D6) (NN isoenzyme)))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN metabolized) (PP (IN by) (NP (DT this) (NN isoenzyme))))))) (, ,) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBP are) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (DT the) (NN CYP2D6) (NN isoenzyme)))) (ADVP (FW in) (FW vitro)))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (NP (NP (CD 15) (JJ male) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NNS ages) (NP (CD 19) (TO to) (CD 35) (NNS years))) (-RRB- -RRB-))) (SBAR (WHNP (WP who)) (S (VP (VBD were) (NP (NP (JJ extensive) (NNS metabolizers)) (PP (IN of) (NP (DT the) (NN CYP2D6) (NN isoenzyme))))))))))) (, ,) (NP (NP (JJ daily) (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN given) (PP (IN as) (NP (NP (CD 150) (NN mg)) (VP (ADVP (RB twice) (RB daily)) (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (ADJP (CD 50) (NN mg)) (NN drug2)))))))))))) (VP (VP (VBD increased) (NP (NP (DT the) (NP (NN Cmax)) (, ,) (NP (NN AUC)) (, ,) (CC and) (NP (NN t1/2))) (PP (IN of) (NP (NN drug3)))) (PP (IN by) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (RB approximately) (CD 2-)) (, ,) (NP (CD 5-))))))) (CC and) (ADVP (RB 2-fold)) (, ,) (ADVP (RB respectively))) (. .)))
(S1 (S (S (NP (DT The) (NN effect)) (VP (VBD was) (ADJP (JJ present)) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 7)) (NNS days))) (PP (IN after) (NP (NP (DT the) (JJ last) (NN dose)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP2D6))))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB formally)) (VP (VBN studied))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN CYP2D6) (NN isoenzyme)) (PP (VBG including) (NP (NP (NP (JJ certain) (NNS drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (CD drug9)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (QP (CD drug10) (, ,) (CD drug11) (, ,) (CD drug12)) (-RRB- -RRB-))) (, ,) (NP (NP (CD drug13)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (CD drug14)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (CD drug15)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug16))) (, ,) (NP (CD drug17)) (-RRB- -RRB-)))) (, ,)))))))))))) (VP (VP (MD should) (VP (VB be) (VP (VBN approached) (PP (IN with) (NP (NN caution)))))) (CC and) (VP (MD should) (VP (VB be) (VP (VBN initiated) (PP (IN at) (NP (NP (DT the) (JJR lower) (NN end)) (PP (IN of) (NP (NP (DT the) (NN dose) (NN range)) (PP (IN of) (NP (DT the) (JJ concomitant) (NN medication))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN treatment) (NN regimen)) (PP (IN of) (NP (NP (DT a) (NN patient)) (VP (ADVP (RB already)) (VBG receiving) (NP (NP (DT a) (NN drug)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP2D6)))))))))))))) (, ,) (NP (DT the) (NN need) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT the) (JJ original) (NN medication)))))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (, ,) (ADVP (RB particularly)) (PP (IN for) (NP (NP (DT those) (JJ concomitant) (NNS medications)) (PP (IN with) (NP (DT a) (JJ narrow) (JJ therapeutic) (NN index))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NNS Studies)) (PP (IN in) (NP (NNS animals)))) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (DT the) (JJ acute) (NN toxicity)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN enhanced) (PP (IN by) (NP (DT the) (NN drug3) (NN drug4))))))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (: :) (S (NP (JJ Limited) (JJ clinical) (NNS data)) (VP (VBP suggest) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (NP (JJ adverse) (NNS experiences)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug3))))) (PP (ADVP (RB concurrently)) (IN with) (NP (CC either) (NP (NN drug4)) (CC or) (NP (NN drug5))))))))) (. .))))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (JJ drug1) (NNS Tablets))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (CC either) (NP (NN drug2)) (CC or) (NP (NN drug3))))))) (ADVP (RB concurrently)) (VP (MD should) (VP (VB be) (VP (VBN undertaken) (PP (IN with) (NP (NN caution))) (, ,) (S (VP (VBG using) (NP (NP (JJ small) (JJ initial) (NNS doses)) (CC and) (NP (JJ small) (JJ gradual) (NN dose) (NNS increases))))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Drugs)) (PP (IN that) (NP (JJR Lower) (NN Seizure) (NN Threshold)))) (: :) (NP (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (NP (NNS agents)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (JJ other) (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (JJ systemic) (NN drug5)) (, ,) (NP (NN etc.))) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (NP (JJR lower) (NN seizure) (NN threshold)) (VP (MD should) (VP (VB be) (VP (VBN undertaken) (ADVP (RB only)) (PP (IN with) (NP (JJ extreme) (NN caution)))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Low) (JJ initial) (NN dosing)) (CC and) (NP (JJ small) (JJ gradual) (NN dose) (NNS increases))) (VP (MD should) (VP (VB be) (VP (VBN employed))))) (. .)))
(S1 (S (S (ADJP (NN drug1) (JJ Transdermal) (NN System) (: :))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (JJ post-marketing) (VBP experience))) (, ,) (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ rare) (NNS reports)) (PP (IN of) (NP (NP (JJ adverse) (JJ neuropsychiatric) (NNS events)) (CC or) (NP (VBN reduced) (NN drug2) (NN tolerance)))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBG drinking) (NP (NN drug3)) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug4))))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN consumption)) (PP (IN of) (NP (NN drug1))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug2)))))) (VP (MD should) (VP (VB be) (VP (VP (VBN minimized)) (CC or) (VP (VBN avoided)))))) (PRN (-LRB- -LRB-) (ADVP (RB also)) (VP (VB see) (NP (DT a) (CD href=) (NP (NN bupropz_od.htm) (NN #) (CD CI)) (NNS CONTRAINDICATIONS))) (-RRB- -RRB-))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (DT The) (NN action)) (PP (IN of) (NP (JJ nondepolarizing) (NNS relaxants)))) (VP (VBZ is) (VP (VBN augmented) (PP (IN by) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (ADJP (JJR Less) (PP (IN than) (NP (NP (DT the) (JJ usual) (NNS amounts)) (PP (IN of) (NP (DT these) (NNS medicines))))))) (VP (MD should) (VP (VB be) (VP (VBN used))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (DT the) (JJ usual) (NNS amounts)) (PP (IN of) (NP (JJ nondepolarizing) (NNS relaxants)))) (VP (VBP are) (VP (VBN given))))) (, ,) (NP (NP (DT the) (NN time)) (PP (IN for) (NP (NP (NN recovery)) (PP (IN from) (NP (JJ neuromuscular) (NN blockade)))))) (VP (MD will) (VP (VB be) (ADJP (ADJP (JJR longer)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug1))))) (PP (IN than) (SBAR (WHADVP (WRB when)) (S (NP (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (PP (IN with) (NP (DT a) (JJ balanced) (NN technique)))) (VP (VBP are) (VP (VBN used)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (NN rate)) (PP (IN of) (NP (NN metabolism)))) (CC and) (NP (NP (DT the) (JJ leukopenic) (NN activity)) (PP (IN of) (NP (NN drug1))))) (ADVP (RB reportedly)) (VP (VBP are) (VP (VBN increased) (PP (IN by) (NP (NP (JJ chronic) (NN administration)) (PP (IN of) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN physician)) (VP (MD should) (VP (VB be) (ADJP (JJ alert) (PP (IN for) (NP (NP (JJ possible) (JJ combined) (NN drug) (NNS actions)) (, ,) (ADJP (ADJP (JJ desirable)) (CC or) (ADJP (JJ undesirable))) (, ,) (VP (VBG involving) (NP (NN drug1)))))) (SBAR (RB even) (IN though) (S (NP (NN drug2)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB successfully)) (PP (ADVP (RB concurrently)) (IN with) (NP (NP (JJ other) (NNS drugs)) (, ,) (PP (VBG including) (NP (JJ other) (JJ cytotoxic) (NNS drugs))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN treatment)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ causes) (NP (NP (DT a) (ADJP (ADJP (JJ marked)) (CC and) (ADJP (JJ persistent))) (NN inhibition)) (PP (IN of) (NP (NN cholinesterase) (NN activity))))))) (, ,)) (VP (VBZ potentiates) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug2)))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT a) (NN patient)) (VP (VBZ has) (VP (VBN been) (VP (VBN treated) (PP (IN with) (NP (NN drug1))) (PP (IN within) (NP (NP (CD 10) (NNS days)) (PP (IN of) (NP (JJ general) (NN anesthesia)))))))))) (, ,) (NP (DT the) (NN anesthesiologist)) (VP (MD should) (VP (VB be) (VP (VBN alerted))))) (. .)))
(S1 (S (S (NP (NP (CC Both) (DT the) (NP (NN magnitude)) (CC and) (NP (NN duration))) (PP (IN of) (NP (NP (JJ central) (JJ nervous) (NN system)) (CC and) (NP (JJ cardiovascular) (NNS effects))))) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (NNS drug2)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (NN inhalation) (JJ general) (NN drug6)))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Postoperative) (JJ respiratory) (NN depression)) (VP (VP (MD may) (VP (VB be) (VP (VBN enhanced)))) (CC or) (VP (VBD prolonged) (PP (IN by) (NP (DT these) (NNS agents)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ such) (NNS cases)) (PP (IN of) (NP (JJ combined) (NN treatment))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (CD one)) (CC or) (NP (DT both)) (NP (NNS agents))))) (VP (MD should) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (S (NP (JJ Limited) (JJ clinical) (VBP experience)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (NNS requirements)) (PP (IN for) (NP (NN drug1)))) (VP (VBP are) (VP (VBN reduced) (PP (IN by) (NP (NP (QP (CD 30) (TO to) (CD 50)) (NN %)) (PP (IN for) (NP (NP (DT the) (JJ first) (NN sixty) (-LRB- -LRB-) (CD 60) (-RRB- -RRB-) (NNS minutes)) (PP (VBG following) (NP (NP (NN drug2) (NN induction)) (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NN drug4)))) (VP (VP (MD can) (ADVP (RB significantly)) (VP (VB inhibit) (NP (NN drug5) (NN clearance)))) (CC and) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (ADJP (ADJP (JJ prolonged)) (CC or) (ADJP (VBN delayed))) (JJ respiratory) (NN depression)))))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ reduces) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (ADJP (RB Therefore) (JJR smaller)) (NN drug1) (NNS doses)) (VP (MD will) (VP (VB be) (VP (VBN required) (PP (IN with) (NP (JJ prolonged) (NN administration))))))) (CC and) (S (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NN drug2) (NNS my)))))) (VP (VB be) (VP (VBN extended)))) (. .)))
(S1 (S (S (NP (NP (JJ Perioperative) (NN administration)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBG affecting) (NP (NP (JJ hepatic) (NN blood) (NN flow)) (CC or) (NP (NN enzyme) (NN function))))))) (VP (MD may) (VP (VP (VB reduce) (NP (NN plasma) (NN clearance))) (CC and) (VP (VB prolong) (NP (NN recovery)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (NN drug6)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drugs))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB fully)) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (NNS studies)) (VP (VBN designed) (S (VP (TO to) (VP (VB examine) (NP (NN drug) (NNS interactions))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN done)))))) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN noted) (SBAR (IN that) (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2) (NN treatment))) (PP (IN of) (NP (NNS relapses))) (PP (IN for) (NP (NP (NNS periods)) (PP (IN of) (NP (QP (RB up) (TO to) (CD 28)) (NNS days)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (PP (TO to) (NP (NP (NP (NNS patients)) (PRN (-LRB- -LRB-) (NP (NN N=180)) (-RRB- -RRB-))) (VP (VBG receiving) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ drug1) (NN administration)) (PP (TO to) (NP (NP (CD three) (NN cancer) (NNS patients)) (PP (IN over) (NP (NP (DT a) (NN dose) (NN range)) (PP (IN of) (NP (QP (CD 0.025) (NN mg) (TO to) (CD 2.2)) (NN mg)))))))) (VP (VBD led) (PP (TO to) (NP (NP (DT a) (JJ dose-dependent) (NN inhibition)) (PP (IN of) (NP (NP (NN drug2) (NN elimination.14)) (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (JJ alternate-day) (NN administration)) (PP (IN of) (NP (NP (CD 0.25) (NN mg)) (PP (IN of) (NP (NN drug3))))))) (PP (IN on) (NP (NP (NN drug) (NN metabolism)) (PP (IN in) (NP (NN MS) (NNS patients)))))) (VP (VBZ is) (ADJP (JJ unknown)))))))))) (. .)))
(S1 (S (NP (NP (JJ Drug-Drug) (NNS Interactions)) (NP (NP (NN drug1)) (CC -) (NP (NN drug2)))) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution))) (PP (TO to) (NP (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (ADJP (ADJP (JJ systemically-administered)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ oral)) (CC or) (ADJP (JJ intravenous))) (-RRB- -RRB-))) (NN drug3)))))) (-LRB- -LRB-) (CC or) (NP (JJ other) (NNS drug4)) (-RRB- -RRB-))) (SBAR (IN because) (S (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug5))) (PP (IN on) (NP (DT the) (JJ cardiovascular) (NN system)))) (VP (MD can) (VP (VB be) (VP (VBN potentiated) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (CC and) (NP (NN blood) (NN pressure)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN CYP2D6)) (NP (NNS inhibitors)) (CC -) (NP (NN drug1))) (VP (VBZ is) (ADVP (RB primarily)) (VP (VBN metabolized) (PP (IN by) (NP (NP (DT the) (NN CYP2D6) (NN pathway)) (PP (TO to) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN EMs))) (, ,) (NP (NP (JJ selective) (NNS inhibitors)) (PP (IN of) (NP (NN CYP2D6)))) (VP (VBP increase) (NP (JJ drug1) (JJ steady-state) (NN plasma) (NNS concentrations)) (PP (TO to) (NP (NP (NNS exposures)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (NN PMs))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Dosage) (NN adjustment)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NP (NN CYP2D6) (NNS inhibitors)) (, ,) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ EM) (NNS individuals)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))))) (, ,) (S (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug3)))) (VP (VBZ is) (NP (RB approximately) (CD 6-) (TO to) (JJ 8-fold)))) (CC and) (S (NP (NP (NN Css)) (, ,) (NP (NN max))) (VP (VBZ is) (ADJP (NP (RB about) (CD 3-) (TO to) (RB 4-fold)) (JJR greater) (PP (IN than) (NP (NP (NN drug4)) (ADVP (RB alone)))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN coadministration)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NNS inhibitors))) (PP (TO to) (NP (NN PMs)))) (VP (MD will) (RB not) (VP (VB increase) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (NP (JJ Pressor) (NNS agents)) (: -) (PP (IN Because) (PP (IN of) (NP (NP (JJ possible) (NNS effects)) (PP (IN on) (NP (NN blood) (NN pressure)))))) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN with) (NP (JJ pressor) (NNS agents))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBP are) (VP (VBN given) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Usually)) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (NN one-half)))) (PRN (-LRB- -LRB-) (PP (VBG depending) (PP (IN on) (NP (DT the) (JJ individual) (NN case)))) (-RRB- -RRB-))) (S (VP (TO to) (VP (VB maintain) (NP (DT the) (NN prothrombin) (NN time)) (PP (IN at) (NP (DT the) (JJ desired) (NN level) (S (VP (TO to) (VP (VB prevent) (NP (JJ bleeding) (NNS complications)))))))))))) (. .)))
(S1 (S (S (NP (JJ Frequent) (NN prothrombin) (NNS determinations)) (VP (VBP are) (ADJP (JJ advisable) (SBAR (IN until) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN determined) (ADVP (RB definitely)) (SBAR (IN that) (S (NP (DT the) (NN prothrombin) (NN level)) (VP (VBZ has) (VP (VBN been) (VP (VBN stabilized)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB displace) (NP (NP (JJ acidic) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (PP (IN from) (NP (PRP$ their) (NN binding) (NNS sites))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG treating) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT either)) (PP (IN of) (NP (NP (DT these) (NNS drugs)) (CC or) (NP (NP (JJ other) (ADJP (RB highly) (JJ protein-bound)) (NNS drugs)) (CC and) (NP (NN drug1))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ hypoglycemic) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB increase) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concurrently))))))))))))) (. .)))
(S1 (S (S (NP (JJ Fulminant) (NN rhabdomyolysis)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN seen) (ADVP (RB as) (RB early)) (PP (IN as) (NP (NP (CD three) (NNS weeks)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (JJ combined) (NN therapy)) (PP (IN with) (NP (DT another) (NP (NN drug1)) (CC and) (NP (NN drug2))))))))))))) (CC but) (VP (MD may) (VP (VB be) (VP (VBN seen) (PP (IN after) (NP (JJ several) (NNS months)))))))) (. .)))
(S1 (S (S (PP (IN For) (NP (DT these) (NNS reasons))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN felt) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (NP (JJS most) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (S (VP (VBD had) (NP (NP (DT an) (JJ unsatisfactory) (NN lipid) (NN response)) (PP (TO to) (NP (NP (DT either) (NN drug)) (ADVP (RB alone)))))))))))) (, ,) (NP (NP (DT the) (JJ possible) (NNS benefits)) (PP (IN of) (NP (NP (JJ combined) (NN therapy)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (DT a) (NN drug2))))))) (VP (VBP do) (RB not) (VP (VB outweigh) (NP (NP (DT the) (NNS risks)) (PP (IN of) (NP (NP (JJ severe) (NN myopathy)) (, ,) (NP (NN rhabdomyolysis)) (, ,) (CC and) (NP (JJ acute) (JJ renal) (NN failure)))))))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (DT this) (NN interaction)) (VP (VBZ occurs) (PP (IN with) (NP (NP (NN drug1)) (CONJP (JJ other) (IN than)) (NP (NN drug2))))))))))) (, ,) (NP (NP (NN myopathy)) (CC and) (NP (NN rhabdomyolysis))) (VP (VBP have) (ADVP (RB occasionally)) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NN drug3)) (ADVP (RB alone)) (, ,) (PP (VBG including) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (JJ combined) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (MD should) (ADVP (RB generally)) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (NP (NP (NN Drug) (NNS Interactions)) (: :) (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (DT some) (NNS drugs)) (, ,) (PP (IN like) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))))))))) (: :) (S (NP (NN drug4)) (VP (MD could) (ADVP (RB theoretically)) (VP (VB affect) (NP (NP (NN drug5) (NNS pharmacodynamics)) (: -) (NP (NP (NN drug6)) (CC -) (NP (NP (NN Eproxindine)) (CC -) (NP (NN drug7)))))))) (: :) (S (NP (NP (NN drug8)) (CC and) (NP (NN drug9))) (VP (VBP cause) (NP (NP (JJ additive) (NN CNS) (NN depression)) (CC -) (NP (NN drug10))))) (: :) (S (NP (NN drug11)) (VP (VBZ increases) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug12))))))))))
(S1 (S (S (NP (NP (DT The) (JJ vasodilating) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ additive) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (JJ other) (NNS drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (PP (IN in) (NP (JJ particular))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VBP exhibit) (NP (NP (JJ additive) (NNS effects)) (PP (IN of) (NP (DT this) (NN variety))))))))))) (. .)))
(S1 (S (S (NP (JJ Marked) (JJ symptomatic) (JJ orthostatic) (NN hypotension)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (JJ organic) (NN drug2))) (VP (VBD were) (VP (VBN used) (PP (IN in) (NP (NN combination))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Dose) (NNS adjustments)) (PP (IN of) (NP (NP (DT either) (NN class)) (PP (IN of) (NP (NNS agents)))))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ clinical) (NNS studies)) (VP (VBN performed) (PP (IN with) (NP (NN drug1)))))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NP (JJ oral) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN drug7)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN drug8))))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics/pharmacodynamics)) (PP (IN of) (NP (NN drug9))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN drug1)) (ADVP (RB neither)) (VP (VBD influenced) (NP (NP (NP (DT the) (NNS pharmacodynamics)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))) (, ,) (CC nor) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug6))))) (PP (IN at) (NP (JJ steady) (NN state))))) (. .)))
(S1 (S (S (NP (NP (NNS Agents)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN hemorrhage))))))))) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (PP (JJ prior) (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NN drug1) (NN therapy))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN co-administration)) (VP (VBZ is) (ADJP (JJ essential))))) (, ,) (NP (JJ close) (NN monitoring)) (VP (MD may) (VP (VB be) (ADJP (JJ appropriate))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT an) (ADJP (FW in) (FW vitro)) (NN study)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes))))) (, ,) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN CYP2A6) (NN hydroxylation)) (PP (IN of) (NP (NN drug1))))) (PP (IN by) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 200) (NN m) (NN m) (NN M)) (PP (FW i.e.) (, ,) (NP (CD 350) (NN mg/L))) (-RRB- -RRB-))))) (VP (VBD was) (NP (CD 17-28) (NN %)))) (. .)))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (DT the) (JJ other) (NNS isozymes)) (VP (VBN evaluated) (PRN (-LRB- -LRB-) (NP (NNS CYPs) (NP (NP (NN 2A1)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (NP (NN 2D6)) (, ,) (NP (NN 3A4)) (, ,) (CC and) (NP (NN 3E1)))) (-RRB- -RRB-)))))) (VP (VBD was) (NP (CD 0-16) (NN %)))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (ADVP (RB markedly)) (VP (VB inhibit) (NP (NP (NNS CYP450s)) (PRN (-LRB- -LRB-) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2A6)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2C19)) (, ,) (NP (NN CYP2D6)) (, ,) (NP (NN CYP2E1)) (, ,) (CC or) (NP (NN CYP3A4))) (-RRB- -RRB-))) (ADVP (FW in) (FW vitro)))))) (, ,) (NP (NN drug2)) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB interact) (PP (IN with) (NP (JJ other) (NNS drugs))) (ADVP (FW in) (FW vivo)) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN metabolism)) (VP (VBN mediated) (PP (IN by) (NP (DT these) (NNS isozymes)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB bind) (ADVP (RB significantly)) (PP (TO to) (NP (NP (NN plasma) (NNS proteins)) (ADJP (JJ other) (PP (IN than) (NP (NN ATIII)))))))))) (, ,) (NP (NP (DT no) (NN drug) (NNS interactions)) (PP (IN by) (NP (JJ protein-binding) (NN displacement)))) (VP (VBP are) (VP (VBN expected)))) (. .)))
(S1 (S (S (NP (NP (JJ Prospective) (NNS studies)) (PP (IN on) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN drug1))) (VP (TO to) (VP (VB interact) (PP (IN with) (NP (JJ other) (NNS drugs)))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (JJ other) (JJ myelosuppressive) (NNS agents)) (CC or) (NP (NN radiation) (NN therapy)))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (NP (NN bone) (NN marrow) (NN depression)) (CC or) (NP (JJ other) (JJ adverse) (NNS events)))))))) (. .)))
(S1 (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (MD may) (VP (VB raise) (NP (DT the) (NN serum) (NN uric) (NN acid) (NN level)))))) (, ,) (S (NP (NP (NN dosage) (NN adjustment)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (VP (JJ necessary)))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (JJ oral)))))
(S1 (S (S (NP (-LRB- -LRB-) (NNS Effects)) (VP (MD may) (VP (VB be) (VP (VBN decreased) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug1)))))))))) (: ;)))
(S1 (S (S (NP (NN dosage) (NNS adjustments)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .) (-RRB- -RRB-)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (-LRB- -LRB-) (NP (NN drug1)) (VP (MD may) (VP (VB raise) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN blood) (JJ uric) (NN acid))))))) (: ;)))
(S1 (S (S (NP (NP (JJ dosage) (NN adjustment)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB control) (NP (NP (NN hyperuricemia)) (CC and) (NP (NN gout))))))))) (. .)) (-RRB- -RRB-)))
(S1 (S (NP (NP (NP (NP (NP (NP (NN drug1)) (, ,) (NP (NP (ADJP (JJ other))) (, ,) (NP (ADJP (RB especially) (JJ drug2))) (, ,) (CC or) (NP (ADJP (JJ preanesthetic)))) (CC and) (NP (NN drug3))) (NNS agents)) (VP (VBN used) (PP (IN in) (NP (NP (NN surgery)) (CC or) (NP (NN drug4)))))) (, ,) (NP (NN nondepolarizing)) (, ,)) (VP (VBN used) (PP (IN in) (NP (NN surgery)))))))
(S1 (S (S (NP (-LRB- -LRB-) (NNS Effects)) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug1)))))))))) (: ;)))
(S1 (S (S (NP (NN dosage) (NNS adjustments)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .) (-RRB- -RRB-)))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (CC or) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))))))
(S1 (S (-LRB- -LRB-) (NP (NP (JJ Concurrent) (NN use)) (PP (IN with) (NP (NN drug1)))) (VP (MD may) (VP (VB intensify) (NP (NP (NN electrolyte) (NN imbalance)) (, ,) (NP (ADVP (RB particularly)) (NP (NN hypokalemia))) (. .)))) (-RRB- -RRB-)))
(S1 (S (NP (NN drug1))))
(S1 (S (-LRB- -LRB-) (NP (NP (JJ Concurrent) (NN use)) (PP (IN with) (NP (NN drug1)))) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NN drug2) (NN toxicity))) (VP (VBN associated) (PP (IN with) (NP (NN hypokalemia)))) (. .)))) (-RRB- -RRB-)))
(S1 (S (NP (NN drug1))))
(S1 (S (-LRB- -LRB-) (VP (MD May) (VP (VB inhibit) (NP (NP (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (DT the) (NN drug1)))))) (: ;)))
(S1 (S (NP (NP (NN administration) (CD 1) (NN hour)) (PP (IN before) (NP (CC or) (CD 4) (NNS hours))) (PP (IN after) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN recommended))) (. .) (-RRB- -RRB-)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (-LRB- -LRB-) (NP (NN drug1)) (VP (MD may) (VP (VB raise) (NP (NN blood) (NN glucose) (NNS levels))))) (: ;)))
(S1 (S (PP (IN for) (NP (JJ adult-onset) (NNS diabetics))) (, ,) (NP (NP (NN dosage) (NN adjustment)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (PP (PP (IN during)) (CC and) (PP (IN after) (NP (NN drug2) (NN therapy))))))) (: ;)))
(S1 (S (S (NP (NN drug1) (NNS requirements)) (VP (MD may) (VP (VB be) (ADJP (ADJP (VBN increased)) (, ,) (ADJP (VBN decreased)) (, ,) (CC or) (ADJP (JJ unchanged))))) (. .)) (-RRB- -RRB-)))
(S1 (S (NP (NN drug1) (NNS salts))))
(S1 (S (PRN (-LRB- -LRB-) (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN with) (NP (NN drug1)))) (VP (VBZ is) (RB not) (VP (VBN recommended) (, ,) (SBAR (IN as) (S (NP (PRP they)) (VP (MD may) (VP (VB provoke) (NP (NN drug2) (NN toxicity)) (PP (IN because) (IN of) (NP (VBN reduced) (JJ renal) (NN clearance))))))))) (. .)) (-RRB- -RRB-))))
(S1 (S (NP (NN drug1))))
(S1 (S (-LRB- -LRB-) (NP (NN Effectiveness)) (VP (MD may) (VP (VB be) (VP (VBN decreased) (SBAR (WHADVP (WRB when)) (S (S (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug1))) (PP (IN because) (IN of) (NP (NP (NN alkalinization)) (PP (IN of) (NP (DT the) (NN urine))))))) (. .)))))) (-RRB- -RRB-)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (-LRB- -LRB-) (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (DT the) (NN drug1)) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (ADJP (ADJP (JJ diuretic)) (, ,) (ADJP (JJ natriuretic)) (, ,) (CC and) (ADJP (JJ antihypertensive))) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ desired) (NN effect)) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (VBZ is) (VP (VBN obtained))))))))))) (. .) (-RRB- -RRB-)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (-LRB- -LRB-) (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (JJ arterial) (NN responsiveness)) (PP (TO to) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (DT This) (NN diminution)) (VP (VBZ is) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB preclude) (NP (NP (NN effectiveness)) (PP (IN of) (NP (DT the) (JJ pressor) (NN agent))) (PP (IN for) (NP (JJ therapeutic) (NN use))))))))) (. .)) (-RRB- -RRB-)))
(S1 (S (NP (NN drug1))))
(S1 (S (-LRB- -LRB-) (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (DT the) (NN responsiveness) (PP (TO to) (NP (NN drug2))) (. .)))) (-RRB- -RRB-)))
(S1 (S (NP (NP (NP (JJ DIAGNOSTIC) (NN INTERFERENCE)) (PP (IN With) (NP (NP (VBN expected) (JJ physiologic) (NNS effects)) (PRN (: :) (S (NP (NP (NP (NP (NN Blood)) (CC and) (NP (NN urine) (NN glucose) (NNS levels))) (PRN (-LRB- -LRB-) (ADVP (RB usually) (RB only)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN predisposition)) (PP (IN for) (NP (NN glucose) (NN intolerance))))))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NP (NN Serum) (NN bilirubin) (NNS levels)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (NP (NN displacement)) (PP (IN from) (NP (NN albumin) (NN binding))))) (-RRB- -RRB-))) (CC and) (NP (NN Serum) (NN calcium) (NNS levels))) (-LRB- -LRB-) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (PP (IN before) (NP (JJ parathyroid-function) (NNS tests)))))))) (VP (VBP are) (VP (VBN carried) (RP out)))) (-RRB- -RRB-))))) (CC and) (NP (NP (NP (NN Serum) (JJ uric) (NN acid)) (NNS levels)) (-LRB- -LRB-) (VP (MD may) (VP (VB be) (VP (VBN increased)))) (-RRB- -RRB-)) (NP (NN Serum) (NN magnesium) (, ,) (NN potassium) (, ,) (CC and) (NN sodium) (NNS levels))) (-LRB- -LRB-) (VP (MD may) (VP (VB be) (VP (VBN decreased)))) (: ;)))
(S1 (S (S (NP (NN serum) (NN magnesium) (NNS levels)) (VP (MD may) (VP (VB increase) (PP (IN in) (NP (JJ uremic) (NNS patients))) (-RRB- -RRB-) (NP (NP (NN Serum) (JJ protein-bound) (NN iodine) (-LRB- -LRB-) (NN PBI) (-RRB- -RRB-) (NNS levels)) (-LRB- -LRB-) (VP (MD may) (VP (VB be) (VP (VBN decreased)))) (-RRB- -RRB-) (SBAR (WHNP (WDT drug1)) (S (VP (MD should) (VP (VB be) (VP (VBN discontinued) (PP (IN before) (S (VP (VBG carrying) (PRT (RP out)) (NP (NP (NNS tests)) (PP (IN for) (NP (JJ parathyroid) (NN function)))))))))))))))) (. .)))
(S1 (S (NP (NP (NNS Tablets)) (: :) (S (NP (NP (DT The) (NNS drug1)) (, ,) (PP (VBG including) (NP (NN drug2))) (, ,)) (VP (VBP produce) (NP (JJ CNS-depressant) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (JJ such) (NNS medications))) (PP (IN as) (NP (NP (NN drug3)) (CC or) (NP (NN drug4))))))))) (. .))))
(S1 (S (S (S (NP (NP (NN Injection)) (: :) (S (NP (NN drug1) (NN injection)) (, ,) (PP (IN like) (NP (JJ other) (JJ injectable) (NN drug2))) (, ,) (VP (VBZ produces) (NP (NP (NN depression)) (PP (IN of) (NP (DT the) (JJ central) (JJ nervous) (NN system)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (JJ other) (NN drug7) (JJ .When) (NN drug8)))))))))) (VP (VBZ is) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ injectable) (NN drug9)) (, ,) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NN sedation)))) (, ,) (NP (NNS hallucinations))))))) (, ,) (CC and) (S (NP (JJ irrational) (NN behavior)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ appears) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (NN rate)) (SBAR (WHPP (IN at) (WHNP (WDT which))) (S (NP (JJ certain) (NNS drugs)) (VP (VBP are) (VP (VBN metabolized)))))))))) (CC and) (ADVP (RB therefore)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN blood) (NNS levels)) (CC and) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (JJ clinical) (NN toxicity)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN given) (ADVP (RB concomitantly))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD SHOULD) (VP (VB BE) (VP (VBN USED) (PP (IN WITH) (NP (NN CAUTION))) (PP (IN IN) (NP (NP (DT THOSE) (NNS PATIENTS)) (VP (VBG REVEIVING) (NP (NP (NN drug2)) (CC AND) (NP (PRP$ ITS) (NNS CONGENERS)))))))))) (. .)))
(S1 (S (SBAR (IN SINCE) (S (NP (NP (DT THE) (JJ CONCOMITANT) (NN ADMINISTRATION)) (PP (IN OF) (NP (DT THESE) (CD TWO) (NNS DRUGS)))) (VP (MD CAN) (VP (VB LEAD) (PP (TO TO) (NP (NN drug1) (NN INTOXICATION))))))) (, ,) (PP (JJ PRIOR) (TO TO) (S (VP (VBG ADMINISTERING) (NP (NN drug2)) (PP (TO TO) (NP (NP (DT A) (NN PATIENT)) (PP (IN ON) (NP (NN drug3) (NN THERAPY)))))))) (, ,) (NP (DT A) (NN BASELINE) (NN drug4) (NN SERUM) (NN LEVEL)) (VP (MD SHOULD) (VP (VB BE) (VP (VBN OBTAINED)))) (. .)))
(S1 (S (S (ADJP (JJ SUBSEQUENT) (PP (TO TO) (NP (NP (NN INITIATION)) (PP (IN OF) (NP (NN drug1) (NN THERAPY))))))) (. .)))
(S1 (S (S (NP (NP (NN SERUM) (NNS LEVELS)) (PP (IN OF) (NP (NN drug1)))) (VP (MD SHOULD) (VP (VB BE) (VP (VBN DETERMINED) (PP (IN ON) (NP (NP (JJ DIFFERENT) (NNS DAYS)) (PP (PP (IN FOR) (NP (NP (NN EVIDENCE)) (PP (IN OF) (NP (DT AN) (NN INCREASE))))) (CC OR) (PP (IN FOR) (NP (NP (DT A) (VBG CONTINUING) (NN RISE)) (PP (IN IN) (NP (NNS LEVELS)))))))))))) (. .)))
(S1 (S (S (NP (VBN INCREASED) (NN drug1) (NNS LEVELS)) (VP (MD SHOULD) (VP (VB BE) (VP (VBN TREATED) (PP (IN WITH) (NP (JJ APPROPRIATE) (NN DOSAGE) (NN ADJUSTMENT))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (S (S (VP (TO to) (VP (VB adjust) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (JJ oral) (NN drug1)))) (PP (IN upon) (NP (NP (NN beginning)) (CC or) (NP (NN stopping) (NN drug2))))))) (. .))) (SBAR (IN since) (S (NP (NN drug3)) (VP (MD may) (VP (VB prolong) (NP (NN prothrombin) (NN time))))))))) (. .)))
(S1 (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NP (NN drug1)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN given)))))))) (VP (MD should) (VP (VB be) (VP (VBN observed) (PP (IN for) (NP (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NN unsteady) (NN gait)))) (CC or) (NP (NP (JJ marked) (NNS changes)) (PP (IN in) (NP (JJ mental) (NN status))))))))) (: ;)))
(S1 (S (S (NP (DT the) (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (SBAR (IN if) (S (NP (JJ such) (NNS signs)) (VP (VBP appear)))))))) (. .)))
(S1 (S (S (S (PP (IN In) (NP (NNS rats))) (, ,) (NP (NP (JJ simultaneous) (NN ingestion)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NP (DT the) (NN diet)) (PP (IN for) (NP (CD 78) (NNS weeks)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (NNS tumors))))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (SBAR (IN that) (S (NP (NN drug3)) (VP (MD may) (VP (VB react) (PP (IN with) (NP (NP (NN drug4)) (PP (IN in) (NP (DT the) (NN rat) (NN stomach))))) (S (VP (TO to) (VP (VB form) (NP (NP (DT a) (NN nitrosamine)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ tumorigenic)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (ADVP (RB alone))) (PP (IN in) (NP (DT the) (NN rat) (NN s) (NN diet)))) (VP (VBD did) (RB not) (VP (VB lead) (PP (TO to) (NP (JJ such) (NNS tumors)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN relevance)) (PP (IN of) (NP (DT this) (NN finding))) (PP (TO to) (NP (NNS humans)))) (VP (VBZ is) (RB not) (VP (VBN known) (PP (IN at) (NP (DT this) (NN time)))))) (. .)))
(S1 (S (S (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (JJ CYP3A4-) (NN drug1) (NN metabolism)))) (VP (VBZ is) (ADVP (RB predominantly)) (VP (VBN mediated) (PP (IN via) (NP (NN CYP3A4)))))) (. .)))
(S1 (S (NP (NP (DT A) (JJ pharmacokinetic) (NN study)) (VP (VBG evaluating) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NN drug1) (CD 100) (NN mg)) (PP (IN with) (NP (NP (NN drug2) (CD 200) (NN mg) (NN BID)) (, ,) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (DT the) (NN CYP3A4) (NN pathway)))) (, ,)))))))))) (VP (VBD showed) (NP (NP (NP (DT a) (JJ 1.7-fold) (NN increase)) (PP (IN in) (NP (NP (NN Cmax)) (PP (IN of) (NP (NN drug3)))))) (CC and) (NP (NP (DT a) (JJ 5.4-fold) (NN increase)) (PP (IN in) (NP (NP (NN AUC)) (PP (IN of) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN described) (PP (IN as) (NP (NP (JJ strong) (NNS inhibitors)) (PP (IN of) (NP (NN CYP3A4))))) (PP (IN in) (NP (PRP$ their) (NN labeling)))))))))) (. .)))
(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN with) (NP (NP (JJ other) (JJ CYP3A4) (NNS inhibitors)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NP (NN drug2) (CD 500) (NN mg)) (NP (NN BID))) (, ,) (NP (NN drug3) (NN 240) (NN mg) (NN QD)) (, ,) (NP (NP (NN drug4) (CD 1200) (NN mg)) (NP (NN TID))) (, ,) (NP (NN drug5) (CD 200) (NN mg)))) (NP (NN QD)) (-RRB- -RRB-))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NP (NN Cmax)) (PP (IN of) (NP (NP (NN drug6)) (VP (VBG ranging) (PP (IN from) (NP (NN 1.4-))) (PP (TO to) (NP (JJ 1.6-) (NN fold))))))) (CC and) (NP (NP (NN AUC)) (PP (IN from) (NP (NP (NN 2.0-)) (PP (TO to) (NP (NN 2.9-) (NN fold))))))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (JJ Congestive) (NN Heart) (NN Failure)) (JJ Post-Myocardial) (NN Infarction)) (-RRB- -RRB-))) (: -) (S (ADVP (FW In) (FW EPHESUS)) (, ,) (NP (NP (CD 3020) (PRN (-LRB- -LRB-) (NP (CD 91) (NN %)) (-RRB- -RRB-)) (NNS patients)) (VP (VBG receiving) (NP (NN drug3) (QP (CD 25) (TO to) (CD 50)) (NN mg)))) (ADVP (RB also)) (VP (VBD received) (NP (NP (NP (NN drug4)) (CC or) (NP (NN drug5))) (PRN (-LRB- -LRB-) (NP (NP (NN drug6)) (: /) (NP (NN drug7))) (-RRB- -RRB-))))) (. .))))
(S1 (S (S (NP (NP (NNS Rates)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN maximum) (NN potassium) (NNS levels) (CD 5.5) (NN mEq/L)))))) (VP (VBD were) (ADJP (JJ similar) (ADVP (RB regardless) (PP (IN of) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1) (: /) (NN drug2))))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NN Hypertension)) (-RRB- -RRB-))) (: -) (S (PP (IN In) (NP (NP (JJ clinical) (NNS studies)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN hypertension))))))) (, ,) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug3) (CD 50))) (PP (TO to) (NP (CD 100) (NN mg))) (PP (TO to) (NP (NP (NN drug4)) (CC and) (NP (NN drug5))))) (VP (VBD increased) (NP (NN mean) (NN serum) (NN potassium)) (ADVP (ADVP (RB slightly)) (PRN (-LRB- -LRB-) (NP (QP (RB about) (CD 0.09-0.13)) (NN mEq/L)) (-RRB- -RRB-))))) (. .))))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (NP (NNS diabetics)) (PP (IN with) (NP (NN microalbuminuria) (NN drug1))))))) (NP (NP (CD 200) (NN mg)) (VP (VBN combined) (PP (IN with) (NP (DT the) (NN drug2) (NN drug3) (CD 10) (NN mg))))) (VP (VBD increased) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NP (NN hyperkalemia)) (PRN (-LRB- -LRB-) (NP (NN serum) (NN potassium) (CD 5.5) (NN mEq/L)) (-RRB- -RRB-))))) (PP (IN from) (NP (CD 17) (NN %))) (PP (IN on) (NP (NP (NN drug4)) (ADVP (RB alone)))) (PP (TO to) (NP (CD 38) (NN %)))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN -A) (NN drug) (NN interaction) (NN study)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NN Serum) (NN drug1) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB frequently)) (SBAR (IN if) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (NN drug1) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-) (JJ -A)) (NN drug) (NN interaction) (NN study)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (DT an) (NN drug4)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (JJ other) (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VP (VB reduce) (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN in) (NP (DT some) (NNS patients)))) (CC and) (VP (VB result) (PP (IN in) (NP (JJ severe) (NN hyperkalemia))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ impaired) (JJ renal) (NN function))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN observed) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT the) (JJ desired) (NN effect)) (PP (IN on) (NP (NN blood) (NN pressure)))) (VP (VBZ is) (VP (VBN obtained)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Tissue) (NN culture)) (CC and) (NP (NN animal) (NNS studies))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD can) (VP (VP (VB diminish)) (CC or) (VP (VB abolish) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (JJ malignant) (NN cells.14))))) (NP (DT This) (NN effect) (SBAR (IN on) (S (NP (NN drug3) (NN activity)) (VP (VBZ persists) (SBAR (RB as) (RB long) (IN as) (S (NP (NN plasma) (NN asparagine) (NNS levels)) (VP (VBP are) (VP (VBN suppressed))))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (MD would) (VP (VB seem) (S (VP (TO to) (VP (VB dictate) (PP (IN against) (NP (NP (DT the) (JJ clinical) (NN use)) (PP (IN of) (NP (NN drug1))))) (PP (PP (IN with) (NP (NN drug2))) (, ,) (CC or) (PP (IN during) (NP (NP (DT the) (NN period)) (PP (VBG following) (NP (NN drug3) (NN therapy)))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NN plasma) (NN asparagine) (NNS levels)) (VP (VBP are) (PP (IN below) (NP (JJ normal)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBZ gets) (VP (VBN absorbed) (PP (IN into) (NP (JJ your) (NN body))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT the) (NN case)) (SBAR (WHNP (WDT that)) (S (ADVP (RB you)) (VP (VBP are) (VP (VBG taking) (NP (NN drug1) (SBAR (IN while) (S (VP (VBG taking) (NP (NN drug2)))))))))))) (, ,) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN drug3)))) (VP (MD may) (VP (VB be) (VP (VBN needed))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB also)) (VP (VB decrease) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug2))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NN a) (NN deficiency))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (NP (NN you)) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB take) (NP (DT a) (JJ drug1) (NN supplement)) (SBAR (IN while) (S (VP (VBG taking) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB augment) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ other) (NNS drug2))))))) (. .)))
(S1 (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN with) (NP (JJ other) (NN drug1)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (DT No) (NN information)) (VP (VBZ is) (ADJP (JJ available)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB accentuate) (NP (NP (DT the) (NN electrolyte) (NN loss)) (VP (VBN associated) (PP (IN with) (NP (NN drug2) (NN therapy)))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (JJ other) (NN drug1) (NNS s)))) (, ,) (NP (NP (JJ general) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (CC or) (NP (JJ other) (NN drug7)))) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (NN drug8))) (-RRB- -RRB-))) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN drug9)))) (VP (MD may) (VP (VBP exhibit) (NP (DT an) (JJ additive) (NN CNS) (NN depression)))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (JJ combined) (NN therapy)) (VP (VBZ is) (VP (VBN contemplated))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (CD one)) (CC or) (NP (DT both)) (NP (NNS agents))))) (VP (MD should) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (S (NP (DT No) (JJ significant) (JJ drug-drug) (ADJP (ADJP (JJ pharmacokinetic)) (-LRB- -LRB-) (CC or) (ADJP (JJ pharmacodynamic)) (-RRB- -RRB-)) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN found) (PP (IN in) (NP (NP (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP show) (NP (NP (JJ significant) (NN inhibition)) (PP (IN of) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (VBN oxidized) (NN irbesartan) (NNS metabolites)) (PP (IN with) (NP (NP (DT the) (JJ known) (NN cytochrome) (NN CYP) (NN 2C9) (NN substrates/inhibitors) (NN drug1)) (, ,) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (JJ clinical) (NNS studies))) (NP (NP (DT the) (NNS consequences)) (PP (IN of) (NP (JJ concomitant) (NN drug1))) (PP (IN on) (NP (NP (DT the) (NNS pharmacodynamics)) (PP (IN of) (NP (NN drug2)))))) (VP (VBD were) (ADJP (JJ negligible)))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (ADJP (FW in) (FW vitro)) (NNS data)))) (, ,) (NP (DT no) (NN interaction)) (VP (MD would) (VP (VB be) (VP (VBN expected) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WP$ whose) (NN metabolism)) (S (VP (VBZ is) (ADJP (JJ dependent) (PP (IN upon) (NP (NP (NN cytochrome) (NN P450) (NNS isozymes) (NN 1A1)) (, ,) (NP (NN 1A2,2A6,2B6,2D6,2E1)) (, ,) (CC or) (NP (NN 3A4)))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ separate) (NNS studies)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN maintenance) (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC or) (NP (NN drug3)))))))))) (, ,) (NP (NP (NN drug4) (NN administration)) (PP (IN for) (NP (CD 7) (NNS days)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NP (NP (DT the) (NNS pharmacodynamics)) (PP (IN of) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN prothrombin) (NN time)) (-RRB- -RRB-))))) (CC or) (NP (NNS pharmacokinetics))) (PP (IN of) (NP (NN drug6))))))) (. .)))
(S1 (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drugs))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB fully)) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (NP (NP (NNS Results)) (PP (IN from) (NP (JJ existing) (JJ clinical) (NNS trials)))) (VP (VBP suggest) (NP (NP (DT no) (JJ significant) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (JJ other) (NNS therapies)) (VP (ADVP (RB commonly)) (VBN used) (PP (IN in) (NP (NN MS) (NNS patients))))))) (, ,) (PP (VBG including) (NP (NP (DT the) (JJ concurrent) (NN use)) (PP (IN of) (NP (NN drug2))) (PP (IN for) (NP (QP (RB up) (TO to) (CD 28)) (NNS days)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB formally)) (VP (VBN evaluated) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (CD 10) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD switched) (PP (IN from) (NP (NN therapy))) (PP (IN with) (NP (NP (NN drug1)) (PP (TO to) (NP (NN drug2))))))))) (VP (VBD did) (RB not) (VP (VBP report) (NP (NP (DT any) (ADJP (ADJP (JJ serious)) (CC and) (ADJP (JJ unexpected))) (JJ adverse) (NNS reactions)) (VP (VBN thought) (S (VP (TO to) (VP (VB be) (ADJP (JJ related) (PP (TO to) (NP (NN treatment)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB extensively)) (VP (VBN metabolized) (PP (IN in) (NP (DT the) (NN liver))) (PP (IN by) (NP (NP (NN CYP2C19)) (CC and) (NP (NN CYP3A4))))))) (. .)))
(S1 (S (S (NP (ADJP (ADJP (FW In) (FW vitro)) (CC and) (ADJP (FW in) (FW vivo))) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (ADJP (JJ likely) (S (VP (TO to) (VP (VB inhibit) (NP (NNS CYPs) (NP (NP (NN 1A2)) (, ,) (NP (NN 2A6)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2D6)) (, ,) (NP (NN 2E1)) (CC and) (NP (NN 3A4)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (ADJP (RB clinically) (JJ relevant)) (NNS interactions)) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT these) (JJ CYP) (NNS enzymes))))))) (VP (MD would) (VP (VB be) (VP (VBN expected))))) (. .)))
(S1 (S (S (NP (NN Drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB have) (NP (NP (DT any) (ADJP (RB clinically) (JJ significant)) (NNS interactions)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC or) (NP (NN drug6)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Post-marketing) (NNS reports)) (PP (IN of) (NP (NP (NNS changes)) (PP (IN in) (NP (NN prothrombin) (NNS measures)))))) (VP (VBP have) (VP (VBN been) (VP (VBN received) (PP (IN among) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (JJ concomitant) (NN drug1)) (CC and) (NP (JJ drug2) (NN therapy)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Increases)) (PP (IN in) (NP (NP (NN INR)) (CC and) (NP (NN prothrombin) (NN time))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (JJ abnormal) (JJ bleeding)) (CC and) (NP (JJ even) (NN death))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (ADVP (RB concomitantly)))) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN INR)) (CC and) (NP (NN prothrombin) (NN time))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB potentially)) (VP (VB interfere) (PP (IN with) (NP (NP (NN CYP2C19)) (, ,) (NP (DT the) (JJ major) (NN drug2) (NN metabolizing) (NN enzyme))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug1) (CD 30) (NN mg)) (CC and) (NP (NP (NN drug2)) (, ,) (NP (DT a) (NN CYP2C19) (NN substrate)) (, ,))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (CD 45) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (NN clearance)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (VBN Increased) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (VP (VBN observed) (PP (NP (CD 12) (NNS hours)) (IN after) (NP (NP (NN dosing)) (CC and) (NP (NN onwards))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (PP (IN at) (NP (DT that) (NN time))) (, ,) (S (S (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (PP (IN below) (NP (DT the) (JJ therapeutic) (NN interval))))) (, ,) (CC and) (S (ADVP (RB thus)) (NP (DT this) (NN interaction)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ clinical) (NN relevance))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (JJ gastric) (NN acid) (NN secretion)))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHADVP (WRB where)) (S (NP (JJ gastric) (NN pH)) (VP (VBZ is) (NP (NP (DT an) (JJ important) (NN determinant)) (PP (IN of) (NP (NP (NN bioavailability)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3) (NNS salts)) (CC and) (NP (NN drug4))) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (JJ oral) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4))))) (VP (VBD did) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB change) (NP (NP (DT the) (JJ pharmacokinetic) (NN profile)) (PP (IN of) (NP (NN drug5)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (S (NP (DT No) (JJ significant) (JJ drug-drug) (JJ pharmacokinetic) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN found) (PP (IN in) (NP (NP (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN drug5)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (NN drug) (NN metabolism)))) (, ,)) (VP (VBD decreased) (NP (NP (DT the) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (PRP$ its) (JJ active) (NN metabolite))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NNS humans))) (, ,) (NP (NP (CD two) (NNS inhibitors)) (PP (IN of) (NP (NN P450) (NN 3A4)))) (VP (VBP have) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN conversion)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NP (DT the) (JJ active) (NN metabolite)) (PP (IN after) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NN drug3))))))))))) (, ,) (CC and) (S (NP (NN drug4)) (VP (VBD had) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NN effect)) (PP (IN after) (NP (JJ oral) (NN administration)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN P450) (NNS 2C9)))) (, ,)) (VP (VP (VBD decreased) (NP (JJ active) (NN metabolite) (NN concentration))) (CC and) (VP (VBD increased) (NP (NN drug2) (NN concentration))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ pharmacodynamic) (NNS consequences)) (PP (IN of) (NP (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NN P450) (NNS 2C9))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN examined))))) (. .)))
(S1 (S (S (NP (NP (NNS Subjects)) (SBAR (WHNP (WP who)) (S (VP (VBP do) (RB not) (VP (VB metabolize) (NP (NP (NN drug1)) (PP (TO to) (NP (JJ active) (NN metabolite))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB have) (NP (DT a) (ADJP (ADJP (JJ specific)) (, ,) (ADJP (JJ rare))) (NN defect)) (PP (IN in) (NP (NN cytochrome) (NN P450) (NN 2C9)))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN conversion)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (PRP$ its) (JJ active) (NN metabolite)))) (VP (VP (VBZ is) (VP (VBN mediated) (ADVP (RB primarily)) (PP (IN by) (NP (NN P450) (NN 2C9))))) (CC and) (VP (ADVP (RB not)) (NP (NN P450) (NN 3A4)))))))) (. .)))
(S1 (S (PP (IN As) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP block) (NP (NP (NN angiotensin) (CD II)) (CC or) (NP (PRP$ its) (NNS effects))))))))) (, ,) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (, ,) (NP (NN drug5) (NNS supplements)) (, ,) (CC or) (NP (NN salt) (VBZ substitutes) (VP (VBG containing) (NP (NN potassium))))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NNS increases)) (PP (IN in) (NP (NN serum) (NN potassium))))))) (. .)))
(S1 (S (PP (IN As) (PP (IN with) (NP (JJ other) (NN drug1)))) (, ,) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (VP (VBN blunted) (PP (IN by) (NP (DT the) (NN drug3) (NN drug4))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2))))))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ other) (JJ potent) (JJ parental) (NNS drug1)) (, ,) (PP (JJ such) (IN as) (NP (NN drug2))) (, ,)) (VP (VBP are) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug3))))))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (ADVP (RB continuously)) (VP (VBN observed) (PP (IN for) (NP (NP (JJ several) (NNS hours)) (PP (IN for) (NP (NP (DT any) (JJ excessive)) (VP (VBP fall) (PP (IN in) (NP (NN blood) (NN pressure))))))))))) (. .)))
(S1 (S (S (NP (JJ Profound) (JJ hypotensive) (NNS episodes)) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1) (NN infection)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (NN serum) (NNS concentrations)) (CC and) (NP (JJ pharmacologic) (NNS effects))) (VP (MD may) (VP (VB be) (VP (VBN increased))))) (. .)))
(S1 (S (S (VP (VB Monitor) (NP (JJ cardiovascular) (NN status)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ increases) (NP (NN drug2) (NN s) (NN serum) (NNS concentrations)))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (PRN (-LRB- -LRB-) (NP (NP (JJ low) (JJ hepatic) (NN clearance)) (CC or) (NP (NN no) (NN first-pass) (NN metabolism))) (-RRB- -RRB-))) (VP (VBP are) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB be) (VP (VBN affected)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (JJ hemodynamic) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (: ;)))
(S1 (S (VP (VB avoid) (VP (VB use) (SBAR (IN if) (FRAG (JJ possible)))) (CC or) (ADVP (RB closely)) (VP (VB monitor) (NP (JJ cardiovascular) (NN status)) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NN drug) (NNS interactions)))))))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (CD Twelve) (JJ healthy) (JJ male) (NNS volunteers)) (VP (VBD were) (VP (VBN administered) (NP (CD one) (NN 200-mg) (NN drug2) (NN capsule)) (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (CD 6) (NNS days)))))) (. .))))
(S1 (S (S (PP (IN With) (NP (NP (DT the) (NN morning) (NN dose)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN day) (CD 6))))) (, ,) (NP (DT each) (NN volunteer)) (VP (VBD received) (NP (NP (DT a) (JJ single) (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN mg/kg)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (RB not) (VP (VBN altered)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NNS drug2)) (VP (VBN administered) (ADVP (RB orally)))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN investigated))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (: :) (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (VBN increased) (JJ gastric) (NN pH))) (PP (IN on) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug3)))))) (VP (VBD was) (VP (VBN evaluated) (PP (IN in) (NP (CD 18) (JJ healthy) (JJ adult) (NNS volunteers)))))) (. .))))
(S1 (S (S (NP (DT Each) (NN volunteer)) (VP (VBD was) (VP (VBN administered) (NP (CD one) (NN 400-mg) (NN drug1) (NN capsule))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ single) (NN dose)) (PP (IN of) (NP (JJ liquid) (NN drug1)))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN C) (NN max)) (CC or) (NP (NP (NN AUC)) (PP (IN of) (NP (NNS drug2)))))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (NP (CD 150) (NN mg)) (PP (IN of) (NP (NN drug1))) (PP (IN q12h) (PP (IN for) (NP (CD 3) (NNS days))))) (VP (VBD increased) (NP (DT the) (NN drug2) (NN C) (NN max)) (PP (IN by) (NP (NP (CD 23) (NN %)) (CC and) (NP (NN drug3) (NN AUC)))) (PP (IN by) (NP (CD 16) (NN %))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN relevance)) (PP (IN of) (NP (DT these) (NNS increases)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (NP (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (DT no) (ADJP (ADJP (JJ chemical)) (CC or) (ADJP (JJ laboratory))) (NN test) (NNS interactions)) (PP (IN with) (NP (NP (NN drug1)) (VP (VBN noted) (PP (TO to) (NP (NN date)))))))))) (. .))))
(S1 (S (S (NP (JJ False-positive) (JJ direct) (NN Coombs) (NNS tests)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (JJ other) (NN drug1))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN recognized) (SBAR (IN that) (S (NP (DT a) (JJ positive) (NN Coombs) (NN test)) (VP (MD could) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (DT the) (NN drug)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (NP (NNS assays)) (VP (VBG using) (NP (NP (JJ red) (NNS cells)) (PP (IN from) (NP (JJ healthy) (NNS subjects)))) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NN drug1)) (VP (MD would) (VP (VB cause) (NP (JJ direct) (NN Coombs) (NNS reactions)) (ADVP (FW in) (FW vitro))))))))))))) (VP (VBD showed) (NP (DT no) (JJ positive) (NN reaction)) (PP (IN at) (NP (NP (NN drug2) (NNS concentrations)) (ADJP (RB as) (JJ high) (PP (IN as) (NP (CD 40) (NN g/mL)))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (DT the) (NN occurrence)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NN drug1)))))))) (, ,) (NP (NN nephrotoxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (VBG following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (JJ other) (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (NP (NN acid-base)) (CC and) (NP (NN electrolyte))) (NNS disturbances)) (VP (VBD were) (RB not) (VP (VBN reported) (PP (IN in) (NP (NP (DT the) (JJ clinical) (NNS trials)) (PP (IN with) (NP (NN drug1))))))))) (, ,) (NP (DT these) (NNS disturbances)) (VP (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (JJ oral) (NN drug2)))))) (CC and) (VP (VBP have) (, ,) (PP (IN in) (NP (DT some) (NNS instances))) (, ,) (S (VP (VBD resulted) (PP (IN in) (NP (NP (NN drug) (NNS interactions)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN toxicity)) (VP (VBN associated) (PP (IN with) (NP (JJ high-dose) (NN drug3) (NN therapy)))))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (JJ such) (NN drug) (NNS interactions)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NNS Interactions)) (VP (MD may) (VP (VB occur) (PP (IN between) (NP (NP (NP (NN drug1) (NNS supplements) (NP (CC and) (NP (NN drug2)) (CC and) (NP (JJ other) (NN drug3)))) (CC and) (NP (NNS herbs))) (PP (JJ such) (IN as) (NP (NP (NP (NN garlic)) (PRN (-LRB- -LRB-) (NP (NNP Allium) (FW sativum)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (JJ Such) (NNS interactions)) (VP (MD might) (VP (VB be) (VP (VBN manifested) (PP (IN by) (NP (NP (VBN increased) (NN susceptibility)) (PP (TO to) (NP (NP (NP (NN bruising)) (, ,) (NP (NN nosebleeds)) (, ,) (NP (NN hemoptysis)) (, ,) (NP (NN hematemesis)) (, ,) (NP (NN hematuria)) (CC and) (NP (NN blood))) (PP (IN in) (NP (DT the) (NN stool))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NP (JJS Most)) (SBAR (WHNP (WP who)) (S (VP (VBP take) (NP (NN drug1) (NNS supplements)))))) (CC and) (NP (NP (DT the) (JJ above) (NNS drugs)) (CC or) (NP (NNS herbs)))) (VP (VBP do) (RB not) (VP (VB suffer) (PP (IN from) (NP (DT these) (NNS problems)))))) (CC and) (S (SBAR (IN if) (S (NP (PRP they)) (VP (VBP occur)))) (, ,) (NP (PRP they)) (VP (VBP are) (ADJP (JJ rare))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (PRP they)) (VP (VBP do) (VP (VB occur))))) (, ,) (NP (DT the) (NN drug1) (NN dose)) (VP (MD should) (VP (VB be) (ADJP (ADJP (JJ lowered)) (CC or) (ADJP (JJ discontinued)))))) (. .)))
(S1 (S (S (NP (VBG Conflicting) (NNS results)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (VBG regarding) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1) (NNS supplements))) (PP (IN on) (NP (NP (JJ glycemic) (NN control)) (PP (IN in) (NP (NP (NNS non-diabetics)) (PP (IN with) (NP (NN glucose) (NN intolerance)))))))) (, ,) (CC and) (NP (NP (DT those)) (PP (IN with) (NP (NN type) (CD 2) (NNS diabetes))))))))))) (. .)))
(S1 (S (S (NP (DT Some) (JJ early) (NNS studies)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NN drug1) (NNS supplements)) (VP (MD might) (VP (VB have) (NP (JJ detrimental) (NNS effects)) (PP (IN in) (NP (DT those) (NNS groups))))))))) (. .)))
(S1 (S (S (NP (JJ Recent) (, ,) (ADJP (RBR better) (VBN designed)) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN reported) (NP (DT these) (JJ adverse) (NNS effects))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (DT no) (NN evidence) (SBAR (IN that) (S (NP (NN drug1) (NNS supplements)) (VP (VBP have) (NP (JJ detrimental) (NNS effects)) (PP (IN on) (NP (NP (NP (NN glucose) (NN tolerance)) (, ,) (NP (NN insulin) (NN secretion)) (CC or) (NP (NN insulin) (NN resistance))) (PP (IN in) (NP (JJ non-diabetic) (NNS subjects))))))))))) (. .)))
(S1 (S (S (NP (NN Diabetics)) (VP (MD should) (VP (VP (VBP discuss) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT these) (NNS supplements))) (PP (IN with) (NP (PRP$ their) (NNS physicians))))) (CC and) (VP (VB note) (SBAR (IN if) (S (NP (DT the) (NNS supplements)) (VP (VBP affect) (NP (PRP$ their) (JJ glycemic) (NN control))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Diabetics)) (SBAR (WHNP (WP who)) (S (VP (VBP take) (NP (NN drug1) (NNS supplements)))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN by) (NP (PRP$ their) (NNS physicians))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN advised) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ concomitant) (JJ high-dose) (NN drug1)) (CC and) (NP (NN drug2)))))) (, ,) (SBAR (IN as) (S (NP (NP (NN anorexia)) (, ,) (NP (NN tachypnea)) (, ,) (NP (NN lethargy)) (CC and) (NP (NN coma))) (VP (VBP have) (VP (VBN been) (ADVP (RB rarely)) (VP (VBN reported) (PP (JJ due) (TO to) (NP (DT a) (JJ possible) (NN drug) (NN interaction))))))))))) (. .)))
(S1 (S (NP (DT No) (JJ specific) (NN information) (JJ available))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB influence) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Carcinogenesis)) (, ,) (NP (NN Mutagenesis)) (, ,) (NP (NP (NN Impairment)) (PP (IN of) (NP (NN Fertility) (NN No))))) (JJ long-term) (NN carcinogenicity) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN carried) (PRT (RP out)) (PP (IN with) (NP (NP (NN drug1)) (PP (IN in) (NP (NNS animals))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBD was) (RB not) (ADJP (JJ mutagenic) (PP (IN in) (NP (DT the) (NN Ames) (NN test))))) (CC but) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (JJ clastogenic) (PP (PP (TO to) (NP (NP (JJ human) (NNS lymphocytes)) (ADVP (FW in) (FW vitro)))) (CC and) (PP (TO to) (NP (NP (NN mouse) (NN bone) (NN marrow)) (NNS erythrocytes)))) (ADVP (FW in) (FW vivo)) (PRN (-LRB- -LRB-) (NP (NN micronucleus) (NN test)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ possible) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN fertility)) (PP (IN of) (NP (NP (NP (NNS humans)) (CC and) (NP (JJ experimental) (NNS animals))) (, ,) (ADJP (ADJP (JJ male)) (CC or) (ADJP (JJ female))) (, ,)))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB adequately)) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (JJ Testicular) (NN atrophy)) (VP (VBD was) (VP (VBN seen) (PP (IN with) (NP (NN drug1) (NN administration))) (PP (IN at) (NP (NP (NNS doses)) (ADJP (RB as) (JJ low) (PP (IN as) (NP (NP (NP (NP (CD 30) (NN mg/kg) (RB weekly)) (PP (IN for) (NP (NP (CD 6) (NNS weeks)) (PP (IN in) (NP (NP (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD 1/3)) (NP (NP (DT the) (JJ human) (NN dose)) (PP (IN on) (NP (DT a) (NN mg/m) (CD 2) (NN basis))))) (-RRB- -RRB-))))))) (CC and) (NP (NP (QP (RB as) (JJ low) (IN as) (CD 20)) (NN mg/kg)) (ADVP (RB weekly)))) (PP (IN for) (NP (NP (CD 13) (NNS weeks)) (PP (IN in) (NP (NP (NNS dogs)) (PRN (-LRB- -LRB-) (ADJP (RB approximately) (JJ equal) (PP (TO to) (NP (NP (DT the) (JJ human) (NN dose)) (PP (IN on) (NP (DT a) (NN mg/m) (CD 2) (NN basis)))))) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Persons)) (VP (VBG taking) (NP (NP (JJ most) (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBP invalidate) (NP (NP (NN drug4)) (CC and) (NP (NN drug5) (JJ diagnostic) (NN blood) (NNS assays))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ drug1) (NN drug2)) (CC and) (NP (JJ heavy) (NN drug3) (NN intake))) (PP (IN for) (NP (QP (JJR longer) (IN than) (CD 2)) (NNS weeks)))) (VP (MD may) (VP (VB produce) (NP (NP (NN malabsorption)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (DT No) (NNS drugs)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN conversion)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (S (NP (NN Conversion)) (VP (MD could) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN phosphatase) (NN activity))))))))))) (, ,) (CC but) (S (PP (IN given) (NP (NP (DT the) (NP (NN abundance)) (CC and) (NP (JJ wide) (NN distribution))) (PP (IN of) (NP (NNS phosphatases))) (PP (IN in) (NP (DT the) (NN body))))) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unlikely) (SBAR (IN that) (S (NP (NNS drugs)) (VP (MD would) (VP (VB affect) (NP (NP (DT this) (NN activity)) (SBAR (ADVP (RB enough)) (S (VP (TO to) (VP (VB affect) (NP (NP (NN conversion)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NN drug2))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (VP (ADVP (RB highly)) (VBN bound) (PP (TO to) (NP (NN albumin))))) (VP (MD could) (VP (VB increase) (NP (NP (DT the) (JJ unbound) (NN fraction)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (, ,) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unknown)) (SBAR (IN whether) (S (NP (DT this)) (VP (MD could) (VP (VB result) (PP (IN in) (NP (ADJP (RB clinically) (JJ significant)) (NNS effects)))))))))) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN advised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (ADVP (RB significantly)) (VP (VBP bind) (PP (TO to) (NP (NN serum) (NN albumin)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (NNS pharmacokinetics)) (CC and) (NP (NN protein) (NN binding))) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))) (VP (VBD were) (RB not) (VP (VBN altered)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug4)) (CC and) (NP (NN drug5))) (VP (VBD were) (ADVP (RB concurrently)) (VP (VBN administered) (PP (IN in) (NP (JJ single) (JJ submaximal) (NNS doses))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (ADJP (RBS most) (JJ significant)) (NN drug) (NNS interactions)) (VP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug1)))))) (VP (VBP are) (VP (VBN expected) (S (VP (TO to) (VP (VB occur) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP interact) (PP (IN with) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ is) (ADVP (RB extensively)) (VP (VBN bound) (PP (TO to) (NP (NN serum) (NN plasma) (NNS proteins))))) (CC and) (VP (VBZ is) (ADJP (JJ prone) (PP (TO to) (NP (JJ competitive) (NN displacement))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (JJ hepatic) (NN cytochrome) (NN P450) (NNS enzymes))))) (CC and) (VP (VBZ is) (ADJP (RB particularly) (JJ susceptible) (PP (TO to) (NP (JJ inhibitory) (NN drug) (NNS interactions)))) (SBAR (IN because) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ subject) (PP (TO to) (NP (JJ saturable) (NN metabolism)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN metabolism)))) (VP (MD may) (VP (VP (VB produce) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (VBG circulating) (NN drug1) (NNS concentrations))))) (CC and) (VP (VB enhance) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug) (NN toxicity)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (NN inducer)) (PP (IN of) (NP (JJ hepatic) (JJ drug-metabolizing) (NNS enzymes)))))) (. .)))
(S1 (S (ADVP (DT The) (RBS most) (RB commonly)) (VP (VBG occurring) (S (NP (NN drug) (NNS interactions)) (VP (VBP are) (VP (VBN listed) (PP (IN below) (NP (UCP (: :) (: -) (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB increase) (S (NP (NN plasma) (NN drug1) (NNS concentrations)) (VP (VBP include) (: :) (NP (NP (NP (JJ acute) (NN drug2) (NN intake)) (, ,) (NP (NN drug3)) (, ,) (NP (NN chboramphenicol)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (CD drug10))) (, ,) (NP (NN drug11)) (, ,) (QP (CD drug12) (, ,) (CD drug13) (, ,) (CD drug14) (, ,) (CD drug15) (, ,) (CD drug16) (, ,) (CD drug17) (, ,) (CD drug18) (, ,) (CD drug19) (, ,) (CD drug20) (, ,) (CD drug21)))))))))) (, ,)) (NN drug22)))))))))
(S1 (S (. .)))
(S1 (S (CC -) (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB decrease) (NP (NN plasma) (NN drug1) (NNS concentrations))))))) (VP (VBP include) (: :) (NP (NP (NN drug2)) (, ,) (NP (JJ chronic) (NN drug3) (NN abuse)) (, ,) (NP (NN drug4))))))
(S1 (S (. .)))
(S1 (S (S (NP (NP (CC -) (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (ADVP (RB either)) (VP (VP (VB increase)) (CC or) (VP (VB decrease) (NP (NN plasma) (NN drug1) (NNS concentrations)))))))) (VP (VBP include) (: :) (NP (NP (NN drug2)) (, ,) (NP (JJ vaiproic) (NN acid)) (, ,) (CC and) (NP (NN drug3))))) (. .)))
(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN sodium)) (NP (NN plasma) (NN drug4) (NNS concentrations))))) (VP (VBP are) (NP (NN unpredictable)))))
(S1 (S (. .)))
(S1 (S (CC -) (SBAR (IN Although) (FRAG (RB not) (NP (DT a) (JJ true) (NN drug) (NN interaction)))) (, ,) (S (S (NP (NN drug1)) (VP (MD may) (VP (VB precipitate) (NP (NP (NNS seizures)) (PP (IN in) (NP (JJ susceptible) (NNS patients))))))) (CC and) (S (NP (NN drug2) (NN dosage)) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN adjusted)))))))))))
(S1 (S (. .)))
(S1 (S (NP (NP (CC -) (NNS Drugs)) (SBAR (WHNP (WP$ whose) (NN efficacy)) (S (VP (VBZ is) (VP (VBN impaired) (PP (IN by) (NP (NP (NP (NN drug1)) (VP (VBP include))) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (JJ oral) (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (NN drug13))))))))) (. .))))
(S1 (S (S (NP (NP (NN Monitoring)) (PP (IN of) (NP (NN plasma) (NN drug1) (NNS concentrations)))) (VP (MD may) (VP (VB be) (ADJP (JJ helpful) (SBAR (WHADVP (WRB when)) (S (NP (JJ possible) (NN drug) (NNS interactions)) (VP (VBP are) (VP (VBN suspected))))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (NP (NN drug1))) (VP (MD may) (VP (VB decrease) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (CD 14))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (MD may) (ADVP (RB also)) (VP (VB produce) (NP (ADJP (RB artifactually) (JJ low)) (NNS results)) (PP (IN in) (NP (NP (NN dexamethasone)) (CC or) (NP (NN metyrapone) (NNS tests))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB also)) (VP (VB cause) (NP (NP (VBN increased) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NN glucose)) (, ,) (NP (NN alkaline) (NN phosphatase)) (, ,) (CC and) (NP (NP (NN gamma) (NN glutamyl) (NN transpeptidase)) (PRN (-LRB- -LRB-) (NP (NN GGT)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NN Care)) (VP (MD should) (VP (VB be) (VP (VBN taken) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (JJ immunoanalytical) (NNS methods)) (S (VP (TO to) (VP (VB measure) (NP (NN plasma) (NN drug1) (NNS concentrations)) (PP (VBG following) (NP (NN drug2) (NN administration))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (NN Administration)) (PP (IN of) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))) (PP (IN in) (NP (NP (NP (NNS patients)) (PRN (-LRB- -LRB-) (NP (NN n=13)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (CD n=96)) (-RRB- -RRB-)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (ADJP (JJ rapid)) (CC and) (ADJP (JJ significant))) (NN decrease)) (PP (IN in) (NP (NN plasma) (NP (NP (NN M1)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (JJ active) (NN metabolite)) (PP (IN of) (NP (NN drug5)))) (-RRB- -RRB-))) (NN concentration))))))) (. .)))
(S1 (S (S (NP (NP (JJ Hepatotoxic) (NNS Drugs)) (VBN Increased) (NN side) (NNS effects)) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ hepatotoxic) (NNS substances)))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ is) (ADVP (RB also)) (S (VP (TO to) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1) (NN treatment)) (VP (VBZ is) (VP (VBN followed) (PP (IN by) (NP (JJ such) (NNS drugs))) (PP (IN without) (NP (DT a) (NN drug) (NN elimination) (NN procedure))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (ADJP (ADJP (JJ small)) (PRN (-LRB- -LRB-) (NP (NN n=30)) (-RRB- -RRB-))) (NN combination) (NN study)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2))))) (, ,) (NP (NP (DT a) (ADJP (CD 2-) (TO to) (JJ 3-fold)) (NN elevation)) (PP (IN in) (NP (NN liver) (NNS enzymes)))) (VP (VBD was) (VP (VBN seen) (PP (IN in) (NP (NP (CD 5)) (PP (IN of) (NP (CD 30) (NNS patients)))))))) (. .)))
(S1 (S (S (NP (DT All) (NNS elevations)) (VP (VBN resolved) (, ,) (NP (NP (NP (CD 2)) (PP (IN with) (NP (NP (NN continuation)) (PP (IN of) (NP (DT both) (NNS drugs)))))) (CC and) (NP (NP (CD 3)) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (DT A) (JJ 3-fold) (NN increase)) (VP (VBD was) (VP (VBN seen) (PP (IN in) (NP (DT another) (CD 5) (NNS patients)))))) (. .)))
(S1 (S (S (NP (NP (DT All)) (PP (IN of) (NP (DT these)))) (ADVP (RB also)) (VP (VBN resolved) (, ,) (NP (NP (NP (CD 2)) (PP (IN with) (NP (NP (NN continuation)) (PP (IN of) (NP (DT both) (NNS drugs)))))) (CC and) (NP (NP (CD 3)) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (CD Three) (NNS patients)) (VP (NN met) (NP (NP (NN ACR) (NNS criteria)) (PP (IN for) (NP (NP (NN liver) (NN biopsy)) (PRN (-LRB- -LRB-) (NP (CD 1)) (: :) (NP (NP (NN Roegnik) (NN Grade) (CD I)) (, ,) (NP (CD 2)) (: :) (NP (NP (NNP Roegnik) (NN Grade)) (NP (NN IIIa)))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ pharmacokinetic) (NN interaction)) (VP (VBD was) (VP (VBN identified)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (ADJP (FW in) (FW vitro)) (NNS studies))) (, ,) (NP (NN M1)) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB cause) (NP (NP (NNS increases)) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 13) (TO -) (CD 50)) (NN %))) (PP (IN in) (NP (NP (DT the) (JJ free) (NN fraction)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN in) (NP (DT the) (JJ clinical) (NN range))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN finding)))) (VP (VBZ is) (ADJP (JJ unknown)))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (S (NP (EX there)) (VP (VBD was) (NP (NP (JJ extensive) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (JJ clinical) (NNS studies)))))) (CC and) (S (NP (DT no) (JJ differential) (NN effect)) (VP (VBD was) (VP (VBN observed))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (ADJP (FW in) (FW vitro)) (NNS studies))) (, ,) (NP (NN M1)) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB cause) (NP (NP (NNS increases)) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 13) (TO -) (CD 50)) (NN %))) (PP (IN in) (NP (NP (DT the) (JJ free) (NN fraction)) (PP (IN of) (NP (NN drug2))))) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN in) (NP (DT the) (JJ clinical) (NN range))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN finding)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (VBG Following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug2))))) (PP (TO to) (NP (NP (NNS subjects)) (VP (VBG receiving) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NN drug3))))))))) (, ,) (NP (NN M1) (NN peak) (NNS levels)) (VP (VBD were) (VP (VBN increased) (PRN (-LRB- -LRB-) (NP (CD ~40) (NN %)) (-RRB- -RRB-)) (PP (IN over) (NP (NP (DT those)) (VP (VBN seen) (SBAR (WHADVP (WRB when)) (S (NP (NN drug4)) (VP (VBD was) (VP (VBN given) (ADVP (RB alone)))))))))))) (. .))))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN drug1) (NNS levels))) (S (VP (TO to) (VP (VBP continue) (S (VP (TO to) (VP (VB increase) (PP (IN with) (NP (JJ multiple) (NN dosing)))))))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (IN if) (S (NP (NNS patients)) (VP (VBP are) (S (VP (TO to) (VP (VB be) (VP (VBG receiving) (NP (CC both) (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (NP (VBN Increased) (NN INR)) (PRN (-LRB- -LRB-) (NP (NP (NNP International)) (VBN Normalized) (NN Ratio)) (-RRB- -RRB-))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBD were) (VP (VBN co-administered))))))) (VP (VBZ has) (VP (VBN been) (ADVP (RB rarely)) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN potential)) (PP (IN for) (NP (NP (ADJP (RB clinically) (JJ significant)) (JJ drug-drug) (NNS interactions)) (VP (VBN posed) (PP (IN by) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (ADJP (JJ low) (PP (IN for) (NP (NP (NNS drugs)) (VP (ADVP (RB commonly)) (VBN used) (PP (IN in) (NP (NP (NN chemotherapy)) (CC or) (NP (NN surgery))))))))))) (, ,) (SBAR (IN because) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN eliminated) (PP (IN by) (NP (JJ multiple) (NNS routes))))))))) (. .)))
(S1 (S (S (NP (NP (NN Blood) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (VP (VBD increased) (NP (CD 24) (NN %)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (JJ nonselective) (NN inhibitor)) (PP (IN of) (NP (NN cytochrome) (NN P-450)))) (-RRB- -RRB-))) (PP (IN for) (NP (CD 7) (NNS days)))))))))) (, ,) (CC and) (VP (VBD decreased) (NP (CD 28) (NN %)) (PP (IN with) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug4))))) (PRN (-LRB- -LRB-) (NP (NP (JJ potent) (NN inducer)) (PP (IN of) (NP (NN cytochrome) (NN P-450)))) (-RRB- -RRB-)) (PP (IN for) (NP (CD 7) (NNS days)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (ADVP (RB safely)) (VP (VBN coadministered) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN used) (PP (IN in) (NP (NP (NN chemotherapy)) (CC and) (NP (NN surgery))))))))))) (. .)))
(S1 (S (S (PP (IN As) (PP (IN with) (NP (NP (JJ other) (NNS agents)) (SBAR (WHNP (WDT which)) (S (VP (VBP prolong) (NP (NN ECG) (NNS intervals)))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP prolong) (NP (NP (NN ECG) (NNS intervals)) (, ,) (ADVP (RB particularly)) (NP (NN QTc)))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (PP (VBG taking) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (JJ various) (NN chemotherapy) (NNS agents)))))) (, ,) (NP (DT no) (NN effect)) (VP (VBD was) (VP (VBN shown) (PP (IN on) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug8)))))))) (. .)))
(S1 (S (S (NP (NP (NN Clearance)) (PP (IN of) (NP (NN drug1)))) (VP (VBD decreased) (PP (IN by) (NP (QP (RB about) (CD 27)) (NN %))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN administered) (ADVP (RB intravenously)) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB influence) (NP (NP (NN anesthesia) (NN recovery) (NN time)) (PP (IN in) (NP (NNS patients))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB inhibit) (NP (NP (DT the) (JJ antitumor) (NN activity)) (PP (IN of) (NP (NP (CD four) (NNS drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-)))) (PP (IN in) (NP (CD four) (JJ murine) (NNS models))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NN pancreatitis)))))))))))) (VP (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (DT this) (NN toxicity)))) (PRN (-LRB- -LRB-) (S (VP (VB see) (NP (NNS WARNINGS)))) (-RRB- -RRB-)))) (CC and) (VP (MD should) (VP (VB be) (VP (VBN done) (PP (IN with) (NP (JJ extreme) (NN caution))) (, ,) (SBAR (SBAR (RB only) (IN if) (S (NP (JJ other) (NNS alternatives)) (VP (VBP are) (RB not) (ADJP (JJ available))))) (, ,) (CC and) (SBAR (RB only) (IN if) (S (ADVP (RB clearly)) (VP (VBN indicated)))))))))) (. .)))
(S1 (S (S (S (NP (NN Neuropathy)) (VP (VBZ has) (VP (VBN occurred) (ADVP (RBR more) (RB frequently)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN neuropathy)))) (CC or) (NP (JJ neurotoxic) (NN drug) (NN therapy)))) (, ,) (PP (VBG including) (NP (NN drug1)))))))) (, ,) (CC and) (S (NP (DT these) (NNS patients)) (VP (MD may) (VP (VB be) (PP (IN at) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NN neuropathy))))) (PP (IN during) (NP (NP (NN drug2) (NN therapy)) (PRN (-LRB- -LRB-) (S (VP (VB see) (NP (JJ ADVERSE) (NNS REACTIONS)))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN AUC)) (PP (IN of) (NP (NN drug2)))) (VP (VBD was) (VP (VBN increased) (ADVP (RB about) (RB 4-fold)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug3)) (PP (IN at) (NP (CD 300) (NN mg/day)))) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (NP (DT a) (JJ single) (NN 200-mg) (NN dose)) (PP (IN of) (NP (NN drug4))) (PP (TO to) (NP (NP (CD two) (NNS patients)) (PP (IN with) (NP (NP (JJ renal) (NN impairment)) (PRN (-LRB- -LRB-) (NP (QP (CD CLcr=15) (CC and) (CD 18)) (NN mL/min)) (-RRB- -RRB-))))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NN drug2) (NNS pharmacokinetics)) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN with) (NP (JJ normal) (JJ renal) (NN function)))))))) (VP (VBP are) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NNS drug2)) (VP (VBG containing) (NP (NP (NP (NN drug3)) (CC or) (NP (NN drug4))) (PP (IN with) (NP (NN drug5) (NP (JJ Chewable/Dispersible) (JJ Buffered) (NNS Tablets)) (CC or) (NP (JJ Pediatric) (NN Powder)))) (PP (IN for) (NP (JJ Oral) (NN Solution)))))))) (VP (MD may) (VP (VB potentiate) (NP (NP (JJ adverse) (NNS events)) (VP (VBN associated) (PP (IN with) (NP (DT the) (NN drug6) (NNS components)))))))) (. .))))
(S1 (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WP$ Whose) (NN Absorption)) (S (VP (MD Can) (VP (VB Be) (VP (VBN Affected) (PP (IN by) (NP (NP (DT the) (NN Level)) (PP (IN of) (NP (NN Acidity))) (PP (IN in) (NP (DT the) (NN Stomach))))))))))) (: :) (S (NP (NP (NNS Drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD should) (VP (VB be) (VP (VBN administered) (ADVP (NP (QP (IN at) (JJS least) (CD 2)) (NNS hours)) (RB prior) (PP (TO to) (NP (NN dosing)))) (PP (IN with) (NP (NN drug3))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NN drug2) (CD 2) (NNS hours)) (ADVP (ADVP (RB prior)) (TO to) (CC or) (ADVP (JJ concurrent) (PP (IN with) (NP (JJ oral) (NN drug3)))))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN 111) (-LRB- -LRB-) (CD 114) (-RRB- -RRB-) (NN %) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ steady-state) (NN AUC)) (PP (IN of) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 12)) (-RRB- -RRB-))))))))))) (. .))))
(S1 (S (S (NP (NP (DT A) (ADJP (CD 21) (-LRB- -LRB-) (CD 17) (-RRB- -RRB-) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (DT the) (JJ steady-state) (NN AUC)) (PP (IN of) (NP (NN drug1)))))) (VP (VBD was) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN administered) (ADVP (NP (CD 2) (NNS hours)) (RB prior) (PP (TO to) (NP (NN drug3))))))))) (, ,) (SBAR (CONJP (CC but) (RB not)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (CD two) (NNS drugs)) (VP (VBD were) (VP (VBN administered) (ADVP (RB simultaneously)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 12)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (NP (NP (NN drug1) (NNS s)) (: :) (S (NP (NN drug2)) (VP (MD should) (VP (VB be) (VP (VBN administered) (NP (NP (NP (QP (IN at) (JJS least) (CD 2)) (NNS hours)) (PP (IN after))) (CC or) (NP (NP (CD 6) (NNS hours)) (PP (IN before) (NP (NP (NN dosing)) (PP (IN with) (NP (NN drug3))))))) (SBAR (IN because) (S (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug4)))) (VP (VBP are) (VP (VBN decreased) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NP (NN drug5)) (VP (VBG containing) (NP (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC or) (NP (NN drug8))))))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (CD eight) (JJ HIV-infected) (NNS patients))) (, ,) (NP (NP (DT the) (JJ steady-state) (NN AUC)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN decreased) (NP (NP (DT an) (JJ average) (IN of) (CD 26) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN CI) (JJ =) (CD 14) (NN %) (, ,) (CD 37) (NN %)) (-RRB- -RRB-)))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN administered) (ADVP (NP (CD 2) (NNS hours)) (RB prior) (PP (TO to) (NP (NP (DT a) (VBN marketed) (NN chewable/dispersible) (NN tablet) (NN formulation)) (PP (IN of) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN AUC)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN decreased) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (JJ 15-fold)))) (PP (IN in) (NP (NP (CD 12) (JJ healthy) (NNS subjects)) (PP (IN given) (NP (NP (NN drug2)) (CC and) (NP (NP (NN drug3) (NN -placebo) (NNS tablets)) (ADVP (RB concurrently)))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (JJ single) (NN subject)) (VP (VBN given) (NP (NP (CD one) (NN dose)) (PP (IN of) (NP (NN drug1) (CD 2) (NNS hours)))) (PP (IN after) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NN drug2) (NN -placebo) (NNS tablets)))))))) (, ,) (NP (NP (DT a) (ADJP (QP (JJR greater) (IN than) (CD 50)) (NN %)) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug3)))))) (VP (VBD was) (VP (VBN observed))) (. .)))
(S1 (S (S (NP (NP (NN Plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (VP (VBN decreased) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NP (NN drug2)) (VP (VBG containing) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ optimal) (NN dosing) (NN interval)) (PP (IN for) (NP (NP (NN coadministration)) (PP (IN with) (NP (NN drug1)))))) (VP (MD should) (VP (VB be) (VP (VBN determined) (PP (IN by) (S (VP (VBG consulting) (NP (DT the) (JJ appropriate) (NN drug2) (NN package) (NN insert))))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Interactions)) (PP (IN with) (NP (JJ Other) (NN drug1)))) (: :) (S (NP (NP (JJ Significant) (NNS decreases)) (PP (IN in) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 84) (NN %)) (-RRB- -RRB-)))))))) (VP (VBD occurred) (PP (VBG following) (NP (NP (JJ simultaneous) (NN administration)) (PP (IN of) (NP (DT these) (NNS agents))) (PP (IN with) (NP (NN drug4))))))) (. .))))
(S1 (S (S (VP (TO To) (VP (VB avoid) (NP (DT this) (NN interaction))))) (, ,) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (VP (MD should) (VP (VB be) (PP (IN given) (NP (CD 1) (NN hour))) (ADVP (ADVP (RB prior)) (PP (TO to) (NP (NP (NN dosing)) (PP (IN with) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (RB not) (VP (VBN altered) (PP (TO to) (NP (NP (DT a) (ADJP (RB clinically) (JJ significant)) (NN degree)) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (DT a) (JJ light) (NN meal))) (PP (NP (CD 1) (NN hour)) (IN after) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (JJ other) (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (PP (IN during) (NP (NN drug4) (NN treatment))))))) (. .)))
(S1 (S (S (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (NNS Increases)) (PP (IN in) (NP (NP (NN lymphocyte) (NNS counts)) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (JJ pharmacologic) (NN mechanism)) (PP (IN of) (NP (NN action))))))))) (VP (VBP are) (ADVP (RB frequently)) (VP (VBN observed) (PP (IN during) (NP (NN drug1) (NN treatment)))))) (. .)))
(S1 (S (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (DT another) (NN TNF) (NN -blocking) (NN agent)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (DT an) (NN drug3)) (-RRB- -RRB-)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ serious) (NNS infections))))))))) (, ,) (CC and) (S (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NP (NN neutropenia)) (CC and) (NP (DT no) (JJ additional) (NN benefit))))) (VP (VBN compared) (PP (TO to) (NP (DT these) (JJ medicinal) (NNS products))) (ADVP (RB alone))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Other) (NNS drug1)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (NN drug2))) (-RRB- -RRB-))) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug3))))))) (VP (MD may) (ADVP (RB also)) (VP (VB result) (PP (IN in) (NP (JJ similar) (NNS toxicities)))))) (. .)))
(S1 (S (S (NP (NP (JJ Specific) (NN drug) (NN interaction) (NNS studies)) (, ,) (PP (VBG including) (NP (NP (NNS interactions)) (PP (IN with) (NP (NN drug1))))) (, ,)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NP (JJ rheumatoid) (NN arthritis)) (CC or) (NP (NN Crohn) (NN s) (NN disease)) (NP (JJ clinical) (NNS studies))))))) (VP (VBD received) (NP (QP (CD one) (CC or) (JJR more)) (JJ concomitant) (NNS medications)))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ rheumatoid) (NN arthritis))) (, ,) (NP (NP (JJ concomitant) (NNS medications)) (PP (IN besides) (NP (NN drug1)))) (VP (VBD were) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and/or) (NP (NN drug5))))) (. .)))
(S1 (S (NP (NP (JJ Concomitant) (NN Crohn) (NN s) (NN disease)) (NNS medications)) (VP (VBD were) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (: /) (NP (NN drug5)) (CC and) (NP (NN aminosalicylates)))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ psoriatic) (NN arthritis)) (JJ clinical) (NNS trials))) (, ,) (NP (JJ concomitant) (NNS medications)) (VP (VBD included) (NP (NP (NN drug1)) (PP (IN in) (NP (NP (NP (RB approximately) (NN half)) (PP (IN of) (NP (DT the) (NNS patients)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NN Crohn) (NN s) (NN disease))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN drug1)))))) (VP (VBD tended) (S (VP (TO to) (VP (VBP experience) (NP (JJR fewer) (NN infusion) (NNS reactions)) (PP (VBN compared) (PP (TO to) (NP (NP (NNS patients)) (PP (IN on) (NP (NN no) (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NN Serum) (NN drug1) (NNS concentrations)) (VP (VBD appeared) (S (VP (TO to) (VP (VB be) (VP (VBN unaffected) (PP (IN by) (NP (NP (NN baseline) (NN use)) (PP (IN of) (NP (NNS medications))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN Crohn) (NN s) (NN disease)) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (NN drug4)) (CC or) (NP (NN drug5))) (-RRB- -RRB-))) (CC and) (NP (NNS aminosalicylates)))))))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN given) (ADVP (RB concurrently))))) (NP (DT the) (JJ following) (NNS drugs)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN drug1)))))) (. .)))
(S1 (S (NP (NP (CC -) (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC or) (NP (NN drug3))) (: :) (S (NP (NP (NN Potentiation)) (PP (IN of) (NP (JJ otthostatic) (NN hypotension)))) (VP (MD may) (VP (VB occur)))))))
(S1 (S (. .)))
(S1 (S (NP (NP (CC -) (NP (NP (NN drug1) (: :)) (PRN (-LRB- -LRB-) (NP (NP (JJ Oral) (NNS agents)) (CC and) (NP (NN drug2))) (-RRB- -RRB-))) (NN Dosage) (NN adjustment)) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (MD may) (VP (VB be) (VP (VBN required))))))
(S1 (S (. .)))
(S1 (S (NP (CC -) (NP (JJ Other) (NN drug1)) (: :) (NP (JJ Additive) (NN effect)) (CC or) (NP (NN potentiation)))))
(S1 (S (. .)))
(S1 (S (NP (NP (CC -) (NP (NN drug1)) (CC and) (NP (NN drug2) (NN drug3))) (: :) (S (NP (NP (NN drug4)) (CC and) (NP (NN drug5) (NN drug6))) (VP (VP (VBP have) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (NN binding) (NN drug7))))) (CC and) (VP (VBG reducing) (NP (NP (NN drug8) (NN absorption)) (PP (IN from) (NP (DT the) (JJ gastrointestinal) (NN tract))))))))))
(S1 (S (. .)))
(S1 (S (NP (NP (CC -) (NP (NN drug1)) (, ,) (NP (NN drug2)) (: :) (NP (JJ Intensified) (NN electrolyte) (NN depletion))) (, ,) (NP (ADVP (RB particularly)) (NP (NN hypokalemia))))))
(S1 (S (. .)))
(S1 (S (UCP (CC -) (NP (NP (NP (JJ Pressor) (NNS amines)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (-RRB- -RRB-))) (: :) (NP (JJ Possible) (VBN decreased) (NN response)) (TO to) (NP (JJ pressor) (NNS amines))) (CC but) (ADJP (RB not) (JJ sufficient) (S (VP (TO to) (VP (VB preclude) (NP (PRP$ their) (NN use)))))))))
(S1 (S (. .)))
(S1 (S (NP (NP (NP (CC -) (NP (NN drug1)) (, ,) (NP (NN nondepolarizing))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (NP (NP (JJ Possible) (VBN increased) (NN responsiveness)) (PP (TO to) (NP (DT the) (NN drug3)))))))
(S1 (S (. .)))
(S1 (S (S (S (: -) (NP (NN drug1))) (: :) (S (ADVP (RB Generally)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBP reduce) (NP (NP (DT the) (JJ renal) (NN clearance)) (PP (IN of) (NP (NN drug2))))) (CC and) (VP (VBP add) (NP (NP (DT a) (JJ high) (NN risk)) (PP (IN of) (NP (NN drug3) (NN toxicity))))))) (. .)))
(S1 (S (VP (VBP Refer) (PP (TO to) (NP (NP (DT the) (JJ package) (NN insert)) (PP (IN for) (NP (NN drug1) (NNS preparations))))) (PP (IN before) (NP (NP (NN use)) (PP (IN of) (NP (JJ such) (NNS preparations))) (PP (IN with) (NP (NN drug2))))))))
(S1 (S (. .)))
(S1 (S (NP (NP (CC -) (NN drug1)) (: :) (S (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT a) (NN drug2)))) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (ADJP (ADJP (JJ diuretic)) (, ,) (ADJP (JJ natriuretic)) (, ,) (CC and) (ADJP (JJ antihypertensive))) (NNS effects)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN drug5)))))))) (. .))))
(S1 (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (S (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ desired) (NN effect)) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (VBZ is) (VP (VBN obtained))))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NP (CC -) (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (PP (IN before) (S (VP (VBG carrying) (PRT (RP out)) (NP (NP (NNS tests)) (PP (IN for) (NP (JJ parathyroid) (NN function))))))))))) (. .))))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (VBG following) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (VP (VBN given) (PP (IN with) (NP (NP (NN drug3)) (CC or) (NP (NP (NN drug4)) (CC -) (NP (NN drug5) (NN combination) (NNS products)))))))))))))))) (. .)))
(S1 (S (S (PP (IN For) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))) (, ,) (VP (VB see) (NP (NNS CONTRAINDICATIONS)))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (CC and) (NP (NN drug5))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (JJ therapeutic) (NNS effects)) (PP (IN of) (NP (NN drug6))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (JJ beneficial) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NN Parkinsons) (NN disease)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (VP (VBN reversed) (PP (IN by) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NP (NP (DT these) (NNS drugs)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (CC or) (NP (NP (NP (NN drug3)) (CC -) (NP (NN drug4))) (NN combination) (NNS products))))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN observed) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (JJ therapeutic) (NN response))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS salts)) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ clinical) (NN relevance)) (VP (VBZ is) (ADJP (JJ unclear)))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (S (VP (VBG increasing) (NP (JJ gastric) (NN emptying))))))))) (, ,) (NP (NN drug3)) (VP (MD may) (ADVP (RB also)) (VP (ADVP (RB adversely)) (VP (VBP affect) (NP (NN disease) (NN control)) (PP (IN by) (NP (PRP$ its) (NN dopamine) (NN receptor)))) (NP (JJ antagonistic) (NNS properties))))) (. .)))
(S1 (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB increase) (NP (NN drug1) (NN plasma) (NNS concentrations) (NP (JJ CYP3A4) (NNS Inhibitors)))))))) (: :) (S (NP (NN drug2)) (VP (VBZ is) (NP (DT a) (NN CYP3A4) (NN substrate)))) (. .))))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NP (NN CYP3A4)) (PRN (-LRB- -LRB-) (NP (NN eg)) (, ,) (NP (NN drug2) (, ,) (NN drug3) (, ,) (NN drug4) (, ,) (NN drug5) (, ,) (NN drug6) (, ,) (NN drug7) (, ,) (NN drug8) (, ,) (NN drug9) (, ,) (NN drug10) (, ,) (NN drug11) (, ,) (CD drug12)) (-RRB- -RRB-)))))))))) (VP (VP (MD may) (VP (VB increase) (NP (NP (NN exposure)) (PP (TO to) (NP (NN drug13)))))) (CC and) (VP (MD should) (VP (VB be) (VP (VBN avoided)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug1))))))) (, ,) (NP (NP (JJ close) (NN monitoring)) (PP (IN for) (NP (NP (NN toxicity)) (CC and) (NP (DT a) (NN drug2) (NN dose) (NN reduction))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (IN if) (S (NP (NP (JJ systemic) (NN administration)) (PP (IN of) (NP (DT a) (JJ potent) (NN CYP3A4) (NN inhibitor)))) (VP (MD cannot) (VP (VB be) (VP (VBN avoided)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB decrease) (NP (NN drug1) (NN plasma) (NNS concentrations))))))) (NP (JJ CYP3A4) (NNS Inducers)) (: :) (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NN CYP3A4) (NN activity))))))) (VP (MD may) (VP (VB decrease) (NP (NN drug2) (NN plasma) (NNS concentrations))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (JJ CYP3A4) (NNS inducers)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5))) (-RRB- -RRB-))) (VP (VBP are) (VP (VBN indicated))))))) (, ,) (NP (NP (JJ alternative) (NNS agents)) (PP (IN with) (NP (RBR less) (NN enzyme) (NN induction) (NN potential)))) (VP (MD should) (VP (VB be) (VP (VBN used))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (MD must) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (DT a) (NN CYP3A4) (NN inducer)))))))) (, ,) (NP (NP (DT a) (NN dose) (NN increase)) (PP (IN in) (NP (NN drug2)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (NP (NP (NN St.) (NNP Johns) (NN wort)) (PRN (-LRB- -LRB-) (NP (NN Hypericum) (NN perforatum)) (-RRB- -RRB-))) (VP (MD may) (VP (VB decrease) (NP (NN drug1) (NN plasma) (NNS concentrations)) (ADVP (RB unpredictably))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NN drug1)))) (VP (MD should) (RB not) (VP (VB take) (NP (NN St.) (NNP Johns) (NN wort))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (NN Nonclinical) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (DT the) (NN solubility)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ is) (ADJP (NN pH) (JJ dependent))))))) (. .)))
(S1 (S (S (NP (NP (JJ Simultaneous) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1) (NN therapy)) (VP (VBZ is) (VP (VBN needed))))) (, ,) (NP (DT the) (JJ antacid) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN administered) (ADVP (NP (QP (IN at) (JJS least) (CD 2)) (NNS hours)) (RB prior) (PP (TO to) (NP (CC or) (CD 2) (NNS hours)))) (PP (IN after) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (NP (NP (JJ Long-term) (NN suppression)) (PP (IN of) (NP (JJ gastric) (NN acid) (NN secretion))) (PP (IN by) (NP (NP (NN drug3)) (CC or) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6))) (-RRB- -RRB-))))))) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB reduce) (NP (NN drug7) (NN exposure)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (PP (IN with) (NP (NN drug3)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (NP (NN place)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug4) (NN therapy))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB have) (NP (PRP$ their) (NN plasma) (NN concentration))))))) (VP (VBN altered) (PP (IN by) (NP (NN drug1) (NN CYP3A4) (NNS Substrates))))) (: :) (S (NP (NN drug2)) (VP (VBZ is) (NP (NP (DT a) (JJ time-dependent) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN CYP3A4) (NNS substrates)) (VP (VBN known) (S (VP (TO to) (VP (VB have) (NP (NP (DT a) (JJ narrow) (JJ therapeutic) (NN index)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (CC or) (NP (NN drug11))))) (PRN (-LRB- -LRB-) (NP (CD drug12)) (, ,) (NP (CD drug13)) (-RRB- -RRB-))))))) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug14)))))))) (. .)))
(S1 (S (NP (NP (JJ Hepatic) (NN Impairment)) (S (NP (EX There)) (VP (VBP are) (ADVP (RB currently)) (NP (NP (DT no) (JJ clinical) (NNS studies)) (PP (IN with) (NP (NP (NN drug1)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ impaired) (NN liver) (NN function)) (PRN (-LRB- -LRB-) (S (NP (JJ clinical) (NNS studies)) (VP (VBP have) (VP (VBN excluded) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN ALT)) (CC and/or) (NP (NN AST)) (NP (NP (CD 2.5) (NNS times)) (NP (NP (NP (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (DT the) (JJ normal) (NN range)))) (CC and/or) (NP (NP (JJ total) (NN bilirubin)) (NP (CD 2) (NNS times) (NP (NP (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (DT the) (JJ normal) (NN range)))))))))))))) (-RRB- -RRB-))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Metabolism)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (ADVP (RB mainly)) (ADJP (JJ hepatic)))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN recommended) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ hepatic) (NN impairment)))))))) (. .)))
(S1 (S (NP (NP (JJ Renal) (NN Impairment)) (S (NP (EX There)) (VP (VBP are) (ADVP (RB currently)) (NP (NP (DT no) (JJ clinical) (NNS studies)) (PP (IN with) (NP (NP (NN drug1)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ impaired) (JJ renal) (NN function)) (PRN (-LRB- -LRB-) (S (NP (JJ clinical) (NNS studies)) (VP (VBP have) (VP (VBN excluded) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN serum) (NN creatinine) (NN concentration)) (VP (CD 1.5) (NNS times) (NP (NP (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (DT the) (JJ normal) (NN range))))))))))) (-RRB- -RRB-))))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (PRP$ its) (NNS metabolites))) (VP (VBP are) (ADVP (RB minimally)) (VP (VBN excreted) (PP (IN via) (NP (DT the) (NN kidney)))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (DT the) (JJ renal) (NN excretion)) (PP (IN of) (NP (NP (JJ unchanged) (NN drug1)) (CC and) (NP (PRP$ its) (NNS metabolites))))) (VP (VBZ is) (NP (CD 4) (NN %))))) (, ,) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ total) (NN body) (NN clearance)))) (VP (VBZ is) (RB not) (VP (VBN expected) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ renal) (NN insufficiency)))))))) (. .)))
(S1 (S (S (NP (NN Drug) (NN interaction) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ formal) (JJ drug-drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (NP (DT No) (VBN confirmed) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drugs)))))))))
(S1 (S (S (NP (NN drug1) (NN Inhalation) (NN Aerosol)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (, ,) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))) (, ,) (VP (ADVP (RB commonly)) (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ chronic) (JJ obstructive) (JJ pulmonary) (NN disease)))))))))))) (. .)))
(S1 (S (S (PP (IN With) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (JJ formal) (NNS studies)) (VP (ADVP (RB fully)) (VBG evaluating) (NP (NP (DT the) (NN interaction) (NNS effects)) (PP (IN of) (NP (NP (NN drug2) (NN Inhalation) (NN Aerosol)) (CC and) (NP (NP (DT these) (NNS drugs)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NN effectiveness))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN Although) (S (NP (NN drug2)) (VP (VBZ is) (ADVP (RB minimally)) (VP (VBN absorbed) (PP (IN into) (NP (DT the) (JJ systemic) (NN circulation))))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT some) (NN potential)) (PP (IN for) (NP (NP (DT an) (JJ additive) (NN interaction)) (PP (IN with) (NP (ADJP (RB concomitantly) (VBN used)) (NN drug3)))))))) (. .))))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (ADVP (RB therefore)) (VP (VBN advised) (PP (IN in) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NN drug1) (NN Inhalation) (NN Aerosol))) (PP (IN with) (NP (JJ other) (NN drug2) (JJ -containing) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN treatment)) (PP (IN with) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN rt-PA)) (CC or) (NP (NN drug2))) (-RRB- -RRB-))))) (VP (MD may)) (: :)) (S (VP (TO -) (VP (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ bleeding) (NNS complications))))) (CC -) (ADVP (RB considerably)) (VP (VB enhance) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug3))) (PP (IN on) (NP (NN aPTT) (NN prolongation))))))))))
(S1 (S (S (NP (NP (JJ Concomitant) (NN treatment)) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP affect) (NP (NN platelet) (NN function))))))))) (VP (MD may) (ADVP (RB also)) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ bleeding))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN at) (NP (NN steady-state))) (PP (IN with) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN at) (NP (NN steady-state))) (PP (IN with) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug2)))) (PRN (-LRB- -LRB-) (NP (CD 2) (CC x) (CD 600) (NN mg) (NP (NNS tablets))) (-RRB- -RRB-))))) (VP (VBZ results) (PP (IN in) (NP (VBN increased) (NN drug3) (NN serum) (NNS concentrations))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (NP (DT a) (NN dose) (NN adjustment)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))))))) (, ,) (NP (NP (JJ close) (NN monitoring)) (PP (IN for) (NP (NP (JJ known) (JJ side) (NNS effects)) (PP (IN of) (NP (NN drug3))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN liver) (NN enzyme) (NNS abnormalities)) (CC and) (NP (NN hearing) (NN impairment)))) (, ,)))) (VP (VBZ is) (VP (VBN warranted))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN prothrombin) (NN time) (NN response)) (PP (TO to) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (JJ prudent) (JJ medical) (NN practice)) (VP (VBZ dictates) (NP (NP (JJ careful) (NN monitoring)) (PP (IN of) (NP (NN prothrombin) (NN time))) (PP (IN in) (NP (NP (DT all) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (JJ clinical) (NN practice)))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (JJ anticoagulant) (NNS effects))))))) (. .)))
(S1 (S (S (NP (NN Drug) (NN interaction) (NNS studies)) (VP (VBD were) (VP (VBN performed) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drugs)))) (S (ADVP (RB likely)) (VP (TO to) (VP (VB be) (VP (VBN co-administered)))))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN used) (PP (IN in) (NP (JJ therapeutic) (NNS doses)))))) (, ,) (NP (NN drug1)) (VP (VBD had) (NP (DT a) (JJ modest) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NP (NP (CD drug12)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ intravenous)) (CC and) (ADJP (JJ oral))) (-RRB- -RRB-))) (, ,) (NP (CD drug13)) (, ,) (NP (CD drug14)) (: /) (NP (CD drug15))) (CC or) (NP (NN drug16))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN with) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))) (VP (VBD had) (NP (DT a) (JJ modest) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ dosage) (NN adjustment)) (PP (IN of) (NP (DT either) (NN drug)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB co)) (VP (VBN administered) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ above) (NNS agents)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN with) (NP (NP (DT the) (NNS drugs)) (VP (VBN listed) (PP (IN below)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (JJ clinical) (NNS trials)) (PP (IN with) (NP (NN drug1))))))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (DT no) (JJ specific) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (S (VP (TO to) (VP (VB evaluate) (NP (JJ potential) (JJ drug-drug) (NN interaction))))))))) (. .)))
(S1 (S (S (ADVP (RB Nonetheless)) (, ,) (NP (PRP they)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (SBAR (IN Until) (S (NP (JJ further) (NNS data)) (VP (VBP are) (VP (VBN developed) (S (VP (VBG regarding) (NP (NN drug) (NNS interactions))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (DT these) (NNS drugs))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly))))))))) (, ,) (NP (NP (JJ careful) (NN monitoring)) (PP (IN of) (NP (NNS patients)))) (VP (VBZ is) (ADJP (JJ advised)))) (: :) (S (NP (NN drug2)) (VP (VBD elevated) (NP (NN drug3) (NNS concentrations)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC or) (NP (NN drug2) (JJ acute) (NN ergot) (NN toxicity))) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ severe) (JJ peripheral) (NN vasospasm)) (CC and) (NP (NN dysesthesia)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (NNS concentrations))) (. .)))
(S1 (S (S (NP (NN Laboratory) (NN Test) (NNS Interactions)) (ADVP (RB There)) (VP (VBP are) (NP (DT no) (VBN reported) (NN laboratory) (NN test) (NNS interactions)))) (. .)))
(S1 (S (S (NP (NP (NN Repeat) (NN Treatment) (NNS Studies)) (VP (VBG evaluating) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ repeated) (NNS courses)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NP (JJ Oral) (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP appear) (S (VP (TO to) (VP (VB increase) (NP (NP (NN catabolism)) (PP (IN of) (NP (NN vitamin) (NN K-dependent) (NN clotting) (NNS factors))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (JJ oral) (NN drug1)) (VP (VBP are) (ADVP (RB also)) (VP (VBG being) (VP (VBN given)))))) (, ,) (NP (NP (JJ compensatory) (NNS increases)) (PP (IN in) (NP (JJ clotting) (NN factor) (NN synthesis)))) (VP (VBP are) (VP (VBN impaired)))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Patients)) (VP (VBN stabilized) (PP (IN on) (NP (JJ oral) (NN drug1))))) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBN found) (S (VP (TO to) (VP (VB require) (NP (NN drug2) (NN replacement) (NN therapy)))))))))) (VP (MD should) (VP (VB be) (VP (VBD watched) (ADVP (RB very) (RB closely)) (SBAR (WHADVP (WRB when)) (S (NP (NN thyroid)) (VP (VBZ is) (VP (VBN started))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT a) (NN patient)) (VP (VBZ is) (ADJP (RB truly) (JJ hypothyroid))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ likely) (SBAR (IN that) (S (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN drug1) (NN dosage)))) (VP (MD will) (VP (VB be) (VP (VBN required))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ special) (NNS precautions)) (VP (VBP appear) (S (VP (TO to) (VP (VB be) (ADJP (JJ necessary))) (SBAR (WHADVP (WRB when)) (S (NP (JJ oral) (NN anticoagulant) (NN therapy)) (VP (VBZ is) (VP (VBN begun) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (ADVP (RB already)) (VBN stabilized) (PP (IN on) (NP (NN maintenance) (NN thyroid) (NN replacement) (NN therapy)))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (JJ Oral) (NN drug2))) (: :) (S (NP (VBG Initiating) (NN thyroid) (NN replacement) (NN therapy)) (VP (MD may) (VP (VB cause) (NP (NP (NNS increases)) (PP (IN in) (NP (ADJP (ADJP (JJ drug3)) (CC or) (ADJP (JJ oral))) (NN drug4) (NNS requirements))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (VP (VBN seen))) (VP (VP (VBP are) (VP (ADVP (RB poorly)) (VBN understood))) (CC and) (VP (VB depend) (PP (IN upon) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNS factors)) (PP (JJ such) (IN as) (NP (NP (NP (NP (NP (NN dose)) (CC and) (NP (NN type))) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (JJ endocrine) (NN status))) (PP (IN of) (NP (DT the) (NN patient)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC or) (NP (JJ oral) (NN drug2))))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBD watched) (PP (IN during) (NP (NP (NN initiation)) (PP (IN of) (NP (NN thyroid) (NN replacement) (NN therapy))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ binds) (NP (NP (CC both) (NP (NN drug3)) (CC and) (NP (NN drug4))) (PP (IN in) (NP (DT the) (NN intestine)))) (, ,) (S (ADVP (RB thus)) (VP (VBG impairing) (NP (NP (NN absorption)) (PP (IN of) (NP (DT these) (NNS drug5)))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT the) (NN binding)) (VP (VBZ is) (RB not) (ADVP (RB easily)) (VP (VBN removed))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (QP (CD 4) (TO to) (CD 5)) (NNS hours)) (VP (MD should) (VP (VB elapse) (PP (IN between) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (JJ Oral) (NN drug2) (: :) (NN drug3))) (VP (VBP tend) (S (VP (TO to) (VP (VB increase) (NP (NP (NN serum) (NN thyroxine-binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN TBg)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (DT a) (JJ nonfunctioning) (NN thyroid) (NN gland))) (SBAR (WHNP (WP who)) (S (VP (VBZ is) (VP (VBG receiving) (NP (NN thyroid) (NN replacement) (NN therapy)))))))) (, ,) (NP (JJ free) (NN drug1)) (VP (MD may) (VP (VB be) (VP (VBN decreased) (SBAR (WHADVP (WRB when)) (S (NP (NNS drug2)) (VP (VBP are) (VP (VBN started) (S (ADVP (RB thus)) (VP (VBG increasing) (NP (NN drug3) (NNS requirements)))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (SBAR (IN if) (S (NP (DT the) (NNS patients) (NN thyroid) (NN gland)) (VP (VBZ has) (NP (JJ sufficient) (NN function))))) (, ,) (NP (DT the) (VBN decreased) (JJ free) (NN drug1) (NN e)) (VP (MD will) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ compensatory) (NN increase)) (PP (IN in) (NP (NP (JJ thyroxine) (NN output)) (PP (IN by) (NP (DT the) (NN thyroid)))))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS patients)) (PP (IN without) (NP (DT a) (VBG functioning) (NN drug1) (NN gland))) (SBAR (WHNP (WP who)) (S (VP (VBP are) (PP (IN on) (NP (NN thyroid) (NN replacement) (NN therapy))))))) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB increase) (NP (PRP$ their) (NN thyroid) (NN dose)) (SBAR (IN if) (S (NP (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (JJ -containing) (JJ oral) (NNS drug4)) (VP (VBP are) (VP (VBN given)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Use)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NP (NN drug3)) (CC and) (NP (JJ other) (NNS drug4))))) (VP (MD may) (VP (VP (VP (VB increase) (NP (NN receptor) (NN sensitivity))) (CC and) (VP (VB enhance) (NP (JJ antidepressant) (NN activity)))) (NP (JJ transient) (JJ cardiac) (NNS arrhythmias)))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN activity)) (VP (MD may) (ADVP (RB also)) (VP (VB be) (VP (VBN enhanced))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ toxic) (NNS effects)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NN Thyroid) (JJ hormonal) (NN replacement)) (VP (VBZ increases) (NP (NP (JJ metabolic) (NN rate)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ requires) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ drug1) (NN dosage)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (VP (VBN administered) (PP (TO to) (NP (NNS patients))) (PP (IN on) (NP (DT a) (NN drug2)))))) (, ,) (NP (DT this) (JJ parenteral) (NN drug3)) (VP (MD may) (VP (VB cause) (NP (NP (NN hypertension)) (CC and) (NP (NN tachycardia)))))) (. .))))
(S1 (S (S (NP (NP (NN Use)) (PP (IN with) (NP (NN caution)))) (VP (CC and) (VP (VB be) (VP (VBN prepared) (S (VP (TO to) (VP (VB treat) (NP (NN hypertension))))))) (, ,) (SBAR (IN if) (FRAG (JJ necessary))))) (. .)))
(S1 (S (NP (NP (NN drug1) (NNS s)) (: :) (S (NP (NN drug2)) (VP (VBZ increases) (NP (NP (DT the) (JJ adrenergic) (NN effect)) (PP (IN of) (NP (NP (NNS catecholamines)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN injection)) (PP (IN of) (NP (DT these) (NNS agents))) (PP (IN into) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)))))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (S (VP (VBG precipitating) (NP (JJ coronary) (NN insufficiency)) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ coronary) (NN artery) (NN disease))))))))))) (. .)))
(S1 (S (S (NP (JJ Careful) (NN observation)) (VP (VBZ is) (VP (VBN required)))) (. .)))
(S1 (S (S (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (NP (DT The) (NP (JJ following) (NNS drugs)) (CC or) (NP (NNS moieties)))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (NP (NN laboratory) (NNS tests)) (VP (VBN performed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug1) (NN therapy))))))) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (JJ oral) (NN drug5) (NN containing) (NN drug6)) (, ,) (NP (NN drug7) (JJ -containing) (NNS preparations)) (CC and) (NP (NP (DT the) (JJ numerous) (NNS preparations)) (VP (VBG containing) (NP (NN drug8))))))))))))) (. .)))
(S1 (S (S (NP (NP (CC -) (NNS Changes)) (PP (IN in) (NP (NN TBg) (NN concentration)))) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN into) (NP (NN consideration))) (PP (IN in) (NP (NP (DT the) (NN interpretation)) (PP (IN of) (NP (NP (NP (NN T4)) (CC and) (NP (NN T3))) (NNS values))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ such) (NNS cases))) (, ,) (NP (DT the) (ADJP (ADJP (JJ unbound)) (PRN (-LRB- -LRB-) (ADJP (JJ free)) (-RRB- -RRB-))) (NN hormone)) (VP (MD should) (VP (VB be) (VP (VBN measured))))) (. .)))
(S1 (S (S (NP (NP (NN Pregnancy) (NN drug1)) (CC and) (NP (NN drug2) (JJ -containing) (JJ oral) (NN drug3))) (VP (VBP increase) (NP (NN TBg) (NNS concentrations)))) (. .)))
(S1 (S (S (NP (NN TBg)) (VP (MD may) (ADVP (RB also)) (VP (VB be) (VP (VBN increased) (PP (IN during) (NP (JJ infectious) (NN hepatitis))))))) (. .)))
(S1 (S (S (NP (NP (NNS Decreases)) (PP (IN in) (NP (NN TBg) (NNS concentrations)))) (VP (VBP are) (VP (VBN observed) (PP (PP (IN in) (NP (NP (NN nephrosis)) (, ,) (NP (NN acromegaly)))) (CC and) (PP (IN after) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)) (NP (NN therapy)))))))) (. .)))
(S1 (S (S (NP (JJ Familial) (NP (ADJP (JJ hyper-))) (CC or) (NP (ADJP (JJ hypo-thyroxine-binding-globulinemias)))) (VP (VBP have) (VP (VBN been) (VP (VBN described))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NN TBg) (NN deficiency)))) (VP (VBZ approximates) (NP (NP (CD 1)) (PP (IN in) (NP (CD 9000)))))) (. .)))
(S1 (S (NP (NP (DT The) (NN binding)) (PP (IN of) (NP (NN thyroxine))) (PP (IN by) (NP (NP (JJ thyroxine-binding) (NN prealbumin)) (PRN (-LRB- -LRB-) (NP (NN TBPA)) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP (NN drug1)))))))
(S1 (S (. .)))
(S1 (S (NP (NP (CC -) (NP (NN Medicinal)) (CC or) (NP (NN dietary) (NN drug1))) (VP (VBZ interferes) (PP (IN with) (NP (NP (DT all) (ADJP (FW in) (FW vivo)) (NNS tests)) (PP (IN of) (NP (NN radio-iodine) (NN uptake))) (VP (VBG producing) (NP (NP (JJ low) (NNS uptakes)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (RB not) (VP (VB be) (ADJP (JJ reflective) (PP (IN of) (NP (NP (DT a) (JJ true) (NN decrease)) (PP (IN in) (NP (NN hormone) (NN synthesis))))))))))))))))))
(S1 (S (. .)))
(S1 (S (S (NP (NP (CC -) (DT The) (NN persistence)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ laboratory))) (NN evidence)) (PP (IN of) (NP (NN hypothyroidism))))) (PP (IN in) (NP (NP (NN spite)) (PP (IN of) (NP (JJ adequate) (NN dosage) (NN replacement)))))) (VP (VBZ indicates) (NP (NP (DT either) (JJ poor) (NN patient) (NN compliance)) (, ,) (NP (JJ poor) (NN absorption)) (, ,) (NP (JJ excessive) (NN fecal) (NN loss)) (, ,) (CC or) (NP (NP (NN inactivity)) (PP (IN of) (NP (DT the) (NN preparation))))))) (. .)))
(S1 (S (S (NP (NP (JJ Intracellular) (NN resistance)) (PP (TO to) (NP (NN drug1)))) (VP (VBZ is) (ADJP (RB quite) (JJ rare)))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN injection)) (CC and) (NP (NN drug2))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB simultaneously)) (SBAR (IN because) (S (S (NP (DT both) (NNS drugs)) (VP (VBP are) (NP (JJ direct) (JJ cardiac) (NNS stimulants)))) (CC and) (S (NP (PRP$ their) (JJ combined) (NNS effects)) (VP (MD may) (VP (VB induce) (NP (JJ serious) (NNS arrhythmias))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS drugs)) (VP (MD may) (, ,) (ADVP (RB however)) (, ,) (VP (VB be) (VP (VBN administered) (ADVP (RB alternately)) (VP (VBN provided) (S (NP (DT a) (JJ proper) (NN interval)) (VP (VBZ has) (VP (VBN elapsed) (PP (IN between) (NP (NNS doses))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (, ,) (SBAR (IN if) (S (PP (IN at) (NP (NN all))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ potent) (JJ inhalational) (NNS drug2)) (PP (JJ such) (IN as) (NP (NN drug3)))) (VP (VBP are) (VP (VBN employed) (PP (IN because) (IN of) (NP (NN potential))) (S (VP (TO to) (VP (VB sensitize) (NP (DT the) (NN myocardium)) (PP (TO to) (NP (NP (NNS effects)) (PP (IN of) (NP (NN drug4)))))))))))))))))) (. .)))
(S1 (S (S (S (VP (VBG Taking) (NP (NN drug1)) (PP (IN after) (NP (JJ drinking) (NN drug2))))) (VP (VP (MD may) (VP (VB worsen) (NP (JJ side) (NNS effects)))) (CC and) (VP (MD may) (VP (VB cause) (NP (NP (JJ severe) (NN hypotension)) (CC and) (NP (JJ cardiovascular) (NN collapse))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NN mixing)) (PP (IN of) (NP (DT an) (NN drug1))) (PP (IN with) (NP (NP (JJ beta-lactamtype) (NNS drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (CC or) (NP (NN drug4))) (-RRB- -RRB-))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (DT a) (JJ significant) (JJ mutual) (NN inactivation)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (RB Even) (WRB when)) (S (NP (NP (DT an) (NN drug1)) (CC and) (NP (DT a) (NN drug2) (JJ -type) (NN drug))) (VP (VBP are) (VP (VBN administered) (ADVP (RB separately)) (PP (IN by) (NP (JJ different) (NNS routes))))))) (, ,) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (NN drug3) (NN serum) (NN half-life)) (CC or) (NP (NN serum) (NNS levels))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ impaired) (JJ renal) (NN function))))) (CC and) (PP (IN in) (NP (NP (DT some) (NNS patients)) (PP (IN with) (NP (JJ normal) (JJ renal) (NN function)))))))))) (. .)))
(S1 (S (S (S (ADVP (RB Usually)) (, ,) (NP (NP (JJ such) (NN inactivation)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (VBZ is) (ADJP (RB clinically) (JJ significant) (PP (ADVP (RB only)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (RB severely) (JJ impaired)) (JJ renal) (NN function)))))))) (. .)) (. .)))
(S1 (S (VP (VB See))))
(S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NP (NN drug2)) (SBAR (WHNP (WDT which)) (S (VP (VBZ inhibits) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ pressor) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drug2))))) (VP (MD can) (VP (VB combine) (S (VP (TO to) (VP (VB cause) (NP (JJ dangerous) (NN hypertension)))))))) (. .)))
(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NP (ADJP (ADJP (JJ 0.1-mg/kg)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN x) (NN ED95)) (-RRB- -RRB-))) (NN drug1)) (PP (IN at) (NP (CD 10) (NN %)))) (CC or) (NP (NP (ADJP (CD 95) (NN %)) (NN recovery)) (PP (VBG following) (NP (NP (NP (DT an) (JJ intubating) (NN dose)) (PP (IN of) (NP (NN drug2)))) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-)))))))) (VP (VBD produced) (NP (ADJP (CD 95) (NN %)) (NN neuromuscular) (NN block))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN time)) (PP (TO to) (NP (NP (NN onset)) (PP (IN of) (NP (NP (NN maximum) (NN block)) (PP (VBG following) (NP (NN drug1)))))))) (VP (VBZ is) (ADJP (NP (QP (RB approximately) (CD 2)) (NNS minutes)) (JJR faster) (PP (IN with) (NP (NP (JJ prior) (NN administration)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Prior) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (JJ neuromuscular) (NN block)) (PP (VBG following) (NP (NP (JJ initial) (CC or) (NN maintenance) (NN bolus) (NNS doses)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Infusion) (NNS requirements)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN administered) (ADVP (NP (NN drug2)) (RB prior)) (PP (TO to) (NP (NP (NNS infusions)) (PP (IN of) (NP (NN drug3))))))))))) (VP (VBD were) (ADJP (ADJP (JJ comparable) (PP (TO to))) (CC or) (ADJP (ADJP (RB slightly) (JJR greater)) (PP (IN than) (SBAR (WHADVP (WRB when)) (S (NP (NN drug4)) (VP (VBD was) (RB not) (VP (VBN administered)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN before) (NP (NN drug2))))) (S (VP (TO to) (VP (VB attenuate) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NNS drug3)))))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (VP (RB not) (VBN studied) (ADVP (RB systematically)) (PP (IN in) (NP (JJ clinical) (NNS trials)))))) (, ,) (NP (DT no) (NN drug) (NNS interactions)) (VP (VBD were) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC or) (NP (NN drug3))) (VP (VBD were) (VP (VBN administered) (PP (VBG following) (NP (NP (VBG varying) (NNS degrees)) (PP (IN of) (NP (NP (NN recovery)) (PP (IN from) (NP (NP (NP (JJ single) (NNS doses)) (CC or) (NP (NNS infusions))) (PP (IN of) (NP (NN drug4)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (VP (VBN administered) (PP (IN with) (NP (NN drug3))))) (: /) (NP (NN drug4)) (VP (TO to) (VP (VB achieve) (NP (ADJP (CD 1.25) (NN MAC)) (NN -LSB-Minimum) (NN Alveolar) (NN Concentration)))) (-RRB- -RSB-)) (VP (MD may) (VP (VP (VB prolong) (NP (NP (DT the) (ADJP (RB clinically) (JJ effective)) (NN duration)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NP (JJ initial) (CC and) (NN maintenance) (NNS doses)) (PP (IN of) (NP (NN drug5))))))))) (CC and) (VP (VB decrease) (NP (NP (DT the) (JJ required) (NN infusion) (NN rate)) (PP (IN of) (NP (NN drug6)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN magnitude)) (PP (IN of) (NP (DT these) (NNS effects)))) (VP (MD may) (VP (VB depend) (PP (IN on) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (JJ volatile) (NNS agents)))))))))) (. .)))
(S1 (S (S (NP (NP (CD Fifteen) (TO to) (CD 30) (NNS minutes)) (PP (IN of) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (ADJP (CD 1.25) (NN MAC)) (NN drug1)) (CC or) (NP (NN drug2))))))) (VP (VBD had) (NP (JJ minimal) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NP (JJ initial) (NNS doses)) (PP (IN of) (NP (NN drug3))))))))))) (CC and) (S (ADVP (RB therefore)) (, ,) (NP (NP (DT no) (NN adjustment)) (PP (TO to) (NP (DT the) (JJ initial) (NN dose)))) (VP (MD should) (VP (VB be) (ADJP (JJ necessary))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug4)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB shortly)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ volatile) (NNS agents))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (JJ long) (JJ surgical) (NNS procedures)) (PP (IN during) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)) (NP (NN anesthesia)))))) (, ,) (NP (NP (ADJP (RBR less) (JJ frequent)) (NN maintenance) (NN dosing)) (, ,) (NP (JJR lower) (NN maintenance) (NNS doses)) (, ,) (CC or) (NP (NP (VBN reduced) (NN infusion) (NNS rates)) (PP (IN of) (NP (NN drug3))))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary)))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ average) (NN infusion) (NN rate)) (NN requirement)) (VP (MD may) (VP (VB be) (VP (VBN decreased) (PP (IN by) (NP (QP (RB as) (JJ much) (IN as) (CD 30)) (NN %))) (PP (TO to) (NP (CD 40) (NN %))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS studies))) (NP (NN drug1)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN action)))) (CC or) (NP (NP (NN dosing) (NNS requirements)) (PP (IN for) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ neuromuscular) (NN blocking) (NN action)) (PP (IN of) (NP (NP (NN drug1)) (PP (JJ such) (IN as) (NP (NN drug2))))))))))) (VP (VBP include) (NP (NP (NP (JJ certain) (NN drug3)) (PRN (-LRB- -LRB-) (NP (FW e.) (FW g.) (, ,) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (CC and) (NP (NN drug11)))) (-RRB- -RRB-))) (, ,) (NP (NN drug12) (NNS salts)) (, ,) (NP (NN drug13)) (, ,) (NP (JJ local) (NN drug14)) (, ,) (NP (NN drug15)) (, ,) (CC and) (NP (NN drug16))))) (. .)))
(S1 (S (S (NP (NP (NN Resistance)) (PP (TO to) (NP (NP (DT the) (JJ neuromuscular) (NN blocking) (NN action)) (PP (IN of) (NP (NN drug1)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB chronically)) (VBN administered) (S (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ chronic) (NN drug1)) (CC or) (NP (JJ drug2) (NN therapy)))) (PP (IN on) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug3)))))) (VP (VBP are) (ADJP (JJ unknown))))) (, ,) (S (NP (NP (ADJP (RB slightly) (JJR shorter)) (NNS durations)) (PP (IN of) (NP (JJ neuromuscular) (NN block)))) (VP (MD may) (VP (VB be) (VP (VBN anticipated))))) (CC and) (S (NP (NN infusion) (NN rate) (NNS requirements)) (VP (MD may) (VP (VB be) (ADJP (JJR higher)))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (VP (NN None) (VBN known))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS studies))) (, ,) (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN co-administered) (PP (IN with) (NP (NP (JJ other) (NN anti-asthma) (NNS medications)) (, ,) (PP (VBG including) (NP (NP (ADJP (ADJP (JJ inhaled)) (CC and) (ADJP (JJ oral))) (NN drug2)) (, ,) (CC and) (NP (JJ inhaled) (NN drug3)))) (, ,))) (PP (IN with) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (VBN increased) (NN frequency)) (PP (IN of) (NP (NP (JJ adverse) (NNS events)) (CC or) (NP (NN laboratory) (NNS abnormalities)))))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ formal) (JJ drug-drug) (NN interaction) (NNS studies)) (, ,) (ADVP (RB however)) (, ,) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (NP (NN drug1)) (VP (MD can) (VP (VB interact) (PP (IN with) (NP (NP (NP (NP (NN drug2)) (CC or) (NP (JJ other) (NN drug3))) (PRN (-LRB- -LRB-) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN CNS) (NN depressant) (NNS effects)) (PP (IN of) (NP (CC either) (DT these) (NP (NNS medications)) (CC or) (NP (NNS drug4))))))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN drug5)) (CC or) (NP (NP (JJ other) (NNS medications)) (PP (IN with) (NP (JJ anticholinergic) (NN activity))))) (PRN (-LRB- -LRB-) (S (NP (JJ anticholinergic) (NNS effects)) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS medications)) (VP (VBP are) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug6))))))))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (S (NP (NP (JJ concurrent) (NN use)) (PP (IN with) (NP (NN drug8)))) (VP (MD may) (VP (VP (VB prolong)) (CC and) (VP (VB intensify) (NP (NP (DT the) (NN anticholinergic) (CC and) (NN CNS) (NN depressant) (NNS effects)) (PP (IN of) (NP (NN drug9)))))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug5)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug7)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug9)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug10)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug11)) (-RRB- -RRB-)))))) (: :) (S (S (VP (VBG Using) (NP (DT these) (NNS medicines)) (PP (IN with) (NP (NN drug12))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN chance)) (PP (IN of) (NP (JJ side) (NNS effects))))))) (. .))))
(S1 (S (S (NP (NP (NN Addition)) (CC or) (NP (NP (NN deletion)) (PP (IN of) (NP (DT any) (NN drug))) (PP (IN from) (NP (NP (DT the) (JJ therapeutic) (NN regimen)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ oral) (NN drug1))))))))) (VP (MD may) (VP (VB affect) (NP (NP (NN patient) (NN response)) (PP (TO to) (NP (DT the) (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (JJ Frequent) (NN determination)) (PP (IN of) (NP (NN prothrombin) (NN time)))) (CC and) (NP (JJ close) (NN monitoring))) (PP (IN of) (NP (DT the) (NN patient)))) (VP (VBZ is) (ADJP (JJ essential) (S (VP (TO to) (VP (VB ascertain) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN adjustment)) (PP (IN of) (NP (NP (NN dosage)) (PP (IN of) (NP (NN drug1)))))) (VP (MD may) (VP (VB be) (VP (VBN needed)))))))))))) (. .)))
(S1 (S (PP (IN Because) (PP (IN of) (NP (NP (NP (DT the) (NN variability)) (PP (IN of) (NP (JJ individual) (NN patient) (NN response)))) (, ,) (NP (NP (JJ multiple) (VBG interacting) (NNS mechanisms)) (PP (IN with) (NP (DT some) (NNS drugs)))) (, ,) (NP (NP (DT the) (NN dependency)) (PP (IN of) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN on) (NP (NP (DT the) (NP (NN dosage)) (CC and) (NP (NN duration))) (PP (IN of) (NP (NN therapy)))))))))) (, ,) (CC and) (NP (NP (DT the) (JJ possible) (NN administration)) (PP (IN of) (NP (NP (JJ several) (VBG interacting) (NNS drugs)) (ADVP (RB simultaneously)))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ difficult) (S (VP (TO to) (VP (VB predict) (NP (NP (DT the) (NP (NN direction)) (CC and) (NP (NN degree))) (PP (IN of) (NP (NP (DT the) (JJ ultimate) (NN effect)) (PP (IN of) (NP (JJ concomitant) (NNS medications))) (PP (IN on) (NP (NN drug1) (NN response))))))))))) (. .)))
(S1 (S (S (PP (IN For) (NP (NN example))) (, ,) (SBAR (IN since) (S (NP (NN drug1)) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (CC both) (NP (DT the) (JJ oral) (NN drug2)) (CC and) (NP (NN drug3))))))))) (, ,) (NP (DT the) (JJ net) (NNS effects)) (VP (VBP are) (ADJP (JJ unpredictable)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB cause) (NP (DT an) (VBN increased) (NN prothrombin) (NN response)) (PP (IN by) (S (VP (VBG displacing) (NP (NP (NP (DT the) (NN drug2)) (PP (IN from) (NP (NN protein) (NN binding) (NNS sites)))) (CC or) (NP (DT a) (VBN diminished) (NN prothrombin) (NN response))) (PP (IN through) (NP (NP (VBN increased) (NN metabolism)) (PP (IN of) (NP (DT the) (JJ unbound) (NN drug))) (PP (IN by) (NP (JJ hepatic) (NN enzyme) (NN induction))))) (, ,) (S (ADVP (RB thus)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ inter-patient) (NN variation)) (PP (IN in) (NP (JJ ultimate) (NN prothrombin) (NN effect))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (VBG interacting) (NN drug)) (SBAR (WHNP (WDT which)) (S (VP (VBZ leads) (PP (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN prothrombin) (NN time))))) (S (VP (VBG necessitating) (NP (NP (DT an) (VBN increased) (NN dose)) (PP (IN of) (NP (JJ oral) (NN drug1)))) (S (VP (TO to) (VP (VB maintain) (NP (NP (DT an) (JJ adequate) (NN degree)) (PP (IN of) (NP (NN anticoagulation))))))))))))) (VP (MD may) (, ,) (SBAR (IN if) (S (ADVP (RB abruptly)) (VP (VBN discontinued)))) (, ,) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ subsequent) (JJ bleeding))))))) (. .)))
(S1 (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB diminish) (NP (NP (JJ oral) (NN drug1) (NN response)) (, ,) (NP (NN ie)) (, ,) (NP (VBN decreased) (JJ prothrom-bin) (NN time) (NN response)) (, ,)) (PP (IN in) (NP (NN man)))))))))))) (ADVP (RB significantly)) (VP (VBP include) (: :) (NP (NN drug2))) (: ;)))
(S1 (S (NP (NNP drug1) (NNP *) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (NNP *) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (S (NP (NN diet)) (VP (JJ high) (PP (IN in) (NP (NN drug1))))) (: ;)))
(S1 (S (NP (NNP drug1) (NNP *) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NP (JJ oral) (NN drug1)) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (NNP *) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NP (JJ unreliable) (NN prothrombin) (NN time) (NNS determinations)) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB diminish) (NP (JJ oral) (NN drug1) (NN response)) (, ,) (S (NP (NP (NN ie)) (, ,) (VP (VBD decreased) (NP (NN prothrom-bin) (NN time) (NN response))) (, ,)) (PP (IN in) (NP (NN man))) (ADVP (RB significantly)) (VP (VBP include) (: :) (NP (NP (NN drug2)) (: ;) (NP (NN drug3) (NN *)) (: ;) (NP (NN drug4)) (: ;) (NP (NN drug5)) (: ;) (NP (NP (NN drug6)) (: ;) (NP (NN drug7)) (: ;) (NP (NN drug8) (NN *)) (: ;) (NP (NN drug9)) (: ;) (CD drug10)) (: ;) (NP (NN diet) (ADJP (JJ high) (PP (IN in) (NP (NP (NP (NN drug11)) (: ;) (NP (CD drug12) (NN *)) (: ;) (NP (CD drug13)) (: ;) (CD drug14) (: ;) (CD drug15) (: ;) (CD drug16) (: ;) (CD drug17)) (: ;) (NP (JJ oral) (NN drug18)) (: ;) (NP (CD drug19)) (: ;) (NP (CD drug20) (: ;) (CD drug21) (NN *)) (: ;) (NP (CD drug22)) (: ;) (NP (JJ unreliable) (NN prothrombin) (NN time) (NNS determinations)) (: ;) (CD drug23) (: ;) (CD drug24)))) (NN under-dosage))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (ADVP (RB reportedly)) (VP (MD may) (VP (VB increase) (NP (NP (JJ oral) (NN drug1) (NN response)) (, ,) (NP (NN ie)) (, ,) (NP (VBN increased) (NN prothrombin) (NN response)) (, ,)) (PP (IN in) (NP (NN man)))))))) (VP (VBP include) (: :) (NP (NN drug2) (NNS *)))) (: ;)))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (NNP *) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NP (JJ dietary) (NNS deficiencies)) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (NNP *) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NP (NNS drugs)) (VP (VBG affecting) (NP (NN blood) (NNS elements))) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NP (JJ hepatotoxic) (NNS drugs)) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NP (NN inhalation) (NN drug1)) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NP (JJ prolonged) (JJ hot) (NN weather)) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (NNP *) (: ;))))
(S1 (S (NP (NP (NN drug1)) (: ;) (NP (NN drug2)) (: ;))))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (JJ long) (NN acting)) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: ;))))
(S1 (S (NP (NP (JJ unreliable) (NN prothrombin) (NN time) (NNS determinations)) (: ;))))
(S1 (S (NNS Drugs) (IN that) (RB reportedly) (MD may) (NN increase) (JJ oral) (NN drug1) (NN response) (, ,) (JJ ie) (, ,) (VBN increased) (NN prothrombin) (NN response) (, ,) (IN in) (NN man) (VBP include) (: :) (NN drug2) (NN *) (: ;) (NN drug3) (: ;) (NN drug4) (: ;) (NN drug5) (: ;) (NN drug6) (: ;) (NN drug7) (: ;) (NN drug8) (: ;) (NN drug9) (NN *) (: ;) (NN drug10) (: ;) (NN drug11) (: ;) (NN drug12) (: ;) (NN drug13) (: ;) (NN drug14) (: ;) (NN drug15) (: ;) (NN drug16) (: ;) (NN drug17) (: ;) (JJ dietary) (NNS deficiencies) (: ;) (NN drug18) (: ;) (NN drug19) (: ;) (NNS drugs) (VBG affecting) (NN blood) (NNS elements) (: ;) (CD drug20) (: ;) (NN drug21) (: ;) (NN drug22) (: ;) (JJ hepatotoxic) (NNS drugs) (: ;) (NN drug23) (: ;) (CD drug24) (: ;) (CD drug25) (: ;) (NN inhalation) (CD drug26) (: ;) (NN drug27) (: ;) (NN drug28) (: ;) (CD drug29) (: ;) (CD drug30) (: ;) (CD drug31) (: ;) (NN drug32) (: ;) (CD drug33) (: ;) (NN drug34) (: ;) (CD drug35) (: ;) (CD drug36) (: ;) (CD drug37) (: ;) (CD drug38) (: ;) (CD drug39) (: ;) (NN drug40) (: ;) (JJ prolonged) (JJ hot) (NN weather) (: ;) (CD drug41) (: ;) (CD drug42) (: ;) (NN drug43) (: ;) (CD drug44) (: ;) (CD drug45) (NN *) (: ;) (CD drug46) (: ;) (CD drug47) (: ;) (CD drug48) (, ,) (JJ long) (VBG acting) (: ;) (CD drug49) (: ;) (CD drug50) (: ;) (CD drug51) (: ;) (CD drug52) (: ;) (CD drug53) (: /) (CD drug54) (: ;) (JJ unreliable) (NN prothrombin) (NN time) (NNS determinations) (: ;) (CD drug55) (NN overdosage) (. .)))
(S1 (S (S (NP (JJ Oral) (NN drug1)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ hypoglycemic) (NN action)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN eg)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4))))) (, ,) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (PRP$ their) (NN metabolism)) (PP (IN in) (NP (DT the) (NN liver)))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (JJ oral) (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (JJ hepatic) (NN metabolism)) (PP (IN of) (NP (NN drug2))))))))) (, ,) (NP (NP (JJ toxic) (NNS levels)) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT an) (JJ oral) (NN drug4)) (CC and) (NP (NN drug5))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concurrently))))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP reduce) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN blood) (NNS platelets)))) (PP (IN by) (S (VP (VBG causing) (NP (NP (NN bone) (NN marrow) (NN depression)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug1)))) (-RRB- -RRB-)))))))))) (CC or) (NP (NNS drugs))) (SBAR (WHNP (WDT which)) (S (VP (VBP inhibit) (NP (NN platelet) (NN function)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug2)) (CC and) (NP (JJ other) (NN drug3))) (, ,) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7))) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (JJ bleeding) (NN tendency)) (VP (VBN produced) (PP (IN by) (NP (NN drug8))) (PP (IN without) (S (VP (VBG altering) (NP (NN prothrombin) (NN time) (NNS determinations))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ beneficial) (NNS effects)) (PP (IN on) (NP (JJ arterial) (NN thrombus) (NN formation))) (PP (IN from) (NP (NP (JJ combined) (NN therapy)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (MD must) (VP (VB be) (VP (VBN weighed) (PP (IN against) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN inducing) (NN hemorrhage))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (JJ *) (VBN Increased))) (CC and) (NP (VBN decreased) (NN prothrombin) (NN time)) (NP (NNS responses))) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interferences)) (: :) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (, ,) (PP (VBG including) (NP (NN drug3))) (, ,)) (CC or) (NP (PRP$ their) (NNS metabolites))) (VP (MD may) (VP (NN color) (NP (NP (NN alkaline) (NN urine) (JJ red-orange)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (ADJP (RB spectrophotometrically) (VBN determined)) (JJ urinary) (NN laboratory) (NNS tests))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN color)) (VP (VBZ reverses) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN test) (NN sample)) (VP (VBZ is) (VP (VBN acidified) (ADVP (FW in) (FW vitro)) (PP (TO to) (NP (NP (DT a) (NN pH)) (PP (IN below) (NP (CD 4))))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS preparations)) (VP (VBP are) (ADJP (JJ incompatible) (PP (IN with) (NP (NN drug2) (NNS preparations)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC -) (NP (JJ Concomitant) (NN use))) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB enhance) (NP (JJ nutrient) (NN absorption)) (PP (IN in) (NP (NP (DT those)) (PP (IN with) (NP (JJ severe) (JJ short) (NN bowel) (NN syndrome)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (NP (NN orphan) (NN drug) (NN status)) (PP (IN for) (NP (DT this) (NN indication))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC -) (NP (JJ Concomitant) (NN use))) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB ameliorate) (NP (NP (VBN increased) (JJ intestinal) (NN permeability)) (VP (VBN caused) (PP (IN by) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (VBN reported) (NN dose)) (VP (VBN used) (PP (IN for) (NP (NN drug1))))) (VP (VBD was) (NP (NP (CD 21) (NNS grams)) (VP (ADVP (RB daily)) (VBN taken) (PP (IN in) (NP (JJ divided) (NNS doses))))) (NP (NP (CD three) (NNS times)) (NP (DT a) (NN day))))) (. .)))
(S1 (S (S (ADVP (RB Further)) (, ,) (NP (NN drug1)) (VP (VBZ is) (VP (VBN reported) (S (VP (TO to) (VP (VB have) (NP (DT a) (JJ synergistic) (NN effect)) (PP (IN with) (NP (DT this) (NN combination))) (PP (IN in) (S (VP (VBG ameliorating) (NP (JJ intestinal) (NN permeability))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: -) (S (NP (EX There)) (VP (VBZ is) (NP (NP (CD one) (NN report)) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (JJ possible) (NN effectiveness)) (PP (IN of) (NP (JJ supplemental) (NN drug3))) (PP (IN for) (NP (JJ chemotherapy-induced) (NN mucositis))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT another) (NN report))) (, ,) (NP (NP (CD nine) (NNS patients)) (PP (IN with) (NP (NN breast) (NN cancer)))) (VP (VBD were) (VP (VBN reported) (S (VP (TO to) (VP (VB have) (NP (NP (VBN decreased) (NNS symptoms)) (PP (IN of) (NP (NN drug1) (JJ -related) (NN toxicity)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (JJ supplemental) (NN drug2)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 0.5) (NN gram/kilogram/day)))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: -) (S (PP (IN In) (NP (CD one) (NN report))) (, ,) (NP (NP (NN drug2)) (PP (IN at) (NP (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 10) (NNS grams))) (ADVP (NP (CD three) (NNS times)) (RB daily))) (, ,) (VP (VBN given) (PP (NP (CD 24) (NNS hours)) (IN after) (S (VP (VBG receiving) (NP (NN drug3)))))) (, ,)))) (VP (VBD appeared) (S (VP (TO to) (VP (VB prevent) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NP (NN myalgia)) (CC and) (NP (NN arthralgia))) (, ,) (NP (NP (JJ adverse) (NNS reactions)) (PP (IN of) (NP (NN drug4)))))))))))) (. .))))
(S1 (S (PP (IN In) (NP (NP (CD two) (JJ controlled) (NN crossover) (JJ clinical) (NN pharmacology) (NNS studies)) (PP (IN in) (NP (ADJP (ADJP (JJ healthy)) (ADJP (JJ male) (PRN (-LRB- -LRB-) (NP (NP (NN n=12)) (PP (IN in) (NP (DT each) (NN study)))) (-RRB- -RRB-)))) (NP (NP (DT a) (JJ nd) (NN female)) (PRN (-LRB- -LRB-) (NP (NN n=12)) (PP (IN in) (NP (DT each) (NN study))) (-RRB- -RRB-))) (NNS volunteers))))) (, ,) (NP (NP (NP (NN drug1) (CD 7.5) (NN mg)) (PRN (-LRB- -LRB-) (NP (NP (CD 1.5) (NNS times)) (NP (DT the) (JJ daily) (NN dose))) (-RRB- -RRB-))) (ADVP (RB once) (RB daily))) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (NP (NP (NN drug2) (CD 500) (NN mg)) (NP (DT every) (CD 8) (NNS hours))) (CC or) (NP (NP (NP (NN drug3) (CD 200) (NN mg)) (NP (DT every) (CD 12) (NNS hours))) (PP (IN for) (NP (CD 10) (NNS days)))))))) (. .)))
(S1 (S (PP (IN In) (NP (CD three) (JJ separate) (JJ controlled) (, ,) (JJ parallel) (NN group) (JJ clinical) (NN pharmacology) (NNS studies))) (, ,) (NP (NP (NN drug1)) (PP (IN at) (NP (NP (DT the) (JJ clinical) (NN dose)) (PP (IN of) (NP (CD 5) (NN mg)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN coadministered) (PP (PP (IN with) (NP (NP (NN drug2) (CD 500) (NN mg)) (VP (VBN followed) (PP (IN by) (NP (NP (CD 250) (NN mg)) (PP (IN once) (NP (ADJP (JJ daily) (PP (IN for) (NP (NP (CD 4) (NNS days)) (PRN (-LRB- -LRB-) (NP (NN n=18)) (-RRB- -RRB-)))))))))))) (CC or) (PP (IN with) (NP (NP (NN drug3) (CD 20) (NN mg)) (ADJP (RB once) (JJ daily) (PP (IN for) (NP (NP (CD 7) (NNS days)) (PP (PP (IN after) (NP (NP (DT a) (ADJP (CD 23) (NN day)) (NN pretreatment) (NN period)) (PP (IN with) (NP (NN drug4) (-LRB- -LRB-) (CD n=18) (-RRB- -RRB-))))) (CC or) (PP (IN with) (NP (NP (NP (NN drug5) (CD 600) (NN mg)) (NP (DT every) (CD 12) (NNS hours))) (PP (IN for) (NP (NP (CD 14) (NNS days)) (PRN (-LRB- -LRB-) (NP (CD n=18)) (-RRB- -RRB-)))))) (PP (IN under) (NP (NP (JJ steady) (NN state) (NNS conditions)) (PP (TO to) (NP (JJ normal) (JJ healthy) (ADJP (ADJP (JJ male)) (CC and) (ADJP (JJ female))) (NNS volunteers))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NN C) (NN max) (CC and) (NN AUC) (CD 0-24) (NNS hrs)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD were) (VP (VBN observed))))) (, ,) (NP (EX there)) (VP (VBD were) (NP (DT no) (ADJP (RB clinically) (JJ relevant)) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN safety) (NN profile)) (PP (IN of) (NP (NN drug3))))) (, ,) (SBAR (IN as) (S (VP (VBN assessed) (PP (IN by) (NP (NP (NP (JJ electrocardiographic) (NNS parameters)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (DT the) (JJ corrected) (JJ QT) (NN interval))) (-RRB- -RRB-))) (, ,) (NP (JJ clinical) (NN laboratory) (NNS tests)) (, ,) (NP (JJ vital) (NNS signs)) (, ,) (CC and) (NP (JJ adverse) (NNS events))))))))) (. .)))
(S1 (S (NP (NP (NN Table) (CD 1) (NNS Changes)) (PP (IN in) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (NNS Pharmacokinetics)))) (PP (IN in) (NP (JJ Healthy) (ADJP (ADJP (JJ Male)) (CC and) (ADJP (JJ Female))) (NNS Volunteers))))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN drug1) (NN drug2))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN C) (NN max) (NN AUC) (CD 0-24) (NNS hrs) (NN C) (NN max) (NN AUC) (NN 0-24) (NNS hrs))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (-LRB- -LRB-) (NP (ADJP (CD 500) (NN mg)) (NN Q8h)) (-RRB- -RRB-))))
(S1 (S (NP (NP (CD +24) (NN %) (CD +14) (NN %) (CD +43) (NN %)) (NP (CD +40) (NN %)))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (-LRB- -LRB-) (NP (CD 200) (NN mg)) (PP (IN Q12h)) (-RRB- -RRB-))))
(S1 (S (NP (NP (NN +45) (NN %) (CD +39) (NN %) (CD +43) (NN %)) (NP (CD +72) (NN %)))))
(S1 (S (NP (NN drug1))))
(S1 (S (PRN (-LRB- -LRB-) (NP (CD 500) (NN mg) (NN day) (CD 1)) (, ,) (NP (CD 250) (NN mg) (NN QD) (CD 4) (NNS days)) (-RRB- -RRB-))))
(S1 (S (NP (NP (CD +15) (NN %) (NN +5) (NN %) (CD +15) (NN %)) (NP (CD +4) (NN %)))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (-LRB- -LRB-) (NP (ADJP (CD 20) (NN mg)) (NN QD)) (-RRB- -RRB-))))
(S1 (S (NP (CD +15) (NN %) (NN +0) (NN %) (CD +17) (NN %) (CD +13) (NN %))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (-LRB- -LRB-) (NP (CD 600) (NN mg)) (PP (IN Q12h)) (-RRB- -RRB-))))
(S1 (S (NP (NP (CD +12) (NN %)) (NP (CD +19) (NN %) (NN -11) (NN %) (CD -3) (NN %)))))
(S1 (S (S (NP (DT No) (JJ specific) (ADJP (ADJP (JJ pharmacokinetic)) (CC or) (ADJP (JJ other))) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBD were) (VP (VBN conducted)))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (JJ Supraventricular) (NNS arrhythmias)) (VP (MD may) (VP (VB mask) (NP (NP (DT the) (NN cardiotoxicity)) (VP (VBN associated) (PP (IN with) (NP (JJ excessive) (NN drug2) (NNS levels)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ advisable) (S (VP (TO to) (VP (VB be) (ADJP (RB particularly) (JJ cautious) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP$ whose) (NN plasma) (NN drug1) (NNS levels)) (S (VP (VBP are) (VP (ADJP (JJ above)) (CC or) (VP (VBN suspected) (S (VP (TO to) (VP (VB be) (PP (IN above) (NP (DT the) (JJ usual) (JJ therapeutic) (NN range)))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD did) (RB not) (VP (VB have) (NP (NP (NNS effects)) (PP (IN on) (NP (NP (CC either) (DT the) (NP (NN safety)) (CC or) (NP (NN efficacy))) (PP (IN of) (NP (NN drug2)))))) (PP (IN in) (NP (DT the) (JJ clinical) (NNS trials)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug2)))) (VP (VBD did) (RB not) (VP (VB have) (NP (DT any) (NN effect)) (PP (IN on) (NP (NP (CC either) (DT the) (NP (NN safety)) (CC or) (NP (NN efficacy))) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (DT the) (JJ clinical) (NNS trials)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug2)))) (VP (VBD did) (RB not) (VP (VB have) (NP (DT any) (NN effect)) (PP (IN on) (NP (NP (CC either) (DT the) (NP (NN safety)) (CC or) (NP (NN efficacy))) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (DT the) (JJ clinical) (NNS trials)))))))) (. .))))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBZ has) (ADVP (RB previously)) (VP (VBN received) (NP (NN drug2))))))))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN cardiotoxicity)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (ADVP (RB previously)) (VP (VBN received) (NP (NP (DT the) (VBN recommended) (JJ maximum) (JJ cumulative) (NNS doses)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2))))) (VP (MD may) (ADVP (RB also)) (VP (VB result) (PP (IN in) (NP (VBN increased) (NN cardiotoxicity)))))) (. .)))
(S1 (S (S (NP (NP (JJ Dosage) (NN reduction)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (JJ other) (JJ myelosuppressive) (NNS agents)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Hepatotoxic) (NNS medications)) (, ,) (PP (JJ such) (IN as) (NP (JJ high-dose) (NN drug1))) (, ,)) (VP (MD may) (VP (VP (VB impair) (NP (NN liver) (NN function))) (CC and) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN toxicity)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP) (NN 3A4))) (ADVP (FW in) (FW vitro))))) (. .)))
(S1 (S (S (NP (NP (JJ Clinical) (NNS studies)) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ strong) (NN CYP) (NN 3A4) (NNS inhibitors))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (NP (NP (NP (NN Carcinogenesis)) (, ,) (NP (NN Mutagenesis)) (CC and) (NP (NP (NN Impairment)) (PP (IN of) (NP (NN Fertility))))) (S (NP (DT A) (JJ two-year) (NN carcinogenesis) (NN study)) (VP (VBD was) (VP (VBN conducted) (PP (IN in) (NP (ADJP (ADJP (JJ female)) (CC and) (ADJP (JJ male))) (NNS rats))) (, ,) (PP (IN at) (NP (NP (JJ intramuscular) (NNS doses)) (PP (IN of) (NP (NP (CD 15) (NN mg/kg/30) (NNS days)) (, ,) (NP (NP (CD 10) (NN mg/rat/30) (NNS days)) (CC and) (NP (CD 10) (NN mg/rat/15) (NNS days)))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS doses)) (VP (VBP correspond) (PP (TO to) (NP (NP (RB approximately) (CD 1-)) (, ,) (NP (CD 3-)) (, ,) (CC and) (NP (NP (NP (NP (JJ 5-fold)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NNS females))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN 1.3-)) (, ,) (NP (NN 1.3-)) (, ,) (CC and) (NP (NN 1.6-fold))) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NNS males))) (-RRB- -RRB-) (NP (NP (DT the) (JJ systemic) (NN exposure)) (NP (CD -LSB-AUC0-30) (NNS days))) (-RRB- -RSB-) (-RRB- -RSB-)))) (VP (VBN achieved) (PP (IN in) (NP (NP (NNS women)) (VP (VBG receiving) (NP (NP (DT the) (VBN recommended) (NN dose)) (PP (IN of) (NP (CD 250) (NN mg/month))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (VBN increased) (NN incidence)) (PP (IN of) (NP (NP (JJ benign) (JJ ovarian) (NN granulosa) (NN cell) (NNS tumors)) (CC and) (NP (JJ testicular) (NN Leydig) (NN cell) (NNS tumors))))) (VP (VBD was) (ADJP (JJ evident)) (, ,) (PP (IN in) (NP (NP (NP (NNS females)) (VP (VBN dosed) (PP (IN at) (NP (CD 10) (NN mg/rat/15) (NNS days))))) (CC and) (NP (NP (NNS males)) (VP (VBN dosed) (PP (IN at) (NP (CD 15) (NN mg/rat/30) (NNS days))))))) (, ,) (ADVP (RB respectively)))) (. .)))
(S1 (S (S (NP (NP (NN Induction)) (PP (IN of) (NP (JJ such) (NNS tumors)))) (VP (VBZ is) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (JJ pharmacology-related) (JJ endocrine) (NN feedback) (NNS alterations)) (PP (IN in) (NP (NN gonadotropin) (NNS levels))) (VP (VBN caused) (PP (IN by) (NP (DT an) (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (RB not) (ADJP (ADJP (JJ mutagenic)) (CC or) (ADJP (JJ clastogenic))) (PP (IN in) (NP (JJ multiple) (ADJP (FW in) (FW vitro)) (NNS tests))) (PP (IN with) (CC and) (PP (IN without) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (DT a) (JJ mammalian) (NN liver) (JJ metabolic) (NN activation) (NN factor)))))) (-LRB- -LRB-) (NP (NP (NP (JJ bacterial) (NN mutation) (NN assay)) (PP (IN in) (NP (NP (NNS strains)) (PP (IN of) (NP (NP (FW Salmonella) (FW typhimurium)) (CC and) (NP (FW Escherichia) (FW coli))))))) (, ,) (NP (NP (ADJP (FW in) (FW vitro)) (NNS cytogenetics) (NN study)) (PP (IN in) (NP (JJ human) (NNS lymphocytes)))) (, ,) (NP (NP (JJ mammalian) (NN cell) (NN mutation) (NN assay)) (PP (IN in) (NP (NN mouse) (NN lymphoma) (NNS cells)))) (CC and) (NP (NP (ADJP (FW in) (FW vivo)) (NN micronucleus) (NN test)) (PP (IN in) (NP (NN rat))))))) (. .)))
(S1 (S (PP (IN In) (NP (JJ female) (NNS rats))) (, ,) (NP (NP (NN drug1)) (VP (VBN administered) (PP (PP (IN at) (NP (NP (NNS doses)) (NP (NP (CD 0.01) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (NP (NP (RB approximately) (CD one-hundredth)) (PP (IN of) (NP (NP (DT the) (JJ human) (VBN recommended) (NN dose)) (VP (VBN based) (PP (IN on) (NP (NN body) (NN surface) (NN area) (NN -LSB-BSA))))))) (-RRB- -RSB-))))) (, ,) (PP (IN for) (NP (NP (CD 2) (NNS weeks)) (ADJP (JJ prior) (PP (TO to))))) (CC and) (PP (IN for) (NP (NP (CD 1) (NN week)) (PP (VBG following) (NP (NN mating))))))) (, ,)) (VP (VBD caused) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (NN fertility)) (CC and) (NP (JJ embryonic) (NN survival)))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ adverse) (NNS effects)) (PP (IN on) (NP (NP (NN female) (NN fertility)) (CC and) (NP (JJ embryonic) (NN survival))))) (VP (VBD were) (ADJP (JJ evident) (PP (IN in) (NP (NP (JJ female) (NNS animals)) (VP (VBN dosed) (PP (IN at) (NP (NP (CD 0.001) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (NP (NP (RB approximately) (CD one-thousandth)) (PP (IN of) (NP (NP (DT the) (JJ human) (NN dose)) (VP (VBN based) (PP (IN on) (NP (NN BSA))))))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Restoration)) (PP (IN of) (NP (NN female) (NN fertility))) (PP (TO to) (NP (NP (NNS values)) (ADJP (JJ similar) (PP (TO to) (NP (NNS controls))))))) (VP (VBD was) (ADJP (JJ evident)) (PP (VBG following) (NP (DT a) (JJ 29-day) (NN withdrawal) (NN period))) (PP (IN after) (NP (NP (NN dosing)) (PP (IN at) (NP (CD 2) (NN mg/kg/day))))) (PRN (-LRB- -LRB-) (NP (NP (RB twice) (DT the) (JJ human) (NN dose)) (VP (VBN based) (PP (IN on) (NP (NN BSA))))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN fertility)) (PP (IN of) (NP (JJ female) (NNS rats)))))) (VP (VBP appear) (S (VP (TO to) (VP (VB be) (ADJP (JJ consistent) (PP (IN with) (NP (PRP$ its) (JJ anti-estrogenic) (NN activity))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (JJ potential) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN fertility)) (PP (IN of) (NP (JJ male) (NNS animals)))))) (VP (VBD were) (RB not) (VP (VBN studied)))) (CC but) (S (PP (IN in) (NP (DT a) (JJ 6-month) (NN toxicology) (NN study))) (, ,) (NP (NP (JJ male) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ intramuscular) (NNS doses)) (PP (IN of) (NP (NP (NP (CD 15) (NN mg/kg/30) (NNS days)) (, ,) (NP (CD 10) (NN mg/rat/30) (NNS days)) (, ,) (CC or) (NP (CD 10) (NN mg/rat/15) (NNS days))) (NN drug2))))))) (VP (VBD showed) (NP (NP (NP (DT a) (NN loss)) (PP (IN of) (NP (NP (NN spermatozoa)) (PP (IN from) (NP (DT the) (JJ seminiferous) (NNS tubules)))))) (, ,) (NP (JJ seminiferous) (JJ tubular) (NN atrophy)) (, ,) (CC and) (NP (NP (JJ degenerative) (NNS changes)) (PP (IN in) (NP (DT the) (NNS epididymides)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Changes)) (PP (IN in) (NP (DT the) (NP (NNS testes)) (CC and) (NP (NNS epididymides))))) (VP (VBD had) (RB not) (VP (VBN recovered) (PP (NP (CD 20) (NNS weeks)) (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (NN dosing)))))))) (. .)))
(S1 (S (S (NP (DT These) (NN drug1) (NNS doses)) (VP (VBP correspond) (PP (TO to) (NP (RB approximately) (NP (CD 2-)) (, ,) (NP (CD 3-)) (, ,) (CC and) (NP (NP (ADVP (RB 3-fold)) (DT the) (JJ systemic) (NN exposure) (CD -LSB-AUC0-30) (NNS days) (-RRB- -RSB-)) (VP (VBN achieved) (PP (IN in) (NP (NNS women))))))))) (. .)))
(S1 (S (NP (NP (NP (NN Pregnancy) (NN Pregnancy) (NN Category) (NN D)) (: :)) (. .))))
(S1 (S (PP (IN In) (NP (NP (NNS studies)) (PP (IN in) (NP (NP (JJ female) (NNS rats)) (PP (IN at) (NP (NNS doses) (CD 0.01) (NN mg/kg/day))))))) (PRN (-LRB- -LRB-) (NP (NN IM))) (: ;)))
(S1 (S (S (NP (NP (NP (RB approximately) (CD one-hundredth)) (PP (IN of) (NP (NP (DT the) (JJ human) (VBN recommended) (NN dose)) (VP (VBN based) (PP (IN on) (NP (NP (NN body) (NN surface) (NN area)) (PRN (NN -LSB-BSA) (-RRB- -RSB-) (-RRB- -RRB-)))))))) (, ,) (NP (NN drug1))) (VP (VBD caused) (NP (NP (NP (DT a) (JJ reversible) (NN reduction)) (PP (IN in) (NP (NN female) (NN fertility)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNS effects)) (PP (IN on) (NP (JJ embryo/fetal) (NN development))))) (S (ADJP (JJ consistent) (PP (IN with) (NP (PRP$ its) (JJ anti-estrogenic) (NN activity))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD caused) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (JJ fetal) (NNS abnormalities))) (PP (IN in) (NP (NNS rats)))) (-LRB- -LRB-) (NP (NP (JJ tarsal) (NN flexure)) (PP (IN of) (NP (DT the) (JJ hind) (NN paw)))) (PP (IN at) (NP (CD 2) (NN mg/kg/day) (CD IM))))) (: ;)))
(S1 (S (S (NP (RB twice) (DT the) (JJ human) (NN dose)) (VP (PP (IN on) (NP (NP (NN BSA) (-RRB- -RRB-)) (CC and) (NP (NP (NN non-ossification)) (PP (IN of) (NP (NP (DT the) (ADJP (ADJP (JJ odontoid)) (CC and) (ADJP (JJ ventral))) (NN tubercle)) (PP (IN of) (NP (DT the) (JJ first) (JJ cervical) (NN vertebra))))) (PP (IN at) (NP (NNS doses) (NP (NP (ADJP (CD 0.1) (NN mg/kg/day)) (NN IM)) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD one-tenth)) (PP (IN of) (NP (NP (DT the) (JJ human) (NN dose)) (PP (IN on) (NP (NN BSA)))))) (-RRB- -RRB-)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN during) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (NN organogenesis)))))))))) (. .)))
(S1 (S (S (NP (NNS Rabbits)) (VP (VBD failed) (S (VP (TO to) (VP (VB maintain) (NP (NP (NN pregnancy)) (SBAR (WHADVP (WRB when)) (S (VP (VBN dosed) (PP (IN with) (NP (NP (ADJP (CD 1) (NN mg/kg/day)) (NN drug1) (NN IM)) (PRN (-LRB- -LRB-) (NP (NP (RB twice) (DT the) (JJ human) (NN dose)) (PP (IN on) (NP (NN BSA)))) (-RRB- -RRB-)))))))) (PP (IN during) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (NN organogenesis)))))))))) (. .)))
(S1 (S (S (ADVP (RB Further)) (, ,) (PP (IN in) (NP (NP (NNS rabbits)) (VP (VBN dosed) (PP (IN at) (NP (NP (CD 0.25) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (PP (IN about) (NP (NN one-half))) (NP (NP (DT the) (JJ human) (NN dose)) (PP (IN on) (NP (NN BSA)))) (-RRB- -RRB-))))))) (, ,) (S (NP (NP (NNS increases)) (PP (IN in) (NP (NP (JJ placental) (NN weight)) (CC and) (NP (NN post-implantation) (NN loss))))) (VP (VBD were) (VP (VBN observed)))) (CC but) (, ,) (S (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (VBN observed) (NNS effects)) (PP (IN on) (NP (JJ fetal) (NN development))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NP (JJ fetal) (NNS variations)) (PP (IN in) (NP (NNS rabbits))))))) (PRN (-LRB- -LRB-) (NP (NP (NNS backwards)) (NP (NP (NN displacement)) (PP (IN of) (NP (DT the) (JJ pelvic) (NN girdle)))) (, ,) (CC and) (NP (NP (CD 27) (JJ pre-sacral) (NNS vertebrae)) (PP (IN at) (NP (CD 0.25) (NN mg/kg/day) (CD IM))))))))) (: ;)))
(S1 (S (S (NP (NN one-half) (NP (DT the) (JJ human) (NN dose))) (VP (PP (IN on) (NP (NN BSA) (-RRB- -RRB-))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN during) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (NN organogenesis)))))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (NN pregnancy)) (VP (MD could) (RB not) (VP (VB be) (VP (VBN maintained) (PP (IN in) (NP (DT the) (NN rabbit))) (PP (VBG following) (NP (NP (NP (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN of) (NP (CD 1) (NN mg/kg/day)))))) (CC and) (NP (ADJP (JJ above)))))))))) (, ,) (NP (DT this) (NN study)) (VP (VBD was) (ADJP (JJ inadequate) (S (VP (TO to) (ADVP (RB fully)) (VP (VB define) (NP (NP (DT the) (JJ possible) (JJ adverse) (NNS effects)) (PP (IN on) (NP (JJ fetal) (NN development))) (PP (IN at) (NP (ADJP (RB clinically) (JJ relevant)) (NNS exposures))))))))) (. .)))
(S1 (S (S (NP (JJ Nursing) (NNS Mothers) (NN drug1)) (VP (VBZ is) (VP (VBN found) (PP (IN in) (NP (NN rat) (NN milk))) (PP (IN at) (NP (NP (NNS levels)) (ADJP (RB significantly) (JJR higher) (PRN (-LRB- -LRB-) (ADJP (RB approximately) (JJ 12-fold)) (-RRB- -RRB-)) (PP (IN than) (NP (NP (NN plasma)) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (CD 2) (NN mg/kg))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NN exposure)) (PP (IN in) (NP (NP (JJ rodent) (NNS pups)) (PP (IN from) (NP (NN drug1) (JJ -treated) (JJ lactating) (NNS dams)))))) (VP (VBD was) (VP (VBN estimated) (PP (IN as) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (DT the) (VBN administered) (NN dose)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN excreted) (PP (IN in) (NP (JJ human) (NN milk)))))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (JJ many) (NNS drugs)) (VP (VP (VBP are) (VP (VBN excreted) (PP (IN in) (NP (JJ human) (NN milk))))) (, ,) (CC and) (PP (IN because) (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (JJ serious) (JJ adverse) (NNS reactions)) (PP (IN from) (NP (NP (NN drug1)) (PP (IN in) (NP (JJ nursing) (NNS infants)))))))))))) (, ,) (NP (DT a) (NN decision)) (VP (MD should) (VP (VB be) (VP (VBN made) (SBAR (IN whether) (S (VP (VP (TO to) (VP (VBP discontinue) (NP (NN nursing)))) (CC or) (VP (TO to) (VP (VBP discontinue) (NP (NP (DT the) (NN drug)) (VP (VBG taking) (SBAR (IN into) (S (VP (VBP account) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (DT the) (NN drug))) (PP (TO to) (NP (DT the) (NN mother))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Pediatric) (NN Use) (NP (DT The) (NP (NN safety)) (CC and) (NP (NN efficacy)))) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (JJ pediatric) (NNS patients)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (NP (JJ Geriatric) (NN Use)) (SBAR (WHADVP (WRB When)) (S (NP (NN tumor) (NN response)) (VP (VBD was) (VP (VBN considered) (PP (IN by) (NP (NN age))))))) (, ,) (NP (NN objective) (NNS responses)) (VP (VBD were) (VP (VBN seen) (PP (PP (IN in) (NP (NP (NP (CD 24) (NN %)) (CC and) (NP (CD 22) (NN %))) (PP (IN of) (NP (NP (NNS patients)) (PP (IN under) (NP (NP (CD 65) (NNS years)) (PP (IN of) (NP (NN age))))))))) (CC and) (PP (IN in) (NP (NP (CD 16) (NN %)) (CC and) (NP (NP (CD 11) (NN %)) (PP (IN of) (NP (NP (NNS patients) (CD 65) (NNS years)) (PP (IN of) (NP (NP (NN age)) (CC and) (NP (JJR older)))) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NN drug1))) (PP (IN in) (NP (DT the) (NP (NNP European)) (CC and) (NP (NNP North) (NNP American)) (NP (NNS trials))))))))))) (, ,) (ADVP (RB respectively))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB predominantly)) (VP (VBN eliminated) (PP (IN in) (NP (DT the) (NN urine))) (PP (IN by) (NP (JJ active) (JJ organic) (NN cationic) (NN secretion)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN administered) (ADVP (RB concurrently)))))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (, ,) (SBAR (WHADVP (RB particularly) (WRB when)) (S (NP (NP (PRP$ their) (JJ main) (NN route)) (PP (IN of) (NP (NN elimination)))) (VP (VBZ is) (NP (JJ active) (JJ renal) (NN secretion)) (PP (IN via) (NP (NP (DT the) (JJ organic) (NN cationic) (NN transport) (NN system)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug1)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN change)) (PP (IN in) (NP (NP (NN dose)) (PP (IN of) (NP (DT either) (NN drug)))))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (NN information)) (PP (VBG regarding) (NP (NP (DT the) (NN effect)) (PP (IN on) (NP (NP (NN drug1) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN drug2) (: /) (NN drug3))))) (PP (JJ such) (IN as) (NP (NP (DT those)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NN Pneumocystis) (NN carinii) (NN pneumonia))))))))))))))) (. .)))
(S1 (S (S (NP (DT No) (NNS data)) (VP (VBP are) (ADJP (JJ available) (PP (VBG regarding) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (NP (JJ renal) (NN clearance) (NNS mechanisms)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NN drug1))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (JJ intracellular) (NN phosphorylation)) (PP (IN of) (NP (CD one) (DT another))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN drug1)) (VP (VP (VBZ decreases) (NP (NN drug2) (NN clearance)) (PP (IN by) (NP (QP (RB up) (TO to) (CD 25)) (NN %)))) (, ,) (CC and) (VP (MD may) (VP (VB produce) (NP (NNS AUCs) (NP (NN 1500) (NN M) (NN min))) (PP (IN in) (NP (DT some) (NNS patients)))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN drug1)) (, ,) (CC and) (NP (DT the) (NN drug2) (NN drug3))) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-)))) (VP (VBP have) (ADVP (RB all)) (VP (VBN been) (VP (VBN used) (PP (IN with) (NP (NN drug7))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ increases) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (NP (CD 15) (NN %)) (CC or) (NP (JJR more)))) (, ,) (PP (ADVP (RB possibly)) (JJ due) (TO to) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN glutathione-S-transferase))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (VP (VBN studied) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug2)))))))))) (, ,) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3))) (PP (IN at) (NP (DT the) (VBN recommended) (NN dose)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (JJR lower)) (CC and) (ADJP (NP (NP (NN exposure)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (VP (RB not) (VBN treated) (PP (IN with) (NP (NN drug4)))))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN eliminated) (PP (IN from) (NP (DT the) (NN body))) (PP (IN via) (NP (NP (NN conjugation)) (PP (IN with) (NP (NN glutathione))))))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (NP (NP (JJ drug2)) (ADJP (JJ prior) (PP (TO to)))) (PRN (-LRB- -LRB-) (NP (CD 72) (NNS hours)) (-RRB- -RRB-))) (CC or) (NP (ADJP (JJ concurrent) (PP (IN with) (NP (NN drug3)))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN reduced) (NN drug4) (NN clearance)) (VP (VBN based) (PP (IN upon) (NP (NP (DT the) (JJ known) (NN property)) (PP (IN of) (NP (NN drug5))) (S (VP (TO to) (VP (VB decrease) (NP (NP (NN glutathione) (NNS levels)) (PP (IN in) (NP (DT the) (NP (NN blood)) (CC and) (NP (NNS tissues))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Catecholamine-depleting) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug1))) (-RRB- -RRB-))) (VP (MD may) (VP (VB have) (NP (DT an) (JJ additive) (NN effect)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (CD drug2) (NN s))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC plus) (NP (DT a) (NN catecholamine) (NN depletor)))))) (VP (MD should) (ADVP (RB therefore)) (VP (VB be) (ADVP (RB closely)) (VP (VBN observed) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NP (NN hypotension)) (CC and/or) (NP (JJ marked) (NN bradycardia))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB produce) (NP (NP (NN vertigo)) (, ,) (NP (NN syncope)) (, ,) (CC or) (NP (JJ postural) (NN hypotension))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB also)) (VP (VB have) (NP (DT an) (JJ additive) (NN effect)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB exacerbate) (NP (NP (DT the) (JJ rebound) (NN hypertension)) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VBP follow) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT the) (CD two) (NNS drugs)) (VP (VBP are) (VP (VBN coadministered))))) (, ,) (NP (DT the) (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN withdrawn) (NP (JJ several) (NNS days)) (PP (IN before) (NP (NP (DT the) (JJ gradual) (NN withdrawal)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (PP (IN If) (S (VP (VBG replacing) (NP (NN drug1)) (PP (IN by) (NP (NN drug2) (NN therapy)))))) (, ,) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (NN drug3)))) (VP (MD should) (VP (VB be) (VP (VBN delayed) (PP (IN for) (NP (NP (JJ several) (NNS days)) (PP (IN after) (NP (NP (NN drug4) (NN administration)) (VP (VBZ has) (VP (VBN stopped)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NP (NN prostaglandin) (NN synthase)) (JJ inhibiting) (NNS drugs)) (, ,) (PP (FW eg) (, ,) (NP (NN drug1))) (, ,)))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN Information)) (PP (IN on) (NP (NP (JJ concurrent) (NN usage)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBZ is) (VP (VBN limited)))) (. .)))
(S1 (S (NP (NP (NP (NNS Data)) (PP (IN from) (NP (JJ several) (NNS studies)))) (, ,) (NP (NP (NN ie)) (, ,) (NP (NN TIMI-II)) (, ,) (NP (NN ISIS-2))) (, ,)) (ADVP (RB currently)) (VP (VBP do) (RB not) (VP (VBP suggest) (NP (NP (DT any) (JJ clinical) (NN interaction)) (PP (IN between) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN in) (NP (DT the) (NP (JJ acute) (JJ myocardial) (NN infarction)) (NN setting)))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (VP (VBG taking) (NP (NN drug1))))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ anaphylactic) (NN reaction)) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS allergens)))))))))) (VP (MD may) (VP (VB have) (NP (DT a) (ADJP (RBR more) (JJ severe)) (NN reaction)) (PP (IN on) (NP (NP (JJ repeated) (NN challenge)) (, ,) (UCP (CC either) (ADJP (JJ accidental)) (, ,) (ADJP (ADJP (JJ diagnostic)) (CC or) (ADJP (JJ therapeutic))))))))) (. .)))
(S1 (S (S (NP (JJ Such) (NNS patients)) (VP (MD may) (VP (VB be) (ADJP (JJ unresponsive) (PP (TO to) (NP (NP (DT the) (JJ usual) (NNS doses)) (PP (IN of) (NP (NN drug1))) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (DT the) (JJ allergic) (NN reaction)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ augments) (NP (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug2) (NNS s)))) (CC and) (NP (NP (DT the) (NN muscle) (JJ relaxant) (NNS effects)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB augment) (NP (NP (DT the) (NN hypotension)) (VP (VBN caused) (PP (IN by) (NP (NP (DT the) (JJ ganglionic-blocking) (NN effect)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (PP (IN during) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (NNS patients)) (VP (JJ anaesthetised) (PP (IN with) (NP (NN drug2))) (SBAR (IN as) (S (NP (NNS arrhythmias)) (VP (MD may) (VP (VB be) (ADJP (JJ precipitated))))))))))))))) (. .)))
(S1 (S (S (S (PP (IN For) (NP (DT this) (NN reason))) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN restricted))))) (CC and) (S (NP (NP (DT an) (NN drug2)) (VP (VBN administered) (PP (IN as) (NP (JJ appropriate))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (ADVP (RB also)) (VP (VB be) (VP (VBN applied) (PP (PP (IN for) (NP (JJ other) (NN drug1))) (, ,) (CC and) (PP (IN for) (NP (NP (NN drug2)) (CC and) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (ADVP (RB also)) (VP (VB precipitate) (NP (NN arrhythmias)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Limited) (NP (NP (NN PK)) (CC and/or) (NP (NN PD))) (NNS studies)) (VP (VBG investigating) (NP (NP (JJ possible) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (JJ medicinal) (NNS products))))))) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vivo)) (NN interaction) (NNS studies)) (PP (IN in) (NP (NNS humans)))) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VP (VBP do) (RB not) (VP (VB affect) (NP (NP (DT the) (NN PK) (NNS properties)) (PP (IN of) (NP (NN drug3)))))) (, ,) (CC nor) (VP (VBZ does) (RB drug4) (VP (VB affect) (NP (NP (DT the) (NN PK) (NNS properties)) (PP (IN of) (NP (NP (NN drug5)) (CC or) (NP (NN drug6))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (JJ additional) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted)))))) (, ,) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NNS medications)) (VP (VBN used) (PP (RB concomitantly) (IN with) (NP (NP (NN drug1)) (PP (IN in) (NP (JJ clinical) (NNS trials))))))) (VP (VBD were) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (JJ clinical) (NN evidence)) (S (VP (TO to) (VP (VB suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ interacts) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (NNS compounds)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (ADJP (FW in) (FW vivo)) (NN interaction) (NN study)) (PP (IN in) (NP (NNS humans)))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT a) (JJ single) (NN 1mg) (NN dose)) (PP (IN of) (NP (NN drug1))) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (DT a) (JJ single) (ADJP (CD 900) (NN mg)) (NN dose)) (PP (IN of) (NP (NN drug2))))))) (VP (VBD was) (ADVP (RB generally)) (VP (ADVP (RB well)) (VBN tolerated))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ bleeding) (NN time)) (, ,) (NP (NP (NN PT)) (CC or) (NP (NN aPTT))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (ADJP (RB clinically) (JJ relevant)) (JJ pharmacokinetic) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD were) (VP (VBN observed)))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT that) (JJ same) (NN study))) (, ,) (NP (NN drug1)) (ADVP (RB alone)) (VP (VBD produced) (NP (DT a) (JJ marked) (NN inhibition)) (PP (IN in) (NP (NN platelet) (NN aggregation))) (ADVP (FW ex) (FW vivo)))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB alone)) (VP (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN platelet) (NN aggregation)))) (, ,) (CC but) (VP (VBD did) (ADVP (RB slightly)) (VP (VB enhance) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NN platelet) (NN aggregation))) (PP (IN by) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (PP (IN by) (NP (NN CYP1A2)))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN known) (SBAR (SBAR (IN that) (S (NP (NN CYP1A2)) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP (NP (JJ several) (NN medicinal) (NNS products)) (, ,) (PP (VBG including) (NP (NN drug1))))))))) (, ,) (CC and) (SBAR (IN such) (S (NP (NN medicinal) (NNS products)) (VP (MD could) (ADVP (RB theoretically)) (ADVP (RB adversely)) (VP (VB influence) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ demonstrates) (NP (NP (DT some) (JJ limited) (JJ inhibitory) (NN activity)) (PP (IN towards) (NP (NN CYP1A2))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB present) (NP (NP (DT a) (JJ theoretical) (NN potential)) (PP (IN for) (NP (NP (NN interaction)) (PP (IN with) (NP (JJ other) (JJ coadministered) (NN medicinal) (NNS products))))))))))) (S (VP (VBG sharing) (NP (DT that) (NN clearance) (NN mechanism)))))) (FW e.g.)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ demonstrates) (NP (NP (DT some) (JJ limited) (JJ inhibitory) (NN activity)) (PP (IN towards) (NP (NN CYP1A2))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VBP present) (NP (NP (DT a) (JJ theoretical) (NN potential)) (PP (IN for) (NP (NP (NN interaction)) (PP (IN with) (NP (NP (JJ other) (JJ coadministered) (NN medicinal) (NNS products)) (VP (VBG sharing) (NP (NP (DT that) (NN clearance) (NN mechanism)) (PP (FW e.g.) (NP (NN drug2))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (JJ cyclic) (NN AMP) (NN PDE) (CD III)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN medicinal) (NNS products))) (PP (IN with) (NP (NP (JJ similar) (NNS properties)) (PP (JJ such) (IN as) (NP (NNS inotropes) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN drug5)))))))) (VP (MD may) (VP (VB be) (ADJP (JJ exacerbated) (PP (IN by) (NP (NN drug6))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT a) (JJ single) (NN case) (NN report)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NN drug2) (NN absorption))))))))))))) (. .)))
(S1 (S (S (NP (NN Food)) (VP (VBZ has) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (NP (NP (NN Potential)) (PP (IN for) (NP (NN Interaction))) (PP (IN with) (NP (NN drug1))))))
(S1 (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (DT another) (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))))))))) (, ,) (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (JJ serious) (, ,) (ADJP (RB sometimes) (JJ fatal)) (, ,) (NNS reactions))) (PP (VBG including) (NP (NP (NN hyperthermia)) (, ,) (NP (NN rigidity)) (, ,) (NP (NN myoclonus)) (, ,) (NP (NP (JJ autonomic) (NN instability)) (PP (IN with) (NP (NP (JJ possible) (JJ rapid) (NNS fluctuations)) (PP (IN of) (NP (JJ vital) (NNS signs)))))) (, ,) (CC and) (NP (NP (JJ mental) (NN status) (NNS changes)) (SBAR (WHNP (WDT that)) (S (VP (VBP include) (NP (NP (JJ extreme) (NN agitation)) (VP (VBG progressing) (PP (TO to) (NP (NP (NN delirium)) (CC and) (NP (NN coma))))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS reactions)) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VP (VBP have) (VP (VBN discontinued) (NP (DT that) (NN drug)))) (CC and) (VP (VBP have) (VP (VBN been) (VP (VBN started) (PP (IN on) (NP (DT a) (NN drug1))))))))))))))) (. .)))
(S1 (S (S (NP (DT Some) (NNS cases)) (VP (VBD presented) (PP (IN with) (NP (NP (NNS features)) (VP (VBG resembling) (NP (JJ neuroleptic) (JJ malignant) (NN syndrome))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug1) (NNS Tablets)) (VP (RB not) (VP (VB be) (VP (VBN used) (PP (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2))))) (, ,) (CC or) (PP (IN within) (NP (NP (CD 14) (NNS days)) (PP (IN of) (NP (NP (NN discontinuing) (NN treatment)) (PP (IN with) (NP (DT a) (NN drug3)))))))))))))))) (. .)))
(S1 (S (S (PP (IN After) (S (VP (VBG stopping) (NP (NN drug1) (NNS Tablets))))) (, ,) (NP (QP (IN at) (JJS least) (CD 2)) (NNS weeks)) (VP (MD should) (VP (VB be) (VP (VBN allowed) (PP (IN before) (S (VP (VBG starting) (NP (DT a) (NN drug2))))))))) (. .)))
(S1 (S (NP (NP (JJ Potential) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3) (NNS Interactions)))))
(S1 (S (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBP are) (ADVP (RB all)) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450IIIA4) (NN isozyme)))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN drug4)) (, ,) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN IIIA4)))) (, ,)) (VP (VBZ blocks) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (DT these) (NNS drugs)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (JJ parent) (NN drug))))))))))))))) (. .)))
(S1 (S (S (NP (NP (VBN Increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))) (VP (VP (VBP cause) (NP (NN QT) (NN prolongation))) (CC and) (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NNS torsades)) (PP (FW de) (NP (JJ pointes-type) (JJ ventricular) (NN tachycardia))))) (, ,) (ADVP (RB sometimes)) (ADJP (JJ fatal))))))) (. .)))
(S1 (S (SBAR (IN As) (S (VP (VBN noted) (ADVP (IN below))))) (, ,) (NP (NP (NP (DT a) (NN sub-)) (PP (IN for) (NP (NN drug1))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))) (, ,) (NP (NP (DT a) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (JJ IIIA4) (NN isozyme))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (PRP it)) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB definitively)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (NP (DT a) (JJ potent) (NN IIIA4) (NN inhibitor)))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (, ,) (PP (IN given) (NP (NP (DT the) (JJ substantial) (NN interaction)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug1)) (VP (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (CC either) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (ADJP (RB Potentially) (JJ Important)) (NN Drug) (NNS Interactions)) (: :) (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2)) (VP (VBN metabolized) (PP (IN by) (NP (NP (JJ hepatic) (NN oxidation)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC drug5) (NP (NN elc.)))) (-RRB- -RRB-))))))) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (SBAR (IN because) (S (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (NN drug6))))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN clearance)) (PP (IN of) (NP (NN drug1) (NN metabolized))) (PP (IN by) (NP (NP (NN glucuronidation)) (PRN (-LRB- -LRB-) (NP (FW e.) (FW g.) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))))) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NN drug5)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (PRN (: :) (SBAR (WHADVP (WRB When)) (S (NP (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 100) (NN mg)) (NN qd)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 1) (NN mg)) (NN q.d.)) (VP (VBD were) (VBN co-administered) (PP (TO to) (NP (NP (JJ steady) (NN state)) (, ,) (NP (NP (NN plasma) (NN concentration)) (CC and) (NP (NP (JJ other) (NNS pharmacokinetics) (NNS parameters)) (PRN (-LRB- -LRB-) (NP (NP (NN AUC)) (, ,) (NP (NN Cmax)) (, ,) (NP (NN T1/2)))))) (, ,))))) (-RRB- -RRB-)))) (PP (IN of) (NP (NN drug4)))) (VP (VBD were) (ADVP (RB approximately) (RB twice)) (NP (NP (DT those)) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN drug5)) (VP (VBD was) (VP (VBN administered) (ADVP (RB alone))))))))))) (: ;)))))
(S1 (S (S (NP (JJ oral) (NN clearance)) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (QP (RB about) (CD 50)) (NN %)))))) (. .)))
(S1 (S (S (NP (DT The) (JJ elevated) (NN plasma) (NN drug1) (NNS concentrations)) (VP (VBD resulted) (PP (IN in) (NP (NP (VBN decreased) (NN psychomotor) (NN performance)) (CC and) (NP (NN memory)))))) (. .)))
(S1 (S (NP (NP (DT This) (NN interaction)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN investigated) (S (VP (VBG using) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN drug1))))))))))) (, ,)) (VP (MD may) (VP (VB be) (ADJP (RBR more) (JJ pronounced)) (SBAR (IN if) (S (S (NP (DT a) (ADJP (CD 300) (NN mg)) (JJ daily) (NN dose)) (VP (VBZ is) (VP (VBN co-administered)) (, ,) (SBAR (RB particularly) (S (SBAR (SBAR (IN since) (S (NP (NN drug2)) (VP (VBZ exhibits) (NP (JJ non-linear) (NNS pharmacokinetics)) (PP (IN over) (NP (DT the) (NN dosage) (NN range) (CD 100-300)))))) (CC mg.) (SBAR (IN If) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NN drug4) (NNS Tablets)))))))) (, ,) (NP (DT the) (JJ initial) (NN drug5) (NN dosage)) (VP (MD should) (VP (VB be) (ADVP (IN at) (JJS least)) (VP (VBN halved)))))))) (CC and) (S (NP (NP (NN titration)) (PP (TO to) (NP (DT the) (ADJP (JJS lowest) (JJ effective)) (NN dose)))) (VP (VBZ is) (VP (VBN recommended)))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ dosage) (NN adjustment)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (JJ drug1) (NNS Tablets)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN co-administration)) (PP (IN of) (NP (NP (NN drug2) (NNS Tablets)) (CC and) (NP (NNS drug3))))) (VP (VBZ is) (ADVP (RB generally)) (RB not) (ADJP (JJ advisable)))) (. .))))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ reduces) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (CC both) (NP (NN drug2)) (CC and) (NP (NP (PRP$ its) (JJ active) (NN metabolite)) (, ,) (NP (NN drug3))))))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ strong) (NN likelihood)) (PP (IN of) (NP (NP (JJ substantial) (NN accumulation)) (PP (IN of) (NP (DT both) (NNS species))) (PP (IN during) (NP (JJ chronic) (NN co-administration)))))))) (. .)))
(S1 (S (S (NP (NP (NN Evidence)) (VP (VBG supporting) (NP (DT the) (NN conclusion) (SBAR (IN that) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ inadvisable) (PP (TO to) (NP (NP (NN co-administer) (NN drug1)) (CC and) (NP (NN drug2))))))))))) (VP (VBZ is) (VP (VBN derived) (PP (IN from) (NP (NP (DT a) (NN study)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (JJ healthy) (NNS volunteers)) (VP (VBG taking) (NP (NP (CD 150) (NN mg/day)) (PP (IN of) (NP (NN drug3)))))) (VP (VBD were) (VP (VBN administered) (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (NP (CD 10) (NN mg)) (PP (IN of) (NP (NN drug4))))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT these) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NN R=) (NN B)) (-RRB- -RRB-)))) (, ,) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (NP (CD 65) (NN %)) (CC and) (NP (NP (DT that)) (PP (IN of) (NP (NN drug2)))))) (PP (TO to) (NP (NP (DT a) (NN level)) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (ADJP (RB too) (JJ low) (S (VP (TO to) (VP (VB measure) (PP (IN over) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (DT the) (ADJP (CD 2) (NN week)) (JJ long) (NN study))))))))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ likely) (SBAR (IN that) (S (VP (VBP experience) (S (ADVP (RB significantly)) (VP (VBZ underestimates) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NN accumulation)) (SBAR (WHNP (WDT that)) (S (VP (MD might) (VP (VB occur) (PP (IN with) (NP (JJ repealed) (NN drug1) (NN administration)))))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (SBAR (IN as) (S (VP (VBN noted) (PP (IN with) (NP (NN drug1)))))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (ADVP (RB even)) (VP (VB be) (ADJP (RBR more) (JJ pronounced)) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN administered) (PP (IN at) (NP (JJR higher) (NNS doses)))))))))) (. .)))
(S1 (S (S (ADVP (RB Accordingly)) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD should) (RB not) (ADVP (RB ordinarily)) (VP (VB be) (VP (VBN co-administered))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ steady-state) (NN drug2) (NN l50) (NN mg) (NN bid))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug3)))) (PRN (-LRB- -LRB-) (NP (CD 375) (NN mg)) (-RRB- -RRB-)))) (PP (IN as) (NP (ADJP (CD 442) (NN mg)) (NN drug4)))))) (VP (VBD was) (VP (VBN evaluated) (PP (IN in) (NP (CD 12) (ADJP (ADJP (ADJP (JJ healthy)) (ADJP (JJ non-smoking))) (, ,) (ADJP (JJ male))) (NNS volunteers)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN decreased) (ADVP (RB approximately) (RB 3-fold))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NN drug2))))))) (, ,) (NP (PRP$ its) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (TO to) (NP (NP (CD one) (JJ third)) (PP (IN of) (NP (NP (DT the) (NP (JJ usual) (JJ daily) (NN maintenance) (NN dose)) (CC and) (NP (NN plasma) (NNS concentrations))) (PP (IN of) (NP (NN drug3))) (S (MD should) (VP (TO to) (VP (VBN monitored)))))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ dosage) (NN adjustment)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (JJ drug1) (NNS Tablets)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 50) (NN mg)) (NN tid)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3))) (PP (IN for) (NP (CD two) (NNS weeks))))))) (, ,) (S (S (NP (NN drug4) (NN plasma) (NNS concentrations)) (VP (VBD increased) (PP (IN by) (NP (CD 98) (NN %))))) (CC and) (S (NP (NN prothrombin) (NNS times)) (VP (VBD were) (ADJP (JJ prolonged)))))) (. .))))
(S1 (S (ADVP (RB Thus)) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ oral) (NN drug1)) (CC and) (NP (NN drug2) (NNS Tablets))))) (VP (MD should) (VP (VBP have) (NP (NP (NP (PRP$ their) (NN prothrombin) (NN time)) (VP (VBN monitored))) (CC and) (NP (NP (PRP$ their) (NN drug3) (NN dose)) (VP (VBN adjusted) (ADVP (RB accordingly))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ dosage) (NN adjustment)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (JJ drug1) (NNS Tablets)))))) (. .)))
(S1 (S (PP (PP (IN In) (NP (JJ occasional) (JJ susceptible) (NNS patients))) (CC or) (PP (IN in) (NP (NP (DT those)) (VP (VBG receiving) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (NN antiparkinsonism) (NNS agents))) (-RRB- -RRB-))) (PP (IN in) (NP (NN addition))))))) (, ,) (NP (DT the) (JJ atropine-like) (NNS effects)) (VP (MD may) (VP (VB become) (ADJP (ADJP (RBR more) (JJ pronounced)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (JJ paralytic) (NNS ileus))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Close) (NN supervision)) (CC and) (NP (JJ careful) (NN adjustment))) (PP (IN of) (NP (NN dosage)))) (VP (VBZ is) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (NP (DT this) (NN drug)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (VP (VB Avoid) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNS preparations)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug1)) (CC and) (NP (JJ local) (NN drug2))) (SBAR (WHNP (WDT which)) (S (VP (VBP contain) (NP (NP (DT any) (NN drug3)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug4))) (, ,) (NP (NNS drug5)) (-RRB- -RRB-))))))))))) (, ,) (SBAR (IN since) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (NN drug6)) (VP (MD can) (VP (VB potentiate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNS catecholamines))))))))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (PP (IN with) (NP (NP (NNS agents)) (PP (IN that) (NP (JJR lower) (NN blood) (NN pressure))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VP (VB increase) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN drug)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ hepatic) (NN enzyme) (NNS inhibitors)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (, ,) (NP (NN drug3)) (-RRB- -RRB-))))))))) (CC and) (VP (VB decrease) (PP (IN by) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (JJ hepatic) (NN enzyme) (NNS inducers)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug4))) (, ,) (NP (NN drug5)) (-RRB- -RRB-)))))))))) (, ,) (CC and) (S (NP (NP (NN adjustment)) (PP (IN of) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NN drug6)))))) (VP (MD may) (ADVP (RB therefore)) (VP (VB be) (ADJP (JJ necessary))))) (. .)))
(S1 (S (S (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))) (S (NP (NP (DT The) (JJ biochemical) (NN activity)) (PP (IN of) (NP (NP (DT the) (NN drug) (NN metabolizing) (NN isozyme) (NN cytochrome) (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NN debrisoquin) (NN hydroxylase)) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN reduced) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (DT the) (NN caucasian) (NN population))))) (PRN (-LRB- -LRB-) (S (NP (NP (QP (RB about) (CD 7) (TO to) (CD 10)) (NN %)) (PP (IN of) (NP (NNS caucasians)))) (VP (VBP are) (ADVP (RB so)) (VP (VBN called) (NP (JJ poor) (NNS metabolizers))))) (-RRB- -RRB-)))) (: ;))))
(S1 (S (S (NP (NP (JJ reliable) (NNS estimates)) (PP (IN of) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (VBN reduced) (NN P450) (NN 2D6) (NN isozyme) (NN activity))) (PP (IN among) (NP (ADJP (ADJP (JJ Asian)) (, ,) (ADJP (JJ African)) (CC and) (ADJP (JJ other))) (NNS populations)))))) (VP (VBP are) (RB not) (ADVP (RB yet)) (ADJP (JJ available)))) (. .)))
(S1 (S (S (NP (JJ Poor) (NNS metabolizers)) (VP (VBP have) (NP (NP (JJR higher) (IN than) (VBN expected) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (JJ usual) (NNS doses))))))) (. .)))
(S1 (S (S (PP (VBG Depending) (PP (IN on) (NP (NP (DT the) (NN fraction)) (PP (IN of) (NP (NP (NN drug)) (VP (VBN metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))))))) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN plasma) (NN concentration)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (JJ small)) (, ,) (CC or) (RB quite) (ADJP (ADJP (JJ large)) (PRN (-LRB- -LRB-) (NP (NP (JJ 8-fold) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NN AUC)) (PP (IN of) (NP (DT the) (NN drug1)))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ certain) (NNS drugs)) (VP (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT this) (NN isozyme))))) (CC and) (VP (VB make) (NP (JJ normal) (NNS metabolizers)))) (VP (VBP resemble) (NP (NN p.o.)))))
(S1 (S (NP (NP (NN metabolizers)) (. .))))
(S1 (S (S (NP (NP (DT An) (JJ individual)) (SBAR (WHNP (WP who)) (S (VP (VBZ is) (ADJP (JJ stable) (PP (IN on) (NP (NP (DT a) (JJ given) (NN dose)) (PP (IN of) (NP (NN drug1)))))))))) (VP (MD may) (VP (VB become) (ADJP (RB abruptly) (JJ toxic)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT these) (JJ inhibiting) (NNS drugs)) (PP (IN as) (NP (JJ concomitant) (NN therapy)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6)))))) (VP (VBP include) (NP (NP (DT some)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN enzyme) (-LRB- -LRB-) (NN drug1)))))))))) (: ;)))
(S1 (S (NP (NP (NP (NNP drug1) (-RRB- -RRB-)) (CC and) (NP (NP (JJ many)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN for) (NP (NP (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NP (JJ many) (JJ other) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NP (DT the) (NN drug4) (NN drug5)) (CC and) (NP (NN drug6)))) (-RRB- -RRB-)))))))))) (. .))))
(S1 (S (S (SBAR (IN While) (S (NP (NP (NP (PDT all) (DT the) (NNS drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (NP (FW e.) (FW g.) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))) (, ,)) (VP (VBP inhibit) (NP (NN P450) (NN 2D6))))) (, ,) (NP (PRP they)) (VP (MD may) (VP (VB vary) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN inhibition)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN extent)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (NNS interactions)) (VP (MD may) (VP (VBP pose) (NP (JJ clinical) (NNS problems))))))) (VP (MD will) (VP (VB depend) (PP (IN on) (NP (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN inhibition)))) (, ,) (CC and) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT the) (NN drug3)) (VP (VBN involved)))))))))) (. .)))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN indicated) (PP (PP (IN in) (NP (NP (DT the) (NN co-administration)) (PP (IN of) (NP (NN TCA5))) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NN drug1))))))) (CC and) (PP (RB also) (IN in) (NP (NP (NN switching)) (PP (IN from) (NP (CD one) (NN class))) (PP (TO to) (NP (DT the) (JJ other))))))))) (. .)))
(S1 (S (PP (IN Of) (NP (JJ particular) (NN importance))) (, ,) (NP (JJ sufficient) (NN time)) (VP (MD must) (VP (VB elapse) (PP (IN before) (S (VP (VBG initiating) (NP (NN TCA) (NN treatment)) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG being) (VP (VBN withdrawn) (PP (IN from) (NP (NP (NP (NN drug1)) (, ,) (VP (VBN given) (NP (NP (DT the) (JJ long) (NN half-life)) (PP (IN of) (NP (DT the) (NN parent)))))) (CC and) (NP (NP (JJ active) (NN metabolite)) (PRN (-LRB- -LRB-) (NP (NP (QP (IN at) (JJS least) (CD 5)) (NNS weeks)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6))))))))) (VP (MD may) (VP (VB require) (NP (NP (JJR lower) (NNS doses)) (VP (ADVP (IN than) (RB usually)) (VBN prescribed) (PP (IN for) (NP (CC either) (NP (DT the) (NN drug2)) (CC or) (NP (DT the) (JJ other) (NN drug))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (S (ADVP (RB whenever)) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (JJ other) (NNS drugs)))) (VP (VBZ is) (VP (VBN withdrawn) (PP (IN from) (NP (NN cotherapy)))))) (, ,) (NP (NP (DT an) (VBN increased) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ desirable)) (S (VP (TO to) (VP (VB monitor) (NP (NN drug1) (NN plasma) (NNS levels)) (S (ADVP (RB whenever)) (NP (DT a) (NN drug2)) (VP (VBZ is) (ADJP (JJ going) (S (VP (TO to) (VP (VB be) (VP (VBN co-administered) (PP (IN with) (NP (NP (DT another) (NN drug)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN P450) (NN 2D6)))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (JJ Metal) (NNS Cations)) (, ,) (CC drug3) (NP (NN drug4))) (VP (VBP form) (NP (NNS chelates)) (PP (IN with) (NP (NP (NN alkaline) (NN earth)) (CC and) (NP (NN transition) (JJ metal) (NNS cations)))))) (. .)))
(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NN drug1)) (PP (PP (IN with) (NP (NP (NNS drug2)) (VP (VBG containing) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))))) (, ,) (PP (IN with) (NP (NN drug6))) (, ,) (PP (IN with) (NP (NP (JJ metal) (NNS cations)) (PP (JJ such) (IN as) (NP (NN drug7))))) (, ,) (CC or) (PP (IN with) (NP (NN drug8)))) (VP (VBG containing) (NP (NP (NN drug9)) (CC or) (NP (NN drug10))))))) (, ,) (PP (CC or) (PP (IN with) (NP (NP (NNS formulations)) (VP (VBG containing) (NP (NP (JJ divalent) (CC and) (JJ trivalent) (NNS cations)) (PP (JJ such) (IN as) (NP (NP (NN drug11) (-LRB- -LRB-) (CD drug12) (-RRB- -RRB-) (JJ chewable/buffered) (NNS tablets)) (CC or) (NP (NP (DT the) (JJ pediatric) (NN powder)) (PP (IN for) (NP (JJ oral) (NN solution))))))))))) (, ,) (VP (MD may) (ADVP (RB substantially)) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug13))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJ systemic) (NNS concentrations)) (ADJP (RB considerably) (JJR lower) (PP (IN than) (NP (JJ desired)))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS agents)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN within) (NP (NP (NP (CD 4) (NNS hours)) (PP (IN before))) (CC or) (NP (NP (CD 4) (NNS hours)) (PP (IN after) (NP (NN drug1) (NN administration)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN drug2) (NNS drug3)) (, ,) (PP (IN like) (NP (JJ other) (NNS drug4))) (, ,)) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug5)) (CC and) (NP (NN drug6)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS stimulants)) (VP (VBP are) (ADVP (RB commonly)) (VP (VBN found) (PP (IN in) (NP (NP (NN coffee)) (CC and) (NP (NN tea)))) (, ,) (ADVP (RB respectively))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (DT this)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (VBN reduced) (NN clearance)) (, ,) (NP (NP (NN prolongation)) (PP (IN of) (NP (NN plasma) (NN half-life)))) (, ,) (CC and) (NP (NP (VBN enhanced) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ is) (NP (NP (DT a) (JJ competitive) (NN inhibitor)) (PP (IN of) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NN Serum) (NN drug1) (NNS concentrations)) (VP (VBP increase) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN initiated) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN maintained) (PP (IN on) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBG initiating) (NP (NP (DT a) (JJ multi-day) (NN course)) (PP (IN of) (NP (NN drug1)))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN maintained) (PP (IN on) (NP (NN drug2))))))))) (, ,) (S (S (NP (DT the) (NN drug3) (NN maintenance) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN halved) (PP (IN for) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NN drug4))))))))))) (CC and) (S (NP (NP (NN monitoring)) (PP (IN of) (NP (NN serum) (NN drug5) (NNS concentrations)))) (VP (MD should) (VP (VB be) (VP (VBN initiated) (PP (IN as) (NP (NP (DT a) (NN guide)) (PP (TO to) (NP (JJ further) (JJ dosage) (NNS adjustments)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (NNS subjects)) (VP (VBG receiving) (NP (NN drug2))))) (, ,) (NP (NP (DT no) (JJ significant) (NN change)) (PP (IN in) (NP (NN clotting) (NN time)))) (VP (VBD was) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBD was) (VP (VBN coadministered)))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (SBAR (IN because) (S (NP (DT some) (NNS drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (PRP$ its) (NNS derivatives))))))))))))) (, ,) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ suitable) (NN anticoagulation) (NN test))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (SBAR (IN if) (S (NP (DT a) (NN drug3)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NP (NN drug4)) (CC or) (NP (PRP$ its) (NNS derivatives)))))))))))) (. .)))
(S1 (S (S (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NP (NN Cytochrome) (NN P450) (NNS Enzymes)) (S (NP (NP (DT The) (NN drug) (NN interaction) (NN study)) (VP (VBG evaluating) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN drug2)))))) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NN drug3)) (VP (VBZ inhibits) (NP (NP (NN drug4) (NN metabolism)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP (NN CYP1A2))))))))))))))))) (. .)))
(S1 (S (IN While) (S (NP (DT no) (JJ clinical) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN C.P.A.)))))))))))))))
(S1 (S (NP (NNS substrates)) (, ,) (NP (ADJP (FW in) (FW vitro)) (NNS data)) (VP (VBP suggest) (NP (NP (JJ similar) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (JJ CYP3A4) (JJ mediated) (NN metabolism)) (CC and) (NP (NN drug2) (NN metabolism)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ other) (NNS drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (JJ CYP3A4-mediated) (NN metabolism)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NNP C.P.A.)))))))
(S1 (S (S (VP (VBP include) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN relevance)) (PP (IN of) (NP (NP (DT the) (JJ potential) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN C.P.A.) (NNS substrates)))))))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (NNS substrates)) (PP (IN of) (NP (NNP C.P.A.)))))))) (VP (VBD were) (RB not) (VP (VBN excluded) (PP (IN from) (NP (NP (JJ clinical) (NNS trials)) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (DT a) (NN drug3)) (PP (IN with) (NP (DT a) (NN drug4)))))) (VP (MD may) (VP (VBP increase) (NP (NP (DT the) (NNS risks)) (PP (IN of) (NP (NP (NN CNS)) (NP (NN stimulation)) (CC and) (NP (NN convulsions)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NNS Disturbances)) (PP (IN of) (NP (NN blood) (NN glucose))) (, ,) (PP (VBG including) (NP (NP (NN hyperglycemia)) (CC and) (NP (NN hypoglycemia)))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (DT an) (NN drug3))))))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ careful) (NN monitoring)) (PP (IN of) (NP (NN blood) (NN glucose)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS agents)) (VP (VBP are) (VP (VBN coadministered)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN absorption)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NP (NP (DT the) (JJ simultaneous) (NN administration)) (PP (IN of) (NP (NN indigestion) (NNS remedies)))) (, ,) (NP (NN drug2)) (CC or) (NP (NN drug3) (NNS supplements)))))))) (. .)))
(S1 (S (S (NP (JJ Oral) (NN drug1)) (VP (MD may) (VP (VB be) (ADJP (RBR less) (JJ effective)) (SBAR (IN while) (S (NP (NN you)) (VP (VBP are) (VP (VBG taking) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Potential) (NN drug) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1) (-LRB- -LRB-) (NN drug2) (NN cream) (-RRB- -RRB-) (NN Cream)) (, ,) (NP (CD 1) (NN %)) (, ,) (CC and) (NP (JJ other) (NNS drugs))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB systematically)) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))) (VP (VBZ has) (VP (VBN been) (ADVP (RB safely)) (VP (VBN coadministered) (PP (IN with) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (DT A) (NN study)) (PP (IN in) (NP (JJ normal) (JJ healthy) (NNS volunteers))))) (VP (VBZ has) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (CC and) (NP (NN drug4))))) (VP (VBZ does) (RB not) (VP (VB result) (PP (IN in) (NP (NP (JJ altered) (NNS pharmacoktnetics)) (PP (IN of) (NP (DT either) (NN drug)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (JJ hypertensive) (NNS patients))))) (, ,) (S (NP (NP (NN addition)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NN existing) (NN drug2) (NN therapy)))) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (DT any) (JJ unexpected) (JJ adverse) (NNS effects)))))) (, ,) (CC and) (S (NP (NN drug3)) (VP (VBD had) (NP (DT an) (JJ additional) (JJ antihypertensive) (NN effect))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (JJ single) (NN dose) (NN study)) (PP (IN in) (NP (JJ normal) (NNS volunteers))))) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug2)))) (VP (VBD had) (NP (NP (NP (DT a) (JJ small) (NN effect)) (PP (IN on) (NP (DT the) (NN rate)))) (CC but) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN drug3) (NN bioavailability))))))))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Significant) (NNS increases)) (PP (IN In) (NP (NP (NP (NN AUC)) (PRN (-LRB- -LRB-) (NP (CD 27) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NN Cmax)) (PRN (-LRB- -LRB-) (NP (CD 58) (NN %)) (-RRB- -RRB-)))))) (CC and) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NP (NN tmax)) (PRN (-LRB- -LRB-) (NP (CD 23) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug1))))))) (VP (VBD were) (VP (VBN noted) (PP (IN in) (NP (DT this) (NN study)))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (ADJP (CD 5) (NN mg)) (NN b.i.d.) (NN drug1)) (CC and) (NP (ADJP (CD 40) (NN mg)) (NN b.i.d.)))))))
(S1 (S (S (NP (NP (NN drug1)) (PP (TO to) (NP (JJ healthy) (NNS volunteers))) (PP (IN under) (NP (JJ steady-state) (NNS conditions)))) (VP (VBD had) (NP (NP (NP (DT no) (JJ relevant) (NN effect)) (PP (IN on) (NP (DT either) (NN drug) (NN s) (NN bioavailability)))) (, ,) (NP (NP (NN AUC)) (CC and) (NP (NN Cmax))) (, ,) (NP (NP (NNS differences)) (VP (VBD were) (NP (CD 20) (NN %)) (PP (PP (IN between) (NP (NP (NN drug2)) (VP (VBN given) (UCP (ADVP (RB singly)) (CC and) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug3))))))))) (, ,) (CC and) (PP (IN between) (NP (NP (NNS drug4)) (VP (VBN given) (UCP (ADVP (RB singly)) (CC and) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug5))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))) (, ,) (NP (NP (DT a) (JJ one-week) (NN course)) (PP (IN of) (NP (NP (NN drug2)) (PP (IN at) (NP (ADJP (CD 400) (NN mg)) (NN b.i.d.))) (PP (IN with) (NP (NP (DT a) (JJ single) (ADJP (CD 5) (NN mg)) (NN dose)) (PP (IN of) (NP (NP (NN drug3)) (PP (IN on) (NP (DT the) (JJ sixth) (NN day)))))))))) (VP (VBD showed) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ drug4) (JJ mean) (NN peak) (NN plasma) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (CD 36) (NN %)) (-RRB- -RRB-))))) (CC and) (NP (NP (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NN area)) (PP (IN under) (NP (NP (DT the) (NN curve)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN %)) (-RRB- -RRB-)))))))))) (. .))))
(S1 (S (S (S (SBAR (IN If) (S (NP (NN drug1) (NN therapy)) (VP (VBZ is) (VP (VBN initiated) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (ADVP (RB currently)) (VBG receiving) (NP (NP (NN drug2) (JJ careful) (NN monitoring)) (PP (IN for) (NP (JJ adverse) (NNS reactions))))))))))) (VP (VBZ is) (ADJP (JJ advised)))) (CC and) (S (NP (JJ downward) (NN dose) (NN adjustment)) (VP (MD may) (VP (VB be) (VP (VBN required)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))) (, ,) (NP (NP (DT a) (JJ six-day) (NN course)) (PP (IN of) (NP (NN drug2))) (PP (IN at) (NP (NP (CD 600) (NN mg/day)) (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ single) (ADJP (CD 5) (NN mg)) (NN dose)) (PP (IN of) (NP (NN drug3))))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN drug4) (NNS levels))) (PP (TO to)) (PP (IN below) (NP (JJ detectable) (NNS limits))))))) (. .))))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1) (NN therapy)) (VP (VBZ is) (VP (VBN required))))) (, ,) (NP (NP (NN drug2) (NNS concentrations)) (CC and) (NP (JJ therapeutic) (NNS effects))) (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (VP (ADVP (RB markedly)) (VP (VBN reduced)) (CC or) (VP (VBN abolished) (PP (IN as) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (NP (VBN increased) (NN metabolism)) (CC and) (NP (NP (JJR higher) (NN clearance)) (PP (IN of) (NP (NN drug3)))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))) (, ,) (NP (NP (DT no) (ADJP (RB clinically) (JJ relevant)) (ADJP (ADJP (JJ pharmacokinetic)) (CC or) (ADJP (JJ pharmacodynamic))) (NN interaction)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (JJ racemic) (NN drug3))))) (VP (VBD was) (VP (VBN seen) (SBAR (WHADVP (WRB when)) (S (NP (NP (CD two) (JJ single) (JJ oral) (NNS doses)) (PP (IN of) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 0.7) (NN mg/kg) (NN body) (NN weight)) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN administered) (PP (IN during) (NP (NP (CD 11) (NNS days)) (PP (IN of) (NP (NP (NN multipledose) (NN treatment)) (PP (IN with) (NP (ADJP (CD 5) (NN mg)) (NN b.i.d.) (NN drug5)))))))))))))) (. .))))
(S1 (S (S (NP (CC Neither) (NP (JJ racemic) (NN drug1)) (CC nor) (NP (NP (NN drug2) (NN binding)) (PP (TO to) (NP (NN plasma) (NNS proteins))) (ADVP (FW in) (FW vitro)))) (VP (VBD was) (VP (VBN altered) (PP (IN by) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (DT the) (JJ other) (NN drug)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (CC and) (NP (NN drug4)))) (PP (IN in) (NP (DT a) (JJ single-dose) (JJ pharmacokinetic) (NN study)))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (ADJP (ADJP (JJ renal)) (, ,) (ADJP (JJ nonrenal)) (CC and) (ADJP (JJ total))) (NN body) (NN clearance)) (PP (IN of) (NP (NN drug5))))))) (. .))))
(S1 (S (NP (NP (JJ drug1) (NN Anesthesia)) (: :) (S (NP (JJ Severe) (NN hypotension)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (NN drug2) (NN anesthesia)) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (DT a) (NN drug3)) (CC and) (NP (DT a) (NN drug4)))))))))))) (. .))))
(S1 (S (S (SBAR (RB Even) (IN though) (S (NP (JJ such) (NNS interactions)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN seen) (PP (IN in) (NP (NP (JJ clinical) (NNS studies)) (PP (IN with) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))))))))) (, ,) (NP (NP (DT an) (VBN increased) (NN volume)) (PP (IN of) (NP (VBG circulating) (NNS fluids)))) (VP (MD might) (VP (VB be) (VP (VBN required) (SBAR (IN if) (S (NP (PDT such) (DT an) (NN interaction)) (VP (VBD were) (S (VP (TO to) (VP (VB occur))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ normal) (NNS volunteers)) (VP (VBG receiving) (NP (NN drug1))))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug2)))) (VP (VP (VBD decreased) (NP (DT the) (JJ renal) (NN clearance))) (CC and) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (NP (JJ combined) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (JJ fatal) (JJ gastrointestinal) (NN hemorrhage))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (JJ normal) (NNS volunteers))))) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN found) (SBAR (IN that) (S (NP (NP (JJ chronic) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (CD 3.6) (NN g)) (PP (IN of) (NP (NN drug1))) (PP (IN per) (NP (NN day)))))) (VP (VBZ decreases) (NP (NP (NN drug2) (NN blood) (NNS levels)) (ADJP (QP (RB approximately) (CD 20)) (NN %))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NNS drug2)))) (VP (VBZ is) (RB not) (VP (VBN recommended) (PP (JJ due) (TO to) (NP (NP (DT the) (VBN increased) (NN possibility)) (PP (IN of) (NP (JJ gastrointestinal) (NN toxicity))))) (, ,) (PP (IN with) (NP (NP (ADJP (JJ little))) (CC or) (NP (DT no)) (NP (NP (NN increase)) (PP (IN in) (NP (NN efficacy))))))))) (. .)))
(S1 (S (S (NP (JJ Clinical) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB influence) (NP (NP (DT the) (NN hypoprothrombinemia)) (VP (VBN produced) (PP (IN by) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT any) (JJ additional) (NN drug)) (, ,) (PP (VBG including) (NP (NN drug1))) (, ,)) (VP (VBZ is) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug2) (NN therapy))))))))))) (, ,) (NP (DT the) (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN observed) (PP (IN for) (NP (NP (NNS alterations)) (PP (IN of) (NP (DT the) (NN prothrombin) (NN time))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ post-marketing) (VBP experience))) (, ,) (NP (JJ bleeding)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2))))))))) (, ,) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug3)))) (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (VP (VBN increased)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT a) (ADJP (RBR lower) (JJ total)) (JJ daily) (NN dosage)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB produce) (NP (DT a) (JJ satisfactory) (JJ therapeutic) (NN effect))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NNS increases)) (PP (IN in) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))))) (VP (VBP are) (VP (VBN made))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN made) (UCP (ADVP (RB carefully)) (CC and) (PP (IN in) (NP (JJ small) (NNS increments)))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB simultaneously)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN drug2)))))) (CC and) (VP (TO to) (VP (VB potentiate) (NP (PRP$ its) (NN toxicity)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (RB concomitantly) (IN with) (NP (NN drug2)))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN drug3) (JJ -induced) (NN toxicity))))) (, ,) (PP (ADVP (RB possibly)) (JJ due) (TO to) (NP (NP (VBN decreased) (NN synthesis)) (PP (IN of) (NP (JJ renal) (NN prostacyclin))))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug2))))))))) (, ,) (CC and) (S (NP (JJ renal) (NN function)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored)))))) (. .)))
(S1 (S (S (NP (NP (NNS Capsules)) (PP (IN drug1) (NP (ADJP (CD 50) (NN mg)) (NN t.i.d.)))) (VP (VBD produced) (NP (NP (NP (DT a) (ADJP (RB clinically) (JJ relevant)) (NN elevation)) (PP (IN of) (NP (NN plasma) (NN drug2)))) (CC and) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (JJ renal) (NN drug3) (NN clearance)) (PP (IN in) (NP (NP (NP (JJ psychiatric) (NNS patients)) (CC and) (NP (JJ normal) (NNS subjects))) (PP (IN with) (NP (JJ steady) (NN state) (NN plasma) (NN drug4) (NNS concentrations))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN effect)) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN prostaglandin) (NN synthesis))))))))) (. .)))
(S1 (S (S (PP (IN As) (NP (DT a) (NN consequence))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN given) (ADVP (RB concomitantly)))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN observed) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NN drug3) (NN toxicity))))))))) (. .)))
(S1 (S (NP (-LRB- -LRB-) (NP (NP (VBN Read) (NNS circulars)) (PP (IN for) (NP (NN drug1) (NNS preparations))) (PP (IN before) (NP (NP (NN use)) (PP (IN of) (NP (JJ such) (JJ concomitant) (NN therapy))))) (. .)) (-RRB- -RRB-))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (NN frequency)) (PP (IN of) (S (VP (VBG monitoring) (NP (NN serum) (NN drug1) (NN concentration)))))) (VP (MD should) (VP (VB be) (VP (VBN increased) (PP (IN at) (NP (NP (DT the) (NN outset)) (PP (IN of) (NP (JJ such) (NN combination) (NN drug) (NN treatment))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VP (VB increase) (NP (DT the) (NN serum) (NN concentration))) (CC and) (VP (VB prolong) (NP (NP (DT the) (NN half-life)) (PP (IN of) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (NP (NN serum) (NN drug3) (NNS levels)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (ADJP (ADJP (JJ diuretic)) (, ,) (ADJP (JJ natriuretic)) (, ,) (CC and) (ADJP (JJ antihypertensive))) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (PP (IN when) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (. .)))
(S1 (S (S (S (NP (-LRB- -LRB-) (NN drug1) (-RRB- -RRB-) (NNS drug2)) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly))))) (, ,) (S (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ desired) (NN effect)) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (VBZ is) (VP (VBN obtained))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ reduces) (NP (NP (NP (JJ basal) (NN plasma) (NN renin) (NN activity)) (PRN (-LRB- -LRB-) (NP (NN PRA)) (-RRB- -RRB-))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT those) (NNS elevations)) (PP (IN of) (NP (NP (NN PRA)) (VP (VBN induced) (PP (IN by) (NP (NP (NN drug2) (NN administration)) (, ,) (CC or) (NP (NN salt)) (CC or) (NP (NN volume) (NN depletion))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS facts)) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (VP (VBG evaluating) (NP (NP (NP (NN plasma) (NN renin)) (NN activity)) (PP (IN in) (NP (JJ hypertensive) (NNS patients))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (DT a) (NN maintenance) (NN schedule)) (PP (IN of) (NP (NN drug2)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ reversible) (JJ acute) (JJ renal) (NN failure)) (PP (IN in) (NP (NP (CD two)) (PP (IN of) (NP (CD four) (JJ healthy) (NNS volunteers)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB together)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (NP (DT each))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (NN serum) (NN potassium) (NNS levels))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ potential) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN on) (NP (NP (NN potassium) (NNS kinetics)) (CC and) (NP (JJ renal) (NN function))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS agents)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concurrently)))))))))) (. .)))
(S1 (S (S (NP (NP (JJS Most)) (PP (IN of) (NP (NP (DT the) (JJ above) (NNS effects)) (VP (VBG concerning) (NP (NN drug1)))))) (VP (VBP have) (VP (VBN been) (VP (VBN attributed) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (PP (TO to) (NP (NP (NNS mechanisms)) (VP (VBG involving) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN prostaglandin) (NN synthesis))) (PP (IN by) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Blunting)) (PP (IN of) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug1))))) (PP (IN by) (NP (NP (NNS drug2)) (PP (VBG including) (NP (NN drug3)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (DT these) (VBG blocking) (NNS agents)) (S (VP (TO to) (VP (VB treat) (NP (NN hypertension)))))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB carefully)) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB confirm) (SBAR (IN that) (S (NP (DT the) (JJ desired) (JJ therapeutic) (NN effect)) (VP (VBZ has) (VP (VBN been) (VP (VBN obtained)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (JJ antihypertensive) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (JJ False-negative) (NNS results)) (PP (IN in) (NP (NP (NP (DT the) (NN dexamethasone) (NN suppression) (NN test)) (PRN (-LRB- -LRB-) (NP (NN DST)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN drug1)))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (NNS results)) (PP (IN of) (NP (DT the) (NN DST)))) (VP (MD should) (VP (VB be) (VP (VBN interpreted) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (DT these) (NNS patients))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug1) (NN therapy)))) (VP (MD may) (VP (VB require) (NP (NP (NN dosage) (NN adjustment)) (PP (IN of) (NP (DT the) (NN anticoagulant)))) (PP (PP (IN during)) (CC and) (PP (IN after) (NP (NN drug2) (NN therapy))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (VP (ADVP (RB usually)) (VBZ depresses) (NP (NN drug2) (NN activity))) (CC and) (VP (MD may) (VP (VBP necessitate) (S (VP (VBG raising) (NP (DT the) (NN dosage)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (JJ oral) (NN drug2)))))) (CC and) (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ breakthrough) (JJ bleeding)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (JJ -containing) (NN drug3))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB formally)) (VP (VBN studied))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NN drug1)) (VP (VBZ has) (NP (NP (DT a) (JJR lower) (NN affinity)) (PP (IN for) (NP (NN drug2))) (PP (IN than) (PP (IN for) (NP (NN drug3)))))))) (, ,) (NP (NN drug4)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN with) (NP (ADJP (NN drug5) (JJ -containing)) (NN drug6))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ healthy) (NNS volunteers))) (, ,) (NP (NN drug1)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN drug2) (NNS pharmacokinetics)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB formally)) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Doses)) (PP (IN of) (NP (NN drug1)))) (NP (QP (RB up) (TO to) (CD 200)) (NN mg))) (VP (VBD were) (VP (VBN allowed) (PP (IN in) (NP (NP (JJ clinical) (NNS studies)) (PP (IN without) (NP (JJ negative) (NNS consequences)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB formally)) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN inhibition)) (PP (IN of) (NP (NN drug1) (NN metabolism))) (PP (IN by) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN expected) (PP (VBN based) (PP (IN on) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (DT an) (ADJP (FW in) (FW vitro)) (NN study))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN combined) (PP (IN with) (NP (JJ other) (NN iron) (NN chelator) (NNS therapies))) (, ,) (SBAR (IN as) (S (NP (NP (NN safety)) (PP (IN of) (NP (JJ such) (NNS combinations)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug/Food) (NNS Interactions) (NP (NP (DT The) (NN bioavailability)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-)))) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (ADVP (RB variably)) (VP (VBN increased)) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN with) (NP (DT a) (NN meal)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN on) (NP (DT an) (JJ empty) (NN stomach))) (PP (NP (CD 30) (NNS minutes)) (IN before) (NP (NN eating))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NNS tablets)) (PP (IN for) (NP (JJ oral) (NN suspension)))) (VP (MD can) (VP (VB be) (VP (VBN dispersed) (PP (IN in) (NP (NP (NN water)) (, ,) (NP (NN orange) (NN juice)) (, ,) (CC or) (NP (NN apple) (NN juice)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG receiving) (NP (NN drug2))))))))) (VP (MD may) (VP (VB potentiate) (NP (JJ renal) (NN disease) (NNS states))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1) (NN anion)) (, ,) (PP (IN because) (PP (IN of) (NP (NP (PRP$ its) (NN affinity)) (PP (IN for) (NP (NN protein)))))) (, ,) (VP (MD may) (VP (VB displace) (PP (IN from) (NP (PRP$ their) (NN binding) (NNS sites))) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (ADVP (RB also)) (ADJP (JJ albumin-bound))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Theoretically)) (, ,) (NP (DT the) (NN drug1) (NN anion) (PRP itself)) (VP (MD could) (ADVP (RB likewise)) (VP (VB be) (VP (VBN displaced))))) (. .)))
(S1 (S (S (NP (JJ Short-term) (JJ controlled) (NNS studies)) (VP (VBD failed) (S (VP (TO to) (VP (VB show) (SBAR (IN that) (S (S (VP (VBG taking) (NP (DT the) (NN drug)))) (ADVP (RB significantly)) (VP (VBZ affects) (NP (NN prothrombin) (NNS times)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (TO to) (NP (NP (NNS individuals)) (PP (IN on) (NP (NN drug1)))))))))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN advised) (ADVP (RB nonetheless)) (, ,) (SBAR (IN since) (S (NP (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN seen) (PP (IN with) (NP (NP (JJ other) (JJ nonsteroidal) (NNS agents)) (PP (IN of) (NP (DT this) (NN class))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (DT the) (NN drug)) (CC and) (NP (NP (DT a) (NN drug1)) (, ,) (NP (NN drug2)) (CC or) (NP (NN drug3)))))) (VP (MD should) (VP (VB be) (VP (VBN observed) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NP (NN toxicity)) (PP (TO to) (NP (DT these) (NNS drugs))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (IN because) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN displaced) (PP (IN from) (NP (PRP$ its) (NN binding) (NNS sites))) (PP (IN during) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug4)))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJR lower) (NN plasma) (NNS concentrations)) (CC and) (NP (NN peak) (NN plasma) (NNS levels)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ natriuretic) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (VP (VBN inhibited) (PP (IN by) (NP (NP (DT some) (NNS drugs)) (PP (IN of) (NP (DT this) (NN class))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (JJ renal) (NN drug1) (NN clearance)) (VP (VBG leading) (PP (TO to) (NP (NP (NNS increases)) (PP (IN in) (NP (NN plasma) (NN drug2) (NNS concentrations))))))))) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NN drug2))) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (JJ other) (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN given) (ADVP (RB concurrently)))) (VP (VP (VBZ increases) (NP (NN drug2) (NN anion) (NN plasma) (NNS levels))) (CC and) (VP (VBZ extends) (NP (PRP$ its) (NN plasma) (NN half-life)) (ADVP (RB significantly))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (JJ other) (NN drug3))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN drug4))) (PP (IN in) (NP (DT an) (JJ animal) (NN model)))) (, ,) (S (ADVP (RB possibly)) (VP (VBG increasing) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN drug5))))))))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (NP (NN drug1))) (VP (MD may) (VP (VP (VB decrease) (NP (NN platelet) (NN aggregation))) (CC and) (VP (VB prolong) (NP (JJ bleeding) (NN time)))))) (. .)))
(S1 (S (S (NP (DT This) (NN effect)) (VP (MD should) (VP (VB be) (VP (VBN kept) (PP (IN in) (NP (NN mind))))) (SBAR (WHADVP (WRB when)) (S (NP (JJ bleeding) (NNS times)) (VP (VBP are) (VP (VBN determined))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (JJ urinary) (NNS values)) (PP (IN for) (NP (JJ 17-ketogenic) (NNS steroids))))) (PP (IN because) (IN of) (NP (NP (DT an) (NN interaction)) (PP (IN between) (NP (NP (DT the) (NN drug)) (CC and/or) (NP (PRP$ its) (NNS metabolites)))) (PP (IN with) (NP (NP (NN m-dinitrobenzene)) (VP (VBN used) (PP (IN in) (NP (DT this) (NN assay))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (JJ 17-hydroxy-corticosteroid) (NNS measurements)) (PRN (-LRB- -LRB-) (NP (NN Porter-Silber) (NN test)) (-RRB- -RRB-))) (VP (VBP do) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB be) (ADVP (RB artifactually)) (VP (VBN altered))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug1)))) (VP (VB be) (VP (ADVP (RB temporarily)) (VBN discontinued) (PP (NP (CD 72) (NNS hours)) (IN before) (NP (NP (JJ adrenal) (NN function) (NNS tests)) (VP (VBP are) (VP (VBN performed) (SBAR (IN if) (S (NP (DT the) (NN Porter-Silber) (NN test)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN used))))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT some) (JJ urinary) (NNS assays)) (PP (IN of) (NP (NP (JJ 5-hydroxy) (JJ indoleacetic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN 5HIAA)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (QP (CD two) (CC or) (JJR more)) (NNS drugs)) (PP (IN with) (NP (JJ anticholinergic) (NN activity--such))) (PP (IN as) (NP (NP (NP (DT an) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN eg)) (, ,) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN eg)) (, ,) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (CC and/or) (NP (NP (DT a) (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN eg)) (, ,) (NP (NN drug6)) (-RRB- -RRB-)))))))) (ADVP (RB --commonly)) (VP (VBZ results) (PP (IN in) (NP (NP (JJ excessive) (JJ anticholinergic) (NNS effects)) (, ,) (PP (VBG including) (NP (NP (JJ dry) (NN mouth)) (CC and) (NP (VBN associated) (JJ dental) (NNS complications)) (, ,) (NP (JJ blurred) (NN vision)) (, ,) (CC and) (, ,) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN exposed) (PP (TO to) (NP (NP (JJ high) (NN temperature)) (CC and) (NP (NN humidity))))))) (, ,) (NP (NN hyperpyrexia)))))))) (. .)))
(S1 (S (NP (NNS Interactions)) (VP (MD may) (ADVP (RB also)) (VP (VB occur) (PP (IN with) (NP (NP (DT the) (NN following)) (: :) (NP (NN drug1)) (: /) (NP (NN drug2)) (, ,) (NP (NP (NNS drugs)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (DT an) (JJ overactive) (NN thyroid))))))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NP (NN drug12) (NN pain) (NN medication)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug13)) (-RRB- -RRB-))) (, ,) (NP (NP (NNS drugs)) (VP (VBN used) (S (VP (TO to) (VP (VB aid) (NP (NN sleep))))))) (, ,) (NP (NP (JJ drowsiness-causing) (NN drug14)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug15)) (-RRB- -RRB-))) (, ,) (NP (NP (DT any) (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB make) (ADJP (RB you) (JJ drowsy))))))))))) (. .)))
(S1 (S (NP (NP (NN Drug) (NNS Interactions)) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (PP (IN without) (NP (JJ adverse) (NNS effects)))))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (NP (NN administration)) (PP (IN of) (NP (NP (JJ multiple) (JJ oral) (NNS doses)) (PP (IN of) (NP (NN drug1))))) (PP (TO to) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBN stabilized) (PP (IN on) (NP (NP (DT a) (NN maintenance) (NN dose)) (PP (IN of) (NP (NN drug2)))))))))) (, ,) (NP (NP (DT a) (ADJP (CD 13) (NN %)) (ADJP (CD -19) (NN %)) (NN increase)) (PP (IN in) (NP (NN plasma) (NN drug3) (NNS levels)))) (VP (VBD occurred) (PP (IN at) (NP (CD six) (NNS hours))) (NP (NN postdose)))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (VP (VBG involving) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (S (ADVP (RB concurrently)) (, ,) (S (NP (NN plasma) (NN drug3) (NNS levels)) (VP (VBD were) (VP (VBN increased) (PP (IN about) (NP (CD 20) (NN %)))))) (CC and) (S (NP (NN drug4) (NNS levels)) (VP (VBD were) (VP (VBN increased) (PP (IN about) (NP (CD 30) (NN %))) (S (VP (VBN compared) (PP (TO to) (NP (NN control) (NNS values))))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT this) (JJ formal) (NN interaction) (NN study))) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD were) (DT each) (VP (VBN found) (S (VP (TO to) (VP (VB have) (NP (JJ negative) (JJ inotropic) (NNS effects))))))) (: ;)))
(S1 (S (S (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NNS drugs)) (VP (VBD were) (VP (VBN administered) (ADVP (RB together)))))) (, ,) (NP (DT the) (NNS effects)) (VP (VBD were) (ADJP (JJ additive)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (PP (IN on) (NP (DT the) (NN PR) (NNS interval)))) (VP (VBD were) (ADJP (ADJP (JJR less)) (PP (IN than) (ADJP (JJ additive)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN drug1) (JJ clinical) (NNS trials))) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBG receiving) (NP (NN drug2))))))) (ADVP (RB concurrently)) (VP (VBD did) (RB not) (VP (VBP experience) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (JJ side) (NNS effects))))))) (. .)))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (JJ additive) (JJ negative) (JJ inotropic) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (MD should) (VP (VB be) (VP (VBN recognized))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (ADVP (RB extensively)) (VP (VBN bound) (PP (TO to) (NP (NN plasma) (NNS proteins)))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN with) (NP (NP (JJ several) (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (VP (VBN administered) (ADVP (RB concomitantly)))))))))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (NN drug1) (NN binding)) (PP (TO to) (NP (JJ human) (NN plasma) (NNS proteins)))))) (VP (VBZ is) (ADJP (CC either) (ADJP (JJ unchanged)) (CC or) (ADJP (ADVP (RB only) (RB slightly)) (JJR less)))))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (ADVP (RB highly)) (ADJP (NN protein) (VBN bound)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug1)) (-RRB- -RRB-)))))))) (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (PP (IN in) (NP (NP (DT a) (JJ large) (NN number)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)) (PP (IN without) (NP (JJ apparent) (NN interaction)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Limited) (NNS data)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ known) (NN enzyme) (NNS inducers)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))))))) (VP (VBP indicate) (NP (NP (RB only) (DT a) (CD 30) (NN %) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN drug4) (NN elimination)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBG receiving) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN gm) (JJ daily)) (-RRB- -RRB-))) (PP (IN for) (NP (CD one) (NN week)))))) (, ,) (S (S (NP (NN plasma) (NN drug2) (NNS levels)) (VP (VBD increased) (PP (IN by) (NP (QP (RB about) (CD 30)) (NN %))))) (CC and) (S (NP (NN half-life)) (VP (VBD increased) (PP (IN by) (NP (QP (RB about) (CD 10)) (NN %))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN added) (PP (TO to) (NP (NN drug2) (NN therapy))))))) (, ,) (NP (NN plasma) (NN drug3) (NNS levels)) (VP (MD may) (VP (VB increase) (ADVP (ADVP (RB two-fold)) (CC or) (RBR more)) (PP (IN in) (NP (DT some) (NNS patients))) (, ,) (SBAR (IN if) (S (NP (NN drug4) (NN dosage)) (VP (VBZ is) (RB not) (VP (VBN reduced)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN cytochrome) (NN P450IID6))))) (, ,) (PP (JJ such) (IN as) (NP (NN drug1))) (, ,)) (VP (MD might) (VP (VB increase) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (PP (IN on) (NP (JJ chronic) (NN drug3) (NN therapy)))))))))))) (: ;)))
(S1 (S (S (PP (ADVP (RB especially)) (IN if) (NP (DT these) (NNS patients))) (VP (VBP are) (NP (JJ extensive) (NNS metabolizers)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ has) (VP (VBN been) (NP (JJ little) (VBP experience)) (PP (IN with) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (CC either) (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NP (DT both)) (SBAR (IN of) (S (NP (DT these) (NNS drugs)) (VP (VBP have) (NP (NP (JJ negative) (JJ inotropic) (NNS properties)) (CC and) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN coadministration)) (PP (IN with) (NP (NN drug1))))))))))) (VP (VBP are) (ADJP (JJ unknown))))) (, ,) (NP (CC neither) (NP (NN drug2)) (CC nor) (NP (NN drug3))) (VP (MD should) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug4))) (SBAR (IN unless) (S (, ,) (PP (IN in) (NP (NP (DT the) (NN judgment)) (PP (IN of) (NP (DT the) (NN physician))))) (, ,) (NP (NP (DT the) (NNS benefits)) (PP (IN of) (NP (DT this) (NN combination)))) (VP (VBP outweigh) (NP (DT the) (NNS risks))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ has) (VP (VBN been) (ADJP (RB too) (JJ little) (S (VP (VBP experience) (PP (IN with) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))) (S (VP (TO to) (VP (VB recommend) (NP (JJ concomitant) (NN use))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (DT an) (NN drug2)))) (: -) (CC and) (NP (NP (NN drug3) (JJ -containing) (NN drug4) (-LRB- -LRB-) (NN drug5) (-RRB- -RRB-) (NN *)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug6))))))) (VP (VBD was) (VP (VBN investigated) (PP (IN in) (NP (CD 12) (NN cancer) (NNS patients)))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (NP (DT a) (JJ small) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))))) (CC and) (NP (NP (CD one) (NN metabolite)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))) (: ;)))
(S1 (S (S (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (CD 3) (JJ major) (NNS metabolites)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (JJ drug1) (JJ Altered) (NN coagulation) (NNS parameters)) (CC and/or) (NP (ADJP (JJ bleeding)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (PP (VBN drug2) (PP (RB concomitantly) (IN with) (NP (NP (NNS drug3)) (PP (JJ such) (IN as) (NP (NP (NN drug4)) (CC and) (NP (NN drug5)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NN drug1)))) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN drug2)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB regularly)) (PP (IN for) (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (PRP$ their) (NN coagulation) (NNS parameters)) (PRN (-LRB- -LRB-) (NP (NP (NN PT)) (CC or) (NP (NN INR))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NP (DT The) (NN concentration)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN increased)))) (CC and) (S (NP (PRP$ its) (NN toxicity)) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (PP (IN by) (NP (NN drug3)))))))) (. .))))
(S1 (S (S (NP (NP (NNS Deaths)) (PP (IN from) (NP (NP (JJ severe) (NN enterocolitis)) (, ,) (NP (NN diarrhea)) (, ,) (CC and) (NP (NN dehydration))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (VP (VBG receiving) (NP (ADVP (RB weekly)) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Cytochrome) (NN P450) (NN 1A2)) (PRN (-LRB- -LRB-) (NP (NN CYP1A2)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (JJ major) (NN enzyme)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug1))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (VBZ has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VP (VB interact) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN for) (NP (NN CYP1A2)))))))))) (, ,) (VP (VB inhibit) (NP (NN CYP1A2))) (, ,) (CC or) (VP (VB induce) (NP (NN CYP1A2))))))))) (. .)))
(S1 (S (S (NP (JJ Few) (NNS data)) (VP (VBP exist) (PP (IN on) (NP (NP (NN drug) (NNS interactions)) (PP (IN with) (NP (NP (NN drug1)) (PP (IN in) (NP (NN preterm) (NNS neonates))))))))) (. .)))
(S1 (S (PP (VBN Based) (PP (IN on) (NP (JJ adult) (NNS data)))) (, ,) (S (S (NP (NP (JJR lower) (NNS doses)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN needed) (PP (VBG following) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN reported) (S (VP (TO to) (VP (VB decrease) (NP (NN drug2) (NN elimination)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (-RRB- -RRB-))))))))))))))))) (CC and) (S (NP (JJR higher) (NN drug5) (NNS doses)) (VP (MD may) (VP (VB be) (VP (VBN needed) (PP (VBG following) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP increase) (NP (NP (NN drug6) (NN elimination)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug7)) (CC and) (NP (NN drug8)))) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2))))) (VP (VBD reduced) (NP (DT the) (NN urine) (NN volume)) (PP (IN in) (NP (CD 4) (JJ healthy) (NNS volunteers))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN interaction))) (PP (IN in) (NP (NN preterm) (NNS neonates)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NP (NN Interconversion)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NN preterm) (NNS neonates))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (DT No) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NNS medicines)) (: -) (S (SBAR (IN Although) (S (NP (JJ certain) (NNS medicines)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB together)) (PP (IN at) (NP (NN all)))))))) (, ,) (PP (IN in) (NP (JJ other) (NNS cases))) (NP (CD two) (JJ different) (NNS medicines)) (VP (MD may) (VP (VB be) (VP (VBN used) (ADVP (RB together)) (SBAR (RB even) (IN if) (S (NP (DT an) (NN interaction)) (VP (MD might) (VP (VB occur))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT these) (NNS cases))) (, ,) (S (NP (NN your) (NN doctor)) (VP (MD may) (VP (VBP want) (S (VP (TO to) (VP (VB change) (NP (DT the) (NN dose)))))))) (, ,) (CC or) (S (NP (JJ other) (NNS precautions)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (ADVP (RB you)) (VP (VBP are) (VP (VBG using) (NP (NN drug1)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (RB especially) (JJ important)) (SBAR (IN that) (S (NP (NN your) (NN health) (NN care) (NN professional)) (VP (VB know) (SBAR (IN if) (S (NP (NN you)) (VP (VBP are) (VP (VBG using) (NP (DT the) (NN following))))))))))) (: :) (NP (NP (NN Eye) (NN product)) (VP (VBG containing) (NP (NN drug2)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (DT the) (NN drug2) (NN preparation)) (VP (VBG causing) (NP (DT a) (NN gritty) (NN substance))))) (S (VP (TO to) (VP (VB form)))))) (CC or) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (DT the) (NN preservative)) (PP (IN in) (NP (NP (DT the) (NN drug3) (NN preparation)) (VP (VBG causing) (NP (DT a) (JJ toxic) (NN effect)) (PP (IN in) (NP (DT the) (NN eye)))))))))))) (. .)))
(S1 (S (NP (NP (DT No) (JJ well-known) (NN drug) (NNS interactions)) (PP (IN with) (NP (NN drug1))))))
(S1 (S (S (NP (JJ Clinical) (NNS trials)) (VP (VBP have) (VP (VBN indicated) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD can) (VP (VB be) (ADVP (ADVP (RB effectively)) (CC and) (ADVP (RB safely))) (VP (VBN used) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NP (JJ standard) (JJ cystic) (NN fibrosis)) (NNS therapies)) (PP (VBG including) (NP (NP (ADJP (ADJP (JJ oral)) (, ,) (ADJP (JJ inhaled)) (CC and/or) (ADJP (JJ parenteral))) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN enzyme) (NNS supplements)) (, ,) (NP (NN drug4)) (, ,) (NP (ADJP (ADJP (JJ oral)) (CC or) (ADJP (JJ inhaled))) (NN drug5)) (, ,) (CC and) (NP (NN drug6)))))))))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (S (NP (ADJP (RB Clinically) (JJ meaningful)) (NN drug) (NNS interactions)) (VP (VP (VBP have) (VP (VBN occurred) (PP (IN with) (NP (NP (JJ concomitant) (NNS medications)) (CC and) (NP (VBP include)))))) (, ,) (CC but) (VP (VBP are) (RB not) (ADJP (JJ limited) (PP (TO to) (NP (DT the) (NN following))))))) (: :) (S (NP (NP (NNS Agents)) (VP (ADVP (RB Highly)) (VBN Bound) (PP (TO to) (NP (NN Plasma) (NN Protein) (NN drug1))))) (VP (VBZ is) (RB not) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NN plasma) (NNS proteins)))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG taking) (NP (NP (DT another) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADVP (RB highly)) (VP (NN protein) (VBN bound)))))))))) (VP (MD should) (RB not) (VP (VB cause) (NP (NP (VBN increased) (JJ free) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ other) (NN drug))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NNS Agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP Inhibit) (NP (NN Cytochrome) (NN P450) (NNS Isoenzymes)))))) (CC and/or) (NP (NN Epoxide) (NN Hydrolase))) (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (ADVP (RB mainly)) (PP (IN by) (NP (NP (NP (NN cytochrome) (NN P450) (-LRB- -LRB-) (NN CYP) (-RRB- -RRB-) (NN 3A4)) (TO to) (NP (DT the) (JJ active) (NN drug2))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADVP (RB further)) (VP (VBN metabolized) (PP (TO to) (NP (DT the) (NN trans-diol))) (PP (IN by) (NP (NN epoxide) (NN hydrolase)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (DT the) (NN potential)) (VP (VBZ exists) (PP (IN for) (NP (NP (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (DT any) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VBZ inhibits) (NP (NN CYP3A4) (CC and/or) (NN epoxide) (NN hydrolase)))))))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (JJ CYP3A4) (NNS inhibitors)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VP (VBN found)) (, ,) (CC or) (VP (VBP are) (VP (VBN expected) (, ,) (S (VP (TO to) (VP (VB increase) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBP are) (NP (DT the) (NN following))))))))))))))))))))) (: :) (NP (NP (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,)) (NN drug10)) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (NN grapefruit) (NN juice)) (, ,) (NP (NN drug13)) (, ,) (NP (NN drug14)) (, ,) (NP (NN drug15)) (, ,) (NP (NN drug16)) (, ,) (NP (CD drug17)) (, ,) (NP (NN drug18)) (, ,) (NP (NN drug19)) (, ,) (NP (NN drug20)) (, ,) (NP (NN drug21)) (, ,) (NP (NN drug22)) (, ,) (NP (NN drug23)) (, ,) (NP (NN drug24)) (, ,) (NP (NN drug25) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-)) (, ,) (NP (NN drug26)) (, ,) (NP (NN drug27))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (, ,) (SBAR (IN if) (S (NP (DT a) (NN patient)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN titrated) (PP (TO to) (NP (NP (DT a) (JJ stable) (NN dosage)) (PP (IN of) (NP (NN drug1)))))))) (, ,) (CC and) (VP (ADVP (RB then)) (VBZ begins) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NN treatment)))) (PP (IN with) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (JJ CYP3A4) (CC or) (NN epoxide) (NN hydrolase) (NNS inhibitors))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ reasonable) (S (VP (TO to) (VP (VB expect) (SBAR (IN that) (S (NP (NP (DT a) (NN dose) (NN reduction)) (PP (IN for) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary)))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP Induce) (NP (NN Cytochrome) (NN P450) (NNS Isoenzymes)))))) (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (DT the) (NN potential)) (VP (VBZ exists) (PP (IN for) (NP (NP (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (DT any) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VBZ induces) (NP (NN CYP3A4)))))))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NNS Agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (JJ CYP) (NNS inducers)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP have) (VP (VBN been) (VP (VBN found)))) (, ,) (CC or) (VP (VBP are) (VP (VBN expected) (, ,) (S (VP (TO to) (VP (VB decrease) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (S (VP (VBP are) (NP (DT the) (NN following))))))))))))))))) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC and) (NP (NN drug10)))) (S (ADVP (RB Thus)) (, ,) (SBAR (IN if) (S (NP (DT a) (NN patient)) (VP (VBZ has) (VP (VBN been) (VP (VBN titrated) (PP (TO to) (NP (DT a) (JJ stable) (NN dosage))) (PP (IN on) (NP (NN drug11)))) (, ,) (CC and) (VP (ADVP (RB then)) (VBZ begins) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (JJ CYP3A4) (NNS inducers))))))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ reasonable) (S (VP (TO to) (VP (VB expect) (SBAR (IN that) (S (NP (NP (DT a) (NN dose) (NN increase)) (PP (IN for) (NP (NN drug12)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary)))))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Agents)) (PP (IN with) (NP (NP (VBN Decreased) (NNS Levels)) (PP (IN in) (NP (NP (DT the) (NN Presence)) (PP (IN of) (NP (NP (NN drug1)) (ADJP (JJ due) (PP (TO to) (NP (NP (NN Induction)) (PP (IN of) (NP (NN Cytochrome) (NN P450) (NNS Enzymes))))))))))))) (VP (VBP drug2) (S (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NP (NN CYP1A2)) (CC and) (NP (NN CYP3A4))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (DT the) (NN potential)) (VP (VBZ exists) (PP (IN for) (NP (NP (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (DT any) (NN agent)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NP (CD one)) (-LRB- -LRB-) (CC or) (NP (JJR more)) (-RRB- -RRB-)) (PP (IN of) (NP (DT these) (NNS enzymes))))))))))))) (. .)))
(S1 (S (NP (NP (NNS Agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VP (VBN found)) (, ,) (CC or) (VP (VBP are) (VP (VBN expected) (S (VP (TO to) (VP (VB have) (NP (VBN decreased) (NN plasma) (NNS levels)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN drug1)) (PP (JJ due) (TO to) (NP (NP (NN induction)) (PP (IN of) (NP (JJ CYP) (NNS enzymes))) (VP (VBP are) (NP (NP (DT the) (NN following)) (: :) (S (NP (NP (NP (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (CD drug10)) (, ,) (NP (NN drug11))) (, ,) (NP (CD drug12)) (, ,)) (CD drug13) (, ,) (CD drug14) (, ,) (CD drug15) (, ,) (CD drug16) (, ,) (CD drug17) (, ,) (CD drug18) (, ,) (CD drug19) (, ,) (CD drug20) (, ,) (CD drug21) (, ,) (CD drug22) (, ,) (CD drug23) (, ,) (CD drug24) (, ,) (CD drug25) (, ,) (NP (CD drug26)) (, ,) (NP (NN drug27)) (, ,) (NP (CD drug28)) (, ,) (NP (CD drug29)) (, ,) (NP (NN drug30)) (, ,)) (JJ oral) (NN drug31) (-LRB- -LRB-) (CD 3) (-RRB- -RRB-)) (, ,) (NP (NN drug32)) (, ,) (NP (NN drug33) (-LRB- -LRB-) (CD 4) (-RRB- -RRB-))) (VP (, ,) (CD drug34) (, ,) (CD drug35) (, ,) (CD drug36) (, ,) (CD drug37) (, ,) (CD drug38) (, ,) (CD drug39) (, ,) (NP (NP (NN drug40)) (, ,) (NP (NN drug41)) (, ,) (NP (NN drug42)) (, ,) (NP (NP (CD drug43)) (, ,) (NP (CD drug44) (-LRB- -LRB-) (CD 5) (-RRB- -RRB-)) (, ,) (NP (CD drug45)) (, ,) (CC and) (NP (CD drug46)))))))))))))))))))))))) (. .))))
(S1 (S (ADVP (RB Thus)) (, ,) (SBAR (IN if) (S (NP (DT a) (NN patient)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN titrated) (PP (TO to) (NP (DT a) (JJ stable) (NN dosage))) (PP (IN on) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS agents)) (PP (IN in) (NP (DT this) (NN category)))))))))) (, ,) (CC and) (VP (ADVP (RB then)) (VBZ begins) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NN treatment)))) (PP (IN with) (NP (NN drug1))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ reasonable) (S (VP (TO to) (VP (VB expect) (SBAR (IN that) (S (NP (NP (DT a) (NN dose) (NN increase)) (PP (IN for) (NP (DT the) (JJ concomitant) (NN agent)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NP (NNS Agents)) (PP (IN with) (NP (NP (VBN Increased) (NNS Levels)) (PP (IN in) (NP (NP (DT the) (NN Presence)) (PP (IN of) (NP (NN drug1)))))))) (: :) (S (NP (NN drug2)) (VP (VBZ increases) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (DT the) (JJ following) (NNS agents)))))) (: :) (NP (NP (NN drug3)) (, ,) (NP (NN drug4) (-LRB- -LRB-) (CD 6) (-RRB- -RRB-)) (, ,) (CC and) (NP (NN drug5))))) (S (ADVP (RB Thus)) (, ,) (SBAR (IN if) (S (NP (DT a) (NN patient)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN titrated) (PP (TO to) (NP (NP (DT a) (JJ stable) (NN dosage)) (PP (IN on) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS agents)) (PP (IN in) (NP (DT this) (NN category)))))))))))) (, ,) (CC and) (VP (ADVP (RB then)) (VBZ begins) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NP (DT the) (NN treatment)) (PP (IN with) (NP (NN drug6)))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ reasonable) (S (VP (TO to) (VP (VB expect) (SBAR (IN that) (S (NP (NP (DT a) (NN dose) (NN decrease)) (PP (IN for) (NP (DT the) (JJ concomitant) (NN agent)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Pharmacological/Pharmacodynamic) (NNS Interactions)) (PP (IN with) (NP (NP (JJ drug1) (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ neurotoxic) (JJ side) (NNS effects))))))) (. .)))
(S1 (S (S (PP (IN Given) (NP (NP (DT the) (JJ anticonvulsant) (NNS properties)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NN drug2)) (VP (MD may) (VP (VB reduce) (NP (DT the) (NN thyroid) (NN function)) (SBAR (IN as) (S (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (JJ other) (NN drug3))))))))))) (. .)))
(S1 (S (S (ADVP (RB Additionally)) (, ,) (NP (NP (NN drug1)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (, ,)) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (ADVP (RB Thus) (SBAR (IN if) (S (NP (DT a) (NN patient)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN titrated) (PP (TO to) (NP (NP (DT a) (JJ stable) (NN dosage)) (PP (IN on) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS agents)) (PP (IN in) (NP (DT this) (NN category)))))))))))) (, ,) (CC and) (VP (ADVP (RB then)) (VBZ begins) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug1))))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ reasonable) (S (VP (TO to) (VP (VB expect) (SBAR (IN that) (S (NP (DT a) (NN dose) (NN adjustment)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary)))))))))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (PRP$ its) (JJ primary) (NN CNS) (NN effect)))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN taken) (PP (IN with) (NP (NP (JJ other) (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (VP (MD may) (VP (VB counteract) (NP (NP (DT the) (JJ antinaturetic) (NN effect)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug3)))) (SBAR (IN if) (S (VP (VBN taken) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Organic) (NN drug1)) (CC -) (NP (NN drug2))) (NNS supplements)) (ADVP (RB theoretically)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ organic) (NN drug3)))) (SBAR (IN if) (S (VP (VBN taken) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: -) (S (ADVP (RB Theoretically)) (, ,) (NP (NP (NN drug2) (NNS supplements)) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3)))) (, ,)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT the) (NN drug))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (NN drug2) (NN response)) (PP (TO to) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (DT the) (NN cytochrome) (NN P450) (NN isoform) (NN CYP3A4)))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NNS drugs))) (VP (ADVP (RB primarily)) (VBN metabolized) (PP (IN by) (NP (NN CYP3A4))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (DT the) (JJ other) (NN drug)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VP (VB increase)) (CC or) (VP (VB prolong) (NP (PRP$ its) (ADJP (ADJP (JJ therapeutic)) (CC and) (ADJP (JJ adverse))) (NNS effects)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4)))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NN CYP3A4) (NN activity)))))) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJ lowered) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ other))) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN CYP3A4)))))))) (VP (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug2)))))) (CC and) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (NP (NN Table) (CD 8))))
(S1 (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (MD Should) (RB Not) (VP (VB Be) (VP (VBN Coadministered) (PP (IN with) (NP (NN drug1)))))))))))
(S1 (S (NP (NP (NN Drug) (NN Class)) (: :) (NP (NN Drug) (NN Name) (JJ Clinical) (NN Comment)))))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)))))
(S1 (S (S (VP (VBN CONTRAINDICATED) (PP (JJ due) (TO to) (NP (NP (NN potential)) (PP (IN for) (NP (NP (ADJP (ADJP (JJ serious)) (CC and/or) (ADJP (JJ life-threatening))) (NNS reactions)) (PP (JJ such) (IN as) (NP (JJ cardiac) (NNS arrhythmias))))))))) (. .)))
(S1 (S (NP (NP (NN Ergot) (NNS derivatives)) (: :) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))))))
(S1 (S (S (VP (VBN CONTRAINDICATED) (PP (JJ due) (TO to) (NP (NP (NN potential)) (PP (IN for) (NP (NP (ADJP (ADJP (JJ serious)) (CC and/or) (ADJP (JJ life-threatening))) (NNS reactions)) (PP (JJ such) (IN as) (NP (NP (JJ acute) (NN ergot) (NN toxicity)) (VP (VBN characterized) (PP (IN by) (NP (NP (NP (JJ peripheral) (NN vasospasm)) (CC and) (NP (NN ischemia))) (PP (IN of) (NP (DT the) (NP (NN extremities)) (CC and) (NP (JJ other) (NNS tissues))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (NP (NP (NN drug3)) (, ,) (NP (NN drug4))))))
(S1 (S (S (VP (VBN CONTRAINDICATED) (PP (JJ due) (TO to) (NP (NP (NN potential)) (PP (IN for) (NP (NP (ADJP (ADJP (JJ serious)) (CC and/or) (ADJP (JJ life-threatening))) (NNS reactions)) (PP (JJ such) (IN as) (NP (NP (ADJP (ADJP (JJ prolonged)) (CC or) (ADJP (VBN increased))) (NN sedation)) (CC or) (NP (JJ respiratory) (NN depression)))))))))) (. .)))
(S1 (S (NP (NP (NN GI) (NN motility) (NNS agents)) (: :) (NP (NN drug1)))))
(S1 (S (S (VP (VBN CONTRAINDICATED) (PP (JJ due) (TO to) (NP (NP (NN potential)) (PP (IN for) (NP (NP (ADJP (ADJP (JJ serious)) (CC and/or) (ADJP (JJ life-threatening))) (NNS reactions)) (PP (JJ such) (IN as) (NP (JJ cardiac) (NNS arrhythmias))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)))))
(S1 (S (S (VP (VBN CONTRAINDICATED) (PP (JJ due) (TO to) (NP (NP (NN potential)) (PP (IN for) (NP (NP (ADJP (ADJP (JJ serious)) (CC and/or) (ADJP (JJ life-threatening))) (NNS reactions)) (PP (JJ such) (IN as) (NP (JJ cardiac) (NNS arrhythmias))))))))) (. .)))
(S1 (S (NP (NP (JJ Herbal) (NNS products)) (: :) (NP (NP (NN St.) (NN John) (NN s) (NN wort)) (PRN (-LRB- -LRB-) (NP (NN Hypericum) (NN perforatum)) (-RRB- -RRB-))))))
(S1 (S (S (VP (MD May) (VP (VB lead) (PP (TO to) (NP (NP (NN loss)) (PP (IN of) (NP (NP (JJ virologic) (NN response)) (CC and) (NP (JJ possible) (NN resistance)))) (PP (PP (TO to) (NP (NN drug1))) (CC or) (PP (TO to) (NP (NP (DT the) (NN class)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)))))
(S1 (S (S (VP (MD May) (VP (VB lead) (PP (TO to) (NP (NP (NN loss)) (PP (IN of) (NP (NP (JJ virologic) (NN response)) (CC and) (NP (JJ possible) (NN resistance)))) (PP (PP (TO to) (NP (NN drug1))) (CC or) (PP (TO to) (NP (NP (DT the) (NN class)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (JJ other) (JJ coadministered) (NN drug3)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)) (, ,) (NP (NN drug3)))))
(S1 (S (S (ADJP (JJ Potential) (PP (IN for) (NP (NP (JJ serious) (NNS reactions)) (PP (JJ such) (IN as) (NP (NP (NN risk)) (PP (IN of) (NP (NN myopathy))))) (PP (VBG including) (NP (NN rhabdomyolysis))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)))))
(S1 (S (S (NP (CC Both) (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (JJ indirect) (-LRB- -LRB-) (JJ unconjugated) (-RRB- -RRB-) (NN hyperbilirubinemia)))))) (. .)))
(S1 (S (S (S (NP (NP (NNS Combinations)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (CC and) (S (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (RB not) (VP (VBN recommended))))) (. .)))
(S1 (S (NP (NN Table) (CD 9))))
(S1 (S (NP (NP (ADJP (ADJP (JJ Established)) (CC and) (ADJP (JJ Other))) (ADJP (RB Potentially) (JJ Significant)) (NN Drug) (NNS Interactions)) (: :) (S (NP (NP (NN Alteration)) (PP (IN in) (NP (NP (NN Dose)) (CC or) (NP (NN Regimen))))) (VP (MD May) (VP (VB Be) (VP (VBN Recommended) (PP (VBN Based) (PP (IN on) (NP (NP (NN Drug) (NN Interaction) (NNS Studies)) (CC or) (NP (VBN Predicted) (NN Interaction))))))))))))
(S1 (S (NP (NN Drug) (NN Name))))
(S1 (S (NP (NN Effect))))
(S1 (S (NP (JJ Clinical) (NN Comment))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (NP (NP (NN Dose) (NN reduction)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (CD 600) (NN mg)) (NP (DT every) (CD 8) (NNS hours))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (VP (VBG taking) (NP (NP (NN drug2) (CD 400) (NN mg) (CD three) (NNS times)) (NP (DT a) (NN day))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (NNS formulations)) (VP (VBG containing) (NP (NN buffer)))) (VP (MD should) (VP (VB be) (VP (VBN administered) (ADVP (NP (QP (IN at) (JJS least) (CD one)) (NN hour)) (RB apart)) (PP (IN on) (NP (DT an) (JJ empty) (NN stomach))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NP (DT The) (JJ optimal) (NN dose)) (PP (IN of) (NP (NN drug1))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))) (, ,)) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (S (VP (VBG Increasing) (NP (DT the) (NN drug1) (NN dose)) (PP (TO to) (NP (NP (CD 1000) (NN mg)) (NP (DT every) (CD 8) (NNS hours)))))) (VP (VBZ does) (RB not) (VP (VB compensate) (PP (IN for) (NP (NP (DT the) (VBN increased) (NN drug2) (NN metabolism)) (ADJP (JJ due) (PP (TO to) (NP (NN drug3))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NP (DT The) (JJ appropriate) (NNS doses)) (PP (IN for) (NP (DT this) (NN combination))) (, ,) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NN efficacy)) (CC and) (NP (NN safety)))))) (, ,)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NN drug1) (NNS concentrations)) (VP (MD may) (VP (VB be) (VP (VBN decreased) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ appropriate) (NNS doses)) (PP (IN for) (NP (DT this) (NN combination))) (, ,) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NN efficacy)) (CC and) (NP (NN safety)))))) (, ,)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration) (NN drug2) (NN concentration))))
(S1 (S (S (NP (NP (DT The) (JJ appropriate) (NNS doses)) (PP (IN for) (NP (DT this) (NN combination))) (, ,) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NN efficacy)) (CC and) (NP (NN safety)))))) (, ,)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (S (NP (JJ Preliminary) (JJ clinical) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NN nephrolithiasis)))) (VP (VBZ is) (ADJP (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))) (PP (IN than) (NP (NP (DT those)) (VP (VBG receiving) (NP (NP (NN drug3) (CD 800) (NN mg)) (NN q8h))))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NP (DT The) (JJ appropriate) (NNS doses)) (PP (IN for) (NP (DT this) (NN combination))) (, ,) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NN efficacy)) (CC and) (NP (NN safety)))))) (, ,)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (NP (JJ Other) (NNS Agents))))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (JJ systemic)) (-RRB- -RRB-))) (CC and) (NP (NN drug4)))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN warranted)))) (CC and) (S (NP (JJ therapeutic) (NN concentration) (NN monitoring)) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NN drug1))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (NP (NP (NN Use)) (PP (IN with) (NP (NN caution))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (RB not) (VP (VB be) (VP (JJ effective) (PP (JJ due) (TO to) (NP (NP (VBN decreased) (NN drug2) (NNS concentrations)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (DT these) (NNS agents))))))) (ADVP (RB concomitantly)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NP (NNP drug2)) (: :) (NP (FW e.g.))) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN warranted)))) (CC and) (S (NP (NP (JJ clinical) (NN monitoring)) (PP (IN of) (NP (NNS patients)))) (VP (VBZ is) (VP (VBN recommended))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration) (NN drug2) (NN concentration))))
(S1 (S (S (NP (NP (DT The) (JJ appropriate) (NNS doses)) (PP (IN for) (NP (DT this) (NN combination))) (, ,) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NN efficacy)) (CC and) (NP (NN safety)))))) (, ,)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (VP (VP (VB Use) (NP (NP (JJS lowest) (JJ possible) (NN dose)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN with) (NP (JJ careful) (NN monitoring))))))) (, ,) (CC or) (VP (VB consider) (NP (NP (NNS drug2)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (ADVP (RB primarily)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN CYP3A4)) (, ,) (CONJP (JJ such) (IN as)) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug6))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NN Plasma) (NNS concentrations)) (VP (MD may) (VP (VB be) (VP (VBN increased) (PP (IN by) (NP (NN drug1))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NP (NN Dose) (NN reduction)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (CD 600) (NN mg)) (NP (DT every) (CD 8) (NNS hours))))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NP (NN drug2)) (ADVP (RB concurrently))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NP (NN Dose) (NN reduction)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (CD 600) (NN mg)) (NP (DT every) (CD 8) (NNS hours))))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration) (NN drug2) (NN concentration))))
(S1 (S (S (NP (NP (NP (NN Dose) (NN reduction)) (PP (IN of) (NP (NP (NN drug1)) (PP (TO to) (NP (NN half) (NP (DT the) (JJ standard) (NN dose))))))) (CC and) (NP (NP (DT a) (NN dose) (NN increase)) (PP (IN of) (NP (NP (NN drug2) (TO to) (CD 1000) (NN mg)) (PRN (-LRB- -LRB-) (NP (CD three) (NN 333-mg) (NNS capsules)) (-RRB- -RRB-))))) (NP (DT every) (CD 8) (NNS hours))) (VP (VBP are) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBP are) (VP (VBN coadministered)))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NN drug1) (NN dose)) (VP (MD should) (RB not) (VP (VB exceed) (NP (NP (DT a) (NN maximum)) (PP (IN of) (NP (CD 25) (NN mg)))) (PP (IN in) (NP (NP (DT a) (ADJP (CD 48-) (NN hour)) (NN period)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ concomitant) (NN drug2) (NN therapy)))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NN drug1) (NN dose)) (VP (MD should) (RB not) (VP (VB exceed) (NP (NP (DT a) (NN maximum)) (PP (IN of) (NP (CD 10) (NN mg)))) (PP (IN in) (NP (NP (DT a) (NN 72-) (NN hour) (NN period)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ concomitant) (NN drug2) (NN therapy)))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NN drug1) (NN dose)) (VP (MD should) (RB not) (VP (VB exceed) (NP (NP (DT a) (NN maximum)) (PP (IN of) (NP (CD 2.5) (NN mg)))) (PP (IN in) (NP (NP (DT a) (JJ 24-hour) (NN period)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ concomitant) (NN drug2) (NN therapy)))))))))) (. .)))
(S1 (S (NP (NP (NN Note)) (: :))))
(S1 (S (S (VP (VBG =) (NP (NN increase)))) (: ;)))
(S1 (S (VP (VBD =) (NP (NN decrease)))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NP (NP (NP (NNS Interactions)) (PP (IN for) (NP (NN drug1)))) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))) (-RRB- -RRB-))) (: :) (NP (NP (NN drug6)) (: :) (S (NP (NN drug7)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NN drug8)))))))))))) (: ;))))
(S1 (S (S (PP (IN as) (NP (JJ such))) (NP (PRP it)) (VP (MD may) (VP (VB impair) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))))) (VP (MD will) (RB not) (VP (VB affect) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug5))))) (, ,) (CC but) (VP (MD may) (VP (VB reduce) (NP (NP (JJ endogenous) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug6) (NN /ergocalcitriol)))) (PP (IN by) (S (VP (VBG accelerating) (NP (NN metabolism))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (NN blood) (NN level)) (PP (IN of) (NP (NN drug1) (NN /ergocalcitriol)))) (VP (MD will) (VP (VB be) (VP (VBN reduced)))))) (, ,) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary)) (SBAR (IN if) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (ADVP (RB simultaneously))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NN hypercalcemia)) (PP (IN by) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NN calcium) (NN excretion))) (PP (IN in) (NP (NN urine))))))))))) (. .)))
(S1 (S (S (NP (DT Some) (NNS reports)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ causes) (NP (NN hypercalcemia)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN precaution)) (VP (MD should) (VP (VB be) (VP (VBN taken) (SBAR (WHADVP (WRB when)) (S (NP (NN coadministration)) (VP (VBZ is) (ADJP (JJ necessary))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2) (NN dosage)) (VP (MD must) (VP (VB be) (VP (VBN determined) (PP (IN with) (NP (NN care))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug3))))))) (, ,) (SBAR (IN as) (S (NP (NP (NN hypercalcemia)) (PP (IN in) (NP (JJ such) (NNS patients)))) (VP (MD may) (VP (VB precipitate) (NP (JJ cardiac) (NN arrhythmias)))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (VP (VB inhibit) (NP (NP (ADJP (CC both) (ADJP (JJ synthetic)) (CC and) (ADJP (JJ catabolic))) (NNS enzymes)) (PP (IN of) (NP (NN drug3))))))) (. .))))
(S1 (S (S (NP (NP (NNS Reductions)) (PP (IN in) (NP (NN serum) (NP (JJ endogenous) (NN vitamin) (NN D)) (NNS concentrations)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (CD 300) (NN mg/day))) (PP (TO to) (NP (NP (ADJP (CD 1200) (NN mg/day)) (NN drug1)) (PP (IN for) (NP (NP (DT a) (NN week)) (PP (TO to) (NP (JJ healthy) (NNS men))))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (ADJP (FW in) (FW vivo)) (NN drug) (NN interaction) (NNS studies)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN investigated))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT A) (NN relationship)) (PP (IN of) (NP (JJ functional) (NN antagonism)))) (VP (VBZ exists) (PP (IN between) (NP (NP (NP (NP (NN drug2)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP promote) (NP (NN calcium) (NN absorption))))) (, ,)) (CC and) (NP (NN drug3))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP inhibit) (NP (NN calcium) (NN absorption))))))))) (. .))))
(S1 (S (NP (NP (JJ Phosphate-Binding) (NNS Agents)) (: :) (S (SBAR (IN Since) (S (NP (NN drug1)) (ADVP (RB also)) (VP (VBZ has) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (NN phosphate) (NN transport)))) (PP (IN in) (NP (DT the) (NP (NP (NN intestine)) (, ,) (NP (NN kidneys)) (CC and) (NP (NN bones)))))))) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (JJ phosphate-binding) (NNS agents)))) (VP (MD must) (VP (VB be) (VP (VBN adjusted) (PP (IN in) (NP (NP (NN accordance)) (PP (IN with) (NP (DT the) (NN serum) (NN phosphate) (NN concentration))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NNS drug2)))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (IN as) (S (NP (DT this)) (VP (MD could) (VP (VB create) (NP (NP (JJ possible) (JJ additive) (NNS effects)) (CC and) (NP (NN hypercalcemia))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1) (NNS Supplements)) (: :) (S (NP (NP (JJ Uncontrolled) (NN intake)) (PP (IN of) (NP (JJ additional) (NN drug2) (JJ -containing) (NNS preparations)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2) (JJ -containing) (NNS preparations)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (VP (VP (MD may) (VP (VB cause) (NP (NN hypermagnesemia)))) (CC and) (VP (MD should) (ADVP (RB therefore)) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN during) (NP (NN therapy))) (PP (IN with) (NP (NN drug4))) (PP (IN by) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ chronic) (JJ renal) (NN dialysis)))))))))) (. .))))
(S1 (S (S (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))) (: -) (S (NP (NP (DT The) (JJ biochemical) (NN activity)) (PP (IN of) (NP (NP (DT the) (NN drug) (NN metabolizing) (NN isozyme) (NN cytochrome) (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NN debrisoquin) (NN hydroxylase)) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN reduced) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (DT the) (NN caucasian) (NN population))))) (PRN (-LRB- -LRB-) (S (NP (NP (QP (RB about) (CD 7-10)) (NN %)) (PP (IN of) (NP (NNS caucasians)))) (VP (VBP are) (ADVP (RB so)) (VP (VBN called) (NP (JJ poor) (NNS metabolizers))))) (-RRB- -RRB-))))) (: ;)))
(S1 (S (S (NP (NP (JJ reliable) (NNS estimates)) (PP (IN of) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (VBN reduced) (NN P450) (NN 2D6) (NN isozyme) (NN activity))) (PP (IN among) (NP (ADJP (ADJP (JJ Asian)) (, ,) (ADJP (JJ African)) (CC and) (ADJP (JJ other))) (NNS populations)))))) (VP (VBP are) (RB not) (ADVP (RB yet)) (ADJP (JJ available)))) (. .)))
(S1 (S (S (NP (JJ Poor) (NNS metabolizers)) (VP (VBP have) (NP (NP (JJR higher) (IN than) (VBN expected) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (JJ usual) (NNS doses))))))) (. .)))
(S1 (S (S (PP (VBG Depending) (PP (IN on) (NP (NP (DT the) (NN fraction)) (PP (IN of) (NP (NP (NN drug)) (VP (VBN metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))))))) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN plasma) (NN concentration)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (JJ small)) (, ,) (CC or) (RB quite) (ADJP (ADJP (JJ large)) (PRN (-LRB- -LRB-) (NP (NP (JJ 8-fold) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NN AUC)) (PP (IN of) (NP (DT the) (NN drug1)))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ certain) (NNS drugs)) (VP (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT this) (NN isozyme))))) (CC and) (VP (VB make) (NP (JJ normal) (NNS metabolizers)))) (VP (VBP resemble) (NP (JJ poor) (NNS metabolizers)))) (. .)))
(S1 (S (S (NP (NP (DT An) (JJ individual)) (SBAR (WHNP (WP who)) (S (VP (VBZ is) (ADJP (JJ stable) (PP (IN on) (NP (NP (DT a) (JJ given) (NN dose)) (PP (IN of) (NP (NN drug1)))))))))) (VP (MD may) (VP (VB become) (ADJP (RB abruptly) (JJ toxic)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT these) (JJ inhibiting) (NNS drugs)) (PP (IN as) (NP (JJ concomitant) (NN therapy)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6)))))) (VP (VBP include) (NP (NP (DT some)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN enzyme) (-LRB- -LRB-) (NN drug1)))))))))) (: ;)))
(S1 (S (NP (NP (NP (NNP drug1) (-RRB- -RRB-)) (CC and) (NP (NP (JJ many)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN for) (NP (NP (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NP (JJ many) (JJ other) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NP (DT the) (NN drug4) (NN drug5)) (CC and) (NP (NN drug6)))) (-RRB- -RRB-)))))))))) (. .))))
(S1 (S (S (SBAR (IN While) (S (NP (NP (NP (PDT all) (DT the) (JJ selective) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))) (, ,)) (VP (VBP inhibit) (NP (NN P450) (NN 2D6))))) (, ,) (NP (PRP they)) (VP (MD may) (VP (VB vary) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN inhibition)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN extent)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (NNS interactions)) (VP (MD may) (VP (VBP pose) (NP (JJ clinical) (NNS problems))))))) (VP (MD will) (VP (VB depend) (PP (IN on) (NP (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN inhibition)))) (CC and) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT the) (NN drug3)) (VP (VBN involved)))))))))) (. .)))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN indicated) (PP (PP (IN in) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NN drug2))))))) (CC and) (PP (RB also) (IN in) (NP (NP (NN switching)) (PP (IN from) (NP (CD one) (NN class))) (PP (TO to) (NP (DT the) (JJ other))))))))) (. .)))
(S1 (S (PP (IN Of) (NP (JJ particular) (NN importance))) (, ,) (NP (JJ sufficient) (NN time)) (VP (MD must) (VP (VB elapse) (PP (IN before) (S (VP (VBG initiating) (NP (NN TCA) (NN treatment)) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG being) (VP (VBN withdrawn) (PP (IN from) (NP (NP (NP (NN drug1)) (, ,) (VP (VBN given) (NP (NP (DT the) (JJ long) (NN half-life)) (PP (IN of) (NP (DT the) (NN parent)))))) (CC and) (NP (NP (JJ active) (NN metabolite)) (PRN (-LRB- -LRB-) (NP (NP (QP (IN at) (JJS least) (CD 5)) (NNS weeks)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6))))))))) (VP (MD may) (VP (VB require) (NP (NP (JJR lower) (NNS doses)) (VP (ADVP (IN than) (RB usually)) (VBN prescribed) (PP (IN for) (NP (CC either) (NP (DT the) (NN drug2)) (CC or) (NP (DT the) (JJ other) (NN drug))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (S (ADVP (RB whenever)) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (JJ other) (NNS drugs)))) (VP (VBZ is) (VP (VBN withdrawn) (PP (IN from) (NP (NN co-therapy)))))) (, ,) (NP (NP (DT an) (VBN increased) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ desirable)) (S (VP (TO to) (VP (VB monitor) (NP (NN drug1) (NN plasma) (NNS levels)) (S (ADVP (RB whenever)) (NP (DT a) (NN drug2)) (VP (VBZ is) (ADJP (JJ going) (S (VP (TO to) (VP (VB be) (VP (VBN coadministered) (PP (IN with) (NP (NP (DT another) (NN drug)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN P450) (NN 2D6)))))))))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (ADJP (ADJP (JJ drug2)) (CC or) (ADJP (RB similarly) (VBG acting))) (NNS compounds)) (: ;))))
(S1 (S (NP (NP (NN drug1)) (NP (NN medication) (: ;)))))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (JJ other) (NN drug3) (: ;)))))
(S1 (S (S (NP (NP (CC and) (NN drug1)) (SBAR (WHADVP (WRB When)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN given) (PP (IN with) (NP (NP (NP (NN drug3) (NNS agents)) (CC or) (NP (NN drug4) (NNS drugs))) (, ,) (PP (VBG including) (NP (NP (NN drug5)) (VP (VBN combined) (PP (IN with) (NP (NP (JJ local) (NN drug6)) (, ,) (NP (JJ close) (NN supervision)) (CC and) (NP (NP (JJ careful) (NN adjustment)) (PP (IN of) (NP (NNS dosages)))))))))))))))) (VP (VBP are) (VP (VBN required)))) (. .)))
(S1 (S (S (NP (NN Hyperpyrexia)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (PP (IN with) (NP (JJ drug2) (NNS agents))) (CC or) (PP (IN with) (NP (NN drug3) (NNS drugs)))) (, ,) (PP (ADVP (RB particularly)) (IN during) (NP (JJ hot) (NN weather))))))))))) (. .)))
(S1 (S (S (NP (JJ Paralytic) (NN ileus)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ drug2) (JJ -type) (NNS drugs))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (NP (JJ hepatic) (NN metabolism)) (PP (IN of) (NP (JJ certain) (NNS drug2)))))))) (, ,) (S (ADVP (RB thereby)) (VP (VP (VBG delaying) (NP (NN elimination))) (CC and) (VP (VBG increasing) (NP (NP (JJ steady-state) (NNS concentrations)) (PP (IN of) (NP (DT these) (NNS drug3))))))))) (. .)))
(S1 (S (S (NP (ADJP (RB Clinically) (JJ significant)) (NNS effects)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (DT the) (NN drug1)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Increases)) (PP (PP (IN in) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1))))) (, ,) (CC and) (PP (IN in) (NP (NP (DT the) (NP (NN frequency)) (CC and) (NP (NN severity))) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (, ,) (ADVP (RB particularly)) (NP (NN drug2)) (, ,))))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBD was) (VP (VBN added) (PP (TO to) (NP (DT the) (NN drug4) (NN regimen))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Discontinuation)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (JJ well-controlled) (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN plasma) (NNS levels)) (CC and) (NP (NP (NN efficacy)) (PP (IN of) (NP (DT the) (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN advised) (SBAR (IN if) (S (NP (NNS patients)) (VP (VBP receive) (NP (NP (JJ large) (NNS doses)) (PP (IN of) (NP (NN drug1)))) (ADVP (RB concurrently)))))))) (. .)))
(S1 (S (S (NP (JJ Transient) (NN delirium)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (CD one) (NN gram)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (CD 75) (: -) (CD 150) (NN mg)) (PP (IN of) (NP (NN drug2)))))))))))))))) (. .)))
(S1 (S (S (NP (VBN Increased) (NN nephrotoxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (VBG following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions) (CD drug1)) (, ,) (PP (VBG including) (NP (NN drug2))) (, ,)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (ADVP (RB occasionally)) (VP (VB induce) (NP (DT a) (JJ positive) (JJ direct) (NN Coombs) (NN test)))))))) (. .)))
(S1 (S (S (NP (JJ Steady) (NN state) (NN plasma) (NN drug1) (NNS concentrations)) (VP (VBD did) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB change))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN monitoring)) (PP (IN of) (NP (NN plasma) (NN drug1) (NNS levels)))) (VP (MD may) (VP (VB be) (VP (VBN indicated) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ similar) (NN combination) (NN chemotherapy) (NNS regimens))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN utilization)) (PP (IN of) (NP (NN drug1))) (PP (IN for) (NP (JJ such) (NNS patients)))) (VP (MD may) (VP (VB be) (VP (VBN considered) (PP (IN as) (NP (DT an) (NN alternative))))))) (. .)))
(S1 (S (S (ADVP (RB Also)) (VP (VBN drug1))) (. .)))
(S1 (S (NP (NP (DT No) (NN information)) (VP (VBN provided)))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Aerosol) (NN drug2)) (PP (IN of) (NP (DT the) (JJ short-acting) (JJ adrenergic) (NN stimulant) (NN type)))) (VP (MD may) (VP (VB be) (VP (VBN used) (PP (IN for) (NP (NP (NN relief)) (PP (IN of) (NP (NN breakthrough) (NNS symptoms))))) (SBAR (IN while) (S (VP (VBG using) (NP (NN drug3))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (VBG increasing) (NN use)) (PP (IN of) (NP (JJ such) (NNS preparations))) (PP (TO to) (NP (JJ control) (NNS symptoms)))) (VP (VBZ indicates) (NP (NP (NN deterioration)) (PP (IN of) (NP (NP (NN asthma) (NN control)) (CC and) (NP (DT the) (NN need) (S (VP (TO to) (VP (VB reassess) (NP (DT the) (NN patient) (NN s) (NN therapy))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (JJ other) (NN drug1)))) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ undesirable) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (: :) (S (NP (NN drug3)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NP (JJ extreme) (NN caution)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug4)) (CC or) (NP (NN drug5)))) (SBAR (IN because) (S (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug6))) (PP (IN on) (NP (DT the) (JJ cardiovascular) (NN system)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (DT these) (NNS agents)))))))))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (: :) (S (NP (NP (JJ Concomitant) (NN treatment)) (PP (IN with) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (NN drug6))))) (VP (MD may) (VP (VB potentiate) (NP (NP (DT a) (JJ possible) (JJ hypokalemic) (NN effect)) (PP (IN of) (NP (NN drug7))))))))))
(S1 (S (S (NP (NN Hypokalemia)) (VP (MD may) (VP (VB increase) (NP (NP (NN susceptibility)) (PP (TO to) (NP (JJ cardiac) (NNS arrhythmias)))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (JJ -adrenergic) (NN Blockers) (: :) (JJ -adrenergic) (NNS blockers)) (VP (MD may) (VP (VP (VB weaken)) (CC or) (VP (VB antagonise) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN given) (ADVP (RB together)) (PP (IN with) (NP (NP (JJ -adrenergic) (NNS blockers)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (NN eye) (NN drops))) (-RRB- -RRB-)))) (SBAR (IN unless) (S (NP (EX there)) (VP (VBP are) (NP (NP (JJ compelling) (NNS reasons)) (PP (IN for) (NP (PRP$ their) (NN use))))))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NNS Drugs)) (: :) (S (NP (NP (NNS Drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (JJ QT-interval) (NN prolongation)) (CC and) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ ventricular) (NN arrhythmia)))))))))) (. .))))
(S1 (S (S (S (NP (NN INFORMATION)) (VP (TO TO) (VP (VB BE) (VP (VBN PROVIDED) (PP (TO TO) (NP (DT THE) (NN PATIENT))))))) (CC OR) (S (NP (NNP GUARDIAN)) (VP (VB See) (VP (VBN illustrated) (NP (NP (NN Information)) (PP (IN For) (NP (DT The) (NN Patient) (CC or) (NN Guardian) (NN section)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ important)) (SBAR (IN that) (S (NP (NNS patients)) (VP (VB understand) (SBAR (SBAR (WRB how) (S (VP (TO to) (VP (VB use) (NP (NP (NN drug1) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-) (NNS capsules)) (PP (IN with) (NP (DT the) (VBN supplied) (NN AerolizerTM) (NN inhalation) (NN device)))))))) (CC and) (SBAR (WHADVP (WRB how)) (S (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (JJ other) (NN asthma) (CC or) (NN COPD) (NNS medications))))) (S (NP (PRP they)) (VP (VBP are) (VP (VBG taking))))))))))))))) (. .)))
(S1 (S (S (NP (NN Patients/Guardians)) (VP (MD should) (VP (VB be) (VP (VBN given) (S (NP (DT the) (VBG following) (NN information)) (: :) (NP (NN i))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (VBN recommended) (NN dosage)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD one) (CC or) (CD two)) (NNS capsules)) (ADVP (RB twice) (RB daily))) (, ,) (NP (NP (NN morning)) (CC and) (NP (NN evening)))) (-RRB- -RRB-))) (VP (MD should) (RB not) (VP (VB be) (VP (VBD exceeded))))) (. .)))
(S1 (S (NP (NP (NN ii)) (. .))))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (ADJP (JJ meant)) (S (VP (TO to) (VP (VBP relieve) (NP (JJ acute) (NN asthma) (CC or) (NN COPD) (NNS symptoms))))))) (CC and) (S (NP (JJ extra) (NNS doses)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN for) (NP (DT that) (NN purpose)))))))) (. .)))
(S1 (S (S (NP (JJ Acute) (NNS symptoms)) (VP (MD should) (VP (VB be) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ short-acting) (, ,) (JJ inhaled) (NN drug1)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (S (NP (DT the) (NN physician)) (VP (VP (MD should) (VP (VB provide) (NP (NP (DT the) (NN patient)) (PP (IN with) (NP (JJ such) (NN medication)))))) (CC and) (VP (VBP instruct) (NP (DT the) (NN patient)) (PP (IN in) (SBAR (WHADVP (WRB how)) (S (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN used)))))))))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (NP (NP (CD iii)) (. .))))
(S1 (S (S (NP (DT The) (NN physician)) (VP (MD should) (VP (VB be) (VP (VBN notified) (ADVP (RB immediately)) (SBAR (IN if) (S (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ following) (NNS situations)))) (VP (VBP occur) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN sign)) (PP (IN of) (NP (ADJP (RB seriously) (JJ worsening)) (NN asthma))))))))))))))) (: :) (NP (NP (VBN Decreased) (NN effectiveness)) (PP (IN of) (NP (NN drug1)))) (: ;)))
(S1 (S (S (VP (VBP Need) (PP (IN for) (NP (NP (JJR more) (NNS inhalations)) (PP (IN than) (NP (NP (JJ usual)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (NP (NP (NN iv)) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (DT a)) (VP (VB substitute) (PP (IN for) (NP (ADJP (ADJP (JJ oral)) (CC or) (ADJP (JJ inhaled))) (NN drug2)))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NN dosage)) (PP (IN of) (NP (DT these) (NNS medications)))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN changed))))) (CC and) (S (NP (PRP they)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN stopped) (PP (IN without) (S (VP (VBG consulting) (NP (DT the) (NN physician))))) (, ,) (SBAR (RB even) (IN if) (S (NP (DT the) (NN patient)) (VP (VBZ feels) (ADVP (RB better)) (PP (IN after) (S (VP (VBG initiating) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug1))))))))))))))) (. .)))
(S1 (S (S (NP (NN v.) (NNS Patients)) (VP (MD should) (VP (VB be) (VP (VBN cautioned) (PP (VBG regarding) (NP (NP (JJ potential) (JJ adverse) (JJ cardiovascular) (NNS effects)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNS palpitations)) (CC or) (NP (NN chest) (NN pain)))))))))) (. .)))
(S1 (S (LST (LS vi)) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))) (, ,) (NP (JJ other) (JJ inhaled) (NNS medications)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB only)) (SBAR (IN as) (S (VP (VBN directed) (PP (IN by) (NP (DT the) (NN physician)))))))))) (. .)))
(S1 (S (NP (NP (NN vii)) (. .))))
(S1 (S (NP (NP (NNS Guardians)) (PP (IN of) (NP (NP (NNS children)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN been) (VP (VBN prescribed) (NP (NN drug1)))))))))) (VP (MD should) (VP (VB be) (VP (VBN alerted) (PP (TO to) (NP (NP (DT the) (JJ general) (NN concern)) (VP (VBG regarding) (NP (NN asthma) (NN therapy) (NP (NN compliance)) (, ,) (NP (NP (RB especially) (NN neglect)) (PP (IN of) (NP (JJ anti-inflammatory) (NN therapy)))) (CC and) (NP (NP (NN overuse)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (ADVP (RB slightly)) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug2)))) (, ,) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5))))))) (. .)))
(S1 (S (S (NP (JJ Other) (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug2))))) (, ,) (SBAR (IN since) (S (NP (DT the) (NNS effects)) (VP (MD may) (VP (VB be) (ADJP (JJ additive)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (VBG including) (NP (NP (NN coumarin) (NNS derivatives)) (, ,) (NP (NN indandione) (NNS derivatives)) (, ,) (CC and) (NP (NP (NNS drug2)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN drug5)))))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ bleeding)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug6))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (ADJP (QP (CD 30) (TO to) (CD 45)) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NP (NN AUC)) (CC and) (NP (NN Cmax))) (PP (IN of) (NP (NN drug1)))))) (VP (VBD was) (VP (VBN observed) (PP (IN with) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))) (ADVP (RB twice) (RB daily))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (CD 150) (NN mg)) (ADVP (RB twice) (RB daily))) (VP (VBD did) (RB not) (VP (VB interact) (ADVP (RB significantly)) (PP (IN with) (NP (NN drug2))) (PRN (-LRB- -LRB-) (S (NP (NN AUC)) (VP (VBD was) (VP (VBN decreased) (PP (IN by) (NP (CD 15-20) (NN %)))))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ pharmacodynamic) (NNS effects)) (PP (IN of) (NP (DT either) (NN drug1)))) (VP (VBD were) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (CD 40) (NN mg) (NN drug2) (NNS tablets)) (PP (IN in) (NP (JJ epileptic) (NNS patients)))))) (VP (VBD lowered) (NP (DT the) (NN drug3) (NN plasma) (NNS concentrations)) (PP (TO to) (NP (JJ undetectable) (NNS levels))))) (. .)))
(S1 (S (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (DT any) (JJ known) (NN CYP3A4) (NN inducer))))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (CC and) (S (NP (JJ alternative) (NN drug3) (NN therapy)) (VP (MD should) (VP (VB be) (VP (VBN considered)))))) (. .)))
(S1 (S (S (NP (NP (JJ Pharmacokinetic) (NNS interactions)) (PP (IN between) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))))) (VP (VBD were) (ADJP (ADJP (JJ variable)) (CC and) (ADJP (RB not) (JJ significant))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD attenuated) (NP (DT the) (NN heart) (NN rate) (NN increase)) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (JJ immediate) (NN release) (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN blood) (NN pressure) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (VBD tended) (S (VP (TO to) (VP (VB be) (ADJP (ADJP (JJR greater)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug2))))) (PP (IN than) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (DT no) (JJ other) (NN drug3) (NN therapy)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN at) (NP (ADJP (CD 648) (NN mg)) (NN bid)))) (VP (VBD decreased) (NP (NP (NP (DT the) (NN bioavailability)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (CD 26) (NN %))) (, ,) (CONJP (CC but) (RB not)) (NP (DT the) (JJ peak) (NN concentration)))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ immediate) (NN release)) (, ,) (CONJP (CC but) (RB not)) (NP (NP (DT the) (JJ coat-core) (NN formulation)) (PP (IN of) (NP (NN drug1))))) (VP (VBD increased) (NP (NN plasma) (NN drug2) (NNS concentrations)) (PP (IN by) (NP (QP (RB about) (CD 20)) (NN %))))) (. .)))
(S1 (S (S (S (NP (DT This) (NN interaction)) (VP (VBD was) (RB not) (VP (VBN accompanied) (PP (IN by) (NP (NN ECG) (NNS changes)))))) (CC and) (S (NP (PRP$ its) (JJ clinical) (NN significance)) (VP (VBZ is) (RB not) (VP (VBN known))))) (. .)))
(S1 (S (S (NP (DT No) (JJ significant) (NNS interactions)) (VP (VBD were) (VP (VBN found) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (CC or) (NP (NN drug3))))))) (. .)))
(S1 (S (NP (NP (NN Hypotension)) (: :) (S (NP (NP (NP (NP (NNS Patients)) (PP (IN on) (NP (JJ Diuretic) (NN Therapy)))) (: :) (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug1))))) (CC and) (ADVP (RB especially)) (NP (NP (DT those)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ diuretic) (NN therapy)) (VP (VBD was) (ADVP (RB recently)) (VP (VBN instituted)))))) (, ,)) (VP (MD may) (ADVP (RB occasionally)) (VP (VBP experience) (NP (NP (DT an) (JJ excessive) (NN reduction)) (PP (IN of) (NP (NN blood) (NN pressure))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN therapy)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (NP (JJ hypotensive) (NNS effects)) (PP (IN with) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))))) (VP (MD can) (VP (VB be) (VP (VBN minimized) (PP (IN by) (S (VP (CC either) (VP (VBG discontinuing) (NP (DT the) (NN drug3))) (CC or) (VP (VBG increasing) (NP (NP (DT the) (NN salt) (NN intake)) (ADVP (ADVP (RB prior)) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN drug4)) (CC or) (NP (NN drug5)))))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ necessary) (S (VP (TO to) (VP (VBP continue) (NP (DT the) (NN drug1))))))))) (, ,) (VP (VBP provide) (NP (NP (JJ close) (JJ medical) (NN supervision)) (PP (IN after) (NP (DT the) (JJ initial) (NN dose))) (PP (PP (IN for) (NP (QP (IN at) (JJS least) (CD two)) (NNS hours))) (CC and) (PP (IN until) (NP (NN blood) (NN pressure))))) (VP (VBZ has) (VP (VBN stabilized) (PP (IN for) (NP (ADVP (IN at) (JJS least)) (NP (DT an) (JJ additional) (NN hour))))))) (. .)) (. .)))
(S1 (S (NP (NP (NP (NNS Agents)) (VP (VBG Causing) (NP (NN Renin) (NN Release)))) (: :) (S (NP (NP (DT The) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (CD IV))))) (VP (VBZ is) (VP (VBN augmented) (PP (IN by) (NP (NP (NN drug3)) (SBAR (WHNP (WDT that)) (S (VP (VBP cause) (NP (NP (NN renin) (NN release)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug4)) (-RRB- -RRB-))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT some) (NNS patients)) (PP (IN with) (NP (VBN compromised) (JJ renal) (NN function))) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN drug2)))))))))) (, ,) (NP (NP (DT the) (NN co-administration)) (PP (IN of) (NP (NN drug3)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ further) (NN deterioration)) (PP (IN of) (NP (JJ renal) (NN function)))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (VBP are) (ADVP (RB usually)) (ADJP (JJ reversible)))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT a) (JJ clinical) (NN pharmacology) (NN study))) (, ,) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (VP (VBD was) (VP (VBN administered) (PP (TO to) (NP (NP (JJ hypertensive) (NNS patients)) (VP (VBG receiving) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (DT a) (NN blunting)) (PP (IN of) (NP (NP (DT the) (JJ antihypertensive) (NN action)) (PP (IN of) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NNS reports)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN interaction)) (VP (MD should) (VP (VB be) (VP (VBN given) (NP (NP (NN consideration)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)))))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NN Cardiovascular) (NNS Agents)) (: :) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (CD IV)))) (VP (VBP have) (VP (VBN been) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (CC and) (NP (NN drug9)))) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (ADJP (RB clinically) (JJ significant)) (JJ adverse) (NNS interactions))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (CD IV)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (ADJP (RB clinically) (JJ significant)) (JJ adverse) (NNS reactions))))))))) (. .)))
(S1 (S (S (S (NP (NNS Agents)) (VP (VBG Increasing) (NP (NN Serum) (NN Potassium)))) (: :) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (CD IV))) (VP (VBP attenuate) (NP (NP (NN potassium) (NN loss)) (VP (VBN caused) (PP (IN by) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))) (-RRB- -RRB-))) (, ,) (NP (NN drug5) (NNS supplements)) (, ,) (CC or) (NP (NN drug6) (JJ -containing) (NN salt) (VBZ substitutes))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (NN serum) (NN potassium)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN if) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (VBZ is) (VP (VBN indicated) (PP (IN because) (IN of) (NP (VBN demonstrated) (NN hypokalemia))))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (PP (IN with) (NP (NN caution))) (CC and) (PP (IN with) (NP (NP (JJ frequent) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN potassium)))))))))) (. .)))
(S1 (S (S (NP (NN Potassium) (NN sparing) (NNS agents)) (VP (MD should) (ADVP (RB generally)) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN heart) (NN failure))) (VP (VBG receiving) (NP (NN drug1))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ drug2) (NN toxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug3)))) (PP (ADVP (RB concomitantly)) (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP cause) (NP (NP (NN elimination)) (PP (IN of) (NP (NN sodium))))))) (, ,) (PP (VBG including) (NP (NN drug4))))))))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN serum) (NN drug1) (NNS levels)) (VP (VB be) (VP (VBN monitored) (ADVP (RB frequently)) (SBAR (IN if) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN Wyeth-Ayerst) (NNS Laboratories))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT a) (JJ single) (NN study))) (, ,) (NP (NP (NNS rats)) (VP (VBN given) (NP (NP (JJ high) (JJ intraperitoneal) (NNS doses)) (PP (IN of) (NP (DT an) (NP (NN drug1)) (CC plus) (NP (NN drug2))))))) (VP (VBN experienced) (NP (JJ severe) (NN toxicity)) (, ,) (PP (VBG including) (NP (NP (NN convulsions)) (CC and) (NP (NN death)))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drug2))))) (VP (VBZ is) (ADVP (RB generally)) (RB not) (VP (VBN recommended) (PP (IN because) (IN of) (NP (JJ possible) (NN potentiating) (NNS effects)))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ is) (ADJP (RB especially) (JJ true) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (MD may) (VP (NN subject) (NP (PRP themselves)) (PP (TO to) (NP (NP (DT an) (NN overdosage)) (PP (IN of) (NP (NNS drugs)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN combination) (NN therapy)) (VP (VBZ is) (VP (VBN needed))))) (, ,) (NP (JJ careful) (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (DT the) (NN pharmacology)) (PP (IN of) (NP (DT all) (NNS agents))) (S (VP (TO to) (VP (VB be) (VP (VBN used))))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NP (NN monoamine) (NN oxidase)) (JJ inhibitory) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB persist) (PP (IN for) (NP (NP (DT a) (JJ substantial) (NN period)) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug)))))))))) (, ,) (CC and) (S (NP (DT this)) (VP (MD should) (VP (VB be) (VP (VBN borne) (PP (IN in) (NP (NN mind))) (SBAR (WHADVP (WRB when)) (S (NP (DT another) (NN drug)) (VP (VBZ is) (VP (VBN prescribed) (PP (VBG following) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (S (VP (TO To) (VP (VB avoid) (NP (NN potentiation))))) (, ,) (NP (DT the) (NN physician)) (VP (VBG wishing) (S (VP (TO to) (VP (VP (VB terminate) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug1))))) (CC and) (VP (VBP begin) (S (NP (NP (NN therapy)) (PP (IN with) (NP (DT another) (NN agent)))) (VP (MD should) (VP (VB allow) (PP (IN for) (NP (NP (DT an) (NN interval)) (PP (IN of) (NP (CD 10) (NNS days)))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: /) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,)) (PP (VBG Including) (NP (NN drug4)))))))
(S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJ local) (NN drug1)) (VP (VBG containing) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC or) (NP (NN drug6)))))))))) (VP (MD may) (VP (VB produce) (NP (ADJP (ADJP (JJ severe)) (, ,) (ADJP (JJ prolonged))) (NP (NN hypotension)) (CC or) (NP (NN hypertension)))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (MD should) (ADVP (RB generally)) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS situations)) (SBAR (WHADVP (WRB when)) (S (NP (JJ concurrent) (NN therapy)) (VP (VBZ is) (ADJP (JJ necessary))))))) (, ,) (NP (JJ careful) (NN patient) (NN monitoring)) (VP (VBZ is) (ADJP (JJ essential)))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN hypotension))) (ADJP (JJ related) (PP (TO to) (NP (JJ obstetric) (NNS blocks)))))) (-RRB- -RRB-))) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB cause) (NP (NP (JJ severe) (, ,) (JJ persistent) (NN hypertension)) (CC or) (NP (JJ cerebrovascular) (NN accidents)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ para-aminobenzoic) (NN acid) (NN metabolite)) (PP (IN of) (NP (NN chloroprocaine)))) (VP (VBZ inhibits) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug1)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (DT any) (NN condition)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT a) (NN drug2)) (VP (VBZ is) (VP (VBG being) (VP (VBN employed)))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4) (NN HC1))))) (: :) (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug5)))) (CC and) (NP (JJ non-selective) (NN drug6))) (VP (MD may) (VP (VB cause) (NP (NN hypertension))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN with) (NP (NP (ADJP (ADJP (JJ drug1)) (CC or) (ADJP (JJ other))) (NNS drugs)) (VP (ADVP (RB significantly)) (VBN eliminated) (PP (IN by) (NP (JJ active) (JJ renal) (JJ tubular) (NN secretion))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN conversion)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN catalyzed) (PP (IN by) (NP (NN aldehyde) (NN oxidase)))))) (. .)))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT this) (NN enzyme))))))) (VP (MD could) (ADVP (RB potentially)) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ enhances) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug2))))))))) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NN drug3)))) (VP (MD should) (VP (VB be) (VP (VBN reduced))) (S (VP (TO to) (VP (VB prevent) (NP (NP (JJ excessive) (NN prolongation)) (PP (IN of) (NP (DT the) (NN prothrombin) (NN time))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (JJR lower) (NP (NN drug3) (NN plasma) (NNS levels)) (, ,) (PP (ADVP (RB possibly)) (IN by) (S (VP (VBG competing) (PP (IN for) (NP (JJ protein-binding) (NNS sites))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ urinary) (NN excretion)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN unaffected) (PP (IN by) (NP (NN drug2))) (, ,) (S (VP (VBG indicating) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NN drug3) (NN absorption))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NN serum) (NN drug2) (NNS levels))))) (. .)))
(S1 (S (S (NP (JJR Greater) (NN fecal) (NN blood) (NN loss)) (VP (VBZ results) (PP (IN from) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (DT both) (NNS drugs))) (PP (IN than) (PP (IN from) (NP (NP (DT either) (NN drug)) (ADVP (RB alone))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (NP (NP (DT The) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (NNS s)))) (VP (VBZ does) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (NN absorption)) (PP (IN of) (NP (NN drug4)))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB affect) (NP (JJ central) (JJ nervous) (NN function))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NNS interactions)) (VP (MD could) (VP (VB occur) (PP (VBG following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBG possessing) (NP (ADJP (ADJP (JJ nephrotoxic) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (, ,) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (ADJP (JJ myelotoxic) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug3) (NN chemotherapy))) (-RRB- -RRB-))) (, ,) (ADJP (JJ cardiotoxic) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug4)) (-RRB- -RRB-))) (CC or) (ADJP (JJ hepatotoxic) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug5))) (, ,) (NP (NN drug6)) (-RRB- -RRB-)))) (NNS effects)) (PP (IN with) (NP (NN drug7))))))) (VP (MD may) (VP (VB increase) (NP (NN toxicity)) (PP (IN in) (NP (DT these) (NN organ) (NNS systems))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (NN safety)) (CC and) (NP (NN efficacy))) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (DT any) (NN drug2)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (VBN reduced) (NP (NP (NN kidney)) (CC and) (NP (NN liver))) (NN function)) (ADJP (JJ secondary) (PP (TO to) (NP (NN drug1) (NN treatment))))) (VP (MD may) (VP (VP (VB delay) (NP (NP (NN elimination)) (PP (IN of) (NP (JJ concomitant) (NNS medications))))) (CC and) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ adverse) (NNS events))) (PP (IN from) (NP (DT those) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (NN Hypersensitivity) (NNS reactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN combination) (NNS regimens)) (VP (VBG containing) (NP (NP (NP (JJ sequential) (JJ high) (NN dose) (NN drug1)) (CC and) (NP (NN drug2))) (, ,) (ADVP (RB specifically)) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS reactions)) (VP (VP (VBD consisted) (PP (IN of) (NP (NP (NN erythema)) (, ,) (NP (NN pruritus)) (, ,) (CC and) (NP (NN hypotension))))) (CC and) (VP (VBD occurred) (PP (IN within) (NP (NP (NNS hours)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (NN chemotherapy)))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS events)) (VP (VBD required) (NP (NP (JJ medical) (NN intervention)) (PP (IN in) (NP (DT some) (NNS patients)))))) (. .)))
(S1 (S (S (NP (NP (JJ Myocardial) (NN injury)) (, ,) (PP (VBG including) (NP (NP (JJ myocardial) (NN infarction)) (, ,) (NP (NN myocarditis)) (, ,) (NP (JJ ventricular) (NN hypokinesia)) (, ,) (CC and) (NP (JJ severe) (NN rhabdomyolysis))))) (VP (VBP appear) (S (VP (TO to) (VP (VB be) (VP (VBN increased) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (ADVP (RB concurrently)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Exacerbation)) (CC or) (NP (DT the) (JJ initial) (NN presentation))) (PP (IN of) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (ADJP (ADJP (JJ autoimmune)) (CC and) (ADJP (JJ inflammatory))) (NNS disorders)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (VBG following) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,) (PP (VBG including) (NP (NP (JJ crescentic) (NN IgA) (NN glomerulonephritis)) (, ,) (NP (JJ oculo-bulbar) (NN myasthenia) (NN gravis)) (, ,) (NP (JJ inflammatory) (NN arthritis)) (, ,) (NP (NN thyroiditis)) (, ,) (NP (NN bullous) (NN pemphigoid)) (, ,) (CC and) (NP (NN Stevens-Johnson) (NN syndrome)))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NN drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB reduce) (NP (NP (NN drug2) (JJ -induced) (JJ side) (NNS effects)) (PP (VBG including) (NP (NP (NN fever)) (, ,) (NP (JJ renal) (NN insufficiency)) (, ,) (NP (NN hyperbilirubinemia)) (, ,) (NP (NN confusion)) (, ,) (CC and) (NP (NN dyspnea))))))))))))) (, ,) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (DT these) (NNS agents))) (PP (IN with) (NP (NN drug3)))) (VP (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (JJ antitumor) (NN effectiveness)) (PP (IN of) (NP (NN drug4)))))) (CC and) (ADVP (RB thus)) (VP (MD should) (VP (VB be) (VP (VBN avoided.) (NP (CD 12) (NN drug5))))))) (CC and) (S (NP (JJ other) (NN drug6)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN hypotension)) (VP (VBN seen) (PP (IN with) (NP (NN drug7))))))))) (. .)))
(S1 (S (NP (NP (NP (VBN Delayed) (JJ Adverse) (NNS Reactions)) (PP (TO to) (NP (NN drug1)))) (: :) (NP (NP (DT A) (NN review)) (PP (IN of) (NP (NP (DT the) (NN literature)) (VP (VBN revealed) (PP (IN that) (NP (NP (NP (CD 12.6) (NN %)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 11-28) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (CD 501) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ various) (NN drug2) (NN containing) (NNS regimens)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB subsequently)) (VP (VBN administered) (NP (NP (NN drug3)) (VP (VBN experienced) (NP (ADJP (ADJP (JJ acute)) (, ,) (ADJP (JJ atypical))) (JJ adverse) (NNS reactions))))))))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN onset)) (PP (IN of) (NP (NNS symptoms)))) (ADVP (RB usually)) (VP (VBD occurred) (PP (IN within) (NP (NP (NP (NNS hours)) (PRN (-LRB- -LRB-) (NP (ADVP (RBS most) (RB commonly)) (QP (CD 1) (TO to) (CD 4)) (NNS hours)) (-RRB- -RRB-))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN contrast) (NNS media))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS reactions)) (VP (VBP include) (NP (NP (NN fever)) (, ,) (NP (NN chills)) (, ,) (NP (NP (NN nausea)) (, ,) (NP (NN vomiting)) (, ,) (NP (NN pruritus)) (, ,) (NP (NN rash)) (, ,) (NP (NN diarrhea)) (, ,) (NP (NN hypotension)) (, ,) (NP (NN edema)) (, ,) (CC and) (NP (NN oliguria)))))) (. .)))
(S1 (S (S (NP (DT Some) (NNS clinicians)) (VP (VBP have) (VP (VBN noted) (SBAR (IN that) (S (S (NP (DT these) (NNS reactions)) (VP (VBP resemble) (NP (NP (DT the) (JJ immediate) (JJ side) (NNS effects)) (VP (VBN caused) (PP (IN by) (NP (NN drug1) (NN administration))))))) (, ,) (S (ADVP (RB however)) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (NN contrast) (NNS reactions))) (PP (IN after) (NP (NN interleukin-2) (NN therapy)))) (VP (VBZ is) (ADJP (JJ unknown))))))))) (. .)))
(S1 (S (S (NP (JJ Most) (NNS events)) (VP (VBD were) (VP (VBN reported) (S (VP (TO to) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN contrast) (NNS media)) (VP (VBD was) (VP (VBN given) (PP (IN within) (NP (CD 4) (NNS weeks))) (PP (IN after) (NP (NP (DT the) (JJ last) (NN dose)) (PP (IN of) (NP (NN drug1))))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS events)) (VP (VBD were) (ADVP (RB also)) (VP (VBN reported) (S (VP (TO to) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN contrast) (NNS media)) (VP (VBD was) (VP (VBN given) (NP (JJ several) (NNS months)) (PP (IN after) (NP (NN drug1) (NN treatment))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB alter) (NP (NN drug1) (NN plasma) (NNS concentrations))))))) (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB increase) (NP (NN drug2) (NN plasma) (NNS concentrations)))))))) (: :) (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug3)) (PP (IN with) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NP (DT the) (NN CYP3A4) (NN family)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7))) (-RRB- -RRB-)))))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Substances)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (DT the) (NN cytochrome) (NN P450) (NN isoenzyme) (-LRB- -LRB-) (NN CYP3A4) (-RRB- -RRB-) (NN activity)))))) (VP (MD may) (VP (VP (VB decrease) (NP (NN metabolism))) (CC and) (VP (VB increase) (NP (NN drug1) (NNS concentrations)))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NN exposure)) (PP (TO to) (NP (NN drug1)))))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN CYP3A4) (NN inhibitor)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB decrease) (NP (NN drug1) (NN plasma) (NNS concentrations))))))) (: :) (NP (NP (NNS Substances)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS inducers)) (PP (IN of) (NP (NN CYP3A4) (NN activity))))))))) (VP (MD may) (VP (VP (VBP increase) (NP (NN metabolism))) (CC and) (VP (VBP decrease) (NP (NN drug2) (NN plasma) (NNS concentrations)))))) (. .)))
(S1 (S (NP (NP (NP (NNS Co-medications)) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NN CYP3A4)))))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC or) (NP (NN St.))))))))
(S1 (S (S (NP (NNP Johns) (NNP Wort) (-RRB- -RRB-)) (VP (MD may) (ADVP (RB significantly)) (VP (VB reduce) (NP (NP (NN exposure)) (PP (TO to) (NP (NN drug1))))))) (. .)))
(S1 (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (JJ healthy) (NNS volunteers))) (PP (IN with) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug2)))))))))) (, ,)) (VP (VBD increased) (NP (NN drug3) (JJ oral-dose) (NN clearance)) (PP (IN by) (NP (JJ 3.8-fold))) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NN p) (CD 0.05)) (-RRB- -RRB-))) (VP (VBD decreased) (NP (NP (NN mean) (NN cmax)) (CC and) (NP (NP (NN AUC)) (PRN (-LRB- -LRB-) (NP (NN 0-8)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (SBAR (WHADVP (WRB where)) (S (NP (NP (NN drug1)) (CC or) (NP (JJ other) (NN CYP3A4) (NNS inducers))) (VP (VBP are) (VP (VBN indicated))))))) (, ,) (NP (NP (JJ alternative) (JJ therapeutic) (NNS agents)) (PP (IN with) (NP (RBR less) (NN enzyme) (NN induction) (NN potential)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB have) (NP (PRP$ their) (NN plasma) (NN concentration))))))) (VP (VBN altered) (SBAR (IN by) (S (NP (NN drug1) (NN drug2)) (VP (VBZ increases) (NP (NP (DT the) (JJ mean) (NP (NN cmax)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (NP (NN drug3) (PRN (-LRB- -LRB-) (NP (NN CYP3A4) (NN substrate)) (-RRB- -RRB-)) (CD 2-)) (CC and) (NP (NN 3.5-fold)) (, ,) (ADVP (RB respectively))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT an) (NN inhibition)) (PP (IN of) (NP (DT the) (NN CYP3A4))) (PP (IN by) (NP (NN drug4)))))))))) (. .)))
(S1 (S (S (NP (JJ Particular) (NN caution)) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (IN with) (NP (NP (JJ CYP3A4) (NNS substrates)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (NP (DT a) (JJ narrow) (JJ therapeutic) (NN window)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD will) (VP (VB increase) (NP (NP (NN plasmaconcentration)) (PP (IN of) (NP (NP (JJ other) (JJ CYP3A4) (JJ metabolized) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (JJ triazolo-) (NNS drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (JJ certain) (NNS drug4)) (, ,) (NP (NN etc)) (. .)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN CYP2C9)) (CC and) (NP (NN CYP3A4)))))))) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP require) (NP (NN anticoagulation)))))) (VP (MD should) (VP (VBP receive) (NP (NP (JJ low-molecular) (NN weight)) (CC or) (NP (JJ standard) (NN drug2)))))) (. .)))
(S1 (S (S (ADVP (FW in) (FW vitro)) (, ,) (NP (NN drug1)) (VP (VBZ inhibits) (NP (DT the) (NP (NN cytochrome) (NN P450)) (NN isoenzyme) (NN CYP2D6) (NN activity)) (PP (IN at) (NP (NP (JJ similar) (NNS concentrations)) (SBAR (WHNP (WDT that)) (S (VP (VBP affect) (NP (NN CYP3A4) (NN activity))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Systemic) (NN exposure)) (PP (TO to) (NP (NP (NNS substrates)) (PP (IN of) (NP (NN CYP2D6)))))) (VP (VBZ is) (VP (VBN expected) (S (VP (TO to) (VP (VB be) (VP (VBN increased))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NNP Gleevec))))))))))) (. .)))
(S1 (S (S (S (NP (DT No) (JJ specific) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed))))) (CC and) (S (NP (NN caution)) (VP (VBZ is) (VP (VBN recommended))))) (. .)))
(S1 (S (S (ADVP (FW in) (FW vitro)) (, ,) (NP (NN drug1)) (VP (VBZ inhibits) (NP (NP (NN acetaminophen) (NN O-glucuronidation)) (PRN (-LRB- -LRB-) (NP (NP (NN Ki) (NN value)) (PP (IN of) (NP (CD 58.5) (NN M)))) (-RRB- -RRB-))) (PP (IN at) (NP (JJ therapeutic) (NNS levels))))) (. .)))
(S1 (S (S (NP (NP (JJ Systemic) (NN exposure)) (PP (TO to) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN expected) (S (VP (TO to) (VP (VB be) (VP (VBN increased) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT No) (JJ specific) (NNS studies)) (PP (IN in) (NP (NNS humans)))) (VP (VBP have) (VP (VBN been) (VP (VBN performed))))) (CC and) (S (NP (NN caution)) (VP (VBZ is) (VP (VBN recommended))))) (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (JJ Careful) (NN observation)) (VP (VBZ is) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB worsen) (NP (NP (DT the) (NN tremor)) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (PP (IN with) (NP (JJ Parkinsons) (NN disease))))))))))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN if) (S (NP (JJ other) (NNS drug1)) (VP (VBP produce) (NP (DT a) (JJ similar) (NN response)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN with) (NP (NN drug1) (NNS s)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT the) (VBN reduced) (NN absorption)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN precipitation)) (VP (VBZ occurs) (SBAR (WHADVP (WRB when)) (S (NP (NN eye) (NN drops) (NN containing) (NN drug1)) (VP (VBP are) (VP (VBN mixed) (PP (IN with) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN used))))) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NP (DT an) (NN interval)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD 5)) (NNS minutes))) (PP (IN between) (NP (NNS applications))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (NN drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (NP (NN Drug) (NN Effect))))
(S1 (S (NP (NP (NN drug1) (JJ Prolonged) (NN action)) (PP (IN of) (NP (NN drug2))))))
(S1 (S (NP (NN drug1) (NN Hypotension))))
(S1 (S (NP (NN drug1) (NN drug2) (NN antagonism))))
(S1 (S (NP (NP (NN drug1)) (NP (VBN Decreased) (JJ antinociceptive) (NN action)))))
(S1 (S (NP (NN drug1) (NN drug2) (NN antagonism))))
(S1 (S (NP (NN drug1) (NN Synergism))))
(S1 (S (S (NP (NP (NN CNS) (NN depression)) (VP (VBG producing) (NP (NP (NNS medications)) (CC -) (NP (JJ concurrent) (NN use))))) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (CC either) (NP (DT these) (NNS medications)) (CC or) (NP (NN drug1)))))))) (: ;)))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (JJ other) (NNS medications))) (PP (IN with) (NP (NP (JJ anticholinergic) (NN activity)) (CC -) (NP (JJ anticholinergic) (NNS effects))))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS medications)) (VP (VBP are) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2)))))))))) (: ;)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC -) (NP (JJ prior) (NN ingestion))) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN drug3) (NN response)) (PP (TO to) (NP (NN drug4))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN poisoning))))))))) (. .)))
(S1 (S (S (NP (NN Nephrotoxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (VBG following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD doubled) (NP (DT the) (NN AUC)) (PP (IN for) (NP (NN drug2))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN bioavailability)) (PP (IN of) (NP (NP (DT the) (JJ capsule) (NN formulation)) (PP (IN of) (NP (NN drug1)))))) (VP (VBD was) (RB not) (VP (VBN affected)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (NP (CD 5) (NNS minutes)) (PP (VBG following) (NP (DT an) (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NN Nephrotoxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (VBG following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NP (JJ potent) (NNS drug3)) (PP (JJ such) (IN as) (NP (NN drug4)))))))))))) (. .)))
(S1 (S (S (NP (JJ Renal) (NN function)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored)) (, ,) (SBAR (SBAR (RB especially) (IN if) (S (NP (NP (JJR higher) (NNS dosages)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (VBP are) (S (VP (TO to) (VP (VB be) (VP (VBN administered)))))))) (CC or) (SBAR (IN if) (S (NP (NN therapy)) (VP (VBZ is) (ADJP (JJ prolonged)) (, ,) (PP (IN because) (IN of) (NP (NP (DT the) (NP (JJ potential) (NN nephrotoxicity)) (CC and) (NP (NN ototoxicity))) (PP (IN of) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Nephrotoxicity)) (CC and) (NP (NN ototoxicity))) (VP (VBD were) (RB not) (VP (VBN noted)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN given) (ADVP (RB alone)) (PP (IN in) (NP (JJ clinical) (NNS trials))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ antagonistic) (PP (TO to) (NP (NP (NN drug2)) (, ,) (PP (VBG including) (NP (NN drug3))) (, ,) (VP (VBN based) (PP (IN on) (NP (NP (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (CC and) (NP (NN time) (VB kill) (NNS curves))) (PP (IN with) (NP (JJ enteric) (JJ gram-negative) (NNS bacilli)))))))))))))))) (. .)))
(S1 (S (S (PP (IN Due) (PP (TO to) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (NN antagonism)) (ADVP (FW in) (FW vivo))))))) (, ,) (SBAR (WHADVP (RB particularly) (WRB when)) (S (NP (JJ bactericidal) (NN activity)) (VP (VBZ is) (VP (VBN desired))))) (, ,) (NP (DT this) (NN drug) (NN combination)) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (DT the) (NN urine)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (NP (NN CLINITEST) (NNS tablets)) (, ,) (NP (NN Benedicts) (NN solution)) (, ,) (CC or) (NP (NN Fehlings) (NN solution)))))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (NN glucose) (NNS tests)) (VP (VBN based) (PP (IN on) (NP (NP (JJ enzymatic) (NN glucose) (NN oxidase) (NNS reactions)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN CLINISTIX)) (CC or) (NP (NN TES-TAPE))))) (-RRB- -RRB-)))))) (VP (VB be) (VP (VBN used)))))))) (. .)))
(S1 (S (S (NP (NP (DT Some) (NNS drug1)) (, ,) (PP (VBG including) (NP (NN drug2))) (, ,)) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NP (VBN reduced) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT a) (NN prolongation)) (PP (IN of) (NP (PRP$ its) (NN serum) (NN half-life))))))))) (. .)))
(S1 (S (S (NP (NP (DT Some) (NNS drug1)) (, ,) (PP (VBG including) (NP (NN drug2))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ transient) (NNS elevations)) (PP (IN in) (NP (NP (NN serum) (NN creatinine)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug3))))))))) (ADVP (RB concomitantly)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (DT the) (NN drug3) (NN drug4)))) (VP (VBZ has) (, ,) (PP (IN on) (NP (JJ rare) (NNS occasions))) (, ,) (VP (VBD resulted) (PP (IN in) (NP (JJ severe) (NN hypoglycemia)))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP appear) (S (VP (TO to) (VP (VB have) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (JJ Renal) (JJ tubular) (NN transport)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (VP (VBN inhibited) (PP (IN by) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug3))))) (, ,) (S (ADVP (RB potentially)) (VP (VBG leading) (PP (TO to) (NP (NP (VBN increased) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD might) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ drug1) (JJ toxic) (NNS reactions))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS patients)) (PP (IN under) (NP (NN drug1) (NN therapy)))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))) (SBAR (WHADVP (WRB when)) (S (NP (JJ concomitant) (NN drug2) (NN therapy)) (VP (VBZ is) (VP (VBN indicated))))))) (. .)))
(S1 (S (NP (NP (JJ Multivalent) (JJ Cation-Containing) (NNS Products)) (: :) (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (DT a) (NN drug1)) (, ,) (VP (VBG including) (NP (NN drug2))) (, ,))) (PP (IN with) (NP (NP (NP (NP (NP (JJ multivalent) (JJ cation-containing) (NNS products)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC or) (NP (NN drug4) (NN drug5))))) (, ,) (NP (NP (NN drug6)) (, ,) (NP (NN drug7) (JJ chewable/buffered) (NNS tablets)) (CC or) (NP (JJ pediatric) (NN powder))) (, ,)) (CC or) (NP (NNS products))) (VP (VBG containing) (NP (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC or) (NP (NN drug10))))))) (VP (MD may) (ADVP (RB substantially)) (VP (VB decrease) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug11)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NP (NP (NN serum)) (CC and) (NP (NN urine))) (NNS levels)) (ADJP (ADJP (RB considerably) (JJR lower)) (PP (IN than) (NP (JJ desired))))))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN administered) (NP (NP (NP (QP (IN at) (JJS least) (CD 4)) (NNS hours)) (PP (IN before))) (CC or) (NP (NP (CD 2) (NNS hours)) (PP (IN after) (NP (DT these) (NNS products))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN time) (NN window)) (VP (VBZ is) (ADJP (JJ different) (PP (IN than) (PP (IN for) (NP (NP (JJ other) (JJ oral) (NNS formulations)) (PP (IN of) (NP (NN drug1))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (ADVP (RB usually)) (VP (VBN administered) (NP (NP (NP (CD 2) (NNS hours)) (PP (IN before))) (CC or) (NP (NP (CD 6) (NNS hours)) (PP (IN after) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (CONJP (CC but) (RB not)) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (S (NP (NP (DT These) (NNS drugs)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (ADJP (RB very) (JJ high)) (NNS doses)) (PP (IN of) (NP (NN drug3)))))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB provoke) (NP (NN convulsions)) (PP (IN in) (NP (JJ pre-clinical) (NNS studies)))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NP (NN rate)) (CC and) (NP (NN extent))) (PP (IN of) (NP (NP (NN absorption)) (PP (IN of) (NP (NN drug2)))))) (VP (VBD was) (ADJP (JJ bioequivalent)) (SBAR (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBD was) (VP (VBN given) (ADVP (RB alone)))))) (CC or) (SBAR (WHADVP (WRB when)) (S (NP (NN drug4)) (VP (VBD was) (VP (VBN given) (PP (NP (CD 2) (NNS hours)) (IN after) (NP (NN drug5))) (PP (IN at) (NP (NP (DT the) (NN dose)) (SBAR (WHNP (WDT that)) (S (ADVP (RB maximally)) (VP (VBZ suppresses) (NP (JJ gastric) (NN acid) (NN secretion)))))))))))))) (. .))))
(S1 (S (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN taken) (SBAR (IN as) (S (VP (VBN directed)))))))) (CC and) (S (NP (NN drug2)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN with) (NP (NP (NP (DT a) (JJ main) (NN meal)) (PP (IN of) (NP (DT the) (NN day)))) (, ,) (NP (RB preferably) (DT the) (NN evening) (NN meal)))))))) (. .)) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Altered) (NN serum) (NNS levels)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (VP (VP (VBN increased)) (CC and) (VP (VBN decreased))) (-RRB- -RRB-))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ concomitant) (NN drug3))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VP (VBZ interferes) (PP (IN with) (NP (NP (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN drug3)))))) (CC and) (VP (VBZ produces) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN drug4))) (PP (IN in) (NP (NN serum))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN As) (PP (IN with) (NP (DT some) (JJ other) (NNS drug2)))) (, ,) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NN drug4)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (JJ elevated) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NN drug5)) (CC and) (NP (NN prolongation))) (PP (IN of) (NP (PRP$ its) (NN elimination) (NN half-life)))))))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (JJ drug1) (JJ -related) (JJ adverse) (NNS reactions)))))))) (. .)))
(S1 (S (S (S (SBAR (IN If) (S (NP (JJ concomitant) (NN use)) (VP (MD cannot) (VP (VB be) (VP (VBN avoided)))))) (, ,) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN monitored))))) (CC and) (S (NP (NN dosage) (NNS adjustments)) (VP (VBD made) (PP (IN as) (NP (JJ appropriate)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ oral) (NN drug3) (NN drug4)) (CC or) (NP (PRP$ its) (NNS derivatives)))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT these) (NNS products)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))) (, ,) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ suitable) (NN coagulation) (NNS tests))) (VP (MD should) (VP (VB be) (VP (VBN monitored))))) (. .)))
(S1 (S (NP (NN DRUG) (NNS INTERACTIONS))))
(S1 (S (S (NP (JJ Several) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN completed) (PP (IN with) (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Observations)) (PP (IN from) (NP (NP (NN drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN drug1)))))) (VP (MD may) (RB not) (VP (VB be) (ADJP (JJ predictive) (PP (IN for) (NP (NN drug2))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN coadministered))))) (, ,) (NP (NNS prescribers)) (VP (MD should) (ADVP (RB also)) (VP (VBP refer) (PP (TO to) (NP (NP (DT the) (JJ prescribing) (NN information)) (PP (IN for) (NP (NN drug2))) (PP (VBG regarding) (NP (NP (NN drug) (NNS interactions)) (VP (VBN associated) (PP (IN with) (NP (DT this) (NN agent))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN metabolism)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP (NN cytochrome) (NN P450))) (, ,) (PP (IN with) (NP (NP (DT the) (JJ specific) (NN isoenzyme) (NN CYP3A4)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (CD 90) (NN %)) (PP (IN of) (NP (DT the) (JJ hepatic) (NN metabolism))))))))))) (. .)))
(S1 (S (S (ADVP (RB Additionally)) (, ,) (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NP (NN P-Glycoprotein)) (PRN (-LRB- -LRB-) (NP (NN Pgp)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP affect) (NP (NP (NN CYP3A4)) (CC and/or) (NP (NN Pgp))))))) (, ,) (VP (MD may) (VP (VB modify) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (NN drug1)) (VP (MD might) (ADVP (RB also)) (VP (VB modify) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN for) (NP (NP (NN CYP3A4)) (CC or) (NP (NN Pgp)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN contraindicated) (PP (ADVP (RB specifically)) (JJ due) (TO to) (NP (NP (DT the) (VBN expected) (NN magnitude)) (PP (IN of) (NP (NP (NN interaction)) (CC and) (NP (NN potential)))) (PP (IN for) (NP (JJ serious) (JJ adverse) (NNS events)))))))))) (VP (VBP are) (NP (JJ listed) (NNS CONTRAINDICATIONS)))) (. .)))
(S1 (S (S (NP (NP (JJ Additional) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (VP (VBN recommended) (PP (IN for) (NP (NP (NN coadministration)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))))) (VP (VBP are) (VP (VBN included) (PP (IN below))))) (. .)))
(S1 (S (S (NP (DT These) (NNS recommendations)) (VP (VBP are) (VP (VBN based) (PP (IN on) (NP (CC either) (NP (NN drug) (NN interaction) (NNS studies)) (CC or) (NP (NP (VBN predicted) (NNS interactions)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (VBN expected) (NN magnitude)) (PP (IN of) (NP (NP (NN interaction)) (CC and) (NP (NN potential)))) (PP (IN for) (NP (NP (JJ serious) (NNS events)) (CC or) (NP (NP (NN loss)) (PP (IN of) (NP (NN efficacy))))))))))))))) (. .)))
(S1 (S (S (PP (IN With) (NP (DT some) (NNS agents))) (, ,) (NP (DT the) (NN metabolism)) (VP (MD may) (VP (VB be) (VP (VBN induced) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (VBN decreased) (NNS concentrations))))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (MD Should) (RB Not) (VP (VB Be) (VP (VBN Coadministered) (PP (IN With) (NP (NN drug1))))))))) (: /) (NP (NN drug2)))))
(S1 (S (NP (NP (NN Drug) (NN Class)) (: :) (NP (NN Drug) (NN Name) (JJ Clinical) (NN Comment)))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)))) (VP (VBN CONTRAINDICATED) (PP (JJ due) (TO to) (NP (NP (NN potential)) (PP (IN for) (NP (ADJP (ADJP (JJ serious)) (CC and/or) (ADJP (JJ life-threatening))) (NNS reactions))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2) (NN *) (, ,) (NN drug3) (NN *))) (VP (VBN CONTRAINDICATED) (PP (JJ due) (TO to) (NP (NP (NN potential)) (PP (IN for) (NP (ADJP (ADJP (JJ serious)) (CC and/or) (ADJP (JJ life-threatening))) (JJ cardiac) (NNS arrhythmias))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)))) (VP (VBN CONTRAINDICATED) (PP (JJ due) (TO to) (NP (NP (NN potential)) (PP (IN for) (NP (NP (ADJP (ADJP (JJ serious)) (CC and) (ADJP (JJ life-threatening))) (NNS reactions)) (PP (JJ such) (IN as) (NP (NP (JJ acute) (NN drug6) (NN toxicity)) (VP (VBN characterized) (PP (IN by) (NP (NP (NP (JJ peripheral) (NN vasospasm)) (CC and) (NP (NN ischemia))) (PP (IN of) (NP (NP (DT the) (NNS extremities)) (CC and) (NP (JJ other) (NNS tissues))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (VP (VBP drug2) (VP (VBN CONTRAINDICATED) (SBAR (IN since) (S (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (DT this) (NN product))) (PP (IN with) (NP (NN drug3))) (PP (IN in) (NP (DT an) (NN drug4) (NN regimen)))) (VP (VBZ reduces) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug5)))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Garlic) (NNS Capsules)) (JJ Garlic) (NNS capsules)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (SBAR (IN while) (S (VP (VBG taking) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (PP (IN as) (NP (NP (DT the) (JJ sole) (NN drug3)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (VBN decreased) (NN drug4) (NN plasma) (NNS concentrations))))))))))))))) (. .)))
(S1 (S (S (NP (DT No) (NNS data)) (VP (VBP are) (ADJP (JJ available) (PP (IN for) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NP (NN drug1)) (: /) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (: /) (NP (NP (NN drug4)) (CC and) (NP (JJ garlic) (NNS capsules)))))))))) (. .)))
(S1 (S (NP (NP (NN GI) (NN Motility) (NN Agent)) (: :) (S (NP (NN drug1)) (VP (VBD *) (VP (VBN CONTRAINDICATED) (PP (JJ due) (TO to) (NP (NP (NN potential)) (PP (IN for) (NP (NP (ADJP (ADJP (JJ serious)) (CC and/or) (ADJP (JJ life-threatening))) (NNS reactions)) (PP (JJ such) (IN as) (NP (JJ cardiac) (NNS arrhythmias)))))))))) (. .))))
(S1 (S (NP (NP (JJ Herbal) (NNS Products)) (: :) (S (NP (NN St.) (NN John) (NN s) (NN wort) (-LRB- -LRB-) (NN hypericum) (NN perforatum) (-RRB- -RRB-) (NN WARNING) (NN coadministration)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NN loss)) (PP (IN of) (NP (NP (JJ virologic) (NN response)) (CC and) (NP (JJ possible) (NN resistance)))))) (PP (PP (TO to) (NP (NN drug1))) (CC or) (PP (TO to) (NP (NP (DT the) (NN class)) (PP (IN of) (NP (NN protease) (NNS inhibitors))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2)) (, ,) (NP (NP (NN drug3) (NN WARNING) (NN potential)) (PP (IN for) (NP (NP (JJ serious) (NNS reactions)) (PP (JJ such) (IN as) (NP (NP (NN risk)) (PP (IN of) (NP (NN myopathy))) (PP (VBG including) (NP (NN rhabdomyolysis))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)))) (VP (VBN CONTRAINDICATED) (PP (JJ due) (TO to) (NP (NP (NN potential)) (PP (IN for) (NP (NP (ADJP (ADJP (JJ serious)) (CC and/or) (ADJP (JJ life-threatening))) (NNS reactions)) (PP (JJ such) (IN as) (NP (NP (ADJP (ADJP (JJ prolonged)) (CC or) (ADJP (VBN increased))) (NN sedation)) (CC or) (NP (JJ respiratory) (NN depression)))))))))) (. .)))
(S1 (S (S (NP (NN *) (NN No)) (ADVP (RB longer)) (VP (VBN marketed) (PP (IN in) (NP (DT the) (NP (PRP US)))))) (. .)))
(S1 (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (VBP Are) (ADVP (RB Mainly)) (VP (VBN Metabolized) (PP (IN by) (NP (NN CYP3A4))))))))))
(S1 (S (SBAR (IN Although) (S (NP (JJ specific) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed)))))) (, ,) (S (NP (NP (NN coadministration)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB mainly)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN CYP3A4)) (PRN (-LRB- -LRB-) (NP (NN eg)) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (QP (CD drug10) (, ,) (CD drug11) (, ,) (CD drug12) (, ,) (CD drug13) (, ,) (CD drug14) (, ,) (CD drug15) (, ,) (CC and) (CD drug16))) (-RRB- -RRB-))))))))))) (VP (MD may) (VP (VBP have) (NP (JJ elevated) (NN plasma) (NNS concentrations)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug17))))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (DT these) (NNS combinations)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NN drug2))))))) (, ,) (NP (NP (DT the) (NN drug3)) (VP (VB label))) (VP (MD should) (VP (VB be) (VP (VBN reviewed) (PP (IN for) (NP (NP (JJ additional) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD should) (RB not) (VP (VB be) (VP (VBN coadministered)))))))))))) (. .)))
(S1 (S (NP (NP (NNS Inducers)) (PP (IN of) (NP (NN CYP3A4))))))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN with) (NP (NP (NNS compounds)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (JJ potent) (NNS inducers)) (PP (IN of) (NP (NP (NN CYP3A4)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))))))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN decreased) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (DT no) (NN evidence)) (PP (IN in) (NP (NP (JJ clinical) (NNS trials)) (PP (IN of) (NP (NP (NN drug) (NNS interactions)) (PP (IN with) (NP (JJ concurrent) (NNS medications))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN drug1)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VP (VB inhibit)) (CC or) (VP (VB induce) (NP (NN cytochrome) (NN P450) (NNS enzymes)))))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NN metabolism) (NNS studies)) (VP (VBP have) (VP (VBN suggested) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (DT the) (JJ human) (NN liver) (NN cytochrome) (NN P450) (NNS enzymes)))))))))) (. .)))
(S1 (S (S (SBAR (IN As) (S (NP (NP (NN plasma) (NN protein) (NN binding)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (ADJP (ADJP (JJ negligible)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN %)) (-RRB- -RRB-)))))) (, ,) (NP (NP (NNS interactions)) (ADJP (JJ due) (PP (TO to) (NP (NP (NN displacement)) (PP (IN of) (NP (ADJP (RBR more) (RB highly) (NN protein) (JJ bound)) (NNS drugs))) (PP (IN from) (NP (NN plasma) (NNS proteins))))))) (VP (VBP are) (RB not) (VP (VBN expected)))) (. .)))
(S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (SBAR (IN Until) (S (NP (JJ specific) (NN compatibility) (NNS data)) (VP (VBP are) (ADJP (JJ available))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug1)) (VP (VB be) (VP (VBN mixed) (PP (IN with) (NP (JJ other) (NNS drugs)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NP (DT the) (JJ conventional) (NN formulation)) (PP (IN of) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (S (VP (MD May) (VP (VB interact) (PP (IN with) (NP (NP (NP (NN wthionamide)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (NN sensitivity)) (PP (TO to) (NP (JJ oral) (NNS anticoagulahts))))))) (. .)))
(S1 (S (S (NP (NP (NN Dosage)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (MD may) (VP (VB require) (NP (NN reduction))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB maintain) (NP (JJ satisfactory) (JJ therapeutic) (NN hypoprothrombinemia)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ diabetic) (NNS patients))) (, ,) (NP (NP (DT the) (JJ metabolic) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VP (VB decrease) (NP (NN blood) (NN glucose))) (CC and) (ADVP (RB therefore)) (, ,) (NP (NN drug2) (NNS requirements))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VBP have) (NP (NP (JJ neuromuscular) (NN blocking) (NNS properties)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (JJ other) (NN drug2)))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ such) (NNS agents))))))))) (. .)))
(S1 (S (S (NP (NP (NN Antagonism)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (ADVP (FW in) (FW vitro))) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (JJ possible) (JJ clinical) (NN significance)))) (, ,) (NP (DT the) (CD two) (NNS drugs)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN drug1)) (, ,) (PP (VBG including) (NP (NN drug2))) (, ,)) (VP (VBP produce) (NP (JJ additive) (NN CNS) (NN depressant) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NP (NP (JJ other) (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT which)) (S (NP (PRP themselves)) (VP (VBP produce) (NP (NN CNS) (NN depression)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ steady) (NN state) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (VP (VBN increased) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (CD 31) (NN %)) (CC and) (NP (CD 20) (NN %)) (, ,) (ADVP (RB respectively))))) (, ,) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug3) (NNS tablets)) (PP (IN in) (NP (NP (NNS doses)) (ADJP (QP (RB up) (TO to) (CD 4)) (NN mg/day)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT these) (NNS changes)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (VBP Inhibit) (NP (NN drug1) (NN Metabolism)) (PP (IN Via) (NP (NN Cytochrome) (NN P450) (NN 3A))))))) (: :) (S (NP (NP (DT The) (JJ initial) (NN step)) (PP (IN in) (NP (NN drug2) (NN metabolism)))) (VP (VBZ is) (NP (NP (NN hydroxylation)) (VP (VBN catalyzed) (PP (IN by) (NP (NN cytochrome) (NN P450) (NP (NP (NN 3A)) (PRN (-LRB- -LRB-) (NP (NN CYP) (NN 3A)) (-RRB- -RRB-))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP inhibit) (NP (DT this) (JJ metabolic) (NN pathway)))))) (VP (MD may) (VP (VB have) (NP (DT a) (JJ profound) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (NP (NNS Drugs)) (VP (VBD Demonstrated) (S (VP (TO to) (VP (VB be) (NP (NP (NN CYP) (NN 3A) (NNS Inhibitors)) (PP (IN of) (NP (JJ Possible) (JJ Clinical) (NN Significance)))) (PP (IN on) (DT the) (NN Basis) (IN of) (NP (NP (JJ Clinical) (NNS Studies)) (VP (VBG Involving) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN caution)) (VP (VBZ is) (VP (VBN recommended) (PP (IN during) (NP (NP (NN coadministration)) (PP (IN with) (NP (NNS drug2)))))))) (-RRB- -RRB-))))))))))) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NN drug4)))) (VP (VP (VBD increased) (NP (NP (DT the) (JJ maximum) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug5)))) (PP (IN by) (NP (CD 46) (NN %)))) (, ,) (VP (VBD decreased) (NP (NN clearance)) (PP (IN by) (NP (CD 21) (NN %)))) (, ,) (VP (VBD increased) (NP (NN half-life)) (PP (IN by) (NP (CD 17) (NN %)))) (, ,) (CC and) (VP (VBD decreased) (NP (VBN measured) (NN psychomotor) (NN performance))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1)))) (VP (VP (VBD decreased) (NP (NP (DT the) (JJ maximum) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (CD 6) (NN %)))) (, ,) (VP (VBD decreased) (NP (NN clearance)) (PP (IN by) (NP (CD 38) (NN %)))) (, ,) (CC and) (VP (VBD increased) (NP (NN half-life)) (PP (IN by) (NP (CD 58) (NN %)))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (JJ oral) (NN drug1)))) (VP (VP (VBD increased) (NP (NP (DT the) (JJ maximum) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (CD 18) (NN %)))) (, ,) (VP (VBD decreased) (NP (NN clearance)) (PP (IN by) (NP (CD 22) (NN %)))) (, ,) (CC and) (VP (VBD increased) (NP (NN half-life)) (PP (IN by) (NP (CD 29) (NN %)))))) (. .)))
(S1 (S (NP (NP (NNS Drugs)) (CC and) (NP (JJ other) (NNS substances))) (VP (VBD demonstrated) (S (VP (TO to) (VP (VB be) (NP (NP (NN CYP) (NN 3A) (NNS inhibitors)) (PP (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (JJ clinical) (NNS studies)) (VP (VBG involving) (NP (NP (NN drug1)) (VP (VBN metabolized) (PP (ADVP (RB similarly)) (TO to) (NP (NN drug2)))))))))) (CC or) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (PP (IN with) (NP (NP (NN drug3)) (CC or) (NP (NP (JJ other) (NN drug4)) (PRN (-LRB- -LRB-) (S (NP (NN caution)) (VP (VBZ is) (VP (VBN recommended) (PP (IN during) (NP (NP (NN coadministration)) (PP (IN with) (NP (NN drug5) (-RRB- -RRB-) (: :) (S (NP (NP (JJ Available) (NNS data)) (PP (IN from) (NP (NP (JJ clinical) (NNS studies)) (PP (IN of) (NP (NP (NN drug6)) (CONJP (JJ other) (IN than)) (NP (NN drug7))))))) (VP (VBP suggest) (NP (NP (DT a) (JJ possible) (NN drug) (NN interaction)) (PP (IN with) (NP (NN drug8))) (PP (IN for) (NP (NP (DT the) (NN following)) (: :) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NP (NN drug11)) (PP (JJ such) (IN as) (NP (NP (NN drug12)) (CC and) (NP (NN drug13))))) (, ,) (CC and) (NP (NN grapefruit) (NN juice)))))))))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Data)) (PP (IN from) (NP (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (PP (IN of) (NP (NN drug1)))))) (VP (VBP suggest) (NP (NP (DT a) (JJ possible) (NN drug) (NN interaction)) (PP (IN with) (NP (NP (NP (NNS drug2)) (PP (IN for) (NP (DT the) (NN following)))) (: :) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Data)) (PP (IN from) (NP (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (PP (IN of) (NP (NP (NN drug1)) (CONJP (JJ other) (IN than)) (NP (NN drug2))))))) (VP (VBP suggest) (NP (NP (DT a) (JJ possible) (NN drug) (NN interaction)) (PP (IN for) (NP (NP (DT the) (NN following)) (: :) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN recommended) (PP (IN during) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT these)) (PP (IN with) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (PP (IN In) (NP (DT some) (JJ normal) (NNS volunteers))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN prolongation)) (PP (IN of) (NP (NN prothrombin) (NN time))))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB occur) (SBAR (IN because) (S (NP (NN drug1)) (ADVP (RB competitively)) (VP (VBZ displaces) (NP (NN drug2)) (PP (IN from) (NP (NN protein) (NN binding) (NNS sites))))))))) (. .)))
(S1 (S (S (ADVP (RB Accordingly)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (JJ oral) (NN drug2))))))) (, ,) (NP (DT the) (NN prothrombin) (NN time)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored) (PP (PP (IN during)) (CC and) (PP (IN for) (NP (NP (JJ several) (NNS days)) (PP (IN after) (NP (JJ concomitant) (NN drug) (NN administration)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Adjustment)) (PP (IN of) (NP (NP (NN dosage)) (PP (IN of) (NP (JJ oral) (NN drug1)))))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (JJ diabetic) (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))) (, ,) (NP (DT no) (JJ significant) (NNS effects)) (VP (VBD were) (VP (VBN seen) (PP (IN on) (NP (NP (NN drug4) (NN plasma) (NNS levels)) (CC or) (NP (JJ fasting) (NN blood) (NN glucose))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (: :) (PP (IN In) (NP (JJ normal) (NNS volunteers))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD resulted) (PP (IN in) (NP (NP (ADJP (RB significantly) (VBN increased)) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD decreased) (NP (NP (DT the) (JJ hyperuricemic) (NN effect)) (PP (IN of) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (PP (IN In) (NP (JJ normal) (NNS volunteers))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ diuretic) (NN activity)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD decreased) (NP (NP (DT the) (JJ hyperuricemic) (NN effect)) (PP (IN of) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))))) (VP (MD may) (VP (VB reduce) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (DT This) (NN effect)) (VP (VP (VBZ is) (ADJP (JJ small) (PP (IN with) (NP (NP (JJ occasional) (NNS doses)) (PP (IN of) (NP (NN drug1))))))) (, ,) (CC but) (VP (MD may) (VP (VB be) (ADJP (RB clinically) (JJ significant) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBP are) (VP (VBN used) (PP (IN on) (NP (DT a) (JJ continuous) (NN schedule)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (PP (IN In) (NP (JJ normal) (NNS volunteers))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ approximate) (ADJP (CD 50) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (NN drug1)) (PP (IN in) (NP (JJ high) (NNS doses)))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NN hepatotoxicity)))))))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (, ,) (PP (IN with) (NP (NP (JJ careful) (NN monitoring)) (PP (IN of) (NP (NNS patients))))))))) (. .)))
(S1 (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (PP (IN in) (NP (NNS dogs))) (, ,) (CC but) (RB not) (PP (IN in) (NP (NNS rats))) (, ,)) (PP (IN at) (NP (QP (RB approximately) (CD 2) (NNS times)) (NP (NP (DT the) (VBN recommended) (JJ maximum) (JJ human) (JJ therapeutic) (NN dose)) (PP (IN of) (NP (DT each)))) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 40) (TO to) (CD 52)) (NN mg/kg/day)) (PP (IN of) (NP (NN drug3)))) (: /) (NP (NN drug4))) (-RRB- -RRB-))))) (VP (VBD resulted) (PP (IN in) (NP (JJR greater) (JJ gastrointestinal) (NN toxicity))) (PP (IN than) (SBAR (WHADVP (WRB when)) (S (NP (DT either) (NN drug)) (VP (VBD was) (VP (VBN administered) (ADVP (RB alone)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT these) (NNS findings)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (IN if) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3))))))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN drug2)))))) (CC and) (VP (TO to) (VP (VB potentiate) (NP (PRP$ its) (NN toxicity)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug2))) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN drug3)))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN drug4) (JJ -induced) (NN toxicity))))) (, ,) (PP (ADVP (RB possibly)) (JJ due) (TO to) (NP (NP (VBN decreased) (NN synthesis)) (PP (IN of) (NP (JJ renal) (NN prostacyclin))))))))) (. .))))
(S1 (S (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug2))))))))) (, ,) (CC and) (S (NP (JJ renal) (NN function)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NP (JJ normal) (NNS volunteers)) (VP (VBG receiving) (NP (NN drug3)))))) (VP (VP (VBD decreased) (NP (DT the) (JJ renal) (NN clearance))) (CC and) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug4))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT some) (NNS patients))) (NP (NP (DT the) (JJ combined) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (JJ fatal) (JJ gastrointestinal) (NN hemorrhage))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (JJ drug1) (NNS tablets)) (CC and) (NP (JJ other) (NNS drug2))))) (VP (VBZ is) (RB not) (VP (VBN recommended) (PP (JJ due) (TO to) (NP (NP (DT the) (VBN increased) (NN possibility)) (PP (IN of) (NP (JJ gastrointestinal) (NN toxicity))))) (, ,) (PP (IN with) (NP (NP (ADJP (JJ little))) (CC or) (NP (DT no)) (NP (NP (NN increase)) (PP (IN in) (NP (NN efficacy))))))))) (. .)))
(S1 (S (S (NP (DT The) (VBG following) (NN information)) (VP (VBD was) (VP (VBN obtained) (PP (IN from) (NP (NP (NNS studies)) (PP (IN in) (NP (JJ normal) (NNS volunteers)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (JJ normal) (NNS volunteers))) (, ,) (NP (NP (DT a) (JJ small) (NN decrease)) (PP (IN in) (NP (NN drug2) (NNS levels)))) (VP (VBD was) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))) (VP (VBD were) (VP (VBN administered) (ADVP (RB concomitantly))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN in) (NP (JJ normal) (NNS volunteers)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN lowering)) (PP (IN of) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (DT the) (JJ active) (NN sulindac) (NN sulfide) (NN metabolite))))) (PP (IN by) (NP (RB approximately) (CD one-third))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN in) (NP (JJ normal) (NNS volunteers)))) (VP (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug4)))))) (, ,) (CC but) (VP (ADVP (RB significantly)) (VBD decreased) (NP (NP (DT the) (JJ urinary) (NN excretion)) (PP (IN of) (NP (NP (NN drug5)) (CC and) (NP (PRP$ its) (JJ glucuronide) (NN metabolite)))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN Drug) (NN laboratory) (NN Test) (NNS Interactions) (NN Serum) (NN Salicylate) (NNS Assays)) (: :) (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN in) (S (VP (VBG interpreting) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NN serum) (NN salicylate) (NNS assays))))))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (ADJP (JJ present))))))))) (. .))))
(S1 (S (S (NP (NN drug1) (NNS levels)) (VP (VBP have) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADVP (RB falsely)) (VP (VBN elevated) (PP (IN with) (NP (DT some) (NN assay) (NNS methods))))))))))) (. .)))
(S1 (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (CC or) (NP (NP (NP (JJ other) (NNS agents)) (VP (VBG interfering) (PP (IN with) (NP (JJ neuromuscular) (NN transmission))))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug3)) (-RRB- -RRB-)))))) (VP (MD should) (ADVP (RB only)) (VP (VB be) (VP (VBN performed) (PP (IN with) (NP (NN caution))) (SBAR (IN as) (S (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT the) (NNS drug4)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (S (VP (VBG administering) (NP (JJ different) (NN drug1) (NNS serotypes)) (PP (PP (IN at) (NP (DT the) (JJ same) (NN time))) (CC or) (PP (IN within) (NP (NP (JJ several) (NNS months)) (PP (IN of) (NP (DT each) (JJ other)))))))))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (JJ Excessive) (NN neuromuscular) (NN weakness)) (VP (MD may) (VP (VB be) (ADJP (JJ exacerbated) (PP (IN by) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT another) (NN drug1)) (ADJP (JJ prior) (PP (TO to) (NP (NP (DT the) (NN resolution)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT a) (ADJP (RB previously) (VBN administered)) (NN drug2)))))))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ known) (NN drug) (NNS interactions)) (PP (IN with) (NP (NN drug1) (NN Injection)))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (IN if) (S (NP (NN drug1) (NN Injection)) (VP (VBZ is) (VP (VBN administered) (PP (PP (IN before)) (, ,) (PP (IN after)) (, ,) (CC or) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NP (NN immunosuppression)) (CC or) (NP (NN myelosuppression)))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NN Drug) (NN Metabolizing) (NNS Enzymes)) (CC and) (NP (NN Drug) (NN Transport) (NNS Systems))))) (VP (VBP drug2) (S (VP (VBZ inhibits) (NP (NP (NN CYP3A4)) (CC and) (NP (NN CYP2C8))) (ADVP (FW in) (FW vitro)) (PP (IN at) (NP (ADJP (RB clinically) (JJ relevant)) (NNS concentrations))))))) (. .)))
(S1 (S (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised))))) (CC and) (S (NP (NP (NN dose) (NN reduction)) (PP (IN of) (NP (DT the) (JJ concomitant) (NN substrate) (NN drug)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN when) (NP (NP (NN dosing) (NN drug1)) (PP (ADVP (RB concurrently)) (IN with) (NP (NP (NNS medications)) (PP (IN with) (NP (NP (ADJP (ADJP (JJ narrow)) (ADJP (JJ therapeutic))) (NNS windows)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN of) (NP (NP (NN CYP3A4)) (CC or) (NP (NN CYP2C8))))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB inhibit) (NP (NP (NP (NP (DT the) (JJ following) (NNS enzymes)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))) (: :) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2C19)) (, ,) (CC and) (NP (NN CYP2D6)))) (CC or) (NP (NN UGT) (NNS enzymes))) (ADVP (FW in) (FW vitro))))) (, ,) (S (ADVP (RB however)) (, ,) (NP (DT the) (JJ clinical) (NN significance)) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (JJ human) (NN P-glycoprotein)))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN of) (NP (NN Pgp))))))))))))) (, ,) (S (S (NP (NP (VBN increased) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ substrate) (NN drug)))) (VP (VBP are) (ADJP (JJ likely)))) (, ,) (CC and) (S (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised))))))) (. .)))
(S1 (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP Inhibit)) (CC or) (VP (VBP Induce) (NP (NP (NP (NN Cytochrome) (NN P450) (NN 3A4)) (NNS Enzymes)) (S (S (NP (NN drug1)) (VP (VBZ undergoes) (NP (JJ extensive) (NN metabolism)) (PP (IN by) (NP (NN CYP3A4))))) (, ,) (CC and) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (JJ strong) (NNS inhibitors)) (CC or) (NP (NP (NNS inducers)) (PP (IN of) (NP (NN CYP3A4))))))) (VP (VB alter) (NP (NN drug2) (NNS concentrations)) (ADVP (RB significantly)))))))))) (. .))))
(S1 (S (S (NP (NP (NN Dose) (NN adjustment)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (MD must) (VP (VBP receive) (NP (NP (NP (JJ concomitant) (JJ strong) (NNS inhibitors)) (CC or) (NP (JJ concomitant) (JJ strong) (NNS inducers))) (PP (IN of) (NP (JJ CYP3A4) (NNS enzymes)))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBG receiving) (NP (NP (NN drug2)) (, ,) (NP (DT a) (NN CYP3A4) (NN inhibitor)) (, ,)) (PP (IN at) (NP (NP (CD 200) (NN mg)) (ADVP (RB twice) (RB daily) (PP (IN for) (NP (CD 7) (NNS days))))))))) (, ,) (NP (NP (NP (JJ systemic) (NN exposure)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (TO to) (NP (NN drug3)))) (VP (VBD was) (VP (VBN increased) (PP (TO to) (NP (NP (RB approximately) (NN 3.6-fold)) (PP (IN of) (NP (NP (NN control)) (CC and) (NP (NN half-life)))) (VP (VBD increased) (PP (TO to) (NP (NP (NN 1.7-fold)) (PP (IN of) (NP (NN control))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBG receiving) (NP (NP (DT the) (NN CYP3A4) (NN inducer)) (, ,) (NP (NN drug2)) (, ,)) (PP (IN at) (NP (NP (NP (CD 100) (NN mg)) (ADJP (RB twice) (JJ daily) (PP (IN for) (NP (CD 3) (NNS days))))) (CC and) (NP (NP (CD 200) (NN mg)) (ADJP (RB twice) (JJ daily) (PP (IN for) (NP (CD 17) (NNS days)))))))))) (, ,) (NP (NP (NP (JJ systemic) (NN exposure)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (TO to) (NP (NN drug3)))) (VP (VBD was) (VP (VBN decreased) (NP (QP (RB approximately) (CD 72)) (NN %))))) (. .))))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP Inhibit) (NP (NP (NN Drug) (NN Transport) (NNS Systems)) (NN drug1)))))) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN of) (NP (NP (DT the) (NN efflux) (NN transporter) (NN P-glycoprotein)) (PRN (-LRB- -LRB-) (NP (NP (NN Pgp)) (, ,) (NP (NN ABCB1))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN Pgp))))))))))) (, ,) (S (S (NP (NP (VBN increased) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))) (VP (VBP are) (ADJP (JJ likely)))) (, ,) (CC and) (S (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised))))))) (. .)))
(S1 (S (S (PP (NP (JJ Other) (NN Chemotherapy) (NNS Agents)) (IN In) (NP (DT a) (JJ separate) (NN study))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBD did) (RB not) (ADVP (RB meaningfully)) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT either) (NN agent)) (PRN (-LRB- -LRB-) (CC or) (NP (NP (DT the) (NNS metabolites)) (PP (IN of) (NP (NN drug3)))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (S (VP (VBZ increases) (NP (NN bioavailability)) (PP (IN by) (NP (CD 50) (NN %))))) (-RRB- -RRB-))) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN valproates))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NP (NN long-)) (CC and) (NP (JJ short-acting) (NN drug3))))) (VP (VBZ has) (VP (VBN been) (ADVP (RB safely)) (VP (VBN tolerated) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ stable) (NN angina) (NN pectoris))))))))) (. .))))
(S1 (S (S (NP (JJ Sublingual) (NN drug1)) (VP (MD may) (VP (VB be) (VP (VBN taken) (SBAR (IN if) (ADJP (JJ necessary) (PP (IN for) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (JJ acute) (NN angina) (NNS attacks)) (PP (IN during) (NP (NN drug2) (NN therapy))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ has) (VP (VBN been) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ stable) (NNS angina))))))))) (. .))))
(S1 (S (S (NP (JJ Available) (NNS data)) (VP (VBP are) (RB not) (ADJP (JJ sufficient) (S (, ,) (ADVP (RB however)) (, ,) (VP (TO to) (VP (VB predict) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ concomitant) (NN medication))) (PP (IN on) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ impaired) (JJ ventricular) (NN function)) (CC or) (NP (JJ cardiac) (JJ conduction) (NNS abnormalities))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (JJ controlled) (NNS studies)) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))) (, ,) (NP (NN drug2)) (VP (CC either) (VP (VBD had) (NP (DT no) (NN effect)) (PRN (-LRB- -LRB-) (NP (CD one) (NN study)) (-RRB- -RRB-))) (CC or) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NP (JJ modest) (NNS increases)) (, ,) (NP (QP (RB about) (CD 30)) (NN %))) (PRN (-LRB- -LRB-) (NP (CD two) (NNS studies)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ steady-state) (NN serum) (NN drug3) (NNS concentrations))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Limited) (JJ clinical) (NNS data)) (PP (IN in) (NP (NP (JJ angina) (NNS patients)) (VP (VBG receiving) (NP (JJ concomitant) (NN drug1) (CC and) (NN drug2) (NN therapy)))))) (VP (VBP indicate) (NP (NP (DT no) (JJ discernible) (NNS changes)) (PP (IN in) (NP (NN serum) (NN digoxin) (NNS levels)))))) (. .)))
(S1 (S (S (NP (JJ Available) (NNS data)) (VP (VBP are) (ADJP (CC neither) (ADJP (JJ sufficient))) (PP (TO to) (NP (NP (NP (NN rule)) (PP (IN out) (NP (NP (JJ possible) (NNS increases)) (PP (IN in) (NP (NP (NN serum) (NN drug1)) (PP (IN with) (NP (NP (JJ concomitant) (NN treatment)) (PP (IN in) (NP (DT some) (NNS patients)))))))))) (, ,) (CC nor) (NP (JJ other) (JJ possible) (NNS interactions)) (, ,) (ADVP (RB particularly)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ cardiac) (NN conduction) (NNS abnormalities))))) (PRN (-LRB- -LRB-) (ADVP (RB Also)) (VP (VB see) (NP (NNS WARNINGS) (NP (JJ Congestive) (NN Heart) (NN Failure)))) (-RRB- -RRB-)))) (. .)))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ has) (VP (VBN been) (VP (ADVP (RB safely)) (VBN used) (PP (IN in) (NP (JJ diabetic) (NNS patients))) (PP (IN without) (S (ADVP (RB significantly)) (VP (VP (VBG lowering) (NP (PRP$ their) (NN blood) (NN glucose) (NNS levels))) (CC or) (VP (VBG altering) (NP (NP (PRP$ their) (NN need)) (PP (IN for) (NP (NP (NN drug3)) (CC or) (NP (JJ oral) (NN drug4))))))))))))) (. .))))
(S1 (S (NP (NP (JJ General) (NNS Interactions)) (: :) (S (NP (JJ Certain) (NNS drugs)) (VP (MD could) (VP (VB increase) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (NP (ADJP (RB potentially) (JJ serious)) (JJ adverse) (NNS effects)) (PP (IN with) (NP (NN drug1))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ general))) (, ,) (NP (DT these)) (VP (VBP are) (NP (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (NP (QP (CD one) (CC or) (JJR more)) (JJ pharmacologic) (NNS activities)) (ADJP (JJ similar) (PP (TO to) (NP (NN drug1))))))))) (, ,) (PP (VBG including) (NP (NP (NNS drug2)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))))) (, ,) (NP (NP (NN drug5)) (CC and) (NP (NN drug6)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD could) (VP (VB exaggerate) (NP (NP (DT the) (NN prolongation)) (PP (IN of) (NP (NP (DT the) (JJ QT) (NN interval)) (VP (VBN observed) (PP (IN with) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD could) (VP (VB exaggerate) (NP (NP (DT the) (NN depression)) (PP (IN of) (NP (NP (NN AV) (JJ nodal) (NN conduction)) (VP (VBN observed) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (JJ specific) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN drug1)))))))) (, ,) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (DT an) (JJ additive) (NN or) (NN potentiating) (NN effect))) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC or) (NP (NN drug7))) (-RRB- -RRB-))))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (NP (NN drug1)) (, ,) (PP (IN as) (NP (DT a) (NN class))) (, ,) (VP (MD may) (VP (VB reduce) (NP (NP (NN pulse)) (CC and) (NP (NN blood) (NN pressure)))))) (. .)))
(S1 (S (S (NP (NP (NN Caution)) (PP (IN in) (S (VP (VBG using) (NP (NP (JJ concomitant) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ ophthalmic)) (CC and) (ADJP (JJ systemic))) (-RRB- -RRB-))) (, ,) (NP (NN drug2)) (CC and/or) (NP (NN drug3))))))))) (VP (VBZ is) (VP (VBN advised)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB blunt) (S (NP (NP (DT the) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (JJ systemic) (NN drug2) (NN .It)))) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (NP (DT the) (JJ concurrent) (NN use)) (PP (IN of) (NP (DT these) (NNS agents))) (PP (IN with) (NP (NP (NN drug3)) (PP (IN in) (NP (NNS humans)))))) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (VBG resulting) (NN interference)) (PP (IN with) (NP (DT the) (NN IOP) (JJ lowering) (NN effect))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NNS data)) (PP (IN on) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ circulating) (NNS catecholamines))) (PP (IN after) (NP (NN drug1) (NN administration)))))) (VP (VBP are) (ADJP (JJ available)))) (. .)))
(S1 (S (S (NP (NN Caution)) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ is) (VP (VBN advised) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NN drug1)) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB affect) (NP (NP (DT the) (NP (NN metabolism)) (CC and) (NP (NN uptake))) (PP (IN of) (NP (VBG circulating) (NNS amines))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (VP (MD may) (VP (VP (VB sterilize) (NP (DT the) (NN bowel))) (CC and) (VP (VB decrease) (NP (NP (DT the) (NN drug3) (NN contribution)) (PP (TO to) (NP (DT the) (NN body))) (PP (IN by) (NP (DT the) (JJ intestinal) (NNS microflora)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (VP (VBG containing) (NP (NP (JJ side) (NNS chains)) (PP (IN of) (NP (NP (NP (NN N-methylthiotetrazole)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7))) (-RRB- -RRB-))) (CC or) (NP (NP (NN methylthiadiazole)) (PRN (-LRB- -LRB-) (NP (NN drug8)) (-RRB- -RRB-)))))))) (VP (MD can) (VP (VB cause) (NP (NP (NN vitamin) (NN K) (NN deficiency)) (CC and) (NP (NN hypoprothrombinemia)))))) (. .)))
(S1 (S (S (NP (DT These) (NNS drug1)) (VP (VBP are) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (JJ hepatic) (NN vitamin) (NN K) (NN epoxide) (NN reductase)))))) (. .)))
(S1 (S (S (NP (NP (JJ drug1) (JJ -Concomitant) (NN intake)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (JJ drug1) (JJ -Concomitant) (NN intake)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (JJ drug1) (JJ -Concomitant) (NN intake)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (PP (IN in) (NP (JJ large) (NNS doses)))) (VP (MD may) (VP (VB inhibit) (NP (NP (NN vitamin) (NN K) (NN epoxide) (NN reductase)) (VP (VBG resulting) (PP (IN in) (NP (NN vitamin) (NN K) (NN deficiency)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (VP (MD can) (VP (VB antagonize) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug3))))))))
(S1 (S (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NN myopathy))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNS drugs)) (PP (IN of) (NP (DT this) (NN class)))))))) (VP (VBZ is) (VP (VBN increased) (PP (IN with) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3) (NN suspension))) (VP (VBD were) (VP (VBN coadministered))))) (, ,) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NNS drug4)))) (VP (VBD decreased) (NP (QP (RB approximately) (CD 35)) (NN %)))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN LDL-C) (NN reduction)) (VP (VBD was) (RB not) (VP (VBN altered)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN Because) (S (NP (NN drug2)) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3)))))))) (, ,) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (JJ other) (NNS drug4)) (VP (VBN metabolized) (PP (IN via) (NP (DT the) (JJ same) (NN cytochrome) (NNS isozymes))))))) (VP (VBP are) (RB not) (VP (VBN expected)))) (. .))))
(S1 (S (S (NP (NP (NN drug1) (: :) (NN Plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))) (VP (VBD decreased) (NP (QP (RB approximately) (CD 25)) (NN %)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBD were) (VP (VBN coadministered))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN LDL-C) (NN reduction)) (VP (VBD was) (ADJP (JJR greater)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD were) (VP (VBN coadministered) (PP (IN than) (SBAR (WHADVP (WRB when)) (S (NP (DT either) (NN drug)) (VP (VBD was) (VP (VBN given) (ADVP (RB alone))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2) (NN plasma) (NNS concentrations)) (CC and) (NP (JJ LDL-C) (NN reduction))) (VP (VBD were) (RB not) (VP (VBN altered) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD were) (VP (VBN coadministered))))) (, ,) (NP (JJ steady-state) (NN plasma) (NN drug4) (NNS concentrations)) (VP (VBD increased) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %))))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB appropriately)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (JJ healthy) (NNS individuals))) (, ,) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))) (VP (VBD increased) (NP (QP (RB approximately) (CD 40)) (NN %)) (PP (IN with) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (, ,) (NP (NP (DT a) (JJ known) (NN inhibitor)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 3A4)))))))))) (. .))))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (NP (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug2)))) (CC and) (NP (DT an) (JJ oral) (NN drug3))) (VP (VBD increased) (NP (NP (NN AUC) (NNS values)) (PP (IN for) (NP (NP (NN drug4)) (CC and) (NP (NN drug5))))) (PP (IN by) (NP (NP (QP (RB approximately) (CD 30)) (NN %)) (CC and) (NP (CD 20) (NN %)))))) (. .))))
(S1 (S (S (NP (DT These) (NNS increases)) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (VP (VBG selecting) (NP (NP (DT an) (JJ oral) (NN drug1)) (PP (IN for) (NP (NP (DT a) (NN woman)) (VP (VBG taking) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBD had) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NN effect)) (PP (IN on) (NP (NN prothrombin) (NN time))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ chronic) (NN drug3) (NN treatment)))))))))) (. .)))
(S1 (S (S (NP (JJ Endocrine) (NN Function) (NNS drug1)) (VP (VP (VBP interfere) (PP (IN with) (NP (NN cholesterol) (NN synthesis)))) (CC and) (VP (ADVP (RB theoretically)) (VP (MD might) (VP (VB blunt) (NP (ADJP (ADJP (JJ adrenal)) (CC and/or) (ADJP (JJ gonadal))) (NN steroid) (NN production))))))) (. .)))
(S1 (S (S (NP (JJ Clinical) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VP (VB reduce) (NP (JJ basal) (NN plasma) (NN cortisol) (NN concentration))) (CC or) (VP (VB impair) (NP (JJ adrenal) (NN reserve)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (JJ male) (NN fertility)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NP (JJ adequate) (NNS numbers)) (PP (IN of) (NP (NNS patients))))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (NNS effects)) (PRN (, ,) (SBAR (IN if) (FRAG (DT any))) (, ,))) (PP (IN on) (NP (DT the) (JJ pituitary-gonadal) (NN axis))) (PP (IN in) (NP (JJ premenopausal) (NNS women)))) (VP (VBP are) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (IN if) (S (NP (DT an) (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NP (NNS levels)) (CC or) (NP (NN activity))) (PP (IN of) (NP (JJ endogenous) (NN steroid) (NNS hormones)))))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))))))))))) (. .)))
(S1 (S (S (NP (NN CNS) (NN Toxicity) (NN Brain) (NN hemorrhage)) (VP (VBD was) (VP (VBN seen) (PP (IN in) (NP (NP (DT a) (JJ female) (NNS dog)) (VP (VBN treated) (PP (IN for) (NP (CD 3) (NNS months))) (PP (IN at) (NP (CD 120) (NN mg/kg/day))))))))) (. .)))
(S1 (S (S (NP (NP (NN Brain) (NN hemorrhage)) (CC and) (NP (JJ optic) (NN nerve) (NN vacuolation))) (VP (VBD were) (VP (VBN seen) (PP (IN in) (NP (NP (DT another) (JJ female) (NN dog)) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (VP (VBN sacrificed) (PP (IN in) (NP (NN moribund) (NN condition))) (PP (IN after) (NP (NP (CD 11) (NNS weeks)) (PP (IN of) (NP (NP (JJ escalating) (NNS doses)) (PP (RP up) (TO to) (NP (CD 280) (NN mg/kg/day)))))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (CD 120) (NN mg/kg) (NN dose)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ systemic) (NN exposure)) (NP (NP (QP (RB approximately) (CD 16)) (NNS times)) (NP (NP (NP (DT the) (JJ human) (NN plasma) (NN area-under-the-curve)) (PRN (-LRB- -LRB-) (NP (NP (NN AUC)) (, ,) (NP (CD 0-24) (NNS hours))) (-RRB- -RRB-))) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (JJ maximum) (JJ human) (NN dose)) (PP (IN of) (NP (CD 80) (NN mg/day)))))))))))) (. .)))
(S1 (S (S (NP (DT A) (JJ single) (JJ tonic) (NN convulsion)) (VP (VBD was) (VP (VBN seen) (PP (IN in) (NP (NP (DT each)) (PP (IN of) (NP (CD 2) (JJ male) (NNS dogs))))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD one)) (VP (VBN treated) (PP (IN at) (NP (CD 10) (NN mg/kg/day))))) (CC and) (NP (NP (CD one)) (PP (IN at) (NP (CD 120) (NN mg/kg/day))))) (-RRB- -RRB-)) (PP (IN in) (NP (DT a) (JJ 2-year) (NN study)))))) (. .)))
(S1 (S (S (NP (DT No) (NN CNS) (NNS lesions)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NNS mice))) (PP (IN after) (NP (NP (JJ chronic) (NN treatment)) (PP (IN for) (NP (QP (RB up) (TO to) (CD 2)) (NNS years))))) (PP (PP (IN at) (NP (NP (NNS doses)) (NP (QP (RB up) (TO to) (CD 400)) (NN mg/kg/day)))) (CC or) (PP (IN in) (NP (NNS rats))) (PP (IN at) (NP (NP (NNS doses)) (PP (RP up) (TO to) (NP (CD 100) (NN mg/kg/day)))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS doses)) (VP (VBD were) (NP (NP (NP (QP (CD 6) (TO to) (CD 11)) (NNS times)) (PRN (-LRB- -LRB-) (NP (NN mouse)) (-RRB- -RRB-))) (CC and) (NP (NP (QP (CD 8) (TO to) (CD 16)) (NNS times)) (PRN (-LRB- -LRB-) (NP (NN rat)) (-RRB- -RRB-))) (NP (NP (DT the) (JJ human) (NN AUC)) (PRN (-LRB- -LRB-) (NP (NN 0-24)) (-RRB- -RRB-)))) (PP (VBN based) (PP (IN on) (NP (NP (DT the) (JJ maximum) (VBN recommended) (JJ human) (NN dose)) (PP (IN of) (NP (CD 80) (NN mg/day)))))))) (. .)))
(S1 (S (S (NP (NP (NN CNS) (JJ vascular) (NNS lesions)) (, ,) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ perivascular) (NNS hemorrhages)) (, ,) (NP (NN edema)) (, ,) (CC and) (NP (NP (JJ mononuclear) (NN cell) (NN infiltration)) (PP (IN of) (NP (JJ perivascular) (NNS spaces))))))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NP (NNS dogs)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ other) (NNS members)) (PP (IN of) (NP (DT this) (NN class)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (ADJP (RB chemically) (JJ similar)) (NN drug)) (PP (IN in) (NP (DT this) (NN class)))) (VP (VBD produced) (NP (NP (JJ optic) (NN nerve) (NN degeneration)) (PRN (-LRB- -LRB-) (NP (NP (NNP Wallerian) (NN degeneration)) (PP (IN of) (NP (NN retinogeniculate) (NNS fibers)))) (-RRB- -RRB-))) (PP (IN in) (NP (ADJP (RB clinically) (JJ normal)) (NNS dogs))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN fashion))) (PP (IN at) (NP (NP (DT a) (NN dose)) (SBAR (WHNP (WDT that)) (S (VP (VBD produced) (NP (NP (NN plasma) (NN drug) (NNS levels)) (ADJP (NP (QP (RB about) (CD 30)) (NNS times)) (JJR higher) (PP (IN than) (NP (NP (DT the) (JJ mean) (NN drug) (NN level)) (PP (IN in) (NP (NP (NNS humans)) (VP (VBG taking) (NP (DT the) (JJS highest) (VBN recommended) (NN dose)))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)))) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (: :) (NP (JJ Skeletal) (NN Muscle)) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (S (NP (NN drug3) (NN plasma) (NNS concentrations)) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug4)))))))) (. .))))
(S1 (S (S (NP (NN drug1) (: :) (NN drug2) (NN plasma) (NNS concentrations)) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (DT the) (JJ bile-acidsequestering) (NN agent) (NN drug2))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetits)) (PP (IN of) (NP (NN drug3)))))) (VP (VBD was) (VP (VBN evaluated) (PP (IN in) (NP (NP (CD 12) (JJ healthy) (NNS males)) (PP (IN in) (NP (CD 2) (JJ separate) (JJ randomized) (NN crossover) (NNS studies)))))))) (. .))))
(S1 (S (PP (IN In) (NP (DT the) (JJ first) (NN study))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (ADJP (CD 0.2) (NN mg)) (NN drug1)) (CC and) (NP (ADJP (CD 12) (NN g)) (NN drug2))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS decreases)) (PP (IN of) (NP (NP (NP (QP (JJR more) (IN than) (CD 22)) (NN %)) (PP (IN for) (NP (NN AUC)))) (CC and) (NP (NP (CD 40) (NN %)) (PP (IN for) (NP (NN Cmax)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NN dosing) (NN drug3))) (ADVP (RB alone)))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (DT the) (JJ second) (NN study))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (CD 12) (NN g) (NN drug1) (CD 1) (NN hour))) (PP (IN before) (NP (NP (NP (DT the) (NN evening) (NN meal)) (CC and) (NP (ADJP (CD 0.3) (NN mg)) (NN drug2)) (NP (QP (RB approximately) (CD 4)) (NNS hours))) (PP (IN after) (NP (DT the) (JJ same) (NN evening) (NN meal)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN drug3) (NN AUC)) (PP (IN of) (NP (QP (JJR less) (IN than) (CD 8)) (NN %)))))) (, ,) (CC and) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN Cmax)) (PP (IN of) (NP (QP (RB about) (CD 30)) (NN %)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (NN dosing) (NN drug4)) (ADVP (RB alone)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (MD would) (VP (VB be) (VP (VBN expected) (SBAR (IN that) (S (NP (NP (DT a) (NN dosing) (NN schedule)) (PP (IN of) (NP (NN drug1))) (VP (VBN given) (PP (IN at) (NP (NP (NP (NN bedtime)) (CC and) (NP (NN drug2))) (VP (VBN given) (PP (IN before) (NP (DT the) (NN evening) (NN meal)))))))) (VP (MD would) (RB not) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (DT the) (JJ clinical) (NN effect)) (PP (IN of) (NP (NN drug3))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (: :) (NN Plasma) (NN drug2) (NNS levels)) (CC and) (NP (NP (NN drug3) (NN clearance)) (PP (IN at) (NP (NN steady-state))))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN co-administration)) (PP (IN of) (NP (ADJP (CD 0.2) (NN mg)) (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN plasma) (NNS concentrations)) (VP (VBD were) (ADVP (RB also)) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Co-) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (TO to) (NP (JJ healthy) (NNS volunteers)))) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (DT any) (NNS changes)) (PP (IN in) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (NN clotting) (NN factor) (NN VII))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN drug4)) (CC and) (NP (NN placebo))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NP (NN AUC)) (CC and) (NP (NN Cmax))) (PP (IN of) (NP (NP (DT both) (NP (NP (DT the)) (PRN (-LRB- -LRB-) (NP (NN R)) (-RRB- -RRB-)) (CC and) (PRN (-LRB- -LRB-) (NP (NN S)) (-RRB- -RRB-))) (NNS isomers)) (PP (IN of) (NP (NN drug1)))))) (VP (VBD were) (VP (VBN unaffected) (PP (IN by) (NP (NP (JJ concurrent) (NN dosing)) (PP (IN of) (NP (ADJP (CD 0.3) (NN mg)) (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (JJ hypercholesterolemic) (NNS patients))) (, ,) (NP (NP (JJ steady-state) (NN drug2) (NN AUC)) (CC and) (NP (NN Cmax))) (VP (VBD increased) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (CC and) (NP (CD 24) (NN %))) (ADVP (RB respectively)) (PP (IN after) (NP (NP (CD 10) (NNS days)) (PP (IN with) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (NP (DT a) (JJ known) (NN inhibitor)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 3A4)))))))))))) (. .))))
(S1 (S (NP (NP (JJ OTHER) (JJ CONCOMITANT) (NN THERAPY)) (: :) (S (SBAR (IN Although) (S (NP (JJ specific) (NN interaction) (NNS studies)) (VP (VBD were) (RB not) (VP (VBN performed) (, ,) (PP (IN in) (NP (JJ clinical) (NNS studies))))))) (, ,) (NP (NN drug1)) (VP (VBD was) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN drug7)) (-RRB- -RRB-))))) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (ADJP (RB clinically) (JJ significant)) (JJ adverse) (NNS interactions)))))))) (. .))))
(S1 (S (S (NP (NP (JJ Additive) (JJ adverse) (NNS effects)) (VP (VBG resulting) (PP (IN from) (NP (JJ cholinergic) (NN blockade))))) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ other) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (CC or) (NP (DT some) (NN drug8))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (NN Administer) (NN drug1)) (PP (IN before) (NP (NN meals))) (: ;))))
(S1 (S (S (NP (NN drug1)) (PP (IN after) (NP (NN meals)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (TO to) (NP (NN drug2))) (PP (IN by) (NP (NP (NP (DT the) (NP (NP (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP450)) (-RRB- -RRB-))) (NN enzyme) (NN group)) (, ,) (NP (ADVP (RB specifically)) (NP (NP (NN cytochromes) (NN P450) (NN 3A4)) (PRN (-LRB- -LRB-) (NP (NN CYP3A4)) (-RRB- -RRB-))))) (CC and) (NP (NN CYP2C8))))))) (. .)))
(S1 (S (S (NP (DT The) (NN CYP3A4) (NN isoenzyme)) (VP (VBZ is) (ADJP (JJ present) (PP (IN in) (NP (CC both) (DT the) (NP (NN liver)) (CC and) (NP (NNS intestines))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4)))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (VBZ has) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (NP (NNS drugs)) (CC or) (NP (NNS substances))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (NP (NP (NP (NNS substrates)) (, ,) (NP (NNS inhibitors)) (CC or) (NP (NNS inducers))) (PP (IN of) (NP (NN CYP3A4))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (NP (NP (RB only) (DT a) (JJ limited) (NN number)) (PP (IN of) (NP (NP (ADJP (FW in) (FW vivo)) (JJ drug-drug) (NNS interactions)) (PP (IN with) (NP (NN drug1)))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (, ,) (ADVP (RB chiefly)) (PP (IN with) (NP (DT the) (JJ oral) (NN formulation)))))))) (, ,) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (JJ other) (NNS interactions)))) (VP (MD should) (VP (VB be) (VP (VBN anticipated))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ is) (ADJP (RB especially) (JJ important) (PP (IN for) (NP (NP (NNS drugs)) (VP (VBN associated) (PP (IN with) (NP (JJ serious) (NN toxicity)))) (, ,) (PP (JJ such) (IN as) (NP (JJ other) (NN drug1)))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN needed))))) (, ,) (NP (PRP$ their) (NN dose)) (VP (VP (MD should) (VP (VB be) (VP (VBN reassessed)))) (CC and) (, ,) (SBAR (WHADVP (WRB where)) (FRAG (JJ appropriate))) (, ,) (NP (NP (NN plasma) (NN concentration)) (VP (VBN measured))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (ADJP (ADJP (JJ long)) (CC and) (ADJP (JJ variable))) (NN half-life)) (PP (IN of) (NP (NN drug1))))))) (, ,) (NP (NP (NN potential)) (PP (IN for) (NP (NN drug) (NNS interactions)))) (VP (VBZ exists) (PP (CONJP (RB not) (RB only)) (PP (IN with) (NP (JJ concomitant) (NN medication))) (CONJP (CC but) (RB also)) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN administered) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NP (NN CYP3A4)) (CC and) (NP (NN CYP2C8)))))))) (, ,) (NP (NP (NNS drugs/substances)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (DT these) (NNS isoenzymes)))))) (VP (MD may) (VP (VP (VB decrease) (NP (DT the) (NN metabolism))) (CC and) (VP (VB increase) (NP (NP (NN serum) (NN concentration)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (VBN Reported) (NNS examples)) (VP (VBP include) (NP (NP (DT the) (NN following)) (: :) (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (NP (NN CYP3A4)) (PP (TO to) (NP (VBG varying) (NNS degrees))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN case) (NN report)) (PP (IN of) (NP (NP (CD one) (NN patient)) (VP (VBG taking) (NP (NP (NN drug1) (CD 200) (NN mg)) (CC and) (NP (NN drug2) (CD 800) (NN mg)) (NP (NP (CD three) (NNS times)) (NP (DT a) (NN day)))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN drug3) (NNS concentrations)) (PP (IN from) (NP (QP (CD 0.9) (NN mg/L) (TO to) (CD 1.3)) (NN mg/L))))))))) (. .)))
(S1 (S (S (NP (NN DEA) (NNS concentrations)) (VP (VBD were) (RB not) (VP (VBN affected)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NN toxicity)))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN Monitoring)) (PP (IN for) (NP (NN drug1) (NN toxicity)))) (CC and) (NP (NP (JJ serial) (NN measurement)) (PP (IN of) (NP (NN drug2) (NN serum) (NN concentration))))) (PP (IN during) (NP (JJ concomitant) (NN drug3) (NN therapy)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VP (VBZ inhibits) (NP (NN CYP3A4))) (CC and) (VP (MD can) (VP (VB increase) (NP (NN serum) (NN drug3) (NNS levels)))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NNS substances)) (: :) (S (NP (NP (NN Grapefruit) (NN juice)) (VP (VBN given) (PP (TO to) (NP (JJ healthy) (NNS volunteers))))) (VP (VBD increased) (NP (NN drug1) (NN AUC)) (PP (IN by) (NP (NP (CD 50) (NN %)) (CC and) (NP (NN Cmax)))) (PP (IN by) (NP (CD 84) (NN %))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug2))))))))) (. .))))
(S1 (S (S (NP (NN Grapefruit) (NN juice)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (JJ oral) (NN amiodarone))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN information)) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (VP (VBG changing) (PP (IN from) (NP (NP (JJ intravenous) (NN drug1)) (PP (TO to) (NP (JJ oral) (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VBP suppress) (NP (NP (JJ certain) (NN CYP450) (NNS enzymes)) (, ,) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (DT This) (NN inhibition)) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (ADJP (RB unexpectedly) (JJ high)) (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (JJ other) (NNS drug1)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT those) (CD CYP450) (NNS enzymes)))))))))))))) (. .)))
(S1 (S (S (NP (NP (VBN Reported) (NNS examples)) (PP (IN of) (NP (DT this) (NN interaction)))) (VP (VBP include) (NP (DT the) (NN following)))) (: :) (S (NP (NP (NP (NN drug1) (NN s) (: :) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3) (NN substrate)) (-RRB- -RRB-))) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ oral) (NNS drug4))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB produce) (NP (NP (ADJP (RB persistently) (JJ elevated)) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug5)) (VP (VBG resulting) (PP (IN in) (NP (JJ elevated) (NN creatinine))))))) (, ,) (PP (IN despite) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (NN dose)) (PP (IN of) (NP (NN drug6)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3) (NN substrate)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug4))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NNS reports)) (PP (IN of) (NP (NN myopathy/rhabdomyolysis))))))))) (. .)))
(S1 (S (NP (NP (NN Cardiovasculars)) (: :) (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2) (NN therapy))))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (JJ oral) (NN drug3)))) (ADVP (RB regularly)) (VP (VBZ results) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN serum) (NN drug4) (NN concentration)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB reach) (NP (JJ toxic) (NNS levels)) (PP (IN with) (NP (JJ resultant) (JJ clinical) (NN toxicity))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))) (VP (VBZ increases) (NP (DT the) (NN serum) (NN drug3) (NN concentration)) (PP (IN by) (NP (CD 70) (NN %))) (PP (IN after) (NP (CD one) (NN day))))) (. .)))
(S1 (S (S (PP (IN On) (NP (NP (NN administration)) (PP (IN of) (NP (JJ oral) (NN drug1))))) (, ,) (S (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NN drug2) (NN therapy)))) (VP (MD should) (VP (VB be) (VP (VBN reviewed))))) (CC and) (S (NP (DT the) (NN dose)) (VP (VP (VBN reduced) (PP (IN by) (NP (QP (RB approximately) (CD 50)) (NN %)))) (CC or) (VP (VBN discontinued))))) (. .)))
(S1 (S (S (S (SBAR (IN If) (S (NP (NN drug1) (NN treatment)) (VP (VBZ is) (VP (VBN continued))))) (, ,) (NP (NN serum) (NNS levels)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (CC and) (S (NP (NNS patients)) (VP (VBN observed) (PP (IN for) (NP (NP (JJ clinical) (NN evidence)) (PP (IN of) (NP (NN toxicity)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS precautions)) (VP (ADVP (RB probably)) (MD should) (VP (VB apply) (PP (TO to) (NP (NN drug1) (NN administration))) (PP (IN as) (NP (NN well)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Other) (NN drug2) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug7))))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NN case) (NNS reports)) (PP (IN of) (NP (NP (VBN increased) (JJ steady-state) (NNS levels)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))))) (PP (IN during) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ decreases) (NP (NN serum) (NN amiodarone) (NNS levels)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))) (VP (VBZ increases) (NP (NN drug3) (NN serum) (NN concentration)) (PP (IN by) (NP (CD 33) (NN %))) (PP (IN after) (NP (CD two) (NNS days))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))) (PP (IN for) (NP (QP (JJR less) (IN than) (CD seven)) (NNS days))))) (VP (VBZ increases) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (JJ n-acetyl) (NN drug4))))) (PP (IN by) (NP (NP (CD 55) (NN %)) (CC and) (NP (CD 33) (NN %)) (, ,) (ADVP (RB respectively)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN procainamide))) (NNS doses)) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (CD one-third))) (SBAR (WHADVP (WRB when)) (S (NP (DT either)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB increase) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ oral) (NN drug2)))))))))))) (: ;)))
(S1 (S (S (PP (IN because) (IN of) (NP (DT this))) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN adjusted) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS drug2)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ general))) (, ,) (NP (DT any) (VBN added) (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN initiated) (PP (IN at) (NP (NP (DT a) (JJR lower) (IN than) (JJ usual) (NN dose)) (PP (IN with) (NP (JJ careful) (NN monitoring))))))))) (. .)))
(S1 (S (S (NP (NP (NN Combination)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NN drug2) (NN therapy)))) (VP (MD should) (VP (VB be) (VP (VBN reserved) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ life-threatening) (JJ ventricular) (NNS arrhythmias))) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADJP (ADJP (RB incompletely) (JJ responsive) (PP (TO to) (NP (DT a) (JJ single) (NN agent)))) (CC or) (ADJP (RB incompletely) (JJ responsive) (PP (TO to) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (NP (NN transfer)) (PP (TO to) (NP (JJ oral) (NN drug1))))) (, ,) (NP (NP (DT the) (NN dose) (NNS levels)) (PP (IN of) (NP (ADJP (RB previously) (VBN administered)) (NNS agents)))) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (QP (CD 30) (TO to) (CD 50)) (NN %))) (PP (NP (JJ several) (NNS days)) (IN after) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (JJ oral) (NN drug2))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (JJ continued) (NN need)) (PP (IN for) (NP (DT the) (JJ other) (NN drug1) (NN agent)))) (VP (MD should) (VP (VB be) (VP (VBN reviewed) (SBAR (IN after) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2)))) (VP (VBP have) (VP (VBN been) (VP (VBN established)))))))))) (, ,) (CC and) (S (NP (NN discontinuation)) (ADVP (RB ordinarily)) (VP (MD should) (VP (VB be) (VP (VBN attempted)))))) (. .)))
(S1 (S (SBAR (IN If) (S (NP (DT the) (NN treatment)) (VP (VBZ is) (VP (VBN continued))))) (, ,) (NP (DT these) (NNS patients)) (VP (MD should) (VP (VB be) (ADVP (RB particularly)) (VP (ADVP (RB carefully)) (VBN monitored) (PP (IN for) (NP (NP (JJ adverse) (NNS effects)) (, ,) (ADVP (RB especially)) (NP (NN conduction) (NNS disturbances)) (CC and) (NP (NP (NN exacerbation)) (PP (IN of) (NP (NN tachyarrhythmias)))))) (, ,) (SBAR (IN as) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN continued)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ drug1) (JJ -treated) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP require) (NP (JJ additional) (NN drug2) (NN therapy))))))) (, ,) (NP (NP (DT the) (JJ initial) (NN dose)) (PP (IN of) (NP (JJ such) (NNS agents)))) (VP (MD should) (VP (VB be) (NP (NP (RB approximately) (NN half)) (PP (IN of) (NP (DT the) (JJ usual) (VBN recommended) (NN dose))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (CC -) (NP (NP (NN drug3) (NN blocking) (NNS agents)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug4)) (, ,) (NP (DT a) (NN drug5) (NN inhibitor)))) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug6) (NNS antagonists)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug7)) (, ,) (NP (DT a) (NN drug8) (NN substrate)) (, ,) (CC and) (NP (NP (NN drug9)) (, ,) (NP (DT a) (NN drug10) (NN inhibitor))))) (-RRB- -RRB-)))) (PP (IN because) (IN of) (NP (NP (DT the) (JJ possible) (NN potentiation)) (PP (IN of) (NP (NP (NN bradycardia)) (, ,) (NP (NN sinus) (NN arrest)) (, ,) (CC and) (NP (NN AV) (NN block))))))))))))) (: ;))))
(S1 (S (S (SBAR (IN if) (FRAG (JJ necessary))) (, ,) (NP (NN drug1)) (VP (MD can) (VP (VBP continue) (S (VP (TO to) (VP (VB be) (VP (VBN used) (PP (IN after) (NP (NP (NN insertion)) (PP (IN of) (NP (DT a) (NN pacemaker))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ severe) (NN bradycardia)) (CC or) (NP (NN sinus) (NN arrest))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Potentiation)) (PP (IN of) (NP (ADJP (ADJP (NN drug2) (JJ -type)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)) (NP (NN substrate))) (-RRB- -RRB-))) (NN drug5) (NN response)))) (VP (VP (VBZ is) (ADVP (RB almost) (RB always)) (VP (VBN seen) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug6))))))) (CC and) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (ADJP (JJ serious))) (CC or) (NP (JJ fatal) (JJ bleeding)))))))) (. .))))
(S1 (S (SBAR (IN Since) (S (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ increases) (NP (DT the) (NN prothrombin) (NN time)) (PP (IN by) (NP (CD 100) (NN %))) (PP (IN after) (NP (QP (CD 3) (TO to) (CD 4)) (NNS days)))))) (, ,) (S (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (NP (CD one-third)) (PP (TO to) (NP (NN one-half))))))))) (, ,) (CC and) (S (NP (NN prothrombin) (NNS times)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely))))))) (. .)))
(S1 (S (S (NP (DT Some) (JJ drug1) (NNS /substances)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB accelerate) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (S (VP (VBG stimulating) (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN enzyme) (NN induction)) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (JJ low) (NN drug1) (NN serum) (NNS levels)) (CC and) (NP (NP (JJ potential) (NN decrease)) (PP (IN in) (NP (NN efficacy))))))))) (. .)))
(S1 (S (S (NP (NP (VBN Reported) (NNS examples)) (PP (IN of) (NP (DT this) (NN interaction)))) (VP (VBP include) (NP (NP (DT the) (NN following)) (: :) (NP (NN drug1)) (: :) (NP (NP (NN drug2)) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (NN inducer)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (ADVP (RB concomitantly)) (IN with) (NP (JJ oral) (NN drug2)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))))))))))) (. .)))
(S1 (S (NP (NP (NP (JJ Other) (NNS substances)) (, ,) (PP (VBG including) (NP (NN herbal) (NNS preparations)))) (: :) (S (NP (NP (NN St.) (NN John) (NN s) (NN Wort)) (PRN (-LRB- -LRB-) (NP (NN Hypericum) (NN perforatum)) (-RRB- -RRB-))) (VP (VBZ induces) (NP (NN CYP3A4)))) (. .))))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NN drug2))))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (DT the) (NN potential) (SBAR (IN that) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN St.) (NP (NNP John) (NNP s) (NNP Wort)))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug3)))))) (VP (MD could) (VP (VB result) (PP (IN in) (NP (VBN reduced) (NN drug4) (NNS levels)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Other) (VBN reported) (NNS interactions)) (PP (IN with) (NP (NN drug1)))) (: :) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3) (NN substrate)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug4))))))) (VP (MD may) (VP (VB cause) (NP (NP (NN hypotension)) (, ,) (NP (NN bradycardia)) (, ,) (CC and) (NP (VBN decreased) (JJ cardiac) (NN output)))))) (. .)))
(S1 (S (S (NP (NN Sinus) (NN bradycardia)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ oral) (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3) (NN substrate)) (-RRB- -RRB-))) (VP (VBN given) (PP (IN for) (NP (JJ local) (NN drug4)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Seizure)) (, ,) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (NN drug1) (NNS concentrations)))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (JJ intravenous) (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (CC both) (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (NN drug2)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ increases) (NP (NP (JJ enterohepatic) (NN elimination)) (PP (IN of) (NP (NN drug2))))) (CC and) (VP (MD may) (VP (VB reduce) (NP (NP (PRP$ its) (NN serum) (NNS levels)) (CC and) (NP (NN drug3) (CD /2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ increases) (NP (NP (NN QT) (NN prolongation)) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB cause) (NP (NN arrhythmia))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN azoles))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NN QTc) (NN prolongation)))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NN QTc) (NN prolongation)))) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NN TdP)))) (, ,) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN azoles))) (VP (VBD were) (VP (VBN administered) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (ADJP (ADJP (JJ Hemodynamic)) (CC and) (ADJP (JJ electrophysiologic))) (NNS interactions)) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN observed) (PP (IN after) (NP (NP (JJ concomitant) (NN administration)) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (NP (NP (NP (JJ Volatile) (NN drug1) (NNS Agents)) (: :)) (. .))))
(S1 (S (S (PP (IN In) (NN addition) (TO to) (NP (NP (DT the) (NNS interactions)) (VP (VBN noted) (ADVP (RB above))))) (, ,) (NP (JJ chronic) (PRN (-LRB- -LRB-) (NP (CD 2) (NNS weeks)) (-RRB- -RRB-)) (JJ oral) (NN drug1) (NN administration)) (VP (VBZ impairs) (NP (NP (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (NN Electrolyte) (NNS Disturbances)) (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NN hypokalemia)) (CC or) (NP (NN hypomagnesemia)))))) (VP (MD should) (VP (VB have) (NP (NP (DT the) (NN condition)) (VP (VBN corrected) (S (ADJP (NN whenever) (JJ possible))))) (PP (IN before) (S (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))))) (, ,) (SBAR (IN as) (S (NP (DT these) (NNS disorders)) (VP (MD can) (VP (VP (VB exaggerate) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN QTc) (NN prolongation))))) (CC and) (VP (VB increase) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN TdP)))))))))))) (. .)))
(S1 (S (S (NP (JJ Special) (NN attention)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (NP (NN electrolyte)) (CC and) (NP (NN acid-base) (NN balance))) (PP (PP (IN in) (NP (NP (NNS patients)) (VP (VBG experiencing) (NP (ADJP (ADJP (JJ severe)) (CC or) (ADJP (JJ prolonged))) (NN diarrhea))))) (CC or) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ concomitant) (NN drug1)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ known) (NN inhibitor)) (PP (IN of) (NP (NP (NN CYP3A4) (NN activity)) (PP (PP (IN in) (NP (DT the) (NN liver))) (CC and) (PP (IN in) (NP (DT the) (JJ intestinal) (NN mucosa))))))) (-RRB- -RRB-))))) (VP (VBD caused) (NP (NP (DT an) (JJ eight-fold) (NN increase)) (PP (IN of) (NP (NP (DT the) (JJ systemic) (NN exposure)) (PP (TO to) (NP (JJ oral) (NN drug2)))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NP (NN CYP3A4) (NN activity)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (JJ such) (PP (IN as) (NP (NN drug1))))) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN etc.))) (-RRB- -RRB-))))))) (VP (VBZ is) (VP (VBN indicated))))) (, ,) (NP (NP (NN reduction)) (PP (IN of) (NP (DT the) (NN drug7) (NN dose)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (PP (IN After) (NP (NP (JJ extensive) (NN intake)) (PP (IN of) (NP (NP (NN grapefruit) (NN juice)) (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (VBZ inhibits) (NP (NN CYP3A4) (NN activity)) (ADVP (RB predominantly)) (PP (IN in) (NP (DT the) (JJ intestinal) (NN mucosa)))))) (-RRB- -RRB-))))) (, ,) (NP (NP (DT the) (JJ systemic) (NN exposure)) (PP (IN for) (NP (JJ oral) (NN drug1)))) (VP (VBD increased) (NP (QP (RB about) (CD two)) (NNS times)))) (. .)))
(S1 (S (S (PP (IN As) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (ADVP (RB primarily)) (VBG being) (VP (VBN metabolized) (PP (IN through) (NP (NN CYP3A4)))))))) (, ,) (NP (NP (NN ingestion)) (PP (IN of) (NP (NP (NN grapefruit)) (CC or) (NP (NN grapefruit)) (NP (NN juice))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN in) (NP (NP (NN connection)) (PP (IN with) (NP (NN drug1) (NN administration))))))))) (. .)))
(S1 (S (S (NP (NP (NN Plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB become) (ADJP (JJ subtherapeutic)) (PP (IN during) (NP (NN drug2) (NN therapy)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN action)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN potentiated) (PP (IN by) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (NN sensitivity)) (PP (TO to) (NP (DT the) (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN Response)) (PP (TO to) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (PP (IN by) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (DT No) (JJ formal) (NNS assessments)) (PP (IN of) (NP (NP (JJ drug-drug) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS agents))))))) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN Since) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN contraindicated) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (NN drug3) (JJ -induced)) (NN thrombocytopenia))))))))) (, ,) (NP (NP (DT the) (NN co-administration)) (PP (IN of) (NP (NP (NN drug4)) (CC and) (NP (NN drug5))))) (VP (VBZ is) (ADJP (JJ unlikely) (PP (IN for) (NP (DT this) (NN indication)))))) (. .))))
(S1 (S (ADVP (RB However)) (, ,) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN initiated) (PP (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (NN drug2) (NN therapy)))))))))))) (, ,) (VP (VBP allow) (NP (JJ sufficient) (NN time)) (PP (IN for) (NP (NP (NN heparins) (NN effect)) (PP (IN on) (NP (DT the) (NN aPTT) (S (VP (TO to) (VP (VB decrease) (ADVP (RB prior)) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NN drug3) (NN therapy))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (S (NP (ADJP (ADJP (JJ Pharmacokinetic)) (CC or) (ADJP (JJ pharmacodynamic))) (JJ drug-drug) (NNS interactions)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN demonstrated) (PP (IN between) (NP (NP (NP (NP (NN drug3)) (CC and) (NP (ADJP (RB concomitantly) (VBN administered)) (NN drug4))) (PRN (-LRB- -LRB-) (NP (NP (CD 162.5) (NN mg)) (ADVP (RB orally) (PP (IN given) (NP (NP (QP (CD 26) (CC and) (CD 2)) (NNS hours)) (ADJP (JJ prior) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN drug5) (CD 1) (NN g/kg/min.)) (PP (IN over) (NP (CD 4) (NNS hours)))))))))))) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000) (NN mg)) (VP (ADVP (RB orally)) (VBN given) (PP (NP (NP (NP (CD 12) (, ,) (CD 6) (CC and) (CD 0) (NNS hours)) (ADJP (JJ prior) (PP (TO to)))) (, ,) (CC and) (NP (NP (QP (CD 6) (CC and) (CD 12)) (NNS hours)) (ADJP (JJ subsequent) (PP (TO to)))) (, ,) (NP (NP (NN initiation)) (PP (IN of) (NP (NN drug7) (CD 1.5) (NN g/kg/min.))))) (IN over) (NP (CD 18) (NNS hours))))) (-RRB- -RRB-))))))))) (. .))))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (NP (NP (JJ Pharmacokinetic) (JJ drug-drug) (NNS interactions)) (PP (IN between) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (PRN (-LRB- -LRB-) (NP (CD 7.5) (NN mg) (JJ single) (JJ oral) (NN dose)) (-RRB- -RRB-))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN demonstrated))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 5-7.5) (NN mg)) (JJ initial) (JJ oral) (NN dose)) (VP (VBN followed) (PP (IN by) (NP (NP (CD 2.5-6) (NN mg/day)) (ADVP (RB orally) (PP (IN for) (NP (CD 6-10) (NNS days)))))))) (-RRB- -RRB-)))))) (VP (VBZ results) (PP (IN in) (NP (NP (NN prolongation)) (PP (IN of) (NP (NP (NP (DT the) (NN prothrombin) (NN time)) (PRN (-LRB- -LRB-) (NP (NN PT)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NNP International)) (VBN Normalized) (NN Ratio)) (PRN (-LRB- -LRB-) (NP (NN INR)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NP (NN safety)) (CC and) (NP (NN effectiveness))) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .))))
(S1 (S (NP (NP (NN Co-administration)) (: :) (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (JJ other) (NNS drug4))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ bleeding))))))) (. .))))
(S1 (S (S (NP (JJ Drug-drug) (NNS interactions)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN observed) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (CC or) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Possible) (NN drug) (NNS interactions)) (PP (IN of) (NP (NN drug1))) (PP (PP (IN with) (NP (NN drug2))) (CC or) (PP (IN with) (NP (JJ other) (NN drug3)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VBP have) (NP (NP (JJ life-threatening) (NNS interactions)) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (JJ other) (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB block) (NP (NP (DT the) (JJ antihypertensive) (NN action)) (PP (IN of) (NP (ADJP (ADJP (JJ drug2)) (CC and) (ADJP (RB similarly) (VBG acting))) (NNS compounds))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ seizure) (NN risk)) (PP (IN in) (NP (NNS patients))))))) (S (VP (VBG taking) (NP (NN drug2))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN in) (NP (JJ large) (NNS amounts)))) (VP (MD may) (VP (VP (VB counteract) (NP (NP (DT the) (JJ antiepileptic) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4)))))) (, ,) (CC and) (VP (VB increase) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNS seizures))) (PP (IN in) (NP (JJ susceptible) (JJ pediatric) (NNS patients)))))))) (. .)))
(S1 (S (S (NP (JJ Preliminary) (ADJP (ADJP (JJ animal)) (CC and) (ADJP (JJ human))) (NNS studies)) (VP (VBP have) (VP (VBN shown) (PP (IN that) (S (NP (NP (JJ small) (NNS quantities)) (PP (IN of) (NP (ADJP (RB systemically) (VBN administered)) (NN drug1)))) (VP (VP (VBP enter) (NP (DT the) (NN CSF)) (PP (ADVP (RB primarily)) (IN as) (NP (NN 5-methyltetrahydro-folate)))) (CC and) (, ,) (PP (IN in) (NP (NNS humans))) (, ,) (VP (VBP remain) (NP (NP (QP (CD 1) (TO to) (CD 3)) (NNS orders)) (PP (IN of) (NP (NN magnitude))) (ADJP (JJR lower) (PP (IN than) (NP (NP (DT the) (JJ usual) (NN drug2) (NNS concentrations)) (VP (VBG following) (NP (JJ intrathecal) (NN administration)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (ADJP (RB intrathecally) (VBN administered)) (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (JJ Certain) (NN endocrine) (CC and) (NN liver) (NN function) (NNS tests)) (VP (MD may) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NN drug1) (JJ -containing) (JJ oral) (NNS drug2))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (JJ similar) (NNS changes)) (VP (MD may) (VP (VB be) (VP (VBN expected) (PP (IN with) (NP (NP (JJR larger) (NNS doses)) (PP (IN of) (NP (NN drug1))))))))) (: :) (NP (VBN Increased) (NN sulfobromophthalein) (NN retention)) (: ;)))
(S1 (S (NP (VBN increased) (NP (NP (NN prothrombin)) (CC and) (NP (NP (NNS factors) (NN VII)) (, ,) (NP (NN VIII)) (, ,) (NP (NN IX)) (, ,) (CC and) (NP (NN X))) (: ;)))))
(S1 (S (S (VP (VBD decreased) (NP (NN antithrombin) (CD 3)))) (: ;)))
(S1 (S (NP (VBN increased) (NP (JJ norepinephrine-induced) (NN platel) (FW et) (NN aggregation) (: ;)))))
(S1 (S (S (NP (NP (VBN increased) (NN thyroid) (NN binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN TBG)) (-RRB- -RRB-))) (VP (VBG leading) (PP (TO to) (NP (VBN increased) (VBG circulating) (JJ total) (NN thyroid) (NN hormone))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (NN PBI)) (, ,) (NP (NP (NN T4)) (PP (IN by) (NP (NN column)))) (, ,) (CC or) (NP (NN T4)))) (PP (IN by) (NP (NN radioimmunoassay)))))))) (. .)))
(S1 (S (S (NP (JJ Free) (NN T3) (NN resin) (NN uptake)) (VP (VBZ is) (VP (VBN decreased) (, ,) (S (VP (VBG reflecting) (NP (DT the) (JJ elevated) (NN TBG))))))) (: ;)))
(S1 (S (S (NP (JJ free) (NN T4) (NN concentration)) (VP (VBZ is) (ADJP (JJ unaltered)))) (: :) (NP (JJ impaired) (NN glucose) (NN tolerance)) (: ;)))
(S1 (S (NP (NP (VBN decreased) (NN pregnanediol) (NN excretion)) (: ;))))
(S1 (S (NP (NP (VBN reduced) (NN response)) (PP (TO to) (NP (NN metyrapone) (NN test))) (: ;))))
(S1 (S (NP (NP (VBN reduced) (NN serum) (NN folate) (NN concentration)) (: ;))))
(S1 (S (S (VP (VBN increased) (NP (NP (NN serum) (NN triglyceride)) (CC and) (NP (NN phospholipid) (NN concentration))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJ local) (NN drug1)) (VP (VBG containing) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug4)) (CC or) (NP (NN drug5)))))))))) (VP (MD may) (VP (VB produce) (NP (ADJP (ADJP (JJ severe)) (, ,) (ADJP (JJ prolonged))) (NN hypertension))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (MD should) (ADVP (RB generally)) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS situations)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (JJ concurrent) (NN therapy)) (VP (VBZ is) (ADJP (JJ necessary))))))) (, ,) (NP (JJ careful) (NN patient) (NN monitoring)) (VP (VBZ is) (ADJP (JJ essential)))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (PP (IN of) (NP (NN drug1))) (CC and) (PP (IN of) (NP (NN drug2))))) (VP (MD may) (VP (VB cause) (NP (JJ severe) (, ,) (NP (NP (JJ persistent) (NN hypertension)) (CC or) (NP (JJ cerebrovascular) (NN accidents))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD may) (VP (VP (VB reduce)) (CC or) (VP (VB reverse) (NP (NP (DT the) (JJ pressor) (NN effect)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ decreases) (NP (NP (DT the) (JJ biologic) (NN half-life)) (PP (IN of) (NP (NN drug2)))) (PP (IN because) (IN of) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ metabolic) (NN clearance)) (SBAR (WHNP (WDT that)) (S (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (JJR greater) (NN amount)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (DT the) (NN urine)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBZ is) (RB not) (ADVP (RB totally)) (VP (VBN known))))) (, ,) (NP (NP (NP (NN enzyme) (NN induction)) (CC and) (NP (NP (NN displacement)) (PP (IN of) (NP (NN drug3))) (PP (IN from) (NP (NN plasma) (NN albumin))))) (NN binding) (NNS sites)) (VP (VBP are) (NP (NNS possibilities)))) (. .)))
(S1 (S (S (SBAR (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB produce) (NP (DT any) (JJ additional) (NN effect)) (PP (IN beyond) (NP (NP (DT that)) (VP (VBN obtained) (PP (IN with) (NP (NP (NN drug2)) (ADVP (RB alone))))))))))))))) (CC and) (SBAR (IN because) (S (NP (NN drug3)) (VP (VBZ increases) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (NN excretion)) (PP (IN of) (NP (NN drug4)))))))))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug5)) (CC and) (NP (NN drug6))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NP (JJ Chronic) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (DT a) (JJ known) (NN enzyme) (NN inducer)) (, ,)))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NN half-life)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VP (VBN added) (PP (TO to))) (CC or) (VP (VBN withdrawn) (PP (IN from) (NP (NN treatment)))))))) (, ,) (NP (NP (NN dosage) (NN adjustment)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (S (NP (NN drug1)) (, ,) (PP (IN because) (PP (IN of) (NP (NP (PRP$ its) (NN affinity)) (PP (IN for) (NP (NN albumin)))))) (, ,) (VP (MD may) (VP (VB displace) (PP (IN from) (NP (PRP$ their) (NN binding) (NNS sites))) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB also)) (VP (NN albumin) (VBN bound))))))))) (, ,) (CC and) (S (NP (DT this)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NN drug) (NN interaction))))))))))) (. .)))
(S1 (S (S (ADVP (RB Theoretically)) (, ,) (NP (NN drug1)) (VP (MD could) (ADVP (RB likewise)) (VP (VB be) (VP (VBN displaced))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC or) (NP (NN drug3))))) (VP (VP (MD should) (VP (VB be) (VP (VBN observed) (PP (IN for) (NP (NP (VBN increased) (NN activity)) (PP (IN of) (NP (DT these) (NNS drugs)))))))) (CC and) (, ,) (ADVP (RB therefore)) (, ,) (NP (NP (NNS signs)) (PP (IN of) (NP (NN toxicity))) (PP (IN from) (NP (DT these) (NNS drugs)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))) (, ,) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NN therapy)))) (VP (MD could) (VP (VB prolong) (NP (DT the) (NN prothrombin) (NN time))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (DT both) (NNS drugs)))) (VP (MD should) (VP (VB be) (PP (IN under) (NP (JJ careful) (NN observation)))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))) (VP (MD may) (VP (VB be) (ADJP (JJ resistant) (PP (TO to) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NP (DT a) (NN drug2)) (ADVP (RB concomitantly))))))) (, ,) (NP (NP (DT any) (NN reduction)) (PP (IN in) (NP (NN drug3) (NN dosage)))) (VP (MD should) (VP (VB be) (ADJP (JJ gradual))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB avoid) (NP (NP (DT the) (JJ possible) (NNS complications)) (PP (IN of) (NP (CD sudden) (NN drug4) (NN withdrawal)))))))))) (. .)))
(S1 (S (S (NP (DT No) (NN information)) (VP (JJ available))) (. .)))
(S1 (S (NP (NP (NN None)) (VP (VBN Reported)))))
(S1 (S (S (NP (NP (JJ Clinical) (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (DT these) (NNS drugs)))) (VP (VBZ does) (RB not) (VP (VB result) (PP (IN in) (NP (JJ clinically-) (JJ significant) (NN drug) (NNS interactions))))))))) (. .)))
(S1 (S (S (NP (S (-LRB- -LRB-) (VP (VB See) (NP (JJ CLINICAL) (NN PHARMACOLOGY))) (-RRB- -RRB-)) (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (NN drug2) (CD 20) (NN mg)) (ADVP (RB daily)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NN drug3) (NN plasma) (NNS levels))) (PP (IN by) (NP (NP (CD 38) (NN %)) (PP (IN on) (NP (NN average))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (JJ clinical) (VBP experience)) (PP (TO to) (NP (NN date))) (PP (IN on) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (JJ anticancer) (NNS agents)))))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test-Interactions) (NN None)) (VP (VBN observed))) (. .)))
(S1 (S (S (NP (NP (JJ Urinary) (JJ acidifying) (NNS agents)) (NP (NP (DT These) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN etc.))) (-RRB- -RRB-)))) (VP (VBP increase) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (DT the) (VBN ionized) (NNS species))) (PP (IN of) (NP (DT the) (NN drug3) (NN molecule)))) (, ,) (S (ADVP (RB thereby)) (VP (VBG increasing) (NP (JJ urinary) (NN excretion)))))) (. .)))
(S1 (S (S (NP (NP (CC Both) (NNS groups)) (PP (IN of) (NP (NNS agents)))) (VP (JJR lower) (NP (NP (NN blood) (NNS levels)) (CC and) (NP (NP (NN efficacy)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS drug2)) (VP (VBP are) (VP (VBN inhibited) (PP (IN by) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2) (NN drug3))) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NN drug4)) (CC or) (NP (NN drug5)))))))) (: ;)))
(S1 (S (NP (NP (NP (NN drug1)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))) (CC and) (ADVP (RB possibly)) (NP (JJ other) (NNS drug4))) (VP (VBP cause) (NP (NP (ADJP (ADJP (JJ striking)) (CC and) (ADJP (JJ sustained))) (NNS increases)) (PP (IN in) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NN drug5))) (PP (IN in) (NP (DT the) (NN brain))))))) (: ;)))
(S1 (S (S (NP (JJ cardiovascular) (NNS effects)) (VP (MD can) (VP (VB be) (VP (VBN potentiated))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN drug2)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT a) (NN metabolite)) (PP (IN of) (NP (NN drug3)))) (, ,)) (NP (JJ slow) (NN drug4) (NN metabolism))) (. .)))
(S1 (S (S (NP (DT This) (NN slowing)) (VP (VBZ potentiates) (NP (NN drug1)) (, ,) (S (VP (VBG increasing) (NP (NP (PRP$ their) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NP (NN norepinephrine)) (CC and) (NP (JJ other) (NNS monoamines)))) (PP (IN from) (NP (JJ adrenergic) (NN nerve) (NNS endings)))))))))) (: ;)))
(S1 (S (S (NP (DT this)) (VP (MD can) (VP (VB cause) (NP (NP (NP (NNS headaches)) (CC and) (NP (JJ other) (NNS signs))) (PP (IN of) (NP (JJ hypertensive) (NN crisis))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN variety)) (PP (IN of) (NP (NP (JJ toxic) (JJ neurological) (NNS effects)) (CC and) (NP (JJ malignant) (NN hyperpyrexia))))) (VP (MD can) (VP (VB occur) (, ,) (PP (ADVP (RB sometimes)) (IN with) (NP (JJ fatal) (NNS results)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB counteract) (NP (NP (DT the) (JJ sedative) (NN effect)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VP (VBZ blocks) (NP (NP (NP (NN dopamine)) (CC and) (NP (NN norepinephrine))) (NNS receptors)) (, ,) (S (ADVP (RB thus)) (VP (VBG inhibiting) (NP (NP (DT the) (JJ central) (JJ stimulant) (NNS effects)) (PP (IN of) (NP (NN drug3))))))) (CC and) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NN drug4) (NN poisoning)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB delay) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ blocks) (NP (NN dopamine) (NNS receptors)) (, ,) (S (ADVP (RB thus)) (VP (VBG inhibiting) (NP (NP (DT the) (JJ central) (JJ stimulant) (NNS effects)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (DT The) (ADJP (ADJP (JJ anorectic)) (CC and) (ADJP (JJ stimulatory))) (NNS effects)) (PP (IN of) (NP (NN drug2))))) (VP (MD may) (VP (VB be) (VP (VBN inhibited) (PP (IN by) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VB potentiate) (NP (NP (DT the) (JJ analgesic) (NN effect)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1) (NN therapy) (JJ Urinary) (NN excretion)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN increased)))) (, ,) (CC and) (S (NP (NN efficacy)) (VP (VBZ is) (VP (VBN reduced) (PP (IN by) (S (VP (VBG acidifying) (NP (NP (NNS agents)) (VP (VBN used) (PP (IN in) (NP (NN drug3) (NN therapy)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP enhance) (NP (NP (DT the) (JJ adrenergic) (NN effect)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (VP (VB delay) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NN drug3))))))) (: ;))))
(S1 (S (S (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB produce) (NP (DT a) (JJ synergistic) (JJ anticonvulsant) (NN action))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (VP (VB delay) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NN drug3))))))) (: ;))))
(S1 (S (S (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB produce) (NP (DT a) (JJ synergistic) (JJ anticonvulsant) (NN action))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (NNS cases)) (PP (IN of) (NP (NN drug2) (NN overdosage))))) (, ,) (S (NP (NN drug3) (NN CNS) (NN stimulation)) (VP (VBZ is) (VP (VBN potentiated)))) (CC and) (S (NP (JJ fatal) (NNS convulsions)) (VP (MD can) (VP (VB occur))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP inhibit) (NP (NP (DT the) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (: :) (NP (NN drug1))) (VP (MD can) (VP (VB cause) (NP (NP (DT a) (JJ significant) (NN elevation)) (PP (IN in) (NP (NN plasma) (NN corticosteroid) (NNS levels))))))) (. .)))
(S1 (S (S (NP (DT This) (NN increase)) (VP (VBZ is) (ADJP (JJS greatest) (PP (IN in) (NP (DT the) (NN evening)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (JJ urinary) (NN steroid) (NNS determinations)))))) (. .)))
(S1 (S (S (NP (DT No) (NN drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (DT the) (JJ drug1) (NN Implant))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (VP (VBN limited) (PP (VBP experience) (PP (IN with) (NP (NP (NN use)) (PP (IN of) (NP (JJ retinal) (NNS tamponades))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (DT the) (NN drug1) (NN Implant))))))))))) (. .)))
(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (DT an) (NN drug2)) (VP (VBG containing) (NP (NN drug3)) (PP (TO to) (NP (NP (CD 13) (NNS patients)) (PP (IN with) (NP (NN tuberculosis))))))))))))) (VP (VBD showed) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (JJ mean) (NN serum) (NNS concentrations)) (CC and) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NP (NNS drug4)) (PP (IN of) (NP (NP (QP (RB approximately) (CD 20)) (NN %)) (CC and) (NP (CD 13) (NN %)) (, ,) (ADVP (RB respectively)))))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (DT the) (JJ oral) (NN absorption)) (PP (IN of) (NP (NN drug5)))) (VP (MD may) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (DT these) (NN drug6))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (S (VP (TO to) (VP (VB avoid) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN drug1)))) (PP (IN with) (NP (NP (NN drug2)) (VP (VBG containing) (NP (NP (NN drug3)) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 4)) (NNS hours))) (PP (VBG following) (NP (NN drug4) (NN administration))))))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ specific) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (PP (IN For) (NP (NP (NN information)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NN combination))))))) (, ,) (VP (VB see) (NP (NN Drug) (NNS Interactions)) (PP (IN under) (NP (JJ CLINICAL) (NN PHARMACOLOGY) (NN section)))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN given) (ADVP (RB concurrently))))) (NP (DT the) (JJ following) (NNS drugs)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC or) (NP (NN drug3))) (: :) (NP (NP (NN potentiation)) (PP (IN of) (NP (JJ orthostatic) (NN hypotension))))) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN drug1) (: :)) (PRN (-LRB- -LRB-) (NP (NP (JJ oral) (NNS agents)) (CC and) (NP (NNS drug2))) (-RRB- -RRB-))) (CC -) (NP (NN dosage) (NN adjustment))) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NN drug1)) (: :) (NP (JJ additive) (NN effect)) (CC or) (NP (NN potentiation)))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (NN drug3))) (: :) (S (NP (NP (NN Absorption)) (PP (IN of) (NP (NN drug4)))) (VP (VBZ is) (VP (VBN impaired) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug5)))))))) (. .))))
(S1 (S (S (NP (NP (JJ Single) (NNS doses)) (PP (IN of) (NP (CC either) (NP (NN drug1)) (CC or) (NP (NN drug2) (NN drug3))))) (VP (VP (VB bind) (NP (DT the) (NN drug4))) (CC and) (VP (VB reduce) (NP (NP (PRP$ its) (NN absorption)) (PP (IN from) (NP (DT the) (JJ gastrointestinal) (NN tract)))) (PP (IN by) (NP (NP (QP (RB up) (TO to) (CD 85) (CC and) (CD 43)) (NN percent)) (, ,) (ADVP (RB respectively))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (: :) (NP (NP (JJ intensified) (NN electrolyte) (NN depletion)) (, ,) (ADVP (RB particularly)) (NP (NN hypokalemia))) (. .))))
(S1 (S (NP (NP (NP (JJ Pressor) (NNS amines)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (-RRB- -RRB-))) (: :) (S (NP (JJ possible)) (VP (VP (VBD decreased) (NP (NP (NN response)) (PP (TO to) (NP (JJ pressor) (NNS amines))))) (CC but) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB preclude) (NP (PRP$ their) (NN use)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NP (NN nondepolarizing)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (NP (NP (JJ possible) (VBN increased) (NN responsiveness)) (PP (TO to) (NP (DT the) (NN drug3)))) (. .))))
(S1 (S (S (S (NP (NN drug1))) (: :) (S (ADVP (RB generally)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBP reduce) (NP (NP (DT the) (JJ renal) (NN clearance)) (PP (IN of) (NP (NN drug2))))) (CC and) (VP (VBP add) (NP (NP (DT a) (JJ high) (NN risk)) (PP (IN of) (NP (NN drug3) (NN toxicity))))))) (. .)))
(S1 (S (S (VP (VBP Refer) (PP (TO to) (NP (NP (DT the) (JJ package) (NN insert)) (PP (IN for) (NP (NP (JJ drug1) (NNS preparations)) (PP (IN before) (NP (NP (NN use)) (PP (IN of) (NP (NP (JJ such) (NNS preparations)) (PP (IN with) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT a) (NN drug2)))) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (ADJP (ADJP (JJ diuretic)) (, ,) (ADJP (JJ natriuretic)) (, ,) (CC and) (ADJP (JJ antihypertensive))) (NNS effects)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN drug5)))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ desired) (NN effect)) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (VBZ is) (VP (VBN obtained)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (NN relationship)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NN drug3)))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN advised) (PP (IN against) (S (VP (VBG taking) (NP (NN drug4) (NN containing) (NN drug5)) (S (VP (TO to) (VP (VB avoid) (NP (JJ additive) (JJ toxic) (NNS effects)))))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN treatment)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (IN because) (S (NP (NN drug4) (NN use)) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NNS cases)) (PP (IN of) (NP (NP (JJ pseudotumor) (NN cerebri)) (PRN (-LRB- -LRB-) (NP (JJ benign) (JJ intracranial) (NN hypertension)) (-RRB- -RRB-)))))) (, ,) (SBAR (WHNP (NP (DT some)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBD involved) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug5)))))))))))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NP (JJ Micro-dosed) (NN drug1) (NNS Preparations)) (: :) (S (NP (NP (JJ Micro-dosed) (NN drug2) (NNS preparations)) (PRN (-LRB- -LRB-) (NP (NP (NNS minipills)) (SBAR (WHNP (WDT that)) (S (VP (VBP do) (RB not) (VP (VB contain) (NP (DT an) (NN drug3))))))) (-RRB- -RRB-))) (VP (MD may) (VP (VB be) (NP (NP (DT an) (JJ inadequate) (NN method)) (PP (IN of) (NP (NN contraception))) (PP (IN during) (NP (NN drug4) (NN therapy))))))) (. .))))
(S1 (S (SBAR (IN Although) (S (NP (JJ other) (NNS drug1)) (VP (VBP are) (ADJP (RB highly) (JJ effective))))) (, ,) (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (NP (NNS reports)) (PP (IN of) (NP (NN pregnancy))) (PP (IN from) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN used) (NP (NN drug2))))))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ topical/injectable/implantable/insertable) (JJ hormonal) (NN birth) (NN control) (NNS products))))) (. .)))
(S1 (S (S (NP (DT These) (NNS reports)) (VP (VBP are) (ADJP (RBR more) (JJ frequent)) (PP (IN for) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBP use) (ADVP (RB only)) (NP (NP (DT a) (JJ single) (NN method)) (PP (IN of) (NP (NN contraception))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBP differ) (PP (IN in) (NP (PRP$ their) (NN effectiveness))) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN with) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (RB critically) (JJ important) (PP (IN for) (NP (NP (NNS women)) (PP (IN of) (NP (NP (JJ childbearing) (NN potential)) (S (VP (TO to) (VP (VP (VB select)) (CC and) (VP (VB commit) (S (VP (TO to) (VP (VB use) (NP (NP (CD 2) (NNS forms)) (PP (IN of) (NP (JJ effective) (NN contraception)))) (ADVP (RB simultaneously)))))))))))))) (, ,) (SBAR (WHNP (NP (ADVP (IN at) (JJS least)) (NP (CD 1))) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (MD must) (VP (VB be) (NP (DT a) (JJ primary) (NN form)) (, ,) (SBAR (IN unless) (S (S (NP (JJ absolute) (NN abstinence)) (VP (VBZ is) (NP (DT the) (VBN chosen) (NN method)))) (, ,) (CC or) (S (NP (DT the) (NN patient)) (VP (VBZ has) (VP (VBN undergone) (NP (DT a) (NN hysterectomy))))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (CD seven) (JJ healthy) (NNS volunteers))))))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (ADJP (FW in) (FW vitro)) (NN finding)) (SBAR (IN that) (S (NP (CC neither) (NP (NN drug1)) (CC nor) (NP (PRP$ its) (NNS metabolites))) (VP (VP (VBP induce)) (CC or) (VP (VBP inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (NN CYP) (NN 2C9) (JJ human) (JJ hepatic) (NN P450) (NN enzyme))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NN osteomalacia)))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ formal) (JJ clinical) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (S (VP (TO to) (VP (VB assess) (SBAR (IN if) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT an) (JJ interactive) (NN effect)) (PP (IN on) (NP (NN bone) (NN loss))) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (DT these) (NNS drugs)) (ADVP (RB together))))))))))
(S1 (S (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NN osteoporosis)))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ formal) (JJ clinical) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (S (VP (TO to) (VP (VB assess) (SBAR (IN if) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT an) (JJ interactive) (NN effect)) (PP (IN on) (NP (NN bone) (NN loss))) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (DT these) (NNS drugs)) (ADVP (RB together))))))))) (. .)))
(S1 (S (S (NP (NNS Prescribers)) (VP (VBP are) (VP (VBN advised) (S (VP (TO to) (VP (VB consult) (NP (NP (DT the) (JJ package) (NN insert)) (PP (IN of) (NP (NP (NN medication)) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug1)))))))))) (, ,) (SBAR (IN since) (S (NP (DT some) (NNS medications)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (DT these) (NN birth) (NN control) (NNS products))))))))))) (. .)))
(S1 (S (S (NP (JJ drug1) (NN use)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NN depression)) (PP (IN in) (NP (DT some) (NNS patients)))))))) (. .)))
(S1 (S (S (NP (NNS Pregnancies)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN by) (NP (NP (NNS users)) (PP (IN of) (NP (NN drug1))) (SBAR (WHNP (WP who)) (S (ADVP (RB also)) (VP (VBD used) (NP (NP (DT some) (NN form)) (PP (IN of) (NP (NN St.) (NNP Johns) (NNP Wort))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN Laboratory) (NNS Tests)) (NN Pregnancy) (NN Test)) (NP (JJ Female) (NNS patients))) (PP (IN of) (NP (JJ childbearing) (NN potential)))) (VP (MD must) (VP (VB have) (NP (NP (JJ negative) (NNS results)) (PP (IN from) (NP (NP (CD 2) (NN urine)) (CC or) (NP (NN serum) (NN pregnancy) (NNS tests)))) (PP (IN with) (NP (NP (DT a) (NN sensitivity)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD 25)) (NN mIU/mL)))))) (PP (IN before) (S (VP (VBG receiving) (NP (DT the) (JJ initial) (NN drug1) (NN prescription)))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ first) (NN test)) (VP (VBZ is) (VP (VBN obtained) (PP (IN by) (NP (DT the) (NN prescriber))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN decision)) (VP (VBZ is) (VP (VBN made) (S (VP (TO to) (VP (VBP pursue) (NP (NP (NN qualification)) (PP (IN of) (NP (DT the) (NN patient))) (PP (IN for) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (DT a) (JJ screening) (NN test)) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ second) (NN pregnancy) (NN test)) (PRN (-LRB- -LRB-) (NP (DT a) (NN confirmation) (NN test)) (-RRB- -RRB-))) (VP (MD should) (VP (VB be) (VP (VBN done) (PP (IN during) (NP (NP (DT the) (JJ first) (CD 5) (NNS days)) (PP (IN of) (NP (NP (DT the) (JJ menstrual) (NN period)) (VP (ADVP (RB immediately)) (VBG preceding) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NN drug1) (NN therapy))))))))))))) (. .)))
(S1 (S (S (PP (IN For) (NP (NP (NNS patients)) (PP (IN with) (NP (NN amenorrhea))))) (, ,) (NP (DT the) (JJ second) (NN test)) (VP (MD should) (VP (VB be) (VP (VBN done) (PP (NP (QP (IN at) (JJS least) (CD 11)) (NNS days)) (IN after) (NP (NP (DT the) (JJ last) (VBP act)) (PP (IN of) (NP (NP (JJ unprotected) (JJ sexual) (NN intercourse)) (PRN (-LRB- -LRB-) (PP (IN without) (S (VP (VBG using) (NP (NP (CD 2) (JJ effective) (NNS forms)) (PP (IN of) (NP (NN contraception))))))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (DT Each) (NN month)) (PP (IN of) (NP (NN therapy)))) (, ,) (NP (DT the) (NN patient)) (VP (MD must) (VP (VB have) (NP (DT a) (JJ negative) (NN result)) (PP (IN from) (NP (DT a) (NN urine) (CC or) (NN serum) (NN pregnancy) (NN test)))))) (. .)))
(S1 (S (NP (DT A) (NN pregnancy) (NN test)) (VP (MD must) (VP (VB be) (VP (VBN repeated) (ADVP (NP (DT each) (NN month)) (RB prior) (PP (TO to) (NP (NP (DT the) (JJ female) (NN patient)) (VP (VBG receiving) (NP (DT each) (NN prescription)))))))))))
(S1 (S (. .)))
(S1 (S (S (NP (NP (NNS Lipids)) (: :) (NP (NN Pretreatment)) (CC and) (NP (JJ follow-up) (NN blood) (NNS lipids))) (VP (MD should) (VP (VB be) (VP (VBN obtained) (PP (IN under) (NP (JJ fasting) (NNS conditions))))))) (. .)))
(S1 (S (S (PP (IN After) (NP (NP (NN consumption)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (QP (IN at) (JJS least) (CD 36)) (NNS hours)) (VP (MD should) (VP (VB elapse) (SBAR (IN before) (S (NP (DT these) (NNS determinations)) (VP (VBP are) (VP (VBN made)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (DT these) (NNS tests)) (VP (VB be) (VP (VBN performed) (PP (IN at) (NP (ADJP (ADJP (JJ weekly)) (CC or) (ADJP (JJ biweekly))) (NNS intervals))) (SBAR (IN until) (S (NP (NP (DT the) (NN lipid) (NN response)) (PP (TO to) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN established)))))))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNS hypertriglyceridemia)))) (VP (VBZ is) (NP (NP (CD 1) (NN patient)) (PP (IN in) (NP (CD 4))) (PP (IN on) (NP (NN drug1) (NN therapy)))))))
(S1 (S (. .)))
(S1 (S (NP (NP (NN Liver) (NN Function) (NNS Tests)) (: :) (S (SBAR (IN Since) (S (S (NP (NP (NNS elevations)) (PP (IN of) (NP (NN liver) (NNS enzymes)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN during) (NP (JJ clinical) (NNS trials))))))) (, ,) (CC and) (S (NP (NN hepatitis)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))))) (, ,) (NP (NP (NN pretreatment)) (CC and) (NP (JJ follow-up) (NN liver) (NN function) (NNS tests))) (VP (MD should) (VP (VB be) (VP (VBN performed) (PP (IN at) (NP (ADJP (ADJP (JJ weekly)) (CC or) (ADJP (JJ biweekly))) (NNS intervals))) (SBAR (IN until) (S (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NN drug1)))) (VP (VBZ has) (VP (VBN been) (VP (VBN established)))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NP (NN Glucose)) (: :) (S (NP (NP (DT Some) (NNS patients)) (VP (VBG receiving) (NP (NN drug1)))) (VP (VBP have) (VP (VBN experienced) (NP (NNS problems)) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (PRP$ their) (NN blood) (NN sugar)))))))) (. .))))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ new) (NNS cases)) (PP (IN of) (NP (NNS diabetes)))) (VP (VBP have) (VP (VBN been) (VP (VBN diagnosed) (PP (IN during) (NP (NN drug1) (NN therapy))))) (, ,) (SBAR (IN although) (S (NP (DT no) (JJ causal) (NN relationship)) (VP (VBZ has) (VP (VBN been) (VP (VBN established)))))))))
(S1 (S (. .)))
(S1 (S (NP (NP (NN CPK)) (: :) (S (NP (NP (DT Some) (NNS patients)) (VP (VBG undergoing) (NP (JJ vigorous) (JJ physical) (NN activity)) (PP (IN while) (PP (IN on) (NP (NN drug1) (NN therapy)))))) (VP (VBP have) (VP (VBN experienced) (NP (JJ elevated) (NN CPK) (NNS levels))))) (: ;))))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (DT the) (JJ clinical) (NN significance)) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NP (JJ rare) (JJ postmarketing) (NNS reports)) (PP (IN of) (NP (NN rhabdomyolysis)))) (, ,) (NP (NP (DT some)) (VP (VBN associated) (PP (IN with) (NP (JJ strenuous) (JJ physical) (NN activity))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (JJ clinical) (NN trial)) (PP (IN of) (NP (NP (NP (CD 217) (JJ pediatric) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP (CD 12) (TO to) (CD 17)) (NNS years)) (-RRB- -RRB-))) (PP (IN with) (NP (JJ severe) (JJ recalcitrant) (JJ nodular) (NN acne))))))) (, ,) (NP (NP (JJ transient) (NNS elevations)) (PP (IN in) (NP (NN CPK)))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (CD 12) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (, ,) (PP (VBG including) (NP (NP (DT those) (VBG undergoing) (JJ strenuous) (JJ physical) (NN activity)) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (VBN reported) (JJ musculoskeletal) (JJ adverse) (NNS events)) (PP (JJ such) (IN as) (NP (RB back) (NP (NN pain)) (, ,) (NP (NN arthralgia)) (, ,) (NP (NN limb) (NN injury)) (, ,) (CC or) (NP (NN muscle) (NN sprain)))))))))))))))) (. .)))
(S1 (S (S (S (PP (IN In) (NP (DT these) (NNS patients))) (, ,) (NP (NP (RB approximately) (NN half)) (PP (IN of) (NP (DT the) (NN CPK) (NNS elevations)))) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN within) (NP (CD 2) (NNS weeks))))) (CC and) (S (NP (NN half)) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN within) (NP (CD 4) (NNS weeks)))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NNS cases)) (PP (IN of) (NP (NN rhabdomyolysis)))) (VP (VBD were) (VP (VBN reported) (PP (IN in) (NP (DT this) (NN trial)))))) (. .)))
(S1 (S (S (NP (DT No) (NN drug) (NN interaction) (NNS studies)) (VP (VBD were) (VP (VBN performed)))) (. .)))
(S1 (S (S (NP (DT No) (ADJP (FW in) (FW vitro)) (NN metabolism) (NNS studies)) (VP (VBD were) (VP (VBN performed)))) (. .)))
(S1 (S (S (NP (CC Both) (NP (NN drug1)) (CC and) (NP (NP (PRP$ its) (JJ major) (NN metabolite)) (, ,) (NP (NN drug2)) (, ,))) (VP (VBP are) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (DT the) (NP (NN cytochrome) (NN P450) (NN 3A4)) (NN enzyme) (NN system)))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NNS drugs))) (VP (ADVP (RB primarily)) (VBN metabolized) (PP (IN by) (NP (DT the) (NP (NN cytochrome) (NN P450) (NN 3A4)) (NN enzyme) (NN system))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (DT the) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VP (VB increase)) (CC or) (VP (VB prolong) (NP (ADJP (CC both) (ADJP (JJ therapeutic)) (CC and) (ADJP (JJ adverse))) (NNS effects)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN unless) (S (VP (ADVP (RB otherwise)) (VBN specified)))) (, ,) (NP (JJ appropriate) (NN dosage) (NNS adjustments)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ has) (VP (VBN led) (PP (TO to) (NP (NP (JJ elevated) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug3))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJ rare) (NNS instances)) (PP (IN of) (NP (NP (JJ life-) (NN threatening) (JJ cardiac) (NNS dysrhythmias)) (CC and) (NP (CD one) (NN death))))))))))) (. .)))
(S1 (S (S (NP (NP (DT Another) (JJ oral) (NN drug1)) (, ,) (NP (NN drug2)) (, ,)) (VP (VBZ inhibits) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJ elevated) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NP (NN drug4)) (CC and) (NP (PRP$ its) (JJ active) (NN metabolite))) (NNS drug5)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB prolong) (NP (VBG QT) (NNS intervals)))))))))))))) (. .)))
(S1 (S (S (NP (FW In) (FW vitro) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NN drug2)))))) (, ,) (VP (VBZ has) (NP (NP (DT a) (ADJP (RBR less) (JJ pronounced)) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN biotransformation) (NN system)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (NP (DT the) (JJ chemical) (NN resemblance)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NN drug4)))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (S (NP (JJ Human) (NNS pharmacokinetics) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ oral) (NN drug1)) (ADVP (RB potently)) (VP (VBZ inhibits) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (VP (VBG resulting) (PP (IN in) (NP (NP (DT an) (JJ eight-fold) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ mean) (NN AUC)) (PP (IN of) (NP (NN drug3)))))))))))))))) (. .)))
(S1 (S (S (NP (NNS Data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (JJ oral) (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (NN prolongation)) (PP (IN of) (NP (NP (DT the) (JJ QT) (NN interval)) (PP (IN on) (NP (DT the) (NN ECG))))))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (ADVP (RB also)) (ADVP (RB markedly)) (VP (VBZ inhibits) (NP (NP (DT the) (NN biotransformation) (NN system)) (ADJP (RB mainly) (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2)))))))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ oral) (NN drug2)) (CC or) (NP (NN drug3))))) (VP (VBZ has) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ elevated) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ latter) (CD two) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VP (VB potentiate)) (CC and) (VP (VB prolong) (NP (ADJP (ADJP (JJ hypnotic)) (CC and) (ADJP (JJ sedative))) (NNS effects)))))) (. .)))
(S1 (S (S (NP (DT These) (NNS agents)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB parenterally)))))) (, ,) (NP (JJ special) (NN precaution)) (VP (VBZ is) (VP (VBN required) (SBAR (IN since) (S (NP (DT the) (JJ sedative) (NN effect)) (VP (MD may) (VP (VB be) (ADJP (JJ prolonged))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC or) (NP (NN drug4))))) (VP (VBZ has) (VP (VBN led) (PP (TO to) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ latter) (CD three) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (NNS concentrations)) (VP (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN at) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN drug4) (NN therapy)))))))) (CC and) (ADVP (RB frequently)) (ADVP (RB thereafter)))) (, ,) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT these) (CD three) (NN drug) (NNS products)))) (VP (VBN adjusted) (ADVP (RB appropriately)))) (. .)))
(S1 (S (S (NP (NN Rhabdomyolysis)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (VP (VBN administered) (ADVP (ADVP (ADVP (RB alone)) (PRN (-LRB- -LRB-) (PP (IN at) (NP (VBN recommended) (NNS dosages))) (-RRB- -RRB-))) (CC or) (ADVP (RB concomitantly))) (PP (IN with) (NP (NP (NNS drug2)) (PP (VBG including) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN H2antagonists)))))))) (, ,) (NP (NP (VBN reduced) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug4)))) (VP (VBD were) (VP (VBN reported)))) (. .)))
(S1 (S (S (NP (DT The) (NN physician)) (VP (VBZ is) (VP (VBN advised) (S (VP (VP (TO to) (VP (VB monitor) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT any)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (VBZ is) (VP (VBN taken) (ADVP (RB concurrently)))))))) (, ,) (CC and) (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug2)))) (SBAR (IN if) (FRAG (JJ necessary)))))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (DT no) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted)))))) (, ,) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB alter) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (ADVP (RB also)) (VP (VB be) (VP (VBN monitored) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ enhances) (NP (NP (DT the) (JJ anticoagulant) (NN effect)) (PP (IN of) (NP (JJ drug2) (JJ -like) (NNS drugs))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN prothrombin) (NN time)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (JJ -like) (NNS drugs))))) (ADVP (RB simultaneously)))))) (. .)))
(S1 (S (S (NP (NP (NN Plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (VP (VBN reduced) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN plasma) (NNS concentrations)) (VP (MD should) (VP (VB be) (VP (VBN monitored))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBP are) (VP (VBN coadministered))))))) (. .)))
(S1 (S (S (NP (JJ Severe) (NN hypoglycemia)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concomitantly)) (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (JJ oral) (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NN Blood) (NN glucose) (NNS concentrations)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (JJ oral) (NN drug2))) (VP (VBP are) (VP (VBN coadministered))))))) (. .)))
(S1 (S (S (NP (NP (NN Tinnitus)) (CC and) (NP (VBN decreased) (NN hearing))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concomitantly)) (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NN Edema)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concomitantly)) (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (JJ Appropriate) (NN dosage) (NNS adjustments)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .)))
(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN from) (NP (NP (NP (DT a) (NN study)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (CD eight) (JJ HIV-infected) (NNS individuals)) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NN drug1)))))))) (, ,) (NP (QP (CD 8) (CC +/-) (CD 0.4)) (NN mg/kg/day)) (, ,)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2)))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN during) (NP (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug3)))) (, ,) (NP (ADJP (CD 100) (NN mg)) (NN b.i.d.)))))))))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (ADVP (RB temporarily)) (VP (VBP raise) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NP (JJ other) (NNS drug2)) (VP (VBN administered) (ADVP (RB concomitantly))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ particular))) (, ,) (NP (NNS convulsions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (SBAR (WHADVP (WRB when)) (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NN drug2)))))) (CC and) (S (NP (JJ special) (NN care)) (VP (MD should) (VP (VB be) (VP (VBN taken) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN treatment) (NN regimen)) (VP (VBZ includes) (NP (NP (DT both)) (PP (IN of) (NP (DT these) (NNS drugs))))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Excessive) (NN drug1) (NN ingestion)) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (IN because) (S (NP (DT a) (JJ psychotic) (NN reaction)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported)))))))))) (. .)))
(S1 (S (S (NP (ADJP (RB Potentially) (JJ fatal)) (NN drug) (NNS interactions)) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug1))) (, ,) (SBAR (IN as) (S (S (NP (DT this)) (VP (MD may) (VP (VB enhance) (NP (JJ cardiovascular) (NN depression))))) (CC and) (S (NP (NNS bradyarrhythmias)) (VP (MD may) (VP (VB occur)))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN neostgmine)) (, ,) (NP (NN drug2))) (-RRB- -RRB-))) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5))) (VP (MD can) (VP (VP (VB enhance) (NP (NN toxicity))) (CC and) (VP (VB cause) (NP (NN cardio) (JJ respiratory) (NN depression)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ neuromuscular) (NN blocking) (NN action)) (VP (VBZ is) (VP (VBN enhanced) (PP (IN by) (NP (NP (JJ general) (NN drug1)) (, ,) (NP (NP (JJ local) (NN drug2)) (PP (IN like) (NP (NN drug3)))) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8))))))) (. .)))
(S1 (S (S (NP (DT This) (NN drug)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NN drug1)) (CC or) (NP (NP (JJ other) (NNS drug2)) (-LRB- -LRB-) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN CNS) (NN depressant) (NNS effects)) (PP (IN of) (NP (CC either) (DT these) (NP (NNS medications)) (CC or) (NP (NN drug3))))))) (-RRB- -RRB-) (, ,) (NP (NN drug4)) (CC or) (NP (JJ other) (NNS medications))))) (PP (IN with) (NP (NP (NP (JJ anticholinergic) (NN activity)) (PRN (-LRB- -LRB-) (S (NP (JJ anticholinergic) (NNS effects)) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS medications)) (VP (VBP are) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug5))))))))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (S (NP (NP (JJ concurrent) (NN use)) (PP (IN with) (NP (NN drug7)))) (VP (MD may) (VP (VP (VB prolong)) (CC and) (VP (VB intensify) (NP (NP (DT the) (JJ anticholinergic) (CC and) (NN CNS) (NN depressant) (NNS effects)) (PP (IN of) (NP (NN drug8)))))))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NNS Results)) (PP (IN from) (NP (NP (JJ human) (ADJP (FW in) (FW vitro)) (NN metabolism) (NNS studies)) (CC and) (NP (JJ nonclinical) (NNS studies))))) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (VP (VBZ is) (ADVP (RB neither)) (VP (VBN metabolized) (SBAR (IN by) (S (CC nor) (VP (VP (VBZ inhibits)) (CC or) (VP (VBZ induces) (NP (NP (DT the) (NN cytochrome) (NN P450) (NN pathway)) (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN drug3)) (VP (VBZ is) (RB not) (ADJP (JJ likely) (S (VP (TO to) (VP (VP (VB cause)) (CC or) (VP (VB be) (ADJP (JJ subject) (PP (TO to) (NP (NP (JJ P450-based) (JJ metabolic) (NN drug) (NNS interactions)) (PP (IN in) (NP (NN man))))))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NP (CD 10) (NN mg)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NP (DT the) (JJ single) (NN dose)) (NP (NNS pharmacokinetics))) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (JJ single) (NN 25-mg) (NN dose) (NN drug1)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (JJ total) (NN drug2))))))) (. .)))
(S1 (S (S (S (NP (NP (VBN Expected) (NNS changes)) (PP (IN in) (NP (NP (JJ laboratory) (NNS assessments)) (PP (IN of) (NP (NP (NN PT)) (CC and) (NP (NN INR))))))) (VP (VBD were) (VP (VBN observed) (PP (IN after) (NP (NN drug1) (NN administration)))))) (, ,) (CC but) (S (NP (DT these) (NNS changes)) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (JJ concomitant) (NN drug2) (NN administration))))))) (. .)))
(S1 (S (NP (NP (NNS Agents)) (VP (VBG Affecting) (NP (NP (NP (NN Cytochrome) (NN P450) (NN 3A4)) (S (NP (NN Isoenzyme) (NN System) (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (ADVP (RB mainly)) (PP (IN via) (NP (DT the) (NP (JJ human) (NN cytochrome) (NN P450) (NN 3A4)) (NN isoenzyme) (NN system))))))) (PRN (-LRB- -LRB-) (NP (NN CYP3A4)) (-RRB- -RRB-))))) (, ,) (ADVP (RB therefore)) (NP (JJ potential) (NNS interactions)) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP affect) (NP (NN CYP3A4) (NN activity))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadminstration)) (PP (IN with) (NP (NP (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NN 3A4) (NN activity)))))))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (JJ transdermal) (NN drug1)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NP (JJ other) (JJ potent) (NN 3A4) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN nefazadone)))))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN drug8) (NN plasma) (NNS concentrations)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (JJ other) (JJ CYP3A4) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN with) (NP (JJ transdermal) (NN drug3)))))))) (VP (VP (MD may) (ADVP (RB also)) (VP (VB result) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN drug4) (NN plasma) (NNS concentrations))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VP (VB increase)) (CC or) (VP (VB prolong) (NP (JJ adverse) (NN drug) (NNS effects))))))))))) (CC and) (VP (MD may) (VP (VB cause) (NP (JJ serious) (JJ respiratory) (NN depression)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN situation))) (, ,) (NP (NP (JJ special) (NN patient) (NN care)) (CC and) (NP (NN observation))) (VP (VBP are) (ADJP (JJ appropriate)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3) (JJ transdermal) (NN system)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (JJ other) (NNS drug4)) (, ,) (VP (VP (VBG including)) (CC but) (VP (RB not) (VBN limited) (PP (TO to) (NP (NP (JJ other) (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug9)) (-RRB- -RRB-))) (, ,) (NP (JJ general) (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (CC and) (NP (NN drug13)))))) (, ,)))))) (VP (VP (MD may) (VP (VB cause) (NP (NP (JJ respiratory) (NN depression)) (, ,) (NP (NN hypotension)) (, ,) (CC and) (NP (JJ profound) (NN sedation))))) (, ,) (CC or) (ADVP (RB potentially)) (VP (VB result) (PP (IN in) (NP (NP (NN coma)) (CC or) (NP (NN death))))))) (. .))))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (JJ combined) (NN therapy)) (VP (VBZ is) (VP (VBN contemplated))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (CD one)) (CC or) (NP (DT both)) (NP (NNS agents))))) (VP (MD should) (VP (VB be) (VP (ADVP (RB significantly)) (VBN reduced))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ is) (RB not) (VP (VBN recommended) (PP (IN for) (NP (NN use))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN received) (NP (NP (NN drug3)) (PP (IN within) (NP (CD 14) (NNS days)))) (SBAR (IN because) (S (NP (NP (ADJP (ADJP (JJ severe)) (CC and) (ADJP (JJ unpredictable))) (NN potentiation)) (PP (IN by) (NP (NN drug4)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NN drug5))))))))))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (ADVP (RB apparently)) (PP (IN through) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (JJ certain) (JJ microsomal) (NN enzyme) (NNS systems))))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (JJ hepatic) (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (JJ certain) (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (CC and) (NP (NN drug11)))))))))) (, ,) (S (ADVP (RB thereby)) (VP (VP (VBG delaying) (NP (NN elimination))) (CC and) (VP (VBG increasing) (NP (NP (NN blood) (NNS levels)) (PP (IN of) (NP (DT these) (NNS drugs))))))))) (. .)))
(S1 (S (S (NP (ADJP (RB Clinically) (JJ significant)) (NNS effects)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (DT the) (NN drug1))))))) (: ;)))
(S1 (S (S (S (ADVP (RB therefore)) (, ,) (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (NN prothrombin) (NN time)))) (VP (VBZ is) (VP (VBN recommended)))) (, ,) (CC and) (S (NP (NP (NN adjustment)) (PP (IN of) (NP (DT the) (NN drug1) (NN dose)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Interaction)) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB produce) (NP (JJ adverse) (JJ clinical) (NNS effects))))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT a) (NN crossover) (NN study)) (PP (IN in) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBG receiving) (NP (CC either) (NP (NN drug1) (CD 300) (NN mg) (CD q.i.d.)) (CC or) (NP (NP (CD 800) (NN mg)) (VP (VBG h.s.) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (DT a) (ADJP (CD 300) (NN mg)) (NN b.i.d.) (NN dosage)) (PP (IN of) (NP (NN drug2))))) (PRN (-LRB- -LRB-) (NP (NN drug3)) (, ,) (NP (JJ Key) (NP (NNP Pharmaceuticals) (, ,) (NNP Inc.))) (-RRB- -RRB-))))))))) (VP (VBD demonstrated) (NP (RBR less) (NN alteration)) (PP (IN in) (NP (NP (JJ steady-state) (NN drug4) (NN peak) (NN serum) (NNS levels)) (PP (IN with) (NP (DT the) (ADJP (CD 800) (NN mg)) (NN h.s.) (NN regimen))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (NNS subjects)) (ADJP (JJ aged) (NP (NP (CD 54) (NNS years)) (CC and) (NP (JJR older))))))) (. .)))
(S1 (S (S (NP (NP (NNS Data)) (PP (IN beyond) (NP (CD 10) (NNS days)))) (VP (VBP are) (RB not) (ADJP (JJ available)))) (. .)))
(S1 (S (PRN (-LRB- -LRB-) (NP (NP (NN Note)) (: :) (S (NP (NP (DT All) (NNS patients)) (VP (VBG receiving) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB appropriately)) (, ,) (ADVP (RB regardless) (PP (IN of) (NP (JJ concomitant) (NN drug) (NN therapy)))))))) (. .)) (-RRB- -RRB-))))
(S1 (S (S (NP (NP (NN Dosage)) (PP (IN of) (NP (NP (NP (DT the) (NNS drugs)) (VP (VBN mentioned) (ADVP (RB above)))) (CC and) (NP (NP (JJ other) (ADJP (RB similarly) (VBN metabolized)) (NNS drugs)) (, ,) (NP (NP (RB particularly) (DT those)) (PP (PP (IN of) (NP (JJ low) (JJ therapeutic) (NN ratio))) (CC or) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (ADJP (JJ renal)) (CC and/or) (ADJP (JJ hepatic))) (NN impairment))))))) (, ,))))) (VP (MD may) (VP (VB require) (NP (NP (NN adjustment)) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG starting)) (CC or) (VP (VBG stopping) (NP (NP (ADJP (RB concomitantly) (VBN administered)) (NN drug1)) (S (VP (TO to) (VP (VB maintain) (NP (JJ optimum) (JJ therapeutic) (NN blood) (NNS levels)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Alteration)) (PP (IN of) (NP (NN pH)))) (VP (MD may) (VP (VB affect) (NP (NP (NN absorption)) (PP (IN of) (NP (NP (JJ certain) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT these) (NNS products)) (VP (VBP are) (VP (VBN needed))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN given) (NP (QP (IN at) (JJS least) (CD 2)) (NNS hours)) (PP (IN before) (NP (NN drug1) (NN administration))))))) (. .)))
(S1 (S (S (NP (JJ Additional) (JJ clinical) (VBP experience)) (VP (MD may) (VP (VBP reveal) (NP (NP (JJ other) (NNS drugs)) (VP (VBN affected) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (NP (ADJP (ADJP (JJ General)) (: :) (ADJP (JJ Significant))) (NNS interactions)) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB together)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN P450) (NN 2C9)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN metabolism)) (VP (VBZ is) (ADVP (RB predominantly)) (VP (VBN mediated) (PP (IN via) (NP (NP (NN cytochrome) (NN P450) (NN 2C9)) (PP (IN in) (NP (DT the) (NN liver)))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (NNS 2C9)))))))))))) (VP (MD should) (VP (VB be) (VP (VBN done) (PP (IN with) (NP (NN caution))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (NP (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 2C9)))) (, ,) (NP (NP (NN 2C19)) (CC or) (NP (NN 3A4))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (ADVP (RB also)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN drug1)) (, ,) (CONJP (IN although) (RB not)) (NP (DT a) (NN substrate)) (, ,)) (VP (VBZ is) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 2D6))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (NN potential)) (PP (IN for) (NP (NP (DT an) (ADJP (FW in) (FW vivo)) (NN drug) (NN interaction)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (NN P450) (NN 2D6)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Clinical) (NNS studies)) (PP (IN with) (NP (NN drug1)))) (VP (VBP have) (VP (VBN identified) (NP (NP (ADJP (RB potentially) (JJ significant)) (NNS interactions)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (VBP Experience)) (PP (IN with) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (VP (VBZ suggests) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NNS effects)) (PP (JJ drug1) (IN on) (NP (NP (DT the) (NP (NNS pharmacokinetics)) (CC and/or) (NP (NNS pharmacodynamics))) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7))))))) (VP (VBP have) (VP (VBN been) (VP (VBN studied) (ADVP (FW in) (FW vivo)))))) (CC and) (S (NP (ADJP (RB clinically) (JJ important)) (NNS interactions)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN found)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NNS Reports)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug3)))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN interaction)) (VP (MD should) (VP (VB be) (VP (VBN given) (NP (NP (NN consideration)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)))))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Clinical) (NNS studies)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ post) (JJ marketing) (NNS observations)) (, ,)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (JJ natriuretic) (NN effect)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))) (PP (IN in) (NP (DT some) (NNS patients))))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN response)) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ renal) (NN prostaglandin) (NN synthesis))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD can) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (JJ low) (NN dose) (NN drug3))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT an) (VBN increased) (NN rate)) (PP (IN of) (NP (NP (NN GI) (NN ulceration)) (CC or) (NP (JJ other) (NNS complications)))))) (, ,) (PP (VBN compared) (PP (TO to) (NP (NP (NN use)) (PP (IN of) (NP (NP (NN drug3)) (ADVP (RB alone))))))))) (. .)))
(S1 (S (S (PP (IN Because) (IN of) (NP (NP (PRP$ its) (NN lack)) (PP (IN of) (NP (NN platelet) (NNS effects))))) (, ,) (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (DT a) (VP (VB substitute) (PP (IN for) (NP (NN drug2))) (PP (IN for) (NP (JJ cardiovascular) (NNS prophylaxis))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (IN at) (NP (ADJP (CD 200) (NN mg)) (NN QD)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ two-fold) (NN increase)) (PP (IN in) (NP (NN drug3) (NN plasma) (NN concentration))))))) (. .))))
(S1 (S (S (NP (DT This) (NN increase)) (VP (VBZ is) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NN drug1) (NN metabolism)))))) (PP (IN via) (NP (NN P450) (NN 2C9))) (PP (IN by) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (VB see) (NP (JJ CLINICAL) (NN PHARMACOLOGY))) (: -) (NP (NNS Pharmacokinetics)) (: :) (NP (NN Metabolism))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN introduced) (PP (IN at) (NP (NP (DT the) (JJS lowest) (VBN recommended) (NN dose)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (NN study)) (VP (VBN conducted) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))) (, ,) (NP (JJ mean) (JJ steady-state) (NN drug2) (NN plasma) (NNS levels)) (VP (VBD increased) (NP (QP (RB approximately) (CD 17)) (NN %)) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBG receiving) (NP (NP (NN drug3) (CD 450) (NN mg)) (ADJP (JJ BID) (PP (IN with) (NP (NP (NN drug4) (ADJP (CD 200) (NN mg)) (NN BID)) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (NNS subjects)) (VP (VBG receiving) (NP (NP (NN drug5)) (ADVP (RB alone)))))))))))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug1) (NN treatment)))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VP (VBN introduced)) (CC or) (VP (VBN withdrawn)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT an) (NN interaction) (NN study)) (PP (IN of) (NP (NP (JJ rheumatoid) (NN arthritis) (NNS patients)) (VP (VBG taking) (NP (NN drug2))))))) (, ,) (NP (NN drug3)) (VP (VBD did) (RB not) (VP (VB have) (NP (DT a) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug4)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NP (DT the) (JJ anti-coagulant) (NN effect)) (PP (IN of) (NP (NN drug3)))))) (VP (VBD was) (VP (VBN studied) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBG receiving) (NP (NP (JJ daily) (NNS doses)) (PP (IN of) (NP (NP (CD 2-5) (NN mg)) (PP (IN of) (NP (NN drug4)))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT these) (NNS subjects))) (, ,) (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (JJ anticoagulant) (NN effect)) (PP (IN of) (NP (NN drug2)))) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NN prothrombin) (NN time))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (IN with) (NP (NN drug2))) (SBAR (IN since) (S (NP (DT these) (NNS patients)) (VP (VBP are) (PP (IN at) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (JJ bleeding) (NNS complications))))))))))))) (. .)))
(S1 (S (S (VP (MD May) (VP (VB interact) (PP (IN with) (NP (NP (JJ other) (NNS creams)) (, ,) (NP (NNS lotions)) (, ,) (CC or) (NP (NN skin) (NNS medicines)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN placed) (PP (IN on) (NP (NP (DT the) (JJ same) (NNS areas)) (PP (IN of) (NP (NP (NN your) (NN skin)) (SBAR (WHNP (WDT that)) (S (ADVP (RB you)) (VP (VBP are) (VP (VBG using) (NP (NN drug1)))))))))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (, ,) (PP (IN because) (PP (IN of) (NP (NP (PRP$ its) (NN affinity)) (PP (IN for) (NP (NN protein)))))) (, ,) (NP (NN drug1)) (VP (MD may) (VP (VB displace) (NP (JJ other) (JJ protein-bound) (NNS drugs)) (PP (IN from) (NP (PRP$ their) (VBG binding) (NN site)))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (IN with) (NP (NN drug2))) (SBAR (IN since) (S (NP (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN seen) (PP (IN with) (NP (JJ other) (NN drug3))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (DT an) (ADJP (NN drug1) (JJ -containing)) (NN drug2)))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN in) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN administered) (PP (IN with) (NP (NP (NN food)) (CC or) (NP (NN milk))))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (ADJP (RBR more) (JJ rapid)) (NN absorption))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (NP (DT the) (JJ total) (NN amount)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (DT the) (NN plasma)))) (VP (VBZ is) (ADJP (JJ unchanged)))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN Hypotension) (NNS Patients)) (PP (IN on) (NP (NN drug1) (NN Therapy)))) (: :) (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug2))))) (CC and) (ADVP (RB especially)) (NP (NP (DT those)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NN drug3) (NN therapy)) (VP (VBD was) (ADVP (RB recently)) (VP (VBN instituted)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT those)) (PP (IN on) (NP (NP (JJ severe) (JJ dietary) (NN salt) (NN restriction)) (CC or) (NP (NN dialysis))))) (, ,)) (VP (MD may) (ADVP (RB occasionally)) (VP (VBP experience) (NP (NP (DT a) (JJ precipitous) (NN reduction)) (PP (IN of) (NP (NN blood) (NN pressure)))) (ADVP (RB usually)) (PP (IN within) (NP (NP (DT the) (JJ first) (NN hour)) (PP (IN after) (S (VP (VBG receiving) (NP (NP (DT the) (JJ initial) (NN dose)) (PP (IN of) (NP (NN drug4)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (NP (JJ hypotensive) (NNS effects)) (PP (IN with) (NP (NN drug1)))))) (VP (MD can) (VP (VB be) (VP (VBN minimized) (PP (IN by) (S (VP (VP (CC either) (VP (VBG discontinuing) (NP (DT the) (NN drug2))) (CC or) (VP (VBG increasing) (NP (DT the) (NN salt) (NN intake))) (NP (NP (QP (RB approximately) (CD one)) (NN week)) (ADJP (JJ prior) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4) (NNS tablets)) (, ,) (NP (NN USP)) (-RRB- -RRB-))))))))))) (CC or) (VP (VBG initiating) (NP (NP (NN therapy)) (PP (IN with) (NP (NP (JJ small) (NNS doses)) (PRN (-LRB- -LRB-) (NP (QP (CD 6.25) (CC or) (CD 12.5)) (NN mg)) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Alternatively)) (, ,) (VP (VBP provide) (NP (NP (JJ medical) (NN supervision)) (PP (IN for) (NP (QP (IN at) (JJS least) (CD one)) (NN hour))) (PP (IN after) (NP (DT the) (JJ initial) (NN dose)))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN hypotension)) (VP (VBZ occurs)))) (, ,) (NP (DT the) (NN patient)) (VP (VP (MD should) (VP (VB be) (VP (VBN placed) (PP (IN in) (NP (DT a) (JJ supine) (NN position)))))) (CC and) (, ,) (SBAR (IN if) (ADJP (JJ necessary))) (, ,) (VP (VBP receive) (NP (NP (DT an) (JJ intravenous) (NN infusion)) (PP (IN of) (NP (JJ normal) (NN saline))))))) (. .)))
(S1 (S (S (NP (DT This) (JJ transient) (JJ hypotensive) (NN response)) (VP (VBZ is) (RB not) (NP (NP (DT a) (NN contraindication)) (PP (TO to) (NP (NP (JJ further) (NNS doses)) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB be) (VP (VBN given) (PP (IN without) (NP (NN difficulty))) (SBAR (IN once) (S (NP (DT the) (NN blood) (NN pressure)) (VP (VBZ has) (VP (VBN increased) (PP (IN after) (NP (NN volume) (NN expansion))))))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Agents)) (VP (VBG Having) (NP (NN Vasodilator) (NN Activity)))) (: :) (S (NP (NP (NNS Data)) (PP (IN on) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (JJ other) (NN drug1))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)) (PP (IN for) (NP (NN heart) (NN failure))))))))))) (VP (VBP are) (RB not) (ADJP (JJ available)))) (: ;))))
(S1 (S (ADVP (RB therefore)) (, ,) (NP (NP (NP (ADJP (ADJP (JJ drug1)) (CC or) (ADJP (JJ other))) (NNS drug2)) (PRN (-LRB- -LRB-) (ADVP (RB as)) (VP (VBN used) (PP (IN for) (NP (NP (NN management)) (PP (IN of) (NP (NN angina)))))) (-RRB- -RRB-))) (CC or) (NP (NP (JJ other) (NNS drugs)) (VP (VBG having) (NP (NN vasodilator) (NN activity))))) (VP (MD should) (, ,) (PP (IN if) (NP (JJ possible))) (, ,) (VP (VB be) (VP (VBN discontinued) (PP (IN before) (S (VP (VBG starting) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (VP (VBN resumed) (PP (IN during) (NP (NN drug1) (NN therapy)))))) (, ,) (NP (JJ such) (NNS agents)) (VP (MD should) (VP (VB be) (VP (VBN administered) (ADVP (ADVP (RB cautiously)) (, ,) (CC and) (ADVP (RB perhaps))) (PP (IN at) (NP (JJR lower) (NN dosage))))))) (. .)))
(S1 (S (S (NP (NP (NNS Agents)) (VP (VBG Causing) (NP (NP (NN Renin) (NN Release)) (NP (NN drug1) (POS 's) (NN effect))))) (VP (MD will) (VP (VB be) (VP (VBN augmented) (PP (IN by) (NP (NP (NN drug2)) (SBAR (WHNP (WDT that)) (S (VP (VBP cause) (NP (NN renin) (NN release))))))))))) (. .)))
(S1 (S (S (PP (IN For) (NP (NN example))) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-))) (VP (MD may) (VP (VB activate) (NP (DT the) (JJ renin-angiotensin-aldosterone) (NN system))))) (. .)))
(S1 (S (S (NP (NP (NNS Agents)) (VP (VBG Affecting) (NP (JJ Sympathetic) (NN Activity) (NP (DT The) (JJ sympathetic) (JJ nervous) (NN system))))) (VP (MD may) (VP (VB be) (ADJP (RB especially) (JJ important) (PP (IN in) (S (VP (VBG supporting) (NP (NP (NN blood) (NN pressure)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))) (UCP (ADVP (RB alone)) (CC or) (PP (IN with) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS agents)) (VP (VBG affecting) (NP (NP (JJ sympathetic) (NN activity)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (-RRB- -RRB-))))) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBP add) (NP (DT some) (JJ further) (JJ antihypertensive) (NN effect)) (PP (TO to) (NP (NN drug2))))) (, ,) (CC but) (S (NP (DT the) (JJ overall) (NN response)) (VP (VBZ is) (ADJP (ADJP (JJR less)) (PP (IN than) (ADJP (JJ additive))))))) (. .)))
(S1 (S (S (S (NP (NNS Agents)) (VP (VBG Increasing) (NP (NN Serum) (NN Potassium)) (PP (IN Since) (NP (NN drug1))))) (VP (VBZ decreases) (NP (NN aldosterone) (NN production)) (, ,) (S (NP (NP (NN elevation)) (PP (IN of) (NP (NN serum) (NN potassium)))) (VP (MD may) (VP (VB occur)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5) (NNS supplements))))) (VP (MD should) (VP (VB be) (VP (VBN given) (ADVP (RB only)) (PP (PP (IN for) (NP (JJ documented) (NN hypokalemia))) (, ,) (CC and) (ADVP (RB then)) (PP (IN with) (NP (NN caution)))) (, ,) (SBAR (IN since) (S (NP (PRP they)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN of) (NP (NN serum) (NN potassium)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Salt) (VBZ substitutes)) (VP (VBG containing) (NP (NN drug1)))) (VP (MD should) (ADVP (RB also)) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Inhibitors)) (PP (IN Of) (NP (JJ Endogenous) (NN Prostaglandin) (NN Synthesis)))) (NP (PRP It))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug2)))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (JJ low) (NN renin) (NN hypertension))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug2)) (-RRB- -RRB-))) (VP (MD may) (ADVP (RB also)) (VP (VB have) (NP (DT this) (NN effect))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (VBN Increased) (NN serum) (NN drug2) (NNS levels)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NN drug3) (NN toxicity)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ concomitant) (NN drug4) (CC and) (NN drug5) (NN therapy))))))))) (. .))))
(S1 (S (S (S (NP (DT These) (NNS drugs)) (VP (MD should) (VP (VB be) (VP (VBN coad-ministered) (PP (IN with) (NP (NN caution))))))) (CC and) (S (NP (NP (JJ frequent) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN drug1) (NNS levels)))) (VP (VBZ is) (VP (VBN recommended))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT a) (NN drug1)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN used))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2) (NN toxicity))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (JJ young) (JJ healthy) (JJ male) (NNS subjects))))) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (DT a) (JJ direct) (JJ pharmacokinetic) (NN drug2) (: -) (NN drug3) (NN interaction)))) (VP (MD could) (VP (VB be) (VP (VBN found))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2)) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug3))))) (VP (VBZ does) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug4))) (PP (IN in) (NP (ADJP (RB renally) (JJ impaired)) (NN hypertensive) (NNS patients))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (: :) (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (JJ healthy) (JJ male) (NNS volunteers))))) (NP (DT no) (JJ significant) (JJ pharmacokinetic) (NN interaction)) (VP (VBD occurred) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBD were) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN for) (NP (CD 6) (NNS days))))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NN Interaction) (NN drug1)) (VP (MD may) (VP (VB cause) (NP (NP (DT a) (JJ false-positive) (NN urine) (NN test)) (PP (IN for) (NP (NN acetone))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug2)))) (, ,) (ADVP (RB especially)) (NP (NP (DT those)) (PP (IN with) (NP (JJ intravascular) (NN volume) (NN depletion)))) (, ,)) (VP (MD may) (ADVP (RB occasionally)) (VP (VBP experience) (NP (NP (DT an) (JJ excessive) (NN reduction)) (PP (IN of) (NP (NN blood) (NN pressure))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN therapy))) (PP (IN with) (NP (NN drug3))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (JJ hypotensive) (NNS effects)))) (VP (MD can) (VP (VB be) (VP (VBN minimized) (PP (IN by) (S (VP (CC either) (VP (VBG discontinuing) (NP (DT the) (NN drug1))) (CC or) (VP (VBG increasing) (NP (NP (NN salt) (NN intake)) (ADVP (ADVP (RB prior)) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug2))))))))))))))))) (. .)))
(S1 (S (SBAR (IN If) (S (NP (DT this)) (VP (VBZ is) (RB not) (ADJP (JJ possible))))) (, ,) (S (S (NP (DT the) (VBG starting) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN reduced))))) (CC and) (S (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (JJ several) (NNS hours))) (PP (VBG following) (NP (DT an) (JJ initial) (NN dose)))) (CC and) (SBAR (IN until) (S (NP (NN blood) (NN pressure)) (VP (VBZ has) (VP (VBN stabilized) (PRN (-LRB- -LRB-) (NP (VB see) (NP (NP (NN DOSAGE)) (CC AND) (NP (NN ADMINISTRATION))) (. .)) (-RRB- -RRB-))))))))))))
(S1 (S (NP (NP (NP (NN drug1) (NNS Supplements)) (CC and) (NP (NNS drug2))) (: :) (S (NP (NN drug3)) (VP (MD can) (VP (VB attenuate) (NP (NP (NN potassium) (NN loss)) (VP (VBN caused) (PP (IN by) (NP (NN drug4)))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NNS others))) (-RRB- -RRB-))) (CC or) (NP (NN drug5) (NNS supplements))) (VP (MD can) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN hyperkalemia))))))) (. .)))
(S1 (S (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN if) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (JJ such) (NNS agents)))) (VP (VBZ is) (VP (VBN indicated))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NN caution))))))) (, ,) (CC and) (S (NP (DT the) (NNS patients) (NN serum) (NN potassium)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB frequently))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (VBN Increased) (NN serum) (NN drug2) (NNS levels)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NN drug3) (NN toxicity)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug4)) (PP (IN during) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug5)))))))))))) (. .))))
(S1 (S (S (S (NP (DT These) (NNS drugs)) (VP (MD should) (VP (VB be) (VP (VBN coadministered) (PP (IN with) (NP (NN caution))))))) (, ,) (CC and) (S (NP (NP (JJ frequent) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN drug1) (NNS levels)))) (VP (VBZ is) (VP (VBN recommended))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT a) (NN drug1)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN used))))) (, ,) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN lithium) (NN toxicity)))) (VP (MD may) (VP (VB be) (VP (VBN increased))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (DT a) (JJ clinical) (NN pharmacology) (NN study))) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (DT an) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))) (-RRB- -RRB-)))) (PP (IN with) (NP (NN drug6)))) (VP (VBD reduced) (NP (NP (NN serum) (NNS levels)) (CC and) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NN drug7))))) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (NN drug8)) (VP (VBN administered) (ADVP (RB alone)))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN drug9)) (VP (MD may) (VP (VB impair) (NP (NP (NN absorption)) (PP (IN of) (NP (NN drug10)))))))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN if) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (VBZ is) (VP (VBN indicated))))) (, ,) (NP (NN dosing)) (VP (MD should) (VP (VB be) (VP (VBN separated) (PP (IN by) (NP (CD 2) (NNS hours))))))) (. .)))
(S1 (S (S (NP (JJ Other) (: :) (CC Neither) (NP (NN drug1)) (CC nor) (NP (PRP$ its) (NNS metabolites))) (VP (VBP have) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NN food)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ separate) (ADJP (ADJP (JJ single)) (CC or) (ADJP (JJ multiple))) (NN dose) (JJ pharmacokinetic) (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (CC and) (NP (NN drug9)))))) (, ,) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug10)))) (VP (VBD was) (RB not) (VP (VBN altered) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug11))) (PP (IN with) (NP (NP (DT any) (CD one)) (PP (IN of) (NP (DT these) (NNS drugs)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN with) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (, ,) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (JJ unbound) (NN drug3)))) (VP (VBD was) (RB not) (VP (VBN altered)))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (JJ pharmacokinetic) (NN interaction) (NN study)) (PP (IN with) (NP (NN drug1))))) (, ,) (NP (NP (NN bioavailability) (NNS parameters)) (, ,) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN protein) (NN binding)))) (, ,) (CC and) (NP (NP (NP (DT the) (JJ anticoagulant) (NN effect)) (PRN (-LRB- -LRB-) (VP (VBN measured) (PP (IN by) (NP (NN prothrombin) (NN time)))) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug2))))) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN changed)))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NN Interaction) (NN drug1)) (VP (MD may) (VP (VB cause) (NP (NP (DT a) (JJ false) (JJ low) (NN measurement)) (PP (IN of) (NP (NN serum) (NN drug2) (NNS levels))) (PP (IN with) (NP (NP (DT the) (NN Digi-) (NN Tab) (NN RIA) (NN Kit)) (PP (IN for) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS kits)) (, ,) (PP (JJ such) (IN as) (NP (DT the) (JJ Coat-A-Count) (NN RIA) (NN Kit))) (, ,)) (VP (MD may) (VP (VB be) (VP (VBN used))))) (. .)))
(S1 (S (S (ADVP (FW In) (FW vitro)) (, ,) (NP (NN drug1)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN liver) (NN cytochrome) (NN P-450) (NNS isoenzymes)))))))))) (CC and) (VP (ADVP (RB therefore)) (, ,) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NNS compounds)) (VP (VBG requiring) (NP (DT these) (NNS systems))))))))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NP (NNS drugs)) (PP (IN with) (NP (DT a) (JJ low) (JJ therapeutic) (NN margin))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3)))) (, ,)) (VP (MD could) (VP (VB have) (NP (NP (DT a) (VBN delayed) (NN elimination)) (CC and) (NP (NNS increases))) (PP (IN in) (NP (NP (PRP$ their) (NN serum) (NN half-life)) (VP (VBG leading) (PP (TO to) (NP (DT a) (JJ toxic) (NN level))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN dosage)) (PP (IN of) (NP (NP (DT these) (NP (NNS drugs)) (CC or) (NP (NNS others))) (PP (IN with) (NP (DT a) (JJ similar) (NN metabolism)))))) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN modified) (SBAR (IN if) (S (NP (PRP they)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug1)))))))))))))) (. .)))
(S1 (S (S (PP (IN For) (NP (NN example))) (, ,) (S (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))) (, ,) (NP (NN prothrombin) (NN time)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (CC and) (S (SBAR (IN if) (FRAG (JJ necessary))) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NN drug3)))) (VP (MD should) (VP (VB be) (VP (VBN reduced)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ hypoglycemic) (NN action)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NP (JJ certain) (NNS drugs)) (PP (VBG including) (NP (NP (NP (NP (NN drug2)) (CC and) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB highly)) (VP (NN protein) (VBN bound)))))) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (CC and) (NP (NN drug9)))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NN hypoglycemia))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN withdrawn) (PP (IN from) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (NN control))))))))) (. .)))
(S1 (S (S (NP (JJ Certain) (NNS drugs)) (VP (VBP tend) (S (VP (VP (TO to) (VP (VB produce) (NP (NN hyperglycemia)))) (CC and) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NN loss)) (PP (IN of) (NP (NN control))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS drugs)) (VP (VBP include) (NP (NP (NP (DT the) (NN drug1)) (CC and) (NP (JJ other) (NNS drug2))) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN phe-nothiazines)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (JJ oral) (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN sympathomimet-ics)) (, ,) (NP (NN drug9)) (, ,) (CC and) (NP (NN drug10)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN observed) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (NN control))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN withdrawn) (PP (IN from) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NN hypoglycemia))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ possible) (NN interaction)) (PP (IN between) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,) (NP (DT a) (NN drug3)) (, ,)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (NN potentiation)) (PP (IN of) (NP (NP (DT the) (JJ hypoglycemic) (NN action)) (PP (IN of) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN for) (NP (DT this) (NN interaction)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ potential) (NN interaction)) (PP (IN between) (NP (NP (NP (JJ oral) (NN drug1)) (CC and) (NP (JJ oral) (NN drug2))) (VP (VBG leading) (PP (TO to) (NP (JJ severe) (NN hypoglycemia))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (SBAR (IN Whether) (S (NP (DT this) (NN interaction)) (ADVP (RB also)) (VP (VBZ occurs) (PP (IN with) (NP (NP (DT the) (ADJP (ADJP (JJ intravenous)) (, ,) (ADJP (JJ topical)) (CC or) (ADJP (JJ vaginal))) (NNS preparations)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (JJ single-dose) (NN interaction) (NN study)) (PP (IN in) (NP (NN NIDDM) (NNS subjects))))) (, ,) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NNS drug2)) (NP (NP (NN AUC)) (CC and) (NP (NN Cmax)))))) (VP (VP (VBD were) (VP (VBN observed))) (, ,) (CC but) (VP (VBD were) (ADJP (RB highly) (JJ variable))))) (. .))))
(S1 (S (S (NP (NP (NP (DT The) (JJ single-dose) (NN nature)) (PP (IN of) (NP (DT this) (NN study)))) (CC and) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NP (NN correlation)) (PP (IN between) (NP (NP (NN drug1) (NN blood) (NNS levels)) (CC and) (NP (JJ pharmaco-dynamic) (NNS effects))))))) (, ,)) (VP (VBZ makes) (NP (NP (DT the) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN interaction) (JJ uncertain)))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN gly-buride)) (CC and) (NP (NN drug1))))) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (DT any) (NNS changes)) (PP (IN in) (NP (CC either) (NP (NN drug2) (NNS pharmacokinetics)) (CC or) (NP (NNS pharmaco-dynamics))))))))) (. .)))
(S1 (S (NP (NN Interations))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NN following))) (: :)))))) (: -) (NP (NP (NP (CD drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug3))) (-RRB- -RRB-) (-LRB- -LRB-) (PP (IN with) (NP (ADJP (ADJP (JJ long-term)) (, ,) (ADJP (JJ high-dose))) (NN use))) (-RRB- -RRB-))) (CC or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (PRN (: -) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2) (NN -LSB-e.g.)) (, ,) (NP (NN drug3))) (-RRB- -RSB-))) (, ,) (NP (NN drug4) (NN -LSB-e.g.)) (, ,) (NP (NN drug5) (-RRB- -RSB-)) (, ,) (NP (NN drug6) (NN -LSB-e.g.)) (, ,) (NP (NN drug7) (-RRB- -RSB-)) (, ,) (NP (NN drug8) (NN -LSB-e.g.)) (, ,) (NP (NN drug9))) (-RRB- -RSB-) (-RRB- -RRB-)) (CC or)))
(S1 (S (NP (NP (NP (CC -) (CD drug1)) (PRN (-LRB- -LRB-) (NP (JJ male) (NNS hormones)) (-RRB- -RRB-))) (CC or))))
(S1 (S (NP (NP (NP (CC -) (CD drug1)) (PRN (-LRB- -LRB-) (NP (NN medicine)) (PP (IN for) (NP (JJ overactive) (NN thyroid))) (-RRB- -RRB-))) (CC or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (NP (NP (CC -) (CD drug1)) (PRN (-LRB- -LRB-) (NP (NN female) (NNS hormones)) (-RRB- -RRB-))) (CC or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NP (NP (JJ drug1) (NNS salts)) (PRN (-LRB- -LRB-) (NP (NN medicine)) (PP (IN for) (NP (NN arthritis))) (-RRB- -RRB-))) (CC or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (NP (NP (CC -) (CD drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-) (-LRB- -LRB-) (PP (IN with) (NP (ADJP (ADJP (JJ long-term)) (, ,) (ADJP (JJ high-dose))) (NN use))) (-RRB- -RRB-))) (CC or))))
(S1 (S (NP (NP (CC -) (NP (NP (JJ Oral) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN birth) (NN control) (NNS pills)) (-RRB- -RRB-)))) (VP (VBG containing) (NP (NN drug2) (NN or))))))
(S1 (S (NP (NP (CC -) (JJ Other) (NN drug1)) (PP (PP (IN by) (NP (NN mouth))) (CC or) (PP (IN by) (NP (NN injection))))) (PRN (-LRB- -LRB-) (NP (NN medicine)) (PP (IN for) (NP (NN infection))) (-RRB- -RRB-)) (CC or)))
(S1 (S (NP (NP (CC -) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2) (NN -LSB-e.g.) (, ,) (NN drug3) (-RRB- -RSB-)) (, ,) (NP (NN drug4) (NN -LSB-e.g.)) (, ,) (NP (NN drug5))) (-RRB- -RSB-))) (, ,) (NP (NN drug6) (NN -LSB-e.g.)) (, ,) (NP (NN drug7) (-RRB- -RSB-)) (, ,) (NP (NN drug8) (NN -LSB-e.g.)) (, ,) (NP (NN drug9) (-RRB- -RSB-)) (, ,) (NP (NN drug10) (CD -LSB-e.g.) (, ,) (CD drug11) (-RRB- -RSB-)) (, ,) (NP (NN drug12) (NN -LSB-e.g.)) (, ,) (NP (NN drug13))) (-RRB- -RSB-)) (PRN (, ,) (FRAG (NP (NNP drug14) (CD -LSB-e.g.) (, ,) (CD drug15) (-RRB- -RSB-)) (, ,) (NP (NNP drug16) (CD -LSB-e.g.) (, ,) (CD drug17) (-RRB- -RSB-)) (, ,) (NP (CD drug18) (NN -LSB-e.g.)) (, ,) (NP (CD drug19) (-RRB- -RSB-)) (, ,) (NP (CD drug20) (NN -LSB-e.g.)) (, ,) (NP (CD drug21) (-RRB- -RSB-)) (, ,) (NP (CD drug22) (NN -LSB-e.g.)) (, ,) (NP (CD drug23) (-RRB- -RSB-)) (, ,) (NP (CD drug24) (NN -LSB-e.g.)) (, ,) (NP (CD drug25)) (-RRB- -RSB-)) (-RRB- -RRB-))) (NP (CC or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug2)) (-RRB- -RRB-)) (NN Use)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (DT these) (NNS medicines)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN chance)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (VP (VBG affecting) (NP (DT the) (NN liver))))))))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (CC -) (NP (NN drug1) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (CC -) (NP (NN drug1) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (, ,) (NP (NNS drug3)) (-RRB- -RRB-)) (NN Use)) (PP (IN of) (NP (NN drug4))) (PP (IN with) (NP (DT these) (NNS medicines)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN chance)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (VP (VBG affecting) (NP (DT the) (NN blood))))))))))
(S1 (S (CC -) (NP (NN drug1) (-LRB- -LRB-) (NN drug2) (NN s) (-RRB- -RRB-) (NN or))))
(S1 (S (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)) (NN or))))
(S1 (S (NP (NP (CC -) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug2)) (-RRB- -RRB-))) (NN Use)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (DT these) (NNS medicines)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN chance)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (PP (IN of) (NP (DT these) (NNS medicines))))))))))
(S1 (S (PP (TO -) (NP (NN drug1))) (, ,) (S (NP (NP (ADJP (ADJP (JJ oral)) (PRN (-LRB- -LRB-) (S (NP (NN diabetes) (NN medicine)) (VP (VBN you) (VP (VB take) (PP (IN by) (NP (NN mouth)))))) (-RRB- -RRB-))) (NN Use)) (PP (IN of) (NP (NP (JJ oral) (NN drug2)) (PP (IN with) (NP (NN drug3)))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN chance)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (VP (VBG affecting) (NP (NP (DT the) (NN blood)) (CC and/or) (NP (NP (DT the) (JJ side) (NNS effects)) (CC or) (NP (JJ oral) (NNS drug4)))))))))))))
(S1 (S (NP (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug2)) (-RRB- -RRB-)) (NN Use)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NN drug4)))) (VP (MD may) (VP (VB increase) (NP (NP (NP (DT the) (NN chance)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (VP (VBG affecting) (NP (DT the) (NN liver)))))) (CC and/or) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NN drug5)))))))))
(S1 (S (NP (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug2)) (-RRB- -RRB-)) (NN Use)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NN drug4)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN chance)) (PP (IN of) (NP (JJ side) (NNS effects)))) (PP (VBG affecting) (NP (NP (DT the) (NN liver)) (CC and/or) (NP (DT the) (NN blood))))))))
(S1 (S (NP (NP (CC -) (NN drug1) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug2)) (-RRB- -RRB-)) (NN Use)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NN drug4)))) (VP (MD may) (VP (VB increase) (NP (NP (NP (DT the) (NN chance)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (VP (VBG affecting) (NP (DT the) (NN liver)))))) (CC and/or) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NN drug5)))))))))
(S1 (S (S (NP (JJ drug1) (NN toxicity)) (VP (MD may) (VP (VB be) (VP (VBN aggravated) (PP (IN by) (NP (NP (DT the) (JJ initial) (NN release)) (PP (IN of) (NP (NP (NN norepinephrine)) (VP (VBN caused) (PP (IN by) (NP (NN drug2) (NN Injection)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN pressor) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))) (VP (VBP are) (VP (VBN enhanced) (PP (IN by) (NP (NN drug4)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBP are) (VP (VBN administered))))) (, ,) (S (S (NP (NN dilute) (NNS solutions)) (VP (MD should) (VP (VB be) (VP (VBN used))))) (CC and) (S (NP (NN blood) (NN pressure)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBZ is) (NP (NP (JJ little) (VBN published) (NN information)) (PP (IN on) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (, ,) (NP (DT these) (NNS drugs)) (VP (VBP are) (ADVP (RB often)) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN without) (NP (NP (DT any) (NN evidence)) (PP (IN of) (NP (NP (NNS interactions)) (VP (VBG resulting) (PP (IN in) (NP (NP (JJ adverse) (NNS effects)) (CC or) (NP (VBN diminished) (NN efficacy)))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (JJ other) (NN drug2)) (-LRB- -LRB-) (NP (JJ concurrent) (NN use))) (PP (IN with) (NP (NN drug3)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NN uterine) (NN hypertonus))) (, ,) (S (ADVP (RB possibly)) (VP (VBG causing) (NP (NP (NN uterine) (NN rupture)) (CC or) (NP (JJ cervical) (NN laceration))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ adequate) (JJ cervical) (NN dilatation))))))))) (: ;)))
(S1 (S (S (SBAR (IN although) (S (NP (NNS combinations)) (VP (VBP are) (ADVP (RB sometimes)) (VP (VBN used) (PP (IN for) (NP (JJ therapeutic) (NN advantage))))))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (ADVP (RB concurrently))))) (, ,) (NP (NN patient)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (. .)))
(S1 (S (S (NP (DT No) (JJ clinical) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (DT a) (JJ single) (ADJP (FW in) (FW vivo)) (JJ rodent) (NN study))) (NP (NN drug1)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN P450) (NNS levels))))) (. .)))
(S1 (S (S (S (NP (DT No) (JJ formal) (NN drug-interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed))))) (, ,) (CC and) (S (NP (NP (DT a) (ADJP (RB clinically) (JJ significant)) (NN interaction)) (PP (IN with) (NP (NP (JJ other) (NNS medications)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ hypoxic) (JJ respiratory) (NN failure))))))))) (VP (MD cannot) (VP (VB be) (VP (VBN excluded) (PP (VBN based) (PP (IN on) (NP (DT the) (JJ available) (NNS data))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (VBP high-frequency) (NN ventilation)))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBP are) (NP (DT no) (NN study) (NN data)) (S (VP (TO to) (VP (VB evaluate) (NP (DT the) (NN possibility)))))))) (, ,) (NP (NP (NN drug1)) (, ,) (PP (VBG including) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (, ,)) (VP (MD may) (VP (VB have) (NP (NP (DT an) (JJ additive) (NN effect)) (PP (IN with) (NP (NN drug4))) (PP (IN on) (NP (NP (DT the) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NN methemoglobinemia)))))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (NN association)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN methaemoglobinaemia)))))) (, ,) (ADVP (RB particularly)) (PP (IN in) (NP (NNS infants))) (, ,)) (VP (VBZ has) (ADVP (RB specifically)) (VP (VBN been) (VP (VBN described) (PP (IN in) (NP (DT a) (NN literature) (NN case) (NN report))))))) (. .)))
(S1 (S (S (NP (DT This) (NN risk)) (VP (VBZ is) (ADJP (JJ present)) (SBAR (IN whether) (S (NP (DT the) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (PP (IN as) (NP (ADJP (ADJP (JJ oral)) (, ,) (ADJP (JJ parenteral)) (, ,) (CC or) (ADJP (JJ topical))) (NNS formulations))))))))) (. .)))
(S1 (S (NP (NNS Interactions)) (VP (MD may) (VP (VB occur) (PP (IN with) (NP (NP (DT the) (NN following)) (: :) (NP (NP (NN adrenocorticoids)) (PRN (-LRB- -LRB-) (NP (JJ cortisone-like) (NN medicine)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD drug2) (NN s)) (-RRB- -RRB-))) (, ,) (NP (NN drug3)) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NP (NN drug5)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT these) (NNS medicines))))))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (-LRB- -LRB-) (VP (VBG using) (NP (NP (DT these) (NNS medicines)) (SBAR (IN with) (S (NP (NN drug7)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (VBN increased) (NN CNS) (NN depressant) (NNS effects))))))))) (-RRB- -RRB-)) (, ,) (NP (NN drug8)) (, ,) (NP (NP (NN drug9)) (-LRB- -LRB-) (VP (VBG using) (NP (NP (DT these) (NNS medicines)) (PP (IN with) (NP (NN drug10))) (VP (MD may) (VP (VB change) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (DT either) (NN medicine)) (SBAR (WHNP (WDT that)) (S (VP (VBZ you) (S (NP (NN need)) (VP (TO to) (VP (VB take)))))))))))))) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (JJ oral) (NN drug11) (NN containing) (NN drug12)) (PRN (-LRB- -LRB-) (S (NP (NN drug13)) (VP (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (DT these) (JJ oral) (NN drug14)))))) (, ,) (CC and) (ADVP (RB you)) (VP (MD may) (VP (VBP need) (PP (TO to) (NP (NN change))) (PP (TO to) (NP (NP (DT a) (JJ different) (NN type)) (PP (IN of) (NP (NN birth) (NN control))))))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (NP (DT A) (JJ drug-drug) (NN interaction) (NN study)) (VP (VBD evaluated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NN drug1) (NN Gel)) (, ,) (NP (CD 5) (NN %)) (, ,))))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NP (JJ double) (NN strength)) (PRN (-LRB- -LRB-) (NP (CD 160) (CD mg/800) (NN mg)) (-RRB- -RRB-))) (NP (NN drug2)) (: /) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (NN drug4)) (: /) (NP (NN drug5))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (NN co-administration))) (, ,) (NP (NP (JJ systemic) (NNS levels)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD were) (ADJP (RB essentially) (JJ unchanged)))) (. .)))
(S1 (S (S (ADVP (RB Notably)) (, ,) (NP (NP (NP (JJ systemic) (NN exposure)) (PRN (-LRB- -LRB-) (NP (CD AUC0-12)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (VP (VBD was) (ADVP (RBR more) (IN than)) (VP (VBN doubled) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug3) (: /) (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NP (NN Exposure)) (PP (IN from) (NP (DT the) (JJ proposed) (JJ topical) (NN dose)))) (VP (VBZ is) (PP (IN about) (NP (NP (CD 1) (NN %)) (PP (IN of) (NP (NP (DT that)) (PP (IN from) (NP (DT the) (ADJP (CD 100) (NN mg)) (JJ oral) (NN dose))))))) (, ,) (SBAR (WHADVP (RB even) (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NN drug1) (: /) (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (JJ Certain) (JJ concomitant) (NNS medications)) (-LRB- -LRB-) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN St.)))))))
(S1 (S (S (NP (NN John) (NN s) (NN wort) (-RRB- -RRB-)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (NN metabolite)) (PP (IN of) (NP (NP (NNS drug2)) (VP (VBN associated) (PP (IN with) (NP (NN hemolysis))))))))))))) (. .)))
(S1 (S (PP (IN With) (NP (JJ oral) (NN drug1) (NN treatment))) (, ,) (NP (NP (NNS drug2)) (PP (JJ such) (IN as) (NP (NN drug3)))) (VP (VBP have) (VP (VBN been) (VP (VBN noted) (S (VP (TO to) (ADVP (RB possibly)) (VP (VB increase) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (JJ hematologic) (NNS reactions))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (DT An) (JJ encephalopathic) (NN syndrome)) (-LRB- -LRB-) (VP (VBN characterized) (PP (IN by) (NP (NP (NN weakness)) (, ,) (NP (NN lethargy)) (, ,) (NP (NN fever)) (, ,) (NP (NN tremulousness)) (CC and) (NP (NN confusion)) (, ,) (NP (JJ extrapyramidal) (NNS symptoms)) (, ,) (NP (NN leukocytosis)) (, ,) (NP (JJ elevated) (NN serum) (NNS enzymes)) (, ,) (NP (NN BUN)) (, ,) (CC and) (NP (NN FBS))))) (-RRB- -RRB-) (VP (VBN followed) (PP (IN by) (NP (JJ irreversible) (NN brain) (NN damage))))) (VP (VBZ has) (VP (VBN occurred) (PP (IN in) (NP (NP (DT a) (JJ few) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC plus) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT A) (JJ causal) (NN relationship)) (PP (IN between) (NP (DT these) (NNS events)))) (CC and) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established))))) (: ;)))
(S1 (S (ADVP (RB however)) (, ,) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ such) (JJ combined) (NN therapy)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (PP (IN for) (NP (NP (JJ early) (NN evidence)) (PP (IN of) (NP (NP (JJ neurological) (NN toxicity)) (CC and) (NP (NN treatment)))))))))))) (VP (VBD discontinued) (ADVP (RB promptly)) (SBAR (IN if) (S (NP (JJ such) (NNS signs)) (VP (VBP appear))))) (. .)))
(S1 (S (S (PP (IN As) (PP (IN with) (NP (JJ other) (NN drug1)))) (, ,) (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN noted) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD may) (VP (VB be) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG potentiating) (NP (NP (NN drug3)) (PP (JJ such) (IN as) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))))))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (CD 12) (JJ schizophrenic) (NNS patients) (NP (NP (JJ coadministered) (JJ oral) (NN drug1)) (CC and) (NP (NN drug2))))))) (, ,) (S (S (NP (NN plasma) (NN drug3) (NNS levels)) (VP (VBD were) (VP (VBN decreased) (PP (IN by) (DT a) (NN mean) (IN of) (NP (CD 70) (NN %)))))) (CC and) (S (NP (NP (NN mean) (NNS scores)) (PP (IN on) (NP (DT the) (JJ Brief) (JJ Psychiatric) (NN Rating) (NN Scale)))) (VP (VBD were) (VP (VBN increased) (PP (IN from) (NP (NN baseline))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (CD 5) (JJ other) (JJ schizophrenic) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ oral) (NN drug1)) (CC and) (NP (NN drug2))))))) (, ,) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN drug3)))) (VP (VBD produced) (NP (NP (DT a) (JJ mean) (RB 3.3-fold) (NN increase)) (PP (IN in) (NP (NN drug4) (NNS concentrations)))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (JJ careful) (NN monitoring)) (PP (IN of) (NP (JJ clinical) (NN status)))) (VP (VBZ is) (VP (VBN warranted) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VP (VBN administered)) (CC or) (VP (VBN discontinued) (PP (IN in) (NP (JJ drug2) (JJ -treated) (NNS patients))))))))))) (. .)))
(S1 (S (S (NP (NN Food) (: :) (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN food))))))) (. .)))
(S1 (S (S (NP (NNS Studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN reduced) (ADVP (RB significantly)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NN food))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (DT A) (NN report)) (PP (IN of) (NP (JJ severe) (NN drug2) (NN toxicity))))) (VP (VBD was) (VP (VBN reported) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN believed) (SBAR (IN that) (S (S (NP (DT the) (NN toxicity)) (VP (MD may) (VP (VB have) (VP (VBD resulted) (PP (IN from) (NP (NP (DT a) (ADJP (RB previously) (JJ unrecognized)) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (CC and) (S (NP (NP (DT a) (JJ molecular) (NN basis)) (PP (IN for) (NP (DT this) (NN interaction)))) (VP (VBZ has) (VP (VBN been) (VP (VBN proposed)))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (JJ current) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (VP (VB induce) (NP (NP (NN P-450IIE1)) (, ,) (NP (NP (DT a) (JJ mixed-function) (NN oxidase) (NN enzyme)) (SBAR (WHNP (WDT that)) (S (VP (VBZ appears) (S (VP (TO to) (VP (VB generate) (NP (DT the) (JJ toxic) (NNS metabolites)))))))))) (, ,) (PP (IN in) (NP (DT the) (NN liver))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN proposed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD resulted) (PP (IN In) (NP (NP (NN induction)) (PP (IN of) (NP (NP (NN P-450IIE1)) (PP (IN in) (NP (NP (DT the) (NNS patients) (NN liver)) (SBAR (WHNP (WDT which)) (S (, ,) (PP (IN in) (NP (NN turn))) (, ,) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJR greater) (NN proportion)) (PP (IN of) (NP (NP (DT the) (VBN ingested) (NN drug2)) (VP (VBG being) (VP (VBN converted) (PP (TO to) (NP (DT the) (JJ toxic) (NNS metabolites))))))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NNS Studies)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (NN drug1)))) (VP (VBZ potentiates) (NP (NP (DT a) (JJ cetaminophen) (NN hepatoxicity)) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (JJ slow) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN increase)) (NP (PRP$ its) (NN serum) (NNS levels)))) (S (S (NP (NN drug4) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN determined) (ADVP (ADVP (RB prior)) (PP (TO to) (NP (JJ concurrent) (NN administration)))) (PP (IN with) (NP (NN drug5))))))) (, ,) (S (NP (NP (NP (NNS signs)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NN drug6) (NN toxicity)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)))))) (, ,) (CC and) (S (NP (NP (JJ appropriate) (NN dosage) (NN adjustment)) (PP (IN of) (NP (DT the) (NN drug7)))) (VP (MD should) (VP (VB be) (VP (VBN made))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Potential) (NN interaction)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB exist)))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB increase) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (S (VP (TO To) (VP (VB avoid) (NP (NN drug1) (NN intoxication))))) (, ,) (NP (NP (JJ appropriate) (NN adjustment)) (PP (IN of) (NP (DT the) (NN drug2)))) (VP (MD should) (VP (VB be) (VP (VBN made))))) (. .)))
(S1 (S (NP (NP (NN Therophylline)) (: :) (S (NP (DT A) (JJ recent) (NN study)) (VP (VBZ has) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (NN concomitan) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB cause) (NP (NP (JJ elevated) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug3)))) (, ,) (PP (CC and) (PP (IN in) (NP (DT some) (NNS instances))) (NP (NP (DT a) (JJ slight) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NN drug4)))))))))))))) (. .))))
(S1 (S (S (S (SBAR (IN Since) (S (NP (NP (DT the) (JJ therapeutic) (NN range)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (ADJP (JJ narrow))))) (NP (NN drug2) (NN serum) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)))))) (, ,) (CC and) (S (NP (NP (JJ appropriate) (NN dosage) (NNS adjustments)) (PP (IN of) (NP (NN drug3)))) (VP (MD should) (VP (VB be) (VP (VBN made)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (DT A) (JJ recent) (NN case) (NN study)) (VP (VBZ has) (VP (VBN shown) (NP (NP (DT a) (JJ possible) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NN level)) (PP (IN of) (NP (NN drug2))))) (SBAR (WHADVP (WRB when)) (S (ADVP (RB co)) (VP (VBN administered) (PP (IN with) (NP (NN drug3)))))))))) (. .))))
(S1 (S (S (S (NP (NN Plasma) (NN drug1) (NN concentration)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBP are) (ADVP (RB co)) (VP (VBN administered))))))))) (, ,) (CC and) (S (NP (NP (JJ appropriate) (NN dosage) (NNS adjustments)) (PP (IN of) (NP (NN drug4)))) (VP (MD should) (VP (VB be) (VP (VBN made)))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB cause) (NP (NP (JJ severe) (JJ orthostatic) (NN hypotension.) (NN drug3)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (JJ microsomal) (NN drug) (NN metabolism)) (, ,) (NP (VBN increased) (NN drug4) (NN s) (NN half-life)) (CC and) (NP (NN toxicity)))))) (PP (IN in) (NP (DT a) (NN rat) (NN model)))))) (. .)))
(S1 (S (S (NP (NP (NNS Data)) (PP (IN from) (NP (NP (DT a) (JJ randomized) (NN trial)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (ADJP (ADJP (JJ plus)) (CC or) (ADJP (JJ minus))) (NN drug3)))) (PP (IN in) (NP (JJ ovarian) (NN cancer)))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (NN drug4)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NN neurotoxicity))))))) (: ;)))
(S1 (S (ADVP (RB however)) (, ,) (NP (PRP it)) (ADVP (RB adversely)) (VP (VBD affected) (NP (NN response) (NN duration)) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NP (NN drug2)) (CC and/or) (NP (NN drug3)) (NP (NN .1))))))))))))))
(S1 (S (S (NP (NP (DT No) (JJ Important) (NNS Interactions)) (PP (TO To) (NP (NN Date) (NN drug1)))) (VP (VBZ does) (RB not) (VP (VB have) (NP (NP (ADJP (RB clinically) (JJ important)) (JJ pharmacokinetic) (NNS interactions)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (CC or) (NP (NN drug10)))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN drug1)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ severe) (NN sepsis))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (SBAR (IN since) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ bleeding))) (PP (IN with) (NP (NN drug1))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN employed))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN used) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP affect) (NP (NN hemostasis))))))))))))) (. .)))
(S1 (S (S (NP (NP (RB Approximately) (CD 2/3)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (DT the) (NN Phase) (CD 3) (NN study)))))) (VP (VBD received) (NP (CC either) (NP (NP (JJ prophylactic) (JJ low) (NN dose) (CD drug1)) (PRN (-LRB- -LRB-) (NP (QP (CD drug2) (RP up) (TO to) (CD 15,000)) (NN units/day)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ prophylactic) (NNS doses)) (PP (IN of) (NP (NN drug3))))) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN in) (NP (NP (DT the) (JJ prescribing) (NN information)) (PP (IN for) (NP (DT the) (JJ specific) (NNS products)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (JJ prophylactic) (JJ low) (NN dose) (NN drug1)))) (VP (VBD did) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB affect) (NP (NP (NN safety)) (, ,) (S (ADVP (RB however)) (, ,) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NN drug2)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN evaluated) (PP (IN in) (NP (DT an) (ADJP (ADJP (JJ adequate)) (CC and) (ADJP (JJ well-controlled))) (JJ clinical) (NN trial)))))))))))))) (. .)))
(S1 (S (NP (JJ Drug/Laboratory) (NN Test) (NN Interaction)) (SBAR (IN Because) (S (NP (NN drug1)) (VP (MD may) (VP (VB affect) (NP (DT the) (NN APTT) (NN assay)))))) (, ,) (NP (NP (NN drug2) (NN present)) (PP (IN in) (NP (NN plasma) (NNS samples)))) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (JJ one-stage) (NN coagulation) (NNS assays)) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (NN APTT)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN factor) (NN VIII)) (, ,) (NP (NN IX)) (, ,) (CC and) (NP (NN XI) (NNS assays))))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN interference)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT an) (JJ apparent) (NN factor) (NN concentration)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (DT the) (JJ true) (NN concentration)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN present)) (PP (IN in) (NP (NN plasma) (NNS samples)))) (VP (VBZ does) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (JJ one-stage) (NN factor) (NNS assays)) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (NN PT)) (PRN (-LRB- -LRB-) (CONJP (JJ such) (IN as)) (NP (NP (NN factor) (NN II)) (, ,) (NP (NN V)) (, ,) (NP (NN VII)) (, ,) (CC and) (NP (NN X) (NNS assays))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (JJ known) (NN drug) (NN interference)) (PP (IN with) (NP (JJ standard) (JJ clinical) (NN laboratory) (NNS tests)))))) (. .)))
(S1 (S (NP (S (NP (NP (NN drug1)) (VP (VB enhance) (NP (NP (DT the) (JJ renal) (NN toxicity)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (NN animals.) (CD 7) (NN drug3)))))) (VP (VBZ interferes) (PP (IN with) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug4) (NNS preparations))))) (PP (IN by) (NP (NN chelating))))) (NP (DT the) (NN drug5)) (. .) (CD 7))))
(S1 (S (NP (NN drug1)) (VP (MD can) (VP (VB interact) (PP (IN with) (NP (NP (NP (NP (NN drug2)) (CC or) (NP (JJ other) (NN drug3))) (PRN (-LRB- -LRB-) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN CNS) (NN depressant) (NNS effects)) (PP (IN of) (NP (CC either) (DT these) (NP (NNS medications)) (CC or) (NP (NNS drug4))))))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN drug5)) (CC or) (NP (NP (JJ other) (NNS medications)) (PP (IN with) (NP (JJ anticholinergic) (NN activity))))) (PRN (-LRB- -LRB-) (S (NP (JJ anticholinergic) (NNS effects)) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS medications)) (VP (VBP are) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug6))))))))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (S (NP (NP (JJ concurrent) (NN use)) (PP (IN with) (NP (NN drug8)))) (VP (MD may) (VP (VP (VB prolong)) (CC and) (VP (VB intensify) (NP (NP (DT the) (NN anticholinergic) (CC and) (NN CNS) (NN depressant) (NNS effects)) (PP (IN of) (NP (NN drug9)))))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (DT A) (NN drug) (NN interaction) (NN study)) (VP (VBD was) (VP (VBN performed) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (DT any) (JJ pharmacokinetic) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (NP (NN phosphatase) (NNS activities)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug2)) (-RRB- -RRB-))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ High-dose) (NN drug1)) (VP (VBG resulting) (PP (IN in) (NP (NP (NNS concentrations)) (PP (IN above) (NP (NP (CD 2000) (NN ng/mL)) (VP (VBN administered) (PP (IN with) (NP (JJ oral) (NN drug2)))))))))) (VP (VBZ has) (VP (VBN led) (PP (TO to) (NP (NP (DT an) (ADJP (CD 80) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NN drug3) (NN exposure)) (PP (IN with) (NP (NP (DT a) (ADJP (CD 38) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (JJ total) (NN body) (NN clearance)) (PP (IN of) (NP (NN drug4))))) (VP (VBN compared) (PP (TO to) (NP (NP (NN drug5)) (ADVP (RB alone)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBD inhibited) (NP (NP (ADJP (FW in) (FW vitro)) (JJ metabolic) (NNS reactions)) (VP (VBN catalyzed) (PP (IN by) (NP (NN cytochromes) (NN P450) (NP (NN 1A2)) (, ,) (NP (NN 2C8/9)) (, ,) (CC and) (NP (NN 3A4))))))) (CC but) (VP (ADVP (RB only)) (PP (IN at) (NP (ADJP (RB relatively) (JJ high)) (NNS concentrations)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB inhibit) (NP (NP (NP (NN P450) (NN 2A6)) (CC or) (NP (DT the) (JJ polymorphic) (NN P450) (NN 2D6))) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (DT no) (JJ formal) (NN interaction) (NNS studies)) (CONJP (JJ other) (IN than)) (PP (IN with) (NP (NN drug1)))))))) (, ,) (PP (VBN based) (PP (IN on) (NP (DT these) (ADJP (ADJP (FW in) (FW vivo)) (CC and) (ADJP (FW in) (FW vitro))) (NNS studies)))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unlikely) (SBAR (IN that) (S (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (DT a) (ADJP (CD 1) (NN mg)) (NN dose)) (PP (IN of) (NP (NN drug2))))) (PP (IN with) (NP (JJ other) (NNS drugs)))) (VP (MD will) (VP (VB result) (PP (IN in) (NP (NP (ADJP (RB clinically) (JJ significant)) (NN drug) (NN inhibition)) (PP (IN of) (NP (NP (NN cytochrome) (JJ P450-mediated) (NN metabolism)) (PP (IN of) (NP (DT the) (JJ other) (NNS drugs)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (NN interaction) (NN study)) (PP (IN with) (NP (NN drug1)))) (VP (VBD showed) (NP (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NP (NN drug3) (NNS pharmacokinetics)) (CC or) (NP (JJ anticoagulant) (NN activity))))))) (. .)))
(S1 (S (S (PP (IN At) (NP (NP (DT a) (NN median) (NN follow-up)) (PP (IN of) (NP (CD 33) (NNS months))))) (, ,) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD did) (RB not) (VP (VB demonstrate) (NP (DT any) (NN efficacy) (NN benefit))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NN drug3))) (PP (PP (IN in) (NP (DT all) (NNS patients))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (DT the) (ADJP (NN hormone) (JJ receptor-positive)) (NN subpopulation))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN treatment) (NN arm)) (VP (VBD was) (VP (VBN discontinued) (PP (IN from) (NP (DT the) (NN trial)))))) (. .)))
(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ pharmacokinetic))) (NNS results)) (PP (IN from) (NP (DT the) (NN ATAC) (NN trial)))))) (, ,) (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (S (VP (VB see) (NP (JJ CLINICAL) (NN PHARMACOLOGY) (NP (NN Drug) (NNS Interactions)) (CC and) (NP (NP (NP (JJ CLINICAL) (NN PHARMACOLOGY)) (CC -) (NP (JJ Clinical) (NNS Studies)) (CC -) (NP (JJ Adjuvant) (NN Treatment))) (PP (IN of) (NP (NN Breast) (NN Cancer))) (PP (IN in) (NP (JJ Postmenopausal) (NNS Women)))) (NP (NNS subsections))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NN drug3) (NN plasma) (NNS levels))) (PP (IN by) (NP (NP (CD 27) (NN %)) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (VP (VBN achieved) (PP (IN with) (NP (NP (NN drug4)) (ADVP (RB alone)))))))))))))) (. .)))
(S1 (S (S (NP (JJ drug1) (JJ -containing) (NNS therapies)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN drug2))) (SBAR (IN as) (S (NP (PRP they)) (VP (MD may) (VP (VB diminish) (NP (PRP$ its) (JJ pharmacologic) (NN action)))))))))) (. .)))
(S1 (S (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (S (NP (NP (DT No) (ADJP (RB clinically) (JJ significant)) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (JJ clinical) (NN laboratory) (NNS tests)))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN drug1))) (PP (ADVP (RB once) (RB weekly)) (IN for) (NP (NP (CD 4) (NNS weeks)) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT an) (NN inhibition)) (PP (IN of) (NP (NN P450) (NN 1A2)))) (CC and) (NP (NP (DT a) (ADJP (CD 25) (NN %)) (NN increase)) (PP (IN in) (NP (NN drug2) (NN AUC))))))))) (. .)))
(S1 (S (S (S (NP (NN drug1) (NN serum) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored))))) (CC and) (S (NP (JJ appropriate) (NN dose) (NNS adjustments)) (VP (VBN considered) (PP (IN for) (NP (NP (NNS patients)) (PP (IN given) (NP (CC both) (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (JJ representative) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN CYP) (NN 2C9)) (, ,) (NP (NN CYP) (NN 2C19)) (, ,) (NP (NN CYP) (NN 2D6)) (CC or) (NP (NN CYP) (NN 3A4)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (NN hepatitis) (NN C))) (VP (VBN treated) (PP (IN with) (NP (NN drug1))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))) (, ,) (NP (NN drug3) (NN treatment)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (NN drug4) (NN distribution)) (CC or) (NP (NN clearance)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Nucleoside) (NNS Analogues)) (NN drug1) (NN Co-administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NP (NNS Reports)) (PP (IN of) (NP (NP (JJ fatal) (JJ hepatic) (NN failure)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ peripheral) (NN neuropathy)) (, ,) (NP (NN pancreatitis)) (, ,) (CC and) (NP (JJ symptomatic) (JJ hyperlactatemia/lactic) (NN acidosis))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (JJ clinical) (NNS trials))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (NN drug3))) (VP (MD can) (VP (VB antagonize) (NP (NP (DT the) (ADJP (FW in) (FW vitro)) (JJ antiviral) (NN activity)) (PP (IN of) (NP (NP (NN drug4)) (CC and) (NP (NN drug5)))) (PP (IN against) (NP (NN HIV))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (DT either)) (PP (IN of) (NP (DT these) (NNS drugs)))))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Carcinogenesis)) (, ,) (NP (NN Mutagenesis)) (, ,) (NP (NN Impairment))) (PP (IN of) (NP (NN Fertility) (NN Carcinogenesis) (NN drug1)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN tested) (PP (IN for) (NP (PRP$ its) (JJ carcinogenic) (NN potential))))))) (. .)))
(S1 (S (S (NP (NN Mutagenesis) (NN drug1)) (VP (VBD did) (RB not) (VP (VB cause) (NP (NN DNA) (NN damage)) (SBAR (WHADVP (WRB when)) (S (VP (VBN tested) (PP (PP (IN in) (NP (DT the) (NN Ames) (JJ bacterial) (NN mutagenicity) (NN assay))) (CC and) (PP (IN in) (NP (NP (DT the) (ADJP (FW in) (FW vitro)) (NN chromosomal) (NN aberration) (NN assay)) (PP (IN in) (NP (JJ human) (NNS lymphocytes))))) (, ,) (CC either) (PP (IN in) (NP (NP (DT the) (NP (NN presence)) (CC or) (NP (NN absence))) (PP (IN of) (NP (JJ metabolic) (NN activation)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN With) (NP (NN drug1) (NNS drug2)))) (VP (VBZ is) (ADJP (ADJP (JJ genotoxic)) (CC and) (ADJP (JJ mutagenic))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ carcinogenic) (NN potential)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB fully)) (VP (VBN determined))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NP (NP (DT a) (NN p53)) (-LRB- -LRB-) (CC +/-) (-RRB- -RRB-)) (NN mouse) (NN carcinogenicity) (NN study)) (PP (IN at) (NP (NP (NNS doses)) (PP (RP up) (TO to) (NP (NP (DT the) (JJ maximum) (VBN tolerated) (NN dose)) (PP (IN of) (NP (ADJP (CD 100) (NN mg/kg/day)) (NN drug1))))))))) (VP (VBD was) (RB not) (ADJP (JJ oncogenic)))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (PP (IN on) (NP (NP (DT a) (NN body) (NN surface) (NN area)) (NN basis))) (, ,) (NP (DT this) (NN dose)) (VP (VBD was) (NP (NP (CD 0.5) (NNS times) (JJ maximum) (VBN recommended) (JJ human) (JJ 24-hour) (NN dose)) (PP (IN of) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN study)) (PP (IN in) (NP (NNS rats))) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (JJ carcinogenic) (NN potential)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBZ is) (ADJP (JJ ongoing)))) (. .)))
(S1 (S (S (NP (NP (NN Mutagenesis) (NN Impairment)) (PP (IN of) (NP (NN Fertility) (NN drug1)))) (VP (MD may) (VP (VB impair) (NP (NP (NN fertility)) (PP (IN in) (NP (NNS women))))))) (. .)))
(S1 (S (S (NP (NP (JJ Prolonged) (JJ menstrual) (NNS cycles)) (CC and/or) (NP (NN amenorrhea))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (JJ female) (NN cynomolgus) (NNS monkeys)) (VP (VBN given) (NP (NP (NN sc) (NNS injections)) (PP (IN of) (NP (NP (ADJP (CD 600) (NN m)) (NN g/kg/dose)) (PRN (-LRB- -LRB-) (NP (CD 7200) (NN m) (NN g/m2/dose)) (-RRB- -RRB-)))) (PP (IN of) (NP (NN drug1)))) (PP (NP (DT every) (JJ other) (NN day)) (IN for) (NP (CD one) (NN month)))))) (, ,) (PP (IN at) (NP (NP (QP (RB approximately) (CD 180)) (NNS times)) (NP (DT the) (VBN recommended) (NP (NP (JJ weekly) (JJ human) (NN dose)) (PP (IN for) (NP (NP (DT a) (ADJP (CD 60) (NN kg)) (NN person)) (-LRB- -LRB-) (VP (VBN based) (PP (IN on) (NP (NN body) (NN surface) (NN area)))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (JJ Menstrual) (NN cycle) (NNS irregularities)) (VP (VBD were) (VP (VBN accompanied) (PP (IN by) (NP (NP (CC both) (NP (DT a) (NN decrease)) (CC and) (NP (NN delay))) (PP (IN in) (NP (NP (DT the) (NN peak) (NN 17b) (NN -estradiol) (CC and) (NN progesterone) (NNS levels)) (VP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (JJ female) (NNS monkeys)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN return)) (PP (TO to) (NP (JJ normal) (JJ menstrual) (NN rhythm)))) (VP (VBD followed) (NP (NP (NN cessation)) (PP (IN of) (NP (NN treatment)))))) (. .)))
(S1 (S (S (NP (NP (NP (DT Every) (JJ other) (NN day)) (NN dosing)) (PP (IN with) (NP (NP (NN 100m) (NN g/kg) (-LRB- -LRB-) (NN 1200m) (NN g/m2) (-RRB- -RRB-) (NN drug1)) (PRN (-LRB- -LRB-) (NP (ADJP (JJ equivalent) (PP (TO to) (NP (QP (RB approximately) (CD 30)) (NNS times)))) (NP (DT the) (VBN recommended) (JJ human) (NN dose))) (-RRB- -RRB-))))) (VP (VBD had) (NP (NP (DT no) (NNS effects)) (PP (IN on) (NP (NP (NN cycle) (NN duration)) (CC or) (NP (JJ reproductive) (NN hormone) (NN status))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (JJ male) (NN fertility)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT no) (JJ adverse) (NNS effects)) (PP (IN on) (NP (NN fertility)))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (JJ male) (NN Rhesus) (NNS monkeys)) (VP (VBN treated) (PP (IN with) (NP (NP (NN non-) (NN drug1)) (PP (IN for) (NP (CD 5) (NNS months))))) (PP (IN at) (NP (NP (NNS doses)) (PP (RP up) (TO to) (NP (QP (CD 25) (CC x) (CD 106)) (NN IU/kg/day))))))))))) (. .)))
(S1 (S (S (NP (NN Pregnancy) (NN Pregnancy) (: :) (NN Category) (NN C) (NN drug1)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied) (PP (IN for) (NP (PRP$ its) (JJ teratogenic) (NN effect))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN treatment)) (PP (IN of) (NP (JJ pregnant) (NN Rhesus) (NNS monkeys))) (PP (IN at) (NP (QP (RB approximately) (CD 20) (TO to) (CD 500) (NNS times)) (NP (DT the) (JJ human) (JJ weekly) (NN dose))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN increase)) (PP (IN in) (NP (NNS abortions))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ teratogenic) (NNS effects)) (VP (VBD were) (VP (VBN seen) (PP (IN in) (NP (NP (DT the) (NN offspring)) (VP (VBN delivered) (PP (IN at) (NP (NN term))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN assumed) (S (VP (TO to) (VP (VB have) (NP (JJ abortifacient) (NN potential))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (ADJP (ADJP (JJ adequate)) (CC and) (ADJP (JJ well-controlled))) (NNS studies)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (JJ pregnant) (NNS women)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN used) (PP (IN during) (NP (NN pregnancy))) (SBAR (RB only) (IN if) (S (NP (DT the) (JJ potential) (NN benefit)) (VP (VBZ justifies) (NP (NP (DT the) (JJ potential) (NN risk)) (PP (TO to) (NP (DT the) (NN fetus))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NP (NN use)) (PP (IN in) (NP (NP (NNS women)) (PP (IN of) (NP (JJ childbearing) (NN potential))))))) (SBAR (WHADVP (RB only) (WRB when)) (S (NP (PRP they)) (VP (VBP are) (VP (VBG using) (NP (JJ effective) (NN contraception)) (PP (IN during) (NP (NN therapy)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN Pregnancy)) (: :) (NP (NN Category) (NN X)) (: :) (NP (NP (NN Use)) (PP (IN With) (NP (NN drug1))))) (PRN (-LRB- -LRB-) (S (VP (VB see) (NP (NNS CONTRAINDICATIONS)))) (-RRB- -RRB-))) (JJ Significant) (ADJP (ADJP (JJ teratogenic)) (CC and/or) (ADJP (JJ embryocidal))) (NNS effects)) (VP (VBP have) (VP (VBN been) (VP (VBN demonstrated) (PP (IN in) (NP (NP (DT all) (JJ animal) (NNS species)) (VP (VBN exposed) (PP (TO to) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (JJ drug1) (NN therapy)) (VP (VBZ is) (VP (VBN contraindicated) (PP (PP (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADJP (JJ pregnant))))))) (CC and) (PP (IN in) (NP (NP (DT the) (JJ male) (NNS partners)) (PP (IN of) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADJP (JJ pregnant))))))))))))) (. .)))
(S1 (S (SBAR (IN If) (S (NP (NN pregnancy)) (VP (VBZ occurs) (PP (IN in) (NP (NP (DT a) (NN patient) (CC or) (NN partner)) (PP (IN of) (NP (DT a) (NN patient))))) (PP (PP (IN during) (NP (NN treatment))) (CC or) (PP (IN during) (NP (NP (DT the) (CD 6) (NNS months)) (PP (IN after) (NP (NN treatment) (NN cessation))))))))) (, ,) (NP (JJ such) (NNS cases)) (VP (MD should) (VP (VB be) (VP (VBN reported) (PP (TO to) (NP (DT the) (NN drug1) (NN Pregnancy) (NN Registry))) (PP (IN at) (NP (NN 1-800-526-6367)))))) (. .)))
(S1 (S (S (S (VP (VBG Nursing) (NP (NNS Mothers)))) (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (CC or) (NP (PRP$ its) (NNS components))) (VP (VBP are) (VP (VBN excreted) (PP (IN in) (NP (JJ human) (NN milk)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (ADJP (RB orally) (VBN ingested)) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (PP (IN from) (NP (NN breast) (NN milk))))) (PP (IN on) (NP (DT the) (JJ nursing) (NN infant)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated))))) (. .)))
(S1 (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (JJ adverse) (NNS reactions)) (PP (IN from) (NP (NP (DT the) (NNS drugs)) (PP (IN in) (NP (JJ nursing) (NNS infants)))))))))) (, ,) (NP (DT a) (NN decision)) (VP (MD must) (VP (VB be) (VP (VBN made) (SBAR (IN whether) (S (VP (TO to) (VP (VBP discontinue) (PP (VBG nursing) (NP (CC or) (NP (NN discontinue) (NN drug1)) (CC and) (NP (NN drug2) (NN treatment))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Pediatric) (NN Use) (NP (DT The) (NP (NN safety)) (CC and) (NP (NN effectiveness)))) (PP (IN of) (NP (NP (NN drug1)) (, ,) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN below) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (CD 18) (NNS years))))))))))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ contains) (NP (NN drug2)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (JJ neurological) (CC and) (JJ other) (NNS complications))) (PP (IN in) (NP (NP (NNS neonates)) (CC and) (NP (NNS infants)))))))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (ADVP (RB sometimes)) (ADJP (JJ fatal))))))) (. .)))
(S1 (S (S (NP (JJ Geriatric) (ADJP (NP (NN Use)) (JJR Younger)) (NNS patients)) (VP (VBP have) (NP (JJR higher) (JJ virologic) (NN response) (NNS rates)) (PP (IN than) (NP (JJR older) (NNS patients))))) (. .)))
(S1 (S (S (NP (NP (JJ Clinical) (NNS studies)) (PP (IN of) (NP (NP (NN drug1)) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2))))))))) (VP (VBD did) (RB not) (VP (VB include) (NP (NP (JJ sufficient) (NNS numbers)) (PP (PP (IN of) (NP (NP (NNS subjects)) (ADJP (JJ aged) (NP (CD 65))))) (CC or) (PP (IN over) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (PRP they)) (VP (VBP respond) (ADVP (RB differently)) (PP (IN from) (NP (JJR younger) (NNS subjects))))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (JJ Adverse) (NNS reactions)) (ADJP (JJ related) (PP (TO to) (NP (NP (NN drug1) (NNS s)) (, ,) (NP (NP (ADJP (JJ such) (PP (IN as) (NP (NN CNS))))) (, ,) (NP (ADJP (JJ cardiac))) (, ,) (CC and) (NP (ADJP (ADJP (JJ systemic)) (PRN (-LRB- -LRB-) (PP (FW eg)) (, ,) (ADJP (JJ flu-like)) (-RRB- -RRB-))) (NNS effects))))))) (VP (MD may) (VP (VB be) (ADJP (RBR more) (JJ severe)) (PP (IN in) (NP (DT the) (JJ elderly)))))) (CC and) (S (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (DT this) (NN population)))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN excreted) (PP (IN by) (NP (DT the) (NN kidney)))))) (, ,) (CC and) (S (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ toxic) (NNS reactions)) (PP (TO to) (NP (DT this) (NN therapy)))))) (VP (MD may) (VP (VB be) (ADJP (JJR greater) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ impaired) (JJ renal) (NN function)))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (JJ elderly) (NNS patients)) (VP (VBP are) (ADJP (RBR more) (JJ likely)) (S (VP (TO to) (VP (VB have) (NP (VBN decreased) (JJ renal) (NN function)))))))) (, ,) (S (S (NP (NN care)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN in) (NP (NN dose) (NN selection))))))) (CC and) (S (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ useful) (S (VP (TO to) (VP (VB monitor) (NP (JJ renal) (NN function))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN creatinine) (NN clearance) (CD 50) (NN mL/min))))))))) (CC and) (S (NP (NN drug2)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NN creatinine) (NN clearance) (CD 50) (NN mL/min)))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (JJ General) (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBD demonstrated) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN cytochrome) (JJ P450-mediated) (NN drug) (NNS interactions)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ clinical) (NN relevance))))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: /) (NP (NN drug3)) (: /) (NP (NN drug4))) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug5))) (PP (IN with) (NP (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (CC and) (NP (NN drug9))))) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB lead) (PP (TO to) (NP (NP (DT an) (NN enhancement)) (PP (IN of) (NP (NNS effects))))))))))) (. .))))
(S1 (S (S (NP (JJ Specific) (NNS studies)) (VP (VBP have) (VP (VBN confirmed) (NP (DT these) (NNS effects)) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ pharmacokinetic) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))) (VP (VBP have) (VP (VBN been) (VP (VBN demonstrated))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (PP (IN due) (PP (TO to) (NP (JJ possible) (JJ pharmacodynamic) (NNS interactions)))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NN drug1)))))) (, ,) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (NN dosage)) (PP (IN of) (NP (NN drug2))))) (PP (IN on) (NP (NP (DT the) (JJ concomitant) (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC or) (NP (NN drug6))))) (VP (MD may) (VP (VB be) (VP (VBN required)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (CD one) (NN study)) (PP (IN of) (NP (CD 10) (JJ healthy) (NNS volunteers))))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (IN for) (NP (CD 45) (NNS minutes))) (PP (IN at) (NP (NP (DT a) (NN plasma) (NN concentration)) (PP (IN of) (NP (CD 1) (-LRB- -LRB-) (CD one) (-RRB- -RRB-) (NN ng/mL)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (ADJP (RB clinically) (JJ meaningful)) (NNS increases)) (PP (IN in) (NP (NP (NP (DT the) (NN magnitude)) (CC or) (NP (JJ neuromuscular) (NN blockade))) (VP (VBN associated) (PP (IN with) (NP (NN drug3) (NN administration)))))))))) (. .))))
(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (JJ other) (NNS drugs))) (PP (IN on) (NP (NN drug1))))))
(S1 (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (: :) (S (NP (NP (NNS Studies)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (VP (VP (VBN metabolized) (ADVP (RB primarily)) (PP (IN by) (NP (NP (NP (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NNS isoforms) (NN 3A4/5)))) (, ,) (CC and) (PP (TO to) (NP (DT a) (JJR lesser) (NN degree))) (PP (IN by) (NP (NN CYP2C9))))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (DT these) (NNS enzymes)))) (VP (VBP are) (VP (VBN expected) (S (VP (TO to) (VP (VB reduce) (NP (NN drug1) (NN clearance)))))))) (. .)))
(S1 (S (NP (NP (ADJP (FW In) (FW vivo)) (NNS studies)) (: :) (NP (NN Cytochrome) (NN P450) (NNS Inhibitors)))))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 400) (NN mg)) (NN b.i.d.)) (-RRB- -RRB-))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NP (NP (NN drug2) (NN bioavailability)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ maximum) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN Cmax)) (-RRB- -RRB-)))) (PP (IN of) (NP (NN drug3))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NP (ADJP (CD 20) (NN mg)) (NN drug4)) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 500) (NN mg)) (NN t.i.d)) (-RRB- -RRB-))) (VP (VBD produced) (NP (NP (NP (DT a) (JJ 4-fold) (NN increase)) (PP (IN in) (NP (NN drug2) (NN AUC)))) (CC and) (NP (NP (DT a) (JJ 3-fold) (NN increase)) (PP (IN in) (NP (NN Cmax))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NP (NN drug3) (CD 5) (NN mg)) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (S (VP (RB not) (TO to) (VP (VB exceed) (NP (NP (DT a) (JJ single) (ADJP (CD 5) (NN mg)) (NN dose)) (PP (IN of) (NP (NN drug1)))) (PP (IN in) (NP (NP (DT a) (JJ 24-hour) (NN period)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 200) (NN mg)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-))) (VP (VBD produced) (NP (NP (NP (DT a) (JJ 10-fold) (NN increase)) (PP (IN in) (NP (NN drug2) (NN AUC)))) (CC and) (NP (NP (DT a) (JJ 4-fold) (NN increase)) (PP (IN in) (NP (NN Cmax))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))))))))) (. .)))
(S1 (S (S (NP (DT A) (JJ 5-mg) (NN drug1) (NN dose)) (VP (MD should) (RB not) (VP (VB be) (VP (VBD exceeded) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (CD 200) (NN mg)) (PP (IN once) (NP (JJ daily) (NN drug2)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN drug1)))) (PRN (-LRB- -LRB-) (NP (NP (CD 400) (NN mg)) (ADVP (RB daily))) (-RRB- -RRB-))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJR higher) (NNS increases)) (PP (IN in) (NP (NP (NN Cmax)) (CC and) (NP (NN AUC)))))))))) (, ,) (NP (NP (DT a) (JJ single) (ADJP (CD 2.5) (NN mg)) (NN dose)) (PP (IN of) (NP (NN drug2)))) (VP (MD should) (RB not) (VP (VB be) (VP (VBD exceeded) (PP (IN in) (NP (DT a) (JJ 24-hour) (NN period))) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug3) (CD 400) (NN mg)) (ADVP (RB daily))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 800) (NN mg)) (NN t.i.d.)) (-RRB- -RRB-))) (VP (VBN co-administered) (PP (IN with) (NP (NN drug3) (CD 10) (NN mg))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (JJ 16-fold) (NN increase)) (PP (IN in) (NP (NN drug4) (NN AUC)))) (, ,) (NP (NP (DT a) (JJ 7-fold) (NN increase)) (PP (IN in) (NP (NN drug5) (NN Cmax)))) (CC and) (NP (NP (DT a) (JJ 2-fold) (NN increase)) (PP (IN in) (NP (NN drug6) (NN half-life)))))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (S (VP (RB not) (TO to) (VP (VB exceed) (NP (DT a) (JJ single) (ADJP (CD 2.5) (NN mg)) (NN drug1) (NN dose)) (PP (IN in) (NP (NP (DT a) (JJ 24-hour) (NN period)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 600) (NN mg)) (NN b.i.d.)) (-RRB- -RRB-))) (VP (VBN co-administered) (PP (IN with) (NP (NN drug2) (CD 5) (NN mg))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (JJ 49-fold) (NN increase)) (PP (IN in) (NP (NN drug3) (NN AUC)))) (CC and) (NP (NP (DT a) (ADJP (RB 13-fold)) (NN increase)) (PP (IN in) (NP (NN drug4) (NN Cmax)))))))) (. .)))
(S1 (S (S (NP (DT The) (NN interaction)) (VP (VBZ is) (NP (NP (DT a) (NN consequence)) (PP (IN of) (S (VP (VBG blocking) (NP (NP (JJ hepatic) (NN metabolism)) (PP (IN of) (NP (NN drug1)))) (PP (IN by) (NP (NP (NN drug2)) (, ,) (NP (NP (DT a) (ADJP (RB highly) (JJ potent)) (NN CYP3A4) (NN inhibitor)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB also)) (VP (VBZ inhibits) (NP (NN CYP2C9)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB significantly)) (VP (VBD prolonged) (NP (NP (DT the) (NN half-life)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (CD 26) (NNS hours)))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (S (VP (RB not) (TO to) (VP (VB exceed) (NP (DT a) (JJ single) (ADJP (CD 2.5) (NN mg)) (NN drug1) (NN dose)) (PP (IN in) (NP (NP (DT a) (JJ 72-hour) (NN period)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NN Drug) (NNS Interactions)) (: :) (S (NP (DT No) (JJ pharmacokinetic) (NNS interactions)) (VP (VBD were) (VP (VBN observed) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (DT the) (JJ following) (NNS drugs))))))) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ drug1) (NN study))) (, ,) (NP (NN drug2)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ pharmacodynamic) (NNS parameters)))))) (. .)))
(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (JJ other) (NNS drugs))))))
(S1 (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (: :) (S (NP (NP (NN drug1)) (CC and) (NP (PRP$ its) (NNS metabolites))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN CYP1A2)) (, ,) (NP (NN 2A6)) (, ,) (CC and) (NP (NP (NN 2E1)) (PRN (-LRB- -LRB-) (NP (NN Ki) (NN 100uM)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Weak) (JJ inhibitory) (NNS effects)) (PP (IN toward) (NP (NP (JJ other) (NNS isoforms)) (PRN (-LRB- -LRB-) (NP (NP (NN CYP2C8)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (NP (NN 2D6)) (, ,) (NP (NN 3A4))) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN found)))) (, ,) (CC but) (S (NP (NN Ki) (NNS values)) (VP (VBD were) (PP (IN in) (NP (NP (NN excess)) (PP (IN of) (NP (NP (NN plasma) (NNS concentrations)) (VP (VBN achieved) (PP (VBG following) (NP (NN dosing))))))))))) (. .)))
(S1 (S (S (NP (DT The) (ADJP (RBS most) (JJ potent)) (JJ inhibitory) (NN activity)) (VP (VBD was) (VP (VBN observed) (PP (IN for) (NP (NP (NN vardenafil) (NN metabolite) (NN M1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD had) (NP (NP (DT a) (NN Ki)) (PP (IN of) (NP (NP (CD 1.4) (NN uM)) (PP (IN toward) (NP (NN CYP3A4))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (ADJP (QP (RB about) (CD 20) (NNS times)) (JJR higher)) (PP (IN than) (NP (NP (DT the) (NN M1) (NN Cmax) (NNS values)) (PP (IN after) (NP (DT an) (ADJP (CD 80) (NN mg)) (NN drug1) (NN dose)))))))))))))))))) (. .)))
(S1 (S (NP (ADJP (FW In) (FW vivo)) (NNS studies)) (: :) (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (DT The) (NN blood) (NN pressure) (JJ lowering) (NNS effects)) (PP (IN of) (NP (NP (NP (JJ sublingual) (NNS drug2)) (PRN (-LRB- -LRB-) (NP (CD 0.4) (NN mg)) (-RRB- -RRB-))) (VP (VBN taken) (PP (NP (QP (CD 1) (CC and) (CD 4)) (NNS hours)) (IN after) (NP (NN drug3))))))) (CC and) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN at) (NP (QP (CD 1) (, ,) (CD 4) (CC and) (CD 8)) (NNS hours)))))))))) (VP (VBD were) (VP (VBN potentiated) (PP (IN by) (NP (NP (DT a) (ADJP (CD 20) (NN mg)) (NN dose)) (PP (IN of) (NP (NP (NN drug4)) (PP (IN in) (NP (JJ healthy) (JJ middle-aged) (NNS subjects)))))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (VBD were) (RB not) (VP (VBN observed)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1) (CD 20) (NN mg)) (VP (VBD was) (VP (VBN taken) (PP (NP (CD 24) (NNS hours)) (IN before) (NP (DT the) (NN drug2))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN Potentiation)) (PP (IN of) (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ ischemic) (NN heart) (NN disease)))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated))))) (, ,) (CC and) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ is) (VP (VBN contraindicated))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2) (CD 20) (NN mg)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NP (JJ slow-release) (NN drug3) (CD 30) (NN mg)) (CC or) (NP (NP (CD 60) (NN mg)) (ADVP (RB once) (RB daily)))))))) (, ,)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (NP (NP (DT the) (JJ relative) (NN bioavailability)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ maximum) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN Cmax)) (-RRB- -RRB-)))) (PP (IN of) (NP (NP (NN drug4)) (, ,) (NP (NP (DT a) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN metabolized) (PP (IN via) (NP (NN CYP3A4)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug2))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN in) (NP (NN combination)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT these) (NNS patients)) (SBAR (WHNP (WP$ whose) (NN hypertension)) (S (VP (VBD was) (VP (VBN controlled) (PP (IN with) (NP (NN drug1))))))))) (, ,) (NP (NN drug2) (CD 20) (NN mg)) (VP (VBD produced) (NP (NP (NP (JJ mean) (JJ additional) (NN supine) (JJ systolic/diastolic) (NN blood) (NN pressure)) (NNS reductions)) (PP (IN of) (NP (ADJP (CD 6/5) (NN mm)) (NN Hg)))) (PP (VBN compared) (PP (TO to) (NP (NN placebo)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug2) (CD 10) (CC or) (CD 20) (NN mg)) (VP (VBD was) (UCP (VP (VBN given) (PP (TO to) (NP (JJ healthy) (NNS volunteers)))) (CC either) (ADVP (RB simultaneously)) (CC or) (PP (NP (CD 6) (NNS hours)) (IN after) (NP (NP (DT a) (ADJP (CD 10) (NN mg)) (NN dose)) (PP (IN of) (NP (NN drug3))))))))) (, ,) (NP (JJ significant) (NN hypotension)) (VP (VBD developed) (PP (IN in) (NP (NP (DT a) (JJ substantial) (NN number)) (PP (IN of) (NP (NNS subjects))))))) (. .))))
(S1 (S (S (PP (IN With) (NP (NP (JJ simultaneous) (NN dosing)) (PP (IN of) (NP (NP (NN drug1) (CD 10) (NN mg)) (CC and) (NP (NN drug2) (CD 10) (NN mg)))))) (, ,) (NP (QP (CD 6) (IN of) (CD 8)) (NNS subjects)) (VP (VBN experienced) (NP (NP (DT a) (JJ standing) (JJ systolic) (NN blood) (NN pressure)) (PP (IN of) (NP (QP (JJR less) (IN than) (CD 85)) (NN mm) (NN Hg)))))) (. .)))
(S1 (S (S (PP (IN With) (NP (NP (JJ simultaneous) (NN dosing)) (PP (IN of) (NP (NP (NN drug1) (CD 20) (NN mg)) (CC and) (NP (NN drug2) (CD 10) (NN mg)))))) (, ,) (NP (QP (CD 2) (IN of) (CD 9)) (NNS subjects)) (VP (VBN experienced) (NP (NP (DT a) (JJ standing) (JJ systolic) (NN blood) (NN pressure)) (PP (IN of) (NP (QP (JJR less) (IN than) (CD 85)) (NN mm) (NN Hg)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1) (NN dosing)) (VP (VBD was) (VP (VBN separated) (PP (IN from) (NP (NP (NN drug2)) (ADJP (CD 10) (NN mg)))) (PP (IN by) (NP (CD 6) (NNS hours))))))) (, ,) (NP (NP (QP (CD 7) (IN of) (CD 28)) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (CD 20) (NN mg)) (PP (IN of) (NP (NN drug3)))))))) (VP (VBN experienced) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ standing) (JJ systolic) (NN blood) (NN pressure)) (PP (IN below) (NP (ADJP (CD 85) (NN mm)) (NN Hg)))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (JJ similar) (NN study)) (PP (IN with) (NP (NN drug1))) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))) (, ,) (NP (NP (QP (CD 1) (IN of) (CD 24)) (NNS subjects)) (VP (VBN dosed) (PP (IN with) (NP (NP (NP (NN drug2) (CD 20) (NN mg)) (CC and) (NP (NN drug3) (CD 0.4) (NN mg))) (VP (VBN separated) (PP (IN by) (NP (CD 6) (NNS hours)))))))) (VP (VBN experienced) (NP (NP (DT a) (JJ standing) (JJ systolic) (NN blood) (NN pressure)) (PP (IN below) (NP (ADJP (CD 85) (NN mm)) (NN Hg))))) (. .)))
(S1 (S (S (NP (NP (CD Two)) (PP (IN of) (NP (NP (CD 16) (NNS subjects)) (VP (VBN dosed) (ADVP (RB simultaneously)) (PP (IN with) (NP (NP (NN drug1) (CD 10) (NN mg)) (CC and) (NP (NN drug2) (CD 0.4) (NN mg)))))))) (VP (VBN experienced) (NP (NP (DT a) (JJ standing) (JJ systolic) (NN blood) (NN pressure)) (PP (IN below) (NP (ADJP (CD 85) (NN mm)) (NN Hg)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJR lower) (NNS doses)) (PP (IN of) (NP (NN drug1))))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB completely)) (VP (VBN evaluated) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (PRP they)) (VP (MD can) (VP (VB be) (ADVP (RB safely)) (VP (VBN administered) (ADVP (RB together)))))))))))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (DT these) (NNS data)))) (, ,) (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug2) (NN therapy))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (: :) (S (PP (IN Upon) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (CD 5) (NN mg)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (ADJP (CD 600) (NN mg)) (NN BID) (NN drug4))))))) (, ,) (NP (NP (DT the) (NP (NN Cmax)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (NN drug5)))) (VP (VBD were) (VP (VBN reduced) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %)))))) (. .))))
(S1 (S (S (PP (IN Upon) (NP (NP (NN administration)) (PP (IN of) (NP (NP (CD 10) (NN mg)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (ADJP (CD 800) (NN mg)) (NN TID) (NN drug2))))))) (, ,) (NP (NP (DT the) (NP (NN Cmax)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (NN drug3)))) (VP (VBD were) (VP (VBN reduced) (PP (IN by) (NP (NP (CD 40) (NN %)) (CC and) (NP (CD 30) (NN %)) (, ,) (ADVP (RB respectively))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN g/kg) (NN body) (NN weight)) (: :) (NP (NP (QP (RB approximately) (CD 40)) (NN mL)) (PP (IN of) (NP (NP (JJ absolute) (NN alcohol)) (PP (IN in) (NP (DT a) (ADJP (CD 70) (NN kg)) (NN person)))))) (-RRB- -RRB-))) (CC and) (NP (NN drug3) (NN plasma) (NNS levels))) (VP (VBD were) (RB not) (VP (VBN altered)) (SBAR (WHADVP (WRB when)) (S (VP (VBN dosed) (ADVP (RB simultaneously))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg)) (-RRB- -RRB-))) (VP (VBD did) (RB not) (VP (VB potentiate) (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NN drug2))) (PP (IN during) (NP (NP (DT the) (JJ 4-hour) (NN observation) (NN period)) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN g/kg) (NN body) (NN weight)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg) (CC and) (CD 20) (NN mg)) (-RRB- -RRB-)))) (VP (VBD did) (RB not) (VP (VB potentiate) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (JJ bleeding) (NN time)) (VP (VBN caused) (PP (IN by) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD two) (CD 81) (NN mg) (NNS tablets)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NNS interactions)) (: :) (S (NP (NN drug1)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacodynamics)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN glucose)) (CC and) (NP (NN insulin))) (NNS concentrations)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ pharmacodynamic) (NNS parameters))) (-RRB- -RRB-))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug2)))))) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NP (DT a) (NN drug)) (SBAR (WHNP (WDT which)) (S (VP (VBZ increases) (NP (JJ gastrointestinal) (NN motility)))))) (, ,)) (VP (VBZ lowers) (NP (NP (DT the) (NP (NN serum) (NN concentration)) (CC and) (NP (JJ urinary) (NN excretion))) (PP (IN of) (NP (NN drug4)))))) (. .))))
(S1 (S (S (NP (NP (JJ Other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP increase) (NP (JJ gastrointestinal) (NN motility)))))) (VP (MD may) (VP (VB produce) (NP (JJ similar) (NNS effects))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (JJ mean) (NN half-life)) (CC and) (NP (NP (DT the) (NN area)) (PP (IN under) (NP (DT the) (JJ concentration-time) (NN curve)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Urinary) (NN excretion)) (CC and) (NP (JJ renal) (NN clearance))) (VP (VBD were) (ADVP (RB correspondingly)) (VP (VBN reduced)))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NNS effects)) (PP (IN of) (NP (DT this) (NN combination)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NN No)) (VP (VBD reported) (NP (NNS interactions)))) (. .)))
(S1 (S (S (NP (NP (JJ Steady-state) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (VP (VBN reported) (S (VP (TO to) (VP (VB fluctuate) (ADVP (RB significantly)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (CC either) (VP (VBN added)) (CC or) (VP (VBN deleted) (PP (IN from) (NP (DT the) (NN drug) (NN regimen)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Serious) (JJ anticholinergic) (NNS symptoms)) (PRN (-LRB- -LRB-) (NP (NP (JJ severe) (JJ dry) (NN mouth)) (, ,) (NP (JJ urinary) (NN retention)) (, ,) (NP (JJ blurred) (NN vision))) (-RRB- -RRB-))) (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NNS elevations)) (PP (IN in) (NP (NP (DT the) (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug1))))))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN added) (PP (TO to) (NP (DT the) (NN drug) (NN regimen))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ higher-than) (VBN expected) (NN steady-state) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN therapy)) (VP (VBZ is) (VP (VBN initiated) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB already)) (VBG taking) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ well-controlled) (NNS patients)) (VP (VBG undergoing) (NP (NP (JJ concurrent) (NN therapy)) (PP (IN with) (NP (NN drug1))))))) (, ,) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (JJ steady-state) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))))) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (JJ cime-tidine) (NN therapy)) (VP (VBZ is) (VP (VBN discontinued)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ therapeutic) (NN efficacy)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN compromised) (PP (IN in) (NP (DT these) (NNS patients))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN discontinued))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Several)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN cited) (PP (IN in) (NP (DT these) (NNS reports))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (ADJP (JJR greater) (PP (IN than) (NP (NP (JJ 2-fold) (NNS increases)) (PP (IN in) (NP (NP (ADJP (RB previously) (JJ stable)) (NN plasma) (NNS levels)) (PP (IN of) (NP (JJ other) (NN drug1))))) (, ,) (PP (VBG including) (NP (NN drug2))))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (DT these) (NNS agents)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NP (PRP$ its) (JJ active) (NN metabolite)) (, ,) (NP (NN norfluoxe-tine)) (, ,))) (VP (VBP have) (NP (NP (NP (JJ long) (NNS half-lives)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 4) (TO to) (CD 16)) (NNS days)) (PP (IN for) (NP (NN drug2)))) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB affect) (NP (NNS strategies)) (PP (IN during) (NP (NP (NN conversion)) (PP (IN from) (NP (CD one) (NN drug))) (PP (TO to) (NP (DT the) (JJ other)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (IN during) (NP (NN therapy))) (PP (IN with) (NP (DT a) (NN drug2)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB produce) (NP (DT a) (JJ stimulating) (NN effect)) (PP (IN in) (NP (DT some) (JJ depressed) (NNS patients)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Close) (NN supervision)) (CC and) (NP (JJ careful) (NN adjustment))) (PP (IN of) (NP (DT the) (NN dosage)))) (VP (VBP are) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (PP (IN with) (NP (JJ other) (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN informed) (SBAR (IN that) (S (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN exaggerated)))))))))) (. .)))
(S1 (S (S (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NP (NN P450IID6)) (S (NP (NP (NP (DT A) (NN subset)) (PRN (-LRB- -LRB-) (NP (CD 3) (NN %) (TO to) (CD 10) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN population)))) (VP (VBZ has) (NP (NP (VBN reduced) (NN activity)) (PP (IN of) (NP (NP (JJ certain) (NN drug) (NN metabolizing) (NNS enzymes)) (PP (JJ such) (IN as) (NP (DT the) (NN cytochrome) (NN P450) (NN isoenzyme) (NN P450IID6)))))))))))) (. .)))
(S1 (S (S (NP (JJ Such) (NNS individuals)) (VP (VBP are) (VP (VBN referred) (PP (TO to)) (PP (IN as) (NP (NP (JJ poor) (NNS metabolizers)) (PP (IN of) (NP (NP (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (DT the) (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS individuals)) (VP (MD may) (VP (VBP have) (NP (NP (JJR higher) (IN than) (VBN expected) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (JJ usual) (NNS doses)))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (JJ certain) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT this) (NN isoenzyme)))))))) (, ,) (PP (VBG including) (NP (NP (JJ many) (NNS drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NNS others))) (-RRB- -RRB-)))) (, ,)) (VP (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT this) (NN isoenzyme)))))) (, ,) (CC and) (ADVP (RB thus)) (VP (MD may) (VP (VB make) (S (NP (JJ normal) (NNS metab-olizers)) (VP (VBP resemble) (NP (JJ poor) (NNS metabolizers)) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT this) (NN enzyme) (NN system)))))))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NN drug) (NNS interactions)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NN cytochrome) (NN P450IID6))))))) (VP (MD may) (VP (VB require) (NP (NP (JJR lower) (NNS doses)) (VP (ADVP (IN than) (RB usually)) (VBN prescribed) (PP (IN for) (NP (CC either) (NP (DT the) (NN drug2)) (CC or) (NP (DT the) (JJ other) (NN drug))))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT this) (NN isoenzyme))) (, ,) (PP (VBG including) (NP (NP (JJ other) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8))) (-RRB- -RRB-))))))))) (, ,) (CC or) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NP (DT this) (NN enzyme)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug9))) (-RRB- -RRB-))))))) (, ,)))) (VP (MD should) (VP (VB be) (VP (VBN approached) (PP (IN with) (NP (NN caution)))))) (. .)))
(S1 (S (S (NP (DT No) (NN drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN identified))))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (PP (IN with) (NP (NN drug1))) (PP (PP (IN in) (NP (NN man))) (, ,) (PP (IN in) (NP (NN animal) (NNS models))) (, ,) (CC and) (PP (IN in) (NP (FW vitro))))) (VP (VBP have) (VP (VBN shown) (NP (NP (DT no) (JJ significant) (NN interference)) (PP (IN with) (NP (NP (DT the) (NN disposition)) (PP (IN of) (NP (NP (NNS compounds)) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (JJ hepatic) (JJ microsomal) (NNS enzymes)))) (, ,) (PP (FW e.g.) (, ,) (NP (NP (NN cytochrome) (NN P450)) (NN system))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Compounds)) (VP (VBN tested) (PP (IN in) (NP (NN man))))) (VP (VBP include) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (PP (IN as) (NP (NP (DT an) (NN index)) (PP (IN of) (NP (JJ hepatic) (NN drug) (NN extraction)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN tested))))) (CC and) (S (NP (DT no) (JJ significant) (NNS effects)) (VP (VBP have) (VP (VBN been) (VP (VBN found)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN administered) (ADVP (RB concurrently))))) (, ,) (NP (DT the) (VBG following) (NNS drugs)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN drug1)))))) (: :) (NP (NP (NN drug2)) (, ,) (NP (ADJP (JJ general))) (: :) (NP (NP (NN exaggeration)) (PP (IN of) (NP (NP (DT the) (NN hypotension)) (VP (VBN induced) (PP (IN by) (NP (JJ general) (NN drug3)))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (JJ oral) (NNS agents)) (CC and) (NP (NNS drug2))) (-RRB- -RRB-))) (: :) (NP (NP (NN hypoglycemia)) (CC or) (NP (NN hyperglycemia))) (: ;))))
(S1 (S (S (VP (VB adjust) (NP (NP (NN dosage)) (PP (IN of) (NP (NN drug1)))) (ADVP (RB accordingly)))) (. .)))
(S1 (S (NP (NP (NP (JJ Catecholamine-depleting) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (-RRB- -RRB-))) (: :) (NP (JJ additive) (NN effect)) (: ;))))
(S1 (S (S (NP (NN monitor)) (ADVP (RB closely)) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NN hypotension)) (CC and/or) (NP (NP (JJ excessive) (NN bradycardia)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN vertigo)) (, ,) (NP (NN syncope)) (, ,) (NP (JJ postural) (NN hypotension))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NP (NN Response)) (PP (TO to) (NP (NN Treatment))) (PP (IN for) (NP (JJ Anaphylactic) (NN Reaction)))) (: :) (S (SBAR (IN While) (S (VP (VBG taking) (NP (NN drug1))))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ severe) (JJ anaphylactic) (NN reaction)) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS allergens)))))))))) (VP (MD may) (VP (VB be) (ADJP (ADJP (RBR more) (JJ reactive) (PP (TO to) (NP (JJ repeated) (NN challenge)))) (, ,) (CC either) (ADJP (JJ accidental)) (, ,) (ADJP (JJ diagnostic)) (, ,) (CC or) (ADJP (JJ therapeutic)))))) (. .))))
(S1 (S (S (NP (JJ Such) (NNS patients)) (VP (MD may) (VP (VB be) (ADJP (JJ unresponsive) (PP (TO to) (NP (NP (DT the) (JJ usual) (NNS doses)) (PP (IN of) (NP (NN drug1))) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (JJ allergic) (NN reaction)))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (ADJP (RB concurrently) (VBN administered)) (NN drug3))))))) (, ,) (NP (NP (JJ periodic) (NN serum) (NN level) (NNS determinations)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (JJ necessary)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (S (S (NP (NN drug4)) (VP (MD may) (VP (VBP elevate) (NP (NN drug5) (NN serum) (NNS levels))))) (CC and) (S (NP (NN drug6)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (TO to) (NP (CC both) (NP (NN increase)) (CC and) (NP (NN decrease)) (NP (NN drug7) (NNS levels)))))))))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NP (NNS Results)) (PP (IN of) (NP (NP (JJ preliminary) (NNS studies)) (PP (IN in) (NP (NP (NNS humans)) (CC and) (NP (NNS rats))))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ nonabsorbable) (NN drug1)) (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2))))) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (JJ desired) (NN drug3) (JJ -induced) (NN drop)) (PP (IN in) (NP (JJ colonic) (NN pH)))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT a) (JJ possible) (NN lack)) (PP (IN of) (NP (NP (JJ desired) (NN effect)) (PP (IN of) (NP (NN treatment)))))) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN into) (NP (NN consideration))) (SBAR (IN before) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug1))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Substances)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS inducers)) (PP (IN of) (NP (NN CYP3A4) (NN activity)))))))) (VP (VP (VBP increase) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug1))))) (CC and) (VP (VBP decrease) (NP (PRP$ its) (NN plasma) (NNS concentrations))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (DT a) (JJ potent) (NN CYP3A4) (NN inducer)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))))))) (, ,) (S (NP (NP (DT a) (NN dose) (NN increase)) (PP (TO to) (NP (NP (CD 500) (NN mg)) (ADVP (RB daily))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ severe) (JJ adverse) (NN drug) (NN reaction))))))))) (, ,) (CC and) (S (NP (NP (JJ clinical) (NN response)) (CC and) (NP (JJ adverse) (NNS events))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored) (PRN (-LRB- -LRB-) (S (VP (VB see) (NP (NP (JJ CLINICAL) (JJ PHARMACOLOGY-Pharmacokinetics-Drug-Drug) (NNS Interactions)) (CC and) (NP (NP (NP (NN DOSAGE)) (CC AND) (NP (JJ ADMINISTRATION-Dosage) (NN Adjustment))) (NNS sections))))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NP (NP (NNP International)) (VBN Normalized) (NN Ratio) (-LRB- -LRB-) (NN INR) (-RRB- -RRB-) (NNS elevations)) (CC and/or) (NP (JJ bleeding) (NNS events))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (DT some) (NNS patients)) (VP (VBG taking) (NP (NN drug1)) (PP (IN while) (PP (IN on) (NP (NN drug2) (NN therapy))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB regularly)) (PP (IN for) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (NN INR)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Substances)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (JJ potent) (NNS inhibitors)) (PP (IN of) (NP (NN CYP3A4) (NN activity)))))))) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug1)) (CC and) (NP (NN drug2))) (-RRB- -RRB-))) (VP (VP (VBP decrease) (NP (NN drug3) (NN metabolism))) (CC and) (VP (VBP increase) (NP (NN drug4) (NN plasma) (NNS concentrations))))) (. .)))
(S1 (S (S (NP (DT This) (NN increase)) (VP (MD may) (VP (VB be) (ADJP (RB clinically) (JJ relevant)) (SBAR (IN as) (S (NP (JJ adverse) (NNS experiences)) (VP (VBP are) (ADJP (JJ related) (PP (TO to) (NP (NP (NN dose)) (CC and) (NP (NN exposure))))))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (JJ CYP3A4) (NNS inhibitors)) (PP (IN with) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP cause) (NP (NP (JJ significant) (JJ sustained) (NN elevation)) (PP (IN in) (NP (NP (JJ gastric) (NN pH)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))) (-RRB- -RRB-))))))))) (VP (VP (MD may) (VP (VB reduce) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug4)))))) (CC and) (ADVP (RB therefore)) (ADVP (RB potentially)) (VP (MD may) (VP (VB reduce) (NP (NN efficacy)))))) (. .)))
(S1 (S (S (NP (NP (NN Phase) (CD II) (JJ clinical) (NN trial) (NNS data)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP have) (VP (VBN been) (VP (VBN used) (ADVP (RB concomitantly))))))) (, ,)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug3)) (VP (MD may) (VP (VB exacerbate) (NP (NP (DT the) (JJ neutropenic) (NN effect)) (PP (IN of) (NP (NN drug4)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3) (NN s)) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NP (NN allergy)) (, ,) (NP (NN cold)) (, ,) (CC and) (NP (NN sinus) (NNS medicines))) (-RRB- -RRB-))) (, ,) (NP (JJ diabetic) (NNS drugs)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NP (NN drug7)) (PP (IN like) (NP (NP (NN drug8)) (CC or) (NP (NN drug9))))) (, ,) (CC and) (NP (JJ high) (NN blood) (NN pressure)) (NP (NNS medications))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN drug) (NNS interactions)) (PP (IN of) (NP (JJ clinical) (NN importance)))) (VP (VBP have) (VP (VBN been) (VP (VBN identified))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB affect) (NP (DT the) (NN cytochrome) (JJ P450-linked) (NN drug-metabolizing) (NN enzyme) (NN system)))))))) (. .)))
(S1 (S (S (S (NP (NP (NNS Compounds)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VBN tested) (PP (IN in) (NP (NN man))))))))) (VP (VBP include) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))) (CC and) (S (NP (DT no) (ADJP (RB clinically) (JJ meaningful)) (NNS interactions)) (VP (VBD were) (VP (VBN found))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (JJ concomitant) (NN therapy)) (PP (IN Although) (NP (JJ specific) (NN interaction) (NNS studies)))) (VP (VBD were) (RB not) (VP (VBN performed)))) (, ,) (S (NP (NP (NP (NN drug1) (NNS doses)) (PP (IN of) (NP (CD 1) (NN mg)))) (CC or) (NP (JJR more))) (VP (VBD were) (ADVP (RB concomitantly)) (VP (VBN used) (PP (IN in) (NP (NP (JJ clinical) (NNS studies)) (PP (IN with) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN a-blockers)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (JJ cardiac) (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (NN drug13)) (, ,) (NP (NP (NN drug14)) (PRN (-LRB- -LRB-) (ADVP (RB also)) (VP (VBN referred) (PP (TO to) (NP (JJ as) (NN drug15)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN drug16))) (PP (IN without) (NP (NN evidence))) (PP (IN of) (NP (ADJP (RB clinically) (JJ significant)) (JJ adverse) (NNS interactions)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (NN drug1)) (VP (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ circulating) (NNS levels)) (PP (IN of) (NP (NP (NN cortisol)) (, ,) (NP (JJ thyroid-stimulating) (NN hormone)) (, ,) (CC or) (NP (NN thyroxine))))))) (, ,) (CC nor) (VP (VBD did) (NP (PRP it)) (VP (VB affect) (NP (NP (NP (DT the) (NN plasma) (NN lipid) (NN profile)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (JJ total) (NN cholesterol)) (, ,) (NP (JJ low-density) (NNS lipoproteins)) (, ,) (NP (JJ high-density) (NNS lipoproteins)) (CC and) (NP (NNS triglycerides)))) (-RRB- -RRB-))) (CC or) (NP (NN bone) (JJ mineral) (NN density))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS studies)) (PP (IN with) (NP (NN drug1))))) (, ,) (NP (NP (DT no) (ADJP (RB clinically) (JJ meaningful)) (NNS changes)) (PP (IN in) (NP (NP (NP (JJ luteinizing) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN LH)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ follicle-stimulating) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN FSH)) (-RRB- -RRB-))) (CC or) (NP (NN prolactin))))) (VP (VBD were) (VP (VBN detected)))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ healthy) (NNS volunteers))) (, ,) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug1)))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (NP (NN LH)) (CC and) (NP (NN FSH)))) (PP (TO to) (NP (JJ gonadotropin-releasing) (NN hormone))))) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (DT the) (JJ hypothalamic-pituitary-testicular) (NN axis)) (VP (VBD was) (RB not) (VP (VBN affected))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (JJ clinical) (NNS studies)) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (CD 1) (NN mg))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NNS men) (CD 18-41) (NNS years)) (PP (IN of) (NP (NN age))))))))) (, ,) (NP (NP (DT the) (NN mean) (NN value)) (PP (IN of) (NP (NP (NN serum) (JJ prostate-specific) (NN antigen)) (PRN (-LRB- -LRB-) (NP (NN PSA)) (-RRB- -RRB-))))) (VP (VBD decreased) (PP (IN from) (NP (CD 0.7) (NN ng/mL))) (PP (IN at) (NP (NN baseline))) (PP (TO to) (NP (NP (CD 0.5) (NN ng/mL)) (PP (IN at) (NP (NN Month) (CD 12)))))) (. .)))
(S1 (S (S (ADVP (RB Further)) (, ,) (PP (IN in) (NP (NP (JJ clinical) (NNS studies)) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (CD 5) (NN mg))) (-RRB- -RRB-))) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (JJR older) (NNS men)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (NP (NP (JJ benign) (JJ prostatic) (NN hyperplasia)) (PRN (-LRB- -LRB-) (NP (NN BPH)) (-RRB- -RRB-))))))))))))))) (, ,) (NP (NN PSA) (NNS levels)) (VP (VBP are) (VP (VBN decreased) (PP (IN by) (NP (QP (RB approximately) (CD 50)) (NN %)))))) (. .)))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN into) (NP (NN account))) (PP (IN for) (NP (NP (JJ proper) (NN interpretation)) (PP (IN of) (NP (NN serum) (NN PSA))))) (SBAR (WHADVP (WRB when)) (S (VP (VBG evaluating) (NP (NP (NNS men)) (VP (VBN treated) (PP (IN with) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NNS Reports)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug3)))))))))) (. .))))
(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mild) (TO to) (JJ moderate) (NN hypertension))))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NP (CD 25) (NN mg) (RB daily)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (DT the) (NN drug2) (NN drug3)))) (, ,) (NP (NP (QP (CD 10) (TO to) (CD 40)) (NN mg)) (PP (IN for) (NP (CD 4) (NNS weeks)))) (, ,)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ average) (NN increase)) (PP (IN in) (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (IN of) (NP (QP (RB about) (CD 3)) (NN mm) (NN Hg))) (PP (VBN compared) (PP (TO to) (NP (NP (NN drug4)) (ADVP (RB alone))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN interaction)) (VP (MD should) (VP (VB be) (VP (VBN given) (NP (NP (NN consideration)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)))))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (JJ low-dose) (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT an) (VBN increased) (NN rate)) (PP (IN of) (NP (NP (NN GI) (NN ulceration)) (CC or) (NP (JJ other) (NNS complications)))))) (, ,) (PP (VBN compared) (PP (TO to) (NP (NP (NN use)) (PP (IN of) (NP (NP (NN drug4)) (ADVP (RB alone)))))))))) (. .))))
(S1 (S (PP (IN In) (NP (NP (DT a) (JJ 12-week) (NN endoscopy) (NN study)) (VP (VBN conducted) (PP (IN in) (NP (JJ OA) (NNS patients)))))) (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (DT the) (JJ cumulative) (NN incidence)) (PP (IN of) (NP (JJ endoscopic) (JJ gastroduodenal) (NNS ulcers))))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (ADJP (ADJP (JJ low-dose)) (PRN (-LRB- -LRB-) (NP (CD 81) (NN mg)) (-RRB- -RRB-))) (JJ enteric) (JJ coated) (NN drug1)) (CC plus) (NP (NP (NN drug2) (CD 25) (NN mg)) (ADVP (RB daily)))))))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (DT those)) (VP (VBG taking) (NP (NP (NN drug3) (CD 2400) (NN mg) (RB daily)) (ADVP (RB alone)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (JJ low-dose) (NP (NN drug1)) (CC plus) (NP (NN drug2))))) (VP (VBD were) (RB not) (VP (VBN studied)))) (. .)))
(S1 (S (PP (IN At) (NP (JJ steady) (NN state))) (, ,) (NP (NP (NN drug1) (CD 50) (NN mg)) (ADVP (RB once) (RB daily))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ anti-platelet) (NN activity)) (PP (IN of) (NP (ADJP (ADJP (JJ low-dose)) (PRN (-LRB- -LRB-) (NP (NP (CD 81) (NN mg)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-))) (NN drug2))))) (, ,) (SBAR (IN as) (S (VP (VBN assessed) (PP (IN by) (NP (NP (NP (ADJP (FW ex) (FW vivo)) (NN platelet) (NN aggregation)) (CC and) (NP (NN serum) (NN TXB2) (NN generation))) (PP (IN in) (NP (JJ clotting) (NN blood))))))))) (. .)))
(S1 (S (S (PP (IN Because) (IN of) (NP (NP (PRP$ its) (NN lack)) (PP (IN of) (NP (NN platelet) (NNS effects))))) (, ,) (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (DT a) (VP (VB substitute) (PP (IN for) (NP (NN drug2))) (PP (IN for) (NP (JJ cardiovascular) (NNS prophylaxis))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1))))) (, ,) (NP (NN antiplatelet) (NNS therapies)) (VP (VP (MD should) (RB not) (VP (VB be) (VP (VBN discontinued)))) (CC and) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT an) (NN indication)) (PP (IN for) (NP (JJ cardiovascular) (NNS prophylaxis)))))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (ADJP (JJ Prospective)) (, ,) (ADJP (JJ long-term))) (NNS studies)) (PP (IN on) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Co-administration)) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PRN (PP (IN of) (NP (NN drug2))) (NP (NP (CD -LSB-800) (NN mg)) (ADVP (RB twice) (RB daily))) (-RRB- -RSB-))))) (VP (VBD increased) (NP (NP (DT the) (NN Cmax)) (PP (IN of) (NP (NN drug3)))) (PP (IN by) (NP (CD 21) (NN %))) (, ,) (NP (NP (NP (DT the) (NN AUC0-120hr)) (PP (IN by) (NP (CD 23) (NN %)))) (CC and) (NP (NP (DT the) (NN t1/2)) (PP (IN by) (NP (CD 15) (NN %))))))) (. .))))
(S1 (S (S (S (NP (DT These) (JJ small) (NNS changes)) (VP (VBP are) (RB not) (ADJP (RB clinically) (JJ significant)))) (CC and) (S (NP (DT no) (NN dose) (NN adjustment)) (VP (VBZ is) (ADJP (JJ necessary))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2) (CD 75) (NN mg)) (ADJP (RB once) (JJ daily) (PP (IN for) (NP (CD 11) (NNS days))))) (VP (VBZ does) (RB not) (VP (VB alter) (NP (NP (DT the) (NN plasma) (NN concentration) (NN profile)) (CC or) (NP (NP (JJ renal) (NN elimination)) (PP (IN of) (NP (NN drug3))))) (PP (IN after) (NP (DT a) (JJ single) (ADJP (CD 0.5) (NN mg)) (JJ oral) (NN dose)))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Clinical) (NNS studies)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ post-marketing) (NNS observations)) (, ,)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (JJ natriuretic) (NN effect)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))) (PP (IN in) (NP (DT some) (NNS patients))))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN response)) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ renal) (NN prostaglandin) (NN synthesis))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2) (CD 400) (NN mg)) (ADVP (RB daily)))) (VP (VBD did) (RB not) (VP (VB have) (NP (DT any) (ADJP (RB clinically) (JJ important)) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP have) (VP (VBN produced) (NP (NP (NP (DT an) (NN elevation)) (PP (IN of) (NP (NN plasma) (NN drug3) (NNS levels)))) (CC and) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (JJ renal) (NN drug4) (NN clearance)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ post-marketing) (VBP experience))) (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (NNS increases)) (PP (IN in) (NP (NN plasma) (NN drug1) (NNS levels))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concurrently)))))) (, ,) (NP (NNS subjects)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB carefully)) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NN drug3) (NN toxicity))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1) (NN drug2)) (ADJP (QP (CD 12.5) (, ,) (CD 25) (, ,) (CC and) (CD 50)) (NN mg))) (, ,) (NP (NP (DT each) (NN dose)) (VP (VBN administered) (ADVP (RB once) (RB daily)) (PP (IN for) (NP (CD 7) (NNS days))))) (, ,)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug3))))) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (NN AUC0-24hr)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ single) (JJ weekly) (NN drug4) (NNS doses)) (PP (IN of) (NP (QP (CD 7.5) (TO to) (CD 20)) (NN mg)))) (PP (IN for) (NP (JJ rheumatoid) (NN arthritis))))))))))))) (. .)))
(S1 (S (S (PP (IN At) (NP (JJR higher) (IN than) (VBN recommended) (NNS doses))) (, ,) (NP (NP (NN drug1) (CD 75) (NN mg)) (VP (VBN administered) (ADVP (RB once) (RB daily)) (PP (IN for) (NP (CD 10) (NNS days))))) (VP (VBD increased) (NP (NN plasma) (NNS concentrations)) (PP (IN by) (NP (CD 23) (NN %))) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (NN AUC0-24hr)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2) (CD 7.5) (TO to) (CD 15) (NN mg/week)) (PP (IN for) (NP (JJ rheumatoid) (NN arthritis)))))))))))))) (. .)))
(S1 (S (PP (IN At) (NP (CD 24) (NNS hours) (NN postdose))) (, ,) (NP (NP (DT a) (JJ similar) (NN proportion)) (PP (IN of) (NP (NP (NNS patients)) (VP (VP (VBN treated) (PP (IN with) (NP (NN drug1))) (ADVP (ADVP (RB alone)) (PRN (-LRB- -LRB-) (NP (CD 94) (NN %)) (-RRB- -RRB-)))) (CC and) (VP (ADVP (RB subsequently)) (VBN treated) (PP (IN with) (NP (NN drug2) (NN co-administered))) (PP (IN with) (NP (NP (NP (CD 75) (NN mg)) (PP (IN of) (NP (NN drug3)))) (PRN (-LRB- -LRB-) (NP (CD 88) (NN %)) (-RRB- -RRB-))))))))) (VP (VBD had) (NP (NP (NN drug4) (NN plasma) (NNS concentrations)) (PP (IN below) (NP (NP (DT the) (JJ measurable) (NN limit)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN ng/mL)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NP (JJ Standard) (NN monitoring)) (PP (IN of) (NP (NN drug1) (JJ -related) (NN toxicity)))) (VP (MD should) (VP (VB be) (VP (VBN continued) (SBAR (IN if) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))))))) (. .)))
(S1 (S (S (NP (JJ Oral) (NN drug1) (NN drug2)) (VP (VBD did) (RB not) (VP (VB have) (NP (DT any) (ADJP (RB clinically) (JJ important)) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (NP (NN drug3))) (VP (VBD did) (RB not) (VP (VB have) (NP (DT any) (ADJP (RB clinically) (JJ important)) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug4)) (CC or) (NP (NN drug5))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NP (NP (NN drug3) (CD 600) (NN mg)) (ADVP (RB daily))) (, ,) (NP (NP (DT a) (JJ potent) (NN inducer)) (PP (IN of) (NP (JJ hepatic) (NN metabolism)))) (, ,)))) (VP (VBD produced) (NP (NP (DT an) (JJ approximate) (ADJP (CD 50) (NN %)) (NN decrease)) (PP (IN in) (NP (NN drug4) (NN plasma) (NNS concentrations)))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT a) (VBG starting) (JJ daily) (NN dose)) (PP (IN of) (NP (NP (CD 25) (NN mg)) (PP (IN of) (NP (NN drug1)))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN osteoarthritis))))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NP (JJ potent) (NNS inducers)) (PP (IN of) (NP (JJ hepatic) (NN metabolism))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN drug2) (QP (CD 12.5) (, ,) (CD 25) (, ,) (CC and) (CD 50)) (NN mg)) (VP (VBN administered) (ADVP (RB once) (RB daily)) (PP (IN for) (NP (CD 7) (NNS days))))) (VP (VBD increased) (NP (NP (NN plasma) (NN drug3) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NN AUC) (-LRB- -LRB-) (CD 0-) (-RRB- -RRB-)) (-RRB- -RRB-))) (PP (IN by) (NP (NP (QP (CD 38) (TO to) (CD 60)) (NN %)) (PP (IN in) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBN administered) (NP (NP (DT a) (JJ single) (JJ 300-mg) (NN dose)) (PP (IN of) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Adequate) (NN monitoring)) (PP (IN of) (NP (NN drug1) (NN plasma) (NNS concentrations)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug2)))) (VP (VBZ is) (VP (VP (VBN initiated)) (CC or) (VP (VBN changed) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB produce) (NP (NP (DT a) (JJ modest) (NN inhibition)) (PP (IN of) (NP (NP (NP (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NN 1A2)))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (NN potential)) (PP (IN for) (NP (NP (DT an) (NN interaction)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (S (VP (VBG CYP) (NP (NP (NN 1A2)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3)))) (-RRB- -RRB-))))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN Anticoagulant) (NN activity)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (DT the) (JJ first) (JJ few) (NNS days)) (PP (IN after) (S (VP (VP (VBG initiating)) (CC or) (VP (VBG changing) (NP (NP (NN drug2) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (ADJP (ADJP (JJ drug3)) (CC or) (ADJP (JJ similar))) (NNS agents)))))))))))) (, ,) (SBAR (IN since) (S (NP (DT these) (NNS patients)) (VP (VBP are) (PP (IN at) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ bleeding) (NNS complications)))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (ADJP (ADJP (JJ single)) (CC and) (ADJP (JJ multiple))) (NN dose) (NNS studies)) (PP (IN in) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBG receiving) (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (, ,) (NP (NP (NN prothrombin) (NN time)) (PRN (-LRB- -LRB-) (VP (VBN measured) (PP (IN as) (NP (NN INR)))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN increased) (PP (IN by) (NP (QP (RB approximately) (CD 8) (NN %) (TO to) (CD 11)) (NN %)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ post-marketing) (VBP experience))) (, ,) (NP (JJ bleeding) (NNS events)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (, ,) (PP (ADVP (RB predominantly)) (IN in) (NP (DT the) (JJ elderly))) (, ,) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (NNS increases)) (PP (IN in) (NP (NN prothrombin) (NN time))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)) (PP (ADVP (RB concurrently)) (IN with) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN administered) (ADVP (RB concurrently))))) (, ,) (NP (DT the) (JJ following) (NNS drugs)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN drug1)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (VBN Increased) (NN possibility)) (PP (IN of) (NP (NN skin) (NN rash))) (, ,) (ADVP (RB particularly)) (PP (IN in) (NP (JJ hyperuricemic) (NNS patients)))) (VP (MD may) (VP (VB occur)))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5))) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (JJ bactericidal) (NN effect)) (PP (IN of) (NP (NN drug6)))))))) (. .)))
(S1 (S (S (S (NP (DT This)) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (PP (IN in) (NP (NN view))))))) (, ,) (ADVP (RB however)) (, ,) (NP (NP (DT the) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN interaction)))) (VP (VBZ is) (RB not) (ADVP (RB well)) (VP (VBN documented)))) (. .)))
(S1 (S (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (VP (VP (MD May) (VP (VB be) (ADJP (RBR less) (JJ effective)))) (CC and) (VP (VBD increased) (ADJP (RB breakthrough) (JJ bleeding)))))) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (NN drug1) (: :)) (VP (MD May) (VP (VB decrease) (NP (NP (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NP (NN drug2)) (VP (VBG resulting) (PP (IN in) (NP (NP (VBN increased) (NN blood) (NNS levels)) (CC and/or) (NP (NN drug3) (NN toxicity))))))))))) (. .)))
(S1 (S (NP (NP (JJ Drug/Laboratory) (NN Test) (NN Interaction)) (PP (IN After) (NP (NN treatment))) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NP (NN glucose)) (PP (IN in) (NP (DT the) (NN urine))))))))) (VP (MD may) (VP (VB occur) (PP (PP (IN with) (NP (NP (NN drug2) (NNS tests)) (PRN (-LRB- -LRB-) (NP (NNS Benedicts) (NP (NP (NN solution)) (, ,) (NP (NN Fehlings) (NN solution)) (, ,) (CC or) (NP (NN Clinitest) (NNS tablets)))) (-RRB- -RRB-)))) (CC but) (PP (RB not) (IN with) (NP (NP (NN enzyme) (NN based) (NNS tests)) (PP (JJ such) (IN as) (NP (NP (NN Clinistix)) (CC and) (NP (NN Glucose) (JJ Enzymatic) (NN Test) (NN Strip) (NN USP))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW in) (FW vitro)) (NNS data)) (PP (IN on) (NP (JJ metabolic) (NNS interactions)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VP (VB produce)) (, ,) (CC or) (VP (VB be) (ADJP (JJ subject) (PP (TO to) (NP (, ,) (JJ pharmacokinetic) (NNS interactions)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (PRP$ its) (JJ major) (NN metabolite))) (, ,) (PP (IN at) (NP (NP (NNS concentrations)) (PP (ADVP (RB well)) (IN above) (NP (NN cmax) (NNS levels))) (VP (VBN achieved) (PP (IN within) (NP (DT the) (JJ therapeutic) (NN dose) (NN range)))))) (, ,) (VP (VBP are) (NP (CC neither) (NP (NP (NNS inhibitors)) (PP (IN of))) (CC nor) (NP (NP (JJ high) (NN affinity) (NNS substrates)) (PP (IN for) (NP (NP (NP (JJ human) (NN liver) (NN cytochrome) (NN P450)) (NNS isoforms)) (, ,) (NP (NP (NN epoxide) (NN hydrolase)) (CC or) (NP (JJ UDP-glucuronidation) (NNS enzymes))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (DT the) (ADJP (FW in) (FW vitro)) (NN glucuronidation)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ circulates) (ADJP (RB largely) (JJ unbound) (PRN (-LRB- -LRB-) (ADJP (NP (CD 10) (NN %)) (JJ bound)) (-RRB- -RRB-)) (PP (TO to) (NP (NN plasma) (NNS proteins)))))) (: ;)))
(S1 (S (S (NP (NP (ADJP (RB clinically) (JJ significant)) (NNS interactions)) (PP (IN with) (NP (JJ other) (NNS drugs))) (PP (IN through) (NP (NP (NN competition)) (PP (IN for) (NP (NN protein) (NN binding) (NNS sites)))))) (VP (VBP are) (ADVP (RB therefore)) (ADJP (JJ unlikely)))) (. .)))
(S1 (S (S (NP (JJ Potential) (JJ pharmacokinetic) (NNS interactions)) (VP (VBD were) (VP (VBN assessed) (PP (PP (IN in) (NP (NP (JJ clinical) (JJ pharmacokinetic) (NNS studies)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (JJ oral) (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-)))) (CC and) (PP (IN through) (NP (NP (JJ pharmacokinetic) (NN screening)) (PP (IN in) (NP (NP (DT the) (ADJP (JJ placebo-controlled) (JJ clinical)) (NNS studies)) (PP (IN in) (NP (JJ epilepsy) (NNS patients))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Drug-Drug) (NNS Interactions)) (PP (IN Between) (NP (NP (NN drug1)) (CC And) (NP (NP (JJ Other) (NN drug2) (-LRB- -LRB-) (NN drug3) (-RRB- -RRB-) (NN drug4) (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (CD 3000) (NN mg)) (ADVP (RB daily))) (-RRB- -RRB-)))))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ pharmacokinetic) (NN disposition)) (PP (IN of) (NP (NP (NN drug6)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ refractory) (NN epilepsy))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (ADVP (RB also)) (RB not) (VP (VBN affected) (PP (IN by) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (JJ drug1) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 1500) (NN mg)) (ADVP (RB twice) (RB daily))) (-RRB- -RRB-))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (CD 500) (NN mg)) (ADVP (RB twice) (RB daily))) (VP (VBD did) (RB not) (VP (VB modify) (NP (NP (NP (DT the) (NP (NN rate)) (CC or) (NP (NN extent))) (PP (IN of) (NP (NN drug2) (NN absorption)))) (CC or) (NP (NP (PRP$ its) (NN plasma) (NN clearance)) (CC or) (NP (JJ urinary) (NN excretion))))))) (. .)))
(S1 (S (S (NP (EX There)) (ADVP (RB also)) (VP (VBD was) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (CC and) (DT the) (NN excretion)) (PP (IN of) (NP (NP (DT the) (JJ primary) (NN metabolite)) (, ,) (NP (NN ucb) (NN L057))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Potential) (NN drug) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (JJ other) (NNS drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (CC and) (NP (NN drug9))) (-RRB- -RRB-)))))) (VP (VBD were) (ADVP (RB also)) (VP (VBN assessed) (PP (IN by) (S (VP (VBG evaluating) (NP (NP (DT the) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug10)) (CC and) (NP (DT these) (NN drug11))))) (PP (IN during) (NP (ADJP (JJ placebo-controlled) (JJ clinical)) (NNS studies))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB influence) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (JJ other) (NN drug2)))))))) (CC and) (SBAR (IN that) (S (NP (DT these) (NNS drug3)) (VP (VBP do) (RB not) (VP (VB influence) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (JJ Pediatric) (NNS Patients)))) (S (NP (EX There)) (VP (VBD was) (PP (IN about) (NP (NP (DT a) (ADJP (CD 22) (NN %)) (NN increase)) (PP (IN of) (NP (NP (JJ apparent) (JJ total) (NN body) (NN clearance)) (PP (IN of) (NP (NN drug2))))))) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBD was) (VP (VBN co-administered) (PP (IN with) (NP (JJ enzyme-inducing) (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NN Dose) (NN adjustment)) (VP (VBZ is) (RB not) (NP (NP (NN recommended.) (NN drug1)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))))))))) (. .)))
(S1 (S (S (NP (JJ Other) (NN Drug) (NNS Interactions) (NP (NP (JJ Oral) (NN drug1) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 500) (NN mg)) (ADVP (RB twice) (RB daily))) (-RRB- -RRB-)))) (VP (VBD did) (RB not) (VP (VB influence) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (PP (IN of) (NP (NP (DT an) (JJ oral) (NN drug3)) (VP (VBG containing) (NP (NP (ADJP (CD 0.03) (NN mg)) (NN drug4)) (CC and) (NP (ADJP (CD 0.15) (NN mg)) (NN drug5)))))) (, ,) (CC or) (PP (IN of) (NP (NP (DT the) (JJ luteinizing) (NN hormone)) (CC and) (NP (NN progesterone) (NNS levels))))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (NN impairment)) (PP (IN of) (NP (JJ contraceptive) (NN efficacy)))) (VP (VBZ is) (ADJP (JJ unlikely))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (DT this) (JJ oral) (NN drug1)))) (VP (VBD did) (RB not) (VP (VB influence) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000) (NN mg)) (ADVP (RB twice) (RB daily))) (-RRB- -RRB-))) (VP (VBD did) (RB not) (VP (VB influence) (NP (NP (NP (DT the) (NP (NNS pharmacokinetics)) (CC and) (NP (NNS pharmacodynamics))) (PRN (-LRB- -LRB-) (NP (NN ECG)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN drug3)) (VP (VBN given) (PP (IN as) (NP (NP (DT a) (ADJP (CD 0.25) (NN mg)) (NN dose)) (VP (DT every) (NN day))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD did) (RB not) (VP (VB influence) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000) (NN mg)) (ADVP (RB twice) (RB daily))) (-RRB- -RRB-))) (VP (VBD did) (RB not) (VP (VB influence) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NN Prothrombin) (NN time)) (VP (VBD was) (RB not) (VP (VBN affected) (PP (IN by) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2)) (, ,) (NP (NP (DT a) (JJ renal) (JJ tubular) (NN secretion) (NN blocking) (NN agent)) (, ,) (VP (VBN administered) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD 500) (NN mg) (CD four) (NNS times)) (NP (DT a) (NN day)))))))) (, ,)) (VP (VBD did) (RB not) (VP (VB change) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug3) (CD 1000) (NN mg)) (ADVP (RB twice) (RB daily)))))))) (. .))))
(S1 (S (S (NP (NP (NN Cssmax)) (PP (IN of) (NP (NP (DT the) (NN metabolite)) (, ,) (NP (NN ucb) (NN L057)) (, ,)))) (VP (VBD was) (RB approximately) (VP (VBN doubled) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug1)))))) (SBAR (IN while) (S (NP (NP (DT the) (NN fraction)) (PP (IN of) (NP (NN drug)))) (VP (VBD excreted) (ADJP (JJ unchanged)) (PP (IN in) (NP (NP (DT the) (NN urine)) (VP (VBD remained) (NP (DT the) (JJ same)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Renal) (NN clearance)) (PP (IN of) (NP (NN ucb) (NN L057))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug1)))))) (VP (VBD decreased) (NP (NP (CD 60) (NN %)) (, ,) (ADJP (RB probably) (JJ related) (PP (TO to) (NP (NP (JJ competitive) (NN inhibition)) (PP (IN of) (NP (NP (JJ tubular) (NN secretion)) (PP (IN of) (NP (JJ ucb) (NN L057))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN drug2)))) (VP (VBD was) (RB not) (VP (VBN studied)))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (CC or) (NP (NN drug2) (NN excess))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug3))))))) (, ,) (CC and) (S (NP (DT an) (NN drug4) (NN deficiency)) (VP (MD can) (VP (VB increase) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (NP (NN Serum) (NN concentration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB increase) (SBAR (WHADVP (WRB when)) (S (NP (NNS patients)) (VP (VBP take) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN decrease)) (PP (IN of) (NP (DT the) (NN dosage)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (SBAR (WHADVP (WRB when)) (S (NP (NN patient)) (VP (VBZ becomes) (ADJP (JJ euthyroid))))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (JJ thyroidal) (NN uptake)) (PP (IN of) (NP (NN drug2))))))) (, ,) (NP (NP (DT a) (NN rebound)) (PP (IN in) (NP (NN uptake)))) (VP (MD may) (VP (VB occur) (PP (RP up) (TO to) (NP (NP (CD 5) (NNS days)) (PP (IN after) (NP (NP (CD sudden) (NN withdrawal)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients) (NN response)) (PP (TO to) (NP (JJ oral) (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NP (JJ his/her) (NN thyroid)) (CC and) (NP (JJ metabolic) (NN status)))))))) (. .)))
(S1 (S (NP (NP (NP (DT An) (NN evaluation)) (PP (IN of) (NP (NN prothrombin) (NN time)))) (CC and) (NP (NP (DT an) (NN adjustment)) (PP (IN of) (NP (NN drug1) (NN dosage))))) (VP (VBP are) (VP (VBN recommended)))))
(S1 (S (S (NP (DT No) (NN information)) (VP (JJ available))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NP (JJ other) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))) (, ,) (SBAR (IN as) (S (NP (DT these) (NNS agents)) (VP (MD may) (VP (VB increase) (NP (ADJP (ADJP (JJ respiratory)) (CC and) (ADJP (JJ circulatory))) (NN depression)))))))))))))) (. .)))
(S1 (S (NP (NP (JJ CNS-Active) (NNS Drugs)) (: drug1) (S (NP (NP (DT An) (JJ additive) (NN effect)) (PP (IN on) (NP (NN psychomotor) (NN performance)))) (VP (VBD was) (VP (VBN seen) (PP (IN with) (NP (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug2)))) (CC and) (NP (NP (NN drug3) (CD 0.70) (NN g/kg)) (PP (IN for) (NP (NP (QP (RB up) (TO to) (CD 4)) (NNS hours)) (PP (IN after) (NP (NN drug4) (NN administration))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (JJ single) (NNS doses)) (PP (IN of) (NP (NP (NP (NN drug2) (CD 3) (NN mg)) (CC and) (NP (NN drug3) (CD 20) (NN mg))) (ADJP (JJ daily) (PP (IN for) (NP (CD 7) (NNS days))))))))) (VP (VBD produced) (NP (DT no) (ADJP (ADJP (JJ pharmacokinetic)) (CC or) (ADJP (JJ pharmacodynamic))) (NN interaction)))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (JJ single) (NNS doses)) (PP (IN of) (NP (NP (NN drug2) (CD 3) (NN mg)) (CC and) (NP (NN drug3) (CD 2) (NN mg))))))) (VP (VBD did) (RB not) (VP (VB have) (NP (ADJP (RB clinically) (JJ relevant)) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NP (NNS pharmacodynamics)) (CC or) (NP (NNS pharmacokinetics))) (PP (IN of) (NP (DT either) (NN drug)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug2) (CD 3) (NN mg)) (CC and) (NP (NN drug3) (CD 10) (NN mg))))) (VP (VBD produced) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN DSST) (NNS scores)))))) (. .))))
(S1 (S (S (NP (DT The) (NN interaction)) (VP (VBD was) (ADJP (JJ pharmacodynamic)))) (: ;)))
(S1 (S (S (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN alteration)) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN drug)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (VBP Inhibit) (NP (NN CYP3A4) (-LRB- -LRB-) (NN drug1) (-RRB- -RRB-) (NN CYP3A4)))))) (VP (VBZ is) (NP (NP (DT a) (JJ major) (JJ metabolic) (NN pathway)) (PP (IN for) (NP (NP (NN elimination)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN AUC)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN increased) (ADVP (RB 2.2-fold)) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4)))) (, ,) (NP (NP (CD 400) (NN mg)) (ADJP (JJ daily) (PP (IN for) (NP (CD 5) (NNS days))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Cmax)) (CC and) (NP (NN t1/2))) (VP (VBD were) (VP (VBN increased) (ADVP (ADVP (RB 1.4-fold)) (CC and) (ADVP (RB 1.3-fold))) (, ,) (ADVP (RB respectively))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Other) (JJ strong) (NNS inhibitors)) (PP (IN of) (NP (NN CYP3A4)))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-))) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VBP behave) (ADVP (RB similarly))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (VBP Induce) (NP (ADJP (NN CYP3A4) (-LRB- -LRB-) (NN drug1) (-RRB- -RRB-) (JJ Racemic)) (NN drug2) (NN exposure)))))) (VP (VBD was) (VP (VBN decreased) (NP (CD 80) (NN %)) (PP (IN by) (NP (NP (JJ concomitant) (NN useof) (NN drug3)) (, ,) (NP (NP (DT a) (JJ potent) (NN inducer)) (PP (IN of) (NP (NN CYP3A4))))))))) (. .)))
(S1 (S (S (NP (DT A) (JJ similar) (NN effect)) (VP (MD would) (VP (VB be) (VP (VBN expected) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (NP (NP (NNS Drugs)) (VP (ADVP (RB Highly)) (VBN Bound) (PP (TO To) (NP (NN Plasma) (NN Protein) (NN drug1))))) (VP (VBZ is) (RB not) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NN plasma) (NNS proteins))) (PRN (-LRB- -LRB-) (NP (NP (CD 52-59) (NN %)) (VP (VBD bound))) (-RRB- -RRB-)))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (DT the) (NN disposition)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB be) (ADJP (JJ sensitive) (PP (TO to) (NP (NP (NNS alterations)) (PP (IN in) (NP (NN protein) (NN binding)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1) (CD 3) (NN mg))) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG taking) (NP (NP (DT another) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (RB highly) (JJ protein-bound)))))))))) (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB cause) (NP (NP (DT an) (NN alteration)) (PP (IN in) (NP (NP (DT the) (JJ free) (NN concentration)) (PP (IN of) (NP (DT either) (NN drug))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Drugs)) (PP (IN With) (NP (DT A) (JJ Narrow) (JJ Therapeutic) (NN Index) (NN drug1)))) (NP (NP (DT A) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug2) (CD 3) (NN mg))))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug3)) (VP (VBN measured) (PP (IN at) (NP (JJ steady) (NN state))) (PP (VBG following) (NP (NP (NN dosing)) (PP (IN of) (NP (NP (NP (CD 0.5) (NN mg)) (ADJP (RB twice) (JJ daily) (PP (IN for) (NP (CD one) (NN day))))) (CC and) (NP (NP (CD 0.25) (NN mg)) (ADJP (JJ daily) (PP (IN for) (NP (DT the) (JJ next) (CD 6) (NNS days)))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2) (CD 3) (NN mg)) (VP (VBN administered) (ADVP (RB daily)) (PP (IN for) (NP (CD 5) (NNS days))))) (VP (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug3)) (: -) (CC or) (NP (NN drug4))))))) (, ,) (CC nor) (VP (VBD were) (ADVP (RB there)) (NP (NP (DT any) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ pharmacodynamic) (NN profile)) (PRN (-LRB- -LRB-) (NP (NN prothrombin) (NN time)) (-RRB- -RRB-)))) (PP (VBG following) (NP (NP (DT a) (JJ single) (CD 25) (NN mg) (JJ oral) (NN dose)) (PP (IN of) (NP (NN drug5))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (JJ Elevated) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (JJ concomitant) (NN drug2) (NN use))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (JJ drug1) (JJ -related) (JJ side) (NNS effects)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN monitoring)) (PP (IN of) (NP (NN drug1) (NN plasma) (NNS levels)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (CC and) (S (NP (NP (NN dosage)) (PP (IN of) (NP (NN drug2)))) (VP (VBN adjusted) (PP (IN as) (NP (VBN required)))))) (. .)))
(S1 (S (S (NP (NP (JJ Elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1) (NN serum) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored))))) (CC and) (S (NP (JJ appropriate) (NN drug2) (NN dosage) (NNS adjustments)) (VP (VBD made) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (PP (VBG including) (NP (NN drug2))) (, ,)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ oral) (NN drug3))) (, ,) (PP (VBG including) (NP (NP (NN drug4)) (CC or) (NP (NP (PRP$ its) (NNS derivatives)) (CC or) (NP (JJ similar) (NNS agents))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT these) (NNS products)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))) (, ,) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ suitable) (NN coagulation) (NNS tests))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (VBG including) (NP (NP (NN drug2)) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (DT a) (NN drug4)) (-RRB- -RRB-))))))) (VP (VBZ has) (, ,) (PP (IN on) (NP (JJ rare) (NNS occasions))) (, ,) (VP (VBD resulted) (PP (IN in) (NP (JJ severe) (NN hypoglycemia)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN monitoring)) (PP (IN of) (NP (NN blood) (NN glucose)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS agents)) (VP (VBP are) (NP (NN co-administered)))))))) (. .)))
(S1 (S (S (NP (NP (VBN Diminished) (JJ urinary) (NN excretion)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (IN since) (S (NP (NN drug2)) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (JJ antibacterial) (NN effect)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (DT the) (JJ urinary) (NN tract))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (, ,) (CC or) (NP (JJ other) (NNS products))) (VP (VBG containing) (NP (NP (NN drug2)) (CC or) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC or) (NP (NN drug5)))))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (PP (IN with)) (, ,) (CC or) (PP (IN within) (NP (NP (CD 2) (NNS hours) (IN of)) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug6))))))) (, ,) (SBAR (IN because) (S (NP (PRP they)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (NN absorption)) (VP (VBG resulting) (PP (IN in) (NP (NP (JJR lower) (NN serum) (CC and) (NN urine) (NNS levels)) (PP (IN of) (NP (NN drug7))))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-) (JJ chewable/buffered) (NNS tablets)) (CC or) (NP (DT the) (JJ pediatric) (NN powder))) (PP (IN for) (NP (JJ oral) (NN solution)))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (PP (IN with)) (, ,) (CC or) (PP (IN within) (NP (NP (NP (CD 2) (NNS hours)) (PP (IN of))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug3))))))) (, ,) (SBAR (IN because) (S (NP (DT these) (NNS products)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (NN absorption)) (VP (VBG resulting) (PP (IN in) (NP (NP (JJR lower) (NN serum) (CC and) (NN urine) (NNS levels)) (PP (IN of) (NP (NN drug4))))))))))))))) (. .)))
(S1 (S (S (NP (DT Some) (NNS drug1)) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NP (VBN reduced) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT a) (NN prolongation)) (PP (IN of) (NP (PRP$ its) (NN plasma) (NN half-life))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ pharmacokinetic-based) (JJ drug-drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (SBAR (IN because) (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN peptide)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADVP (RB primarily)) (VP (VBN degraded) (PP (PP (IN by) (NP (NN peptidase))) (CC and) (PP (RB not) (IN by) (NP (NP (NN cytochrome) (NN P-450)) (NNS enzymes))))))))))) (, ,) (CC and) (S (NP (DT the) (NN drug)) (VP (VBZ is) (ADVP (RB only)) (NP (NP (QP (RB about) (CD 80)) (NN %)) (VP (VBD bound) (PP (TO to) (NP (NN plasma) (NNS proteins))) (PP (IN at) (NP (CD 4) (NN C))))))))) (, ,) (NP (NN drug) (NNS interactions)) (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB occur))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS Reports)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN interaction)) (VP (MD should) (VP (VB be) (VP (VBN given) (NP (NP (NN consideration)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)))))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ has) (NP (DT no) (JJ apparent) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (NN absorption)) (PP (IN of) (NP (NN drug3))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN drug1)) (VP (MD can) (VP (VP (VB decrease) (NP (NP (DT the) (JJ peak) (NN concentration)) (VP (VBN reached) (PP (IN by) (NP (QP (CD 15) (NN %) (TO to) (CD 20)) (NN %)))))) (CC but) (VP (VB have) (NP (DT no) (JJ detectable) (NN effect)) (PP (IN on) (NP (DT the) (NN time-to-peak))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NN drug3))))))) (, ,) (NP (PRP$ its) (NN protein) (NN binding)) (VP (VBZ is) (VP (VBN reduced)) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (JJ free) (NNS drug4)))) (VP (VBZ is) (RB not) (VP (VBN altered))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN interaction)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (PP (IN as) (PP (IN with) (NP (JJ other) (NN drug1)))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ is) (RB not) (ADVP (RB generally)) (VP (VBN recommended) (PP (IN because) (IN of) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (VBN increased) (JJ adverse) (NNS effects)))))))) (. .)))
(S1 (S (S (NP (NP (NN Cyclosporine)) (, ,) (NP (NN Digoxin)) (, ,) (NP (NN Methotrexate) (NN drug1)) (, ,)) (PP (IN like) (NP (JJ other) (NN drug2))) (, ,) (PP (IN through) (NP (NP (NNS effects)) (PP (IN on) (NP (JJ renal) (NNS prostaglandins))))) (, ,) (VP (MD may) (VP (VB cause) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NP (DT these) (NNS drugs)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (VBN increased) (NN toxicity))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Nephrotoxicity)) (VP (VBN associated) (PP (IN with) (NP (NN drug1))))) (VP (MD may) (ADVP (RB also)) (VP (VB be) (VP (VBN enhanced))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NP (DT these) (NNS drugs)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBN given) (NP (NN drug1))))))) (, ,) (CC or) (NP (DT any) (JJ other) (NNS drug2))))) (, ,) (CONJP (CC and) (RB particularly)) (NP (NP (DT those) (NNS patients)) (PP (IN with) (NP (JJ altered) (JJ renal) (NN function)))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN observed) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (DT the) (JJ specific) (NNS toxicities)) (PP (IN of) (NP (DT these) (NNS drugs))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN Etodolac))) (VP (VBZ has) (NP (DT no) (JJ apparent) (JJ pharmacokinetic) (NN interaction)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (NP (NP (JJ clinical) (NNS studies)) (, ,) (CONJP (RB as) (RB well) (IN as)) (VP (VBG postmarketing) (NP (NNS observations)))) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (JJ natriuretic) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN in) (NP (DT some) (NNS patients))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN response)) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ renal) (NN prostaglandin) (NN synthesis))))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NN drug1))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (JJ renal) (NN failure))))) (, ,) (S (CONJP (RB as) (RB well) (IN as)) (VP (TO to) (VP (VB assure) (NP (JJ diuretic) (NN efficacy))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ has) (NP (DT no) (JJ apparent) (JJ pharmacokinetic) (NN interaction)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP have) (VP (VBN produced) (NP (NP (NP (DT an) (NN elevation)) (PP (IN of) (NP (NN plasma) (NN drug3) (NNS levels)))) (CC and) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (JJ renal) (NN drug4) (NN clearance)))))))) (. .)))
(S1 (S (S (S (NP (DT The) (JJ mean) (JJ minimum) (NN drug1) (NN concentration)) (VP (VBD increased) (NP (CD 15) (NN %)))) (CC and) (S (NP (DT the) (JJ renal) (NN clearance)) (VP (VBD was) (VP (VBN decreased) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (VBP have) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ renal) (NN prostaglandin) (NN synthesis))) (PP (IN by) (NP (DT the) (NN drug1))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concurrently)))))) (, ,) (NP (NNS subjects)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB carefully)) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NN drug3) (NN toxicity))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ causes) (NP (NP (NN increase)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (RB about) (CD 80)) (NN %))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (JJ free) (NN fraction)) (PP (IN of) (NP (NN drug3))))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (ADJP (FW in) (FW vivo)) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN done) (S (VP (TO to) (VP (VB see) (SBAR (IN if) (S (NP (NN drug1) (NN clearance)) (VP (VBZ is) (VP (VBN changed) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NNS drug2))))))))))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (IN that) (S (NP (PRP they)) (VP (VB be) (VP (VBN coadministered)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ has) (NP (DT no) (JJ apparent) (JJ pharmacokinetic) (NN interaction)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NN drug3)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN on) (NP (JJ GI) (JJ bleeding)))) (VP (VBP are) (ADJP (JJ synergistic)) (, ,) (SBAR (JJ such) (IN that) (S (NP (NP (NNS users)) (PP (IN of) (NP (DT both) (NNS drugs)))) (ADVP (RB together)) (VP (VBP have) (NP (NP (DT a) (NN risk)) (PP (IN of) (NP (JJ serious) (JJ GI) (JJ bleeding))) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NP (NNS users)) (PP (IN of) (NP (NP (DT either) (NN drug)) (ADVP (RB alone))))))))))))))) (. .))))
(S1 (S (S (S (NP (JJ Short-term) (JJ pharmacokinetic) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (NNS drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3) (NNS capsules)) (CC and) (NP (NNS tablets))) (-RRB- -RRB-)))))) (VP (VBZ results) (PP (IN in) (NP (NP (VBN reduced) (NN protein) (NN binding)) (PP (IN of) (NP (NN drug4))))))))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (JJ free) (NN drug5))))))))) (. .)))
(S1 (S (S (S (NP (EX There)) (VP (VBD was) (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (DT the) (JJ pharmacodynamic) (NN effect)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN administered) (ADVP (RB alone))))))))) (CC and) (S (NP (NN drug2)) (VP (VBN administered) (PP (IN with) (NP (NN drug3))) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NN prothrombin) (NN time))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD should) (RB not) (VP (VBP require) (NP (NP (JJ dosage) (NN adjustment)) (PP (IN of) (NP (DT either) (NN drug))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (IN because) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (DT a) (JJ few) (JJ spontaneous) (NNS reports)) (PP (IN of) (NP (JJ prolonged) (NN prothrombin) (NNS times)))) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ bleeding)))) (, ,) (PP (IN in) (NP (NP (JJ drug1) (JJ -treated) (NNS patients)) (VP (VBG receiving) (NP (JJ concomitant) (NN drug2) (NN therapy))))))))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (NP (NP (DT The) (NN urine)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP take) (NP (NN drug1))))))))) (VP (MD can) (VP (VBP give) (NP (NP (DT a) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NP (JJ urinary) (NN bilirubin)) (PRN (-LRB- -LRB-) (NP (NN urobilin)) (-RRB- -RRB-))))) (PP (JJ due) (TO to) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ phenolic) (NNS metabolites)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Diagnostic) (JJ dip-stick) (NN methodology)) (, ,) (VP (VBN used) (S (VP (TO to) (VP (VB detect) (NP (NN ketone) (NNS bodies)) (PP (IN in) (NP (NN urine))))))) (, ,)) (VP (VBZ has) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ false-positive) (NNS findings)) (PP (IN in) (NP (NP (DT some) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))))))))) (. .)))
(S1 (S (S (ADVP (RB Generally)) (, ,) (NP (DT this) (NN phenomenon)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (JJ other) (ADJP (RB clinically) (JJ significant)) (NNS events))))))) (. .)))
(S1 (S (S (NP (DT No) (NN dose) (NN relationship)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN treatment)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ small) (NN decrease)) (PP (IN in) (NP (NN serum) (JJ uric) (NN acid) (NNS levels)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NP (JJ mean) (NNS decreases)) (PP (IN of) (NP (QP (CD 1) (TO to) (CD 2)) (NN mg/dL)))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (JJ arthritic) (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 600) (NN mg) (TO to) (CD 1000) (NN mg/day)) (-RRB- -RRB-))) (PP (IN after) (NP (NP (CD 4) (NNS weeks)) (PP (IN of) (NP (NN therapy))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS levels)) (ADVP (RB then)) (VP (VBD remained) (ADJP (JJ stable)) (PP (IN for) (NP (NP (QP (RB up) (TO to) (CD 1)) (NN year)) (PP (IN of) (NP (NN therapy))))))) (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (JJ Drug-drug) (NNS interactions)) (PP (IN with) (NP (NN drug1)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN explored) (PP (IN in) (NP (NN detail))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (CD one) (NN report)) (PP (IN of) (NP (NN cardiopulmonary) (NN arrest)))) (, ,) (PP (IN with) (NP (JJ full) (NN recovery))) (, ,) (PP (IN in) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD was) (VP (VBG taking) (NP (NP (DT a) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN Mefloquineuine))) (PP (IN on) (NP (DT the) (VBN compromised) (JJ cardiovascular) (NN system)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS benefits)) (PP (IN of) (NP (NN drug1) (NN therapy)))) (VP (MD should) (VP (VB be) (VP (VBN weighed) (PP (IN against) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (JJ adverse) (NNS effects)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ cardiac) (NN disease))))))))))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (NN danger)) (PP (IN of) (NP (NP (DT a) (ADJP (RB potentially) (JJ fatal)) (NN prolongation)) (PP (IN of) (NP (DT the) (NN QTc) (NN interval)))))))) (, ,) (NP (NN drug1)) (VP (MD must) (RB not) (VP (VB be) (VP (VBN given) (ADVP (RB simultaneously)) (PP (IN with) (NP (NP (NN or)) (ADJP (JJ subsequent) (PP (TO to) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (JJ other) (JJ related) (NNS compounds)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4))) (-RRB- -RRB-)))))) (VP (MD may) (VP (VP (VB produce) (NP (JJ electrocardiographic) (NNS abnormalities))) (CC and) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNS convulsions)))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (S (VP (TO to) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (JJ initial) (NN treatment)) (PP (IN of) (NP (JJ severe) (NN malaria)))))))))))) (, ,) (NP (NN drug1) (NN administration)) (VP (MD should) (VP (VB be) (VP (VBN delayed) (PP (NP (QP (IN at) (JJS least) (CD 12)) (NNS hours)) (IN after) (NP (DT the) (JJ last) (NN dose))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN after) (NP (NN Mefloquineuine)))) (VP (VBZ causes) (NP (NP (DT a) (JJ significant) (NN lengthening)) (PP (IN of) (NP (DT the) (NN QTc) (NN interval)))))))))) (. .)))
(S1 (S (S (NP (ADJP (RB Clinically) (JJ significant)) (NN QTc) (NN prolongation)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN found) (PP (IN with) (NP (NP (NN Mefloquineuine)) (ADVP (RB alone)))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (ADJP (RB only) (RB clinically) (JJ relevant)) (NN interaction)) (PP (IN of) (NP (DT this) (NN kind))) (PP (IN with) (NP (NN drug1))))))) (, ,) (SBAR (IN although) (S (ADVP (RB theoretically)) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB alter) (NP (JJ cardiac) (NN conduction)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug2)) (CC or) (NP (NN drug3))) (, ,) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC or) (NP (NN drug6))) (, ,) (NP (NP (NN drug7)) (CC and) (NP (NN drug8))) (-RRB- -RRB-))))))))) (VP (MD might) (ADVP (RB also)) (VP (VB contribute) (PP (TO to) (NP (NP (DT a) (NN prolongation)) (PP (IN of) (NP (DT the) (NN QTc) (NN interval))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (NNS data)) (SBAR (WHNP (WDT that)) (S (ADVP (RB conclusively)) (VP (VBP establish) (SBAR (IN whether) (S (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN Mefloquineuine)) (CC and) (NP (DT the) (JJ above) (JJ listed) (NNS agents))))) (VP (VBZ has) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (JJ cardiac) (NN function))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (DT an) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC or) (NP (NN drug5))) (-RRB- -RRB-)))))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug6)))) (VP (MD may) (VP (VB reduce) (NP (NN seizure) (NN control)) (PP (IN by) (S (VP (VBG lowering) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (DT the) (NN drug7)))))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS patients)) (VP (ADVP (RB concurrently)) (VBG taking) (NP (NP (NN antiseizure) (NN medication)) (CC and) (NP (NN drug1))))) (VP (MD should) (VP (VBP have) (NP (NP (DT the) (NN blood) (NN level)) (PP (IN of) (NP (NP (NP (PRP$ their) (JJ antiseizure) (NN medication)) (VP (VBN monitored))) (CC and) (NP (NP (DT the) (NN dosage)) (VP (VBN adjusted) (ADVP (RB appropriately))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN taken) (ADVP (RB concurrently)) (PP (IN with) (NP (JJ oral) (NN drug2))))))) (, ,) (NP (NP (NN attenuation)) (PP (IN of) (NP (NN immunization)))) (VP (MD cannot) (VP (VB be) (VP (VBN excluded))))) (. .)))
(S1 (S (S (NP (NP (NNS Vaccinations)) (PP (IN with) (NP (VBN attenuated) (JJ live) (NNS bacteria)))) (VP (MD should) (ADVP (RB therefore)) (VP (VB be) (VP (VBN completed) (NP (QP (IN at) (JJS least) (CD 3)) (NNS days)) (PP (IN before) (NP (NP (DT the) (JJ first) (NN dose)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ other) (NN drug) (NNS interactions)) (VP (VBP are) (VP (VBN known)))) (. .)))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NNS travelers)) (VP (VBG receiving) (NP (NP (NN comedication)) (, ,) (NP (ADVP (RB particularly)) (NP (NP (NNS diabetics)) (CC or) (NP (NP (NNS patients)) (VP (VBG using) (NP (NN drug2)))))) (, ,)))))) (VP (MD should) (VP (VB be) (VP (VBN checked) (PP (IN before) (NP (NN departure))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (DT the) (JJ adverse) (NN reaction) (NN profile))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NP (DT a) (JJ potential) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (NNS concentrates))))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB adequately)) (VP (VBN evaluated) (PP (IN in) (NP (ADJP (ADJP (JJ preclinical)) (CC or) (ADJP (JJ clinical))) (NNS studies))))))) (. .)))
(S1 (S (S (NP (NP (JJ Simultaneous) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (DT the) (JJ specific) (NN drug) (NN interaction)) (VP (VBD was) (RB not) (VP (VBN studied) (PP (IN in) (NP (DT a) (JJ clinical) (NN trial))))))) (, ,) (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (QP (JJR more) (IN than) (CD 50)) (NNS episodes)) (PP (IN of) (NP (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (JJ antifibrinolytic) (NNS therapies)) (PRN (-LRB- -LRB-) (PP (FW i.e.) (, ,) (NP (NN drug1))) (, ,) (NP (NNS drug2)) (-RRB- -RRB-))))) (CC and) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN mixed) (PP (IN with) (NP (NN infusion) (NNS solutions))) (SBAR (IN until) (S (NP (JJ clinical) (NNS data)) (VP (VBP are) (ADJP (JJ available) (S (VP (TO to) (VP (VB direct) (NP (DT this) (NN use))))))))))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB together)))))) (, ,) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (NP (NN atropinization)) (PRN (-LRB- -LRB-) (NP (NP (NN flushing)) (, ,) (NP (NN mydriasis)) (, ,) (NP (NN tachycardia)) (, ,) (NP (NP (NN dryness)) (PP (IN of) (NP (DT the) (NN mouth)))) (CC and) (NP (NN nose))) (-RRB- -RRB-))))) (VP (MD may) (VP (VB occur) (ADVP (RBR earlier)) (PP (IN than) (S (VP (MD might) (VP (VB be) (VP (VBN expected) (PP (IN than) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN used) (ADVP (RB alone)) (SBAR (IN because) (S (NP (NN drug4)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug5)))))))))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (NNS precautions)) (VP (MD should) (VP (VB be) (VP (VBN kept) (PP (IN in) (NP (NN mind))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN anticholinesterase) (NN poisoning))))) (SBAR (IN although) (S (NP (PRP they)) (VP (VBP do) (RB not) (VP (VB bear) (ADVP (RB directly)) (PP (IN on) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBP are) (VP (VBN potentiated) (PP (IN by) (NP (DT the) (NN drug2))))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNS convulsions))))))))) (. .)))
(S1 (S (S (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))) (: :) (S (NP (NP (DT The) (JJ biochemical) (NN activity)) (PP (IN of) (NP (NP (DT the) (NN drug) (NN metabolizing) (NN isozyme) (NN cytochrome) (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NN debrisoquin) (NN hydroxylase)) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN reduced) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (DT the) (NN Caucasian) (NN population))))) (PRN (-LRB- -LRB-) (S (NP (NP (QP (RB about) (CD 7-10)) (NN %)) (PP (IN of) (NP (NNS Caucasians)))) (VP (VBP are) (NP (JJ so-called) (JJ poor) (NNS metabolizers)))) (-RRB- -RRB-))))) (: ;)))
(S1 (S (S (NP (NP (JJ reliable) (NNS estimates)) (PP (IN of) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (VBN reduced) (NN P450) (NN 2D6) (NN isozyme) (NN activity))) (PP (IN among) (NP (ADJP (ADJP (JJ Asian)) (, ,) (ADJP (JJ African)) (CC and) (ADJP (JJ other))) (NNS populations)))))) (VP (VBP are) (RB not) (ADVP (RB yet)) (ADJP (JJ available)))) (. .)))
(S1 (S (S (NP (JJ Poor) (NNS metabolizers)) (VP (VBP have) (NP (NP (JJR higher) (IN than) (VBN expected) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (JJ usual) (NNS doses))))))) (. .)))
(S1 (S (S (PP (VBG Depending) (PP (IN on) (NP (NP (DT the) (NN fraction)) (PP (IN of) (NP (NP (NN drug)) (VP (VBN metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))))))) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN plasma) (NN concentration)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (JJ small)) (, ,) (CC or) (RB quite) (ADJP (ADJP (JJ large)) (PRN (-LRB- -LRB-) (NP (NP (JJ 8-fold) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NN AUC)) (PP (IN of) (NP (DT the) (NN TCA)))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ certain) (NNS drugs)) (VP (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT this) (NN isozyme))))) (CC and) (VP (VB make) (NP (JJ normal) (NNS metabolizers)))) (VP (VBP resemble) (NP (JJ poor) (NNS metabolizers)))) (. .)))
(S1 (S (S (NP (NP (DT An) (JJ individual)) (SBAR (WHNP (WP who)) (S (VP (VBZ is) (ADJP (JJ stable) (PP (IN on) (NP (NP (DT a) (JJ given) (NN dose)) (PP (IN of) (NP (NN drug1)))))))))) (VP (MD may) (VP (VB become) (ADJP (RB abruptly) (JJ toxic)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT these) (JJ inhibiting) (NNS drugs)) (PP (IN as) (NP (JJ concomitant) (NN therapy)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6)))))) (VP (VBP include) (NP (NP (DT some)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN enzyme) (-LRB- -LRB-) (NN drug1)))))))))) (: ;)))
(S1 (S (NP (NP (NP (NNP drug1) (-RRB- -RRB-)) (CC and) (NP (NP (JJ many)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN for) (NP (NP (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NP (JJ many) (JJ other) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NP (DT the) (NN drug4) (NN drug5)) (CC and) (NP (NN drug6)))) (-RRB- -RRB-)))))))))) (. .))))
(S1 (S (S (SBAR (IN While) (S (NP (NP (NP (PDT all) (DT the) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7)))) (, ,)) (VP (VBP inhibit) (NP (NN P450) (NN 2D6))))) (, ,) (NP (PRP they)) (VP (MD may) (VP (VB vary) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN inhibition)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN extent)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (NNS interactions)) (VP (MD may) (VP (VBP pose) (NP (JJ clinical) (NNS problems))))))) (VP (MD will) (VP (VB depend) (PP (IN on) (NP (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN inhibition)))) (CC and) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT the) (NN drug3)) (VP (VBN involved)))))))))) (. .)))
(S1 (S (ADVP (RB Nevertheless)) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN indicated) (PP (PP (IN in) (NP (NP (DT the) (NN co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NN drug2))))))) (CC and) (ADVP (RB also)) (PP (IN in) (NP (NP (NN switching)) (PP (IN from) (NP (CD one) (NN class))) (PP (TO to) (NP (DT the) (JJ other)))))))) (. .)))
(S1 (S (PP (IN Of) (NP (JJ particular) (NN importance))) (, ,) (NP (JJ sufficient) (NN time)) (VP (MD must) (VP (VB elapse) (PP (IN before) (S (VP (VBG initiating) (NP (NN TCA) (NN treatment)) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG being) (VP (VBN withdrawn) (PP (IN from) (NP (NP (NP (NN drug1)) (, ,) (VP (VBN given) (NP (NP (DT the) (JJ long) (NN half-life)) (PP (IN of) (NP (DT the) (NN parent)))))) (CC and) (NP (NP (JJ active) (NN metabolite)) (PRN (-LRB- -LRB-) (NP (NP (QP (IN at) (JJS least) (CD 5)) (NNS weeks)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6))))))))) (VP (MD may) (VP (VB require) (NP (NP (JJR lower) (NNS doses)) (VP (ADVP (IN than) (RB usually)) (VBN prescribed) (PP (IN for) (NP (CC either) (NP (DT the) (NN drug2)) (CC or) (NP (DT the) (JJ other) (NN drug))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (S (ADVP (RB whenever)) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (JJ other) (NNS drugs)))) (VP (VBZ is) (VP (VBN withdrawn) (PP (IN from) (NP (NN co-therapy)))))) (, ,) (NP (NP (DT an) (VBN increased) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ desirable)) (S (VP (TO to) (VP (VB monitor) (NP (NN drug1) (NN plasma) (NNS levels)) (S (ADVP (RB whenever)) (NP (DT a) (NN drug2)) (VP (VBZ is) (ADJP (JJ going) (S (VP (TO to) (VP (VB be) (VP (VBN co-administered) (PP (IN with) (NP (NP (DT another) (NN drug)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN P450) (NN 2D6)))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB primarily)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN CYP2D6)) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NP (NN CYP1A2)) (CC and) (NP (NN CYP3A4)))) (PP (IN as) (NP (JJ minor) (NNS pathways))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Inhibitors)) (CC or) (NP (NNS substrates))) (PP (IN of) (NP (NP (NN CYP2D6)) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2) (-LRB- -LSB-) (CD drug3) (-RRB- -RSB-))) (-RRB- -RRB-))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug4)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NN interaction)))) (VP (VBZ depends) (PP (IN on) (NP (NP (DT the) (NN variability)) (PP (IN of) (NP (NN effect))) (PP (IN on) (NP (NN CYP2D6))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (NP (DT this) (NN interaction)) (PP (IN with) (NP (NN drug1)))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB systematically)) (VP (VBN evaluated))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Serious) (JJ side) (NNS effects)) (CC and) (NP (JJ even) (NN death))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (VBG following) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (JJ certain) (NNS drugs)) (PP (IN with) (NP (NN drug2))))))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (NP (NP (QP (IN at) (JJS least) (CD two)) (NNS weeks)) (ADJP (JJ prior) (PP (TO to) (NP (NP (DT the) (JJ cautious) (NN initiation)) (PP (IN of) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ exact) (NN length)) (PP (IN of) (NP (NN time)))) (VP (VP (MD may) (VP (VB vary))) (CC and) (VP (VBZ is) (ADJP (JJ dependent) (PP (IN upon) (NP (NP (NP (DT the) (JJ particular) (NN drug1)) (VP (VBG being) (VP (VBN used)))) (, ,) (NP (NP (DT the) (NN length)) (PP (IN of) (NP (NN time))) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered)))))) (, ,) (CC and) (NP (NP (DT the) (NN dosage)) (VP (VBN involved))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB produce) (NP (NP (ADJP (RB clinically) (JJ significant)) (NNS fluctuations)) (PP (IN in) (NP (NP (JJ steady-state) (NN serum) (NNS concentrations)) (PP (IN of) (NP (JJ various) (NNS drug3))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Serious) (JJ anticholinergic) (NNS symptoms)) (PRN (-LRB- -LRB-) (PP (FW i.e.) (, ,) (NP (NP (JJ severe) (JJ dry) (NN mouth)) (, ,) (NP (JJ urinary) (NN retention)) (CC and) (NP (JJ blurred) (NN vision)))) (-RRB- -RRB-))) (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NNS elevations)) (PP (IN in) (NP (NP (DT the) (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug1))))))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2) (NN therapy)) (VP (VBZ is) (VP (VBN initiated))))))))) (. .)))
(S1 (S (S (ADVP (RB Additionally)) (, ,) (NP (JJR higher) (IN than) (VBN expected) (NN drug1) (NNS levels)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (PRP they)) (VP (VBP are) (VP (VBN begun) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB already)) (VBG taking) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (ADVP (RB well)) (VP (VBN controlled) (PP (IN on) (NP (NP (NN drug1)) (VP (VBG receiving) (NP (JJ concurrent) (NN drug2) (NN therapy)))))))))))))))) (, ,) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN drug3)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VP (VB decrease) (NP (JJ established) (JJ steady-state) (NN serum) (NN drug4) (NNS levels))) (CC and) (VP (VB compromise) (NP (PRP$ their) (JJ therapeutic) (NNS effects)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (PRP It)) (VP (MD should) (VP (VB be) (VP (VBN borne) (PP (IN in) (NP (NN mind))) (SBAR (IN that) (S (NP (NN drug2) (NN ingestion)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN danger)) (ADJP (JJ inherent) (PP (IN in) (NP (DT any) (ADJP (ADJP (JJ intentional)) (CC or) (ADJP (JJ unintentional))) (NN drug3) (NN overdosage))))))))))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (VBZ is) (ADJP (RB especially) (JJ important) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (MD may) (VP (VB use) (NP (NN drug1)) (ADVP (RB excessively))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ severe) (NN hypoglycemia)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (DT a) (NN type) (CD II) (JJ diabetic) (NN patient)) (VP (VBN maintained) (PP (IN on) (NP (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN gm/day)) (-RRB- -RRB-))) (CD 11) (NNS days)) (PP (IN after) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 75) (NN mg/day)) (-RRB- -RRB-))))))))))))))) (. .))))
(S1 (S (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2))))))))) (. .)) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT no) (JJ specific) (NN drug) (NNS interactions)) (PP (IN with) (NP (NP (JJ topical) (NN glaucoma) (NNS drugs)) (CC or) (NP (JJ systemic) (NNS medications))))) (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (NP (JJ clinical) (NNS studies)) (PP (IN of) (NP (JJ drug1) (ADJP (CD 0.5) (NN %)) (JJ Ophthalmic) (NN Solution))))))))) (, ,) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (DT an) (JJ additive) (NN or) (NN potentiating) (NN effect)) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7))) (-RRB- -RRB-))))))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB blunt) (NP (NP (DT the) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (JJ systemic) (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (NP (DT the) (JJ concurrent) (NN use)) (PP (IN of) (NP (DT these) (NNS agents))) (PP (IN with) (NP (NN drug1)))) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN IOP) (JJ lowering) (NN effect)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NNS data)) (PP (IN on) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ circulating) (NNS catecholamines))) (PP (IN after) (NP (NN drug1) (NN withdrawal)))))) (VP (VBP are) (ADJP (JJ available)))) (. .)))
(S1 (S (S (NP (NN Caution)) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ is) (VP (VBN advised) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NN drug1)) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB affect) (NP (NP (DT the) (NP (NN metabolism)) (CC and) (NP (NN uptake))) (PP (IN of) (NP (VBG circulating) (NNS amines))))))))))))))) (. .)))
(S1 (S (S (NP (DT An) (JJ additive) (JJ hypotensive) (NN effect)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (JJ systemic) (NN drug1)) (CC and) (NP (JJ drug2) (NN therapy)))))))))) (. .)))
(S1 (S (S (NP (JJ Systemic) (NN drug1)) (VP (MD may) (VP (VP (VB inhibit) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NNS catecholamines))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (JJ insulin-induced) (NN hypoglycemia))))))) (CC and) (VP (VB mask) (NP (NP (DT the) (NP (NNS signs)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NN hypoglycemia)))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (MD may) (VP (VB reduce) (NP (NN pulse) (CC and) (NN blood) (NN pressure)))))) (, ,) (NP (NP (NN caution)) (PP (IN in) (S (VP (VBG using) (NP (NP (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ ophthalmic)) (CC and) (ADJP (JJ systemic))) (-RRB- -RRB-))) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))))))))) (VP (VBZ is) (ADJP (JJ advised)))) (. .)))
(S1 (S (NP (NP (NNS Patients)) (VP (VBG using) (NP (NP (JJ cardiovascular) (NNS drugs)) (PP (ADVP (RB concurrently)) (IN with) (NP (JJ drug1) (ADJP (CD 0.5) (NN %)) (JJ Ophthalmic) (NN Solution)))))) (VP (MD should) (VP (VB have) (S (NP (NP (NN pulse)) (CC and) (NP (NN blood) (NNS pressures))) (VP (ADVP (RB frequently)) (VBN monitored))))) (. .)))
(S1 (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (PP (IN with) (NP (NP (NP (JJ simultaneous) (NN use)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (JJ other) (JJ similar) (JJ pharmacologic) (NNS agents)))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NP (ADJP (ADJP (JJ Immediate)) (CC and) (ADJP (JJ Extended))) (NN Release) (NNS Tablets)) (S (NP (NP (DT The) (JJ hypoglycemic) (NN action)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NP (JJ certain) (NNS drugs)) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NP (NP (DT some) (NN drug3)) (CC and) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB highly)) (VP (NN protein) (VBN bound)))))) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC and) (NP (NN drug10)))))))))) (. .))))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NN hypoglycemia))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN withdrawn) (PP (IN from) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (NN control))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NN binding) (NNS studies)) (PP (IN with) (NP (JJ human) (NN serum) (NNS proteins)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VP (VBZ binds) (ADVP (RB differently)) (PP (IN than) (NP (NN drug2)))) (CC and) (VP (VBZ does) (RB not) (VP (VB interact) (PP (IN with) (NP (NP (NN drug3)) (CC or) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN caution)) (VP (MD must) (VP (VB be) (VP (VBN exercised) (PP (PP (IN in) (S (VP (VBG extrapolating) (NP (DT these) (NNS findings)) (PP (TO to) (NP (DT the) (JJ clinical) (NN situation)))))) (CC and) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (DT these) (NNS drugs)))))))))) (. .)))
(S1 (S (S (NP (JJ Certain) (NNS drugs)) (VP (VBP tend) (S (VP (VP (TO to) (VP (VB produce) (NP (NN hyperglycemia)))) (CC and) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NN loss)) (PP (IN of) (NP (NN control))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS drugs)) (VP (VBP include) (NP (NP (NP (DT the) (NN drug1)) (CC and) (NP (JJ other) (NNS drug2))) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (JJ oral) (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (CC and) (NP (NN drug12)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN observed) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (NN control))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN withdrawn) (PP (IN from) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NN hypoglycemia))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ potential) (NN interaction)) (PP (IN between) (NP (NP (NP (JJ oral) (NN drug1)) (CC and) (NP (JJ oral) (NN drug2))) (VP (VBG leading) (PP (TO to) (NP (JJ severe) (NN hypoglycemia))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (SBAR (IN Whether) (S (NP (DT this) (NN interaction)) (ADVP (RB also)) (VP (VBZ occurs) (PP (IN with) (NP (NP (DT the) (ADJP (ADJP (JJ intravenous)) (, ,) (ADJP (JJ topical)) (, ,) (CC or) (ADJP (JJ vaginal))) (NNS preparations)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (PP (IN in) (NP (NP (DT a) (JJ placebo-controlled) (NN crossover) (NN study)) (PP (IN in) (NP (JJ normal) (NNS volunteers))))))))) (. .)))
(S1 (S (S (NP (DT All) (NNS subjects)) (VP (VBD received) (NP (NP (NP (NN drug1)) (ADVP (RB alone))) (CC and) (NP (NP (VBG following) (NN treatment)) (PP (IN with) (NP (NP (CD 100) (NN mg)) (PP (IN of) (NP (NN drug2))))))) (PP (IN as) (NP (NP (DT a) (JJ single) (JJ daily) (JJ oral) (NN dose)) (PP (IN for) (NP (CD seven) (NNS days))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ mean) (NN percentage) (NN increase)) (PP (IN in) (NP (DT the) (NN drug1) (NN AUC))) (PP (IN after) (NP (NN drug2) (NN administration)))) (VP (VBD was) (NP (NP (CD 56.9) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (: :) (NP (CD 35) (TO to) (CD 81))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (JJ Intravenous) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (ADVP (RB effectively)) (VP (VBN administered) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ other) (JJ cardioactive) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)))))))) (, ,) (PP (IN without) (NP (NP (DT any) (NN change)) (PP (IN in) (NP (DT the) (JJ adverse) (NN reaction) (NN profile))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (NN use))) (VP (MD may) (VP (VB be) (ADVP (RB rarely)) (VP (VBN associated) (PP (IN with) (NP (JJ ventricular) (NN fibrillation))) (SBAR (WHADVP (WRB when)) (S (VP (VBN combined) (PP (IN with) (NP (NN drug3)))))))))) (. .)))
(S1 (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (ADJP (ADJP (JJ additive)) (CC or) (ADJP (JJ synergistic))) (NN depressant) (NNS effects)) (PP (IN on) (NP (DT the) (NN SA) (CC and) (NN AV) (NNS nodes)))))))) (, ,) (ADVP (RB however)) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT these) (NNS agents)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)))))) (VP (MD may) (VP (VB be) (ADVP (RB rarely)) (VP (VBN associated) (PP (IN with) (NP (JJ ventricular) (NN fibrillation))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (VP (VBN antagonized) (PP (IN by) (NP (NP (NNS drug2)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT these) (NN drug1))))) (, ,) (S (NP (NP (JJR larger) (NNS doses)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (CC or) (S (NP (NN drug3)) (VP (MD may) (RB not) (VP (VB be) (ADJP (JJ effective)))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS effects)) (VP (VBP are) (VP (VBN potentiated) (PP (IN by) (NP (NN drug2)))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (JJR smaller) (NNS doses)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ effective) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NN heart) (NN block)) (VP (VBN produced) (PP (IN by) (NP (JJ other) (NNS agents)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN As) (S (NP (NP (DT the) (JJ primary) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (S (VP (TO to) (VP (VB decrease) (NP (NN conduction)) (PP (IN through) (NP (DT the) (NN A-V) (NN node))))))))) (, ,) (NP (NP (JJR higher) (NNS degrees)) (PP (IN of) (NP (NN heart) (NN block)))) (VP (MD may) (VP (VB be) (VP (VBN produced) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ potentiates) (NP (NP (DT the) (NN muscle) (JJ relaxant) (NN effect)) (PP (IN of) (NP (NP (DT all) (NNS drug2)) (, ,) (ADVP (RBS most) (RB notably)) (NP (NN drug3))))))) (, ,) (CC and) (S (NP (NP (NN MAC)) (PRN (-LRB- -LRB-) (NP (JJ minimum) (JJ alveolar) (NN concentration)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN reduced) (PP (IN by) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN N) (NN 2O))))))))) (. .)))
(S1 (S (S (VP (VB See) (NP (JJ CLINICAL) (NN PHARMACOLOGY)))) (. .)))
(S1 (S (S (NP (NP (JJ Oral) (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 10-20) (NN mg/kg)) (-RRB- -RRB-)))) (, ,) (PP (IN via) (NP (NP (NN alcohol) (NN dehydrogenase)) (NN inhibition))) (, ,)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (NN elimination)) (PP (IN of) (NP (NN drug2))))) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (RB approximately) (CD 40)) (NN %))) (-RRB- -RRB-)) (VP (VBN given) (PP (TO to) (NP (NP (JJ healthy) (NNS volunteers)) (PP (IN in) (NP (JJ moderate) (NNS doses))))))))) (. .)))
(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (NN drug1)) (VP (VBD decreased) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (NN elimination)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (RB approximately) (CD 50)) (NN %))) (-RRB- -RRB-))))))) (PP (IN by) (NP (DT the) (JJ same) (NN mechanism))))) (. .)))
(S1 (S (S (NP (JJ Reciprocal) (NNS interactions)) (VP (MD may) (VP (VB occur) (PP (IN with) (NP (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VP (VBP increase)) (CC or) (VP (VBP inhibit) (NP (DT the) (NN cytochrome) (NN P450) (NN system)))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5))) (-RRB- -RRB-))))))))))) (, ,) (IN though) (S (NP (DT this)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied)))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (NP (NN Drug) (NN Interaction)) (PP (IN During) (NP (NN Pregnancy)))) (: :) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (VP (VBD were) (VP (VBN studied) (PP (VBG following) (NP (NP (JJ subcutaneous) (NNS injections)) (PP (IN in) (NP (JJ pregnant) (NNS mice)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (ADVP (RB alone))) (PP (IN in) (NP (NP (NNS doses)) (NP (NP (QP (RB up) (TO to) (CD 540)) (NN mg/kg/day)) (-LRB- -LRB-) (NP (QP (RB approximately) (CD 340) (NNS times)) (NP (NP (DT the) (JJ maximum) (VBN recommended) (JJ daily) (NN inhalation) (NN dose)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN on) (NP (DT a) (NN mg/m2) (NN basis))))))) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB cause) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (NP (NNS resorptions)) (CC or) (NP (JJ major) (NNS malformations)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (ADVP (RB alone)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD 2.7) (NN mg/kg/day)) (-LRB- -LRB-) (NP (QP (RB approximately) (CD 7) (NNS times)) (NP (NP (DT the) (JJ maximum) (VBN recommended) (JJ daily) (NN inhalation) (NN dose)) (PP (IN in) (NP (NNS adults))))) (PP (IN on) (NP (DT a) (JJ mg/m2) (NN basis))) (-RRB- -RRB-)))))) (VP (VBD increased) (NP (CC both) (NP (NNS resorptions)) (CC and) (NP (NNS malformations))))) (. .)))
(S1 (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NP (NP (CD 540) (NN mg/kg/day)) (PP (IN of) (NP (NN drug1)))) (-LRB- -LRB-) (NP (QP (RB approximately) (CD 340) (NNS times)) (NP (NP (NP (DT the) (JJ maximum) (VBN recommended) (JJ daily) (NN inhalation) (NN dose)) (PP (IN in) (NP (NNS adults)))) (PP (IN on) (NP (DT a) (NN mg/m2) (NN basis))))) (-RRB- -RRB-))) (PP (TO to) (NP (NP (NP (CD 2.7) (NN mg/kg/day)) (PP (IN of) (NP (NN drug2)))) (-LRB- -LRB-) (NP (QP (RB approximately) (CD 7) (NNS times)) (NP (NP (NP (DT the) (JJ maximum) (VBN recommended) (JJ daily) (NN inhalation) (NN dose)) (PP (IN in) (NP (NNS adults)))) (PP (IN on) (NP (DT a) (NN mg/m2) (NN basis))))) (-RRB- -RRB-)))) (VP (VBZ appears) (S (VP (TO to) (VP (VB have) (VP (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (CC both) (NP (NNS resorptions)) (CC and) (NP (NNS malformations)))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (ADJP (NP (NN LABORATORY) (NN TEST) (NNS FINDINGS)) (JJ Asymptomatic)) (, ,) (ADJP (JJ transitory))) (NNS changes)) (PP (IN in) (NP (NN serum) (NN iron)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed))))) (. .)))
(S1 (S (S (NP (DT The) (JJ clinical) (NN significance)) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ interferes) (PP (IN with) (NP (NN serum) (NN calcium) (NNS measurements))) (PP (IN with) (NP (NP (DT some) (JJ colorimetric) (-LRB- -LRB-) (JJ complexometric) (-RRB- -RRB-) (NNS methods)) (VP (ADVP (RB commonly)) (VBN used) (PP (IN in) (NP (NNS hospitals)))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NN serum) (NN calcium) (NNS concentrations)) (ADJP (JJR lower) (PP (IN than) (NP (DT the) (JJ true) (NNS values)))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (S (VP (RB not) (TO to) (VP (VB use) (NP (JJ such) (NNS methods)) (PP (IN for) (NP (CD 12-24) (NNS hours))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug1))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (JJ such) (NNS measurements)) (VP (VBP are) (ADJP (JJ necessary))))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ other) (NNS methods)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NP (DT All) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (DT this) (NN effect)) (VP (VBD was) (VP (VBN observed)))))) (VP (VBD remained) (ADJP (JJ asymptomatic)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (JJ ototoxic) (NN potential)) (PP (IN of) (NP (NN drug2)))) (, ,) (PP (ADVP (RB especially)) (IN in) (DT the) (NN presence) (IN of) (NP (JJ impaired) (JJ renal) (NN function)))))) (. .)))
(S1 (S (S (PP (IN Except) (PP (IN in) (NP (JJ life-threatening) (NNS situations)))) (, ,) (VP (VB avoid) (NP (DT this) (NN combination)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))) (PP (IN because) (IN of) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NN ototoxicity))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN drug1)))))) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN drug2)))) (, ,) (PP (IN as) (PP (IN in) (NP (JJ rheumatic) (NN disease)))) (, ,) (VP (MD may) (VP (VBP experience) (NP (NN drug3) (NN toxicity)) (PP (IN at) (NP (NP (JJR lower) (NNS doses)) (PP (IN because) (PP (IN of) (NP (JJ competitive) (JJ renal) (NN excretory) (NNS sites))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ has) (NP (NP (DT a) (NN tendency)) (S (VP (TO to) (VP (VB antagonize) (NP (NP (DT the) (JJ skeletal) (NN muscle) (NN relaxing) (NN effect)) (PP (IN of) (NP (NN drug2))))))))) (CC and) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB generally)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NN drug2))) (SBAR (IN because) (S (NP (PRP they)) (VP (VP (VBP reduce) (NP (NN drug3) (NN s) (JJ renal) (NN clearance))) (CC and) (VP (VBP add) (NP (NP (DT a) (JJ high) (NN risk)) (PP (IN of) (NP (NN drug4) (NN toxicity)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VP (VBP add) (PP (TO to))) (CC or) (VP (VB potentiate) (NP (NP (DT the) (JJ therapeutic) (NN effect)) (PP (IN of) (NP (JJ other) (NNS drug2)))))))) (. .)))
(S1 (S (S (NP (NN Potentiation)) (VP (VBZ occurs) (PP (IN with) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (JJ arterial) (NN responsiveness)) (PP (TO to) (NP (NN drug2))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN drug1)) (VP (MD may) (ADVP (RB still)) (VP (VB be) (VP (VBN used) (ADVP (RB effectively)))))) (. .)))
(S1 (S (S (NP (NP (NNS Tablets) (JJ Simultaneous) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (NNS tablets))))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (ADJP (ADJP (JJ natriuretic)) (CC and) (ADJP (JJ antihypertensive))) (NNS effects)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (DT both) (NNS drugs)))) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ desired) (ADJP (ADJP (JJ diuretic)) (CC and/or) (ADJP (JJ antihypertensive))) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN achieved)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN intake)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD should) (VP (VB be) (VP (VBN separated) (PP (IN by) (NP (QP (IN at) (JJS least) (CD two)) (NNS hours))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Tablets)) (, ,) (NP (NN Injection)) (, ,) (CC and) (NP (JJ Oral) (NN Solution) (CD One) (NN study))) (PP (IN in) (NP (CD six) (NNS subjects)))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (ADVP (RB temporarily)) (VP (VBD reduced) (NP (NN creatinine) (NN clearance)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ renal) (NN insufficiency)))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (NN case) (NNS reports)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (VBN increased) (NP (NP (NN BUN)) (, ,) (NP (NN serum) (NN creatinine)) (CC and) (NP (NN serum) (NN potassium) (NNS levels)))) (, ,) (CC and) (NP (NN weight) (NN gain))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN used) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NN drug2))))))))))))))))) (. .)))
(S1 (S (S (NP (NN Literature) (NNS reports)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (ADJP (ADJP (JJ natriuretic)) (CC and) (ADJP (JJ antihypertensive))) (NNS effects)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (DT some) (NNS patients)))) (PP (IN by) (S (VP (VBG inhibiting) (NP (NN prostaglandin) (NN synthesis))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB also)) (VP (VB affect) (NP (NP (NN plasma) (NN renin) (NNS levels)) (, ,) (NP (NN aldosterone) (NN excretion)) (, ,) (CC and) (NP (NN renin) (NN profile) (NN evaluation)))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ desired) (ADJP (ADJP (JJ diuretic)) (CC and/or) (ADJP (JJ antihypertensive))) (NN effect)) (PP (IN of) (NP (NN drug3)))) (VP (VBZ is) (VP (VBN achieved)))))))))))) (. .)))
(S1 (S (S (PP (IN After) (NP (JJ multiple) (NN dosing))) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2) (CD 30) (NN mcg) (NN IM)) (ADVP (RB once) (RB weekly))) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NN drug3) (NN clearance)) (PP (IN by) (NP (QP (RB approximately) (CD 30)) (NN %))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN similarity)) (PP (IN of) (NP (DT the) (ADJP (NN drug1) (JJ -associated)) (JJ adverse) (NN event) (NN profile))) (PP (IN between) (NP (NP (NP (NN Study) (CD 1)) (PRN (-LRB- -LRB-) (PP (IN without) (NP (NP (NN co-administered)) (NN drug2))) (-RRB- -RRB-))) (CC and) (NP (NP (NN Study) (CD 2)) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NP (NN co-administered)) (NN drug3))) (-RRB- -RRB-)))))) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (DT this) (NN alteration)) (PP (IN in) (NP (NN clearance)))) (VP (VBZ does) (RB not) (VP (VBP necessitate) (NP (NP (NN reduction)) (PP (IN of) (NP (DT the) (NN drug4) (NN dose))) (S (VP (TO to) (VP (VB maintain) (NP (NN safety)) (PRN (, ,) (NP (JJ General)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (NP (NP (NNS Results)) (PP (IN of) (NP (NP (NNS studies)) (PP (IN in) (NP (NP (NP (JJ multiple) (NN sclerosis)) (NNS patients)) (VP (VBG taking) (NP (NP (NP (NP (NN drug1)) (CC and) (NP (JJ concomitant) (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (NN drug3) (CD 30) (NN mcg) (NN IM)) (ADVP (RB once) (RB weekly))) (-RRB- -RRB-))) (CC or) (NP (NN drug4))))))))) (VP (VBD were) (ADJP (JJ inconclusive) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NN dose) (NN adjustment)) (PP (IN of) (NP (DT the) (NP (NN drug5)) (CC or) (NP (NN drug6)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN with) (NP (NP (NN drug1)) (: :) (NP (NP (DT The) (JJ principal) (NN pathway)) (PP (IN for) (NP (NP (NN detoxification)) (PP (IN of) (NP (NN drug2))))))))) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (ADVP (RB concomitantly))))) (VP (MD should) (VP (VB have) (NP (NP (DT a) (NN dose) (NN reduction)) (PP (IN of) (NP (NN drug3)))) (, ,) (PP (TO to) (NP (QP (RB approximately) (CD 1/3) (TO to) (CD 1/4)) (NP (DT the) (JJ usual) (NN dose))))))) (. .)))
(S1 (S (NP (NP (NP (NN Use)) (PP (IN with) (NP (NP (JJ Other) (NNS Agents)) (VP (VBG Affecting) (NP (NN Myelopoesis)))))) (: :) (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB affect) (NP (NN leukocyte) (NN production)))))) (, ,) (PP (VBG including) (NP (NN drug1))) (, ,)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (JJ exaggerated) (NN leukopenia))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (JJ renal) (NN transplant) (NNS recipients)))))) (. .))))
(S1 (S (NP (NP (NP (NN Use)) (PP (IN with) (NP (NN drug1)))) (: :) (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NP (NN control) (NN hypertension)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug3)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB induce) (NP (JJ severe) (NN leukopenia))))))))) (. .))))
(S1 (S (S (NP (NP (NN Interaction)) (PP (IN with) (NP (NP (NN drug1)) (CONJP (JJ other) (IN than)) (NP (NN drug2))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB specifically)) (VP (VBN studied))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (DT no) (JJ deleterious) (NNS interactions)) (VP (VBD were) (VP (VBN seen) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (IN after) (NP (NP (NP (NN drug2)) (, ,) (NP (JJ inhalational) (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN muscle) (NN relaxant) (NNS antagonists))) (VP (VBN administered) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NN sedation)) (CC or) (NP (NN anesthesia)))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Particular) (NN caution)) (VP (VBZ is) (ADJP (JJ necessary) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (NP (NN drug1)) (PP (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (JJ mixed) (NN drug) (NN overdosage)))))))))) (SBAR (IN since) (S (NP (NP (NP (DT the) (JJ toxic) (NNS effects)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN convulsions)) (CC and) (NP (JJ cardiac) (NNS dysrhythmias))))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (VP (VBN taken) (PP (IN in) (NP (NN overdose))) (PRN (-LRB- -LRB-) (RB especially) (NP (NN drug2)) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB emerge) (PP (IN with) (NP (NP (DT the) (NN reversal)) (PP (IN of) (NP (DT the) (NN drug3) (NN effect))) (PP (IN by) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (RB not) (VP (VBN recommended) (PP (IN in) (NP (NP (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN been) (VP (VBG receiving) (NP (NN benzodiazepine) (NN treatment)) (PP (IN for) (NP (DT a) (JJ prolonged) (NN period))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NN drug1)) (VP (VBZ exerts) (NP (DT a) (JJ slight) (JJ intrinsic) (JJ anticonvulsant) (NN effect))))) (, ,) (NP (NP (PRP$ its) (JJ abrupt) (NN suppression)) (PP (IN of) (NP (NP (DT the) (JJ protective) (NN effect)) (PP (IN of) (NP (DT a) (NN drug2) (NN agonist)))))) (VP (MD can) (VP (VBP give) (NP (NN rise)) (PP (TO to) (NP (NP (NNS convulsions)) (PP (IN in) (NP (JJ epileptic) (NNS patients)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ blocks) (NP (NP (DT the) (JJ central) (NNS effects)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (NP (JJ competitive) (NN interaction)) (PP (IN at) (NP (DT the) (NN receptor) (NN level))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN nonbenzodiazepine) (NNS agonists))) (PP (IN at) (NP (NP (NN benzodiazepine) (NNS receptors)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN triazolopyridazines)) (CC and) (NP (NNS others)))) (, ,)))) (VP (VBP are) (ADVP (RB also)) (VP (VBN blocked) (PP (IN by) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (UCP (ADJP (JJ unaltered) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2)))))) (CC and) (ADVP (RB vice) (RB versa))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Use)) (PP (IN in) (NP (JJ Ambulatory) (NNS Patients)))) (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1))))) (VP (MD may) (VP (JJ wear) (RP off) (SBAR (IN before) (S (NP (DT a) (NN drug2)) (VP (VBZ is) (ADVP (RB completely)) (VP (VBN cleared) (PP (IN from) (NP (DT the) (NN body)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ general))) (, ,) (SBAR (IN if) (S (NP (DT a) (NN patient)) (VP (VBZ shows) (NP (NP (DT no) (NNS signs)) (PP (IN of) (NP (NN sedation)))) (PP (IN within) (NP (NP (CD 2) (NNS hours)) (PP (IN after) (NP (NP (DT a) (JJ 1-mg) (NN dose)) (PP (IN of) (NP (NN drug1)))))))))) (, ,) (NP (NP (JJ serious) (NN resedation)) (PP (IN at) (NP (DT a) (JJ later) (NN time)))) (VP (VBZ is) (ADJP (JJ unlikely)))) (. .)))
(S1 (S (NP (NP (DT An) (JJ adequate) (NN period)) (PP (IN of) (NP (NN observation)))) (VP (MD must) (VP (VB be) (VP (VBN provided) (PP (IN for) (NP (NP (DT any) (NN patient)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (CC either) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug2)))) (-RRB- -RRB-))) (CC or) (NP (NP (NP (JJ large) (NNS doses)) (PP (IN of) (NP (NN drug3)))) (PRN (-LRB- -LRB-) (CONJP (JJ such) (IN as)) (NP (NP (CD 10) (NN mg)) (PP (IN of) (NP (NN drug4)))) (-RRB- -RRB-)))) (VP (VBP have) (VP (VBN been) (VP (VBN used))))))))))) (. .)))
(S1 (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ adverse) (NNS reactions))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN been) (S (VP (VBG taking) (NP (NN drug1)) (PP (IN on) (NP (DT a) (JJ regular) (NN basis)))))))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (RB particularly) (JJ important)) (SBAR (IN that) (S (NP (NNS physicians)) (VP (VB query) (NP (NP (NNS patients)) (CC or) (NP (PRP$ their) (NNS guardians))) (ADVP (RB carefully)) (PP (IN about) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4) (NN use)))) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT the) (NN history)) (ADVP (ADVP (RB prior)) (PP (TO to) (NP (NP (DT any) (NN procedure)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug5)))) (VP (VBZ is) (VP (VBN planned)))))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN Substrate)) (PP (IN of) (NP (NP (NNS CYP2D6)) (PRN (-LRB- -LRB-) (NP (JJ minor)) (-RRB- -RRB-))))) (, ,) (NP (NN 3A4) (-LRB- -LRB-) (JJ major) (-RRB- -RRB-) (: ;)))))
(S1 (S (S (VP (VBZ Inhibits) (NP (NP (NN CYP2D6)) (PRN (-LRB- -LRB-) (NP (JJ weak)) (-RRB- -RRB-))))) (. .)))
(S1 (S (NP (NP (NP (VBN Increased) (NN toxicity)) (PRN (-LRB- -LRB-) (NP (NN CNS) (NN depression)) (-RRB- -RRB-))) (: :) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (. .))))
(S1 (S (S (NP (JJ CYP3A4) (NNS inhibitors) (: :)) (VP (MD May) (VP (VB increase) (NP (NP (DT the) (NNS levels/effects)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN Example) (NNS inhibitors)) (VP (VBP include) (NP (NP (NN drug1)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (NN drug13)) (, ,) (CC and) (NP (NN drug14)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN fruit) (NNS juices)) (, ,) (NP (NN etc.))) (-RRB- -RRB-))) (JJR lower) (NN absorption)) (PP (IN of) (NP (NN drug7)))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN etc.))) (-RRB- -RRB-))) (VP (VBP increase) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (DT the) (VBN ionized) (NNS species)) (PP (IN of) (NP (DT the) (NN drug4) (NN molecule)))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG increasing) (NP (JJ urinary) (NN excretion)))))) (. .)))
(S1 (S (S (NP (NP (CC Both) (NNS groups)) (PP (IN of) (NP (NNS agents)))) (VP (JJR lower) (NP (NP (NN blood) (NNS levels)) (CC and) (NP (NP (NN efficacy)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP are) (VP (VBN inhibited) (PP (IN by) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NP (NN Alkalinizing) (NNS agents)) (: :) (NP (NP (JJ Gastrointestinal) (NN alkalinizing) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN etc.))) (-RRB- -RRB-)))) (VP (VBP increase) (NP (NP (NN absorption)) (PP (IN of) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (JJ Urinary) (NN alkalinizing) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (DT some) (NNS drug2))) (-RRB- -RRB-))) (VP (VBP increase) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (DT the) (JJ non-ionized) (NNS species)) (PP (IN of) (NP (DT the) (NN drug3) (NN molecule)))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG decreasing) (NP (JJ urinary) (NN excretion)))))) (. .)))
(S1 (S (S (NP (NP (DT Both) (NNS groups)) (PP (IN of) (NP (NNS agents)))) (VP (VP (VBP increase) (NP (NN blood) (NNS levels))) (CC and) (ADVP (RB therefore)) (VP (VB potentiate) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (, ,) (NP (NN drug2))) (: :) (S (NP (NN drug3)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NN drug4)) (CC or) (NP (NN drug5)))))))) (: ;)))
(S1 (S (NP (NP (NP (NN drug1)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))) (CC and) (ADVP (RB possibly)) (NP (JJ other) (NNS drug4))) (VP (VBP cause) (NP (NP (ADJP (ADJP (JJ striking)) (CC and) (ADJP (JJ sustained))) (NNS increases)) (PP (IN in) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NN drug5))) (PP (IN in) (NP (DT the) (NN brain))))))) (: ;)))
(S1 (S (S (NP (JJ cardiovascular) (NNS effects)) (VP (MD can) (VP (VB be) (VP (VBN potentiated))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NP (DT a) (NN metabolite)) (PP (IN of) (NP (NN drug3)))) (, ,) (NP (JJ slow) (NN drug4) (NN metabolism)))) (. .))))
(S1 (S (S (NP (DT This) (NN slowing)) (VP (VBZ potentiates) (NP (NN drug1)) (, ,) (S (VP (VBG increasing) (NP (NP (PRP$ their) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NP (NN norepinephrine)) (CC and) (NP (JJ other) (NNS monoamines)))) (PP (IN from) (NP (JJ adrenergic) (NN nerve) (NNS endings)))))))))) (: ;)))
(S1 (S (S (NP (DT this)) (VP (MD can) (VP (VB cause) (NP (NP (NP (NNS headaches)) (CC and) (NP (JJ other) (NNS signs))) (PP (IN of) (NP (JJ hypertensive) (NN crisis))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN variety)) (PP (IN of) (NP (NP (JJ neurological) (JJ toxic) (NNS effects)) (CC and) (NP (JJ malignant) (NN hyperpyrexia))))) (VP (MD can) (VP (VB occur) (, ,) (PP (ADVP (RB sometimes)) (IN with) (NP (JJ fatal) (NNS results)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB counteract) (NP (NP (DT the) (JJ sedative) (NN effect)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VP (VBZ blocks) (NP (NP (NN dopamine)) (CC and) (NP (NN norepinephrine)) (NP (NN reuptake))) (, ,) (S (ADVP (RB thus)) (VP (VBG inhibiting) (NP (NP (DT the) (JJ central) (NN stimulant) (NNS effects)) (PP (IN of) (NP (NN drug3))))))) (, ,) (CC and) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NN drug4) (NN poisoning)))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB delay) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ blocks) (NP (NP (NN dopamine)) (CC and) (NP (NN norepinephrine)) (NP (NN reuptake))) (, ,) (S (ADVP (RB thus)) (VP (VBG inhibiting) (NP (NP (DT the) (JJ central) (JJ stimulant) (NNS effects)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (DT The) (JJ stimulatory) (NNS effects)) (PP (IN of) (NP (NN drug2))))) (VP (MD may) (VP (VB be) (VP (VBN inhibited) (PP (IN by) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VB potentiate) (NP (NP (DT the) (JJ analgesic) (NN effect)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN therapy)) (: :) (S (NP (NP (JJ Urinary) (NN excretion)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN increased)))) (, ,) (CC and) (S (NP (NN efficacy)) (VP (VBZ is) (VP (VBN reduced) (, ,) (PP (IN by) (NP (NP (NN drug3)) (VP (VBN used) (PP (IN in) (NP (NN drug4) (NN therapy)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP enhance) (NP (NP (DT the) (JJ adrenergic) (NN effect)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (VP (VB delay) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NN drug3))))))) (: ;))))
(S1 (S (S (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB produce) (NP (DT a) (JJ synergistic) (JJ anticonvulsant) (NN action))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (VP (VB delay) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NN drug3))))))) (: ;))))
(S1 (S (S (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB produce) (NP (DT a) (JJ synergistic) (JJ anticonvulsant) (NN action))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (NNS cases)) (PP (IN of) (NP (NN drug2) (NN overdosage))))) (, ,) (S (NP (NN drug3) (NN CNS) (NN stimulation)) (VP (VBZ is) (VP (VBN potentiated)))) (CC and) (S (NP (JJ fatal) (NNS convulsions)) (VP (MD can) (VP (VB occur))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP inhibit) (NP (NP (DT the) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (: :) (NP (NN drug1))) (VP (MD can) (VP (VB cause) (NP (NP (DT a) (JJ significant) (NN elevation)) (PP (IN in) (NP (NN plasma) (NN drug2) (NNS levels))))))) (. .)))
(S1 (S (S (NP (DT This) (NN increase)) (VP (VBZ is) (ADJP (JJS greatest) (PP (IN in) (NP (DT the) (NN evening)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (JJ urinary) (NN steroid) (NNS determinations)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (ADVP (RB mainly)) (PP (IN via) (NP (DT the) (NP (NN cytochrome) (NN P450) (NN 3A4)) (NP (NN enzyme))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT some) (NNS cases)) (SBAR (WHADVP (WRB where)) (S (NP (NP (JJ serious) (JJ ventricular) (NNS arrhythmias)) (, ,) (NP (NN QT) (NN prolongation)) (, ,) (CC and) (NP (NP (NNS torsades)) (ADJP (FW de) (FW pointes)))) (VP (VBP have) (VP (VBN occurred) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN taken) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NN cytochrome) (NN P450) (NN 3A4)) (NNS inhibitors))))))))))))))))) (, ,) (NP (JJ elevated) (NN blood) (NN drug2) (NNS levels)) (VP (VBD were) (VP (VBN noted) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (DT the) (NN QT) (NN prolongation)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (ADJP (ADJP (FW In) (FW vitro)) (CC and/or) (ADJP (FW in) (FW vivo))) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))) (ADVP (RB markedly)) (VP (VBP inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug5))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN plasma) (NN drug6) (NNS levels)))) (CC and) (NP (NP (NN prolongation)) (PP (IN of) (NP (NP (DT the) (JJ QT) (NN interval)) (PP (IN on) (NP (DT the) (NN ECG)))))))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (JJ certain) (NNS drug2)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))) (, ,)))) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB compromise) (NP (NP (DT the) (JJ beneficial) (NNS effects)) (PP (IN of) (NP (NN drug5))))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1) (-LRB- -LRB-) (JJ Oral) (-RRB- -RRB-) (: :)) (PP (IN In) (NP (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ oral) (NN drug2)))) (, ,) (NP (DT the) (NN coagulation) (NNS times))))) (VP (VBD were) (VP (VBN increased) (PP (IN in) (NP (DT some) (NNS cases)))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ advisable) (S (VP (TO to) (VP (VB check) (NP (NN coagulation) (NN time)) (PP (IN within) (NP (NP (DT the) (JJ first) (JJ few) (NNS days)) (PP (IN after) (NP (NP (DT the) (NP (NN start)) (CC and) (NP (NN discontinuation))) (PP (IN of) (NP (NN drug1) (NN therapy))))))) (, ,) (PP (IN with) (NP (NP (DT an) (JJ appropriate) (NN adjustment)) (PP (IN of) (NP (DT the) (NN drug2) (NN dose))))) (, ,) (SBAR (IN if) (FRAG (JJ necessary))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (ADJP (FW In) (FW vitro)) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug2)) (VP (VBZ inhibits) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN plasma) (NN drug4) (NNS levels)))) (CC and) (NP (NP (NN prolongation)) (PP (IN of) (NP (NP (DT the) (JJ QT) (NN interval)) (PP (IN on) (NP (DT the) (NN ECG)))))))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (ADJP (ADJP (FW In) (FW vitro)) (CC and/or) (ADJP (FW in) (FW vivo))) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (JJ oral) (NN drug4))) (ADVP (RB markedly)) (VP (VBP inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug5))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN plasma) (NN drug6) (NNS levels)))) (CC and) (NP (NP (NN prolongation)) (PP (IN of) (NP (NP (DT the) (JJ QT) (NN interval)) (PP (IN on) (NP (DT the) (NN ECG)))))))))))))))))) (. .))))
(S1 (S (S (NP (JJ Human) (JJ pharmacokinetic) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ oral) (NN drug1)) (ADVP (RB markedly)) (VP (VBZ inhibits) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (ADJP (NN mean) (JJ eight-fold)) (NN increase)) (PP (IN in) (NP (NP (NN AUC)) (PP (IN of) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN study)) (PP (IN in) (NP (CD 14) (JJ normal) (ADJP (ADJP (JJ male)) (CC and) (ADJP (JJ female))) (NNS volunteers)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (NN prolongation)) (PP (IN of) (NP (NP (DT the) (JJ QT) (NN interval)) (PP (IN on) (NP (DT the) (NN ECG))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NN drug2) (NN coadministration)) (VP (VBZ leads) (PP (TO to) (NP (NP (DT an) (VBN increased) (JJ peak) (NN plasma) (NN concentration)) (CC and) (NP (NP (NN AUC)) (PP (IN of) (NP (NN drug3)))))))) (, ,) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug4) (NN absorption)))) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NN drug5)))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (VP (VBN accelerated) (SBAR (WHADVP (WRB when)) (S (NP (PRP they)) (VP (VBP are) (VP (VBN coadministered) (PP (IN with) (NP (NN drug3)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (ADJP (FW In) (FW vitro)) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (ADVP (RB markedly)) (VP (VBP inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug4))) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN plasma) (NN drug5) (NNS levels)))) (CC and) (NP (NP (NN prolongation)) (PP (IN of) (NP (NP (DT the) (JJ QT) (NN interval)) (PP (IN on) (NP (DT the) (NN ECG)))))))))))))))))) (. .))))
(S1 (S (S (S (NP (NP (ADJP (ADJP (JJ Other)) (: :)) (NN Coadministration)) (PP (IN of) (NP (NN grapefruit) (NN juice))) (PP (IN with) (NP (NN drug1)))) (VP (VBZ increases) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug2)))))) (CC and) (S (NP (JJ concomitant) (NN use)) (VP (MD should) (VP (VB be) (VP (VBN avoided)))))) (. .)))
(S1 (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB prolong) (NP (DT the) (JJ QT) (NN interval))))))))))) (: :) (NP (NP (JJ certain) (NNS drug2)) (, ,) (PP (VBG including) (NP (NP (DT those)) (PP (IN of) (NP (NP (NP (NN Class) (CD IA)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))) (-RRB- -RRB-))) (CC and) (NP (NP (NN Class) (CD III)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug5)))) (-RRB- -RRB-)))))))) (: ;)))
(S1 (S (NP (NP (NP (NNP drug1)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug2)))) (-RRB- -RRB-))) (: ;))))
(S1 (S (NP (NP (NP (JJ certain) (JJ drug1)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug2)))) (-RRB- -RRB-))) (: ;))))
(S1 (S (NP (NP (NP (JJ certain) (JJ drug1)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug2)))) (-RRB- -RRB-))) (: ;))))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ preceding) (NNS lists)) (PP (IN of) (NP (NNS drugs)))) (VP (VBP are) (RB not) (ADJP (JJ comprehensive)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN acceleration)) (PP (IN of) (NP (JJ gastric) (NN emptying))) (PP (IN by) (NP (NN drug1)))) (VP (MD could) (VP (VB affect) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (NN absorption)) (PP (IN of) (NP (JJ other) (NNS drugs))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NP (JJ narrow) (JJ therapeutic) (NN ratio) (NNS drugs)) (CC or) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP require) (NP (JJ careful) (NN titration)))))))) (VP (MD should) (VP (VB be) (VP (VBN followed) (ADVP (RB closely)))))) (: ;)))
(S1 (S (S (SBAR (IN if) (S (NP (NN plasma) (NNS levels)) (VP (VBP are) (VP (VBG being) (VP (VBN monitored)))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN reassessed))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS risks)) (PP (IN of) (S (VP (VBG using) (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS drugs))))))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB systematically)) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (PP (IN Given) (NP (NP (DT the) (JJ primary) (NN CNS) (NNS effects)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN advised) (PP (IN in) (S (VP (VBG using) (NP (NP (PRP it)) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ other) (JJ CNS-active) (NNS drugs)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Close) (NN supervision)) (CC and) (NP (JJ careful) (NN adjustment))) (PP (IN of) (NP (NN dosage)))) (VP (VBP are) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (S (NP (JJ Several) (NNS drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB block) (NP (NP (DT the) (JJ pharmacologic) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (JJ similar) (NNS agents)))))))))))) (, ,) (CC and) (S (NP (PDT such) (DT an) (NN effect)) (VP (MD may) (VP (VB be) (VP (VBN anticipated) (PP (IN with) (NP (NN drug4))) (PP (IN because) (IN of) (NP (NP (PRP$ its) (JJ structural) (NN similarity)) (PP (TO to) (NP (JJ other) (NNS drug5)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (VP (VBN increased) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))))))))))))) (: ;)))
(S1 (S (S (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (JJ several) (ADJP (RB closely) (JJ related)) (NNS drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (VP (VP (VBN increased) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NP (JJ hepatic) (NN enzyme) (NNS inhibitors)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug3))) (, ,) (NP (NNS drug4)) (-RRB- -RRB-)))))))) (CC and) (VP (VBN decreased) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (JJ hepatic) (NN enzyme) (NNS inducers)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug5))) (, ,) (NP (NNS drug6)) (-RRB- -RRB-))))))))))))))) (, ,) (CC and) (S (NP (PDT such) (DT an) (NN effect)) (VP (MD may) (VP (VB be) (VP (VBN anticipated) (PP (IN with) (NP (NN drug7))) (PP (IN as) (NP (NN well))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug2))))))))) (, ,) (SBAR (IN if) (S (VP (VBN given) (ADVP (RB concomitantly))))))) (. .)))
(S1 (S (S (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))) (: :) (S (NP (NP (DT The) (JJ biochemical) (NN activity)) (PP (IN of) (NP (NP (DT the) (NN drug) (NN metabolizing) (NN isozyme) (NN cytochrome) (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NN debrisoquin) (NN hydroxylase)) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN reduced) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NP (DT the) (JJ aucasian) (NN population)) (PRN (-LRB- -LRB-) (NP (NP (QP (RB about) (CD 7)) (NN %) (CD -10) (NN %)) (PP (IN of) (NP (NP (NNP Caucasians)) (VP (VBP are) (NP (JJ so-called) (JJ poor) (NNS metabolizers)))))) (-RRB- -RRB-))))))))) (: ;)))
(S1 (S (S (NP (NP (JJ reliable) (NNS estimates)) (PP (IN of) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (VBN reduced) (NN P450) (NN 2D6) (NN isozyme) (NN activity))) (PP (IN among) (NP (ADJP (ADJP (JJ Asian)) (, ,) (ADJP (JJ African)) (CC and) (ADJP (JJ other))) (NNS populations)))))) (VP (VBP are) (RB not) (ADVP (RB yet)) (ADJP (JJ available)))) (. .)))
(S1 (S (S (NP (JJ Poor) (NNS metabolizers)) (VP (VBP have) (NP (NP (JJR higher) (IN than) (VBN expected) (NN lasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (JJ usual) (NNS doses))))))) (. .)))
(S1 (S (S (PP (VBG Depending) (PP (IN on) (NP (NP (DT the) (NN fraction)) (PP (IN of) (NP (NP (NN drug)) (VP (VBN metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))))))) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN plasma) (NN concentration)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (JJ small)) (, ,) (CC or) (RB quite) (ADJP (ADJP (JJ large)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 8) (JJ fold)) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NN AUC)) (PP (IN of) (NP (DT the) (NN drug1)))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ certain) (NNS drugs)) (VP (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT this) (NN isozyme))))) (CC and) (VP (VB make) (NP (JJ normal) (NNS metabolizers)))) (VP (VBP resemble) (NP (JJ poor) (NNS metabolizers)))) (. .)))
(S1 (S (S (NP (NP (DT An) (JJ individual)) (SBAR (WHNP (WP who)) (S (VP (VBZ is) (ADJP (JJ stable) (PP (IN on) (NP (NP (DT a) (JJ given) (NN dose)) (PP (IN of) (NP (NN drug1)))))))))) (VP (MD may) (VP (VB become) (ADJP (RB abruptly) (JJ toxic)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT these) (JJ inhibiting) (NNS drugs)) (PP (IN as) (NP (JJ concomitant) (NN therapy)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6)))))) (VP (VBP include) (NP (NP (DT some)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN enzyme) (-LRB- -LRB-) (NN drug1)))))))))) (: ;)))
(S1 (S (NP (NP (NP (NNP drug1) (-RRB- -RRB-)) (CC and) (NP (NP (JJ many)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN for) (NP (NP (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NP (JJ many) (JJ other) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NP (DT the) (NN drug4) (NN drug5)) (CC and) (NP (NN drug6)))) (-RRB- -RRB-)))))))))) (. .))))
(S1 (S (S (SBAR (IN While) (S (NP (NP (NP (PDT all) (DT the) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)))) (, ,)) (VP (VBP inhibit) (NP (NN P450) (NN 2D6))))) (, ,) (NP (PRP they)) (VP (MD may) (VP (VB vary) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN inhibition)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB inhibit) (NP (NP (NN P450) (NN 1A2)) (, ,) (NP (NP (DT an) (NN isoform)) (VP (ADVP (RB also)) (VBN involved) (PP (IN in) (NP (NN drug2) (NN metabolism))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN extent)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (NNS interactions)) (VP (MD may) (VP (VBP pose) (NP (JJ clinical) (NNS problems))))))) (VP (MD will) (VP (VB depend) (PP (IN on) (NP (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN inhibition)))) (CC and) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT the) (NN drug3)) (VP (VBN involved)))))))))) (. .)))
(S1 (S (ADVP (RB Nevertheless)) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN indicated) (PP (PP (IN in) (NP (NP (DT the) (NN co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NN drug2))))))) (CC and) (ADVP (RB also)) (PP (IN in) (NP (NP (NN switching)) (PP (IN from) (NP (CD one) (NN class))) (PP (TO to) (NP (DT the) (JJ other)))))))) (. .)))
(S1 (S (PP (IN Of) (NP (JJ particular) (NN importance))) (, ,) (NP (JJ sufficient) (NN time)) (VP (MD must) (VP (VB elapse) (PP (IN before) (S (VP (VBG initiating) (NP (NN drug1) (NN treatment)) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG being) (VP (VBN withdrawn) (PP (IN from) (NP (NP (NP (NN drug2)) (, ,) (VP (VBN given) (NP (NP (DT the) (JJ long) (NN half-life)) (PP (IN of) (NP (DT the) (NN parent)))))) (CC and) (NP (NP (JJ active) (NN metabolite)) (PRN (-LRB- -LRB-) (NP (NP (QP (IN at) (JJS least) (CD 5)) (NNS weeks)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NNS agents)) (PP (IN in) (NP (NP (DT the) (NN drug1)) (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (VBZ includes) (NP (NN drug2))))) (-RRB- -RRB-))))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6))))))))) (VP (MD may) (VP (VB require) (NP (NP (JJR lower) (NNS doses)) (VP (ADVP (IN than) (RB usually)) (VBN prescribed) (PP (IN for) (NP (CC either) (NP (DT the) (NN drug3)) (CC or) (NP (DT the) (JJ other) (NN drug))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (S (ADVP (RB whenever)) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (VBZ is) (VP (VBN withdrawn) (PP (IN from) (NP (NN co-therapy)))))) (, ,) (NP (NP (DT an) (VBN increased) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ desirable) (S (VP (TO to) (VP (VB monitor) (NP (NN drug1) (NN plasma) (NNS levels)) (S (ADVP (RB whenever)) (NP (NP (DT an) (NN agent)) (PP (IN of) (NP (NP (DT the) (NNS drug2)) (PP (VBG including) (NP (NN drug3)))))) (VP (VBZ is) (ADJP (JJ going) (S (VP (TO to) (VP (VB be) (VP (VBN co-administered) (PP (IN with) (NP (NP (DT another) (NN drug)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (NN P450) (NN 2D6)) (-LRB- -LRB-) (CC and/or) (NP (NN P450) (NN 1A2)) (-RRB- -RRB-))))))))))))))))))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NN serum) (NN protein))))))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NN protein)))))))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug3))) (, ,) (NP (NNS drug4)) (-RRB- -RRB-))))))) (VP (MD may) (VP (VB cause) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (DT these) (NNS drugs)))))) (, ,) (S (ADVP (RB potentially)) (VP (VBG resulting) (PP (IN in) (NP (JJ adverse) (NNS effects))))))) (. .)))
(S1 (S (S (ADVP (RB Conversely)) (, ,) (NP (JJ adverse) (NNS effects)) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (NN displacement)) (PP (IN of) (NP (JJ protein-bound) (NN drug1))) (PP (IN by) (NP (JJ other) (ADJP (RB highly) (VBN bound)) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NNS trials)) (VP (ADVP (RB specifically)) (VBG examining) (NP (NP (JJ potential) (NN drug) (NNS interactions)) (PP (IN with) (NP (NN drug1)))))) (VP (VBD were) (VP (VBN conducted)) (, ,) (SBAR (IN although) (S (NP (JJ many) (JJ concomitant) (NNS drugs)) (VP (VBD were) (VP (VBN used) (PP (IN in) (NP (JJ clinical) (NNS trials))))))))) (. .)))
(S1 (S (S (NP (DT No) (NN drug) (NNS interactions)) (VP (VBD were) (VP (VBN detected) (PP (IN except) (PP (IN for) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ symptomatic) (NN hypotension)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ oral) (NN drug1))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN IV) (NNS drug2)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (CD IV) (NN drug6))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated) (PRN (-LRB- -LRB-) (S (NP (DT these) (NNS drugs)) (VP (VBD were) (RB not) (VP (VBN co-administered) (PP (IN with) (NP (NN drug7))) (PP (IN in) (NP (JJ clinical) (NNS trials)))))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (JJ other) (NN drug3)))) (, ,) (S (VP (VBG causing) (NP (VBN increased) (JJ sedative) (NNS effects))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (MD may) (ADVP (RB also)) (VP (VB interact) (PP (IN with) (NP (NP (ADJP (ADJP (JJ drug1)) (CC or) (ADJP (JJ other))) (NP (NN drug2)) (CC or) (NP (NN drug3))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB intensify) (NP (DT the) (JJ anticholinergic) (NN action))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD can) (VP (VB interact) (PP (IN with) (NP (NN drug2))) (, ,) (S (VP (VBG increasing) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Additional) (NNS reductions)) (PP (IN in) (NP (NN blood) (NN pressure)))) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (JJ other) (NN drug4))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ other) (NN drug1)) (CC or) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN drug3))) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ bleeding)))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NNS infusions)) (PP (IN of) (NP (NN drug1)))) (PP (IN in) (NP (JJ clinical) (NNS trials))))) (VP (VBD were) (VP (VBN maintained) (PP (IN on) (NP (NN drug2))) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (VBN increased) (JJ bleeding)))))))) (. .)))
(S1 (S (PP (IN In) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NN drug1)) (VP (VBD was) (VP (VBN used) (PP (IN with) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (JJ oral) (NN drug5)) (, ,) (CC and) (NP (JJ supplemental) (NN drug6) (NN .In)) (NP (DT a) (JJ pharmacokinetic) (NN substudy))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ congestive) (NN heart) (NN failure))) (VP (VBG receiving) (NP (NP (NP (NN drug7)) (CC or) (NP (NN drug8))) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (S (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug9)))) (VP (VBD was) (VP (VBN initiated)))) (, ,) (NP (NP (NP (NP (JJ apparent) (JJ oral) (NN clearance) (NNS values)) (PP (IN for) (NP (NP (NN drug10)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 23)) (-RRB- -RRB-))))) (CC and) (NP (NN drug11))) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 30)) (-RRB- -RRB-))) (VP (VP (VBD were) (VP (VBN decreased) (PP (IN by) (NP (NP (CD 13) (NN %)) (CC and) (NP (CD 15) (NN %)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN on) (NP (NP (DT the) (JJ second) (NN day)) (PP (IN of) (NP (NN therapy))))))) (CC and) (VP (VBD had) (VP (VBD returned) (PP (TO to) (NP (NN baseline) (NNS values))) (PP (IN by) (NP (NN day) (CD 87)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN change)) (PP (IN in) (NP (NN drug1) (NN clearance) (NN value)))) (VP (VBZ is) (RB not) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (ADJP (RB clinically) (JJ significant)))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug1)))) (VP (MD may) (VP (VB show) (NP (NP (NNS elevations)) (PP (IN of) (NP (NN drug2) (NNS concentrations)))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN therapy))) (PP (IN with) (NP (NP (NN drug3)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (ADJP (RB clinically) (JJ significant) (PP (IN in) (NP (NP (NNS patients)) (ADJP (JJ prone) (PP (TO to) (NP (NN drug4) (NN toxicity))))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Specific) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ systemic) (NN administration)) (PP (IN of) (NP (DT some) (NN drug1)))) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VP (VBP elevate) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2))))) (, ,) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3)))))) (, ,) (CC and) (VP (VBP enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ oral) (NN drug4) (NN drug5)) (CC and) (NP (PRP$ its) (NNS derivatives)))))))))))) (, ,) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ transient) (NNS elevations)) (PP (IN in) (NP (NP (NN serum) (NN creatinine)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ systemic) (NN drug6)) (ADVP (RB concomitantly))))))))))))))) (. .)))
(S1 (S (S (NP (DT No) (NP (NP (NN drug)) (, ,) (NP (JJ nutritional) (NN supplement)) (, ,) (NP (NN food)) (CC or) (NP (NN herb))) (NNS interactions)) (VP (VBP are) (VP (VBN known)))) (. .)))
(S1 (S (PP (IN Before) (S (VP (VBG using) (NP (DT this) (NN medication))))) (, ,) (NP (NP (NP (NN tell) (NN your) (NN doctor)) (CC or) (NP (NN pharmacist))) (PP (IN of) (NP (DT all) (NN prescription) (CC and) (NN nonprescription) (NNS products)))) (VP (VBZ you) (S (VP (MD may) (VP (VBP use) (, ,) (PP (ADVP (RB especially)) (IN of) (: :) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (, ,) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NP (JJ drug6) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug7))) (-RRB- -RRB-))) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)))))))) (. .)))
(S1 (S (S (VP (VP (VBP Do) (RB not) (VP (VBP start))) (CC or) (VP (NN stop) (NP (DT any) (NN medicine)) (PP (IN without) (NP (NP (NN doctor)) (CC or) (NP (NN pharmacist)) (NP (NN approval))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ hypoglycemic) (NN action)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NP (JJ certain) (NNS drugs)) (PP (VBG including) (NP (NP (NP (NP (NN drug2)) (CC and) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB highly)) (VP (NN protein) (VBN bound)))))) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (CC and) (NP (NN drug9)))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NN hypoglycemia))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN withdrawn) (PP (IN from) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (NN control))))))))) (. .)))
(S1 (S (S (NP (JJ Certain) (NNS drugs)) (VP (VBP tend) (S (VP (VP (TO to) (VP (VB produce) (NP (NN hyperglycemia)))) (CC and) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NN loss)) (PP (IN of) (NP (NN control))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS drugs)) (VP (VBP include) (NP (NP (NP (DT the) (NN drug1)) (CC and) (NP (JJ other) (NNS drug2))) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN thyroid) (NNS products)) (, ,) (NP (NN drug5)) (, ,) (NP (JJ oral) (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (CC and) (NP (NN drug11)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN observed) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (NN control))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN withdrawn) (PP (IN from) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NN hypoglycemia))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN animal) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ prolonged) (PP (IN by) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug2))))))))))))) (, ,) (NP (NN drug3)) (VP (MD should) (VP (VB be) (VP (VBN employed) (PP (IN with) (NP (NN caution))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (DT a) (JJ drug1) (JJ -like) (NN reaction)) (VP (MD may) (VP (VB be) (VP (VBN produced) (PP (IN by) (NP (NP (DT the) (NN ingestion)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ potential) (NN interaction)) (PP (IN between) (NP (NP (NP (JJ oral) (NN drug1)) (CC and) (NP (JJ oral) (NN drug2))) (VP (VBG leading) (PP (TO to) (NP (JJ severe) (NN hypoglycemia))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (SBAR (IN Whether) (S (NP (DT this) (NN interaction)) (ADVP (RB also)) (VP (VBZ occurs) (PP (IN with) (NP (NP (DT the) (ADJP (ADJP (JJ intravenous)) (, ,) (ADJP (JJ topical)) (, ,) (CC or) (ADJP (JJ vaginal))) (NNS preparations)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)))) (-RRB- -RRB-))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (VBN increased) (NN drug7) (NNS effects)))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (JJ such) (NNS drugs)))))) (, ,) (S (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (NP (DT the) (JJ smallest) (JJ effective) (NN dose))))) (CC and) (S (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NN dosing)))) (VP (VBD reduced) (ADJP (ADVP (RB as) (RB much)) (RB as) (JJ possible)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VB potentiate) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug2)))))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ healthy) (NNS volunteers))) (, ,) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT a) (JJ 1-mg) (NN dose)) (PP (IN of) (NP (NN drug1))) (VP (VBN administered) (PP (IN as) (NP (NN drug2))))))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NP (DT a) (JJ single) (JJ 6-mg) (NN subcutaneous) (NN dose)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (NP (DT another) (NN study)) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))) (, ,) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN altered) (PRN (-LRB- -LRB-) (NP (NP (NP (ADJP (CD 29) (NN %)) (NN decrease)) (PP (IN in) (NP (NN AUC)))) (CC and) (NP (NP (ADJP (CD 38) (NN %)) (NN decrease)) (PP (IN in) (NP (NN Cmax))))) (-RRB- -RRB-))) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT a) (JJ 1-mg) (NN dose)) (PP (IN of) (NP (NN drug2)))) (VP (VBD was) (VP (VBN administered) (PP (NP (CD 1) (NN minute)) (IN after) (NP (NP (DT a) (JJ 20-mg) (NN dose)) (PP (IN of) (NP (NN drug3) (JJ nasal) (NN spray))))))))))) (. .)))
(S1 (S (PRN (-LRB- -LRB-) (S (S (NP (DT The) (CD two) (NNS drugs)) (VP (VBD were) (VP (VBN administered) (PP (IN in) (NP (JJ opposite) (NNS nostrils)))))) (. .)) (-RRB- -RRB-))))
(S1 (S (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (NP (CD 30) (NNS minutes)) (IN after) (NP (DT the) (NN drug2) (JJ nasal) (NN spray))))))) (, ,) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug3)))) (VP (VBD increased) (NP (CD 11) (NN %)))) (CC and) (S (NP (NN Cmax)) (VP (VBD decreased) (NP (CD 18) (NN %))))) (. .)))
(S1 (S (S (NP (NP (NN In)) (CC neither) (NP (NN case))) (VP (VBD were) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN affected) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (NP (DT the) (JJ analgesic) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN diminished) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB shortly)) (PP (IN after) (NP (NN drug2) (JJ nasal) (NN spray))))))))))) (, ,) (CC but) (S (PP (IN by) (NP (CD 30) (NNS minutes))) (NP (NP (DT any) (JJ such) (NN reduction)) (PP (IN in) (NP (NN effect)))) (VP (MD should) (VP (VB be) (ADJP (JJ minimal))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN safety)) (PP (IN of) (S (VP (VBG using) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (-LRB- -LRB-) (NN drug3) (-RRB- -RRB-) (JJ Nasal) (NN Spray))) (PP (IN during) (NP (NP (DT the) (JJ same) (NN episode)) (PP (IN of) (NP (NN migraine))))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN noted) (SBAR (IN that) (S (NP (DT both) (NNS products)) (VP (VBP are) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG producing) (NP (NP (JJ transient) (NNS increases)) (PP (IN in) (NP (NN blood) (NN pressure))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT a) (JJ 1-mg) (NN dose)) (PP (IN of) (NP (NN drug1))) (VP (VBN administered) (PP (IN as) (NP (NN drug2))))))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 300) (NN mg) (JJ QID)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (ADVP (RB Conversely)) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg) (JJ drug2) (JJ QID)) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT a) (JJ 300-mg) (NN dose)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN if) (S (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (VP (VBN altered) (PP (IN by) (NP (NP (JJ concomitant) (NNS medications)) (SBAR (WHNP (WDT that)) (S (VP (VBP affect) (NP (NP (JJ hepatic) (NN metabolism)) (PP (IN of) (NP (NP (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN etc.))) (-RRB- -RRB-))))))))))))) (, ,) (CC but) (S (NP (NNS physicians)) (VP (MD should) (VP (VB be) (ADJP (JJ alert) (PP (TO to) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NP (DT a) (JJR smaller) (JJ initial) (NN dose)) (CC and) (NP (NP (JJR longer) (NNS intervals)) (PP (IN between) (NP (NNS doses))))) (VP (MD may) (VP (VB be) (VP (VBN needed))))))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NN fraction)) (PP (IN of) (NP (NN drug1) (NN absorbed)))) (VP (VBZ is) (VP (VBN unaffected) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (DT a) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))))))))) (, ,) (CC but) (S (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN absorption)))) (VP (VBZ is) (VP (VBN decreased))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (DT a) (JJR slower) (NN onset)) (VP (MD can) (VP (VB be) (VP (VBN anticipated) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (PP (IN with)) (, ,) (CC or) (ADVP (RB immediately)) (VP (VBG following))) (, ,) (NP (DT a) (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (DT No) (NN information)) (VP (VBZ is) (ADJP (JJ available) (PP (IN about) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (ADVP (RB concurrently)) (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN hyperthyroidism)) (, ,) (NP (NN hypertension)) (CC and) (NP (JJ cardiac) (NNS arrhythmias)))))))))) (. .)))
(S1 (S (S (NP (DT All) (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ other) (NNS drug2)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug3)))) (-RRB- -RRB-)))) (PP (IN because) (IN of) (NP (NP (JJ possible) (JJ additive) (NNS effects)) (CC and) (NP (VBN increased) (NN toxicity)))))))) (. .)))
(S1 (S (S (NP (JJ Combined) (NNS effects)) (VP (MD may) (VP (VB induce) (NP (JJ serious) (JJ cardiac) (NNS arrhythmias))))) (. .)))
(S1 (S (S (NP (PRP They)) (VP (MD may) (VP (VB be) (VP (VBN administered) (ADVP (RB alternately)) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (JJ preceding) (NN effect)) (PP (IN of) (NP (JJ other) (JJ such) (NN drug)))) (VP (VBZ has) (VP (VBN subsided))))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (PP (JJ such) (IN as) (NP (NN drug4))) (SBAR (WHNP (WDT which)) (S (VP (VB sensitize) (NP (DT the) (NN myocardium))))) (, ,)))))) (VP (MD may) (VP (VB induce) (NP (JJ cardiac) (NN arrhythmia)))) (. .)) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN encountered)))) (, ,) (NP (JJ such) (NNS arrhythmias)) (VP (MD may) (VP (VB respond) (PP (TO to) (NP (NP (NN administration)) (PP (IN of) (NP (DT a) (NN drug1)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (ADVP (RB also)) (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN with) (NP (NP (NP (JJ other) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (, ,) (NP (NNS drug3)) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VB sensitize) (NP (DT the) (NN myocardium)) (PP (TO to) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (NN drug4)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (JJ vascular) (NN response)) (PP (TO to) (NP (NP (JJ pressor) (NNS drugs)) (PP (JJ such) (IN as) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (NN neuron) (NN blockade)) (VP (VBN produced) (PP (IN by) (NP (NP (NN drug2)) (VP (VP (VBG resulting) (PP (IN in) (NP (VBN decreased) (JJ antihypertensive) (NN effect)))) (CC and) (VP (VBG requiring) (NP (NP (VBN increased) (NN dosage)) (PP (IN of) (NP (DT the) (JJ latter))))))))))))) (. .)))
(S1 (S (S (VP (MD May) (VP (VB interact) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (JJ altered) (JJ hypo-prothrombinemic) (NN effect)) (-RRB- -RRB-))) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NP (NP (JJ other) (NNS inducers)) (PP (IN of) (NP (NP (JJ hepatic) (JJ microsomal) (NN enzyme) (NN oxidation) (NN system)) (PRN (-LRB- -LRB-) (NP (NP (VBN decreased) (NN effect)) (PP (IN of) (NP (NNS drug4)))) (-RRB- -RRB-))))) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (VBN increased) (NN effect) (IN of) (NN drug6)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (IN because) (S (NP (NN drug4)) (VP (VBZ is) (VP (VBN displaced) (PP (IN from) (NP (PRP$ its) (NN binding) (NNS sites))) (PP (IN during) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug5)))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJR lower) (NN plasma) (NNS concentrations)) (, ,) (NP (NN peak) (NN plasma) (NNS levels)) (, ,) (CC and) (NP (NN AUC) (NNS values)))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN While) (S (NP (NNS studies)) (VP (VBP have) (RB not) (VP (VBN shown) (NP (NN drug2)) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NN drug3)))))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (, ,) (ADVP (RB nonetheless)) (, ,) (SBAR (IN since) (S (NP (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN seen) (PP (IN with) (NP (JJ other) (NN drug4)))))))))))) (. .))))
(S1 (S (SBAR (IN Because) (S (S (NP (NNS prostaglandins)) (VP (VBP play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NN hemostasis))))) (, ,) (CC and) (S (NP (NN drug1)) (VP (VBP affect) (NP (NN platelet) (NN function)) (PP (IN as) (NP (NN well))))))) (, ,) (NP (NP (JJ concurrent) (NN therapy)) (PP (IN with) (NP (NP (NP (DT all) (NNS drug2)) (, ,) (PP (VBG including) (NP (NN drug3))) (, ,)) (CC and) (NP (NNS drug4))))) (VP (VBZ requires) (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (NNS patients)))) (S (VP (TO to) (VP (VB be) (ADJP (JJ certain) (SBAR (IN that) (S (NP (NP (DT no) (NN change)) (PP (IN in) (NP (PRP$ their) (NN drug5) (NN dosage)))) (VP (VBZ is) (VP (VBN required)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3))) (: :) (NP (NN drug4))) (, ,) (PP (IN like) (NP (JJ other) (NN drug5))) (, ,) (VP (MD may) (VP (VP (VB affect) (NP (JJ renal) (NNS prostaglandins))) (CC and) (VP (VB increase) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (JJ certain) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (NP (NN Ingestion)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VP (VB increase) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))) (CC and) (VP (VB increase) (NP (NN drug4) (NN s) (NN nephrotoxicity)))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (SBAR (SBAR (WHNP (WP who)) (S (VP (VBP begin) (VP (VBG taking) (NP (NN drug1)))))) (CC or) (SBAR (WHNP (WP who)) (S (VP (VBP increase) (NP (NP (PRP$ their) (NN drug2) (NN dose)) (CC or) (NP (DT any) (JJ other) (NN drug3))) (SBAR (IN while) (S (VP (VBG taking) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (NN drug6))))))))))) (VP (MD may) (VP (VBP develop) (NP (NP (NN toxicity) (NNS characteristics)) (PP (IN for) (NP (DT these) (NNS drugs))))))) (. .)))
(S1 (S (S (NP (PRP They)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (, ,) (SBAR (RB particularly) (IN if) (S (NP (JJ renal) (NN function)) (VP (VBZ is) (VP (VBN impaired))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NN serum) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VP (VBZ decreases) (NP (NN drug3) (JJ renal) (NN clearance))) (CC and) (VP (VBZ increases) (NP (NN drug4) (NN plasma) (NNS levels))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (ADVP (RB concomitantly)))))) (, ,) (NP (NN drug3) (NN toxicity)) (VP (MD may) (VP (VB develop)))) (. .)))
(S1 (S (S (NP (JJ Oral) (NN drug1) (: :) (NN drug2)) (VP (VP (VBZ does) (RB not) (VP (VB alter) (NP (NP (NN glucose) (NN metabolism)) (PP (IN in) (NP (JJ normal) (NNS subjects)))))) (CC nor) (VP (VBZ does) (NP (NP (PRP it)) (VP (VBP alter) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ oral) (NN drug3))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (JJ rare) (NNS reports)) (, ,) (ADVP (RB however)) (, ,) (PP (IN from) (NP (JJ marketing) (NNS experiences))) (, ,) (PP (IN of) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (JJ oral) (NN drug2)))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN drug3)) (SBAR (WHNP (WDT that)) (S (VP (VBD necessitated) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS doses)) (PP (IN of) (NP (JJ such) (NNS agents)))))))))))))))))))) (. .)))
(S1 (S (S (NP (ADJP (CC Both) (ADJP (JJ hypo-)) (CC and) (ADJP (JJ hyperglycemic))) (NNS effects)) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (S (NP (DT A) (JJ direct) (JJ causal) (NN relationship)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established))))) (, ,) (CC but) (S (NP (NNS physicians)) (VP (MD should) (VP (VB consider) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB alter) (NP (NP (DT a) (JJ diabetic) (NN patient) (NN s) (NN response)) (PP (TO to) (NP (NP (NN drug2)) (CC or) (NP (JJ oral) (NN drug3)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)) (CC and) (NP (JJ other) (NN drug3))) (VP (MD can) (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN treatment)) (PP (IN with) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (NN serum) (NN potassium) (NNS levels))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NNS Drugs)) (: :) (S (PP (IN In) (NP (NP (JJ small) (NNS groups)) (PP (IN of) (NP (NP (NNS patients)) (PRN (-LRB- -LRB-) (NP (JJ 7-10/interaction) (NN study)) (-RRB- -RRB-)))))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC or) (NP (NN drug7))))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (DT the) (NN peak) (NNS levels)) (CC and) (NP (NP (NN AUC) (NNS values)) (PP (IN of) (NP (NN drug8)))))))) (. .))))
(S1 (S (S (NP (JJ drug1) (NN toxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB have) (VP (VBN occurred) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN on) (NP (NP (JJ chronic) (NN drug2) (NN treatment)) (PP (VBG following) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN drug3) (NN therapy))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Protein) (NN Binding)) (ADVP (FW In) (FW vitro)) (, ,) (NP (NN drug1))) (VP (VBZ interferes) (UCP (ADVP (RB minimally)) (CC or) (PP (RB not) (IN at) (NP (NP (DT all)) (PP (IN with) (NP (NP (DT the) (NN protein) (NN binding)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 20) (NN %)) (NN decrease)) (PP (IN in) (NP (NN binding)))) (-RRB- -RRB-))) (, ,) (NP (NN drug3)) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 10) (NN %)) (NN decrease)) (PP (IN in) (NP (NN binding)))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NN drug5))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8))) (VP (VBP have) (NP (DT no) (NN influence)) (ADVP (FW in) (FW vitro)) (PP (IN on) (NP (NP (DT the) (NN protein) (NN binding)) (PP (IN of) (NP (NN drug9))) (PP (IN in) (NP (JJ human) (NN serum))))))) (. .)))
(S1 (S (S (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (VP (NN Effect) (PP (IN on) (NP (NN Blood) (NN Coagulation))))) (: :) (S (NP (NN drug1)) (VP (VP (VBZ increases) (NP (NP (NN platelet) (NN aggregation)) (NN time))) (CC but) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (JJ bleeding) (NN time)) (, ,) (NP (NN plasma) (NN thrombin) (NN clotting) (NN time)) (, ,) (NP (NN plasma) (NN fibrinogen)) (, ,) (CC or) (NP (NP (NNS factors) (NP (NP (CD V)) (CC and) (NP (NN VII)))) (PP (TO to) (NP (NN XII))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (RB Statistically) (JJ significant)) (NNS changes)) (PP (IN in) (NP (ADJP (ADJP (JJ prothrombin)) (CC and) (ADJP (JJ partial))) (NN thromboplastin) (NNS times)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (JJ normal) (NNS volunteers))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ mean) (NNS changes)) (VP (VP (VBD were) (VP (VBN observed) (S (VP (TO to) (VP (VB be) (ADJP (ADJP (RBR less)) (PP (IN than) (NP (CD 1) (NN second))) (PP (IN in) (NP (DT both) (NNS instances))) (, ,) (ADVP (RB however)))))))) (, ,) (CC and) (VP (VBP are) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB be) (ADJP (RB clinically) (JJ important))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN prostaglandin) (NN synthetase) (NN inhibitor)) (, ,) (NP (RB however))))) (, ,) (CC and) (S (NP (NP (DT all) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN prostaglandin) (NN synthesis)))))) (VP (VBP interfere) (PP (IN with) (NP (NN platelet) (NN function))) (PP (TO to) (NP (DT some) (NN degree))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (MD may) (VP (VB be) (VP (ADVP (RB adversely)) (VBN affected) (PP (IN by) (NP (PDT such) (DT an) (NN action))))))))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN observed))))) (. .)))
(S1 (S (S (NP (NP (JJ Certain) (JJ other) (NNS drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (-RRB- -RRB-))) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (DT the) (NN nerve) (NN transmission))) (PP (IN at) (NP (DT the) (JJ neuromuscular) (NN junction)))))))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (DT this) (VBN reported) (NN activity)))) (, ,) (NP (PRP they)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug1) (JJ Parenteral))) (PP (IN except) (PP (IN with) (NP (DT the) (JJS greatest) (NN caution)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug2))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ other) (NNS drugs)) (, ,) (PP (VBG including) (NP (NP (NN ether)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6)))) (, ,))) (VP (VP (VB potentiate) (NP (DT the) (JJ neuromuscular) (NN blocking) (NN effect))) (CC and) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NP (JJ extreme) (NN caution)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN drug7) (JJ Parenteral)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN nephrotoxicity)) (PP (IN of) (NP (NN drug2) (JJ Parenteral))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (JJ Parenteral))))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (NP (NP (NN Antiacid)) (, ,) (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NNP Indanavir) (, ,) (NN drug5) (, ,) (NN drug6) (, ,) (NN Phenobarbitol) (, ,) (NN drug7) (, ,) (NN drug8) (, ,) (NN drug9) (, ,) (NNP Ritanovir)) (, ,) (NP (NN drug10)) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (NN drug1)) (VP (VBN used) (ADVP (RB alone)))) (VP (VBZ has) (NP (NP (ADJP (JJ little))) (CC or) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN pupil) (NN size)))))))) (, ,) (NP (NP (NNS mydriasis)) (VP (VBG resulting) (PP (IN from) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (NP (JJ Close) (NN observation)) (PP (IN of) (NP (DT the) (NN patient)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (DT a) (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ catecholamine-depleting) (NNS drugs)) (PP (JJ such) (IN as) (NP (NN drug2))) (, ,) (PP (IN because) (PP (IN of) (NP (NP (JJ possible) (JJ additive) (NNS effects)) (CC and) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (NN hypotension)) (CC and/or) (NP (JJ marked) (NN bradycardia)))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB produce) (NP (NP (NN vertigo)) (, ,) (NP (NN syncope)) (CC or) (NP (JJ postural) (NN hypotension)))))))))))))))))) (. .)))
(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NN drug1)) (PP (IN along) (PP (IN with) (NP (ADJP (CC either) (ADJP (JJ oral)) (CC or) (ADJP (JJ intravenous))) (NNS drug2)))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (NP (JJ possible) (JJ atrioventricular) (NN conduction) (NNS disturbances)) (, ,) (NP (JJ left) (JJ ventricular) (NN failure)) (CC and) (NP (NN hypotension))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ impaired) (JJ cardiac) (NN function))))) (, ,) (NP (JJ simultaneous) (NN use)) (VP (MD should) (VP (VB be) (VP (VBN avoided) (ADVP (RB altogether)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (NNS s)))) (VP (MD may) (VP (VB have) (NP (JJ additive) (NNS effects)) (PP (IN on) (S (VP (VBG prolonging) (NP (JJ atrioventricular) (NN conduction) (NN time)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD may) (VP (VB have) (NP (JJ additive) (JJ hypotensite) (NNS effects)) (PP (JJ due) (TO to) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (DT each) (JJ other) (NN s) (NN metabolism)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ concurrent) (NN use)) (VP (MD may) (VP (VB blunt) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NN drug2))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN withdrawn) (PP (IN at) (NP (QP (JJS least) (CD 48)) (NNS hours))) (PP (IN before) (S (VP (VBG conducting) (NP (DT an) (JJ drug2) (JJ -mediated) (NN stress) (NN test))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (CONJP (JJ such) (IN as)) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4))) (-RRB- -RRB-))) (: :) (S (NP (NP (JJ concurrent) (NN use)) (PP (IN with) (NP (NN drug5)))) (VP (MD may) (VP (VB have) (NP (DT a) (JJ proarrhythmic) (NN effect))))) (. .))))
(S1 (S (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (NP (ADJP (ADJP (JJ drug3)) (CC or) (ADJP (JJ other))) (NN drug4)) (, ,) (CC or) (NP (NN drug5))) (: :) (S (NP (NP (JJ concurrent) (NN use)) (PP (IN with) (NP (NN drug6)))) (VP (MD may) (VP (VB produce) (NP (JJ additive) (ADJP (ADJP (JJ inotropic)) (CC and/or) (ADJP (JJ chronotropic))) (NNS effects))))) (. .))))
(S1 (S (S (NP (NP (JJ Other) (NNS drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (JJ general) (NN drug5)))) (-RRB- -RRB-))) (VP (VBP have) (NP (JJ additive) (CC or) (NN potentiating) (NNS effects)) (PP (IN with) (NP (NN drug6))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NNS patients)) (VP (VBP have) (VP (VBN received) (NP (JJ such) (NNS drugs)))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN required))))) (VP (MD will) (VP (VB be) (ADJP (ADJP (JJR less)) (PP (IN than) (NP (JJ usual))))))) (. .)))
(S1 (S (S (PP (VBG Following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (JJ other) (NNS drug2)))) (VP (MD should) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ known) (NN drug/drug) (NNS interactions)) (PP (IN with) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VBP have) (NP (NP (JJ neuromuscular) (NN blocking) (NNS properties)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (JJ other) (NN drug2)))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ such) (NNS agents))))))))) (. .)))
(S1 (S (S (NP (NN Antagonism)) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (ADVP (FW in) (FW vitro)))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (JJ possible) (JJ clinical) (NN significance)))) (, ,) (NP (DT these) (CD two) (NNS drugs)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently)))))) (. .)))
(S1 (S (NP (NP (NP (NNS Interactions)) (PP (IN with) (NP (JJ Other) (NN CNS) (NNS Agents)))) (: :) (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (DT all) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (JJ other) (NN drug6)) (, ,) (NP (JJ general) (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (CC and) (NP (NN drug13))) (-RRB- -RRB-))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ additive) (JJ central) (JJ nervous) (NN system) (NN depressant) (NNS effects)))))) (. .))))
(S1 (S (S (NP (NP (JJ Respiratory) (NN depression)) (, ,) (NP (NN hypotension)) (, ,) (CC and) (NP (JJ profound) (NP (NP (NN sedation)) (CC or) (NP (NN coma))))) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (JJ combined) (NN therapy)) (VP (VBZ is) (VP (VBN contemplated))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (CD one)) (CC or) (NP (DT both)) (NP (NNS agents))))) (VP (MD should) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT no) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN observed)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN recommended) (PP (IN for) (NP (NP (NN use)) (PP (IN with) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (JJS Most) (NNS cases)) (PP (IN of) (NP (NP (JJ serious) (CC or) (JJ fatal) (JJ adverse) (NNS events)) (VP (VBG involving) (NP (NP (NN drug1)) (VP (VBN reported) (PP (TO to) (NP (DT the) (NP (NN manufacturer)) (CC or) (NP (DT the) (NN FDA)))))))))) (VP (VBP have) (VP (VBN involved) (NP (CC either) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NP (JJ large) (JJ initial) (NNS doses)) (CC or) (NP (ADJP (RB too) (JJ frequent)) (NNS doses))) (PP (IN of) (NP (DT the) (NN drug))))) (PP (TO to) (NP (JJ nonopioid) (JJ tolerant) (NNS patients)))) (, ,) (CC or) (NP (NP (DT the) (JJ simultaneous) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBG affecting) (NP (NN respiration)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ initial) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (CC or) (NP (JJR more)))) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN given) (PP (TO to) (NP (NNS patients))) (PP (IN along) (PP (IN with) (NP (NP (DT another) (NN drug)) (VP (VBG affecting) (NP (NN respiration)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Interactions)) (PP (IN with) (NP (NN drug1)))) (: :) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (CC and) (NP (NN drug7))) (-RRB- -RRB-)))) (VP (MD should) (RB NOT) (VP (VB be) (VP (VBN administered) (PP (TO to) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VP (VBZ has) (VP (VBN received))) (CC or) (VP (VBZ is) (VP (VBG receiving) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NP (NN therapy)) (PP (IN with) (NP (NP (DT a) (NN drug8)) (PP (JJ such) (IN as) (NP (NN drug9))))))))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ drug1) (JJ -dependent) (NNS patients))) (, ,) (NP (NN drug2)) (VP (MD may) (VP (VB precipitate) (NP (NN withdrawal) (NNS symptoms))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN mg)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN coadministered) (PP (IN with) (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))) (PP (IN in) (NP (NP (JJ controlled) (JJ clinical) (NN pharmacology) (NNS studies)) (PP (IN in) (NP (JJ adult) (NNS volunteers))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NN AUC) (CD 0-24) (NNS hrs)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN drug1)) (CC and/or) (NP (NN drug2))))) (VP (VBD were) (VP (VBN observed) (PP (VBG following) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug3)) (PP (IN with) (NP (NP (DT each)) (PP (IN of) (NP (DT these) (NNS drugs))))) (PP (IN in) (NP (NP (JJ normal) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 24)) (PP (IN in) (NP (DT each) (NN study))) (-RRB- -RRB-)))))))))))) (, ,) (NP (EX there)) (VP (VBD were) (NP (DT no) (ADJP (RB clinically) (JJ relevant)) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN safety) (NN profile)) (PP (IN of) (NP (NN drug4))))) (, ,) (SBAR (IN as) (S (VP (VBN assessed) (PP (IN by) (NP (NP (JJ electrocardiographic) (NNS parameters)) (, ,) (NP (JJ clinical) (NN laboratory) (NNS tests)) (, ,) (NP (JJ vital) (NNS signs)) (, ,) (CC and) (NP (JJ adverse) (NNS events))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (NP (DT no) (JJ significant) (NNS effects)) (PP (IN on) (NP (NN QTc) (NNS intervals)))) (, ,) (CC and) (NP (NP (DT no) (NNS reports)) (PP (IN of) (NP (NP (NN sedation)) (CC or) (NP (NN syncope)))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NNS effects)) (PP (IN on) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))))) (VP (VBD were) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (NP (NN Plasma) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NN AUC) (NN 0-24) (NNS hrs)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug1)))) (VP (VBD decreased) (NP (CD 15) (NN %)) (PP (IN with) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NNS drug2)) (ADJP (JJ relative) (PP (TO to) (NP (NP (DT that)) (VP (VBN observed) (PP (IN with) (NP (NP (NN drug3)) (ADVP (RB alone)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN relevance)) (PP (IN of) (NP (DT this) (NN difference)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (DT These) (JJ above) (NNS findings)) (VP (VBP are) (VP (VBN summarized) (PP (IN in) (NP (NN TABLE) (CD 1)))))) (. .)))
(S1 (S (NP (NP (NN TABLE) (CD 1) (NNS Effects)) (PP (IN on) (NP (NP (NP (NN Plasma) (NNS Concentrations)) (PRN (-LRB- -LRB-) (NP (NN AUC) (NN 0-24) (NNS hrs)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN After) (NP (NP (CD 10) (NNS Days)) (PP (IN of) (NP (NP (NN Coadministration)) (PRN (-LRB- -LRB-) (NP (NN drug3) (CD 10) (NN mg)) (-RRB- -RRB-)))))))))) (PP (IN in) (NP (JJ Normal) (NNS Volunteers))))))
(S1 (S (NP (NN drug1) (NN drug2))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mg) (NN q8h)) (-RRB- -RRB-))) (CC +) (NP (CD 40) (NN %) (CD +46) (NN %)))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 300) (NN mg) (JJ qid)) (-RRB- -RRB-))) (NP (NP (CD +103) (NN %)) (CC +) (NP (CD 6) (NN %))))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 200) (NN mg)) (PP (IN q12h))) (-RRB- -RRB-))) (NP (NN +307) (NN %) (CD +73) (NN %)))))
(S1 (S (S (NP (EX There)) (VP (VBZ does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ adverse) (NNS events)) (PP (IN in) (NP (NP (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (JJ oral) (NN drug1)) (CC and) (NP (NN drug2))))))))))))))))) (. .)))
(S1 (S (S (NP (DT No) (NN drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NP (NP (DT the) (NN metabolism)) (CC or) (NP (JJ renal) (JJ tubular) (NN excretion))) (PP (IN of) (NP (NP (JJ many) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (QP (CD drug11) (, ,) (CD drug12) (, ,) (CD drug13) (, ,) (CD drug14)) (NNS agents)) (, ,) (NP (NN drug15)) (, ,) (CC and) (NP (NN drug16)))) (-RRB- -RRB-)))))))))))) (. .))))
(S1 (S (S (NP (JJ Concomitant) (NNS medications)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN assessed))))) (. .)))
(S1 (S (NP (NN drug1)) (VP (VP (MD should) (ADVP (RB either)) (VP (VB be) (ADVP (RB temporarily)) (VP (VBN discontinued)))) (CC or) (VP (VBD decreased) (PP (IN by) (NP (CD 50) (NN %))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug2))) (PP (IN on) (NP (NP (DT the) (NN day)) (PP (IN of) (NP (NN drug3) (NN infusion)))))))))) (. .)))
(S1 (S (NP (NP (JJ Nephrotoxic) (NNS agents)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NNS agents)))) (PP (IN with) (NP (NP (JJ nephrotoxic) (JJ potential) (NN -LSB-e.g.)) (, ,) (NP (NP (JJ intravenous) (NN drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))) (-RRB- -RRB-))) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (JJ intravenous) (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC and) (NP (NN drug10)) (-RRB- -RSB-)))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .))))
(S1 (S (S (NP (JJ Such) (NNS agents)) (VP (MD must) (VP (VB be) (VP (VBN discontinued) (NP (NP (QP (IN at) (JJS least) (CD seven)) (NNS days)) (ADJP (JJ prior) (PP (TO to) (S (VP (VBG starting) (NP (NN therapy)) (PP (IN with) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (, ,) (NP (DT a) (NN drug2)) (, ,)) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (JJ bactericidal) (NN effect)) (PP (IN of) (NP (NN drug3))))))) (CC and) (S (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD should) (VP (VB be) (VP (VBN avoided)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (JJ other) (NNS drug2))))) (VP (MD may) (VP (VB have) (NP (DT an) (JJ additive) (NN effect))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (JJ significant) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN confirmed) (ADVP (RB clinically)))))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (ADVP (RB also)) (VP (VBZ has) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ intracellular) (NN phosphorylation)) (PP (IN of) (NP (NN drug2))))) (, ,) (SBAR (IN as) (S (VP (VBN shown) (ADVP (FW in) (FW vitro)) (PP (PP (IN in) (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))) (CC or) (PP (IN in) (NP (NP (CD two) (JJ other) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP (NP (NN U937)) (CC and) (NP (NN Molt-4))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ same) (NN study))) (NP (PRP it)) (VP (VBD was) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ intracellular) (NN phosphorylation)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN in) (NP (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)) (, ,) (NP (NN U937)) (CC and) (NP (NN Molt-4) (NNS cells))))) (VP (VBD revealed) (SBAR (IN that) (S (NP (NN drug2)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN drug3) (NN phosphorylation)) (PP (IN in) (NP (DT a) (ADJP (NN dose) (JJ dependent)) (NN manner)))))))) (. .))))
(S1 (S (S (S (NP (NNS Effects)) (VP (VBD were) (ADVP (RB already)) (VP (VBN seen) (PP (IN with) (NP (NP (NNS doses)) (VP (VBG corresponding) (PP (TO to) (NP (NP (JJ relevant) (NN plasma) (NNS levels)) (PP (IN in) (NP (NNS humans))))))))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ intracellular) (NN phosphorylation)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (PRP$ its) (CD three) (NNS metabolites)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (DT the) (JJ active) (NN zalcitabine) (NN triphosphate) (NN metabolite))) (-RRB- -RRB-))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN inhibited))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD inhibited) (NP (NN drug2) (NN phosphorylation)) (PP (IN at) (NP (JJ high) (NN concentration) (NNS ratios))) (PRN (-LRB- -LRB-) (QP (CD 10) (CC and) (CD 100)) (-RRB- -RRB-)))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (ADJP (JJ unlikely) (SBAR (IN that) (S (NP (NP (DT this) (NN decrease)) (PP (IN of) (NP (VBN phosphorylated) (NN drug1) (NN concentration)))) (VP (VBZ is) (PP (IN of) (NP (JJ clinical) (NN significance))) (, ,) (SBAR (IN as) (S (NP (NN drug2)) (VP (VBZ is) (NP (NP (DT a) (ADJP (RBR more) (JJ efficient)) (NN substrate)) (PP (IN for) (NP (NN deoxycytidine) (NN kinase))) (PP (IN than) (NP (NN drug3))))))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (ADJP (FW in) (FW vitro)) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NNS humans)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ sub-therapeutic) (NNS concentrations)) (PP (IN of) (NP (NP (JJ active) (JJ phosphorylated) (NN drug3)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (VBN decreased) (NN drug4) (NN effect)) (PP (IN of) (NP (NN drug5))))))))))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ unknown)) (SBAR (WHADVP (WRB how)) (S (NP (NP (DT the) (NN effect)) (VP (VBN seen) (PP (IN in) (NP (DT these) (ADJP (FW in) (FW vitro)) (NNS studies))))) (VP (VBZ translates) (PP (IN into) (NP (JJ clinical) (NNS consequences)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))))) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (PRN (-LRB- -LRB-) (PP (IN as) (NP (JJ triple) (NN combination))) (-RRB- -RRB-)) (PP (IN in) (NP (NNS adults))))))) (. .))))
(S1 (S (S (NP (JJ Pharmacokinetic) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NP (NN absorption)) (, ,) (NP (NN metabolism)) (, ,) (CC and) (NP (NN elimination))) (PP (IN of) (NP (NP (DT each)) (PP (IN of) (NP (DT these) (NNS drugs)))))) (VP (VBP are) (ADJP (JJ unchanged)) (SBAR (WHADVP (WRB when)) (S (NP (PRP they)) (VP (VBP are) (VP (VBN used) (ADVP (RB together))))))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Drugs)) (VP (VBN Associated) (PP (IN With) (NP (JJ Peripheral) (NN Neuropathy))))) (: :) (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB cause) (NP (JJ peripheral) (NN neuropathy)))))))))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (WHADVP (WRB where)) (FRAG (JJ possible))))))) (. .))))
(S1 (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (JJ peripheral) (NN neuropathy))) (S (VP (VBP include) (NP (NP (NN drug1)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (NN drug13)) (, ,) (NP (NN drug14)) (, ,) (NP (NN drug15)) (, ,) (CC and) (NP (NN drug16))))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (JJ Intravenous) (NN drug1)) (: :) (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN drug2)))) (VP (MD should) (VP (VB be) (VP (VBN interrupted))) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (DT a) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (VBZ has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB cause) (NP (NN pancreatitis)))))))))))) (VP (VBZ is) (VP (VBN required))))))) (. .))))
(S1 (S (S (NP (NP (NN Death)) (PP (IN due) (TO to) (NP (JJ fulminant) (NN pancreatitis))) (ADJP (ADVP (RB possibly)) (JJ related) (PP (TO to) (NP (NP (JJ intravenous) (NN drug1)) (CC and) (NP (NN drug2)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (JJ intravenous) (NN drug1)) (VP (VBZ is) (VP (VBN required) (S (VP (TO to) (VP (VB treat) (NP (NN Pneumocystis) (NN carinii) (NNS pneumonia))))))))) (, ,) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug2)))) (VP (MD should) (VP (VB be) (VP (VBN interrupted))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (: :) (S (NP (NP (NNS Drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NP (NP (JJ peripheral) (NN neuropathy)) (CC or) (NP (JJ other) (NN drug7))) (JJ -associated) (JJ adverse) (NNS events)) (PP (IN by) (S (VP (VBG interfering) (PP (IN with) (NP (NP (NP (DT the) (JJ renal) (NN clearance)) (PP (IN of) (NP (NN drug8)))) (PRN (-LRB- -LRB-) (ADVP (RB thereby)) (VP (VBG raising) (NP (JJ systemic) (NN exposure))) (-RRB- -RRB-)))))))))))))) (. .))))
(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP require) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (NNS drugs))))) (PP (IN with) (NP (NN drug1)))))))) (VP (MD should) (VP (VBP have) (NP (JJ frequent) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ laboratory))) (NN monitoring)) (PP (IN with) (NP (NP (JJ dosage) (NN adjustment)) (PP (IN for) (NP (NP (DT any) (JJ significant) (NN change)) (PP (IN in) (NP (JJ renal) (NN function))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug3)) (CC or) (NP (NN drug4))))) (VP (VBZ decreases) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NN drug5)))) (, ,) (PP (ADVP (RBS most) (RB likely)) (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN drug6))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (DT these) (NNS drugs)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug1))))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NN toxicity))))))))) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug2)))) (VP (VBD reduced) (SBAR (IN if) (S (VP (VBN warranted)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2) (JJ -containing) (NN drug3)) (: :) (NP (NP (NN Absorption)) (PP (IN of) (NP (NN drug4))))) (VP (VBZ is) (ADVP (RB moderately)) (VP (VBN reduced) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD 25)) (NN %)) (-RRB- -RRB-)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug5) (: /) (NN drug6) (JJ -containing) (NN drug7))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN reduction)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (, ,) (ADVP (RB hence)) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN recommended) (S (VP (TO to) (VP (VB be) (VP (VBN ingested) (ADVP (RB simultaneously)) (PP (IN with) (NP (NN drug2) (: /) (NN drug3) (JJ -containing) (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN Bioavailability))) (VP (VBZ is) (ADVP (RB mildly)) (VP (VBN reduced) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD 10)) (NN %)) (-RRB- -RRB-)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBP are) (VP (VBN coadministered)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBD caused) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN drug3) (NN phosphorylation)))) (-LRB- -LRB-) (NP (NP (ADJP (CD 50) (NN %)) (NN inhibition)) (PP (IN of) (NP (JJ total) (NN phosphate) (NN formation)))) (-RRB- -RRB-)) (PP (IN in) (NP (NN U937/Molt) (CD 4) (NNS cells))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (MD may) (VP (VB be) (NP (VBN decreased) (NN drug1) (NN activity)) (PP (IN because) (IN of) (NP (JJ lessened) (JJ active) (NN metabolite) (NN formation))))))) (, ,) (NP (NP (DT the) (JJ clinical) (NN relevance)) (PP (IN of) (NP (DT these) (ADJP (FW in) (FW vitro)) (NNS results)))) (VP (VBP are) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (NP (NP (DT No) (NN Information)) (VP (VBN Provided)))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VP (VBP add) (PP (TO to))) (CC or) (VP (VB potentiate) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (JJ other) (NNS drug2)))))))) (. .)))
(S1 (S (S (NP (NN Potentiation)) (VP (VBZ occurs) (PP (IN with) (NP (NN drug1))))) (. .)))
(S1 (S (S (NP (NP (NN Medication)) (PP (JJ such) (IN as) (NP (NN drug1)))) (VP (MD may) (ADVP (RB also)) (VP (VB influence) (NP (NN serum) (NNS electrolytes))))) (. .)))
(S1 (S (S (NP (NP (JJ Warning) (NNS signs)) (, ,) (ADJP (JJ irrespective) (PP (IN of) (NP (NN cause)))) (, ,)) (VP (VBP are) (: :) (NP (NP (NP (NP (NN dryness)) (PP (IN of) (NP (NP (NN mouth)) (, ,) (NP (NN thirst)) (, ,) (NP (NN weakness)) (, ,) (NP (NN lethargy)) (, ,) (NP (NN drowsiness)) (, ,) (NP (NN restlessness)) (, ,) (NP (NN muscle) (NNS pains)) (CC or) (NP (NN cramps))))) (, ,) (NP (JJ muscular) (NN fatigue)) (, ,) (NP (NN hypotension)) (, ,) (NP (NN oliguria)) (, ,) (NP (NN tachycardia)) (, ,) (CC and) (NP (JJ gastrointestinal) (NNS disturbances))) (PP (JJ such) (IN as) (NP (NP (NN nausea)) (CC and) (NP (NN vomiting))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NNS requirements)) (PP (IN in) (NP (JJ diabetic) (NNS patients)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (VBN increased)) (, ,) (ADJP (VBN decreased)) (, ,) (CC or) (ADJP (JJ unchanged)))))) (. .)))
(S1 (S (S (NP (NP (JJR Higher) (NN dosage)) (PP (IN of) (NP (JJ oral) (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (NP (JJ Latent) (NN diabetes) (NN mellitus)) (VP (MD may) (VP (VB become) (VP (VBP manifest) (PP (IN during) (NP (NN drug1) (NN administration))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (JJ related) (NNS drugs))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN responsiveness)) (PP (TO to) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (JJ related) (NNS drugs))) (VP (MD may) (VP (VB decrease) (NP (NP (JJ arterial) (NN responsiveness)) (PP (TO to) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (DT This) (NN diminution)) (VP (VBZ is) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB preclude) (NP (NP (NN effectiveness)) (PP (IN of) (NP (NP (DT the) (JJ pressor) (NN agent)) (PP (IN for) (NP (JJ therapeutic) (NN use)))))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (S (NP (NN drug1)) (VP (MD can) (VP (VB displace) (NP (NN drug2) (NNS s)) (, ,) (PP (JJ such) (IN as) (NP (NN drug3))) (, ,) (PP (IN from) (NP (PRP$ their) (JJ protein-binding) (NNS sites))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN started) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB already)) (VBG receiving) (NP (NN drug2))))))))) (, ,) (S (S (NP (NN prothrombin) (NNS times)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (CC and) (S (NP (NP (NN adjustment)) (PP (IN of) (NP (DT the) (NN drug3) (NN dose)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Prior) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ has) (NP (DT no) (ADJP (RB clinically) (JJ important)) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ neuromuscular) (NN blocking) (NN action)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN before) (NP (NN drug2))))) (S (VP (TO to) (VP (VB attenuate) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NNS drug3)))))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ clinical) (NNS data)) (PP (IN on) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (JJ nondepolarizing) (NNS drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (VP (VBP decrease) (NP (NP (DT the) (NN ED50)) (PP (IN of) (NP (NN drug4)))) (PP (IN by) (NP (CD 30) (NN %) (TO to) (CD 45) (NN %))))) (. .)))
(S1 (S (S (NP (DT These) (NNS agents)) (VP (MD may) (ADVP (RB also)) (VP (VB prolong) (NP (NP (DT the) (ADJP (RB clinically) (JJ effective)) (NN duration)) (PP (IN of) (NP (NN action)))) (PP (IN by) (NP (QP (RB up) (TO to) (CD 25)) (NN %)))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ neuromuscular) (NN blocking) (NN action)) (PP (IN of) (NP (NP (JJ nondepolarizing) (NNS agents)) (PP (JJ such) (IN as) (NP (NN drug1))))))))))) (VP (VBP include) (NP (NP (NP (JJ certain) (NN drug2)) (PRN (-LRB- -LRB-) (NP (FW e.) (FW g.)) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC and) (NP (CD drug10))) (-RRB- -RRB-))) (, ,) (NP (NN drug11) (NNS salts)) (, ,) (NP (NN drug12)) (, ,) (NP (JJ local) (NN drug13)) (, ,) (NP (NN drug14)) (, ,) (CC and) (NP (NN drug15))))) (. .)))
(S1 (S (S (PP (IN As) (PP (IN with) (NP (DT some) (JJ other) (NN drug1)))) (, ,) (S (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN onset)) (PP (IN of) (NP (NP (JJ neuromuscular) (NN block)) (VP (VBN induced) (PP (IN by) (NP (NN drug2))))))))) (VP (VBZ is) (VP (VBN lengthened)))) (CC and) (S (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN block)))) (VP (VBZ is) (VP (VBD shortened) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))))))))) (. .)))
(S1 (S (S (NP (NNS Oils)) (VP (MD may) (VP (VB enhance) (NP (NN absorption))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ simultaneous) (NN use)) (PP (IN of) (NP (NP (NNS creams)) (, ,) (NP (NNS ointments)) (CC or) (NP (NNS oils))))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (NN CYP2D6))) (: ;))))
(S1 (S (NP (NP (NP (JJ poor) (NNS metabolizers)) (PP (IN of) (NP (NN drug1)))) (: :) (S (S (NP (NP (NNS Interactions)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NP (JJ strong) (NNS inhibitors)) (PP (IN of) (NP (NP (NNS CYP2D6)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))))) (-RRB- -RRB-))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (, ,) (CC but) (S (NP (DT these) (NNS drugs)) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NP (NN blood) (NNS levels)) (PP (IN of) (NP (NP (DT the) (NP (NP (NN R)) (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NN enantiomer)) (PP (IN of) (NP (NN drug7)))))))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Retrospective) (NN analysis)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (PP (IN in) (NP (JJ clinical) (NNS trials)))))) (VP (VBD showed) (SBAR (IN that) (S (NP (JJ poor) (NN 2D6) (NNS metabolizers)) (VP (VBD had) (NP (NP (DT a) (JJR higher) (NN rate)) (PP (IN of) (NP (NN dizziness)))) (PP (IN during) (NP (NN up-titration))) (, ,) (S (ADVP (RB presumably)) (VP (VBG resulting) (PP (IN from) (NP (NP (JJ vasodilating) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJR higher) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ a-blocking) (NP (NP (NN R)) (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NN enantiomer)))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Catecholamine-depleting) (NNS Agents)) (: :) (S (NP (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NP (CC both) (NP (NN drug1)) (CC and) (NP (DT a) (NN drug))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB deplete) (NP (NNS catecholamines))))))))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (-RRB- -RRB-))) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NP (NN hypotension)) (CC and/or) (NP (JJ severe) (NN bradycardia)))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (MD may) (VP (VB potentiate) (NP (ADJP (ADJP (JJ blood-pressure-)) (CC and) (ADJP (JJ heart-rate-lowering))) (NNS effects))))) (. .))))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN terminated)))))))) (, ,) (NP (DT the) (NN drug3)) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (ADVP (RB first)))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN therapy)) (VP (MD can) (ADVP (RB then)) (VP (VB be) (VP (VBN discontinued) (ADVP (NP (JJ several) (NNS days)) (RB later)) (PP (IN by) (S (VP (ADVP (RB gradually)) (VBG decreasing) (NP (DT the) (NN dosage))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Modest) (NNS increases)) (PP (IN in) (NP (JJ mean) (NN trough) (NN drug2) (NNS concentrations)))) (VP (VBD were) (VP (VBN observed) (PP (VBG following) (NP (NP (NN initiation)) (PP (IN of) (NP (NN drug3) (NN treatment))) (PP (IN in) (NP (NP (CD 21) (JJ renal) (NN transplant) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (JJ chronic) (JJ vascular) (NN rejection))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (QP (RB about) (CD 30)) (NN %)) (PP (IN of) (NP (NNS patients))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (VBD had) (S (VP (TO to) (VP (VB be) (VP (VBN reduced) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB maintain) (NP (NN drug2) (NNS concentrations)) (PP (IN within) (NP (DT the) (JJ therapeutic) (NN range))))))))))) (, ,) (SBAR (IN while) (S (PP (IN in) (NP (DT the) (NN remainder))) (NP (DT no) (NN adjustment)) (VP (VBD was) (VP (VBN needed))))))) (. .)))
(S1 (S (S (PP (IN On) (NP (NP (DT the) (NN average)) (PP (IN for) (NP (DT the) (NN group))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN reduced) (NP (QP (RB about) (CD 20)) (NN %)) (PP (IN in) (NP (DT these) (NNS patients)))))) (. .)))
(S1 (S (S (PP (JJ Due) (TO to) (NP (NP (JJ wide) (JJ interindividual) (NN variability)) (PP (IN in) (NP (NP (DT the) (NN dose) (NN adjustment)) (VP (VBN required)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (SBAR (IN that) (S (NP (NN drug1) (NNS concentrations)) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN drug2) (NN therapy))))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug3)))) (VP (VB be) (VP (VBN adjusted) (PP (IN as) (NP (JJ appropriate))))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (NN drug2) (NNS concentrations)) (VP (VBP are) (VP (VBN increased) (PP (IN by) (NP (QP (RB about) (CD 15)) (NN %))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly))))))))) (. .)))
(S1 (S (S (NP (CC Both) (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (JJ slow) (NP (NN AV) (NN conduction)))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (VBN increased) (NN monitoring)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG initiating)) (, ,) (VP (VBG adjusting)) (, ,) (CC or) (VP (VBG discontinuing) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NNS Inducers)) (CC and) (NP (NNS Inhibitors))) (PP (IN of) (NP (JJ Hepatic) (NN Metabolism)))) (: :) (S (NP (NN drug1)) (VP (VBD reduced) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (QP (RB about) (CD 70)) (NN %))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBD increased) (NP (NN AUC)) (PP (IN by) (NP (QP (RB about) (CD 30)) (NN %)))) (CC but) (VP (VBD caused) (NP (DT no) (NN change)) (PP (IN in) (NP (NN Cmax)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (VBN Isolated) (NNS cases)) (PP (IN of) (NP (NP (NN conduction) (NN disturbance)) (PRN (-LRB- -LRB-) (ADVP (RB rarely)) (PP (IN with) (NP (JJ hemodynamic) (VB compromise))) (-RRB- -RRB-))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NN drug3))))))))))) (. .))))
(S1 (S (S (PP (IN As) (PP (IN with) (NP (JJ other) (NN drug1)))) (, ,) (SBAR (IN if) (S (NP (NN drug2)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN administered) (ADVP (RB orally)) (PP (IN with) (NP (NP (NN drug3)) (PP (IN of) (NP (DT the) (NN drug4) (CC or) (NN drug5) (NN type)))))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (NN ECG)) (CC and) (NP (NN blood) (NN pressure))) (VP (VB be) (VP (VBN monitored)))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (JJ Oral) (NN drug2))) (: :) (S (NP (NN drug3)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ blood-sugar-reducing) (NN effect)) (PP (IN of) (NP (NP (NN drug4)) (CC and) (NP (JJ oral) (NN drug5)))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NN drug1)) (CC or) (NP (JJ oral) (NN drug2)))))) (, ,) (NP (NP (JJ regular) (NN monitoring)) (PP (IN of) (NP (NN blood) (NN glucose)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB principally)) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN liver))) (PP (IN via) (NP (NP (DT the) (NN cytochrome) (NN P450) (NNS isoenzymes)) (, ,) (NP (NP (NN 3A4)) (CC and) (NP (NN 2B6)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (DT these) (NNS enzymes)))))))))) (. .)))
(S1 (S (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT these) (NN enzyme) (NNS systems)))))))) (VP (MD may) (VP (VBP have) (NP (JJR lower) (IN than) (VBN expected) (NN plasma) (NNS levels)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ specific) (JJ pharmacokinetic) (NNS changes)) (SBAR (WHNP (WDT that)) (S (VP (VBP occur) (PP (IN with) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drugs)))))))))) (VP (VBP are) (VP (VBN listed) (PP (IN in) (NP (NP (JJ CLINICAL) (NN PHARMACOLOGY)) (, ,) (NP (NN Table) (CD 1))))))) (. .)))
(S1 (S (S (NP (NP (JJ Clinical) (NNS comments)) (PP (IN about) (NP (NP (JJ possible) (NN dosage) (NNS modifications)) (VP (VBN based) (PP (IN on) (NP (DT these) (JJ pharmacokinetic) (NNS changes))))))) (VP (VBP are) (VP (VBN listed) (PP (IN in) (NP (NN Table) (CD 3)))))) (. .)))
(S1 (S (S (NP (DT The) (NN data) (NNS inTables) (NP (NP (CD 1)) (CC and) (NP (CD 3)))) (VP (VBP are) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NP (NN drug) (NN interaction) (NNS studies)) (VP (VBN conducted) (PP (IN in) (NP (NN HIV-1) (JJ seropositive) (NNS subjects))) (SBAR (IN unless) (S (ADVP (RB otherwise)) (VP (VBN indicated)))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (JJ established) (NN drug) (NNS interactions))))) (, ,) (NP (EX there)) (VP (MD may) (VP (VB be) (NP (NP (JJ potential) (JJ pharmacokinetic) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NN drug) (NNS classes)))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NN system)))))))))) (. .)))
(S1 (S (S (NP (DT These) (JJ potential) (NN drug) (NNS interactions)) (VP (VBP are) (VP (VBN listed) (PP (IN in) (NP (NN Table) (CD 4)))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (JJ specific) (NN drug) (NN interaction) (NNS studies)) (PP (IN in) (NP (NN HIV-1) (JJ seropositive) (NNS subjects)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted) (PP (IN for) (NP (NP (DT the) (NNS classes)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN listed) (PP (IN in) (NP (NN Table) (CD 4))))))))))))) (, ,) (NP (JJ additional) (JJ clinical) (NN monitoring)) (VP (MD may) (VP (VB be) (VP (VBN warranted) (SBAR (WHADVP (WRB when)) (S (VP (JJ co-administering) (NP (DT these) (NNS drugs))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (ADJP (FW in) (FW vitro)) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (DT the) (NN drug2) (NN drug3))))) (VP (VBZ is) (NP (NN complex)))) (. .)))
(S1 (S (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG giving) (NP (DT these) (NNS drugs)) (ADVP (RB concomitantly))))) (, ,) (NP (NN plasma) (NN drug1) (NNS levels)) (VP (MD may) (VP (VB change) (PP (IN with) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (NNS increases)) (PP (IN in) (NP (NN coagulation) (NN time)))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NN drug2))))))) (, ,) (NP (NN anticoagulation) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB frequently)))))) (. .)))
(S1 (S (NP (NP (NN Table) (CD 3) (JJ Established) (NN Drug) (NNS Interactions)) (: :) (S (NP (NP (NN Alteration)) (PP (IN in) (NP (NP (NN Dose)) (CC or) (NP (NN Regimen))))) (VP (MD May) (VP (VB Be) (VP (VBN Recommended) (PP (VBN Based) (PP (IN on) (NP (NN Drug) (NN Interaction) (NNS Studies)))))))))))
(S1 (S (NP (NN Drug) (NN Name))))
(S1 (S (NP (NP (NN Effect)) (PP (IN on) (NP (NN Concentration))) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (JJ Concomitant) (NN Drug)))))))
(S1 (S (NP (JJ Clinical) (NN Comment))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN 14OH-) (NN clarithromycin))))
(S1 (S (S (NP (NN drug1) (NN exposure)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN decreased) (PP (IN by) (NP (NN drug2)))))) (: ;)))
(S1 (S (ADVP (RB however)) (, ,) (NP (NN 14-OH) (NN metabolite) (NNS concentrations)) (VP (VBD were) (ADJP (JJ increased.Because)) (SBAR (IN drug1) (S (NP (JJ active) (NN metabolite)) (VP (VBZ has) (NP (NP (VBN reduced) (NN activity)) (PP (IN against) (NP (NN Mycobacteriumavium-intracellulare) (NN complex)))) (, ,) (S (NP (NP (NN overallactivity)) (PP (IN against) (NP (DT this) (NN pathogen)))) (VP (MD may) (VP (JJ bealtered)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Alternatives)) (PP (TO to) (NP (NN drug1))) (, ,) (PP (JJ such) (IN as) (NP (NN drug2))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (NP (JJ Appropriate) (NNS doses)) (PP (IN for) (NP (DT this) (NN combination)))) (VP (VBP are) (RB not) (VP (VBN established)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))
(S1 (S (NP (NN drug1) (NN drug2))))
(S1 (S (NP (NP (NP (JJ Oral) (NN drug1)) (CC and) (NP (JJ other) (NNS hormonalmethods))) (PP (IN of) (NP (NN birth) (NN control)))) (VP (MD should) (RB not) (VP (VB be) (NN usedas) (NP (NP (DT the) (JJ sole) (NN method)) (PP (IN of) (NP (NP (NN contraception) (CD inwomen)) (VP (VBG taking) (NP (NN drug2)))))) (, ,) (SBAR (IN since) (S (NP (NN nevirapinemay)) (VP (JJR lower) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NNS thesemedications))))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (ADJP (ADJP (JJ alternative)) (CC or) (ADJP (JJ additional))) (NN method)) (PP (IN of) (NP (NN contraception)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (VBN increased) (NN exposure)) (PP (TO to) (NP (NN drug1)))))))) (, ,) (S (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (NP (NN inconcomitant) (NN administration)))))) (, ,) (CC and) (S (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (PP (IN for) (NP (JJ nevirapine-associated) (JJ adverse) (NNS events)))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (S (S (NP (NP (JJ Appropriate) (NNS doses)) (PP (IN for) (NP (DT this) (NN combination) (NN arenot)))) (VP (VBN established))) (, ,) (CC but) (S (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN thedosage)) (PP (IN of) (NP (NN drug1)))))) (VP (MD may) (VP (VB be) (VP (VBN required)))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD should) (RB not) (VP (VB beadministered) (ADVP (RB concomitantly)) (NP (NP (NNS becausedecreases)) (PP (IN in) (NP (NP (NN drug3) (NNS plasmaconcentrations)) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (DT the) (NN drug)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NP (DT A) (NN dose) (NN increase)) (PP (IN of) (NP (NN drug1)))) (: /) (NP (NP (NN drug2) (TO to) (CD 533/133) (NN mg)) (ADJP (RB twice) (JJ daily) (PP (IN with) (NP (NP (NN food)) (VP (VBN isrecommended) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug3)))))))))) (. .))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN Methadonea))))
(S1 (S (S (NP (NN drug1) (NNS levels)) (VP (MD may) (VP (VB be) (VP (VBN decreased))))) (: ;) (S (NP (VBN increased) (NNS dosages)) (VP (MD may) (VP (VB be) (VP (VBN required) (S (VP (TO to) (VP (VB prevent) (NP (NP (NNS symptoms)) (PP (IN of) (S (S (NP (NP (NN drug2) (CD withdrawal.) (NN drug3) (JJ maintained) (NNS patients)) (VP (VBG beginning) (NP (NN drug4) (NN therapy)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (NP (NP (NN forevidence)) (PP (IN of) (NP (NN withdrawal)))))))) (CC and) (S (NP (NN drug5) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN adjusted) (ADVP (RB accordingly)))))))))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NNP drug1) (NNP M8))))
(S1 (S (S (NP (NP (DT The) (JJ appropriate) (NN dose)) (PP (IN for) (NP (NP (NN drug1) (NN incombination)) (PP (IN with) (NP (NN drug2))))) (, ,) (PP (IN with) (NP (NN respectto) (NP (NP (NN safety)) (CC and) (NP (NN efficacy))))) (, ,)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (PRP$ its) (NN metabolite))) (VP (VBD concentrationswere) (ADVP (RB moderately)) (VP (VBN increased)))) (. .)))
(S1 (S (PP (IN Due) (PP (TO to) (NP (NN highintersubject) (NN variability)))) (, ,) (ADVP (RB however)) (, ,) (NP (NNS somepatients)) (VP (VP (MD may) (VP (VBP experience) (NP (NP (JJ large) (NNS increases)) (PP (IN in) (NP (NN drug1) (NN exposure)))))) (CC and) (VP (MD may) (VP (VB be) (PP (IN at) (NP (JJR higher) (NN riskfor) (NN rifabutin) (NN toxicity)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (JJ concomitant) (NN administration))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD should) (RB not) (VP (VB beadministered) (ADVP (RB concomitantly)) (NP (NP (NNS becausedecreases)) (PP (IN in) (NP (NP (NN drug3) (NNS plasmaconcentrations)) (VP (MD may) (VP (VB reduce) (NP (DT the) (NN efficacy) (NN ofthe) (NN drug))))))))) (. .)))
(S1 (S (S (NP (NNS Physicians)) (VP (VBG needing) (PP (TO to) (NP (NP (NNS treatpatients)) (VP (VBN co-infected) (PP (IN with) (NP (NP (NN tuberculosis)) (VP (VBG andusing) (NP (NP (DT a) (NN drug1)) (VP (VBG containing) (NP (NP (NN regimen) (NN mayuse) (NN drug2)) (ADVP (RB instead))))))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (S (S (NP (NP (JJ Appropriate) (NNS doses)) (PP (IN for) (NP (DT this) (NN combination) (NN arenot)))) (VP (VBN established))) (, ,) (CC but) (S (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN thedosage)) (PP (IN of) (NP (NN drug1)))))) (VP (MD may) (VP (VB be) (VP (VBN required)))))) (. .)))
(S1 (S (S (VP (VBN aBased) (PP (IN on) (NP (NP (NP (NNS reports)) (PP (IN of) (NP (NP (JJ narcotic) (NN withdrawal) (NN syndrome)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (ADVP (RB concurrently)))))))) (, ,) (CC and) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (VBN decreased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (NP (NP (NN Table) (CD 4) (JJ Potential) (NN Drug) (NNS Interactions)) (: :) (S (NP (NP (NN Use)) (PP (IN With) (NP (NP (NN Caution)) (, ,) (NP (NP (NN Dose) (NN Adjustment)) (PP (IN of) (NP (NN Co-administered) (NN Drug))))))) (VP (MD May) (VP (VB Be) (VP (VBN Needed) (PP (JJ due) (TO to) (NP (NP (JJ Possible) (NN Decrease)) (PP (IN in) (NP (JJ Clinical) (NN Effect))))))))))))
(S1 (S (NP (NP (NNS Examples)) (PP (IN of) (NP (NNS Drugs))) (SBAR (WHPP (IN in) (WHNP (WDT Which))) (S (NP (NN Plasma) (NNS Concentrations)) (VP (MD May) (VP (VB Be) (VP (VBN Decreased) (PP (IN By) (NP (NP (NN Co-administration)) (PP (IN With) (NP (NN drug1)))))))))))))
(S1 (S (NP (NP (NN Drug) (NN Class) (NNS Examples)) (PP (IN of) (NP (NNS Drugs))))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)))))
(S1 (S (NP (NN Cancer) (NN chemotherapy))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)))))
(S1 (S (NP (NN Motility) (NNS agents))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NNS Examples)) (PP (IN of) (NP (NNS Drugs))) (SBAR (WHPP (IN in) (WHNP (WDT Which))) (S (NP (NN Plasma) (NNS Concentrations)) (VP (MD May) (VP (VB Be) (VP (VBN Increased) (PP (IN By) (NP (NP (NN Co-administration)) (PP (IN With) (NP (NN drug1)))))))))))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (JJ Potential) (NN effect)) (PP (IN on) (NP (NN anticoagulation))) (. .))))
(S1 (S (S (NP (NP (NN Monitoring)) (PP (IN of) (NP (NN anticoagulation) (NNS levels)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (JJ Fat) (NN redistribution)) (: :) (S (NP (NP (NN Redistribution/accumulation)) (PP (IN of) (NP (NN body) (NN fat))) (PP (VBG including) (NP (NP (JJ central) (NN obesity)) (, ,) (NP (NP (JJ dorsocervical) (JJ fat) (NN enlargement)) (PRN (-LRB- -LRB-) (NP (JJ buffalo) (NN hump)) (-RRB- -RRB-))) (, ,) (NP (JJ peripheral) (NN wasting)) (, ,) (NP (NN facial) (NN wasting)) (, ,) (NP (NN breast) (NN enlargement)) (, ,) (CC and) (NP (JJ cushingoid) (NN appearance))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1) (NN therapy))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NP (NN mechanism)) (CC and) (NP (JJ long-term) (NNS consequences))) (PP (IN of) (NP (DT these) (NNS events)))) (VP (VBP are) (ADVP (RB currently)) (ADJP (JJ unknown)))) (. .)))
(S1 (S (NP (DT A) (JJ causal) (NN relationship)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (JJ Physiological) (NNS changes)) (VP (VBG resulting) (PP (IN from) (NP (NN smoking) (NN cessation)))) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NN drug1) (NN replacement)))) (, ,)) (VP (MD may) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (JJ certain) (JJ concomitant) (NNS medications)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Doses)) (PP (IN of) (NP (ADJP (ADJP (DT these)) (CC and) (ADJP (ADVP (RB perhaps)) (JJ other))) (NNS medications)))) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN adjusted) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (ADVP (RB successfully)) (VP (VB quit) (NP (NN smoking)))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NN risk)) (PP (IN of) (S (VP (VBG using) (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS drugs))))))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB systematically)) (VP (VBN evaluated))))) (, ,) (CC but) (S (NP (NN drug2)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (JJ certain) (JJ other) (NNS agents))))))) (. .)))
(S1 (S (S (NP (NP (NNS Compounds)) (PP (IN in) (NP (DT these) (NNS categories)))) (VP (VBP result) (PP (IN in) (NP (NP (NP (DT a) (VBN decreased) (NN efficacy)) (PP (IN of) (NP (NN drug1)))) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NNS drug2)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (JJ Drug-Drug) (NNS Interactions)) (: :) (S (NP (NP (DT The) (ADJP (ADJP (JJ pharmacokinetic)) (CC and) (ADJP (JJ pharmacodynamic))) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NN drug2))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN determined))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (S (NP (NNS interactions)) (VP (MD may) (VP (VB be) (VP (VBN expected))))) (, ,) (CC and) (S (NP (NN drug1)) (VP (MD should) (RB NOT) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS drug2)))))))))) (. .)))
(S1 (S (S (NP (NN Animal) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB be) (ADJP (JJ ineffective)) (SBAR (IN if) (S (NP (DT the) (NN patient)) (VP (VBZ has) (ADVP (RB recently)) (VP (VBN received) (NP (DT a) (NN drug2)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (PDT such) (DT a) (NN case))) (, ,) (NP (DT the) (JJ peripheral) (JJ vascular) (NN resistance)) (VP (MD may) (VP (VB increase)))) (. .)))
(S1 (S (S (NP (JJ Preliminary) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (JJR higher) (JJ cardiac) (NN output)) (CC and) (, ,) (ADVP (RB usually)) (, ,) (NP (NP (DT a) (JJR lower) (JJ pulmonary) (NN wedge) (NN pressure)) (PP (IN than) (SBAR (WHADVP (WRB when)) (S (NP (DT either) (NN drug)) (VP (VBZ is) (VP (VBN used) (ADVP (RB alone))))))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN drug) (NNS interactions)) (PP (IN in) (NP (NP (JJ clinical) (NNS studies)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (, ,) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (NN drug13)) (, ,) (CC and) (NP (NN drug14))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ drug-drug) (NN interaction) (NNS studies)) (PP (IN in) (NP (JJ human) (NNS subjects)))) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NP (ADJP (ADJP (JJ Toxicologic)) (CC and) (ADJP (JJ toxicokinetic))) (NNS studies)) (PP (IN in) (NP (NNS rats)))) (VP (VBD did) (RB not) (VP (VB demonstrate) (NP (NP (DT any) (NNS alterations)) (PP (IN in) (NP (NP (DT the) (NP (NN clearance)) (CC or) (NP (JJ toxicologic) (NN profile))) (PP (IN of) (NP (CC either) (NP (NN drug1)) (CC or) (NP (NN drug2)))))))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (CD two) (NNS agents)) (VP (VBD were) (VP (VBN administered) (ADVP (RB together)))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NNS patients)) (PP (IN with) (NP (JJ active) (NN RA)))) (VP (VBD were) (VP (VBN treated) (PP (IN for) (NP (QP (RB up) (TO to) (CD 24)) (NNS weeks))) (PP (IN with) (NP (NP (JJ concurrent) (NN drug1)) (CC and) (NP (JJ drug2) (NN therapy)))))))))) (, ,) (NP (NP (DT a) (ADJP (CD 7) (NN %)) (NN rate)) (PP (IN of) (NP (JJ serious) (NNS infections)))) (VP (VBD was) (VP (VBN observed) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT that)) (VP (VBN observed) (PP (IN with) (NP (NP (NN drug3)) (ADVP (RB alone)))))))) (PRN (-LRB- -LRB-) (NP (CD 0) (NN %)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (CD Two) (NN percent)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (VP (VBD developed) (NP (NP (NN neutropenia)) (PRN (-LRB- -LRB-) (NP (NN ANC) (CD 1) (NN x) (NN 109/L)) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN containing) (NNS drug2)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3)))))) (, ,)) (VP (VBP reduce) (NP (NP (CC both) (DT the) (NP (NN rate)) (CC and) (NP (NN extent))) (PP (IN of) (NP (NN absorption)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN for) (NP (DT this) (NN interaction)))) (ADVP (RB probably)) (VP (VBZ is) (NP (NP (NN adsorption)) (PP (IN of) (NP (NN drug1))) (PP (IN onto) (NP (NP (DT the) (NN surface)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (, ,)) (VP (MD can) (VP (VB inhibit) (NP (NP (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (VBG resulting) (NN increase)) (PP (IN in) (NP (NN drug1) (NN serum) (NNS levels)))) (VP (MD may) (VP (VB increase) (NP (NN toxicity))))) (, ,) (CC and) (S (NP (DT the) (VBN decreased) (JJ urinary) (NNS levels)) (VP (MD could) (VP (VB lessen) (NP (PRP$ its) (NN efficacy)) (PP (IN as) (NP (DT a) (JJ urinary) (NN tract) (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (PP (IN As) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (DT the) (NN urine))))))))))) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (PP (IN with) (NP (NP (NP (NNP Benedict) (NNP s)) (CC and) (NP (NNP Fehling) (NNP s))) (NNS solutions))) (CC but) (PP (RB not) (IN with) (NP (DT the) (NN glucose) (JJ enzymatic) (NN test)))))))) (. .)))
(S1 (S (S (PP (IN In) (S (VP (VBG evaluating) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (NNS interactions)) (PP (IN among) (NP (NP (NN co-administered) (NN antiepilepsy) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-)))))))))) (, ,) (SBAR (IN whether) (CC or) (RB not) (S (NP (DT an) (NN drug2)) (VP (VP (VBZ induces)) (CC or) (VP (VBZ does) (RB not) (VP (VB induce) (NP (JJ metabolic) (NNS enzymes))))))) (VP (VBZ is) (NP (DT an) (JJ important) (NN consideration)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBP are) (ADVP (NN ge) (RB nerally)) (VP (VBN classified) (PP (IN as) (NP (NN enzyme) (NNS inducers)))))) (: ;)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (RB not))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (NP (DT a) (JJ non-enzyme) (NN inducing) (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN drug) (NN interaction) (NNS data)) (VP (VBN described) (PP (IN in) (NP (DT this) (NN section))))) (VP (VBD were) (VP (VBN obtained) (PP (IN from) (NP (NP (NNS studies)) (VP (VBG involving) (NP (CC either) (NP (JJ healthy) (NNS subjects)) (CC or) (NP (NP (NNS patients)) (PP (IN with) (NP (NN epilepsy))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NP (JJ other) (NN Antiepilepsy) (NNS Drugs)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (NP (NN drug3)) (: :) (NP (NNS drug4))))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ steady-state) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug5)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN epilepsy))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NP (DT the) (JJ steady-state) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug3)))) (CC or) (NP (NP (PRP$ its) (NN epoxide) (NN metabolite)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN epilepsy)))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ causes) (NP (NP (DT a) (JJ slight) (NN decrease)) (PRN (-LRB- -LRB-) (NP (QP (RB about) (CD 10)) (NN %)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ steady-state) (NN drug3) (NNS concentrations))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (: :) (S (NP (DT No) (JJ formal) (JJ pharmacokinetic) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (S (VP (VBG examining) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug3))) (PP (TO to) (NP (NP (NNS regimens)) (VP (VBG containing) (NP (NP (NN drug4)) (CC or) (NP (NN drug5))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (DT a) (JJ limited) (NN number)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (CD three) (JJ well-controlled) (NNS studies)))))))) (VP (VBD caused) (NP (DT no) (JJ systematic) (NNS changes)) (PP (IN in) (NP (NP (NN drug2)) (CC or) (NP (NN drug3) (NNS concentrations)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NN placebo)))))))) (. .)))
(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (JJ other) (NN Antiepilepsy) (NNS Drugs)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-)))) (PP (IN on) (NP (NN drug2)))) (: :) (NP (NP (NN drug3)) (: :) (S (NP (NN Population) (JJ pharmacokinetic) (NNS analyses)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug4) (NN clearance)) (VP (VBZ is) (ADJP (NP (CD 60) (NN %)) (JJR greater) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug5)) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ other) (NN enzyme-) (NN inducing) (NN drug6))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN Population) (JJ pharmacokinetic) (NNS analyses)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug2) (NN clearance)) (VP (VBZ is) (ADJP (NP (CD 60) (NN %)) (JJR greater) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug3)) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ other) (NN enzyme-) (NN inducing) (NN drug4))))))))))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (S (NP (NN Population) (JJ pharmacokinetic) (NNS analyses)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug3) (NN clearance)) (VP (VBZ is) (ADJP (NP (CD 60) (NN %)) (JJR greater) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ other) (JJ enzyme-inducing) (NN drug6))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug3)))))) (ADVP (RB chronically)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug4) (NNS pharmacokinetics))))) (, ,) (CC but) (S (NP (NN drug5)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NN drug6) (NN binding)) (ADVP (FW in) (FW vitro)) (PP (IN from) (NP (NP (QP (CD 96.3) (TO to) (CD 94.8)) (NN %)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (QP (RB approximately) (CD 40)) (NN %))) (PP (IN in) (NP (DT the) (JJ free) (NN tiagabine) (NN concentration))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN relevance)) (PP (IN of) (NP (DT this) (ADJP (FW in) (FW vitro)) (NN finding)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (NP (NP (NP (NN Interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ Other) (NNS Drugs)))) (: :) (NP (NN drug2)) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 800) (NN mg/day)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug4)))))) (ADVP (RB chronically)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug5) (NNS pharmacokinetics))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (DT A) (JJ single) (ADJP (CD 10) (NN mg)) (NN dose)) (PP (IN of) (NP (NN drug2))))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3))) (PP (IN at) (NP (JJ steady) (NN state))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (DT No) (JJ significant) (NNS differences)) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (JJ steady-state) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))) (PP (IN with) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (NNS drug4)) (VP (VBN given) (PP (IN as) (NP (DT a) (JJ single) (NN dose))))))))))))) (. .))))
(S1 (S (S (NP (NN Prothrombin) (NNS times)) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NN drug1)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug2)))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (NP (DT the) (JJ steady-state) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3)))) (CC or) (NP (NP (DT the) (JJ mean) (JJ daily) (NN trough) (NN serum) (NN level)) (PP (IN of) (NP (NN drug4)))))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (: :) (S (NP (DT No) (JJ significant) (NNS differences)) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 0.125) (NN mg)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg)) (-RRB- -RRB-))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB together)) (PP (IN as) (NP (DT a) (JJ single) (NN dose))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (JJ multiple-dose) (NN administration)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN shown) (NP (NP (DT no) (ADJP (RB clinically) (JJ important)) (NN potentiation)) (PP (IN of) (NP (NP (DT the) (JJ pharmacodynamic) (NNS effects)) (PP (IN of) (NP (NP (NN triazo)) (NP (NN lam)) (CC or) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (JJ possible) (JJ additive) (NNS effects)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB depress) (NP (DT the) (JJ nervous) (NN system))))))))))) (, ,) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug3))))))))) (. .)))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (NP (NP (JJ Multiple) (NN dose) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 8) (NN mg/day) (NN monotherapy)) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (JJ oral) (NN drug3))) (PP (IN in) (NP (NP (JJ healthy) (NNS women)) (PP (IN of) (NP (JJ childbearing) (NN age))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2) (NNS pharmacokinetics)) (VP (VBD were) (RB not) (ADJP (RB significantly) (JJ different)) (PP (PP (IN before)) (CC and) (PP (IN after) (NP (NN drug3) (NN multiple-dose) (NNS regimens)))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB cause) (NP (NP (NP (NN induction)) (CC or) (NP (NN inhibition))) (PP (IN of) (NP (NP (DT the) (JJ hepatic) (JJ microsomal) (NN enzyme) (NNS systems)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (NP (NP (NN Interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (ADJP (RB Highly) (NN Protein) (JJ Bound)) (NNS Drugs)) (: :) (NP (ADJP (FW In) (FW vitro)) (NNS data))))) (VP (VBD showed) (SBAR (IN that) (S (NP (NN drug2)) (VP (VP (VBZ is) (NP (NP (CD 96) (NN %)) (VP (VBD bound) (PP (TO to) (NP (JJ human) (NN plasma) (NN protein)))))) (CC and) (ADVP (RB therefore)) (VP (VBZ has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (JJ other) (ADJP (RB highly) (NN protein) (JJ bound)) (NNS compounds)))))))))))) (. .)))
(S1 (S (S (NP (PDT Such) (DT an) (NN interaction)) (VP (MD can) (ADVP (RB potentially)) (VP (VB lead) (PP (TO to) (NP (NP (JJR higher) (JJ free) (NNS fractions)) (PP (IN of) (NP (CC either) (NP (NN drug1)) (CC or) (NP (DT the) (VBG competing) (NN drug))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN dosed) (PP (IN as) (NP (NP (DT a) (ADJP (CD 1.0) (NN mg/kg)) (NN subcutaneous) (NN injection)) (PP (IN q12h) (PP (IN for) (NP (CD four) (NNS doses)))))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN platelet) (NN aggregation)))))) (PP (IN in) (NP (JJ healthy) (NNS adults))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NN drug1))) (, ,) (ADJP (JJ such) (PP (IN as) (NP (NP (NN myelosuppression)) (CC and) (NP (NN diarrhea))))) (, ,)) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB be) (ADJP (JJ exacerbated) (PP (IN by) (NP (NP (JJ other) (NNS drug2)) (VP (VBG having) (NP (JJ similar) (JJ adverse) (NNS effects))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (ADVP (RB previously)) (VP (VBN received) (NP (NN pelvic/) (JJ abdominal) (NN irradiation))))))) (VP (VBP are) (PP (IN at) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (JJ severe) (NN myelosuppression))))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN irradiation)))) (VP (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB adequately)) (VP (VBN studied)))) (CC and) (VP (VBZ is) (RB not) (VP (VBN recommended))))) (. .)))
(S1 (S (S (S (NP (NN Lymphocytopenia)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (PP (IN as) (NP (JJ antiemetic) (NNS prophylaxis)))))) (VP (MD may) (VP (VB have) (VP (VBD enhanced) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (DT this) (NN effect)))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (S (NP (JJ serious) (JJ opportunistic) (NNS infections)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN observed))))) (, ,) (CC and) (S (NP (DT no) (NNS complications)) (VP (VBP have) (ADVP (RB specifically)) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NN lymphocytopenia)))))))) (. .)))
(S1 (S (S (NP (NN Hyperglycemia)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (ADVP (RB Usually)) (, ,) (NP (DT this)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN diabetes) (NN mellitus)))) (CC or) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NN glucose) (NN intolerance)) (ADJP (JJ prior) (PP (TO to) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug1))))))))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ probable)) (SBAR (IN that) (S (NP (NP (NN drug1)) (, ,) (VP (VBN given) (PP (IN as) (NP (NN antiemetic) (NN prophylaxis)))) (, ,)) (VP (VBD contributed) (PP (TO to) (NP (NP (NN hyperglycemia)) (PP (IN in) (NP (DT some) (NNS patients)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NN akathisia))) (PP (IN in) (NP (NP (JJ clinical) (NNS trials)) (PP (IN of) (NP (DT the) (JJ weekly) (NN dosage) (NN schedule)))))) (VP (VBD was) (ADJP (ADJP (JJR greater)) (PRN (-LRB- -LRB-) (NP (NP (CD 8.5) (NN %)) (, ,) (NP (CD 4/47) (NNS patients))) (-RRB- -RRB-))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (IN on) (NP (DT the) (JJ same) (NN day))) (PP (IN as) (NP (NP (NN drug2)) (PP (IN than) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS drugs)) (VP (VBD were) (VP (VBN given) (PP (IN on) (NP (NP (JJ separate) (NNS days)) (PRN (-LRB- -LRB-) (NP (CD 1.3) (NN %)) (, ,) (NP (CD 1/80) (NNS patients)) (-RRB- -RRB-))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (ADJP (CD 8.5) (NN %)) (NN incidence)) (PP (IN of) (NP (NN akathisia)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ is) (PP (IN within) (NP (NP (DT the) (NN range)) (VP (VBN reported) (PP (IN for) (NP (NP (NN use)) (PP (IN of) (NP (NN drug1)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN as) (NP (NP (DT a) (NN premedication)) (PP (IN for) (NP (JJ other) (NNS chemotherapies)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (MD would) (VP (VB be) (VP (VBN expected) (SBAR (IN that) (S (S (NP (NP (NN drug1) (NN use)) (PP (IN during) (NP (NN therapy))) (PP (IN with) (NP (NN drug2)))) (VP (MD would) (VP (VB worsen) (NP (NP (DT the) (NP (NN incidence)) (CC or) (NP (NN severity))) (PP (IN of) (NP (NN diarrhea))))))) (, ,) (CC but) (S (NP (DT this)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (JJ potential) (NN risk)) (PP (IN of) (NP (NP (NN dehydration)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (NP (NN vomiting)) (CC and/or) (NP (NN diarrhea))) (VP (VBN induced) (PP (IN by) (NP (NN drug1))))))))))))) (, ,) (NP (DT the) (NN physician)) (VP (MD may) (VP (VP (VB wish) (PP (TO to) (NP (JJ withhold) (NN drug2))) (PP (IN during) (NP (NP (NN dosing)) (PP (IN with) (NP (NN drug3)))))) (CC and) (, ,) (ADVP (RB certainly)) (, ,) (PP (IN during) (NP (NP (NNS periods)) (PP (IN of) (NP (JJ active) (NP (NN vomiting)) (CC or) (NP (NN diarrhea)))))))) (. .)))
(S1 (S (S (NP (JJ Drug-Laboratory) (NN Test) (NNS Interactions)) (ADVP (RB There)) (VP (VBP are) (NP (NP (DT no) (JJ known) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN laboratory) (NNS tests))))))) (. .)))
(S1 (S (NP (DT No) (JJ specific) (NN information) (JJ available))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN drug2)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (ADVP (RB concurrently))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (ADJP (ADJP (VBN increased)) (CC and) (ADJP (RBR more) (JJ prolonged))) (NN drug3) (NN blood) (NNS levels)))))))) (. .)))
(S1 (S (NP (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (S (NP (NP (DT A) (ADJP (ADJP (JJ false)) (ADJP (JJ positive))) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (DT the) (NN urine)))) (VP (MD may) (VP (VB occur) (PP (IN with) (NP (NP (NN Benedicts) (NN solution)) (, ,) (NP (NN Fehlings) (NN solution)))) (PP (CC or) (PP (IN with) (NP (JJ CLINITEST) (NNS tablets))) (, ,) (CC but) (PP (RB not) (IN with) (NP (NP (JJ enzyme-based) (NNS tests)) (PP (JJ such) (IN as) (NP (NN CLINISTIX))))))))) (. .))))
(S1 (S (S (NP (JJ Positive) (ADJP (ADJP (JJ direct)) (CC and) (ADJP (JJ indirect))) (NN antiglobulin) (-LRB- -LRB-) (NN Coombs) (-RRB- -RRB-) (NNS tests)) (VP (VBP have) (VP (VBN occurred)))) (: ;)))
(S1 (S (S (NP (DT these)) (VP (MD may) (ADVP (RB also)) (VP (VB occur) (PP (IN in) (NP (NP (NNS neonates)) (SBAR (WHNP (WP$ whose) (NNS mothers)) (S (VP (VBD received) (NP (NN drug1)) (PP (IN before) (NP (NN delivery))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NNS D2-antagonists)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))))))))) (. .)))
(S1 (S (S (NP (JJ Oral) (NN drug1) (NN CAUTION)) (VP (MD SHOULD) (VP (VB BE) (VP (VBN EXERCISED) (SBAR (WHADVP (WRB WHEN)) (S (NP (NN drug2)) (VP (VBP ARE) (VP (VBN GIVEN) (PP (IN IN) (NP (NP (NN CONJUNCTION)) (PP (IN WITH) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT THE) (NN DOSAGE)) (PP (IN OF) (NP (DT THE) (NN drug1)))) (VP (MD SHOULD) (VP (VB BE) (VP (VBN REDUCED) (S (VP (TO TO) (VP (VB MAINTAIN) (NP (NP (DT THE) (NN PROTHROMBIN) (NN TIME/INR)) (PP (IN AT) (NP (DT THE) (JJ DESIRED) (NN LEVEL))) (S (VP (TO TO) (VP (VB PREVENT) (NP (JJ BLEEDING) (NNS COMPLICATIONS))))))))))))) (. .)))
(S1 (S (S (NP (JJ FREQUENT) (NN PROTHROMBIN) (NN TIME/INR) (NNS DETERMINATIONS)) (VP (VBP ARE) (ADJP (JJ ADVISABLE) (SBAR (IN UNTIL) (S (NP (PRP IT)) (VP (VBZ HAS) (VP (VBN BEEN) (ADVP (RB DEFINITELY)) (VP (VBN DETERMINED) (SBAR (IN THAT) (S (NP (DT THE) (NN PROTHROMBIN) (NN TIME/INR)) (VP (VBZ HAS) (VP (VBN STABILIZED))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (JJ combined) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (IN unless) (S (NP (NP (DT the) (NN benefit)) (PP (IN of) (NP (JJ further) (NNS alterations))) (PP (IN in) (NP (NN lipid) (NNS levels)))) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB outweigh) (NP (NP (DT the) (VBN increased) (NN risk)) (PP (IN of) (NP (DT this) (NN drug) (NN combination))))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN Since) (S (NP (NN drug2)) (VP (MD may) (VP (VB bind) (NP (NP (JJ other) (NNS drugs)) (VP (VBN given) (ADVP (RB concurrently)))))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB take) (NP (NN drug3)) (PP (NP (QP (IN at) (JJS least) (CD 1)) (NN hour)) (IN before) (NP (NP (CC or) (CD 4-6) (NNS hours)) (PP (IN after) (NP (NP (DT a) (NN drug4)) (S (VP (TO to) (VP (VB avoid) (S (VP (VBG impeding) (NP (PRP$ its) (NN absorption)))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (SBAR (IN Because) (S (NP (NN drug2)) (VP (VP (MD can) (VP (VB produce) (NP (NN nephrotoxicity)) (PP (IN with) (NP (NP (NNS decreases)) (PP (IN in) (NP (NN creatinine) (NN clearance))))))) (CC and) (VP (VBZ rises) (PP (IN in) (NP (NN serum) (NN creatinine))))))) (, ,) (CC and) (SBAR (IN because) (S (NP (JJ renal) (NN excretion)) (VP (VBZ is) (NP (NP (DT the) (JJ primary) (NN elimination) (NN route)) (PP (IN of) (NP (NP (NNS drug3)) (PP (VBG including) (NP (NN drug4)))))))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (NN risk)) (SBAR (IN that) (S (NP (DT an) (NN interaction)) (VP (MD will) (VP (VB lead) (PP (TO to) (NP (NN deterioration)))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NP (NNS benefits)) (CC and) (NP (NNS risks))) (PP (IN of) (NP (VBG using) (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (JJ other) (ADJP (RB potentially) (JJ nephrotoxic)) (NNS agents))))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN considered))))) (, ,) (CC and) (S (NP (DT the) (ADJP (JJS lowest) (JJ effective)) (NN dose)) (VP (VBN employed)))))
(S1 (S (. .)))
(S1 (S (NP (NP (JJ Drug-drug) (NNS interactions)) (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBG using) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (RB not) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NN cytochrome) (-LRB- -LRB-) (NN CYP) (-RRB- -RRB-) (NN P450) (NNS isoforms) (NP (NP (NN CYP3A4)) (, ,) (NP (NN CYP2D6)) (, ,) (NP (NN CYP2E1)) (, ,) (CC or) (NP (NN CYP1A2))))))))))) (. .))))
(S1 (S (S (NP (PRP They)) (VP (VBP are) (NP (NP (NP (JJ weak) (NNS inhibitors)) (PP (IN of) (NP (NP (NN CYP2C19)) (CC and) (NP (NN CYP2A6))))) (, ,) (CC and) (NP (NP (JJ mild-to-moderate) (NNS inhibitors)) (PP (IN of) (NP (NN CYP2C9))))) (PP (IN at) (NP (JJ therapeutic) (NNS concentrations))))) (. .)))
(S1 (S (S (NP (NP (NN Potentiation)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (NP (NN prolongation)) (PP (IN of) (NP (DT the) (NN prothrombin) (NN time/INR))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB bind) (NP (NP (JJ other) (NNS drugs)) (VP (VBN given) (ADVP (RB concurrently))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (NP (QP (IN at) (JJS least) (CD 1)) (NN hour)) (IN before) (NP (NP (CC or) (CD 4-6) (NNS hours)) (PP (IN after) (NP (DT a) (NN drug2) (S (VP (TO to) (VP (VB avoid) (S (VP (VBG impeding) (NP (PRP$ its) (NN absorption))))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (ADJP (JJ equivalent) (PP (TO to) (NP (NN 145mg)))) (NN drug2)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN mg)) (-RRB- -RRB-))) (ADJP (RB once) (JJ daily) (PP (IN for) (NP (CD 10) (NNS days))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN mean) (NN Cmax) (CC and) (NN AUC) (NNS values)) (PP (PP (IN for) (NP (NP (NN drug4)) (PP (IN by) (NP (NP (NP (CD 36) (NN %)) (PRN (-LRB- -LRB-) (NP (NN range)) (PP (IN from) (NP (NP (ADJP (CD 69) (NN %)) (NN decrease)) (PP (TO to) (NP (ADJP (CD 321) (NN %)) (NN increase))))) (-RRB- -RRB-))) (CC and) (NP (NP (CD 28) (NN %)) (PRN (-LRB- -LRB-) (NP (NN range)) (PP (IN from) (NP (NP (ADJP (CD 54) (NN %)) (NN decrease)) (PP (TO to) (NP (ADJP (CD 128) (NN %)) (NN increase))))) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively)))))) (, ,) (CC and) (PP (IN for) (NP (CD 3) (NN -hydroxy-iso-pravastatin))))) (PP (IN by) (NP (NP (NP (CD 55) (NN %)) (PRN (-LRB- -LRB-) (NP (NN range)) (PP (IN from) (NP (NP (ADJP (CD 32) (NN %)) (NN decrease)) (PP (TO to) (NP (ADJP (CD 314) (NN %)) (NN increase))))) (-RRB- -RRB-))) (CC and) (NP (NP (CD 39) (NN %)) (PRN (-LRB- -LRB-) (NP (NN range)) (PP (IN from) (NP (NP (ADJP (CD 24) (NN %)) (NN decrease)) (PP (TO to) (NP (ADJP (CD 261) (NN %)) (NN increase))))) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively)))) (PP (IN in) (NP (CD 23) (JJ healthy) (NNS adults))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (VBD had) (NP (DT no) (ADJP (RB clinically) (JJ important)) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (-LRB- -LRB-) (ADJP (JJ equivalent) (PP (TO to) (NP (ADJP (CD 145) (NN mg)) (NN drug2)))) (-RRB- -RRB-))) (PP (IN with) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg)) (-RRB- -RRB-))) (ADJP (RB once) (JJ daily) (PP (IN for) (NP (CD 10) (NNS days))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (ADJP (QP (RB approximately) (CD 17)) (NN %)) (NN decrease)) (PRN (-LRB- -LRB-) (NP (NN range)) (PP (IN from) (NP (NP (ADJP (CD 67) (NN %)) (NN decrease)) (PP (TO to) (NP (ADJP (CD 44) (NN %)) (NN increase))))) (-RRB- -RRB-))) (PP (IN in) (NP (NN drug4) (NN AUC) (NNS values))) (PP (IN in) (NP (CD 22) (JJ healthy) (NNS males)))))) (. .)))
(S1 (S (S (NP (DT The) (JJ drug1) (NN Cmax) (NNS values)) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN affected) (PP (IN by) (NP (NN drug2)))))) (. .)))
(S1 (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN affected) (PP (IN by) (NP (NN drug2)))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (SBAR (IN If) (S (NP (JJ additional) (NNS drug1)) (VP (VBP are) (S (VP (TO to) (VP (VB be) (VP (VBN administered) (PP (IN by) (NP (DT any) (NN route)))))))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (SBAR (IN because) (S (NP (NP (DT the) (ADJP (RB pharmacologically) (JJ predictable)) (JJ sympathetic) (NNS effects)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated)))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN CYP2D6)))) (, ,)) (VP (VBD was) (VP (VBN co-administered) (PP (IN with) (NP (NN drug2))) (PP (IN at) (NP (NN steady-state))))))) (, ,) (NP (NP (NN exposure)) (PP (TO to) (NP (DT either) (NN drug)))) (VP (VBD was) (RB not) (VP (VBN altered)))) (. .)))
(S1 (S (S (NP (NP (NN Dosage) (NNS adjustments)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (RB not) (ADJP (JJ necessary)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN drug)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ potent) (NN CYP2D6) (NNS inhibitors))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN treatment)) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5))))) (VP (MD may) (VP (VB potentiate) (NP (NP (DT any) (JJ hypokalemic) (NN effect)) (PP (IN of) (NP (NN drug6))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (NN ECG) (NNS changes)) (CC and/or) (NP (NN hypokalemia))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))) (-RRB- -RRB-))))))))))) (VP (MD can) (VP (VB be) (VP (ADVP (RB acutely)) (VBN worsened) (PP (IN by) (NP (NN drug4))) (, ,) (SBAR (WHADVP (RB especially) (WRB when)) (S (NP (NP (DT the) (VBN recommended) (NN dose)) (PP (IN of) (NP (DT the) (NN drug5)))) (VP (VBZ is) (VP (VBD exceeded))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT these) (NNS effects)))) (VP (VBZ is) (RB not) (VP (VBN known))))) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN advised) (PP (IN in) (NP (NP (DT the) (NN co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (CONJP (RB as) (IN with)) (NP (JJ other) (NNS drug2)) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NP (JJ extreme) (NN caution)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NP (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB prolong) (NP (DT the) (NN QTc) (NN interval)) (SBAR (IN because) (S (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug5))) (PP (IN on) (NP (DT the) (JJ cardiovascular) (NN system)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (DT these) (NNS agents))))))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB prolong) (NP (DT the) (NN QTc) (NN interval)))))))))) (VP (VBP have) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ ventricular) (NNS arrhythmias)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (ADJP (RB intravenously) (CC or) (ADJP (RB orally) (VBN administered))) (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (, ,) (NP (NN drug3)) (-RRB- -RRB-)))) (PP (IN by) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug4)))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB completely)) (VP (VBN evaluated))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (CD two) (JJ combined) (JJ 12-week) (NN placebo) (JJ controlled) (NNS trials)) (SBAR (WHNP (WDT that)) (S (VP (VBD included) (NP (NP (NN drug1) (NNS doses)) (PP (IN of) (NP (NP (NP (CD 15) (NN mcg)) (ADVP (RB twice) (RB daily))) (, ,) (NP (NP (CD 25) (NN mcg)) (ADVP (RB twice) (RB daily))) (, ,) (CC and) (NP (NP (CD 50) (NN mcg)) (ADVP (RB once) (RB daily))))))))))) (, ,) (NP (NP (CD 54)) (PP (IN of) (NP (CD 873) (JJ drug2) (JJ -treated) (NNS subjects)))) (VP (VBD received) (NP (JJ concomitant) (NN drug3)) (PP (IN at) (NP (NN study) (NN entry)))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (JJ 12-month) (JJ controlled) (NN trial)) (SBAR (WHNP (WDT that)) (S (VP (VBD included) (NP (DT a) (CD 50) (NN mcg) (ADJP (RB once) (JJ daily)) (NN drug1) (NN dose))))))) (, ,) (NP (NP (CD 30)) (PP (IN of) (NP (DT the) (CD 528) (JJ drug2) (JJ -treated) (NNS subjects)))) (VP (VBD received) (NP (JJ concomitant) (NN drug3)) (PP (IN at) (NP (NN study) (NN entry))))) (. .)))
(S1 (S (PP (IN In) (NP (DT these) (NNS trials))) (, ,) (NP (NP (NN heart) (NN rate)) (CC and) (NP (JJ systolic) (NN blood) (NN pressure))) (VP (VBD were) (ADJP (NP (NP (ADJP (QP (RB approximately) (CD 2-3)) (NN bpm))) (CC and) (NP (ADJP (CD 6-8) (NN mm)) (NN Hg))) (JJR higher)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN on) (NP (NP (JJ concomitant) (NN drug1)) (PP (VBN compared) (PP (IN with) (NP (DT the) (JJ overall) (NN population))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NN drug3))) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT each) (JJ other))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (ADVP (RB concurrently)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (CONJP (RB not) (RB only)) (VP (VBP block) (NP (NP (DT the) (JJ therapeutic) (NNS effects)) (PP (IN of) (NP (NN drug2))))) (, ,) (CC but) (VP (MD may) (VP (VB produce) (NP (NP (JJ severe) (NN bronchospasm)) (PP (IN in) (NP (NN COPD) (NNS patients)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NN COPD)))) (VP (MD should) (RB not) (ADVP (RB normally)) (VP (VB be) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (PP (IN under) (NP (NP (JJ certain) (NNS circumstances)) (, ,) (PP (FW e.g.)))) (, ,) (PP (IN as) (NP (NP (NN prophylaxis)) (PP (IN after) (NP (JJ myocardial) (NN infarction))))) (, ,) (NP (EX there)) (VP (MD may) (VP (VB be) (NP (NP (DT no) (JJ acceptable) (NNS alternatives)) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN COPD)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN setting))) (, ,) (NP (NN drug1)) (VP (MD could) (VP (VB be) (VP (VBN considered) (, ,) (SBAR (IN although) (S (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution)))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (VBN Reduced) (NN efficacy)) (CC and) (NP (VBN increased) (NN incidence))) (PP (IN of) (NP (JJ breakthrough) (JJ bleeding)))) (CC and) (NP (JJ menstrual) (NNS irregularities))) (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (NP (NP (DT A) (JJ similar) (NN association)) (, ,) (ADJP (RB though) (RBR less) (JJ marked)) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NN phenyl-butazone)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (ADVP (RB possibly)) (PP (IN with) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6) (-LRB- -LRB-) (CD 72) (-RRB- -RRB-)))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VP (MD may) (VP (VB increase) (NP (NP (NN excretion)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))))) (CC and) (VP (MD may) (ADVP (RB also)) (VP (VB increase) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))))) (VP (MD may) (VP (VB cause) (NP (NN hypokalemia))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug2))))) (, ,) (PP (IN because) (IN of) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NN conduction) (NNS disturbances))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (PP (IN with) (NP (NP (JJ parasympathomimetic) (NNS effects)) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug1))))))) (VP (MD can) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB have) (NP (JJ additive) (NNS effects))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD might) (VP (VB interfere) (PP (IN with) (NP (NP (JJ desirable) (JJ antimuscarinic) (NNS effects)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN used) (ADVP (RB concomitantly)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP inhibit) (NP (NP (NN CYP2D6)) (CC and) (NP (NN CYP3A3/4))))))) (ADVP (RB also)) (VP (VBP inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NP (NN caution)) (PP (IN in) (NP (NP (NNS individuals)) (ADJP (ADJP (VBN known)) (CC or) (ADJP (VBN suspected))))) (S (VP (TO to) (VP (VB be) (ADJP (JJ deficient) (PP (IN in) (NP (NP (NN CYP2D6) (NN activity)) (, ,) (VP (VBN based) (PP (IN on) (NP (JJ previous) (VBP experience))))))) (, ,) (SBAR (IN as) (S (NP (PRP they)) (VP (MD may) (VP (VB be) (PP (IN at) (NP (NP (DT a) (JJR higher) (NN risk)) (PP (IN of) (NP (JJ adverse) (NNS events)))))))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT an) (ADJP (FW in) (FW vitro)) (NN study))) (, ,) (NP (NN cytochrome) (NN P450) (NNS isozymes) (NP (NP (NN 1A2)) (, ,) (NP (NN 2A6)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (NP (NN 2D6)) (, ,) (NP (NN 2E1)) (, ,) (CC and) (NP (NN 3A4)))) (VP (VBD were) (RB not) (VP (VBN inhibited) (PP (IN by) (NP (NP (NN exposure)) (PP (TO to) (NP (NN drug1)))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN Phase) (NN I) (NN trial)) (VP (VBG using) (NP (NP (NP (JJ escalating) (NNS doses)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 110-200) (NN mg/m2)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CC or) (CD 75)) (NN mg/m2)) (-RRB- -RRB-)))))) (VP (VBN given) (PP (IN as) (NP (JJ sequential) (NNS infusions)))))))) (, ,) (NP (NN myelosuppression)) (VP (VBD was) (ADJP (RBR more) (JJ profound)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBD was) (VP (VBN given) (PP (IN after) (NP (NN drug4))) (PP (IN than) (PP (IN with) (NP (NP (DT the) (JJ alternate) (NN sequence)) (PRN (-LRB- -LRB-) (PP (FW ie)) (, ,) (NP (NP (NN drug5)) (PP (IN before) (NP (NN drug6)))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Pharmacokinetic) (NNS data)) (PP (IN from) (NP (DT these) (NNS patients)))) (VP (VBD demonstrated) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN drug1) (NN clearance)) (PP (IN of) (NP (QP (RB approximately) (CD 33)) (NN %)))))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN administered) (PP (VBG following) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN metabolism)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN catalyzed) (PP (IN by) (NP (NN cytochrome) (NN P450) (NNS isoen-zymes) (NP (NP (NN CYP2C8)) (CC and) (NP (NN CYP3A4)))))))) (. .)))
(S1 (S (S (PP (IN In) (DT the) (NN absence) (IN of) (NP (JJ formal) (JJ clinical) (NN drug) (NN interaction) (NNS studies))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (RB concomitantly) (IN with) (NP (NP (JJ known) (NNS substrates)) (CC or) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (DT the) (NN cytochrome) (NN P450) (NNS isoenzymes) (NP (NP (NN CYP2C8)) (CC and) (NP (NN CYP3A4))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Potential) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (NN substrate)) (PP (IN of) (NP (NN CYP3A4)))) (, ,) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))) (-RRB- -RRB-))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (NP (NP (NP (NNS substrates)) (CC and/or) (NP (NNS inhibitors))) (PP (IN of) (NP (NN CYP3A4))))))) (, ,)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN evaluated) (PP (IN in) (NP (JJ clinical) (NNS trials))))))) (. .)))
(S1 (S (S (NP (NP (NNS Reports)) (PP (IN in) (NP (DT the) (NN literature)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (-LRB- -LRB-) (CC and) (NP (PRP$ its) (JJ active) (NN metabolite) (NN drug2)) (-RRB- -RRB-)) (VP (MD may) (VP (VB be) (VP (VBN increased) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBP are) (VP (VBN used) (PP (IN in) (NP (NN combination)))))))))))))) (. .)))
(S1 (S (NP (NP (NNP Hematology)) (: :) (S (NP (NN drug1) (NN therapy)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN baseline) (NN neutrophil) (NNS counts)) (PP (IN of) (NP (QP (JJR less) (IN than) (CD 1,500)) (NN cells/mm3))))))))))) (. .))))
(S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB monitor) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NN myelotoxicity)))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (JJ frequent) (JJ peripheral) (NN blood) (NN cell) (NNS counts)) (VP (VB be) (VP (VBN performed) (PP (IN on) (NP (NP (DT all) (NNS patients)) (VP (VBG receiving) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN re-treated) (PP (IN with) (NP (NP (JJ subsequent) (NNS cycles)) (PP (IN of) (NP (NN drug1))))) (SBAR (IN until) (S (S (NP (NNS neutrophils)) (VP (VBP recover) (PP (TO to) (NP (NP (DT a) (NN level)) (ADJP (CD 1500) (NN cells/mm3)))))) (CC and) (S (NP (NNS platelets)) (VP (VBP recover) (PP (TO to) (NP (NP (DT a) (NN level)) (ADJP (CD 100,000) (NN cells/mm3)))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (JJ severe) (NN neutropenia)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN cells/mm3)) (PP (IN for) (NP (NP (CD seven) (NNS days)) (CC or) (NP (JJR more)))) (-RRB- -RRB-)))) (PP (IN during) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NN drug1) (NN therapy))))))) (, ,) (NP (NP (DT a) (CD 20) (NN %) (NN reduction)) (PP (IN in) (NP (NN dose))) (PP (IN for) (NP (NP (JJ subsequent) (NNS courses)) (PP (IN of) (NP (NN therapy)))))) (VP (VBZ is) (VP (VBN recommended))) (. .)))
(S1 (S (S (PP (IN For) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ advanced) (NN HIV) (NN disease)) (CC and) (NP (JJ poor-risk) (JJ AIDS-related) (NN Kaposi) (NN s) (NN sarcoma)))))) (, ,) (NP (NP (NN drug1)) (, ,) (PP (IN at) (NP (NP (DT the) (VBN recommended) (NN dose)) (PP (IN for) (NP (DT this) (NN disease))))) (, ,)) (VP (MD can) (VP (VB be) (VP (VP (VBN initiated)) (CC and) (VP (VBN repeated) (SBAR (IN if) (S (NP (DT the) (NN neutrophil) (NN count)) (VP (VBZ is) (NP (QP (IN at) (JJS least) (CD 1000)) (NN cells/mm3)))))))))) (. .)))
(S1 (S (NP (NP (NN Hypersensitivity) (NNS Reactions)) (: :) (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ severe) (NN hypersensitivity) (NNS reactions)) (PP (TO to) (NP (NP (NNS products)) (VP (VBG containing) (NP (NP (NN Cremophor) (NN EL)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NP (NP (CD drug1)) (PP (IN for) (NP (NN injection) (NN concentrate)))) (CC and) (NP (NP (CD drug2)) (PP (IN for) (NP (NN injection) (NN concentrate)))))) (-RRB- -RRB-))))))))))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN treated) (PP (IN with) (NP (NN drug3))))))) (. .))))
(S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB avoid) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ severe) (NN hypersensitivity) (NNS reactions)))))))) (, ,) (NP (NP (DT all) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))) (VP (MD should) (VP (VB be) (VP (VBN premedicated) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug3)))) (-RRB- -RRB-))) (, ,) (NP (NN diphen-hydramine)) (CC and) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug5)) (CC or) (NP (NN drug6))))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Minor) (NNS symptoms)) (PP (JJ such) (IN as) (NP (NP (NN flushing)) (, ,) (NP (NN skin) (NNS reactions)) (, ,) (NP (NN dyspnea)) (, ,) (NP (NN hypotension)) (, ,) (CC or) (NP (NN tachycardia))))) (VP (VBP do) (RB not) (VP (VB require) (NP (NP (NN interruption)) (PP (IN of) (NP (NN therapy))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (JJ severe) (NNS reactions)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN hypotension)) (VP (VBG requiring) (NP (NP (NN treatment)) (, ,) (NP (NP (NN dyspnea)) (VP (VBG requiring) (NP (NN drug1)))) (, ,) (NP (NN angioedema)) (, ,) (CC or) (NP (VBN generalized) (NN urticaria))))))) (VP (VBP require) (NP (NP (JJ immediate) (NN discontinuation)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (JJ aggressive) (JJ symptomatic) (NN therapy))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN developed) (NP (JJ severe) (NN hypersensitivity) (NNS reactions))))))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN rechallenged) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (NP (NP (NN Cardiovascular)) (: :) (S (S (NP (NP (NN Hypotension)) (, ,) (NP (NN bradycardia)) (, ,) (CC and) (NP (NN hypertension))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN during) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug1))))))))) (, ,) (CC but) (S (ADVP (RB generally)) (VP (VBP do) (RB not) (VP (VB require) (NP (NN treatment)))))) (. .))))
(S1 (S (S (ADVP (RB Occasionally)) (NP (NN drug1) (NNS infusions)) (VP (VP (MD must) (VP (VB be) (VP (VBN interrupted)))) (CC or) (VP (VBD discontinued) (PP (IN because) (IN of) (NP (ADJP (ADJP (JJ initial)) (CC or) (ADJP (JJ recurrent))) (NN hypertension)))))) (. .)))
(S1 (S (S (NP (NP (JJ Frequent) (JJ vital) (NN sign) (NN monitoring)) (, ,) (ADVP (RB particularly)) (PP (IN during) (NP (NP (DT the) (JJ first) (NN hour)) (PP (IN of) (NP (NN drug1) (NN infusion))))) (, ,)) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (JJ Continuous) (JJ cardiac) (NN monitoring)) (VP (VBZ is) (RB not) (VP (VBN required) (PP (IN except) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ serious) (NN conduction) (NNS abnormalities))))))))) (. .)))
(S1 (S (NP (NP (JJ Nervous) (NN System)) (: :) (S (SBAR (IN Although) (S (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ peripheral) (NN neuropathy)))) (VP (VBZ is) (ADJP (JJ frequent))))) (, ,) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ severe) (NN symptomatology)))) (VP (VP (VBZ is) (ADJP (JJ unusual))) (CC and) (VP (VBZ requires) (NP (NP (DT a) (NN dose) (NN reduction)) (PP (IN of) (NP (CD 20) (NN %))) (PP (IN for) (NP (NP (DT all) (NNS subsequentcourses)) (PP (IN of) (NP (NN drug1))))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ contains) (NP (NP (JJ dehydrated) (NN alcohol) (NN USP)) (, ,) (NP (CD 396) (NN mg/mL))))) (: ;)))
(S1 (S (S (NP (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (NP (JJ possible) (NNS CNS)) (CC and) (NP (JJ other) (NNS effects))) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (NP (NP (JJ Hepatic)) (: :) (S (NP (EX There)) (VP (VBZ is) (NP (JJ limited) (NN evidence) (SBAR (IN that) (S (NP (NP (DT the) (NN myelotoxicity)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ exacerbated) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN serum) (JJ total) (NN bilirubin) (CD 2) (NNS times) (NN ULN))))))))))))) (. .))))
(S1 (S (S (NP (JJ Extreme) (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (TO to) (NP (JJ such) (NNS patients)))))) (, ,) (PP (IN with) (NP (NN dose) (NN reduction))) (SBAR (IN as) (S (VP (VBN recommended) (PP (IN in) (NP (NP (NN DOSAGE)) (CC AND) (NP (NP (NN ADMINISTRATION)) (, ,) (NP (NN Table) (CD 17)))))))))))) (. .)))
(S1 (S (NP (NP (NN InjectionSite) (NN Reaction)) (: :) (S (NP (NP (NN Injection) (NN site) (NNS reactions)) (, ,) (PP (VBG including) (NP (NP (NNS reactions)) (ADJP (JJ secondary) (PP (TO to) (NP (NN extravasation)))))) (, ,)) (VP (VP (VBD were) (ADJP (RB usually) (JJ mild))) (CC and) (VP (VBD consisted) (PP (IN of) (NP (NP (NN erythema)) (, ,) (NP (NN tenderness)) (, ,) (NP (NN skin) (NN discoloration)) (, ,) (CC or) (NP (NN swelling)))) (PP (IN at) (NP (DT the) (NN injection) (NN site)))))) (. .))))
(S1 (S (S (NP (DT These) (NNS reactions)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (ADVP (RBR more) (RB frequently)) (PP (IN with) (NP (DT the) (JJ 24-hour) (NN infusion))) (PP (IN than) (PP (IN with) (NP (DT the) (JJ 3-hour) (NN infusion)))))))) (. .)))
(S1 (S (S (NP (NP (NN Recurrence)) (PP (IN of) (NP (NN skin) (NNS reactions))) (PP (IN at) (NP (NP (DT a) (NN site)) (PP (IN of) (NP (JJ previous) (NN extravasation))) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN at) (NP (DT a) (JJ different) (NN site))))))) (, ,) (PP (FW ie) (, ,) (NP (NN recall))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (ADVP (RB rarely)))))) (. .)))
(S1 (S (S (NP (NP (JJ Rare) (NNS reports)) (PP (IN of) (NP (NP (ADJP (RBR more) (JJ severe)) (NNS events)) (PP (JJ such) (IN as) (NP (NP (NN phlebitis)) (, ,) (NP (NN cellulitis)) (, ,) (NP (NN induration)) (, ,) (NP (NN skin) (NN exfoliation)) (, ,) (NP (NN necrosis)) (, ,) (CC and) (NP (NN fibrosis))))))) (VP (VBP have) (VP (VBN been) (VP (VBN received) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT the) (VBG continuing) (NN surveillance)) (PP (IN of) (NP (NN drug1) (NN safety))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT some) (NNS cases))) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (DT the) (NN injection) (NN site) (NN reaction)))) (ADVP (RB either)) (VP (VP (VBD occurred) (PP (IN during) (NP (DT a) (JJ prolonged) (NN infusion)))) (CC or) (VP (VBD was) (VP (VBN delayed) (PP (IN by) (NP (NP (DT a) (NN week)) (PP (TO to) (NP (CD ten) (NNS days))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ specific) (NN treatment)) (PP (IN for) (NP (NN extravasation) (NNS reactions)))) (VP (VBZ is) (ADJP (JJ unknown)) (PP (IN at) (NP (DT this) (NN time))))) (. .)))
(S1 (S (S (PP (IN Given) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NN extravasation))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ advisable) (S (VP (TO to) (ADVP (RB closely)) (VP (VB monitor) (NP (NP (DT the) (NN infusion) (NN site)) (PP (IN for) (NP (NP (JJ possible) (NN infiltration)) (PP (IN during) (NP (NN drug) (NN administration)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN CYP2C9)) (CC and) (NP (NN CYP3A4))))))) (. .)))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (DT these) (NNS isoenzymes)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (NP (NN CYP3A4)) (CC and) (NP (NN CYP2C9))))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT these) (CD two) (NNS isoenzymes))))))) (VP (MD will) (VP (VB be) (VP (VBN decreased) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (NP (NN co-administered))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD had) (NP (DT no) (JJ relevant) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NP (DT any) (JJ CYP) (NNS isoenzymes)) (VP (VBN tested) (PRN (-LRB- -LRB-) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2C19)) (, ,) (NP (NN CYP2D6)) (, ,) (NP (NN CYP3A4))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT these) (NNS enzymes))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (, ,) (VP (VBG Including) (NP (ADJP (ADJP (JJ Oral)) (, ,) (ADJP (JJ Injectable)) (, ,) (ADJP (JJ Transdermal)) (, ,) (CC and) (ADJP (JJ Implantable))) (NNS drug2)))) (: :) (S (NP (DT An) (NN interaction) (NN study)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug3)))) (CC and) (NP (DT the) (JJ oral) (NN drug4) (NN drug5))) (VP (VBD produced) (NP (NP (NP (JJ average) (NNS decreases)) (PP (IN of) (NP (NN drug6)))) (CC and) (NP (NP (NN drug7) (NNS levels)) (PP (IN of) (NP (NP (CD 14) (NN %)) (CC and) (NP (CD 31) (NN %)) (, ,) (ADVP (RB respectively))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (NNS decreases)) (PP (IN in) (NP (NN exposure)))) (VP (VBD were) (NP (NP (QP (RB as) (JJ much) (IN as) (CD 56)) (NN %)) (CC and) (NP (CD 66) (NN %)) (, ,) (ADVP (RB respectively))) (, ,) (PP (IN in) (NP (JJ individual) (NNS subjects))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN drug1)) (, ,) (PP (VBG including) (NP (ADJP (ADJP (JJ oral)) (, ,) (ADJP (JJ injectable)) (, ,) (ADJP (JJ transdermal)) (, ,) (CC and) (ADJP (JJ implantable))) (NNS forms))) (, ,)) (VP (MD may) (RB not) (VP (VB be) (ADJP (JJ reliable) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (NP (NN co-administered))))))))) (. .)))
(S1 (S (S (NP (NNS Women)) (VP (MD should) (VP (VP (NN practice) (NP (NP (JJ additional) (NNS methods)) (PP (IN of) (NP (NN contraception))))) (CC and) (RB not) (VP (VBP rely) (PP (IN on) (NP (NP (JJ hormonal) (NN contraception)) (ADVP (RB alone)))) (SBAR (WHADVP (WRB when)) (S (VP (VBG taking) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (JJ Specific) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (NP (NP (DT the) (NN following)) (: :) (S (NP (NN drug1)) (: :) (PP (IN During) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (JJ concomitant) (NN administration))))) (, ,) (NP (NP (NN trough) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))) (VP (VBD were) (VP (VBN increased) (PP (IN by) (NP (RB about) (RB 30-fold)))))))))) (. .)))
(S1 (S (S (NP (JJ Steady-state) (NN drug1) (NN plasma) (NNS concentrations)) (VP (VBD were) (ADJP (ADJP (NP (CD 3-) (TO to) (RB 4-fold)) (JJR higher)) (PP (IN than) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD decreased) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (DT a) (NN CYP3A4) (NN substrate)) (-RRB- -RRB-))))) (PP (IN by) (NP (QP (RB approximately) (CD 50)) (NN %))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (: :) (NN Co-administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NN man))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD resulted) (PP (IN in) (NP (NP (ADJP (RB markedly) (VBN increased)) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug3)) (PP (IN in) (NP (NNS animals))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (IN if) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB together)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT An) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ elevated) (NN liver) (NNS aminotransferases)))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NN drug2)))))))))) (. .))))
(S1 (S (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (VP (VBN contraindicated)))) (, ,) (CC and) (S (NP (JJ alternative) (NN drug3)) (VP (MD should) (VP (VB be) (VP (VBN considered)))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD decreased) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (QP (RB approximately) (CD 40)) (NN %))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (ADVP (RB also)) (VP (VBN decreased) (PP (IN by) (NP (QP (RB approximately) (CD 30)) (NN %)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN expected) (S (VP (TO to) (VP (VB reduce) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (JJ other) (JJ oral) (NNS drug2)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB predominantly)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN CYP2C9)) (CC or) (NP (NN CYP3A4))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (JJ worsened) (NN glucose) (NN control))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG using) (NP (DT these) (NNS agents)))))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN drug2) (CD 125) (NN mg) (NN b.i.d.)) (CC and) (NP (NP (NN drug3)) (, ,) (NP (DT a) (JJ potent) (NN CYP3A4) (NN inhibitor)) (, ,))))) (VP (VBD increased) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug4)))) (PP (IN by) (NP (RB approximately) (RB 2-fold))))) (. .))))
(S1 (S (S (S (NP (NP (DT No) (NN dose) (NN adjustment)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (ADJP (JJ necessary)))) (, ,) (CC but) (S (NP (NP (VBN increased) (NNS effects)) (PP (IN of) (NP (NN drug2)))) (VP (MD should) (VP (VB be) (VP (VBN considered)))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (JJ Other) (NN drug2))) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug3)))) (VP (VBD decreased) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (DT a) (NN CYP3A4) (NN substrate)) (-RRB- -RRB-))) (, ,) (CC and) (NP (PRP$ its) (JJ active) (NN -hydroxy) (NN acid) (NN metabolite))))) (, ,) (PP (IN by) (NP (QP (RB approximately) (CD 50)) (NN %))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (RB not) (VP (VBN affected)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN expected) (S (VP (TO to) (VP (VB reduce) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (JJ other) (NNS drug2)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (JJ significant) (NN metabolism)) (PP (IN by) (NP (NN CYP3A4)))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (VBN reduced) (NN drug1) (NN efficacy)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG using) (NP (NN CYP3A4) (NN metabolized) (NN drug1)))) (VP (MD should) (VP (VB have) (NP (NP (NN cholesterol) (NNS levels)) (VP (VBN monitored) (PP (IN after) (NP (NN drug2)))))))) (VP (VBZ is) (VP (VBN initiated) (S (VP (TO to) (VP (VB see) (SBAR (IN whether) (S (NP (DT the) (NN drug3) (NN dose)) (VP (VBZ needs) (NP (NN adjustment)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN drug2) (CD 500) (NN mg) (NN b.i.d.)) (PP (IN for) (NP (CD 6) (NNS days)))))) (VP (VBD decreased) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (CC both) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (DT a) (NN CYP2C9) (NN substrate)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (DT a) (NN CYP3A4) (NN substrate)) (-RRB- -RRB-)))))) (PP (IN by) (NP (QP (CD 29) (CC and) (CD 38)) (NN %))) (, ,) (ADVP (RB respectively)))) (. .))))
(S1 (S (S (NP (JJ Clinical)) (VP (VBP experience) (SBAR (IN with) (S (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ pulmonary) (JJ arterial) (NN hypertension)))))))) (VP (VBD did) (RB not) (VP (VB show) (NP (NP (ADJP (RB clinically) (JJ relevant)) (NNS changes)) (PP (IN in) (NP (NP (NP (NN INR)) (CC or) (NP (NN drug3) (NN dose))) (PRN (-LRB- -LRB-) (NP (NP (NN baseline)) (CC vs.) (NP (NP (NN end)) (PP (IN of) (NP (DT the) (JJ clinical) (NNS studies))))) (-RRB- -RRB-)))))))) (, ,) (CC and) (S (NP (DT the) (NN need) (S (VP (TO to) (VP (VB change) (NP (DT the) (NN drug4) (NN dose)) (PP (IN during) (NP (NP (DT the) (NNS trials)) (ADJP (ADJP (JJ due) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (NN INR)))))) (CC or) (ADJP (JJ due) (PP (TO to) (NP (JJ adverse) (NNS events))))))))))) (VP (VBD was) (ADJP (JJ similar) (PP (IN among) (NP (NN drug5)))))))))) (: -) (CC and) (NP (JJ placebo-treated) (NNS patients)) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (: :) (S (S (NP (NN drug4)) (VP (VBZ has) (NP (DT no) (JJ significant) (JJ pharmacokinetic) (NNS interactions)) (PP (IN with) (NP (NP (NN drug5)) (CC and) (NP (NN drug6)))))) (, ,) (CC and) (S (NP (NN drug7)) (VP (VBZ has) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug8)))))))) (. .))))
(S1 (S (S (NP (DT No) (NN drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (DT the) (NN therapy) (JJ standard)) (PP (IN in) (NP (NNS neonates))) (PP (IN with) (NP (JJ restricted) (ADJP (ADJP (JJ pulmonary)) (CC or) (ADJP (JJ systemic))) (NN blood) (NN flow)))))))))) (. .)))
(S1 (S (S (NP (JJ Standard) (NN therapy)) (VP (VBZ includes) (NP (NN drug1)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))) (: ;)))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NP (JJ such)) (PP (IN as) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (: ;)))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (S (CC and) (NP (NN drug1)) (, ,) (PP (JJ such) (IN as) (NP (NN drug2)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (DT The) (NN potential)) (PP (IN for) (NP (NP (JJ pharmacokinetic) (JJ drug-drug) (NNS interactions)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (JJ other) (NNS agents)))))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB formally)) (VP (VBN studied))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (VP (VBZ is) (VP (VBN used) (PP (IN at) (NP (DT the) (JJ same) (NN time))) (PP (IN as) (NP (NP (JJ other) (NNS medicines)) (CC or) (NP (NNS substances)))))))) (NP (DT the) (JJ following) (NNS interactions)) (VP (MD must) (VP (VB be) (VP (VBN taken) (PP (IN into) (NP (NN account))))))) (: :) (S (NP (CC -) (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug5))))))) (. .)))
(S1 (S (PP (IN For) (NP (DT this) (NN reason))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VP (VBN reduced) (PP (IN by) (NP (QP (CD 30) (TO -) (CD 50)) (NN %))) (PP (IN at) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NP (NN drug3)) (VP (VB retard)))))))))) (CC and) (VP (ADVP (RB then)) (VBN titrated) (PP (VBG according) (PP (TO to) (NP (DT the) (NN blood) (NN clotting) (NNS parameters))))))))))
(S1 (S (. .)))
(S1 (S (S (NP (NP (CC -) (DT The) (NN action)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (PP (IN by) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))))))) (. .)))
(S1 (S (NP (DT This)) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (NP (DT an) (JJ improved) (NN glucose) (NN utilization)) (PP (IN with) (NP (NP (JJ simultaneous) (NN reduction)) (PP (IN in) (NP (NN drug1) (NN requirement))))))))))))
(S1 (S (. .)))
(S1 (S (S (PP (CC -) (PP (IN In) (NP (VBN isolated) (NNS cases)))) (, ,) (NP (NP (DT a) (ADJP (ADJP (JJ pronounced)) (ADJP (RB though) (JJ reversible))) (, ,) (NN impairment)) (PP (IN of) (NP (JJ renal) (NN function))) (-LRB- -LRB-) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ corresponding) (NN increase)) (PP (IN in) (NP (DT the) (NN serum) (NN creatinine) (NN level)))))) (-RRB- -RRB-)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NN organ) (NN transplant) (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1) (NN therapy)) (CC and) (NP (JJ concomitant) (NN drug2)))))))))) (. .)))
(S1 (S (S (ADVP (RB Accordingly)) (, ,) (NP (JJ renal) (NN function)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored) (PP (IN in) (NP (DT these) (NNS patients))))))) (CC and) (, ,) (S (PP (IN in) (NP (NP (DT the) (NN event)) (PP (IN of) (NP (NP (JJ relevant) (JJ significant) (NNS changes)) (PP (IN in) (NP (JJ laboratory) (NNS parameters))))))) (, ,) (NP (NN drug1)) (VP (MD should) (, ,) (PP (IN if) (ADJP (JJ necessary))) (, ,) (VP (VB be) (VP (VBN discontinued)))))))
(S1 (S (. .)))
(S1 (S (UCP (CC -) (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (VP (VBZ is) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (NP (NNS drug4)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN interval)) (PP (IN of) (NP (NP (QP (IN at) (JJS least) (CD 2)) (NNS hours)) (VP (MD should) (VP (VB be) (VP (VBN maintained) (PP (IN between) (NP (DT the) (CD two) (NNS medicines))))))))))) (, ,) (SBAR (IN since) (S (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (NN drug5)) (CC or) (NP (NN drug6))))) (VP (VBZ is) (VP (VBN impaired))))))))))))
(S1 (S (. .)))
(S1 (S (S (NP (NP (CC -) (NP (NN drug1)) (CC or) (NP (NN drug2))) (PRN (-LRB- -LRB-) (PP (IN with) (NP (JJ hepatotoxic) (NN potential))) (-RRB- -RRB-))) (VP (MD must) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB together)) (PP (IN with) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NN Care)) (VP (MD should) (VP (VB be) (VP (VBN given) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (DT this) (NN drug)) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNS symptoms)) (PP (IN of) (NP (JJ myasthenic) (NN weakness))))) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB also)) (PP (IN on) (NP (NN drug1))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (NNS symptoms)) (PP (IN of) (NP (NP (NN anticholinesterase) (NN overdose)) (PRN (-LRB- -LRB-) (NP (JJ cholinergic) (NN crisis)) (-RRB- -RRB-))))) (VP (MD may) (VP (VB mimic) (NP (NP (NN underdosage)) (PRN (-LRB- -LRB-) (NP (JJ myasthenic) (NN weakness)) (-RRB- -RRB-))))))) (, ,) (NP (PRP$ their) (NN condition)) (VP (MD may) (VP (VB be) (VP (VBN worsened) (PP (IN by) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT this) (NN drug))))))))) (. .)))
(S1 (S (S (VP (MD May) (VP (VB interact) (PP (IN with) (NP (NP (NP (NN thyroid) (NN medication)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug1)) (-RRB- -RRB-))) (, ,) (NP (JJ drug2) (JJ -containing) (NNS products)) (, ,) (NP (NN drug3)) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug5))) (, ,) (NP (NN drug6)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug8))) (, ,) (NP (NNS drug9)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (DT This) (NN product)) (VP (MD can) (VP (VB affect) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (JJ certain) (NN lab) (NNS tests))))))) (. .)))
(S1 (S (S (NP (NN Drug/LaboratoryTest) (NNS Interactions) (CD drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (NN bioassay) (NNS procedures)) (PP (IN for) (NP (NP (DT the) (NN determination)) (PP (IN of) (NP (NN drug2) (NNS levels)))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB primarily)) (VP (VBN eliminated) (PP (IN by) (NP (DT the) (NNS kidneys))))))) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP reduce) (NP (JJ renal) (NN function))) (CC or) (VP (VBP compete) (PP (IN for) (NP (JJ active) (JJ tubular) (NN secretion)))))))))) (VP (MD may) (VP (VB increase) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (CC either) (NP (NN drug3)) (CC or) (NP (DT the) (JJ coadministered) (NN drug)))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4))))) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (JJ significant) (NN drug) (NNS interactions)))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP are) (ADVP (RB renally)) (VP (VBN eliminated))) (CC or) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB affect) (NP (JJ renal) (NN function))))))))))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN evaluated))))) (, ,) (CC and) (S (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (PP (IN for) (NP (JJ adverse) (NNS events))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (JJ such) (NNS drugs)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (NP (JJ additive) (NNS effects)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NP (JJ other) (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN etc))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBP prolong)) (CC and) (VP (VBP intensify) (NP (NP (DT the) (ADJP (ADJP (JJ anticholinergic)) (PRN (-LRB- -LRB-) (NP (NN drying)) (-RRB- -RRB-))) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (JJ Formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN Population) (JJ pharmacokinetic) (NNS analyses)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))) (VP (VBD did) (RB not) (VP (VB influence) (NP (NN drug5) (NN clearance)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NN RA) (JJ clinical) (NNS studies)))))) (VP (VBD received) (NP (QP (CD one) (CC or) (JJR more)) (PP (IN of) (NP (DT the) (VBG following) (NP (NP (JJ concomitant) (NNS medications)) (PP (IN with) (NP (NN drug1)))) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (CC and) (NP (NN drug12)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (DT a) (NN drug1)) (PP (IN with) (NP (NN drug2)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ serious) (NNS infections)))) (CC and) (NP (NP (DT no) (JJ significant) (JJ additional) (NN efficacy)) (PP (IN over) (NP (NP (NN use)) (PP (IN of) (NP (NP (DT the) (NN drug3)) (ADVP (RB alone))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN therapy)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (S (NP (EX There)) (VP (VBZ is) (ADJP (JJ insufficient) (S (VP (VBP experience) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NP (NN safety)) (CC and) (NP (NN efficacy))) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NNS drug2))))))))))))))) (, ,) (CC and) (S (ADVP (RB therefore)) (NP (JJ such) (NN use)) (VP (VBZ is) (RB not) (VP (VBN recommended))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN anti-glaucoma) (NN action)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))) (: ;)))
(S1 (S (S (ADVP (RB also)) (, ,) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (DT this) (NN medication)))) (VP (MD may) (VP (VB antagonise) (NP (NP (DT the) (NP (NN anti-glaucoma)) (CC and) (NP (JJ miotic) (NNS actions))) (PP (IN of) (NP (JJ ophthalmic) (NN drug1))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (DT These) (NNS drugs)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (JJ prolonged) (JJ vasospastic) (NNS reactions))))))))) (. .))))
(S1 (S (SBAR (IN Because) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ theoretical) (NN basis)) (SBAR (IN that) (S (NP (DT these) (NNS effects)) (VP (MD may) (VP (VB be) (ADJP (JJ additive)))))))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (NP (ADJP (JJ drug1) (JJ -containing) (CC or)) (NN drug2)) (PRN (-LRB- -LRB-) (PP (IN like) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))) (-RRB- -RRB-))) (CC and) (NP (NN drug5)))) (PP (IN within) (NP (NP (CD 24) (NNS hours)) (PP (IN of) (NP (DT each) (JJ other)))))) (VP (MD should) (VP (VB be) (VP (VBN avoided)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug2)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (ADJP (CD 27) (NN %)) (NN decrease)) (PP (IN in) (NP (NN drug3) (NN clearance)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN Cmax)) (PP (IN of) (NP (QP (RB approximately) (CD 6)) (NN %)))))))))) (. .))))
(S1 (S (S (NP (DT No) (NN dose) (NN adjustment)) (VP (VBZ is) (ADJP (JJ necessary)))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NN drug1) (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (JJ other) (NNS drug2)) (PP (IN within) (NP (NP (CD 24) (NNS hours)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug3)))))))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2)))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug3)))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7))) (-RRB- -RRB-)))) (VP (VBP have) (VP (VBN been) (ADVP (RB rarely)) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (NP (NN weakness)) (, ,) (NP (NN hyperreflexia)) (, ,) (CC and) (NP (NN incoordination))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug8))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (DT an) (NN drug2))))) (VP (VBZ is) (ADVP (RB clinically)) (VP (VBN warranted))))) (, ,) (NP (NP (JJ appropriate) (NN observation)) (PP (IN of) (NP (DT the) (NN patient)))) (VP (VBZ is) (VP (VBN advised)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (CD 24) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug4))))))))) (. .))))
(S1 (S (S (NP (DT No) (NN dose) (NN adjustment)) (VP (VBZ is) (ADJP (JJ necessary)))) (. .)))
(S1 (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (DT the) (JJ potent) (NN CYP3A4) (NN inhibitor) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 400) (NN mg)) (NN q.d.)) (PP (IN for) (NP (CD 3) (NNS days)))) (-RRB- -RRB-)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (ADJP (QP (RB approximately) (CD 60)) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NP (DT the) (NN area)) (PP (IN under) (NP (DT the) (NN plasma) (NN concentration-time) (NN curve)))) (CC and) (NP (NP (JJ maximal) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (JJ other) (JJ potent) (JJ CYP3A4) (NNS inhibitors)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))) (-RRB- -RRB-)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied)))))) (, ,) (NP (NP (VBN increased) (NNS exposures)) (PP (TO to) (NP (NN drug5)))) (VP (MD may) (VP (VB be) (VP (VBN expected) (SBAR (WHADVP (WRB when)) (S (NP (NN drug6)) (VP (VBZ is) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (DT these) (NNS medications))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN known) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (ADJP (RB commonly) (VBN employed)) (JJ clinical) (NN laboratory) (NNS tests))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (NP (NP (NN D)) (. .))))
(S1 (S (S (NP (NP (NN Drug)) (CC and) (NP (NN Laboratory) (NN Test) (NNS Interactions))) (NP (CD 1))) (. .)))
(S1 (S (NP (NP (VBN Accelerated) (NN prothrombin) (NN time)) (, ,) (NP (JJ partial) (NN thromboplastin) (NN time)) (, ,) (CC and) (NP (NP (NN platelet) (NN aggregation) (NN time)) (: ;)))))
(S1 (S (NP (NP (VBN increased) (NN platelet) (NN count)) (: ;))))
(S1 (S (NP (NP (VBN increased) (NNS factors) (NP (CD II))) (, ,) (NP (NP (NN VII) (NN antigen)) (, ,) (NP (NN VIII) (NN antigen)) (, ,) (NP (NN VIII) (NN coagulant) (NN activity)) (, ,) (NP (NN IX)) (, ,) (NP (NN X)) (, ,) (NP (NN XII)) (, ,) (NP (NN VII-X) (NN complex)) (, ,) (NP (NN II-VII-X) (NN complex)) (, ,) (CC and) (NP (NN beta-thromboglobulin))) (: ;))))
(S1 (S (S (NP (NP (VBN decreased) (NNS levels)) (PP (IN of) (NP (NP (NN anti-factor) (NN Xa)) (CC and) (NP (NN antithrombin) (CD III)))) (, ,)) (VP (VBD decreased) (NP (NN antithrombin) (CD III) (NN activity)))) (: ;)))
(S1 (S (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NP (NN fibrinogen)) (CC and) (NP (NN fibrinogen)) (NP (NN activity)))) (: ;))))
(S1 (S (S (NP (NP (VBN increased) (NN plasminogen) (NN antigen)) (CC and) (NP (NN activity)))) (. .)))
(S1 (S (NP (NP (CD 2)) (. .))))
(S1 (S (S (VP (VBN Increased) (NP (NP (NP (JJ thyroid-binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN TBG)) (-RRB- -RRB-))) (VP (VBG leading) (PP (TO to) (NP (VBN increased) (JJ circulating) (JJ total) (NN thyroid) (NN hormone) (NNS levels))))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (NP (JJ protein-bound) (NN iodine)) (PRN (-LRB- -LRB-) (NP (NN PBI)) (-RRB- -RRB-))) (, ,) (NP (NP (NN T4) (NNS levels)) (PRN (-LRB- -LRB-) (PP (PP (IN by) (NP (NN column))) (CC or) (PP (IN by) (NP (NN radioimmunoassay)))) (-RRB- -RRB-))) (CC or) (NP (NN T3) (NNS levels)))) (PP (IN by) (NP (NN radioimmunoassay)))))))) (. .)))
(S1 (S (S (NP (NN T3) (NN resin) (NN uptake)) (VP (VBZ is) (VP (VBN decreased) (, ,) (S (VP (VBG reflecting) (NP (DT the) (JJ elevated) (NN TBG))))))) (. .)))
(S1 (S (S (NP (JJ Free) (NP (NP (NN T4)) (CC and) (NP (NN T3))) (NNS concentrations)) (VP (VBP are) (ADJP (JJ unaltered)))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN thyroid) (NN replacement) (NN therapy)))) (VP (MD may) (VP (VBP require) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (NP (NP (CD 3)) (. .))))
(S1 (S (S (NP (JJ Other) (NN binding) (NNS proteins)) (VP (MD may) (VP (VB be) (VP (VBN elevated) (PP (IN in) (NP (NP (NN serum)) (, ,) (FW i.e.) (, ,) (NP (NP (NN corticosteroid) (NN binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN CBG)) (-RRB- -RRB-))) (, ,) (NP (NP (NN sex) (NN hormone-binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN SHBG)) (-RRB- -RRB-))))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (VBN increased) (JJ total) (JJ circulating) (NN drug1)) (CC and) (NP (NN drug2)))) (, ,) (ADVP (RB respectively)))))) (. .)))
(S1 (S (S (NP (JJ Free) (NN hormone) (NNS concentrations)) (VP (MD may) (VP (VB be) (VP (VBN decreased))))) (. .)))
(S1 (S (S (NP (JJ Other) (NN plasma) (NNS proteins)) (VP (MD may) (VP (VB be) (VP (VBN increased) (PRN (-LRB- -LRB-) (NP (NP (NN angiotensinogen/renin) (NN substrate)) (, ,) (NP (ADJP (JJ alpha-1-antitrypsin))) (, ,) (NP (NN ceruloplasmin))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (CD 4))) (. .)))
(S1 (S (S (NP (VBN Increased) (NN plasma) (NN HDL) (CC and) (NN HDL2) (NN cholesterol) (NN subfraction) (NNS concentrations)) (, ,) (VP (VP (VBD reduced) (NP (NN LDL) (NN cholesterol) (NN concentration))) (, ,) (VP (VBD increased) (NP (NN triglyceride) (NNS levels))))) (. .)))
(S1 (S (NP (NP (CD 5)) (. .))))
(S1 (S (NP (NP (JJ Impaired) (NN glucose) (NN tolerance)) (. .))))
(S1 (S (NP (NP (CD 6)) (. .))))
(S1 (S (S (VP (VBN Reduced) (NP (NP (NN response)) (PP (TO to) (NP (NN metyrapone) (NN test)))))) (. .)))
(S1 (S (NP (NP (NN http)) (: :) (NP (NN //www.rxlist.com/cgi/generic3/guanethidine_od.htm)))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBN given) (NP (NP (JJ single) (CD 500) (NN mg) (NNS doses)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))) (, ,) (S (NP (NP (NN plasma) (NN drug4) (NN mean) (NN cmax)) (CC and) (NP (NN AUC))) (VP (VBD increased) (PP (IN by) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (CD 34) (NN %)) (CC and) (NP (CD 24) (NN %)) (, ,) (ADVP (RB respectively)))))))) (, ,) (CC and) (S (NP (VBN drug5) (JJ mean) (JJ renal) (NN clearance)) (VP (VBD decreased) (PP (IN by) (NP (CD 14) (NN %)))))) (. .))))
(S1 (S (S (NP (DT No) (NN information)) (VP (VBZ is) (ADJP (JJ available) (PP (IN about) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (VBG following) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (DT either) (NN drug)))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (VP (RB not) (VBN observed) (PP (IN in) (NP (DT this) (NN study)))))) (, ,) (NP (JJ adverse) (NNS effects)) (VP (MD could) (ADVP (RB potentially)) (VP (VB arise) (PP (IN from) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (JJ tubular) (NN secretion)) (PP (IN via) (NP (JJ organic) (JJ cationic) (NN transporter) (NNS systems)))))))))) (. .)))
(S1 (S (S (ADVP (RB Accordingly)) (, ,) (NP (NP (NP (JJ careful) (NN patient) (NN monitoring)) (CC and) (NP (NN dose) (NN adjustment))) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concomitantly)) (VBG taking) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (PP (IN As) (PP (IN with) (NP (JJ other) (NNS drug2)))) (, ,) (NP (NP (DT the) (JJ renal) (NN excretion)) (PP (IN of) (NP (NN drug3)))) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP (NN drug4)))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (: /) (NN Laboratory) (NN Test) (NNS Interactions)) (PP (IN As) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (DT the) (NN urine))))))))))) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (PP (IN with) (NP (NP (NP (NNP Benedict) (NNP s)) (CC and) (NP (NNP Fehling) (NNP s))) (NNS solutions))) (CC and) (PP (RB also) (IN with) (NP (JJ Clinitest) (NNS tablets)))))))) (. .)))
(S1 (S (S (VP (MD May) (VP (VB interact) (PP (IN with) (NP (DT the) (NN following)))))) (: :) (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2) (-LRB- -LRB-) (NN use))) (PP (IN with) (NP (NN drug3)))) (VP (MD may) (VP (VB prevent) (NP (NP (DT the) (NN drug4)) (PP (IN from) (NP (NNP working)))) (ADVP (RB properly))))) (: ;)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN liver)))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBZ is) (ADJP (RB theoretically) (JJ possible)) (SBAR (IN that) (S (NP (PRP$ its) (NN metabolism)) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (PP (IN by) (NP (NP (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (JJ hepatic) (JJ microsomal) (NNS enzymes)))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (CC neither) (NP (NN drug1)) (CC nor) (NP (NN drug2))) (VP (VBZ appears) (S (VP (TO to) (VP (VB affect) (NP (NN drug3) (NN metabolism))))))) (. .)))
(S1 (S (S (NP (NP (NN Binding)) (PP (TO to) (NP (NN plasma) (NN protein)))) (VP (VBZ is) (RB not) (ADVP (RB significantly)) (VP (VBN altered) (PP (IN by) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC or) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN Binding)) (PP (TO to) (NP (NN plasma) (NNS proteins)))) (VP (VBZ is) (VP (VP (VBN reduced) (PP (IN by) (NP (NP (NN drug1)) (CC and) (NP (NN clotibrate))))) (CC and) (VP (VBN increased) (PP (IN by) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (JJ Cardiovascular) (NN collapse)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (ADVP (RB simultaneously)) (PP (IN with) (NP (NP (NN varapamil)) (CC and) (NP (NN drug1)))))))) (VP (VBZ is) (NP (NN rare)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (NP (NP (JJ intravenous) (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN in) (NP (NN drug3) (JJ a-chloralose) (JJ anesthetized) (NN swine)))))))) (VP (VBZ has) (VP (VBD resulted) (PP (IN in) (NP (NP (NN ventricular) (NN fibrillation)) (CC and) (NP (JJ cardiovascular) (NN collapse)))) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (JJ marked) (NN hyperkalemia)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (JJ intravenous) (NN drug1)) (CC and) (NP (NN drug2)) (, ,) (CONJP (JJ such) (IN as)) (NP (NN drug3)) (, ,)))) (VP (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB together)) (PP (IN during) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (JJ malignant) (NN hyperthermia)) (NN crisis))))) (SBAR (IN until) (S (NP (NP (DT the) (NN relevance)) (PP (IN of) (NP (DT these) (NNS findings))) (PP (TO to) (NP (NNS humans)))) (VP (VBZ is) (VP (VBN established))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB potentiate) (NP (JJ drug2) (JJ -induced) (NN neuromuscular) (NN block))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effectiveness)) (PP (IN of) (NP (NN drug1) (NN -only) (NNS pills)))) (VP (VBZ is) (VP (VBN reduced) (PP (IN by) (NP (NP (JJ hepatic) (JJ enzyme-inducing) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (DT the) (NN drug2) (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)) (, ,) (CC and) (NP (DT the) (NN drug6) (NN drug7))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ significant) (NN interaction)) (VP (VBZ has) (VP (VBN been) (VP (VBN found) (PP (IN with) (NP (NN broad-spectrum) (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD can) (VP (VP (VB inhibit) (NP (NN CYP2C19))) (CC and) (VP (VB induce) (NP (NP (NN CYP3A4/5)) (PP (IN with) (NP (NP (ADJP (RB potentially) (JJ important)) (NNS effects)) (PP (IN on) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (JJ other) (NNS drugs)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ several) (NN drug1) (NNS s)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NN cytochrome) (NN P450)) (NNS inducers)))))) (VP (MD can) (VP (VBP decrease) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (VP (VBN evaluated) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes))) (S (VP (TO to) (VP (VB determine) (NP (PRP$ its) (NN capacity) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (JJ major) (NN cytochrome) (NN P450) (NNS enzymes)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (JJ other) (NNS drugs))))))))))))))))) (. .)))
(S1 (S (S (NP (NNS Results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC and) (NP (NP (PRP$ its) (ADJP (RB pharmacologically) (JJ active)) (JJ 10-monohydroxy) (NN metabolite)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))) (VP (VBP have) (NP (NP (ADJP (JJ little))) (CC or) (NP (DT no) (NN capacity) (S (VP (TO to) (VP (VB function) (PP (IN as) (NP (NP (NNS inhibitors)) (PP (IN for) (NP (NP (JJS most)) (PP (IN of) (NP (NP (NP (DT the) (JJ human) (NN cytochrome) (NN P450)) (NNS enzymes)) (VP (VBN evaluated) (PRN (-LRB- -LRB-) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2A6)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2D6)) (, ,) (NP (NN CYP2E1)) (, ,) (NP (NN CYP4A9)) (CC and) (NP (NN CYP4A11))) (-RRB- -RRB-)) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (NN CYP2C19)) (CC and) (NP (NN CYP3A4/5))))))))))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN CYP) (NN 3A4/5))) (PP (IN by) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD did) (VP (VB occur) (PP (IN at) (NP (JJ high) (NNS concentrations))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ clinical) (NN significance))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN inhibition)) (PP (IN of) (NP (NN CYP-2C19))) (PP (IN by) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ is) (ADJP (RB clinically) (JJ relevant)))) (. .)))
(S1 (S (S (ADVP (FW In) (FW vitro)) (, ,) (NP (DT the) (JJ UDP-glucuronyl) (NN transferase) (NN level)) (VP (VBD was) (VP (VBN increased) (, ,) (S (VP (VBG indicating) (NP (NP (NN induction)) (PP (IN of) (NP (DT this) (NN enzyme))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Increases)) (PP (IN of) (NP (NP (NP (CD 22) (NN %)) (PP (IN with) (NP (NN drug1)))) (CC and) (NP (NP (CD 47) (NN %)) (PP (IN with) (NP (NN drug2))))))) (VP (VBD were) (VP (VBN observed)))) (. .)))
(S1 (S (SBAR (IN As) (S (NP (NP (NN drug1)) (, ,) (NP (DT the) (JJ predominant) (NN plasma) (NN substrate)) (, ,)) (VP (VBZ is) (ADVP (RB only)) (NP (NP (DT a) (JJ weak) (NN inducer)) (PP (IN of) (NP (NN UDP-glucuronyl) (NN transferase))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB have) (NP (DT an) (NN effect)) (PP (IN on) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB mainly)) (VP (VBN eliminated) (PP (IN by) (NP (NN conjugation))) (PP (IN through) (NP (NP (JJ UDP-glucuronyl) (NN transferase)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (, ,) (NP (NN drug3)) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP induce) (NP (NP (NP (NP (DT a) (NN subgroup)) (PP (IN of) (NP (DT the) (NN cytochrome) (NN P450) (NN 3A) (NN family)))) (PRN (-LRB- -LRB-) (NP (NP (NN CYP3A4)) (CC and) (NP (NN CYP3A5))) (-RRB- -RRB-))) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (JJ oral) (NN drug4)))))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJR lower) (NN plasma) (NN concentration)) (PP (IN of) (NP (DT these) (NNS drugs)))))))) (. .)))
(S1 (S (S (SBAR (IN As) (S (NP (NP (NN binding)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NN plasma) (NNS proteins)))) (VP (VBZ is) (ADJP (ADJP (JJ low)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN %)) (-RRB- -RRB-)))))) (, ,) (NP (NP (ADJP (RB clinically) (JJ significant)) (NNS interactions)) (PP (IN with) (NP (JJ other) (NNS drugs))) (PP (IN through) (NP (NP (NN competition)) (PP (IN for) (NP (NN protein) (NN binding) (NNS sites)))))) (VP (VBP are) (ADJP (JJ unlikely)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Potential) (NNS interactions)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (JJ other) (NN drug3))))) (VP (VBD were) (VP (VBN assessed) (PP (IN in) (NP (JJ clinical) (NNS studies)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (DT these) (NNS interactions))) (PP (IN on) (NP (NP (JJ mean) (NNS AUCs)) (CC and) (NP (NN Cmin))))) (VP (VBP are) (VP (VBN summarized) (PP (IN in) (NP (NN Table) (CD 2)))))) (: :) (NP (NN Table) (CD 2)) (: :) (NP (NP (NN Summary)) (PP (IN of) (NP (NP (JJ AED) (NNS interactions)) (PP (IN with) (NP (NN drug1))))))))
(S1 (S (NP (NN drug1) (NN Co-administered))))
(S1 (S (NP (NP (NP (NN Dose)) (PP (IN of) (NP (NN drug1)))) (PRN (-LRB- -LRB-) (NP (NN mg/day)) (-RRB- -RRB-)))))
(S1 (S (NP (NP (NN drug1) (NN dose)) (PRN (-LRB- -LRB-) (NP (NN mg/day)) (-RRB- -RRB-)))))
(S1 (S (NP (NP (NN Influence)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NN drug2) (NN Concentration)) (PRN (-LRB- -LRB-) (NP (NP (NN Mean) (NN change)) (, ,) (NP (ADJP (CD 90) (NN %)) (NN Confidence) (NN Interval))) (-RRB- -RRB-)))))))
(S1 (S (NP (NP (NN Influence)) (PP (IN of) (NP (NN drug1))) (PP (IN On) (NP (NP (NN drug2) (NN Concentration)) (PRN (-LRB- -LRB-) (NP (NP (NN Mean) (NN change)) (, ,) (NP (ADJP (CD 90) (NN %)) (NN Confidence) (NN Interval))) (-RRB- -RRB-)))))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN 400-2000))))
(S1 (S (NP (CD 900))))
(S1 (S (NP (NP (NN nc1)) (PRN (NP (CD 40) (NN %) (NN decrease) (CD -LSB-CI)) (: :) (NP (CD 17) (NN %) (NN decrease)) (, ,) (NP (CD 57) (NN %) (NN decrease)) (-RRB- -RSB-)))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (CD 100-150))))
(S1 (S (NP (NN 600-1800))))
(S1 (S (NP (NP (ADJP (CD 14) (NN %)) (NN increase) (NN -LSB-CI)) (PRN (: :) (NP (ADJP (CD 2) (NN %)) (NN increase)) (, ,) (NP (CD 24) (NN %) (NN increase) (-RRB- -RSB-) (CD 25) (NN %) (NN decrease) (CD -LSB-CI)) (: :) (NP (ADJP (CD 12) (NN %)) (NN decrease)) (, ,) (NP (CD 51) (NN %) (NN decrease)) (-RRB- -RSB-)))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (CD 250-500))))
(S1 (S (NP (NN 600-1800))))
(S1 (S (NP (NP (NN nc1,2)) (PRN (NP (CD 30) (NN %) (NN decrease) (CD -LSB-CI)) (: :) (NP (CD 3) (NN %) (NN decrease)) (, ,) (NP (CD 48) (NN %) (NN decrease)) (-RRB- -RSB-)))))
(S1 (S (PRN (NP (QP (CD 1200-2400) (RP up) (TO to) (CD 40)) (NN %) (NN increase3) (NN -LSB-CI) (: :) (CD 12) (NN %) (NN increase)) (, ,) (NP (ADJP (CD 60) (NN %)) (NN increase)) (-RRB- -RSB-))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN 400-2800))))
(S1 (S (NP (NN 600-1800))))
(S1 (S (NP (NP (NN nc1) (CD 18) (NN %) (NN decrease) (NN -LSB-CI)) (PRN (: :) (NP (CD 13) (NN %) (NN decrease)) (, ,) (NP (ADJP (CD 40) (NN %)) (NN decrease)) (-RRB- -RSB-)))))
(S1 (S (S (NP (CD 1-) (NN nc)) (VP (VBZ denotes) (NP (NP (DT a) (JJ mean) (NN change)) (PP (IN of) (NP (NP (QP (JJR less) (IN than) (CD 10)) (NN %) (CD 2-) (NN Pediatrics) (CD 3-) (NN Mean) (NN increase)) (PP (IN in) (NP (NNS adults))) (PP (IN at) (NP (JJ high) (NN drug1) (NNS doses)))))) (ADVP (FW In) (FW vivo)))) (, ,) (S (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug2)))) (VP (VBD increased) (PP (IN by) (NP (QP (RB up) (TO to) (CD 40)) (NN %))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBD was) (VP (VBN given) (PP (IN at) (NP (NP (NNS doses)) (PP (IN above) (NP (CD 1200) (NN mg/day))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (NP (NNS doses)) (PP (IN of) (NP (NN drug1))) (ADJP (QP (JJR greater) (IN than) (CD 1200)) (NN mg/day))) (PP (IN during) (NP (JJ adjunctive) (NN therapy)))))) (, ,) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug2)))))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN increase)) (PP (IN of) (NP (NN drug1) (NN level)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ is) (ADJP (ADJP (JJ small)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN %)) (-RRB- -RRB-))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Strong) (NNS inducers)) (PP (IN of) (NP (NP (NN cytochrome) (NN P450) (NNS enzymes)) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (-RRB- -RRB-))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 29-40) (NN %)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (NP (DT No) (NN autoinduction)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (JJ Hormonal) (NN drug1) (NN Co-administration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (DT an) (JJ oral) (NN drug3)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB influence) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (DT the) (CD two) (JJ hormonal) (NNS components)) (, ,) (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN EE)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN LNG)) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ mean) (NN AUC) (NNS values)) (PP (IN of) (NP (NN EE)))) (VP (VBD were) (VP (VBN decreased) (PP (IN by) (NP (NP (NP (CD 48) (NN %) (CD -LSB-90) (NN %) (CD CI) (: :) (CD 22-65) (-RRB- -RSB-)) (PP (IN in) (NP (CD one) (NN study)))) (CC and) (NP (NP (CD 52) (NN %) (CD -LSB-90) (NN %) (CD CI) (: :) (CD 38-52) (-RRB- -RSB-)) (PP (IN in) (NP (DT another) (NN study) (NN -LSB-1,2)))) (-RRB- -RSB-)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ mean) (NN AUC) (NNS values)) (PP (IN of) (NP (NN LNG)))) (VP (VBD were) (VP (VBN decreased) (PP (IN by) (NP (NP (NP (CD 32) (NN %) (CD -LSB-90) (NN %) (CD CI) (: :) (CD 20-45) (-RRB- -RSB-)) (PP (IN in) (NP (CD one) (NN study)))) (CC and) (NP (NP (NP (CD 52) (NN %)) (NP (CD -LSB-90) (NN %) (CD CI) (: :) (CD 42-52) (-RRB- -RSB-))) (PP (IN in) (NP (DT another) (NN study))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (MD may) (VP (VB render) (NP (NP (DT these) (NNS drug3)) (ADJP (RBR less) (JJ effective)))))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (PP (IN with) (NP (JJ other) (ADJP (ADJP (JJ oral)) (CC or) (ADJP (JJ implant))) (NNS drug1)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (NP (NP (NN drug1) (NNS s)) (: :) (S (PP (IN After) (NP (NP (JJ repeated) (NN co-administration)) (PP (IN of) (NP (NN drug2))))) (, ,) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug3)))) (VP (VBD was) (VP (VBN lowered) (PP (IN by) (NP (NP (CD 28) (NN %) (CD -LSB-90) (NN %)) (CD CI) (: :) (CD 20-33) (-RRB- -RSB-)))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBD produced) (NP (NP (DT a) (NN decrease)) (PP (IN of) (NP (NP (CD 20) (NN %) (CD -LSB-90) (NN %) (CD CI) (: :) (CD 18-27) (-RRB- -RSB-)) (PP (IN of) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (JJ Other) (NN drug) (NNS interactions) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (NNS Results)) (PP (IN with) (NP (NN drug1)))) (VP (VBP wshow) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN interaction)) (PP (IN with) (NP (NP (ADJP (CC either) (ADJP (JJ single)) (CC or) (ADJP (JJ repeated))) (NNS doses)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (DT THE) (NN POTENTIATING) (NN ACTION)) (PP (IN OF) (NP (NN drug1)))) (VP (MD MUST) (VP (VB BE) (VP (VBN CONSIDERED))) (SBAR (WHADVP (WRB WHEN)) (S (NP (DT THE) (NN DRUG)) (VP (VBZ IS) (VP (VBN USED) (PP (IN IN) (NP (NP (NN CONJUNCTION)) (PP (IN WITH) (NP (NP (NNS drug2)) (PP (JJ SUCH) (IN AS) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC AND) (NP (NN drug5)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))) (NP (PRP$ their) (NN dosage)) (VP (MD should) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (SBAR (IN Since) (S (NP (NN drowsiness)) (VP (MD may) (VP (VB occur) (PP (IN with) (NP (NP (NN use)) (PP (IN of) (NP (DT this) (NN drug))))))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VP (VBN warned) (PP (IN of) (NP (DT this) (NN possibility)))) (CC and) (VP (VBN cautioned) (PP (IN against) (S (S (VP (VBG driving) (NP (DT a) (NN car)))) (CC or) (S (VP (VBG operating) (NP (NN dangerous) (NN machinery)) (PP (IN while) (S (VP (VBG taking) (NP (NN drug1))))))))))))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (VP (MD should) (VP (VB be) (VP (VBN advised) (PP (IN against) (NP (NP (DT the) (JJ simultaneous) (NN use)) (PP (IN of) (NP (JJ other) (NN drug1)))))))) (, ,) (CC and) (VP (VBN cautioned) (SBAR (IN that) (S (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (VP (VBN increased))))))))) (. .)))
(S1 (S (S (NP (JJ Additive) (NN CNS) (NN depression)) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ other) (NNS drug2)) (PP (VBG including) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN advised) (PP (IN against) (NP (NP (DT the) (JJ concurrent) (NN use)) (PP (IN of) (NP (JJ other) (NNS drug2))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBP prolong)) (CC and) (VP (VBP intensify) (NP (NP (DT the) (JJ anticholinergic) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (NP (DT the) (JJ cardiovascular) (NN action)) (PP (IN of) (NP (JJ other) (NN drug1)))) (VP (MD could) (VP (VB be) (VP (VBN enhanced) (PP (IN by) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN Europe))) (, ,) (NP (NN drug1)) (VP (VBD was) (VP (VBN observed) (S (VP (TO to) (ADVP (RB occasionally)) (VP (VB intensify) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NNS drug2)) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN by) (NP (NP (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NN hypertension))))))))))))))) (: ;)))
(S1 (S (S (NP (DT this) (NN phenomenon)) (VP (VBD was) (RB not) (VP (VBN observed) (PP (IN in) (NP (NP (NNP North) (NNP American)) (JJ clinical) (NNS trials)))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN study)) (PP (IN in) (NP (CD eight) (JJ healthy) (NNS volunteers)))) (VP (VBZ has) (VP (VBN shown) (NP (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN increase)) (PP (IN in) (NP (JJ mean) (NN peak) (NN drug1) (NN plasma) (NNS concentrations)))) (CC and) (NP (NP (DT a) (ADJP (CD 90) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NN mean) (NN area)) (PP (IN under) (NP (DT the) (NN curve))))))) (, ,) (PP (IN after) (NP (NP (DT a) (CD one) (NN week) (NN course)) (PP (IN of) (NP (NP (NN drug2)) (PP (IN at) (NP (NP (NP (CD 1,000) (NN mg/day)) (CC and) (NP (NN drug3))) (PP (IN at) (NP (CD 90) (NN mg/day)))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN effect)) (VP (MD may) (VP (VB be) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (JJ known) (NN inhibition)) (PP (IN of) (NP (JJ hepatic) (NN cytochrome) (NN P-) (CD 450))) (PP (IN by) (NP (NP (NN drug1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB decrease) (NP (NP (JJ first) (NN pass) (NN metabolism)) (PP (IN of) (NP (NN drug2)))))))))))))))) (. .)))
(S1 (S (S (VP (VBG Taking) (NP (DT a) (NN drug1) (SBAR (IN while) (S (ADVP (RB you)) (VP (VBP are) (VP (VBG taking) (PP (CC or) (IN within) (NP (NP (CD 2) (NNS weeks)) (PP (IN of) (NP (VBG taking) (NNS drug2)))))))))))) (VP (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ central) (JJ nervous) (NN system)) (NN depression)))))) (CC or) (VP (MD may) (VP (VB cause) (NP (NP (DT a) (JJ severe) (JJ high) (NN blood) (NN pressure)) (NN reaction))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN Study) (CD 1))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ colorectal) (NN cancer)))) (VP (VBD were) (VP (VBN given) (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: /) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN bolus-IFL)) (-RRB- -RRB-)))) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS concentrations)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN bolus-IFL)))))) (UCP (ADVP (RB alone)) (CC and) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (DT the) (JJ active) (NN metabolite)) (PP (IN of) (NP (NN drug2)))) (, ,)))) (VP (VBD were) (PP (IN on) (NP (NN average))) (ADJP (NP (CD 33) (NN %)) (JJR higher) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN bolus-IFL)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug3))))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (NN bolus-IFL)) (ADVP (RB alone))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN Study) (CD 1))) (, ,) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN bolus-IFL)) (CC plus) (NP (NN drug1))))) (VP (VBD had) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (NP (NN Grade) (JJ 3-4) (NN diarrhea)) (CC and) (NP (NN neutropenia))))))) (. .)))
(S1 (S (S (PP (JJ Due) (TO to) (NP (NP (JJ high) (JJ inter-patient) (NN variability)) (CC and) (NP (JJ limited) (NN sampling)))) (, ,) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (NN drug1) (NNS levels)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ concurrent) (NN drug2)) (CC and) (NP (NN drug3))))))))))) (VP (VBZ is) (ADJP (JJ uncertain)))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN number)) (PP (IN of) (NP (NNS substances)))) (VP (VP (VBP affect) (NP (NN glucose) (NN metabolism))) (CC and) (VP (MD may) (VP (VBP require) (NP (NP (NN drug1) (NN dose) (NN adjustment)) (CC and) (ADVP (RB particularly)) (NP (JJ close) (NN monitoring))))))) (. .)))
(S1 (S (S (NP (DT The) (NN following)) (VP (VBP are) (NP (NP (NP (NNS examples)) (PP (IN of) (NP (NP (NNS substances)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB increase) (NP (NP (DT the) (JJ blood-glucose-lowering) (NN effect)) (CC and) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NN hypoglycemia)))))))))))) (: :) (NP (NP (JJ oral) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NP (NN drug9)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug10))) (-RRB- -RRB-))) (, ,) (NP (NN drug11)))))) (. .)))
(S1 (S (S (NP (DT The) (NN following)) (VP (VBP are) (NP (NP (NP (NNS examples)) (PP (IN of) (NP (NP (NNS substances)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB reduce) (NP (DT the) (JJ blood-glucose-lowering) (NN effect))))))))) (: :) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (FW e.g.) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8))) (-RRB- -RRB-))) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (NN drug13)) (, ,) (NP (NN drug14)))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (PP (IN in) (NP (JJ oral) (NN drug15))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3) (NNS salts)) (, ,) (CC and) (NP (NN drug4))) (VP (MD may) (VP (CC either) (VP (VB potentiate)) (CC or) (VP (VB weaken) (NP (NP (DT the) (JJ blood-glucose-lowering) (NN effect)) (PP (IN of) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB cause) (NP (NP (NN hypoglycemia)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (ADVP (RB sometimes)) (VP (VB be) (VP (VBN followed) (PP (IN by) (NP (NN hyperglycemia)))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (PP (IN under) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (JJ sympatholytic) (NN medicinal) (NNS products)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))))) (, ,) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (NN hypoglycemia)))) (VP (MD may) (VP (VP (VB be) (VP (VBN reduced))) (CC or) (ADJP (JJ absent)))) (. .)))
(S1 (S (NP (NP (NN Mixing)) (PP (IN of) (NP (NN drug1))))))
(S1 (S (S (NP (NP (DT A) (JJ clinical) (NN study)) (PP (IN in) (NP (NP (JJ healthy) (JJ male) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NN n=24)) (-RRB- -RRB-))))) (VP (VBD demonstrated) (SBAR (SBAR (IN that) (S (NP (NP (JJ mixing) (NN drug1)) (PP (IN with) (NP (NP (NN drug2)) (PP (ADVP (RB immediately)) (IN before) (NP (NN injection)))))) (VP (VBD produced) (NP (NP (DT some) (NN attenuation)) (PP (IN in) (NP (NP (DT the) (JJ peak) (NN concentration)) (PP (IN of) (NP (NN drug3))))))))) (, ,) (CC but) (SBAR (IN that) (S (NP (NP (NP (DT the) (NN time)) (PP (TO to) (NP (NN peak)))) (CC and) (NP (NP (DT the) (JJ total) (NN bioavailability)) (PP (IN of) (NP (NN drug4))))) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN affected)))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN mixed) (PP (IN with) (NP (NN drug2))))))) (, ,) (NP (NN drug3)) (VP (MD should) (VP (VB be) (VP (VBN drawn) (PP (IN into) (NP (DT the) (NN syringe) (JJ first))))))) (. .)))
(S1 (S (S (NP (DT The) (NN injection)) (VP (MD should) (VP (VB be) (VP (VBN made) (PP (ADVP (RB immediately)) (IN after) (NP (NN mixing))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (NNS data)) (PP (IN on) (NP (NP (DT the) (NN compatibility)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN crystalline) (NN drug2))) (NNS preparations))))))))) (, ,) (NP (NN drug3)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN mixed) (PP (IN with) (NP (DT these) (NNS preparations))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN mixing) (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (PP (IN of) (NP (NP (NN animal) (NN source) (CC or) (NN drug3) (NNS preparations)) (VP (VBN produced) (PP (IN by) (NP (JJ other) (NNS manufacturers))))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NN Mixtures)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB intravenously)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN used) (PP (IN in) (NP (NP (JJ external) (JJ subcutaneous) (NN infusion) (VBZ pumps)) (PP (IN for) (NP (NN drug1)))))))) (, ,) (NP (NN drug2)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN mixed) (PP (IN with) (NP (DT any) (JJ other) (NP (NN drug3)) (CC or) (NP (NN diluent)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB diminish) (NP (NP (JJ adrenal) (NN suppression)) (PP (IN by) (NP (NN drug3))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1) (NN injection)) (CC and) (NP (JJ potassium-depleting) (NNS agents))) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NNS drug2)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ potassium-depleting) (NNS agents))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug3))) (, ,) (NP (NNS drug4)) (-RRB- -RRB-)))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NN development)) (PP (IN of) (NP (NN hypokalemia))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS cases)) (VP (VBN reported)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD was) (VP (VBN followed) (PP (IN by) (NP (NP (JJ cardiac) (NN enlargement)) (CC and) (NP (JJ congestive) (NN heart) (NN failure)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NN drug3) (NN clearance))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB produce) (NP (NP (JJ severe) (NN weakness)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ myasthenia) (NNS gravis))))))))) (. .))))
(S1 (S (S (SBAR (IN If) (FRAG (JJ possible))) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN withdrawn) (PP (IN at) (NP (QP (JJS least) (CD 24)) (NNS hours))) (PP (IN before) (S (VP (VBG initiating) (NP (NN drug2) (NN therapy))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (JJ oral)) (: :) (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))) (ADVP (RB usually)) (VP (VBZ results) (PP (IN in) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN response)) (PP (TO to) (NP (NN drug4))))))) (, ,) (SBAR (IN although) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (DT some) (VBG conflicting) (NNS reports)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN coagulation) (NNS indices)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB frequently)) (S (VP (TO to) (VP (VB maintain) (NP (DT the) (JJ desired) (JJ anticoagulant) (NN effect))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN Because) (S (NP (NN drug2)) (VP (MD may) (VP (VB increase) (NP (NN blood) (NN glucose) (NNS concentrations)))))) (, ,) (NP (NP (NN dosage) (NNS adjustments)) (PP (IN of) (NP (NN drug3)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .))))
(S1 (S (NP (NP (JJ Antitubercular) (NNS drugs)) (: :) (S (NP (NP (NN Serum) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN decreased))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (VBN Increased) (NN activity)) (PP (IN of) (NP (CC both) (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (CD two)) (VP (VBP are) (VP (VBN used) (ADVP (RB concurrently))))))))) (. .))))
(S1 (S (S (NP (NNS Convulsions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (DT this) (JJ concurrent) (NN use))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN Dexamethasone) (NN suppression) (NN test)) (PRN (-LRB- -LRB-) (NP (NN DST)) (-RRB- -RRB-))) (: :) (JJ False-negative) (NNS results)) (PP (IN in) (NP (NP (NP (DT the) (NN dexamethasone) (NN suppression) (NN test)) (PRN (-LRB- -LRB-) (NP (NN DST)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN drug1)))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (NNS results)) (PP (IN of) (NP (DT the) (NN DST)))) (VP (MD should) (VP (VB be) (VP (VBN interpreted) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (DT these) (NNS patients))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (PP (IN at) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NN arrhythmias))) (PP (IN due) (TO to) (NP (NN hypokalemia)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ metabolic) (NN clearance)) (PP (IN of) (NP (NN drug3)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (VBN decreased) (NN blood) (NNS levels)) (CC and) (NP (JJ lessened) (JJ physiologic) (NN activity)))))) (, ,) (S (ADVP (RB thus)) (VP (VBG requiring) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ drug4) (NN dosage))))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN drug1)) (, ,) (PP (VBG including) (NP (JJ oral) (NN drug2)))) (: :) (NP (NN drug3))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (JJ hepatic) (NN metabolism)) (PP (IN of) (NP (JJ certain) (NNS drug4)))) (, ,) (S (ADVP (RB thereby)) (VP (VBG increasing) (NP (PRP$ their) (NN effect))))))) (. .)))
(S1 (S (NP (NP (NP (JJ Hepatic) (NN Enzyme) (NNS Inducers)) (, ,) (NP (NNS Inhibitors)) (CC and) (NP (NNS Substrates))) (: :) (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP induce) (NP (NP (NP (NP (NN cytochrome) (NN P450) (NN 3A4)) (PRN (-LRB- -LRB-) (NP (CD CYP) (NN 3A4)) (-RRB- -RRB-))) (NN enzyme) (NN activity)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))))))) (VP (MD may) (VP (VP (VB enhance) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug5))))) (CC and) (VP (VB require) (SBAR (IN that) (S (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (DT the) (NN drug6)))) (VP (VB be) (VP (VBN increased))))))))) (. .))))
(S1 (S (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP inhibit) (NP (NN CYP) (NN 3A4)))))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (, ,) (NP (NP (NNS drug2)) (PP (JJ such) (IN as) (NP (NN drug3)))) (-RRB- -RRB-))) (VP (VBP have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ moderate) (NN inducer)) (PP (IN of) (NP (NN CYP) (NN 3A4)))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN CYP) (NN 3A4)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (, ,) (NP (NNS drug2)) (-RRB- -RRB-))))))))))) (VP (MD may) (VP (VB increase) (NP (PRP$ their) (NN clearance)) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (VBN decreased) (NN plasma) (NN concentration)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (JJ certain) (NNS drug3))) (PP (IN by) (NP (QP (RB up) (TO to) (CD 60)) (NN %))))))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (JJ drug4) (JJ side) (NNS effects))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN drug1)) (ADVP (RB alone))) (VP (VP (MD can) (VP (VB inhibit) (NP (JJ adrenal) (NN drug2) (NN synthesis)))) (CC and) (VP (MD may) (VP (VBP cause) (NP (JJ adrenal) (NN insufficiency)) (PP (IN during) (NP (NN corticosteroid) (NN withdrawal))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (S (NP (NP (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug3)))) (PRN (-LRB- -LRB-) (CC or) (NP (JJ other) (NN drug4)) (-RRB- -RRB-))) (CC and) (NP (NN drug5))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ gastrointestinal) (JJ side) (NNS effects)))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NN hypoprothrombinemia))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN increased) (PP (IN with) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (JJ post-marketing) (VBP experience))) (, ,) (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (CC both) (NP (NNS increases)) (CC and) (NP (NNS decreases))) (PP (IN in) (NP (NP (NN drug2) (NNS levels)) (PP (IN with) (NP (NN drug3) (NN co-administration))))))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (NNS alterations)) (PP (IN in) (NP (NN seizure) (NN control))))))))) (. .))))
(S1 (S (NP (NP (NN Skin) (NNS tests)) (: :) (S (NP (NN drug1)) (VP (MD may) (VP (VB suppress) (NP (NP (NNS reactions)) (PP (TO to) (NP (NN skin) (NNS tests))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Co-administration)) (PP (IN with) (NP (NN drug2)))) (VP (MD should) (VP (VB be) (VP (VBN employed) (ADVP (RB cautiously)) (, ,) (PP (IN as) (NP (JJ toxic) (JJ epidermal) (NNS necrolysis)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (JJ concomitant) (NN use))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug2) (NN therapy)))) (VP (MD may) (VP (VBP exhibit) (NP (NP (DT a) (VBN diminished) (NN response)) (PP (TO to) (NP (NP (NN toxoids)) (CC and) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))))) (PP (IN due) (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN antibody) (NN response)))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB also)) (VP (VB potentiate) (NP (NP (DT the) (NN replication)) (PP (IN of) (NP (NP (DT some) (NNS organisms)) (VP (VBN contained) (PP (IN in) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Routine) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN toxoids))))) (VP (MD should) (VP (VB be) (VP (VBN deferred) (SBAR (IN until) (S (NP (NN drug2) (NN therapy)) (VP (VBZ is) (VP (VBN discontinued) (SBAR (IN if) (FRAG (JJ possible))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (DT a) (NN P-glycoprotein) (NN substrate)) (, ,))) (PP (IN with) (NP (JJ oral) (NN drug3)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN clearance)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN drug4) (NN Cmax) (CC and) (NN AUC) (NNS values)))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NN drug2))))))) (, ,) (NP (DT the) (NN clinician)) (VP (MD should) (VP (VB be) (ADJP (JJ alert) (PP (TO to) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (NNS increases)) (PP (IN in) (NP (NN drug3) (NNS levels))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NNS Inhibitors)) (NN Felodipine)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (JJ CYP3A4) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN grapefruit) (NN juice)) (, ,) (NP (NN drug4))) (-RRB- -RRB-)))) (PP (IN with) (NP (NN drug5)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (JJ several-) (NN fold) (NNS increases))) (PP (IN in) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug6))))) (, ,) (ADJP (CC either) (ADJP (JJ due) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN bioavailability)))))) (CC or) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN metabolism)))))))))) (. .)))
(S1 (S (S (NP (NP (DT These) (NNS increases)) (PP (IN in) (NP (NN concentration)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (VBN increased) (NNS effects)) (PRN (, ,) (-LRB- -LRB-) (NP (NP (JJR lower) (NN blood) (NN pressure)) (CC and) (NP (VBN increased) (NN heart) (NN rate))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (DT a) (JJ potent) (NN drug2) (NN inhibitor)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1) (NNS inhibitors)) (VP (VBP are) (VP (VBN co-administered) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ conservative) (NN approach)) (PP (TO to) (NP (NN dosing) (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN taken))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (JJ specific) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (: :) (S (NP (NP (NN Itraconazole) (NN Co-administration)) (PP (IN of) (NP (NP (DT another) (VBN extended) (NN release) (NN formulation)) (PP (IN of) (NP (NN drug1))))) (PP (IN with) (NP (NN drug2)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (ADJP (RB approximately) (JJ 8-fold)) (NN increase)) (PP (IN in) (NP (DT the) (NN AUC)))) (, ,) (NP (NP (ADJP (QP (JJR more) (IN than) (CD 6-)) (JJ fold)) (NN increase)) (PP (IN in) (NP (DT the) (NN Cmax)))) (, ,) (CC and) (NP (NP (JJ 2-fold) (NN prolongation)) (PP (IN in) (NP (NP (DT the) (JJ half-) (NN life)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (NP (NP (NN Erythromycin) (NN Co-administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))) (PP (IN with) (NP (NN drug3)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (ADJP (QP (RB approximately) (CD 2.5-)) (JJ fold)) (NN increase)) (PP (IN in) (NP (DT the) (NP (NP (NN AUC)) (CC and) (NP (NN Cmax)))))) (, ,) (CC and) (NP (NP (ADJP (QP (RB about) (CD 2-)) (NN fold)) (NN prolongation)) (PP (IN in) (NP (NP (DT the) (JJ half-) (NN life)) (PP (IN of) (NP (NN drug4))))))))) (. .)))
(S1 (S (NP (NP (NN Grapefruit) (NN juice) (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN grapefruit) (NN juice)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (ADJP (JJR more) (IN than) (JJ 2-fold)) (NN increase)) (PP (IN in) (NP (DT the) (NP (NN AUC)) (CC and) (NP (NN Cmax))))) (, ,) (CC but) (NP (NP (DT no) (NN prolongation)) (PP (IN in) (NP (NP (DT the) (JJ half-) (NN life)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NN Cimetidine) (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (DT a) (JJ non-specific) (NN CYP-450) (NN inhibitor)) (-RRB- -RRB-))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (QP (RB approximately) (CD 50)) (NN %))) (PP (IN in) (NP (DT the) (NP (NN AUC)) (CC and) (NP (NP (DT the) (NN Cmax)) (, ,) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Beta-Blocking) (NNS Agents)) (NP (NP (DT A) (JJ pharmacokinetic) (NN study)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NN drug2))))))) (VP (VBD demonstrated) (NP (NP (DT no) (JJ significant) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (NN AUC)) (CC and) (NP (NN Cmax))) (PP (IN of) (NP (NN drug1)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBD were) (VP (VBN increased) (NP (QP (RB approximately) (CD 31) (CC and) (CD 38)) (NN %)) (, ,) (ADVP (RB respectively))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ controlled) (JJ clinical) (NNS trials))) (, ,) (ADVP (RB however)) (, ,) (NP (NP (NN drug1)) (PP (VBG including) (NP (NN drug2)))) (VP (VP (VBD were) (ADVP (RB concurrently)) (VP (VBN administered) (PP (IN with) (NP (NN drug3))))) (CC and) (VP (VBD were) (VP (ADVP (RB well)) (VBN tolerated))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN Digoxin)) (SBAR (WHADVP (WRB When)) (S (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug1))))))) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN heart) (NN failure)))))) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN altered)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (DT a) (JJ pharmacokinetic) (NN study))) (, ,) (NP (NP (JJ maximum) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))) (VP (VBD were) (ADJP (ADJP (RB considerably) (JJR lower)) (PP (IN in) (NP (NP (JJ epileptic) (NNS patients)) (PP (IN on) (NP (NP (JJ long-term) (NN drug3) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (NN drug6))) (-RRB- -RRB-)))))) (PP (IN than) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ such) (NNS patients))) (, ,) (NP (NP (DT the) (JJ mean) (NN area)) (PP (IN under) (NP (DT the) (NN drug1) (NN plasma) (NN concentration-time) (NN curve)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN reduced) (PP (TO to) (NP (NP (QP (RB approximately) (CD 6)) (NN %)) (PP (IN of) (NP (NP (DT that)) (VP (VBN observed) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (DT a) (ADJP (RB clinically) (JJ significant)) (NN interaction)) (VP (MD may) (VP (VB be) (VP (VBN anticipated)))))) (, ,) (NP (JJ alternative) (NN drug1) (NN therapy)) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (DT these) (NNS patients))))))) (. .)))
(S1 (S (S (NP (NN Tacrolimus) (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN blood) (NN concentration)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug1)))))) (, ,) (S (S (NP (DT the) (NN drug2) (NN blood) (NN concentration)) (VP (MD should) (VP (VB be) (VP (VBN followed))))) (CC and) (S (NP (DT the) (NN tacrolimus) (NN dose)) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN adjusted)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (JJ Concomitant) (NN Therapy)) (PP (IN In) (NP (JJ healthy) (NNS subjects)))) (VP (ADVP (RB there)) (VBD were) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NNS interactions)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Interaction)) (PP (IN with) (NP (NN Food)))) (VP (VB See) (NP (NP (JJ CLINICAL) (NN PHARMACOLOGY)) (, ,) (NP (NNS Pharmacokinetics)) (CC and) (NP (NN Metabolism))))) (. .)))
(S1 (S (S (NP (NN DRUG/LABORATORY)) (VP (VB TEST) (NP (NNS INTERACTIONS) (CD 1)))) (. .)))
(S1 (S (NP (NP (VBN Accelerated) (NN prothrombin) (NN time)) (, ,) (NP (JJ partial) (NN thromboplastin) (NN time)) (, ,) (CC and) (NP (NP (NN platelet) (NN aggregation) (NN time)) (: ;)))))
(S1 (S (NP (NP (VBN increased) (NN platelet) (NN count)) (: ;))))
(S1 (S (NP (NP (VBN increased) (NNS factors) (NP (CD II))) (, ,) (NP (NP (NN VII) (NN antigen)) (, ,) (NP (NN VIII) (NN antigen)) (, ,) (NP (NN VIII) (NN coagulant) (NN activity)) (, ,) (NP (NN IX)) (, ,) (NP (NN X)) (, ,) (NP (NN XII)) (, ,) (NP (NN VII-X) (NN complex)) (, ,) (NP (NN II-VII-X) (NN complex)) (, ,) (CC and) (NP (NN beta-thromboglobulin))) (: ;))))
(S1 (S (S (NP (NP (VBN decreased) (NNS levels)) (PP (IN of) (NP (NP (NN anti-factor) (NN Xa)) (CC and) (NP (NN drug1)))) (, ,)) (VP (VBD decreased) (NP (NN drug2) (NN activity)))) (: ;)))
(S1 (S (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (NN activity)))) (: ;))))
(S1 (S (S (NP (NP (VBN increased) (NN plasminogen) (NN antigen)) (CC and) (NP (NN activity)))) (. .)))
(S1 (S (NP (NP (CD 2)) (. .))))
(S1 (S (S (VP (VBN Increased) (NP (NP (NP (NP (JJ thyroid-binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN TBG)) (-RRB- -RRB-))) (NNS levels)) (VP (VBG leading) (PP (TO to) (NP (VBN increased) (JJ circulating) (JJ total) (NN thyroid) (NN hormone) (NNS levels))))) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (NP (JJ protein-bound) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN PBI)) (-RRB- -RRB-))) (, ,) (NP (NP (NN T4) (NNS levels)) (PRN (-LRB- -LRB-) (PP (PP (IN by) (NP (NN column))) (CC or) (PP (IN by) (NP (NN radioimmunoassay)))) (-RRB- -RRB-))) (CC or) (NP (NN T3) (NNS levels)))) (PP (IN by) (NP (NN radioimmunoassay)))))))) (. .)))
(S1 (S (S (NP (NN T3) (NN resin) (NN uptake)) (VP (VBZ is) (VP (VBN decreased) (, ,) (S (VP (VBG reflecting) (NP (DT the) (JJ elevated) (NN TBG))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Free) (NN T4)) (CC and) (NP (JJ free) (NN T3))) (NNS concentrations)) (VP (VBP are) (ADJP (JJ unaltered)))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN thyroid) (NN replacement) (NN therapy)))) (VP (MD may) (VP (VBP require) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (NP (NP (CD 3)) (. .))))
(S1 (S (S (NP (JJ Other) (NN binding) (NNS proteins)) (VP (MD may) (VP (VB be) (VP (VBN elevated) (PP (IN in) (NP (NN serum))))) (, ,) (S (PRN (-LRB- -LRB-) (PP (FW i.e.)) (, ,) (NP (NP (NP (NN corticosteroid) (NN binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN CBG)) (-RRB- -RRB-))) (, ,) (NP (NP (NN sex) (NN hormone) (NN binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN SHBG)) (-RRB- -RRB-)))) (-RRB- -RRB-)) (VP (VBG leading) (PP (TO to) (NP (NP (VBN increased) (JJ total) (JJ circulating) (NN drug1)) (CC and) (NP (NN drug2)))) (, ,) (ADVP (RB respectively)))))) (. .)))
(S1 (S (S (NP (JJ Free) (NN hormone) (NNS concentrations)) (VP (MD may) (VP (VB be) (VP (VBN decreased))))) (. .)))
(S1 (S (S (NP (JJ Other) (NN plasma) (NNS proteins)) (VP (MD may) (VP (VB be) (VP (VBN increased) (PRN (-LRB- -LRB-) (NP (NP (NN angiotensinogen/renin) (NN substrate)) (, ,) (NP (ADJP (JJ alpha-1-antitrypsin))) (, ,) (NP (NN ceruloplasmin))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (CD 4))) (. .)))
(S1 (S (S (NP (VBN Increased) (NN plasma) (NN HDL) (CC and) (NN HDL2) (NN cholesterol) (NN subfraction) (NNS concentrations)) (, ,) (VP (VP (VBD reduced) (NP (NN LDL) (NN cholesterol) (NN concentration))) (, ,) (VP (VBD increased) (NP (NN triglyceride) (NNS levels))))) (. .)))
(S1 (S (NP (NP (CD 5)) (. .))))
(S1 (S (NP (NP (JJ Impaired) (NN glucose) (NN tolerance)) (. .))))
(S1 (S (NP (NP (CD 6)) (. .))))
(S1 (S (S (VP (VBN Reduced) (NP (NP (NN response)) (PP (TO to) (NP (NN metyrapone) (NN test)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN administered) (ADVP (RB concurrently))))) (, ,) (NP (DT the) (JJ following) (NNS drugs)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN drug1)))))) (: :) (S (NP (NN drug2) (: :)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (JJ renal) (NN toxicity)) (, ,) (NP (NN bronchospasm)) (CC and) (NP (NN hypotension)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (FW e.) (FW g.) (, ,) (NP (NN drug2)) (, ,) (NP (NN etc.))) (-RRB- -RRB-))) (VP (MD should) (VP (VB be) (VP (VBN given) (ADVP (RB concomitantly)) (PP (ADVP (RB only)) (IN with) (NP (JJ great) (NN caution))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (: :) (S (VP (MD may) (VP (VB potentiate) (NP (NP (NP (NN drug4)) (CC -) (NP (VBN induced) (NN hypokalemia))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB predispose) (NP (DT the) (NN patient)) (PP (TO to) (NP (JJ cardiac) (NN dysfunction))))))))))) (. .))))
(S1 (S (S (VP (VB Avoid) (NP (NP (JJ concomitant) (NN use)) (PP (IN unless) (NP (JJ necessary))) (S (VP (TO to) (VP (VB control) (NP (NP (JJ side) (NNS effects)) (PP (IN of) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (VP (VBN used) (ADVP (RB concomitantly))))) (, ,) (ADVP (RB closely)) (VP (VB monitor) (NP (NP (NN serum) (NNS electrolytes)) (CC and) (NP (JJ cardiac) (NN function))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2) (JJ -induced) (NN hypokalemia))) (VP (MD may) (VP (VB potentiate) (NP (NN drug3) (NN toxicity))))) (. .)))
(S1 (S (S (S (NP (NP (NN Serum) (NN potassium) (NNS levels)) (CC and) (NP (JJ cardiac) (NN function))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (CC and) (S (NP (DT any) (NN deficit)) (VP (ADVP (RB promptly)) (VBN corrected)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN while) (S (NP (NP (DT a) (JJ synergistic) (NN relationship)) (PP (IN with) (NP (NN drug2)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported)))))) (, ,) (NP (JJ concomitant) (NN use)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN drug3)))) (PP (IN by) (S (ADVP (RB possibly)) (VP (VP (VBG increasing) (NP (PRP$ its) (JJ cellular) (NN uptake))) (CC and/or) (VP (VBG impairing) (NP (PRP$ its) (JJ renal) (NN excretion))))))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NNP e.) (NNP g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN etc.))) (-RRB- -RRB-))) (: :) (S (NP (NP (ADJP (ADJP (FW in) (FW vitro)) (CC and) (ADJP (JJ animal))) (NNS studies)) (PP (IN with) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN drug6)) (CC and) (NP (NN drug7))))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug8)) (VP (MD may) (VP (VB induce) (NP (NP (JJ fungal) (NN resistance)) (PP (TO to) (NP (NN drug9)))))))))) (. .))))
(S1 (S (S (NP (NN Combination) (NN therapy)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (JJ immunocompromised) (NNS patients))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (JJ nephrotoxic) (NNS medications)) (: :) (S (NP (NP (NNS agents)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))) (VP (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (JJ drug-induced) (JJ renal) (NN toxicity)))))) (, ,) (CC and) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)) (PP (ADVP (RB only)) (IN with) (NP (JJ great) (NN caution)))))))) (. .))))
(S1 (S (S (NP (NP (JJ Intensive) (NN monitoring)) (PP (IN of) (NP (JJ renal) (NN function)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG requiring) (NP (NP (DT any) (NN combination)) (PP (IN of) (NP (JJ nephrotoxic) (NNS medications)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2) (JJ -induced) (NN hypokalemia)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ curariform) (NN effect)) (PP (IN of) (NP (NN drug3)))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug4)) (-RRB- -RRB-))))) (. .))))
(S1 (S (S (S (NP (NN Serum) (NN potassium) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored))))) (CC and) (S (NP (NNS deficiencies)) (VP (VBN corrected)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (JJ acute) (JJ pulmonary) (NN toxicity))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ intravenous) (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP inhibit)) (CC or) (VP (VBP Induce) (NP (NP (NN CYP) (NN 2D6)) (CC and) (NP (NN CYP) (NN 3A4)))))))) (VP (MD may) (VP (VB affect) (NP (NP (DT the) (NN concentration)) (PP (IN on) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (JJ other) (JJ local) (NNS drug2)) (CC or) (NP (NNS agents))) (ADJP (RB structurally) (JJ related) (PP (TO to) (NP (JJ amide-type) (JJ local) (NNS anesthetics)))))))) (SBAR (IN since) (S (NP (NP (DT the) (JJ toxic) (NNS effects)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD could) (VP (VB be) (ADJP (JJ additive)))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP indicate) (S (NP (NP (NN CYP3A4) (NN isoform)) (CC and) (NP (NN CYP1A2) (NN isoform))) (VP (VBP mediate) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (, ,) (ADVP (RB respectively)))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (NP (NP (NNS agents)) (VP (ADVP (RB likely)) (TO to) (VP (VB be) (ADVP (RB concomitantly)) (VP (VBN administered) (PP (IN with) (NP (NP (NN drug1)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT this) (NN isoenzyme) (NN family))))))))))))) (VP (MD may) (ADVP (RB potentially)) (VP (VB interact) (PP (IN with) (NP (NN drug2)))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (DT no) (JJ clinical) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ likely) (SBAR (IN that) (S (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NP (NP (DT the) (JJ known) (NN CYP3A4) (NNS inducers)) (PRN (-LRB- -LRB-) (CONJP (JJ such) (IN as)) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ CYP3A4) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (JJ azole) (NNS antimycotics)) (PP (FW e.g.)))) (, ,) (NP (NN drug5))))))))))) (: ;)))
(S1 (S (NP (NP (JJ certain) (NNS drug1)) (PP (FW e.g.) (, ,) (NP (NN ritanovir))) (: ;))))
(S1 (S (NP (NNP drug1) (FW e.g.) (, ,) (NP (NN drug2) (: ;)))))
(S1 (S (CC and) (NP (NP (NP (NN drug1)) (PRN (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-))) (, ,) (NP (NP (NN CYP1A2) (NNS inducers)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (CC and) (NP (NP (NN CYP1A2) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NP (NN drug4)) (CC and) (NP (NN drug5))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NN Dosage) (NN adjustment)) (VP (MD may) (VP (VB be) (VP (VBN warranted) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB concurrently)) (VP (VBN administered) (PP (IN with) (NP (NP (JJ CYP3A4) (NNS inhibitors)) (CC and) (NP (NN CYP1A2) (NNS inhibitors)))) (SBAR (IN as) (S (NP (JJ systemic) (NN drug2) (NNS levels)) (VP (MD may) (VP (VB rise) (S (VP (VBG resulting) (PP (IN in) (NP (NN toxicity))))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Steady-state) (NN trough) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))) (VP (VBD were) (ADJP (NP (QP (RB about) (CD 56)) (NN %)) (JJR higher)) (SBAR (WHADVP (WRB when)) (S (NP (ADJP (CD 8) (NN mg)) (NN drug3)) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (NP (DT each) (NN dose)) (PP (IN of) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg/kg/day)) (-RRB- -RRB-)))) (PP (IN in) (NP (CD eight) (NN neurocysticercosis) (NNS patients))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (DT the) (JJ fed) (NN state))) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBD increased) (NP (NP (NN mean) (NN maximum) (NN plasma) (NN concentration)) (CC and) (NP (NP (NN area)) (PP (IN under) (NP (NP (DT the) (NN curve)) (PP (IN of) (NP (NN drug3))))))) (PP (IN by) (NP (NP (QP (RB about) (CD 50)) (NN %)) (PP (IN in) (NP (NP (JJ healthy) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NN n=10)) (-RRB- -RRB-)))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT a) (JJ separate) (NN group)) (PP (IN of) (NP (NP (NP (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NN n=6)) (-RRB- -RRB-))) (PP (IN given) (NP (NP (NN drug4)) (ADVP (RB alone))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Mean) (NN T) (NN max) (CC and) (NN mean) (NN plasma) (NN elimination) (NN half-life)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (ADJP (JJ unchanged)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (ADJP (JJ unchanged)) (PP (VBG following) (NP (NP (NN coadministration)) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 400) (NN mg)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2) (NNS concentrations)) (PP (IN in) (NP (NP (NN bile)) (CC and) (NP (JJ cystic) (NN fluid))))) (VP (VBD were) (VP (VBN increased) (PRN (-LRB- -LRB-) (ADVP (RB about) (RB 2-fold)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (JJ hydatid) (NN cyst) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg/day)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN n=7)) (-RRB- -RRB-)))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg/kg/day)) (-RRB- -RRB-))) (ADVP (RB alone))) (PRN (-LRB- -LRB-) (NP (NN n=12)) (-RRB- -RRB-))))))))))) (. .))))
(S1 (S (S (NP (NN drug1) (NN plasma) (NNS concentrations)) (VP (VBD were) (ADJP (JJ unchanged)) (PP (NP (CD 4) (NNS hours)) (IN after) (NP (NN dosing))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3) (CD 5.8) (NN mg/kg)) (VP (VBN infused) (PP (IN over) (NP (CD 20) (NNS minutes))))) (-RRB- -RRB-))))) (VP (VBD were) (ADJP (JJ unchanged)) (PP (VBG following) (NP (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (NN drug4)))) (PRN (-LRB- -LRB-) (NP (CD 400) (NN mg)) (-RRB- -RRB-)))) (PP (IN in) (NP (CD 6) (JJ healthy) (NNS subjects))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (VP (MD may) (VP (VB increase) (NP (NP (JJ anticholinergic) (NN effect)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))))) (. .)))
(S1 (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (CC or) (NP (NP (NP (JJ other) (NNS agents)) (VP (VBG interfering) (PP (IN with) (NP (JJ neuromuscular) (NN transmission))))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug3)) (-RRB- -RRB-)))))) (VP (MD should) (ADVP (RB only)) (VP (VB be) (VP (VBN performed) (PP (IN with) (NP (NN caution))) (SBAR (IN as) (S (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT the) (NNS drug4)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (S (VP (VBG administering) (NP (JJ different) (NN drug1) (NNS serotypes)) (PP (PP (IN at) (NP (DT the) (JJ same) (NN time))) (CC or) (PP (IN within) (NP (NP (QP (JJR less) (IN than) (CD 4)) (NNS months)) (PP (IN of) (NP (DT each) (JJ other)))))))))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN neuromuscular) (NN paralysis)) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NP (NP (NN co-administration)) (CC or) (NP (JJ overlapping) (NN administration))) (PP (IN of) (NP (JJ different) (NN drug1) (NNS serotypes))))))))) (. .)))
(S1 (S (S (PP (IN As) (PP (IN with) (NP (DT all) (NNS drugs)))) (, ,) (NP (DT the) (NN potential)) (VP (VBZ exists) (PP (IN for) (NP (NP (NN interaction)) (PP (IN with) (NP (JJ other) (NNS drugs))))) (PP (IN by) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS mechanisms))))))) (. .)))
(S1 (S (NP (NP (JJ CNS-Active) (NNS Drugs) (NN drug1)) (: :) (S (NP (NN drug2) (CD 10) (NN mg)) (VP (VBD potentiated) (NP (NP (DT the) (JJ CNS-impairing) (NNS effects)) (PP (IN of) (NP (NN drug3) (CD 0.75) (NNS g/kg))) (PP (PP (IN on) (NP (NP (NP (NN balance) (NN testing)) (CC and) (NP (NN reaction) (NN time))) (PP (IN for) (NP (CD 1) (NN hour))) (PP (IN after) (NP (NN drug4) (NN administration))))) (CC and) (PP (IN on) (NP (NP (NP (DT the) (NN digit) (NN symbol) (NN substitution) (NN test)) (PRN (-LRB- -LRB-) (NP (NN DSST)) (-RRB- -RRB-))) (, ,) (NP (NN symbol) (NN copying) (NN test)) (, ,) (CC and) (NP (NP (DT the) (NN variability) (NN component)) (PP (IN of) (NP (DT the) (JJ divided) (NN attention) (NN test))) (PP (IN for) (NP (NP (CD 2.5) (NNS hours)) (PP (IN after) (NP (NN drug5) (NN administration)))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NN potentiation)) (VP (VBD resulted) (PP (IN from) (NP (DT a) (NN CNS) (JJ pharmacodynamic) (NN interaction))))) (: ;)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (JJ single) (NNS doses)) (PP (IN of) (NP (NP (NN drug2) (CD 20) (NN mg)) (CC and) (NP (NN drug3) (CD 75) (NN mg))))))) (VP (VBD produced) (NP (NP (JJ additive) (NNS effects)) (PP (IN on) (NP (NP (VBN decreased) (NN alertness)) (CC and) (NP (JJ impaired) (NN psychomotor) (NN performance)))) (PP (IN for) (NP (QP (CD 2) (TO to) (CD 4)) (NNS hours)))) (PP (IN after) (NP (NN administration))))) (. .))))
(S1 (S (S (NP (DT The) (NN interaction)) (VP (VBD was) (ADJP (JJ pharmacodynamic) (PP (IN with) (NP (NP (DT no) (NN alteration)) (PP (IN of) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN drug)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NN drug2) (CD 20) (NN mg)) (CC and) (NP (NP (NN drug3) (CD 20) (NN mg)) (ADVP (RB daily)) (PP (IN for) (NP (CD 7) (NNS days))))))))) (VP (VBD did) (RB not) (VP (VB produce) (NP (NP (DT any) (NN interaction)) (PP (IN on) (NP (NN psychomotor) (NN performance))))))) (. .))))
(S1 (S (S (ADVP (RB Additionally)) (, ,) (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2)))) (, ,) (S (VP (VBG reflecting) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (DT a) (NN role)) (PP (IN of) (NP (NN CYP2D6))) (PP (IN in) (NP (NN drug3) (NN s) (NN metabolism))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (JJ single) (NNS doses)) (PP (IN of) (NP (NP (NN drug2) (CD 20) (NN mg)) (CC and) (NP (NN drug3) (CD 50) (NN mg))))))) (VP (VBD produced) (NP (NP (JJ additive) (NNS effects)) (PP (IN on) (NP (NP (VBN decreased) (NN alertness)) (CC and) (NP (JJ impaired) (NN psychomotor) (NN performance)))) (PP (IN for) (NP (QP (CD 2) (TO to) (CD 4)) (NNS hours)))) (PP (IN after) (NP (NN administration))))) (. .))))
(S1 (S (S (NP (DT The) (NN interaction)) (VP (VBD was) (ADJP (JJ pharmacodynamic) (PP (IN with) (NP (NP (DT no) (NN alteration)) (PP (IN of) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN drug)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug2) (CD 10) (NN mg)))) (CC and) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NN drug3) (NN ER) (-LRB- -LRB-) (JJ extended) (NN release) (-RRB- -RRB-) (CD 150) (NN mg))))))) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (DT any) (JJ significant) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (CC either) (NP (NN drug4)) (CC or) (NP (NN drug5))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (EX there)) (VP (VBD was) (NP (DT no) (JJ pharmacodynamic) (NN interaction)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (NN ER)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 10) (CC and) (CD 25)) (NN mg)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (ADJP (CD 15) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (JJ maximal) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug4)))))) (, ,) (CC but) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (DT the) (NN area)) (PP (IN under) (NP (DT the) (NN plasma) (NN concentration-time) (NN curve)))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NNS pharmacodynamics)) (PP (IN of) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (CD 2) (NNS agents)) (VP (VBP are) (VP (VBN coadministered))))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (VBP Induce) (NP (NN CYP3A4) (NN drug1)))))) (: :) (S (NP (NN CYP3A4)) (VP (VBZ is) (ADVP (RB ordinarily)) (NP (NP (DT a) (JJ minor) (NN metabolizing) (NN enzyme)) (PP (IN of) (NP (NN drug2)))))) (. .))))
(S1 (S (S (NP (NP (JJ Multiple-dose) (NN administration)) (PP (IN of) (NP (NP (DT the) (JJ potent) (NN CYP3A4) (NN inducer) (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 600) (NN mg) (NP (NP (DT every) (CD 24) (NNS hours)) (, ,) (NP (NN q24h)) (, ,))) (PP (IN for) (NP (CD 14) (NNS days))) (-RRB- -RRB-))))) (, ,) (ADVP (RB however)) (, ,) (VP (VBD reduced) (NP (NP (NN drug2) (NN Cmax)) (CC and) (NP (NN AUC))) (PP (IN by) (NP (QP (RB approximately) (CD 80)) (NN %))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (DT a) (JJ potent) (NN CYP3A4) (NN enzyme) (NN inducer)))) (, ,) (SBAR (IN although) (S (VP (RB not) (VBG posing) (NP (DT a) (NN safety) (NN concern))))) (, ,) (ADVP (RB thus)) (VP (MD could) (VP (VB lead) (PP (TO to) (NP (NP (NN ineffectiveness)) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (NP (DT An) (JJ alternative) (NN non-CYP3A4) (NN substrate) (NN drug1)) (VP (MD may) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (JJ CYP3A4) (NNS inducers)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (VBP Inhibit) (NP (NP (NP (NN CYP3A4) (NN CYP3A4)) (VP (VBZ is) (NP (NP (DT a) (JJ minor) (JJ metabolic) (NN pathway)) (PP (IN for) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NN drug1)))))) (PP (IN because) (NP (NP (DT the) (NN sum)) (PP (IN of) (NP (NN desethylzaleplon))) (-LRB- -LRB-) (VP (VBN formed) (PP (IN via) (NP (NN CYP3A4))) (ADVP (FW in) (FW vitro))) (-RRB- -RRB-))))) (CC and) (NP (PRP$ its) (NNS metabolites))))))) (, ,) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (, ,)) (VP (VBP account) (PP (IN for) (NP (NP (QP (RB only) (CD 9)) (NN %)) (PP (IN of) (NP (NP (DT the) (JJ urinary) (NN recovery)) (PP (IN of) (NP (DT a) (NN drug4) (NN dose))))))))) (. .)))
(S1 (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ single)) (, ,) (ADJP (JJ oral))) (NNS doses)) (PP (IN of) (NP (NN drug1))))) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 10) (NN mg)) (CC and) (NP (CD 800) (NN mg))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (, ,) (NP (DT a) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ selective))) (NN CYP3A4) (NN inhibitor))))) (VP (VBD produced) (NP (NP (NP (DT a) (ADJP (CD 34) (NN %)) (NN increase)) (PP (IN in) (NP (NN drug3) (NN s) (JJ maximal) (NN plasma) (NNS concentrations)))) (CC and) (NP (NP (DT a) (ADJP (CD 20) (NN %)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN area)) (PP (IN under) (NP (DT the) (NN plasma) (NN concentration-time) (NN curve)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN magnitude)) (PP (IN of) (NP (NP (NN interaction)) (PP (IN with) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (JJ strong) (JJ selective) (JJ CYP3A4) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NN drug1)))) (VP (MD can) (ADVP (RB also)) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN exposure)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ routine) (NN dosage) (NN adjustment)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (RB not) (VP (VBN considered) (ADJP (JJ necessary))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (VBP Inhibit) (NP (NN Aldehyde) (NN Oxidase)))))) (NP (DT The) (NN aldehyde) (NN oxidase) (NN enzyme)) (NN system)) (VP (VBZ is) (ADVP (RBR less) (RB well)) (VP (VBN studied) (PP (IN than) (NP (DT the) (NN cytochrome) (NN P450) (NN enzyme) (NN system)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (NP (NP (DT a) (JJ weak) (NN inhibitor)) (PP (IN of) (NP (NN aldehyde) (NN oxidase))) (PP (IN in) (NP (NN rat) (NN liver)))))))))) (, ,) (CC but) (S (NP (NP (PRP$ its) (JJ inhibitory) (NNS effects)) (PP (IN in) (NP (JJ human) (NN liver)))) (VP (VBP are) (RB not) (VP (VBN known))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN mg) (CC and) (NP (CD 50) (NN mg))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN of) (NP (DT each) (NN drug)))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (SBAR (IN because) (S (NP (NP (DT both)) (PP (IN of) (NP (DT these) (NNS compounds)))) (VP (VBP have) (NP (NN CNS) (NNS effects))))) (, ,) (NP (DT an) (JJ additive) (JJ pharmacodynamic) (NN effect)) (VP (VBZ is) (ADJP (JJ possible)))) (. .)))
(S1 (S (NP (NP (NP (NP (NNS Drugs)) (SBAR (IN That) (S (VP (VBP Inhibit) (NP (DT Both) (NN Aldehyde) (NN Oxidase)))))) (CC and) (NP (NN CYP3A4) (NN drug1))) (: :) (S (NP (NN drug2)) (VP (VBZ inhibits) (NP (CC both) (NP (NP (NN aldehyde) (NN oxidase)) (PRN (-LRB- -LRB-) (NP (FW in) (FW vitro)) (-RRB- -RRB-))) (CC and) (NP (NN CYP3A4))) (PRN (-LRB- -LRB-) (NP (NP (FW in) (FW vitro)) (CC and) (NP (FW in) (FW vivo))) (-RRB- -RRB-)) (, ,) (NP (NP (DT the) (ADJP (ADJP (JJ primary)) (CC and) (ADJP (JJ secondary))) (NNS enzymes)) (, ,) (ADVP (RB respectively)) (, ,) (ADJP (JJ responsible) (PP (IN for) (NP (NN drug3) (NN metabolism))))))) (. .))))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 800) (NN mg)) (-RRB- -RRB-)))))) (VP (VBD produced) (NP (NP (DT an) (ADJP (CD 85) (NN %)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NP (JJ mean) (NN Cmax)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (JJ initial) (NN dose)) (PP (IN of) (NP (CD 5) (NN mg)))) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB concomitantly)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN drug1)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (VP (ADVP (RB Highly)) (VBN Bound) (PP (TO to) (NP (NN Plasma) (NN Protein) (NN drug1))))) (VP (VBZ is) (RB not) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NP (NN plasma) (NNS proteins)) (PRN (-LRB- -LRB-) (NP (NN fraction) (JJ bound) (CD 60) (NN %) (CD 15) (NN %)) (-RRB- -RRB-))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (DT the) (NN disposition)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB be) (ADJP (JJ sensitive) (PP (TO to) (NP (NP (NNS alterations)) (PP (IN in) (NP (NN protein) (NN binding)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG taking) (NP (NP (DT another) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADVP (RB highly)) (VP (NN protein) (VBN bound)))))))))) (VP (MD should) (RB not) (VP (VB cause) (NP (NP (JJ transient) (NN increase)) (PP (IN in) (NP (NP (JJ free) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ other) (NN drug))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (PP (IN with) (NP (NP (DT a) (JJ Narrow) (JJ Therapeutic) (NN Index) (NN drug1)) (: :) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg)) (-RRB- -RRB-)))))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (ADJP (ADJP (JJ pharmacokinetic)) (CC or) (ADJP (JJ pharmacodynamic))) (NN profile)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 0.375) (NN mg) (NN q24h)) (PP (IN for) (NP (CD 8) (NNS days))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Multiple) (JJ oral) (NNS doses)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 20) (NN mg)) (NN q24h)) (PP (IN for) (NP (CD 13) (NNS days)))) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (JJ R+)) (-RRB- -RRB-)) (: -)) (CC or) (NP (-LRB- -LRB-) (NN S-) (-RRB- -RRB-) (NNS -enantiomers))))) (CC or) (NP (NP (NP (DT the) (NNS pharmacodynamics)) (PRN (-LRB- -LRB-) (NP (NN prothrombin) (NN time)) (-RRB- -RRB-))) (PP (VBG following) (NP (NP (DT a) (JJ single) (JJ 25-mg) (JJ oral) (NN dose)) (PP (IN of) (NP (NN drug4)))))))))) (. .))))
(S1 (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (VBP Alter) (NP (JJ Renal) (NN Excretion) (NN drug1)))))) (: :) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN known) (S (VP (VP (TO to) (VP (VB affect) (NP (JJ renal) (NN function)))) (CC and) (, ,) (ADVP (RB consequently)) (, ,) (VP (VB alter) (NP (NP (DT the) (JJ renal) (NN excretion)) (PP (IN of) (NP (JJ other) (NNS drugs)))))))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (JJ apparent) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (PP (VBG following) (NP (NP (NP (JJ single) (NN dose) (NN administration)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 10) (NN mg)) (CC and) (NP (CD 600) (NN mg))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN of) (NP (DT each) (NN drug))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBD was) (VP (VBN expected) (SBAR (IN because) (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB primarily)) (VP (VBN metabolized)))) (CC and) (S (NP (NP (JJ renal) (NN excretion)) (PP (IN of) (NP (JJ unchanged) (NNS drug2)))) (VP (VBZ accounts) (PP (IN for) (NP (NP (QP (JJR less) (IN than) (CD 1)) (NN %)) (PP (IN of) (NP (DT the) (VBN administered) (NN dose)))))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN monoamine) (NN oxidase)) (PRN (-LRB- -LRB-) (NP (NN MAO)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (NN inhibition)) (PP (IN of) (NP (DT this) (NN enzyme)))) (VP (VP (VBZ prolongs)) (CC and) (VP (VBZ potentiates) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN been) (VP (VBN treated) (PP (IN with) (NP (NN drug1))) (PP (IN within) (NP (NP (QP (CD two) (TO to) (CD three)) (NNS weeks)) (ADJP (JJ prior) (PP (TO to) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug2)))))))))))))) (VP (MD should) (VP (VBP receive) (NP (NP (JJ initial) (NNS doses)) (PP (IN of) (NP (NN drug3))) (ADJP (RB no) (JJR greater) (PP (IN than) (NP (NP (NP (CD one-tenth)) (PRN (-LRB- -LRB-) (NP (CD 1/10)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (JJ usual) (NN dose)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (JJ low-dose) (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB produce) (NP (NP (DT an) (JJ additive) (NN or) (NN potentiating) (NN effect)) (PP (IN on) (NP (NN urine) (NN flow))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ cardiovascular) (NNS effects)) (PP (IN of) (NP (JJ adreneric) (NNS agents))))))) (. .)))
(S1 (S (S (NP (NP (JJ Cardiac) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (VP (VBN antagonized) (PP (IN by) (NP (NN drug2))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ peripheral) (NN vasoconstriction)) (VP (VBN caused) (PP (IN by) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN drug1))))))) (VP (VBZ is) (VP (VBN antagonized) (PP (IN by) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (ADJP (NN drug1) (JJ -induced)) (ADJP (ADJP (JJ renal)) (CC and) (ADJP (JJ mesenteric))) (NN vasodilation)) (VP (VBZ is) (RB not) (VP (VBN antagonized) (PP (IN by) (NP (CC either) (NP (NN drug2)) (CC or) (NP (NN drug3))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug2)))) (-RRB- -RRB-))) (CC and) (NP (NN drug3))) (VP (MD can) (VP (VB suppress) (NP (NP (DT the) (NN drug4) (JJ rgic) (ADJP (ADJP (JJ renal)) (CC and) (ADJP (JJ mesenteric))) (NN vasodilation)) (VP (VBN induced) (PP (IN with) (NP (JJ low) (NN dose) (NN dopamine) (NN infusion))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (VP (VP (VBP increase) (NP (JJ cardiac) (JJ autonomic) (NN irritability))) (CC and) (VP (MD may) (VP (VB sensitize) (NP (DT the) (NN myocardium)) (PP (TO to) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NP (JJ certain) (ADJP (RB intravenously) (VBN administered)) (NNS drug3)) (, ,) (PP (JJ such) (IN as) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN interaction)) (VP (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (ADJP (JJ related) (PP (CC both) (PP (TO to) (NP (NN pressor) (NN activity))) (CC and) (PP (TO to) (NP (NP (JJ beta-adrenergic) (JJ stimulating) (NNS properties)) (PP (IN of) (NP (DT these) (NN drug1))))))))))) (CC and) (VP (MD may) (VP (VB produce) (NP (NP (JJ ventricular) (NNS arrhythmias)) (CC and) (NP (NN hypertension))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (JJ EXTREME) (NN CAUTION)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (NP (NNS results)) (PP (IN of) (NP (NP (NNS studies)) (PP (IN in) (NP (NNS animals)))))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN drug1) (JJ -induced) (JJ ventricular) (NNS arrhythmias)) (PP (IN during) (NP (NN anesthesia)))) (VP (MD can) (VP (VB be) (VP (VBN reversed) (PP (IN by) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1) (NNS s)) (, ,) (NP (NP (VBG vasoconstricting) (NNS agents)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug2)))) (-RRB- -RRB-))) (CC and) (NP (DT some) (NNS drug3))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ severe) (NN hypertension)))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB lead) (PP (TO to) (NP (NP (NN hypotension)) (CC and) (NP (NN bradycardia))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN suggested) (SBAR (IN that) (S (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))) (, ,) (NP (NP (NNS alternatives)) (PP (TO to) (NP (NN drug2)))) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (IN if) (S (NP (NN drug3) (NN therapy)) (VP (VBZ is) (VP (VBN needed))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (: -)) (VP (VBG Taking) (NP (NP (NN drug2)) (CC and) (NP (NP (DT a) (NN drug3)) (ADVP (RB together)))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNS convulsions)) (PRN (-LRB- -LRB-) (NP (NNS seizures)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug2)) (-RRB- -RRB-))) (: -) (S (S (VP (VBG Taking) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (ADVP (RB together)))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug5))))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (VBN isolated) (NNS reports)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG experiencing) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (PRP$ their) (NN prothrombin) (NNS times)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN added) (PP (TO to) (NP (NN drug2) (NN therapy))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (DT these) (NNS reports)))) (VP (VBD concerned) (NP (NP (JJ variable) (NNS elevations)) (PP (IN in) (NP (NP (NN prothrombin) (NNS times)) (PP (IN without) (NP (ADJP (RB clinically) (JJ significant)) (NN sequelae)))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (NP (DT the) (NN relevance)) (PP (IN of) (NP (DT these) (NNS reports)))) (CC and) (NP (NP (DT any) (NN mechanism)) (PP (IN of) (NP (NN coagulation) (NNS alterations))))) (VP (VBZ is) (ADJP (JJ unclear))))) (, ,) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug1)))) (VP (MD should) (VP (VB have) (NP (NP (PRP$ their) (NN prothrombin) (NN time)) (VP (VBN monitored)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN drug1)))) (VP (VBD were) (VP (VBN performed) (PP (CC both) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NP (DT a) (ADJP (RB rapidly) (JJ hydrolyzed)) (JJ intravenous) (NN prodrug)) (NN form)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS results)) (PP (IN from) (NP (NP (NNS trials)) (VP (VBG using) (NP (DT the) (JJ intravenous) (NN prodrug)))))) (VP (VBP are) (VP (VBN reported) (PP (IN in) (NP (DT this) (NN section))) (SBAR (IN as) (S (NP (PRP they)) (VP (VB relate) (PP (TO to) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NN drug) (NNS interactions))))))))))) (. .)))
(S1 (S (S (NP (JJ General)) (: :) (PP (IN In) (NP (NNS humans))) (, ,) (NP (NN drug1) (NN metabolism)) (VP (VBZ is) (ADVP (RB predominantly)) (VP (VBN mediated) (PP (IN via) (S (VP (VBG CYP) (NP (NP (NN 3A4)) (CC and) (NP (NN 2C9))) (PP (IN with) (S (NP (NN glucuronidation)) (VP (VBG being) (NP (NP (DT a) (ADJP (ADJP (JJ further)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-))) (NN route)) (PP (IN of) (NP (NN metabolism))))))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (NP (NP (NP (NP (DT a) (JJ moderate) (NN inhibitor)) (PP (IN of) (NP (NN CYP) (NN 2C19)))) (PRN (-LRB- -LRB-) (NP (NP (NN IC50)) (ADJP (JJ =) (NP (QP (CD 6) (NN g/mL) (CC or) (CD 19)) (NN M)))) (-RRB- -RRB-))) (CC and) (NP (NN 2C9))) (PRN (-LRB- -LRB-) (NP (NP (NN IC50)) (ADJP (JJ =) (NP (QP (CD 13) (NN g/mL) (CC or) (CD 41)) (NN M)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NP (NP (NP (DT a) (JJ weak) (NN inhibitor)) (PP (IN of) (NP (NN CYP) (NN 2D6)))) (PRN (-LRB- -LRB-) (NP (NP (NN IC50)) (ADJP (JJ =) (NP (QP (CD 31) (NN g/mL) (CC or) (CD 100)) (NN M)))) (-RRB- -RRB-))) (CC and) (NP (NN 3A4))) (PRN (-LRB- -LRB-) (NP (NP (NN IC50)) (ADJP (JJ =) (NP (QP (CD 44) (NN g/mL) (CC or) (CD 141)) (NN M)))) (-RRB- -RRB-)))))))) (. .)) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NP (NN GI) (NN ulceration)) (CC and) (NP (NNS complications)))))) (PP (VBN compared) (PP (TO to) (NP (NP (NN drug4)) (ADVP (RB alone)))))))) (. .))))
(S1 (S (S (PP (IN Because) (IN of) (NP (NP (PRP$ its) (NN lack)) (PP (IN of) (NP (JJ anti-platelet) (NN effect) (NN drug1))))) (VP (VBZ is) (RB not) (VP (DT a) (VP (VB substitute) (PP (IN for) (NP (NN drug2))) (PP (IN for) (NP (JJ cardiovascular) (NN prophylaxis))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (JJ parallel) (NN group) (NN drug) (NN interaction) (NN study)) (VP (VBG comparing) (NP (NP (DT the) (JJ intravenous) (NN prodrug) (NN form)) (PP (IN of) (NP (NN drug1)))) (PP (IN at) (NP (NP (NP (CD 40) (NN mg) (JJ BID)) (PRN (-LRB- -LRB-) (NP (NN n=10)) (-RRB- -RRB-))) (CC vs) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NN n=9)) (-RRB- -RRB-)))))))) (, ,) (NP (NN drug2)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (ADJP (NP (ADJP (FW in) (FW vitro)) (NN drug3)) (JJ -mediated)) (NN inhibition)) (PP (IN of) (NP (NP (NN arachidonate-)) (CC or) (NP (JJ collagen-stimulated) (NN platelet) (NN aggregation))))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (NN drug2) (NN BID)) (VP (VBD did) (RB not) (VP (VB show) (NP (NP (DT a) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN plasma) (NN exposure)) (CC or) (NP (NP (JJ renal) (NN clearance)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NNS Reports)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug3)))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN interaction)) (VP (MD should) (VP (VB be) (VP (VBN given) (NP (NP (NN consideration)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)))))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Clinical) (NNS studies)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ post-marketing) (NNS observations)) (, ,)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (JJ natriuretic) (NN effect)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))) (PP (IN in) (NP (DT some) (NNS patients))))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN response)) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ renal) (NN prostaglandin) (NN synthesis))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (S (NP (NP (NP (JJ Steady) (NN state) (NN plasma) (NN exposure)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 40) (NN mg)) (NN BID)) (PP (IN for) (NP (CD 12) (NNS days)))) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN decreased) (PP (IN by) (NP (CD 27) (NN %))) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NP (NP (JJ multiple) (NNS doses)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 300) (NN mg)) (NN QD)) (PP (IN for) (NP (CD 12) (NNS days)))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (DT a) (NN CYP) (NN 3A4) (NN inducer)) (-RRB- -RRB-)))))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (VP (ADVP (RB already)) (VBN stabilized) (PP (IN on) (NP (NN drug1))))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (NP (JJ symptom) (NN control)) (PP (IN with) (NP (NN drug2) (NN coadministration))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB have) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (DT a) (NN CYP) (NN 2C9) (CC and) (NN CYP) (NN 2C19) (NN substrate)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (JJ other) (NN drug1)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (JJ Routine) (NN monitoring)) (VP (MD should) (VP (VB be) (VP (VBN performed))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug1)))) (VP (VBZ is) (VP (CC either) (VP (VBN initiated)) (CC or) (VP (VBN discontinued) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ anticonvulsant) (NN therapy)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ is) (VP (VP (ADVP (RB primarily)) (VBN metabolized) (PP (IN by) (NP (NN CYP) (NN 2D6)))) (CC and) (VP (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (PP (IN by) (NP (NN 3A4))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN with) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 40) (NN mg)) (ADJP (JJ BID) (PP (IN for) (NP (CD 7) (NNS days))))) (-RRB- -RRB-))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NN drug2) (NN plasma) (NNS levels))))) (S (VP (VBG suggesting) (SBAR (IN that) (S (, ,) (PP (IN at) (NP (DT these) (NNS doses))) (, ,) (NP (NN drug3)) (VP (VBZ is) (NP (NP (DT a) (JJ weak) (NN inhibitor)) (PP (IN of) (NP (NN 2D6))))))))))) (. .)))
(S1 (S (S (ADVP (RB Even) (RB so)) (NP (NP (NN drug1) (NN plasma) (NNS concentrations)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN drug2)))))))) (VP (VBD were) (ADJP (ADJP (ADVP (RB almost) (RB 5-fold)) (JJR lower)) (PP (IN than) (NP (NP (DT those)) (VP (VBN seen) (PP (IN in) (NP (NP (NP (NN CYP) (NN 2D6)) (JJ poor) (NNS metabolizers)) (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN dose) (NN adjustment)) (VP (VBZ is) (RB not) (ADJP (JJ necessary)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2) (ADJP (CD 40) (NN mg)) (NN BID)) (PP (IN for) (NP (CD 7) (NNS days))))) (VP (VBD produced) (NP (NP (JJ significant) (NNS decreases)) (PP (IN in) (NP (NP (NP (NN drug3) (NN serum) (NN clearance)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ renal) (NN clearance)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN %)) (-RRB- -RRB-)))))) (PP (IN with) (NP (NP (DT a) (ADJP (NP (CD 34) (NN %)) (JJR higher)) (NN serum) (NN exposure)) (PP (VBN compared) (PP (TO to) (NP (NP (NN drug4)) (ADVP (RB alone))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN serum) (NNS concentrations)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG initiating)) (CC or) (VP (VBG changing) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug2))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 450) (NN mg)) (ADJP (JJ BID) (PP (IN for) (NP (CD 7) (NNS days))))) (-RRB- -RRB-))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug2) (NNS pharmacokinetics))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NP (DT the) (JJ anticoagulant) (NN effect)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (: -) (CD 8)) (NN mg/day)) (-RRB- -RRB-))))))) (VP (VBD was) (VP (VBN studied) (PP (IN in) (NP (JJ healthy) (NNS subjects))) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug4) (CD 40) (NN mg) (NN BID))))) (PP (IN for) (NP (CD 7) (NNS days)))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBD caused) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN increase)) (PP (PP (IN in) (NP (NP (NN plasma) (NNS exposures)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 12) (NN %)) (CC and) (NP (CD 15) (NN %))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))))))) (, ,) (CC and) (PP (IN in) (NP (NP (NP (DT the) (JJ pharmacodynamic) (NNS effects)) (PRN (-LRB- -LRB-) (NP (NP (NN prothrombin) (NN time)) (, ,) (VP (VBN measured) (PP (IN as) (NP (NN INR))))) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (NP (NN mean) (NN INR) (NNS values)) (VP (VBD were) (ADVP (RB only) (RB slightly)) (VP (VBN increased) (PP (IN with) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1))))))))) (, ,) (NP (NP (DT the) (JJ day-to-day) (NN variability)) (PP (IN in) (NP (JJ individual) (NN INR) (NNS values)))) (VP (VBD was) (VP (VBN increased)))) (. .)))
(S1 (S (NP (NN drug1) (NN therapy)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (, ,) (PP (ADVP (RB particularly)) (IN during) (NP (DT the) (JJ first) (JJ few) (NNS weeks))) (, ,) (PP (IN after) (S (VP (VBG initiating) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug2))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (ADJP (ADJP (JJ drug3)) (CC or) (ADJP (JJ similar))) (NNS agents)))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (: :) (S (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBP are) (NP (ADJP (RB predominantly) (JJ CYP)) (NP (NP (NN 3A4)) (CC and) (NP (NN 2C9))) (NNS inhibitors)) (, ,) (ADVP (RB respectively)))) (. .))))
(S1 (S (S (NP (NP (JJ Concomitant) (JJ single) (NN dose) (NN administration)) (PP (IN of) (NP (NN drug1) (CD 20) (NN mg))) (PP (IN with) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (VP (VBD produced) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NN exposure)) (PP (IN of) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Plasma) (NN exposure)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (TO to) (NP (NN drug1)))) (VP (VBD was) (VP (VBN increased) (NP (NP (NP (CD 62) (NN %)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug2))))))) (CC and) (NP (NP (CD 38) (NN %)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ is) (NP (DT a) (NN CYP) (NN 2C9) (NN substrate)))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 10) (NN mg)) (NN BID)) (PP (IN for) (NP (CD 7) (NNS days)))) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 5) (NN mg)) (NN QD)) (CC or) (NP (ADJP (CD 10) (NN mg)) (NN BID))) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (NP (DT the) (NNS pharmacokinetics)) (PRN (-LRB- -LRB-) (NP (NN exposure)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 40) (NN mg) (JJ BID)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 1)) (-RRB- -RRB-))) (CC and) (NP (NP (ADJP (CD 40) (NN mg)) (NN QD)) (PRN (-LRB- -LRB-) (NP (NNS days) (NP (CD 2-7))) (-RRB- -RRB-)))) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 5) (NN mg)) (NN QD)) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB affect) (NP (CC either) (NP (NP (DT the) (NNS pharmacokinetics)) (PRN (-LRB- -LRB-) (NP (NN exposure)) (-RRB- -RRB-))) (CC or) (NP (NP (NP (DT the) (NNS pharmacodynamics)) (PRN (-LRB- -LRB-) (NP (NP (NN blood) (NN glucose)) (CC and) (NP (NN insulin) (NNS levels))) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 40) (NN mg) (JJ BID)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 1)) (-RRB- -RRB-))) (CC and) (NP (NP (ADJP (CD 40) (NN mg)) (NN QD)) (PRN (-LRB- -LRB-) (NP (NNS days) (NP (CD 2-7))) (-RRB- -RRB-)))) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 10) (NN mg)) (NN drug3) (NN BID)) (-RRB- -RRB-))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (ADJP (CD 21) (NN %)) (NN increase)) (PP (IN in) (NP (NN drug4) (CD AUC0-12)))) (CC and) (NP (NP (DT a) (CD 16) (NN %) (NN increase)) (PP (IN in) (NP (NP (NN drug5) (NN Cmax)) (VP (VBG leading) (PP (TO to) (NP (NP (DT a) (ADJP (CD 16) (NN %)) (NN decrease)) (PP (IN in) (NP (NN glucose) (CD AUC0-24)))))))))))) (. .)))
(S1 (S (S (NP (NN Insulin) (NNS parameters)) (VP (VBD were) (RB not) (VP (VBN affected)))) (. .)))
(S1 (S (SBAR (IN Because) (S (S (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN glucose) (NNS concentrations)) (PP (IN with) (NP (NN drug1) (NN coadministration)))))) (VP (VBD were) (PP (IN within) (NP (DT the) (JJ normal) (NN variability))))) (CC and) (S (NP (JJ individual) (NN glucose) (NNS concentrations)) (VP (VBD were) (UCP (ADVP (RB above)) (CC or) (PP (IN near) (NP (CD 70) (NN mg/dL)))))))) (, ,) (NP (NP (NN dose) (NN adjustment)) (PP (IN for) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 5) (NN mg)) (NN QD)) (CC and) (NP (ADJP (CD 10) (NN mg)) (NN BID))) (-RRB- -RRB-))) (PP (IN with) (NP (NP (NN drug3) (NN coadministration)) (PRN (-LRB- -LRB-) (NP (QP (RB up) (TO to) (CD 40)) (NN mg) (NN QD)) (-RRB- -RRB-))))))) (VP (VBZ is) (RB not) (VP (VBN indicated))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS doses)) (ADJP (JJR higher) (PP (IN than) (NP (NP (ADJP (CD 40) (NN mg)) (NN drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (ADJP (CD 40) (NN mg)) (NN BID))) (-RRB- -RRB-)))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ is) (NP (NP (DT a) (JJ CYP) (NN 3A4) (NN substrate)) (CC and) (NP (NP (NN CYP) (NN 2C19) (NN substrate)) (CC and) (NP (NN inhibitor)))))) (. .))))
(S1 (S (S (NP (NP (JJ drug1) (JJ steady) (NN state) (NN plasma) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN mg) (JJ BID)) (-RRB- -RRB-))) (VP (VBD were) (RB not) (VP (VBN affected) (ADVP (RB significantly)) (PP (IN with) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 40) (NN mg)) (NN QD)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN with) (NP (NN drug1)))) (VP (VBD increased) (NP (NP (NN exposure)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))))) (PP (IN by) (NP (CD 46) (NN %))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WP$ whose) (NN absorption)) (S (VP (VBZ is) (ADJP (JJ sensitive) (PP (TO to) (NP (NN pH)))))))) (VP (MD may) (VP (VB be) (ADVP (RB negatively)) (VP (VBN impacted) (PP (IN by) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (SBAR (IN because) (S (NP (NP (NP (JJR higher) (NNS doses)) (PRN (-LRB- -LRB-) (NP (QP (RB up) (TO to) (CD 360)) (NN mg) (NN QD)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (VP (VBN tolerated) (PP (IN in) (NP (NP (NP (NN Zollinger-Ellison)) (PRN (-LRB- -LRB-) (NP (NN ZE)) (-RRB- -RRB-))) (NNS patients))))))) (, ,) (NP (NP (DT no) (NN dose) (NN adjustment)) (PP (IN for) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN at) (NP (JJ current) (NNS doses))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS doses)) (ADJP (JJR higher) (PP (IN than) (NP (ADJP (CD 40) (NN mg)) (NN QD) (NN drug2))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 40) (NN mg)) (NN BID)) (-RRB- -RRB-))) (VP (VBD did) (RB not) (VP (VB induce) (NP (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (DT the) (NN combination) (JJ oral) (NN drug3) (NN drug4)))) (: /) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 1) (NN mg)) (NP (CD /35) (NN mcg) (NN combination))) (, ,) (NP (NN drug6) (NN 1/35))) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (ADVP (RB 1/35)) (VP (VBD increased) (NP (NP (DT the) (NN exposure)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))) (PP (IN by) (NP (NP (CD 20) (NN %)) (CC and) (NP (CD 34) (NN %)) (, ,) (ADVP (RB respectively)))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBZ is) (NP (NP (JJ little) (NN risk)) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (JJ contraceptive) (NN efficacy))))))))) (, ,) (NP (NP (DT the) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT these) (VBN increased) (NNS exposures))) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NN safety)))))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NP (DT These) (VBN increased) (NNS exposures)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN into) (NP (NN consideration))) (SBAR (WHADVP (WRB when)) (S (VP (VBG selecting) (NP (NP (DT an) (JJ oral) (NN drug3)) (PP (IN for) (NP (NP (NNS women)) (VP (VBG taking) (NP (NN drug4))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (VP (VBZ is) (NP (DT a) (NN CYP) (NN 3A4) (CC and) (NN CYP) (NN 2C19) (NN substrate)))) (. .))))
(S1 (S (S (NP (NP (NN Plasma) (NN exposure)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 10) (NN mg)) (NN BID)) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN increased) (PP (IN by) (NP (CD 28) (NN %))) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 40) (NN mg)) (NN BID)) (-RRB- -RRB-))) (PP (IN for) (NP (CD 12) (NNS days)))))))) (, ,) (SBAR (IN while) (S (NP (NP (NN plasma) (NN exposure)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 40) (NN mg)) (NN BID)) (-RRB- -RRB-))))) (VP (VBD was) (RB not) (ADVP (RB substantially)) (VP (VBN increased) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 10) (NN mg)) (NN BID)) (-RRB- -RRB-))) (PP (IN for) (NP (CD 12) (NNS days))))))))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ drug1) (NN plasma) (NN exposure))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug2))))))))) (VP (VBD were) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VBP warrant) (NP (NN dosage) (NNS adjustments))))))))) (, ,) (NP (NNS patients)) (VP (MD may) (VP (VBP experience) (NP (NP (VBN enhanced) (JJ sedative) (JJ side) (NNS effects)) (VP (VBN caused) (PP (IN by) (NP (NP (VBN increased) (NN exposure)) (PP (IN of) (NP (NN drug3))) (PP (IN under) (NP (DT this) (NN circumstance))))))))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (MD should) (VP (VB be) (VP (VBN cautioned) (PP (IN against) (NP (NP (NN engaging)) (PP (IN in) (NP (NP (JJ hazardous) (NNS activities)) (VP (VP (VBG requiring) (NP (NP (JJ complete) (JJ mental) (NN alertness)) (PP (JJ such) (IN as) (NP (VBG operating) (NN machinery))))) (CC or) (VP (VBG driving) (NP (DT a) (NN motor) (NN vehicle)))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 500) (NN mg)) (NN p.o.)) (NP (DT every) (CD 6) (NNS hours))) (-RRB- -RRB-)))))))) (, ,) (NP (NN drug3)) (VP (VP (VBZ competes) (PP (IN for) (NP (JJ active) (JJ tubular) (NN secretion)))) (CC and) (VP (VBZ reduces) (NP (NP (DT the) (JJ renal) (NN clearance)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (JJ total) (NN drug1) (NNS concentrations)))) (, ,) (NP (NN drug2)) (VP (VP (VBD increased) (NP (DT the) (NN AUC)) (PP (IN by) (NP (CD 25) (NN %)))) (CC and) (VP (VBD reduced) (NP (DT the) (NN plasma) (CC and) (JJ renal) (NNS clearances)) (PP (IN by) (NP (NP (CD 20) (NN %)) (CC and) (NP (CD 35) (NN %)) (, ,) (ADVP (RB respectively))))))) (. .)))
(S1 (S (S (NP (DT The) (NN half-life)) (VP (VBD increased) (PP (IN from) (NP (QP (CD 4.0) (TO to) (CD 4.8)) (NNS hours))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (JJ small) (NN effect)) (PP (IN on) (NP (NN half-life)))))) (, ,) (NP (NP (DT the) (NN coadministration)) (PP (IN with) (NP (NN drug1))) (S (VP (TO to) (VP (VB extend) (NP (NP (DT the) (NN half-life)) (PP (IN of) (NP (NN drug2)))))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB inhibit) (NP (NP (JJ P-glycoprotein-mediated) (NN transport)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))) (CC and) (SBAR (IN that) (S (NP (NN drug4)) (VP (VBZ is) (RB not) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (JJ P-glycoprotein-mediated) (NN transport)))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB inhibit) (NP (NP (NN metabolism)) (VP (VBN mediated) (PP (IN by) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (JJ following) (NP (NP (CD six) (NN cytochrome) (NN p450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NNS isoforms)) (: :) (NP (NP (NN 1A2)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (NP (NN 2D6)) (, ,) (NP (NN 2E1)) (CC and) (NP (NN 3A4))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NNS interactions)) (VP (VBN caused) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (JJ P-glycoprotein-mediated) (NN drug) (NN clearance)) (CC or) (NP (JJ CYP-mediated) (NN drug) (NN clearance)))) (PP (IN with) (NP (DT the) (JJ listed) (NNS isoforms))))))) (VP (VBP are) (ADJP (JJ unlikely)))) (. .)))
(S1 (S (ADVP (JJ Other) (PP (IN than) (PP (IN with) (NP (NN drug1))))) (, ,) (NP (DT no) (JJ specific) (JJ clinical) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN in) (NP (NP (ADJP (ADJP (JJ concurrent)) (CC or) (ADJP (JJ serial))) (NN use)) (PP (IN of) (NP (NP (JJ other) (JJ neurotoxic) (NN and/) (CC or) (JJ nephrotoxic) (NNS drugs)) (PP (IN because) (PP (IN of) (NP (NP (JJ possible) (NN enhancement)) (PP (IN of) (NP (NP (DT the) (NP (NN nephrotoxicity)) (CC and/or) (NP (NN ototoxicity))) (PP (IN of) (NP (NN drug1)))))))))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (ADVP (RB also)) (VP (VB be) (VP (VBN taken) (PP (IN in) (NP (NP (NP (ADJP (ADJP (JJ concurrent)) (CC or) (ADJP (JJ serial))) (NN use)) (PP (IN of) (NP (JJ other) (NN drug1)))) (CC and) (NP (NN drug2)))) (SBAR (IN because) (S (NP (PRP they)) (VP (MD may) (VP (VP (VB enhance) (NP (NP (NN neomycin) (NN s) (NN nephrotoxicity)) (CC and/or) (NP (NN ototoxicity)))) (CC and) (VP (VB potentiate) (NP (NN drug3) (NN neuromuscular) (NN blocking) (NNS effects))))))))))) (. .)))
(S1 (S (S (NP (JJ Oral) (NN drug1)) (VP (VBZ inhibits) (NP (NP (DT the) (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (JJ oral) (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN drug5))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (NN drug1)))) (ADVP (RB also)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (VP (VBN inhibited))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1) (NN serum) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored))))) (. .)))
(S1 (S (S (NP (JJ Oral) (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (NN drug3)))) (PP (IN by) (S (VP (VBG decreasing) (NP (NN vitamin) (NN K) (NN availability)))))))) (. .)))
(S1 (S (NP (NP (CC -) (NP (NNS Drugs)) (PP (IN with) (NP (JJ ototoxic) (NN potential)))) (: :) (S (PP (ADVP (RB Especially)) (IN in) (DT the) (NN presence) (IN of) (NP (JJ impaired) (JJ renal) (NN function))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (ADJP (RB parenterally) (VBN administered)) (NN drug1))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHPP (TO to) (WHNP (WP whom) (NN drug2))) (S (VP (VBP are) (ADVP (RB also)) (VP (VBG being) (VP (VBN given))))))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (, ,) (PP (IN except) (PP (IN in) (NP (JJ life-threatening) (NNS conditions)))))))) (. .))))
(S1 (S (NP (NP (CC -) (NP (NNS Drugs)) (PP (IN with) (NP (JJ nephrotoxic) (NN potential)))) (: :) (S (NP (EX There)) (VP (VBZ has) (VP (VBN been) (NP (NP (DT no)) (PP (VBP experience) (PP (IN on) (NP (NP (DT the) (JJ concurrent) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB have) (NP (DT a) (JJ nephrotoxic) (NN potential))))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (JJ simultaneous) (NN administration)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (NP (NP (CC -) (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD should) (ADVP (RB generally)) (RB not) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug4)))) (-RRB- -RRB-)))) (SBAR (IN because) (S (NP (PRP they)) (VP (VP (VBP reduce) (NP (PRP$ its) (JJ renal) (NN clearance))) (CC and) (VP (VBP add) (NP (NP (DT a) (JJ high) (NN risk)) (PP (IN of) (NP (NN drug5) (NN toxicity)))))))))))) (. .))))
(S1 (S (NP (NP (CC -) (NN drug1)) (: :) (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NN drug2)))) (VP (VBZ reduces) (NP (NP (CC both) (DT the) (NP (NN natriuresis)) (CC and) (NP (NN hyperreninemia))) (VP (VBN produced) (PP (IN by) (NP (NN drug3))))))) (. .))))
(S1 (S (S (NP (NP (DT This) (JJ antagonistic) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN drug2) (NN natriuresis)))) (VP (VP (VBZ is) (RB not) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (JJ direct) (NN action)) (PP (IN on) (NP (NN sodium) (NN excretion))))))) (CC but) (VP (VBZ is) (ADVP (RB probably)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (PRP$ its) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NP (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (CC -) (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VP (VBZ blunts) (NP (NP (DT the) (NNS increases)) (PP (IN in) (NP (NP (NP (NN urine) (NN volume)) (CC and) (NP (NN sodium) (NN excretion))) (VP (VBN seen) (PP (IN during) (NP (NN drug3) (NN treatment)))))))) (CC and) (VP (VBZ inhibits) (NP (NP (DT the) (ADJP (NN drug4) (JJ -induced)) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NN renin)) (NN activity))))))) (. .))))
(S1 (S (S (NP (NP (JJ Concurrent) (NN therapy)) (PP (IN with) (NP (NN drug1)))) (VP (VBZ is) (ADVP (RB thus)) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (CC -) (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ various) (NNS drug3)))) (, ,) (S (VP (VBG necessitating) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (DT these) (NNS drugs))))))))))) (. .))))
(S1 (S (NP (NP (CC -) (NN drug1)) (: :) (S (NP (NP (NN Interaction) (NNS studies)) (PP (IN in) (NP (NNS humans)))) (VP (VBP have) (VP (VBN shown) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug2) (NN blood) (NNS levels))))))) (. .))))
(S1 (S (NP (NP (CC -) (NN drug1)) (: :) (S (NP (NP (NN Interaction) (NNS studies)) (PP (IN in) (NP (NNS humans)))) (VP (VBP have) (VP (VBN shown) (NP (NN drug2)) (S (VP (TO to) (VP (VB have) (NP (DT no) (NN effect)) (PP (PP (IN on) (NP (NN drug3) (NN metabolism))) (CC or) (PP (IN on) (NP (NN plasma) (NN prothrombin) (NN activity)))))))))) (. .))))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG receiving) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (DT an) (JJ additive) (JJ pressor) (NN effect)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN received) (NP (NN drug1)))))))) (, ,) (NP (NN drug2)) (VP (MD may) (ADVP (RB temporarily)) (VP (VB mask) (NP (NP (DT the) (JJ residual) (NNS effects)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN received) (NP (NP (JJ general) (NN anesthesia)) (VP (VBG utilizing) (NP (NP (DT a) (JJ volatile) (NN agent)) (VP (VBN known) (S (VP (TO to) (VP (VB sensitize) (NP (NP (DT the) (NN myocardium)) (PP (TO to) (NP (NNS catecholamines))))))))))))))))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN delayed) (SBAR (IN until) (S (NP (DT the) (JJ volatile) (NN agent)) (VP (VBZ has) (VP (VBN been) (VP (VBN excreted) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB lessen) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (NNS arrhythmias)) (, ,) (PP (VBG including) (NP (NP (JJ ventricular) (NN tachycardia)) (CC and) (NP (JJ ventricular) (NN fibrillation)))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NNS Pharmacokinetics)) (PP (IN of) (NP (JJ Other) (NNS Drugs)))))) (: :) (NP (NN drug2)) (VP (VBZ does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (JJ other) (NNS drugs)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN investigated))))) (. .)))
(S1 (S (S (NP (NP (NN Effect)) (PP (IN of) (NP (JJ Other) (NNS Drugs))) (PP (IN on) (NP (NP (DT the) (NNS Pharmacokinetics)) (PP (IN of) (NP (NN drug1) (: :) (NN Literature) (NNS reports)))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN drug2)) (, ,) (NP (NP (DT an) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VBZ decreases) (NP (NN stomach) (NN acidity)))))) (, ,)) (VP (VBZ does) (RB not) (ADVP (RB greatly)) (VP (VB alter) (NP (NN drug3) (NNS pharmacokinetics)))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT the) (ADJP (CD 2) (NN mg)) (NN drug1)) (VP (ADVP (RB orally)) (VBG disintegrating) (NP (NN tablet)))) (VP (VBD was) (VP (VBN administered) (PP (IN with) (CC and) (PP (IN without) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN drug3)) (PP (IN with) (NP (NP (JJ multiple) (NNS effects)) (PP (IN on) (NP (DT the) (JJ GI) (NN tract)))))) (-RRB- -RRB-))))) (PP (TO to) (NP (JJ healthy) (NNS volunteers))))))))) (, ,) (NP (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NP (NNS drug4)) (VP (VBD was) (ADJP (NP (CD 10) (NN %)) (JJR lower)))))) (CC and) (NP (NP (DT the) (NN Cmax)) (PP (IN of) (NP (NN drug5))))) (VP (VBD was) (ADJP (NP (CD 20) (NN %)) (JJR lower)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (ADJP (RB orally) (JJ disintegrating)) (NN tablet)) (VP (VBD was) (VP (VBN given) (PP (IN with) (NP (NN drug6))) (PP (VBN compared) (PP (TO to) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBD was) (VP (VBN given) (ADVP (RB alone))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Cytochrome) (NN P-450)) (NNS inducers)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3)))) (, ,)) (VP (VBP induce) (NP (NN drug4) (NN metabolism)) (, ,) (S (VP (VBG causing) (NP (NP (DT an) (ADJP (QP (RB approximately) (CD 30)) (NN %)) (NN decrease)) (PP (IN in) (NP (NN plasma) (NN drug5) (NNS levels)))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (JJ clinical) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed) (, ,) (PP (VBN based) (PP (IN on) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (DT the) (NP (NN cytochrome) (NN P-450)) (NN 3A) (NN family))) (PP (IN in) (NP (NN drug1) (NN metabolism))))))))))) (, ,) (NP (NP (NP (NNS inhibitors)) (PP (IN of) (NP (DT this) (NN enzyme) (NN system)))) (, ,) (NP (ADVP (RB notably)) (NP (JJ oral) (NN drug2))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug3))))))))) (. .)))
(S1 (S (NP (NP (JJ Pharmacodynamic) (NNS Interactions)) (: :) (S (NP (NP (DT The) (JJ CNS-depressant) (NN action)) (PP (IN of) (NP (NP (DT the) (NN drug1)) (PP (IN of) (NP (NNS drugs)))))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (PP (IN by) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (DT the) (NN drug7)) (, ,) (NP (NN drug8)) (CC and) (NP (NN drug9)) (, ,) (NP (NN drug10)) (CC and) (NP (DT the) (NN drug11)))) (, ,) (CC and) (PP (IN by) (NP (JJ other) (NN drug12)))))))) (. .))))
(S1 (S (NP (NP (NN Hypotension)) (: -) (S (NP (NP (NP (NNS Patients)) (PP (IN on) (NP (JJ Diuretic) (NN Therapy)))) (: :) (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug1)))) (, ,) (CC and) (ADVP (RB especially)) (NP (NP (DT those)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ diuretic) (NN therapy)) (VP (VBD was) (ADVP (RB recently)) (VP (VBN instituted)))))) (, ,)) (VP (MD may) (ADVP (RB occasionally)) (VP (VBP experience) (NP (NP (DT an) (JJ excessive) (NN reduction)) (PP (IN of) (NP (NN blood) (NN pressure))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug2))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (NP (JJ hypotensive) (NNS effects)) (PP (IN with) (NP (NN drug1)))))) (VP (MD can) (VP (VB be) (VP (VBN minimized) (PP (IN by) (S (VP (CC either) (VP (VBG discontinuing) (NP (DT the) (NN drug2))) (CC or) (VP (VBG increasing) (NP (NP (DT the) (NN salt) (NN intake)) (ADJP (JJ prior) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug3))))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ necessary) (S (VP (TO to) (VP (VP (VB continue) (NP (DT the) (NN drug1))) (, ,) (VP (VB initiate) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug2)))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD 5) (NN mg)) (ADVP (RB daily))))))) (, ,) (CC and) (VP (VB provide) (NP (NP (JJ close) (JJ medical) (NN supervision)) (PP (IN after) (NP (DT the) (JJ initial) (NN dose)))) (PP (IN until) (NP (NN blood) (NN pressure))))))))))) (VP (VBZ has) (VP (VBN stabilized)))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT a) (NN drug1)) (VP (VBZ is) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN therapy)) (PP (IN of) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug2))))))))))) (, ,) (NP (DT an) (JJ additional) (JJ antihypertensive) (NN effect)) (VP (VBZ is) (ADVP (RB usually)) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (PP (IN with) (NP (NN drug1))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (MD can) (VP (VB be) (VP (VBN reduced))) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN given) (PP (IN with) (NP (DT a) (NN drug4)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT some) (NNS patients)) (PP (IN with) (NP (VBN compromised) (JJ renal) (NN function))) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN drug2)))))))))) (, ,) (NP (NP (DT the) (NN co-administration)) (PP (IN of) (NP (NN drug3)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ further) (NN deterioration)) (PP (IN of) (NP (JJ renal) (NN function)))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (VBP are) (ADVP (RB usually)) (ADJP (JJ reversible)))) (. .)))
(S1 (S (S (NP (NNS Reports)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug2)))) (, ,) (PP (VBG including) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN interaction)) (VP (MD should) (VP (VB be) (VP (VBN given) (NP (NP (NN consideration)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)))))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (NP (CD 36) (NNS patients)) (PP (IN with) (NP (NP (ADJP (JJ mild) (TO to) (JJ moderate)) (NN hypertension)) (SBAR (WHADVP (WRB where)) (S (NP (NP (DT the) (JJ antihypertensive) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (ADVP (RB alone))))) (VP (VBD were) (VP (VBN compared) (PP (TO to) (NP (NP (NNS drug2)) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3)))))))))))))))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug4)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (DT a) (VBN reduced) (JJ antihypertensive) (NN effect)))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (NN difference)) (PP (IN between) (NP (DT the) (CD two) (NNS regimens)))) (VP (VBD was) (RB not) (ADJP (JJ significant)))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NNS Agents)) (: :) (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (CC and/or) (NP (NN drug3)))) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (ADJP (RB clinically) (JJ significant)) (JJ adverse) (NNS interactions))))))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (VBD included) (NP (NP (JJ post) (JJ myocardial) (NN infarction) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBG receiving) (NP (ADJP (ADJP (JJ intravenous)) (CC or) (ADJP (JJ transdermal))) (NN drug1))))))))) (. .)))
(S1 (S (S (NP (DT No) (ADJP (RB clinically) (JJ important)) (JJ pharmacokinetic) (NNS interactions)) (VP (VBD occurred) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (NN food))) (PP (IN in) (NP (DT the) (NN stomach)))) (VP (VBZ does) (RB not) (VP (VB alter) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (S (NP (NNS Agents)) (VP (VBG Increasing) (NP (NN Serum) (NN Potassium)))) (: :) (S (NP (NN drug1)) (VP (VBZ attenuates) (NP (NP (NN potassium) (NN loss)) (VP (VBN caused) (PP (IN by) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))) (-RRB- -RRB-))) (, ,) (NP (NN drug6) (NNS supplements)) (, ,) (CC or) (NP (JJ potassium-containing) (NN salt) (VBZ substitutes))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (NN serum) (NN potassium)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN if) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (VBZ is) (VP (VBN indicated) (PP (IN because) (IN of) (NP (VBN demonstrated) (NN hypokalemia))))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (PP (IN with) (NP (NN caution))) (CC and) (PP (IN with) (NP (NP (JJ frequent) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN potassium)))))))))) (. .)))
(S1 (S (S (NP (NN Potassium) (NN sparing) (NNS agents)) (VP (MD should) (ADVP (RB generally)) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN heart) (NN failure))) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG receiving) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ drug2) (NN toxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug3)))) (PP (ADVP (RB concomitantly)) (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP cause) (NP (NP (NN elimination)) (PP (IN of) (NP (NN sodium))))))) (, ,) (PP (VBG including) (NP (NN drug4))))))))))) (. .))))
(S1 (S (S (NP (JJ drug1) (NN toxicity)) (VP (VBD was) (ADJP (RB usually) (JJ reversible) (PP (IN upon) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (DT the) (NN drug3))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN serum) (NN drug1) (NNS levels)) (VP (VB be) (VP (VBN monitored) (ADVP (RB frequently)) (SBAR (IN if) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN combined) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBG acting) (PP (IN on) (NP (DT the) (JJ central) (JJ nervous) (NN system))))))))))))) (, ,) (NP (JJ careful) (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (DT the) (NN pharmacology)) (PP (IN of) (NP (DT the) (NNS agents))) (S (VP (TO to) (VP (VB be) (VP (VBN employed))))))))))) (. .)))
(S1 (S (S (NP (JJ Animal) (VBP experience)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NN drug1)) (VP (VP (VBZ prolongs) (NP (NP (DT the) (JJ sleeping) (NN time)) (PP (PP (IN after) (NP (NN drug2))) (CC or) (PP (IN after) (NP (NN drug3)))))) (, ,) (VP (VBZ increases) (NP (NP (DT the) (JJ inhibitory) (NNS effects)) (PP (IN of) (NP (NN drug4))))) (, ,) (CC but) (VP (VBZ does) (RB not) (VP (VB exhibit) (NP (NP (NN monoamine) (NN oxidase)) (NN inhibition))))))))) (. .)))
(S1 (S (S (NP (JJ Clinical) (NNS studies)) (VP (VBP have) (VP (VBN shown) (NP (NP (VBN increased) (NN sedation)) (PP (IN with) (NP (JJ concurrent) (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS actions)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC or) (NP (JJ other) (NN drug6)))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1) (NNS tablets)) (VP (VBP are) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (NN anxiety)) (VP (VBN associated) (PP (IN with) (NP (JJ somatic) (NN disease) (NNS states)))))))))))) (, ,) (NP (JJ careful) (NN attention)) (VP (MD must) (VP (VB be) (ADJP (JJ paid) (PP (TO to) (NP (NP (JJ possible) (NN drug) (NN interaction)) (PP (IN with) (NP (JJ concomitant) (NN medication))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ bioavailability) (NNS studies)) (PP (IN with) (NP (JJ normal) (NNS subjects))))) (, ,) (NP (NP (DT the) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN at) (NP (JJ therapeutic) (NNS levels)))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB influence) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (JJ drug2) (NNS tablets))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (JJ clinical) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN established) (NP (NP (DT a) (NN cause)) (CC and) (NP (NN effect)) (NP (NN relationship))))))) (, ,) (NP (NNS physicians)) (VP (MD should) (VP (VB be) (NP (NN aware)) (SBAR (IN that) (S (NP (NP (JJ variable) (NNS effects)) (NP (DT an) (NN blood) (NN coagulation))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (ADVP (RB very) (RB rarely)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ oral) (NN drug1)) (CC and) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (JJ other) (NNS drug2))))) (VP (MD may) (VP (VB have) (NP (DT an) (JJ additive) (NN effect))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 6) (NN mg/kg)) (PP (IN once) (NP (DT every) (CD 24) (NNS hours))) (PP (IN for) (NP (CD 5) (NNS days)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN mg) (JJ single) (JJ oral) (NN dose)) (-RRB- -RRB-)))))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN drug))))))) (, ,) (CC and) (S (NP (DT the) (NN INR)) (VP (VBD was) (RB not) (ADVP (RB significantly)) (VP (VBN altered))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB cause) (NP (NP (NN myopathy)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN manifested) (PP (IN as) (NP (NP (NP (NN muscle) (NN pain)) (CC or) (NP (NN weakness))) (VP (VBN associated) (PP (IN with) (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (NN CPK)))))))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (NNS reports)) (PP (IN of) (NP (JJ skeletal) (NN myopathy)))) (PP (IN in) (NP (NP (DT a) (JJ placebo-controlled) (NN Phase) (NN I) (NN trial)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (CD 10) (JJ healthy) (NNS subjects)) (PP (IN on) (NP (JJ stable) (NN drug1) (NN therapy)))) (VP (VBD were) (VP (VBN treated) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN mg/kg) (RB once) (NP (DT every) (CD 24) (NNS hours))) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 14) (NNS days))))))))))) (. .)))
(S1 (S (S (VP (VBP Experience) (SBAR (IN with) (S (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NNS patients)))) (VP (VBZ is) (VP (VBN limited))))) (, ,) (S (ADVP (RB therefore)) (, ,) (NP (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (ADJP (RB temporarily) (JJ suspending)) (NN use)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug4))))))))))))) (. .)))
(S1 (S (S (NP (JJ Drug-Laboratory) (NN Test) (NNS Interactions)) (: :) (NP (EX There)) (VP (VBP are) (NP (DT no) (VBN reported) (JJ drug-laboratory) (NN test) (NNS interactions)))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBG acting) (PP (IN on) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))))))) (, ,) (NP (JJ careful) (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (DT the) (NN pharmacology)) (PP (IN of) (NP (DT all) (NNS agents))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN action)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC or) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP produce) (NP (NN CNS) (NN depression)))))))))))) (. .)))
(S1 (S (S (NP (NNS Smokers)) (VP (VBP have) (NP (NP (DT an) (VBN increased) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NNS nonsmokers)))))))) (: ;)))
(S1 (S (S (NP (DT this)) (VP (VBD was) (VP (VBN seen) (PP (IN in) (NP (NP (NNS studies)) (PP (IN with) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (NP (DT no) (ADJP (FW in) (FW vivo)) (JJ drug-drug) (NN interaction) (NNS studies)) (VP (VBD were) (VP (VBN conducted) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (NNS inducers)) (PP (IN of) (NP (NN CYP3A)))))))))) (, ,) (NP (NP (NNS compounds)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (JJ potent) (NN CYP3A) (NNS inducers)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))) (-RRB- -RRB-))))))) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB decrease) (NP (NN drug6) (NNS concentrations))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (NN Interaction)) (PP (IN with) (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP Inhibit) (NP (NN Metabolism)) (PP (IN via) (NP (NN Cytochrome) (NN P450) (NP (NP (NN 3A)) (PRN (-LRB- -LRB-) (NP (NN CYP3A)) (-RRB- -RRB-))))))))))) (: :) (S (NP (NP (DT The) (NN metabolism)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NP (DT the) (JJ major) (JJ circulating) (NN metabolite) (NN drug3)) (CC and) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (JJ other) (NNS drug4))))))) (VP (VBZ is) (VP (VBN catalyzed) (PP (IN by) (NP (NN CYP3A)))))) (. .))))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (NP (NP (ADJP (RB very) (JJ potent)) (NNS inhibitors)) (PP (IN of) (NP (NN CYP3A))))))))))))))) (. .)))
(S1 (S (PP (IN With) (NP (NP (NNS drugs)) (VP (VBG inhibiting) (NP (NN CYP3A)) (PP (TO to) (NP (DT a) (ADJP (ADJP (JJR lesser)) (, ,) (CC but) (ADJP (ADVP (RB still)) (JJ significant))) (NN degree)))))) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB only)) (PP (IN with) (NP (NP (NN caution)) (CC and) (NP (NP (NN consideration)) (PP (IN of) (NP (JJ appropriate) (NN dosage) (NN reduction))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN following)) (VP (VBP are) (NP (NP (NP (NNS examples)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (JJ other) (JJ related) (NN drug1)))) (, ,) (PP (ADVP (RB presumably)) (IN through) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN CYP3A)))))))))))) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (DT some) (NN drug7)))))) (. .)))
(S1 (S (NP (NP (NP (NN Drug) (NN Interaction)) (PP (IN with) (NP (NN drug1)))) (: :) (S (NP (DT A) (JJ multiple-dose) (NN study)) (VP (VBD was) (VP (VBN conducted) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug2) (ADJP (CD 20) (NN mg)) (NN BID))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3) (CD 2) (NN mg) (NNS QHS)))))) (PP (IN after) (NP (CD seven) (NNS days))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN Cmax)) (CC and) (NP (NN AUC))) (-RRB- -RRB-))))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN during) (NP (NN multiple-dose) (NN drug2))) (, ,) (S (VP (VBG suggesting) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (JJ pharmacokinetic) (NN interaction))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (NN Interaction)) (PP (IN with) (NP (NP (JJ Other) (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN Metabolized) (PP (IN by) (NP (NP (NN Cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))))))))))) (: :) (S (PP (IN At) (NP (ADJP (RB clinically) (JJ relevant)) (NNS concentrations))) (, ,) (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 0.6) (NN M)) (-RRB- -RRB-))) (VP (VBD was) (RB not) (ADJP (JJ inhibitory) (PP (IN towards) (NP (NP (DT the) (JJ major) (NN cytochrome) (NN P450) (NNS isoforms) (NN CYP1A2)) (, ,) (NP (NN CYP2A6)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2C19)) (, ,) (NP (NN CYP2D6)) (, ,) (NP (NN CYP2E1)) (, ,) (CC and) (NP (NN CYP3A)))))))))) (. .))))
(S1 (S (ADVP (RB Therefore)) (, ,) (PP (VBN based) (PP (IN on) (NP (DT these) (ADJP (FW in) (FW vitro)) (NNS data)))) (, ,) (NP (NN drug1)) (VP (VBZ is) (ADJP (RB very) (JJ unlikely) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (NN biotransformation)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT these) (JJ CYP) (NNS isoforms))))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (S (NP (JJ Elevated) (NN drug2) (NNS levels)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NN postmarketing)))))))) (VP (VBP experience) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (NN Drug) (NN monitoring)) (VP (MD may) (VP (VB be) (PP (IN of) (NP (NN assistance))) (PP (IN in) (S (VP (VBG detecting) (NP (NP (NNS alterations)) (PP (IN in) (NP (NN drug1) (NN plasma) (NNS concentrations)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (: :) (NP (VBN Increased) (NN prothrombin) (NN time))) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ clinical) (JJ bleeding)))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)))))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (NP (NP (DT A) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NP (NNS ketones)) (PP (IN in) (NP (DT the) (NN urine))))))) (VP (MD may) (VP (VB occur) (PP (PP (IN with) (NP (NP (NNS tests)) (VP (VBG using) (NP (NN drug1))))) (CC but) (PP (RB not) (IN with) (NP (NP (DT those)) (VP (VBG using) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (NP (DT the) (NN urine)) (VP (VBG using) (NP (NP (NNP Clinitest) (NN **) (, ,) (NNP Benedict) (NNP s) (NN solution)) (, ,) (CC or) (NP (JJ Fehling) (NN s) (NN solution))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (NN glucose) (NNS tests)) (VP (VBN based) (PP (IN on) (NP (NP (JJ enzymatic) (NN glucose) (NN oxidase) (NNS reactions)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN Clinistix) (NN *) (NN *)) (CC or) (NP (JJ Tes-Tape) (NN **))))) (-RRB- -RRB-)))))) (VP (VB be) (VP (VBN used)))))))) (. .)))
(S1 (S (S (NP (DT A) (JJ false-positive) (JJ direct) (NN Coombs) (NN test)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (JJ other) (NN drug1))))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN recognized) (SBAR (IN that) (S (NP (DT a) (JJ positive) (NN Coombs) (NN test)) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (DT the) (NN drug)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A)))) (PRN (-LRB- -LRB-) (NP (NN cytochrome) (NN P450) (NN 3A)) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (NP (NNS drugs)) (VP (ADVP (RB primarily)) (VBN metabolized) (PP (IN by) (NP (NN CYP3A))))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug2)) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (DT the) (JJ other) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VP (VB increase)) (CC or) (VP (VB prolong) (NP (DT both) (PRP$ its) (ADJP (ADJP (JJ therapeutic)) (CC and) (ADJP (JJ adverse))) (NNS effects)))))))))))))) (. .)))
(S1 (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN in) (NP (NN proof))) (PP (IN by) (NP (NN C.P.A.)))))))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NP (NNS drug1)) (CC and) (NP (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NN CYP3A)))))))) (VP (MD may) (VP (VP (VB decrease) (NP (NN drug2) (NN plasma) (NNS concentrations))) (CC and) (VP (VB reduce) (NP (PRP$ its) (JJ therapeutic) (NN effect)))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NP (NNS drug1)) (CC and) (NP (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN CYP3A)))))))) (VP (MD may) (VP (VB increase) (NP (NN drug2) (NN plasma) (NNS concentrations))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (JJ known) (JJ metabolic) (NNS profiles)))) (, ,) (NP (ADJP (RB clinically) (JJ significant)) (NN drug) (NNS interactions)) (VP (VBP are) (RB not) (VP (VBN expected) (PP (IN between) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,) (NP (NP (NN drug3)) (: /) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (CC or) (NP (NN drug8)))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (MD Should) (RB Not) (VP (VB Be) (VP (VBN Coadministered) (PP (IN With) (NP (NN drug1) (NN drug2))))))))) (: :) (NP (NP (NN drug3)) (, ,) (NP (NN drug4) (NN drug5)) (: :) (NP (NN drug6)) (, ,) (NP (NN drug7) (NN Antimigraine)) (: :) (NP (NN drug8) (NN drug9)) (: :) (NP (NP (CD drug10) (NN drug11) (CD drug12)) (, ,) (NP (CD drug13) (NN GI) (NN motility) (NNS agents))) (: :) (NP (NN drug14))))))
(S1 (S (NP (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT Which)) (S (VP (VBP Require) (NP (NP (DT a) (NN Dose) (NN Reduction)) (SBAR (WHADVP (WRB When)) (S (VP (VBN Coadminstered) (PP (IN With) (NP (NN drug1) (NN drug2))))))))))) (: :) (NP (NN drug3)))))
(S1 (S (ADVP (RB *)) (NP (DT This) (NN table)) (VP (VBZ is) (RB not) (NP (NP (DT all) (JJ inclusive) (NN *) (NN *) (NN drug1)) (VP (MD may) (RB not) (VP (VB be) (ADJP (JJ effective) (PP (JJ due) (TO to) (NP (NP (VBN decreased) (NN drug2) (NN plasma) (NNS concentrations)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (DT these) (NNS agents))))))))))) (ADVP (RB concomitantly)))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (JJ unchanged) (NNS drug4))) (PP (IN in) (NP (NN plasma))))))) (: ;))))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2))) (PP (IN because) (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (ADJP (ADJP (JJ serious)) (CC and/or) (ADJP (JJ life-threatening))) (JJ cardiac) (NNS arrhythmias))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (DT a) (JJ similar) (NN interaction)) (VP (VBZ is) (ADJP (JJ likely))))) (, ,) (NP (NN drug1)) (VP (MD should) (ADVP (RB also)) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT an) (ADJP (CD 83) (NN %)) (NN increase)) (PP (IN in) (NP (NN drug4) (NN plasma) (NN AUC)))) (CC and) (NP (NP (DT a) (ADJP (CD 51) (NN %)) (NN increase)) (PP (IN in) (NP (NN drug5) (NN plasma) (NN A.C.)))))))))))
(S1 (S (S (ADVP (RB Currently)) (, ,) (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (NP (NP (NN safety)) (CC and) (NP (NN efficacy))) (NNS data)) (ADJP (JJ available) (PP (IN from) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT this) (NN combination))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (ADJP (CD 152) (NN %)) (NN increase)) (PP (IN in) (NP (NN drug4) (NN plasma) (NN AUC)))) (CC and) (NP (NP (ADJP (RB very) (JJ little)) (NN change)) (PP (IN in) (NP (NN drug5) (NN plasma) (NN A.C.)))))))))))
(S1 (S (S (ADVP (RB Currently)) (, ,) (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (NP (NP (NN safety)) (CC and) (NP (NN efficacy))) (NNS data)) (ADJP (JJ available) (PP (IN from) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT this) (NN combination))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug2))) (-LRB- -LRB-) (VP (VBG using) (NP (NP (DT an) (JJ experimental) (NN soft-gelatin) (NN capsule) (NN formulation)) (PP (IN of) (NP (NN drug3) (NN 1200mg))))) (-RRB- -RRB-) (PP (IN with) (NP (NN drug4)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT an) (ADJP (CD 18) (NN %)) (NN increase)) (PP (IN in) (NP (NN drug5) (NN plasma) (NN AUC)))) (CC and) (NP (NP (DT a) (JJ 4-fold) (NN increase)) (PP (IN in) (NP (NN drug6) (NN plasma) (NN A.C.)))))))))))
(S1 (S (S (SBAR (IN If) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug1) (NN hard) (NN gelatin) (NNS capsules)) (PP (IN at) (NP (NP (DT the) (VBN recommended) (NN dose)) (PP (IN of) (NP (ADJP (CD 600) (NN mg)) (NN tid)))))))))))) (, ,) (NP (DT no) (NN dose) (NNS adjustments)) (VP (VBP are) (VP (VBN needed)))) (. .)))
(S1 (S (S (ADVP (RB Currently)) (, ,) (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (NP (NP (NN safety)) (CC and) (NP (NN efficacy))) (NNS data)) (ADJP (JJ available) (PP (IN from) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT this) (NN combination))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (CD 35) (NN %)) (NN increase)) (PP (IN in) (NP (NN drug4) (NN plasma) (NN A.C.))))))))))
(S1 (S (S (S (NP (DT This) (NN change)) (VP (VBD was) (RB not) (VP (VBN considered) (ADJP (RB clinically) (JJ significant))))) (CC and) (S (NP (DT no) (NN dose) (NN adjustment)) (VP (VBZ is) (VP (VBN needed) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN coadministered))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug2)) (VP (VB be) (VP (VBN administered) (PP (IN on) (NP (DT an) (JJ empty) (NN stomach)))))))))) (: ;))))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NN food))) (-RRB- -RRB-)) (PP (NP (CD one) (NN hour)) (IN after) (NP (NP (QP (CC or) (JJR more) (IN than) (CD two)) (NNS hours)) (PP (IN before) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (DT A) (NN dose) (NN adjustment)) (VP (VBZ is) (RB not) (VP (VBN needed) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (JJ Little))) (CC or) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN drug))))))) (VP (VBD was) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (ADJP (CD 32) (NN %)) (NN decrease)) (PP (IN in) (NP (NN drug4) (NN plasma) (NN AUC)))) (CC and) (NP (NP (DT a) (ADJP (CD 207) (NN %)) (NN increase)) (PP (IN in) (NP (NN drug5) (NN plasma) (NN A.C.)))))))))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (VB be) (VP (VBN reduced) (PP (TO to) (NP (NN one-half) (NP (DT the) (JJ usual) (NN dose)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (ADJP (CD 82) (NN %)) (NN decrease)) (PP (IN in) (NP (NN drug4) (NN plasma) (NN A.C.))))))))))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN coadministered))))) (. .)))
(S1 (S (NP (JJ Oral) (NN drug1))))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NN drug4)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (ADJP (CD 47) (NN %)) (NN decrease)) (PP (IN in) (NP (NN drug5)))) (CC and) (NP (NP (DT an) (ADJP (CD 18) (NN %)) (NN decrease)) (PP (IN in) (NP (NN drug6) (NN plasma) (NNS concentrations)))))))) (. .))))
(S1 (S (NP (JJ Alternate) (CC or) (JJ additional) (NN contraceptive) (NNS measures)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN during) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug1))))))))))
(S1 (S (S (NP (JJ Specific) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN observed) (SBAR (IN that) (S (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (ADJP (JJ unaltered) (PP (IN by) (NP (NP (JJ concomitant) (NN drug2)) (PP (IN in) (NP (JJ rheumatoid) (NN arthritis) (NNS patients)))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NNS patients)) (PP (IN with) (NP (JJ active) (NN RA)))) (VP (VBD were) (VP (VBN treated) (PP (IN for) (NP (QP (RB up) (TO to) (CD 24)) (NNS weeks))) (PP (IN with) (NP (NP (JJ concurrent) (NN drug1)) (CC and) (NP (JJ drug2) (NN therapy)))))))))) (, ,) (NP (NP (DT a) (ADJP (CD 7) (NN %)) (NN rate)) (PP (IN of) (NP (JJ serious) (NNS infections)))) (VP (VBD was) (VP (VBN observed) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT that)) (VP (VBN observed) (PP (IN with) (NP (NP (NN drug3)) (ADVP (RB alone)))))))) (PRN (-LRB- -LRB-) (NP (CD 0) (NN %)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (CD Two) (NN percent)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (VP (VBD developed) (NP (NP (NN neutropenia)) (PRN (-LRB- -LRB-) (NP (NN ANC) (CD 1) (NN x) (NN 109/L)) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN in) (NP (DT a) (JJ clinical) (NN study))) (SBAR (WHNP (WP who)) (S (VP (VBD were) (PP (IN on) (NP (NP (JJ established) (NN therapy)) (PP (IN with) (NP (NP (NN drug1)) (, ,) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN added))))) (, ,))))))))) (VP (VBD were) (VP (VBN noted) (S (VP (TO to) (VP (VB develop) (NP (NP (DT a) (JJ mild) (NN decrease)) (PP (IN in) (NP (NP (NN mean) (NN neutrophil) (NNS counts)) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NP (NNS groups)) (VP (VBN treated) (PP (IN with) (NP (CC either) (NP (NN drug3) (CD CI)) (CC or) (NP (NN drug4)))) (ADVP (RB alone)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN observation)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (DT This) (NN drug)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NN drug1)) (CC or) (NP (NP (JJ other) (NNS drug2)) (-LRB- -LRB-) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN CNS) (NN depressant) (NNS effects)) (PP (IN of) (NP (CC either) (DT these) (NP (NNS medications)) (CC or) (NP (NN drug3))))))) (-RRB- -RRB-) (, ,) (NP (NN drug4)) (CC or) (NP (JJ other) (NNS medications))))) (PP (IN with) (NP (NP (NP (JJ anticholinergic) (NN activity)) (PRN (-LRB- -LRB-) (S (NP (JJ anticholinergic) (NNS effects)) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS medications)) (VP (VBP are) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug5))))))))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (S (NP (NP (JJ concurrent) (NN use)) (PP (IN with) (NP (NN drug7)))) (VP (MD may) (VP (VP (VB prolong)) (CC and) (VP (VB intensify) (NP (NP (DT the) (JJ anticholinergic) (CC and) (NN CNS) (NN depressant) (NNS effects)) (PP (IN of) (NP (NN drug8)))))))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)))))
(S1 (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1) (NNS supplements)) (CC and) (NP (NNS drug2))))) (VP (MD may) (VP (VB increase) (NP (NN drug3) (NN absorption))))))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ is) (NP (DT an) (NN drug2))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB have) (NP (NP (DT a) (JJ strong) (NN affinity)) (PP (IN for) (NP (NP (NNS anions)) (ADJP (JJ other) (PP (IN than) (NP (DT the) (JJ bile) (NNS acids)))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN indicated) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ binds) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS drugs)))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1) (NNS Tablets)) (VP (MD may) (VP (VP (VB delay)) (CC or) (VP (VB reduce) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (JJ concomitant) (JJ oral) (NN medication)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN interval)) (PP (IN between) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NN drug1) (NNS Tablets)) (CC and) (NP (DT any) (JJ other) (NN medication))))))) (VP (MD should) (VP (VB be) (ADJP (RB as) (JJ long) (PP (IN as) (NP (JJ possible))))))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (MD should) (VP (VB take) (NP (JJ other) (NNS drugs)) (PP (NP (QP (IN at) (JJS least) (CD one)) (NN hour)) (IN before) (NP (NP (CC or) (CD four) (NNS hours)) (PP (IN after) (NP (JJ drug1) (NNS Tablets)))))) (S (VP (TO to) (VP (VB avoid) (S (VP (VBG impeding) (NP (PRP$ their) (NN absorption))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Repeated) (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN given) (PP (JJ prior) (TO to) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NN drug2)) (PP (IN in) (NP (JJ human) (NNS trials))))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB decrease) (NP (NN drug3) (NN absorption))))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (NP (DT a) (JJ follow-up) (NN study)) (PP (IN in) (NP (JJ normal) (NNS subjects))))) (, ,) (NP (NP (NP (JJ single-dose) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (CC and) (NP (NP (JJ twice-a-day) (NN administration)) (PP (IN for) (NP (NP (CD 5) (NNS days)) (PP (IN of) (NP (DT both) (NNS agents))))))) (VP (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN drug3) (NN absorption)))))) (, ,) (CC but) (VP (VBD had) (NP (DT a) (ADJP (ADJP (JJ small)) (CC yet) (ADJP (RB statistically) (JJ significant))) (NN effect)) (PP (IN on) (NP (NP (PRP$ its) (NN rate)) (PP (IN of) (NP (NN absorption))))))) (: ;)))
(S1 (S (S (NP (DT the) (NN time) (S (VP (TO to) (VP (VB reach) (NP (NN maximum) (NN concentration)))))) (VP (VBD was) (VP (VBN delayed) (NP (QP (RB approximately) (CD 30)) (NNS minutes))))) (. .)))
(S1 (S (S (NP (NP (NNS Effects)) (PP (IN on) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (JJ other) (NN drug1)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN determined))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2) (NNS Tablets)) (VP (VBP are) (VP (CC either) (VP (VBN added)) (CC or) (VP (VBN deleted) (PP (IN from) (NP (DT a) (JJ therapeutic) (NNS regimen)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (PP (IN in) (NP (NNS humans)))) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug1))) (SBAR (IN as) (S (VP (VBN reflected) (PP (IN in) (NP (JJ urinary) (NN excretion))))))) (VP (VBZ is) (ADVP (RB markedly)) (VP (VBN decreased) (SBAR (WHADVP (RB even) (WRB when)) (S (VP (VBN administered) (PP (NP (CD one) (NN hour)) (IN before) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN absorption)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN decreased)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB simultaneously)) (PP (IN with) (NP (NN drug6)))))))) (: ;)))
(S1 (S (S (NP (DT these) (NNS drugs)) (VP (VBD were) (RB not) (VP (VBN tested) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN administration))) (PP (NP (CD one) (NN hour)) (IN before) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ depressant) (NN effect)) (PP (IN on) (NP (NP (NN blood) (NNS levels)) (PP (IN in) (NP (NNS humans)))))) (VP (VBD was) (VP (VBN noted)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (JJ following) (NNS drugs)) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN drug7)) (-RRB- -RRB-))) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (CC or) (NP (NN drug10))))))))))))) (. .)))
(S1 (S (S (NP (JJ Particular) (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN observed) (PP (IN with) (NP (NN drug1))))) (SBAR (IN since) (S (NP (EX there)) (VP (VBP are) (NP (VBG conflicting) (NNS results)) (PP (IN for) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NP (DT the) (NN availability)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN potential)) (PP (IN for) (NP (NP (NN binding)) (PP (IN of) (NP (DT these) (NNS drugs)))))) (SBAR (IN if) (S (VP (VBN given) (ADVP (RB concomitantly))))) (VP (VBZ is) (ADJP (JJ present)))) (. .)))
(S1 (S (S (NP (JJ Discontinuing) (NN drug1)) (VP (MD could) (VP (VB pose) (NP (NP (DT a) (NN hazard)) (PP (TO to) (NP (NN health)))) (SBAR (IN if) (S (NP (NP (DT a) (ADJP (RB potentially) (JJ toxic)) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADVP (RB significantly)) (VP (VBN bound) (PP (TO to) (NP (DT the) (NN drug2)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN titrated) (PP (TO to) (NP (DT a) (NN maintenance) (NN level))) (SBAR (IN while) (S (NP (DT the) (NN patient)) (VP (VBD was) (VP (VBG taking) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB also)) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (JJ oral) (NN drug2) (NNS supplements)) (CC and) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (VP (TO to) (VP (VB evaluate) (NP (NP (JJ possible) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (NNS drugs)) (ADJP (JJ other) (PP (IN than) (NP (NN drug2))))))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN advised) (SBAR (IN if) (S (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drugs))))) (VP (VBZ is) (VP (VBN required)))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NP (NN safety)) (CC and) (NP (NN efficacy))) (PP (IN of) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBZ is) (ADJP (JJ unknown)))) (, ,) (CC and) (S (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (CD two) (ADJP (RB potentially) (JJ hepatotoxic)) (NNS medications)))) (VP (VBZ is) (RB not) (ADVP (RB ordinarily)) (VP (VBN recommended) (SBAR (IN unless) (S (NP (DT the) (JJ probable) (NNS benefits)) (VP (VBP outweigh) (NP (DT the) (JJ known) (NNS risks))))))))) (. .)))
(S1 (S (S (NP (NP (NN Lethargy)) (CC and) (NP (NN somnolence))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (VBG following) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NN drug1)))) (VP (MD may) (RB not) (VP (VB benefit) (PP (IN from) (NP (NP (NNS drug2)) (VP (VBG containing) (NP (NNS medicines))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN cough)) (CC and) (NP (JJ cold) (NNS preparations)))) (, ,) (NP (JJ antidiarrheal) (NNS preparations)) (, ,) (CC and) (NP (NN drug3))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT an) (NN emergency) (NN situation)) (SBAR (WHADVP (WRB when)) (S (NP (NN opioid) (NN analgesia)) (VP (MD must) (VP (VB be) (VP (VBN administered) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1)))))))))))) (, ,) (S (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NN drug2))) (VP (VBN required))) (VP (MD may) (VP (VB be) (ADJP (JJR greater) (PP (IN than) (NP (JJ usual))))))) (, ,) (CC and) (S (NP (DT the) (VBG resulting) (JJ respiratory) (NN depression)) (VP (MD may) (VP (VB be) (ADJP (ADJP (JJR deeper)) (CC and) (ADJP (RBR more) (JJ prolonged))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NN repeat) (NNS doses)) (PP (IN of) (NP (NN drug1)))))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN repeat) (NN dose) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC or) (NP (NP (DT an) (NN drug4) (NN /levonorgestrol) (JJ oral) (NN drug5)) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (DT an) (NN drug5) (: /) (NN drug6) (JJ oral) (NN drug7))))) (VP (VBD produced) (NP (NP (JJ minor) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug8))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD were) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (PP (IN without) (NP (JJ clinical) (NN significance))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (CD 45) (NN %)) (NN increase)) (PP (IN in) (NP (NP (JJ systemic) (NN exposure)) (PP (TO to) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ anticoagulant) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (PP (IN in) (NP (JJ healthy) (NNS subjects))))) (PP (IN on) (NP (JJ stable) (NN drug3) (NN therapy))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (SBAR (IN because) (S (NP (DT some) (NNS drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB enhance) (NP (NP (DT the) (JJ anticoagulant) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (PRP$ its) (NNS derivatives)))) (PP (IN in) (NP (NNS patients)))))))))))) (, ,) (NP (NP (DT the) (NN prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ suitable) (NN coagulation) (NN test))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored) (SBAR (IN if) (S (NP (DT a) (NN drug3)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug4)) (CC or) (NP (PRP$ its) (NNS derivatives)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP form) (NP (NNS chelates)) (PP (IN with) (NP (NP (NN alkaline) (NN earth)) (CC and) (NP (NN transition) (NNS metals)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN absorption)) (PP (IN of) (NP (JJ oral) (NN drug1)))) (VP (VBZ is) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (DT an) (NN drug2)) (VP (VBG containing) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: -) (S (NP (CC and/or) (NP (NP (NN drug2) (JJ -containing) (NN drug3)) (, ,) (NP (NP (NNS products)) (VP (VBG containing) (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (VP (VBG containing) (NP (NP (NN drug7)) (CC or) (NP (JJ other) (JJ metal) (NNS cations))))) (, ,) (CC or) (NP (ADJP (NN drug8) (-LRB- -LRB-) (NN drug9) (-RRB- -RRB-) (JJ chewable/buffered)) (NNS tablets)))))) (CC or) (NP (NP (DT the) (JJ pediatric) (NN powder)) (PP (IN for) (NP (JJ oral) (NN solution))))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN within) (NP (NP (NP (CD 3) (NNS hours)) (PP (IN before))) (CC or) (NP (NP (CD 2) (NNS hours)) (PP (IN after) (NP (NN drug10)))))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN within) (NP (NP (CD 2) (NNS hours)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ pressor) (NN activity)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (ADJP (RB very) (JJ low) (PP (VBN compared) (PP (TO to) (NP (PRP$ its) (JJ antidiuretic) (NN activity)))))))) (, ,) (NP (NP (JJ large) (NNS doses)) (PP (IN of) (NP (NN drug2) (NNS Tablets)))) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NP (JJ other) (JJ pressor) (NNS agents)) (PP (ADVP (RB only)) (IN with) (NP (JJ careful) (NN patient) (NN monitoring))))))))) (. .)))
(S1 (S (S (NP (NN None)) (VP (VBN known))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (ADVP (FW in) (FW vitro))) (VP (VBP show) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (DT any) (NN enzyme))) (PP (IN in) (NP (DT the) (NP (NP (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NN system))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS studies))) (, ,) (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB induce) (NP (NP (DT the) (NN CYP3A4) (NN metabolism)) (PP (IN of) (NP (JJ other) (NNS drugs))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ is) (RB not) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NN P-glycoprotein))))) (CC and) (VP (VBZ is) (NP (NP (DT a) (JJ poor) (NN substrate)) (PP (IN for) (NP (NN cytochrome) (NN P450) (NNS enzymes))))))) (. .)))
(S1 (S (S (NP (NP (JJ Clinical) (NNS studies)) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (RB not) (VP (VBN altered) (PP (IN by) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (NN drug6)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NP (DT the) (JJ active) (NN metabolite)) (PP (IN of) (NP (NN mycophenolate)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD reduced) (NP (NP (DT the) (NN blood) (CD AUC0-12)) (PP (IN of) (NP (NP (NP (NN drug2)) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %)))) (, ,) (NP (NP (NP (JJ peak) (NN blood) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN Cmax)) (-RRB- -RRB-))) (PP (IN by) (NP (CD 16) (NN %)))) (, ,) (CC and) (NP (NP (JJ 12-hour) (NN blood) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN C12hr)) (-RRB- -RRB-)))))) (PP (IN by) (NP (NP (CD 26) (NN %)) (PP (IN in) (NP (JJ healthy) (NNS subjects))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (CD 2) (NNS doses)) (PP (IN of) (NP (QP (CD 0.1) (NN mg/kg) (CD 12)) (NNS hours))) (ADVP (RB apart))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN administered) (PP (IN on) (NP (NP (DT the) (JJ 10th) (NN day)) (PP (IN of) (NP (NP (NN drug4) (CD 70) (NN mg)) (ADVP (RB daily))))))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (NNS results)) (PP (IN from) (NP (NP (DT a) (NN control) (NN period)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN drug5)) (VP (VBD was) (VP (VBN administered) (ADVP (RB alone)))))))))))))))))) (. .)))
(S1 (S (S (PP (IN For) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT both) (NNS therapies))))) (, ,) (NP (NP (JJ standard) (NN monitoring)) (PP (IN of) (NP (NP (NN drug1) (NN blood) (NNS concentrations)) (CC and) (NP (JJ appropriate) (NN drug2) (NN dosage) (NNS adjustments))))) (VP (VBP are) (VP (VBN recommended)))) (. .)))
(S1 (S (S (PP (IN In) (NP (CD two) (JJ clinical) (NNS studies))) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD one) (NP (CD 4) (NN mg/kg)) (NN dose)) (CC or) (NP (CD two) (CD 3) (NN mg/kg) (NNS doses))) (-RRB- -RRB-))) (VP (VBD increased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (QP (RB approximately) (CD 35)) (NN %))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB increase) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (JJ transient) (NNS increases)) (PP (IN in) (NP (NP (NN liver) (NN ALT)) (CC and) (NP (NN AST))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD were) (VP (VBN co-administered))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ drug-drug) (NN interaction) (NN study)) (PP (IN with) (NP (NN drug1))) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))) (VP (VBZ has) (VP (VBN shown) (NP (NP (DT a) (ADJP (CD 30) (NN %)) (NN decrease)) (PP (IN in) (NP (NN drug2) (NN trough) (NNS concentrations))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug1)))) (VP (MD should) (VP (VBP receive) (NP (NP (CD 70) (NN mg)) (PP (IN of) (NP (NN drug2)))) (ADVP (RB daily))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNS results)) (PP (IN from) (NP (NP (NN regression) (NNS analyses)) (PP (IN of) (NP (NN patient) (JJ pharmacokinetic) (NNS data)))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (JJ other) (NNS inducers)) (PP (IN of) (NP (NP (NN drug) (NN clearance)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5))) (-RRB- -RRB-)))))) (PP (IN with) (NP (NN drug6)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (ADJP (RB clinically) (JJ meaningful)) (NNS reductions)) (PP (IN in) (NP (NN drug7) (NNS concentrations)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (WHNP (WDT which)) (S (NP (NP (NN drug) (NN clearance) (NN mechanism)) (VP (VBN involved) (PP (IN in) (NP (NN drug1) (NN disposition))))) (VP (MD may) (VP (VB be) (ADJP (JJ inducible))))))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NP (NNS inducers)) (PP (IN of) (NP (NN drug) (NN clearance))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (NN drug6)))))))))) (, ,) (S (NP (NP (NN use)) (PP (IN of) (NP (NP (DT a) (JJ daily) (NN dose)) (PP (IN of) (NP (NP (CD 70) (NN mg)) (PP (IN of) (NP (NN drug7)))))))) (VP (MD should) (VP (VB be) (VP (VBN considered)))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN As) (PP (IN with) (NP (JJ other) (NN drug2)))) (, ,) (NP (NP (JJ renal) (NN excretion)) (PP (IN of) (NP (NN drug3)))) (VP (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP (NN drug4))))) (CC and) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ approximate) (ADJP (CD 80) (NN %)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN AUC)) (PP (IN for) (NP (NN drug5)))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1) (NNS requirements)) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (, ,) (NP (NNS drug2)) (-RRB- -RRB-))) (VP (MD may) (VP (VB be) (VP (VBN altered))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN with) (NP (JJ general) (NN drug1)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NN arrhythmias)))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (JJ pressor) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT those)) (PP (IN of) (NP (JJ other) (NNS drugs))))) (VP (MD may) (VP (VB be) (ADJP (JJ additive))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NNS drugs)) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))))) (: ;)))
(S1 (S (S (ADVP (RB conversely)) (, ,) (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (NNS drug2)) (PRN (-LRB- -LRB-) (PP (FW i.e.) (, ,) (NP (NN drug3))) (, ,) (NP (NNS drug4)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (JJ anorectic) (NN effect)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ Clinical) (NN evidence)) (VP (VBZ has) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD can) (VP (VB be) (VP (VBN formed) (PP (IN with) (NP (NP (JJ concurrent) (NN ingestion)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (CD 7) (JJ healthy) (JJ male) (NNS volunteers))))) (, ,) (NP (NN drug2) (NN treatment)) (VP (VBD potentiated) (NP (NP (DT the) (NN blood) (NN glucose) (JJ lowering) (NN effect)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN drug4)) (ADJP (JJ similar) (PP (TO to) (NP (NN drug5))))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (CD 3)) (PP (IN of) (NP (DT the) (CD 7) (NNS subjects)))))))) (. .))))
(S1 (S (S (S (VP (VBG Repeating) (NP (NP (DT the) (NN study)) (PP (IN with) (NP (CD 6) (JJ healthy) (JJ male) (NNS volunteers))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBD did) (RB not) (VP (VB detect) (NP (NP (DT an) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NN glucose) (NN tolerance))))))) (. .)))
(S1 (S (S (NP (NP (JJ Careful) (NN supervision)) (PP (IN of) (NP (JJ diabetic) (NNS patients))) (PP (IN under) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug1)))))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (PRP It)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established) (SBAR (IN if) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN established) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ interferes) (PP (IN with) (NP (NP (DT the) (JJ contraceptive) (NN effect)) (PP (IN of) (NP (JJ microdosed) (NN drug2) (NN minipill) (NNS preparations)))))))))))) (. .)))
(S1 (S (S (NP (JJ Microdosed) (NN minipill) (NN drug1) (NNS preparations)) (VP (VBP are) (RB not) (VP (VBN recommended) (PP (IN for) (NP (NP (NN use)) (PP (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (NP (JJ other) (NNS drug1)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNS implants)) (CC and) (NP (NNS injectables)))) (, ,)) (VP (VBP are) (NP (NP (JJ adequate) (NNS methods)) (PP (IN of) (NP (NN contraception)))) (PP (IN during) (NP (NN drug2) (NN therapy))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (DT An) (VBN increased) (NN risk)) (PP (IN of) (NP (NN hepatitis))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB result) (PP (IN from) (NP (NP (JJ combined) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ is) (ADVP (RB also)) (VP (VBN contraindicated)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN If) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug3))))))) (, ,) (NP (NP (DT the) (NN protein) (NN binding)) (PP (IN of) (NP (NN drug4)))) (VP (MD may) (VP (VB be) (VP (VBN reduced))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN Since) (S (NP (CC both) (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (MD can) (VP (VB cause) (NP (VBN increased) (JJ intracranial) (NN pressure)))))) (, ,) (NP (PRP$ their) (JJ combined) (NN use)) (VP (VBZ is) (VP (VBN contraindicated)))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (JJ oral) (NN drug2))) (: :) (S (NP (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug3)))) (CC and/or) (NP (NP (JJ other) (JJ oral) (NNS drug4)) (PP (IN with) (NP (NN drug5))))) (VP (MD must) (VP (VB be) (VP (VBN avoided) (PP (IN because) (IN of) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN hypervitaminosis) (NN A))))))))) (. .))))
(S1 (S (S (NP (JJ Other) (: :) (EX There)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (NP (NP (DT no) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Investigations)) (PP (IN into) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN protein) (NN binding)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))))))))) (VP (VBD revealed) (NP (DT no) (NN interaction)))) (. .)))
(S1 (S (S (S (NP (NP (NN Laboratory) (NNS Tests)) (PP (IN If) (NP (JJ significant) (JJ abnormal) (NN laboratory) (NNS results)))) (VP (VBP are) (VP (VBN obtained)))) (, ,) (CC either) (S (NP (NP (NN dosage) (NN reduction)) (PP (IN with) (NP (NP (JJ careful) (NN monitoring)) (CC or) (NP (NN treatment) (NN discontinuation))))) (VP (VBZ is) (VP (VBN recommended) (, ,) (PP (VBG depending) (PP (IN on) (NP (JJ clinical) (NN judgement)))))))) (. .)))
(S1 (S (NP (NP (NN Blood) (NN Sugar)) (: :) (S (NP (NP (DT Some) (NNS patients)) (VP (VBG receiving) (NP (NN drug1)))) (VP (VBP have) (VP (VBN experienced) (NP (NNS problems)) (PP (IN with) (NP (NN blood) (NN sugar) (NN control)))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ new) (NNS cases)) (PP (IN of) (NP (NNS diabetes)))) (VP (VBP have) (VP (VBN been) (VP (VBN diagnosed) (PP (IN during) (NP (NN drug1) (NN therapy))) (, ,) (PP (VBG including) (NP (JJ diabetic) (NN ketoacidosis))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN diabetics))) (, ,) (NP (JJ blood-sugar) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB very) (RB carefully)))))) (. .)))
(S1 (S (NP (NP (NNS Lipids)) (: :) (S (PP (IN In) (NP (JJ clinical) (NNS studies))) (, ,) (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNS hypertriglyceridemia)))) (VP (VBD was) (NP (CD 66) (NN %)))) (, ,) (S (NP (NN hypercholesterolemia)) (VP (VBD was) (NP (CD 33) (NN %)))) (CC and) (S (NP (NP (DT that)) (PP (IN of) (NP (VBN decreased) (NN HDL)))) (VP (VBD was) (NP (CD 40) (NN %))))) (. .))))
(S1 (S (S (NP (NP (NP (NN Pretreatment)) (CC and) (NP (NN follow-up))) (NNS measurements)) (VP (MD should) (VP (VB be) (VP (VBN obtained) (PP (IN under) (NP (JJ fasting) (NNS conditions))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (S (NP (DT these) (NNS tests)) (VP (VB be) (VP (VBN performed) (ADVP (RB weekly))))) (CC or) (S (NP (NP (DT every) (JJ other) (NN week)) (PP (IN until) (NP (NP (DT the) (NN lipid) (NN response)) (PP (TO to) (NP (NN drug1)))))) (VP (VBZ has) (VP (VBN stabilized))))))))) (. .)))
(S1 (S (NP (NP (NN Liver) (NN Function) (NNS Tests)) (: :) (S (NP (NP (NNS Elevations)) (PP (IN of) (NP (NP (NP (NN AST)) (PRN (-LRB- -LRB-) (NP (NN SGOT)) (-RRB- -RRB-))) (, ,) (NP (NP (NN ALT)) (PRN (-LRB- -LRB-) (NP (NN SGPT)) (-RRB- -RRB-))) (CC or) (NP (NN LDH))))) (VP (VBD were) (VP (VBN experienced) (PP (IN by) (NP (NP (RB approximately) (CD 1)) (PP (IN in) (NP (NP (CD 3) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))))))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (DT these) (NNS tests)) (VP (VB be) (VP (VBN performed) (ADVP (ADVP (RB prior)) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NN drug1) (NN therapy)))))) (, ,) (PP (PP (IN at) (NP (NP (CD 1-) (TO to) (JJ 2-week) (NNS intervals)) (PP (IN until) (NP (JJ stable))))) (CC and) (ADVP (RB thereafter)) (PP (IN at) (NP (NNS intervals)))) (SBAR (IN as) (S (ADVP (RB clinically)) (VP (VBN indicated))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NP (NN plasma) (NN protein)) (PRN (-LRB- -LRB-) (NP (CD 99.9) (NN %)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NP (NN drug1)) (PP (ADVP (RB concurrently)) (IN with) (NP (JJ other) (ADJP (RB highly) (NN plasma) (JJ protein-bound)) (NNS drugs)))) (PP (IN with) (NP (JJ narrow) (JJ therapeutic) (NNS indices)))))) (, ,) (SBAR (IN as) (S (NP (NP (NN competition)) (PP (IN for) (NP (NN binding) (NNS sites)))) (VP (MD may) (VP (VB occur)))))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug2)) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NN metabolism) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ has) (NP (DT no) (JJ significant) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NN cytochrome) (NN P450) (NNS enzymes))))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (DT no) (JJ drug-drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (ADVP (FW in) (FW vivo))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN expected) (SBAR (IN that) (S (NP (DT no) (JJ significant) (NN interaction)) (VP (MD would) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (ADVP (RB either)) (VP (VP (VBP are) (VP (VBN metabolized) (PP (IN by)))) (CC or) (VP (VB inhibit) (NP (NN cytochrome) (NN P450) (NNS enzymes)))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (NN sensitivity)) (PP (TO to) (NP (JJ oral) (NNS anticoagulahts))))))) (. .)))
(S1 (S (S (NP (NP (NN Dosage)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (MD may) (VP (VB require) (NP (NN reduction))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB maintain) (NP (JJ satisfactory) (JJ therapeutic) (NN hypoprothrombinemia)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ diabetic) (NNS patients))) (, ,) (NP (NP (DT the) (JJ metabolic) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VP (VB decrease) (NP (NN blood) (NN glucose))) (CC and) (ADVP (RB therefore)) (, ,) (NP (NN drug2) (NNS requirements))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1) (NN HCl)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (DT an) (NN drug2))))))) (, ,) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN hyperkalemia)))) (VP (MD may) (VP (VB be) (VP (VBN increased))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN if) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (VBZ is) (VP (VBN indicated) (PP (IN because) (IN of) (NP (VBN demonstrated) (NN hypokalemia))))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (PP (IN with) (NP (NN caution))) (CC and) (PP (IN with) (NP (NP (JJ frequent) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN potassium)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB generally)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NN drug2))) (SBAR (IN because) (S (NP (PRP they)) (VP (VP (VBP reduce) (NP (PRP$ its) (JJ renal) (NN clearance))) (CC and) (VP (VBP add) (NP (NP (DT a) (JJ high) (NN risk)) (PP (IN of) (NP (NN lithium) (NN toxicity)))))))))))) (. .)))
(S1 (S (S (NP (VBN Read)) (VP (VBZ circulars) (PP (IN for) (NP (NP (JJ drug1) (NNS preparations)) (PP (IN before) (NP (NP (NN use)) (PP (IN of) (NP (JJ such) (JJ concomitant) (NN therapy))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT a) (NN drug1)))) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (ADJP (ADJP (JJ diuretic)) (, ,) (ADJP (JJ natriuretic)) (, ,) (CC and) (ADJP (JJ antihypertensive))) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ desired) (NN effect)) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (VBZ is) (VP (VBN obtained)))))))))))) (. .)))
(S1 (S (SBAR (IN Since) (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,) (PP (VBG including) (NP (NN drug3))) (, ,)) (VP (MD may) (DT each) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (NN serum) (NN potassium) (NNS levels)))))))) (, ,) (NP (NP (DT the) (JJ potential) (NNS effects)) (PP (IN on) (NP (NP (NN potassium) (NNS kinetics)) (CC and) (NP (JJ renal) (NN function))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS agents)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concurrently))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (VP (VBN Based) (PP (IN on) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (JJ profound) (NN hypotension)) (CC and) (NP (NP (NN loss)) (PP (IN of) (NP (NN consciousness)))))))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN administered) (PP (IN with) (NP (NN drug3))))))))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug4))) (PP (IN with) (NP (NP (NNS drugs)) (PP (IN of) (NP (NP (DT the) (NN drug5)) (PRN (-LRB- -LRB-) (S (VP (VBG including) (, ,) (PP (IN for) (NP (NP (NN example)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC and) (NP (NN drug10)))))) (-RRB- -RRB-))))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .))))
(S1 (S (NP (NP (NP (NN drug1) (NNS s)) (CC and) (NP (NN drug2))) (: :) (S (NP (DT The) (JJ following) (JJ adverse) (NNS events)) (VP (VBD were) (VP (VBN experienced) (ADVP (RBR more) (RB commonly)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ concomitant) (NN drug3)) (CC or) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 94)) (-RRB- -RRB-)))) (PP (VBN compared) (PP (TO to) (NP (NP (NNS patients)) (VP (RB not) (VBG receiving) (NP (NP (NP (DT these) (JJ concomitant) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 456)) (-RRB- -RRB-))) (: :) (NP (NP (NN hypotension) (CD 10) (NN %) (CC vs) (CD 4) (NN %)) (, ,) (NP (JJ myocardial) (NN infarction) (CD 3) (NN %) (CC vs) (CD 1) (NN %)) (, ,) (NP (JJ serious) (NN pneumonia) (CD 5) (NN %) (CC vs) (CD 3) (NN %)) (, ,) (NP (NP (JJ serious) (NNS falls)) (CD 9) (NN %) (CC vs) (CD 3) (NN %)) (, ,) (CC and) (NP (NN bone) (CC and) (NN joint) (NNS injuries) (NP (NP (CD 6) (NN %)) (CC vs) (NP (CD 2) (NN %)))))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN mechanism)) (VP (VBG underlying) (NP (NP (JJ many)) (PP (IN of) (NP (DT these) (NNS events)))))) (VP (VP (VBZ is) (ADJP (JJ unknown))) (, ,) (CC but) (VP (MD may) (VP (VB represent) (NP (VBN increased) (NN hypotension)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN Since) (S (NP (NN drug2)) (VP (VBZ is) (NP (DT a) (NN drug3))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (NP (NNS drug4)) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (DT the) (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8))) (-RRB- -RRB-))) (CC or) (NP (NN drug9)))) (, ,)) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NN drug10)))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (JJ major) (JJ psychotic) (NNS disorders))) (, ,) (VP (VBN treated) (PP (IN with) (NP (NN drug1)))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN treated) (PP (IN with) (NP (NN drug2))) (SBAR (RB only) (IN if) (S (NP (DT the) (JJ potential) (NNS benefits)) (VP (VBP outweigh) (NP (DT the) (NNS risks))))))))) (. .)))
(S1 (S (NP (NP (NNS Drugs)) (VP (VBG Prolonging) (NP (DT the) (NN QT/QTc) (NN Interval) (NN Caution)))) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (NN drug1)) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP prolong) (NP (DT the) (NN QT/QTc) (NN interval))))))))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (ADVP (RB There)) (VP (VBP are) (NP (NP (DT no) (JJ known) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN laboratory) (NNS tests))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB extensively)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN cytochrome) (NN P-450)) (NNS isoenzymes))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NNP C.P.A.))) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))) (CC or) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NN CYP2C19))) (PP (JJ such) (IN as) (NP (NN drug5)))))))))))))) (. .)))
(S1 (S (S (NP (JJ Pharmacokinetic) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (DT the) (JJ systemic) (NN exposure)) (PP (IN of) (NP (NP (NN drug3)) (CC and/or) (NP (PRP$ its) (JJ major) (NNS metabolites))))))))))) (. .)))
(S1 (S (S (NP (NN Population) (JJ pharmacokinetic) (NNS studies)) (VP (VBD showed) (NP (NP (JJR higher) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (PP (IN among) (NP (NP (NNS patients)) (VP (ADVP (RB concurrently)) (VBN treated) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN C.P.A.))))))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ does) (RB not))) (, ,) (ADVP (RB however)) (, ,) (VP (VBP appear) (S (VP (TO to) (VP (VB cause) (NP (NP (VBN increased) (NN blood) (NNS levels)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4)))))))))) (, ,) (SBAR (IN as) (S (NP (PRP it)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN drug2)) (, ,) (NP (NP (DT a) (NN drug)) (PP (IN with) (NP (NP (NN metabolism)) (ADJP (RB very) (JJ sensitive) (PP (TO to) (NP (NN C.P.A.) (NN inhibition)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN known) (S (VP (TO to) (ADVP (RB adversely)) (VP (VB affect) (NP (DT the) (JJ hematopoietic) (NN system)))))))))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (IN if) (FRAG (JJ possible))))))) (. .)))
(S1 (S (S (NP (JJ Considerable) (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))) (SBAR (IN since) (S (NP (JJ paranoid) (NNS symptoms)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (NN therapy)) (PP (IN with) (NP (DT this) (NN combination)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ two-way) (NN interaction)) (PP (IN between) (NP (NP (DT the) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (DT the) (NN drug3) (NNS s))))) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested))))) (. .)))
(S1 (S (S (ADVP (RB Presumably)) (, ,) (NP (NN drug1)) (VP (VP (VBZ acts) (PP (IN as) (NP (NP (DT a) (NN stimulator)) (PP (IN of) (NP (NN drug2) (NN metabolism)))))) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (NP (NP (VBN decreased) (NN serum) (NNS levels)) (PP (IN of) (NP (DT the) (NN drug3)))) (CC and) (NP (VBN increased) (NN prothrombin-proconvertin) (NNS concentrations))))))))))) (. .)))
(S1 (S (S (ADVP (RB Conversely)) (, ,) (NP (DT the) (NNS drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VP (VP (VB increase) (NP (DT the) (NN serum) (NNS levels))) (CC and) (VP (VB prolong) (NP (NP (DT the) (NN serum) (NN half-life)) (PP (IN of) (NP (NN drug2)))))) (PP (IN by) (S (VP (VBG inhibiting) (NP (PRP$ its) (NN metabolism)))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (NN documentation)) (PP (IN of) (NP (JJ such))))))) (, ,) (NP (NP (DT a) (JJ similar) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (DT the) (NN drug2))))) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (ADVP (RB therefore)) (VP (VBN advised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (VBN Reduced) (NN efficacy)) (CC and) (NP (VBN increased) (NN incidence))) (PP (IN of) (NP (JJ breakthrough) (JJ bleeding)))) (CC and) (NP (JJ menstrual) (NNS irregularities))) (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ similar) (NN association)) (, ,) (ADJP (RB though) (RBR less) (JJ marked)) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (ADVP (RB possibly)) (PP (IN with) (NP (NP (NN drug7)) (CC and) (NP (NN drug8) (CD 72)))))))))) (. .)))
(S1 (S (S (NP (DT A) (JJ possible) (NN interaction)) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (PP (IN with) (NP (NP (NP (NN drug1)) (CC and) (NP (DT the) (JJ herbal) (JJ supplement) (NN St.)) (NP (NNP Johns) (NNP Wort))) (VP (VBN based) (PP (IN on) (NP (NP (DT some) (NNS reports)) (PP (IN of) (NP (NP (JJ oral) (NN drug2) (NNS users)) (VP (VBG experiencing) (NP (JJ breakthrough) (JJ bleeding)) (PP (ADVP (RB shortly)) (IN after) (S (VP (VBG starting) (NP (NN St.) (NP (NNP Johns) (NNP Wort)))))))))))))))))) (. .)))
(S1 (S (S (NP (NNS Pregnancies)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN by) (NP (NP (NNS users)) (PP (IN of) (NP (NN drug1))) (SBAR (WHNP (WP who)) (S (ADVP (RB also)) (VP (VBD used) (NP (NP (DT some) (NN form)) (PP (IN of) (NP (NN St.) (NNP Johns) (NNP Wort))))))))))))) (. .)))
(S1 (S (S (NP (NN Healthcare) (NNS prescribers)) (VP (VBP are) (VP (VBN advised) (S (VP (TO to) (VP (VB consult) (NP (NP (DT the) (JJ package) (NNS inserts)) (PP (IN of) (NP (NP (NN medication)) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ oral) (NN drug1))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Combination) (NN Therapy)) (: :) (NP (NP (DT Any) (NN form)) (PP (IN of) (NP (NN therapy))) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ adds) (PP (TO to) (NP (NP (DT the) (NN stress)) (PP (IN of) (NP (DT the) (NN patient)))))) (, ,) (VP (VBZ interferes) (PP (IN with) (NP (NN nutrition)))) (CC or) (VP (VBZ depresses) (NP (NP (NN bone) (NN marrow)) (NN function)))))))) (VP (MD will) (VP (VB increase) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))))) (, ,) (NP (NN drug1)) (VP (VBZ appears) (S (VP (TO to) (VP (VB have) (NP (DT no) (JJ inhibitory) (NN or) (NN induction) (NN potential)) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (S (VP (VBG CYP) (NP (CD 450) (NNS enzymes)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ inhibitory) (NN potential)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN CYP450) (NNS isoenzymes)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (NN plasma) (NN protein) (NN binding)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))) (, ,) (S (VP (VBG indicating) (NP (NP (DT no) (NN potential)) (PP (IN for) (NP (NN protein) (JJ binding-based) (NN drug) (NNS interactions)))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT a) (NN drug) (NN interaction) (NN study))) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (ADJP (RB orally) (VBN inhaled)) (NP (NP (NN drug1)) (CC and) (NP (JJ oral) (NN drug2)))) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 3A4)))) (, ,)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (CC either) (NP (NN drug3)) (CC or) (NP (NN drug4))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT another) (NN drug) (NN interaction) (NN study))) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NP (ADJP (RB orally) (VBN inhaled)) (NN drug1)) (CC and) (NP (JJ oral) (NN drug2))) (, ,) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 3A4)))) (, ,)))) (VP (VBD increased) (NP (NP (NP (DT the) (NN exposure)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug3)))) (PP (IN by) (NP (NP (RB approximately) (NN 3.6-fold)) (PP (IN at) (NP (JJ steady) (NN state))))) (, ,) (SBAR (IN while) (S (NP (NP (NNS levels)) (PP (IN of) (NP (NN drug4)))) (VP (VBD remained) (ADJP (JJ unchanged)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution))) (PP (IN with) (NP (JJ intranasal) (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (ADJP (RB clinically) (JJ significant)) (JJ adverse) (NNS interactions)) (PP (IN with) (NP (NP (ADJP (RB commonly) (VBN used)) (JJ preanesthetic) (NNS drugs)) (, ,) (CC or) (NP (NP (NP (NNS drugs)) (VP (VBN used) (PP (IN during) (NP (NN anesthesia))))) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (JJ intravenous) (NNS agents)) (, ,) (CC and) (NP (JJ local) (NN drug2))) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN reported) (PP (IN in) (NP (JJ clinical) (NNS trials)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN disposition)) (PP (IN of) (NP (JJ other) (NNS drugs)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN determined))))) (. .)))
(S1 (S (S (PP (IN Like) (NP (NN drug1))) (, ,) (NP (NN drug2)) (VP (VBZ does) (RB not) (VP (VB predispose) (PP (TO to) (NP (JJ premature) (JJ ventricular) (NNS arrhythmias))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (ADJP (RB exogenously) (VBN infused)) (NN drug3))) (PP (IN in) (NP (NN swine)))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ hepatic) (JJ CYP) (JJ drug-metabolizing) (NNS enzymes))))))))) (, ,) (NP (NP (NP (NNS inducers)) (CC or) (NP (NNS inhibitors))) (PP (IN of) (NP (DT these) (NNS enzymes)))) (VP (MD may) (VP (VB change) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ known) (JJ strong) (NN inhibitor)) (PP (IN of) (NP (NN CYP1A2)))))) (CC and) (S (ADVP (RB also)) (VP (VBZ inhibits) (NP (NP (NN CYP3A4)) (, ,) (NP (NN CYP2C9)) (, ,) (CC and) (NP (NN CYP2C19)))))) (. .)))
(S1 (S (PP (IN In) (NP (DT a) (JJ pharmacokinetic) (NN study))) (, ,) (NP (CD 40) (JJ healthy) (NN female) (NNS subjects)) (VP (VBD received) (NP (NP (NN drug1)) (PP (IN in) (NP (NP (JJ escalating) (NNS doses)) (PP (IN from) (NP (NP (QP (CD 50) (TO to) (CD 200)) (NN mg)) (PP (IN per) (NP (NN day))) (PP (IN for) (NP (CD 16) (NNS days)))))))) (, ,) (PP (IN with) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug2) (CD 1) (NN mg)) (PP (IN on) (NP (DT the) (JJ last) (NN day)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBD increased) (NP (NP (JJ mean) (NN drug2) (NN plasma) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (ADVP (RB approximately) (RB 6-fold))) (CC and) (VP (VBD prolonged) (NP (DT the) (NN half-life)) (PP (IN by) (NP (RB approximately) (RB 3-fold)))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ moderate))) (NN CYP1A2) (NNS inhibitors)) (, ,) (PP (VBG including) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (, ,)))) (VP (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated)))) (, ,) (CC but) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN unless) (ADJP (RB clinically) (JJ necessary))) (PP (IN because) (IN of) (NP (JJ similar) (JJ potential) (NN drug) (NNS interactions)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ known) (JJ strong) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT a) (JJ pharmacokinetic) (NN study))) (, ,) (NP (CD 38) (JJ healthy) (JJ female) (NNS subjects)) (VP (VBD received) (NP (NP (NN drug1) (CD 200) (NN mg)) (ADJP (RB twice) (JJ daily) (PP (IN for) (NP (CD 7) (NNS days))))) (, ,) (PP (IN with) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug2) (CD 1) (NN mg)) (PP (IN on) (NP (DT the) (JJ last) (NN day))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD increased) (NP (NP (JJ mean) (NN drug2) (NN plasma) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (IN by) (NP (CD 29) (NN %))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ strong))) (JJ CYP3A4) (NNS inhibitors)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))))))) (VP (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated)))) (CC but) (VP (MD should) (VP (VB be) (VP (VBN undertaken) (PP (IN with) (NP (NN caution))) (PP (IN because) (IN of) (NP (JJ similar) (JJ potential) (NN drug) (NNS interactions)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NP (NN induction)) (CC or) (NP (NN inhibition))) (PP (IN of) (NP (JJ other) (NNS pathways))))) (PP (IN on) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NN drug1)) (CC and) (NP (PRP$ its) (NNS metabolites))))))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (JJ human) (NN liver) (NN microsome) (NNS studies)) (CC and) (NP (DT an) (ADJP (FW in) (FW vivo)) (JJ metabolic) (NN probe) (NN study))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB inhibit) (NP (JJ CYP) (NNS enzymes) (NP (NP (NN 2D6)) (, ,) (NP (NN 3A4)) (, ,) (NP (NN 2C9)) (, ,) (CC or) (NP (NN 2C19)))))))))) (. .)))
(S1 (S (ADVP (FW In) (FW vitro)) (, ,) (PP (IN at) (NP (NP (JJ total) (NN drug) (NNS concentrations)) (ADJP (RB 27-fold) (JJR higher) (PP (IN than) (NP (NP (NN peak) (NN plasma) (NNS concentrations)) (VP (VBN observed) (PP (IN with) (NP (DT the) (JJ 1-mg) (NN dosage))))))))) (, ,) (NP (NN drug1)) (VP (VBD inhibited) (NP (NP (NP (CD CYP) (NNS enzymes) (NN 1A2)) (PRN (-LRB- -LRB-) (NP (CD 60) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NN 2E1)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN %)) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT an) (ADJP (FW in) (FW vivo)) (JJ metabolic) (NN probe) (NN study))) (, ,) (NP (NN drug1)) (VP (VP (VBD did) (RB not) (VP (VB inhibit) (NP (NN CYP2E1)))) (CC but) (VP (VBD did) (VP (VB produce) (NP (NP (ADJP (CD 30) (NN %)) (NN inhibition)) (PP (IN of) (NP (CC both) (NP (NN CYP1A2)) (CC and) (NP (NN N-acetyltransferase))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (VP (RB not) (VBN studied) (PP (IN with) (NP (NN drug1)))))) (, ,) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN N-acetyltransferase)))) (VP (MD may) (VP (VB have) (NP (ADJP (RB clinically) (JJ relevant)) (NNS consequences)) (PP (IN for) (NP (NP (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NN effect)) (PP (IN on) (NP (NN CYP1A2)))) (VP (VBD was) (VP (VBN explored) (ADVP (RB further)) (PP (IN in) (NP (NP (DT a) (JJ clinical) (NN interaction) (NN study)) (PP (IN with) (NP (NN drug1)))))))) (CC and) (S (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN metabolism)))) (VP (VBD was) (VP (VBN observed))))) (. .)))
(S1 (S (S (NP (DT Another) (NN study)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD had) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NN effect)) (PP (IN on) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (DT the) (JJ oral) (NN drug2) (NN drug3)) (CC and) (NP (NP (NNS drug4)) (PRN (-LRB- -LRB-) (NP (NN CYP3A4) (NNS substrates)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (NP (DT A) (JJ clinical) (NN interaction) (NN study)) (VP (VBD was) (ADVP (RB also)) (VP (VBN conducted) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (DT the) (NN CYP3A4) (NN substrate) (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ significant) (NNS effects)) (PP (IN on) (NP (NP (NN drug1) (NN metabolism)) (CC or) (NP (NN QT) (NN interval))))) (VP (VBD were) (VP (VBN noted)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (PP (IN on) (NP (NN monoamine) (NNS oxidases))) (CC and) (PP (IN on) (NP (NP (JJ intestinal) (JJ first) (NN pass)) (ADJP (JJ secondary) (PP (TO to) (NP (JJ high) (JJ intraluminal) (NNS concentrations)))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN examined))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (NP (DT the) (JJ above) (NNS data)) (PP (IN from) (NP (ADJP (ADJP (FW in) (FW vitro)) (CC and) (ADJP (FW in) (FW vivo))) (NNS studies)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unlikely) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD will) (VP (VB inhibit) (NP (NP (DT the) (JJ hepatic) (JJ metabolic) (NN clearance)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NP (DT the) (JJ major) (NN CYP) (NN enzyme) (NN 3A4)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (DT the) (NN CYP) (NNS enzymes) (NN 2D6)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (NP (NN 2E1)) (, ,) (CC or) (NP (NN 1A2))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB induce) (NP (NP (NP (DT the) (JJ major) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NP (NN drug) (NN metabolizing) (NN enzyme) (NN 3A))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB also)) (VP (VBZ does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB induce) (NP (JJ CYP) (NNS enzymes) (NP (NP (NN 2E1)) (CC or) (NP (NN 2C19)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (NN drug1)) (VP (MD might) (VP (VBP induce) (NP (JJ other) (NNS enzymes))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (VP (VBD was) (VP (VBN observed) (S (VP (TO to) (VP (VBP enhance) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NN tissue) (NN culture))) (-RRB- -RRB-)) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (S (VP (VBG reducing) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ human) (NN breast) (NN cancer) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (PP (IN in) (NP (DT the) (NN S) (NN phase))))))))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (: -) (S (SBAR (IN Although) (S (VP (RB not) (VBN reported)))) (, ,) (NP (NP (NN drug3)) (, ,) (PP (IN via) (NP (NP (PRP$ its) (NN metabolism)) (PP (TO to) (NP (NN histamine))))) (, ,)) (VP (MD might) (VP (VB decrease) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (NN drug4)) (CC and) (NP (NN drug5)))))))) (. .))))
(S1 (S (S (VP (MD May) (VP (VB interact) (PP (IN with) (NP (NP (NN skin) (NNS products)) (CC or) (NP (NP (NNS shampoos)) (PP (IN for) (NP (NP (NN dandruff)) (CC or) (NP (NN psoriasis)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJS Most)) (PRN (-LRB- -LRB-) (NP (CD 98) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NN plasma) (NN drug1)))) (VP (VBZ is) (VP (NN protein) (VBN bound)))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS data)) (PP (IN in) (NP (JJ human) (NN plasma)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN protein) (NN binding)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC or) (NP (NN drug5))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (NN information)) (PP (IN on) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ other) (ADJP (RB highly) (NP (NN plasma) (NN protein)) (VBN bound)) (NNS drugs))) (PP (IN on) (NP (NN drug1) (NN binding)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (PP (IN without) (NP (NP (DT any) (NN evidence)) (PP (IN of) (NP (NP (DT an) (JJ adverse) (NN drug) (NN interaction)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2)) (, ,) (NP (NN drug3) (NN s)) (, ,) (CC and) (NP (NN drug4)))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (JJ placebo-controlled) (NN trial)) (PP (IN in) (NP (JJ normal) (NNS volunteers))))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (ADJP (CD 1) (NN mg)) (NN dose)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN on) (NP (NP (NN day) (CD 1)) (PP (IN of) (NP (NP (DT a) (JJ four-day) (NN regimen)) (PP (IN of) (NP (JJ oral) (NN drug2)))))))))) (PRN (-LRB- -LRB-) (NP (NP (CD 400) (NN mg)) (ADVP (RB twice) (RB daily))) (-RRB- -RRB-))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (ADJP (CD 10) (NN %)) (NN increase)) (PP (IN in) (NP (NP (JJ mean) (NN AUC)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN p=0.006)) (-RRB- -RRB-))))))) (, ,) (CC and) (NP (NP (DT a) (ADJP (ADJP (JJ slight)) (CC but) (ADJP (RB not) (RB statistically) (JJ significant))) (NN increase)) (PP (IN in) (NP (NP (NP (JJ mean) (NN Cmax)) (CC and) (NP (JJ mean) (NN half-life))) (PP (IN of) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN increase))) (PP (IN in) (NP (NN drug1) (NN AUC)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (PP (IN In) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NN drug1) (NNS tablets)) (VP (VBP have) (VP (VBN been) (VP (VBN administered) (PP (TO to) (NP (NNS patients))) (PP (IN on) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ concomitant) (NNS medications)))))))) (: ;)))
(S1 (S (S (SBAR (IN while) (S (NP (DT no) (JJ formal) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted)))))) (, ,) (NP (DT no) (NNS interactions)) (VP (VBD were) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS tablets)) (VP (VBP have) (VP (VBN been) (VP (VBN used) (PP (IN with) (NP (NP (DT the) (JJ following) (NNS drugs)) (CC or) (NP (NN drug) (NNS classes)) (: :) (NP (CD 1)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: /) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6)) (NP (NNS combinations)))) (, ,) (NP (NP (NN drug7)) (, ,) (NP (NN drug8))) (-RRB- -RRB-))) (. .))))
(S1 (S (NP (NP (CD 2)) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4)))) (, ,) (NP (NN drug5)) (-RRB- -RRB-))) (. .))))
(S1 (S (NP (NP (CD 3)) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (CD 4))) (. .)))
(S1 (S (S (NP (NP (JJ Cardiovascular) (NNS agents)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)))) (-RRB- -RRB-)))) (. .)))
(S1 (S (NP (NP (CD 5)) (. .))))
(S1 (S (NP (NP (NN drug1)) (. .))))
(S1 (S (NP (NP (CD 6)) (. .))))
(S1 (S (S (NP (NP (JJ Gastrointestinal) (NNS agents)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (-RRB- -RRB-)))) (. .)))
(S1 (S (NP (NP (CD 7)) (. .))))
(S1 (S (NP (NP (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ endocrine))) (NNS drugs)) (. .))))
(S1 (S (NP (NP (CD 8)) (. .))))
(S1 (S (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (. .))))
(S1 (S (NP (NP (CD 9)) (. .))))
(S1 (S (NP (NP (NP (NP (NN Cold)) (CC and) (NP (NN flu))) (NNS remedies)) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ modifies) (NP (NN drug2) (NN metabolism)) (PP (IN with) (NP (NP (VBN increased) (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VP (VB increase)) (CC or) (VP (VB enhance) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NN osteomalacia))) (PP (IN in) (NP (NP (DT some) (NNS patients)) (VP (VBG receiving) (NP (JJ chronic) (NN drug1) (NN therapy)))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN advised) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ chronic) (JJ concomitant) (NN therapy)))))))) (. .)))
(S1 (S (S (PP (IN By) (S (VP (VBG decreasing) (NP (NP (DT the) (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (NN drug1))))))) (, ,) (NP (NN drug2)) (VP (MD may) (VP (VB decrease) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (PRP$ its) (NNS metabolites))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ consequent) (JJ possible) (NN decrease)) (PP (IN in) (NP (JJ anticonvulsant) (NN effect)))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (ADJP (JJ advised)) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG beginning)) (, ,) (VP (VBG discontinuing)) (, ,) (CC or) (VP (VBG changing) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (JJ possible) (JJ additive) (NNS effects)) (PP (IN with) (NP (JJ other) (NN drug1)))))) (, ,) (NP (JJ concomitant) (NN use)) (VP (VBZ is) (RB not) (ADJP (JJ advisable)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ other) (NNS drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VP (VB increase)) (CC or) (VP (VB decrease) (NP (NN blood) (NN glucose) (NNS levels)))))) (. .)))
(S1 (S (S (NP (NN Consideration)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ drug1) (NNS agents))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ decreases) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NN drug2))))) (CC and) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NP (NP (NN magnitude)) (CC and) (NP (NN duration)))) (PP (IN of) (NP (PRP$ their) (NN effect)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ reduces) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NN drug2))))) (CC and) (VP (MD may) (VP (VB enhance) (NP (PRP$ its) (NN effect)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB prevent) (NP (NP (DT the) (JJ urinary) (JJ antiseptic) (NN effect)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ increases) (NP (NN drug2) (NN excretion)))) (CC and) (S (NP (DT the) (NN drug3)) (VP (MD may) (VP (VB be) (VP (VBN decreased)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBN used))) (ADVP (RB concurrently)) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ renal) (NNS calculus) (NN formation)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VBP elevate) (NP (NN drug2) (NNS levels))))) (. .)))
(S1 (S (S (NP (DT The) (NN drug1) (NN test)) (VP (MD should) (VP (VB be) (VP (VBN conducted) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT which)) (S (ADVP (RB directly)) (VP (VBP affect) (NP (NP (DT the) (JJ pituitary) (NN secretion)) (PP (IN of) (NP (DT the) (NNS gonadotropins))))))))))))))) (. .)))
(S1 (S (S (NP (DT These)) (VP (MD would) (VP (VBP include) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNS preparations)) (SBAR (WHNP (WDT which)) (S (VP (VBP contain) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN gonadotropin) (NNS levels)) (VP (MD may) (VP (VB be) (VP (VP (ADVP (RB transiently)) (VBN elevated) (PP (IN by) (NP (NN drug1)))) (, ,) (VP (ADVP (RB minimally)) (VBN elevated) (PP (IN by) (NP (NN drug2)))) (, ,) (CC and) (VP (VBN suppressed) (PP (IN by) (NP (NP (JJ oral) (NN drug3)) (CC and) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN response)) (PP (TO to) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN blunted) (PP (IN by) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (SBAR (WHNP (WDT which)) (S (VP (VBP cause) (NP (NP (DT a) (NN rise)) (PP (IN in) (NP (NN prolactin))))))))))))) (. .)))
(S1 (S (SBAR (IN As) (S (NP (NN drug1) (NN Gel)) (VP (VBZ has) (NP (NP (DT the) (NN potential)) (VP (TO to) (VP (VB produce) (NP (JJ local) (NN irritation)) (PP (IN in) (NP (DT some) (NNS patients))))))))) (, ,) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (JJ other) (ADJP (RB potentially) (JJ irritating)) (JJ topical) (NNS products)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (ADJP (ADJP (JJ medicated)) (CC or) (ADJP (JJ abrasive))) (NP (NP (NNS soaps)) (CC and) (NP (NNS cleansers)))) (, ,) (NP (NP (NP (NNS soaps)) (CC and) (NP (NNS cosmetics))) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (DT a) (JJ strong) (NN drying) (NN effect)))))) (, ,) (CC and) (NP (NNS products))) (PP (IN with) (NP (NP (JJ high) (NNS concentrations)) (PP (IN of) (NP (NN alcohol)))))) (, ,) (NP (NNS astringents)) (, ,) (NP (NNS spices)) (CC or) (NP (NN lime))) (-RRB- -RRB-))))) (VP (MD should) (VP (VB be) (VP (VBN approached) (PP (IN with) (NP (NN caution)))))) (. .)))
(S1 (S (S (NP (JJ Particular) (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (PP (IN in) (S (VP (VBG using) (NP (NP (NNS preparations)) (VP (VBG containing) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC or) (NP (NN drug3))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug4) (NN Gel)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT these) (NNS preparations)) (VP (VBP have) (VP (VBN been) (VP (VBN used)))))) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ advisable) (PP (RB not) (TO to) (NP (NP (NN start) (NN therapy)) (PP (IN with) (NP (NN drug1) (NN Gel)))))) (SBAR (IN until) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ such) (NNS preparations))) (PP (IN in) (NP (DT the) (NN skin)))) (VP (VBP have) (VP (VBN subsided))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (DT no) (JJ formal) (JJ clinical) (NNS studies)) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN drug) (NNS interactions)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NNS medications)))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN modified) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NNS compounds)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP induce)) (, ,) (VP (VBP inhibit)) (, ,) (CC or) (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (NN cytochrome) (NN P450) (NN 3A4)))))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)))))))))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (PP (IN with) (NP (DT these) (NNS drugs))) (SBAR (WHADVP (WRB when)) (S (VP (VBG treating) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1) (SBAR (IN as) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (NN potential)) (PP (IN for) (NP (DT a) (JJ significant) (NN interaction))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ accelerates) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2)))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (SBAR (IN if) (S (NP (NN drug1) (NN replacement)) (VP (VBZ is) (VP (VBN needed))))) (, ,) (NP (NN drug2)) (VP (MD should) (VP (VB be) (VP (VBN prescribed))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ diminishes) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (: :) (S (VP (VBP Experience) (PP (IN in) (NP (QP (IN over) (CD 1400)) (NNS patients))) (PP (IN in) (NP (DT a) (JJ non-comparative) (JJ clinical) (NN trial)))))) (VP (VBZ has) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ is) (ADVP (RB usually)) (VP (ADVP (RB well)) (VBN tolerated)))))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ occasional) (NN literature) (NNS reports)) (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT the) (NN combination)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (NP (JJ severe) (NN hypotension)) (CC or) (NP (NP (NN exacerbation)) (PP (IN of) (NP (NN angina))))))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Long) (NN Acting) (NN drug1)) (: :) (S (S (NP (NN drug2)) (VP (MD may) (VP (VB be) (ADVP (RB safely)) (VP (VBN co-administered) (PP (IN with) (NP (NN drug3))))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (DT no) (JJ controlled) (NNS studies)) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ antianginal) (NN effectiveness)) (PP (IN of) (NP (DT this) (NN combination))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1) (: :) (NP (JJ Immediate) (NN Release) (NNS Capsules))) (: :) (S (SBAR (IN Since) (S (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (VBN isolated) (NNS reports)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ elevated) (NN drug2) (NNS levels))))))))) (, ,) (CC and) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ possible) (NN interaction)) (PP (IN between) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug5) (NNS levels)) (VP (VB be) (VP (VBN monitored) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG initiating)) (, ,) (VP (VBG adjusting)) (, ,) (CC and) (VP (VBG discontinuing) (NP (NN drug6)) (S (VP (TO to) (VP (VB avoid) (NP (NP (JJ possible) (NN over-)) (CC or) (NP (NN under-digitalization))))))))))))))))) (. .))))
(S1 (S (NP (NP (JJ Extended) (NN Release) (NNS Tablets)) (: :) (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBD increased) (NP (NN drug3) (NNS levels)) (PP (IN in) (NP (NP (CD 9)) (PP (IN of) (NP (CD 12) (JJ normal) (NNS volunteers))))))) (. .))))
(S1 (S (S (NP (DT The) (JJ average) (NN increase)) (VP (VBD was) (NP (CD 45) (NN %)))) (. .)))
(S1 (S (S (NP (DT Another) (NN investigator)) (VP (VBD found) (NP (NP (DT no) (NN increase)) (PP (IN in) (NP (NP (NN drug1) (NNS levels)) (PP (IN in) (NP (NP (CD 13) (NNS patients)) (PP (IN with) (NP (JJ coronary) (NN artery) (NN disease)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT an) (JJ uncontrolled) (NN study)) (PP (IN of) (NP (NP (QP (IN over) (CD 200)) (NNS patients)) (PP (IN with) (NP (JJ congestive) (NN heart) (NN failure))) (SBAR (WHPP (IN during) (WHNP (WDT which))) (S (NP (NN drug1) (NN blood) (NNS levels)) (VP (VBD were) (RB not) (VP (VBN measured))))))))) (, ,) (NP (NN digitalis) (NN toxicity)) (VP (VBD was) (RB not) (VP (VBN observed)))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (VBN isolated) (NNS reports)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ elevated) (NN drug1) (NNS levels)))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug2) (NNS levels)) (VP (VB be) (VP (VBN monitored) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG initiating)) (, ,) (VP (VBG adjusting)) (, ,) (CC and) (VP (VBG discontinuing) (NP (NN drug3)) (S (VP (TO to) (VP (VB avoid) (NP (NP (JJ possible) (NN over-)) (CC or) (NP (NN under-digitalization))))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1) (: :) (NP (JJ Immediate) (NN Release) (NNS Capsules))) (: :) (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ rare) (NNS reports)) (PP (IN of) (NP (NP (DT an) (NN interaction)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (-LRB- -LRB-) (PP (IN with) (NP (NP (DT a) (VBN decreased) (NN plasma) (NN level)) (PP (IN of) (NP (NN drug4))))) (-RRB- -RRB-))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ rare) (NNS reports)) (PP (IN of) (NP (VBN increased) (NN prothrombin) (NN time))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NN drug2)) (SBAR (WHPP (TO to) (WHNP (WP whom))) (S (NP (NN drug3)) (VP (VBD was) (VP (VBN administered))))))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN relationship)) (PP (TO to) (NP (NN drug1) (NN therapy)))) (VP (VBZ is) (ADJP (JJ uncertain)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT A) (NN study)) (PP (IN in) (NP (CD 6) (JJ healthy) (NNS volunteers)))) (VP (VBZ has) (VP (VBN shown) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NP (NN peak) (NN drug2) (NN plasma) (NNS levels)) (PRN (-LRB- -LRB-) (NP (CD 80) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ area-under-the-curve)) (PRN (-LRB- -LRB-) (NP (CD 74) (NN %)) (-RRB- -RRB-)))))) (PP (IN after) (NP (NP (DT a) (CD 1) (NN week) (NN course)) (PP (IN of) (NP (NP (NN drug3)) (PP (IN at) (NP (NP (CD 1000) (NN mg)) (PP (IN per) (NP (NP (NN day)) (CC and) (NP (NN drug4)))) (PP (IN at) (NP (NP (CD 40) (NN mg)) (PP (IN per) (NP (NN day)))))))))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBD produced) (NP (ADJP (ADJP (JJR smaller)) (, ,) (ADJP (JJ non-significant))) (NNS increases)))) (. .)))
(S1 (S (S (NP (DT The) (NN effect)) (VP (MD may) (VP (VB be) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (JJ known) (NN inhibition)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (JJ hepatic) (NN cytochrome) (NN P-450)) (, ,) (NP (NP (DT the) (NN enzyme) (NN system)) (ADJP (ADVP (RB probably)) (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN first-pass) (NN metabolism)) (PP (IN of) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1) (NN therapy)) (VP (VBZ is) (VP (VBN initiated) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (ADVP (RB currently)) (VBG receiving) (NP (NN drug2))))))))) (, ,) (NP (JJ cautious) (NN titration)) (VP (VBZ is) (VP (VBN advised)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN by) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ serious) (NN reaction))) (PP (TO to) (NP (NP (DT any) (NNS drug2)) (, ,) (PP (VBG including) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB together)) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (, ,) (NP (DT another) (NN arthritis) (NN medication)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (MD should) (ADVP (RB also)) (VP (VB be) (VP (VBN avoided) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN blood)) (, ,) (NP (NN liver)) (CC or) (NP (NN kidney) (NNS diseases)) (, ,) (NP (JJ recent) (NN radiation) (NN treatment)) (, ,) (CC or) (NP (JJ uncontrolled) (NN diabetes)))))))))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (MD should) (VP (VBP report) (PP (TO to) (NP (NP (PRP$ their) (NNS practitioners)) (NP (NP (DT any) (JJ new) (NN rashes)) (, ,) (NP (NN itching)) (, ,) (NP (NN mouth) (NNS sores)) (, ,) (CC or) (NP (JJ unusual) (NN taste)))))) (SBAR (IN while) (S (VP (VBG taking) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN excreted) (ADVP (RB slowly)) (PP (IN from) (NP (DT the) (NN body)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Safety)) (CC and) (NP (NN effectiveness))) (PP (IN in) (NP (NNS children)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN potential)) (PP (IN for) (NP (NP (NN drug) (NNS interactions)) (PP (IN with) (NP (NN drug1)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))))))))) (. .)))
(S1 (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NN drug) (NNS interactions)) (PP (IN for) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (NNS drugs)))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (VP (MD May) (VP (VB interact) (PP (IN with) (NP (NP (JJ addictive) (NNS medications)) (, ,) (ADVP (RB especially)) (NP (NN drug1)))) (PP (IN with) (NP (NP (NP (JJ habituating) (NN potential)) (PRN (-LRB- -LRB-) (S (NP (JJ prolonged) (JJ concurrent) (NN use)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN habituation))))))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN drug2)) (CC or) (NP (NN CNS) (NN depression))) (VP (VBG producing) (NP (NP (NNS medications)) (PRN (-LRB- -LRB-) (S (NP (JJ concurrent) (NN use)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN CNS) (NN depressant) (NNS effects)) (PP (IN of) (NP (CC either) (DT these) (NP (NNS medications)) (CC or) (NP (NNS drug3)))))))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ potentiates) (NP (NP (JJ other) (NNS drug2)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC or) (NP (NP (NN drug4)) (CC and) (NP (NN drug5)) (NP (NN s)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG undergoing) (NP (JJ systemic) (NN anticholinesterase) (NN treatment)))) (VP (MD should) (VP (VB be) (VP (VBN warned) (PP (IN of) (NP (NP (DT the) (JJ possible) (JJ additive) (NNS effects)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (JJ Renal) (NN function)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB carefully)) (SBAR (IN if) (S (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (S (VP (TO to) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN drug2))) (PP (IN because) (IN of) (NP (NP (DT the) (VBN increased) (NN potential)) (PP (IN of) (NP (NP (NP (NN nephrotoxicity)) (CC and) (NP (NN ototoxicity))) (PP (IN of) (NP (NN drug3)))))))))))))))))) (. .)))
(S1 (S (S (NP (NN Nephrotoxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (VBG following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (JJ other) (NN drug1))) (PP (IN with) (NP (NP (JJ potent) (NNS drug2)) (PP (JJ such) (IN as) (NP (NN drug3))))))))))) (. .)))
(S1 (S (NP (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (DT the) (NN urine))))) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (NN Clinitest) (NNS tablets)))))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (NN glucose) (NNS tests)) (VP (VBN based) (PP (IN on) (NP (NP (JJ enzymatic) (NN glucose) (NN oxidase) (NNS reactions)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN Clinistix)) (CC or) (NP (NN Tes-Tape))))) (-RRB- -RRB-)))))) (VP (VB be) (VP (VBN used)))))))) (. .)))
(S1 (S (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (DT no) (JJ formal) (NNS studies)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN for) (NP (NP (JJ Topical) (NN Solution)) (PP (IN with) (NP (DT any) (JJ other) (NNS drugs))))))))))))) (, ,) (CC and) (S (NP (DT no) (JJ drug-specific) (NNS interactions)) (VP (VBD were) (VP (VBN noted) (PP (IN during) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ controlled) (JJ clinical) (NNS trials))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (, ,) (ADVP (RB however)) (, ,) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (JJ other) (JJ known) (NN drug1))) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (CC and) (NP (NN drug7))))) (VP (MD might) (VP (VB increase) (NP (NP (DT the) (NN photosensitivity) (NN reaction)) (PP (IN of) (NP (NP (JJ actinic) (NNS keratoses)) (VP (VBN treated) (PP (IN with) (NP (DT the) (NN drug8))) (PP (IN for) (NP (JJ Topical) (NN Solution))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (TO to) (NP (NN drug2))) (PP (IN by) (NP (NN cytochrome) (NN CYP) (NN 3A4)))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (NN CYP) (NN 3A4) (NNS inhibitors)) (VP (MD may) (VP (VB increase) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))))))) (, ,) (NP (NNS patients)) (ADVP (RB already)) (PP (IN on) (NP (NP (NN CYP) (NN 3A4) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.)))))))))
(S1 (S (NP (NP (NN drug1) (-RRB- -RRB-)) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (NP (NP (NN drug5)) (, ,) (NP (NN drug6)) (CC and) (NP (NN drug7))) (-RRB- -RRB-)))) (VP (MD should) (VP (VB have) (NP (NP (PRP$ their) (NN dose)) (PP (IN of) (NP (NP (NP (NN drug8)) (CC or) (NP (NN drug9))) (VP (VBN adjusted))))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (JJ anecdotal) (NNS reports)))) (, ,) (NP (EX there)) (VP (MD may) (VP (VB be) (NP (NP (DT an) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NNS reports)) (PP (IN in) (NP (NP (DT the) (JJ post-marketing) (VBP experience)) (PP (IN of) (NP (NP (NP (NN coma)) (CC and) (NP (NN death))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ concomitant) (JJ intravenous) (NN misuse)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN by) (NP (NNS addicts)))))))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ many)) (PP (IN of) (NP (DT these) (NNS cases))))) (, ,) (NP (NN drug1)) (VP (VBD was) (ADJP (JJ misused) (PP (IN by) (NP (NP (NN self-injection)) (PP (IN of) (NP (JJ crushed) (NN drug2) (NNS tablets)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD should) (VP (VB be) (VP (VBN prescribed) (PP (IN with) (NP (NP (NN caution)) (PP (TO to) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (NN drug3)) (CC or) (NP (JJ other) (NNS drugs)))) (SBAR (WHNP (WDT that)) (S (VP (VBP act) (PP (IN on) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))))))) (, ,) (ADVP (RB regardless) (PP (IN of) (SBAR (IN whether) (S (NP (DT these) (NNS drugs)) (VP (VP (VBP are) (VP (VBN taken) (PP (IN on) (NP (NP (DT the) (NN advice)) (PP (IN of) (NP (DT a) (NN physician))))))) (CC or) (VP (VBP are) (VP (VBN taken) (PP (IN as) (NP (NP (NNS drugs)) (PP (IN of) (NP (NN abuse)))))))))))))))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (MD should) (VP (VB be) (VP (VBN warned) (PP (IN of) (NP (NP (DT the) (JJ potential) (NN danger)) (PP (IN of) (NP (NP (DT the) (JJ intravenous) (NN self-administration)) (PP (IN of) (NP (NN drug1))))))) (PP (IN while) (PP (IN under) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB produce) (NP (JJ ANTABUSE-like) (JJ side) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN physician)) (VP (VBZ is) (VP (VBN advised) (S (VP (VP (TO to) (VP (VB monitor) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))))) (CC and) (VP (TO to) (VP (VB decrease) (NP (DT the) (NN dose) (SBAR (IN if) (FRAG (JJ necessary))))))))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (NN prolongation)) (PP (IN of) (NP (NP (DT the) (NN prothrombin) (NN time)) (PP (IN beyond) (NP (NP (DT the) (JJ therapeutic) (NN range)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (JJ concurrent) (NN drug1)) (CC and) (NP (NN drug2))))))))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN suggested) (SBAR (IN that) (S (S (NP (DT the) (NN prothrombin) (NN time)) (VP (VB be) (VP (VBN monitored) (ADVP (RB carefully))))) (, ,) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (NN drug3)) (CC or) (NP (JJ other) (NN drug4) (JJ -like) (NNS drugs))))) (VP (MD should) (VP (VB be) (VP (VBN adjusted) (ADVP (RB accordingly)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (DT both) (NNS drugs)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (, ,) (NP (DT a) (JJ moderate) (NN inhibitor)) (, ,) (CC and) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (NN CYP3A4))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB also)) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (NN CYP2C9)))))) (. .)))
(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (JJ other) (NNS agents))))))))
(S1 (S (S (PP (IN As) (NP (NP (DT a) (JJ moderate) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4))))) (, ,) (NP (NN drug1)) (VP (MD can) (VP (VB increase) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (JJ coadministered) (NN medicinal) (NNS products)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN through) (NP (NN CYP3A4))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB induce) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN through) (NP (NN CYP2C9))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NP (DT these) (NP (NNS drugs)) (CC or) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP2C9)))))))))))) (, ,) (PP (JJ such) (IN as) (NP (NN drug2))) (, ,)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJR lower) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (DT these) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN for) (NP (DT the) (NN P-glycoprotein) (NN transporter)))) (, ,) (SBAR (IN as) (S (VP (VBN demonstrated) (PP (IN by) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NP (NN interaction)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3))))) (PP (IN in) (NP (DT a) (JJ clinical) (NN drug) (NN interaction) (NN study))))))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (JJ clinical) (NN drug) (NN interaction) (NNS studies))) (, ,) (NP (NN drug2)) (VP (VBD did) (RB not) (VP (VB have) (NP (ADJP (RB clinically) (JJ important)) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug3)) (CC or) (NP (NN drug4))))))))) (. .))))
(S1 (S (S (NP (DT No) (JJ clinical) (NN or) (NN drug) (NN interaction) (NN study)) (VP (VBD was) (VP (VBN conducted) (PP (IN with) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)) (: :) (NP (NP (NN drug3)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN as) (NP (NP (DT a) (NN regimen)) (PP (IN of) (NP (NP (NN 125mg)) (PP (IN with) (NP (NP (NN drug4)) (VP (VBN coadministered) (ADVP (RB orally)) (PP (IN as) (NP (NP (CD 20) (NN mg)) (PP (IN on) (NP (NN Day) (CD 1))))))))))))))) (, ,)) (CC and) (NP (NN drug5))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN as) (NP (CD 80) (NN mg/day))) (PP (IN with) (NP (NP (NN drug6)) (VP (VBN coadministered) (ADVP (RB orally)) (PP (IN as) (NP (NP (CD 8) (NN mg)) (PP (IN on) (NP (NNS Days) (QP (CD 2) (IN through) (CD 5)))))))))))) (, ,) (VP (VBD increased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NP (NN drug7)) (, ,) (NP (NP (DT a) (NN CYP3A4) (NN substrate)) (PP (IN by) (NP (NN 2.2-fold)))) (, ,)))) (PP (IN on) (NP (NNS Days) (CD 1) (CC and) (CD 5))))) (. .)))
(S1 (S (S (NP (DT The) (JJ oral) (NN drug1) (NNS doses)) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (QP (RB approximately) (CD 50)) (NN %))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug2))) (, ,) (S (VP (TO to) (VP (VB achieve) (NP (NP (NNS exposures)) (PP (IN of) (NP (NN drug3))) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN obtained) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN given) (PP (IN without) (NP (NN drug4)))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ daily) (NN dose)) (PP (IN of) (NP (NN drug1))) (VP (VBN administered) (PP (IN in) (NP (NP (JJ clinical) (NNS studies)) (PP (IN with) (NP (NN drug2))))))) (VP (VBZ reflects) (NP (NP (DT an) (JJ approximate) (ADJP (CD 50) (NN %)) (NN reduction)) (PP (IN of) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NP (NN drug1)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN as) (NP (NP (DT a) (NN regimen)) (PP (IN of) (NP (CD 125) (NN mg))))) (PP (IN on) (NP (NP (NP (NN Day) (CD 1)) (CC and) (NP (CD 80) (NN mg/day))) (PP (IN on) (NP (NNS Days) (CD 2) (CC and) (CD 3)))))))) (, ,)) (VP (VBD increased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (DT a) (NN CYP3A4) (NN substrate)) (, ,)))) (PP (IN by) (NP (NP (JJ 1.34-fold)) (PP (PP (IN on) (NP (NN Day) (CD 1))) (CC and) (PP (IN by) (NP (NP (RB 2.5-fold)) (PP (IN on) (NP (NP (NN Day) (CD 3)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBD was) (VP (VBN coadministered) (ADVP (RB intravenously)) (PP (PP (IN as) (NP (NP (CD 125) (NN mg)) (PP (IN on) (NP (NN Day) (CD 1))))) (CC and) (ADVP (RB orally)) (PP (IN as) (NP (NP (CD 40) (NN mg)) (PP (IN on) (NP (NNS Days) (CD 2) (CC and) (CD 3)))))))))))))))))) (. .)))
(S1 (S (S (S (NP (DT The) (NN IV) (NN drug1) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (QP (RB approximately) (CD 25)) (NN %))))))) (, ,) (CC and) (S (NP (DT the) (JJ oral) (NN drug2) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (QP (RB approximately) (CD 50)) (NN %))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug3))) (S (VP (TO to) (VP (VB achieve) (NP (NP (NNS exposures)) (PP (IN of) (NP (NP (NN drug4)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN obtained) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN given) (PP (IN without) (NP (NN drug5))))))))))))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT A) (JJ single) (NN 125-mg) (NN dose)) (PP (IN of) (NP (NN drug2)))) (VP (VBD was) (VP (VBN administered) (PP (IN on) (NP (NP (NN Day) (CD 1)) (CC and) (NP (NP (CD 80) (NN mg/day)) (PP (IN on) (NP (NNS Days) (CD 2) (CC and) (CD 3))) (PP (TO to) (NP (NP (JJ healthy) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN stabilized) (PP (IN on) (NP (JJ chronic) (NN drug3) (NN therapy))))))))))))))) (. .))))
(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN plasma) (NN AUC)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))) (VP (VBN determined) (PP (IN on) (NP (NN Day) (CD 3)))))))))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (ADJP (CD 34) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (DT a) (NN CYP2C9) (NN substrate)) (-RRB- -RRB-))) (NN trough) (NN concentration)) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (ADJP (CD 14) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (NP (DT the) (NN prothrombin) (NN time)) (PRN (-LRB- -LRB-) (VP (VBN reported) (PP (IN as) (NP (NP (NP (NNP International)) (VBN Normalized) (NN Ratio)) (CC or) (NP (NN INR))))) (-RRB- -RRB-))) (NP (NP (CD 5) (NNS days)) (PP (IN after) (NP (NP (NN completion)) (PP (IN of) (NP (NP (NN dosing)) (PP (IN with) (NP (NN drug5))))))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ chronic) (NN drug1) (NN therapy))))) (, ,) (NP (NP (DT the) (NN prothrombin) (NN time)) (PRN (-LRB- -LRB-) (NP (NN INR)) (-RRB- -RRB-))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored) (PP (IN in) (NP (DT the) (JJ 2-week) (NN period))) (, ,) (PP (ADVP (RB particularly)) (IN at) (NP (QP (CD 7) (TO to) (CD 10)) (NNS days))) (, ,) (PP (VBG following) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (DT the) (JJ 3-day) (NN regimen)) (PP (IN of) (NP (NN drug2))))) (PP (IN with) (NP (DT each) (NN chemotherapy) (NN cycle)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN as) (NP (NP (CD 125) (NN mg)) (PP (PP (IN on) (NP (NP (NP (NP (NN Day) (CD 1)) (CC and) (NP (CD 80) (NN mg/day))) (PP (IN on) (NP (NNS Days) (CD 2) (CC and) (CD 3))) (, ,) (VP (VBD decreased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (DT a) (NN CYP2C9) (NN substrate)) (-RRB- -RRB-))))) (PP (IN by) (NP (NP (NP (NP (CD 23) (NN %)) (PP (IN on) (NP (NN Day) (CD 4)))) (, ,) (NP (NP (CD 28) (NN %)) (PP (IN on) (NP (NN Day) (CD 8)))) (, ,) (CC and) (NP (CD 15) (NN %))) (PP (IN on) (NP (NN Day) (CD 15))))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug4) (CD 500) (NN mg)))) (VP (VBD was) (NP (NNS admini)))))) (, ,) (JJ stered)) (ADJP (RB orally) (JJ prior) (PP (TO to) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (DT the) (JJ 3-day) (NN regimen)) (PP (IN of) (NP (NN drug5)))))))))) (CC and) (PP (IN on) (NP (NNS Days) (NP (NN 4,8)) (, ,) (CC and) (NP (CD 15))))))))))) (. .))))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (NP (NN drug2)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB once) (RB daily)) (PP (IN for) (NP (CD 14) (NNS days))) (PP (IN as) (NP (NP (DT a) (JJ 100-mg) (NN capsule)) (PP (IN with) (NP (NP (DT an) (JJ oral) (NN drug3)) (VP (VBG containing) (NP (NP (NP (CD 35) (NN mcg)) (PP (IN of) (NP (NN drug4)))) (CC and) (NP (NP (CD 1) (NN mg)) (PP (IN of) (NP (NN drug5))))))))))))) (, ,) (VP (VP (VBD decreased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug6)))) (PP (IN by) (NP (CD 43) (NN %)))) (, ,) (CC and) (VP (VBD decreased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug7)))) (PP (IN by) (NP (CD 8) (NN %)))))) (: ;))))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (JJ oral) (NN drug1))) (PP (IN during) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug2)))))) (VP (MD may) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT a) (JJ 3-day) (NN regimen)) (PP (IN of) (NP (NN drug1))) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ oral) (NN drug2))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied)))))) (, ,) (NP (NP (ADJP (ADJP (JJ alternative)) (CC or) (ADJP (JJ back-up))) (NNS methods)) (PP (IN of) (NP (NN contraception)))) (VP (MD should) (VP (VB be) (VP (VBN used))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBD increased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (DT a) (JJ sensitive) (NN CYP3A4) (NN substrate)) (, ,)))) (PP (IN by) (NP (NN 2.3-fold))) (PP (PP (IN on) (NP (NN Day) (CD 1))) (CC and) (RB 3.3-fold) (PP (IN on) (NP (NN Day) (CD 5)))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (NN drug4) (CD 2) (NN mg)))) (VP (VBD was) (VP (VBN coadministered) (PP (IN on) (NP (NP (NP (NN Day) (CD 1)) (CC and) (NP (NN Day) (CD 5))) (PP (IN of) (NP (NP (DT a) (NN regimen)) (PP (IN of) (NP (NP (NN drug5) (CD 125) (NN mg)) (PP (IN on) (NP (NP (NP (NN Day) (CD 1)) (CC and) (NP (CD 80) (NN mg/day))) (PP (IN on) (NP (NNS Days) (QP (CD 2) (IN through) (CD 5)))))))))))))))))) (. .))))
(S1 (S (NP (NP (DT The) (JJ potential) (NNS effects)) (PP (IN of) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ drug1)) (CC or) (ADJP (JJ other))) (NNS drug2)) (VP (VBN metabolized) (PP (IN via) (NP (NP (NN CYP3A4)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-)))))))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (VP (VBG coadministering) (NP (DT these) (NNS agents)) (PP (IN with) (NP (NN drug5))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT another) (NN study)) (PP (IN with) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NN drug1))))))) (, ,) (S (S (NP (NN drug2)) (VP (VBD was) (VP (VBN given) (PP (IN as) (NP (NP (NP (CD 125) (NN mg)) (PP (IN on) (NP (NN Day) (CD 1)))) (CC and) (NP (CD 80) (NN mg/day)))) (PP (IN on) (NP (NNS Days) (CD 2) (CC and) (CD 3)))))) (, ,) (CC and) (S (NP (NN drug3) (CD 2) (NN mg) (CD IV)) (VP (VBD was) (VP (VBN given) (PP (JJ prior) (TO to) (NP (NP (DT the) (NN administration)) (PP (PP (IN of) (NP (NP (DT the) (JJ 3-day) (NN regimen)) (PP (IN of) (NP (NN drug4))))) (CC and) (PP (IN on) (NP (NNS Days) (QP (CD 4) (, ,) (CD 8) (, ,) (CC and) (CD 15))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBD increased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (NP (CD 25) (NN %)) (PP (IN on) (NP (NN Day) (CD 4)))))) (CC and) (VP (VBD decreased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug3)))) (PP (IN by) (NP (NP (CD 19) (NN %)) (PP (IN on) (NP (NN Day) (CD 8) (ADJP (JJ relative) (PP (TO to) (NP (NP (DT the) (NN dosing)) (PP (IN of) (NP (NP (NN drug4)) (PP (IN on) (NP (NNS Days) (QP (CD 1) (IN through) (CD 3)))))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (VBD were) (RB not) (VP (VBN considered) (S (ADJP (RB clinically) (JJ important)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN AUC)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN Day) (CD 15)))) (VP (VBD was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN observed) (PP (IN at) (NP (NN baseline))))))))) (. .)))
(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (JJ other) (NNS agents))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinefics)) (PP (IN of) (NP (NN drug1))))))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NN CYP3A4)))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN CYP3A4) (NN activity)))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ strong) (JJ CYP3A4) (NNS inhibitors)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)))) (-RRB- -RRB-))))) (VP (MD should) (VP (VB be) (VP (VBN approached) (PP (IN with) (NP (NN caution))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NP (JJ moderate) (JJ CYP3A4) (NNS inhibitors)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (-RRB- -RRB-))) (VP (VBP result) (PP (IN in) (NP (NP (JJ 2-fold) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))))))))) (, ,) (NP (JJ concomitant) (NN administration)) (VP (MD should) (ADVP (RB also)) (VP (VB be) (VP (VBN approached) (PP (IN with) (NP (NN caution))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NN CYP3A4)))))) (: ;)))
(S1 (S (ADVP (RB therefore)) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (ADVP (RB strongly)) (VP (VBP induce) (NP (NP (NN CYP3A4) (NN activity)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN reduced) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug5))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN decreased) (NN efficacy)) (PP (IN of) (NP (NN drug6))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1) (: :)) (SBAR (WHADVP (WRB When)) (S (NP (NP (DT a) (JJ single) (NN 125-mg) (NN dose)) (PP (IN of) (NP (NN drug2)))) (VP (VBD was) (VP (VBN administered) (PP (IN on) (NP (NP (NN Day5)) (PP (IN of) (NP (NN a))))))))))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT a) (JJ single) (NN 125-mg) (NN dose)) (PP (IN of) (NP (NN drug2)))) (VP (VBD was) (VP (VBN administered) (PP (IN on) (NP (NP (NN Day5)) (PP (IN of) (NP (NP (DT a) (JJ 10-day) (NN regimen)) (PP (IN of) (NP (NP (CD 400) (NN mg/day)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (DT a) (JJ strong) (NN CYP3A4) (NN inhibitor)))))))))))))) (, ,) (S (S (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug4)))) (VP (VBD increased) (ADVP (RB approximately) (RB 5-fold)))) (CC and) (S (NP (NP (DT the) (JJ mean) (JJ terminal) (NN half-life)) (PP (IN of) (NP (NN drug5)))) (VP (VBD increased) (ADVP (RB approximately) (RB 3-fold)))))) (. .))))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ strong) (JJ CYP3A4) (NNS inhibitors)))) (VP (MD should) (VP (VB be) (VP (VBN approached) (ADVP (RB cautiously)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT a) (JJ single) (JJ 375-mg) (NN dose)) (PP (IN of) (NP (NN drug2)))) (VP (VBD was) (VP (VBN administered) (PP (IN on) (NP (NP (NN Day9)) (PP (IN of) (NP (NP (DT a) (JJ 14-day) (NN regimen)) (PP (IN of) (NP (NP (CD 600) (NN mg/day)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (DT a) (JJ strong) (NN CYP3A4) (NN inducer)))))))))))))) (, ,) (S (S (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug4)))) (VP (VBD decreased) (ADVP (RB approximately) (RB 11-fold)))) (CC and) (S (NP (DT the) (JJ mean) (JJ terminal) (NN half-life)) (VP (VBD decreased) (ADVP (RB approximately) (RB 3-fold)))))) (. .))))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NN CYP3A4) (NN activity)))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN reduced) (NN plasma) (NNS concentrations)) (CC and) (NP (NP (VBN decreased) (NN efficacy)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (JJ Additional) (NNS interactions))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (JJ mild) (TO to) (JJ moderate)) (NN hypertension))))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNS drug2)) (ADJP (RB once) (JJ daily)) (, ,) (PP (IN as) (NP (NP (DT a) (NN tablet) (NN formulation)) (ADJP (JJ comparable) (PP (TO to) (NP (NP (CD 230) (NN mg)) (PP (IN of) (NP (DT the) (JJ capsule) (NN formulation))))))))))) (, ,) (PP (IN with) (NP (NP (NN drug3) (CD 120) (NN mg) (CD 3) (NNS times)) (ADJP (JJ daily) (PP (IN for) (NP (CD 5) (NNS days)))))) (, ,) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (JJ 2-fold) (NN increase)) (PP (IN of) (NP (NN drug4) (NN AUC)))) (CC and) (NP (NP (DT a) (JJ simultaneous) (JJ 1.7-fold) (NN increase)) (PP (IN of) (NP (NN drug5) (NN AUC)))))))) (. .))))
(S1 (S (S (NP (DT These) (JJ pharmacokinetic) (NNS effects)) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (ADJP (RB clinically) (JJ meaningful)) (NNS changes)) (PP (IN in) (NP (NP (NN ECG)) (, ,) (NP (NN heart) (NN rate)) (CC or) (NP (NN blood) (NN pressure)))))) (PP (IN beyond) (NP (NP (DT those) (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (NP (NN drug1)) (ADVP (RB alone)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (ADJP (RB once) (JJ daily)) (NNS doses)) (PP (IN of) (NP (NN drug2))))) (, ,) (PP (IN as) (NP (NP (DT a) (NN tablet) (NN formulation)) (ADJP (JJ comparable) (PP (TO to) (NP (NP (NP (CD 85) (NN mg)) (CC or) (NP (CD 170) (NN mg))) (PP (IN of) (NP (DT the) (JJ capsule) (NN formulation)))))))) (, ,) (PP (IN with) (NP (NP (NN drug3) (CD 20) (NN mg)) (ADJP (RB once) (JJ daily)))) (, ,)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NP (NN AUC)) (PP (IN by) (NP (QP (RB approximately) (CD 25)) (NN %)))) (CC and) (NP (NN Cmax)))))) (, ,) (PP (IN by) (NP (NP (QP (RB approximately) (CD 20)) (NN %)) (PP (IN of) (NP (CC both) (NP (NN drug4)) (CC and) (NP (NN drug5)))))))) (. .))))
(S1 (S (NP (NP (DT No) (NN information)) (VP (VBN provided)))))
(S1 (S (NP (NP (NP (NP (NNS Interactions)) (PP (IN for) (NP (NN drug1)))) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))) (-RRB- -RRB-))) (: :) (NP (NP (NN drug6)) (: :) (S (NP (NN drug7)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NN drug8)))))))))))) (: ;))))
(S1 (S (S (PP (IN as) (NP (JJ such))) (NP (PRP it)) (VP (MD may) (VP (VB impair) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))))) (VP (MD will) (RB not) (VP (VB affect) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug5))))) (, ,) (CC but) (VP (MD may) (VP (VB reduce) (NP (NP (JJ endogenous) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug6) (NN /ergocalcitriol)))) (PP (IN by) (S (VP (VBG accelerating) (NP (NN metabolism))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (NN blood) (NN level)) (PP (IN of) (NP (NN drug1) (NN /ergocalcitriol)))) (VP (MD will) (VP (VB be) (VP (VBN reduced)))))) (, ,) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary)) (SBAR (IN if) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (ADVP (RB simultaneously))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NN hypercalcemia)) (PP (IN by) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NN drug3) (NN excretion))) (PP (IN in) (NP (NN urine))))))))))) (. .)))
(S1 (S (S (NP (DT Some) (NNS reports)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ causes) (NP (NN hypercalcemia)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN precaution)) (VP (MD should) (VP (VB be) (VP (VBN taken) (SBAR (WHADVP (WRB when)) (S (NP (NN coadministration)) (VP (VBZ is) (ADJP (JJ necessary))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2) (NN dosage)) (VP (MD must) (VP (VB be) (VP (VBN determined) (PP (IN with) (NP (NN care))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug3))))))) (, ,) (SBAR (IN as) (S (NP (NP (NN hypercalcemia)) (PP (IN in) (NP (JJ such) (NNS patients)))) (VP (MD may) (VP (VB precipitate) (NP (JJ cardiac) (NN arrhythmias)))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (VP (VB inhibit) (NP (NP (ADJP (CC both) (ADJP (JJ synthetic)) (CC and) (ADJP (JJ catabolic))) (NNS enzymes)) (PP (IN of) (NP (NN drug3))))))) (. .))))
(S1 (S (S (NP (NP (NNS Reductions)) (PP (IN in) (NP (NN serum) (NP (JJ endogenous) (NN vitamin) (NN D)) (NNS concentrations)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (CD 300) (NN mg/day))) (PP (TO to) (NP (NP (ADJP (CD 1200) (NN mg/day)) (NN drug1)) (PP (IN for) (NP (NP (DT a) (NN week)) (PP (TO to) (NP (JJ healthy) (NNS men))))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (ADJP (FW in) (FW vivo)) (NN drug) (NN interaction) (NNS studies)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN investigated))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT A) (NN relationship)) (PP (IN of) (NP (JJ functional) (NN antagonism)))) (VP (VBZ exists) (PP (IN between) (NP (NP (NP (NP (NN drug2)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP promote) (NP (NN calcium) (NN absorption))))) (, ,)) (CC and) (NP (NN drug3))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP inhibit) (NP (NN calcium) (NN absorption))))))))) (. .))))
(S1 (S (NP (NP (JJ Phosphate-Binding) (NNS Agents)) (: :) (S (SBAR (IN Since) (S (NP (NN drug1)) (ADVP (RB also)) (VP (VBZ has) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (NN phosphate) (NN transport)))) (PP (IN in) (NP (DT the) (NP (NP (NN intestine)) (, ,) (NP (NN kidneys)) (CC and) (NP (NN bones)))))))) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (JJ phosphate-binding) (NNS agents)))) (VP (MD must) (VP (VB be) (VP (VBN adjusted) (PP (IN in) (NP (NP (NN accordance)) (PP (IN with) (NP (DT the) (NN serum) (NN phosphate) (NN concentration))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NNS drug2)))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (IN as) (S (NP (DT this)) (VP (MD could) (VP (VB create) (NP (NP (JJ possible) (JJ additive) (NNS effects)) (CC and) (NP (NN hypercalcemia))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1) (NNS Supplements)) (: :) (S (NP (NP (JJ Uncontrolled) (NN intake)) (PP (IN of) (NP (JJ additional) (NN drug2) (JJ -containing) (NNS preparations)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2) (JJ -containing) (NNS preparations)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (VP (VP (MD may) (VP (VB cause) (NP (NN hypermagnesemia)))) (CC and) (VP (MD should) (ADVP (RB therefore)) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN during) (NP (NN therapy))) (PP (IN with) (NP (NN drug4))) (PP (IN by) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ chronic) (JJ renal) (NN dialysis)))))))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN if) (S (NP (NN drug1) (NN Gel)) (VP (VBZ interacts) (PP (IN with) (NP (NP (JJ other) (JJ topical) (NNS medications)) (VP (VBN applied) (PP (TO to) (NP (DT the) (NN ulcer) (NN site)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (NN drug1) (NN Gel)) (PP (IN with) (NP (JJ other) (JJ topical) (NNS drugs)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (CD 1))) (. .)))
(S1 (S (S (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))) (: :) (S (NP (NP (DT The) (JJ biochemical) (NN activity)) (PP (IN of) (NP (NP (DT the) (NN drug) (NN metabolizing) (NN isozyme) (NN cytochrome) (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NN debrisoquin) (NN hydroxylase)) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN reduced) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (DT the) (NN caucasian) (NN population))))) (PRN (-LRB- -LRB-) (S (NP (NP (QP (RB about) (CD 7) (TO to) (CD 10)) (NN %)) (PP (IN of) (NP (NNS caucasians)))) (VP (VBP are) (ADVP (RB so)) (VP (VBN called) (NP (JJ poor) (NNS metabolizers))))) (-RRB- -RRB-))))) (: ;)))
(S1 (S (S (NP (NP (JJ reliable) (NNS estimates)) (PP (IN of) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (VBN reduced) (NN P450) (NN 2D6) (NN isozyme) (NN activity))) (PP (IN among) (NP (ADJP (ADJP (JJ Asian)) (, ,) (ADJP (JJ African)) (CC and) (ADJP (JJ other))) (NNS populations)))))) (VP (VBP are) (RB not) (ADVP (RB yet)) (ADJP (JJ available)))) (. .)))
(S1 (S (S (NP (JJ Poor) (NNS metabolizers)) (VP (VBP have) (NP (NP (JJR higher) (IN than) (VBN expected) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (JJ usual) (NNS doses))))))) (. .)))
(S1 (S (PP (VBG Depending) (PP (IN on) (NP (NP (DT the) (NN traction)) (PP (IN of) (NP (NN drug) (NN metabolized))) (PP (IN by) (NP (NN P450) (NN 2D6)))))) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN plasma) (NN concentration)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (JJ small)) (, ,) (CC or) (RB quite) (ADJP (ADJP (JJ large)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 8) (JJ fold)) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NN AUC)) (PP (IN of) (NP (DT the) (NN drug1)))))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ certain) (NNS drugs)) (VP (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT this) (NN isozyme))))) (CC and) (VP (VB make) (NP (JJ normal) (NNS metabolizers)))) (VP (VBP resemble) (NP (NN p.o.)))))
(S1 (S (NP (NP (NN metabolizers)) (. .))))
(S1 (S (S (NP (NP (DT An) (JJ individual)) (SBAR (WHNP (WP who)) (S (VP (VBZ is) (ADJP (JJ stable) (PP (IN on) (NP (NP (DT a) (JJ given) (NN dose)) (PP (IN of) (NP (NN drug1)))))))))) (VP (MD may) (VP (VB become) (ADJP (RB abruptly) (JJ toxic)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT these) (JJ inhibiting) (NNS drugs)) (PP (IN as) (NP (JJ concomitant) (NN therapy)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6)))))) (VP (VBP include) (NP (NP (DT some)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN enzyme) (-LRB- -LRB-) (NN drug1)))))))))) (: ;)))
(S1 (S (NP (NP (NP (NN drug1) (-RRB- -RRB-)) (CC and) (NP (NP (JJ many)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN for) (NP (NP (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NP (JJ many) (JJ other) (NNS drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NP (DT the) (NN Type) (NN 1C) (NNS antiarrhythrnics)) (NP (NP (NN propatenone)) (CC and) (NP (NN drug4))))) (-RRB- -RRB-)))))))))) (. .))))
(S1 (S (S (SBAR (IN While) (S (NP (NP (NP (PDT all) (DT the) (NNS drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (PP (FW e.g.) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN seriraline)) (, ,) (CC and) (NP (NN drug4)))) (, ,)) (VP (VBP inhibit) (NP (NN P450) (NN 2D6))))) (, ,) (NP (PRP they)) (VP (MD may) (VP (VB vary) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN inhibition)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN extent)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (NNS interactions)) (VP (MD may) (VP (VBP pose) (NP (JJ clinical) (NNS problems))))))) (VP (MD will) (VP (VB depend) (PP (IN on) (NP (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN inhibition)))) (CC and) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT the) (NN drug3)) (VP (VBN involved)))))))))) (. .)))
(S1 (S (ADVP (RB Nevertheless)) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN indicated) (PP (PP (IN in) (NP (NP (DT the) (NN co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NN drug2))))))) (CC and) (ADVP (RB also)) (PP (IN in) (NP (NP (NN switching)) (PP (IN from) (NP (CD one) (NN class))) (PP (TO to) (NP (DT the) (JJ other)))))))) (. .)))
(S1 (S (PP (IN Of) (NP (JJ particular) (NN importance))) (, ,) (NP (JJ sufficient) (NN time)) (VP (MD must) (VP (VB elapse) (PP (IN before) (S (VP (VBG initiating) (NP (NN TCA) (NN treatment)) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG being) (VP (VBN withdrawn) (PP (IN from) (NP (NP (NP (NN drug1)) (, ,) (VP (VBN given) (NP (NP (DT the) (JJ long) (NN half-life)) (PP (IN of) (NP (DT the) (NN parent)))))) (CC and) (NP (NP (JJ active) (NN metabolite)) (PRN (-LRB- -LRB-) (NP (NP (QP (IN at) (JJS least) (CD 5)) (NNS weeks)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6))))))))) (VP (MD may) (VP (VB require) (NP (NP (JJR lower) (NNS doses)) (VP (ADVP (IN than) (RB usually)) (VBN prescribed) (PP (IN for) (NP (CC either) (NP (DT the) (NN drug2)) (CC or) (NP (DT the) (JJ other) (NN drug))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (S (ADVP (RB whenever)) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (JJ other) (NNS drugs)))) (VP (VBZ is) (VP (VBN withdrawn) (PP (IN from) (NP (NN co-therapy)))))) (, ,) (NP (NP (DT an) (VBN increased) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ desirable)) (S (VP (TO to) (VP (VB monitor) (NP (NN drug1) (NN plasma) (NNS levels)) (S (ADVP (RB whenever)) (NP (DT a) (NN drug2)) (VP (VBZ is) (ADJP (JJ going) (S (VP (TO to) (VP (VB be) (VP (VBN co-administered) (PP (IN with) (NP (NP (DT another) (NN drug)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN P450) (NN 2D6)))))))))))))))))))))) (. .)))
(S1 (S (NP (NP (CD 2)) (. .))))
(S1 (S (S (NP (NP (NP (JJ Close) (NN supervision)) (CC and) (NP (JJ careful) (NN adjustment))) (PP (IN of) (NP (NN dosage)))) (VP (VBP are) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (NP (DT this) (NN drug)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))))))))) (. .)))
(S1 (S (NP (NP (CD 3)) (. .))))
(S1 (S (S (NP (JJ Clinical)) (VP (VBP experience) (SBAR (IN in) (S (NP (NP (DT the) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (NN ECT)) (CC and) (NP (NN drug1))))) (VP (VBZ is) (VP (VBN limited))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (SBAR (IN if) (S (NP (JJ such) (NN treatment)) (VP (VBZ is) (ADJP (JJ essential))))) (, ,) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (VBN increased) (NN risk)) (ADJP (JJ relative) (PP (TO to) (NP (NNS benefits))))))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (NP (CD 4))) (. .)))
(S1 (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN combined) (PP (IN with) (NP (NP (JJ other) (NNS drug2)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))))) (: /) (NP (NN drug5))))))))) (, ,) (NP (JJ careful) (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (DT the) (NN pharmacology)) (PP (IN of) (NP (NP (DT the) (NNS agents)) (VP (VBN employed) (SBAR (IN since) (S (NP (NP (DT the) (JJ sedative) (NNS effects)) (PP (IN of) (NP (NP (NP (NN drug6)) (CC and) (NP (NN drug7))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug8)) (CC or) (NP (NN drug9)))) (-RRB- -RRB-))))) (VP (VBP are) (ADJP (JJ additive))))))))))))) (. .)))
(S1 (S (S (NP (NP (CC Both) (DT the) (ADJP (ADJP (JJ sedative)) (CC and) (ADJP (JJ anticholinergic))) (NNS effects)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (VBP are) (ADVP (RB also)) (ADJP (JJ additive) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (CD 5)) (. .))))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD can) (VP (VBP produce) (NP (NP (ADJP (RB clinically) (JJ significant)) (NNS increases)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (DT the) (NN drug3))))))))) (. .)))
(S1 (S (S (ADVP (RB Conversely)) (, ,) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (DT the) (NN drug1)))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN upon) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NP (NN drug2)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (NP (DT the) (JJ therapeutic) (NN efficacy)) (PP (IN of) (NP (DT the) (NN drug3) (CD 6))))))))))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (ADJP (ADJP (JJR greater)) (PP (IN than) (NP (NP (JJ two-fold) (NNS increases)) (PP (IN of) (NP (NP (ADJP (RB previously) (JJ stable)) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))))))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (DT these) (NNS agents))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Potential) (NN drug) (NNS interactions)) (PP (IN for) (NP (NN drug1)))) (VP (VBP include) (, ,) (NP (NP (VBN increased) (NN sedation)) (SBAR (IN if) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN combined) (PP (IN with) (NP (JJ other) (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB partially)) (VP (VB counteract) (NP (NP (DT the) (NN anticoagulation) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (PP (JJ such) (IN as) (NP (NN drug2))) (, ,)) (VP (MD may) (VP (VB have) (NP (DT an) (JJ additive) (NN effect)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC plus) (NP (NN drug2)))))) (VP (MD should) (, ,) (ADVP (RB therefore)) (, ,) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NP (JJ marked) (NN bradycardia)) (CC or) (NP (NN hypotension))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VBP present) (PP (IN as) (NP (NP (NN vertigo)) (, ,) (NP (NN syncope/presyncope)) (, ,) (CC or) (NP (NP (JJ orthostatic) (NNS changes)) (PP (IN in) (NP (NN blood) (NN pressure))) (PP (IN without) (NP (JJ compensatory) (NN tachycardia)))))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Exaggerated) (JJ hypertensive) (NNS responses)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN from) (NP (NP (DT the) (JJ combined) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (, ,) (PP (VBG including) (NP (NP (DT those)) (VP (VBN contained) (PP (IN in) (NP (NP (JJ proprietary) (JJ cold) (NNS remedies)) (CC and) (NP (JJ vasoconstrictive) (JJ nasal) (NN drops))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN warned) (PP (IN of) (NP (DT this) (JJ potential) (NN hazard))))))) (. .)))
(S1 (S (S (NP (NP (NN Blunting)) (PP (IN of) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug1))))) (PP (IN by) (NP (NN drug2)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ significant) (NNS interactions)) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (JJ oral) (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC or) (NP (NN drug7))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (JJ other) (NN drug5)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBP prolong)) (CC and) (VP (VBP intensify) (NP (NP (DT the) (JJ anticholinergic) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (JJ antihypertensive) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (VP (VBN increased) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (JJ such) (PP (IN as) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))) (: ;)))
(S1 (S (NP (NP (NN drug1)) (. .))))
(S1 (S (NP (DT No) (JJ separate) (NN information) (JJ available))))
(S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG applying) (NP (NN drug1) (NN gel))))))) (VP (MD should) (RB not) (ADVP (RB concurrently)) (VP (VB use) (NP (NP (NNS products)) (SBAR (WHNP (WDT that)) (S (VP (VBP contain) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN N)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ common) (NN component)) (PP (IN of) (NP (NN insect) (NN repellent) (NNS products)))))))))))) (. .)))
(S1 (S (S (NP (NN Animal) (NN toxicology) (NNS studies)) (VP (VBD showed) (NP (VBN increased) (NN drug1) (NN toxicity)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN included) (PP (IN as) (NP (NP (NN proof)) (PP (IN of) (NP (DT the) (NN formulation))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBD was) (NP (DT no) (JJ clinical) (NN evidence)) (PP (IN in) (NP (NP (DT the) (JJ vehicle-controlled) (NNS studies)) (PP (IN of) (NP (NP (NN drug) (NNS interactions)) (PP (IN with) (NP (JJ systemic) (NN drug1))))) (, ,) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))))))))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug5) (NN gel))) (PP (IN on) (NP (NP (DT the) (JJ steady-state) (NNS concentrations)) (PP (IN of) (NP (DT these) (NNS drugs)))))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (DT No) (NN drug) (NN interaction) (NNS data)) (VP (VBP are) (ADJP (JJ available) (PP (IN on) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1) (NN gel)) (CC and) (NP (JJ systemic) (JJ anti-KS) (NNS agents))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Pharmacokinetic) (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NN drug1)) (PP (IN in) (NP (NNS adults)))))) (VP (VBD were) (VP (VBN conducted) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6))))))) (. .)))
(S1 (S (S (NP (DT No) (NNS interactions)) (VP (VBD were) (VP (VBN observed)))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (JJ multiple) (NN dose) (NN study)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 400) (NN mg)) (ADJP (RB once) (JJ daily) (PP (IN for) (NP (CD 3) (NNS days))))) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN mg)) (ADJP (RB once) (JJ daily) (PP (IN for) (NP (CD 3) (NNS days))))) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT a) (ADJP (CD 16) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3)))))) (VP (VBD was) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN disposition)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (RB not) (VP (VBN altered) (PP (IN by) (NP (JJ concomitant) (NN drug2) (NN administration)))))) (. .)))
(S1 (S (NP (NP (JJ Drug-Drug) (NNS Interactions)) (: :) (S (NP (DT No) (ADJP (RB clinically) (JJ significant)) (NN drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN found) (PP (IN with) (NP (NN drug1))) (PP (IN at) (NP (NP (DT a) (JJ low) (NN dose)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT a) (JJ small) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN caused) (PP (IN by) (NP (NP (DT a) (JJ 400-mg) (NN dose)) (PP (IN of) (NP (NN drug2))))))))))))) (: ;)))
(S1 (S (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (JJR larger) (NN drug1) (NNS doses)) (VP (MD could) (VP (VB have) (NP (DT a) (JJR greater) (NN effect)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN augmented) (PP (IN by) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ most) (JJ other) (NNS drug2)) (, ,) (PP (VBG including) (NP (NP (NN drug3)) (, ,) (NP (JJ negative) (JJ inotropic) (NNS agents)) (, ,) (CC and) (NP (JJ inhaled) (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (S (NP (NP (NN drug2)) (, ,) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug3)) (CC or) (NP (CD 60) (NNS minutes)))) (PP (VBG following) (NP (NN drug4) (NN administration)))) (, ,)) (VP (VBN decreased) (NP (NN drug5) (NN bioavailability)) (PP (IN by) (NP (QP (RB approximately) (CD 25)) (NN %)))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NP (DT the) (NP (NN cytochrome) (NN P-450)) (NNS isozymes)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT a) (JJ multiple-dose) (NN study))) (, ,) (NP (NN drug1)) (VP (VBD caused) (NP (NP (DT a) (JJ dose-related) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ mean) (NN elimination) (NN half-life)) (PP (IN of) (NP (NN drug2)))))) (, ,) (S (ADVP (RB thereby)) (VP (VP (VBG decreasing) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3)))) (PP (IN by) (NP (QP (RB up) (TO to) (CD 80)) (NN %)))) (CC and) (VP (VBG leading) (PP (TO to) (NP (NP (NP (DT a) (JJ five-fold) (NN increase)) (PP (IN in) (NP (DT the) (NN AUC)))) (CC and) (NP (NP (DT the) (NN half-life)) (PP (IN of) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (NN Trough) (NN plasma) (NN drug1) (NNS levels)) (VP (VBD were) (ADVP (RB also)) (ADJP (NP (CD 20) (NN %)) (JJR higher)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBD were) (VP (VBN administered) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (NN drug1) (JJ -related) (JJ adverse) (NNS effects)) (VP (VBP have) (VP (VBN occurred) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG consuming) (NP (NN drug2)) (PP (IN while) (PP (IN on) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug2)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NP (JJ other) (NNS members)) (PP (IN of) (NP (DT the) (NN drug4))))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VBP raise) (NP (NN serum) (NN drug3) (NNS levels)) (PP (IN in) (NP (DT some) (NNS individuals)))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (NNS signs)) (CC and) (NP (NP (NNS symptoms)) (ADVP (JJ suggestive) (PP (IN of) (NP (NN drug1) (NN toxicity)))))) (VP (VBP occur) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBP are) (VP (VBN given) (ADVP (RB concomitantly))))))))) (, ,) (NP (NNS physicians)) (VP (VBP are) (VP (VBN advised) (S (VP (TO to) (VP (VP (VB obtain) (NP (NN serum) (NN drug4) (NNS levels))) (CC and) (VP (VB adjust) (NP (NN drug5) (NNS doses)) (ADVP (RB appropriately))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NNS Seizures)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug2)) (PP (ADVP (RB concomitantly)) (IN with) (NP (DT the) (NN drug3) (NN drug4)))))))))) (. .))))
(S1 (S (S (NP (NN Animal) (NNS studies)) (ADVP (RB also)) (VP (VBP suggest) (NP (NP (DT an) (VBN increased) (NN potential)) (PP (IN for) (NP (NNS seizures)))) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (CD two) (NNS drugs)) (VP (VBP are) (VP (VBN given) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (ADJP (JJ approved)) (PP (IN in) (NP (DT the) (JJ United) (NNS States))) (PP (IN at) (NP (DT this) (NN time))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (: :) (NP (NN drug3))) (VP (VBP form) (NP (NNS chelates)) (PP (IN with) (NP (JJ metal) (NNS cations))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBG containing) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))) (: ;)))
(S1 (S (PP (IN with) (NP (NN drug1))) (: ;)))
(S1 (S (PP (IN with) (NP (NP (ADJP (ADJP (JJ divalent)) (CC or) (ADJP (JJ trivalent))) (NNS cations)) (PP (JJ such) (IN as) (NP (NN drug1))))) (: ;)))
(S1 (S (S (NP (NP (NN or)) (PP (IN with) (NP (NP (NN drug1)) (VP (VBG containing) (NP (NN drug2)))))) (VP (MD may) (ADVP (RB substantially)) (VP (VP (VB interfere) (PP (IN with) (NP (NN drug) (NN absorption)))) (CC and) (VP (VB result) (PP (IN in) (NP (NP (JJ insufficient) (NN plasma)) (CC and) (NP (NN tissue) (NN drug3) (NNS concentrations)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBG containing) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBP reduce) (NP (NP (DT the) (JJ oral) (NN absorption)) (PP (IN of) (NP (NN drug4)))) (PP (IN by) (NP (CD 75) (NN %))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ oral) (NN bioavailability)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN reduced) (PP (IN by) (NP (CD 60) (NN %))) (PP (IN with) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS agents)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN for) (NP (CD 8) (NNS hours))) (PP (PP (IN before)) (CC or) (PP (IN for) (NP (CD 2) (NNS hours))) (PP (IN after) (NP (NN drug1) (NN administration)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NP (DT the) (NP (NN cytochrome) (NN P-450)) (NNS isozymes)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ interferes) (PP (IN with) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (VP (VBG resulting) (PP (IN in) (NP (NP (NP (DT a) (ADJP (NP (CD 42) (NN %) (TO to) (CD 74) (NN %)) (JJ dose-related)) (NN decrease)) (PP (IN in) (NP (NN drug3) (NN clearance)))) (CC and) (NP (NP (DT a) (JJ subsequent) (CD 260) (NN %) (TO to) (CD 350) (NN %) (NN increase)) (PP (IN in) (NP (NN serum) (NN theophylline) (NNS levels))))))))))))) (. .)))
(S1 (S (S (NP (JJ drug1) (JJ -related) (JJ adverse) (NNS effects)) (VP (VBP have) (VP (VBN occurred) (PP (IN in) (NP (NNS patients))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBD were) (VP (VBN coadministered)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2)) (, ,) (PP (VBG including) (NP (NN drug3))) (, ,)) (VP (VBP decrease) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NN drug4)) (, ,) (NP (NP (DT the) (ADJP (RBR less) (JJ active)) (NN isomer)) (PP (IN of) (NP (JJ racemic) (NN drug5))))))))) (. .))))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (DT the) (JJ active) (NN S-isomer))))))) (, ,) (CC and) (S (NP (NP (NNS changes)) (PP (IN in) (NP (NN clotting) (NN time)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBD were) (VP (VBN coadministered)))))))))) (. .)))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (NP (NP (DT the) (NN prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ suitable) (NN coagulation) (NN test))) (VP (MD should) (VP (VB be) (VP (VBN monitored))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NP (NN drug1)) (CC or) (NP (PRP$ its) (NNS derivatives))) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN given) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (JJ other) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NP (JJ other) (NNS drug4)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (NN drug5))) (-RRB- -RRB-)))) (PP (RB concomitantly) (IN with) (NP (NP (NN drug6)) (CC and) (NP (NN drug7) (NNS tablets)))))) (VP (MD may) (VP (VBP exhibit) (NP (DT an) (JJ additive) (NN CNS) (NN depression))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ combined) (NN therapy)) (VP (VBZ is) (VP (VBN contemplated))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (CD one)) (CC or) (NP (DT both)) (NP (NNS agents))))) (VP (MD should) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (PP (IN with) (NP (NN drug3) (NNS preparations)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (CC either) (DT the) (NP (NN drug4)) (CC or) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (MD may) (VP (VB produce) (NP (JJ paralytic) (NN ileus))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN use)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG receiving) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN drug2))))))))))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN serum) (NN drug3) (NNS levels)) (CC and) (NP (JJ potential) (NN drug4) (NN toxicity)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NN case)) (PP (IN of) (NP (NP (NN drug1) (NN toxicity)) (CC and/or) (NP (JJ elevated) (NN serum) (NN drug2) (NNS levels)))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug3)))) (VP (MD should) (VP (VB be) (VP (VBN reduced) (SBAR (IN while) (S (NP (DT the) (NN patient)) (VP (VBZ is) (VP (VBG receiving) (NP (JJ concomitant) (NN drug4) (NN therapy)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (JJ elevated) (NN drug3) (NN serum) (NNS levels)))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (VBN increased) (JJ anticoagulant) (NNS effects)))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (JJ oral) (NN drug2))) (VP (VBD were) (VP (VBN used) (ADVP (RB concomitantly))))))))) (. .)))
(S1 (S (S (NP (NP (VBN Increased) (NN anticoagulation) (NNS effects)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS interactions)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ various) (JJ oral) (NNS anticoagulents))))))) (VP (MD may) (VP (VB be) (ADJP (RBR more) (JJ pronounced)) (PP (IN in) (NP (DT the) (JJ elderly)))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN in) (NP (NP (DT some) (NNS patients)) (PP (IN with) (NP (NP (JJ acute) (NN ergot) (NN toxicity)) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ severe) (JJ peripheral) (NN vasospasm)) (CC and) (NP (NN dysesthesia))))))))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))) (CC and) (S (ADVP (RB thus)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (JJ pharmacologic) (NN effect)) (PP (IN of) (NP (DT these) (NNS drug4)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concurrently)) (VBG taking) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NN system))))))))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NNS elevations)) (PP (IN in) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (DT these) (JJ other) (NNS drugs))))))))))) (. .)))
(S1 (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (NNS interactions)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (NN drug13)) (, ,) (CC and) (NP (NN drug14))))))))) (. .)))
(S1 (S (S (NP (NP (NN Serum) (NNS concentrations)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NN system))))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concurrently)) (VBG receiving) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB alter) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (JJ nonsedating) (NN drug2) (NN drug3)) (CC and) (NP (NN drug4))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (ADVP (RB concomitantly)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Rare) (NNS cases)) (PP (IN of) (NP (NP (JJ serious) (JJ cardiovascular) (JJ adverse) (NNS events)) (, ,) (PP (VBG including) (NP (NP (JJ electrocardiographic) (NN QT/QTc) (NN interval) (NN prolongation)) (, ,) (NP (JJ cardiac) (NN arrest)) (, ,) (NP (NP (NNS torsades)) (ADJP (FW de) (FW pointes))) (, ,) (CC and) (NP (JJ other) (JJ ventricular) (NNS arrhythmias))))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NNS deaths)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (ADVP (RB rarely)) (PP (IN with) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ postmarketing) (NNS reports)) (PP (IN of) (NP (NP (NN drug) (NNS interactions)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NN drug2)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NN QT) (NN prolongation)) (, ,) (NP (JJ cardiac) (NN arrythmias)) (, ,) (NP (JJ ventricular) (NN tachycardia)) (, ,) (NP (JJ ventricular) (NN fibrulation)) (, ,) (CC and) (NP (NP (NNS torsades)) (ADJP (FW de) (FW pointes))))) (, ,) (ADVP (RBS most)) (PP (IN like) (ADJP (JJ due) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (JJ hepatic) (NN metabolism)) (PP (IN of) (NP (NN drug3))))) (PP (IN by) (NP (NN drug4)))))))))))))))))) (. .)))
(S1 (S (S (NP (NNS Fatalities)) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (JJ concomitant) (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (: ;)))
(S1 (S (S (NP (NP (NNS cases)) (PP (IN of) (NP (NN rhabdomyolysis)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (ADJP (RB seriously) (JJ ill)) (NNS patients))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ additive) (NN CNS) (NN depressant) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC or) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP produce) (NP (NN CNS) (NN depression))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Serious) (NN toxicity)) (VP (MD may) (VP (VB result) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ additive) (NN CNS) (NN depressant) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC or) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP produce) (NP (NN CNS) (NN depression))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Preliminary) (NNS data)) (SBAR (WHNP (WDT which)) (S (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (JJ anti-inflammatory) (NN activity)) (PP (IN of) (NP (NNS drug2)))))))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN confirmed))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (JJ leprosy-associated) (JJ inflammatory) (NNS reactions)) (VP (VBP develop) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADVP (RB still)) (ADJP (JJ advisable) (S (VP (TO to) (VP (VBP continue) (NP (NP (NN treatment)) (PP (IN with) (NP (DT both) (NNS drugs)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN As) (PP (IN with) (NP (JJ other) (NNS drug2)))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))) (VP (VBZ is) (RB not) (ADVP (RB generally)) (VP (VBN recommended) (PP (IN because) (IN of) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (VBN increased) (JJ adverse) (NNS effects)))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (ADVP (RB competitively)) (VP (VB inhibit) (NP (NP (NN drug3) (NN accumulation)) (PP (IN in) (NP (NN rabbit) (NN kidney) (NNS slices))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB indicate) (SBAR (IN that) (S (NP (PRP they)) (VP (MD could) (VP (VB enhance) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN drug1))))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NNS Reports)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug3)))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN interaction)) (VP (MD should) (VP (VB be) (VP (VBN given) (NP (NP (NN consideration)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)))))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Clinical) (NNS studies)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ post-marketing) (NNS observations)) (, ,)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (JJ natriuretic) (NN effect)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))) (PP (IN in) (NP (DT some) (NNS patients))))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN response)) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ renal) (NN prostaglandin) (NN synthesis))))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (JJ renal) (NN failure))))) (, ,) (S (CONJP (RB as) (RB well) (IN as)) (VP (TO to) (VP (VB assure) (NP (JJ diuretic) (NN efficacy))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP have) (VP (VBN produced) (NP (NP (NP (DT an) (NN elevation)) (PP (IN of) (NP (NN plasma) (NN drug3) (NNS levels)))) (CC and) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (JJ renal) (NN drug4) (NN clearance)))))))) (. .)))
(S1 (S (S (S (NP (DT The) (JJ mean) (JJ minimum) (NN drug1) (NN concentration)) (VP (VBD increased) (NP (CD 15) (NN %)))) (CC and) (S (NP (DT the) (JJ renal) (NN clearance)) (VP (VBD was) (VP (VBN decreased) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (VBP have) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ renal) (NN prostaglandin) (NN synthesis))) (PP (IN by) (NP (DT the) (NN drug1))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concurrently)))))) (, ,) (NP (NNS subjects)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB carefully)) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NN drug3) (NN toxicity))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN on) (NP (JJ GI) (JJ bleeding)))) (VP (VBP are) (ADJP (JJ synergistic)) (, ,) (SBAR (JJ such) (IN that) (S (NP (NP (NNS users)) (PP (IN of) (NP (DT both) (NNS drugs)))) (ADVP (RB together)) (VP (VBP have) (NP (NP (DT a) (NN risk)) (PP (IN of) (NP (JJ serious) (JJ GI) (JJ bleeding))) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (NNS users)) (PP (IN of) (NP (NP (DT either) (NN drug)) (ADVP (RB alone))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (JJ single) (NN dose) (NN study)) (PRN (-LRB- -LRB-) (NP (NN n=6)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN ingestion)) (PP (IN of) (NP (NP (DT an) (NN drug2)) (VP (VBG containing) (NP (NP (NN 1.7-gram)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NP (NN 500-mg)) (PP (IN of) (NP (NN drug4)))))))))) (VP (VBD increased) (NP (NP (DT the) (NP (NN Cmax)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (NN drug5)))) (PP (IN by) (NP (NP (CD 125) (NN %)) (CC and) (NP (CD 36) (NN %)))) (, ,) (SBAR (IN respectively.) (S (NP (NP (DT A) (NN number)) (PP (IN of) (NP (NNS compounds)))) (VP (VBP are) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NN CYP2C9))) (PP (VBG including) (NP (NP (NN drug6)) (, ,) (NP (NN drug7)) (CC and) (NP (NN drug8)))))))))) (. .))))
(S1 (S (S (NP (NP (NN Drug) (NN interaction) (NNS studies)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (DT these) (NNS compounds))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (NP (JJ altered) (NN safety)) (CC and) (NP (NN efficacy))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (DT these) (NNS drugs))))))))))) (. .)))
(S1 (S (NP (NP (NN Drug) (NNS Interactions)) (: :) (S (NP (DT The) (JJ central) (NN drug1) (NN syndrome)) (VP (MD can) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ anticholinergic) (NNS agents)) (PP (JJ such) (IN as) (NP (NN drug2)))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (JJ secondary) (JJ anticholinergic) (NNS actions)) (, ,) (PP (FW e.g.)) (, ,) (NP (NP (JJ certain) (NNS drug3)) (PP (JJ such) (IN as) (NP (NP (NN drug4)) (, ,) (NP (DT the) (NP (NN drug5)) (CC and) (NP (JJ other) (NN drug6))) (, ,) (NP (NN drug7)) (, ,) (NP (NP (JJ certain) (NNS drug8)) (PP (JJ such) (IN as) (NP (DT the) (NN drug9) (NNS salts)))) (, ,) (CC and) (NP (NN drug10))))))))))))))))) (. .))))
(S1 (S (S (NP (DT No) (JJ drug/drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (DT no) (JJ formal) (NN drug-interaction) (NNS studies)) (VP (VBN performed) (PP (IN with) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN potential)) (PP (IN for) (NP (NP (JJ drug-drug) (NN interaction)) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN affected) (PP (IN by) (NP (NN cytochrome) (NN P450) (NNS enzymes))))))))) (VP (MD may) (RB not) (VP (VB be) (VP (VBN ruled) (PRT (RP out)))))) (. .)))
(S1 (S (NP (NN Laboratory) (NN Test) (NNS Interactions))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN known) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (DT any) (NN routine) (JJ diagnostic) (NNS tests))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN for) (NP (NP (NN drug1) (NNS analogues)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))) (-RRB- -RRB-))))) (: :) (NP (NN drug6))) (: :) (S (NP (NN drug7)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NN drug8))))))))))) (: ;)))
(S1 (S (S (PP (IN as) (NP (JJ such))) (NP (PRP it)) (VP (MD may) (VP (VB impair) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))))) (VP (MD will) (RB not) (VP (VB affect) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug5))))) (, ,) (CC but) (VP (MD may) (VP (VB reduce) (NP (NP (JJ endogenous) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug6) (NN /ergocalcitriol)))) (PP (IN by) (S (VP (VBG accelerating) (NP (NN metabolism))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (NN blood) (NN level)) (PP (IN of) (NP (NN drug1) (NN /ergocalcitriol)))) (VP (MD will) (VP (VB be) (VP (VBN reduced)))))) (, ,) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary)) (SBAR (IN if) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (ADVP (RB simultaneously))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NN hypercalcemia)) (PP (IN by) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NN calcium) (NN excretion))) (PP (IN in) (NP (NN urine))))))))))) (. .)))
(S1 (S (S (NP (DT Some) (NNS reports)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ causes) (NP (NN hypercalcemia)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN precaution)) (VP (MD should) (VP (VB be) (VP (VBN taken) (SBAR (WHADVP (WRB when)) (S (NP (NN coadministration)) (VP (VBZ is) (ADJP (JJ necessary))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2) (NN dosage)) (VP (MD must) (VP (VB be) (VP (VBN determined) (PP (IN with) (NP (NN care))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug3))))))) (, ,) (SBAR (IN as) (S (NP (NP (NN hypercalcemia)) (PP (IN in) (NP (JJ such) (NNS patients)))) (VP (MD may) (VP (VB precipitate) (NP (JJ cardiac) (NN arrhythmias)))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (VP (VB inhibit) (NP (NP (ADJP (CC both) (ADJP (JJ synthetic)) (CC and) (ADJP (JJ catabolic))) (NNS enzymes)) (PP (IN of) (NP (NN drug3))))))) (. .))))
(S1 (S (S (NP (NP (NNS Reductions)) (PP (IN in) (NP (NN serum) (NP (JJ endogenous) (NN vitamin) (NN D)) (NNS concentrations)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (CD 300) (NN mg/day))) (PP (TO to) (NP (NP (ADJP (CD 1200) (NN mg/day)) (NN drug1)) (PP (IN for) (NP (NP (DT a) (NN week)) (PP (TO to) (NP (JJ healthy) (NNS men))))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (ADJP (FW in) (FW vivo)) (NN drug) (NN interaction) (NNS studies)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN investigated))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT A) (NN relationship)) (PP (IN of) (NP (JJ functional) (NN antagonism)))) (VP (VBZ exists) (PP (IN between) (NP (NP (NP (NN drug2) (NNS analogues)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP promote) (NP (NN calcium) (NN absorption))))) (, ,)) (CC and) (NP (NP (NN drug3)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP inhibit) (NP (NN calcium) (NN absorption)))))))))) (. .))))
(S1 (S (NP (NP (JJ Phosphate-Binding) (NNS Agents)) (: :) (S (SBAR (IN Since) (S (NP (NN drug1)) (ADVP (RB also)) (VP (VBZ has) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (NN phosphate) (NN transport)))) (PP (IN in) (NP (DT the) (NP (NP (NN intestine)) (, ,) (NP (NN kidneys)) (CC and) (NP (NN bones)))))))) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (JJ phosphate-binding) (NNS agents)))) (VP (MD must) (VP (VB be) (VP (VBN adjusted) (PP (IN in) (NP (NP (NN accordance)) (PP (IN with) (NP (DT the) (NN serum) (NN phosphate) (NN concentration))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ drug2) (NNS analogues)))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (IN as) (S (NP (DT this)) (VP (MD could) (VP (VB create) (NP (NP (JJ possible) (JJ additive) (NNS effects)) (CC and) (NP (NN hypercalcemia))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1) (NNS Supplements)) (: :) (S (NP (NP (JJ Uncontrolled) (NN intake)) (PP (IN of) (NP (JJ additional) (NN drug2) (JJ -containing) (NNS preparations)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2) (JJ -containing) (NNS preparations)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (VP (VP (MD may) (VP (VB cause) (NP (NN hypermagnesemia)))) (CC and) (VP (MD should) (ADVP (RB therefore)) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN during) (NP (NN therapy))) (PP (IN with) (NP (NN drug4))) (PP (IN by) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ chronic) (JJ renal) (NN dialysis)))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD may) (VP (VB decrease) (NP (JJ hypoprothrombinemic) (NN effect))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS depressasnts)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB enhance) (NP (NN CNS) (NN depression)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (VP (MD May) (VP (VB interact) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug/Laboratory) (NNS Interactions)) (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies))) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (NP (NP (DT An) (JJ immune) (NN response)) (PP (TO to) (NP (NN drug1)))) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (JJ subsequent) (JJ diagnostic) (NN serum) (NNS tests)) (SBAR (WHNP (WDT that)) (S (VP (VBP utilize) (NP (NN drug2)))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (PP (IN Due) (PP (TO to) (NP (NP (DT the) (JJ frequent) (NN occurrence)) (PP (IN of) (NP (ADJP (ADJP (JJ severe)) (CC and) (ADJP (JJ prolonged))) (NN thrombocytopenia)))))) (, ,) (NP (NP (DT the) (JJ potential) (NNS benefits)) (PP (IN of) (NP (NP (NNS medications)) (SBAR (WHNP (WDT which)) (S (VP (VBP interfere) (PP (IN with) (NP (NP (NN platelet) (NN function)) (CC and/or) (NP (NN anticoagulation)))))))))) (VP (MD should) (VP (VB be) (VP (VBN weighed) (PP (IN against) (NP (NP (DT the) (JJ potential) (VBN increased) (NNS risks)) (PP (IN of) (NP (NP (ADJP (JJ bleeding))) (CC and) (NP (ADJP (JJ hemorrhage))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NNS medications)) (SBAR (WHNP (WDT that)) (S (VP (VBP interfere) (PP (IN with) (NP (NP (NN platelet) (NN function)) (CC or) (NP (NN coagulation)))))))))) (VP (MD should) (VP (VB have) (NP (ADJP (RBR more) (JJ frequent)) (NN laboratory) (NN monitoring)) (PP (IN for) (NP (NN thrombocytopenia)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (NN transfusion) (NNS practices)) (PP (IN for) (NP (JJ such) (NNS patients)))) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN modified) (PP (IN given) (NP (NP (DT the) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ bleeding)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN in) (NP (JJ clinical) (NNS studies)))) (VP (VBD were) (VP (VBD prohibited) (PP (IN from) (S (VP (VBG receiving) (NP (NP (NP (NN growth) (NN factor)) (NN treatment)) (PP (IN for) (NP (NP (CD 2) (NNS weeks)) (ADJP (JJ prior) (PP (TO to) (NP (NP (DT the) (JJ drug1) (JJ therapeutic) (NN regimen)) (CONJP (RB as) (RB well) (IN as)) (PP (IN for) (NP (NP (CD 2) (NNS weeks)) (PP (VBG following) (NP (NP (NN completion)) (PP (IN of) (NP (DT the) (NN regimen))))))))))))))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (DT the) (NNS drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB depress) (NP (NN plasma) (NN prothrombin) (NN activity)))))))))) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (PP (IN on) (NP (NN drug2) (NN therapy))))))) (VP (MD may) (VP (VBP require) (NP (NP (JJ downward) (NN adjustment)) (PP (IN of) (NP (PRP$ their) (NN drug3) (NN dosage)))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NP (JJ bacteriostatic) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NP (DT the) (NN drug1)) (PP (IN of) (NP (NN drug2))))) (, ,)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (JJ bactericidal) (NN action)) (PP (IN of) (NP (NN drug3))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ advisable) (S (VP (TO to) (VP (VB administer) (NP (DT these) (NNS drugs)) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ oral) (NN drug2)))) (VP (MD may) (VP (VB render) (NP (NP (JJ oral) (NN drug3)) (ADJP (RBR less) (JJ effective)))))) (. .)))
(S1 (S (NP (JJ Breakthrough) (JJ bleeding)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2) (-LRB- -LRB-) (NN drug3) (-RRB- -RRB-) (NN Injection)) (, ,) (NP (NN USP))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN drug4))) (SBAR (IN because) (S (NP (DT the) (NN combination)) (VP (MD may) (VP (VB cause) (NP (NP (JJ synergistic) (NN elevation)) (PP (IN of) (NP (NN blood) (NN pressure)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NN drug2)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (JJ coronary) (NN artery) (NN vasospasm))))))))) (, ,) (CC and) (S (NP (PRP$ its) (NN effect)) (VP (MD could) (VP (VB be) (ADJP (JJ additive) (PP (IN with) (NP (NP (NN drug3) (-LRB- -LRB-) (NN drug4) (-RRB- -RRB-) (NN Injection)) (, ,) (NP (NN USP))))))))) (. .))))
(S1 (S (S (NP (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (NN Injection)) (, ,) (NP (NN USP))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN within) (NP (NP (CD 24) (NNS hours)) (PP (IN of) (NP (DT each) (JJ other)))))))) (. .)) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN Although) (S (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (DT a) (JJ clinical) (NN study)))) (VP (VBD did) (RB not) (VP (VB indicate) (NP (NP (NP (DT a) (JJ safe) (NN problem)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug2) (-LRB- -LRB-) (NN drug3) (-RRB- -RRB-) (NN Injection))))))) (, ,) (NP (NP (NN USP)) (PP (TO to) (NP (NP (NNS subjects)) (VP (ADVP (RB already)) (VBG receiving) (NP (NN drug4))))))))))) (, ,) (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (SBAR (IN that) (S (NP (NN drug5)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ vasoconstrictive) (NN action)) (PP (IN of) (NP (NN drug6)))) (PP (IN by) (S (VP (VBG blocking) (NP (NP (DT the) (JJ vasodilating) (NN property)) (PP (IN of) (NP (NN epinephrine))))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (VP (VB provoke) (NP (NN vasoconstriction)) (PP (IN in) (NP (DT some) (NNS patients))) (, ,) (PP (VBG predisposing) (PP (TO to) (NP (NP (DT a) (JJR greater) (JJ ischemic) (NN response)) (PP (TO to) (NP (NN drug3) (NN therapy))))))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (FW e.) (FW g.) (NN drug2)) (CC and) (NP (NN drug3))) (-RRB- -RRB-))) (: :) (S (NP (NP (NNS Agents)) (PP (IN of) (NP (NP (DT the) (NNS drug4)) (, ,) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (NP (NP (NN drug5) (-LRB- -LRB-) (NN drug6) (-RRB- -RRB-) (NN Injection)) (, ,) (NP (NN USP))) (VP (VBZ is) (NP (DT a) (NN member))))) (, ,)))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NP (NN drug7)) (PP (IN of) (NP (DT the) (NN drug8))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (JJ unchanged) (NNS alkaloids)) (CC and) (NP (JJ peripheral) (NN vasoconstriction))))))))))))))) (. .))))
(S1 (S (S (NP (JJ Vasospastic) (NNS reactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (JJ drug1) (JJ -containing) (NNS drugs))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (DT these) (NNS drug2)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Weakness)) (NP (NN hyperreflexia)) (, ,) (CC and) (NP (NN incoordination))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (ADVP (RB rarely)) (SBAR (WHADVP (WRB when)) (S (NP (NNS drug2)) (VP (VBP have) (VP (VBN been) (VP (VBN co-administered) (PP (IN with) (NP (NN drug3))) (PRN (-LRB- -LRB-) (NP (NP (NNP e.)) (NP (NN g))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NP (NN drug3)) (PRN (, ,) (NP (NN drug4)) (-RRB- -RRB-))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (DT no) (VBN reported) (NNS cases)) (PP (IN from) (NP (NP (JJ spontaneous) (NNS reports)) (PP (IN of) (NP (NP (NN drug) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)) (NP (NN Injection)) (, ,) (NP (NN USP))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ oral) (NN drug2))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug3) (-LRB- -LRB-) (NN drug4) (-RRB- -RRB-) (NN Injection)) (, ,) (NP (NN USP))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .))))
(S1 (S (S (NP (NP (NP (DT The) (NN magnitude)) (CC and) (NP (JJ relative) (NN importance))) (PP (IN of) (NP (NP (DT the) (NNS effects)) (VP (VBN noted) (PP (IN below)))))) (VP (VBP are) (ADJP (JJ likely) (S (VP (VP (TO to) (VP (VB be) (ADJP (NN patient) (JJ specific)))) (CC and) (VP (MD may) (VP (VB vary) (PP (IN by) (NP (NP (JJ such) (NNS factors)) (PP (IN as) (NP (NP (NN age)) (, ,) (NP (NN gender)) (, ,) (NP (NN race)) (, ,) (NP (NN intercurrent) (NNS illnesses)) (, ,) (NP (NP (NN dose)) (PP (IN of) (NP (DT either) (NN agent)))) (, ,) (NP (JJ additional) (JJ concomitant) (NNS medications)) (, ,) (CC and) (NP (NP (NN timing)) (PP (IN of) (NP (NN drug) (NN administration))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT Any) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VBZ alters) (NP (NP (NN thyroid) (NN hormone) (NN synthesis)) (, ,) (NP (NN secretion)) (, ,) (NP (NN distribution)) (, ,) (NP (NP (NN effect)) (PP (IN on) (NP (NN target) (NNS tissues)))) (, ,) (NP (NN metabolism)) (, ,) (CC or) (NP (NN elimination))))))) (VP (MD may) (VP (VB alter) (NP (NP (DT the) (JJ optimal) (JJ therapeutic) (NN dose)) (PP (IN of) (NP (NN drug1) (NN sodium))))))) (. .)))
(S1 (S (NP (NP (NN drug1) (NN Absorption)) (: :) (S (NP (DT The) (JJ following) (NNS agents)) (VP (MD may) (VP (VP (VB bind)) (CC and) (VP (VB decrease) (NP (NP (NN absorption)) (PP (IN of) (NP (NN drug2))) (PP (IN from) (NP (DT the) (JJ gastrointestinal) (NN tract)))))))) (: :) (NP (NP (NP (NN drug3)) (, ,) (NP (NN drug4) (NN resin)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN soybean) (NN flour))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN infant) (NNS formula)) (-RRB- -RRB-))) (, ,) (NP (NN drug8)) (. .))))
(S1 (S (S (VP (VBG Binding) (PP (TO to) (NP (NP (NP (NP (NN Serum) (NNS Proteins)) (: :) (S (NP (DT The) (VBG following) (NNS agents)) (VP (MD may) (VP (CC either) (VP (VB inhibit) (NP (NP (NN drug1) (NN binding)) (PP (TO to) (NP (NN serum) (NNS proteins))))) (CC or) (VP (VB alter) (NP (NP (DT the) (NNS concentrations)) (PP (IN of) (NP (NN serum) (NN binding) (NNS proteins)))))))) (: :)) (NN drug2)) (CC and) (NP (JJ related) (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NP (NN drug6)) (CC and) (NP (NN drug7))) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NP (CD drug11)) (, ,) (NP (CD drug12)) (, ,) (NP (CD drug13)) (, ,) (NP (CD drug14)) (, ,) (NP (CD drug15)) (, ,) (NP (CD drug16)) (, ,) (NP (CD drug17)) (, ,) (NP (CD drug18))))))) (. .)))
(S1 (S (NP (NP (NN Thyroid) (NN Physiology)) (: :) (S (NP (DT The) (JJ following) (NNS agents)) (VP (MD may) (VP (VB alter) (NP (NN thyroid) (NN hormone) (CC or) (NN TSH) (NNS levels)) (, ,) (ADVP (RB generally)) (PP (IN by) (NP (NP (NP (NP (NP (NP (NP (NNS effects)) (PP (IN on) (NP (NP (NN thyroid) (NN hormone) (NN synthesis)) (, ,) (NP (NN secretion)) (, ,) (NP (NN distribution)) (, ,) (NP (NN metabolism)) (, ,) (NP (NN hormone) (NN action)) (, ,) (CC or) (NP (NN elimination)) (, ,) (CC or) (NP (JJ altered) (NN TSH) (NN secretion)))) (: :) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (JJ related) (JJ anabolic) (NNS hormones))) (, ,) (NP (JJ complex) (NNS anions))) (-LRB- -LRB-) (NP (NN drug5)) (, ,)) (NN drug6)) (PRN (, ,) (NP (NN drug7)) (-RRB- -RRB-))) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NP (CD drug10) (, ,) (CD drug11) (, ,) (CD drug12) (, ,) (CD drug13) (CC and) (CD drug14)) (, ,) (NP (CD drug15)) (, ,) (NP (CD drug16)) (, ,) (NP (CD drug17)) (, ,) (NP (JJ hepatic) (NN enzyme) (NNS inducers)) (, ,) (NP (NN drug18)) (, ,) (NP (JJ iodinated) (JJ cholestographic) (NNS agents)) (, ,) (NP (NN drug19)) (, ,) (NP (CD drug20)) (, ,) (NP (CD drug21)) (, ,) (NP (CD drug22))) (, ,)) (CD drug23) (, ,) (CD drug24) (, ,) (CD drug25) (, ,) (CD drug26) (, ,) (CD drug27) (, ,) (CD drug28) (, ,) (CD drug29) (, ,) (CD drug30) (, ,) (CD drug31) (, ,) (CD drug32) (, ,) (CD drug33) (, ,) (CD drug34)))))) (. .))))
(S1 (S (NP (NP (NNS Adrenocorticoids)) (: :) (S (NP (NP (JJ Metabolic) (NN clearance)) (PP (IN of) (NP (NNS adrenocorticoids)))) (VP (VP (VBZ is) (VP (VP (VBN decreased) (PP (IN in) (NP (JJ hypothyroid) (NNS patients)))) (CC and) (VP (VBN increased) (PP (IN in) (NP (JJ hyperthyroid) (NNS patients)))))) (, ,) (CC and) (VP (MD may) (ADVP (RB therefore)) (VP (VB change) (PP (IN with) (S (VP (VBG changing) (NP (NN thyroid) (NN status))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1) (: :) (NN drug2) (NN therapy)) (ADVP (RB alone))) (VP (MD can) (VP (VB cause) (NP (NP (NN hypothyroidism)) (CC or) (NP (NN hyperthyroidism)))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (JJ Oral)) (-RRB- -RRB-))) (: :) (S (NP (NP (DT The) (JJ hypoprothrombinemic) (NN effect)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (, ,) (ADVP (RB apparently)) (PP (IN by) (NP (NP (VBN increased) (NN catabloism)) (PP (IN of) (NP (NN vitamin) (NN K-dependent) (NN clotting) (NNS factors))))))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (: :) (S (NP (NP (NNS Requirements)) (PP (IN for) (NP (NP (NN drug4)) (CC or) (NP (JJ oral) (NN drug5))))) (VP (VP (MD may) (VP (VB be) (VP (VBN reduced) (PP (IN in) (NP (NP (JJ hypothyroid) (NNS patients)) (PP (IN with) (NP (NN diabetes) (NN mellitus)))))))) (CC and) (VP (MD may) (ADVP (RB subsequently)) (VP (VB increase) (PP (IN with) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN thyroid) (NN hormone) (NN replacement) (NN therapy))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NNS Actions)) (PP (IN of) (NP (NP (DT some)) (PP (IN of) (NP (NN drug2)))))) (VP (MD may) (VP (VB be) (VP (VBN impaired))) (SBAR (WHADVP (WRB when)) (S (NP (JJ hypothyroid) (NNS patients)) (VP (VBP become) (ADJP (JJ euthyroid))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (: :) (NP (NN drug4))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB induce) (NP (CC both) (NP (NN hyperthyroidism)) (CC and) (NP (NN hypothyroidism)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (: :) (JJ Therapeutic) (NNS effects)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (S (NP (NN Serum) (NN drug1) (NNS levels)) (VP (MD may) (VP (VB be) (VP (VBN decreased) (PP (IN in) (NP (NN hyperthyroidism))) (SBAR (CC or) (SBAR (WHADVP (WRB when)) (S (NP (DT a) (JJ hypothyroid) (NN patient)) (VP (VBZ becomes) (NP (NN euthyroid)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ Marked) (NP (NP (NN hypertension)) (CC and) (NP (NN tachycardia)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1) (: :) (NN Risk)) (PP (IN of) (NP (JJ cardiac) (NNS arrhythmias)))) (VP (MD may) (VP (VB increase)))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN 123I)) (CC and) (NP (NN 131I))) (-RRB- -RRB-))) (, ,) (NP (NN drug2)) (: :) (NP (NP (NN Uptake)) (PP (IN of) (NP (VBN radiolabeled) (NNS ions))))) (VP (MD may) (VP (VB be) (VP (VBN decreased))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (NP (NP (JJ Excessive) (JJ concurrent) (NN use)) (PP (IN of) (NP (NN drug3))))) (VP (MD may) (VP (VB accelerate) (NP (JJ epiphyseal) (NN closure))))) (. .)))
(S1 (S (S (NP (JJ Untreated) (NN hypothyroidism)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN growth) (NN response)) (PP (TO to) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2) (NN clearance)) (VP (MD may) (VP (VB decrease) (PP (IN in) (NP (NP (JJ hypothyroid) (NNS patients)) (CC and) (NP (NN return)))) (PP (IN toward) (NP (JJ normal)))) (SBAR (WHADVP (WRB when)) (S (NP (DT a) (JJ euthyroid) (NN state)) (VP (VBZ is) (VP (VBN achieved))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ Concurrent) (NN use)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (ADJP (ADJP (JJ therapeutic)) (CC and) (ADJP (JJ toxic))) (NNS effects)) (PP (IN of) (NP (DT both) (NNS drugs)))) (, ,) (PP (ADVP (RB possibly)) (JJ due) (TO to) (NP (VBN increased) (NN catecholamine) (NN sensitivity)))))) (. .))))
(S1 (S (S (NP (NP (NN Onset)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NN drug1)))))) (VP (MD may) (VP (VB be) (VP (VBN accelerated))))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (NP (NP (JJ Possible) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ coronary) (NN insufficiency))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ coronary) (NN artery) (NN disease))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (CD one) (NN survey))) (, ,) (NP (NP (CD 2.3) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2))))))))) (VP (VBN experienced) (NP (NN tremor)) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (CD 0.7) (NN %)) (VP (VBN reported) (S (VP (TO to) (VP (VB occur) (PP (IN with) (NP (NP (NN drug3)) (ADVP (RB alone))))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NN contribution)) (PP (IN of) (NP (NP (DT each)) (PP (IN of) (NP (DT the) (NNS treatments))))) (PP (TO to) (NP (DT this) (JJ adverse) (NN reaction)))) (VP (VBZ is) (ADJP (JJ unknown)))) (CC but) (S (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (DT a) (NN drug) (NN interaction)))) (VP (MD cannot) (VP (VB be) (VP (VBN excluded)))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (VP (VBG possessing) (NP (JJ beta-blocking) (NNS properties)))) (VP (MD can) (VP (VB blunt) (NP (NP (DT the) (NN bronchodilator) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN bronchospasm))))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (NNS doses)) (ADJP (JJR greater) (PP (IN than) (NP (NP (DT the) (JJ normal) (JJ antiasthmatic) (NN dose)) (PP (IN of) (NP (NN drug1))))))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (DT this)) (VP (MD could) (VP (VB be) (VP (VBN explained) (PP (CC either) (PP (IN by) (NP (VBN enhanced) (NN absorption))) (CC or) (PP (IN by) (NP (NP (DT an) (NN alteration)) (PP (IN of) (NP (NP (JJ hepatic) (NN metabolism)) (PP (IN of) (NP (NN drug1))))))))))))) (, ,) (NP (JJ special) (NN care)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN in) (S (VP (VBG establishing) (NP (NP (DT the) (NN dose)) (VP (VBN required) (PP (IN for) (NP (NP (NN blood) (NN pressure) (NN control)) (PP (IN in) (NP (JJ such) (NNS patients)))))))))))))) (. .)))
(S1 (S (S (NP (NN Synergism)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (PP (IN between) (NP (NP (JJ drug1) (NN anesthesia)) (CC and) (NP (ADJP (RB intravenously) (VBN administered)) (NN drug2)))))))) (. .)))
(S1 (S (PP (IN During) (NP (NP (JJ controlled) (JJ hypotensive) (NN anesthesia)) (VP (VBG using) (NP (NN drug1)) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NN drug2)))))))) (, ,) (NP (NP (NP (JJ high) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NP (CD 3) (NN %)) (CC or) (NP (JJ above))) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug3)))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (SBAR (IN because) (S (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN hypotension)))) (VP (VP (MD will) (VP (VB be) (VP (VBN increased)))) (CC and) (PP (IN because) (IN of) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (NP (DT a) (JJ large) (NN reduction)) (PP (IN in) (NP (JJ cardiac) (NN output)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ central) (JJ venous) (NN pressure)))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN anesthesiologist)) (VP (MD should) (VP (VB be) (VP (VBN informed) (SBAR (WHADVP (WRB when)) (S (NP (DT a) (NN patient)) (VP (VBZ is) (VP (VBG receiving) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ blunts) (NP (NP (DT the) (NN reflex) (NN tachycardia)) (VP (VBN produced) (PP (IN by) (NP (NN drug2))))) (PP (IN without) (S (VP (VBG preventing) (NP (PRP$ its) (JJ hypotensive) (NN effect))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (PP (IN with) (NP (NN drug2))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN angina) (NNS pectoris))))))))) (, ,) (NP (JJ additional) (JJ antihypertensive) (NNS effects)) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (NN Care)) (VP (MD should) (VP (VB be) (VP (VBN taken) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2) (NNS s)) (PP (IN of) (NP (DT the) (NN drug3) (NN type))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Risk)) (PP (IN of) (NP (JJ Anaphylactic) (NN Reaction)))) (SBAR (IN While) (S (VP (VBG taking) (NP (NN drug1))))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ severe) (JJ anaphylactic) (NN reaction)) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS allergens)))))))))) (VP (MD may) (VP (VB be) (ADJP (RBR more) (JJ reactive) (PP (TO to) (NP (NP (JJ repeated) (NN challenge)) (, ,) (UCP (CC either) (ADJP (JJ accidental)) (, ,) (ADJP (JJ diagnostic)) (, ,) (CC or) (ADJP (JJ therapeutic))))))))) (. .)))
(S1 (S (S (NP (JJ Such) (NNS patients)) (VP (MD may) (VP (VB be) (ADJP (JJ unresponsive) (PP (TO to) (NP (NP (DT the) (JJ usual) (NNS doses)) (PP (IN of) (NP (NN drug1))) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (JJ allergic) (NN reaction)))))))))))) (. .)))
(S1 (S (NP (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (NN labetalol) (NNS metabolites))) (PP (IN in) (NP (DT the) (NN urine)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (NP (ADJP (RB falsely) (JJ elevated)) (NNS levels)) (PP (IN of) (NP (JJ urinary) (NNS catecholamines)))) (, ,) (NP (NP (NN metanephrine)) (, ,) (NP (NN normetanephrine)) (CC and) (NP (JJ vanillylmandelic) (NN acid))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN measured) (PP (IN by) (NP (ADJP (ADJP (JJ fluorimetric)) (CC or) (ADJP (JJ photometric))) (NNS methods))))))))) (. .))))
(S1 (S (PP (IN In) (NP (NP (JJ screening) (NNS patients)) (VP (VBN suspected) (PP (IN of) (S (VP (VP (VBG having) (NP (DT a) (NN pheochromocytoma))) (CC and) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))))))))) (, ,) (NP (NP (DT a) (JJ specific) (NN method)) (, ,) (ADJP (JJ such) (PP (IN as) (NP (NP (DT a) (JJ high) (NN performance) (JJ liquid) (JJ chromatographic) (NN assay)) (PP (IN with) (NP (NP (JJ solid) (NN phase) (NN extraction)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNP J) (NNP Chromatogr) (CD 385:241,1987)) (-RRB- -RRB-)))))))) (VP (MD should) (VP (VB be) (VP (VBN employed) (PP (IN in) (S (VP (VBG determining) (NP (NP (NNS levels)) (PP (IN of) (NP (NNS catecholamines)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB produce) (NP (NP (DT a) (JJ false) (JJ positive) (NN test)) (PP (IN for) (NP (NN drug2)))) (SBAR (WHADVP (WRB when)) (S (VP (VBG screening) (NP (NN urine)) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBG using) (NP (DT the) (ADJP (RB commercially) (JJ available)) (NN assay) (NNS methods) (NP (NP (NP (NN Toxi-Lab) (NN A)) (PRN (-LRB- -LRB-) (NP (NN thin-layer) (JJ chromatographic) (NN assay)) (-RRB- -RRB-))) (CC and) (NP (NP (NN Emit-d.a.u.)) (PRN (-LRB- -LRB-) (NP (JJ radioenzymatic) (NN assay)) (-RRB- -RRB-)))))))))))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN drug1)))))) (VP (VBP have) (NP (NP (DT a) (JJ positive) (NN urine) (NN test)) (PP (IN for) (NP (NN drug2))))))) (VP (VBG using) (NP (DT these) (NNS techniques)))) (NP (NN confirmation)) (VP (MD should) (VP (VB be) (VP (VBN made) (PP (IN by) (S (VP (VBG using) (NP (NP (ADJP (RBR more) (JJ specific)) (NNS methods)) (PP (JJ such) (IN as) (NP (DT a) (NN gas) (NN chromatographic-mass) (NN spectrometer) (NN technique)))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (NN drug) (NNS interactions)) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (DT some) (NNS patients)) (VP (VBG undergoing) (NP (NP (NN treatment)) (PP (IN with) (NP (JJ oral) (NN drug1)))))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN pattern)) (PP (IN of) (NP (NN use))) (PP (IN for) (NP (JJ oral) (NN drug1)))) (VP (VBZ includes) (NP (NP (JJR longer) (NN term) (NN therapy)) (, ,) (ADVP (RB particularly)) (PP (IN for) (NP (NP (NN gout)) (CC and) (NP (JJ renal) (NN calculi)))))))) (, ,) (NP (DT the)) (VP (VBP experience) (VP (VBN gained) (S (VP (MD may) (VP (VB be) (ADJP (JJ relevant))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (NP (NN drug3))) (VP (VBZ inhibits) (NP (NP (DT the) (JJ enzymatic) (NN oxidation)) (PP (IN of) (NP (NP (NN drug4)) (CC and) (NP (NN drug5)))) (PP (TO to) (NP (NN drug6)))))) (. .)))
(S1 (S (S (NP (NP (DT This) (NN oxidation)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN catalyzed) (PP (IN by) (NP (NN xanthine) (NN oxidase))))))) (, ,)) (VP (VBZ inactivates) (NP (NN drug1)))) (. .)))
(S1 (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (CD 300-600) (NN mg)) (PP (IN of) (NP (NN drug5))) (PP (IN per) (NP (NN day)))))) (VP (MD will) (VP (VB require) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN dose))) (PP (TO to) (NP (NP (RB approximately) (CD one-third) (TO to) (CD one-fourth)) (PP (IN of) (NP (NP (DT the) (JJ usual) (NN dose)) (PP (IN of) (NP (NP (NN drug6)) (CC or) (NP (NN drug7))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Subsequent) (NN adjustment)) (PP (IN of) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))))) (VP (MD should) (VP (VB be) (VP (VBN made) (PP (IN on) (NP (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (JJ therapeutic) (NN response)))) (CC and) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (JJ toxic) (NNS effects)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (NN drug2)) (VP (VBZ prolongs) (NP (NP (DT the) (NN half-life)) (PP (IN of) (NP (NP (DT the) (NN drug3)) (, ,) (NP (NN drug4)))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN basis)) (PP (IN of) (NP (DT this) (NN drug) (NN interaction)))) (VP (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established)))) (CC but) (VP (MD should) (VP (VB be) (VP (VBN noted) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (TO to) (NP (NNS patients))) (PP (ADVP (RB already)) (IN on) (NP (NN drug2) (NN therapy)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NN prothrombin) (NN time)) (VP (MD should) (VP (VB be) (VP (VBN reassessed) (ADVP (RB periodically)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT both) (NNS drugs))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN Since) (S (NP (NP (DT the) (NN excretion)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ is) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NN urate))))))))) (, ,) (NP (NP (NN drug3)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP increase) (NP (NP (DT the) (NN excretion)) (PP (IN of) (NP (NN urate))))))) (, ,)) (VP (VBP are) (ADVP (RB also)) (ADJP (JJ likely) (S (VP (TO to) (VP (VP (VB increase) (NP (NP (DT the) (NN excretion)) (PP (IN of) (NP (NN drug4))))) (CC and) (VP (ADVP (RB thus)) (JJR lower) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN xanthine) (NN oxidase))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN excretion)) (PP (IN of) (NP (NP (NNS oxypurines)) (PRN (-LRB- -LRB-) (NP (NP (NN hypoxanthine)) (CC and) (NP (NN xanthine))) (-RRB- -RRB-))))))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ urinary) (JJ uric) (NN acid) (NN excretion)) (PP (VBN compared) (PP (IN with) (NP (NP (DT that)) (VP (VBN observed) (PP (IN with) (NP (NP (NN drug3)) (ADVP (RB alone))))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (JJ clinical) (NN evidence)) (PP (TO to) (NP (NN date)))) (VP (VBZ has) (RB not) (VP (VBN demonstrated) (NP (NP (JJ renal) (NN precipitation)) (PP (IN of) (NP (NNS oxypurines))) (PP (PP (IN in) (NP (NNS patients))) (CC either) (PP (IN on) (NP (NN drug1)))) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2))))))))))) (, ,) (NP (DT the) (NN possibility)) (VP (MD should) (VP (VB be) (VP (VBN kept) (PP (IN in) (NP (NN mind))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NNS reports)) (SBAR (IN that) (S (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NN enhancement)) (PP (IN of) (NP (NN drug4) (NN toxicity))) (PP (IN in) (NP (DT some) (NNS patients)))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN reviewed) (PP (IN in) (NP (NP (DT an) (NN attempt)) (S (VP (TO to) (VP (VB establish) (NP (NP (DT a) (JJ cause-and-effect) (NN relationship)) (CC and) (NP (NP (DT a) (NN mechanism)) (PP (IN of) (NP (NN causation)))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Review)) (PP (IN of) (NP (DT these) (NN case) (NNS reports)))) (VP (VBZ indicates) (SBAR (SBAR (IN that) (S (NP (DT the) (NNS patients)) (VP (VBD were) (ADVP (RB mainly)) (VP (VBG receiving) (NP (NP (NN drug1)) (PP (IN for) (NP (NN hypertension)))))))) (CC and) (SBAR (IN that) (S (NP (NP (NNS tests)) (PP (TO to) (NP (NP (NN rule)) (PP (IN out) (NP (NP (VBN decreased) (JJ renal) (NN function)) (ADJP (JJ secondary) (PP (TO to) (NP (NN hypertensive) (NN nephropathy))))))))) (VP (VBD were) (RB not) (ADVP (RB often)) (VP (VBN performed)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT those) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ renal) (NN insufficiency)) (VP (VBD was) (VP (VBN documented))))))) (, ,) (ADVP (RB however)) (, ,) (NP (DT the) (NN recommendation) (S (VP (TO to) (VP (VB lower) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBD was) (RB not) (VP (VBN followed)))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT a) (JJ causal) (NN mechanism)) (CC and) (NP (DT a) (JJ cause-and-effect) (NN relationship))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established)))))) (, ,) (NP (JJ current) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (S (NP (JJ renal) (NN function)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (PP (ADVP (RB even)) (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ renal) (NN failure))))))))) (, ,) (CC and) (S (NP (NN dosage) (NNS levels)) (VP (MD should) (VP (VB be) (ADVP (RB even) (RBR more) (RB conservatively)) (VP (VBN adjusted) (PP (IN in) (NP (NP (DT those) (NNS patients)) (PP (IN on) (NP (JJ such) (JJ combined) (NN therapy))))) (SBAR (IN if) (S (NP (VBN diminished) (JJ renal) (NN function)) (VP (VBZ is) (VP (VBN detected)))))))))))) (. .)) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (NP (NP (DT An) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NN skin) (NN rash))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN among) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (NN drug3)) (CC or) (NP (NN drug4))) (PP (ADVP (RB concurrently)) (IN with) (NP (NN drug5))) (PP (VBN compared) (PP (TO to) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (RB not) (VP (VBG receiving) (NP (DT both) (NNS drugs))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN cause)) (PP (IN of) (NP (DT the) (VBN reported) (NN association)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (VBN Enhanced) (NN bone) (NN marrow)) (NN suppression)) (PP (IN by) (NP (NP (NN drug2)) (CC and) (NP (JJ other) (NNS drug3))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ neoplastic) (NN disease))))) (, ,) (PP (IN except) (NP (NN leukemia))) (, ,) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug4))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (NP (DT a) (JJ well-controlled) (NN study)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN lymphoma))))) (PP (IN on) (NP (NN combination) (NN therapy))))) (, ,) (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB increase) (NP (NP (DT the) (NN marrow) (NN toxicity)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and/or) (NP (NN drug6))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2) (NN s) (NN plasma) (NN half-life)) (VP (MD may) (VP (VB be) (ADJP (JJ prolonged) (PP (IN by) (NP (NN drug3)))) (, ,) (SBAR (IN since) (S (NP (NP (NN drug4)) (CC and) (NP (NN drug5))) (VP (MD may) (VP (VB compete) (PP (IN for) (NP (NN excretion))) (PP (IN in) (NP (DT the) (JJ renal) (NN tubule)))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NP (NN hypoglycemia)) (ADJP (JJ secondary) (PP (TO to) (NP (DT this) (NN mechanism))))))) (VP (MD may) (VP (VB be) (VP (VBN increased) (SBAR (IN if) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ renal) (NN insufficiency))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NNS Reports)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug2) (NNS levels)) (VP (MD may) (VP (VB be) (VP (VBN increased) (PP (IN during) (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NN drug3))) (PP (IN for) (NP (NN injection)))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Monitoring)) (PP (IN of) (NP (NP (NN drug1) (NNS levels)) (CC and) (NP (NP (JJ possible) (NN adjustment)) (PP (IN of) (NP (NN drug2) (NN dosage))))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (VP (VBN co-administered))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN s) (NN conversion)) (PP (TO to) (NP (JJ inactive) (NNS metabolites)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (VP (VBN catalyzed) (PP (IN by) (NP (NP (NN xanthine) (NN oxidase)) (PP (IN from) (NP (NN rat) (NN liver))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (JJ clinical) (NN significance)) (PRN (, ,) (SBAR (IN if) (FRAG (DT any))) (, ,))) (PP (IN of) (NP (DT these) (NNS observations)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB generally)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NN drug2))) (SBAR (IN because) (S (NP (PRP they)) (VP (VP (VBP reduce) (NP (PRP$ its) (JJ renal) (NN clearance))) (CC and) (VP (VBP add) (NP (NP (DT a) (JJ high) (NN risk)) (PP (IN of) (NP (NN drug3) (NN toxicity)))))))))))) (. .)))
(S1 (S (S (NP (VBN Read)) (VP (VBZ circulars) (PP (IN for) (NP (NP (JJ drug1) (NNS preparations)) (PP (IN before) (NP (NP (NN use)) (PP (IN of) (NP (JJ such) (JJ concomitant) (NN therapy))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (JJ ototoxic) (NN potential)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC and) (NP (DT some) (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (PRP$ Their) (JJ concurrent) (NN use)) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN number)) (PP (IN of) (NP (NP (NNS drugs)) (, ,) (PP (VBG including) (NP (NN drug1))) (, ,)))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB displace) (NP (NN drug2)) (PP (IN from) (NP (NN plasma) (NN protein)))))))))) (: ;)))
(S1 (S (S (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (DT the) (JJ usual) (NN drug1) (NN dosage)))) (VP (MD may) (VP (VB be) (VP (VBN required) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT both) (NNS drugs))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT a) (NN drug1)))) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (ADJP (ADJP (JJ diuretic)) (, ,) (ADJP (JJ natriuretic)) (, ,) (CC and) (ADJP (JJ antihypertensive))) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ desired) (NN effect)) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (VBZ is) (VP (VBN obtained)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ Several) (JJ short-term) (JJ controlled) (NNS studies)) (VP (VBD failed) (S (VP (TO to) (VP (VB wshow) (SBAR (IN that) (S (NP (NN drug2)) (ADVP (RB significantly)) (VP (VBD affected) (NP (NP (NN prothrombin) (NNS times)) (CC or) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ other) (NN clotting) (NNS factors))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (TO to) (NP (NP (NNS individuals)) (PP (IN on) (NP (NN drug3)))))))))))))))) (. .))))
(S1 (S (ADVP (RB However)) (, ,) (SBAR (IN because) (S (NP (JJ bleeding)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NN drug2))) (VP (VBP have) (VP (VBN been) (VP (VBN administered) (PP (TO to) (NP (NNS patients))) (PP (IN on) (NP (NN drug3))))))))))))) (, ,) (NP (DT the) (NN physician)) (VP (MD should) (VP (VB be) (ADJP (JJ cautious))) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug4)) (PP (TO to) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug5))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN Animal) (NNS studies)) (VP (VBP wshow) (SBAR (IN that) (S (NP (NP (NN drug2)) (VP (VBN given) (PP (IN with) (NP (NP (NN drug3)) (, ,) (PP (VBG including) (NP (NN drug4))) (, ,))))) (VP (VBZ yields) (NP (NP (DT a) (JJ net) (NN decrease)) (PP (IN in) (NP (NP (JJ anti-inflammatory) (NN activity)) (PP (IN with) (NP (NP (JJ lowered) (NN blood) (NNS levels)) (PP (IN of) (NP (DT the) (JJ non-aspirin) (NN drug))))))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Single) (NN dose) (NN bioavailability) (NNS studies)) (PP (IN in) (NP (JJ normal) (NNS volunteers)))) (VP (VBP have) (VP (VBN failed) (S (VP (TO to) (VP (VB wshow) (NP (NP (DT an) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN drug2) (NN blood) (NNS levels)))))))))) (. .)))
(S1 (S (S (NP (JJ Correlative) (JJ clinical) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ other) (NN drug3)) (, ,)) (ADVP (RB probably)) (VP (VBZ reduces) (NP (NP (DT the) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN drug4))) (PP (VBN based) (PP (IN on) (NP (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (PP (IN in) (NP (NN rabbit) (NN kidney) (NNS slices))))))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD could) (VP (VB enhance) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (NP (NP (NN H-2) (NNS Antagonists)) (: :) (S (PP (IN In) (NP (NP (NNS studies)) (PP (IN with) (NP (JJ human) (NNS volunteers))))) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (PP (IN with) (NP (NN drug3)))) (VP (VBD had) (NP (DT no) (JJ substantive) (NN effect)) (PP (IN on) (NP (NN drug4) (NN serum) (NNS concentrations))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Clinical) (NNS studies)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ random) (NNS observations)) (, ,)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (JJ natriuretic) (NN effect)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))) (PP (IN in) (NP (DT some) (NNS patients))))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN response)) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ renal) (NN prostaglandin) (NN synthesis))))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NN drug1))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (JJ renal) (NN failure))))) (, ,) (S (CONJP (RB as) (RB well) (IN as)) (VP (TO to) (VP (VB assure) (NP (NN drug2) (NN efficacy))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBD produced) (NP (NP (NP (DT an) (NN elevation)) (PP (IN of) (NP (NN plasma) (NN drug3) (NNS levels)))) (CC and) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (JJ renal) (NN drug4) (NN clearance))))) (PP (IN in) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (CD eleven) (JJ normal) (NNS volunteers))))))) (. .)))
(S1 (S (S (S (NP (DT The) (JJ mean) (JJ minimum) (NN drug1) (NN concentration)) (VP (VBD increased) (NP (CD 15) (NN %)))) (CC and) (S (NP (NP (DT the) (JJ renal) (NN clearance)) (PP (IN of) (NP (NN drug2)))) (VP (VBD was) (VP (VBN decreased) (PP (IN by) (NP (CD 19) (NN %))) (PP (IN during) (NP (NP (DT this) (NN period)) (PP (IN of) (NP (JJ concomitant) (NN drug) (NN administration))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN effect)) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ renal) (NN prostaglandin) (NN synthesis))) (PP (IN by) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concurrently)))))) (, ,) (NP (NNS subjects)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB carefully)) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NN drug3) (NN toxicity))))))))) (. .)))
(S1 (S (S (PRN (-LRB- -LRB-) (NP (NP (VBN Read) (NN circulars)) (PP (IN for) (NP (NN drug1) (NN preparation))) (PP (IN before) (NP (NP (NN use)) (PP (IN of) (NP (JJ such) (JJ concurrent) (NN therapy)))))) (-RRB- -RRB-))) (. .)))
(S1 (S (S (NP (NP (JJ Renal) (NN clearance) (NNS measurements)) (PP (IN of) (NP (NN drug1)))) (VP (MD cannot) (VP (VB be) (VP (VBN made) (PP (IN with) (NP (NP (DT any) (JJ significant) (NN accuracy)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS compounds)) (VP (VBP interfere) (PP (IN with) (NP (NP (JJ chemical) (NN color) (NN development)) (ADJP (JJ essential) (PP (TO to) (NP (DT the) (JJ analytical) (NNS procedures)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ depresses) (NP (NP (JJ tubular) (NN secretion)) (PP (IN of) (NP (NP (JJ certain) (JJ weak) (NNS acids)) (PP (JJ such) (IN as) (NP (NN drug2)))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)))) (VP (MD will) (VP (VB have) (NP (NP (ADJP (RB erroneously) (JJ low)) (NN ERPF)) (CC and) (NP (NN Tm) (NN drug2) (NNS values))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ potent) (NNS drug2)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))))) (SBAR (IN as) (S (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN ototoxicity)))) (VP (VBZ is) (VP (VBN enhanced) (PP (IN by) (NP (DT the) (NN combination))))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ increases) (ADVP (RB substantially)) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNS rashes))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT both) (NNS drugs)))))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug3))))) (ADVP (RB alone))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (NP (DT this) (NN potentiation)) (PP (IN of) (NP (NN drug1) (NNS rashes)))) (VP (VBZ is) (ADJP (JJ due) (PP (TO to) (NP (NP (NP (NN drug2)) (CC or) (NP (DT the) (NN hyperuricemia))) (ADJP (JJ present) (PP (IN in) (NP (DT these) (NNS patients))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ controlled) (JJ clinical) (NNS trials)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (CD 22) (NNS patients)) (VP (VBD received) (NP (NP (JJ concomitant) (NN drug2)) (CC and) (NP (NN drug3))))) (. .)))
(S1 (S (S (NP (DT No) (NNS rashes)) (VP (VBD were) (VP (VBN reported) (PP (IN in) (NP (DT these) (NNS patients)))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT this) (NN sample) (NN size)) (VP (VBZ is) (ADJP (RB too) (JJ small) (S (VP (TO to) (VP (VB allow) (SBAR (IN for) (S (NP (DT any) (NNS conclusions)) (VP (TO to) (VP (VB be) (VP (VBN drawn) (PP (VBG regarding) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNS rashes)) (PP (IN with) (NP (NP (JJ concomitant) (NN drug1)) (CC and) (NP (NN drug2) (NN use))))))))))))))))))) (. .)))
(S1 (S (PP (IN In) (NN common) (IN with) (NP (JJ other) (NN drug1))) (, ,) (S (NP (NN drug2)) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (JJ oral) (NN drug3)))))))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (: -) (CC or) (NP (NN drug3) (JJ -containing))) (-RRB- -RRB-))) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN 300-mg) (NN drug4) (NNS capsules)) (PP (IN with) (NP (ADJP (CD 30) (NN mL)) (NN drug5) (NN suspension)))))) (VP (VBZ reduces) (NP (NP (NP (NP (DT the) (NN rate)) (PRN (-LRB- -LRB-) (NP (NN Cmax)) (-RRB- -RRB-))) (CC and) (NP (NP (NN extent)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-)))) (PP (IN of) (NP (NN absorption)))) (PP (IN by) (NP (QP (RB approximately) (CD 40)) (NN %))))) (. .))))
(S1 (S (S (NP (NP (NN Time)) (S (VP (TO to) (VP (VB reach) (NP (NN Cmax)))))) (VP (VBZ is) (ADVP (RB also)) (VP (VBD prolonged) (PP (IN by) (NP (CD 1) (NN hour)))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ significant) (NNS effects)) (PP (IN on) (NP (NN drug1) (NNS pharmacokinetics)))) (SBAR (IN if) (S (NP (DT the) (NN drug2)) (VP (VBZ is) (VP (VBN administered) (NP (NP (NP (CD 2) (NNS hours)) (PP (IN before))) (CC or) (NP (NP (CD 2) (NNS hours)) (PP (IN after) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBP are) (VP (VBN required) (PP (IN during) (NP (NN drug2) (NN therapy))))))) (, ,) (NP (NN drug3)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (PP (NP (QP (IN at) (JJS least) (CD 2)) (NNS hours)) (IN before)) (CC or) (PP (IN after) (NP (DT the) (NN drug4)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN As) (PP (IN with) (NP (JJ other) (NNS drug2)))) (, ,) (NP (NN drug3)) (VP (VBZ inhibits) (NP (NP (DT the) (JJ renal) (NN excretion)) (PP (IN of) (NP (NN drug4)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT an) (JJ approximate) (JJ doubling)) (PP (IN in) (NP (NNP A.C.))))) (NP (NP (NP (DT a) (ADJP (CD 54) (NN %)) (NN increase)) (PP (IN in) (NP (NN peak) (NN drug5) (NN plasma) (NNS levels)))) (, ,) (CC and) (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN prolongation)) (PP (IN in) (NP (DT the) (JJ apparent) (NN elimination) (NN half-life))))))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN Foods))) (VP (VBN Fortified) (PP (IN With) (NP (NP (JJ drug2) (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug3))))) (PP (IN with) (NP (NP (DT a) (JJ therapeutic) (NN drug4)) (VP (VBG containing) (NP (NP (CD 60) (NN mg)) (PP (IN of) (NP (NP (NP (JJ elemental) (NN drug5)) (PRN (-LRB- -LRB-) (PP (IN as) (NP (NN FeSO4))) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug6)) (VP (VBN supplemented) (PP (IN with) (NP (NP (CD 10) (NN mg)) (PP (IN of) (NP (JJ elemental) (NN drug7))))))))))))))) (VP (VBD reduced) (NP (NP (NN extent)) (PP (IN of) (NP (NN absorption)))) (PP (IN by) (NP (NP (CD 80) (NN %)) (CC and) (NP (CD 31) (NN %)) (, ,) (ADVP (RB respectively))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBP are) (VP (VBN required) (PP (IN during) (NP (NN drug2) (NN therapy))))))) (, ,) (NP (NN drug3)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (PP (NP (QP (IN at) (JJS least) (CD 2)) (NNS hours)) (IN before)) (CC or) (PP (IN after) (NP (DT the) (NN supplement)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NNS foods)) (VP (ADVP (RB highly)) (VBN fortified) (PP (IN with) (NP (NP (JJ elemental) (NN drug1)) (PRN (-LRB- -LRB-) (ADVP (RB primarily)) (VP (VBP drug2) (NP (JJ -fortified) (NN breakfast) (NNS cereals))) (-RRB- -RRB-))))))) (PP (IN on) (NP (NN drug3) (NN absorption)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NP (ADJP (RB Concomitantly) (VBN administered)) (NN drug1) (JJ -fortified) (NN infant) (NN formula)) (PRN (-LRB- -LRB-) (NP (CD 2.2) (NN mg) (NN elemental) (NN drug2) (NN /6) (NN oz)) (-RRB- -RRB-))) (VP (VBZ has) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NN drug3) (NNS pharmacokinetics))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN drug1)) (PP (IN for) (NP (JJ Oral) (NN Suspension)))) (VP (MD can) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (JJ drug2) (JJ -fortified) (NN infant) (NN formula))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ rare) (NNS reports)) (PP (IN of) (NP (NN reddish) (NNS stools))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN received) (NP (NN drug1)) (PP (IN in) (NP (NNP Japan))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN reddish) (NN color)) (VP (VBZ is) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (NP (DT a) (JJ nonabsorbable) (NN complex)) (PP (IN between) (NP (NP (NN drug1)) (CC or) (NP (PRP$ its) (NN breakdown) (NNS products))))) (CC and) (NP (NP (NN drug2)) (PP (IN in) (NP (DT the) (JJ gastrointestinal) (NN tract))))))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (NP (NP (DT A) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NP (NNS ketones)) (PP (IN in) (NP (DT the) (NN urine))))))) (VP (MD may) (VP (VB occur) (PP (PP (IN with) (NP (NP (NNS tests)) (VP (VBG using) (NP (NN drug1))))) (, ,) (CC but) (PP (RB not) (IN with) (NP (NP (DT those)) (VP (VBG using) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (NP (NN urine)) (VP (VBG using) (NP (NP (NNP Clinitest) (, ,) (NNP Benedict) (NNP s) (NN solution)) (, ,) (CC or) (NP (NN Fehlings) (NN solution))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (NN glucose) (NNS tests)) (VP (VBN based) (PP (IN on) (NP (NP (JJ enzymatic) (NN glucose) (NN oxidase) (NNS reactions)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN Clinistix)) (CC or) (NP (NN Tes-Tape))))) (-RRB- -RRB-)))))) (VP (VB be) (VP (VBN used)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (ADVP (RB occasionally)) (VP (VB induce) (NP (DT a) (JJ positive) (JJ direct) (NN Coombs) (NN test)))))))) (. .)))
(S1 (S (S (NP (DT No) (NN information)) (VP (JJ available))) (. .)))
(S1 (S (S (NP (NP (JJ Catecholamine-depleting) (NNS drugs)) (, ,) (PP (FW e.g.) (, ,) (NP (NN drug1))) (, ,)) (VP (MD may) (VP (VB have) (NP (DT an) (JJ additive) (NN effect)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBN treated) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (DT a) (NN catecholamine) (NN depletor)))))) (VP (MD should) (ADVP (RB therefore)) (VP (VB be) (ADVP (RB closely)) (VP (VBN observed) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NP (NN hypotension)) (CC or) (NP (JJ marked) (NN bradycardia))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (NN vertigo)) (, ,) (NP (NN syncope)) (, ,) (CC or) (NP (JJ postural) (NN hypotension)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN study)) (PP (IN of) (NP (NP (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))) (VP (VBZ does) (RB not) (VP (VB alter) (NP (NN drug5) (NN plasma) (NNS levels)))))))) (. .)))
(S1 (S (S (S (NP (NN drug1) (NNS concentrations)) (VP (VBD were) (ADJP (RB equivocally) (JJR higher)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (NN drug2)))))))) (, ,) (CC but) (S (NP (DT this)) (VP (VBZ is) (RB not) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (ADJP (RB clinically) (JJ important))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD were) (ADVP (RB concomitantly)) (VP (VBN administered) (ADVP (RB intravenously)) (PP (TO to) (NP (JJ normal) (NNS volunteers))))))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (ADJP (CD 10-20) (NN %)) (NN increase)) (PP (IN in) (NP (NN drug3) (NN blood) (NNS levels)))) (PP (IN at) (NP (DT some) (NN time) (NNS points))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NN drug2) (NNS pharmacokinetics))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ intravenous) (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD were) (ADVP (RB concomitantly)) (VP (VBN administered) (PP (IN in) (NP (JJ normal) (NNS subjects))))))) (, ,) (S (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug3) (NN blood) (NNS levels)))) (VP (VBD was) (VP (VBN seen)))) (, ,) (CC but) (S (NP (NN drug4) (JJ steady-state) (NN blood) (NNS levels)) (VP (VBD were) (VP (VBN increased) (PP (IN by) (NP (CD 46) (NN %))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug5))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ other) (JJ pharmacokinetic) (NNS parameters)) (VP (VBD were) (VP (VBN changed)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN drug2) (JJ -induced) (JJ neuromuscular) (NN blockade)))))) (VP (VBD was) (VP (VBN studied) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NN surgery)))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NN onset)) (PP (IN of) (NP (NP (JJ neuromuscular) (NN blockade)) (PP (IN by) (NP (NN drug1)))))) (VP (VBD was) (VP (VBN unaffected) (PP (IN by) (NP (NN drug2)))))) (, ,) (CC but) (S (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (JJ neuromuscular) (NN blockade)))) (VP (VBD was) (VP (VBD prolonged) (PP (IN from) (NP (NP (CD 5) (NNS minutes)) (PP (TO to) (NP (CD 8) (NNS minutes))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT the) (NNS interactions)) (VP (VBN observed) (PP (IN in) (NP (DT these) (NNS studies))))) (VP (VBP do) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ major) (JJ clinical) (NN importance)))))))))) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN titrated) (PP (IN with) (NP (NP (NN caution)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC or) (NP (NN drug5)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (VP (VBG taking) (NP (NN drug1))))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ severe) (JJ anaphylactic) (NN reaction)) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS allergens)))))))))) (VP (MD may) (VP (VB be) (ADJP (ADJP (RBR more) (JJ reactive) (PP (TO to) (NP (JJ repeated) (NN challenge)))) (, ,) (CC either) (ADJP (JJ accidental)) (, ,) (ADJP (JJ diagnostic)) (, ,) (CC or) (ADJP (JJ therapeutic)))))) (. .)))
(S1 (S (S (NP (JJ Such) (NNS patients)) (VP (MD may) (VP (VB be) (ADJP (JJ unresponsive) (PP (TO to) (NP (NP (DT the) (JJ usual) (NNS doses)) (PP (IN of) (NP (NN drug1))) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (JJ allergic) (NN reaction)))))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG considering) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ depressed) (JJ myocardial) (NN function))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Fatal) (JJ cardiac)) (VBZ arrests)) (VP (VBP have) (VP (VBN occurred) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT both) (NNS drugs)))))))) (. .)))
(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB control) (NP (JJ supraventricular) (NN tachycardia)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNS agents)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (ADJP (ADJP (JJ vasoconstrictive)) (CC and) (ADJP (JJ inotropic))) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))) (PP (IN because) (IN of) (NP (NP (DT the) (NN danger)) (PP (IN of) (S (VP (VBG blocking) (NP (JJ cardiac) (NN contractility)))))))))))))) (SBAR (WHADVP (WRB when)) (S (NP (JJ systemic) (JJ vascular) (NN resistance)) (VP (VBZ is) (ADJP (JJ high))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (JJ nonselective) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9))) (-RRB- -RRB-))))))))) (, ,) (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (JJ serious) (, ,) (ADJP (RB sometimes) (JJ fatal)) (, ,) (NNS reactions)))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (NP (DT a) (NN serotonin) (NN releaser) (CC and) (NN reuptake) (NN inhibitor))))) (, ,) (NP (NN drug2)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (DT a) (NN drug3))))))) (. .)))
(S1 (S (S (NP (QP (IN At) (JJS least) (CD 14)) (NNS days)) (VP (MD should) (VP (VB elapse) (PP (IN between) (NP (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT a) (NN drug1)))) (CC and) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (QP (IN At) (JJS least) (CD 3)) (NNS weeks)) (VP (MD should) (VP (VB elapse) (PP (IN between) (NP (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (DT a) (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (ADJP (ADJP (JJ rare)) (, ,) (CC but) (ADJP (JJ serious)) (, ,)) (NN constellation)) (PP (IN of) (NP (NNS symptoms))) (, ,) (VP (VBN termed) (NP (NN serotonin) (NN syndrome))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS agents)) (PP (IN for) (NP (NN migraine) (NN therapy))) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (CC and) (NP (NN drug5))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN syndrome)) (VP (VP (VBZ requires) (NP (JJ immediate) (JJ medical) (NN attention))) (CC and) (VP (MD may) (VP (VB include) (NP (QP (CD one) (CC or) (JJR more)) (IN of) (NP (NP (NP (NP (DT the) (VBG following) (NNS symptoms)) (: :) (NP (NN excitement)) (, ,) (NP (NN hypomania)) (, ,) (NP (NN restlessness)) (, ,) (NP (NP (NN loss)) (PP (IN of) (NP (NN consciousness)))) (, ,) (NP (NN confusion)) (, ,) (NP (NN disorientation)) (, ,)) (NN anxiety)) (, ,) (NP (NN agitation)) (, ,) (NP (NN motor) (NN weakness)) (, ,) (NP (NN myoclonus)) (, ,) (NP (NN tremor)) (, ,) (NP (NN hemiballismus)) (, ,) (NP (NN hyperreflexia)) (, ,) (NP (NN ataxia)) (, ,) (NP (NN dysarthria)) (, ,) (NP (NN incoordination)) (, ,) (NP (NN hyperthermia)) (, ,) (NP (NN shivering)) (, ,) (NP (JJ pupillary) (NN dilation)) (, ,) (NP (NN diaphoresis)) (, ,) (NP (NN emesis)) (, ,) (CC and) (NP (NN tachycardia)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (JJ other) (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ appropriate) (NN interval)) (PP (IN between) (NP (NP (NP (NN administration)) (PP (IN of) (NP (DT these) (NNS agents)))) (CC and) (NP (NN drug1))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (JJ CNS-active) (NNS drugs)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB systematically)) (VP (VBN evaluated))))) (: ;)))
(S1 (S (S (ADVP (RB consequently)) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN advised) (SBAR (IN if) (S (NP (NP (NN drug1)) (CC and) (NP (JJ such) (NNS drugs))) (VP (VBP are) (VP (VBN prescribed) (ADVP (RB concurrently))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NP (NN plasma) (NN protein)) (PRN (-LRB- -LRB-) (NP (CD 99.9) (NN %)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NP (NN drug1)) (PP (ADVP (RB concurrently)) (IN with) (NP (JJ other) (ADJP (RB highly) (NP (NN plasma) (NN protein-)) (VBN bound)) (NNS drugs)))) (PP (IN with) (NP (JJ narrow) (JJ therapeutic) (NNS indices)))))))) (, ,) (SBAR (IN as) (S (NP (NP (NN competition)) (PP (IN for) (NP (NN binding) (NNS sites)))) (VP (MD may) (VP (VB occur))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NP (NN plasma) (NN protein) (NN binding)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN in) (NP (JJ human) (NN plasma)))))))) (VP (VP (VBZ is) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ therapeutic) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mcg/) (NN mL)) (-RRB- -RRB-)))))))))) (, ,) (CC nor) (VP (VBZ is) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NP (NN drug3)) (VP (VBN affected) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug4)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)) (NP (NN Suspension))))) (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (JJ average) (JJ steady-) (NN state) (NN plasma) (NN drug4) (NNS concentrations))))))) (. .))))
(S1 (S (S (NP (NP (NNS Alternatives)) (PP (TO to) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN during) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NP (NN PCP) (NN treatment)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (DT another) (NN drug2)) (, ,)) (VP (VP (VBZ is) (ADJP (RB structurally) (JJ similar) (PP (TO to) (NP (NN drug3))))) (CC and) (VP (MD may) (ADVP (RB possibly)) (VP (VB have) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ same) (NN drug) (NNS interactions)) (PP (IN as) (NP (NN drug4)))))))))) (. .)))
(S1 (S (S (NP (NN No) (NN interaction) (NNS trials)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (NN Drug/) (NN Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ interferes) (PP (IN with) (NP (JJ clinical) (JJ laboratory) (NN test) (NN or) (NN assay) (NNS results))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Medications)) (SBAR (WHNP (WDT that)) (S (VP (VBP interfere) (PP (IN with) (NP (NP (NN your) (NN bodys) (NN ability)) (S (VP (TO to) (VP (VB use) (NP (NN folate))))))))))) (VP (MD may) (ADVP (RB also)) (VP (VBP increase) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (DT this) (NN drug1))))))) (. .)))
(S1 (S (S (NP (NNS Medications)) (VP (MD can) (VP (VB interfere) (PP (IN with) (NP (NN folate) (NN utilization))) (, ,) (S (VP (VBG including)))))) (: :) (S (NP (NP (NN drug1) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))) (-RRB- -RRB-)) (NNS drug4)) (PRN (-LRB- -LRB-) (ADVP (RB sometimes)) (VP (VBN prescribed) (S (VP (TO to) (VP (VB control) (NP (NP (NN blood) (NN sugar)) (PP (IN in) (NP (NN type) (CD 2) (NNS diabetes)))))))) (-RRB- -RRB-))) (VP (VBN drug5) (NP (PRN (-LRB- -LRB-) (VP (VBN used) (S (VP (TO to) (VP (VB control) (NP (NP (NN inflammation)) (VP (VBN associated) (PP (IN with) (NP (NP (NN Crohns) (NN disease)) (CC and) (NP (JJ ulcerative) (NN colitis)))))))))) (-RRB- -RRB-)) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (DT a) (NN drug7)) (-RRB- -RRB-)))))) (: drug8) (S (NP (EX There)) (VP (VBZ has) (VP (VBN been) (VP (VBN concern) (PP (IN about) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (NN drug9)) (CC and) (NP (NN drug10)))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS supplements)) (VP (MD can) (VP (VB correct) (NP (NP (DT the) (NN anemia)) (VP (VBN associated) (PP (IN with) (NP (NN vitamin) (NN B12) (NN deficiency)))))))) (. .)))
(S1 (S (S (ADVP (RB Unfortunately)) (, ,) (NP (NN drug1)) (VP (MD will) (RB not) (VP (VB correct) (NP (NP (NNS changes)) (PP (IN in) (NP (DT the) (JJ nervous) (NN system))) (SBAR (WHNP (WDT that)) (S (VP (VBP result) (PP (IN from) (NP (NN vitamin) (NN B12) (NN deficiency)))))))))) (. .)))
(S1 (S (S (NP (JJ Permanent) (NN nerve) (NN damage)) (VP (MD could) (ADVP (RB theoretically)) (VP (VB occur) (SBAR (IN if) (S (NP (NN vitamin) (NN B12) (NN deficiency)) (VP (VBZ is) (RB not) (VP (VBN treated)))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN intake)) (PP (IN of) (NP (JJ supplemental) (NN drug1)))) (VP (MD should) (RB not) (VP (VB exceed) (NP (NP (NP (CD 1000) (NNS micrograms)) (PRN (-LRB- -LRB-) (NP (NP (NN g)) (, ,) (ADVP (RB sometimes)) (NP (NN mcg))) (-RRB- -RRB-))) (PP (IN per) (NP (NN day)))) (S (VP (TO to) (VP (VB prevent) (NP (NN drug2)) (PP (IN from) (NP (NP (JJ masking) (NNS symptoms)) (PP (IN of) (NP (NN vitamin) (NN B12) (NN deficiency)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ important) (PP (IN for) (S (NP (JJR older) (NNS adults)) (VP (TO to) (VP (VB be) (NP (NP (NN aware)) (PP (IN of) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (SBAR (IN because) (S (NP (PRP they)) (VP (VBP are) (PP (IN at) (NP (NP (JJR greater) (NN risk)) (PP (IN of) (S (VP (VBG having) (NP (DT a) (NN vitamin) (NN B12) (NN deficiency))))))))))))))))) (. .)))
(S1 (S (SBAR (IN If) (S (ADVP (RB you)) (VP (VBP are) (ADJP (NP (NP (CD 50) (NNS years)) (PP (IN of) (NP (NN age)))) (CC or) (ADJP (JJR older)))))) (, ,) (VP (VB ask) (S (NP (NN your) (NN physician)) (VP (TO to) (VP (VB check) (NP (JJ your) (NN B12) (NN status))) (SBAR (IN before) (S (VP (VBN you) (VP (VB take) (NP (NP (DT a) (NN supplement)) (SBAR (WHNP (WDT that)) (S (VP (VBZ contains) (NP (NN drug1))))))))))))) (. .)))
(S1 (S (S (NP (JJ Ergot-containing) (NNS drugs)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (JJ prolonged) (JJ vasospastic) (NNS reactions))))))))) (. .)))
(S1 (S (PP (IN Due) (PP (TO to) (NP (NP (DT a) (JJ theoretical) (NN risk)) (PP (IN of) (NP (DT a) (JJ pharmacodynamic) (NN interaction)))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (NP (NP (NN drug1) (JJ -containing)) (CC or) (NP (NN drug2))) (PRN (-LRB- -LRB-) (PP (IN like) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))) (-RRB- -RRB-))) (CC and) (NP (NN drug5)))) (PP (IN within) (NP (NP (CD 24) (NNS hours)) (PP (IN of) (NP (DT each) (JJ other)))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PRN (-LRB- -LRB-) (S (VP (VB see) (NP (NP (DT a) (JJ href=) (NN frova_od.htm) (NN #) (CD CI)) (NNS CONTRAINDICATIONS)))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (JJ other) (JJ 5-HT1B/1D) (NNS agonists))) (PP (IN within) (NP (NP (CD 24) (NNS hours)) (PP (IN of) (NP (NN drug1) (NN treatment)))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (, ,) (ADVP (RB rarely)) (, ,) (S (VP (TO to) (VP (VB cause) (NP (NP (NN weakness)) (, ,) (NP (NN hyperreflexia)) (, ,) (CC and) (NP (NN incoordination))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug7))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (DT an) (NN drug2))))) (VP (VBZ is) (ADVP (RB clinically)) (VP (VBN warranted))))) (, ,) (NP (NP (JJ appropriate) (NN observation)) (PP (IN of) (NP (DT the) (NN patient)))) (VP (VBZ is) (VP (VBN advised)))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN known) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (ADJP (RB commonly) (VBN employed)) (JJ clinical) (NN laboratory) (NNS tests))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Elevated) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (JJ concomitant) (NN drug2) (NN use))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (JJ drug1) (JJ -related) (JJ side) (NNS effects)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN monitoring)) (PP (IN of) (NP (NN drug1) (NN plasma) (NNS levels)))) (VP (VP (MD should) (VP (VB be) (VP (VBN considered)))) (CC and) (VP (NP (NP (NN dosage)) (PP (IN of) (NP (NP (NN drug2)) (VP (VBN adjusted))))) (, ,) (SBAR (IN as) (S (VP (VBN required)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NP (VBN reduced) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT the) (NN prolongation)) (PP (IN of) (NP (PRP$ its) (NN plasma) (NN half-life))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (PP (VBG including) (NP (NN drug2))) (, ,)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ oral) (NN drug3) (NN drug4)) (CC or) (NP (PRP$ its) (NNS derivatives)))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT these) (NNS products)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))) (, ,) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ suitable) (NN coagulation) (NN test))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ interferes) (PP (IN with) (NP (NP (DT the) (JJ therapeutic) (NN action)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBG containing) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4))))) (: ;)))
(S1 (S (NP (NP (NN drug1) (ADJP (CC or) (ADJP (JJ divalent)) (CC or) (ADJP (JJ trivalent))) (NNS cations)) (PP (JJ such) (IN as) (NP (NN drug2))) (: ;))))
(S1 (S (S (NP (NN drug1)) (VP (VBG containing) (NP (NN drug2)))) (: ;)))
(S1 (S (S (NP (NP (NP (NP (CC and) (NP (NN drug1)) (, ,)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (NP (JJ chewable/buffered) (NNS tablets)) (CC or) (NP (DT the) (JJ pediatric) (NN powder))) (PP (IN for) (NP (JJ oral) (NN solution)))) (VP (MD may) (ADVP (RB substantially)) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug3))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJ systemic) (NNS levels)) (ADJP (ADJP (RB considerably) (JJR lower)) (SBAR (IN than) (S (VP (VBN desired)))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS agents)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN within) (NP (DT the) (ADJP (CD two) (NN hour)) (NN period))) (PP (PP (IN before)) (CC or) (PP (IN within) (NP (NP (DT the) (JJ two-hour) (NN period)) (PP (IN after) (NP (NN drug1) (NN administration)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (DT some) (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1) (NN serum) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored))))) (CC and) (S (NP (JJ appropriate) (NN drug2) (NN dosage) (NNS adjustments)) (VP (VBD made) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (JJ cytotoxic) (NNS drugs))))))))) (VP (MD may) (VP (VB show) (NP (NP (JJ on-treatment) (JJ additive) (NN toxicity)) (, ,) (NP (ADVP (RB especially)) (NP (ADJP (ADJP (JJ hematologic)) (CC and) (ADJP (JJ gastrointestinal))) (NNS effects))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN with) (NP (NP (JJ other) (JJ cardioactive) (NNS compounds)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB cause) (NP (NP (NN heart) (NN failure)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug2)) (-RRB- -RRB-))))))))))) (, ,)) (VP (VBZ requires) (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (JJ cardiac) (NN function)))) (PP (IN throughout) (NP (NN treatment))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (JJ few) (NNS data)) (PP (VBG regarding) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NP (NN radiation) (NN therapy)) (CC and) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NP (JJ adjuvant) (NNS trials)) (PP (IN of) (NP (ADJP (NN drug1) (JJ -containing)) (NN CEF-120)))) (CC or) (NP (CD FEC-100) (NNS chemotherapies)))) (, ,) (NP (NN breast) (NN irradiation)) (VP (VBD was) (VP (VBN delayed) (SBAR (IN until) (S (PP (IN after) (NP (NN chemotherapy))) (VP (VBD was) (VP (VBN completed)))))))) (. .)))
(S1 (S (S (NP (DT This) (NN practice)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (JJ apparent) (NN increase)) (PP (IN in) (NP (NP (JJ local) (NN breast) (NN cancer) (NN recurrence)) (ADJP (JJ relative) (PP (TO to) (NP (VBN published) (VBZ accounts) (PP (IN in) (NP (DT the) (NN literature)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ small) (NN number)) (PP (IN of) (NP (NNS patients)))) (VP (VP (VBD received) (NP (NN drug1) (JJ -based) (NN chemotherapy)) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN radiation) (NN therapy)))) (CC but) (VP (VBD had) (NP (NP (NN chemotherapy)) (VP (VBN interrupted) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB avoid) (NP (JJ potential) (VBG overlapping) (NNS toxicities))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ likely) (SBAR (IN that) (S (NP (NP (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN radiotherapy)))) (VP (MD may) (VP (VB sensitize) (NP (NNS tissues)) (PP (TO to) (NP (NP (DT the) (JJ cytotoxic) (NNS actions)) (PP (IN of) (NP (NN irradiation)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (IN after) (NP (JJ previous) (NN radiation) (NN therapy)))) (VP (MD may) (VP (VB induce) (NP (DT an) (JJ inflammatory) (NN recall) (NN reaction)) (PP (IN at) (NP (NP (DT the) (NN site)) (PP (IN of) (NP (DT the) (NN irradiation)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB extensively)) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN liver)))))) (. .)))
(S1 (S (S (NP (NP (NNS Changes)) (PP (IN in) (NP (JJ hepatic) (NN function))) (VP (VBN induced) (PP (IN by) (NP (JJ concomitant) (NNS therapies))))) (VP (MD may) (VP (VBP affect) (NP (NP (NN drug1) (NN metabolism)) (, ,) (NP (NNS pharmacokinetics)) (, ,) (NP (JJ therapeutic) (NN efficacy)) (, ,) (CC and/or) (NP (NN toxicity)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD increased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (CD 50) (NN %))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN treatment)) (VP (MD should) (VP (VB be) (VP (VBN stopped) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (JJ Drug-Laboratory) (NN Test) (NNS Interactions)) (ADVP (RB There)) (VP (VBP are) (NP (NP (DT no) (JJ known) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN laboratory) (NNS tests))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (: :) (S (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (MD can) (VP (VB reduce) (NP (NP (NN absorption)) (PP (IN of) (NP (NN drug5))))))) (: ;))))
(S1 (S (S (NP (NP (DT an) (NN interval)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD 4)) (NNS hours))) (PP (IN between) (NP (NP (NP (NN intake)) (PP (IN of) (NP (DT these) (NNS agents)))) (CC and) (NP (NN drug1))))) (VP (MD should) (VP (VB be) (VP (VBN observed))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD can) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3)))) (, ,) (S (VP (VBG increasing) (NP (PRP$ its) (NN plasma) (NN level))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (JJ healthy) (NNS volunteers))))) (, ,) (NP (NN drug2)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NP (DT An) (NN interval)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD two)) (NNS hours))) (PP (IN between) (NP (NP (NP (NN intake)) (PP (IN of) (NP (DT this) (NN agent)))) (CC and) (NP (NN drug1))))) (VP (MD should) (VP (VB be) (VP (VBN observed))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN After) (NP (NP (NN introduction)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (JJ oral) (NN form)) (-RRB- -RRB-)))))) (, ,) (NP (NP (DT a) (JJ sudden) (NN increase)) (PP (IN in) (NP (NN serum) (NN drug3) (NN level)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))) (. .))))
(S1 (S (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN drug1) (NN level)))) (VP (VBZ is) (VP (VBN recommended)))) (CC and) (S (, ,) (SBAR (IN if) (FRAG (JJ necessary))) (, ,) (NP (NN drug2)) (VP (MD should) (VP (VB be) (VP (VBN discontinued)))))) (. .)))
(S1 (S (S (NP (JJ Intravenous) (NN drug1)) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (JJ double) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (JJ oral) (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (PP (IN of) (NP (DT this) (VBN increased) (NN bioavailability))) (CC and) (PP (IN whether) (NP (JJ similar) (NNS increases))))) (VP (MD will) (VP (VB occur) (PP (IN in) (NP (NNS patients))) (SBAR (IN given) (S (NP (JJ oral) (NN drug1)) (VP (VBZ is) (ADJP (JJ unknown))))))) (: ;)))
(S1 (S (S (NP (DT no) (JJ other) (JJ specific) (NN drug) (NN interaction) (NNS studies)) (VP (VBD were) (VP (VBN performed)))) (. .)))
(S1 (S (S (NP (NP (NNS Products)) (VP (VBG containing) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NN drug2))))) (VP (ADVP (RB likely)) (MD will) (VP (VB interfere) (PP (IN with) (NP (NP (NN absorption)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN through) (NP (DT the) (NN cytochrome) (NN P450) (NN system))) (, ,) (PP (ADVP (RB specifically)) (IN through) (NP (DT the) (NN CYP3A) (CC and) (NN CYP2C19) (NNS isozymes)))))) (. .)))
(S1 (S (S (NP (NNS Studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB have) (NP (NP (ADJP (RB clinically) (JJ significant)) (NNS interactions)) (PP (IN with) (NP (NP (NP (JJ other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NN system))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (CC or) (NP (NN drug11))) (PP (IN in) (NP (JJ healthy) (NNS subjects))))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS compounds)) (VP (VBP are) (VP (VBN metabolized) (PP (IN through) (NP (NP (JJ various) (NN cytochrome) (NN P450) (NNS isozymes)) (PP (VBG including) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2C19)) (, ,) (NP (NN CYP2D6)) (, ,) (CC and) (NP (NN CYP3A))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP3A))) (-RRB- -RRB-)))))))) (, ,) (NP (NP (NP (DT a) (JJ minor) (NN increase)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3)))))) (VP (VBD was) (VP (VBN seen)))) (. .)))
(S1 (S (S (PP (IN Because) (NP (NP (DT the) (JJ small) (NN magnitude)) (CC and) (NP (NP (DT the) (NN direction)) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN on) (NP (NN drug1) (NN clearance)))))))) (, ,) (NP (DT this) (NN interaction)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB be) (NP (JJ clinical) (NN concern)))))))) (. .)))
(S1 (S (S (ADVP (RB Nonetheless)) (, ,) (NP (JJ individual) (NNS patients)) (VP (MD may) (VP (VB require) (NP (NP (JJ additional) (NN titration)) (PP (IN of) (NP (PRP$ their) (NN drug1) (NN dosage)))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VP (VBN started)) (CC or) (VP (VBN stopped) (S (VP (TO to) (VP (VB ensure) (NP (ADJP (RB clinically) (JJ effective)) (NN blood) (NNS levels))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VBP have) (NP (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NN interaction)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (JJ single-dose) (NN crossover) (NN study)) (VP (VBG examining) (NP (NP (NP (NP (NN drug1) (CD 30) (NN mg)) (CC and) (NP (NN drug2) (CD 20) (NN mg))) (NP (DT each))) (VP (VBN administered) (ADVP (ADVP (RB alone)) (CC and) (ADVP (RB concomitantly))) (PP (IN with) (NP (NN drug3) (CD 1) (NN gram)))))))) (, ,) (S (NP (NP (NN absorption)) (PP (IN of) (NP (DT the) (NN drug4)))) (VP (VBD was) (VP (VBN delayed)))) (CC and) (S (NP (PRP$ their) (NN bioavailability)) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (NP (CD 17) (NN %)) (CC and) (NP (CD 16) (NN %)) (, ,) (ADVP (RB respectively))))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN taken) (ADVP (NP (QP (IN at) (JJS least) (CD 30)) (NNS minutes)) (RB prior) (PP (TO to) (NP (NN drug2)))))))) (. .)))
(S1 (S (PP (IN In) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NN drug1)) (VP (VBD were) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2) (NN delayed-release) (NNS capsules))))) (: ;)))
(S1 (S (S (NP (DT this)) (VP (VBD did) (RB not) (VP (VB interfere) (PP (IN with) (NP (PRP$ its) (NN effect)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ causes) (NP (NP (DT a) (ADJP (ADJP (JJ profound)) (CC and) (ADJP (JJ long))) (NN lasting) (NN inhibition)) (PP (IN of) (NP (JJ gastric) (NN acid) (NN secretion)))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (RB theoretically) (JJ possible)) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHADVP (WRB where)) (S (NP (JJ gastric) (NN pH)) (VP (VBZ is) (NP (NP (DT an) (JJ important) (NN determinant)) (PP (IN of) (NP (NP (NN bioavailability)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (NP (NP (NNS drug2)) (, ,) (NP (NN drug3) (NNS esters)) (, ,) (NP (NN drug4) (NNS salts)) (, ,) (NP (NN drug5))) (-RRB- -RRB-)))))))))))))))))) (. .)))
(S1 (S (NP (NP (NN APRD00513_IN)) (, ,) (NP (NN txt)))))
(S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (PP (JJ Due) (TO to) (NP (PRP$ its) (NN potential) (S (VP (TO to) (VP (VB cause) (NP (NP (NN neutropenia)) (CC and) (NP (NN lymphopenia)))))))) (, ,) (NP (NP (JJ proper) (NN monitoring)) (PP (IN of) (NP (NNS patients)))) (VP (VBZ is) (VP (VBN required) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ myelosuppressive) (NNS agents)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Also)) (, ,) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (JJ hepatic) (NN injury)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (NNS products)) (VP (VBN associated) (PP (IN with) (NP (JJ hepatic) (NN injury)))))))))))) (, ,) (CC or) (SBAR (WHADVP (WRB when)) (S (NP (JJ new) (NNS agents)) (VP (VBP are) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN regimen)) (PP (IN of) (NP (NP (NNS patients)) (ADVP (RB already)))))) (PP (IN on) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN drug) (NN interaction) (NNS data)) (VP (VBN described) (PP (IN in) (NP (DT this) (NN section))))) (VP (VBD were) (VP (VBN obtained) (PP (IN from) (NP (NP (JJ controlled) (JJ clinical) (NNS trials)) (CC and) (NP (NP (NNS studies)) (VP (VBG involving) (NP (NP (ADJP (RB otherwise) (JJ healthy)) (NNS adults)) (PP (IN with) (NP (NN epilepsy))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN in) (NP (NP (NN Conjunction)) (PP (IN with) (NP (JJ Other) (NN drug1)))))) (: :) (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))))) (VP (VBZ affects) (NP (NP (DT the) (JJ steady-state) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug5)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ net) (NN effect)) (PP (IN of) (NP (DT these) (NNS interactions)))) (VP (VBZ is) (VP (VBN summarized) (PP (IN in) (NP (DT the) (JJ following) (NN table)))))) (: :) (S (NP (NN drug1)) (VP (VBP drug2) (NP (NN drug3))))))
(S1 (S (NP (JJ Coadministered) (NN Concentration) (NN Concentration))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN *) (NN *))))
(S1 (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))
(S1 (S (NP (NN *) (NN CBZ) (NN epoxide))))
(S1 (S (NP (NN drug1))))
(S1 (S (S (S (NP (NN *)) (VP (RB Not) (VBN administered))) (, ,) (CC but) (S (NP (NP (DT an) (JJ active) (NN metabolite)) (PP (IN of) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (NN **)) (NP (DT No) (JJ significant) (NN effect))) (. .)))
(S1 (S (NP (NP (NP (JJ Specific) (NNS Effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (JJ Other) (NN drug2) (NN drug3)))) (: :) (NP (NP (NN drug4)) (VP (VBZ causes) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ steady-state) (NN drug5) (NN plasma) (NNS concentrations)))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (CD 10) (JJ otherwise) (JJ healthy) (NNS subjects)) (PP (IN with) (NP (NP (NN epilepsy)) (VP (VBG ingesting) (NP (NN drug1))))))) (, ,) (NP (DT the) (JJ steadystate) (NN trough) (-LRB- -LRB-) (NN Cmin) (-RRB- -RRB-) (NN drug2) (NN plasma) (NN concentration)) (VP (VBD was) (ADJP (CD 17) (CD 5) (NN micrograms/mL)))) (. .)))
(S1 (S (S (NP (DT The) (JJ steady-state) (NN Cmin)) (VP (VBD increased) (PP (TO to) (NP (CD 21) (CD 5) (NNS micrograms/mL))) (SBAR (WHADVP (WRB when)) (S (NP (NP (CD 1200) (NN mg/day)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN coadministered))))))) (. .)))
(S1 (S (S (VP (VBG Increasing) (NP (DT the) (NN drug1) (NN dose)) (PP (TO to) (NP (CD 1800) (NN mg/day))) (PP (IN in) (NP (NP (CD six)) (PP (IN of) (NP (DT these) (NNS subjects))))))) (VP (VBD increased) (NP (NP (DT the) (JJ steady-state) (NN drug2) (NN Cmin)) (PP (TO to) (NP (QP (CD 25) (CD 7)) (NNS micrograms/mL))))) (. .)))
(S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VP (VB maintain) (NP (NN drug1) (NNS levels))) (, ,) (VP (VB limit) (NP (JJ adverse) (NNS experiences))) (, ,) (CC and) (VP (VB achieve) (NP (NP (DT the) (NN drug2) (NN dose)) (PP (IN of) (NP (CD 3600) (NN mg/day))))))))) (, ,) (NP (NP (DT a) (NN drug3) (NN dose) (NN reduction)) (PP (IN of) (NP (QP (RB approximately) (CD 40)) (NN %)))) (VP (VBD was) (ADJP (JJ necessary) (PP (IN for) (NP (NP (CD eight)) (PP (IN of) (NP (DT these) (CD 10) (NNS subjects)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT a) (JJ controlled) (JJ clinical) (NN trial))) (, ,) (NP (NP (DT a) (CD 20) (NN %) (NN reduction)) (PP (IN of) (NP (NP (DT the) (JJ drug1) (NN dose)) (PP (IN at) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN drug2) (NN therapy)))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN drug3) (NNS levels)) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT those)) (ADJP (JJ prior) (PP (TO to) (NP (NN drug4) (NN administration))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ causes) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (DT the) (JJ steady-state) (NN drug3) (NN plasma) (NNS concentrations)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (DT the) (JJ steady-state) (NN drug4) (NN plasma) (NN concentration))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (CD nine) (JJ otherwise) (JJ healthy) (NNS subjects)) (PP (IN with) (NP (NP (NN epilepsy)) (VP (VBG ingesting) (NP (NN drug1))))))) (, ,) (NP (DT the) (JJ steady-state) (NN trough) (-LRB- -LRB-) (NN Cmin) (-RRB- -RRB-) (NN drug2) (NN concentration)) (VP (VBD was) (ADJP (CD 8) (CD 2) (NN micrograms/mL)))) (. .)))
(S1 (S (S (NP (DT The) (NN drug1) (NN steady-state) (NN Cmin)) (VP (VBD decreased) (NP (CD 31) (NN %)) (PP (TO to) (NP (CD 5) (CD 1) (NNS micrograms/mL))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 3000) (NN mg/day)) (, ,) (VP (VBN divided) (PP (IN into) (NP (CD three) (NNS doses))))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN coadministered))))))) (. .)))
(S1 (S (S (NP (NN drug1) (JJ steady-state) (NN Cmin) (NNS concentrations)) (VP (VBD increased) (NP (CD 57) (NN %)) (PP (IN from) (NP (NP (CD 1.0) (QP (CD 0.3) (TO to) (CD 1.6) (CD 0.4)) (NNS micrograms/mL)) (PP (IN with) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NP (JJ similar) (NNS changes)) (PP (IN in) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD were) (VP (VBN seen)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ causes) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ steady-state) (NN drug3) (NNS concentrations)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (CD four) (NNS subjects)) (PP (IN with) (NP (NP (NN epilepsy)) (VP (VBG ingesting) (NP (NN drug1))))))) (, ,) (NP (DT the) (JJ steady-state) (NN trough) (-LRB- -LRB-) (NN Cmin) (-RRB- -RRB-) (NN drug2) (NN plasma) (NN concentration)) (VP (VBD was) (ADJP (CD 63) (CD 16) (NN micrograms/mL)))) (. .)))
(S1 (S (S (NP (DT The) (JJ steady-state) (NN Cmin)) (VP (VBD increased) (PP (TO to) (NP (QP (CD 78) (CD 14)) (NNS micrograms/mL))) (SBAR (WHADVP (WRB when)) (S (NP (NP (CD 1200) (NN mg/day)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN coadministered))))))) (. .)))
(S1 (S (S (VP (VBG Increasing) (NP (DT the) (NN drug1) (NN dose)) (PP (TO to) (NP (CD 2400) (NN mg/day))))) (VP (VBD increased) (NP (NP (DT the) (JJ steadystate) (NN drug2) (NN Cmin)) (PP (TO to) (NP (QP (CD 96) (CD 25)) (NNS micrograms/mL))))) (. .)))
(S1 (S (S (NP (NP (JJ Corresponding) (NNS values)) (PP (IN for) (NP (JJ free) (NN drug1) (NN Cmin) (NNS concentrations)))) (VP (VBD were) (NP (NP (QP (CD 7) (QP (CD 3) (, ,) (CD 9) (CD 4) (, ,) (CC and) (CD 11) (CD 6))) (NNS micrograms/mL)) (PP (IN for) (NP (QP (CD 0) (, ,) (CD 1200) (, ,) (CC and) (CD 2400)) (NN mg/day) (NN drug2)))) (, ,) (ADVP (RB respectively)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS ratios)) (PP (IN of) (NP (NP (DT the) (NNS AUCs)) (PP (IN of) (NP (JJ unbound) (NN drug1))))) (PP (TO to) (NP (NP (DT the) (NNS AUCs)) (PP (IN of) (NP (DT the) (JJ total) (NN drug2)))))) (VP (VBD were) (NP (NP (CD 11.1) (NN %)) (, ,) (NP (CD 13.0) (NN %)) (, ,) (CC and) (NP (CD 11.5) (NN %))) (, ,) (PP (IN with) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (QP (CD 0) (, ,) (CD 1200) (, ,) (CC and) (CD 2400)) (NN mg/day)) (PP (IN of) (NP (NN drug3))))))) (, ,) (ADVP (RB respectively)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (VBZ causes) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN drug4) (NN plasma) (NNS concentrations)))) (, ,) (PP (IN In) (NP (NP (CD 12) (ADJP (RB otherwise) (JJ healthy)) (JJ male) (NNS volunteers)) (VP (VBG ingesting) (NP (NP (NN drug5)) (, ,) (NP (NP (DT the) (JJ steady-state) (NN trough) (-LRB- -LRB-) (NN Cmin) (-RRB- -RRB-) (NN drug6) (NN concentration)) (VP (VBD was) (NP (CD 14.2) (NN micrograms/mL)))))))))) (. .))))
(S1 (S (S (NP (DT The) (JJ steady-state) (NN Cmin) (NN concentration)) (VP (VBD increased) (PP (TO to) (NP (CD 17.8) (NNS micrograms/mL))) (SBAR (WHADVP (WRB when)) (S (NP (NP (CD 2400) (NN mg/day)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN coadministered) (PP (IN for) (NP (CD one) (NN week))))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ Other) (NN drug1))) (PP (IN on) (NP (NN drug2) (NN drug3)))) (: :) (S (S (NP (NN drug4)) (VP (VBZ causes) (NP (NP (DT an) (JJ approximate) (JJ doubling)) (PP (IN of) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-)))) (PP (IN at) (NP (JJ steady) (NN state)))))))) (CC and) (, ,) (S (ADVP (RB therefore)) (, ,) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug7)))) (VP (VBZ causes) (NP (NP (DT an) (JJ approximate) (ADJP (CD 45) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (DT the) (JJ steady-state) (NN trough) (NNS concentrations)) (PP (IN of) (NP (NN drug8)))))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (DT the) (JJ same) (NN dose)) (PP (IN of) (NP (NN drug9))) (VP (VBN given) (PP (IN as) (NP (NN monotherapy)))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NN drug2)) (VP (VBZ causes) (NP (NP (DT an) (JJ approximate) (ADJP (CD 50) (NN %)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3))) (PP (IN at) (NP (JJ steady) (NN state)))))))) (CC and) (, ,) (S (ADVP (RB therefore)) (, ,) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug4)))) (VP (VBZ results) (PP (IN in) (NP (NP (DT an) (JJ approximate) (ADJP (CD 40) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (DT the) (JJ steady-state) (NN trough) (NNS concentrations)) (PP (IN of) (NP (NN drug5))))))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (DT the) (JJ same) (NN dose)) (PP (IN of) (NP (NN drug6))) (VP (VBN given) (PP (IN as) (NP (NN monotherapy)))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ Available) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (JJ significant) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3))) (PP (IN at) (NP (JJ steady) (NN state)))))))) (, ,) (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug4)))) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB cause) (NP (NP (DT a) (ADJP (RB clinically) (JJ important)) (NN effect)) (PP (IN on) (NP (NN drug5) (-LRB- -LRB-) (NN drug6) (-RRB- -RRB-) (NN plasma) (NNS concentrations)))))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (PRP It)) (VP (VBZ appears) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD may) (VP (VB reduce) (NP (NN plasma) (NN drug3) (NNS concentrations)))))))) (. .))))
(S1 (S (S (NP (JJ Steady-state) (NN plasma) (NN drug1) (NNS concentrations)) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (NP (CD 29) (NN %)) (JJR lower) (PP (IN than) (NP (NP (DT the) (JJ mean) (NNS concentrations)) (PP (IN of) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NP (ADJP (RB newly) (VBN diagnosed)) (NNS subjects)) (PP (IN with) (NP (NN epilepsy)))) (VP (ADVP (RB also)) (VBG receiving) (NP (NP (CD 2400) (NN mg)) (PP (IN of) (NP (NN drug2) (NN a) (NN day)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NN drug2) (NP (DT The) (NP (NN rate)) (CC and) (NP (NN extent)))) (PP (IN of) (NP (NP (NN absorption)) (PP (IN of) (NP (NP (NP (DT a) (ADJP (CD 2400) (NN mg)) (NN dose)) (PP (IN of) (NP (NP (NN drug3)) (PP (IN as) (NP (NN monotherapy)))))) (VP (VBN given) (PP (IN as) (NP (NNS tablets))))))))))) (VP (VBD was) (RB not) (VP (VBN affected)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug4)))))))) (. .)))
(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NN drug2)) (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 1000) (NN mg/day)) (-RRB- -RRB-))) (PP (IN for) (NP (CD 10) (NNS days))))))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (JJ pharmacokinetic) (NNS parameters)) (PP (IN of) (NP (NP (NP (NN Cmax)) (, ,) (NP (NN Cmin)) (, ,) (NP (NN AUC)) (, ,) (NP (NN CI/kg)) (CC or) (NP (NN tmax))) (PP (IN at) (NP (NP (NN drug4) (JJ daily) (NNS doses)) (PP (IN of) (NP (QP (CD 3000) (CC or) (CD 3600)) (NN mg/day))))) (PP (IN in) (NP (NP (CD 10) (JJ otherwise) (JJ healthy) (NNS subjects)) (PP (IN with) (NP (NN epilepsy)))))))))) (. .)))
(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NP (JJ Low-Dose) (NNS drug2)) (NP (NP (DT A) (NN group)) (PP (IN of) (NP (CD 24) (JJ nonsmoking) (, ,) (JJ healthy) (JJ white) (JJ female) (NNS volunteers))))) (VP (VBN established) (PP (IN on) (NP (NP (DT an) (JJ oral) (NN drug3) (NN regimen)) (VP (VBG containing) (NP (NP (NP (ADJP (CD 30) (NN mg)) (NN drug4)) (CC and) (NP (ADJP (CD 75) (NN mg)) (NN drug5))) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 3)) (NNS months))))))))))) (VP (VBD received) (NP (NP (CD 2400) (NN mg/day)) (PP (IN of) (NP (NN drug6)))) (PP (IN from) (NP (NP (NP (NN midcycle)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 15)) (-RRB- -RRB-))) (PP (TO to) (NP (NP (NP (NN midcycle)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 14)) (-RRB- -RRB-))) (PP (IN of) (NP (CD two) (JJ consecutive) (JJ oral) (NN drug7) (NNS cycles)))))))) (. .)))
(S1 (S (S (S (NP (NN drug1) (NN treatment)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (CD 42) (NN %)) (NN decrease)) (PP (IN in) (NP (DT the) (NN drug2) (NN AUC) (CD 0-24))))))) (, ,) (CC but) (S (NP (DT no) (ADJP (RB clinically) (JJ relevant)) (NN effect)) (VP (VBD was) (VP (VBN observed) (PP (IN on) (NP (NP (DT the) (JJ pharmacokinetic) (NNS parameters)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (S (NP (DT No) (NN volunteer)) (VP (VBD showed) (NP (NP (JJ hormonal) (NN evidence)) (PP (IN of) (NP (NN ovulation)))))) (, ,) (CC but) (S (NP (CD one) (NN volunteer)) (VP (VBD reported) (ADJP (JJ intermenstrual) (JJ bleeding)) (PP (IN during) (NP (NN drug1) (NN treatment)))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB extensively)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP) (NN 3A4)))))) (, ,) (CC but) (S (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN CYP) (NN 3A4)))) (, ,)))) (VP (VBZ has) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NN drug3) (NNS pharmacokinetics)))))) (. .)))
(S1 (S (S (NP (NP (JJ Significant) (JJ pharmacokinetic) (NNS interactions)) (VP (VBN mediated) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN CYP) (NNS isoenzymes))))))) (ADVP (RB therefore)) (VP (VBP appear) (ADJP (JJ unlikely)))) (. .)))
(S1 (S (S (NP (NP (NNS Co-medications)) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NP (NN CYP) (NN 3A4)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN St.) (NN John) (NN s) (NN wort)))) (-RRB- -RRB-))))))) (VP (MD may) (ADVP (RB significantly)) (VP (VB decrease) (NP (NP (NN exposure)) (PP (TO to) (NP (NN drug5))))))) (. .)))
(S1 (S (S (NP (NN Dose) (NN modification)) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB also)) (VP (VBG receiving) (NP (DT a) (JJ potent) (NN CYP) (NN 3A4) (NN inducer))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Drug/Laboratory) (NNS Tests)) (VP (NNS Interactions) (NP (DT No) (ADJP (RB clinically) (JJ relevant)) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (JJ clinical) (NN laboratory) (NNS tests))))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed))))) (. .)))
(S1 (S (S (NP (DT No) (NP (NP (NN drug)) (, ,) (NP (JJ nutritional) (NN supplement)) (, ,) (NP (NN food)) (CC or) (NP (NN herb))) (NNS interactions)) (VP (VBP have) (ADVP (RB yet)) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN in) (NP (DT the) (NN liver))) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NN enzyme) (NN system)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (NN CYP3A4)))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (VP (VBG coadministering) (NP (NP (NNS medications)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (, ,) (NP (NP (NP (NNS inhibitors)) (, ,) (CC or) (NP (NNS inducers))) (PP (IN of) (NP (NN CYP3A4)))) (, ,) (CC or) (NP (NP (ADJP (RB potentially) (JJ toxic)) (NNS medications)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4)))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB inhibit) (NP (NP (NN CYP2D6)) (, ,) (NP (NN CYP1A2)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2C19)) (, ,) (NP (NN CYP2E1)) (, ,) (CC or) (NP (NP (NN uridine) (NN glucuronosyltransferase)) (PRN (-LRB- -LRB-) (NP (NN UDPGT)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NP (JJ total) (NN drug) (NNS concentrations)) (PP (IN of) (NP (NP (JJ other) (NNS drug3)) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBG receiving) (NP (DT both) (NNS agents)))))))))) (VP (VBD was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (NNS comparisons)) (PP (TO to) (NP (JJ historical) (NNS data))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1) (JJ steady-state) (NN Cmax)) (, ,) (NP (NNP A.C.)) (CC and) (NP (NN Cmin))) (VP (VBD were) (VP (VBN decreased) (PP (IN by) (NP (NP (CD 22) (NN %)) (, ,) (NP (CD 38) (NN %)) (, ,) (CC and) (NP (CD 27) (NN %)) (, ,) (ADVP (RB respectively)))) (, ,) (PP (IN by) (NP (JJ concomitant) (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (JJ Similar) (NNS decreases)) (PP (IN in) (NP (NP (NN Cmax)) (CC and) (NP (NN AUC))))) (VP (VBD were) (VP (VBN seen) (PP (IN after) (NP (DT the) (JJ first) (NN dose)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (JJ steady-state) (NN Cmax)) (, ,) (NP (NN A.C.)) (CC and) (NP (NN Cmin))) (VP (VBD were) (VP (VP (VBN increased) (NP (CD 21) (NN %))) (, ,) (VP (VBN decreased) (NP (CD 19) (NN %))) (, ,) (CC and) (VP (VBN decreased) (NP (NP (CD 48) (NN %)) (, ,) (ADVP (RB respectively)))) (, ,) (PP (IN by) (NP (JJ concomitant) (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (JJ steady-state) (NN Cmax)) (, ,) (NP (NNP A.C.)) (CC and) (NP (NN Cmin))) (VP (VBD were) (VP (VBN increased) (PP (IN by) (NP (NP (CD 12) (NN %)) (, ,) (NP (CD 15) (NN %)) (, ,) (CC and) (NP (CD 14) (NN %)) (, ,) (ADVP (RB respectively)))) (, ,) (PP (IN by) (NP (JJ concomitant) (NN drug2)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD can) (VP (VB decrease) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug4))))))) (. .))))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (DT a) (JJ non-matched) (NN historicalcontrol) (NN group))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (NP (NP (CD 30) (NN %)) (, ,) (NP (CD 27) (NN %)) (, ,) (CC and) (NP (CD 25) (NN %))) (NN decrease)) (PP (IN in) (NP (NP (NN serum) (NN drug3) (NN AUC)) (, ,) (NP (NN Cmax)) (, ,) (NP (NN andCmin)))))) (, ,) (ADVP (RB respectively)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ is) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (NN cytochrome) (NN P450)) (NNP C.P.A.) (NN metabolism))))) (CC and) (ADVP (RB therefore)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NNS medications)) (PP (IN with) (NP (NP (ADJP (ADJP (JJ narrow)) (ADJP (JJ therapeutic))) (NNS windows)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN of) (NP (NN CYP3A4)))))))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (JJ other) (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB result) (PP (IN in) (NP (ADJP (ADJP (JJ serious)) (CC and/or) (ADJP (JJ life-threatening))) (NN drug) (NNS interactions)))))))))) (. .)))
(S1 (S (NP (NP (NN Laboratory) (NNS Tests)) (: :) (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ low-dose) (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NNS elevations)) (PP (IN of) (NP (NP (NP (NN cholesterol)) (CC and) (NP (NNS triglycerides))) (, ,) (NP (NP (NN SGOT)) (PRN (-LRB- -LRB-) (NP (NN AST)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN SGPT)) (PRN (-LRB- -LRB-) (NP (NN ALT)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT some) (NNS patients))))))))) (. .))))
(S1 (S (S (NP (JJ Appropriate) (NN laboratory) (NN testing)) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (JJ prior) (TO to) (NP (NP (VBG initiating) (NN combination) (NN therapy)) (PP (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (CC and) (PP (IN at) (NP (JJ periodic) (NNS intervals))))))) (CC or) (SBAR (IN if) (S (NP (NP (NP (DT any) (NP (JJ clinical) (NNS signs)) (CC or) (NP (NNS symptoms))) (PP (IN of) (NP (NN hyperlipidemia)))) (CC or) (NP (JJ elevated) (NN liver) (NN function) (NNS tests))) (VP (VBP occur) (PP (IN during) (NP (NN therapy))))))))) (. .)))
(S1 (S (PP (IN For) (NP (NP (JJ comprehensive) (NN information)) (VP (VBG concerning) (NP (NP (NN laboratory) (NN test) (NNS alterations)) (VP (VBN associated) (PP (IN with) (NP (NN drug1)))))))) (, ,) (NP (NNS physicians)) (VP (MD should) (VP (VBP refer) (PP (TO to) (NP (NP (DT the) (JJ complete) (NN prescribing) (NN information)) (PP (IN for) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBD were) (VP (VBN conducted) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (NN drug1))) (S (VP (TO to) (VP (VB inhibit) (NP (NP (NP (DT the) (JJ major) (NN cytochrome) (NN P450) (NNS enzymes)) (PRN (-LRB- -LRB-) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2A6)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2C19)) (, ,) (NP (NN CYP2D6)) (, ,) (NP (NN CYP2E1)) (, ,) (CC and) (NP (NN CYP3A4))) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBP mediate) (NP (NP (NP (NN drug)) (CC and) (NP (JJ xenobiotic) (NN metabolism))) (VP (VBG using) (NP (NP (NN isoform) (JJ selective) (NN marker) (NNS substrates)) (CC and) (NP (JJ human) (NN liver) (JJ microsomal) (NNS preparations))))))))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Only)) (PP (IN at) (NP (NP (DT the) (JJS highest) (NN concentration)) (VP (VBN tested)))) (-LRB- -LRB-) (CD 171))))
(S1 (S (NP (NN g/mL) (: ;))))
(S1 (S (S (NP (CD 1) (NN mM) (-RRB- -RRB-)) (VP (VBD was) (NP (NP (DT a) (JJ slight) (NN degree)) (PP (IN of) (NP (NP (NP (NN inhibition)) (PRN (-LRB- -LRB-) (NP (CD 14) (NN %) (CD -30) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN isoform) (NN CYP2A6)) (VP (VBN observed))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN inhibition)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (JJ other) (NNS isoforms)) (VP (VBN tested))))))) (VP (VBD was) (VP (VBN observed) (PP (IN at) (NP (NP (JJ drug1) (NNS concentrations)) (ADJP (QP (RB up) (TO to) (CD 171)) (NN mg/mL)))) (PRN (-LRB- -LRB-) (NP (NP (QP (RB approximately) (CD 15)) (NNS times)) (NP (NP (DT the) (NN Cmax)) (PP (IN at) (NP (CD 3600) (NN mg/day))))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (ADVP (RB appreciably)) (VP (VBN metabolized)))) (CC nor) (SINV (VBZ does) (NP (PRP it)) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (ADJP (RB commonly) (VBN coadministered)) (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN drug) (NN interaction) (NNS data)) (VP (VBN described) (PP (IN in) (NP (DT this) (NN section))))) (VP (VBD were) (VP (VBN obtained) (PP (IN from) (NP (NP (NNS studies)) (VP (VBG involving) (NP (NP (NP (JJ healthy) (NNS adults)) (CC and) (NP (JJ adult) (NNS patients))) (PP (IN with) (NP (NN epilepsy)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (NP (NP (DT a) (ADJP (ADJP (JJ single) (PRN (-LRB- -LRB-) (NP (CD 400) (NN mg)) (-RRB- -RRB-))) (CC and) (ADJP (JJ multiple))) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 400) (NN mg) (JJ TID)) (-RRB- -RRB-))) (NN study)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (NP (NP (JJ epileptic) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NN N=8)) (-RRB- -RRB-))) (VP (VBN maintained) (PP (IN on) (NP (NN drug3) (NN monotherapy))) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 2)) (NNS months)))))))) (, ,) (S (NP (NN drug4)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ steady-state) (NN trough) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug5))))))) (CC and) (S (NP (NN drug6)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug7) (NNS pharmacokinetics)))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ Steady-state) (NN trough) (NN plasma) (NN drug2) (CC and) (NN drug3) (NNS concentrations)) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (JJ concomitant) (NNS drug4)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 400) (NN mg)) (NN TID))))))) (: ;)))))
(S1 (S (NP (NP (CD N=12) (-RRB- -RRB-) (NN administration)) (. .))))
(S1 (S (S (ADVP (RB Likewise)) (, ,) (NP (NN drug1) (NNS pharmacokinetics)) (VP (VBD were) (ADJP (JJ unaltered) (PP (IN by) (NP (NN drug2) (NN administration)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (NP (DT The) (JJ mean) (JJ steady-state) (NN trough) (NN serum) (NN drug2) (NNS concentrations)) (ADVP (ADVP (RB prior)) (PP (TO to) (CC and) (PP (IN during) (NP (JJ concomitant) (NN drug3) (NN administration)))))) (-LRB- -LRB-) (NP (ADJP (CD 400) (NN mg)) (NN TID))) (: ;))))
(S1 (S (S (S (NP (NN N=17) (-RRB- -RRB-)) (VP (VBD were) (RB not) (ADJP (JJ different)))) (CC and) (S (NP (DT neither)) (VP (VBD were) (NP (NP (NN drug1) (JJ pharmacokinetic) (NNS parameters)) (VP (VBN affected) (PP (IN by) (NP (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (NP (NN Estimates)) (PP (IN of) (NP (NP (JJ steady-state) (JJ pharmacokinetic) (NNS parameters)) (PP (IN for) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))) (-LRB- -LRB-) (NP (ADJP (CD 300) (NN mg)) (NN TID))) (: ;))))
(S1 (S (S (NP (CD N=12) (-RRB- -RRB-)) (VP (VBP are) (ADJP (JJ identical) (SBAR (IN whether) (S (NP (DT the) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (ADVP (ADVP (RB alone)) (CC or) (ADVP (RB together)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (NN Coadministration)) (PRN (-LRB- -LRB-) (NP (NN N=18)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ drug2) (NNS capsules)) (PRN (-LRB- -LRB-) (NP (CD 250) (NN mg)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 125) (NN mg)) (-RRB- -RRB-))))) (VP (VBZ appears) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NNS drug4)) (VP (VBN absorbed) (PP (IN by) (NP (QP (CD 12) (NN %) (TO to) (CD 15)) (NN %)))))))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (JJ drug2) (JJ pharmacokinetic) (NNS parameters))))) (. .)))
(S1 (S (S (NP (DT These) (NNS doses)) (VP (VBP are) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT the) (JJ therapeutic) (NNS doses)) (PP (IN for) (NP (DT both) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN magnitude)) (PP (IN of) (NP (NN interaction))) (PP (IN within) (NP (NP (DT the) (VBN recommended) (NN dose) (NNS ranges)) (PP (IN of) (NP (DT either) (NN drug)))))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug2)))) (-LRB- -LRB-) (NP (QP (CD 125) (TO to) (CD 500)) (NN mg))) (: ;))))
(S1 (S (S (NP (NN N=48) (-RRB- -RRB-)) (VP (VBZ decreases) (NP (NP (NN drug1)) (-LRB- -LRB-) (NP (CD 10) (NN mg))))) (: ;)))
(S1 (S (NP (NP (NN N=50) (-RRB- -RRB-) (NN Cmax) (CC and) (NN AUC) (NNS values)) (PP (IN in) (NP (NP (DT a) (JJ dose-dependent) (NN manner)) (ADJP (JJ relative) (PP (TO to) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (ADVP (RB alone))))))))) (: ;))))
(S1 (S (S (NP (NN Cmax) (CC and) (NN AUC) (NNS values)) (VP (VBP are) (ADJP (ADJP (ADJP (NP (CD 3) (NN %) (TO to) (CD 4) (NN %)) (JJR lower)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (ADJP (CD 125) (NN mg)) (NN drug1)))))) (CC and) (ADJP (ADJP (NP (CD 21) (NN %) (TO to) (CD 22) (NN %)) (JJR lower)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (ADJP (CD 500) (NN mg)) (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN for) (NP (DT this) (NN interaction)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ increases) (NP (NN drug2) (NN AUC) (NNS values)) (PP (IN by) (NP (CD 14) (NN %))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN magnitude)) (PP (IN of) (NP (NN interaction))) (PP (IN at) (NP (JJ other) (NNS doses)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (DT A) (NN literature) (NN article)) (VP (VBD reported) (SBAR (IN that) (S (SBAR (WHADVP (WRB when)) (S (NP (DT a) (JJ 60-mg) (JJ controlled-release) (NN drug2) (NN capsule)) (VP (VBD was) (VP (VBN administered) (ADVP (NP (CD 2) (NNS hours)) (RB prior)) (PP (TO to) (NP (NP (DT a) (JJ 600-mg) (NN drug3) (NN capsule)) (PRN (-LRB- -LRB-) (NP (NN N=12)) (-RRB- -RRB-)))))))) (, ,) (NP (JJ mean) (NN drug4) (NN AUC)) (VP (VBD increased) (PP (IN by) (NP (CD 44) (NN %))) (PP (VBN compared) (PP (TO to) (NP (NP (NN drug5)) (VP (VBN administered) (PP (IN without) (NP (NN drug6)))))))))))) (. .))))
(S1 (S (S (NP (NN drug1) (JJ pharmacokinetic) (NN parameter) (NNS values)) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug2) (CD 2) (NNS hours))) (PP (IN after) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN magnitude)) (PP (IN of) (NP (NN interaction))) (PP (IN at) (NP (JJ other) (NNS doses)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2))) (PP (IN at) (NP (NP (CD 300) (NN mg) (JJ QID)) (PRN (-LRB- -LRB-) (NP (NN N=12)) (-RRB- -RRB-)))))) (NP (NP (NP (DT the) (JJ mean) (JJ apparent) (JJ oral) (NN clearance)) (PP (IN of) (NP (NN drug3) (NN fell))) (PP (IN by) (NP (CD 14) (NN %)))) (CC and) (NP (NN creatinine) (NN clearance))) (VP (VBP fell) (PP (IN by) (NP (CD 10) (NN %))))) (. .))))
(S1 (S (S (ADVP (RB Thus)) (NP (NN drug1)) (VP (VBD appeared) (S (VP (TO to) (VP (VB alter) (NP (NP (DT the) (JJ renal) (NN excretion)) (PP (IN of) (NP (NP (CC both) (NP (NN drug2)) (CC and) (NP (NN creatinine))) (, ,) (NP (NP (DT an) (JJ endogenous) (NN marker)) (PP (IN of) (NP (JJ renal) (NN function)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT This) (JJ small) (NN decrease)) (PP (IN in) (NP (NP (NN excretion)) (PP (IN of) (NP (NN drug1))) (PP (IN by) (NP (NN drug2)))))) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ clinical) (NN importance))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN drug2)))) (VP (VBD was) (RB not) (VP (VBN evaluated)))) (. .)))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (PP (VBN Based) (PP (IN on) (NP (NP (NN AUC)) (CC and) (NP (NN half-life))))) (, ,) (NP (NP (JJ multiple-dose) (JJ pharmacokinetic) (NNS profiles)) (PP (IN of) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNS tablets)) (VP (VBG containing) (NP (NP (CD 2.5) (NN mg)) (PP (IN of) (NP (NP (NP (NN drug4)) (CC and) (NP (CD 50) (NN mcg))) (PP (IN of) (NP (NN drug5)))))))))))))) (VP (VBD were) (ADJP (JJ similar)) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug6)))))) (PRN (-LRB- -LRB-) (NP (ADJP (CD 400) (NN mg)) (NN TID)))) (: ;)))))
(S1 (S (S (NP (NN N=13)) (-RRB- -RRB-)) (. .)))
(S1 (S (S (NP (NP (DT The) (NN Cmax)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (ADJP (NP (CD 13) (NN %)) (JJR higher)) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (NN drug2))))))))) (: ;)))
(S1 (S (S (NP (DT this) (NN interaction)) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ clinical) (NN importance))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (NP (NN drug3))) (VP (VBD reduced) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN N=16)) (-RRB- -RRB-))))) (PP (IN by) (NP (QP (RB about) (CD 20)) (NN %))))) (. .)))
(S1 (S (S (NP (NP (DT This) (NN decrease)) (PP (IN in) (NP (NN bioavailability)))) (VP (VBD was) (NP (QP (RB about) (CD 5)) (NN %)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (NP (CD 2) (NNS hours)) (IN after) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug1)) (VP (VB be) (VP (VBN taken) (PP (NP (QP (IN at) (JJS least) (CD 2)) (NNS hours)) (VBG following) (NP (NN drug2) (NN administration)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN drug1) (: :) (NN drug2)))) (VP (VBZ is) (NP (NP (DT a) (NN blocker)) (PP (IN of) (NP (JJ renal) (JJ tubular) (NN secretion)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (JJ pharmacokinetic) (NNS parameters)) (PP (PP (IN without)) (CC and) (PP (IN with) (NP (NN drug2))))) (VP (VBD were) (ADJP (JJ comparable)))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB undergo) (NP (JJ renal) (JJ tubular) (NN secretion)) (PP (IN by) (NP (NP (DT the) (NN pathway)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN blocked) (PP (IN by) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (NP (NN Drug/Laboratory)) (VP (NNS Tests) (NP (NNS Interactions)) (SBAR (IN Because) (S (NP (ADJP (ADJP (JJ false)) (ADJP (JJ positive))) (NNS readings)) (VP (VBD were) (VP (VBN reported) (PP (IN with) (NP (NP (DT the) (NN Ames) (JJ N-Multistix) (NN SG) (NN dipstick) (NN test)) (PP (IN for) (NP (JJ urinary) (NN protein)))))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN added) (PP (TO to) (NP (JJ other) (NN drug2))) (, ,) (S (NP (DT the) (ADJP (RBR more) (JJ specific)) (JJ sulfosalicylic) (NN acid) (NN precipitation) (NN procedure)) (VP (VBZ is) (VP (VBN recommended) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN urine) (NN protein))))))))))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB accentuate) (NP (NP (DT the) (NN electrolyte) (NN loss)) (VP (VBN associated) (PP (IN with) (NP (NN drug2) (NN therapy)))))))) (. .)))
(S1 (S (NP (NN drug1) (NN Supplements/) (NN drug2))))
(S1 (S (S (NP (NP (NNS Products)) (VP (VBG containing) (NP (NP (NN drug1)) (CC and) (NP (NP (JJ other) (JJ multivalent) (NNS cations)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))))) (-RRB- -RRB-)))))) (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (NN absorption)) (PP (IN of) (NP (NN drug5))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (NP (QP (IN at) (JJS least) (CD 60)) (NNS minutes)) (IN before) (NP (NP (DT any) (JJ oral) (NNS medications)) (VP (VBG containing) (NP (NP (JJ multivalent) (NNS cations)) (PRN (-LRB- -LRB-) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NNS supplements)) (CC or) (NP (NN drug3)))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))))
(S1 (S (PP (IN Of) (IN over) (NP (NP (CD 3500) (NNS patients)) (VP (VBN enrolled) (PP (IN in) (NP (NP (DT the) (JJ drug1) (NN osteoporosis) (NN Treatment)) (CC and) (NP (NN Prevention)) (NP (NNS Studies))))))) (, ,) (NP (CD 15) (NN %)) (VP (VBD used) (NP (NP (JJ anti-peptic) (NNS agents)) (PRN (-LRB- -LRB-) (NP (ADVP (RB primarily)) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (PP (IN Among) (NP (DT these) (NNS patients))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ upper) (JJ gastrointestinal) (JJ adverse) (NNS experiences))) (PP (IN in) (NP (NP (DT the) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))))) (VP (VBD was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (JJ placebo-treated) (NNS patients)))))))) (. .)))
(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (QP (IN of) (IN over) (CD 1600)) (NNS patients)) (VP (VBN enrolled) (PP (IN in) (NP (NP (DT a) (NN study)) (VP (VBG comparing) (NP (ADJP (JJ once-monthly) (PP (IN with) (NP (NP (JJ daily) (NN dosing) (NNS regimens)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (CD 14) (NN %)) (PP (IN of) (NP (NNS patients))))))))) (VBN used) (JJ anti-peptic) (NNS agents))))))) (. .)))
(S1 (S (S (PP (IN Among) (NP (DT these) (NNS patients))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ upper) (JJ gastrointestinal) (JJ adverse) (NNS experiences))) (PP (IN in) (NP (NP (DT the) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1) (CD 150) (NN mg)) (ADVP (RB once) (RB monthly)))))))) (VP (VBD was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug2) (CD 2.5) (NN mg)) (ADVP (RB once) (RB daily)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: /) (NP (NP (NN drug2) (NN s)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))))))
(S1 (S (S (PP (IN In) (NP (DT the) (ADJP (ADJP (JJ large)) (, ,) (ADJP (JJ placebo-controlled))) (NN osteoporosis) (NN Treatment) (NN Study))) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD were) (VP (VBN taken) (PP (IN by) (NP (NP (CD 62) (NN %)) (PP (IN of) (NP (DT the) (CD 2946) (NNS patients)))))))) (. .)))
(S1 (S (S (PP (IN Among) (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (NNS users))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (JJ upper) (JJ gastrointestinal) (JJ adverse) (NNS events)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug3) (CD 2.5) (NN mg) (RB daily)) (PRN (-LRB- -LRB-) (NP (CD 28.9) (NN %)) (-RRB- -RRB-)))))))))) (VP (VBD was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (NP (JJ placebo-treated) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 30.7) (NN %)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (ADVP (RB Similarly)) (, ,) (PP (IN in) (NP (DT the) (JJ 1-year) (JJ monthly) (NN comparison) (NN study))) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD were) (VP (VBN taken) (PP (IN by) (NP (NP (CD 39) (NN %)) (PP (IN of) (NP (DT the) (CD 1602) (NNS patients)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (JJ upper) (JJ gastrointestinal) (NNS events)) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concomitantly)) (VBG taking) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))))))) (VP (VBD was) (ADJP (JJ similar) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NP (NP (NN drug3) (CD 2.5) (NN mg)) (ADVP (RB daily))) (PRN (-LRB- -LRB-) (NP (CD 21.7) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 150) (NN mg) (RB once) (RB monthly)) (PRN (-LRB- -LRB-) (NP (CD 22.0) (NN %)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (SBAR (IN since) (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (VP (VBP are) (ADVP (RB all)) (VP (VBN associated) (PP (IN with) (NP (JJ gastrointestinal) (NN irritation))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (PP (IN in) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug4)) (CC or) (NP (NN drug5)))) (PP (IN with) (NP (NN drug6)))))))) (. .)))
(S1 (S (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions))))
(S1 (S (S (NP (NN drug1)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ bone-imaging) (NNS agents))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Specific) (NNS studies)) (PP (IN with) (NP (NN drug1)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Monoamine) (NN Oxidase)) (NN Inhibition)) (: :) (NP (NN drug1))) (VP (VBZ is) (NP (NP (DT a) (ADJP (ADJP (JJ reversible)) (, ,) (ADJP (JJ nonselective))) (NN inhibitor)) (PP (IN of) (NP (NN monoamine) (NN oxidase)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (VBZ has) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (NN interaction)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT Some) (NNS individuals)) (VP (VBG receiving) (NP (NN drug2)))) (VP (MD may) (VP (VBP experience) (NP (NP (DT a) (JJ reversible) (NN enhancement)) (PP (IN of) (NP (NP (DT the) (JJ pressor) (NN response)) (PP (TO to) (NP (NP (JJ indirect-acting) (NN drug3)) (, ,) (NP (NN drug4)) (CC or) (NP (NN drug5)))))))))) (. .))))
(S1 (S (S (NP (NP (ADJP (RB Commonly) (VBN used)) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBP have) (VP (VBN been) (ADVP (RB specifically)) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NP (JJ Initial) (NNS doses)) (PP (IN of) (NP (NN drug1))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))) (, ,)) (VP (VP (MD should) (VP (VB be) (VP (VBN reduced)))) (CC and) (VP (VBN titrated) (S (VP (TO to) (VP (VB achieve) (NP (DT the) (JJ desired) (NN response)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN serotonin) (NN syndrome)) (PP (IN in) (NP (NN Phase) (CD 1)))) (, ,) (NP (QP (CD 2) (CC or) (CD 3)) (NNS studies))))))) (. .))))
(S1 (S (S (NP (NP (JJ Spontaneous) (NNS reports)) (PP (IN of) (NP (NP (NN serotonin) (NN syndrome)) (VP (VBN associated) (PP (IN with) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (, ,) (PP (VBG including) (NP (NP (NN drug3)) (CONJP (JJ such) (IN as)) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (JJ concomitant) (NN drug2))))))))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN observed) (PP (IN for) (NP (NP (NP (NNS signs)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NP (NN serotonin) (NN syndrome)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (JJ cognitive) (NN dysfunction))) (, ,) (NP (NP (NN hyperpyrexia)) (, ,) (NP (NN hyperreflexia)) (, ,) (NP (NN incoordination))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (DT any) (NNS signs)) (CC or) (NP (NNS symptoms))) (VP (VBP occur)))) (NP (NNS physicians)) (VP (MD should) (VP (VB consider) (NP (NP (NN discontinuation)) (PP (IN of) (NP (CC either) (NP (CD one)) (CC or) (NP (DT both)) (NP (NP (NNS agents)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (CC or) (NP (JJ concomitant) (NN drug2))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (JJ Drug-Laboratory) (NN Test) (NNS Interactions)) (ADVP (RB There)) (VP (VBP are) (NP (DT no) (VBN reported) (JJ drug-laboratory) (NN test) (NNS interactions)))) (. .)))
(S1 (S (S (NP (NP (NNS Increases)) (PP (IN in) (NP (NN prothrombin) (NN time)))) (VP (VBP have) (VP (VBN been) (VP (VBN noted) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN long-) (NN term) (NN drug1) (NN therapy)) (PP (IN after) (NP (NP (NN drug2)) (VP (VBD was) (VBN initiated))))))))))) (. .)))
(S1 (S (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (NN prothrombin) (NN time)))) (VP (VBZ is) (VP (VBN recommended)))) (CC and) (S (NP (NP (NN adjustment)) (PP (IN of) (NP (DT the) (NN drug1) (NN dose)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2) (NNS Capsules)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :)) (VP (VBZ Has) (NP (NP (DT a) (JJ synergistic) (NN effect)) (PP (IN with) (NP (NN drug2)))) (PP (IN in) (S (VP (VBG causing) (NP (JJ gastrointestinal) (JJ bleeding))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN with) (NP (NN drug2)))) (VP (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ gastrointestinal) (NN ulceration)))))) (CC and) (VP (MD may) (VP (VB reduce) (NP (NN serum) (NN salicylate) (NNS levels)))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (ADVP (RB possibly)) (NP (NN drug4))) (-RRB- -RRB-))) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN with) (NP (NN drug5)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ gastrointestinal) (NN ulceration))))))) (. .))))
(S1 (S (NP (NP (NN drug1) (NNS Agents)) (: :) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN contraindicated) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADJP (JJ hypersensitive) (PP (TO to) (NP (JJ drug3) (NNS agents)))))))))))) (. .))))
(S1 (S (NP (NP (JJ Urinary) (NNS Alkalinizers)) (: :) (S (VP (VB Decrease) (NP (NN drug1) (NN effectiveness)) (PP (IN by) (S (VP (VBG increasing) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (JJ drug2) (JJ renal) (NN excretion))))))))) (. .))))
(S1 (S (S (NP (NN drug1) (: :)) (VP (VBZ Decreases) (NP (NN drug2) (NN effectiveness)) (PP (IN by) (NP (NN enzyme) (NN induction))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (NN Serum) (NN drug2) (NNS levels)) (VP (MD may) (VP (VB be) (VP (VBN increased) (PP (IN by) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :)) (VP (MD May) (VP (VB decrease) (NP (NN drug2) (JJ anti-inflammatory) (NN action)) (PP (IN by) (S (VP (VBG competing) (PP (IN for) (NP (DT the) (JJ same) (NNS receptors))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ Enteric) (JJ Coated) (NNS drug2)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug3))) (, ,) (SBAR (IN since) (S (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN pH)) (PP (IN of) (NP (DT the) (NN stomach)))))) (VP (MD may) (VP (VB effect) (NP (NP (DT the) (JJ enteric) (NN coating)) (PP (IN of) (NP (DT the) (NNS tablets)))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN FOR) (NP (NN INJECTION))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))) (VP (VBZ is) (RB not) (VP (VBN recommended) (PP (JJ due) (TO to) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ severe) (JJ pulmonary) (NN toxicity)))))))) (. .)))
(S1 (S (S (NP (DT No) (ADJP (RB clinically) (JJ relevant)) (JJ drug-drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (SBAR (IN with) (S (NP (NNS drugs)) (ADVP (RB likely)) (VP (TO to) (VP (VB be) (VP (VBN co-administered) (PP (IN with) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6) (NNS supplements)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (NN drug13)) (, ,) (CC and) (NP (NN drug14))))))) (. .)))
(S1 (S (NP (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NP (DT A) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (DT the) (NN urine)))) (VP (MD may) (VP (VB occur) (PP (PP (IN with) (NP (NP (NN copper) (NN reduction) (NNS tests)) (PRN (-LRB- -LRB-) (NP (NN Benedict) (NN s) (CC or) (JJ Fehling) (NN s) (NN solution)) (CC or) (PP (IN with) (NP (JJ Clinitest) (NNS tablets))) (-RRB- -RRB-)))) (CC but) (PP (RB not) (IN with) (NP (NP (JJ enzyme-based) (NNS tests)) (PP (IN for) (NP (NN glycosuria))))))))) (. .))))
(S1 (S (S (SBAR (IN As) (S (NP (DT a) (JJ false-negative) (NN result)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (DT the) (NN ferricyanide) (NN test))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (CC either) (DT the) (NP (NN glucose) (NN oxidase)) (CC or) (NP (NN hexokinase) (NN method))) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (NP (NP (NN blood) (NN plasma) (NN glucose) (NNS levels)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN assay)) (PP (IN of) (NP (NP (NN serum)) (CC and) (NP (NN urine)) (NP (NN creatinine)))))) (PP (IN by) (NP (DT the) (NN alkaline) (NN picrate) (NN method)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBP prolong)) (CC and) (VP (VBP intensify) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (JJ other) (NN drug5))))) (VP (MD may) (VP (VB have) (NP (DT an) (JJ additive) (NN effect))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBP are) (VP (VBN given) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2))))))))) (, ,) (NP (NP (JJ hypertensive) (NNS reactions)) (, ,) (PP (VBG including) (NP (JJ hypertensive) (NNS crises))) (, ,)) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ antihypertensive) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))))) (VP (MD may) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (NN drug5))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB also)) (VP (VB interact) (PP (IN with) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (VBN Increased) (JJ ectopic) (NN pacemaker) (NN activity)) (VP (MD can) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP increase) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (NN absorption)) (PP (IN of) (NP (NN drug2)))))) (, ,) (SBAR (IN while) (S (NP (NN drug3)) (VP (VBZ decreases) (NP (PRP it))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN with) (NP (NN drug1))) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (VB consider) (NN drug4) (NN dose) (NN reduction)) (-RRB- -RRB-))) (. .))))
(S1 (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN exercise) (NN caution)) (-RRB- -RRB-))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBP are) (NP (NP (DT a) (JJ major) (VBG contributing) (NN factor)) (PP (TO to) (NP (NN drug2) (NN toxicity)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (, ,) (SBAR (RB particularly) (IN if) (S (VP (VBN administered) (ADVP (RB rapidly)) (PP (IN by) (NP (DT the) (JJ intravenous) (NN route)))))) (, ,) (VP (MD may) (VP (VB produce) (NP (NP (JJ serious) (NNS arrhythmias)) (PP (IN in) (NP (JJ digitalized) (NNS patients))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8))) (VP (VBP raise) (NP (NP (DT the) (NN serum) (NN drug9) (NN concentration)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (NN reduction)) (PP (PP (IN in) (NP (NN clearance))) (CC and/or) (PP (IN in) (NP (NP (NN volume)) (PP (IN of) (NP (NP (NN distribution)) (PP (IN of) (NP (DT the) (NN drug))) (, ,) (SBAR (IN with) (S (NP (NP (DT the) (NN implication)) (PP (IN that) (NP (NN drug10) (NN intoxication)))) (VP (MD may) (VP (VB result)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (CC and) (ADVP (RB possibly)) (NP (JJ other) (NN drug3)) (-RRB- -RRB-))) (CC and) (NP (NN drug4))) (VP (MD may) (VP (VB increase) (NP (NN drug5) (NN absorption)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP inactivate) (NP (NN drug6)) (PP (IN by) (NP (JJ bacterial) (NN metabolism))) (PP (IN in) (NP (DT the) (JJR lower) (NN intestine))) (, ,) (SBAR (IN so) (IN that) (S (NP (NN drug7) (NN intoxication)) (VP (MD may) (VP (VB result))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (DT this) (NN interaction)))) (VP (MD may) (VP (VB be) (VP (VBN reduced) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (IN as) (NP (NNS capsules))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,) (PP (IN by) (S (VP (VBG decreasing) (NP (NN gut) (NN motility))))) (, ,) (VP (MD may) (VP (VB increase) (NP (NN drug3) (NN absorption))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2) (NN -pectin)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (JJ certain) (JJ anticancer) (NNS drugs)) (, ,) (CC and) (NP (NN drug6))) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (JJ intestinal) (NN drug7) (NN absorption))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (ADJP (RB unexpectedly) (JJ low)) (NN serum) (NNS concentrations)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NN serum) (NN drug2) (NN concentration)) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ renal) (NN dysfunction))))) (, ,) (PP (IN by) (S (VP (VBG increasing) (NP (NP (DT the) (JJ non-renal) (NN clearance)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ inconsistent) (NNS reports)) (VP (VBG regarding) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (, ,) (NP (NNS drug2)) (-RRB- -RRB-)))) (PP (IN on) (NP (NN serum) (NN drug3) (NN concentration))))))))) (. .)))
(S1 (S (S (NP (NP (JJ drug1) (NN administration)) (PP (TO to) (NP (DT a) (ADJP (ADJP (JJ digitalized)) (, ,) (ADJP (JJ hypothyroid))) (NN patient)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN dose) (NN requirement)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ cardiac) (NNS arrhythmias)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (MD may) (VP (VB cause) (NP (NP (DT a) (JJ sudden) (NN extrusion)) (PP (IN of) (NP (NN potassium))) (PP (IN from) (NP (NN muscle) (NNS cells)))))) (, ,) (CC and) (VP (MD may) (ADVP (RB thereby)) (VP (VB cause) (NP (NP (NNS arrhythmias)) (PP (IN in) (NP (JJ digitalized) (NNS patients)))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (NP (NN drug1)) (CC or) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (VP (MD may) (VP (VB be) (ADJP (JJ useful) (PP (IN in) (NP (NN combination))))) (S (VP (TO to) (VP (VB control) (NP (NN atrial) (NN fibrillation)))))))) (, ,) (NP (NP (PRP$ their) (JJ additive) (NNS effects)) (PP (IN on) (NP (NN AV) (NN node) (NN conduction)))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (ADJP (ADJP (JJ advanced)) (CC or) (ADJP (JJ complete))) (NN heart) (NN block))))) (. .)))
(S1 (S (S (PP (IN Due) (PP (TO to) (NP (NP (DT the) (JJ considerable) (NN variability)) (PP (IN of) (NP (DT these) (NNS interactions)))))) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN individualized))) (SBAR (WHADVP (WRB when)) (S (NP (NNS patients)) (VP (VBP receive) (NP (DT these) (NNS medications)) (ADVP (RB concurrently))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG combining) (NP (NN drug1)) (PP (IN with) (NP (NP (DT any) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB cause) (NP (DT a) (JJ significant) (NN deterioration)) (PP (IN in) (NP (JJ renal) (NN function)))) (, ,) (SBAR (IN since) (S (NP (NP (DT a) (NN decline)) (PP (IN in) (NP (NP (JJ glomerular) (NN filtration)) (CC or) (NP (JJ tubular) (NN secretion))))) (VP (MD may) (VP (VB impair) (NP (NP (DT the) (NN excretion)) (PP (IN of) (NP (NN drug2)))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NNS interactions)) (PP (IN with) (NP (CD drug1) (NNS tablets) (NN USP)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN documented))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (JJ hypoparathyroid) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB concurrently)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN drug2))))))))))) (VP (MD may) (VP (VB cause) (NP (NN hypercalcemia))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (DT a) (NN drug2)) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB inactivate) (NP (NP (DT the) (JJ antifungal) (NN activity)) (PP (IN of) (NP (NN drug3))) (PP (IN by) (NP (JJ competitive) (NN inhibition))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP impair) (NP (JJ glomerular) (NN filtration)))))) (VP (MD may) (VP (VB prolong) (NP (NP (DT the) (JJ biological) (NN half-life)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (NP (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NP (NN Measurement)) (PP (IN of) (NP (NN serum) (NN creatinine) (NNS levels)))) (VP (MD should) (VP (VB be) (VP (VBN determined) (PP (IN by) (NP (DT the) (NN Jaffe) (NN reaction))))) (, ,) (SBAR (IN since) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN determination)) (PP (IN of) (NP (NN creatinine) (NNS values))) (PP (IN by) (NP (DT this) (NN method))))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Most) (JJ automated) (NN equipment)) (PP (IN for) (NP (NP (NN measurement)) (PP (IN of) (NP (NN creatinine)))))) (VP (VBZ makes) (NP (NP (NN use)) (PP (IN of) (NP (DT the) (NN Jaffe) (NN reaction)))))) (. .)))
(S1 (S (: -) (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN CNS) (JJ depressive) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (JJ other) (NNS drug4))))))))))
(S1 (S (. .)))
(S1 (S (: -) (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2) (NN therapy)))))))))
(S1 (S (. .)))
(S1 (S (S (NP (NP (CC -) (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN of) (NP (JJ human) (JJ CYP) (NNS enzymes)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD inhibited) (NP (NP (DT the) (JJ CYP) (NNS enzymes)) (NP (NP (NN 1A2)) (, ,) (NP (NN 2A6)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (NP (NN 2D6)) (, ,) (NP (NN 2E1)) (CC and) (NP (NN 3A)))) (ADVP (RB only)) (PP (IN at) (NP (NP (ADJP (RB very) (JJ high)) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NP (NN IC50)) (PP (IN from) (NP (QP (CD 200) (TO to) (IN over) (CD 1000)) (NN uM)))))))))))) (: ;)))
(S1 (S (S (NP (DT an) (JJ oral) (ADJP (CD 200) (NN mg)) (NN dose)) (VP (VBZ achieves) (NP (NP (DT a) (JJS highest) (NN level)) (PP (IN of) (NP (QP (RB approximately) (CD 5)) (NN uM))) (PP (IN in) (NP (NN people))) (-RRB- -RRB-)))) (: ;)))
(S1 (S (S (NP (DT these) (NNS enzymes)) (VP (MD would) (ADVP (RB therefore)) (RB not) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB be) (VP (VBN inhibited) (PP (IN in) (NP (JJ clinical) (NN use))))))))))) (. .)))
(S1 (S (NP (NP (NN Protein) (NN Binding)) (: :) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB highly)) (ADJP (NN protein) (VBN bound) (PRN (-LRB- -LRB-) (NP (CD 98) (NN %)) (-RRB- -RRB-))))) (. .))))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (NP (NP (DT no) (VBG binding) (NN displacement)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (JJ other) (ADJP (RB highly) (VBN bound)) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NN drug2))) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NN Catechol-O-methyltransferase) (-LRB- -LRB-) (NN COMT) (-RRB- -RRB-) (: :) (NN Hormone) (NNS levels))))) (: :) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VP (VB depress) (NP (NN prolactin) (NN secretion))) (CC and) (VP (VB increase) (NP (NN growth) (NN hormone) (NNS levels))))))))) (. .))))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN drug1))) (VP (VBN coadministered) (PP (IN with) (NP (NN drug2) (: /) (NN drug3))))) (VP (VBZ does) (RB not) (VP (VB change) (NP (DT these) (NNS effects))))) (. .)))
(S1 (S (S (NP (DT No) (NN interaction)) (VP (VBD was) (VP (VBN noted) (PP (IN with) (NP (DT the) (NN drug1) (NN drug2))) (PP (IN in) (NP (CD two) (NN multiple-dose) (NN interaction) (NNS studies)))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (NP (DT a) (NN drug4)) (: /) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN n=29)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (NP (QP (JJR More) (IN than) (CD 600)) (NN Parkinsons) (NN disease) (NNS patients)) (PP (IN in) (NP (JJ clinical) (NNS trials)))) (VP (VBP have) (VP (VBN used) (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (: /) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (SBAR (IN As) (S (NP (JJ most) (NN drug1) (NN excretion)) (VP (VBZ is) (PP (IN via) (NP (DT the) (NN bile)))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (JJ biliary) (NN excretion)) (, ,) (NP (NN glucuronidation)) (, ,) (CC and) (NP (JJ intestinal) (NN beta-glucuronidase))))))))) (VP (VBP are) (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (DT These)) (VP (VBP include) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NP (DT some) (NN drug3)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (NP (NP (NN drug4)) (, ,) (NP (NN rifamipicin)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN interaction)) (PP (IN with) (NP (DT the) (NN drug1) (NN drug2)))) (VP (VBD was) (VP (VBN shown) (PP (IN in) (NP (NP (DT a) (JJ single-dose) (NN study)) (PP (IN with) (NP (NP (NN drug3)) (PP (IN without) (NP (JJ coadministered) (NN drug4) (: /) (NN drug5)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-treatment)) (PP (IN with) (NP (DT the) (JJ potent) (NN CYP3A4) (NN inhibitor) (NN drug1)))) (VP (VBZ increases) (NP (NN drug2) (NN AUC)) (PP (IN by) (NP (CD 2/3))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (CC or) (VBG taking) (NN drug1)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NP (JJ other) (JJ strong) (JJ CYP3A4) (NNS inhibitors)) (NP (NP (ADJP (ADJP (JJ such) (PP (IN as))) (, ,) (CONJP (CC but) (RB not)) (ADJP (JJ limited) (PP (TO to))) (, ,)) (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12) (-LRB- -LRB-) (CD drug13) (-RRB- -RRB-)) (, ,) (CC and) (NP (NN drug14))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Pre-treatment)) (PP (IN with) (NP (DT the) (NN CYP3A4) (NN inducer) (NN drug1)))) (VP (VBD decreased) (NP (NN drug2) (NN AUC)) (PP (IN by) (NP (RB about) (CD 2/3))))) (. .)))
(S1 (S (S (NP (NP (JJ Alternate) (NNS treatments)) (VP (VBG lacking) (NP (NN CYP3A4) (NN inducing) (NN activity)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT an) (JJ alternative) (NN treatment)) (VP (VBZ is) (ADJP (JJ unavailable))))) (, ,) (NP (NP (DT a) (JJ drug1) (NN dose)) (ADJP (QP (JJR greater) (IN than) (CD 150)) (NN mg))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN for) (NP (NP (NP (NN NSCLC) (NNS patients)) (, ,) (CC and) (NP (ADJP (JJR greater) (PP (IN than) (NP (CD 100) (NN mg)))))) (VP (VBN considered) (PP (IN for) (NP (JJ pancreatic) (NN cancer) (NNS patients)))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT the) (NN drug1) (NN dose)) (VP (VBZ is) (VP (VBN adjusted) (S (NP (NN upward))))))) (, ,) (NP (DT the) (NN dose)) (VP (MD will) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN reduced) (PP (IN upon) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (JJ other) (NNS inducers))))))))))))) (. .)))
(S1 (S (S (NP (JJ Other) (NN CYP3A4) (NNS inducers)) (VP (VP (VBP include)) (, ,) (CC but) (VP (VBP are) (RB not) (ADJP (JJ limited) (PP (TO to) (NP (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN St.)) (NP (NNP Johns) (NNP Wort))))))))) (. .)))
(S1 (S (S (NP (NP (NN Hepatotoxicity) (JJ Asymptomatic) (NNS increases)) (PP (IN in) (NP (NN liver) (NNS transaminases)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (JJ drug1) (JJ treated) (NNS patients))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (JJ periodic) (NN liver) (NN function) (NN testing)) (PRN (-LRB- -LRB-) (NP (NP (NN transaminases)) (, ,) (NP (NN bilirubin)) (, ,) (CC and) (NP (NN alkaline) (NN phosphatase))) (-RRB- -RRB-))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (NP (NP (NN Dose) (NN reduction)) (CC or) (NP (NP (NN interruption)) (PP (IN of) (NP (NN drug1))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (IN if) (S (NP (NP (NNS changes)) (PP (IN in) (NP (NN liver) (NN function)))) (VP (VBP are) (ADJP (JJ severe))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (JJ Hepatic) (NN Impairment)) (ADVP (FW In) (FW vitro))))) (CC and) (NP (ADJP (FW in) (FW vivo)) (NN evidence))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN cleared) (ADVP (RB primarily)) (PP (IN by) (NP (DT the) (NN liver))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1) (NN exposure)) (VP (MD may) (VP (VB be) (VP (VBN increased) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ hepatic) (NN dysfunction))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (JJ Elevated) (NNP International) (VBN Normalized) (NN Ratio)) (CC and) (NP (NP (JJ Potential) (JJ Bleeding) (NNP International) (VBN Normalized) (NN Ratio)) (PRN (-LRB- -LRB-) (NP (NN INR)) (-RRB- -RRB-)))) (NNS elevations)) (CC and) (NP (NP (JJ infrequent) (NNS reports)) (PP (IN of) (NP (NP (JJ bleeding) (NNS events)) (PP (VBG including) (NP (ADJP (ADJP (JJ gastrointestinal)) (CC and) (ADJP (JJ non-gastrointestinal))) (NNS bleedings))))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (JJ clinical) (NNS studies)) (, ,) (NP (NP (DT some)) (VP (VBN associated) (PP (IN with) (NP (JJ concomitant) (NN drug1) (NN administration))))))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NN drug1)))) (CC or) (NP (NP (JJ other) (NNS drug2)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB regularly)) (PP (IN for) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (NN INR)))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (JJ oral) (NN drug2)) (, ,) (NP (JJ certain) (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (DT the) (NP (NN cytochrome) (NN P450) (NN 3A4)) (NN enzyme) (NN system)))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NP (NN drug1) (NNS Tablets)) (CC and) (NP (NNS drugs))) (VP (ADVP (RB primarily)) (VBN metabolized) (PP (IN by) (NP (DT the) (NP (NN cytochrome) (NN P450) (NN 3A4)) (NN enzyme) (NN system))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (DT the) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VP (VB increase)) (CC or) (VP (VB prolong) (NP (ADJP (CC both) (ADJP (JJ therapeutic)) (CC and) (ADJP (JJ adverse))) (NNS effects)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN unless) (S (VP (ADVP (RB otherwise)) (VBN specified)))) (, ,) (NP (JJ appropriate) (NN dosage) (NNS adjustments)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (NN drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN identified) (S (VP (VBG involving) (NP (NP (NP (NN drug1) (NNS Tablets)) (CC and) (NP (JJ other) (NNS drugs))) (VP (VBN metabolized) (PP (IN by) (NP (NP (DT the) (NN cytochrome) (NN P450) (NN 3A4)) (NN enzyme) (NN system))))))))))) (: :) (S (NP (NN drug2) (NNS tablets)) (VP (VBP inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NP (DT an) (VBN increased) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug4)))) (CC and) (NP (NP (DT a) (NN delay)) (PP (IN in) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (PRP$ its) (NN acid) (NN metabolite)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (VBN increased) (NN plasma) (NN concentration)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (PRP$ its) (NN metabolite))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ prolonged) (VBG QT) (NNS intervals)))))) (. .)))
(S1 (S (S (NP (JJ Pharmacokinetic) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ oral) (NN drug1)) (VP (VBZ inhibits) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJ elevated) (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NP (NP (NN drug3)) (CC and) (NP (PRP$ its) (JJ active) (NN metabolite))) (NNS drug4)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB prolong) (NP (VBG QT) (NNS intervals))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2) (NNS tablets)))) (VP (VBZ is) (ADVP (RB therefore)) (VP (VBN contraindicated)))) (. .)))
(S1 (S (S (NP (JJ Human) (NNS pharmacokinetics) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ oral) (NN drug1)) (ADVP (RB potently)) (VP (VBZ inhibits) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (ADJP (NN mean) (JJ eight-fold)) (NN increase)) (PP (IN in) (NP (NP (NN AUC)) (PP (IN of) (NP (NN drug3)))))))))))))))) (. .)))
(S1 (S (S (NP (NNS Data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (JJ oral) (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (NN prolongation)) (PP (IN of) (NP (NP (DT the) (JJ QT) (NN interval)) (PP (IN on) (NP (DT the) (NN ECG))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1) (NNS tablets))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS tablets)) (VP (MD may) (VP (VB alter) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJ elevated) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ latter) (NNS drugs)))))))))) (. .)))
(S1 (S (S (NP (JJ Dosage) (NN adjustment)) (VP (MD may) (VP (VB be) (VP (VBN required) (SBAR (IN if) (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC or) (NP (NN drug3))) (VP (VBP are) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ drug4) (NNS Tablets))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1) (NNS Tablets))) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))) (VP (VBZ has) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ elevated) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ latter) (CD two) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VP (VB potentiate)) (CC and) (VP (VB prolong) (NP (NP (NP (NN hypnotic)) (CC and) (NP (JJ sedative) (NNS effects))) (, ,) (ADVP (RB especially)) (PP (IN with) (NP (NP (NP (JJ repeated) (NN dosing)) (CC or) (NP (JJ chronic) (NN administration))) (PP (IN of) (NP (DT these) (NNS agents)))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS agents)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (JJ drug1) (NNS Tablets)))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB parenterally)))))) (, ,) (NP (JJ special) (NN precaution)) (VP (VBZ is) (VP (VBN required) (SBAR (IN since) (S (NP (DT the) (JJ sedative) (NN effect)) (VP (MD may) (VP (VB be) (ADJP (JJ prolonged))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Rare) (NNS cases)) (PP (IN of) (NP (NP (JJ elevated) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (ADJP (JJ clear)) (SBAR (IN whether) (S (NP (DT this)) (VP (VBD was) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NN therapy))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (, ,) (ADVP (RB therefore)) (, ,) (ADJP (JJ advisable) (S (VP (TO to) (VP (VB monitor) (NP (NP (NN drug1) (NNS concentrations)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN taken) (ADVP (RB orally))))) (, ,) (NP (NP (NN drug1)) (PP (IN like) (NP (NN drug2)))) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ anticoagulant) (NN effect)) (PP (IN of) (NP (JJ drug3) (JJ -like) (NNS drugs))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ simultaneous) (NN treatment)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (, ,) (NP (DT the) (JJ anticoagulant) (NN effect)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VP (VBN titrated)) (CC and) (VP (VBN monitored)))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (JJ severe) (NN hypoglycemia)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concomitantly)) (VBG receiving) (NP (NP (NP (JJ oral) (NN drug1)) (PRN (-LRB- -LRB-) (NP (DT an) (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (JJ oral) (NN drug3))))))))))) (, ,) (NP (NP (PDT such) (DT a) (JJ potential) (NN interaction)) (VP (VBG involving) (NP (NP (DT the) (JJ latter) (NNS agents)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug4) (NNS tablets)) (PRN (-LRB- -LRB-) (NP (DT an) (NN drug5)) (-RRB- -RRB-)))))))))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN ruled) (PRT (RP out)))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1) (NNS tablets))) (PP (IN with) (NP (NN drug2)))) (VP (MD may) (VP (VB alter) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NP (CD one)) (CC or) (NP (DT both))) (PP (IN of) (NP (DT the) (NNS drugs))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN suggested) (S (VP (TO to) (VP (VB monitor) (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2) (NNS tablets)))) (VP (VBZ reduces) (NP (NP (DT the) (NN blood) (NNS levels)) (PP (IN of) (NP (DT the) (JJ latter)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (VP (VBZ is) (ADVP (RB also)) (VP (VBN reported) (S (VP (TO to) (VP (VB affect) (NP (NN drug3) (NNS concentrations)) (ADVP (RB adversely)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS drugs)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN given) (ADVP (RB concomitantly)))))) (. .)))
(S1 (S (PP (IN After) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NP (NP (ADJP (CD 200) (NN mg)) (JJ oral) (NN drug1)) (ADVP (RB twice) (RB daily))) (CC and) (NP (NP (CD one) (ADJP (CD 20) (NN mg)) (NN dose)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (CD 11) (NNS subjects)))))))) (, ,) (NP (NP (DT the) (NP (NN AUC)) (CC and) (NP (NN Cmax))) (PP (IN of) (NP (NN drug3)))) (VP (VBD averaged) (NP (NP (NP (CD 302) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 142) (NN S.D.)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 251) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 68) (NN S.D.)) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN of) (NP (NP (DT those)) (VP (VBN obtained) (PP (IN after) (NP (NP (NN co-treatment)) (PP (IN with) (NP (NN placebo)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (NN AUC)) (CC and) (NP (NN Cmax))) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (DT an) (JJ active) (NN metabolite)) (, ,)))) (VP (VBD averaged) (NP (NP (NP (CD 155) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 27) (NN S.D.)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 141) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 35) (NN S.D.)) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT no) (JJ related) (NNS changes)) (VP (VBD were) (VP (VBN noted) (PP (IN in) (NP (NP (DT the) (NNS QT0)) (PP (IN on) (NP (NP (NN ECG)) (VP (VBN taken) (PP (IN at) (NP (NP (QP (CD 2) (, ,) (CD 6) (, ,) (CC and) (CD 24)) (NNS hours)) (PP (IN after) (NP (DT the) (NN coadministration))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Also)) (, ,) (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NNS differences)) (PP (IN in) (NP (JJ adverse) (NNS events)))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Rare) (NNS cases)) (PP (IN of) (NP (NP (DT a) (JJ disulfiram-like) (NN reaction)) (PP (TO to) (NP (NN drug1)))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (DT These) (NNS experiences)) (VP (VBP have) (VP (VBN been) (VP (VBN characterized) (PP (IN by) (NP (NP (NN flushing)) (, ,) (NP (NN rash)) (, ,) (NP (JJ peripheral) (NN edema)) (, ,) (NP (NN nausea)) (, ,) (CC and) (NP (NN headache)))))))) (. .)))
(S1 (S (S (NP (NNS Symptoms)) (VP (VBN resolved) (PP (IN within) (NP (DT a) (JJ few) (NNS hours))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ daily) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (RB not) (VP (VB exceed) (NP (CD 7.5) (NN mg)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NP (JJ potent) (JJ CYP3A4) (NNS inhibitors)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (CC and) (NP (NN nefazadone)))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN taken) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NNS medications)) (SBAR (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB predominantly)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP2D6))))))) (CC and) (SBAR (WHNP (WDT which)) (S (VP (VBP have) (NP (DT a) (JJ narrow) (JJ therapeutic) (NN window)))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4))) (PRN (-LRB- -LRB-) (VP (VB see) (NP (JJ CLINICAL) (NN PHARMACOLOGY))) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NNS drug2)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NP (NN frequency)) (CC and/or) (NP (NN severity))) (PP (IN of) (NP (NP (JJ dry) (NN mouth)) (, ,) (NP (NN constipation)) (, ,) (NP (JJ blurred) (NN vision)) (CC and) (NP (JJ other) (JJ anticholinergic) (JJ pharmacological) (NNS effects)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB potentially)) (VP (VB alter) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (DT some) (ADJP (RB concomitantly) (VBN administered)) (NNS drugs)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS effects)) (PP (IN on) (NP (JJ gastrointestinal) (NN motility)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NN Laboratory) (NN Test) (NNS Interactions) (NNS Interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN laboratory) (NNS tests))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NN drug) (NN metabolism) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB predominantly)) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NP (NP (NN isozyme) (NN CYP2C9)) (PRN (-LRB- -LRB-) (NP (CD 70) (NN %)) (-RRB- -RRB-))))) (PP (CC and) (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (NP (NP (NN CYP3A4)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN %)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ potential) (NN inhibitor)) (PP (IN of) (NP (DT the) (NN CYP2C9) (NN isoenzyme)))) (ADVP (FW in) (FW vivo)) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (ADJP (FW in) (FW vitro)) (NN metabolism)) (PP (IN of) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (JJ CYP3A4) (JJ metabolic) (NNS reactions)))) (VP (VBD was) (RB not) (VP (VBN detected) (PP (IN in) (NP (ADJP (FW in) (FW vitro)) (NNS experiments)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (DT a) (ADJP (ADJP (JJ randomized)) (, ,) (ADJP (JJ multiple-dose))) (NN crossover) (NN study))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NN Type) (CD 2) (NNS diabetes)))) (VP (VBD were) (VP (VBN administered) (NP (NP (CD 120) (NN mg) (NN drug2) (CD three) (NNS times)) (NP (NP (DT a) (NN day)) (PP (IN before) (NP (NN meals))) (PP (IN for) (NP (CD 1) (NN day))))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug3) (CD 10) (NN mg)) (ADVP (RB daily))))))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (ADJP (RB clinically) (JJ relevant)) (NNS alterations)) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN agent)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug2) (CD 120) (NN mg)) (ADVP (NP (CD three) (NNS times)) (RB daily) (PP (IN before) (NP (NN meals))))) (VP (VBD was) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug3) (CD 500) (NN mg) (CD three) (NNS times)) (ADJP (JJ daily) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NN Type) (CD 2) (NNS diabetes)))))))))))))) (, ,) (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (ADJP (RB clinically) (JJ relevant)) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN agent)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug2) (CD 120) (NN mg)) (PP (IN before) (NP (NN meals)))) (VP (VBD was) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (DT a) (JJ single) (JJ 1-mg) (NN dose)) (PP (IN of) (NP (NN drug3))) (PP (TO to) (NP (JJ healthy) (NNS volunteers))))))))))) (, ,) (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (ADJP (RB clinically) (JJ relevant)) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN agent)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (JJ healthy) (NNS subjects)) (VP (VBD were) (VP (VBN administered) (ADVP (NP (NN drug2) (CD 120) (NN mg) (CD three) (NNS times)) (RB daily)) (PP (IN before) (NP (NN meals))) (PP (IN for) (NP (NP (CD four) (NNS days)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NN drug3) (CD 30) (NN mg)) (PP (IN on) (NP (NN day) (CD 2))))))))))))))) (, ,) (NP (EX there)) (VP (VBD were) (NP (DT no) (NNS alterations)) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN agent))))))) (. .))))
(S1 (S (S (NP (NN Prothrombin) (NN time)) (VP (VBD was) (RB not) (VP (VBN affected)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NP (NP (NN morning)) (CC and) (NP (NN lunch))) (NNS doses)) (PP (IN of) (NP (NP (NN drug2) (CD 120) (NN mg)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (DT a) (JJ single) (NN 75-mg) (NN dose)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))))))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (JJ significant) (NNS changes)) (PP (TO to) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN agent))))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NP (NP (NN plasma) (NNS proteins)) (PRN (-LRB- -LRB-) (NP (CD 98) (NN %)) (-RRB- -RRB-))) (, ,) (NP (ADVP (RB mainly)) (NP (NN albumin)))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NN displacement) (NNS studies)) (PP (IN with) (NP (NP (ADJP (RB highly) (JJ protein-bound)) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (CC and) (NP (NN drug11))))))) (VP (VBD showed) (NP (NP (DT no) (NN influence)) (PP (IN on) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN drug12) (NN protein) (NN binding)))))))) (. .)))
(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (NN drug1)) (VP (VBD had) (NP (DT no) (NN influence)) (PP (IN on) (NP (NP (DT the) (NN serum) (NN protein) (NN binding)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8)))))) (ADVP (FW in) (FW vitro)))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (JJ prudent) (NN evaluation)) (PP (IN of) (NP (JJ individual) (NNS cases)))) (VP (VBZ is) (VP (VBN warranted) (PP (IN in) (NP (DT the) (JJ clinical) (NN setting)))))) (. .)))
(S1 (S (S (NP (NP (JJ Certain) (NNS drugs)) (, ,) (PP (VBG including) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ hypoglycemic) (NN action)) (PP (IN of) (NP (NP (NN drug6)) (CC and) (NP (JJ other) (JJ oral) (NNS drug7)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Certain) (NNS drugs)) (PP (VBG including) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (JJ hypoglycemic) (NN action)) (PP (IN of) (NP (NP (NN drug5)) (CC and) (NP (JJ other) (JJ oral) (NN drug6)))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (VP (VP (VBN administered) (PP (TO to))) (CC or) (VP (VBN withdrawn) (PP (IN from) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ glycemic) (NN control))))))))) (. .)))
(S1 (S (S (NP (JJ Additive) (JJ depressant) (NN effect)) (ADVP (WRB when)) (VP (VBN used) (PP (IN with) (NP (NP (JJ general) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (JJ other) (NN drug6)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN mixing)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NP (DT an) (NN drug3)) (PP (IN in) (NP (FW vitro)))))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (JJ substantial) (NN inactivation)) (PP (IN of) (NP (DT the) (NN drug4)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (VP (VBN used) (PP (IN in) (NP (DT the) (JJ perioperative) (NN period)))))) (, ,) (NP (NN drug2)) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN prolongation)) (PP (IN of) (NP (NP (DT the) (JJ neuromuscular) (NN blockade)) (PP (IN of) (NP (NN drug3))))))))))) (. .))))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN indicated) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (NP (NN perioperatively))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (CD one) (JJ controlled) (JJ clinical) (NN study))) (, ,) (NP (NP (DT the) (NNS ureidopenicillins)) (, ,) (PP (VBG including) (NP (NN drug1))) (, ,)) (VP (VBD were) (VP (VBN reported) (S (VP (TO to) (VP (VB prolong) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (PP (JJ Due) (TO to) (NP (NP (PRP$ their) (JJ similar) (NN mechanism)) (PP (IN of) (NP (NN action))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN expected) (SBAR (IN that) (S (NP (NP (DT the) (JJ neuromuscular) (NN blockade)) (VP (VBN produced) (PP (IN by) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NN drug1))))))) (VP (MD could) (VP (VB be) (VP (VBD prolonged) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (JJ oral) (NN combination)) (PP (IN of) (NP (NN drug2))) (PP (IN before) (NP (NP (JJ intramuscular) (NN injection)) (PP (IN of) (NP (NN drug3)))))) (VP (VBZ produces) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ drug4) (JJ peak) (NN serum) (NN level)) (PP (IN of) (NP (QP (RB about) (CD 30)) (NN %)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN Coagulation) (NNS parameters)) (VP (MD should) (VP (VB be) (VP (VP (VBN tested) (ADVP (RBR more) (RB frequently))) (CC and) (VP (VBN monitored) (ADVP (RB regularly)) (PP (IN during) (NP (NP (JJ simultaneous) (NN administration)) (PP (IN of) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (JJ oral) (NN drug3)) (, ,) (CC or) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB affect) (NP (NP (DT the) (NN blood) (NN coagulation) (NN system)) (CC or) (NP (DT the) (JJ thrombocyte) (NN function))))))))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN excretion)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN in) (NP (NNS patients))))) (S (VP (TO to) (VP (VB avoid) (NP (NN drug) (NN toxicity))))))) (. .)))
(S1 (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (PP (IN As) (PP (IN with) (NP (JJ other) (NN drug1)))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (NP (DT the) (NN urine)) (VP (VBG using) (NP (DT a) (NN copper-reduction) (NN method))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (NN glucose) (NNS tests)) (VP (VBN based) (PP (IN on) (NP (JJ enzymatic) (NN glucose) (NN oxidase) (NNS reactions))))) (VP (VB be) (VP (VBN used)))))))) (. .)))
(S1 (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (JJ positive) (NN test) (NNS results)))) (S (VP (VBG using) (NP (NP (DT the) (NP (JJ Bio-Rad) (NNS Laboratories)) (NN Platelia) (NN Aspergillus) (NN EIA) (NN test)) (PP (IN in) (NP (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1) (: /) (NN drug2) (NN injection)))) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB subsequently)) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (JJ free) (PP (IN of) (NP (JJ Aspergillus) (NN infection)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Cross-reactions)) (PP (IN with) (NP (JJ non-Aspergillus) (NNS polysaccharides)))) (CC and) (NP (NP (NNS polyfuranoses)) (PP (IN with) (NP (DT the) (JJ Bio-Rad) (NNS Laboratories)))) (NP (ADJP (FW Platelia) (FW Aspergillus)) (NN EIA) (NN test))) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ positive) (NN test) (NNS results)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)))))) (VP (MD should) (VP (VB be) (VP (VP (VBN interpreted) (ADVP (RB cautiously))) (CC and) (VP (VBN confirmed) (PP (IN by) (NP (JJ other) (JJ diagnostic) (NNS methods)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug1)) (VP (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (S (SBAR (IN Because) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug3))))) (PP (IN with) (NP (JJS most) (JJ other) (NNS drug4)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied)))))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug5)) (PP (IN with) (NP (JJ other) (JJ CNS-active) (NNS drugs)))))) (VP (MD should) (VP (VB be) (VP (VBN approached) (PP (IN with) (NP (NN caution))))))))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (CD one) (NN report)) (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB have) (VP (VBD caused) (NP (NP (NP (CD 3-) (TO to) (RB 6-fold)) (NNS elevations)) (PP (IN on) (NP (NP (NN SGPT)) (PRN (-LRB- -LRB-) (NP (NN ALT)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT a) (JJ few) (NNS patients)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT a) (JJ similar) (NN study))) (, ,) (S (VP (VBG attempting) (S (VP (TO to) (VP (VB replicate) (NP (DT this) (NN finding))))))) (, ,) (NP (NP (DT no) (JJ interactive) (NN effect)) (PP (IN on) (NP (JJ hepatic) (NNS transaminases)))) (VP (VBD was) (VP (VBN identified)))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (JJ normal) (NNS volunteers))))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD resulted) (PP (IN in) (NP (VBN increased) (NN serum) (NN drug3) (NNS concentrations))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN finding)))) (VP (VBZ is) (RB not) (ADJP (JJ clear)))) (. .)))
(S1 (S (S (ADVP (FW In) (FW vitro)) (, ,) (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB displace) (NP (NP (ADJP (RB tightly) (VBN bound)) (NNS drugs)) (PP (IN like) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))) (PP (IN from) (NP (NN serum) (NNS proteins))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (VBZ has) (VP (VBN been) (NP (NP (CD one) (NN report)) (PP (IN of) (NP (JJ prolonged) (NN prothrombin) (NN time)))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN regimen)) (PP (IN of) (NP (NP (DT a) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD was) (ADVP (RB also)) (ADVP (RB chronically)) (VP (VBG receiving) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))) (. .)))
(S1 (S (S (ADVP (FW In) (FW vitro)) (, ,) (NP (NN drug1)) (VP (MD may) (VP (VB displace) (NP (ADVP (RBR less) (RB firmly)) (VBN bound) (NNS drugs)) (PP (IN like) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN property)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (NN drug2)) (, ,) (NP (JJ general) (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC or) (NP (NP (JJ other) (NNS drug7)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (NN drug8))) (-RRB- -RRB-)))))))) (VP (VBZ has) (NP (JJ additive) (NN depressant) (NNS effects)))) (. .)))
(S1 (S (IN When) (NP (NN s.c.))))
(S1 (S (S (S (NP (NN combination) (NN therapy)) (VP (VBZ is) (VP (VBN contemplated) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (CD one))))))) (CC or) (S (NP (DT both) (NNS agents)) (VP (MD should) (VP (VB be) (VP (VBN reduced)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ vasodilating) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ additive) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (JJ other) (NNS drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (PP (IN in) (NP (JJ particular))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VBP exhibit) (NP (NP (JJ additive) (NNS effects)) (PP (IN of) (NP (DT this) (NN variety))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NN Interaction)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (NN drug3))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB exhibit) (NP (ADJP (ADJP (JJ minimal)) (PRN (-LRB- -LRB-) (PP (FW ca.)) (NP (CD 5) (NN %)) (-RRB- -RRB-))) (NN metabolism))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (NN co) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (CC either) (NP (NN drug2)) (CC or) (NP (NN drug3))))) (VP (VBD led) (PP (TO to) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (CC either) (NP (NN drug2)) (CC or) (NP (NN drug3)))))))) (. .)))
(S1 (S (PP (IN In) (NP (CD 2) (JJ separate) (NNS studies))) (, ,) (NP (NP (NP (NN drug1) (CD 120) (NN mg)) (ADVP (RB twice) (RB daily))) (PRN (-LRB- -LRB-) (NP (CD 240) (NN mg) (JJ total) (JJ daily) (NN dose)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN co-administered) (PP (IN with) (NP (CC either) (NP (NP (NN drug2) (CD 500) (NN mg)) (NP (DT every) (CD 8) (NNS hours))) (CC or) (NP (NP (NN drug3) (CD 400) (NN mg)) (ADJP (RB once) (JJ daily) (PP (IN under) (NP (NP (JJ steady-state) (NNS conditions)) (PP (TO to) (NP (NP (JJ healthy) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NP (NN n=24)) (, ,) (NP (DT each) (NN study))) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NNS differences)) (PP (IN in) (NP (NP (JJ adverse) (NNS events)) (CC or) (NP (NN QTc) (NN interval))))) (VP (VBD were) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NNS subjects)) (VP (VBD were) (VP (VBN administered) (NP (NN drug1)) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (CC either) (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS findings)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (VBP are) (VP (VBN summarized) (PP (IN in) (NP (DT the) (VBG following) (NN table)))))) (: :) (NP (NP (NNS Effects)) (PP (IN on) (NP (NP (JJ steady-state) (NN drug1) (NNS pharmacokinetics)) (PP (IN after) (NP (NP (CD 7) (NNS days)) (PP (IN of) (NP (NP (NN co-administration)) (PP (IN with) (NP (NP (NN drug2) (CD 120) (NN mg)) (NP (NP (DT every) (CD 12) (NNS hours)) (PRN (-LRB- -LRB-) (NP (NP (CD two) (NNS times)) (NP (DT the) (VBN recommended) (NP (RB twice) (JJ daily) (NN dose)))) (-RRB- -RRB-)))))))))))) (PP (IN in) (NP (NP (JJ healthy) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NN n=24)) (-RRB- -RRB-))))))
(S1 (S (NP (JJ Concomitant) (NN Drug))))
(S1 (S (NP (NP (NN cmaxSS)) (PRN (-LRB- -LRB-) (NP (NN Peak) (NN plasma) (NN concentration)) (-RRB- -RRB-)))))
(S1 (S (NP (NP (NP (NN AUCss)) (PRN (-LRB- -LRB-) (NP (NN 0-12h)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (NN Extent)) (PP (IN of) (NP (JJ systemic) (NN exposure)))) (-RRB- -RRB-)))))
(S1 (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mg) (NP (DT every) (CD 8) (NNS hrs))) (-RRB- -RRB-)))))
(S1 (S (NP (CD +82) (NN %))))
(S1 (S (NP (CD +109) (NN %))))
(S1 (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 400) (NN mg)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-)))))
(S1 (S (NP (CD +135) (NN %))))
(S1 (S (NP (CD +164) (NN %))))
(S1 (S (S (NP (NP (DT The) (NNS changes)) (PP (IN in) (NP (NN plasma) (NNS levels)))) (VP (VBD were) (PP (IN within) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (NP (NN plasma) (NNS levels)) (VP (VBN achieved) (PP (IN in) (NP (ADJP (ADJP (JJ adequate)) (CC and) (ADJP (JJ well-controlled))) (JJ clinical) (NNS trials)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (DT these) (NNS interactions)))) (VP (VBZ has) (VP (VBN been) (VP (VBN evaluated) (PP (IN in) (NP (ADJP (ADJP (FW in) (FW vitro)) (, ,) (ADJP (FW in) (FW situ)) (, ,) (CC and) (ADJP (FW in) (FW vivo))) (NN animal) (NNS models))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC or) (NP (NN drug2) (NN co-administration))) (VP (VBZ enhances) (NP (NN drug3) (JJ gastrointestinal) (NN absorption))))))) (. .)))
(S1 (S (S (NP (NP (DT This) (VBN observed) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug1)))))) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ transport-related) (NNS effects)) (, ,) (NP (NP (JJ such)) (SBAR (IN as) (S (NP (JJ p-glycoprotein.) (ADJP (FW in) (FW vivo)) (NN animal) (NNS studies)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN in) (NN addition) (TO to) (S (VP (VBG enhancing) (NP (NN absorption))))) (, ,) (NP (NN drug2)) (VP (VBZ decreases) (NP (NN drug3) (JJ gastrointestinal) (NN secretion)) (, ,) (SBAR (IN while) (S (NP (NN drug4)) (VP (MD may) (ADVP (RB also)) (VP (VB decrease) (NP (JJ biliary) (NN excretion))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NNS Interactions)) (PP (IN with) (NP (NP (NN drug1) (NN Administration)) (PP (IN of) (NP (NP (CD 120) (NN mg)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 2) (CC x) (CD 60) (NN mg) (JJ capsule)) (-RRB- -RRB-)))))))) (PP (IN within) (NP (NP (CD 15) (NNS minutes)) (PP (IN of) (NP (NP (DT an) (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBG containing) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-))))))))) (VP (VBD decreased) (NP (NP (NP (NN drug7) (NN AUC)) (PP (IN by) (NP (CD 41) (NN %)))) (CC and) (NP (NN cmax))) (PP (IN by) (NP (CD 43) (NN %))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (ADVP (RB closely)) (PP (IN in) (NP (NN time))) (PP (IN with) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBG containing) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN with) (NP (NP (NN Fruit) (NNS Juices) (NN Fruit) (NNS juices)) (PP (JJ such) (IN as) (NP (NP (NN grapefruit)) (, ,) (NP (NN orange)) (CC and) (NP (NN apple))))))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NP (NN bioavailability)) (CC and) (NP (NN exposure))) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (NNS results)) (PP (IN from) (NP (NP (CD 3) (JJ clinical) (NNS studies)) (VP (VBG using) (NP (NP (NP (NN drug1) (JJ induced) (NN skin) (NNS wheals)) (CC and) (NP (NNS flares))) (VP (VBN coupled) (PP (IN with) (NP (NN population) (JJ pharmacokinetic) (NN analysis))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN size)) (PP (IN of) (NP (NP (NN wheal)) (CC and) (NP (NN flare))))) (VP (VBD were) (ADJP (RB significantly) (JJR larger)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (IN with) (NP (CC either) (NP (NN grapefruit)) (CC or) (NP (NN orange)) (NP (NNS juices)))) (PP (VBN compared) (PP (TO to) (NP (NN water)))))))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (DT the) (NN literature) (NNS reports)))) (, ,) (NP (DT the) (JJ same) (NNS effects)) (VP (MD may) (VP (VB be) (VP (VBN extrapolated) (PP (TO to) (NP (NP (JJ other) (NN fruit) (NNS juices)) (PP (JJ such) (IN as) (NP (JJ apple) (NN juice))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT these) (NNS observations)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (PP (VBN based) (PP (IN on) (NP (DT the) (NN population) (NNS pharmacokinetics)))) (NP (NP (NN analysis)) (PP (IN of) (NP (NP (DT the) (JJ combined) (NNS data)) (PP (IN from) (NP (NP (NP (NP (NN grapefruit)) (CC and) (NP (NN orange)) (NP (NNS juices))) (NNS studies)) (PP (IN with) (NP (NP (DT the) (NNS data)) (PP (IN from) (NP (NP (DT a) (NN bioequivalence) (NN study)) (, ,) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug1))))))))))))) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (CD 36) (NN %))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (S (VP (TO to) (VP (VB maximize) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN with) (NP (NN water))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (DT No) (JJ formal) (NNS studies)) (VP (TO to) (VP (VB evaluate) (NP (NP (NN drug) (NNS interactions)) (PP (IN with) (NP (NN drug1))))))) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (JJ drug1) (JJ oxidative) (NNS metabolites)) (VP (VBP appear) (S (VP (TO to) (VP (VB be) (VP (VBN formed) (PP (IN by) (NP (NN cytochrome) (NN P450) (NN 3A4))))))))) (. .)))
(S1 (S (S (PP (IN On) (DT the) (NN basis) (IN of) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN by) (NP (NN cytochrome) (NN P450) (NN 3A4))))))) (, ,) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN grapefruit) (NN juice)) (, ,) (CC and) (NP (JJ other) (NNS inhibitors))) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 3A4)))) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB lead) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN plasma) (NN drug6) (NNS concentrations)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (JJ other) (NNS inducers))) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 3A4)))) (VP (MD may) (VP (VB cause) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN plasma) (NN drug4) (NNS concentrations))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1) (NNS capsules)) (CC and) (NP (NNS drug2))))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ substantial) (NNS increases)) (PP (IN in) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug3))))))) (, ,) (ADVP (RB probably)) (ADJP (ADVP (ADVP (IN at) (JJS least)) (RB partially)) (JJ related) (PP (TO to) (NP (NP (NP (NN cytochrome) (NN P450) (NN 3A4)) (NN inhibition)) (PP (IN by) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (PP (IN Under) (NP (JJ similar) (NNS conditions))) (, ,) (NP (NN drug1) (NNS concentrations)) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (JJ concomitant) (NN drug2) (NN administration)))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2) (NNS capsules)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (JJ controlled) (JJ clinical) (NNS studies))) (, ,) (NP (NNS drug2)) (VP (VBP have) (VP (VBN been) (ADVP (RB frequently)) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3))))))) (. .))))
(S1 (S (S (NP (DT The) (NN combination)) (VP (VBZ is) (ADVP (RB well)) (VP (VBN tolerated)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ increases) (NP (NN drug3) (NN plasma) (NNS levels)))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (DT the) (CD two) (NNS drugs)))) (ADVP (RB concomitantly)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (DT Some) (NNS drug2)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (DT the) (NN blood))))))) (. .))))
(S1 (S (S (S (NP (NN drug1)) (ADVP (RB usually)) (VP (VBZ does) (RB not) (VP (VB alter) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug2))))))) (, ,) (S (ADVP (RB however)) (, ,) (NP (NN serum) (NN drug3) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN evaluated) (PP (IN after) (NP (NP (JJ concomitant) (NN therapy)) (SBAR (IN with) (S (NP (NN drug4)) (VP (VBZ is) (VP (VBN initiated)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN *) (NN Coadministration)) (PP (IN of) (NP (NN drug2)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug3) (NN absorption))))) (. .)))
(S1 (S (S (SBAR (RB Even) (IN though) (S (NP (JJ such) (NNS interactions)) (VP (VBD were) (RB not) (VP (VBN seen) (PP (IN during) (NP (NP (JJ clinical) (NNS studies)) (PP (IN with) (NP (NN drug1))))))))) (, ,) (NP (NP (DT an) (VBN increased) (NN volume)) (PP (IN of) (NP (JJ circulating) (NNS fluids)))) (VP (MD might) (VP (VB be) (VP (VBN required) (SBAR (IN if) (S (NP (PDT such) (DT an) (NN interaction)) (VP (VBD were) (S (VP (TO to) (VP (VB occur))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3) (NNS levels))))) (. .))))
(S1 (S (S (S (NP (NP (NN Plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (ADVP (RB therefore)) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (, ,) (CC and) (S (NP (PRP$ its) (NN dosage)) (VP (VBD reduced) (ADVP (RB accordingly)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ therapeutic) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (NN drug6))))) (VP (VBD were) (VP (VBN added) (PP (TO to) (NP (NP (JJ human) (NN plasma)) (PRN (-LRB- -LRB-) (NP (FW in) (FW vitro)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (DT the) (NN plasma) (NN protein) (NN binding)) (PP (IN of) (NP (NN drug7)))) (VP (VBD was) (RB not) (VP (VBN altered)))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ neuromuscular) (NN blocking) (NN action)) (PP (IN of) (NP (NN drug1))))))))) (VP (VBP include) (: :) (NP (NN drug2)))) (: ;)))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NP (JJ certain) (NN drug1)) (, ,) (NP (ADVP (RB especially)) (NP (DT the) (NP (NN drug2)) (CC and) (NP (NN drug3)))) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NP (NN drug1) (NNS salts)) (: ;))))
(S1 (S (NP (NNP drug1) (: ;))))
(S1 (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ neuromuscular) (NN blocking) (NN action)) (PP (IN of) (NP (NN drug1)))) (S (VP (VBP include) (: :) (NP (NP (NN drug2)) (: ;) (NP (NN drug3)) (: ;) (NP (NN drug4)) (: ;) (NP (NP (JJ certain) (NN drug5)) (, ,) (ADVP (RB especially)) (NP (NP (DT the) (NN drug6)) (CC and) (NP (NN drug7)))) (: ;) (NP (NN drug8)) (: ;) (NP (NN drug9) (NNS salts)) (: ;) (NP (CD drug10)) (: ;) (CC and) (NP (NN drug11))))))))) (. .))))
(S1 (S (S (SBAR (IN If) (S (NP (JJ other) (NNS drug1)) (VP (VBP are) (VP (VBN used) (PP (IN during) (NP (DT the) (JJ same) (NN procedure))))))) (, ,) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (DT a) (JJ synergistic) (NN or) (NN antagonist) (NN effect)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ prior) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (VP (VBZ does) (RB not) (VP (VB enhance) (NP (DT the) (NN duration)))) (, ,) (CC but) (VP (VBZ quickens) (NP (DT the) (NN onset))) (CC and) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN depth)) (, ,) (PP (IN of) (NP (NP (JJ neuromuscular) (NN block)) (VP (VBN induced) (PP (IN by) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (SBAR (IN until) (S (NP (DT a) (NN patient)) (VP (VBZ has) (VP (VBN recovered) (PP (IN from) (NP (NN drug2) (JJ -induced) (JJ neuromuscular) (NN block))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ formal) (NNS assessments)) (PP (IN of) (NP (NP (JJ pharmacokinetic) (JJ drug-drug) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS agents))))))) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN advised) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NP (JJ other) (NNS medications)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VP (VB prolong) (NP (NP (DT the) (JJ QT) (NN interval)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (NP (NP (JJ certain) (NN drug2)) (CC or) (NP (NN drug3)))) (-RRB- -RRB-)))) (CC or) (VP (VB lead) (PP (TO to) (NP (NP (NN electrolyte) (NNS abnormalities)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug4)) (CC or) (NP (NN drug5))))) (-RRB- -RRB-)))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ interferes) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (PP (VBG including) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (JJ hypoparathyroid) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB concurrently)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN drug2))))))))))) (VP (MD may) (VP (VB cause) (NP (NN hypercalcemia))))) (. .)))
(S1 (S (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN CNS)) (-RRB- -RRB-))) (NNS drugs)) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NP (NN blood) (NN pressure) (NNS medications)) (PRN (-LRB- -LRB-) (NP (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8))) (-RRB- -RRB-))) (, ,) (NP (NN motion) (NN sickness) (NNS medications)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN sleeping) (NNS pills)) (CC and) (NP (NN drug12)))))))
(S1 (S (S (SBAR (IN Although) (S (NP (DT no) (JJ clinical) (JJ drug-drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (TO to) (NP (NN date)))))))) (, ,) (PP (IN on) (DT the) (NN basis) (IN of) (NP (DT the) (ADJP (FW in) (FW vitro)) (NNS studies))) (, ,) (NP (NP (NN cytochrome) (NN p450) (NNS inhibitors)) (CC and) (NP (NNS inducers))) (VP (VBP are) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB affect) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN cytochrome) (NN p450) (NNS substrates)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (NP (NP (JJ Drug/Laboratory) (NNS Tests) (NNS Interactions)) (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ known) (ADJP (RB clinically) (JJ significant)) (NNS interactions)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS medications)) (CC or) (NP (NN laboratory) (NNS tests))))))) (. .))))
(S1 (S (S (NP (DT No) (JJ formal) (NN drug/laboratory) (NN test) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (SBAR (IN Unless) (S (ADVP (RB really)) (VP (VBN needed)))) (, ,) (NP (NP (NNS agents)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN hemorrhage))))))))) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (PP (JJ prior) (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NN drug1) (NN Injection) (NN therapy)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS agents)) (VP (VBP include) (NP (NP (NNS medications)) (PP (JJ such) (PP (IN as) (: :) (NP (NP (NN drug1)) (, ,) (NP (NP (NN drug2)) (PP (VBG including) (NP (NP (NN drug3)) (, ,) (NP (NN sali-cylates)) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (NN drug5))) (-RRB- -RRB-))) (, ,) (NP (NN drug6)) (, ,) (CC or) (NP (NN drug7))))))))))) (. .)))
(S1 (S (SBAR (IN If) (S (NP (NN co-administration)) (VP (VBZ is) (ADJP (JJ essential))))) (, ,) (VP (VBP conduct) (NP (JJ close) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ laboratory))) (NN monitoring)))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (DT No) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB inhibit) (NP (DT the) (NN cytochrome) (JJ P-450-linked) (NN drug-metabolizing) (NN enzyme) (NN system))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (NN drug) (NNS interactions)) (VP (VBN mediated) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ hepatic) (NN metabolism))))))) (VP (VBP are) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB occur))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN given) (NP (NP (NP (ADJP (RB very) (JJ high)) (NNS doses)) (PRN (-LRB- -LRB-) (NP (NN 3900) (NN mg)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN drug1)) (ADVP (RB daily)))))))) (, ,) (NP (NP (NNS increases)) (PP (IN in) (NP (NN serum) (NN drug2) (NNS levels)))) (VP (VBD were) (VP (VBN seen) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug3)) (, ,) (NP (ADJP (CD 150) (NN mg)) (NN b.i.d.)) (, ,)) (VP (VBD was) (VP (VBN administered) (ADVP (RB concurrently))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN combined) (PP (IN with) (NP (JJ other) (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (JJ catecholamine-depleting) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (, ,)))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored)) (, ,) (SBAR (IN because) (S (NP (NP (DT the) (VBN added) (JJ beta-adrenergic) (NN blocking) (NN action)) (PP (IN of) (NP (NN drug3)))) (VP (MD may) (VP (VB produce) (NP (NP (JJ excessive) (NN reduction)) (PP (IN of) (NP (JJ sympathetic) (NN activity))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ concurrent) (NN therapy)) (PP (IN with) (NP (NN drug1))))))) (, ,) (SBAR (IN if) (S (NP (NN therapy)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN discontinued)))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NN drug2)) (VP (VB be) (VP (VBN discontinued) (PP (IN for) (NP (NP (JJ several) (NNS days)) (PP (IN before) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN care))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NP (NNS drug2)) (CC or) (NP (NNS inhibitors))) (PP (IN of) (NP (NN AV) (NN conduction))) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (JJ certain) (NN drug3)) (PRN (-LRB- -LRB-) (ADVP (RB particularly)) (PP (IN of) (NP (NP (NP (DT the) (NN drug4)) (PRN (-LRB- -LSB-) (NP (NN drug5)) (-RRB- -RSB-))) (CC and) (NP (NN drug6) (-LRB- -LSB-) (NN drug7) (-RRB- -RSB-) (NNS classes)))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NN drug8)))) (, ,) (PP (JJ such) (IN as) (NP (NN drug9))) (, ,)) (VP (VBP are) (VP (VBN used) (ADVP (RB concurrently))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ increases) (NP (NP (DT the) (JJ metabolic) (NN clearance)) (PP (IN of) (NP (NN drug2)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (VBD shortened) (NN elimination) (NN half-life)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (JJ initial) (NN dose) (NN modification)) (VP (VBZ is) (ADVP (RB generally)) (RB not) (ADJP (JJ necessary)))) (. .)))
(S1 (S (S (NP (JJ Pharmacokinetic) (NNS studies)) (VP (VBP document) (NP (NP (DT no) (ADJP (RB clinically) (JJ relevant)) (NNS interactions)) (PP (IN with) (NP (NP (JJ other) (NNS agents)) (VP (VBN given) (ADVP (RB concomitantly))) (, ,) (PP (VBG including) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NN prothrombin) (NN time)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (JJ stable) (NNS doses)) (PP (IN of) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN Risk)) (PP (IN of) (NP (JJ Anaphylactic) (NN Reaction)))) (: :) (S (SBAR (IN While) (S (VP (VBG taking) (NP (NN drug1))))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ severe) (JJ anaphylactic) (NN reaction)) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS allergens)))))))))) (VP (MD may) (VP (VB be) (ADJP (ADJP (RBR more) (JJ reactive) (PP (TO to) (NP (JJ repeated) (NN challenge)))) (, ,) (CC either) (ADJP (JJ accidental)) (, ,) (ADJP (JJ diagnostic)) (, ,) (CC or) (ADJP (JJ therapeutic)))))) (. .))))
(S1 (S (S (NP (JJ Such) (NNS patients)) (VP (MD may) (VP (VB be) (ADJP (JJ unresponsive) (PP (TO to) (NP (NP (DT the) (JJ usual) (NNS doses)) (PP (IN of) (NP (NN drug1))) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (JJ allergic) (NNS reactions)))))))))))) (. .)))
(S1 (S (S (NP (NN Hypertensive) (NNS crises)) (VP (VBP have) (S (VP (VBD resulted) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN used) (ADVP (RB concomitantly)) (PP (NP (CD within14) (NNS days)) (VBG following) (NP (NP (NN use)) (PP (IN of) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ other) (NNS drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (JJ Urinary) (NN alkalinizing) (NNS agents)) (VP (VP (VBP increase) (NP (NN blood) (NNS levels))) (CC and) (VP (VBP decrease) (NP (NP (NN excretion)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS agents)) (VP (VP (VB decrease) (NP (NN blood) (NNS levels))) (CC and) (VP (VB increase) (NP (NP (NN excretion)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (JJ drug1) (JJ -containing) (NNS drugs)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (JJ prolonged) (JJ vasospastic) (NNS reactions))))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ theoretical) (NN basis)) (SBAR (IN that) (S (NP (DT these) (NNS effects)) (VP (MD may) (VP (VB be) (ADJP (JJ additive)))))))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (NP (NN drug1) (ADJP (ADJP (JJ -containing)) (CC or) (ADJP (JJ drug2)))) (PRN (-LRB- -LRB-) (PP (IN like) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))) (-RRB- -RRB-))) (CC and) (NP (NN drug5)))) (PP (IN within) (NP (CD 24) (NNS hours)))) (VP (VBZ is) (VP (VBN contraindicated))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NNS drug2)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated) (PP (IN in) (NP (NN migraine) (NNS patients))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (PRP$ their) (JJ vasospastic) (NNS effects)) (VP (MD may) (VP (VB be) (ADJP (JJ additive)))))) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NN drug2)))) (PP (IN within) (NP (NP (CD 24) (NNS hours)) (PP (IN of) (NP (DT each) (JJ other)))))) (VP (VBZ is) (RB not) (VP (VBN recommended))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (, ,) (ADVP (RB rarely)) (, ,) (S (VP (TO to) (VP (VB cause) (NP (NP (NN weakness)) (, ,) (NP (NN hyperreflexia)) (, ,) (CC and) (NP (NN incoordination))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (JJ 5-HTv) (NNS agonists))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (DT an) (NN drug2))))) (VP (VBZ is) (ADVP (RB clinically)) (VP (VBN warranted))))) (, ,) (NP (NP (JJ appropriate) (NN observation)) (PP (IN of) (NP (DT the) (NN patient)))) (VP (VBZ is) (VP (VBN advised)))) (. .)))
(S1 (S (S (NP (NP (NN Drug/) (NN Laboratory) (NN Test) (NNS Interactions)) (PP (IN drug1) (NP (NNS Tablets)))) (VP (VBP are) (RB not) (VP (VBN known) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (ADJP (RB commonly) (VBN employed)) (JJ clinical) (NN laboratory) (NNS tests))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ vasodilating) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ additive) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (JJ other) (NNS drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (PP (IN in) (NP (JJ particular))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VBP exhibit) (NP (NP (JJ additive) (NNS effects)) (PP (IN of) (NP (DT this) (NN variety))))))))))) (. .)))
(S1 (S (S (NP (JJ Marked) (JJ symptomatic) (JJ orthostatic) (NN hypotension)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD were) (VP (VBN used) (PP (IN in) (NP (NN combination))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Dose) (NNS adjustments)) (PP (IN of) (NP (NP (DT either) (NN class)) (PP (IN of) (NP (NNS agents)))))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS risks)) (PP (IN of) (S (VP (VBG using) (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS drugs))))))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB systematically)) (VP (VBN evaluated))))) (. .)))
(S1 (S (NP (NP (JJ Pharmacodynamic-related) (NNS Interactions)) (: :) (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NN drug1) (JJ induced) (NN agranulocytosis)))) (VP (VBZ is) (ADJP (JJ unknown)))) (: ;))))
(S1 (S (S (ADVP (RB nonetheless)) (, ,) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (JJ causative) (NNS factors)) (VP (MD may) (VP (VB interact) (ADVP (RB synergistically)) (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NP (NN risk)) (CC and/or) (NP (NN severity))) (PP (IN of) (NP (NP (NN bone) (NN marrow)) (NN suppression))))))))))) (VP (VBZ warrants) (NP (NN consideration)))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NP (JJ other) (NNS agents)) (VP (VBG having) (NP (NP (DT a) (JJ well-known) (NN potential)) (S (VP (TO to) (VP (VB suppress) (NP (NP (NN bone) (NN marrow)) (NN function))))))))))))) (. .)))
(S1 (S (S (PP (IN Given) (NP (NP (DT the) (JJ primary) (NN CNS) (NNS effects)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN advised) (PP (IN in) (S (VP (VBG using) (NP (NP (PRP it)) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ other) (JJ CNS-active) (NNS drugs)) (CC or) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Orthostatic) (NN hypotension)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)))))) (VP (MD can) (, ,) (PP (IN in) (NP (NP (JJ rare) (NNS cases)) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD 1)) (NN case)) (PP (IN per) (NP (CD 3,000) (NNS patients))) (-RRB- -RRB-)))) (, ,) (VP (VB be) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ profound) (NN collapse)) (CC and) (NP (ADJP (ADJP (JJ respiratory)) (CC and/or) (ADJP (JJ cardiac))) (NN arrest)))))))) (. .)))
(S1 (S (S (NP (NP (DT Some)) (PP (IN of) (NP (NP (DT the) (NNS cases)) (PP (IN of) (NP (NP (JJ collapse/respiratory) (NN arrest/cardiac) (NN arrest)) (PP (IN during) (NP (JJ initial) (NN treatment)))))))) (VP (VBD occurred) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBG being) (VP (VBN administered) (NP (NN drug1))))))))))) (: ;)))
(S1 (S (S (NP (JJ similar) (NNS events)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VP (VBG taking) (NP (JJ other) (NN drug1))) (CC or) (VP (ADVP (RB even)) (VBN drug2) (PP (IN by) (NP (PRP itself))))))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (PRP it)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established) (SBAR (IN that) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT an) (NN interaction)) (PP (IN between) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (CC or) (NP (JJ other) (NN drug3))))))))))))) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN advised) (SBAR (WHADVP (WRB when)) (S (NP (NN drug4)) (VP (VBZ is) (VP (VBN initiated) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (DT a) (NN drug5)) (CC or) (NP (DT any) (JJ other) (NN drug6)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB potentiate) (NP (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NN drug2)))) (CC and) (NP (NP (DT the) (JJ anticholinergic) (NNS effects)) (PP (IN of) (NP (NN drug3) (NN -type) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (ADJP (NN drug) (VBN induced)) (NN hypotension))))) (PP (IN because) (IN of) (NP (DT a) (JJ possible) (JJ reverse) (NN drug2) (NN effect))))))) (. .)))
(S1 (S (NP (NP (JJ Pharmacokinetic-related) (NNS Interactions)) (: :) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (JJ many) (NN CYP) (CD 450) (NNS isozymes)))) (, ,) (PP (IN in) (NP (NP (JJ particular) (NN 1A2)) (, ,) (NP (NN 2D6)) (, ,) (CC and) (NP (NN 3A4)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (JJ metabolic) (NNS interactions))) (VP (VBN caused) (PP (IN by) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (DT an) (JJ individual) (NN isoform))))))) (VP (VBZ is) (ADVP (RB therefore)) (VP (VBN minimized)))) (. .)))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (CC either) (NP (NNS inhibitors)) (CC or) (NP (NNS inducers))) (PP (IN of) (NP (DT these) (NNS enzymes))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NN cytochrome) (NN P450) (NNS enzymes))))))))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (VP (MD may) (VP (VB decrease) (NP (NN drug4) (NN plasma) (NNS levels)) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN effectiveness)) (PP (IN of) (NP (DT a) (ADJP (RB previously) (JJ effective)) (NN drug5) (NN dose)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NNS isozymes))))))))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (VP (MD may) (VP (VB increase) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug4)))) (, ,) (S (ADVP (RB potentially)) (VP (VBG resulting) (PP (IN in) (NP (JJ adverse) (NNS effects)))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (RB not) (VP (VBN recommended))))) (, ,) (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN noted) (SBAR (IN that) (S (NP (NP (NN discontinuation)) (PP (IN of) (NP (JJ concomitant) (NN drug3) (NN administration)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN drug4) (NN plasma) (NNS levels))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (NP (JJ schizophrenic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN drug1)) (PP (IN under) (NP (JJ steady) (NN state) (NNS conditions)))))))))) (, ,) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (VP (VBD was) (VP (VBN added) (PP (IN in) (NP (QP (CD 16) (CC and) (CD 14)) (NNS patients))) (, ,) (ADVP (RB respectively))))) (. .)))
(S1 (S (PP (IN After) (NP (NP (CD 14) (NNS days)) (PP (IN of) (NP (NN co-administration))))) (, ,) (NP (NP (NP (NN mean) (NN trough) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (PRP$ its) (NNS metabolites)) (, ,) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (, ,))) (VP (VBD were) (VP (VBN elevated) (PP (IN with) (NP (NN drug4))) (PP (IN by) (NP (NP (RB about) (RB three-fold)) (VP (VBN compared) (PP (TO to) (NP (NN baseline) (NNS concentrations)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD produced) (NP (ADJP (RB only) (JJ minor)) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (PRP$ its) (NNS metabolites)))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (JJ other) (VBN published) (NNS reports)) (VP (VBP describe) (NP (NP (NP (JJ modest) (NNS elevations)) (PRN (-LRB- -LRB-) (ADJP (JJR less) (IN than) (JJ two-fold)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN metabolite) (NNS concentrations))))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN taken) (PP (IN with) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))))))))) (. .)))
(S1 (S (S (S (ADVP (RB Therefore)) (, ,) (NP (JJ such) (JJ combined) (NN treatment)) (VP (MD should) (VP (VB be) (VP (VBN approached) (PP (IN with) (NP (NN caution))))))) (CC and) (S (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN combined) (PP (IN with) (NP (DT these) (NNS drugs))) (, ,) (PP (ADVP (RB particularly)) (IN with) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (DT A) (VBN reduced) (NN drug1) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (NP (NP (NP (DT A) (NN subset)) (PRN (-LRB- -LRB-) (NP (CD 3) (NN %) (CD -10) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN population)))) (VP (VBZ has) (NP (NP (VBN reduced) (NN activity)) (PP (IN of) (NP (NP (JJ certain) (NN drug) (NN metabolizing) (NNS enzymes)) (PP (JJ such) (IN as) (NP (DT the) (NN cytochrome) (NN P450) (NN isozyme) (NN P450) (NN 2D6)))))))) (. .)))
(S1 (S (S (NP (JJ Such) (NNS individuals)) (VP (VBP are) (VP (VBN referred) (PP (TO to)) (PP (IN as) (NP (NP (JJ poor) (NNS metabolizers)) (PP (IN of) (NP (NP (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (DT the) (NN drug3)) (, ,) (CC and) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS individuals)) (VP (MD may) (VP (VBP develop) (NP (NP (JJR higher) (IN than) (VBN expected) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (JJ usual) (NNS doses)))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (JJ certain) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT this) (NN isozyme)))))))) (, ,) (PP (VBG including) (NP (NP (JJ many) (NNS drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NNS others))) (-RRB- -RRB-)))) (, ,)) (VP (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT this) (NN isozyme)))))) (, ,) (CC and) (ADVP (RB thus)) (VP (MD may) (VP (VB make) (S (NP (JJ normal) (NNS metabolizers)) (VP (VBP resemble) (NP (JJ poor) (NNS metabolizers)) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT this) (NN enzyme) (NN system)))))))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NN drug) (NN interaction)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NN cytochrome) (NN P450) (NN 2D6))))))) (VP (MD may) (VP (VBP require) (NP (NP (JJR lower) (NNS doses)) (VP (ADVP (IN than) (RB usually)) (VBN prescribed) (PP (IN for) (NP (CC either) (NP (NN drug2)) (CC or) (NP (DT the) (JJ other) (NN drug))))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT this) (NN isozyme))))))) (, ,) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug6)) (, ,) (NP (NN drug7)) (CC and) (NP (NN drug8)))) (-RRB- -RRB-))))) (, ,) (SBAR (CC or) (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NP (DT this) (NN enzyme)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug9)) (-RRB- -RRB-)))))) (, ,)))) (VP (MD should) (VP (VB be) (VP (VBN approached) (PP (IN with) (NP (NN caution)))))) (. .)))
(S1 (S (S (NP (NP (NN Milk)) (, ,) (NP (NN milk) (NNS products)) (, ,) (CC and) (NP (CD drug1) (JJ -rich) (NP (NNS foods)) (CC or) (NP (NNS drugs)))) (VP (MD may) (VP (VB impair) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (VP (VBP Do) (RB not) (VP (VB take) (NP (DT this) (NN medicine)) (PP (PP (IN with) (NP (NN thioridizine))) (, ,) (CC or) (PP (IN within) (NP (NP (CD 5) (NNS weeks)) (PP (IN of) (NP (VBG taking) (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NP (NN Talk)) (PP (TO to) (NP (NN your) (NN doctor))) (PP (IN if) (NP (NN you)))) (VP (VBP are) (VP (VBG taking) (NP (NP (JJ certain) (NNS drug1)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC or) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (DT This) (NN medicine)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG taking) (NP (DT this) (NN medicine) (JJ certain) (NN drug1))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (DT This) (NN medicine)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (VP (VBN you) (VP (VBP think) (ADVP (RB you)))))) (VP (VBP are) (VP (VBG taking) (NP (DT an) (NN drug1) (NN talk)) (PP (TO to) (NP (NP (NN your) (NN doctor)) (CC or) (NP (NN pharmacist))))))) (. .)))
(S1 (S (S (VP (VBP Do) (RB not) (VP (VB take) (NP (NP (DT this) (NN medicine)) (PP (IN with) (NP (NN St.) (NNP Johns) (NNP Wort)))) (PP (IN because) (IN of) (NP (NP (DT the) (JJ additive) (NNS effects)) (PP (IN of) (NP (NN sertonin)))))))) (. .)))
(S1 (S (S (NP (DT This) (NN medication)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (NN Your) (NN doctor)) (CC or) (NP (NN pharmacist))) (VP (MD can) (VP (VB give) (NP (NP (ADJP (RB you) (JJR more)) (NN information)) (PP (IN on) (NP (NN drug1))))))) (. .)))
(S1 (S (S (VP (VBP Wait) (NP (NP (CD 5) (NNS weeks)) (PP (IN after) (S (VP (VBG stopping) (NP (NN drug1)) (PP (IN before) (S (VP (VBG starting) (NP (DT a) (NN drug2))))))))))) (. .)))
(S1 (S (S (VP (VBP Wait) (NP (NP (CD 2) (NNS weeks)) (PP (IN after) (S (VP (VBG stopping) (NP (DT an) (NN drug1)) (PP (IN before) (S (VP (VBG starting) (NP (NN drug2))))))))))) (. .)))
(S1 (S (SBAR (IN If) (S (VP (VBN you)))) (VP (VBP are) (VP (VBG taking) (NP (NP (NNS medications)) (PP (IN for) (NP (NP (NNS migraines)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NP (NN talk)) (PP (TO to) (NP (NN your) (NN doctor))) (PP (IN before) (S (VP (VBG starting) (NP (DT this) (NN medicine))))))))))))) (. .)))
(S1 (S (SBAR (IN If) (S (VP (VBN you)))) (VP (VBP are) (VP (VBG taking) (NP (NP (DT a) (NN drug1)) (, ,) (NP (NP (NN talk)) (PP (TO to) (NP (NN your) (NN doctor))))) (PP (IN before) (S (VP (VBG taking) (NP (DT this) (NN medicine))))))) (. .)))
(S1 (S (S (NP (NN St.) (NNP John) (NNP s) (NNP Wort)) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (IN while) (S (VP (VBG taking) (NP (NP (DT this) (NN medicine)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ additive) (NNS effects)) (PP (IN of) (NP (NN serotonin)))))))))))))) (. .)))
(S1 (S (NP (NP (NN Tell) (NN your) (NN doctor)) (SBAR (IN if) (S (ADVP (RB you)) (VP (VBP are) (VP (VBG taking) (NP (NP (NP (NP (NP (NP (DT any)) (PP (IN of) (NP (DT the) (VBG following) (NNS drugs)))) (: :) (NP (NN drug1) (NN s) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-) (JJ other) (NN drug3) (NN drug4) (NN drug5) (NN drug6) (-LRB- -LRB-) (NN drug7) (-RRB- -RRB-) (NN drug8) (-LRB- -LRB-) (NN drug9) (-RRB- -RRB-) (NN drug10) (NN drug11) (-LRB- -LRB-) (CD drug12) (-RRB- -RRB-) (NN intraconazole) (-LRB- -LRB-) (CD drug13) (-RRB- -RRB-) (NN drug14) (-LRB- -LRB-) (CD drug15) (-RRB- -RRB-) (NN drug16) (NN drug17) (CD drug18) (NN birth) (NN control) (NNS pills))) (NP (JJ sleeping) (NNS pills))) (NN thyroid)) (NNS medications)))))))))
(S1 (S (S (NP (NP (NNS Increases)) (PP (IN in) (NP (NN serum) (NN creatinine)))) (VP (VBP have) (VP (VBN occurred) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN given) (ADVP (RB alone))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (NN drug1)) (CC and) (NP (DT an) (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (NP (JJ renal) (NN function)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored)) (, ,) (SBAR (IN because) (S (NP (NN nephrotoxicity)) (VP (MD may) (VP (VB be) (VP (VBN potentiated))))))))) (. .)))
(S1 (S (NP (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (ADJP (ADJP (JJ false)) (ADJP (JJ positive))) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (NP (DT the) (NN urine)) (VP (VBG using) (NP (NP (NNP Clinitest) (, ,) (NNP Benedicts) (NN solution)) (, ,) (CC or) (NP (NN Fehlings) (NN solution))))))))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (NN glucose) (NNS tests)) (VP (VBN based) (PP (IN on) (NP (JJ enzymatic) (NN glucose) (NN oxidase))))) (VP (VB be) (VP (VBN used)))))))) (. .)))
(S1 (S (PP (IN As) (PP (IN with) (NP (JJ other) (NN drug1)))) (, ,) (NP (NP (JJ high) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VP (VB interfere) (PP (IN with) (NP (NP (NN measurement)) (PP (IN of) (NP (NP (NN serum)) (CC and) (NP (NN urine)) (NP (NN creatinine) (NNS levels)))))) (PP (IN by) (NP (NN Jaffe) (NN reaction)))) (CC and) (VP (VB produce) (NP (NP (JJ false) (NNS increases)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NN creatinine)) (VP (VBD reported)))))))))) (. .)))
(S1 (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (DT the) (JJ following) (NNS medications)) (: :) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PP (JJ such) (IN as) (NP (NP (NN drug5)) (CC and) (NP (NN drug6))))) (, ,) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (NN drug13))) (-RRB- -RRB-))) (, ,) (NP (CD drug14) (-LRB- -LRB-) (CD drug15) (, ,) (CD drug16) (, ,) (CD drug17) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NP (CD drug18) (-LRB- -LRB-) (CD drug19) (-RRB- -RRB-)) (, ,) (NP (CD drug20) (-LRB- -LRB-) (CD drug21) (-RRB- -RRB-)) (, ,) (NP (CD drug22) (-LRB- -LRB-) (CD drug23) (, ,) (CD drug24) (-RRB- -RRB-)) (, ,) (NP (NP (NN HIV) (NNS drugs)) (VP (VBN classified) (PP (IN as) (NP (CD drug25) (-LRB- -LRB-) (CD drug26) (, ,) (CD drug27) (, ,) (CD drug28) (, ,) (CD drug29) (, ,) (CD drug30) (, ,) (CD drug31) (, ,) (CD drug32) (-RRB- -RRB-))))) (, ,) (NP (CD drug33) (-LRB- -LRB-) (CD drug34) (, ,) (CD drug35) (, ,) (CD drug36) (-RRB- -RRB-)) (, ,) (NP (CD drug37)) (, ,) (NP (NP (CD drug38)) (PRN (-LRB- -LRB-) (NP (CD drug39)) (-RRB- -RRB-))) (, ,) (NP (CD drug40) (-LRB- -LRB-) (CD drug41) (-RRB- -RRB-)) (, ,) (NP (NN St.))) (NP (NNP Johns) (NNP wort))) (, ,) (NP (CD drug42)) (, ,) (NP (NP (CD drug43)) (PRN (-LRB- -LRB-) (NP (CD drug44)) (-RRB- -RRB-))) (, ,) (CC and) (NP (CD drug45))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (NN Substrate)) (PP (IN of) (NP (NP (NP (NN CYP3A4)) (PRN (-LRB- -LRB-) (NP (JJ major)) (-RRB- -RRB-))) (, ,) (NP (NP (NN 3A5-7)) (PRN (-LRB- -LRB-) (NP (JJ minor)) (-RRB- -RRB-)))))) (: ;))))
(S1 (S (S (VP (VBZ Inhibits) (NP (NP (NP (NN CYP1A2)) (PRN (-LRB- -LRB-) (NP (JJ weak)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NP (NN 2B6)) (PRN (-LRB- -LRB-) (NP (JJ weak)) (-RRB- -RRB-))) (, ,) (NP (NP (NN 2C19)) (PRN (-LRB- -LRB-) (NP (JJ weak)) (-RRB- -RRB-))) (, ,) (NP (NN 3A4))) (PRN (-LRB- -LRB-) (NP (JJ weak)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :)) (VP (MD May) (VP (VB increase) (NP (NP (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug2)))) (, ,) (PP (ADVP (RB possibly)) (IN by) (S (VP (VBG inhibiting) (NP (NN conjugation)))))))) (. .)))
(S1 (S (S (NP (NN Combination) (NN drug1)) (VP (MD may) (ADVP (RB also)) (VP (VB decrease) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :)) (VP (VBZ Interferes) (PP (IN with) (NP (NP (DT the) (JJ contraceptive) (NN effect)) (PP (IN of) (NP (JJ microdosed) (NN drug2) (JJ -containing) (NN minipill) (NNS preparations))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN on) (NP (NP (JJ other) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NNS implants)) (, ,) (NP (NN injectables))) (-RRB- -RRB-))))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (NN drug1) (: :)) (VP (MD May) (VP (VB increase) (NP (NP (NN CYP) (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ possible) (NN decrease)) (PP (IN in) (NP (JJ contraceptive) (NN effectiveness)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (DT a) (NN drug1)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (: :) (S (NP (NN Pregnancy)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (VBG following) (NP (JJ concomitant) (NN use)))))))) (, ,) (ADVP (RB however)) (, ,) (NP (JJ pharmacokinetic) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN shown) (NP (NP (JJ consistent) (NNS effects)) (PP (IN with) (NP (DT these) (NNS drug4))) (PP (IN on) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug5))))))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (DT a) (NN drug1)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (NN Combination) (NN drug2)) (VP (MD may) (VP (VP (VB increase)) (CC or) (VP (VB decrease) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NN Combination) (NN drug1)) (VP (MD may) (ADVP (RB also)) (VP (VB increase) (NP (NP (NN risk)) (PP (IN of) (NP (JJ thromboembolic) (NNS disorders))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-))) (: :) (NP (NP (NN Increase)) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug7)) (CC and/or) (NP (NP (DT some) (NN drug8)) (, ,) (VP (VBG leading) (PP (TO to) (NP (NP (JJ possible) (NN decrease)) (PP (IN in) (NP (JJ contraceptive) (NN effectiveness))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (DT a) (NN drug1)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NNS Doses)) (PP (IN of) (NP (NN drug2) (-LRB- -LRB-) (NN drug3) (-RRB- -RRB-) (CD 1) (NN g/day)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB increase) (NP (NP (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug4)))) (PP (IN by) (NP (CD ~47) (NN %))) (, ,) (PP (ADVP (RB possibly)) (IN by) (S (VP (VBG inhibiting) (NP (NN conjugation)))))))))))) (: ;))))
(S1 (S (S (NP (JJ clinical) (NNS implications)) (VP (VBP are) (ADJP (JJ unclear)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ increases) (NP (NP (DT the) (NN AUC)) (PP (IN for) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (NN Combination) (NN drug2)) (VP (MD may) (VP (VP (VB decrease) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (DT some) (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-)))))) (CC and) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NNS others)) (PRN (-LRB- -LRB-) (NP (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (NN Combination) (NN drug2)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (NN Combination) (NN drug2)) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3)))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (VBN increased) (NN plasma) (NNS concentrations)))))))) (: ;)))
(S1 (S (S (VP (VB monitor) (NP (NN drug1) (NNS levels)))) (. .)))
(S1 (S (NP (NP (JJ CYP3A4) (NNS inducers)) (: :) (S (NP (NN CYP3A4) (NNS inducers)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NNS levels/effects)) (PP (IN of) (NP (NN drug1))))))) (. .))))
(S1 (S (S (NP (NN Example) (NNS inducers)) (VP (VBP include) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (VP (VB induce) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug3)) (VP (VBG causing) (NP (JJ menstrual) (NNS changes))))))))) (: ;))))
(S1 (S (S (NP (NNS pregnancies)) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (NP (NN barrier) (NN form)) (PP (IN of) (NP (NN contraception)))))) (VP (VBZ is) (VP (VBN suggested) (PP (IN while) (PP (IN on) (NP (NN drug1) (NN therapy))))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (NN Combination) (NN drug2)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (S (NP (NN drug3)) (VP (MD may) (VP (VB decrease) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug4))))))) (: ;))))
(S1 (S (S (NP (NP (NN use)) (PP (IN of) (NP (DT a) (NN drug1)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (DT No) (NNS data)) (PP (IN for) (NP (NN drug1))) (: ;))))
(S1 (S (NP (NP (JJ incomplete) (NNS data)) (PP (IN for) (NP (NN drug1))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3)))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (VBN increased) (NN plasma) (NNS concentrations)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB decrease) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug6))))))))))) (: ;)))
(S1 (S (S (NP (NP (NN use)) (PP (IN of) (NP (DT a) (NN drug1)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB increase) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (DT No) (NNS data)) (PP (IN for) (NP (NN drug1)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ increases) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NP (NP (DT some) (NNS drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (VP (VBG resulting) (PP (IN in) (NP (NP (VBN decreased) (JJ contraceptive) (NN effectiveness)) (CC and) (NP (VBN increased) (JJ menstrual) (NNS irregularities))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (DT a) (NN drug1)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (NN Combination) (NN drug2)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN serum) (NN concentration)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3)))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (VBN increased) (NN plasma) (NNS concentrations)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-)))) (: :) (S (NP (NN Metabolism)) (VP (MD may) (VP (VB be) (VP (VBN inhibited) (PP (IN by) (NP (NN drug5))) (, ,) (S (VP (VBG increasing) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug6)))))))))) (: ;)))
(S1 (S (S (VP (VBP use) (NP (NN caution)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: /) (NP (NN NUTRITION)) (: /) (NP (NN HERB) (NNS INTERACTIONS)) (: :) (NP (NN Food)) (: :) (S (NP (NP (NN CNS) (NNS effects)) (PP (IN of) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (SBAR (IN if) (S (NP (NN drug3)) (VP (VBP are) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug4))))))))))) (. .))))
(S1 (S (S (NP (NN Grapefruit) (NN juice)) (VP (VP (VBZ increases) (NP (NN drug1) (NNS concentrations))) (CC and) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NN drug2) (NN serum) (NNS levels)) (PP (IN as) (NP (NN well))))))))))) (: ;)))
(S1 (S (S (NP (JJ clinical) (NNS implications)) (VP (VBP are) (ADJP (JJ unclear)))) (. .)))
(S1 (S (S (NP (NP (NN Herb/Nutraceutical)) (: :) (NP (JJ St) (NNP Johns) (NN wort))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NN drug1)))) (PP (IN by) (S (VP (VBG inducing) (NP (JJ hepatic) (NNS enzymes)))))))) (. .)))
(S1 (S (S (VP (VB Avoid) (NP (NP (JJ dong) (NN quai)) (CC and) (NP (JJ black) (NN cohosh))) (PRN (-LRB- -LRB-) (VP (VBP have) (NP (NN estrogen) (NN activity))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (VP (VB Avoid) (S (VP (VB saw) (NP (NP (NN palmetto)) (, ,) (NP (JJ red) (NN clover)) (, ,) (NP (NN ginseng))))))) (. .)))
(S1 (S (S (S (NP (DT No) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN for) (NP (NN drug1))))))) (, ,) (ADVP (RB however)) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (ADJP (RB orally) (VBN administered)) (NN drug2)))) (VP (MD could) (, ,) (ADVP (RB theoretically)) (, ,) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (DT the) (NN colon))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ pharmacokinetic) (NNS interactions)) (VP (VBN listed) (PP (IN below)))) (VP (VBP are) (ADJP (RB potentially) (RB clinically) (JJ important)))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NP (JJ hepatic) (NNS enzymes)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (VP (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug4)))))) (CC and) (VP (MD may) (VP (VB require) (NP (NP (NNS increases)) (PP (IN in) (NP (NN drug5) (NN dose)))) (S (VP (TO to) (VP (VB achieve) (NP (DT the) (JJ desired) (NN response))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3))))) (CC and) (ADVP (RB thus)) (VP (VB decrease) (NP (PRP$ their) (NN clearance)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN titrated) (S (VP (TO to) (VP (VB avoid) (NP (NN steroid) (NN toxicity))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (JJ chronic) (JJ high) (NN dose) (NN drug2))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VP (MD could) (VP (VB lead) (PP (TO to) (NP (VBN decreased) (NN drug1) (NN serum) (NNS levels))))) (CC or) (VP (VBP increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2) (NN toxicity)))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN withdrawn)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NN hypopro-thrombinemia)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (JJ oral) (NNS drug2)))) (VP (VBZ is) (NP (NN variable)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (VBN enhanced)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (VBN diminished) (NNS effects)) (PP (IN of) (NP (NN drug1))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN coagulation) (NNS indices)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (S (VP (TO to) (VP (VB maintain) (NP (DT the) (JJ desired) (JJ anticoagulant) (NN effect))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NNS Interactions)) (: :) (NP (FW a.) (NNS Drugs) (NN Enhancing) (NN drug1) (NN Effect)) (: :) (NP (JJ Oral) (NN drug2)) (: :) (NP (NN drug3))) (VP (MD may) (VP (VB prolong) (NP (DT the) (JJ one-stage) (NN prothrombin) (NN time))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))) (, ,) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (NP (NP (QP (IN at) (JJS least) (CD 5)) (NNS hours)) (PP (IN after) (NP (DT the) (JJ last) (JJ intravenous) (NN dose)))) (CC or) (NP (NP (CD 24) (NNS hours)) (PP (IN after) (NP (DT the) (JJ last) (NN subcutaneous) (NN dose))))))) (VP (MD should) (VP (VB elapse) (SBAR (IN before) (S (NP (NN blood)) (VP (VBZ is) (VP (VBN drawn) (SBAR (IN if) (S (NP (DT a) (JJ valid) (NN prothrombin) (NN time)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN obtained))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NNS Drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (CC and) (NP (NP (NNS others)) (SBAR (WHNP (WDT that)) (S (VP (VBP interfere) (PP (IN with) (NP (NP (JJ platelet-aggregation) (NNS reactions)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (JJ main) (JJ hemostatic) (NN defense)) (PP (IN of) (NP (JJ heparinized) (NNS patients)))) (-RRB- -RRB-))))))))))) (VP (VP (MD may) (VP (VB induce) (ADJP (JJ bleeding)))) (CC and) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug9)))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ anticoagulant) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN enhanced) (PP (IN by) (NP (NP (JJ concurrent) (NN treatment)) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN human)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ hereditary) (NN antithrombin) (CD III) (NN deficiency)))))))))))) (. .)))
(S1 (S (ADVP (RB Thus)) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB avoid) (ADJP (JJ bleeding)))))) (, ,) (NP (NP (VBN reduced) (NN dosage)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN human)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NN b)) (. .))))
(S1 (S (S (NP (NP (NP (NNS Drugs)) (VP (VBG Decreasing) (NP (NN drug1) (NN Effect)))) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))) (VP (MD may) (ADVP (RB partially)) (VP (VB counteract) (NP (NP (DT the) (JJ anticoagulant) (NN action)) (PP (IN of) (NP (NN drug6))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN Injection)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN mixed) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))) (, ,) (SBAR (IN since) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (S (NP (DT these) (NNS drugs)) (VP (VBP are) (ADJP (JJ incompatible) (PP (IN with) (NP (NN drug6)))))) (CC and) (S (NP (DT a) (NN precipitate)) (VP (MD may) (VP (VB form))))))))))))))) (. .)))
(S1 (S (S (NP (NN Drug/) (NN Laboratory) (NNS Tests)) (VP (NNS Interactions) (NP (NN Hyperaminotransferasemia)))) (: :) (S (NP (NP (JJ Significant) (NNS elevations)) (PP (IN of) (NP (NP (NP (NN aminotransferase)) (PRN (-LRB- -LRB-) (NP (NN SGOT) (NN -LSB-S-AST)) (-RRB- -RSB-))) (CC and) (NP (NP (NN SGPT)) (PRN (NN -LSB-S-ALT) (-RRB- -RSB-) (-RRB- -RRB-))) (NP (NNS levels))))) (VP (VBP have) (VP (VBN occurred) (PP (IN in) (NP (NP (DT a) (JJ high) (NN percentage)) (PP (IN of) (NP (NP (NP (NNS patients)) (-LRB- -LRB-) (CC and) (NP (JJ healthy) (NNS subjects)) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN received) (NP (NN drug1))))))))))))) (. .)))
(S1 (S (SBAR (IN Since) (S (NP (NN aminotransferase) (NNS determinations)) (VP (VBP are) (ADJP (JJ important) (PP (IN in) (NP (NP (DT the) (JJ differential) (NN diagnosis)) (PP (IN of) (NP (NP (JJ myocardial) (NN infarction)) (, ,) (NP (NN liver) (NN disease)) (CC and) (NP (JJ pulmonary) (NNS emboli)))))))))) (, ,) (NP (NP (VBZ rises)) (SBAR (WHNP (WDT that)) (S (VP (MD might) (VP (VB be) (VP (VBN caused) (PP (IN by) (NP (NP (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-)))))))))) (VP (MD should) (VP (VB be) (VP (VBN interpreted) (PP (IN with) (NP (NN caution)))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (NNS drugs)) (VP (VP (VBP have) (VP (VBN been) (VP (VBN coadministered) (PP (IN with) (NP (NN drug1)))))) (CC and) (VP (VBP have) (RB not) (VP (VBN altered) (NP (NP (PRP$ its) (NNS pharmacokinetics)) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (DT the) (JJ oral) (NN drug2) (NN drug3)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (RB not) (TO to) (VP (VB potentiate) (NP (NP (DT the) (JJ anticoagulant) (NN effect)) (PP (IN of) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Catecholamine-depleting) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (-RRB- -RRB-))) (VP (MD may) (VP (VB have) (NP (DT an) (JJ additive) (NN effect)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (JJ drug2) (NNS agents))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (NN drug1)) (CC plus) (NP (DT a) (NN catecholamine) (NN depletor)))))) (VP (MD should) (ADVP (RB therefore)) (VP (VB be) (ADVP (RB closely)) (VP (VBN observed) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NP (NN hypotension)) (CC or) (NP (JJ marked) (NN bradycardia))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB produce) (NP (NP (NN vertigo)) (, ,) (NP (NN syncope)) (, ,) (CC or) (NP (JJ postural) (NN hypotension))))))))))))))) (. .)))
(S1 (S (S (SINV (MD Should) (NP (PRP it)) (VP (VB be) (VP (VBN decided) (PP (TO to) (NP (NP (NN discontinue) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (ADVP (RB concurrently))))) (, ,) (NP (DT the) (NN drug3)) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (ADVP (RB slowly)) (PP (IN over) (NP (NP (JJ several) (NNS days)) (PP (IN before) (NP (NP (DT the) (JJ gradual) (NN withdrawal)) (PP (IN of) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (NN Literature) (NNS reports)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ oral) (NN drug1)) (VP (VP (MD may) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2))))) (SBAR (WHADVP (WRB when)) (S (NP (NN heart) (NN function)) (VP (VBZ is) (ADJP (JJ normal)))))))) (, ,) (CC but) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ impaired) (JJ cardiac) (NN function))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Hypotension)) (, ,) (NP (NN AV) (NN conduction) (NNS disturbances)) (, ,) (CC and) (NP (JJ left) (JJ ventricular) (NN failure))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (DT some) (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))) (SBAR (WHADVP (WRB when)) (S (NP (DT an) (JJ oral) (NN drug2)) (VP (VBD was) (VP (VBN added) (PP (TO to) (NP (DT the) (NN treatment) (NN regimen))))))))))) (. .)))
(S1 (S (S (NP (NN Hypotension)) (VP (VBD was) (ADJP (RBR more) (JJ likely)) (S (VP (TO to) (VP (VB occur) (SBAR (IN if) (S (NP (DT the) (NN drug1)) (VP (VBD were) (NP (DT a) (NN drug2)) (, ,) (PP (FW e.g.) (, ,) (NP (NN drug3))) (, ,) (SBAR (IN while) (S (NP (NP (NP (NP (JJ left) (NN ventricular)) (NN failure)) (CC and) (NP (NN AV) (NN conduction) (NNS disturbances))) (, ,) (PP (VBG including) (NP (JJ complete) (NN heart) (NN block))) (, ,)) (VP (VBD were) (ADJP (RBR more) (JJ likely)) (S (VP (TO to) (VP (VB occur) (PP (IN with) (NP (CC either) (NP (NN drug4)) (CC or) (NP (NN drug5)))))))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN Risk)) (PP (IN of) (NP (JJ Anaphylactic) (NN Reaction)))) (: :) (S (SBAR (IN Although) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN known) (PP (IN that) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug1))))))))) (VP (MD may) (VP (VB be) (ADJP (JJ refractory) (PP (TO to) (NP (NP (NN drug2)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN anaphylactic) (NN shock))))) (, ,) (SBAR (WHNP (WDT drug3)) (S (VP (MD can) (, ,) (PP (IN in) (NP (NN addition))) (, ,) (VP (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (JJ allergic) (NN reaction)))))) (CC and) (VP (VB lead) (PP (TO to) (NP (NP (DT an) (VBN increased) (NP (NP (NN severity)) (CC and/or) (NP (NN frequency)))) (PP (IN of) (NP (NNS attacks)))))))))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Severe) (JJ allergic) (NNS reactions)) (PP (VBG including) (NP (NN anaphylaxis)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN exposed) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS allergens))))) (PP (CC either) (PP (IN by) (NP (NP (JJ repeated) (NN challenge)) (, ,) (CC or) (NP (JJ accidental) (NN contact)))) (, ,) (CC and) (PP (IN with) (NP (ADJP (ADJP (JJ diagnostic)) (CC or) (ADJP (JJ therapeutic))) (NNS agents)))) (SBAR (IN while) (S (VP (VBG receiving) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (S (NP (JJ Such) (NNS patients)) (VP (MD may) (VP (VB be) (ADJP (JJ unresponsive) (PP (TO to) (NP (NP (DT the) (JJ usual) (NNS doses)) (PP (IN of) (NP (NN drug1))) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (JJ allergic) (NN reaction)))))))))))) (. .)))
(S1 (S (-RRB- -RRB-)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (JJ Clinical) (NN Laboratory))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (VBN increased) (NN creatine))))
(S1 (S (NP (JJ positive) (NN antinuclear))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN phosphokinase))))
(S1 (S (NP (NN antibody))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (VBN increased) (NN bilirubin))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (VBN increased) (NN liver))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NP (NNS transaminases)) (PRN (-LRB- -LRB-) (NP (NN AST))))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (PRN (-LRB- -LRB-) (NP (NN SGOT)) (-RRB- -RRB-)) (, ,) (NP (NP (NN ALT)) (PRN (-LRB- -LRB-) (NP (NN SGPT)) (-RRB- -RRB-)))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (VBN increased) (NN alkaline))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN phophatase))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (JJ Hematopoietic))))
(S1 (S (NP (NN anemia))))
(S1 (S (NP (NN thrombocytopenia))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN leukopenia))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN bone) (NN marrow) (NNS hypoplasia))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN eosinophilia))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (JJ Immunologic))))
(S1 (S (NP (NN angioedema))))
(S1 (S (NP (NN anaphylaxis))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (JJ laryngeal) (NN edema))))
(S1 (S (NP (JJ Lupus-like) (NN syndrome))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN urticaria))))
(S1 (S (NP (NN vasculitis))))
(S1 (S (NP (JJ Integumentary))))
(S1 (S (NP (JJ exfoliative) (NN dermatitis))))
(S1 (S (NP (NN alopecia))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN rash))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN dermatitis))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN pruritus))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (DT No) (JJ formal) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (NP (DT the) (NN period)) (PP (VBG following) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN drug1)) (SBAR (IN before) (S (NP (PRP one)) (VP (MD should) (VP (VB consider) (S (VP (VBG starting) (NP (JJ other) (NN drug2) (NN therapy))))))))))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated))))) (. .)))
(S1 (S (NP (NP (NN Carcinogenesis)) (, ,) (NP (NN Mutagenesis)) (, ,) (CC and) (NP (NN Fertility)))))
(S1 (S (S (PP (IN In) (NP (DT a) (JJ chronic) (NN toxicity) (NN study))) (, ,) (NP (NN cynomolgus) (NNS monkeys)) (VP (VBD were) (VP (VBN dosed) (ADVP (RB weekly)) (PP (IN for) (NP (NP (CD 52) (NNS weeks)) (PP (IN with) (NP (JJ intravenous) (NN drug1))))) (PP (IN at) (NP (NP (CD 1) (NN mg/kg/dose)) (CC or) (NP (CD 20) (NN mg/kg/dose))))))) (. .)))
(S1 (S (S (NP (NP (CD One) (NN animal)) (PP (IN in) (NP (DT the) (JJ high) (NN dose) (NN group)))) (VP (VBD developed) (NP (NP (DT a) (NN B-cell) (NN lymphoma)) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (VP (VBN detected) (PP (IN after) (NP (NP (CD 28) (NNS weeks)) (PP (IN of) (NP (NN dosing)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Additional) (NNS animals)) (PP (IN in) (NP (DT both) (NN dose) (NNS groups)))) (VP (VBD developed) (NP (NP (NN B-cell) (NN hyperplasia)) (PP (IN of) (NP (DT the) (NP (NN spleen)) (CC and) (NP (NN lymph) (NNS nodes))))))) (. .)))
(S1 (S (S (NP (NP (DT All) (NNS animals)) (PP (IN in) (NP (DT the) (NN study)))) (VP (VBD were) (ADJP (JJ positive) (PP (IN for) (NP (NP (DT an) (JJ endemic) (JJ primate) (NN gammaherpes) (NN virus)) (VP (ADVP (RB also)) (VBN known) (PP (IN as) (NP (NP (NN lymphocryptovirus)) (PRN (-LRB- -LRB-) (NP (NN LCV)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (JJ Latent) (NN LCV) (NN infection)) (VP (VP (VBZ is) (ADVP (RB generally)) (ADJP (JJ asymptomatic))) (, ,) (CC but) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NN B-cell) (NNS lymphomas))) (SBAR (WHADVP (WRB when)) (S (NP (NNS animals)) (VP (VBP are) (VP (ADVP (JJ immune)) (VBN suppressed))))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT a) (JJ separate) (NN study))) (, ,) (NP (NP (NP (NNS baboons)) (VP (VBN given) (NP (NP (CD 3) (NNS doses)) (PP (IN of) (NP (NN drug1)))) (PP (IN at) (NP (CD 1) (NN mg/kg))))) (NP (DT every) (CD 8) (NNS weeks))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB have) (NP (JJ centroblast) (NN proliferation)) (PP (IN in) (NP (NP (NN B-cell) (JJ dependent) (NNS areas)) (PP (IN in) (NP (NP (DT the) (JJ germinal) (NNS centers)) (PP (IN of) (NP (DT the) (NN spleen))))))) (PP (VBG following) (NP (DT a) (JJ 116-day) (NN washout) (NN period)))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT the) (JJ lymphoid) (NN malignancy)))) (CC and) (NP (NP (DT the) (NN hyperplasia)) (VP (VBN observed) (PP (IN in) (NP (JJ non-human) (NNS primates)))))))) (CC and) (NP (NP (DT the) (NN relevance)) (PP (TO to) (NP (NNS humans))))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (NP (JJ Immunodeficiency-associated) (NN lymphocyte) (NNS disorders)) (PRN (-LRB- -LRB-) (NP (NP (JJ plasmacytic) (NN hyperplasia)) (, ,) (NP (JJ polymorphic) (NN proliferation)) (, ,) (CC and) (NP (NN B-cell) (NNS lymphomas))) (-RRB- -RRB-))) (VP (VBP occur) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (NP (NP (ADJP (ADJP (JJ congenital)) (CC or) (ADJP (JJ acquired))) (NNS immunodeficiencies)) (PP (VBG including) (NP (NP (DT those)) (VP (VBG resulting) (PP (IN from) (NP (NN drug1) (NN therapy)))))))))))))) (. .)))
(S1 (S (S (NP (DT No) (NN carcinogenicity) (CC or) (NN fertility) (NNS studies)) (VP (VBD were) (VP (VBN conducted)))) (. .)))
(S1 (S (S (NP (NN Mutagenicity) (NNS studies)) (VP (VBD were) (VP (VBN conducted) (ADVP (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo)))))) (: ;)))
(S1 (S (S (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NN mutagenicity)))) (VP (VBD was) (VP (VBN observed)))) (. .)))
(S1 (S (NP (NP (NN Pregnancy)) (PRN (-LRB- -LRB-) (NP (NN Category) (NN B)) (-RRB- -RRB-)))))
(S1 (S (S (NP (NP (NNS Women)) (PP (IN of) (NP (JJ childbearing) (NN potential)))) (VP (VBP make) (PRT (RP up)) (NP (NP (DT a) (JJ considerable) (NN segment)) (PP (IN of) (NP (NP (DT the) (NN patient) (NN population)) (VP (VBN affected) (PP (IN by) (NP (NN psoriasis))))))))) (. .)))
(S1 (S (SBAR (IN Since) (S (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NP (NN pregnancy)) (CC and) (NP (JJ fetal) (NN development))) (, ,) (PP (VBG including) (NP (NP (JJ immune) (NN system)) (NN development))) (, ,)))) (VP (VBZ is) (RB not) (VP (VBN known))))) (, ,) (NP (NN health) (NN care) (NNS providers)) (VP (VBP are) (VP (VBN encouraged) (S (VP (TO to) (VP (VBP enroll) (NP (NP (NP (NNS patients)) (VP (ADVP (RB currently)) (VBG taking) (NP (NN drug2)))) (SBAR (WHNP (WP who)) (S (VP (VBP become) (ADJP (JJ pregnant)) (PP (IN into) (NP (DT the) (NN Biogen) (NN Pregnancy) (NN Registry))) (PP (IN by) (S (VP (VBG calling) (NP (NP (NN 1-866-) (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN 1-866-263-8483)) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (NP (JJ Reproductive) (NN toxicology) (NNS studies)) (VP (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN in) (NP (JJ cynomolgus) (NNS monkeys))) (PP (IN at) (NP (NNS doses) (NP (NP (QP (RB up) (TO to) (CD 5)) (NN mg/kg/week)) (PRN (-LRB- -LRB-) (NP (QP (RB about) (CD 62) (NNS times)) (NP (DT the) (JJ human) (NN dose)) (VP (VBN based) (PP (IN on) (NP (NN body) (NN weight))))) (-RRB- -RRB-)))))))) (CC and) (VP (VBP have) (VP (VBN revealed) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (JJ impaired) (NN fertility)) (CC or) (NP (NP (NN harm)) (PP (TO to) (NP (NP (DT the) (NN fetus)) (ADJP (JJ due) (PP (TO to) (NP (NN drug1))))))))))))) (. .)))
(S1 (S (S (NP (DT No) (ADJP (ADJP (JJ abortifacient)) (CC or) (ADJP (JJ teratogenic))) (NNS effects)) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (JJ cynomolgus) (NNS monkeys))) (PP (VBG following) (NP (NP (JJ intravenous) (NN bolus) (NNS injections)) (PP (IN of) (NP (NN drug1))) (VP (VBN administered) (ADVP (RB weekly)) (PP (IN during) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (NN organogenesis))) (PP (TO to) (NP (NN gestation))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBD underwent) (NP (JJ trans-placental) (NN passage))) (CC and) (VP (VBD produced) (NP (NP (ADJP (FW in) (FW utero)) (NN exposure)) (PP (IN in) (NP (DT the) (VBG developing) (NNS monkeys))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN utero))) (, ,) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NN exposure))) (PP (IN in) (NP (DT these) (NNS monkeys)))) (VP (VBD were) (NP (NP (CD 23) (NN %)) (PP (IN of) (NP (JJ maternal) (NN serum) (NNS levels)))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN evidence)) (PP (IN of) (NP (JJ fetal) (NN toxicity))) (PP (VBG including) (NP (NP (JJ adverse) (NNS effects)) (PP (IN on) (NP (JJ immune) (NN system) (NN development)))))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (NNS animals)))))))) (. .)))
(S1 (S (S (S (NP (NN Animal) (NN reproduction) (NNS studies)) (, ,) (ADVP (RB however)) (, ,) (VP (VBP are) (RB not) (ADVP (RB always)) (ADJP (JJ predictive) (PP (IN of) (NP (JJ human) (NN response)))))) (CC and) (S (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (ADJP (ADJP (JJ adequate)) (CC and) (ADJP (JJ well-controlled))) (NNS studies)) (PP (IN in) (NP (JJ pregnant) (NNS women))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NP (DT the) (NN risk)) (PP (TO to) (NP (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT the) (JJ fetal) (JJ immune) (NN system)))) (CC and) (NP (NP (JJ postnatal) (JJ immune) (NN function)) (PP (IN in) (NP (NNS humans))))))) (VP (VBZ is) (ADJP (JJ unknown))))) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN during) (NP (NN pregnancy))) (SBAR (RB only) (IN if) (S (ADVP (RB clearly)) (VP (VBN needed)))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN pregnancy)) (VP (VBZ occurs) (SBAR (IN while) (S (VP (VBG taking) (NP (NN drug1)))))))) (, ,) (NP (NP (JJ continued) (NN use)) (PP (IN of) (NP (DT the) (NN drug)))) (VP (MD should) (VP (VB be) (VP (VBN assessed))))) (. .)))
(S1 (S (VP (VBG Nursing) (NP (NNS Mothers)))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN excreted) (PP (IN in) (NP (JJ human) (NN milk)))))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (JJ many) (NNS drugs)) (VP (VBP are) (VP (VBN excreted) (PP (IN in) (NP (JJ human) (NN milk))))))) (, ,) (CC and) (SBAR (IN because) (S (NP (EX there)) (VP (VBZ exists) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (JJ serious) (JJ adverse) (NNS reactions)) (PP (IN in) (NP (NP (JJ nursing) (NNS infants)) (PP (IN from) (NP (NN drug1))))))))))) (, ,) (NP (DT a) (NN decision)) (VP (MD should) (VP (VB be) (VP (VBN made) (SBAR (IN whether) (S (VP (VP (TO to) (VP (VBP discontinue) (S (VP (VBG nursing) (SBAR (IN while) (S (VP (VBG taking) (NP (DT the) (NN drug))))))))) (CC or) (VP (TO to) (VP (VBP discontinue) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT the) (NN drug)))) (, ,) (S (VP (VBG taking) (SBAR (IN into) (S (VP (VBP account) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (DT the) (NN drug))) (PP (TO to) (NP (DT the) (NN mother))))))))))))))))) (. .)))
(S1 (S (NP (JJ Geriatric) (NN Use))))
(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 1357) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN drug1)) (PP (IN in) (NP (JJ clinical) (NNS trials)))))))) (, ,) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 100) (NNS patients)))) (VP (VBD were))))
(S1 (S (NP (NP (NP (CD 65) (NNS years)) (PP (IN of) (NP (NN age)))) (CC and) (NP (NP (CD 13) (NNS patients)) (VP (VBD were))))))
(S1 (S (NP (NP (CD 75) (NNS years)) (PP (IN of) (NP (NN age))) (. .))))
(S1 (S (S (S (NP (NP (DT No) (NNS differences)) (PP (IN in) (NP (NP (NN safety)) (CC or) (NP (NN efficacy))))) (VP (VBD were) (VP (VBN observed) (PP (IN between) (NP (ADJP (ADJP (JJR older)) (CC and) (ADJP (JJR younger))) (NNS patients)))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBD were) (RB not) (ADJP (JJ sufficient) (S (NP (NNS data)) (VP (TO to) (VP (VB exclude) (NP (JJ important) (NNS differences))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NNS infections)) (CC and) (NP (JJ certain) (NNS malignancies))))) (VP (VBZ is) (ADJP (JJR higher) (PP (IN in) (NP (DT the) (JJ elderly) (NN population))) (, ,) (PP (IN in) (NP (JJ general))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN in) (S (VP (VBG treating) (NP (DT the) (JJ elderly))))))))) (. .)))
(S1 (S (NP (JJ Pediatric) (NN Use))))
(S1 (S (S (NP (NP (DT The) (NP (NN safety)) (CC and) (NP (NN efficacy))) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (JJ pediatric) (NNS patients)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN indicated) (PP (IN for) (NP (JJ pediatric) (NNS patients)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBP prolong)) (CC and) (VP (VBP intensify) (NP (NP (DT the) (JJ anticholinergic) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB have) (NP (JJ additive) (NNS effects)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (JJ other) (NN drug3)))) (, ,) (PP (FW e.g.) (, ,) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NP (JJ rheumatoid) (NN arthritis) (NNS patients)) (VP (VBG taking) (NP (JJ concomitant) (NN drug3))))))))) (. .))))
(S1 (S (S (NP (DT The) (NNS data)) (VP (VBP do) (RB not) (VP (VBP suggest) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NN dose) (NN adjustment)) (PP (IN of) (NP (CC either) (NP (NN drug1)) (CC or) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (DT an) (NN drug3)) (-RRB- -RRB-))) (CC and) (NP (DT another) (NN drug4))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ serious) (NNS infections)))) (, ,) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN neutropenia)))) (CC and) (NP (NP (DT no) (JJ additional) (NN benefit)) (PP (VBN compared) (PP (TO to) (NP (NP (DT these) (JJ medicinal) (NNS products)) (ADVP (RB alone)))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NP (NN safety)) (CC and) (NP (NN efficacy))) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNS drug2))))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (ADJP (RB Therefore) (DT the)) (, ,) (NP (NP (NN combination)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS drug2)) (, ,) (PP (VBG including) (NP (NN drug3))) (, ,)))) (VP (MD may) (ADVP (RB also)) (VP (VB result) (NP (ADJP (NN i) (NN n) (JJ similar)) (NNS toxicities))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN with) (NP (NP (JJ other) (NN drug1) (JJ -containing) (NNS medicines)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (NN drug2))) (-RRB- -RRB-))))) (VP (MD may) (VP (VB cause) (NP (ADJP (RB too) (JJ much)) (NN drug3)) (PP (IN in) (NP (NP (DT the) (NP (NN blood)) (CC or) (NP (NN urine))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN chance)) (PP (IN of) (NP (JJ side) (NNS effects))))))))))))) (. .)))
(S1 (S (S (S (VP (VBG Using) (NP (NP (NN drug1)) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN heart) (NN medicine)) (-RRB- -RRB-))))))) (VP (MD may) (VP (VB cause) (NP (NP (NP (NN hypercalcemia)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (RB too) (JJ much)) (NN drug3)) (PP (IN in) (NP (DT the) (NN blood)))) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB increase) (NP (NP (DT the) (NN chance)) (PP (IN of) (S (VP (VBG developing) (NP (DT an) (JJ irregular) (NN heartbeat)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Tablet)) (PP (IN If) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1)))))) (VP (VBZ is) (ADVP (RB also)) (VP (VBG taking) (NP (NP (NN drug2)) (, ,) (NP (NP (DT the) (NN effect)) (SBAR (IN of) (S (NP (NN drug3)) (VP (MD may) (VP (VB be) (VP (VBN reduced))))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG necessitating) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN dosage)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ CNS-depressive) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC or) (NP (JJ other) (NN drug4)))))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))) (VP (VBZ enhances) (NP (NP (DT the) (NN manifestation)) (PP (IN of) (NP (NN corneal) (NNS lesions)))) (PP (IN in) (NP (NNS rats))))) (S (NP (JJ Epidural) (NN Injection) (NN drug3)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ CNS-depressive) (NN effect)) (PP (IN of) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC or) (NP (JJ other) (NN drug6))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN drug2) (NN s) (JJ analgesic) (NNS actions)))) (VP (VBP are) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB exacerbate) (NP (NP (DT the) (JJ hypertensive) (NN response)) (VP (VBN seen) (PP (IN with) (NP (NN drug2) (NN withdrawl)))))))) (. .)))
(S1 (S (ADVP (RB Also)) (, ,) (PP (JJ due) (TO to) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (JJ additive) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NN bradycardia)) (CC and) (NP (NN AV)) (NP (NN block)))))))) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN warranted) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (NN drug1)) (PP (IN with) (NP (NP (NNS agents)) (VP (VBN known) (S (VP (TO to) (VP (VB affect) (NP (NP (NN sinus) (NN node)) (NN function))))))))) (CC or) (NP (NP (NN AV) (JJ nodal) (NN conduction)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)) (. .)) (-RRB- -RRB-)))))))))))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (CD one) (VBN reported) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (JJ acute) (NN delirium)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ simultaneous) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ oral) (NN drug2)))))))))))))) (. .)))
(S1 (S (S (NP (NNS Symptoms)) (VP (VP (VBN resolved) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN withdrawn)))))) (CC and) (VP (VBN recurred) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN patient)) (VP (VBD was) (VP (VBN rechallenged) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (JJ Epidural) (NN drug1)) (VP (MD may) (VP (VB prolong) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (JJ pharmacologic) (NNS effects)) (PP (IN of) (NP (JJ epidural) (JJ local) (NN drug2))) (, ,) (PP (VBG including) (NP (CC both) (NP (NN sensory)) (CC and) (NP (NN motor)) (NP (NN blockade)))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN evidence)) (PP (IN of) (NP (NP (NN interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NNS drugs)))))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (JJ clinical) (NNS trials)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2) (JJ ophthalmic) (NN suspension)) (-RRB- -RRB-))) (ADJP (CD 1) (NN %))) (VP (VBZ contains) (NP (DT a) (NN drug3)))) (. .)))
(S1 (S (S (NP (NP (NP (NN Acid-base)) (CC and) (NP (NN electrolyte))) (NNS alterations)) (VP (VBD were) (RB not) (VP (VBN reported) (PP (IN in) (NP (NP (DT the) (JJ clinical) (NNS trials)) (PP (IN with) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (JJ oral) (NN drug1)))))) (, ,) (NP (NP (JJ rare) (NNS instances)) (PP (IN of) (NP (NN drug) (NNS interactions)))) (VP (VBP have) (VP (VBN occurred) (PP (IN with) (NP (JJ high-dose) (NN drug2) (NN therapy)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (JJ such) (NN drug) (NN interaction)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2) (JJ ophthalmic) (NN suspension)) (-RRB- -RRB-))) (ADJP (CD 1) (NN %)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Certain) (NNS drug1)) (, ,) (ADVP (RB especially)) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4))) (, ,)) (VP (VBP have) (NP (NP (DT a) (ADJP (ADJP (JJ mild)) (CC but) (ADJP (JJ definite))) (NN nondepolarizing) (NN blocking) (NN action)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB accentuate) (NP (JJ neuromuscular) (NN block))))))))) (. .)))
(S1 (S (S (S (NP (DT These) (NNS drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (JJ myasthenic) (NN patient)) (SBAR (WHADVP (RB only) (WRB where)) (S (VP (ADVP (RB definitely)) (VBN indicated)))))))))) (, ,) (CC and) (S (ADVP (RB then)) (NP (JJ careful) (NN adjustment)) (VP (MD should) (VP (VB be) (VP (VBN made) (PP (IN of) (NP (JJ adjunctive) (NN drug2) (NN dosage)))))))) (. .)))
(S1 (S (NP (NP (NP (ADJP (ADJP (JJ Local)) (CC and) (ADJP (DT some) (JJ general))) (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP interfere) (PP (IN with) (NP (JJ neuromuscular) (NN transmission))))))) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (, ,) (ADVP (IN if) (IN at) (DT all)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ myasthenia) (NNS gravis)))))))) (: ;)))
(S1 (S (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB have) (S (VP (TO to) (VP (VB be) (VP (VBN increased) (ADVP (RB accordingly))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (NN drug) (NNS interactions)) (VP (VBD were) (VP (VBN studied) (PP (IN with) (NP (NP (JJ drug1) (NNS doses)) (PP (IN of) (NP (CD 200) (NN mg/day)))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (VBN increased) (NN interaction)))) (VP (MD should) (VP (VB be) (VP (VBN kept) (PP (IN in) (NP (NN mind))) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ drug1) (NNS doses)) (ADJP (JJR greater) (PP (IN than) (NP (NP (NP (CD 50) (NN mg)) (PP (IN as) (NP (DT a) (JJ single) (NN dose)))) (CC or) (NP (NP (CD 200) (NN mg)) (PP (IN of) (NP (NN drug2))) (PP (IN per) (NP (NN day)))))))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (ADJP (RB highly) (VBN bound)) (NNS drugs)))))))))) (. .)))
(S1 (S (S (NP (CD 1))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ does) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NP (NN rate)) (CC or) (NP (NN extent))) (PP (IN of) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (NNS drug4)) (VP (VBN administered) (PP (IN as) (NP (NN drug5))))))))))))) (. .))))
(S1 (S (NP (NP (CD 2)) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ does) (RB not) (VP (VB alter) (NP (NN drug3) (NN absorption))))) (: ;))))
(S1 (S (ADVP (RB however)) (, ,) (PP (IN in) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (CD 12) (JJ normal) (NNS subjects))))) (, ,) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD decreased) (NP (NP (NN drug2) (NN protein) (NN binding)) (CC and) (NP (VBN increased) (NN drug3) (NN plasma) (NN clearance))) (PP (IN from) (NP (CD 0.07) (NN L/kg/h))) (PP (IN without) (NP (NN drug4))) (PP (TO to) (NP (NP (NN 0.11) (NN L/kg/h)) (PP (IN with) (NP (NN drug5)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT these) (NNS changes)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB adequately)) (VP (VBN studied))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (CD 3)) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2)) (, ,) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3)))) (, ,)) (VP (VBZ produces) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (JJ urinary) (NN potassium) (CC and) (NN chloride) (NN excretion)))) (PP (VBN compared) (PP (TO to) (NP (NP (NN drug4)) (ADVP (RB alone))))))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NN drug1)))) (VP (VBP are) (PP (IN at) (NP (NP (DT a) (JJR greater) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NP (JJ renal) (NN failure)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ renal) (NN blood) (NN flow)) (VP (VBN caused) (PP (IN by) (NP (NN prostaglandin) (NN inhibition))))))))))))))))) (. .)))
(S1 (S (S (NP (CD 4))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (NP (CD 12) (NNS patients)) (PP (IN with) (NP (NP (JJ congestive) (NN heart) (NN failure)) (SBAR (WHADVP (WRB where)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBD were) (ADVP (RB concomitantly)) (VP (VBN administered))))))))))) (, ,) (NP (NNS drug4)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug5))))))) (. .))))
(S1 (S (NP (NP (CD 5)) (. .))))
(S1 (S (S (NP (NN drug1)) (: :) (PP (IN In) (NP (NP (DT a) (JJ short-term) (JJ controlled) (NN study)) (PP (IN in) (NP (CD 14) (JJ normal) (NNS volunteers))))) (, ,) (NP (NN drug2)) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug3))) (PP (IN on) (NP (NN prothrombin) (NN time)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Bleeding)) (PP (IN from) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS sites)))))) (VP (MD may) (VP (VB be) (NP (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NN drug1) (NN treatment)))) (CC and) (NP (JJ GI) (JJ bleeding)) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NN drug2) (NN treatment)))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NNS prostaglandina)) (VP (VBP play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NN hemostasis)) (CC and) (NP (NN drug1))))))) (VP (VBZ has) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (NN platelet) (NN function)))) (PP (IN as) (NP (NN well))))) (, ,) (S (NP (NP (JJ concurent) (NN therapy)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ requires) (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (NNS patients))) (PP (IN on) (NP (DT both) (NNS drugs)))))) (. .)))
(S1 (S (NP (NP (CD 6)) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ increases) (NP (ADJP (CC both) (ADJP (JJ free)) (CC and) (ADJP (JJ bound))) (NN drug3)) (PP (IN by) (S (VP (VP (VBG reducing) (NP (NP (DT the) (NN plasma) (NN clearance)) (PP (IN of) (NP (NN drug4))) (PP (TO to) (NP (RB about) (CD one-third))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (VP (VBG decreasing) (NP (PRP$ its) (NN protein) (NN binding)))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (CD 7)) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (, ,) (PP (IN like) (NP (JJ other) (NN drug3))) (, ,) (VP (MD may) (VP (VB cause) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NP (NN drug4)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NP (DT the) (NN drug)) (CC and) (NP (VBN increased) (NN toxicity))))))))))))))) (. .)))
(S1 (S (NP (NP (CD 8)) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB increase) (NP (JJ steadystate) (NN plasma) (NN drug3) (NNS levels))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN plasma) (NN drug1) (NNS levels)) (VP (VB be) (VP (VBN monitored) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (NP (NP (NN DRUG/LABORATORY) (NN TEST) (NNS INTERACTIONS)) (: :) (S (NP (NP (NN EFFECT)) (PP (IN ON) (NP (NN BLOOD) (NN COAGULATION) (CD drug1)))) (VP (VBZ decreases) (NP (NP (NN platelet) (NN adhesion)) (CC and) (NP (NN aggregation))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (MD can) (VP (VB prolong) (NP (JJ bleeding) (NN time)) (PP (IN by) (NP (NP (QP (RB approximately) (CD 3) (TO to) (CD 4)) (NNS minutes)) (PP (IN from) (NP (NN baseline) (NNS values)))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (JJ significant) (NN change)) (PP (IN in) (NP (NP (NN platelet) (NN count)) (, ,) (NP (NN prothrombin) (NN time)) (, ,) (NP (JJ partial) (NN thromboplastin) (NN time)) (, ,) (CC or) (NP (NN thrombin) (NN time))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB depress) (NP (NN plasma) (NN prothrombin) (NN activity)))))))))) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (PP (IN on) (NP (NN drug2) (NN therapy))))))) (VP (MD may) (VP (VB require) (NP (NP (JJ downward) (NN adjustment)) (PP (IN of) (NP (PRP$ their) (NN drug3) (NN dosage))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (JJ bacteriostatic) (NNS drugs)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (JJ bactericidal) (NN action)) (PP (IN of) (NP (NN drug1))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ advisable) (S (VP (TO to) (VP (VB avoid) (NP (NN giving) (NN drug2)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Absorption)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN impaired) (PP (IN by) (NP (NP (NN drug2)) (VP (VBG containing) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)) (NP (JJ -containing) (NNS preparations))))))))) (. .)))
(S1 (S (S (NP (NP (NN Absorption)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN impaired) (PP (IN by) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (VP (VBP decrease) (NP (NP (DT the) (NN half-life)) (PP (IN of) (NP (NN drug4)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (JJ fatal) (JJ renal) (NN toxicity)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB render) (NP (NP (JJ oral) (NN drug2)) (ADJP (RBR less) (JJ effective)))))) (. .)))
(S1 (S (S (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (JJ False) (NNS elevations)) (PP (IN of) (NP (JJ urinary) (NN catecholamine) (NNS levels)))) (VP (MD may) (VP (VB occur) (ADJP (JJ due) (PP (TO to) (NP (NP (NN interference)) (PP (IN with) (NP (DT the) (NN fluorescence) (NN test))))))))) (. .)))
(S1 (S (S (NP (JJ General) (NN No) (JJ clinical) (NN drug) (NN interaction) (NNS studies)) (VP (VBD were) (VP (VBN performed)))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN evaluation)) (PP (IN of) (NP (NP (NN drug1) (NN s) (NNS effects)) (PP (IN on) (NP (DT the) (NN cytochrome) (NN P450) (NN system)))))) (VP (VBD was) (VP (VBN conducted)))) (. .)))
(S1 (S (S (PP (IN As) (PP (IN with) (NP (JJ other) (NN drug1)))) (, ,) (NP (NP (NN blood) (NNS concentrations)) (PP (IN of) (NP (JJ dialyzable) (NNS drugs)))) (VP (MD may) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (NN dialysis))))))) (. .)))
(S1 (S (S (NP (NP (JJ Dosage) (NN adjustment)) (PP (IN of) (NP (JJ concomitant) (NNS medications)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG using) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (CC and) (NP (NNS others))) (-RRB- -RRB-)))))) (, ,) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN calcium)) (, ,) (NP (NN potassium)) (CC and) (NP (NN magnesium))))) (VP (MD must) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT A) (JJ clinical) (NN study)) (PP (IN in) (NP (CD 6) (JJ insulin-dependent) (JJ diabetic) (NNS patients)))) (VP (VBD demonstrated) (NP (NP (DT no) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (PP (IN on) (NP (NP (NN drug3) (NN absorption)) (PP (IN from) (NP (DT the) (JJ peritoneal) (NN cavity))))) (CC or) (PP (IN on) (NP (NP (NN drug4) (NN s) (NN ability)) (S (VP (TO to) (VP (VB control) (NP (NN blood) (NN glucose)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug5)) (VP (VBD was) (VP (VBN administered) (ADVP (RB intraperitoneally)) (PP (IN with) (NP (NN drug6)))))))))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (S (NP (NP (JJ appropriate) (NN monitoring)) (PP (IN of) (NP (NN blood) (NN glucose)))) (VP (MD should) (VP (VB be) (VP (VBN performed))) (SBAR (WHADVP (WRB when)) (S (VP (VBG initiating) (NP (NP (NN drug1)) (PP (IN in) (NP (JJ diabetic) (NNS patients))))))))) (CC and) (S (NP (NN drug2) (NN dosage)) (VP (MD should) (VP (VB be) (VP (VBN adjusted) (SBAR (IN if) (S (VP (VBN needed))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT No) (JJ human) (NN drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN drug2)))) (VP (VBD were) (VP (VBN conducted)))) (. .))))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBD demonstrated) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN incompatibility)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT No) (JJ human) (NN drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN drug2)))) (VP (VBD were) (VP (VBN conducted)))) (. .))))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBG evaluating) (NP (NP (NP (DT the) (JJ minimum) (JJ inhibitory) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN MIC)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4) (NN /flucoxacillin)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7))))))) (VP (VBD demonstrated) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN incompatibility)) (PP (IN of) (NP (NP (DT these) (NN drug8)) (PP (IN with) (NP (NN drug9)))))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (NP (NN Blood) (NN Glucose) (NN Blood) (NN glucose) (NN measurement))) (VP (MD must) (VP (VB be) (VP (VBN done) (PP (IN with) (NP (NP (DT a) (JJ glucose-specific) (NN method)) (S (VP (TO to) (VP (VB prevent) (NP (NP (NN maltose) (NN interference)) (PP (IN with) (NP (NN test) (NNS results))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (ADJP (RB falsely) (JJ elevated)) (NN glucose) (NNS levels)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (NP (NP (NN blood) (NN glucose) (NN monitoring) (NNS devices)) (CC and) (NP (NN test) (NNS strips))) (SBAR (WHNP (WDT that)) (S (VP (VBP use) (NP (ADJP (NP (NP (NN glucose) (NN dehydrogenase) (NN pyrroloquinolinequinone)) (PRN (-LRB- -LRB-) (NP (CD GDH) (NN PQQ)) (-RRB- -RRB-))) (JJ -based)) (NNS methods)))))))))))) (, ,) (NP (CD GDH) (JJ PQQ-based) (NNS methods)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB measure) (NP (NN glucose) (NNS levels)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN administered) (S (NP (NN drug1)))))))))))) (. .)) (. .)))
(S1 (S (S (NP (NP (NN Serum) (NN Amylase)) (NP (NP (DT An) (JJ apparent) (NN decrease)) (PP (IN in) (NP (NN serum) (NN amylase) (NN activity))))) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN administered) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (JJ Preliminary) (NNS investigations)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC and) (NP (PRP$ its) (NNS metabolites))) (VP (VBP interfere) (PP (IN with) (NP (JJ enzymatic-based) (NN amylase) (NNS assays))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (ADJP (RB inaccurately) (JJ low)) (NNS values)))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN into) (NP (NN account))) (SBAR (WHADVP (WRB when)) (S (VP (VBG evaluating) (NP (NN serum) (NN amylase) (NNS levels)) (PP (IN for) (NP (NP (NN diagnosis)) (CC or) (NP (NP (NN monitoring)) (PP (IN of) (NP (NN pancreatitis))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG using) (NP (NN drug1))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG receiving) (NP (NP (DT a) (NN drug2)) (ADVP (RB orally))) (PP (IN because) (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (JJ additive) (NNS effects)) (PP (IN on) (NP (JJ systemic) (NN beta-blockade))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Close) (NN observation)) (PP (IN of) (NP (DT the) (NN patient)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (DT a) (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ catecholamine-depleting) (NNS drugs)) (PP (JJ such) (IN as) (NP (NN drug2))) (, ,) (PP (IN because) (PP (IN of) (NP (NP (JJ possible) (JJ additive) (NNS effects)) (CC and) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (NN hypotension)) (CC and/or) (NP (JJ marked) (NN bradycardia)))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB produce) (NP (NP (NN vertigo)) (, ,) (NP (NN syncope)) (, ,) (CC or) (NP (JJ postural) (NN hypotension)))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN plasma-level)) (PP (IN of) (NP (ADJP (RB concomitantly) (VBN given)) (NN drug2))))))) (. .)))
(S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB avoid) (NP (NN drug1) (NN intoxication)))))) (, ,) (NP (NN drug2) (NN plasma) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)))))) (. .)))
(S1 (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))) (, ,) (NP (DT the) (NN drug3) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN reduced)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (RB approx.) (CD 50)) (NN %))) (-RRB- -RRB-)) (, ,) (SBAR (IN because) (S (NP (NN drug4)) (VP (VBZ amplifies) (NP (NP (NP (DT the) (JJ therapeutic) (NNS actions)) (CC and) (NP (NNS side-effects))) (PP (IN of) (NP (NN drug5) (NN massively))))))))) (. .)))
(S1 (S (S (VP (VB Avoid) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (JJ Massive) (NNS seizures)) (VP (MD may) (VP (VB be) (VP (VBN encountered) (PP (IN with) (NP (DT this) (NN combination))))))) (. .)))
(S1 (S (S (VP (VB Consider) (S (NP (NP (JJ additive) (JJ sedative) (NNS effects)) (CC and) (NP (JJ confusional) (NNS states))) (VP (TO to) (VP (VB emerge)))) (, ,) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (VP (VBP Choose) (NP (NP (JJ particular) (JJ low) (NNS doses)) (PP (IN of) (NP (DT these) (NNS drugs)))))) (. .)))
(S1 (S (S (VP (VBP Exert) (NP (JJ particular) (NN caution)) (PP (IN in) (S (VP (VBG combining) (NP (NN drug1)) (PP (IN with) (NP (NP (JJ other) (NNS drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (-RRB- -RRB-))))))))) (: :) (S (NP (RB Particularly) (DT the) (JJ elderly)) (VP (MD may) (VP (VB develop) (NP (NP (NN delirium)) (, ,) (NP (JJ high) (NN fever)) (, ,) (NP (JJ severe) (NN obstipation)) (, ,) (NP (JJ even) (NN ileus)) (CC and) (NP (NN glaucoma)))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ rare) (NNS reports)) (PP (IN of) (NP (NP (JJ significant) (JJ respiratory) (NN depression)) (, ,) (NP (NN stupor)) (CC and/or) (NP (NN hypotension)))) (PP (IN with) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN risk)) (PP (IN of) (S (VP (VBG using) (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ CNS-active) (NNS drugs))))))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB systematically)) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN advised) (SBAR (IN if) (S (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ CNS-active))) (NNS drugs)))) (VP (VBZ is) (VP (VBN required)))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ pharmacokinetic) (JJ drug-drug) (NN interaction) (NNS studies)) (VP (VBD were) (VP (VBN conducted) (PP (IN with) (NP (NN drug1) (-LRB- -LRB-) (NN drug2) (NN USP) (-RRB- -RRB-) (NNS Tablets)))))) (. .)))
(S1 (S (S (NP (DT The) (VBG following) (NN information)) (VP (VBD was) (VP (VBN obtained) (PP (IN from) (NP (DT the) (NN literature)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VP (VB increase) (NP (DT the) (NN plasma) (NNS levels))) (CC and) (VP (VB cardiovascular) (NP (NP (NNS effects)) (PP (IN of) (NP (NN drug3)))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Adjustment)) (PP (IN of) (NP (NN drug1) (NN dosage)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB counteract) (NP (NP (DT the) (NN anticholinesterase) (NN effect)) (PP (IN of) (NP (NN drug3)))) (, ,) (S (ADVP (RB thereby)) (VP (ADVP (RB potentially)) (VBG aggravating) (NP (NN myasthenia) (NN gravis))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (NN drug1)) (CC or) (NP (JJ other) (JJ hepatic) (NN enzyme) (NNS inducers))) (VP (VBP are) (VP (VBN taken) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))) (, ,) (NP (NP (JJR lower) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug4)))) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (NP (NN Monitoring)) (PP (IN of) (NP (NN drug1) (NN plasma) (NNS levels)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN in) (NP (JJ such) (JJ concurrent) (NN use))) (S (VP (TO to) (VP (VB avoid) (NP (JJ ineffective) (NN therapy)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5))) (-RRB- -RRB-))) (VP (VBP have) (ADVP (RB occasionally)) (VP (VBN been) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug6))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Excessive) (NN widening)) (PP (IN of) (NP (DT the) (NN QRS) (NN complex)))) (CC and/or) (NP (NP (NN prolongation)) (PP (IN of) (NP (DT the) (JJ Q-T) (NNS interval))))) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (DT these) (NNS situations)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ healthy) (NNS subjects))) (, ,) (NP (DT no) (JJ significant) (JJ drug-drug) (NN interaction)) (VP (VBD was) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (CC either) (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (JJ slight) (NNS increases)) (PP (IN in) (NP (NN plasma) (NN drug3) (NNS levels)))) (CC and) (NP (NP (JJ slight) (NNS decreases)) (PP (IN in) (NP (NN plasma) (NN drug4) (NNS levels)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB increase) (NP (NN serum) (NN drug2) (NNS levels))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (ADVP (RB concomitantly))))) (VP (MD may) (VP (VB develop) (NP (NP (VBN increased) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug3)) (VP (VBG resulting) (PP (IN in) (NP (NP (NP (JJ excessive) (NN widening)) (PP (IN of) (NP (DT the) (NN QRS) (NN complex)))) (CC and/or) (NP (NP (NN prolongation)) (PP (IN of) (NP (DT the) (JJ Q-T) (NN interval))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ hepatic))) (NN enzyme) (NNS inhibitors)))) (ADVP (RB concomitantly)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (. .)))
(S1 (S (S (SBAR (IN Until) (S (NP (NP (NNS data)) (PP (IN on) (NP (NP (JJ possible) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBP are) (VP (VBN obtained))))) (, ,) (NP (NN drug3)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (PP (IN within) (NP (NP (NP (CD 48) (NNS hours)) (PP (IN before))) (CC or) (NP (NP (CD 24) (NNS hours)) (PP (IN after) (NP (NN drug4) (NN administration)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN potential)) (PP (IN for) (NP (NP (VBN increased) (NN sedation)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (IN with) (NP (JJ other) (NN drug2)))))))))) (VP (MD should) (VP (VB be) (VP (VBN appreciated))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (ADVP (RB concomitantly)) (IN with) (NP (NP (JJ known) (JJ microsomal) (NN enzyme) (NN inducer)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD two) (NNS patients)) (PP (IN with) (NP (JJ renal) (NN impairment)))))) (ADVP (RB reportedly)) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ significant) (NNS reductions)) (PP (IN in) (NP (NP (NN elimination) (NN half-life)) (CC and) (NP (NN plasma) (NN concentration)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ such) (NNS cases))) (, ,) (ADVP (RB therefore)) (, ,) (NP (ADJP (RBR more) (JJ frequent)) (NN dosing)) (VP (MD may) (VP (VB be) (VP (VBN required) (S (VP (TO to) (VP (VP (VB achieve)) (CC or) (VP (VB maintain) (NP (DT the) (JJ desired) (JJ hypotensive) (NN response)))))))))) (. .)))
(S1 (S (S (ADVP (RB Further)) (, ,) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN discontinued) (PP (IN in) (NP (JJ such) (NNS patients)))))))))) (, ,) (NP (NP (JJ careful) (NN tapering)) (PP (IN of) (NP (DT the) (NN dosage)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB avoid) (NP (JJ rebound) (NNS phenomena)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP decrease) (NP (NP (DT the) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN porpranolol)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (VP (MD may) (VP (VB exacerbate) (NP (JJ rebound) (NN hypertension)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug4)) (VP (VBZ is) (VP (VBN withdrawn)))))))) (. .)))
(S1 (S (S (NP (DT The) (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN withdrawn) (ADVP (RB first)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ gradual) (NN withdrawal)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (DT a) (NN drug2))))) (VP (MD could) (VP (VB be) (VP (VBN substituted))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (: :) (CD Ten) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN stabilized) (PP (IN on) (NP (JJ oral) (NN drug2)))))))) (VP (VBD were) (VP (VBN given) (NP (NP (NN drug3)) (, ,) (NP (QP (CD 1-2)) (NN mg/day)) (, ,)) (PP (IN for) (NP (CD 4) (NNS weeks)))))) (. .)))
(S1 (S (S (NP (DT No) (NNS changes)) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN anticoagulation)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ several) (JJ well-controlled) (NNS studies))) (, ,) (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (ADVP (RB together)) (PP (IN with) (NP (NN drug2))) (PP (IN with) (NP (NP (DT no) (NN drug) (NNS interactions)) (VP (VBN reported))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ long-term) (NN safety) (NNS studies))) (, ,) (NP (NN drug1)) (VP (VBD was) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ many) (NNS drugs))) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (DT any) (NNS interactions)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ principal) (NNS drugs)) (VP (VBN given) (PRN (-LRB- -LRB-) (NP (NP (NN number)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NNS parentheses)))))) (-RRB- -RRB-)))) (VP (VBD were))) (: :) (NP (NP (NP (NN drug1) (-LRB- -LRB-) (CD 115) (-RRB- -RRB-)) (, ,) (NP (NN drug2)) (CC and) (NP (NP (NP (NN drug3) (-LRB- -LRB-) (CD 103) (-RRB- -RRB-)) (, ,) (NP (NN drug4) (-LRB- -LRB-) (CD 52) (-RRB- -RRB-)) (, ,) (NP (NP (JJ oral) (NN drug5)) (PRN (-LRB- -LRB-) (NP (CD 45)) (-RRB- -RRB-))) (, ,) (NP (NN cough)) (CC and) (NP (JJ cold) (NNS preparations))) (PRN (-LRB- -LRB-) (NP (CD 45)) (-RRB- -RRB-)))) (, ,) (NP (NN drug6) (-LRB- -LRB-) (CD 38) (-RRB- -RRB-)) (, ,) (NP (NN drug7) (-LRB- -LRB-) (CD 29) (-RRB- -RRB-)) (, ,) (NP (NN drug8) (-LRB- -LRB-) (CD 24) (-RRB- -RRB-)) (, ,) (NP (NP (JJ oral) (NN drug9)) (PRN (-LRB- -LRB-) (NP (CD 18)) (-RRB- -RRB-))) (, ,) (NP (NN drug10) (-LRB- -LRB-) (CD 13) (-RRB- -RRB-)) (, ,) (NP (NN drug11) (-LRB- -LRB-) (CD 10) (-RRB- -RRB-)) (, ,) (CC and) (NP (NN drug12) (-LRB- -LRB-) (CD 10) (-RRB- -RRB-))) (. .)))
(S1 (S (S (NP (NP (NN Laboratory) (NN Test)) (PP (IN In) (NP (NP (JJ clinical) (NNS trials)) (, ,) (NP (DT no) (ADJP (RB clinically) (JJ relevant)) (NN laboratory) (NN test) (NNS abnormalities))))) (VP (VBD were) (VP (VBN identified) (PP (IN as) (ADJP (RB causally) (JJ related) (PP (TO to) (NP (NP (NN drug)) (PP (IN during) (NP (NP (JJ short-term) (NN treatment)) (PP (IN with) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (NN No) (NN laboratory) (NN test) (NNS abnormalities)) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1))))))) (VP (VBP have) (VP (VBN been) (VP (VBN identified))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (ADJP (ADJP (JJ cardioactive)) (CC or) (ADJP (JJ cerebroactive))) (NNS drugs)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NP (JJ bleeding)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (, ,) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP alter) (NP (NN platelet) (NN function)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN drug5))))) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ bleeding)) (SBAR (IN if) (S (VP (VBN administered) (ADVP (ADVP (RB prior)) (PP (TO to))))))))) (, ,) (PP (PP (IN during)) (, ,) (CC or) (PP (IN after) (NP (NN drug6) (NN therapy))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Use)) (PP (IN of) (NP (NN drug1) (NN drug2)))) (CC and) (NP (NN drug3))) (VP (VBP have) (VP (VBN been) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (CC and) (VBG following) (NNS infusions)) (PP (IN of) (NP (NN drug4))))) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (JJ acute) (JJ myocardial) (NN infarction)) (CC or) (NP (JJ pulmonary) (NN embolism)))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC or) (NP (NN drug3))) (VP (MD may) (VP (VB cause) (NP (JJ bleeding) (NNS complications)))))) (, ,) (NP (NP (JJ careful) (NN monitoring)) (PP (IN for) (NP (JJ bleeding)))) (VP (VBZ is) (ADJP (JJ advised)) (, ,) (PP (ADVP (RB especially)) (IN at) (NP (JJ arterial) (NN puncture) (NNS sites))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (PP (IN during) (NP (NP (DT the) (JJ first) (CD 24) (NNS hours)) (PP (VBG following) (NP (NN symptom) (NN onset)))))) (VP (VBD were) (VP (VBD prohibited) (PP (IN in) (NP (DT The) (NN NINDS) (NN t-PA) (JJ Stroke) (NN Trial)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN safety)) (PP (IN of) (NP (NP (JJ such) (JJ concomitant) (NN use)) (PP (IN with) (NP (NN drug1))))) (PP (IN for) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ acute) (JJ ischemic) (NN stroke)))))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (JJ Drug-Drug) (NNS Interactions)) (PP (IN Given) (NP (NP (DT the) (JJ primary) (NN CNS) (NNS effects)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN taken) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (NN drug3)) (CC and) (NP (NN drug4)))))))))))))) (. .)))
(S1 (S (ADJP (JJ Due) (PP (TO to) (NP (PRP$ its))))))
(S1 (S (S (NP (NP (CD 1-) (JJ adrenergic) (NN receptor) (NN antagonism)) (, ,) (NP (NN drug1))) (VP (VBZ has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB enhance) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ certain) (NNS drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Potential)) (PP (IN for) (NP (NP (JJ Other) (NNS Drugs)) (PP (TO to) (NP (NN Affect) (NN drug1) (NNS drug2)))))) (VP (VBZ is) (RB not) (NP (NP (DT a) (NN substrate)) (PP (IN of) (NP (NP (NP (NN CYP1A1)) (, ,) (NP (NN CYP1A2)) (, ,) (NP (NN CYP2A6)) (, ,) (NP (NN CYP2B6)) (, ,) (NP (NN CYP2C8)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2C19)) (, ,) (CC or) (NP (NN CYP2E1))) (NNS enzymes)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB also)) (VP (VBZ does) (RB not) (VP (VB undergo) (NP (JJ direct) (NN glucuronidation))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT an) (NN interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NP (NNS inhibitors)) (CC or) (NP (NNS inducers))) (PP (IN of) (NP (NP (DT these) (NNS enzymes)) (, ,) (CC or) (NP (JJ other) (NNS factors))))))) (, ,) (PP (IN like) (NP (NN smoking))) (, ,) (VP (VBZ is) (ADJP (JJ unlikely))))))) (. .)))
(S1 (S (S (NP (CC Both) (NP (NN CYP3A4)) (CC and) (NP (NN CYP2D6))) (VP (VBP are) (ADJP (JJ responsible) (PP (IN for) (NP (NN drug1) (NN metabolism)))))) (. .)))
(S1 (S (S (NP (NP (NNS Agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NP (NN CYP3A4)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug1))) (-RRB- -RRB-))))))) (VP (MD could) (VP (VB cause) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN drug2) (NN clearance)) (CC and) (NP (JJR lower) (NN blood) (NNS levels)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (NP (NP (NN CYP3A4)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug1))) (-RRB- -RRB-))) (CC or) (NP (NP (NN CYP2D6)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4))) (-RRB- -RRB-)))))) (VP (MD can) (VP (VP (VB inhibit) (NP (NN drug5) (NN elimination))) (CC and) (VP (VB cause) (NP (VBN increased) (NN blood) (NNS levels)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 200) (NN mg/day)) (PP (IN for) (NP (CD 14) (NNS days)))) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (DT a) (JJ 15-mg) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug3)))))) (VP (VBD increased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NP (NN drug4)) (CC and) (NP (PRP$ its) (JJ active) (NN metabolite))))) (PP (IN by) (NP (NP (CD 63) (NN %)) (CC and) (NP (CD 77) (NN %)))) (, ,) (ADVP (RB respectively)))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJR higher) (NN drug1) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 400) (NN mg/day)) (-RRB- -RRB-))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ occurs)))) (, ,) (NP (NN drug3) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (TO to) (NP (NP (NN one-half)) (PP (IN of) (NP (PRP$ its) (JJ normal) (NN dose))))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Other) (JJ strong) (NNS inhibitors)) (PP (IN of) (NP (NN CYP3A4)))) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VP (VBP have) (NP (JJ similar) (NNS effects))) (CC and) (VP (VBP need) (NP (JJ similar) (NN dose) (NNS reductions)))))))))) (: ;)))
(S1 (S (S (NP (NP (JJR weaker) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN grapefruit) (NN juice))) (-RRB- -RRB-))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NN CYP3A4) (NN inhibitor)) (VP (VBZ is) (VP (VBN withdrawn) (PP (IN from) (NP (DT the) (NN combination) (NN therapy))))))) (, ,) (NP (NN drug1) (NN dose)) (VP (MD should) (ADVP (RB then)) (VP (VB be) (VP (VBN increased))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (DT a) (JJ 10-mg) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug2))))) (PP (IN with) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (CD 166) (NN mg/day)) (PP (IN for) (NP (CD 13) (NNS days)))) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN CYP2D6)))) (, ,)))) (VP (VP (VBD increased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug4)))) (PP (IN by) (NP (CD 112) (NN %)))) (CC but) (VP (VBD decreased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NP (PRP$ its) (JJ active) (NN metabolite)) (, ,) (NP (NN drug5)) (, ,)))) (PP (IN by) (NP (CD 35) (NN %)))))) (. .))))
(S1 (S (S (NP (NN drug1) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (TO to) (NP (NP (NN one-half)) (PP (IN of) (NP (PRP$ its) (JJ normal) (NN dose))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (VBZ occurs)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (JJ significant) (NNS inhibitors)) (PP (IN of) (NP (NN CYP2D6))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (, ,)) (VP (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB have) (NP (JJ similar) (NNS effects)))))))) (CC and) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD should) (VP (VB be) (VP (VBN accompanied) (PP (IN by) (NP (JJ similar) (NN dose) (NNS reductions)))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NN CYP2D6) (NN inhibitor)) (VP (VBZ is) (VP (VBN withdrawn) (PP (IN from) (NP (DT the) (NN combination) (NN therapy))))))) (, ,) (NP (NN drug1) (NN dose)) (VP (MD should) (ADVP (RB then)) (VP (VB be) (VP (VBN increased))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 200) (NN mg)) (NN BID)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ potent) (NN CYP3A4) (NN inducer)) (, ,))) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg) (NN QD)) (-RRB- -RRB-))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ approximate) (ADJP (CD 70) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (NP (NP (NN Cmax)) (CC and) (NP (NN AUC))) (NNS values)) (PP (IN of) (NP (CC both) (NP (NN drug4)) (CC and) (NP (NP (PRP$ its) (JJ active) (NN metabolite)) (, ,) (NP (NN drug5))))))))))) (. .))))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN added) (PP (TO to) (NP (NN drug2) (NN therapy))))))) (, ,) (NP (NN drug3) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN doubled))))) (. .)))
(S1 (S (S (NP (JJ Additional) (NN dose) (NNS increases)) (VP (MD should) (VP (VB be) (VP (VBN based) (PP (IN on) (NP (JJ clinical) (NN evaluation))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN withdrawn) (PP (IN from) (NP (DT the) (NN combination) (NN therapy))))))) (, ,) (NP (NN drug2) (NN dose)) (VP (MD should) (ADVP (RB then)) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (S (NP (NP (DT No) (ADJP (RB clinically) (JJ significant)) (NN effect)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC or) (NP (NN drug3))))) (VP (VBD was) (VP (VBN seen) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug4))))) (PRN (-LRB- -LRB-) (NP (NP (VB see)) (NP (JJ CLINICAL) (NN PHARMACOLOGY)) (: :) (NP (NN Drug-) (NN Drug) (NNS Interactions))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (NN Potential)) (PP (IN for) (NP (NN drug1))) (VP (TO to) (VP (VB Affect) (NP (NP (JJ Other) (NNS Drugs)) (VP (VBN drug2)))))) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB cause) (NP (NP (ADJP (RB clinically) (JJ important)) (JJ pharmacokinetic) (NNS interactions)) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN cytochrome) (NN P450)) (NNS enzymes))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (ADJP (FW in) (FW vivo)) (NNS studies))) (, ,) (NP (NP (ADJP (CD 10-) (TO to) (JJ 30-mg/day)) (NNS doses)) (PP (IN of) (NP (NN drug1)))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (NN metabolism)) (PP (IN by) (NP (NP (NP (NN CYP2D6)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN CYP2C9)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NP (NN CYP2C19)) (PRN (-LRB- -LRB-) (NP (NP (NN drug4)) (, ,) (NP (NN drug5))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN CYP3A4)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-))) (NP (NNS substrates))))))) (. .)))
(S1 (S (S (ADVP (RB Additionally)) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD did) (RB not) (VP (VB show) (NP (NN potential)) (PP (IN for) (S (VP (VBG altering) (NP (JJ CYP1A2-mediated) (NN metabolism)) (ADVP (FW in) (FW vitro)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN between) (NP (NP (NN drug2)) (VP (VBN coadministered) (PP (IN with) (NP (NP (NP (NN drug3)) (CC and) (NP (NN placebo))) (VP (VBN coadministered) (PP (IN with) (NP (NP (NN drug4)) (PP (IN on) (NP (NP (NN performance)) (PP (IN of) (NP (NP (JJ gross) (NN motor) (NNS skills)) (CC or) (NP (NN stimulus) (NN response)))) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))))))))))))) (. .))))
(S1 (S (PP (IN As) (PP (IN with) (NP (JJS most) (JJ psychoactive) (NNS medications)))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN advised) (S (VP (TO to) (VP (VB avoid) (NP (NN drug1)) (SBAR (IN while) (S (VP (VBG taking) (NP (NN drug2)))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN use)) (PP (IN of) (NP (NN drug1) (NN Injection))) (PP (IN with) (NP (NP (NP (JJ other) (NNS drug2)) (CC or) (NP (NNS medications))) (PP (IN with) (NP (JJ anticholinergic) (NN activity))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))) (, ,)))) (VP (VP (MD may) (VP (VB intensify) (NP (DT the) (JJ antimuscarinic) (NNS effects)))) (CC and) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ anticholinergic) (JJ side) (NNS effects))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1) (NN Injection)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (DT a) (NN wax) (NN matrix)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NN potassium) (JJ chloride-induced) (JJ gastrointestinal) (NNS lesions)))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (DT a) (JJR slower) (JJ gastrointestinal) (NN transit) (NN time)))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ possible) (NN drug) (NN interaction)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ intravenous) (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN described))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN treatment)) (PP (IN of) (NP (NP (CD four) (NNS patients)) (PP (IN in) (NP (DT the) (JJ United) (NN Kingdom))))) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (JJ intravenous) (NN drug2))))) (VP (MD may) (VP (VB have) (VP (VBN caused) (NP (NN hypocalcemia)))))) (: ;)))
(S1 (S (S (NP (CD one) (NN patient)) (VP (VBD died) (PP (IN with) (NP (JJ severe) (NN hypocalcemia))))) (. .)))
(S1 (S (S (NP (NP (NN Toxicity)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (JJ aerosolized) (NN drug1))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (PP (IN Because) (PP (IN of) (NP (NP (NN drug1) (NN s) (NN tendency)) (S (VP (TO to) (VP (VB cause) (NP (JJ renal) (NN impairment)))))))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug2)))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (RB potentially) (JJ nephrotoxic) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (JJ intravenous) (NN drug5))) (SBAR (IN unless) (S (NP (DT the) (JJ potential) (NNS benefits)) (VP (VBP outweigh) (NP (NP (DT the) (NNS risks)) (PP (TO to) (NP (DT the) (NN patient)))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ decreases) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (VBN ionized) (NN calcium))))))) (, ,) (NP (NP (JJ concurrent) (NN treatment)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB influence) (NP (NN serum) (NN calcium) (NNS concentrations))))))))) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (JJ particular) (NN caution))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD were) (RB not) (VP (VBN altered) (PP (IN in) (NP (NP (CD 13) (NNS patients)) (VP (VBG receiving) (NP (NP (CC either) (NP (JJ concomitant) (NN therapy)) (CC or) (NP (JJ daily) (VBG alternating) (NN therapy))) (PP (IN for) (NP (NP (NN maintenance)) (PP (IN of) (NP (NN CMV) (NN disease)))))))))))) (. .))))
(S1 (S (S (NP (CC and/or) (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (VP (VB See) (NP (NP (JJ CLINICAL) (NN PHARMACOLOGY)) (, ,) (NP (NNS Pharmacokinetics)) (CC and) (NP (NN Drug) (NNS Interactions))))) (. .)))
(S1 (S (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (JJ other) (NNS drugs)) (: :) (NP (NP (NNS Drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN cytochrome) (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NN CYP2D6)) (-RRB- -RRB-)))))) (: :) (NP (NNS drug2))))) (VP (VBZ is) (NP (NP (DT a) (ADJP (ADJP (JJ strong)) (ADJP (FW in) (FW vitro))) (NN inhibitor)) (PP (IN of) (NP (NN CYP2D6)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN dose) (NNS adjustments)) (PP (IN of) (NP (NP (JJ concomitant) (NNS medications)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP are) (ADVP (RB predominantly)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP2D6))))) (CC and) (VP (VBP have) (NP (NP (DT a) (JJ narrow) (JJ therapeutic) (NN index)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (JJS most) (NNS drug4)))) (-RRB- -RRB-)))))))))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (CD 25) (NN mg)) (CC or) (NP (ADJP (CD 100) (NN mg)) (NN drug2)))) (PP (IN with) (NP (ADJP (CD 50) (NN mg)) (NN drug3)))) (VP (VBD increased) (NP (NP (NN drug4) (NN exposure)) (CC and) (NP (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (JJ active) (NN metabolite)) (-RRB- -RRB-))) (NN exposure))) (PP (IN by) (NP (NP (QP (RB approximately) (CD 20)) (NN %)) (PP (IN in) (NP (NN CYP2D6) (JJ extensive) (NNS metabolizers))))))) (. .))))
(S1 (S (S (NP (NP (NN Effect)) (PP (IN of) (NP (JJ other) (NNS drugs))) (PP (IN on) (NP (NN drug1) (: :) (NN drug2)))) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NP (JJ multiple) (NN cytochrome) (NN P450) (NNS enzymes)) (, ,) (ADVP (RB primarily)) (NP (NP (NN CYP3A4)) (, ,) (NP (NN CYP2D6)) (, ,) (CC and) (NP (NN CYP1A2)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ is) (VP (VBN metabolized) (PP (IN in) (NP (NN part))) (PP (IN by) (NP (NN CYP3A4)))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (JJ strong) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4)))) (, ,)))) (VP (VBD increased) (PP (NP (NN drug2) (NN exposure)) (VBG following) (NP (NP (DT a) (JJ single) (ADJP (CD 90) (NN mg)) (NN dose)) (PP (IN of) (NP (NP (NN drug3)) (PP (IN by) (NP (CD 2.3) (NN fold))))))))) (. .)))
(S1 (S (S (NP (NP (NN Dose) (NN adjustment)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (CC and) (S (NP (NP (NN PTH)) (CC and) (NP (NN serum) (NN calcium) (NNS concentrations))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored) (SBAR (IN if) (S (NP (DT a) (NN patient)) (VP (VBZ initiates) (NP (NP (NN or) (NN discontinues) (NN therapy)) (PP (IN with) (NP (NP (DT a) (JJ strong) (NN CYP3A4) (NN inhibitor)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)))))))))))))) (: ;)))
(S1 (S (S (VP (VB see) (NP (NP (NN DOSAGE)) (CC AND) (NP (NN ADMINISTRATION)))) (-RRB- -RRB-)) (. .)))
(S1 (S (S (NP (JJ Special) (NN care)) (VP (VBZ is) (VP (VBN required) (SBAR (IN if) (S (NP (DT this) (NN drug)) (VP (VBZ is) (VP (VBN given) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))) (SBAR (IN because) (S (NP (NP (DT a) (JJ critical)) (VP (VBP fall) (PP (IN in) (NP (NN blood) (NN pressure))))) (VP (MD may) (VP (VB occur)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Usually)) (, ,) (NP (JJ severe) (JJ abdominal) (NNS symptoms)) (VP (VBP appear) (SBAR (IN before) (S (NP (EX there)) (VP (VBZ is) (PP (IN such) (NP (NP (DT a)) (VP (VBP fall) (PP (IN in) (NP (DT the) (NN blood) (NN pressure))))))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBP are) (NP (JJ strong) (NN drug2)))) (, ,) (CC but) (S (NP (JJ regular) (NNS users)) (VP (VBP develop) (NP (NP (JJ physiological) (NN tolerance)) (VP (VBG allowing) (NP (ADVP (RB gradually)) (VBN increased) (NNS dosages))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NN drug1))))) (, ,) (NP (NN drug2)) (VP (MD may) (ADVP (RB still)) (VP (VB kill) (NP (ADJP (RB even) (VBN experienced)) (NNS users)) (, ,) (SBAR (RB particularly) (IN if) (S (S (NP (NP (PRP$ their) (NN tolerance)) (PP (TO to) (NP (DT the) (NN drug)))) (VP (VBZ has) (VP (VBN reduced)))) (CC or) (S (NP (NP (DT the) (NN strength)) (PP (IN of) (NP (PRP$ their) (JJ usual) (NN dose)))) (VP (VBZ has) (VP (VBN increased))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Toxicology) (NNS studies)) (PP (IN of) (NP (JJ drug1) (JJ -related) (NNS deaths)))) (VP (VBP reveal) (NP (NP (JJ frequent) (NN involvement)) (PP (IN of) (NP (NP (JJ other) (NNS drug2)) (, ,) (PP (VBG including) (NP (NP (NN drug3)) (, ,) (NP (NP (NNS drug4)) (PP (JJ such) (IN as) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-))))) (, ,) (CC and) (, ,) (PP (TO to) (NP (DT a) (JJ rising) (NN degree))) (, ,) (NP (NN drug7))))))))) (. .)))
(S1 (S (S (ADVP (RB Ironically)) (, ,) (NP (NN drug1)) (VP (VBP are) (ADVP (RB often)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN drug2) (NN addiction))))) (SBAR (IN while) (S (NP (PRP they)) (VP (VBP cause) (NP (ADJP (RB much) (RBR more) (JJ severe)) (NN withdrawal) (NNS symptoms)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB sometimes)) (VP (VBZ proves) (S (VP (TO to) (VP (VB be) (ADJP (JJ fatal))) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN physician)) (VP (MD should) (VP (VB be) (ADJP (JJ alert) (PP (IN for) (NP (NP (JJ possible) (JJ combined) (NN drug) (NNS actions)) (, ,) (ADJP (ADJP (JJ desirable)) (CC or) (ADJP (JJ undesirable))) (, ,) (VP (VBG involving) (NP (NN drug1)))))) (SBAR (RB even) (IN though) (S (NP (NN drug2)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB successfully)) (PP (ADVP (RB concurrently)) (IN with) (NP (NP (JJ other) (NNS drugs)) (, ,) (PP (VBG including) (NP (JJ other) (JJ cytotoxic) (NNS drugs))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (CD three) (JJ pharmacokinetic) (NNS studies)) (PP (VBG including) (NP (CD 46) (JJ normal) (, ,) (JJ healthy) (NNS subjects))))) (, ,) (NP (NP (NN drug2) (NN clearance)) (CC and) (NP (NN concentration))) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN altered) (PP (IN by) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug3)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (JJ clinical) (NNS studies)) (SBAR (WHADVP (WRB where)) (S (NP (NNS patients)) (VP (VBD were) (PP (IN on) (NP (JJ chronic) (NN drug1) (NN therapy)))))))) (, ,) (NP (NN drug2)) (VP (VBD had) (NP (DT no) (JJ measurable) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ mean) (NN distribution)) (PP (IN of) (NP (NP (NN drug3) (NNS concentrations)) (CC or) (NP (NP (DT the) (JJ mean) (NNS estimates)) (PP (IN of) (NP (NN drug4) (NN clearance)))))))))) (. .)))
(S1 (S (S (SBAR (IN Though) (S (NP (JJ individual) (NN drug1) (NNS levels)) (VP (VBD fluctuated)))) (, ,) (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NNS symptoms)) (PP (IN of) (NP (NN drug) (NN inter-action)))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (: :) (S (NP (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBG containing) (NP (NP (NP (NN drug5)) (CC or) (NP (NN drug6))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNS formulations)) (VP (VBG containing) (NP (NP (NN divalent)) (CC and) (NP (NP (JJ trivalent) (NNS cations)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NN drug8)) (-RRB- -RRB-))) (, ,) (NP (JJ chewable/buffered) (NNS tablets)) (CC or) (NP (DT the) (JJ pediatric) (NN powder)))) (PP (IN for) (NP (JJ oral) (NN solution)))))))))) (VP (MD can) (VP (VP (VB form) (NP (NP (NN chelation) (NNS complexes)) (PP (IN with) (NP (NN drug9))))) (CC and) (VP (VB interfere) (PP (IN with) (NP (PRP$ its) (NN bioavailability))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN administered) (NP (NP (CD 2) (NNS hours)) (PP (IN before) (NP (NN drug2)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (JJR slower) (NN absorption)) (PRN (-LRB- -LRB-) (S (NP (NP (NN mean) (NN C) (NN max)) (VP (VBD decreased) (PP (IN by) (NP (NP (CD 30) (NN %)) (CC and) (NP (NN mean) (NN T) (NN max)))))) (VP (VBN increased) (PP (IN by) (NP (CD 1) (NN hour))))) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (JJR lesser) (NN extent)) (PP (IN of) (NP (NP (NN absorption)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN AUC)) (VP (VBD decreased) (PP (IN by) (NP (QP (RB approximately) (CD 25)) (NN %))))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC -) (NP (ADJP (CC and) (NN drug2) (JJ -containing)) (NN drug3))) (, ,) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug4)))) (, ,)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NP (DT the) (NN bioavailability)) (PRN (-LRB- -LRB-) (NP (CD 48) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug5)))))) (. .)))
(S1 (S (S (S (VP (VBG Separating) (NP (NP (DT the) (NNS doses)) (PP (IN of) (NP (NN drug1)))))) (CC and) (S (NP (NN drug2)) (VP (VBZ minimizes) (NP (NP (DT this) (NN decrease)) (PP (IN in) (NP (NN bioavailability))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (MD should) (VP (VP (VBP precede) (NP (NN drug1) (NN dosing)) (PP (IN by) (NP (CD 4) (NNS hours)))) (CC or) (VP (VBP follow) (NP (NN drug2) (NN dosing)) (PP (IN by) (NP (QP (IN at) (JJS least) (CD 2)) (NNS hours))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (: :) (NP (QP (CD Two) (CD hundred)) (NN mg))) (PP (IN of) (NP (NP (NN drug2)) (-LRB- -LRB-) (ADJP (JJ equivalent) (PP (TO to) (NP (NP (QP (CD 1) (TO to) (CD 3)) (NNS cups)) (PP (IN of) (NP (NNP American) (NN coffee)))))) (-RRB- -RRB-)))) (VP (VBD was) (VP (VBN administered) (PP (TO to) (NP (NP (CD 16) (ADJP (ADJP (JJ normal)) (, ,) (ADJP (JJ healthy))) (NNS volunteers)) (SBAR (WHNP (WP who)) (S (VP (VBD had) (VP (VBD achieved) (NP (NP (JJ steady-state) (NN blood) (NNS concentrations)) (PP (IN of) (NP (NN drug3)))) (PP (IN after) (S (VP (VBG being) (VP (VBN dosed) (PP (IN at) (NP (ADJP (CD 400) (NN mg)) (NN qd)))))))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (DT any) (ADJP (ADVP (ADVP (RB statistically)) (CC or) (ADVP (RB clinically))) (JJ relevant)) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ pharmacokinetic) (NNS parameters)) (PP (IN of) (NP (CC either) (NP (NN drug1)) (CC or) (NP (NP (PRP$ its) (JJ major) (NN metabolite)) (, ,) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (DT No) (NNS data)) (VP (VBP are) (ADJP (JJ available) (PP (IN on) (NP (NP (JJ potential) (NNS interactions)) (PP (IN in) (NP (NP (NNS individuals)) (SBAR (WHNP (WP who)) (S (VP (VBD consume) (ADJP (ADJP (JJR greater)) (PP (IN than) (NP (NP (CD 200) (NN mg)) (PP (IN of) (NP (NN drug1))) (PP (PP (IN per) (NP (NN day))) (CC or) (PP (IN in) (NP (DT those)))))))))) (, ,) (PP (JJ such) (IN as) (NP (DT the) (JJ geriatric) (NN population))) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB generally)) (VP (VBN believed) (S (VP (TO to) (VP (VB be) (ADJP (RBR more) (JJ susceptible) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ drug-induced) (JJ CNS-related) (JJ adverse) (NNS effects)))))))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Other) (NNS drug1)) (VP (VBP have) (VP (VBN demonstrated) (ADJP (JJ moderate) (PP (TO to) (NP (NP (JJ marked) (NN interference)) (PP (IN with) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NP (NN drug2)) (, ,) (VP (VBG resulting) (PP (IN in) (NP (DT a) (VBN reduced) (NN clearance))))) (, ,) (NP (NP (DT a) (NN prolongation)) (PP (IN of) (NP (NN plasma) (NN half-life)))) (, ,) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NNS symptoms)) (SBAR (WHNP (WDT that)) (S (VP (VBP accompany) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NN drug3)))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (JJ other) (NN drug3)))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN interference)) (VP (VBZ has) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (NP (NN half-life)) (CC and) (NP (NN AUC))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug2)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NP (JJ other) (NNS members)) (PP (IN of) (NP (DT the) (NN drug4))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT No) (ADJP (RB clinically) (JJ significant)) (NNS changes)) (PP (IN in) (NP (NP (NN drug2) (NNS pharmacokinetics)) (PRN (-LRB- -LRB-) (NP (NP (NN AUC)) (, ,) (NP (NN C) (NN max)) (, ,) (CC or) (NP (NN T) (NN max))) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug3) (CD 400) (NN mg)))) (VP (VBD was) (VP (VBN given) (PP (IN after) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 20) (NN mg)) (NN qd)) (-RRB- -RRB-)))))) (PP (IN in) (NP (CD 13) (JJ healthy) (NNS volunteers)))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Changes)) (PP (IN in) (NP (NN drug1) (NNS pharmacokinetics)))) (VP (VBD were) (RB not) (VP (VBN studied)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (DT No) (JJ significant) (NNS differences)) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (JJ mean) (NN drug2) (NN AUC)) (, ,) (NP (NN C) (NN max)) (, ,) (NP (NN C) (NN min)) (CC or) (NP (NN T) (NN max)))) (PRN (-LRB- -LRB-) (PP (IN although) (NP (NP (NN C) (NN max)) (VP (VBN increased) (PP (IN by) (NP (CD 11) (NN %)))))) (-RRB- -RRB-))) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ extended) (NN drug3) (NNS capsules)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 100) (NN mg)) (NN tid)) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN coadministered) (PP (IN with) (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 400) (NN mg)) (NN qd)) (-RRB- -RRB-))) (PP (IN for) (NP (CD five) (NNS days))) (PP (IN in) (NP (CD 15) (JJ healthy) (NNS males))))))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB have) (NP (DT a) (JJ significant) (NN effect)) (PP (IN on) (NP (NN drug2) (NN metabolism))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ slows) (NP (NP (DT the) (JJ renal) (NN elimination)) (PP (IN of) (NP (NN lome-floxacin)))))) (. .)))
(S1 (S (NP (NP (NP (DT An) (NN increase)) (PP (IN of) (NP (CD 63) (NN %))) (PP (IN in) (NP (DT the) (JJ mean) (NN AUC)))) (CC and) (NP (NP (NNS increases)) (PP (IN of) (NP (NP (CD 50) (NN %)) (CC and) (NP (CD 4) (NN %)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN in) (NP (NP (DT the) (JJ mean) (NN T) (NN max)) (CC and) (NP (NN mean) (NN C) (NN max)))))))) (VP (VBD were) (VP (VBN noted) (PP (IN in) (NP (NP (CD 1) (NN study)) (PP (IN of) (NP (CD 6) (NNS individuals))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (DT No) (ADJP (RB clinically) (JJ significant)) (NNS changes)) (VP (VBD occurred) (PP (PP (IN in) (NP (NP (NN heart) (NN rate)) (CC or) (NP (JJ corrected) (VBG QT) (NNS intervals)))) (, ,) (CC or) (PP (IN in) (NP (NP (NN drug2) (NN metabolite)) (CC or) (NP (NN drug3) (NNS pharmacokinetics))))) (, ,) (PP (IN during) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug4)) (CC and) (NP (NN drug5)))) (PP (IN at) (NP (NP (NN steady-state)) (PP (IN in) (NP (CD 28) (JJ healthy) (NNS males))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ oral) (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (PRP$ its) (NNS derivatives)))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT these) (NNS products)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))) (, ,) (NP (NP (NN prothrombin)) (CC or) (NP (JJ other) (JJ suitable) (NN coagulation) (NNS tests))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT no) (ADJP (RB clinically) (CC or) (ADJP (RB statistically) (JJ significant))) (NNS differences)) (PP (IN in) (NP (NP (NN prothrombin) (NN time) (NN ratio)) (CC or) (NP (NN drug1) (NN enantiomer) (NNS pharmacokinetics))))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (DT a) (JJ small) (NN study)) (PP (IN of) (NP (NP (CD 7) (JJ healthy) (NNS males)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (CC both) (NP (NN drug2)) (CC and) (NP (NN drug3))) (PP (IN under) (NP (JJ steady-state) (NNS conditions))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (, ,) (NP (DT a) (NN drug2)) (, ,)) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (JJ bactercidal) (NN effect)) (PP (IN of) (NP (NN drug3))))))) (CC and) (S (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD should) (VP (VB be) (VP (VBN avoided)))))) (. .)))
(S1 (S (S (NP (JJ Prolonged) (NN recovery) (NN time)) (VP (MD may) (VP (VB occur) (SBAR (IN if) (S (NP (NP (NN drug1)) (CC and/or) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADJP (RB clinically) (JJ compatible) (PP (IN with) (NP (DT the) (ADJP (RB commonly) (VBN used)) (ADJP (ADJP (JJ general)) (CC and) (ADJP (JJ local))) (NNS drug2)))) (SBAR (WHADVP (WRB when)) (S (NP (DT an) (JJ adequate) (JJ respiratory) (NN exchange)) (VP (VBZ is) (VP (VBN maintained))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ formal) (NN drug/drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN drug1)))) (VP (VBD were) (VP (VBN performed)))) (. .)))
(S1 (S (S (NP (NN Cytochrome) (NN P-450)) (VP (VBZ is) (RB not) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NP (NN plasma) (NNS proteins)) (PRN (-LRB- -LRB-) (NP (QP (CD 96) (TO to) (CD 99)) (NN %)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (NN Laboratory) (NNS Tests)) (VP (NN Response) (PP (TO to) (NP (NN drug1))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN by) (S (VP (VBG measuring) (NP (NP (NN serum) (JJ total) (NN drug2) (NNS concentrations)) (ADVP (ADVP (RB just) (RB prior)) (PP (TO to) (NP (NN administration))))) (PP (IN on) (NP (NP (NN Day) (CD 29)) (CC and) (NP (NP (DT every) (CD 8) (NNS weeks)) (ADVP (RB thereafter)))))))))))) (. .)))
(S1 (S (S (NP (NN Serum) (NN transaminase) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN obtained) (PP (IN before) (S (VP (VP (VBG starting) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug1))))) (CC and) (VP (ADVP (RB periodically)) (PP (IN during) (NP (NN treatment))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Periodic) (NN measurement)) (PP (IN of) (NP (NN serum) (NN PSA) (NNS levels)))) (VP (MD may) (ADVP (RB also)) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ renal) (NNS effects)) (PP (IN of) (NP (JJ nephrotoxic) (NNS compounds)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (JJ Many) (JJ other) (NNS medicines)) (VP (MD may) (VP (VP (VB increase)) (CC or) (VP (VB decrease) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1))))) (CC or) (VP (VB affect) (NP (NN your) (NN condition)))))) (. .)))
(S1 (S (S (SBAR (IN Before) (S (VP (VBG taking) (NP (NN drug1))))) (, ,) (NP (NP (NN tell) (NN your) (NN doctor)) (PP (IN if) (NP (NN you)))) (VP (VBP are) (VP (VBG taking) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ following) (NNS medicines)))))) (: :)) (: -) (NP (NP (NN drug2)) (CC or) (NP (NP (DT another) (NN drug3)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN drug7)) (, ,) (NP (NNS others)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (NP (NN drug9)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug10)) (PRN (-LRB- -LRB-) (NP (NN drug11)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN drug12)) (PRN (-LRB- -LRB-) (NP (NN drug13)) (-RRB- -RRB-))))))) (: ;)))
(S1 (S (NP (NP (CC -) (DT a) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (ADJP (JJ such) (PP (IN as) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NNS others))) (-RRB- -RRB-))) (, ,) (NP (NN drug7) (-LRB- -LRB-) (NN drug8) (, ,) (NN drug9) (, ,) (CD drug10) (-RRB- -RRB-) (, ,) (NP (CD drug11) (-LRB- -LRB-) (CD drug12) (, ,) (CD drug13) (-RRB- -RRB-) (, ,) (NP (NP (CD drug14)) (PRN (-LRB- -LRB-) (NP (CD drug15)) (-RRB- -RRB-))) (, ,) (NP (NP (CD drug16)) (PRN (-LRB- -LRB-) (NP (CD drug17)) (-RRB- -RRB-))) (, ,) (NP (NP (CD drug18)) (PRN (-LRB- -LRB-) (NP (CD drug19)) (-RRB- -RRB-))) (, ,) (NP (NP (CD drug20)) (PRN (-LRB- -LRB-) (NP (CD drug21)) (-RRB- -RRB-))) (, ,) (CC and) (NP (CD drug22))) (-LRB- -LRB-) (CD drug23) (, ,) (CD drug24) (, ,) (CD drug25) (-RRB- -RRB-) (: ;)))))))
(S1 (S (NP (CC -) (NP (DT a) (JJ sulfa-based) (NN drug)) (PP (JJ such) (IN as) (NP (NP (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NN drug8)) (-RRB- -RRB-)) (: ;)))))))
(S1 (S (NP (CC -) (NP (NP (DT a) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (PP (JJ such) (IN as) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NN drug8)) (-RRB- -RRB-)) (: ;)))))))
(S1 (S (NP (NP (CC -) (DT a) (NN drug1)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN drug7)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (NP (NN drug9)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNS others)))) (: ;))))
(S1 (S (NP (NP (NP (CC -) (DT a) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN water) (NN pill)) (-RRB- -RRB-))) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNS others)))) (: ;))))
(S1 (S (NP (NP (CC -) (DT a) (NN drug1)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NNS others))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (NN drug6)) (, ,) (NP (NNS others))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NNS others))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNS others)))) (: ;))))
(S1 (S (CC -) (NP (NP (DT a) (NN drug1)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NN drug8)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug9)) (PRN (-LRB- -LRB-) (NP (NN drug10)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNS others))))) (: ;)))
(S1 (S (NP (CC -) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: ;))))
(S1 (S (NP (CC -) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: ;))))
(S1 (S (NP (CC -) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (: ;))))
(S1 (S (S (NP (NP (CC or)) (CC -) (NP (JJ over-the-counter) (NP (NP (NN cough)) (, ,) (NP (NN cold)) (, ,) (NP (NN allergy)) (, ,) (CC or) (NP (NN weight) (NN loss))) (NNS medications)))) (. .)))
(S1 (S (S (NP (NN You)) (VP (MD may) (VP (VB require) (NP (NP (DT a) (JJ dosage) (NN adjustment)) (CC or) (NP (JJ special) (NN monitoring))) (SBAR (IN if) (S (ADVP (RB you)) (VP (VBP are) (VP (VBG taking) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (NNS medicines)) (VP (VBN listed) (ADVP (RB above))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (ADJP (JJ other) (PP (IN than) (NP (NP (DT those)) (VP (VBN listed) (ADVP (RB here))))))) (VP (MD may) (ADVP (RB also)) (VP (VP (VB interact) (PP (IN with) (NP (NN drug1)))) (CC or) (VP (VB affect) (NP (NN your) (NN condition)))))) (. .)))
(S1 (S (S (VP (VP (NP (NN Talk)) (PP (TO to) (NP (NN your) (NN doctor)))) (CC and) (VP (VBP pharmacist) (PP (IN before) (S (VP (VBG taking) (NP (NP (DT any) (NN prescription) (CC or) (NN over-the-counter) (NNS medicines)) (, ,) (PP (VBG including) (NP (JJ herbal) (NNS products)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (PP (IN In) (NP (NP (DT a) (JJ prospective) (NN study)) (VP (VBG involving) (NP (JJ six-healthy-male) (NNS volunteers))))) (, ,) (NP (NN drug2)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (DT These) (CD six) (NNS volunteers)) (VP (VBD received) (NP (NP (NP (NN drug1)) (ADVP (RB alone))) (PRN (-LRB- -LRB-) (NP (NP (CD 60) (NN mg)) (ADVP (RB twice) (RB daily))) (-RRB- -RRB-))) (PP (IN for) (NP (CD 8) (NNS days))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (NN drug2)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (CD 500) (NN mg)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-)))))) (PP (IN for) (NP (CD 10) (NNS days))))))))) (. .)))
(S1 (S (PRN (-LRB- -LRB-) (S (S (NP (DT Both) (NNS drugs)) (VP (VBD were) (ADVP (RB thus)) (VP (VBN dosed) (PP (TO to) (NP (JJ steady) (NN state)))))) (. .)) (-RRB- -RRB-))))
(S1 (S (S (NP (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (PRP$ its) (NN acid) (NN metabolite))))) (CC and) (NP (DT the) (JJ electrocardiographic) (JJ QT) (NN c) (NN interval))) (VP (VBD were) (VP (VBN measured) (PP (IN during) (NP (NP (DT both) (NNS periods)) (: :) (PP (PP (IN with) (NP (NP (NN drug2)) (ADVP (RB alone)))) (, ,) (CC and) (PP (IN with) (NP (NP (NN drug3)) (CC plus) (NP (NN drug4)))))))))) (. .)))
(S1 (S (PP (IN In) (NP (CD five) (NNS men))) (, ,) (NP (NN drug1) (NNS levels)) (VP (VBD were) (ADJP (JJ undetectable)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN ng/mL)) (-RRB- -RRB-)) (PP (IN throughout) (NP (DT the) (NN study)))) (: ;)))
(S1 (S (S (PP (IN in) (NP (CD one) (NN man))) (, ,) (NP (NP (DT the) (NN C) (NN max)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (NP (NP (NP (CD 8.1) (NN ng/mL)) (PP (IN with) (NP (NP (NN drug2)) (ADVP (RB alone))))) (CC and) (NP (NP (CD 7.2) (NN ng/mL)) (PP (IN with) (NP (NP (NN drug3)) (CC plus) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ mean) (NN C) (NN max)) (, ,) (NP (NN T) (NN max)) (, ,) (CC and) (NP (NP (NN AUC)) (PP (IN of) (NP (NP (DT the) (NN acid) (NN metabolite)) (PP (IN of) (NP (NN drug1))))))) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN changed)))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ mean) (NN QT) (NN c) (NN interval)) (PRN (-LRB- -LRB-) (NP (NNS msec)) (-RRB- -RRB-))) (VP (VBD was) (NP (NP (NP (CD 369)) (PP (IN with) (NP (NP (NN drug1)) (ADVP (RB alone))))) (CC and) (NP (NP (CD 367)) (PP (IN with) (NP (NP (NN drug2)) (CC plus) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (ADVP (RB Also)) (, ,) (NP (ADJP (FW in) (FW vitro)) (NNS experiments)) (VP (VBD demonstrated) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP (NP (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN interaction)) (VP (VBN observed) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (VP (VBZ is) (RB not) (VP (VBN expected) (PP (IN for) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NP (JJ Serious) (JJ cardiac) (NNS dysrhythmias)) (, ,) (NP (NP (DT some)) (VP (VBG resulting) (PP (IN in) (NP (NN death))))) (, ,)) (VP (VBP have) (VP (VBN occurred) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)) (PP (ADVP (RB concomitantly)) (IN with) (NP (JJ other) (NNS drug2))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (RBS most) (JJ drug1)) (VP (VBP are) (VP (VBN contraindicated) (PP (IN in) (NP (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2) (NN therapy)))) (SBAR (WHNP (WP who)) (S (VP (VBP have) (NP (NP (NP (JJ pre-existing) (JJ cardiac) (NNS abnormalities)) (PRN (-LRB- -LRB-) (NP (NP (NN arrhythmia)) (, ,) (NP (NN bradycardia)) (, ,) (NP (NN QT) (NN c) (NN interval) (NN prolongation)) (, ,) (NP (JJ ischemic) (NN heart) (NN disease)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (NP (NN etc.))) (-RRB- -RRB-))) (CC or) (NP (NN electrolyte) (NNS disturbances))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (VBG Following) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (CD two) (NN 250-mg) (NN drug2) (NNS tablets)) (VP (VBN administered) (ADVP (RB once) (RB daily)) (PP (IN with) (NP (NP (NN 200-mg) (NN drug3) (NNS tablets)) (VP (VBN administered) (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (CD 10) (NNS days))) (PP (TO to) (NP (CD 14) (JJ healthy) (NNS subjects))))))))))) (, ,) (NP (NP (DT the) (JJ steady-state) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug4)))) (VP (VBD was) (RB not) (ADVP (RB significantly)) (VP (VBN altered)))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ general))) (, ,) (NP (NP (NP (JJS most) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG receiving) (NP (JJ concomitant) (NN drug2) (NN therapy))))))) (VP (MD may) (RB not) (VP (VB require) (NP (NP (JJ empiric) (NN adjustment)) (PP (IN of) (NP (NP (NN drug3) (NN dosage)) (CC or) (NP (NP (NN monitoring)) (PP (IN of) (NP (NN drug4) (NN plasma) (NNS concentrations)))))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NN drug1) (NN plasma) (NNS concentrations)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (, ,) (PP (IN with) (NP (NP (NN dosage) (NN adjustment)) (PP (IN as) (NP (JJ appropriate))))) (, ,) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP$ whose) (JJ pulmonary) (NN disease)) (S (VP (VBZ requires) (S (VP (VBG maintaining) (NP (DT a) (JJ given) (NN drug2) (NN plasma) (NN concentration)) (PP (PP (IN for) (NP (JJ optimal) (JJ pulmonary) (NN function))) (CC or) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN drug3) (NNS concentrations)) (PP (IN at) (NP (NP (DT the) (JJR higher) (NN end)) (PP (IN of) (NP (DT the) (JJ therapeutic) (NN range)))))))))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB immediately)) (PP (VBG following) (NP (NP (NN drug4)) (CC or) (NP (NN drug5)))))))) (, ,) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug6)))) (VP (VBZ is) (ADVP (RB slightly)) (VP (VBN enhanced)))) (. .))))
(S1 (S (S (NP (DT The) (JJ following) (NN drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NN drug1) (NNS products))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB presently)) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (DT these) (JJ same) (NN drug) (NNS interactions)) (VP (VBP occur) (PP (IN with) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (SBAR (IN Until) (S (NP (JJ further) (NNS data)) (VP (VBP are) (ADJP (JJ available) (PP (VBG regarding) (NP (NP (DT the) (JJ potential) (NN interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (DT these) (NNS compounds))))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN during) (NP (NN coadministration))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3)))))) (CC and) (, ,) (ADVP (RB thus)) (, ,) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (JJ pharmacologic) (NN effect)) (PP (IN of) (NP (NN drug4)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (JJ elevated) (NN drug4) (NN serum) (NNS levels)))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (VBN increased) (JJ anticoagulant) (NNS effects)))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (CC and) (NP (JJ oral) (NN drug3))) (VP (VBD were) (VP (VBN used) (ADVP (RB concomitantly))))))))) (. .))))
(S1 (S (S (NP (NP (VBN Increased) (NN anticoagulation) (NNS effects)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (NN drug) (NN interaction)) (PP (IN with) (NP (NN drug1))))))) (VP (MD may) (VP (VB be) (ADJP (RBR more) (JJ pronounced)) (PP (IN in) (NP (DT the) (JJ elderly)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)) (CC or) (NP (NN drug4))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN in) (NP (NP (DT some) (NNS patients)) (PP (IN with) (NP (NP (JJ acute) (NN ergot) (NN toxicity)) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ severe) (JJ peripheral) (NN vasospasm)) (CC and) (NP (NN dysesthesia))))))))))))) (. .))))
(S1 (S (S (NP (JJ Other) (NNS drugs) (NN Drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (JJ other) (NNS medications)) (, ,) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (CC and) (NP (NN drug11))))))))))))) (. .)))
(S1 (S (NP (NN Injection) (EX There)) (VP (VBZ is) (NP (NP (JJ inadequate) (JJ systematic)) (VP (VBP experience) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1) (NN injection))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS medications))) (S (VP (TO to) (VP (VB predict) (NP (JJ specific) (JJ drug-drug) (NNS interactions)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Interactions)) (VP (VBN attributed) (PP (TO to) (NP (NP (DT the) (JJ combined) (NN use)) (PP (IN of) (NP (NP (JJ drug1) (NN injection)) (CC and) (NP (JJ epidural) (NN drug2)))))))) (VP (VBP include) (NP (NP (NN hypotension)) (CC and) (NP (NN dyspnea))))) (. .)))
(S1 (S (S (S (NP (NP (JJ SIDE) (NNS EFFECTS)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-)))) (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ adverse) (NN reaction)) (PP (IN during) (NP (NN treatment))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ is) (NP (NP (JJ transient) (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 10-63) (NN %)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (CD one) (JJ controlled) (NN study)) (PP (IN of) (NP (CD 175) (NNS patients))))) (, ,) (NP (JJ transient) (NN drowsiness)) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (CD 63) (NN %)) (PP (IN of) (NP (NP (DT those)) (VP (VBG receiving) (NP (NN drug1) (NNS tablets)) (PP (VBN compared) (PP (TO to) (NP (NP (CD 36) (NN %)) (PP (IN of) (NP (NP (DT those)) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Other) (JJ common) (JJ adverse) (NNS reactions)) (VP (VBP are) (NP (NP (NP (NN dizziness)) (PRN (-LRB- -LRB-) (NP (CD 5-15) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NN weakness)) (PRN (-LRB- -LRB-) (NP (CD 5-15) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NN fatigue)) (PRN (-LRB- -LRB-) (NP (CD 2-4) (NN %)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NNS Others)) (VP (VBN reported))) (: :) (NP (NP (NN Neuropsychiatric)) (: :) (NP (NP (NN Confusion)) (PRN (-LRB- -LRB-) (NP (CD 1-11) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NN headache)) (PRN (-LRB- -LRB-) (NP (CD 4-8) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NN insomnia)) (PRN (-LRB- -LRB-) (NP (CD 2-7) (NN %)) (-RRB- -RRB-)))) (: ;)))
(S1 (S (S (CC and) (, ,) (ADVP (RB rarely)) (, ,) (UCP (NP (NN euphoria)) (, ,) (NP (NN excitement)) (, ,) (NP (NP (NN depression)) (, ,) (NP (NNS hallucinations)) (, ,) (NP (NN paresthesia)) (, ,) (NP (NN muscle) (NN pain)) (, ,) (NP (NN tinnitus)) (, ,) (NP (JJ slurred) (NN speech)) (, ,) (NP (NN coordination) (NN disorder)) (, ,) (NP (NN tremor)) (, ,) (NP (NN rigidity)) (, ,) (NP (NN dystonia)) (, ,) (NP (NN ataxia)) (, ,) (NP (JJ blurred) (NN vision)) (, ,) (NP (NN nystagmus)) (, ,) (NP (NN strabismus)) (, ,) (NP (NN miosis)) (, ,) (NP (NN mydriasis)) (, ,) (NP (NN diplopia)) (, ,) (NP (NN dysarthria)) (, ,) (NP (JJ epileptic) (NN seizure))))) (. .)))
(S1 (S (NP (NP (NN Cardiovascular)) (: :) (NP (NP (NN Hypotension)) (PRN (-LRB- -LRB-) (NP (CD 0-9) (NN %)) (-RRB- -RRB-))) (. .))))
(S1 (S (S (NP (NP (JJ Rare) (NNS instances)) (PP (IN of) (NP (NP (NN dyspnea)) (, ,) (NP (NN palpitation)) (, ,) (NP (NN chest) (NN pain)) (, ,) (NP (NN syncope)))))) (. .)))
(S1 (S (NP (NP (JJ Gastrointestinal)) (: :) (NP (NP (NP (NN Nausea)) (PRN (-LRB- -LRB-) (NP (CD 4-12) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NN constipation)) (PRN (-LRB- -LRB-) (NP (CD 2-6) (NN %)) (-RRB- -RRB-)))) (: ;))))
(S1 (S (CC and) (, ,) (ADVP (RB rarely)) (, ,) (VP (VBP dry) (NP (NP (NP (NN mouth)) (, ,) (NP (NN anorexia)) (, ,) (NP (JJ taste) (NN disorder)) (, ,) (NP (JJ abdominal) (NN pain)) (, ,) (NP (NN vomiting)) (, ,) (NP (NN diarrhea)) (, ,) (CC and) (NP (JJ positive) (NN test))) (PP (IN for) (NP (JJ occult) (NN blood))) (PP (IN in) (NP (NN stool))))) (. .)))
(S1 (S (NP (NP (NN Genitourinary)) (: :) (NP (NP (JJ Urinary) (NN frequency)) (PRN (-LRB- -LRB-) (NP (CD 2-6) (NN %)) (-RRB- -RRB-))) (: ;))))
(S1 (S (S (ADVP (CC and)) (, ,) (ADVP (RB rarely)) (, ,) (NP (NP (NN enuresis)) (, ,) (NP (JJ urinary) (NN retention)) (, ,) (NP (NN dysuria)) (, ,) (NP (NN impotence)) (, ,)) (VP (NN inability) (PP (TO to) (NP (NP (NN ejaculate)) (, ,) (NP (NN nocturia)) (, ,) (NP (NN hematuria)))))) (. .)))
(S1 (S (S (NP (JJ Other)) (: :) (NP (NP (NNS Instances)) (PP (IN of) (NP (NP (NN rash)) (, ,) (NP (NN pruritus)) (, ,) (NP (NN ankle) (NN edema)) (, ,) (NP (JJ excessive) (NN perspiration)) (, ,) (NP (NN weight) (NN gain)) (, ,) (NP (JJ nasal) (NN congestion)))))) (. .)))
(S1 (S (S (NP (NP (DT Some)) (PP (IN of) (NP (DT the) (NP (NN CNS)) (CC and) (NP (JJ genitourinary) (NNS symptoms))))) (VP (MD may) (VP (VB be) (ADJP (JJ related) (PP (PP (TO to) (NP (DT the) (JJ underlying) (NN disease))) (CONJP (RB rather) (IN than)) (PP (TO to) (NP (NN drug) (NN therapy)))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (NN laboratory) (NNS tests)) (VP (VBP have) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (JJ abnormal) (PP (IN in) (NP (NP (NP (DT a) (JJ few) (NNS patients)) (VP (VBG receiving) (NP (NN drug1)))) (: :) (NP (NP (VBN increased) (NN SGOT)) (, ,) (NP (JJ elevated) (NN alkaline) (NN phosphatase)) (, ,) (CC and) (NP (NP (NN elevation)) (PP (IN of) (NP (NN blood) (NN sugar))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ adverse) (VBP experience) (NN profile)) (VP (VBN seen) (PP (IN with) (NP (NN drug1))))) (VP (VBD was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN seen) (PP (IN with) (NP (JJ drug2) (NNS tablets))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,)) (NP (NN drug5))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB have) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2)))) (CC and) (NP (NP (DT the) (NNS pharmacodynamics)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (NP (NN no) (NN dosing) (NNS adjustments)) (VP (VBP are) (ADJP (JJ necessary) (PP (IN during) (NP (NP (JJ concomitant) (NN use)) (PP (IN with) (NP (DT these) (NNS agents)))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NN system))))))) (, ,) (S (S (NP (NP (NNS inhibitors)) (PP (IN of) (NP (CD CYP450) (NN enzyme)))) (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB affect) (NP (PRP$ its) (NN metabolism))))))))) (, ,) (CC and) (S (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (, ,) (NP (NP (JJ potent) (NNS inhibitors)) (PP (IN of) (NP (NP (NN CYP3A)) (CC and) (NP (NN 2C9)) (, ,) (ADVP (RB respectively))))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB have) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug4) (NNS pharmacokinetics))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB also)) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug2) (NNS pharmacokinetics))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (QP (RB up) (TO to) (CD 400)) (NN mg)) (NN b.i.d.)) (CC or) (NP (ADJP (CD 800) (NN mg)) (NN q.d.))) (-RRB- -RRB-))) (NNS doses)) (VP (VBP have) (VP (VBN been) (ADVP (RB safely)) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (DT a) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (JJ drug1) (NNS doses)) (PP (IN of) (NP (ADJP (QP (RB up) (TO to) (CD 300)) (NN mg)) (NN b.i.d.)))) (VP (VBP have) (VP (VBN been) (ADVP (RB safely)) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NP (NN sustained-release) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN sustained-release) (NN drug3)) (-RRB- -RRB-))) (PP (IN with) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (JJ adverse) (NNS interactions))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN administered) (ADVP (RB concurrently))))) (, ,) (NP (DT the) (JJ following) (NNS drugs)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN drug3)) (CC and) (NP (JJ related) (NNS drugs))) (, ,) (NP (NP (NN drug4)) (CC and) (NP (NN drug5)))) (-RRB- -RRB-))) (VP (VBD enhanced) (NP (NN hypokalemia)))) (. .)))
(S1 (S (S (VP (VB Check) (NP (NN serum) (NN potassium) (NNS levels)) (PP (IN at) (NP (JJ frequent) (NNS intervals))))) (: ;)))
(S1 (S (S (NP (NN use) (NN drug1)) (VP (VBZ supplements) (SBAR (IN if) (FRAG (JJ necessary))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD enhanced) (NP (NP (NN possibility)) (PP (IN of) (NP (NP (NP (NNS arrhythmias)) (CC or) (NP (NN drug2) (NN toxicity))) (VP (VBN associated) (PP (IN with) (NP (NN hypokalemia))))))))) (. .)))
(S1 (S (S (VP (VB Monitor) (NP (NN serum) (NN potassium) (NNS levels)))) (: ;)))
(S1 (S (S (NP (NN use) (NN drug1)) (VP (VBZ supplements) (SBAR (IN if) (FRAG (JJ necessary))))) (. .)))
(S1 (S (S (NP (JJ Oral) (NN drug1)) (VP (VBD decreased) (NP (NN prothrombin) (NN time) (NN response)))) (. .)))
(S1 (S (S (VP (VP (VB Monitor) (NP (NN prothrombin) (NNS levels))) (CC and) (VP (VB adjust) (NP (NN drug1) (NN dosage)) (ADVP (RB accordingly))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (JJ oral) (NNS agents)) (CC and) (NP (NNS drug2))) (-RRB- -RRB-))) (VP (VBD diminished) (NP (JJ antidiabetic) (NN effect)))) (. .)))
(S1 (S (NP (NP (NN Monitor)) (PP (IN for) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NN hyperglycemia))))) (: ;))))
(S1 (S (S (NP (NP (NN adjust) (NN dosage)) (PP (IN of) (NP (NN drug1)))) (VP (VBN upward) (SBAR (IN if) (ADJP (JJ necessary))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD increased) (NP (JJ ulcerogenic) (NN effect)))) (: ;)))
(S1 (S (S (VP (VBD decreased) (NP (NP (JJ pharmacologic) (NN effect)) (PP (IN of) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (ADJP (RB Rarely) (JJ drug1)) (NN toxicity)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP discontinue) (VP (VBN drug2) (PP (IN after) (NP (JJ concurrent) (JJ high-dose) (NN drug3) (NN therapy)))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN Monitor) (NN drug1) (NNS levels)) (CC or) (NP (DT the) (JJ therapeutic) (NN effect))) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN given))) (: ;))))))
(S1 (S (S (VP (VB adjust) (NP (NN drug1) (NN dosage)) (ADVP (RB accordingly)) (SBAR (IN if) (S (NP (NN effect)) (VP (VBZ is) (VP (VBN altered))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC or) (NP (NN drug3))) (VP (VBD increased) (NP (NP (JJ metabolic) (NN clearance)) (PP (IN of) (NP (NN drug4)))) (PP (IN because) (IN of) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (JJ hepatic) (NNS enzymes))))))) (. .)))
(S1 (S (S (VP (VP (VBP Observe) (NP (NP (DT the) (NN patient)) (PP (IN for) (NP (NP (JJ possible) (VBN diminished) (NN effect)) (PP (IN of) (NP (NN drug1))))))) (CC and) (VP (VBP increase) (NP (DT the) (NN drug2) (NN dosage)) (ADVP (RB accordingly))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (ADVP (RB particularly)) (NP (NP (NN C-17) (JJ alkylated) (NNS drug2)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (JJ similar) (NNS compounds)))))) (-RRB- -RRB-))) (VP (VBD enhanced) (NP (NP (NN tendency)) (PP (IN toward) (NP (NN edema)))))) (. .)))
(S1 (S (S (VP (VBP Use) (NP (NN caution)) (SBAR (WHADVP (WRB when)) (S (VP (VBG giving) (NP (DT these) (NNS drugs)) (ADVP (RB together)) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (ADJP (JJ hepatic)) (CC or) (ADJP (JJ cardiac))) (NN disease)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ drug1) (JJ neurological) (NNS complications)) (CC and) (NP (NP (NN lack)) (PP (IN of) (NP (NN antibody) (NN response)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD increased) (NP (NP (NNS levels)) (PP (IN of) (NP (JJ corticosteroid-binding) (NN globulin)))) (, ,) (S (ADVP (RB thereby)) (VP (VBG increasing) (NP (DT the) (VBN bound) (-LRB- -LRB-) (JJ inactive) (-RRB- -RRB-) (NN fraction)))))) (: ;)))
(S1 (S (S (NP (DT this) (NN effect)) (VP (VBZ is) (ADVP (IN at) (JJS least)) (ADJP (JJ balanced) (PP (IN by) (NP (NP (VBN decreased) (NN metabolism)) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1) (NN therapy)) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (S (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN drug2) (NN dosage)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (, ,) (CC and) (S (NP (VBN increased) (NNS amounts)) (VP (MD may) (VP (VB be) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN terminated)))))))))) (. .)))
(S1 (S (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (ADVP (RB drug1)) (VP (MD may) (VP (VP (VB affect) (NP (NP (DT the) (NN nitrobluetetrazolium) (NN test)) (PP (IN for) (NP (JJ bacterial) (NN infection))))) (CC and) (VP (VB produce) (NP (JJ false-negative) (NNS results)))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (DT A) (NN number)) (PP (IN of) (NP (NNS substances)))) (VP (VP (VBP affect) (NP (NN glucose) (NN metabolism))) (CC and) (VP (MD may) (VP (VBP require) (NP (NP (NN drug1) (NN dose) (NN adjustment)) (CC and) (ADVP (RB particularly)) (NP (JJ close) (NN monitoring))))))) (. .)))
(S1 (S (S (NP (DT The) (NN following)) (VP (VBP are) (NP (NP (NP (NNS examples)) (PP (IN of) (NP (NP (NNS substances)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB increase) (NP (NP (DT the) (JJ blood-glucose-lowering) (NN effect)) (CC and) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NN hypoglycemia)))))))))))) (: :) (NP (NP (JJ oral) (NNS antidiabetes) (NNS products)) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug9)) (-RRB- -RRB-))) (, ,) (NP (NN drug10))))))) (. .)))
(S1 (S (S (NP (DT The) (NN following)) (VP (VBP are) (NP (NP (NP (NNS examples)) (PP (IN of) (NP (NP (NNS substances)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (JJ blood-glucose-lowering) (NN effect)) (PP (IN of) (NP (NN drug1))))))))))) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (FW e.g.) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8))) (-RRB- -RRB-))) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (QP (CD drug11) (, ,) (CD drug12) (, ,) (CD drug13) (, ,) (CD drug14)))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (PP (IN in) (NP (JJ oral) (NN drug15))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3) (NNS salts)) (, ,) (CC and) (NP (NN drug4))) (VP (MD may) (VP (CC either) (VP (VB potentiate)) (CC or) (VP (VB weaken) (NP (NP (DT the) (JJ blood-glucose-lowering) (NN effect)) (PP (IN of) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB cause) (NP (NP (NN hypoglycemia)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (ADVP (RB sometimes)) (VP (VB be) (VP (VBN followed) (PP (IN by) (NP (NN hyperglycemia)))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (PP (IN under) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (JJ sympatholytic) (NN medicinal) (NNS products)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))))) (, ,) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (NN hypoglycemia)))) (VP (MD may) (VP (VP (VB be) (VP (VBN reduced))) (CC or) (ADJP (JJ absent)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NP (NN drug2)) (CC -) (NP (NN drug3)))) (VP (MD may) (VP (VB decrease) (NP (JJ hepatic) (NN toxicity)) (PP (IN in) (NP (NP (DT those)) (PP (PP (IN with) (NP (NN drug4) (NN overdosage))) (CC or) (PP (IN in) (NP (NP (DT those)) (VP (VBG taking) (NP (NN drug5))))))))))) (. .)))
(S1 (S (S (ADVP (RB Theoretically)) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB decrease) (NP (JJ hepatic) (NN toxicity)) (PP (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (JJ other) (JJ potential) (JJ hepatotoxic) (NNS drugs)) (, ,) (PP (IN as) (NP (NN well)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (VP (MD may) (VP (VB protect) (PP (IN against) (NP (NP (DT the) (JJ ototoxic) (NNS effects)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NP (NNS volunteers)) (PP (PP (IN under) (NP (JJ fasting) (NNS conditions))) (, ,) (CC or) (PP (IN with) (NP (NN drug3) (NN suspension))))))) (VP (VBD yielded) (NP (NP (JJ similar) (NN serum) (NN drug4) (NN time) (NNS profiles)) (PP (IN in) (NP (NP (JJ young) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NN n=12)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (JJ geriatric) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NN n=7)) (-RRB- -RRB-)))) (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN rate)) (CONJP (CC but) (RB not)) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN drug1) (NN absorption))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NP (NN drug2)) (PP (IN like) (NP (JJ other) (NN drug3))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB affect) (NP (NP (JJ bleeding) (NNS parameters)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNS drug4))))))))))))) (, ,) (CC and) (S (NP (JJ serious) (JJ clinical) (JJ bleeding)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported)))))) (. .))))
(S1 (S (S (NP (DT The) (NN physician)) (VP (MD should) (VP (VB be) (ADJP (JJ cautious))) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD resulted) (PP (IN in) (NP (ADJP (NP (CD 50) (NN %)) (JJR lower)) (NN serum) (NN drug4) (NNS concentrations))))) (. .))))
(S1 (S (S (NP (NP (DT This) (NN effect)) (PP (IN of) (NP (NN drug1))) (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (ADVP (RB also)) (VP (VBZ lowers) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (JJ other) (NNS drug2)) (VP (VBN given) (PP (IN with) (NP (PRP it)))))))))) (-RRB- -RRB-)) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (PP (IN in) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ rheumatoid) (NN arthritis)) (PRN (-LRB- -LRB-) (NP (NN n=) (CD 15)) (-RRB- -RRB-))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ normal) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NN n=) (CD 16)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (ADVP (RB therefore)) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NP (NN blood) (NN pressure) (NN response)) (PP (TO to) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))) (VP (VBD was) (VP (VBN evaluated) (PP (IN in) (NP (NP (NNS men)) (PP (IN with) (NP (NP (JJ mild) (JJ uncomplicated) (NN hypertension)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 10)) (-RRB- -RRB-))))))))) (. .))))
(S1 (S (S (NP (NN drug1) (NN pretreatment)) (VP (VBD attenuated) (NP (NP (DT the) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NN drug2)) (CONJP (CC but) (RB not)) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB affect) (NP (NP (DT the) (JJ beta-blocker-mediated) (NN reduction)) (PP (IN in) (NP (NN heart) (NN rate)))))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (JJ pharmacokinetic) (NN profile)) (PP (IN of) (NP (DT either) (NN drug))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN mechanism)) (PP (IN under) (S (VP (VBG lying) (NP (NP (DT the) (NN interference)) (PP (IN with) (NP (NN drug2) (NN s) (JJ hypotensive) (NN effect)))))))) (VP (VBZ is) (ADJP (JJ unknown))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN a) (NN drug2))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (S (VP (TO to) (VP (VB ensure) (SBAR (IN that) (S (NP (DT a) (JJ satisfactory) (JJ hypotensive) (NN effect)) (VP (VBZ is) (VP (VBN achieved)))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2))) (: :) (S (PP (IN In) (NP (NP (JJ normal) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NN n=9)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NN drug3)) (CC or) (NP (NN drug4))))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NN drug5) (NNS pharmacokinetics)) (PP (IN except) (SBAR (IN that) (S (NP (NP (DT a) (ADJP (ADJP (JJ small) (PRN (-LRB- -LRB-) (NP (CD 13) (NN %)) (-RRB- -RRB-))) (CC but) (ADJP (RB statistically) (JJ significant))) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN area)) (PP (IN under) (NP (NP (DT the) (NN serum) (NN concentration) (NN curve)) (PP (IN of) (NP (NN drug6)))))))) (VP (VBD resulted) (PP (IN with) (NP (NN drug7)))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (NNS Studies)) (PP (IN of) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (TO to) (NP (NP (JJ healthy) (NNS men)) (PRN (-LRB- -LRB-) (NP (NN n=) (CD 14)) (-RRB- -RRB-)))))))) (VP (VBD did) (RB not) (VP (VB show) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NP (DT the) (JJ steady) (NN state) (NN serum) (NNS levels)) (PP (IN of) (NP (DT either) (NN drug))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NNS Studies)) (PP (IN in) (NP (JJ normal) (NNS volunteers)))) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug2)) (PP (IN like) (NP (JJ other) (NN drug3))) (, ,) (VP (MD can) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug4)))))))))))) (. .))))
(S1 (S (SBAR (IN Although) (S (NP (NNS results)) (VP (VBP have) (VP (VBD varied) (PP (IN from) (NP (NN study))) (PP (TO to) (NP (NN study))))))) (, ,) (S (NP (NNS effects)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (PP (IN on) (NP (NP (JJ drug1) (JJ -stimulated) (NN diuresis)) (, ,) (NP (NN natriuresis)) (, ,) (CC and) (NP (NN kaliuresis))))))) (. .))))
(S1 (S (S (NP (NP (JJ Other) (NNS drug1)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN prostaglandin) (NN synthesis)))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NN drug2))) (PP (PP (IN in) (NP (DT some) (NNS studies))) (CC and) (PP (IN with) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (CC or) (NP (JJ other) (NN drug3))))) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (DT the) (JJ desired) (NN effect)) (VP (VBZ is) (VP (VBN obtained)))))))))))) (. .)))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (PP (IN In) (NP (CD one) (NN study))) (, ,) (NP (NN drug2)) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (JJ adult) (NNS diabetics)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG receiving) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN n=4)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN n=2)) (-RRB- -RRB-))) (VP (VBN drug5) (PP (IN with) (NP (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN n=) (CD 3)) (-RRB- -RRB-))) (CC or) (NP (NP (NP (NN drug7)) (PP (IN with) (NP (NN drug8)))) (PRN (-LRB- -LRB-) (NP (NN n=6)) (-RRB- -RRB-))))))))))))))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (JJ slight) (NN reduction)) (PP (IN in) (NP (NN blood) (NN sugar) (NNS concentrations)))) (PP (IN during) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (, ,) (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (NP (NNS signs)) (CC or) (NP (NNS symptoms))) (PP (IN of) (NP (NN hypoglycemia)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: -) (S (VP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4)) (NP (NN HC1))))) (. .))))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB cause) (NP (NN hypertension))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (CC and) (NP (DT the) (NN drug3) (NN drug4))) (VP (MD may) (VP (VB have) (NP (JJ synergistic) (JJ antidepressant) (NN activity)) (SBAR (IN if) (S (VP (VBN used) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC -) (NP (NN drug2))) (VP (MD may) (VP (VB potentiate) (NP (NP (NP (DT the) (JJ tardive) (NN dyskinesia)) (JJ side) (NNS reactions)) (PP (IN of) (NP (NN drug3)))) (SBAR (IN if) (S (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (PRP them))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (ADVP (FW in) (FW vivo)) (S (VP (TO to) (VP (VB induce) (NP (NN CYP3A4))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS compounds)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN of) (NP (NN CYP3A4)))))))) (VP (MD may) (VP (VBP have) (NP (VBN decreased) (NN plasma) (NNS concentrations)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (CC and) (NP (NN 3A4) (NNS isozymes))) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (VBN observed) (NN drug2) (NN plasma) (NNS concentrations))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (VP (ADVP (RB primarily)) (VBN metabolized) (PP (IN by) (NP (DT these) (NNS isozymes))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ altered) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ coadministered) (NN drug)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (JJ appropriate) (NN dose) (NNS adjustments)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (PP (IN for) (NP (DT these) (NNS drugs))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP induce) (NP (NP (NN CYP3A4) (NN activity)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))))))) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NNS drug4)) (VP (VBG resulting) (PP (IN in) (NP (JJ lowered) (NN plasma) (NNS concentrations)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NNS interactions)) (PP (IN with) (NP (NN drug1)))) (VP (VBP are) (VP (VBN summarized) (PP (IN in) (NP (NN Table) (CD 5)))))) (. .)))
(S1 (S (NP (NP (JJ Table) (NN 5a)) (: :) (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (MD Should) (RB Not) (VP (VB Be) (VP (VBN Coadministered) (PP (IN With) (NP (NN drug1))))))))))))
(S1 (S (NP (NN Drug) (NN Class))))
(S1 (S (NP (NP (NNS Drugs)) (SBAR (IN Within) (S (NP (NN Class)) (VP (RB Not) (TO To) (VP (VB Be) (VP (VBN Coadministered) (PP (IN With) (NP (NN drug1)))))))))))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2) (NN GI) (NN Motility) (NNS Agents)) (PP (IN drug3) (NP (NN drug4)))))))
(S1 (S (NP (NP (NN drug1) (NN drug2)) (, ,) (CC drug3) (NP (NN drug4) (NN ergot) (NNS derivatives)) (NP (NN drug5)))))
(S1 (S (NP (JJ Established) (NN Drug) (NNS Interactions))))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN Drug) (NN Name))))
(S1 (S (NP (NN Effect))))
(S1 (S (NP (JJ Clinical) (NN Comment))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1))))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN coadministered) (PP (IN with) (NP (NP (NN drug1)) (PP (IN in) (NP (JJ treatment-naive) (NNS patients)))))))) (, ,) (NP (NP (DT the) (VBN recommended) (NN dose)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ is) (NP (NP (CD 300) (NN mg)) (PP (IN with) (NP (NP (NN drug3) (CD 100) (NN mg)) (CC and) (NP (NP (NN drug4) (CD 600) (NN mg)) (PRN (-LRB- -LRB-) (NP (NP (NN all)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (NN Dosing) (NNS recommendations)) (PP (IN for) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN in) (NP (JJ treatment-experienced) (NNS patients)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (NP (NP (JJ Established) (NN Drug) (NNS Interactions)) (PRN (-LRB- -LRB-) (NP (JJ continued)) (-RRB- -RRB-)))))
(S1 (S (NP (NN Drug) (NN Name))))
(S1 (S (NP (NN Effect))))
(S1 (S (NP (JJ Clinical) (NN Comment))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NN Plasma) (NNS concentrations)) (VP (VBD decreased) (PP (IN by) (NP (NN drug1))))) (: ;)))
(S1 (S (S (NP (JJ clinical) (NN significance)) (VP (JJ unknown))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ uninfected) (NNS volunteers))) (, ,) (NP (CD 46) (NN %)) (VP (VBD developed) (NP (NN rash)) (PP (IN while) (S (VP (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN dose) (NN adjustment)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Alternatives)) (PP (TO to) (NP (NN drug1))) (, ,) (PP (JJ such) (IN as) (NP (NN drug2))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS drug1)) (, ,) (PP (JJ such) (IN as) (NP (NN drug2))) (, ,)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug3))))))))) (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (NP (NN 14-OH) (NN metabolite) (NN concentration))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NP (DT The) (JJ optimal) (NN dose)) (PP (IN of) (NP (NN drug1))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))) (, ,)) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (S (VP (VBG Increasing) (NP (DT the) (NN drug1) (NN dose)) (PP (TO to) (NP (NP (CD 1000) (NN mg)) (NP (DT every) (CD 8) (NNS hours)))))) (VP (VBZ does) (RB not) (VP (VB compensate) (PP (IN for) (NP (NP (DT the) (VBN increased) (NN drug2) (NN metabolism)) (ADJP (JJ due) (PP (TO to) (NP (NN drug3))))))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug1)) (PP (IN at) (NP (NP (DT an) (VBN increased) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000) (NN mg)) (NP (DT every) (CD 8) (NNS hours))) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN given) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 600) (NN mg)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-)))))))) (, ,) (NP (NP (DT the) (NN drug3) (NN AUC)) (CC and) (NP (NN Cmin))) (VP (VBD were) (VP (VBN decreased) (PP (IN on) (NP (NN average))) (PP (IN by) (NP (NP (CD 33-46) (NN %)) (CC and) (NP (CD 39-57) (NN %)) (, ,) (ADVP (RB respectively)))) (, ,) (PP (VBN compared) (PP (TO to) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 800) (NN mg) (NP (DT every) (CD 8) (NNS hours))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (ADVP (RB alone)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NP (DT A) (NN dose) (NN increase)) (PP (IN of) (NP (NP (NN drug1)) (: /) (NP (NP (NP (NN drug2) (TO to) (CD 533/133) (NN mg)) (PRN (-LRB- -LRB-) (NP (CD 4) (NNS capsules) (CC or) (CD 6.5) (NN mL)) (-RRB- -RRB-))) (ADVP (RB twice) (RB daily)) (VP (VBN taken) (PP (IN with) (NP (NN food)))))))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug3))))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN in) (NP (JJ HIV-infected) (NNS individuals))) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN injection) (NN drug) (NN use)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (VBN decreased) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (NNS signs)) (PP (IN of) (NP (NN drug2) (NN withdrawal)))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN dose)) (VP (VBD was) (VP (VBN increased) (PP (IN by) (NP (NP (DT a) (NN mean)) (PP (IN of) (NP (CD 22) (NN %))) (S (VP (TO to) (VP (VB alleviate) (NP (NN withdrawal) (NNS symptoms)))))))))) (. .)))
(S1 (S (S (S (NP (NNS Patients)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NN withdrawal))))))))) (CC and) (S (NP (PRP$ their) (NN drug1) (NN dose)) (VP (VBD increased) (SBAR (IN as) (S (VP (VBN required) (S (VP (TO to) (VP (VB alleviate) (NP (NN withdrawal) (NNS symptoms))))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NN Plasma) (NNS concentrations)) (VP (VBD increased) (PP (IN by) (NP (NN drug1))) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))) (: ;)))
(S1 (S (S (NP (JJ clinical) (NN significance)) (VP (JJ unknown))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NP (DT the) (JJ potential) (NN interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ oral) (NN drug2)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB fully)) (VP (VBN characterized)))))) (, ,) (NP (NP (DT a) (JJ reliable) (NN method)) (PP (IN of) (NP (NN barrier) (NN contraception)))) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (JJ oral) (NN drug3))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (VP (VBP Increase) (NP (NP (JJ daily) (NN dose)) (PP (IN of) (NP (NN drug1)))) (PP (IN by) (NP (CD 50) (NN %))))) (. .)))
(S1 (S (S (NP (VB Consider)) (VP (VBG doubling) (NP (DT the) (NN drug1) (NN dose)) (PP (IN in) (NP (NP (NNS regimens)) (SBAR (WHADVP (WRB where)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN given) (NP (NP (QP (CD 2) (CC or) (CD 3)) (NNS times)) (NP (DT a) (NN week))))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NP (JJ Clinical) (NN significance)) (PP (IN of) (NP (VBN reduced) (NN drug1) (NNS concentrations)))) (VP (JJ unknown))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NN Combination)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN frequency)) (PP (IN of) (NP (NP (NP (JJ adverse) (JJ clinical) (NNS experiences)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN dizziness)) (, ,) (NP (NN nausea)) (, ,) (NP (NN paresthesia))) (-RRB- -RRB-))) (CC and) (NP (NP (NN laboratory) (NNS abnormalities)) (PRN (-LRB- -LRB-) (NP (JJ elevated) (NN liver) (NNS enzymes)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Monitoring)) (PP (IN of) (NP (NN liver) (NNS enzymes)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (VP (MD Should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (JJ sole) (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (NP (NN drug1) (NN concentration))))
(S1 (S (S (NP (NP (NNS Increases)) (PP (IN in) (NP (NN drug1) (NN dose)))) (VP (MD should) (VP (VB be) (VP (VBN guided) (PP (IN by) (NP (JJ clinical) (NN response))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (ADJP (RB Potentially) (RB Clinically) (JJ Significant)) (NN Drug) (CC or) (NN Herbal) (NN Product) (NNS Interactions)) (PP (IN With) (NP (NN SUSTIVAb))))))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)))))
(S1 (S (S (NP (NP (NN Plasma) (NNS concentrations)) (CC and) (NP (NNS effects))) (ADVP (RB potentially)) (VP (VP (VBN increased)) (CC or) (VP (VBN decreased) (PP (IN by) (NP (NN drug1)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2) (NN drug3) (NN drug4)))))
(S1 (S (NP (NP (NN Potential)) (PP (IN for) (NP (NN reduction))) (PP (IN in) (NP (NP (NN drug1)) (CC and/or) (NP (NN drug2) (NN plasma) (NNS levels)))) (: ;))))
(S1 (S (S (NP (NP (JJ periodic) (NN monitoring)) (PP (IN of) (NP (NN drug1) (NN plasma) (NNS levels)))) (VP (MD should) (VP (VB be) (VP (VBN conducted))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2) (NN drug3)))))
(S1 (S (S (NP (NP (NN Drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (DT these) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (NP (NP (DT the) (NN potential)) (PP (TO to) (NP (NP (NN decrease) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)) (: /) (CC drug3) (NP (NN combination)))))
(S1 (S (S (NP (DT No) (JJ pharmacokinetic) (NNS data)) (VP (VBP are) (ADJP (JJ available)))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (VP (NNS SUSTIVAhas) (NP (DT the) (NN potential)) (PP (TO to) (NP (NP (NN decrease) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (DT No) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN with) (NP (JJ other) (NN drug1))))))) (. .)))
(S1 (S (NP (NP (NN St.) (NN John) (NN s) (NN wort)) (PRN (-LRB- -LRB-) (NP (NN Hypericum) (NN perforatum)) (-RRB- -RRB-)))))
(S1 (S (S (S (VP (VBN Expected) (S (VP (TO to) (ADVP (RB substantially)) (VP (VB decrease) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1))))))))) (: ;) (S (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NN a)) (VP (VB See) (NP (NNS Tables) (QP (CD 1) (CC and) (CD 2))))) (. .)))
(S1 (S (S (NP (NN b) (NP (DT This)) (NN table)) (VP (VBZ is) (RB not) (ADJP (JJ all-inclusive)))) (. .)))
(S1 (S (NP (NP (JJ Other) (NNS Drugs)) (: :) (S (S (VP (VBN Based) (PP (IN on) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NN drug) (NN interaction) (NNS studies))))))) (, ,) (NP (DT no) (JJ dosage) (NN adjustment)) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN given) (PP (IN with) (NP (NP (DT the) (NN following)) (: :) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (CC and) (NP (NN drug12))))))))))) (. .))))
(S1 (S (S (NP (JJ Specific) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed) (PP (IN with) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (ADJP (JJ other) (PP (IN than) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))))))) (. .)))
(S1 (S (S (NP (ADJP (RB Clinically) (JJ significant)) (NNS interactions)) (VP (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected) (SBAR (IN since) (S (NP (DT the) (NNS drug1)) (VP (VBP are) (VP (VBN metabolized) (PP (IN via) (NP (NP (DT a) (JJ different) (NN route)) (PP (IN than) (NP (NN drug2)))))))))))) (CC and) (VP (MD would) (VP (VB be) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB compete) (PP (IN for) (NP (NP (DT the) (JJ same) (JJ metabolic) (NNS enzymes)) (CC and) (NP (NN elimination) (NNS pathways)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Formal) (NN drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN drug1)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ ischemic) (NN heart) (NN disease))) (VP (VBN treated) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (DT a) (JJ broad) (NN range)) (PP (IN of) (NP (NP (NNS medications)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN angina) (JJ myocardial) (NN infarction)) (CC and) (NP (NN hypertension)))))))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS medications)) (VP (VBP have) (S (VP (VBD included) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (ADJP (ADJP (JJ intravenous)) (CC and) (ADJP (JJ oral))) (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (JJ other) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ bleeding)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NN HACA) (NNS titers)))) (VP (MD may) (VP (VBP have) (NP (JJ allergic) (CC or) (NN hypersensitivity) (NNS reactions)) (SBAR (WHADVP (WRB when)) (S (VP (VBN treated) (PP (IN with) (NP (JJ other) (NP (NN drug1)) (CC or) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ Other) (NNS Drugs))) (PP (IN on) (NP (NN drug1)))) (VP (VBN Based) (PP (IN on) (NP (NP (ADJP (FW in-vitro)) (NNS studies)) (, ,) (SBAR (WHNP (WDT drug2)) (S (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP) (NN 3A4))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3) (, ,) (NN drug4) (, ,) (NN drug5) (, ,) (NN drug6) (, ,) (NN drug7) (, ,) (NN drug8) (, ,) (NN drug9) (, ,) (CD drug10) (CC and) (CD drug11))))) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (ADJP (RB clinically) (JJ significant)) (NNS increases)) (PP (IN in) (NP (NN drug12) (NN exposure)))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD reduced) (NP (NN drug2) (NN Cmax)) (PP (NP (QP (RB up) (TO to) (CD 50)) (NN %)) (IN after) (NP (JJ multiple) (NN dosing))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD resulted) (PP (IN in) (NP (NP (RB about) (DT a) (ADJP (CD 50) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NN drug2) (NN Cmax)) (CC and) (NP (NN AUC)))) (PP (IN after) (NP (JJ multiple) (NN dosing))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (ADJP (CD 200) (NN mg)) (NN twice-daily) (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ approximate) (ADJP (CD 80) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug4))))))))) (. .))))
(S1 (S (S (NP (DT A) (ADJP (CD 400) (NN mg)) (JJ once-daily) (NN dose)) (VP (VP (VBD was) (RB not) (VP (VBN studied))) (CC but) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NN drug1) (NN blood) (NNS levels)) (ADVP (RB further)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (JJ Other) (NNS Drugs)))) (VP (VBP drug2) (S (VP (VBZ does) (RB not) (VP (VP (VB inhibit) (NP (NP (DT the) (CD CYP450) (NNS isoenzymes)) (PRN (-LRB- -LRB-) (NP (NN CYP1A2)) (, ,) (NP (NP (NN 2C8)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (NP (NN 2D6)) (, ,) (NP (NN 2E1)) (, ,) (CC and) (NP (NN CYP) (NN 3A))) (-RRB- -RRB-)))) (CC or) (VP (VB induce) (NP (NN CYP) (NN 3A4)))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (CC or) (NP (NN drug11)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NN drug3) (NNS pharmacokinetics)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN evaluated) (PP (IN in) (NP (DT a) (JJ well-controlled) (JJ clinical) (NN trial))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN co-administered) (PP (IN with) (NP (NN drug3))))))) (, ,) (NP (NP (DT the) (NP (NN AUC)) (CC and) (NP (NN Cmax))) (PP (IN of) (NP (NNS drug4)))) (VP (VBD were) (VP (VBN reduced) (PP (IN by) (NP (NP (QP (RB about) (CD 30)) (NN %)) (CC and) (NP (CD 50) (NN %)) (, ,) (ADVP (RB respectively))))))) (. .))))
(S1 (S (S (NP (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (PP (IN of) (NP (NN drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (S (NP (NP (CD CYP450) (JJ Metabolized) (NNS Drugs) (NNS Results)) (PP (IN from) (NP (ADJP (ADJP (FW in) (FW vitro)) (CC and) (ADJP (FW in) (FW vivo))) (NNS studies)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB have) (NP (NP (JJ significant) (NN drug) (NNS interactions)) (PP (IN with) (NP (NP (ADJP (RB concomitantly) (VBN administered)) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP450) (NNS enzymes)))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT No) (NN drug) (NNS interactions)) (PP (IN with) (NP (JJ other) (NNS drug2)))) (VP (VBP have) (VP (VBN been) (VP (VBN identified) (SBAR (WHNP (WDT that)) (S (VP (MD would) (VP (VBP warrant) (NP (NP (NN alteration)) (PP (IN of) (NP (CC either) (NP (DT the) (NN drug3) (NN dose)) (CC or) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT the) (JJ other) (NNS drug4))))))))))))))) (. .))))
(S1 (S (S (NP (JJ Certain) (NNS drugs)) (VP (VP (VBP tend) (S (VP (TO to) (VP (VB produce) (NP (NN hyperglycemia)))))) (CC and) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NN loss)) (PP (IN of) (NP (NN blood) (NN glucose) (NN control))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS drugs)) (VP (VBP include) (NP (NP (NP (DT the) (NN drug1)) (CC and) (NP (JJ other) (NNS drug2))) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (JJ oral) (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (CC and) (NP (NN drug12)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN drug1))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN observed) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (NN blood) (NN glucose) (NN control))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN withdrawn) (PP (IN from) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (DT any) (NN evidence)) (PP (IN of) (NP (NN hypoglycemia))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (FW e.) (FW g.)) (, ,) (NP (NN drug2))) (-RRB- -RRB-))) (CC and) (NP (NN drug3))) (VP (VBG containing) (NP (NP (JJ carbohydrate-splitting) (NNS enzymes)) (PRN (-LRB- -LRB-) (NP (FW e.) (FW g.) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5))) (-RRB- -RRB-))))) (VP (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug6)))))) (CC and) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (ADVP (RB concomitantly))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB change) (NP (DT the) (NN bioavailabillty) (NN drug2)) (SBAR (WHADVP (WRB when)) (S (NP (PRP they)) (VP (VBP are) (VP (VBN co-administered) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB require) (NP (NN drug3) (NN dose) (NN adjustment))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (CC either) (DT the) (NP (NNS pharmacokinetics)) (CC or) (NP (NNS pharmacodynamics))) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NP (NN absorption)) (CC or) (NP (NN disposition))) (PP (IN of) (NP (DT the) (NN drug2) (NN drug3))) (PP (IN in) (NP (JJ diabetic) (NNS patients)))))))) (. .)))
(S1 (S (NP (NN drug1)) (VP (VP (MD may) (VP (VB affect) (NP (NN drug2) (NN bioavailabillty)))) (CC and) (VP (MD may) (VP (VP (VB require) (NP (NP (NN dose) (NN adjustment)) (PP (IN of) (NP (NN drug3)))) (PP (IN by) (NP (NP (CD 16) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN %) (NN confidence) (NN interval) (: :) (CD 8-23) (NN %)) (-RRB- -RRB-))))) (, ,) (VP (VB decrease) (NP (NP (NN mean) (NN C) (NN max)) (VP (VBN drug4) (PP (IN by) (NP (NP (CD 26) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN %) (NN confidence) (NN interval) (: :) (CD 16-34) (NN %)) (-RRB- -RRB-))))))) (CC and) (VP (VB decrease) (NP (NP (JJ mean) (NN trough) (NNS concentrations)) (PP (IN of) (NP (NN drug5)))) (PP (IN by) (NP (NP (CD 9) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 90) (NN %)) (NN confidence) (NN limit)) (: :) (NP (NP (ADJP (CD 19) (NN %)) (NN decrease)) (PP (TO to) (NP (ADJP (CD 2) (NN %)) (NN increase))))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN amount)) (PP (IN of) (NP (NN drug1)))) (VP (VBD absorbed) (SBAR (IN while) (S (NP (VBG taking) (NN drug2)) (VP (VBD was) (ADJP (JJ bioequivalent) (PP (TO to) (NP (NP (DT the) (NN amount)) (VP (VBN absorbed) (SBAR (WHADVP (WRB when)) (S (VP (VBG taking) (NP (NN placebo))))))))) (, ,) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (DT the) (NN plasma) (NN AUC) (NNS values))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ peak) (NN plasma) (NN level)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %))) (SBAR (WHADVP (WRB when)) (S (VP (VBG taking) (NP (NN drug2)) (PP (IN due) (TO to) (NP (NP (DT a) (JJ slight) (NN delay)) (PP (IN in) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (ADJP (JJ little) (PP (IN if) (NP (NP (DT any) (ADJP (RB clinically) (JJ significant)) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NP (NNS drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (, ,) (NP (NP (NNS drug4)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug5))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ local) (NNS drug6)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug7)) (CC and) (NP (NN drug8)))) (-RRB- -RRB-))) (, ,) (NP (NP (ADJP (NN drug9) (-LRB- -LRB-) (NN drug10) (-RRB- -RRB-) (JJ -containing)) (NNS preparations)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NNS sunscreens)) (CC and) (NP (DT some) (NN drug11))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NP (CD drug12)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (CD drug13)) (-RRB- -RRB-))) (, ,) (NP (NP (CD drug14)) (PRN (-LRB- -LRB-) (NP (NN sulfa) (NNS medicines)) (-RRB- -RRB-))) (, ,) (NP (CD drug15))) (PRN (-LRB- -LRB-) (NP (NP (NN use)) (PP (IN of) (NP (DT these) (NNS medicines)))) (PP (IN during) (NP (NP (DT the) (NN test) (NN period)) (VP (MD will) (VP (VB affect) (NP (DT the) (NN test) (NNS results)))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ pancreatic) (NNS supplements)) (PRN (-LRB- -LRB-) (S (NP (NP (NN use)) (PP (IN of) (NP (JJ pancreatic) (NNS supplements)))) (VP (MD may) (VP (VB give) (NP (JJ false) (NN test) (NNS results))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (JJ Known) (NN drug) (NNS interactions)) (VP (VBP include) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN drug3))) (PP (IN In) (NP (NP (NNS studies)) (PP (IN with) (NP (NP (JJ male) (NNS rats)) (, ,) (SBAR (WHNP (WDT drug4)) (S (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB inhibit) (NP (DT the) (JJ hepatic) (JJ microsomal) (NN enzyme) (NN system)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 2) (NN mg/kg/day))))))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (VBZ has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB prolong) (NP (NP (DT the) (JJ biological) (NNS half-lives)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN elimination)))) (VP (VBZ is) (ADJP (JJ dependent) (PP (IN on) (NP (DT the) (JJ microsomal) (NN drug) (NN metabolizing) (NN enzyme) (NN system)))))))))))))))) (. .)))
(S1 (S (VP (VBZ Interacts) (PP (IN with) (NP (NN drug1))))))
(S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (VP (MD May) (VP (VB interact) (PP (IN with) (NP (DT the) (NN following)))))) (: :) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (S (NP (DT these) (NNS medicines)) (VP (VP (MD may) (VP (VB make) (ADJP (NN your) (NN condition) (JJ worse)))) (CC and) (VP (VB prevent) (NP (NP (DT the) (NN drug2)) (PP (IN from) (NP (NNP working)))) (ADVP (RB properly))))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))) (PRN (-LRB- -LRB-) (S (NP (DT these) (NNS medicines)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN heart) (NNS problems))))))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Interactions)) (PP (IN for) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (: :) (NP (NN drug3) (NN Therapy)) (: :) (NP (NN drug4))) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ drug5)) (CC and) (ADJP (JJ vasoactive))) (NNS drugs)) (VP (VBG resulting) (PP (IN in) (NP (JJ postural) (NN hypotension)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (JJ Concomitant) (NN drug2))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (JJ metabolic) (NN clearance)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN relevance)) (PP (IN of) (NP (DT this) (NN finding)))) (VP (VBZ is) (ADJP (JJ unclear)))) (. .)))
(S1 (S (S (NP (ADJP (ADJP (JJ Other)) (: :) (ADJP (JJ Concomitant))) (ADJP (ADJP (JJ drug1)) (CC or) (ADJP (JJ hot))) (NNS drinks)) (VP (VP (MD may) (VP (VB increase) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NP (NN flushing)) (CC and) (NP (NN pruritus))))))) (CC and) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN drug) (NN ingestion)))))))))) (. .)))
(S1 (S (S (NP (DT The) (VBG following) (NNS agents)) (VP (MD may) (VP (VB increase) (NP (NP (JJ certain) (NNS actions)) (CC or) (NP (NP (NP (JJ side) (NNS effects)) (PP (IN of) (NP (NN drug1))) (. .)) (NP (NP (NN drug2) (NN drug3)) (PP (IN of) (NP (NP (NN class) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (NP (NNS drug4)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug5) (NN drug6)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (NP (NN drug7)) (-RRB- -RRB-))) (, ,) (NP (NN drug8)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (CC and) (NP (NN drug5))) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (JJ other) (NNS drugs))) (VP (VBG having) (NP (JJ anticholinergic) (NN activity)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP antagonize) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (VBN increased) (JJ intraocular) (NN pressure)))))) (VP (MD may) (VP (VB be) (ADJP (JJ hazardous))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NNS agents)) (PP (JJ such) (IN as) (NP (NN corti) (NNS costeroids))))))))) (. .)) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB affect) (NP (NP (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (NP (JJ various) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NP (ADJP (RB slowly) (VBG dissolving)) (NN dosage) (NNS forms)) (PP (IN of) (NP (NN drug2))))))))))) (: ;)))
(S1 (S (S (NP (VBN increased) (NN serum) (NN drug1) (NNS concentrations)) (VP (MD may) (VP (VB result)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT the) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP alter) (NP (JJ gastrointestinal) (NN motility))))) (, ,) (PP (JJ such) (IN as) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug2))))))))) (, ,) (NP (NP (JJ simultaneous) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN inhibiting) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (JJ gastric) (JJ hydrochloric) (NN acid) (NN secretion)))) (VP (VBP are) (VP (VBN antagonized) (PP (IN by) (NP (NP (NP (NNS agents)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NN achlorhydria))))))) (CC and) (NP (NP (DT those)) (VP (VBN used) (S (VP (TO to) (VP (VB test) (NP (JJ gastric) (NN secretion)))))))))))) (. .)))
(S1 (S (S (NP (DT No) (NN dose) (NN adjustment)) (VP (VBZ is) (ADJP (JJ necessary)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN added) (PP (TO to) (NP (NP (JJ triple-immunosuppression) (NNS regimens)) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (CC either) (NP (NN drug4)) (CC or) (NP (NN drug5))))))))))))) (. .)))
(S1 (S (S (NP (CD Three) (JJ clinical) (NNS trials)) (VP (VBP have) (VP (VBN investigated) (NP (NN drug1) (NN use)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ triple-therapy) (NNS regimens)))))))) (. .)))
(S1 (S (S (NP (NNS Pharmacokinetics)) (VP (VBD were) (VP (VBN assessed) (PP (IN in) (NP (NP (CD two)) (PP (IN of) (NP (DT these) (NNS trials)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Total) (NN body) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (NP (DT an) (JJ average) (CD 22) (NN %)) (CC and) (NP (CD 51) (NN %)))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (, ,) (ADVP (RB respectively)) (, ,) (VP (VBD were) (VP (VBN added) (PP (TO to) (NP (NP (DT a) (NN regimen)) (VP (VBG consisting) (PP (IN of) (NP (NP (NN drug4)) (, ,) (NP (NP (NN USP)) (PRN (-LRB- -LRB-) (NP (JJ MODIFIED)) (-RRB- -RRB-))) (CC and) (NP (NN drug5)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Nonetheless)) (, ,) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (NP (JJ individual) (NN drug1) (NN clearance) (NNS values)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 12-57) (NN mL/h)) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 7-54) (NN mL/h)) (-RRB- -RRB-)))))))))) (VP (VBD did) (RB not) (VP (VB extend) (PP (IN outside) (NP (NP (DT the) (NN range)) (VP (VBN observed) (PP (IN with) (NP (NP (JJ dual) (NN therapy)) (PRN (-LRB- -LRB-) (NP (CD 10-78) (NN mL/h)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (NNS medications)) (VP (VBP have) (VP (VBN been) (VP (VBN administered) (PP (IN in) (NP (NP (NP (JJ clinical) (NNS trials)) (PP (IN with) (NP (NN drug1))) (PP (IN with) (NP (NP (DT no) (NN increase)) (PP (IN in) (NP (JJ adverse) (NNS reactions)))))) (: :) (NP (NP (NN ATG/ALG)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (NN blood) (NNS levels)) (VP (VP (MD may) (VP (VB be) (VP (VBN increased)))) (CC and) (VP (VBD prolonged) (PP (IN by) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (NP (NP (NP (NN Drug) (NNS Interactions)) (PP (IN with) (NP (NN drug1)))) (: :) (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .))))
(S1 (S (S (SBAR (IN If) (S (NP (DT the) (NNS drugs)) (VP (VBP are) (VP (VBN used) (ADVP (RB together)))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (IN because) (S (NP (JJ unexpected) (NN hypotension)) (VP (MD could) (VP (VB result) (PP (IN from) (NP (NP (NN beta-blocker) (NN inhibition)) (PP (IN of) (NP (NP (DT the) (JJ sympathetic) (NN reflex) (NN response)) (PP (TO to) (NP (NN drug1))))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN Drug) (NNS Interactions)) (, ,) (NP (JJ General))) (: :) (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (DT no) (JJ formal) (NN interaction) (NNS studies)))))) (, ,) (NP (JJ intravenous) (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (ADVP (RB safely)) (PP (IN with) (NP (NP (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC and) (NP (NN sublingual)) (NP (NN drug3)))))))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (VP (VBN limited) (PP (VBP experience) (PP (IN with) (NP (NP (JJ concomitant) (NN drug1)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))) (PRN (-LRB- -LRB-) (CC both) (NP (NP (NN drug6) (JJ -like)) (CC and) (NP (NN loop))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ significant) (NN drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS studies)) (PP (IN of) (NP (NP (NN drug1)) (VP (VP (VBN given) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (JJ oral) (NN drug7))) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))))))) (, ,) (CC or) (VP (VBN given) (PP (IN with) (NP (NN drug8))) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN heart) (NN failure)) (PRN (-LRB- -LRB-) (NP (NN NYHA) (NN class) (CD II) (CC and) (CD III)) (-RRB- -RRB-)))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VP (VBZ is) (RB not) (ADVP (RB significantly)) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NN system))))) (CC and) (PP (IN at) (NP (JJ therapeutic) (NNS concentrations))) (VP (VBZ has) (NP (NP (DT no) (NNS effects)) (PP (IN on) (NP (NN P450) (NNS enzymes)))))))) (, ,) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP inhibit)) (CC or) (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT those) (NNS enzymes))))))))))) (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (JJ Reversible) (NNS increases)) (PP (IN in) (NP (NP (NN serum) (NN drug2) (NNS concentrations)) (CC and) (NP (NN toxicity))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug3)) (PP (PP (IN with) (NP (NN drug4))) (, ,) (CC and) (PP (IN with) (NP (DT some) (NN drug5)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (NN increase)) (PP (IN in) (NP (NN serum) (NN drug1) (NN concentration)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NN drug3))))))) (, ,) (SBAR (IN so) (S (NP (NP (JJ careful) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN drug4) (NNS levels)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN during) (NP (JJ concomitant) (NN use))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN Potential)) (PP (IN for) (NP (JJ Other) (NNS Drugs)))) (VP (TO to) (VP (VB Affect) (NP (NN drug1))))) (: :) (S (NP (CC Both) (NP (NN CYP1A2)) (CC and) (NP (NN CYP2D6))) (VP (VBP are) (ADJP (JJ responsible) (PP (IN for) (NP (NN drug2) (NN metabolism))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (NN CYP1A2)))) (: :) (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN CYP1A2)))) (, ,)))) (VP (VBZ results) (PP (IN in) (NP (NP (NP (RB approximately) (DT a) (ADJP (RB 6-fold)) (NN increase)) (PP (IN in) (NP (NN AUC)))) (CC and) (NP (NP (RB about) (DT a) (JJ 2.5-fold) (NN increase)) (PP (IN in) (NP (NP (NN Cmax)) (PP (IN of) (NP (NN drug3)))))))))) (. .))))
(S1 (S (S (S (NP (DT Some) (NN drug1)) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB have) (NP (JJ similar) (NNS effects))))))))) (CC and) (S (NP (DT these) (NNS combinations)) (VP (MD should) (VP (VB be) (VP (VBN avoided)))))) (. .)))
(S1 (S (NP (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (NN CYP2D6)))) (: :) (S (SBAR (IN Because) (S (NP (NN CYP2D6)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NN drug1) (NN metabolism))))))) (, ,) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NP (JJ potent) (NNS inhibitors)) (PP (IN of) (NP (NN CYP2D6)))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJR higher) (NNS concentrations)) (PP (IN of) (NP (NN drug3)))))))) (. .))))
(S1 (S (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 20) (NN mg)) (NN QD)) (-RRB- -RRB-))) (VP (VBD increased) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 40) (NN mg)) (NN QD)) (-RRB- -RRB-))))) (PP (IN by) (NP (QP (RB about) (CD 60)) (NN %))))) (, ,) (CC and) (S (NP (NP (JJR greater) (NNS degrees)) (PP (IN of) (NP (NN inhibition)))) (VP (VBP are) (VP (VBN expected) (PP (IN with) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (JJ Similar) (NNS effects)) (VP (MD would) (VP (VB be) (VP (VBN expected) (PP (IN with) (NP (NP (JJ other) (JJ potent) (NN CYP2D6) (NNS inhibitors)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (, ,) (NP (NNS drug2)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (NN Potential)) (PP (IN for) (NP (NN drug1)))) (VP (TO to) (VP (VB Affect) (NP (JJ Other) (NNS Drugs))))) (: :) (S (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NN CYP1A2))))) (: :) (S (NP (ADJP (FW In) (FW vitro)) (NN drug) (NN interaction) (NNS studies)) (VP (VBP demonstrate) (SBAR (IN that) (S (S (NP (NN drug2)) (VP (VBZ does) (RB not) (VP (VB induce) (NP (NN CYP1A2) (NN activity))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB have) (NP (NP (DT a) (ADJP (RB clinically) (JJ significant)) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN CYP1A2) (NNS substrates)))))))))))))))) (. .)))
(S1 (S (S (S (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NN CYP2D6))))) (: :) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ moderate) (NN inhibitor)) (PP (IN of) (NP (NN CYP2D6))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PRN (-LRB- -LRB-) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (ADJP (CD 60) (NN mg)) (NN BID))))) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (DT a) (JJ single) (JJ 50-mg) (NN dose)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (DT a) (NN CYP2D6) (NN substrate)))))))))))) (, ,) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug3)))) (VP (VBD increased) (ADVP (RB 3-fold)))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (ADVP (RB extensively)) (VBN metabolized) (PP (IN by) (NP (DT this) (NN isozyme))))))) (CC and) (SBAR (WHNP (WDT which)) (S (VP (VBP have) (NP (DT a) (JJ narrow) (JJ therapeutic) (NN index)))))) (, ,) (PP (VBG including) (NP (NP (NP (JJ certain) (NNS drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (PRN (-LRB- -LSB-) (NP (NN drug4)) (-RRB- -RSB-))) (, ,) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7))))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug8)) (CC and) (NP (NP (NN drug9)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug10))) (, ,) (NP (NN drug11)) (-RRB- -RRB-)))) (, ,)))))) (VP (MD should) (VP (VB be) (VP (VBN approached) (PP (IN with) (NP (NN caution)))))) (. .)))
(S1 (S (S (S (NP (NN Plasma) (NN drug1) (NNS concentrations)) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN monitored)))))))) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT the) (NN drug2)))) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN reduced) (SBAR (IN if) (S (NP (DT a) (NN drug3)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NN drug4))))))))))))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ serious) (JJ ventricular) (NNS arrhythmias)) (CC and) (NP (NN sudden) (NN death)))) (VP (ADVP (RB potentially)) (VBN associated) (PP (IN with) (NP (NP (JJ elevated) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1))))))))) (, ,) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN co-administered))))) (. .)))
(S1 (S (S (S (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NN CYP3A))))) (: :) (S (NP (NP (NNS Results)) (PP (IN of) (NP (ADJP (FW in) (FW vitro)) (NNS studies)))) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VP (VB inhibit)) (CC or) (VP (VB induce) (NP (NN CYP3A) (NN activity)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD May) (VP (VB Have) (NP (NP (DT a) (ADJP (RB Clinically) (JJ Important)) (NN Interaction)) (PP (IN with) (NP (NP (DT the) (NP (JJ Following) (JJ Other) (NNS Drugs))) (: :) (NP (NN drug2)) (: :)))) (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBD were) (VP (VBN administered) (ADVP (NP (JJ several) (NNS hours)) (RB apart))) (ADVP (RB so)) (SBAR (IN that) (S (S (NP (NP (JJ peak) (NNS concentrations)) (PP (IN of) (NP (DT each)))) (VP (MD would) (VP (VB coincide)))) (, ,) (S (NP (NN drug5)) (VP (VBD did) (RB not) (VP (VB increase) (NP (NP (DT the) (NN impairment)) (PP (IN of) (NP (NP (JJ mental) (CC and) (NN motor) (NNS skills)) (VP (VBN caused) (PP (IN by) (NP (NN drug6)))))))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (NP (JJ drug1) (JJ clinical) (NNS trials)) (NN database))) (, ,) (NP (CD three) (JJ drug2) (JJ -treated) (NNS patients)) (VP (VBD had) (NP (NN liver) (NN injury)) (SBAR (IN as) (S (VP (VBN manifested) (PP (IN by) (NP (NP (NP (NN ALT)) (CC and) (NP (JJ total) (NN bilirubin))) (NNS elevations))) (, ,) (PP (IN with) (NP (NP (NN evidence)) (PP (IN of) (NP (NN obstruction)))))))))) (. .)))
(S1 (S (S (S (NP (JJ Substantial) (NN intercurrent) (NN drug1) (NN use)) (VP (VBD was) (ADJP (JJ present) (PP (IN in) (NP (NP (DT each)) (PP (IN of) (NP (DT these) (NNS cases)))))))) (, ,) (CC and) (S (NP (DT this)) (VP (MD may) (VP (VB have) (VP (VBN contributed) (PP (TO to) (NP (NP (DT the) (NNS abnormalities)) (VP (VBN seen))))))))) (. .)))
(S1 (S (NP (NP (NN CNS) (NN Acting) (NNS Drugs)) (: :) (S (PP (IN Given) (NP (NP (DT the) (JJ primary) (NN CNS) (NNS effects)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN taken) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN or)) (VP (VBN substituted) (PP (IN for) (NP (NP (JJ other) (ADJP (RB centrally) (VBG acting)) (NNS drugs)) (, ,) (PP (VBG including) (NP (NP (DT those)) (PP (IN with) (NP (NP (DT a) (JJ similar) (NN mechanism)) (PP (IN of) (NP (NN action)))))))))))))))))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN Potential)) (PP (IN for) (NP (NP (NN Interaction)) (PP (IN with) (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP Affect) (NP (JJ Gastric) (NN Acidity)))))))))) (: :) (NP (NN drug1))) (VP (VBZ has) (NP (NP (DT an) (JJ enteric) (NN coating)) (SBAR (WHNP (WDT that)) (S (VP (VBZ resists) (NP (NN dissolution)) (PP (IN until) (S (VP (VBG reaching) (NP (NP (DT a) (NN segment)) (PP (IN of) (NP (NP (DT the) (JJ gastrointestinal) (NN tract)) (SBAR (WHADVP (WRB where)) (S (NP (DT the) (NN pH)) (VP (VBZ exceeds) (NP (CD 5.5))))))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (ADJP (RB extremely) (JJ acidic)) (NNS conditions))) (, ,) (NP (NP (NN drug1)) (, ,) (VP (VBN unprotected) (PP (IN by) (NP (DT the) (JJ enteric) (NN coating)))) (, ,)) (VP (MD may) (VP (VB undergo) (NP (NN hydrolysis)) (S (VP (TO to) (VP (VB form) (NP (NN naphthol)))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN advised) (PP (IN in) (S (VP (VBG using) (NP (NP (NN drug1)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNS conditions)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (JJ slow) (NP (NP (JJ gastric) (NN emptying)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (DT some) (NNS diabetics))) (-RRB- -RRB-)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP raise) (NP (DT the) (JJ gastrointestinal) (NN pH)))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT an) (JJR earlier) (NN release)) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (CC -) (NP (CC and) (NP (NP (NN drug3) (JJ -containing) (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 51) (NN mEq)) (-RRB- -RRB-))) (CC or) (NP (NN drug5))))) (PP (IN with) (NP (NN drug6)))) (, ,) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NP (NN rate)) (CC or) (NP (NN extent))) (PP (IN of) (NP (NN drug7) (NN absorption))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT a) (JJ 40-mg) (JJ oral) (NN dose)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ unknown)) (SBAR (IN whether) (S (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ affects) (NP (NN drug2) (NN absorption))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS studies)) (PP (IN in) (NP (JJ normal) (NNS volunteers))))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (JJ pharmacodynamic) (NN interaction)) (PP (IN between) (NP (NP (JJ intravenous) (NN drug1)) (CC and) (NP (DT either) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN drug1)) (VP (VBZ has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (NN platelet) (NN function))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (NN potential)) (PP (IN for) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (JJ bleeding)))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (NNS patients)) (VP (VBN maintained) (PP (IN on) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NN drug1)) (VP (VBD was) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC and) (NP (JJ other) (NNS medications))))))) (. .)))
(S1 (S (S (NP (NP (JJ Intravenous) (NN infusion)) (PP (IN of) (NP (NN drug1)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NN clearance) (-LRB- -LRB-) (NNS pharmacokinetics) (-RRB- -RRB-)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (JJ clinical) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted)))))) (, ,) (NP (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (PP (IN of) (NP (NN drug1)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT no) (JJ relevant) (NN inhibition)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN drug) (NN metabolism)))) (VP (MD would) (VP (VB be) (VP (VBN expected)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Oral) (NN drug1) (JJ Multiple) (NNS doses)) (PP (IN of) (NP (NN drug2)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (NP (DT the) (JJ estrogenic) (NN component)) (PP (IN in) (NP (JJS most) (JJ oral) (NNS drug4)))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (DT the) (JJ clinical) (NN significance)) (VP (VBZ is) (RB not) (VP (VBN known))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug1)) (VP (VB be) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (ADJP (RB intravenously) (VBN administered)) (NN drug2)))) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg)) (-RRB- -RRB-))))) (VP (VBD reduced) (NP (NP (DT the) (JJ oral) (NN absorption)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (ADJP (CD 400) (NN mg)) (NN dose)) (PP (IN of) (NP (NN drug3)))) (VP (VBN administered) (PP (VBG following) (NP (DT a) (NN meal))))))) (, ,) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NP (NP (DT a) (ADJP (CD 27) (NN %)) (NN decrease)) (PP (IN in) (NP (JJ mean) (NN Cmax)))) (CC and) (NP (NP (DT a) (ADJP (CD 22) (NN %)) (NN decrease)) (PP (IN in) (NP (JJ mean) (NN AUC))))))))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (DT the) (JJ clinical) (NN significance)) (VP (VBZ is) (RB not) (VP (VBN known))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug1)) (VP (VB be) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN As) (PP (IN with) (NP (JJ other) (NNS drug2)))) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NN drug4)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NN exposure)) (PP (IN of) (NP (NN drug5))))))) (, ,) (PP (IN with) (NP (NP (NP (DT a) (ADJP (CD 49) (NN %)) (NN increase)) (PP (IN in) (NP (NN mean) (NN Cmax)))) (, ,) (NP (NP (DT a) (CD 122) (NN %) (NN increase)) (PP (IN in) (NP (JJ mean) (NN AUC)))) (, ,) (CC and) (NP (NP (DT a) (CD 53) (NN %) (NN increase)) (PP (IN in) (NP (NN half-life)))))))) (. .))))
(S1 (S (S (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (ADVP (RB drug1)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (ADVP (RB occasionally)) (VP (VB induce) (NP (DT a) (JJ positive) (JJ direct) (NN Coombs) (NN test)))))))) (. .)))
(S1 (S (NP (NP (DT A) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (DT the) (NN urine)))) (VP (MD may) (VP (VB occur) (PP (PP (IN with) (NP (NP (NN copper) (NN reduction) (NNS tests)) (PRN (-LRB- -LRB-) (NP (NP (NNP Benedicts)) (CC or) (NP (NNP Fehlings)) (NP (NN solution))) (CC or) (PP (IN with) (NP (JJ CLINITEST) (NNS tablets))) (-RRB- -RRB-)))) (, ,) (CC but) (PP (RB not) (IN with) (NP (NP (JJ enzyme-based) (NNS tests)) (PP (IN for) (NP (NP (NN glycosuria)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN CLINISTIX)) (, ,) (NP (NN TES-TAPE))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (SBAR (IN As) (S (NP (DT a) (JJ false-negative) (NN result)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (DT the) (NN ferricyanide) (NN test))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (CC either) (DT the) (NP (NN glucose) (NN oxidase)) (CC or) (NP (NN hexokinase) (NN method))) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (NP (NP (NN blood/plasma) (NN glucose) (NNS levels)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NP (JJ several) (JJ human) (NN drug) (NN interaction) (NNS studies)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (PRP it)) (VP (VBD was) (VP (VBN administered) (PP (IN with) (NP (NP (DT a) (NN meal)) (CC and) (NP (DT the) (NN test) (NN drug)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB have) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD decreased) (NP (NP (DT the) (NP (NN Cmax)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (NP (NN sustained-release) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))))) (PP (IN by) (NP (NP (QP (RB approximately) (CD 31)) (NN %)) (CC and) (NP (CD 11) (NN %)) (, ,) (ADVP (RB respectively)))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ high) (NN degree)) (PP (IN of) (NP (NN variability))) (PP (IN in) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug1))))))))) (, ,) (NP (NP (DT the) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN finding)))) (VP (VBZ is) (ADJP (JJ unclear)))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS studies))) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4))))) (VP (VBD did) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (JJ lipid-lowering) (NN activity)) (PP (IN of) (NP (DT the) (NN drug5)))))))) (. .)))
(S1 (S (S (NP (JJ Other) (NNS drugs)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBG administering) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (NP (NNS alterations)) (PP (IN in) (NP (NN blood) (NNS levels)))) (VP (MD could) (VP (VB have) (NP (DT a) (ADJP (RB clinically) (JJ significant)) (NN effect)) (PP (IN on) (NP (NP (NN safety)) (CC or) (NP (NN efficacy)))))))))))) (, ,) (NP (NNS physicians)) (VP (MD should) (VP (VB consider) (NP (NP (NN monitoring) (NN drug) (NNS levels)) (CC or) (NP (NNS effects)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution))) (PP (PP (TO to) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG taking) (NP (NP (JJ other) (NN drug2)) (CC or) (NP (NN drug3))))))) (, ,) (PP (VBG including) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6)))))) (, ,) (CC or) (PP (TO to) (NP (NP (DT those)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ psychiatric) (NN disorder)) (PRN (-LRB- -LRB-) (PP (VBG including) (NP (NP (JJ manic-depressive) (NN illness)) (CC and) (NP (NN schizophrenia)))) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB have) (NP (DT an) (JJ additive) (NN CNS) (JJ depressant) (NN effect)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (CC either) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC or) (NP (NN drug5)))))))))))))) (. .)))
(S1 (S (NP (NP (NN Drug) (NN Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NP (NN Prolongation)) (PP (IN of) (NP (DT the) (NN template) (JJ bleeding) (NN time)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (JJ continuous) (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NN drug1))) (PP (IN at) (NP (NP (NNS dosages)) (VP (VBG exceeding) (NP (CD 24) (NN g/day))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Platelet) (NN function) (NNS studies)) (PP (IN in) (NP (DT these) (NNS patients)))) (VP (VBP have) (RB not) (VP (VBN demonstrated) (NP (DT any) (JJ significant) (NN platelet) (NN dysfunction))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (PP (IN at) (NP (NP (JJ high) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 7.4) (NN mMol/L) (CC or) (CD 0.97)) (NNS mg/mL)) (CC and) (NP (JJR greater))) (-RRB- -RRB-)))) (NP (NN drug1)) (VP (VBZ inhibits) (NP (NP (NN ADP) (CC and) (JJ collagen-induced) (NN platelet) (NN aggregation)) (, ,) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NP (NN ATP)) (CC and) (NP (NN serotonin))))) (, ,) (CC and) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN fibrinogen))) (PP (TO to) (NP (DT the) (NNS platelets))))) (PP (IN in) (NP (DT a) (JJ concentration-response) (NN manner))))))))) (. .)))
(S1 (S (S (PP (VBG Following) (NP (NP (DT a) (CD 10) (NN g) (NN bolus)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NP (JJ transient) (NN peak) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (QP (CD 4.6) (NN mMol/L) (CC or) (CD 0.60)) (NN mg/mL)))) (VP (VBP have) (VP (VBN been) (VP (VBN obtained))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN concentration)) (PP (IN of) (NP (NN drug1))) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB maintain) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN fibrinolysis))))))))) (VP (VBZ is) (NP (QP (CD 0.99) (NN mMol/L) (CC or) (CD 0.13)) (NN mg/mL)))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (DT a) (ADJP (CD 5) (NN g)) (NN bolus)) (VP (VBN followed) (PP (IN by) (NP (QP (CD 1) (TO to) (CD 1.25)) (NN g/hr))))))) (VP (MD should) (VP (VP (VB achieve)) (CC and) (VP (VB sustain) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (CD 0.13) (NN mg/mL)))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (NNS concentrations)) (SBAR (WHNP (WDT which)) (S (VP (VBP have) (VP (VBN been) (VP (VBN obtained) (ADVP (FW in) (FW vivo)) (ADVP (RB clinically)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ normal) (JJ renal) (NN function))))))))))) (VP (VBP are) (ADJP (ADJP (RB considerably) (JJR lower)) (PP (IN than) (NP (NP (DT the) (ADJP (FW in) (FW vitro)) (NNS concentrations)) (VP (VBN found) (S (VP (TO to) (VP (VB induce) (NP (NNS abnormalities)) (PP (IN in) (NP (NN platelet) (NN function) (NNS tests)))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (JJR higher) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ severe) (JJ renal) (NN failure)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Certain) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)))) (. .)))
(S1 (S (NP (DT No) (NN information) (JJ available))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (VBN Increased) (NN nephrotoxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (VBG following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (PP (IN As) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NP (JJ high) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 100) (NNS micrograms/mL)) (-RRB- -RRB-))))))))) (VP (MD may) (VP (VP (VB interfere) (PP (IN with) (NP (NP (NN measurement)) (PP (IN of) (NP (NP (NN serum)) (CC and) (NP (NN urine)) (NP (NN creatinine) (NNS levels)))))) (PP (IN by) (NP (DT the) (NN Jaff) (NN reaction)))) (, ,) (CC and) (VP (VB produce) (NP (NP (JJ false) (NNS increases)) (PP (IN of) (NP (JJ modest) (NN degree))) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NN creatinine)) (VP (VBD reported)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Serum) (NNS samples)) (PP (IN from) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN analyzed) (PP (IN for) (NP (NN creatinine))) (SBAR (IN if) (S (VP (VBN withdrawn) (PP (IN within) (NP (NP (CD 2) (NNS hours)) (PP (IN of) (NP (NN drug) (NN administration)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ High) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN in) (NP (DT the) (NN urine)))))) (VP (MD may) (VP (VP (VB interfere) (PP (IN with) (NP (NP (NN measurement)) (PP (IN of) (NP (JJ urinary) (NNS 17-hydroxy-corticosteroids))))) (PP (IN by) (NP (DT the) (NN Porter-Silber) (NN reaction)))) (, ,) (CC and) (VP (VB produce) (NP (NP (JJ false) (NNS increases)) (PP (IN of) (NP (NP (JJ modest) (NN degree)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (VP (VBN reported))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (DT the) (NN urine)))) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (NP (DT This)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (JJ CLINITEST) (JJ reagent) (NNS tablets))))))))
(S1 (S (. .)))
(S1 (S (NP (NP (NP (JJ Registered) (NN trademark)) (PP (IN of) (NP (NN Ames) (NN Company)))) (, ,) (NP (NP (NN Division)) (PP (IN of) (NP (NN Miles) (NNS Laboratories)))) (, ,) (NP (NNP Inc.)))))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (JJ Positive) (JJ direct) (NN Coombs) (NNS tests)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (DT the) (NN drug1))))))))) (. .)))
(S1 (S (PP (PP (IN In) (NP (JJ hematologic) (NNS studies))) (CC or) (PP (IN in) (NP (NP (NN transfusion) (NN cross-matching) (NNS procedures)) (SBAR (WHADVP (WRB when)) (S (NP (NN anti-globulin) (NNS tests)) (VP (VBP are) (VP (VBN performed) (PP (PP (IN on) (NP (DT the) (JJ minor) (NN side))) (CC or) (PP (IN in) (NP (NP (NN Coombs) (NN testing)) (PP (IN of) (NP (NP (NNS newborns)) (SBAR (WHNP (WP$ whose) (NNS mothers)) (S (VP (VBP have) (VP (VBN received) (NP (NN drug1)) (PP (IN before) (NP (NN parturition))))))))))))))))))) (, ,) (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN recognized) (SBAR (IN that) (S (NP (DT a) (JJ positive) (NN Coombs) (NN test)) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (DT the) (NN drug))))))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (VP (NN None) (VBN known))) (. .)))
(S1 (S (S (S (NP (JJ Drug-Drug) (NNS Interactions)) (NP (NN drug1))) (: :) (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN contraindicated))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (PP (IN at) (NP (NP (NP (CD 400) (NN mg) (JJ BID)) (PRN (-LRB- -LRB-) (NP (DT the) (JJ usual) (NN prescription) (NN dose)) (-RRB- -RRB-))) (VP (VBN co-administered) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mcg) (JJ BID)) (-RRB- -RRB-))))))) (PP (IN for) (NP (CD 7) (NNS days)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB increase) (NP (NN drug3) (NN plasma) (NNS levels)) (PP (IN by) (NP (CD 58) (NN %))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (ADJP (CD 100) (NN mg)) (NN BID)) (PRN (-LRB- -LRB-) (NP (NN OTC) (NN dose)) (-RRB- -RRB-))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (CD 13) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NN drug2) (NN plasma) (NNS levels)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mcg) (JJ single) (NN dose)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (DT No) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN at) (NP (NP (JJ intermediate) (NNS doses)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (SBAR (IN If) (S (NP (DT a) (NN patient)) (VP (VBZ requires) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (NN therapy)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (NN drug6)) (CC and) (NP (NN drug7) (NN s))) (-RRB- -RRB-)))) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (NNS alternatives)) (PP (TO to) (NP (NN drug8))))) (, ,) (SBAR (IN as) (S (NP (DT these) (NNS agents)) (VP (VBP have) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ pharmacokinetic) (NN profile)) (PP (IN of) (NP (NN drug9)))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .))))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN drug3) (NN peak) (NN plasma) (NNS levels)) (PP (IN of) (NP (CD 42) (NN %))))))) (, ,) (SBAR (IN although) (S (NP (NP (JJ overall) (NN exposure)) (PP (TO to) (NP (NN drug4)))) (VP (VBD was) (RB not) (ADVP (RB significantly)) (VP (VBN increased))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT an) (NN analysis)) (PP (IN of) (NP (NP (DT the) (JJ supraventricular) (NNS arrhythmia)) (CC and) (NP (JJ DIAMOND) (NN patient) (NNS populations)))))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN occurrence)) (PP (IN of) (NP (NN torsade) (NN de) (NNS pointes)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN at) (NP (NP (NP (CD 400) (NN mg) (RB daily)) (PRN (-LRB- -LRB-) (NP (DT the) (JJ maximum) (JJ approved) (NN prescription) (NN dose)) (-RRB- -RRB-))) (VP (VBN co-administered) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mcg) (JJ BID)) (-RRB- -RRB-))))))) (PP (IN for) (NP (CD 7) (NNS days)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB increase) (NP (NP (NP (NN drug3) (NN Cmax)) (PP (IN by) (NP (NP (NP (CD 53) (NN %)) (PP (IN in) (NP (NNS males)))) (CC and) (NP (NP (CD 97) (NN %)) (PP (IN in) (NP (NNS females))))))) (, ,) (CC and) (NP (NN AUC))) (PP (IN by) (NP (NP (NP (CD 41) (NN %)) (PP (IN in) (NP (NNS males)))) (CC and) (NP (NP (CD 69) (NN %)) (PP (IN in) (NP (NNS females))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (UCP (ADVP (RB Alone)) (CC or) (PP (IN in) (NP (NP (NN Combination)) (PP (IN with) (NP (NN drug2))))))) (: :) (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug3))) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug4))))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .))))
(S1 (S (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (UCP (ADVP (RB Alone)) (CC or) (PP (IN in) (NP (NP (NN Combination)) (PP (IN with) (NP (NN drug3))))))) (: :) (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug4))) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug5))))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .))))
(S1 (S (NP (NN drug1) (NP (ADJP (CD 50) (NN mg)) (NN QD)) (CC or) (NP (NN drug2) (: /) (NN drug3) (CD 50/100) (NN mg) (NN QD))) (VP (VBD was) (VP (VBN co-administered) (PP (IN with) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mcg) (JJ BID)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (CD 5) (NNS days)) (PRN (-LRB- -LRB-) (NP (NP (VBG following) (CD 2) (NNS days)) (PP (IN of) (NP (NP (NN drug5) (NN use)) (PP (IN at) (NP (NN half) (NN dose)))))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (ADVP (RB alone)))))) (, ,) (NP (NN drug2) (NN AUC)) (VP (VBD increased) (PP (IN by) (NP (NP (CD 27) (NN %)) (CC and) (NP (NN Cmax)))) (PP (IN by) (NP (CD 21) (NN %))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT the) (JJ pharmacodynamic) (NN effect)) (VP (VBD increased) (PP (PP (IN by) (NP (NP (CD 197) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN QTc) (NN increase)) (PP (IN over) (NP (NN time)))) (-RRB- -RRB-)))) (CC and) (PP (IN by) (NP (NP (CD 95) (NN %)) (PRN (-LRB- -LRB-) (NP (NN maximum) (NN QTc) (NN increase)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT the) (JJ pharmacodynamic) (NN effect)) (VP (VBD increased) (PP (PP (IN by) (NP (NP (CD 190) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN QTc) (NN increase)) (PP (IN over) (NP (NN time)))) (-RRB- -RRB-)))) (CC and) (PP (IN by) (NP (NP (CD 84) (NN %)) (PRN (-LRB- -LRB-) (NP (NN Maximum) (NN QTc) (NN increase)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ pharmacodynamic) (NNS effects)) (VP (MD can) (VP (VB be) (VP (VBN explained) (PP (IN by) (NP (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN drug1) (NN exposure)))))) (CC and) (NP (NP (DT the) (NNS reductions)) (PP (IN in) (NP (NN serum) (NN potassium)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ DIAMOND) (NNS trials))) (, ,) (NP (CD 1252) (NNS patients)) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (ADVP (ADVP (RB concomitantly)) (SBAR (WHPP (IN of) (WHNP (WP whom))) (S (NP (CD 493)) (VP (VBD died) (PP (VBN compared) (PP (TO to) (NP (NP (CD 508) (NNS deaths)) (PP (IN among) (NP (NP (DT the) (CD 1248) (NNS patients)) (VP (VBG receiving) (NP (NP (NN placebo)) (CC and) (NP (NN drug3)))))))))))))))) (. .)))
(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 229) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD had) (NP (NP (NN drug1)) (VP (VBN added) (PP (TO to) (NP (NP (PRP$ their) (JJ concomitant) (NNS medications)) (PP (IN in) (NP (DT the) (JJ DIAMOND) (NNS trials)))))))))))) (, ,) (NP (NP (DT the) (NNS patients)) (PP (IN on) (NP (NN drug2)))) (VP (VBD had) (NP (NP (DT a) (ADJP (RB non-significantly) (VBN reduced)) (JJ relative) (NN risk)) (PP (IN for) (NP (NP (NN death)) (PP (IN of) (NP (CD 0.68)))))) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (NN %)) (ADJP (JJR CI) (NP (CD 0.376)))) (, ,) (NP (CD 1.230)) (-RRB- -RRB-))) (. .)))
(S1 (S (S (NP (NP (JJ Potential) (NN Drug) (NNS Interactions)) (NN drug1)) (VP (VBZ is) (VP (VBN eliminated) (PP (IN in) (NP (DT the) (NN kidney))) (PP (IN by) (NP (NN cationic) (NN secretion)))))) (. .)))
(S1 (S (S (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (JJ renal) (NN cationic) (NN secretion)))) (VP (VBP are) (VP (VBN contraindicated) (PP (IN with) (NP (NN drug1)))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB actively)) (VP (VBN secreted) (PP (IN via) (NP (NP (DT this) (NN route)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3)))) (-RRB- -RRB-))))))))) (VP (MD should) (VP (VB be) (VP (VBN co-administered) (PP (IN with) (NP (NN care))) (SBAR (IN as) (S (NP (PRP they)) (VP (MD might) (VP (VB increase) (NP (NN drug4) (NNS levels))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (TO to) (NP (DT a) (JJ small) (NN extent))) (PP (IN by) (NP (NP (DT the) (NN CYP3A4) (NN isoenzyme)) (PP (IN of) (NP (DT the) (NN cytochrome) (NN P450) (NN system)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (DT the) (NN CYP3A4) (NN isoenzyme)))) (VP (MD could) (VP (VB increase) (NP (JJ systemic) (NN drug1) (NN exposure))))) (. .)))
(S1 (S (S (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (NP (DT this) (NN isoenzyme)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN grapefruit) (NN juice)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11))) (-RRB- -RRB-))))) (VP (MD should) (VP (VB be) (ADVP (RB cautiously)) (VP (VBN coadministered) (PP (IN with) (NP (NN drug12))) (SBAR (IN as) (S (NP (PRP they)) (VP (MD can) (ADVP (RB potentially)) (VP (VB increase) (NP (NN drug13) (NNS levels)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ is) (RB not) (NP (NP (DT an) (NN inhibitor)) (PP (PP (IN of) (NP (NN CYP3A4))) (CC nor) (PP (IN of) (NP (NP (JJ other) (NN cytochrome) (NN P450) (NNS isoenzymes)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN CYP2C9))) (, ,) (NP (NNS CYP2D6)) (-RRB- -RRB-))))))) (CC and) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4)))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NN Drug) (NN Interaction) (NN Information) (NN drug1)) (: :) (S (NP (NP (NNS Studies)) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug2)) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NNS patients))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN occurrence)) (PP (IN of) (NP (NN torsade) (NN de) (NNS pointes)))))))) (. .)))
(S1 (S (NP (PRP It)) (VP (VBZ is) (RB not) (ADJP (JJ clear)) (SBAR (IN whether) (S (NP (DT this)) (VP (VBZ represents) (NP (NP (NP (DT an) (NN interaction)) (PP (IN with) (NP (NN drug1)))) (CC or) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (ADJP (ADJP (RBR more) (JJ severe)) (ADJP (JJ structural))) (NN heart) (NN disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug2))))))))))) (: ;)))
(S1 (S (S (NP (JJ structural) (NN heart) (NN disease)) (VP (VBZ is) (NP (NP (DT a) (JJ known) (NN risk) (NN factor)) (PP (IN for) (NP (NN arrhythmia)))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN increase)) (PP (IN in) (NP (NN mortality)))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)) (PP (IN as) (NP (JJ concomitant) (NN medication))))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NNS Drugs)) (: :) (S (PP (IN In) (NP (JJ healthy) (NNS volunteers))) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NP (NN hormone) (NN replacement) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (VBN conjugated) (NP (NN drug6)) (CC and) (NP (NN drug7))))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (NP (QP (CD drug9) (CC and) (CD drug10)) (NNS s)) (-RRB- -RRB-))) (CC and) (NP (NN drug11))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug12))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNS studies)) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (DT the) (NP (NNS pharmacokinetics)) (CC or) (NP (NNS pharmacodynamics))) (PP (IN of) (NP (NP (NN drug2)) (, ,) (CC or) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (CD 40) (NN mg)) (ADVP (RB twice) (RB daily))) (-RRB- -RRB-))) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (JJ oral) (NN drug6))))))))))))))) (. .)))
(S1 (S (S (NP (NN Population) (JJ pharmacokinetic) (NNS analyses)) (VP (VBD were) (VP (VBN conducted) (PP (IN on) (NP (NP (NN plasma) (NN concentration) (NNS data)) (PP (IN from) (NP (NP (CD 1445) (NNS patients)) (PP (IN in) (NP (JJ clinical) (NNS trials))))))) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ concomitant) (NNS medications))) (PP (IN on) (NP (NP (NP (NN clearance)) (CC or) (NP (NN volume))) (PP (IN of) (NP (NP (NN distribution)) (PP (IN of) (NP (NN drug1)))))))))))))) (. .)))
(S1 (S (S (NP (JJ Concomitant) (NNS medications)) (VP (VBD were) (VP (VBN grouped) (PP (IN as) (NP (NP (NN drug1)) (, ,) (NP (JJ oral) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NP (NP (NNS inducers)) (PP (IN of) (NP (NN CYP3A4)))) (, ,) (NP (NP (NP (NNS substrates)) (CC and) (NP (NNS inhibitors))) (PP (IN of) (NP (NN CYP3A4)))) (, ,) (NP (NP (NNS substrates)) (CC and) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NN P-glycoprotein)))))) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NP (NNS substrates)) (CC and) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (JJ tubular) (JJ organic) (NN cation) (NN transport))))) (, ,) (CC and) (NP (JJ QTc-prolonging) (NNS drugs))))))) (. .)))
(S1 (S (S (NP (NP (NNS Differences)) (PP (IN in) (NP (NN clearance))) (PP (IN between) (NP (NP (NP (NNS patients)) (PP (IN on) (NP (DT these) (NNS medications))) (PRN (-LRB- -LRB-) (PP (IN at) (NP (NP (DT any) (NN occasion)) (PP (IN in) (NP (DT the) (NN study))))) (-RRB- -RRB-))) (CC and) (NP (NP (DT those)) (PP (RP off) (NP (NNS medications))))))) (VP (VBD varied) (PP (IN between) (NP (NP (CD -16) (NN %)) (CC and) (NP (CD +3) (NN %)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ mean) (NNS clearances)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (NP (NP (CD 16) (NN %)) (CC and) (NP (NP (CD 15) (NN %) (RBR lower)) (PP (IN in) (NP (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug2)))) (CC and) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (JJ tubular) (JJ organic) (NN cation) (NN transport))))))) (, ,) (ADVP (RB respectively))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN CNS) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (PP (IN by) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (: :) (NP (NP (JJ other) (NN drug4) (NNS s)) (, ,) (NP (NN drug5)) (, ,) (NP (JJ general) (NN drug6)) (, ,) (NP (NN drug7)))) (PP (JJ such) (IN as) (NP (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC or) (NP (JJ other) (NN drug10))))) (, ,) (S (VP (VBG causing) (NP (VBN increased) (NN CNS) (NN depression))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions) (NP (NN drug1))) (VP (MD may) (VP (VB produce) (NP (NP (JJ false-positive) (NN test) (NNS results)) (PP (IN for) (NP (JJ urinary) (JJ 5-hydroxyindoleacetic) (NN acid))))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB cause) (NP (NP (DT an) (JJ excessive) (NN increase)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN stimulation)))))))) (. .)))
(S1 (S (SBAR (IN If) (S (VP (VBN you)))) (VP (VBP are) (ADVP (RB also)) (VP (VP (VBG using) (NP (DT a) (NN drug1) (NN inhaler))) (, ,) (VP (VB take) (NP (NN drug2)) (ADVP (RB first))) (CC and) (ADVP (RB then)) (VP (VBP wait) (PP (IN about) (NP (CD 15) (NNS minutes))) (PP (IN before) (S (VP (VBG using) (NP (DT the) (NN drug3) (NN inhaler)))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ allows) (S (NP (NN drug1)) (VP (TO to) (VP (VB open) (NP (NN air) (NNS passages))))) (, ,) (S (VP (VBG increasing) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (DT the) (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug2)))) (, ,) (ADVP (RB especially)) (NP (NP (DT those)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ diuretic) (NN therapy)) (VP (VBD was) (ADVP (RB recently)) (VP (VBN instituted)))))) (, ,)) (VP (MD may) (ADVP (RB occasionally)) (VP (VBP experience) (NP (NP (DT an) (JJ excessive) (NN reduction)) (PP (IN of) (NP (NN blood) (NN pressure))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN therapy))) (PP (IN with) (NP (NN drug3))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (NP (JJ hypotensive) (NNS effects)) (PP (IN with) (NP (NN drug1)))))) (VP (MD can) (VP (VB be) (VP (VBN minimized) (PP (IN by) (S (VP (CC either) (VP (VBG discontinuing) (NP (DT the) (NN drug2))) (CC or) (VP (VBG increasing) (NP (NP (DT the) (NN salt) (NN intake)) (ADJP (JJ prior) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug3))))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT this)) (VP (VBZ is) (RB not) (ADJP (JJ possible))))) (, ,) (NP (DT the) (VBG starting) (NN dose)) (VP (MD should) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NNS Supplements)) (CC and) (NP (NN drug2) (NN Lotensin))) (VP (MD can) (VP (VB attenuate) (NP (NP (NN potassium) (NN loss)) (VP (VBN caused) (PP (IN by) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NNS others))) (-RRB- -RRB-))) (CC or) (NP (NN drug5) (NNS supplements))) (VP (MD can) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN hyperkalemia))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN if) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (JJ such) (NNS agents)))) (VP (VBZ is) (VP (VBN indicated))))) (, ,) (S (S (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NN caution))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN patient) (POS 's)) (NN serum) (NN potassium)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB frequently)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Oral) (NN drug1) (NN Interaction) (NNS studies)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD failed) (S (VP (TO to) (VP (VB identify) (NP (NP (DT any) (ADJP (RB clinically) (JJ important)) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NP (NN serum) (NNS concentrations)) (CC or) (NP (JJ clinical) (NNS effects))) (PP (IN of) (NP (DT these) (NNS drug4))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (VBN Increased) (NN serum) (NN drug2) (NNS levels)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NN drug3) (NN toxicity)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug4)) (PP (IN during) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug5)))))))))))) (. .))))
(S1 (S (S (S (NP (DT These) (NNS drugs)) (VP (MD should) (VP (VB be) (VP (VBN coadministered) (PP (IN with) (NP (NN caution))))))) (, ,) (CC and) (S (NP (NP (JJ frequent) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN drug1) (NNS levels)))) (VP (VBZ is) (VP (VBN recommended))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT a) (NN drug1)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN used))))) (, ,) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2) (NN toxicity)))) (VP (MD may) (VP (VB be) (VP (VBN increased))))) (. .)))
(S1 (S (S (NP (JJ Other) (NN No)) (S (NP (ADJP (RB clinically) (JJ important)) (JJ pharmacokinetic) (NNS interactions)) (VP (VBD occurred) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (CC or) (NP (NN drug9))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (PP (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)))) (, ,) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (ADJP (RB clinically) (JJ important)) (JJ adverse) (NNS interactions)))))))))) (. .)))
(S1 (S (NP (NN drug1)) (, ,) (PP (IN like) (NP (JJ other) (NNS drug2))) (, ,) (VP (VBZ has) (VP (VBD had) (ADJP (ADJP (JJR less)) (PP (IN than) (NP (NP (JJ additive) (NNS effects)) (PP (IN with) (NP (NN drug3)))))) (, ,) (SBAR (ADVP (RB presumably)) (IN because) (S (NP (DT both) (NNS drugs)) (VP (JJR lower) (NP (NN blood) (NN pressure)) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (NNS parts)) (PP (IN of) (NP (DT the) (JJ renin-angiotensin) (NN system))))))))))))))
(S1 (S (. .)))
(S1 (S (NP (NN fucking) (JJ empty) (NN sentence))))
(S1 (S (S (NP (NP (JJ Elevated) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (DT some) (NNS drug2))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (JJ drug1) (JJ -related) (NNS side-effects)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (JJ concomitant) (NN drug2)) (CC -) (NP (NN drug3) (NN therapy)))))))))))) (. .)))
(S1 (S (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN monitoring)) (PP (IN of) (NP (NN drug1) (NN plasma) (NNS levels)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (CC and) (S (NP (NP (NN dosage)) (PP (IN of) (NP (NN drug2)))) (VP (VBN adjusted) (PP (IN as) (NP (VBN required)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NP (VBN reduced) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT a) (NN prolongation)) (PP (IN of) (NP (PRP$ its) (NN plasma) (NN half-life))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (DT this) (NN interaction)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NN drug1)))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3) (JJ -containing) (NNS products))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (ADVP (RB substantially)) (VP (VBP interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (DT some) (NN drug3))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (JJ low) (NN urine) (NNS levels))))))) (. .)))
(S1 (S (ADVP (RB Also)) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS products)) (VP (VBG containing) (NP (NP (NN drug2)) (, ,) (NP (NN drug3) (NN containing) (NN drug4)) (, ,) (CC or) (NP (NN drug5) (-LRB- -LRB-) (NN drug6) (-RRB- -RRB-) (JJ chewable/buffered) (NNS tablets)) (CC or) (NP (NP (DT the) (JJ pediatric) (NN powder)) (PP (IN for) (NP (JJ oral) (NN solution))))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ low) (NN urine) (NNS levels))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (PP (VBG including) (NP (NN drug2))) (, ,)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ oral) (NN drug3)))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug4)) (CC or) (NP (PRP$ its) (NNS derivatives))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT these) (NNS products)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))) (, ,) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ suitable) (NN coagulation) (NNS tests))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (. .)))
(S1 (S (S (NP (NNS Seizures)) (VP (VBP have) (VP (VBN been) (VP (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (DT another) (NN drug1)))))) (CC and) (VP (NP (DT the) (NN drug2) (NN drug3)) (ADVP (RB concurrently))))))) (. .)))
(S1 (S (S (NP (NN Animal) (NNS studies)) (ADVP (RB also)) (VP (VBP suggest) (NP (NP (DT an) (VBN increased) (NN potential)) (PP (IN for) (NP (NNS seizures)))) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (CD 2) (NNS drugs)) (VP (VBP are) (VP (VBN given) (ADVP (RB concomitantly)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (ADJP (JJ approved)) (PP (IN in) (NP (DT the) (JJ United) (NNS States))) (PP (IN at) (NP (DT this) (NN time))))) (. .)))
(S1 (S (S (NP (NNS Physicians)) (VP (VBP are) (VP (VBN provided) (NP (DT this) (NN information)) (S (VP (TO to) (VP (VB increase) (NP (NP (NN awareness)) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (JJ serious) (NNS interactions)))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (JJ certain) (NN drug2))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))))))))) (. .)))
(S1 (S (S (NP (JJ Elevated) (NN drug1) (NN serum) (NNS levels)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (JJ Special) (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (NN drug2)) (CC or) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VP (VB cause)) (CC or) (VP (VB potentiate) (NP (NN hypotension))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJ local) (NN drug1)) (VP (VBG containing) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug4)) (CC or) (NP (NN drug5)))))))))) (VP (MD may) (VP (VB produce) (NP (ADJP (ADJP (JJ severe)) (, ,) (ADJP (JJ prolonged))) (NN hypertension))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD may) (VP (VP (VB reduce)) (CC or) (VP (VB reverse) (NP (NP (DT the) (JJ pressor) (NN effect)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (MD should) (ADVP (RB generally)) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS situations)) (SBAR (WHADVP (WRB when)) (S (NP (JJ concurrent) (NN therapy)) (VP (VBZ is) (ADJP (JJ necessary))))))) (, ,) (NP (JJ careful) (NN patient) (NN monitoring)) (VP (VBZ is) (ADJP (JJ essential)))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN hypotension))) (ADJP (JJ related) (PP (TO to) (NP (JJ obstetric) (NNS blocks)))))) (-RRB- -RRB-))) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB cause) (NP (NP (JJ severe) (, ,) (JJ persistent) (NN hypertension)) (CC or) (NP (JJ cerebrovascular) (NN accidents)))))) (. .)))
(S1 (S (S (PP (JJ Due) (TO to) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (JJ additive) (NNS effects))))) (, ,) (NP (NP (NN caution)) (CC and) (NP (JJ careful) (NN titration))) (VP (VBP are) (VP (VBN warranted) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)) (PP (ADVP (RB concomitantly)) (IN with) (NP (NP (JJ other) (NNS agents)) (VP (VBN known) (S (VP (TO to) (VP (VB affect) (NP (NP (JJ cardiac) (NN contractility)) (CC and/or) (NP (NN conduction))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Pharmacologic) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (EX there)) (VP (MD may) (VP (VB be) (NP (JJ additive) (NNS effects)) (PP (IN in) (S (VP (VBG prolonging) (NP (NN AV) (NN conduction))))) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (PP (IN As) (PP (IN with) (NP (DT all) (NNS drugs)))) (, ,) (NP (NN care)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG treating) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ multiple) (NNS medications))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (CC both) (NP (DT a) (NN substrate)) (CC and) (NP (DT an) (NN inhibitor))) (PP (IN of) (NP (DT the) (NP (NN cytochrome) (NN P-450)) (NN 3A4) (NN enzyme) (NN system)))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NP (JJ specific) (NNS substrates)) (, ,) (NP (NNS inhibitors)) (, ,) (CC or) (NP (NNS inducers))) (PP (IN of) (NP (DT the) (NN enzyme) (NN system)))))))) (VP (MD may) (VP (VB have) (NP (DT a) (JJ significant) (NN impact)) (PP (IN on) (NP (NP (DT the) (NP (NN efficacy)) (CC and) (NP (JJ side) (NN effect) (NN profile))) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN of) (NP (NN CYP450) (NN 3A4)))))))))) (, ,) (ADVP (RB especially)) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (ADJP (JJ renal)) (CC and/or) (ADJP (JJ hepatic))) (NN impairment)))) (, ,)) (VP (MD may) (VP (VBP require) (NP (NN dosage) (NN adjustment)) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG starting)) (CC or) (VP (VBG stopping) (NP (ADJP (RB concomitantly) (VBN administered)) (NN drug1) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB maintain) (NP (JJ optimum) (JJ therapeutic) (NN blood) (NNS levels)))))))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (JJ Controlled) (CC and) (JJ uncontrolled) (JJ domestic) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (ADVP (RB usually)) (VP (ADVP (RB well)) (VBN tolerated)))) (, ,) (CC but) (S (NP (JJ available) (NNS data)) (VP (VBP are) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB predict) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ concomitant) (NN treatment))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ left) (JJ ventricular) (NN dysfunction)) (CC or) (NP (JJ cardiac) (NN conduction) (NNS abnormalities))))))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (ADVP (RB concomitantly)) (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (CD five) (JJ normal) (NNS volunteers)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (VBN increased) (NN drug3) (NNS levels)) (PP (IN in) (NP (DT all) (NNS subjects))))))) (CC and) (S (NP (NP (NN bioavailability)) (PP (IN of) (NP (NN drug4)))) (VP (VBD was) (VP (VBN increased) (NP (QP (RB approximately) (CD 50)) (NN %)))))) (. .)))
(S1 (S (S (ADVP (FW In) (FW vitro)) (, ,) (NP (NN drug1)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (VP (VBN displaced) (PP (IN from) (NP (PRP$ its) (NN binding) (NNS sites))) (PP (IN by) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN combination) (NN therapy)) (VP (VBZ is) (VP (VP (VBN initiated)) (CC or) (VP (VBN withdrawn) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NN drug1)))))))))) (, ,) (NP (NP (DT an) (NN adjustment)) (PP (IN in) (NP (DT the) (NN drug2) (NN dose)))) (VP (MD may) (VP (VB be) (VP (VBN warranted))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (NP (DT A) (NN study)) (PP (IN in) (NP (CD six) (JJ healthy) (NNS volunteers)))) (VP (VBZ has) (VP (VBN shown) (NP (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NN peak) (NN drug1) (NN plasma) (NNS levels)) (PRN (-LRB- -LRB-) (NP (CD 58) (NN %)) (-RRB- -RRB-))))) (CC and) (NP (NP (NN AUC)) (PRN (-LRB- -LRB-) (NP (CD 53) (NN %)) (-RRB- -RRB-)))) (PP (IN after) (NP (NP (NP (DT a) (JJ 1-week) (NN course)) (PP (IN of) (NP (NN drug2) (CD 1200) (NN mg/day)))) (CC and) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug3) (NN 60mg))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD produced) (NP (ADJP (ADJP (JJR smaller)) (, ,) (ADJP (JJ nonsignificant))) (NNS increases)))) (. .)))
(S1 (S (S (NP (DT The) (NN effect)) (VP (MD may) (VP (VB be) (VP (VBN mediated) (PP (IN by) (NP (NP (NN drug1) (NN s) (JJ known) (NN inhibition)) (PP (IN of) (NP (NP (JJ hepatic) (NN cytochrome) (NN P-450)) (, ,) (NP (NP (DT the) (NN enzyme) (NN system)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN first-pass) (NN metabolism)) (PP (IN of) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (ADVP (RB currently)) (VBG receiving) (NP (NN drug1) (NN therapy)))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored) (PP (IN for) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (JJ pharmacological) (NN effect))))) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG initiating)) (CC and) (VP (VBG discontinuing) (NP (NN therapy)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (NN adjustment)) (PP (IN in) (NP (DT the) (NN drug1) (NN dose)))) (VP (MD may) (VP (VB be) (VP (VBN warranted))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2))) (PP (IN in) (NP (CD 24) (JJ healthy) (JJ male) (NNS subjects)))) (VP (VBD increased) (NP (NP (NN plasma) (NN drug3) (NNS concentrations)) (ADJP (QP (RB approximately) (CD 20)) (NN %))))) (. .)))
(S1 (S (S (NP (DT Another) (NN investigator)) (VP (VBD found) (NP (NP (DT no) (NN increase)) (PP (IN in) (NP (NP (NN drug1) (NNS levels)) (PP (IN in) (NP (NP (CD 12) (NNS patients)) (PP (IN with) (NP (JJ coronary) (NN artery) (NN disease)))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (VBG conflicting) (NNS results)) (PP (VBG regarding) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1) (NNS levels))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug2) (NNS levels)) (VP (VB be) (VP (VBN monitored) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG initiating)) (, ,) (VP (VBG adjusting)) (, ,) (CC and) (VP (VBG discontinuing) (NP (NP (NN drug3) (NN therapy)) (S (VP (TO to) (VP (VB avoid) (NP (NP (JJ possible) (NN over-)) (CC or) (NP (NN under-digitalization)))))))))))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (NP (NP (DT The) (NN depression)) (PP (IN of) (NP (NP (JJ cardiac) (NN contractility)) (, ,) (NP (NN conductivity)) (, ,) (CC and) (NP (NN automaticity))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (JJ vascular) (NN dilation)) (VP (VBN associated) (PP (IN with) (NP (NN drug1)))))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NN drug2))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN used) (ADVP (RB concomitantly))))) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD should) (VP (VB be) (VP (VBN titrated) (ADVP (RB carefully)))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (NP (DT A) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN during) (NP (NP (NNS studies)) (VP (VBG involving) (NP (ADJP (ADJP (JJ renal)) (CC and) (ADJP (JJ cardiac))) (NN transplant) (NNS patients))))))))) (. .)))
(S1 (S (PP (IN In) (NP (ADJP (ADJP (JJ renal)) (CC and) (ADJP (JJ cardiac))) (NN transplant) (NNS recipients))) (, ,) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (NN drug1) (NN dose)) (VP (VBG ranging) (PP (IN from) (NP (CD 15) (NN %))) (PP (TO to) (NP (CD 48) (NN %))))))) (VP (VBD was) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB maintain) (NP (NP (NN drug2) (NN trough) (NNS concentrations)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN seen) (PP (JJ prior) (TO to) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug3))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT these) (NNS agents)) (VP (VBP are) (S (VP (TO to) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently))))))))) (, ,) (NP (NN drug1) (NNS concentrations)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (, ,) (SBAR (WHADVP (RB especially) (WRB when)) (S (NP (NN drug2) (NN therapy)) (VP (VBZ is) (VP (VP (VBN initiated)) (, ,) (VP (VBN adjusted)) (, ,) (CC or) (VP (VBN discontinued)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN drug2) (NN plasma) (NNS concentrations)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (NP (JJ elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (QP (CD 40) (NN %) (TO to) (CD 72)) (NN %) (NN increase)) (-RRB- -RRB-)))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NN toxicity))) (PP (IN in) (NP (DT some) (NNS cases)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (DT these) (NNS drugs)))) (ADVP (RB concurrently)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (DT a) (JJ potential) (NN drug) (NN interaction))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (NNS Studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD increased) (NP (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN by) (NP (JJ 3-4) (NN fold)))) (CC and) (NP (DT the) (NN Cmax))) (PP (IN by) (NP (RB 2-fold))) (, ,) (S (VP (VBN compared) (PP (TO to) (NP (NN placebo)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN elimination) (NN half) (NN life)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (ADVP (RB also)) (VP (VBD increased) (PRN (-LRB- -LRB-) (NP (CD 1.5-2.5) (NN fold)) (-RRB- -RRB-)) (PP (IN during) (NP (NP (NN coadministration)) (PP (IN with) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (DT These) (JJ pharmacokinetic) (NNS effects)) (VP (VBN seen) (PP (IN during) (NP (NN drug1) (NN coadministration))))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (NP (VBN increased) (JJ clinical) (NNS effects)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (JJ prolonged) (NN sodation))) (-RRB- -RRB-))) (PP (IN of) (NP (CC both) (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (PP (IN In) (NP (DT a) (JJ ten-subject) (NN study))) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 120) (NN mg)) (NN bid)) (-RRB- -RRB-)))) (PP (IN with) (NP (NN drug2)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ 3-4) (NNS times) (NN increase)) (PP (IN in) (NP (NP (JJ mean) (NN drug3) (NN AUC)) (CC and) (NP (NP (NP (NN Cmax)) (CC vs.) (NP (NN drug4))) (ADVP (RB alone)))))))) (: ;)))
(S1 (S (S (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (NN drug1) (NN AUC)) (CC and) (NP (NN Cmax))))) (VP (VBD was) (VP (VBN observed) (PP (IN during) (NP (NN drug2) (NN coadministration)))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN plasma) (NNS levels)) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN affected) (PP (IN by) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))) (. .)))
(S1 (S (NP (NN drug1))))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBD lowered) (NP (DT the) (NN drug3) (NN plasma) (NNS concentrations)) (PP (TO to) (NP (JJ undetectable) (NNS levels))))) (. .)))
(S1 (S (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (DT any) (JJ known) (NN CYP3A4) (NN inducer))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (WHADVP (WRB when)) (FRAG (JJ possible))))))) (, ,) (CC and) (S (NP (JJ alternative) (NN therapy)) (VP (VBN considered)))) (. .)))
(S1 (S (S (NP (NN drug1) (NN drug2)) (VP (MD may) (VP (VB delay) (VP (CC or) (VP (VB reduce) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (NP (JJ concomitant) (JJ oral) (NN medication)) (PP (JJ such) (IN as) (NP (NP (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (ADJP (JJ acidic)) (-RRB- -RRB-))) (CC or) (NP (NN drug6))) (PRN (-LRB- -LRB-) (NP (JJ basic)) (-RRB- -RRB-))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NN drug7) (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN thyroid)) (CC and) (NP (NN drug10) (NNS preparations))))) (, ,) (NP (CD drug11) (CC and) (CD drug12)) (, ,) (CC and) (NP (NN drug13)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Interference)) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (JJ oral) (NN drug1) (NNS supplements)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (DT another) (JJ positively-charged) (NN bile) (NN acid) (NN sequestrant))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN drug2)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP undergo) (NP (JJ enterohepatic) (NN circulation)) (, ,) (S (NP (NP (DT The) (NN discontinuance)) (PP (IN of) (NP (NN drug3) (NNS drug4)))) (VP (MD could) (VP (VB pose) (NP (NP (DT a) (NN hazard)) (PP (TO to) (NP (NN health)))) (SBAR (IN if) (S (NP (NP (DT a) (ADJP (RB potentially) (JJ toxic)) (NN drug)) (PP (JJ such) (IN as) (NP (NN drug5)))) (VP (VBZ has) (VP (VBN been) (VP (VBN filtrated) (PP (TO to) (NP (DT a) (NN maintenance) (NN level))) (SBAR (IN while) (S (NP (DT the) (NN patient)) (VP (VBD was) (VP (VBG taking) (NP (NN drug6) (NN drug7)))))))))))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ binds) (NP (JJ bile) (NNS acids))))) (, ,) (NP (NN drug2) (NN drug3)) (VP (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (JJ normal) (JJ fat) (NN digestion)) (CC and) (NP (NN absorption)))))) (CC and) (ADVP (RB thus)) (VP (MD may) (VP (VB prevent) (NP (NP (NN absorption)) (PP (IN of) (NP (NP (NNS drug4)) (PP (JJ such) (IN as) (NP (NP (NN A)) (, ,) (NP (NN D)) (, ,) (NP (NN E)) (, ,) (CC and) (NP (NN K))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1) (NN drug2)) (VP (VBZ is) (VP (VBN given) (PP (IN for) (NP (NP (JJ long) (NNS periods)) (PP (IN of) (NP (NN time))))))))) (, ,) (NP (NP (JJ concomitant) (NN supplementation)) (PP (IN with) (NP (NP (ADJP (ADJP (JJ water-miscible)) (-LRB- -LRB-) (CC or) (ADJP (JJ parenteral)) (-RRB- -RRB-)) (NNS forms)) (PP (IN of) (NP (NN drug3)))))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (SBAR (IN SINCE) (S (NP (NN drug1) (NN drug2)) (VP (MD MAY) (VP (VB BIND) (NP (NP (JJ OTHER) (NNS DRUGS)) (VP (VBN GIVEN) (ADVP (RB CONCURRENTLY)))))))) (, ,) (NP (PRP IT)) (VP (VBZ IS) (VP (VBN RECOMMENDED) (SBAR (IN THAT) (S (NP (NNS PATIENTS)) (VP (VBP TAKE) (NP (NP (NP (JJ OTHER) (NNS DRUGS)) (PP (NP (QP (IN AT) (JJS LEAST) (CD 1)) (NN HOUR)) (IN BEFORE))) (CC OR) (NP (NP (QP (CD 4) (TO TO) (CD 6)) (NNS HOURS)) (PP (IN AFTER) (NP (NP (NN drug3) (NN drug4)) (PRN (-LRB- -LRB-) (CC OR) (PP (IN AT) (NP (NP (RB AS) (JJ GREAT) (DT AN) (NN INTERVAL)) (PP (IN AS) (NP (JJ POSSIBLE))))) (-RRB- -RRB-)))))) (S (VP (TO TO) (VP (VB AVOID) (S (VP (VBG IMPEDING) (NP (PRP$ THEIR) (NN ABSORPTION)))))))))))) (. .)))
(S1 (S (NP (NN CYP3A4) (NNS Interactions))))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4))))) (CC but) (VP (VBZ has) (NP (DT no) (JJ CYP3A4) (JJ inhibitory) (NN activity))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB affect) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Potent) (NNS inhibitors)) (PP (IN of) (NP (NN CYP3A4)))) (PRN (-LRB- -LRB-) (PP (IN below)) (-RRB- -RRB-))) (VP (VBP increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN myopathy)))) (PP (IN by) (S (VP (VBG reducing) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (NP (NP (NNS Pharmacokinetics)) (. .))))
(S1 (S (NP (NP (NN drug1) (NN drug2) (NN drug3) (NN drug4) (NN drug5) (NN drug6) (NN drug7)) (PP (IN drug8) (NP (NP (JJ Large) (NNS quantities)) (PP (IN of) (NP (NN grapefruit) (NN juice))))) (PRN (-LRB- -LRB-) (NP (CD 1) (NN quart) (JJ daily)) (-RRB- -RRB-)))))
(S1 (S (NP (NP (NNS Interactions)) (PP (IN with) (NP (NP (JJ lipid-lowering) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN myopathy)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB alone))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NN myopathy)))) (VP (VBZ is) (ADVP (RB also)) (VP (VBN increased) (PP (IN by) (NP (NP (DT the) (JJ following) (JJ lipid-lowering) (NNS drugs)) (SBAR (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (NP (JJ potent) (JJ CYP3A4) (NNS inhibitors))))) (, ,) (CC but) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB cause) (NP (NN myopathy)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB alone))))))))))))))) (. .)))
(S1 (S (S (VP (VB See) (NP (NP (NNS WARNINGS)) (, ,) (NP (NN Myopathy/Rhabdomyolysis))))) (. .)))
(S1 (S (NP (NP (NP (JJ drug1) (JJ Other) (NN drug2) (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD =1) (NN g/day)) (-RRB- -RRB-)))))
(S1 (S (NP (JJ Other) (NN drug) (NNS interactions))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NN myopathy/rhabdomyolysis)))) (VP (VBZ is) (VP (VBN increased) (PP (IN by) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (ADVP (RB particularly)) (IN with) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN drug3))))))) (PRN (-LRB- -LRB-) (S (VP (VB see) (NP (NP (NNS WARNINGS)) (, ,) (NP (NNP Myopathy/Rhabdomyolysis))))) (-RRB- -RRB-))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (: :) (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NN myopathy/rhabdomyolysis)))) (VP (VBZ is) (VP (VBN increased) (SBAR (WHADVP (WRB when)) (S (NP (CC either) (NP (NN drug3)) (CC or) (NP (NN drug4))) (VP (VBZ is) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (DT a) (ADJP (RB closely) (JJ related)) (NN member)) (PP (IN of) (NP (DT the) (NN drug5))))) (PRN (-LRB- -LRB-) (S (VP (VB see) (NP (NP (NNS WARNINGS)) (, ,) (NP (NNP Myopathy/Rhabdomyolysis))))) (-RRB- -RRB-))))))))) (. .))))
(S1 (S (NP (NP (NN drug1) (NNS s)) (: :) (S (PP (IN In) (NP (NP (DT a) (JJ small) (JJ clinical) (NN trial)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN administered) (S (VP (TO to) (VP (VB drug3) (NP (JJ treated) (NNS patients))))))))))) (, ,) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN prothrombin) (NN time)))) (VP (VBD was) (VP (VBN detected)))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT another) (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VB produce) (NP (NP (DT a) (ADJP (JJR less) (IN than) (JJ two-second)) (NN increase)) (PP (IN in) (NP (NN prothrombin) (NN time))) (PP (IN in) (NP (NP (JJ healthy) (NNS volunteers)) (VP (VBG receiving) (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Also)) (, ,) (NP (NP (ADJP (JJ bleeding))) (CC and/or) (NP (VBN increased) (NN prothrombin) (NN time))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (DT a) (JJ few) (NNS patients)) (VP (VBG taking) (NP (NN drug1) (NNS s)) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1))))) (, ,) (NP (NN prothrombin) (NN time)) (VP (VB be) (VP (VBN determined) (PP (IN before) (S (VP (VP (VBG starting) (NP (NN drug2))) (CC and) (ADVP (RB frequently)) (ADVP (RB enough)) (PP (IN during) (NP (NP (JJ early) (NN therapy)) (PP (TO to) (NP (NN insure))))) (SBAR (IN that) (S (NP (NP (DT no) (JJ significant) (NN alteration)) (PP (IN of) (NP (NN prothrombin) (NN time)))) (VP (VBZ occurs)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Once) (S (NP (DT a) (JJ stable) (NN prothrombin) (NN time)) (VP (VBZ has) (VP (VBN been) (VP (VBN documented)))))) (, ,) (NP (NN prothrombin) (NNS times)) (VP (MD can) (VP (VB be) (VP (VBN monitored) (PP (IN at) (NP (NP (DT the) (NNS intervals)) (VP (ADVP (RB usually)) (VBN recommended) (PP (IN for) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN changed))))) (, ,) (NP (DT the) (JJ same) (NN procedure)) (VP (MD should) (VP (VB be) (VP (VBN repeated))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN therapy)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN associated) (PP (PP (IN with) (NP (JJ bleeding))) (CC or) (PP (IN with) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN prothrombin) (NN time)) (PP (IN in) (NP (NP (NNS patients)) (VP (RB not) (VBG taking) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (JJ normal) (NNS volunteers))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (ADJP (RB clinically) (JJ significant)) (ADJP (ADJP (JJ pharmacokinetic)) (CC or) (ADJP (JJ pharmacodynamic))) (NN interaction)) (PP (IN with) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (JJ single) (NNS doses)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NN hypercholesterolemia))))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug4) (NN plasma) (NNS concentrations))))))) (. .))))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (PP (IN In) (NP (NP (JJ pharmacokinetic) (NNS studies)) (PP (IN of) (NP (NP (NN drug2)) (PP (IN in) (NP (JJ hypercholesterolemic) (ADJP (NN noninsulin) (JJ dependent)) (JJ diabetic) (NNS patients))))))) (, ,) (NP (EX there)) (VP (VBD was) (NP (DT no) (NN drug) (NN interaction)) (PP (PP (IN with) (NP (NN drug3))) (CC or) (PP (IN with) (NP (NN drug4)))))))))
(S1 (S (S (NP (NN CNS) (NNS Drugs)) (: -) (PP (IN Given) (NP (NP (DT the) (JJ primary) (NN CNS) (NNS effects)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN taken) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (ADJP (RB centrally) (VBG acting)) (NNS drugs))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: -) (S (SBAR (IN Although) (S (NP (NN drug2)) (VP (VBD did) (RB not) (VP (VB potentiate) (NP (NP (DT the) (NN cognitive) (CC and) (NN motor) (NNS effects)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (DT a) (JJ clinical) (NN trial)))))))) (, ,) (PP (IN as) (PP (IN with) (NP (JJ other) (NNS drug4)))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug5))) (PP (IN by) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug6)))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .))))
(S1 (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))
(S1 (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (VBP Interfere) (PP (IN With) (NP (NN Hemostasis))))))) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN etc)) (. .)) (-RRB- -RRB-))))
(S1 (S (S (NP (NP (NN Serotonin) (NN release)) (PP (IN by) (NP (NNS platelets)))) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NN hemostasis))))) (. .)))
(S1 (S (S (NP (NP (JJ Epidemiological) (NNS studies)) (PP (IN of) (NP (NP (DT the) (JJ case-control)) (CC and) (NP (NN cohort)) (NP (NN design)))) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN demonstrated) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NP (NN use)) (PP (IN of) (NP (NP (NN drug1)) (SBAR (WHNP (WDT that)) (S (VP (VBP interfere) (PP (IN with) (NP (NN serotonin) (NN reuptake))))))))) (CC and) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ upper) (JJ gastrointestinal) (JJ bleeding)))))))))))) (VP (VBP have) (ADVP (RB also)) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (DT an) (NP (NN drug2)) (CC or) (NP (NN drug3))))) (VP (VBD potentiated) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ bleeding)))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN cautioned) (PP (IN about) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ such) (NNS drugs)) (PP (ADVP (RB concurrently)) (IN with) (NP (NN drug1))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: -) (S (PP (IN In) (NP (NP (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD had) (VP (VBN received) (NP (NP (CD 21) (NNS days)) (PP (IN of) (NP (ADJP (CD 40) (NN mg/day)) (JJ racemic) (NN drug2)))))))))) (, ,) (NP (NP (JJ combined) (NN administration)) (PP (IN of) (NP (ADJP (CD 400) (NN mg/day)) (NN drug3))) (PP (IN for) (NP (CD 8) (NNS days)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NP (NN drug4) (NN AUC)) (CC and) (NP (NN Cmax))) (PP (IN of) (NP (NP (CD 43) (NN %)) (CC and) (NP (CD 39) (NN %)) (, ,) (ADVP (RB respectively)))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT these) (NNS findings)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: -) (S (PP (IN In) (NP (NP (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD had) (VP (VBN received) (NP (NP (CD 21) (NNS days)) (PP (IN of) (NP (ADJP (CD 40) (NN mg/day)) (JJ racemic) (NN drug2)))))))))) (, ,) (NP (NP (JJ combined) (NN administration)) (PP (IN of) (NP (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (PRN (-LRB- -LRB-) (NP (NP (JJ single) (NN dose)) (PP (IN of) (NP (CD 1) (NN mg)))) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (CC either) (NP (NN drug5)) (CC or) (NP (NN drug6)))))))) (. .))))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC -) (NP (NN Coadministration))) (PP (IN of) (NP (NP (NP (JJ racemic) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 40) (NN mg/day)) (PP (IN for) (NP (CD 10) (NNS days)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (CD 30) (NN mmol/day)) (PP (IN for) (NP (CD 5) (NNS days)))) (-RRB- -RRB-)))))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug4)) (CC or) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (NP (NN plasma) (NN drug1) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN with) (NP (NP (JJ appropriate) (NN adjustment)) (PP (TO to) (NP (NP (DT the) (JJ drug2) (NN dose)) (PP (IN in) (NP (NP (NN accordance)) (PP (IN with) (NP (JJ standard) (JJ clinical) (NN practice))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ serotonergic) (NNS effects)) (PP (IN of) (NP (NN drug2)))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBP are) (VP (VBN coadministered))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (: -) (S (PP (IN In) (NP (DT a) (JJ controlled) (NN study))) (, ,) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NN drug3) (CD 2) (NN mg)) (VP (VBN co-administered) (PP (IN with) (NP (NP (JJ racemic) (NN drug4) (CD 40) (NN mg)) (VP (VBN given) (PP (IN once) (NP (JJ daily))) (PP (IN for) (NP (CD 11) (NNS days)))))))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ mean) (NN increase)) (PP (IN in) (NP (NP (NN QTc) (NNS values)) (PP (IN of) (NP (QP (RB approximately) (CD 10)) (NNS msec))))) (VP (VBN compared) (PP (TO to) (NP (NP (NN drug5)) (VP (VBN given) (ADVP (RB alone))))))))))) (. .))))
(S1 (S (S (NP (JJ Racemic) (NN drug1)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (NP (DT the) (JJ mean) (NN AUC)) (CC or) (NP (NN Cmax))) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (DT this) (JJ pharmacodynamic) (NN interaction)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: -) (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ rare) (JJ postmarketing) (NNS reports)) (VP (VBG describing) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN weakness)) (, ,) (NP (NN hyperreflexia)) (, ,) (CC and) (NP (NN incoordination))))))) (PP (VBG following) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NP (DT a) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (CC and) (NP (NN drug4))))))))) (. .))))
(S1 (S (S (SBAR (IN If) (S (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NP (DT an) (NN drug2)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8))) (-RRB- -RRB-)))))) (VP (VBZ is) (ADVP (RB clinically)) (VP (VBN warranted))))) (, ,) (NP (NP (JJ appropriate) (NN observation)) (PP (IN of) (NP (DT the) (NN patient)))) (VP (VBZ is) (ADJP (JJ advised)))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN drug1)) (CC -) (NP (NP (JJ Combined) (NN administration)) (PP (IN of) (NP (JJ racemic) (NN drug2))))) (PRN (-LRB- -LRB-) (NP (NP (CD 40) (NN mg/day)) (PP (IN for) (NP (CD 21) (NNS days)))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN CYP1A2) (NN substrate) (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (JJ single) (NN dose)) (PP (IN of) (NP (CD 300) (NN mg)))) (-RRB- -RRB-)))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NNS drug2)))))) (VP (VBD was) (RB not) (VP (VBN evaluated)))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC -) (NP (NN Administration))) (PP (IN of) (NP (ADJP (CD 40) (NN mg/day)) (JJ racemic) (NN drug2))) (PP (IN for) (NP (CD 21) (NNS days)))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (DT a) (NN CYP3A4) (NN substrate)))))))) (. .)))
(S1 (S (S (NP (NN Prothrombin) (NN time)) (VP (VBD was) (VP (VBN increased) (PP (IN by) (NP (NP (CD 5) (NN %)) (, ,) (SBAR (WHNP (NP (DT the) (JJ clinical) (NN significance)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBZ is) (ADJP (JJ unknown)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: -) (S (NP (NP (JJ Combined) (NN administration)) (PP (IN of) (NP (NP (NP (JJ racemic) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 40) (NN mg/day)) (PP (IN for) (NP (CD 14) (NNS days)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (JJ titrated) (TO to) (CD 400) (NN mg/day)) (PP (IN for) (NP (CD 35) (NNS days)))) (-RRB- -RRB-)))))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug4)) (, ,) (NP (DT a) (NN CYP3A4) (NN substrate)))))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (NN trough) (NN drug1) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ unaffected)) (, ,) (PP (IN given) (NP (NP (DT the) (JJ enzyme-inducing) (NNS properties)) (PP (IN of) (NP (NN drug2)))))))) (, ,) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NN drug3)) (VP (MD might) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug4))))))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (IN if) (S (NP (DT the) (CD two) (NNS drugs)) (VP (VBP are) (VP (VBN coadministered))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN drug1)) (CC -) (NP (NP (JJ Combined) (NN administration)) (PP (IN of) (NP (JJ racemic) (NN drug2))))) (-LRB- -LRB-) (VP (VBN titrated) (PP (TO to) (NP (NP (CD 40) (NN mg/day)) (PP (IN for) (NP (CD 28) (NNS days)))))) (-RRB- -RRB-)) (CC and) (NP (NP (DT the) (NN CYP3A4) (NN substrate) (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (JJ single) (NN dose)) (PP (IN of) (NP (CD 0.25) (NN mg)))) (-RRB- -RRB-)))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (CC either) (NP (NN drug4)) (CC or) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN drug1)) (CC -) (NP (NP (JJ Combined) (NN administration)) (PP (IN of) (NP (JJ racemic) (NN drug2))))) (PRN (-LRB- -LRB-) (NP (CD 40) (NN mg)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 200) (NN mg)) (-RRB- -RRB-)))) (VP (VP (VBD decreased) (NP (NP (DT the) (NP (NN Cmax)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (NN drug4)))) (PP (IN by) (NP (NP (CD 21) (NN %)) (CC and) (NP (CD 10) (NN %)) (, ,) (ADVP (RB respectively))))) (, ,) (CC and) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug5)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: -) (S (NP (NP (JJ Combined) (NN administration)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 600) (NN mg)) (-RRB- -RRB-))) (, ,) (NP (CC both) (NP (DT a) (NN CYP3A4) (NN substrate)) (CC and) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4))))) (, ,)))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg)) (-RRB- -RRB-)))))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (CC either) (NP (NN drug4)) (CC or) (NP (NN drug5)))))))) (. .))))
(S1 (S (S (NP (NP (NP (NP (NN CYP3A4)) (CC and) (NP (NN -2C19))) (NNS Inhibitors)) (CC -) (NP (ADJP (FW In) (FW vitro)) (NNS studies))) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (NN CYP3A4)) (CC and) (NP (NN -2C19))) (VP (VBP are) (NP (NP (DT the) (JJ primary) (NNS enzymes)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 600) (NN mg)) (-RRB- -RRB-)))) (, ,) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4)))) (, ,)))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (JJ multiple) (NN enzyme) (NNS systems))))))) (, ,) (NP (NP (NN inhibition)) (PP (IN of) (NP (DT a) (JJ single) (NN enzyme)))) (VP (MD may) (RB not) (ADVP (RB appreciably)) (VP (VB decrease) (NP (NN drug2) (NN clearance))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NP (NN Cytochrome) (NN P4502D6)) (CC -) (NP (ADJP (FW In) (FW vitro)) (NNS studies)))))) (VP (VBD did) (RB not) (VP (VB reveal) (NP (NP (DT an) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN CYP2D6))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ steady) (NN state) (NNS levels)) (PP (IN of) (NP (JJ racemic) (NN drug1)))) (VP (VBD were) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN in) (NP (NP (JJ poor) (NNS metabolizers)) (CC and) (NP (JJ extensive) (NN CYP2D6) (NNS metabolizers))))) (PP (IN after) (NP (NP (JJ multiple-dose) (NN administration)) (PP (IN of) (NP (NN drug2))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (NN coadministration)) (, ,) (PP (IN with) (NP (NN drug3))) (, ,) (PP (IN of) (NP (NP (DT a) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (VBZ inhibits) (NP (NN CYP2D6))))))) (, ,)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB have) (NP (ADJP (RB clinically) (JJ significant)) (NNS effects)) (PP (IN on) (NP (NN drug4) (NN metabolism)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (VBP are) (VP (VBN limited) (PP (IN in) (NP (NP (FW vivo) (NNS data)) (VP (VBG suggesting) (NP (DT a) (JJ modest) (NN CYP2D6) (JJ inhibitory) (NN effect) (SBAR (IN for) (S (NP (NN drug1)) (, ,) (PP (FW i.e.)) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN mg/day)) (PP (IN for) (NP (CD 21) (NNS days)))) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NP (DT the) (NN drug3) (NN drug4)) (PRN (-LRB- -LRB-) (NP (NP (JJ single) (NN dose)) (PP (IN of) (NP (CD 50) (NN mg)))) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NN CYP2D6)))) (, ,)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (ADJP (CD 40) (NN %)) (NN increase)) (PP (IN in) (NP (NN Cmax)))) (CC and) (NP (NP (DT a) (ADJP (CD 100) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NN AUC)) (PP (IN of) (NP (NN drug5)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN finding)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN indicated) (PP (IN in) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NNS drugs))) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP2D6))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC -) (NP (NN Administration))) (PP (IN of) (NP (ADJP (CD 20) (NN mg/day)) (NN drug2))) (PP (IN for) (NP (NP (CD 21) (NNS days)) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN increase)) (PP (IN in) (NP (NN Cmax)))) (CC and) (NP (NP (ADJP (CD 82) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NN AUC)) (PP (IN of) (NP (DT the) (NN drug3) (NN drug4))) (-LRB- -LRB-) (VP (VBN given) (PP (IN in) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (CD 100) (NN mg)))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (VBN Increased) (NN drug1) (NN plasma) (NNS levels)) (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (VBN decreased) (NN cardioselectivity))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD had) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NNS effects)) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (CC or) (NP (NN heart) (NN rate)))))) (. .)))
(S1 (S (NP (NP (NP (JJ Electroconvulsive) (NN Therapy)) (PRN (-LRB- -LRB-) (NP (NN ECT)) (-RRB- -RRB-))) (: -) (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ clinical) (NNS studies)) (PP (IN of) (NP (NP (DT the) (JJ combined) (NN use)) (PP (IN of) (NP (NP (NN ECT)) (CC and) (NP (NN drug1))))))))) (. .))))
(S1 (S (NP (NP (NP (JJ Concomitant) (NN Administration)) (PP (IN with) (NP (JJ Racemic) (NN drug1) (NN drug2)))) (: -) (S (SBAR (IN Since) (S (NP (NN drug3)) (VP (VBZ is) (NP (NP (DT the) (JJ active) (NN isomer)) (PP (IN of) (NP (NP (JJ racemic) (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-)))))))) (, ,) (NP (DT the) (CD two) (NNS agents)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN coadministered))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB exhibit) (NP (NP (NN binding)) (PP (TO to) (NP (NP (NP (NN plasma) (NNS proteins)) (PRN (-LRB- -LRB-) (ADJP (JJ other) (PP (IN than) (NP (NN thrombin)))) (-RRB- -RRB-))) (CC or) (NP (JJ red) (NN blood) (NNS cells)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ clinical) (NNS trials)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NN PTCA/PCI))))))) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC or) (NP (NN glycoprotein) (NN IIb/IIIa) (NNS inhibitors))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NNS risks)) (PP (IN of) (NP (NP (JJ major) (JJ bleeding) (NNS events)) (PP (VBN compared) (PP (TO to) (NP (NP (NNS patients)) (VP (RB not) (VBG receiving) (NP (DT these) (JJ concomitant) (NNS medications))))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no)) (VP (VBP experience) (PP (IN with) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN drug1) (CC and) (NN plasma) (NNS expanders)) (PP (JJ such) (IN as) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN disease) (NNS states)) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ bleeding)))))))))))))) (. .)))
(S1 (S (NP (NP (NN Immunogenicity/Re-exposure)) (: :) (S (PP (IN In) (NP (ADJP (FW in) (FW vitro)) (NNS studies))) (, ,) (NP (NN drug1)) (VP (VBD exhibited) (NP (DT no) (NN platelet) (NN aggregation) (NN response)) (PP (IN against) (NP (NP (NN sera)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNS HIT/HITTS))))))))))) (. .))))
(S1 (S (S (PP (IN Among) (NP (NP (CD 494) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD received) (NP (NN drug1)) (PP (IN in) (NP (JJ clinical) (NNS trials)))) (CC and) (VP (VBD were) (VP (VBN tested) (PP (IN for) (NP (NNS antibodies)))))))))) (, ,) (NP (CD 2) (NNS subjects)) (VP (VBD had) (NP (JJ treatment-emergent) (JJ positive) (NN drug2) (NN antibody) (NNS tests)))) (. .)))
(S1 (S (S (S (NP (DT Neither) (NN subject)) (VP (VBD demonstrated) (NP (NP (JJ clinical) (NN evidence)) (PP (IN of) (NP (JJ allergic) (CC or) (JJ anaphylactic) (NNS reactions)))))) (CC and) (S (NP (NN repeat) (NN testing)) (VP (VBD was) (RB not) (VP (VBN performed))))) (. .)))
(S1 (S (S (NP (NP (CD Nine) (JJ additional) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD had) (NP (JJ initial) (JJ positive) (NNS tests)))))) (VP (VBD were) (ADJP (JJ negative)) (PP (IN on) (NP (NN repeat) (NN testing))))) (. .)))
(S1 (S (S (NP (JJ Drug/) (NN Laboratory) (NN Test) (NNS Interactions) (NP (NP (JJ Certain) (NN endocrine)) (CC and) (NP (NN liver) (NN function) (NNS tests)))) (VP (MD may) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (ADJP (NN drug1) (JJ -containing)) (JJ oral) (NN drug2))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (JJ similar) (NNS changes)) (VP (MD may) (VP (VB be) (VP (VBN expected) (PP (IN with) (NP (NP (JJR larger) (NNS doses)) (PP (IN of) (NP (NN drug1))))))))) (: :) (CC -) (NP (VBN Increased) (NN sulfobromophthalein) (NN retention))))
(S1 (S (. .)))
(S1 (S (NP (CC -) (NP (VBN Increased) (NN prothrombin)) (CC and) (NP (NNS factors)) (NP (NP (NP (NN VII)) (, ,) (NP (NN VIII)) (, ,) (NP (NN IX)) (, ,) (CC and) (NP (NN X))) (: ;)))))
(S1 (S (S (VP (VBD decreased) (NP (NN drug1)))) (: ;)))
(S1 (S (NP (VBN increased) (JJ norepinephrine-induced) (NN platelet) (NN aggregability))))
(S1 (S (. .)))
(S1 (S (S (NP (NP (CC -) (VBN Increased) (JJ thyroid-binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN TBG)) (-RRB- -RRB-))) (VP (VBG leading) (PP (TO to) (NP (JJ in-creased) (VBG circulating) (JJ total) (NN thyroid) (NN hormone))))) (: ;)))
(S1 (S (S (IN as) (VP (VBN measured) (PP (IN by) (NP (NP (NN PBI)) (, ,) (NP (NN T4)))) (PP (IN by) (NP (NP (NN column)) (, ,) (CC or) (NP (NN T4)))) (PP (IN by) (NP (NN radioimmunoassay))))) (. .)))
(S1 (S (S (NP (JJ Free) (NN T3) (NN resin) (NN uptake)) (VP (VBZ is) (VP (VBN decreased) (, ,) (S (VP (VBG reflecting) (NP (DT the) (JJ elevated) (NN TBG))))))) (: ;)))
(S1 (S (NP (JJ free) (NN T4) (NN concentration)) (VP (VBZ is) (VP (JJ unaltered)))))
(S1 (S (. .)))
(S1 (S (NP (CC -) (JJ Impaired) (NN glucose) (NN tolerance))))
(S1 (S (. .)))
(S1 (S (: -) (NP (VBN Decreased) (NN pregnanediol) (NN excretion))))
(S1 (S (. .)))
(S1 (S (NP (CC -) (NP (JJ Reduced) (NN response)) (PP (TO to) (NP (NN metyrapone) (NN test))))))
(S1 (S (. .)))
(S1 (S (NP (CC -) (JJ Reduced) (NN serum) (NN folate) (NN concentration))))
(S1 (S (. .)))
(S1 (S (S (NP (CC -) (NP (VBN Increased) (NN serum) (NN triglyceride)) (CC and) (NP (NN phospholipid) (NN concentration)))) (. .)))
(S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN with) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB primarily)) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NP (NN cytochrome) (NN P450) (NN 3A4)) (, ,) (NP (NN 2C19)) (, ,) (CC and) (NP (NN 1A2)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB concomitantly)) (VP (VBG receiving) (NP (NP (NP (NN drug1)) (CC and) (NP (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NP (NNS inhibitors)) (CC or) (NP (NNS inducers))) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 3A4))))))))))))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored) (PP (IN for) (NP (CC either) (NP (NNS toxicities)) (CC or) (NP (VBN reduced) (NN efficacy)))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NP (NN hypoglycemia)) (CC and) (NP (NN hyperglycemia))) (VP (VBD were) (VP (VBN reported) (PP (IN in) (NP (NP (JJ diabetic) (NNS patients)) (VP (VBG receiving) (NP (JJ oral) (NN drug1)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (JJ oral) (NN drug1))) (VP (VBG receiving) (NP (NN drug2) (NN treatment)))) (VP (MD may) (VP (VB require) (NP (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (PRP$ their) (NN blood) (NN glucose) (NNS levels)))) (CC and) (NP (NP (NN adjustment)) (PP (IN of) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (PRP$ their) (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NN Drug) (NN Laboratory) (NN Test) (NNS Interactions)) (VP (NN None) (VBN known))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (JJ concomitant) (NN drug1) (NN administration))) (PP (IN on) (NP (NP (DT the) (JJ steady-state) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (`` ') (NN drug2) ('' ')) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB newly) (VBN introduced)) (NN drug3)) (PP (IN with) (NP (NP (VBN demonstrated) (NN efficacy)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ positive)) (CC and) (ADJP (JJ negative))) (NNS symptoms)) (PP (IN of) (NP (NN schizophrenia)))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB extensively)) (VP (VBN metabolized) (, ,) (ADVP (RB predominantly)) (PP (IN by) (NP (NN cytochrome) (NN P450) (NN 3A4)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP induce)) (CC or) (VP (VBP inhibit) (NP (DT this) (NN enzyme))))))))) (VP (MD may) (VP (VB affect) (NP (NN drug1) (NNS pharmacokinetics))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (JJ potent) (NN cytochrome) (NN P450)) (NN enzyme-inducer) (NN drug1)) (VP (VBD did) (RB indeed) (VP (VB have) (NP (DT a) (JJ marked) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJ 5-fold) (NN increase)) (PP (IN in) (NP (NN clearance)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (ADVP (RB concomitantly)) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ DSM-IV-diagnosed) (NN schizophrenia)) (, ,) (NP (JJ schizoaffective) (NN disorder)) (, ,) (CC or) (NP (JJ bipolar) (NN disorder)))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (JJ dosage) (NN adjustment)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (CD two) (NNS drugs)) (VP (VBP are) (VP (VBN given) (ADVP (RB concurrently))))))))))) (CC and) (SBAR (IN that) (S (NP (NN caution)) (VP (MD may) (VP (VB be) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP inhibit)) (CC or) (VP (VBP induce) (NP (NP (NNS cytochromes)) (, ,) (ADVP (RB particularly)) (NP (NN P450) (NN 3A4))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ -LSB-Drug) (NN treatment)) (PP (IN of) (NP (NN erection) (NNS disorders))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ cardiovascular) (NN disease)) (-RRB- -RSB-) (JJ Erectile) (NN dysfunction)))))) (VP (VBZ is) (NP (NP (DT a) (JJ frequent) (NN condition)) (PP (IN in) (NP (JJ cardiovascular) (NNS patients)))))) (. .)))
(S1 (S (S (PP (IN Since) (NP (NP (DT the) (NN arrival)) (PP (IN of) (NP (JJ oral) (NN drug1))))) (, ,) (NP (NNS patients)) (VP (VBP want) (S (VP (TO to) (VP (VB know) (SBAR (WHADVP (WRB how)) (S (NP (JJ safe) (JJ sexual) (NN activity)) (VP (VBZ is) (PP (IN in) (NP (JJ cardiovascular) (NN disease))) (PP (PP (IN in) (NP (JJ general))) (CC and) (PP (IN during) (NP (NP (NN use)) (PP (IN of) (NP (NP (NN drug2)) (PP (IN in) (NP (JJ particular)))))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Sexual) (NN intercourse)) (PP (IN with) (NP (DT a) (JJ steady) (NN partner)))) (VP (VBZ causes) (NP (NP (DT no) (RBR more) (JJ cardiovascular) (NN risk)) (PP (IN than) (NP (NP (JJ normal) (JJ daily) (NNS activities)) (PP (JJ such) (IN as) (NP (NP (NN ironing)) (, ,) (NP (NP (CD 2) (NNS kilometers)) (PP (IN of) (NP (NN walking))) (PP (IN without) (NP (NN climbing)))) (, ,) (NP (NN paperhanging))))))) (, ,) (S (VP (VBG playing) (NP (NP (NN golf)) (CC or) (NP (NN gardening)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ relative) (NN risk)) (PP (IN of) (NP (JJ myocardial) (NN infarction))) (PP (IN during) (NP (JJ sexual) (NN activity)))) (VP (VBZ is) (RB not) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (PP (IN for) (NP (JJ healthy) (NNS persons))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ cardiovascular) (NP (NN morbidity)) (CC and) (NP (NN mortality))))) (VP (VBZ is) (RB not) (ADJP (ADJP (JJR higher)) (PP (IN among) (NP (NP (NNS users)) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN contraindicated) (PP (IN in) (NP (NP (NP (NNS patients)) (VP (VBG using) (NP (NN drug2)))) (SBAR (CC or) (WHNP (WP who)) (S (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB use) (NP (NN drug3))))) (, ,) (SBAR (IN because) (S (NP (DT the) (NN combination)) (VP (MD may) (VP (VB cause) (NP (NP (DT a) (JJ sharp) (VBP fall)) (PP (IN of) (NP (DT the) (NN blood) (NN pressure)))))))))))))))) (. .)))
(S1 (S (S (NP (DT No) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4)) (CC and) (NP (NN drug5)))))))) (. .)))
(S1 (S (PP (IN Before) (S (VP (VBG prescribing) (NP (NP (DT a) (JJ symptomatic) (-LRB- -LRB-) (JJ pharmaceutical) (-RRB- -RRB-) (NN treatment)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (DT an) (JJ erection) (NN disorder))))))))) (, ,) (NP (NN attention)) (VP (MD should) (VP (VB be) (VP (VBN given) (S (VP (NN tot) (NP (NP (DT the) (ADJP (ADJP (JJ sexological)) (, ,) (ADJP (JJ psychological)) (CC and) (ADJP (JJ medical))) (NNS backgrounds)) (PP (IN of) (NP (DT the) (NN disorder))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Secondary) (NN prevention)) (PP (IN of) (NP (JJ atherosclerotic) (NN risk) (NNS factors)))) (VP (VBZ is) (ADVP (RB also)) (ADJP (JJ important)))) (: :) (NP (NP (NN regulation)) (PP (IN of) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NP (NP (NN blood) (NN sugar) (NN level)) (, ,) (NP (NN hyperlipidaemia)) (CC and) (NP (NN obesity))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT a) (NN change)) (PP (IN of) (NP (NP (NN lifestyle)) (-LRB- -LRB-) (VP (VBG giving) (PP (IN up) (NP (NP (NN smoking)) (, ,) (ADJP (JJ adapting) (PP (IN of) (NP (NP (NN diet)) (CC and) (NP (JJR more) (JJ physical) (NN exertion)))))))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (DT a) (ADJP (RB very) (JJ low)) (JJ cardiac) (NN capacity)))) (VP (MD should) (VP (VB be) (VP (VBN advised) (S (VP (TO to) (VP (VB refrain) (PP (IN from) (NP (NP (NN treatment)) (PP (IN of) (NP (DT the) (JJ erection) (NN disorder)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Failure)) (PP (IN of) (NP (NN drug1))) (S (VP (TO to) (VP (VB modify) (NP (NN drug2)))))) (VP (VBD induced) (NP (NN hypertension)) (PP (IN in) (NP (NN sheep))))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (PP (IN in) (NP (NNS rats)))) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1) (NN administration)) (VP (VBZ attenuates) (NP (NP (JJ certain) (NNS types)) (PP (IN of) (NP (ADJP (NN drug2) (JJ dependent)) (NN hypertension))) (, ,) (PP (VBG including) (NP (JJ drug3) (NN hypertension)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (JJ oral) (NN drug1))) (PP (IN on) (NP (ADJP (NN drug2) (VBN induced)) (NN hypertension)))) (VP (VBD were) (VP (VBN examined) (PP (IN in) (NP (JJ conscious) (NN sheep)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN blood) (NN pressure)) (CC or) (NP (NP (JJ metabolic) (NNS responses)) (PP (TO to) (NP (NN drug2))) (PP (IN in) (NP (NN sheep)))))))) (. .)))
(S1 (S (NP (NP (JJ Pharmacokinetic) (NN Interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (CC or) (NP (NN drug3)))) (PP (IN in) (NP (JJ healthy) (NNS males))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ pharmacokinetic) (NN interaction)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))))))) (CC and) (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT these) (NNS drugs))) (PP (IN on) (NP (NP (DT the) (NN erythromycin) (NN breath) (NN test)) (PRN (-LRB- -LRB-) (NP (NN ERMBT)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (CD Twenty-four) (JJ healthy) (JJ male) (NNS subjects)) (VP (VBD were) (VP (VBN randomized) (PP (TO to) (NP (NP (CD one)) (PP (IN of) (NP (CD two) (NNS cohorts)))))))) (. .)))
(S1 (S (NP (DT All) (NNS subjects)) (VP (VBD received) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 1,200) (NN mg) (RB twice) (NP (DT a) (NN day))) (-RRB- -RRB-))) (PP (IN for) (NP (CD 4) (NNS days))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ 7-day) (NN washout) (NN period)) (, ,) (VP (VBN followed) (PP (IN by) (NP (CC either) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 300) (NN mg)) (PP (IN once) (NP (NN a) (NN day) (CD -LSB-QD))) (-RRB- -RSB-) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN cohort) (CD 1)) (-RRB- -RRB-))) (CC or) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 600) (NN mg)) (NN QD)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN cohort) (CD 2)) (-RRB- -RRB-))))) (PP (IN for) (NP (CD 14) (NNS days))))))))) (. .)))
(S1 (S (S (S (NP (NN Cohort) (CD 1)) (ADVP (RB then)) (VP (VBD received) (NP (NP (NP (NN drug1)) (CC plus) (NP (NN drug2))) (PP (IN for) (NP (CD 10) (NNS days)))))) (, ,) (CC and) (S (NP (NN cohort) (CD 2)) (VP (VBD received) (NP (NP (NN drug3)) (CC plus) (NP (NN drug4))) (PP (IN for) (NP (CD 4) (NNS days)))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Serial) (NP (NP (NN plasma)) (CC and) (NP (NN urine))) (NNS samples)) (PP (IN for) (NP (NP (NN measurement)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))))) (CC and) (NP (PRP$ their) (NNS drug4) (, ,))) (VP (VBD were) (VP (VBN measured) (PP (IN by) (NP (JJ high-performance) (JJ liquid) (NN chromatography)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NN drug2) (POS 's) (NNS pharmacokinetics))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (NP (NP (DT the) (NN area)) (PP (IN under) (NP (NP (DT the) (NN curve)) (PP (IN at) (NP (JJ steady) (NN state)))))) (PRN (-LRB- -LRB-) (NP (NP (NN AUC)) (PRN (-LRB- -LRB-) (NP (NN ss)) (-RRB- -RRB-))) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (NP (NP (NN 2.93-fold)) (CC and) (NP (NP (DT the) (NN AUC)) (PRN (-LRB- -LRB-) (NP (NN ss)) (-RRB- -RRB-)))) (PP (IN of) (NP (NN drug3))) (PP (IN by) (NP (NN 13.3-fold))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NP (DT the) (NN AUC)) (PRN (-LRB- -LRB-) (NP (NN ss)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (CD 82) (NN %))))) (, ,) (CC but) (S (NP (NN drug3)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug4) (NNS pharmacokinetics)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD decreased) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (DT the) (NN ERMBT)))) (PP (IN by) (NP (CD 83) (NN %))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (NP (DT the) (NN ERMBT)) (PP (IN after) (NP (NP (CD 2) (NNS weeks)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (NN therapy))))))))) (VP (VBD were) (VP (VBN increased) (NP (NP (QP (CD 187) (CC and) (CD 156)) (NN %)) (, ,) (ADVP (RB respectively)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC plus) (NP (NN drug2))) (VP (VBD was) (VP (ADVP (RB well)) (VBN tolerated)))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (CC plus) (NP (NN drug2))) (VP (VBD was) (VP (ADVP (RB poorly)) (VBN tolerated)))) (, ,) (CC and) (S (NP (NP (CD 5)) (PP (IN of) (NP (CD 11) (NNS subjects)))) (VP (VBD discontinued) (NP (NN therapy))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (ADVP (RB markedly)) (VP (VBZ increases) (NP (NP (DT the) (JJ metabolic) (NN clearance)) (PP (IN of) (NP (NN drug2)))))) (, ,) (CC and) (S (NP (NN coadministration)) (VP (VBZ is) (VP (VBN contraindicated))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (ADVP (RB significantly)) (VP (VBZ decreases) (NP (NP (NN clearance)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (, ,) (CC and) (S (NP (DT the) (NN combination)) (VP (VBZ is) (ADVP (RB poorly)) (VP (VBN tolerated))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (DT the) (NN ERMBT)))) (, ,) (CC and) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBP are) (NP (NP (JJ equipotent) (NNS inducers)) (PP (IN of) (NP (DT the) (NN ERMBT))))))) (. .)))
(S1 (S (S (NP (NP (NN -LSB-The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ mixed-function) (NNS mono-oxidases))) (PP (IN in) (NP (DT the) (NN liver) (NNS microsomes))))) (-RRB- -RSB-)) (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (DT the) (JJ drug2) (NN --the) (NN drug) (NN drug3) (NN --on) (JJ hepatic) (JJ microsomal) (NN monooxygenase) (NNS activities)))) (VP (VBD were) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (DT The) (NN agent)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB produce) (NP (NP (DT some) (NN inhibiting) (NN activity)) (PP (IN against) (NP (JJ hepatic) (JJ microsomal) (NN 7-ethoxycoumarine) (NN deethylase))) (PP (IN in) (NP (JJ male) (NN Wistar) (NNS rats)))) (PP (IN in) (NP (ADJP (ADJP (FW vitro)) (CC and) (ADJP (FW in) (FW vivo))) (NNS experiments))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN given) (PP (IN in) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 50) (NN mg/kg)))))))) (, ,) (NP (NN drug1)) (VP (VBD produced) (NP (NP (DT no) (ADJP (RB statistically) (JJ significant)) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (JJ hexanal-induced) (NN sleep)) (PP (IN in) (NP (NNS mice)))))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (NN agent)) (VP (VBZ has) (NP (JJ slight) (NNS effects)) (PP (IN on) (NP (DT the) (VBN tested) (NNS activities)))))))) (. .)))
(S1 (S (S (NP (NP (VBN Repeated) (JJ oral) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NN sheep)))) (: :) (NP (NP (NNS interactions)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))))) (. .)))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN between) (NP (NP (NNS treatments)) (PP (IN with) (NP (NP (NN drug1)) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (DT an) (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (DT an) (NN drug5)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (JJ microsomal) (NNS enzymes)))) (-RRB- -RRB-)))))))) (VP (VBD were) (VP (VBN investigated) (PP (IN in) (NP (NN sheep)))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ daily) (NN dose)) (PP (IN of) (NP (NP (CD 2) (NN mg)) (PP (IN of) (NP (NP (NN drug1) (NNS /kg)) (PP (IN of) (NP (NP (NN body) (NN weight)) (PP (IN for) (NP (CD 6) (NNS days)))))))))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN plasma) (NNS enzymes)) (CC or) (NP (NP (DT the) (JJ antiprothrombinemic) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (PP (IN in) (NP (NNS wethers)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN treatment)) (PP (IN of) (NP (NNS ewes))) (PP (IN with) (NP (NP (DT an) (JJ intravenous) (-LRB- -LRB-) (NN IV) (-RRB- -RRB-) (NN injection)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (ADJP (JJ insufficient) (S (VP (TO to) (VP (VB produce) (NP (NP (JJ significant) (NN inhibition)) (PP (IN of) (NP (NP (NP (NN erythrocyte) (NN acetylcholinesterase)) (PRN (-LRB- -LRB-) (NP (NN AChE)) (-RRB- -RRB-))) (NN activity)))))))) (, ,)))))) (VP (VBD appeared) (S (VP (TO to) (VP (VB produce) (NP (JJ additive) (NNS effects)) (PP (IN with) (NP (NP (DT those)) (VP (VBN produced) (PP (IN by) (NP (NP (JJ subsequent) (NN treatment)) (PP (IN with) (NP (NP (CD 4) (NN mg)) (PP (IN of) (NP (NN drug2) (NN /kg/day))))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (NNS ewes)) (VP (VBN given) (NP (NP (CD 40) (NN mg)) (PP (IN of) (NP (NN drug1) (NNS /kg))) (PP (IN for) (NP (CD 5) (NNS days)))) (ADVP (RB intraperitoneally)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))))) (, ,) (S (S (NP (NP (DT the) (NN anticholinesterase) (NN effect)) (PP (IN of) (NP (NP (CD 4) (NN mg)) (PP (IN of) (NP (NN drug2) (NNS /kg)))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN reduced)))) (CC and) (S (NP (NP (NNS signs)) (PP (IN of) (NP (NN toxicity)))) (VP (VBD were) (RB not) (ADJP (JJ present))))) (. .)))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NP (JJ daily) (NNS doses)) (PP (IN of) (NP (NP (CD 2) (NN mg)) (PP (IN of) (NP (NN drug1) (NNS /kg))) (PP (IN for) (NP (CD 6) (NNS days)))))))) (VP (VBD did) (RB not) (VP (VB modify) (NP (NP (DT the) (NN anticholinesterase) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ 2nd) (NN series)) (PP (IN of) (NP (NP (NNS treatments)) (VP (VBN given) (ADVP (NP (CD 6) (NNS weeks)) (RB later))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Pharmacokinetic) (NN profile)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (JJ special) (NNS populations))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (JJ healthy) (JJ normal) (NNS volunteers)))) (VP (VP (VBZ has) (VP (VBN been) (ADVP (RB extensively)) (VP (VBN studied)))) (CC and) (VP (VBZ is) (ADVP (RB well)) (VP (VBN described))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN characterised) (PP (IN by) (NP (NP (DT a) (JJ high) (JJ oral) (NN bioavailability)) (, ,) (NP (NP (JJ low) (NN clearance)) (, ,) (NP (NP (DT a) (JJ small) (NN volume)) (PP (IN of) (NP (NN distribution))))) (, ,) (CC and) (NP (DT a) (JJ 7-hour) (NN half-life))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB essentially)) (ADVP (RB completely)) (VP (VBN metabolised)))) (, ,) (S (NP (RB therefore) (JJ little)) (VP (VBZ is) (VP (VBN excreted) (ADJP (JJ unchanged))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB highly)) (VP (NN protein) (VBN bound)))) (. .)))
(S1 (S (S (S (VP (TO To) (VP (VB investigate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN disease) (NNS states)) (CC or) (NP (JJ concomitant) (NN drug) (NN administration)))) (PP (IN on) (NP (NP (NP (DT a) (NN patient) (POS 's)) (NN response)) (PP (TO to) (NP (NN drug1))))))))) (, ,) (NP (JJ additional) (JJ pharmacokinetic) (NNS studies)) (VP (VBD were) (VP (VBN carried) (PRT (RP out)) (PP (IN in) (NP (JJ special) (NNS populations)))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ has) (NP (DT a) (JJ well-defined) (JJ pharmacokinetic-pharmacodynamic) (NN relationship))))) (, ,) (NP (NP (NN measurement)) (PP (IN of) (NP (JJ pharmacokinetic) (NNS parameters)))) (VP (VBZ is) (ADJP (RB clinically) (JJ relevant)))) (. .)))
(S1 (S (S (NP (NP (NNS Data)) (PP (IN from) (NP (NP (NNS studies)) (PP (TO to) (NP (NN date)))))) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN disease) (NNS states)) (, ,) (NP (JJ underlying) (NNS conditions)) (, ,) (CC and) (NP (ADJP (RB concomitantly) (VBN administered)) (ADJP (RB highly) (JJ protein-bound)) (NNS drugs))) (VP (VBP have) (NP (RB essentially) (DT no) (NN effect)) (PP (IN on) (NP (NN drug1) (NNS pharmacokinetics)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (MD can) (ADVP (RB generally)) (VP (VB be) (VP (VBN given) (PP (IN without) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (JJ dosage) (NNS modifications)) (PP (IN in) (NP (NP (JJ special) (NNS populations)) (PP (JJ such) (IN as) (NP (NP (JJ uncompromised) (JJ elderly) (NNS patients)) (, ,) (NP (NP (DT those)) (PP (IN with) (NP (JJ moderate) (JJ renal) (NN impairment)))) (, ,) (CC and) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ stable) (JJ hepatic) (NN disease)))))))))))))))) (. .)))
(S1 (S (S (NP (VBN Enhanced) (NN drug1) (NN clearance)) (VP (JJ secondary) (PP (TO to) (NP (NN drug2) (NN therapy))))) (. .)))
(S1 (S (S (NP (DT This) (NN report)) (VP (VBZ describes) (NP (NP (CD two) (NNS cases)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN drug1) (NN clearance)) (VP (VBD accelerated) (ADVP (RB markedly)) (PP (IN with) (NP (JJ concomitant) (NN drug2) (NN administration))))))))) (. .)))
(S1 (S (S (NP (JJ Maximum) (VBN calculated) (NN drug1) (NN clearance)) (VP (VBD ranged) (PP (IN from) (NP (CD 2) (QP (CD 1/2) (TO to) (CD 3)) (CD 1/2) (NNS times) (NN baseline))))) (. .)))
(S1 (S (S (NP (NP (NN Onset)) (PP (IN of) (NP (DT the) (NN interaction)))) (VP (VBD began) (PP (IN within) (NP (NP (CD five) (NNS days)) (PP (IN of) (NP (ADJP (NN beginning) (JJ concurrent)) (NN therapy))))))) (. .)))
(S1 (S (PP (IN With) (NP (JJ combined) (NN use))) (, ,) (NP (NNS clinicians)) (VP (MD should) (VP (VB be) (NP (NP (NP (NN aware)) (PRN (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN added))))) (, ,))) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (NN reexacerbation)) (PP (IN of) (NP (JJ pulmonary) (NN symptomatology))) (PP (IN due) (TO to) (NP (JJ lowered) (NN serum) (NN drug2) (NNS concentrations)))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NN activity)) (PP (IN of) (NP (NN drug1))) (, ,) (UCP (CC either) (ADVP (RB singly)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))) (, ,) (PP (IN against) (NP (NN Mycobacterium) (NNS ulcerans))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ antimicrobial) (NN effect)) (PP (IN of) (NP (NP (NP (DT a) (NN drug1)) (, ,) (NP (NN drug2)) (, ,)) (UCP (CC either) (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug3))))) (, ,))))) (VP (VBD was) (VP (VBN evaluated) (ADVP (FW in) (FW vitro)) (PP (IN against) (NP (NP (CD two) (NN type) (NNS strains)) (CC and) (NP (NP (CD six) (JJ clinical) (NNS isolates)) (PP (IN of) (NP (NN Mycobacterium) (NNS ulcerans))))))))) (. .)))
(S1 (S (NP (NP (NN Growth)) (PP (IN of) (NP (NN M))) (. .))))
(S1 (S (S (NP (NN ulcerans)) (VP (VBD was) (VP (VBN measured) (PP (IN by) (NP (NP (NN plate) (NNS counts)) (CC and) (NP (DT the) (ADJP (NN BACTEC) (JJ radiometric)) (NN method))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ minimal) (JJ inhibitory) (NN concentration)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ minimal) (JJ bactericidal) (NN concentration)) (PP (IN of) (NP (NN drug1))) (PP (IN against) (NP (NN M)))))) (. .)))
(S1 (S (S (NP (NN ulcerans)) (VP (VBD was) (PP (IN between) (NP (QP (CD 0.012) (CC and) (CD 0.025)) (NN mg/l))) (, ,) (SBAR (IN while) (S (NP (NP (JJ corresponding) (NNS values)) (PP (IN for) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD were) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (NP (NP (CD 0.1-0.8) (NN mg/l)) (CC and) (NP (CD 0.1-0.4) (NN mg/l))) (ADVP (RB respectively))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN combined) (PP (IN with) (NP (NN drug1)))))) (, ,) (NP (NN drug2)) (VP (VBD exhibited) (NP (JJ strong) (JJ synergistic) (NN activity)) (SBAR (IN while) (S (NP (RB only) (JJ additive) (NNS effects)) (VP (VBD were) (VP (VBN observed) (PP (IN with) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (CC or) (NP (NN drug4)) (-RRB- -RRB-))) (CC and) (NP (NN drug5)))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ has) (NP (DT a) (JJ great) (NN potential)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN M)))))))))) (. .)))
(S1 (S (S (NP (NNS ulcerans)) (NP (NN infection))) (. .)))
(S1 (S (NP (NP (NNS Pharmacokinetics)) (PP (IN of) (NP (NN drug1))) (. .))))
(S1 (S (S (NP (NP (JJ Effective) (NN use)) (PP (IN of) (NP (NNS drugs))) (PP (IN in) (NP (NN therapy)))) (VP (VBZ depends) (PP (CONJP (RB not) (RB only)) (PP (IN on) (NP (JJ clinical) (NN acumen))) (CONJP (CC but) (RB also)) (PP (IN on) (NP (NP (DT the) (NN availability)) (PP (IN of) (NP (JJ relevant) (ADJP (ADJP (JJ pharmacokinetic)) (CC and) (ADJP (JJ pharmacodynamic))) (NNS data)))))))) (. .)))
(S1 (S (S (NP (JJ Such) (NN information)) (VP (VBZ assists) (PP (IN in) (NP (NP (NP (NN development)) (PP (IN of) (NP (JJ safe) (NN dosing) (NNS regimens)))) (, ,) (NP (NP (NN prediction)) (PP (IN of) (NP (NP (JJ abnormal) (NN handling)) (PP (IN of) (NP (NNS drugs))) (PP (IN in) (NP (NP (NNS states)) (PP (IN of) (NP (NP (NN disease)) (CC and) (NP (NN disorder))))))))) (CC and) (NP (NP (NN anticipation)) (PP (IN of) (NP (NN drug) (NNS interactions)))))))) (. .)))
(S1 (S (S (PP (IN For) (NP (NP (DT the) (NN drug1)) (ADJP (ADVP (RB now)) (JJ available) (PP (IN in) (NP (NP (DT the) (JJ United) (NNS States)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4))) (-RRB- -RRB-))))))) (, ,) (NP (DT these) (NNS data)) (VP (VBD appeared) (SBAR (RB well) (IN after) (S (NP (NP (JJ clinical) (NNS patterns)) (PP (IN of) (NP (NN use)))) (VP (VBD evolved)))))) (. .)))
(S1 (S (ADVP (RB Nonetheless)) (, ,) (NP (PRP$ their) (NN relevance)) (VP (VBZ continues) (S (VP (TO to) (VP (VP (VB be) (VP (VBN demonstrated) (PP (IN by) (NP (NP (DT the) (NN dependence)) (PP (IN of) (NP (DT each) (NN agent))) (PP (IN on) (NP (JJ intact) (NN liver) (NN blood) (NN flow))))))) (CC and) (VP (VB function) (PP (IN for) (NP (NP (JJ normal) (NNS rates)) (PP (IN of) (NP (NN elimination)))))))))) (: ;)))
(S1 (S (PP (IN by) (NP (NP (NP (DT the) (JJ nonlinear) (JJ kinetic) (NNS characteristics)) (PP (IN for) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (CC and) (RB probably) (PP (IN for) (NP (NN drug3))) (, ,) (PP (IN as) (NP (NN well))) (-RRB- -RRB-))))) (CC and) (NP (NP (DT the) (JJ derivative) (NNS implications)) (PP (IN for) (NP (VBN decreased) (NN dosing) (NN frequency) (NNS requirements)))))) (: ;)))
(S1 (S (S (UCP (CC and) (PP (IN by) (NP (NP (NNS observations)) (VP (ADVP (RB now)) (VBG appearing) (PP (IN on) (NP (NP (DT the) (NN relation)) (PP (IN between) (NP (NP (NN plasma) (NN drug) (NNS levels)) (CC and) (NP (NP (NN drug) (NNS effects)) (, ,) (ADJP (CC both) (ADJP (JJ therapeutic)) (CC and) (ADJP (JJ toxic))))))))))))) (. .)))
(S1 (S (S (NP (JJ Such) (NNS data)) (VP (VBP are) (VP (VBN discussed) (ADVP (RB herein)) (, ,) (PP (IN with) (NP (NP (NN emphasis)) (PP (IN on) (NP (NP (DT those) (NNS aspects)) (PP (IN that) (NP (NP (NN impact)) (PP (IN on) (NP (NP (DT the) (JJ clinical) (NN use)) (PP (IN of) (NP (DT the) (NN drug1)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Herbal) (NNS remedies)) (, ,) (NP (NNS nephropathies)) (, ,) (CC and) (NP (JJ renal) (NN disease)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (JJ herbal) (NNS remedies)))) (VP (VBZ is) (VP (VBG becoming) (ADJP (RB increasingly) (JJ popular) (PP (IN in) (NP (DT the) (JJ United) (NNS States))))))) (. .)))
(S1 (S (S (NP (NN Research)) (VP (VBZ has) (VP (VBN shown) (SBAR (IN that) (S (NP (JJ herbal) (NN remedy) (NN use)) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (JJ acute) (JJ renal) (NN failure))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ herbal) (NNS remedies)))) (VP (MD may) (VP (VB be) (ADJP (JJ detrimental) (PP (IN for) (NP (NP (DT the) (NN patient)) (PP (IN with) (NP (VBN compromised) (JJ renal) (NN function))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (JJ renal) (NN insufficiency)) (CC or) (NP (JJ renal) (NN failure))))) (VP (MD may) (VP (VB be) (PP (IN at) (NP (NP (NN risk)) (PP (IN for) (NP (NP (JJ further) (NN kidney) (NN damage)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNS complications)) (ADJP (JJ related) (PP (TO to) (NP (NP (NNS interactions)) (PP (IN of) (NP (JJ herbal) (NNS remedies))) (PP (IN with) (NP (JJ complex) (JJ renal) (NN therapy) (NNS regimens)))))))))))))) (. .)))
(S1 (S (NP (DT This) (NN article)) (VP (MD will) (VP (VBP describe) (NP (NP (NP (DT the) (JJ escalating) (NN use)) (PP (IN of) (NP (JJ herbal) (NN therapy)))) (CC and) (NP (NP (DT the) (NNS hazards)) (PP (IN of) (NP (NN herbal))))) (PP (IN remedy) (NP (NP (NN use)) (PP (IN among) (NP (NNS patients))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (PRP$ their) (NNS complications))) (. .))))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP suppress) (NP (DT the) (JJ immune) (NN system)))))) (VP (VBP are) (ADVP (RB widely)) (VP (VBN used)))) (. .)))
(S1 (S (S (NP (PRP They)) (VP (VBP are) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN organ) (NNS transplants)) (, ,) (NP (NN malignancy)) (, ,) (CC and) (NP (NP (NP (NP (RB increasingly) (DT those)) (PP (IN with) (NP (NP (NNS conditions)) (PP (JJ such) (IN as) (NP (NP (NN psoriasis)) (, ,) (NP (NN rheumatoid) (NN arthritis)) (, ,) (CC and) (NP (NN liver))))))) (CC and) (NP (NN bowel) (NN disease))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN inflammation)) (VP (VBZ is) (NP (DT an) (JJ aetiological) (NN factor))))))))))))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (NP (DT the) (JJ broadening) (NNS indications)) (PP (IN for) (NP (NN drug1)))) (, ,) (CC and) (NP (NP (DT the) (JJ prolonged) (NN survival)) (PP (IN in) (NP (NP (NNS conditions)) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (PRP they)) (VP (VBP are) (VP (VBG being) (VP (VBN used)))))))))))) (, ,) (NP (NP (JJ many) (NNS patients)) (PP (IN on) (NP (NN immunosuppression)))) (VP (VBP are) (ADVP (RB now)) (VP (VBN cared) (PP (IN for) (UCP (PP (IN in) (NP (DT the) (NN community))) (CC or) (VP (VBN seen) (PP (IN in) (NP (JJ non-specialist) (NNS hospitals))) (, ,) (ADVP (RB usually)) (PP (IN in) (NP (NP (JJ close) (NN collaboration)) (PP (IN with) (NP (DT a) (NN specialist))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN article)) (VP (VBZ looks) (PP (IN at) (NP (NP (CD five) (ADJP (RB commonly) (VBN used)) (NN drug1)) (PP (PP (IN in) (NP (NP (NP (NN turn)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-))) (, ,) (VP (VBG discussing) (NP (NP (DT the) (JJ main)) (, ,) (NP (NN non-infection)) (, ,) (NP (JJ unwanted) (NNS effects)) (, ,) (NP (NNS ways))) (S (VP (TO to) (VP (VB avoid) (NP (PRP them)))))))) (CC and) (SBAR (WHNP (WP what)) (VP (TO to) (VP (VB do) (SBAR (IN if) (S (NP (NNS problems)) (VP (VBP arise)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN management)) (PP (IN of) (NP (NN infection)))) (VP (VBZ is) (VP (VBN dealt) (PRT (IN with)) (PP (IN as) (NP (DT a) (JJ separate) (NN section)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (ADVP (RB similarly)) (VP (VP (VBP inhibit)) (CC and) (VP (VB stimulate) (NP (NP (ADJP (NP (NP (NN drug3)) (CC -) (CC or) (NP (NN drug4))) (JJ -induced)) (NN proliferation)) (PP (IN of) (NP (JJ prostatic) (NN epithelium))))))) (. .)))
(S1 (S (S (NP (JJ Prostatic) (NN epithelium)) (VP (VBZ proliferates) (PP (IN in) (NP (NP (DT a) (VBN defined) (NN medium)) (VP (VBG consisting) (PP (IN of) (NP (NP (JJ basal) (NN medium) (CD RPMI1640)) (VP (VBG containing) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN microgram/ml)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN ng/ml)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 3.7) (NN micrograms/ml) (CC or) (CD 0.1) (NN IU/ml)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (CC neither) (NP (NN drug1)) (CC nor) (NP (NN drug2))) (VP (VBD affected) (NP (NP (DT the) (NN proliferation)) (PP (IN of) (NP (JJ prostatic) (NN epithelium))) (PP (IN in) (NP (NP (NN RPMI1640) (NN containing) (NN drug3)) (ADVP (RB alone)))))))) (, ,) (NP (PRP they)) (VP (VB modify) (NP (NP (DT the) (JJ mitogenic) (NN effect)) (PP (IN of) (NP (NP (NN drug4)) (CC and) (NP (NN drug5)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN at) (NP (NP (CD 10) (-LRB- -LRB-) (CD -10) (-RRB- -RRB-) (NN M)) (CC or) (NP (NN drug2)))) (PP (IN at) (NP (QP (QP (RB about) (CD 3) (CC X) (CD 10)) (PRN (-LRB- -LRB-) (NP (NN -9)) (-RRB- -RRB-))) (NN M)))) (VP (VBZ inhibits) (NP (NP (NN proliferation)) (VP (VBN stimulated) (PP (IN by) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (JJR Higher) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 10) (-LRB- -LRB-) (CD -8) (-RRB- -RRB-) (: -) (CD 10) (-LRB- -LRB-) (CD -6) (-RRB- -RRB-) (NN M)) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 3) (CC X) (CD 10) (-LRB- -LRB-) (CD -8) (-RRB- -RRB-) (: -) (CD 10) (-LRB- -LRB-) (CD -7) (-RRB- -RRB-) (NN M)) (-RRB- -RRB-)))))) (VP (VBP enhance) (NP (NP (DT the) (JJ mitogenic) (NN activity)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD had) (NP (DT a) (JJ similar) (NN effect)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN drug1)) (VP (VP (VBD stimulated)) (, ,) (CC but) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB inhibit) (, ,) (NP (NN proliferation)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,) (CONJP (CC and) (RB possibly)) (NP (NP (JJ other) (NN drug3)) (CC and) (NP (NN drug4))) (, ,)) (VP (MD may) (VP (VB regulate) (NP (NP (DT the) (NN proliferation)) (PP (IN of) (NP (NN prostate) (NN epithelium)))) (PP (IN by) (NP (NP (DT a) (JJ dose-dependent) (NN modification)) (PP (IN of) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NN drug5)) (CC and) (NP (NN drug6)))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN Death)) (PP (IN in) (NP (NN drug1) (NNS users)))) (: :) (NP (NP (NNS causes)) (CC and) (NP (NNS rates))) (. .))))
(S1 (S (S (NP (DT The) (NN world) (JJ medical) (NN literature)) (VP (VBZ contains) (NP (NP (CD 43) (NNS reports)) (PP (IN of) (NP (NP (NNS deaths)) (VP (VBN associated) (PP (IN with) (NP (NN drug1))))))) (PP (IN in) (NP (DT a) (JJ 35-year) (NN period))))) (. .)))
(S1 (S (S (NP (DT These)) (VP (VBD included) (NP (NP (CD seven) (JJ cerebrovascular) (NNS accidents)) (, ,) (NP (NP (CD six) (JJ sudden) (JJ cardiac) (NNS deaths)) (, ,) (NP (NP (NP (CD three) (NNS cases)) (PP (IN of) (NP (NN hyperpyrexia)))) (, ,) (NP (NP (CD eight) (NNS poisonings)) (PP (IN of) (NP (JJ uncertain) (NN mechanism)))) (CC and) (NP (NP (CD seven) (NNS cases)) (PP (IN of) (NP (NP (JJ medical) (NNS complications)) (PP (IN of) (NP (JJ intravenous) (NN injection))))))))))) (: ;)))
(S1 (S (S (NP (DT the) (NN remainder)) (VP (VBD were) (PP (IN of) (NP (JJ uncertain) (NN cause))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (PP (IN in) (NP (NP (NN Ontario)) (ADVP (RB alone)))) (, ,) (PP (IN in) (NP (NP (CD 1972)) (CC and) (NP (CD 1973)))) (NP (EX there)) (VP (VBD were) (NP (NP (CD 26) (NNS deaths)) (PP (IN in) (NP (NN drug1) (NNS users))) (, ,) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (NP (CD 16)) (VP (VBD were) (ADJP (JJ due) (PP (TO to) (NP (NN accident) (NP (NN suicide)) (CC or) (NP (NN homicide))))))))))) (. .)))
(S1 (S (S (S (PP (IN Of) (NP (DT the) (VBG remaining) (NNS cases))) (, ,) (NP (CD two)) (VP (VBD were) (NP (JJ cardiac) (, ,) (NP (CD two) (JJ hepatic))))) (CC and) (S (NP (DT the) (NN rest)) (VP (VBD were) (VP (VBN mixed) (NP (NN drug) (NN overdose)))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Pulmonary) (NN granulomata)) (, ,) (NP (JJ subacute) (NN hepatitis)) (CC and) (NP (JJ other) (NNS lesions))) (VP (VBG resulting) (PP (IN from) (NP (JJ intravenous) (NN drug) (NN use))))) (VP (VBD were) (NP (JJ common) (NNS findings)) (PP (IN at) (NP (NN autopsy))))) (. .)))
(S1 (S (S (PP (IN On) (DT the) (NN basis) (IN of) (NP (NP (DT the) (VBN estimated) (NN number)) (PP (IN of) (NP (NP (JJ regular) (NNS users)) (PP (IN of) (NP (NP (JJ intravenous) (NN drug1)) (PP (IN in) (NP (NN Ontario))))))))) (, ,) (NP (NP (DT the) (NN mortality) (NN rate)) (PP (IN in) (NP (JJ such) (NNS users)))) (VP (VP (VBZ is) (NP (NP (QP (IN at) (JJS least) (CD four)) (NNS times)) (ADJP (RB as) (JJ high) (PP (IN as) (PP (IN in) (NP (NP (DT the) (JJ general) (NN population)) (PP (IN of) (NP (DT the) (JJ same) (NN age))))))))) (, ,) (CC and) (VP (VBZ is) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (NP (NNS alcoholics)) (CC and) (NP (NN drug2) (NNS addicts)))))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ absolute) (NN number)) (PP (IN of) (NP (JJ drug1) (JJ -related) (NNS deaths)))) (VP (VBZ is) (ADJP (ADJP (RB far) (JJR greater)) (PP (IN than) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS deaths)) (PP (IN in) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)) (NP (NNS users)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ -LSB-A) (JJ pharmacological) (NN analysis)) (PP (IN of) (NP (NP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (VBN stimulated) (JJ gastric) (NN secretion))) (-RRB- -RSB-)) (JJ Chronic) (NNS experiments)) (PP (IN on) (NP (NP (NNS dogs)) (PP (IN with) (NP (JJ gastric) (NNS fistulas)))))))) (VP (VBD were) (VP (VBN carried) (PRT (RP out)) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN on) (NP (ADJP (NP (NP (NN drug4)) (CC -) (CC and) (NP (NN drug5))) (JJ -induced)) (JJ gastric) (NN acid) (NN secretion)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBD was) (VP (VBN established) (SBAR (IN that) (S (NP (DT both) (NNS angiotensins)) (VP (VBD inhibited) (NP (NP (JJ gastric) (NN acid) (NN secretion)) (VP (VBN stimulated) (PP (PP (IN by) (NP (NN drug1))) (CC but) (PP (RB not) (IN by) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Comparative) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN stimulation)) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN cholino-)) (CC and) (NP (NN adrenoreceptors))))))) (PP (IN on) (NP (NP (DT this) (JJ inhibitory) (NN action)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBD suggested) (NP (NP (DT the) (NN mediation)) (PP (IN of) (NP (NN drug2)))) (VP (VB influence) (PP (IN through) (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (NP (JJ cholinergic) (NNS reactions)) (PP (IN of) (NP (NP (JJ parietal) (NNS cells)) (PP (IN in) (NP (DT the) (NN stomach)))))))))))) (. .)))
(S1 (S (NP (NP (NN -LSB-Stimulation)) (PP (IN by) (NP (NP (NN drug1) (NN --an) (NN analog)) (PP (IN of) (NP (DT the) (NN octapeptide) (NN cholecystokinin--of) (NN drug2) (NN binding))))) (PP (IN after) (NP (NP (DT the) (JJ long-term) (NN administration)) (PP (IN of) (NP (NN drug3)))))) (-RRB- -RSB-) (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN established) (PP (IN in) (NP (NP (NNS experiments)) (PP (IN on) (NP (NP (JJ white) (JJ male) (NNS rats)) (SBAR (WHNP (WDT that)) (S (NP (NP (NP (JJ prolonged) (NN administration)) (PRN (-LRB- -LRB-) (NP (NP (RB twice) (DT a) (NN day)) (PP (IN for) (NP (CD 14) (NNS days)))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 0.25) (NN mg/kg)) (-RRB- -RRB-))) (CC and) (NP (NN drug5))) (PRN (-LRB- -LRB-) (NP (CD 0.25) (NN mg/kg)) (-RRB- -RRB-))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (VBN reduced) (NN interaction)) (PP (IN between) (NP (NP (NN drug6)) (CC and) (NP (NP (JJ low) (NN affinity) (NN binding) (NNS sites)) (PP (IN for) (NP (NP (NN drug7)) (PP (IN in) (NP (JJ subcortical) (NNS structures)))))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN drug8) (NN binding)) (PP (IN with) (NP (NP (JJ high) (NN affinity) (NN binding) (NNS sites)) (PP (IN for) (NP (NN drug9)))))) (VP (VBD increased) (NP (NP (DT both)) (PP (IN in) (NP (NP (DT the) (JJ frontal) (NN cortex)) (CC and) (NP (NP (JJ subcortical) (NNS structures)) (PP (IN of) (NP (DT the) (NN forebrain)))))))))))))))))))) (. .)))
(S1 (S (S (PP (IN After) (NP (NP (JJ prolonged) (NN administration)) (PP (IN of) (NP (NN drug1))))) (NP (NP (DT the) (JJ displacing) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NP (DT an) (NN analog)) (PP (IN of) (NP (NN cholecystokinin) (NN octapeptide)))) (, ,)))) (VP (VBD was) (VP (VBN replaced) (PP (IN by) (NP (NP (DT the) (JJ stimulant) (NN action)) (PP (IN on) (NP (NN drug3) (NN binding)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN assumed) (SBAR (IN that) (S (NP (NP (VBN increased) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (JJ high) (NN affinity) (NN binding) (NNS sites)) (PP (IN for) (NP (NN drug2)))))) (PP (IN on) (NP (NP (NN dopamine2-)) (CC and) (NP (NN serotonin2-receptors))))) (VP (VBZ underlies) (NP (NP (DT the) (JJ antipsychotic) (NN action)) (PP (IN of) (NP (NP (NN drug3)) (PP (IN after) (NP (PRP$ their) (JJ prolonged) (NN administration)))))))))))) (. .)))
(S1 (S (S (NP (NN Cholecystokinin) (NN octapeptide)) (VP (VBZ is) (NP (NP (DT a) (JJ necessary) (NN factor)) (PP (IN for) (NP (NP (NN realization)) (PP (IN of) (NP (NP (DT this) (NN action)) (PP (IN of) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Interaction)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NNS rats))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN interaction)) (PP (IN of) (NP (NP (ADJP (RB intramuscularly) (VBN injected)) (NN drug1)) (CC and) (NP (NP (PRP$ its) (JJ N-demethylated) (NN metabolite)) (PRN (-LRB- -LRB-) (NP (NN metabolite) (NN I)) (-RRB- -RRB-))))) (PP (IN with) (NP (NN drug2)))) (VP (VBD was) (VP (VBN evaluated) (PP (IN in) (NP (NNS rats)))))) (. .)))
(S1 (S (S (NP (NP (NP (QP (CD Five) (, ,) (CD 10) (, ,) (CD 20) (, ,) (CC or) (CD 50)) (NN mg/kg)) (PP (IN of) (NP (NN drug1)))) (ADVP (RB alone)) (CC or) (NP (NP (QP (CD 20) (, ,) (CD 50) (, ,) (CC or) (CD 100)) (NN mg/kg)) (PP (IN of) (NP (NN metabolite) (NN I)))) (ADVP (RB alone))) (VP (VBD produced) (NP (NP (QP (JJR less) (IN than) (CD 10)) (NNS minutes)) (PP (IN of) (NP (NN hypnosis)))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN drug1) (JJ anesthetic) (NN requirement)) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (, ,) (NP (NN MAC)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN depressed) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN fashion))) (PP (IN as) (ADJP (JJ much) (PP (IN as) (NP (NP (NP (CD 56) (NN %)) (NP (CD 1-2) (NNS hours))) (CC and) (NP (NP (QP (RB as) (JJ much) (IN as) (CD 14)) (NN %)) (NP (NP (CD 5-6) (NNS hours)) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (CD 50) (NN mg/kg)) (, ,) (NP (NN im)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN reduction)) (PP (IN in) (NP (NN MAC)))) (VP (VBD was) (VP (VBN correlated) (PP (IN with) (NP (NP (NN brain) (NNS levels)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN metabolite) (NN I)))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (NN drug2) (: :) (NN metabolite) (NN I) (NN potency) (NN ration)) (PP (IN of) (NP (NN 3:1))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN half-life)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NN plasma)) (CC and) (NP (NN brain))))) (VP (VBD was) (ADJP (ADJP (JJR longer)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2))))) (PP (IN than) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBD was) (VP (VBN given) (ADVP (RB alone)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN concluded) (SBAR (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (NP (DT a) (JJ short-acting) (NN drug))))) (CC and) (SBAR (IN that) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN with) (NP (NN drug2)))) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB prolong) (ADVP (RB further)) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (PRP$ its) (NN action))) (PP (IN on) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NN interaction)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (JJ placental) (NNS vessels))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN interaction)) (PP (IN of) (NP (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ synthetic))) (NN drug2))) (PP (IN on) (NP (JJ placental) (NNS vessels)))) (VP (VBD was) (VP (VBN studied) (ADVP (FW in) (FW vitro))))) (. .)))
(S1 (S (S (NP (NN Resistance)) (VP (VBD was) (VP (VBN measured) (PP (IN near) (NP (NP (DT the) (JJ placental) (NN margin)) (PP (IN after) (NP (JJ spontaneous) (NN term) (NN delivery)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (CD seven) (NNS experiments))) (NP (NP (NNS reactions)) (PP (TO to) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD were) (VP (VBN drug3)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD produced) (NP (ADJP (RB significantly) (VBN increased)) (NN vasoconstriction)) (PP (IN after) (NP (NP (DT a) (JJ single) (NN administration)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (CD eight) (NNS experiments))) (NP (DT the) (NN perfusion) (NN medium)) (VP (VBD contained) (NP (NN drug1)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (DT no) (NN change)) (PP (IN after) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN reaction)) (PP (IN after) (NP (NN drug1)))) (VP (VBD remained) (NP (DT the) (JJ same)) (PP (IN in) (NP (NP (DT both) (NNS groups)) (PP (IN of) (NP (NNS experiments))))))) (. .)))
(S1 (S (NP (EX There)) (VP (VBZ is) (ADVP (RB thus)) (NP (DT an) (NN enhancement) (NN effect)))))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (ADVP (RB thus)) (NP (NP (DT an) (NN enhancement) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN upon) (NP (NP (DT the) (NN reaction)) (PP (IN of) (NP (JJ placental) (NNS vessels))) (PP (TO to) (NP (NN drug2))) (ADJP (FW in) (FW vitro))))))) (. .)))
(S1 (S (NP (NP (NN Note)) (: :) (NP (NP (NN dissolution)) (PP (IN of) (NP (NP (NN aerosol) (NNS particles)) (PP (IN of) (NP (NN drug1))))) (PP (IN in) (NP (NP (NN drug2)) (, ,) (NP (DT a) (JJ model) (NN drug3))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (DT a) (NN drug1) (NN extract)) (PP (IN from) (NP (NP (JJ bovine) (NN lung)) (, ,) (NP (NN drug2)) (, ,))))) (PP (IN on) (NP (NP (DT the) (NN dissolution) (NN rate)) (PP (IN of) (NP (NP (NN aerosol) (NNS particles)) (PP (IN of) (NP (NN drug3)))))))) (VP (VBD was) (VP (VBN determined)))) (. .)))
(S1 (S (S (NP (NP (NN Aerosol) (NNS particles)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (VP (VP (VBN generated) (PP (IN from) (NP (DT an) (JJ drug2) (NN solution)))) (, ,) (VP (VBN dried)) (, ,) (CC and) (VP (VBN collected) (PP (PP (IN by) (NP (NP (DT a) (NN cascade) (NN impactor)) (PP (IN for) (NP (NN characterization))))) (CC or) (PP (IN by) (NP (NP (DT a) (JJ liquid) (NN impinger)) (PP (IN for) (NP (NN dissolution) (NNS experiments)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Powder) (NN x-ray) (NN diffraction)) (, ,) (NP (JJ differential) (NN scanning) (NN calorimetry)) (, ,) (NP (JJ differential) (JJ thermal) (NN analysis)) (, ,) (CC and) (NP (NN scanning) (NN electron) (NN microscopy))) (VP (VBD were) (VP (VBN used) (S (VP (VP (TO to) (VP (VB characterize) (NP (DT the) (NN aerosol) (NNS particles)))) (CC and) (VP (VBG starting) (NP (NN material)))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN change)) (PP (IN in) (NP (NN phase)))) (VP (VBD was) (VP (VBN detected) (, ,) (SBAR (IN although) (S (NP (DT the) (NN aerosol) (NNS particles)) (VP (VBD appeared) (S (VP (TO to) (VP (VB contain) (NP (JJ residual) (NN drug1))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN dissolution) (NN rate)) (PP (IN of) (NP (DT the) (NN aerosol) (NNS particles))) (PP (IN in) (NP (NN saline)))) (VP (VBD was) (ADJP (ADJP (JJ low)) (CC and) (ADJP (JJ variable))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD increased) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (NN dissolution)) (PP (IN of) (NP (NN drug2)))))) (PP (IN in) (NN proportion) (TO to) (NP (NP (DT the) (VBN added) (NN concentration)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADVP (RB also)) (VP (VBN verified) (PP (IN by) (NP (NN equilibrium) (NN solubilization) (NNS studies))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB also)) (VP (VBD increased) (NP (NP (NN rate)) (PP (IN of) (NP (NN dissolution)))) (, ,) (PP (IN in) (NP (NP (DT a) (NN manner)) (ADJP (JJ similar) (PP (TO to) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (NN drug1)) (PP (VBG following) (NP (NN ultracentrifugation)))))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (EX there)) (VP (VBZ is) (NP (NP (JJ rapid) (NN equilibration)) (PP (IN of) (NP (NN drug2))) (PP (IN between) (NP (DT the) (NN drug3) (CC and) (JJ aqueous) (NN phase))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ has) (NP (NP (DT the) (NN potential)) (PP (IN of) (S (VP (VBG enhancing) (NP (NP (DT the) (NP (NN rate)) (CC and) (NP (NN extent))) (PP (IN of) (NP (NP (NN dissolution)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN administered) (PP (TO to) (NP (DT the) (NN lung)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Anaesthesia)) (CC and) (NP (DT the) (JJ epileptic) (NN pateint)))) (. .)))
(S1 (S (NP (NP (DT A) (NN review)) (. .))))
(S1 (S (S (NP (DT A) (NN review)) (VP (VBZ is) (VP (VBN presented) (PP (IN of) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (NNS problems)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB arise) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NN anaesthesia))) (PP (IN for) (NP (JJ epileptic) (NNS patients)))))))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT the) (NN possibility)) (PP (IN of) (S (VP (VBG precipitating) (NP (JJ anticonvulsant) (NN drug) (NN toxicity)))))))) (. .)))
(S1 (S (S (NP (JJ Numerous) (NN drug) (NNS interactions)) (VP (VBP are) (ADJP (JJ possible) (PP (IN with) (NP (NP (DT some) (NNS drug1)) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP affect) (NP (JJ hepatic) (JJ microsomal) (NN enzyme) (NNS systems)))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNS convulsions)) (VP (VBG occurring) (PP (IN in) (NP (JJ susceptible) (NNS patients)))))) (PP (VBG following) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (DT the) (JJ new) (NN drug1)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG inducing) (NP (NN CNS) (NN excitability)))))))))))))))) (. .)))
(S1 (S (NP (NP (NN Interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ spontaneous) (NN motility)) (PP (IN in) (NP (NN chick) (NNS embryos))))))) (. .))))
(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (ADVP (RB also)) (NP (NN drug1)) (VP (NNS fulfils) (NP (NP (DT the) (NN function)) (PP (IN as) (NP (NN co-activator))) (PP (IN in) (NP (NP (JJ glutamatergic) (NN activation)) (PP (IN of) (NP (JJ NMDA) (NNS receptors))) (PP (IN in) (NP (NP (DT the) (JJ neuronal) (NN apparatus)) (PP (IN of) (NP (JJ spontaneous) (NN motility))) (PP (IN in) (NP (NN chick) (NNS embryos)))))))))))) (. .)))
(S1 (S (NP (NP (NP (DT The) (JJ successive) (NN application)) (PP (IN of) (NP (NN drug1)))) (-LRB- -LRB-) (NP (NP (QP (CD 5) (CC or) (CD 10)) (NN mg/kg) (NN egg) (NN weight)) (PRN (-LRB- -LRB-) (NP (NN e.w.)) (-RRB- -RRB-))))))
(S1 (S (CC and) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg/kg) (NN e.w.)) (-RRB- -RRB-)))))
(S1 (S (NP (NP (DT The) (JJ successive) (NN application)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (QP (CD 5) (CC or) (CD 10)) (NN mg/kg) (NN egg) (NN weight)) (-LRB- -LRB-) (NP (NN e.w.)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg/kg) (NN e.w.)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT a) (ADJP (CD 10) (NN min)) (NN interval)))) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NP (JJ spontaneous) (NN motility)) (PP (IN of) (NP (JJ 17-day-old) (NN chick) (NNS embryos)))))) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN drug3)) (ADVP (RB alone))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN effect)) (VP (VBD did) (RB not) (VP (VB depend) (PP (IN on) (NP (NP (DT the) (NN order)) (PP (IN of) (NP (NP (NN application)) (PP (IN of) (NP (DT the) (NNS drugs)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ 13-day-old) (NNS embryos))) (, ,) (NP (NN drug1)) (VP (VBD was) (ADJP (JJ ineffective)) (PP (IN in) (NP (DT both) (NNS doses))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN concluded) (PP (IN from) (NP (DT these) (NNS results))) (SBAR (IN that) (S (NP (NP (DT the) (JJ modulatory) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (ADVP (RB evidently)) (NP (DT a) (JJ later) (JJ developmental) (NN acquisition)) (-LRB- -LRB-) (PP (IN after) (NP (NP (NN day) (CD 15)) (PP (IN of) (NP (NN incubation))))) (-RRB- -RRB-) (PP (IN in) (NP (NP (DT the) (NN embryogenesis)) (PP (IN of) (NP (NP (JJ NMDA-ergic) (NN activation)) (PP (IN of) (NP (JJ spontaneous) (NN motility))) (PP (IN in) (NP (NN chick) (NNS embryos))))))) (PP (ADVP (RB similarly)) (IN as) (NP (JJ glycinergic) (NN inhibition))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Acute) (NN effect)) (PP (IN of) (NP (JJ different) (NNS drug1))) (PP (IN on) (NP (NP (NN glycemia)) (PP (IN in) (NP (ADJP (ADJP (JJ diabetic)) (CC and) (ADJP (JJ non-diabetic))) (NNS rats))))))) (. .)))
(S1 (S (S (NP (JJ Diabetic) (NNS patients)) (VP (VBP have) (NP (NP (DT a) (ADJP (NP (CD 20) (NN %)) (JJR higher)) (NN risk)) (PP (IN of) (NP (NN depression)))) (PP (IN than) (NP (DT the) (JJ general) (NN population))))) (. .)))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN drug1)))) (VP (VP (MD can) (ADVP (RB directly)) (VP (VB interfere) (PP (IN with) (NP (NN blood) (NN glucose) (NNS levels))))) (CC or) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NN treatment)) (PP (IN of) (NP (NN depression))) (PP (IN in) (NP (JJ diabetic) (NNS patients)))) (VP (MD must) (VP (VB take) (SBAR (IN into) (S (VP (VBP account) (NP (NP (NNS variations)) (PP (IN of) (NP (JJ glycemic) (NNS levels)))) (PP (IN at) (NP (JJ different) (NNS times))))))))) (CC and) (S (NP (NP (DT a) (NN comparison)) (PP (IN of) (NP (DT the) (JJ available) (NN drug1)))) (VP (VBZ is) (ADJP (JJ important))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (PRP we)) (VP (VBD evaluated) (NP (NP (DT the) (NN interference)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN blood) (NN glucose) (NNS levels)) (PP (IN of) (NP (ADJP (ADJP (JJ diabetic)) (CC and) (ADJP (JJ non-diabetic))) (NNS rats)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT a) (JJ first) (NN experiment))) (, ,) (NP (JJ male) (JJ adult) (NN Wistar) (NNS rats)) (VP (VBD were) (VP (VBN fasted) (PP (IN for) (NP (CD 12) (NN h)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 0.25) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (ADJP (ADJP (JJ drug4)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg/kg)) (-RRB- -RRB-))) (NN drug5)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NN vehicle))) (VP (VBD was) (VP (VBN administered)))) (. .)))
(S1 (S (S (PP (IN After) (NP (CD 30) (NN min))) (, ,) (NP (JJ fasting) (NN glycemia)) (VP (VBD was) (VP (VBN measured)))) (. .)))
(S1 (S (S (S (NP (NP (DT An) (JJ oral) (NN drug1) (NN overload)) (PP (IN of) (NP (NP (CD 1) (NN ml)) (PP (IN of) (NP (DT a) (ADJP (CD 50) (NN %)) (NN drug2) (NN solution)))))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NNS rats)))))) (CC and) (S (NP (NN blood) (NN glucose)) (VP (VBD was) (VP (VBN determined) (PP (IN after) (NP (QP (CD 30) (, ,) (CD 60) (CC and) (CD 90)) (NN min))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD did) (RB not) (VP (VB change) (NP (NP (NN fasting)) (CC or) (NP (NN overload)) (NP (NN glycemia)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD increased) (NP (NN blood) (NN drug3)) (PP (IN at) (NP (NP (JJ different) (NNS times)) (PP (IN after) (NP (DT the) (NN glucose) (NN overload))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD neutralized) (NP (NP (DT the) (NN increase)) (PP (IN of) (NP (NN glycemia))) (VP (VBN induced) (PP (IN by) (NP (JJ oral) (NN drug2) (NN overload))))))) (. .)))
(S1 (S (S (S (PP (IN In) (NP (DT the) (JJ second) (NN experiment))) (, ,) (NP (JJ non-diabetic) (CC and) (JJ streptozotocin-induced) (JJ diabetic) (NNS rats)) (VP (VBD were) (VP (VBN fasted)))) (, ,) (CC and) (S (NP (DT the) (JJ same) (NNS procedures)) (VP (VBD were) (VP (VBN followed) (PP (IN for) (NP (NP (NN estimation)) (PP (IN of) (NP (NP (NN drug1) (NN tolerance) (CD 30) (NN min)) (PP (IN after) (NP (NN drug2) (NN overload))))))))))) (. .)))
(S1 (S (S (ADVP (RB Again)) (, ,) (NP (NN drug1)) (VP (VBD neutralized) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN glycemia))) (PP (PP (IN after) (NP (NN drug2) (NN overload))) (CC both) (PP (IN in) (NP (ADJP (ADJP (JJ diabetic)) (CC and) (ADJP (JJ non-diabetic))) (NNS rats))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP raise) (NP (NP (DT the) (NN question)) (PP (IN of) (SBAR (IN whether) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT the) (JJS best) (NN choice)) (PP (IN for) (NP (NP (JJ prolonged) (NN use)) (PP (IN for) (NP (JJ diabetic) (NNS individuals)))))) (, ,) (PP (IN because) (IN of) (NP (PRP$ its) (JJ antihyperglycemic) (NNS effects)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD would) (VP (VB be) (ADJP (JJ useful) (PP (IN in) (NP (NP (NNS cases)) (PP (IN with) (NP (NP (JJ potential) (NN risk)) (PP (IN of) (NP (NN hypoglycemia))))))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ promotes) (NP (NP (DT the) (NN translocation)) (PP (IN of) (NP (NN phosphatidate) (NN phosphohydrolase))) (PP (IN from) (NP (DT the) (NN cytosol))) (PP (TO to) (NP (NP (DT the) (JJ microsomal) (NN fraction)) (PP (IN of) (NP (NN rat) (NN liver)))))))) (CC and) (S (NP (PRP it)) (VP (VBZ enhances) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN oleate))) (PP (IN in) (NP (DT this) (NN respect))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN 0.5-2) (NN mM)) (-RRB- -RRB-))) (VP (VBD promoted) (NP (NP (DT the) (NN translocation)) (PP (IN of) (NP (NN phosphatidate) (NN phosphohydrolase))) (PP (IN from) (NP (DT the) (JJ soluble))) (PP (TO to) (NP (DT the) (JJ microsomal) (NN fraction)))) (PP (IN in) (NP (NP (DT a) (JJ cell-free) (NN system)) (VP (VBN derived) (PP (IN from) (NP (NN rat) (NN liver)))))))) (. .)))
(S1 (S (S (PP (IN By) (NP (NN contrast))) (, ,) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mM)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mM)) (-RRB- -RRB-)))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN translocation)) (SBAR (WHADVP (WRB when)) (S (VP (VBN added) (ADVP (RB alone))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (CC and) (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (, ,) (NP (NN drug2)) (, ,)) (VP (VP (VBD enhanced) (NP (NP (DT the) (NN translocating) (NN action)) (PP (IN of) (NP (NN oleate))))) (CC and) (VP (VBD increased) (NP (NP (PRP$ its) (NN effectiveness)) (PP (IN in) (S (VP (VBG transferring) (NP (NP (DT the) (NN phosphohydrolase)) (PP (IN from) (NP (DT the) (JJ soluble))) (PP (TO to) (NP (DT the) (JJ microsomal) (NN fraction))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN proposed) (SBAR (SBAR (IN that) (S (NP (DT the) (NN phosphohydrolase)) (VP (VBZ becomes) (ADJP (RB metabolically) (JJ active)) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ combines) (PP (IN with) (NP (NNS membranes))))))))) (CC and) (SBAR (IN that) (S (NP (NNS polyamines)) (VP (MD might) (VP (VB help) (S (VP (TO to) (VP (VB regulate) (NP (DT this) (NN interaction))))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD could) (VP (VP (VB facilitate) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (JJ fatty) (NNS acids))))) (CC and) (VP (VB enable) (NP (NNS cells)))) (S (VP (TO to) (VP (VB increase) (NP (NP (PRP$ their) (NN capacity)) (PP (IN for) (NP (NN triacylglycerol) (NN synthesis))) (S (VP (TO to) (VP (VBP match) (NP (NP (DT an) (VBN increased) (NN availability)) (PP (IN of) (NP (JJ fatty) (NNS acids))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (PP (IN of) (NP (NN drug1))) (CC and) (PP (IN of) (NP (NN drug2) (NN anesthesia)))) (PP (IN on) (NP (NP (NN drug3) (NN tolerance)) (PP (IN in) (NP (NNS dogs))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (NN comparison)) (PP (IN of) (NP (NP (NN drug1) (NN tolerance)) (PP (IN in) (NP (NP (NNS dogs)) (VP (VBN anesthetized) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4))))))))))) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NN drug5)))) (VP (VBD needed) (S (VP (TO to) (VP (VB cause) (NP (NP (JJ ventricular) (NN tachycardia)) (VP (VBD was) (ADJP (RB significantly) (JJR higher)) (, ,) (SBAR (IN as) (SINV (VBD was) (NP (NP (DT the) (NN LD50)) (PP (IN of) (NP (NN drug6)))))) (, ,) (PP (IN with) (NP (NP (NN drug7)) (CC or) (NP (NN drug8)))))) (PP (IN than) (PP (IN with) (NP (NN drug9))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Ventricular) (NN tachycardia)) (VP (VBN induced) (PP (IN by) (NP (NN drug1))))) (VP (VBD was) (ADVP (RB generally)) (VP (VBN converted) (PP (TO to) (NP (NN sinus) (NN rhythm))) (PP (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))))) (CC but) (PP (RB not) (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NN drug5)) (UCP (ADVP (RB alone)) (CC or) (PP (IN after) (NP (NN drug6)))))))))))) (. .)))
(S1 (S (NP (NP (NN Excretion)) (PP (IN of) (NP (NNS thioethers))) (PP (IN in) (NP (NN urine))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (JJ electrophilic) (NNS chemicals))))) (. .))))
(S1 (S (S (NP (NP (JJ Electrophilic) (NN agents--a) (NN class) (IN of) (NNS chemicals)) (SBAR (WHNP (WDT that)) (S (VP (VBZ includes) (NP (ADJP (RBS most) (JJ genotoxic)) (NN compounds--can)))))) (VP (VB be) (VP (VBN inactivated) (PP (IN by) (NP (NP (NN reaction)) (PP (IN with) (NP (NP (NN glutathione)) (CC or) (NP (JJ other) (JJ SH-bearing) (NNS molecules))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS conjugates)) (VP (ADVP (RB so)) (VBN formed))) (ADVP (RB often)) (VP (VBP appear) (PP (IN in) (NP (DT the) (NN urine))) (PP (IN as) (NP (NP (JJ mercapturic) (NNS acids)) (CC or) (NP (JJ other) (NN thioether) (NNS products)))))) (. .)))
(S1 (S (S (NP (DT This) (NN paper)) (ADVP (RB critically)) (VP (VBZ reviews) (NP (NP (DT the) (NN suitability)) (PP (IN of) (NP (DT the) (JJ urinary) (NN thioether) (NN assay)))) (PP (IN as) (NP (NP (DT a) (NN method)) (PP (IN for) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (JJ electrophilic) (NNS agents)) (CC or) (NP (PRP$ their) (NNS precursors)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN practice))) (, ,) (NP (NP (DT the) (JJS greatest) (NN value)) (PP (IN of) (NP (DT the) (NN thioether) (NN assay)))) (VP (VBZ appears) (S (VP (TO to) (VP (VBP lie) (PP (IN in) (NP (PRP$ its) (NN signal) (NN function)))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ is) (VP (VBN demonstrated) (PP (IN for) (NP (NP (NP (JJ cigarette) (NNS smokers)) (CC and) (NP (JJ industrial) (NNS workers))) (VP (VBN involved) (PP (IN in) (NP (JJ chemical) (NN waste) (NN incineration))))))))) (. .)))
(S1 (S (S (S (ADVP (RB Whenever)) (NP (VBN increased) (NN thioether) (NN excretion)) (VP (VBZ is) (VP (VBN observed)))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (NP (NN exposure)) (PP (TO to) (NP (QP (CD one) (CC or) (JJR more)) (NN suspect) (NNS compounds)))))))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN thioether) (NN concentration)) (VP (VBZ ranges) (PP (IN within) (NP (NP (DT the) (NNS limits)) (PP (IN of) (NP (DT the) (JJ normal) (NN value)))))))) (, ,) (NP (PRP one)) (VP (MD must) (RB not) (VP (VB conclude) (SBAR (IN that) (S (NP (EX there)) (VP (VBZ is) (NP (NP (NP (DT no)) (, ,) (CC or) (NP (JJ negligible))) (, ,) (NP (NN exposure)))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (RBR More) (JJ specific)) (NNS applications)) (PP (IN of) (NP (NP (DT the) (NN assay)) (PP (IN of) (NP (NN thio) (NNS compounds))))) (PP (IN in) (NP (NN urine)))) (VP (VBP allow) (NP (NP (NN development)) (PP (IN of) (NP (NP (JJ selective) (NNS methods)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (ADJP (JJ useful) (PP (IN for) (NP (JJ biological) (NN monitoring))))))))))))) (. .)))
(S1 (S (S (NP (NN Rhabdomyolysis)) (VP (JJ secondary) (PP (TO to) (NP (NP (DT a) (NN drug) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (VP (TO To) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NN rhabdomyolysis)) (VP (VBG resulting) (PP (IN from) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))))))) (. .))))
(S1 (S (NP (NP (NN CASE) (NN SUMMARY)) (: :) (S (NP (DT A) (JJ 64-year-old) (NN African-American) (NN man)) (VP (VBD was) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital))) (PP (IN for) (NP (NP (JJ worsening) (JJ renal) (NN failure)) (, ,) (NP (JJ elevated) (NN creatine) (NN phosphokinase)) (, ,) (NP (JJ diffuse) (NN muscle) (NN pain)) (, ,) (CC and) (NP (JJ severe) (NN muscle) (NN weakness))))))) (. .))))
(S1 (S (S (PP (IN About) (NP (NP (CD three) (NNS weeks)) (ADJP (JJ prior) (PP (TO to) (NP (NN admission)))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD was) (VP (VBN started) (PP (IN on) (NP (NP (NN drug1)) (PP (IN for) (NP (NN sinusitis)))))))) (. .)))
(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (VP (VBN been) (VP (VBG receiving) (NP (NP (NN drug1)) (PP (IN for) (NP (QP (RB approximately) (CD six)) (NNS months)))))))) (. .)))
(S1 (S (S (NP (NN He)) (VP (VBD was) (VP (VBN treated) (ADVP (RB aggressively)) (PP (IN with) (NP (NP (JJ intravenous) (NN hydration)) (, ,) (NP (NN drug1)) (, ,) (CC and) (NP (NN hemodialysis))))))) (. .)))
(S1 (S (S (NP (DT A) (NN muscle) (NN biopsy)) (VP (VBD revealed) (NP (NP (JJ necrotizing) (NN myopathy)) (ADJP (JJ secondary) (PP (TO to) (NP (DT a) (NN toxin))))))) (. .)))
(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD continued) (S (VP (TO to) (VP (VBP receive) (NP (JJ intermittent) (NN hemodialysis)) (PP (IN until) (NP (NP (NN his) (NN death)) (PP (IN from) (NP (NP (JJ infectious) (NNS complications)) (SBAR (WHNP (WDT that)) (S (VP (VBD occurred) (NP (CD three) (NNS months)) (PP (IN after) (NP (NN admission))))))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (JJ several) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VBP have) (NP (NP (VBN increased) (NN his) (NN risk)) (PP (IN for) (S (VP (VBG developing) (NP (NP (NN rhabdomyolysis)) (, ,) (PP (VBG including) (NP (JJ chronic) (JJ renal) (NN failure))))))))))))))) (. .)))
(S1 (S (NP (NP (NN DISCUSSION)) (: :) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4)))) (, ,) (NP (NP (DT the) (JJ major) (NN enzyme)) (ADJP (JJ responsible) (PP (IN for) (NP (NN drug2) (NN metabolism)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NN drug2))))) (VP (VBP have) (S (VP (VBD resulted) (PP (IN in) (NP (NP (JJ previous) (NNS reports)) (PP (IN of) (NP (NN rhabdomyolysis))))))))) (. .)))
(S1 (S (S (NP (JJ Other) (NNS factors)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (DT this) (NN drug) (NN interaction))) (, ,) (PP (VBG including) (NP (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (JJ other) (NNS medications)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NN myopathy)))) (, ,) (S (VP (VBG underlying) (NP (JJ renal) (NN insufficiency)))))))))) (, ,) (CC and) (NP (NP (NN administration)) (PP (IN of) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NN drug1)) (VP (VBP inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NNS drug2)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4))) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-))))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN interaction)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (NN myopathy)) (CC and) (NP (NN rhabdomyolysis)))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ renal) (NN insufficiency)) (CC or) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB concurrently)) (VP (VBG taking) (NP (NP (NNS medications)) (VP (VBN associated) (PP (IN with) (NP (NN myopathy))))))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Optimal) (NNS designs)) (PP (IN for) (NP (DT the) (NP (NN individual)) (CC and) (NP (NN joint)) (NP (NN exposure) (JJ general) (JJ logistic) (NN regression) (NNS models)))) (. .))))
(S1 (S (S (NP (NP (NN Interest)) (PP (IN in) (NP (VBG administering) (NNS compounds))) (PP (IN in) (NP (NN combination)))) (VP (VBZ lies) (PP (CC both) (PP (IN in) (S (VP (VBG enhancing) (NP (JJ efficacious) (NNS effects))))) (CC and) (PP (IN in) (S (VP (VBG limiting) (NP (JJ adverse) (NNS effects)))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (JJ much) (JJ statistical) (NN work)) (VP (VBZ has) (VP (VBN focused) (PP (IN on) (S (VP (VBG developing) (NP (JJ mathematical) (NNS functions)) (S (VP (TO to) (VP (VB model) (NP (DT the) (NN joint) (JJ dose-response) (NNS curves)))))))))))) (, ,) (NP (ADJP (RB relatively) (JJ little)) (NN work)) (VP (VBZ exists) (PP (IN in) (NN regard) (TO to) (NP (JJ designing) (NNS experiments))) (PP (IN for) (S (VP (VBG assessing) (NP (NN joint) (NN action)))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN variety)) (PP (IN of) (NP (NP (JJ parametric) (JJ dose-response) (NNS models)) (VP (VBN based) (PP (IN on) (NP (CC either) (DT the) (ADJP (ADJP (JJ normal)) (CC or) (ADJP (JJ logistic))) (NN probability) (NN distribution))))))) (VP (VBP have) (VP (VBN been) (VP (VBN proposed) (PP (IN in) (NP (DT the) (NN literature))))))) (. .)))
(S1 (S (S (S (NP (DT These) (NNS models)) (VP (VBP are) (ADVP (RB typically)) (ADJP (JJ nonlinear)) (PP (IN in) (NP (DT the) (NNS parameters))))) (, ,) (CC and) (S (PP (IN as) (NP (JJ such))) (, ,) (NP (DT a) (JJ nonlinear) (JJ weighted) (ADJP (RBS least) (JJ squares)) (NN approach)) (VP (MD can) (VP (VB be) (VP (VBN employed) (PP (IN for) (NP (NP (DT the) (NN purpose)) (PP (IN of) (NP (JJ designing) (NNS experiments)))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN approach)) (VP (VBZ is) (ADJP (JJ applicable) (PP (IN across) (NP (NP (DT a) (JJ wide) (NN variety)) (PP (IN of) (NP (NP (NNS settings)) (VP (ADVP (RB commonly)) (VBN associated) (PP (IN with) (NP (NP (NN joint) (NN action) (NNS data)) (, ,) (PP (VBG including) (NP (NP (ADJP (ADJP (JJ continuous)) (CC and) (ADJP (JJ discrete))) (NNS responses)) (, ,) (NP (NN alternative) (NN error) (NNS structures)) (, ,) (CC and) (NP (JJ nonzero) (NN background) (NN response)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Further)) (, ,) (NP (NNS designs)) (VP (MD can) (VP (VB be) (VP (VBN expressed) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (JJ proportionate) (NNS responses)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ individual) (NNS compounds)) (CONJP (RB rather) (IN than)) (NP (NN dose) (NNS levels))))))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG providing) (PP (IN for) (NP (NP (NNS results)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ applicable) (PP (IN across) (NP (NNS compounds))))))))))))))) (. .)))
(S1 (S (S (PP (IN As) (NP (NP (DT a) (NN precursor)) (PP (TO to) (NP (DT this) (NN effort))))) (, ,) (NP (NP (ADJP (ADJP (JJ optimal)) (CC and) (ADJP (JJ minimal))) (JJ experimental) (NNS designs)) (PP (IN for) (NP (NP (DT the) (NN case)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT a) (JJ single) (NN compound)) (VP (VBZ is) (VP (VBN administered)))))))) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN developed))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ proposed) (NN methodology)) (PP (IN for) (S (VP (VBG deriving) (NP (JJ experimental) (NNS designs)))))) (VP (MD can) (VP (VB be) (VP (VBN applied) (PP (TO to) (NP (DT any) (JJ nonlinear) (NN regression) (NN model)))))))) (, ,) (NP (JJ primary) (NN focus)) (VP (VBZ is) (VP (VBN given) (PP (TO to) (NP (NP (DT the) (ADJP (ADJP (JJ additive)) (CC and) (ADJP (JJ nonadditive)) (NP (NP (JJ independent) (NN joint) (NN action)) (PRN (-LRB- -LRB-) (NP (NN IJA)) (-RRB- -RRB-)))) (NNS models)) (PP (IN for) (NP (NP (NN individual)) (CC and) (NP (JJ combined) (NNS exposures)))) (VP (VBN proposed) (PP (IN by) (NP (NP (NNP Barton)) (, ,) (NP (NNP Braunberg)) (, ,) (CC and) (NP (NN Friedman) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (JJ -LSB-The) (JJ GABA-ergic) (NN system)) (CC and) (NP (NP (NN brain) (NN edema) (-RRB- -RSB-)) (NP (PRP It)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (JJ experimental) (ADJP (ADJP (JJ toxic)) (CC and) (ADJP (JJ traumatic))) (NNS edemas))))) (SBAR (IN that) (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-))) (VP (VP (VBZ removes) (NP (NP (DT the) (JJ antiedematous) (NN action)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN drug5)))))) (CC and) (VP (VBZ reduces) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug6)))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN minimized) (PP (TO to) (NP (CD 0.5) (NN mg/kg))))))) (NP (PDT such) (DT an) (NN effect)) (VP (VBZ is) (RB not) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (JJ Prolonged) (JJ daily) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 1) (NN mg/kg)))))) (VP (VBZ results) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN brain) (NN edema))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (JJ GABA-positive) (NNS drugs)) (VP (VB be) (VP (VBN included) (PP (IN into) (NP (NP (DT a) (NN complex)) (PP (IN of) (NP (NP (NN treatment) (NNS measures)) (PP (IN for) (NP (NN edema)))))))))))))) (. .)))
(S1 (S (NP (NP (NP (JJ New) (JJ oral) (NNS therapies)) (PP (IN for) (NP (NN type) (CD 2) (NN diabetes) (NN mellitus)))) (: :) (NP (DT The) (NN drug1) (CC or) (NN insulin) (NNS sensitizers)) (. .))))
(S1 (S (S (NP (NN Type) (CD 2) (NN diabetes) (NN mellitus)) (VP (VBZ is) (NP (NP (DT a) (VBG growing) (NN problem)) (PP (CONJP (RB not) (RB only)) (PP (IN in) (NP (DT the) (JJ United) (NNS States))) (CONJP (CC but) (RB also)) (PP (IN across) (NP (DT the) (NN world))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (ADVP (RB now)) (NP (JJ strong) (NN evidence) (SBAR (IN that) (S (NP (NP (JJ intensive) (NN control)) (PP (IN of) (NP (NN blood) (NN glucose)))) (VP (MD can) (ADVP (RB significantly)) (VP (VP (VB reduce)) (CC and) (VP (VB retard) (NP (NP (DT the) (JJ microvascular) (NNS complications)) (PP (IN of) (NP (NP (NN retinopathy)) (, ,) (NP (NN nephropathy)) (, ,) (CC and) (NP (NN neuropathy))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Ultimately)) (ADVP (RB however)) (, ,) (NP (NP (QP (RB up) (TO to) (CD 80)) (NN %)) (PP (IN of) (NP (NN type) (CD 2) (NN diabetics)))) (VP (VBP die) (PP (IN from) (NP (JJ macrovascular) (JJ cardiovascular) (NN disease))))) (. .)))
(S1 (S (S (NP (NP (DT This) (VBN increased) (NN incidence)) (PP (IN of) (NP (JJ atherosclerotic) (NN disease)))) (VP (VBZ is) (ADVP (RB intricately)) (VP (VBN associated) (PP (IN with) (NP (NP (NN insulin) (NN resistance)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (NP (DT a) (JJ major) (JJ pathophysiologic) (NN abnormality)) (PP (IN in) (NP (NN type) (CD 2) (NNS diabetes)))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (JJ strong) (NN evidence) (SBAR (IN that) (S (NP (NN insulin) (NN resistance)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (CONJP (RB not) (RB only)) (NP (NN hyperglycemia)) (, ,) (CONJP (CC but) (RB also)) (NP (NN dyslipidemia)) (, ,) (NP (NN hypertension)) (, ,) (NP (NN hypercoagulation)) (, ,) (NP (NN vasculopathy)) (, ,) (CC and) (ADVP (RB ultimately)) (NP (JJ atherosclerotic) (JJ cardiovascular) (NN disease))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT This) (NN cluster)) (PP (IN of) (NP (JJ metabolic) (NNS abnormalities)))) (VP (VBZ has) (VP (VBN been) (VP (VBN termed) (NP (NP (DT the) (NN insulin) (NN resistance)) (CC or) (NP (JJ cardiovascular) (JJ dysmetabolic) (NN syndrome))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ new) (NN class)) (PP (IN of) (NP (JJ oral) (NN drug4)))) (, ,)) (VP (VBP are) (ADJP (JJ &quot)))) (: ;) (NP (NN insulin) (NN sensitizers&quot)) (: ;)))
(S1 (S (S (CC and) (VP (VBP exert) (NP (JJ direct) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (NN insulin) (NN resistance))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (CONJP (RB not) (RB only)) (VP (VB improve) (NP (NP (NN insulin) (NN sensitivity)) (CC and) (NP (JJ glycemic) (NN control))) (PP (IN with) (NP (VBN reduced) (NN insulin) (NNS requirements)))) (, ,) (CONJP (CC but) (RB also)) (VP (VBP have) (NP (NP (RB potentially) (JJ favorable) (NNS effects)) (PP (IN on) (NP (NP (JJ other) (NNS components)) (PP (IN of) (NP (DT the) (JJ cardiovascular) (JJ dysmetabolic) (NN syndrome))))))))) (. .)))
(S1 (S (S (NP (JJ Long-term) (NNS studies)) (VP (VBP are) (VP (VBN needed) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT the) (JJ insulin-sensitizing) (NNS effects)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (MD can) (VP (VP (VB prevent)) (CC or) (VP (VBP delay) (NP (NP (JJ premature) (JJ atherosclerotic) (JJ cardiovascular) (NN disease)) (, ,) (NP (NN morbidity)) (, ,) (CC and) (NP (NN death)))))))))))))) (. .)))
(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (JJ apparent) (NN volume)) (PP (IN of) (NP (NP (NP (NN distribution)) (CC and) (NP (NN elimination))) (PP (IN of) (NP (NN drug2))))))) (. .))))
(S1 (S (S (VP (VBG According) (PP (TO to) (NP (NNP Gibaldi) (FW et) (FW al))))) (. .)))
(S1 (S (S (PRN (-LRB- -LRB-) (NP (NP (CD 1968)) (, ,) (NP (CD 1970))) (-RRB- -RRB-)) (, ,) (NP (NP (DT the) (JJR higher) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBN reached) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug3))))))))) (VP (VBP are) (ADJP (JJ due) (PP (CONJP (RB not) (RB only)) (PP (TO to) (NP (JJR slower) (JJ renal) (NN elimination))) (CONJP (CC but) (RB also)) (PP (TO to) (NP (NP (DT an) (JJ altered) (NN distribution)) (PP (IN in) (NP (DT the) (NN body))))))))) (. .)))
(S1 (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (NN drug1)) (VP (VBZ has) (NP (DT a) (JJ direct) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN distribution)) (PP (IN of) (NP (NN drug2))))))))))) (, ,) (NP (NP (DT the) (NP (NN elimination)) (CC and) (NP (NN distribution))) (PP (IN of) (NP (NN drug3)))) (VP (VBD was) (VP (VBN studied) (PP (IN in) (NP (NP (CD six) (NNS patients)) (, ,) (NP (NP (NP (CD five)) (VP (VBG lacking) (NP (NN kidney) (NN function)))) (CC and) (NP (NP (CD one)) (PP (IN with) (NP (DT a) (ADJP (RB partially) (JJ impaired)) (JJ renal) (NN function))))) (, ,))) (PP (IN in) (NP (NP (DT the) (NP (NN presence)) (CC or) (NP (NN absence))) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ significant) (NN difference)) (VP (VBD was) (VP (VBN found) (PP (IN between) (NP (NP (DT the) (JJ mean) (NNS values)) (PP (IN of) (NP (NP (DT the) (NN volume)) (PP (IN of) (NP (NP (NN distribution)) (PP (IN of) (NP (NN drug1))) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 13.0) (CC and) (CD 12.6)) (NNS liters)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN hypothesis)) (PP (IN of) (NP (NNP Gibaldi) (FW et) (FW al))))) (. .)))
(S1 (S (S (VP (MD could) (RB not) (VP (VB be) (VP (VBN confirmed) (PP (IN for) (NP (NN drug1))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG lacking) (NP (NN kidney) (NN function))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (NN spite)) (PP (IN of) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN kidney) (NN function))))))) (, ,) (NP (NP (DT the) (NN value)) (PP (IN of) (NP (DT the) (NN elimination) (NN rate) (NN constant)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN decreased) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (CD 0.326) (TO to) (CD 0.263/h))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD might) (VP (VB be) (VP (VBN explained) (PP (IN by) (NP (NP (DT a) (NN blockade)) (PP (IN by) (NP (NP (NN drug1)) (PP (IN of) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NN drug2))) (PP (IN by) (NP (DT the) (NN liver))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Stereoselective) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NNS pigeons)) (CC and) (NP (NN squirrel) (NNS monkeys)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NP (DT the) (NNS stereoisomers)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))))) (VP (VBD were) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NP (NNS pigeons)) (CC and) (NP (NN squirrel) (NNS monkeys))) (VP (VBG responding) (PP (IN under) (NP (NP (DT a) (JJ multiple) (JJ fixed-interval) (NN fixed-ratio) (-LRB- -LRB-) (NN FI) (NN FR) (-RRB- -RRB-) (NN schedule)) (PP (IN of) (NP (NN food) (NN presentation))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Intermediate) (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))) (VP (VBD produced) (NP (NP (NP (JJ transient) (NNS increases)) (PP (IN in) (NP (NP (NN FI)) (VP (VBG responding) (PP (IN in) (NP (NNS monkeys))))))) (CC and) (NP (NP (JJ sustained) (NNS increases)) (PP (IN in) (NP (NP (NN FI)) (VP (VBG responding) (PP (IN in) (NP (NNS pigeons)))))))))) (: ;)))
(S1 (S (S (NP (JJR higher) (NNS doses)) (VP (VBD decreased) (NP (NP (NP (NN FI)) (CC and) (NP (NN FR))) (VP (VBG responding) (PP (IN in) (NP (DT both) (NNS species))))))) (. .)))
(S1 (S (PP (IN In) (NN contrast) (TO to) (NP (PRP$ its) (NN enantiomer))) (, ,) (NP (NN drug1)) (VP (VBD failed) (S (VP (TO to) (VP (VB increase) (NP (NP (NN FI)) (VP (VBG responding) (ADVP (RB significantly)) (PP (IN in) (NP (DT either) (NNS species))))))))) (: ;)))
(S1 (S (S (PP (IN at) (NP (JJ high) (NNS doses))) (, ,) (NP (NN drug1)) (VP (VBD decreased) (NP (NP (NP (NN FI)) (CC and) (NP (NN FR))) (VP (VBG responding))))) (. .)))
(S1 (S (PP (IN In) (NP (NNS monkeys))) (, ,) (NP (NN drug1)) (VP (VBD was) (NP (NP (QP (RB about) (CD 10)) (NNS times)) (ADJP (RBR more) (JJ potent))) (PP (IN than) (NP (NN drug2))) (PP (IN in) (S (VP (VBG decreasing) (NP (VBG responding))))) (, ,) (SBAR (IN whereas) (S (PP (IN in) (NP (NNS pigeons))) (NP (NN drug3)) (VP (VBD was) (ADJP (RB about) (JJ equipotent) (PP (IN with) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT both) (NNS species))) (, ,) (NP (NP (NN drug1)) (, ,) (CONJP (CC but) (RB not)) (NP (NN drug2)) (, ,)) (VP (VBD antagonized) (NP (NP (DT the) (JJ rate-decreasing) (NNS effects)) (PP (IN of) (NP (NN drug3))) (PP (IN on) (NP (NP (NP (NN FI)) (CC and) (NP (NN FR))) (VP (VBG responding))))))) (. .)))
(S1 (S (PP (IN In) (NP (NNS monkeys))) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (CONJP (CC but) (RB not)) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (, ,)))) (VP (VBD were) (VP (VBN antagonized) (PP (IN by) (NP (NN drug4))))) (: ;)))
(S1 (S (S (NP (NP (DT the) (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN required) (S (VP (TO to) (VP (VB antagonize) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2))))))))))) (VP (VBD were) (ADJP (ADJP (NP (QP (JJR more) (IN than) (CD 100)) (NNS times)) (JJR higher)) (PP (IN than) (NP (NP (DT those)) (VP (VBN required) (S (VP (TO to) (VP (VB antagonize) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NNS pigeons))) (, ,) (NP (NN drug1)) (VP (VBD did) (RB not) (ADVP (RB systematically)) (VP (VB alter) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC or) (NP (NN drug4)))))))) (. .)))
(S1 (S (NP (NN drug1)) (VP (VP (VBD reduced)) (CC or) (VP (VBD eliminated) (NP (NP (DT the) (NNS increases)) (PP (IN in) (NP (NP (NN FI) (VBG responding)) (VP (VBN produced) (PP (IN by) (NP (NP (JJ intermediate) (NNS doses)) (PP (IN of) (NP (CC either) (NP (NN drug2)) (CC or) (NP (NN drug3)))))) (PP (IN in) (NP (NNS pigeons)))))))) (, ,) (CC but) (VP (VBD did) (RB not) (VP (VB antagonize) (NP (NP (DT the) (NNS decreases)) (PP (IN in) (NP (NP (NP (NN FI)) (CC or) (NP (NN FR))) (VP (VBG responding) (VP (VBN produced) (PP (IN by) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NP (NN PCP)) (CC or) (NP (NP (DT either) (NN stereoisomer)) (PP (IN of) (NP (NN drug4)))))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBP demonstrate) (NP (NP (DT a) (JJ high) (NN degree)) (PP (IN of) (NP (NN stereoselectivity))) (PP (IN in) (NP (NP (DT the) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ levorotatory) (NN isomer)) (VP (VBD had) (NP (NP (NP (ADJP (ADJP (JJ opioid-antagonist)) (CC and) (ADJP (JJ non-opioid))) (NN agonist) (NNS effects)) (PP (IN in) (NP (NNS pigeons)))) (CC and) (NP (NP (JJ mixed) (JJ opioid) (JJ agonist-antagonist) (NNS effects)) (PP (IN in) (NP (NNS monkeys))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ dextrorotatory) (NN isomer)) (, ,) (PP (IN on) (NP (DT the) (JJ other) (NN hand))) (, ,)) (VP (VBD had) (NP (NP (NNS effects)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NN drug1))))))) (PP (IN in) (NP (DT both) (NNS species))))) (. .)))
(S1 (S (NP (NP (NP (NN Cancer)) (PP (IN in) (NP (DT the) (JJ elderly)))) (: :) (NP (JJ basic) (NP (NNP science) (CC and) (NP (JJ clinical) (NNS aspects)))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NN cancer)))) (VP (VBZ increases) (ADVP (RB progressively)) (PP (IN with) (NP (NN age))))) (. .)))
(S1 (S (S (NP (NP (NNS Rearrangements)) (PP (IN of) (NP (NNS genomes)))) (VP (VBP have) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VBP accompany) (NP (JJ cellular) (NN aging))))))))) (. .)))
(S1 (S (S (NP (NP (DT These) (NNS factors)) (, ,) (PP (IN in) (NP (NP (NN concert)) (PP (IN with) (NP (NP (JJ age-dependent) (NNS alterations)) (PP (IN in) (NP (NP (JJ immune) (NN function)) (CC and) (NP (NN host) (NN defense)))))))) (, ,)) (VP (MD may) (VP (VB help) (S (VP (TO to) (VP (VB explain) (NP (NP (DT the) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ malignant) (NN disease))) (PP (IN in) (NP (JJ aged) (NNS persons)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (JJ clinical) (NN presentation)) (CC and) (NP (JJ natural) (NN history))) (PP (IN of) (NP (NN neoplasia)))) (VP (VBP are) (ADVP (RB also)) (VP (VBN affected) (PP (IN by) (NP (NN aging)))))) (. .)))
(S1 (S (S (NP (DT This) (NN conference)) (VP (VP (VBZ reviews) (NP (NP (JJ recent) (NNS developments)) (PP (IN in) (NP (DT these) (NNS areas))))) (, ,) (VP (VBZ examines) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug) (NN use))) (PP (IN in) (NP (DT the) (JJ elderly)))) (CC and) (NP (NP (NNS implications)) (PP (IN for) (NP (NN management)))))) (, ,) (CC and) (VP (VBZ discusses) (NP (NP (JJ current) (NN information)) (PP (IN on) (SBAR (WHADVP (WRB how)) (S (NP (NN age)) (VP (MD may) (VP (VB influence) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (NN cancer))) (PP (TO to) (NP (NN therapy))))))))))))) (. .)))
(S1 (S (NP (NP (NN Prescribing)) (. .))))
(S1 (S (S (NP (NNS Keys)) (VP (TO to) (VP (VB maximizing) (NP (NN benefit)) (PP (IN while) (S (VP (VBG avoiding) (NP (JJ adverse) (NN drug) (NNS effects)))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBG prescribing) (PP (IN for) (NP (JJR older) (NNS patients)))))) (, ,) (S (S (NP (DT some) (NNS physicians)) (VP (VBP are) (ADJP (RB overly) (JJ cautious)))) (, ,) (CC and) (S (NP (DT this) (NN strategy)) (VP (MD can) (VP (VB result) (PP (IN in) (NP (DT a) (ADJP (JJR less) (IN than) (JJ optimal)) (NN treatment) (NN outcome)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN reluctance)) (VP (TO to) (VP (VB treat) (ADVP (RB aggressively))))) (VP (VBZ is) (ADJP (JJ understandable)) (SBAR (IN because) (S (NP (DT the) (JJ geriatric) (NN population)) (VP (VBZ is) (ADJP (JJ susceptible) (PP (TO to) (NP (JJ adverse) (NN drug) (NNS reactions))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ key)) (PP (TO to) (NP (JJ maximizing) (NN therapy)))) (VP (VBZ lies) (PP (IN in) (NP (JJ individualizing))) (S (NP (PRP it)) (ADJP (CONJP (RB as) (RB much) (IN as)) (ADJP (JJ possible)))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (S (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS steps) (NNS physicians)))) (VP (MD can) (VP (VB take) (S (VP (TO to) (VP (VB ensure) (SBAR (IN that) (S (NP (PRP$ their) (NNS patients)) (VP (VBP are) (RB not) (VP (VBG being) (ADJP (JJ undertreated)))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS steps)) (VP (VBP include) (NP (NP (NP (JJ regular) (NNS reevaluations)) (PP (IN of) (NP (NP (NNS dosages)) (CC and) (NP (NN plasma) (NN drug) (NNS concentrations))))) (, ,) (NP (NP (NP (NN recognition)) (CC and) (NP (NN understanding))) (PP (IN of) (NP (NN drug) (NN side) (NNS effects)))) (, ,) (CC and) (NP (NP (NN avoidance)) (PP (IN of) (NP (JJ certain) (NNS agents))))))) (. .)))
(S1 (S (S (NP (JJ Close) (NN monitoring)) (VP (VBZ allows) (S (NP (NNS physicians)) (VP (TO to) (VP (VP (VB minimize) (NP (NNS risks))) (, ,) (VP (VB maximize) (NP (NNS benefits))) (, ,) (CC and) (VP (VB get) (NP (NP (DT the) (JJS most)) (PP (RP out) (PP (IN of) (SBAR (WHNP (WP what)) (S (NP (JJ modern) (NNS medications)) (VP (MD can) (VP (VBP do) (S (VP (TO to) (VP (VB help) (NP (JJR older) (NNS patients)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Determinants)) (PP (IN of) (NP (NP (JJ cellular) (NN sensitivity)) (PP (TO to) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB now)) (ADJP (JJ clear)) (SBAR (IN that) (S (NP (NN topoisomerase) (NN activity) (NN level)) (VP (VBZ is) (NP (NP (DT an) (JJ important) (NN determinant)) (PP (IN of) (NP (NP (NN sensitivity)) (PP (TO to) (NP (NN topo) (NNS drugs))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN regulation)) (PP (IN of) (NP (NNS topoisomerases)))) (VP (VP (VBZ is) (NP (NP (DT no) (NN doubt)) (ADJP (ADJP (JJ complex)) (CC and) (ADJP (JJ multifaceted))))) (CC and) (VP (VBZ is) (ADVP (RB probably)) (VP (VBN accomplished) (PP (IN through) (NP (NN redundancy))) (PP (IN at) (NP (JJ many) (JJ control) (NNS levels))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN mechanism) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (PP (IN of) (NP (NP (JJ altered) (NN topo) (NN I) (NN expression)) (PP (IN in) (NP (JJ certain) (NN tumor) (NNS types)))))) (VP (VP (VBZ is) (ADJP (JJ unknown))) (, ,) (CC but) (VP (MD may) (VP (VB be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (JJ central) (NN importance)) (PP (IN of) (NP (NNS topoisomerases))) (PP (IN in) (S (VP (VBG proliferating) (NP (NP (NP (NN cell) (NNS functions)) (PRN (-LRB- -LRB-) (NP (NP (NN transcription)) (, ,) (NP (NN replication)) (, ,) (NP (NN etc.))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (DT the) (ADJP (ADJP (JJ aberrant)) (CC and) (ADJP (JJ chronic))) (NN activation)) (PP (IN of) (NP (DT these) (NNS functions))))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (JJ specific) (JJ tumorigenic) (NNS alterations))))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (JJ Small) (NNS differences)) (PP (IN in) (NP (NP (NN sensitivity)) (PP (TO to) (NP (NN chemotherapy)))))) (VP (MD can) (VP (VB have) (NP (NP (DT a) (JJ dramatic) (NN effect)) (PP (IN on) (NP (NN cure) (NNS rates))))))) (, ,) (CC and) (S (ADVP (RB therefore)) (NP (JJ subtle) (ADJP (NN cell) (JJ type-specific)) (NNS differences)) (VP (MD may) (VP (VB be) (NP (NP (JJ important) (NNS determinants)) (PP (IN of) (NP (NN drug) (NN sensitivity)))))))) (. .)))
(S1 (S (S (SBAR (IN Whether) (S (NP (NP (JJ abnormal) (NN topoisomerase) (NN quantity)) (CC and) (NP (JJ specific) (NN activity))) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN resistance)) (CC or) (NP (NN sensitivity))) (PP (TO to) (NP (JJ topoisomerase-targeted) (NN chemotherapy))) (PP (IN in) (NP (DT the) (NN clinic))))))))) (VP (VBZ is) (ADVP (RB now)) (VP (VBG being) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Determinants)) (ADJP (JJ downstream) (PP (IN of) (NP (NN cleavable) (NN complex) (NN formation))))) (SBAR (WHNP (WDT that)) (S (VP (VBP affect) (NP (NP (DT the) (NN sensitivity)) (PP (IN of) (NP (NN tumor) (CC versus) (JJ normal) (NNS cells))) (PP (TO to) (NP (NN topo) (NNS drugs)))) (PP (IN in) (NP (NP (NP (ADJP (JJ particular))) (CC and) (NP (JJ DNA-damaging) (NNS agents))) (PP (IN in) (NP (JJ general))))))))) (VP (VBP are) (NP (NP (JJ little)) (VP (VBN known))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (NP (JJ enhancing) (JJ selective) (NN tumor) (NN cell) (NN killing)) (ADJP (JJ relative) (PP (TO to) (NP (NP (DT the) (JJ normal) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (NN dose) (VBG limiting))))))))))) (VP (MD may) (VP (VB be) (VP (VBN achieved) (PP (CC either) (PP (IN by) (S (VP (VBG overcoming) (NP (NN tumor) (NN cell) (NN resistance))))) (CC or) (PP (IN by) (S (VP (VBG protecting) (NP (JJ normal) (NNS cells)))))))))) (. .)))
(S1 (S (S (NP (NP (DT Both)) (PP (IN of) (NP (DT these) (NNS strategies)))) (VP (MD will) (VP (VB become) (ADJP (RBR more) (JJ feasible)) (SBAR (IN as) (S (S (NP (NP (JJ specific) (JJ molecular) (NNS differences)) (PP (IN between) (NP (NP (NN tumor)) (CC and) (NP (JJ normal) (NNS cells))))) (VP (VBP are) (VP (VBG being) (ADVP (RB rapidly)) (VP (VBN identified))))) (CC and) (S (NP (NP (JJ new) (NN combination) (NNS therapies)) (SBAR (WHNP (WDT that)) (S (VP (VBP take) (NP (NP (NN advantage)) (PP (IN of) (NP (DT these) (NNS differences)))))))) (VP (VBP are) (VP (VBG being) (VP (VP (VBN designed)) (CC and) (VP (VBN tested))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NP (NN absorption)) (CC and) (NP (NN retention)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ supplementary) (JJ oral) (NN drug1)) (CC and) (NP (NN drug2)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (DT both)) (PP (IN at) (NP (DT the) (NN absorption) (NN site)))))) (, ,) (NP (JJ fecal) (CC and) (JJ urinary) (NN excretion)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN retention)) (PP (IN of) (NP (DT these) (NN trace) (NNS elements))))))) (VP (VBD were) (VP (VBN determined) (PP (IN by) (S (VP (VBG using) (NP (NP (CD four) (NNS diets)) (VP (VBG containing) (NP (CC either) (NP (NP (QP (CD 9) (CC or) (CD 63)) (NNS micrograms/kg)) (PP (IN of) (NP (NN drug3)))) (CC and) (NP (NP (QP (CD 48) (CC or) (CD 446)) (NN mg/kg)) (PP (IN of) (NP (NN drug4))))) (PP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (NP (CD 19) (NNS days)) (PP (IN in) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 24) (NNS rats))))))))))))))))) (. .)))
(S1 (S (S (NP (NN Retention)) (VP (VBD was) (VP (VBN calculated) (PP (PP (IN by) (NP (DT the) (NN balance) (NN technique))) (CC and) (PP (IN by) (NP (DT the) (JJ comparative) (NN slaughter) (NN technique))))))) (. .)))
(S1 (S (S (PP (IN After) (NP (CD one) (NN day))) (, ,) (NP (NP (NN fecal)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (DT both) (NNS elements))))) (VP (VBD had) (ADVP (RB already)) (VP (VBD responded) (PP (TO to) (NP (DT the) (JJ dietary) (NNS treatments))) (, ,) (PP (IN with) (S (NP (NN constant) (NNS values)) (VP (VBG being) (VP (VBN reached) (PP (IN after) (NP (QP (RB approximately) (CD three)) (NNS days)))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN excretion)) (VP (VBD was) (VP (VBN enhanced) (PP (IN by) (NP (JJ supplementary) (NN drug2)))))) (: ;)))
(S1 (S (S (NP (JJ fecal) (NN excretion)) (, ,) (ADVP (RB too)) (, ,) (VP (VBD was) (VP (VBN increased) (PP (IN by) (NP (JJ supplementary) (NN drug1)))))) (: ;)))
(S1 (S (S (IN whereas) (NP (JJ urinary) (NN excretion)) (VP (VBD was) (VP (VBN decreased) (PP (IN in) (NP (DT both) (NNS cases)))))) (. .)))
(S1 (S (S (NP (JJ Additional) (NN drug1)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (DT both) (JJ dietary) (NN drug3) (NNS treatments)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJR lower) (NN rate)) (PP (IN of) (NP (NP (NN absorption)) (PP (IN in) (NP (NP (DT the) (NNS groups)) (VP (VBG receiving) (NP (NP (NP (CD 446) (NN mg)) (NP (NN drug1))) (CONJP (RB instead) (IN of)) (NP (NP (CD 48) (NN mg)) (PP (IN of) (NP (NN drug2))) (PP (IN per) (NP (CD kg) (NN diet))))))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (VBN decreased) (JJ renal) (NN excretion)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN retention)) (PP (IN of) (NP (NN drug2)))))) (VP (VBD was) (ADJP (ADJP (JJR lower)) (PP (IN than) (PP (IN on) (NP (NN absorption))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NNS interactions)) (PP (IN between) (NP (DT the) (CD two) (NNS elements)))) (ADVP (RB only)) (VP (VBP take) (NP (NN place)) (PP (IN at) (NP (NP (DT the) (NN site)) (PP (IN of) (NP (NN absorption)))))))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (JJ low) (JJ dietary) (NN drug1) (NN concentration)) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (DT the) (NN drug2) (NNS contents)) (PP (IN of) (NP (DT the) (NNS diets))))))))))) (, ,) (NP (NP (DT no) (NN effect)) (PP (IN of) (NP (NN drug3))) (PP (IN on) (NP (NP (NN drug4) (NN absorption)) (CC and) (NP (NN excretion))))) (VP (VBD occurred))) (. .)))
(S1 (S (S (NP (NP (NNS Differences)) (PP (IN in) (NP (NN drug1) (NN balance)))) (VP (VBD were) (ADVP (RB only)) (VP (VBN observed) (PP (IN between) (NP (DT both) (JJ dietary) (NNS concentrations)))) (, ,) (S (VP (VBG showing) (NP (NP (DT a) (ADJP (ADJP (JJR higher) (JJ absolute)) (CC but) (ADJP (DT a) (RBR lower) (JJ relative))) (NN absorption)) (CONJP (RB as) (RB well) (IN as)) (NP (NN retention))) (PP (IN in) (NP (NP (DT the) (NNS groups)) (VP (VBN fed) (NP (JJ further) (NN drug2)))))))) (. .)) (PRN (-LRB- -LRB-) (NP (NP (NN ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))
(S1 (S (S (NP (NP (NN -LSB-Importance)) (PP (IN of) (NP (NP (NNS pharmacogenetics)) (-RRB- -RSB-) (NNS Pharmacogenetics)))) (VP (VBZ deals) (PP (IN with) (NP (NP (DT the) (NNS differences)) (PP (IN in) (NP (NP (NN effect)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN caused) (PP (IN by) (NP (JJ genetic) (NN variation)))))))))))) (. .)))
(S1 (S (S (NP (NNS Differences)) (VP (MD can) (VP (VB occur) (PP (PP (IN in) (NP (JJ therapeutic) (NN effect))) (CC and) (PP (IN in) (NP (JJ adverse) (NNS events))))))) (. .)))
(S1 (S (S (NP (NP (JJ Genetic) (NN variation)) (PP (IN in) (NP (NN metabolism)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ high) (NNS concentrations)) (PP (IN of) (NP (NP (NNS drugs)) (CC and) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ adverse) (NNS effects))) (PP (IN in) (NP (NP (JJ slow) (NNS metabolizers)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ important)) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (PP (IN for) (NP (NN example))) (NP (NP (NN drug1)) (CC or) (NP (NN chemotherapy))))))))))))))))))) (. .)))
(S1 (S (NP (JJ Genetic) (NN variation)) (ADVP (RB also)) (VP (VBZ occurs) (PP (IN in) (NP (NP (NNS proteins)) (VP (VBG interacting) (PP (IN with) (NP (NNS drugs)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB change) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (FW e.g.)))))))))))
(S1 (S (NP (NP (NP (NN asthma) (NNS drugs)) (CC and) (NP (NN drug1))) (. .))))
(S1 (S (S (S (NP (NP (DT The) (NN selection)) (PP (IN of) (NP (NP (NNS drugs)) (CC and) (NP (PRP$ their) (NNS dosages))))) (VP (MD may) (VP (VB be) (VP (VBN improved))))) (, ,) (CC and) (S (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ adverse) (NNS effects)))) (VP (VBD reduced) (PP (IN by) (NP (JJ pharmacogenetic) (NNS investigations)))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ important) (PP (ADVP (RB also)) (IN in) (NP (NP (NN case)) (PP (IN of) (NP (NP (JJ medical) (NNS examinations)) (PP (IN for) (NP (NP (NNS insurances)) (CC and) (NP (NN job) (NNS appointments))))))))) (, ,) (SBAR (IN since) (S (NP (DT some) (NNS patients)) (VP (MD may) (VP (NN turn) (RP out) (S (VP (VP (TO to) (VP (VBP need) (NP (JJ expensive) (NNS drugs)))) (CC or) (VP (TO to) (VP (VB be) (ADJP (JJ susceptible) (PP (TO to) (NP (DT a) (JJ certain) (NN disease))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ genetic) (NNS data))) (PP (IN in) (NP (DT these) (NNS instances)))) (VP (VBZ has) (S (VP (TO to) (VP (VB be) (VP (VBN regulated))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN overdose)) (VP (VBN recognized) (PP (IN by) (NP (DT a) (NN drug2) (NN assay))))) (. .)))
(S1 (S (S (S (NP (NP (JJ Altered) (JJ mental) (NN status)) (PP (IN in) (NP (DT an) (JJ adolescent)))) (VP (VBZ presents) (NP (DT a) (JJ diagnostic) (NN challenge)))) (, ,) (CC and) (S (NP (DT the) (NN clinician)) (VP (VBZ depends) (PP (IN on) (NP (NP (JJ clinical) (NN evaluation)) (CC and) (NP (NN laboratory) (NNS studies)))) (S (VP (TO to) (VP (VB determine) (NP (NP (NN therapy)) (CC and) (NP (NN prognosis))))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT an) (JJ adolescent)) (PP (IN with) (NP (NP (JJ altered) (NNS consciousness)) (VP (VBN caused) (PP (IN by) (NP (NP (NN drug1) (NN overdose)) (PP (IN with) (NP (NP (DT a) (JJ positive) (NN drug2) (NN level)) (S (VP (TO to) (VP (VB alert) (NP (NNS clinicians)) (PP (TO to) (NP (NP (DT the) (NN cross-reactivity)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NP (DT a) (JJ toxicology) (NN screen)) (PP (IN for) (NP (NN drug4))))))))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (. .))))
(S1 (S (S (NP (NP (NN Treatment) (NNS plans)) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)))))) (VP (MD can) (VP (VB become) (VP (VBN complicated))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP predispose) (NP (DT a) (NN patient)) (PP (TO to) (NP (JJ bleeding) (NNS problems))))) (. .)))
(S1 (S (S (NP (NP (JJ Many) (NNS drugs)) (VP (VBN used) (PP (IN in) (NP (NN dentistry))))) (VP (MD cannot) (VP (VB be) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (DT these) (NNS medications))))))) (. .)))
(S1 (S (S (NP (JJ Acute) (NN drug1) (NN administration)) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (JJ subjective) (NNS responses)) (PP (TO to) (NP (NP (NN drug2)) (PP (IN in) (NP (NNS humans))))))))) (. .)))
(S1 (S (S (NP (NP (NN RATIONALE)) (: :) (NP (NN Stress)) (CC and) (NP (NN drug1))) (VP (VP (VBP facilitate)) (CC and) (VP (VB reinstate) (NP (NP (JJ psychostimulant) (NN self-administration)) (PP (IN in) (NP (NNS rodents))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN stress)) (CC and) (NP (NN drug1)))) (PP (IN on) (NP (NP (DT the) (ADJP (ADJP (JJ subjective)) (CC and) (ADJP (JJ behavioral))) (NNS effects)) (PP (IN of) (NP (NN drug2)))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB well)) (VP (VBN studied) (PP (IN in) (NP (NNS humans))))))) (. .)))
(S1 (S (NP (NP (NNS OBJECTIVES)) (: :) (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ acute) (NN drug1) (NN pretreatment))) (PP (IN on) (NP (NP (DT the) (ADJP (ADJP (JJ subjective)) (CC and) (ADJP (JJ behavioral))) (NNS effects)) (PP (IN of) (NP (NN drug2))))))))) (. .))))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN mg)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg)) (-RRB- -RRB-)))) (VP (VBD were) (VP (VBN administered) (ADVP (RB orally)) (PP (TO to) (NP (NP (CD 16) (JJ healthy) (ADJP (ADJP (JJ male)) (CC and) (ADJP (JJ female))) (NNS volunteers)) (PP (IN in) (NP (DT a) (ADJP (ADJP (JJ four-session)) (, ,) (ADJP (JJ placebo-controlled)) (, ,) (ADJP (JJ within-subject))) (, ,) (NN crossover) (NN design)))))))) (. .))))
(S1 (S (S (S (VP (TO To) (VP (VB prevent) (NP (NN stomach) (NN irritation))))) (, ,) (NP (NNS subjects)) (VP (VBD received) (NP (NN drug1)) (PP (IN before) (NP (DT each) (JJ experimental) (NN session))))) (. .)))
(S1 (S (S (NP (JJ Dependent) (NNS measures)) (VP (VBD included) (NP (NP (NP (NP (JJ self-reported) (NN mood)) (CC and) (NP (JJ subjective) (NNS effects))) (PRN (-LRB- -LRB-) (NP (NP (NN Addiction) (NN Research) (NN Center) (NN inventory)) (, ,) (NP (NP (DT the) (NN profile)) (PP (IN of) (NP (NN mood) (NNS states)))) (, ,) (CC and) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (JJ visual) (NN analogue) (NNS scales))))) (-RRB- -RRB-))) (, ,) (NP (JJ vital) (NNS signs)) (, ,) (NP (JJ salivary) (NN cortisol)) (, ,) (CC and) (NP (JJ psychomotor) (NN performance))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NN drug1)) (VP (VP (VBD elevated) (NP (JJ salivary) (NN cortisol) (NNS levels))) (, ,) (VP (VBD produced) (NP (JJ modest) (NN dysphoria))) (, ,) (CC and) (VP (VBD reduced) (NP (NP (NNS subjects) (POS ') (NNS reports)) (PP (IN of) (NP (JJ wanting) (JJR more) (NN drug))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN drug1) (NN pretreatment)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (ADJP (ADJP (JJ physiological)) (, ,) (ADJP (JJ behavioral)) (, ,) (CC or) (ADJP (JJ subjective))) (NNS effects)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (JJ rodent) (NNS studies))))))) (, ,) (NP (DT these) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT an) (JJ acute) (NN increase)) (PP (IN in) (NP (NN cortisol)))) (VP (VBZ does) (RB not) (VP (VB enhance) (NP (NP (DT the) (JJ psychostimulant) (NNS effects)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (NNS humans)))))))))) (. .))))
(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (JJ drug2) (JJ -induced) (NNS changes)) (PP (IN in) (NP (NP (NN steroid) (NN hormone) (NNS levels)) (CC and) (NP (NP (NN lethality)) (PP (IN in) (NP (JJ male) (NNS rats)))))))) (. .))))
(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ exogenous) (NN drug1))) (PP (IN on) (NP (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (NN serum) (NN steroid) (NN hormone) (NNS levels)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ nonlethal) (NN dose)) (PP (IN of) (NP (NP (ADJP (FW Escherichia) (FW coli)) (NN drug2)) (PP (IN in) (NP (JJ male) (NNS rats))))))))))) (CC and) (NP (NP (DT the) (NNS deaths)) (ADJP (JJ due) (PP (TO to) (NP (NP (ADJP (ADJP (JJ nonlethal)) (CC and) (ADJP (JJ lethal))) (NNS doses)) (PP (IN of) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Injection)) (PP (IN of) (NP (NP (NN drug1) (CD 5) (NN min)) (PP (IN before) (NP (NP (DT a) (JJ nonlethal) (NN dose)) (PP (IN of) (NP (NN drug2)))))))) (VP (VBD changed) (NP (NP (DT the) (NN serum) (NN sex) (NN steroid) (NN hormone) (NN response)) (PP (IN of) (NP (JJ male) (NNS rats))) (PP (TO to) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN serum) (NN estrogen) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC +) (NP (NN drug2))) (JJ -treated) (NNS rats)))) (VP (VBD decreased) (PP (IN by) (NP (CD 50) (NN %))) (, ,) (SBAR (IN while) (S (NP (NP (DT those)) (PP (IN of) (NP (DT the) (CD drug3) (JJ -treated) (NNS rats)))) (VP (VP (VBD increased)) (PRN (-LRB- -LRB-) (NP (CD 2-) (TO to) (JJ 5-fold)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN serum) (NN androgen) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC +) (NP (NN drug2))) (JJ -treated) (NNS rats)))) (VP (VBD did) (RB not) (VP (VB change) (ADVP (RB significantly))) (, ,) (SBAR (IN while) (S (NP (NP (DT those)) (PP (IN of) (NP (NN drug3) (JJ -treated) (NNS rats)))) (VP (VBD dropped) (PP (TO to) (NP (CD 30-40) (NN %)))))))))
(S1 (S (NP (NP (CD 0.001)) (. .))))
(S1 (S (S (NP (JJ Exogenous) (NN drug1)) (ADVP (RB also)) (VP (VBD appeared) (S (VP (TO to) (VP (VB influence) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (JJ drug2) (JJ -induced) (NNS deaths)))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VP (VBD reduced) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS deaths)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ nonlethal) (PRN (-LRB- -LRB-) (NP (CD 2) (NN mg/kg)) (-RRB- -RRB-)) (NN dose)) (PP (IN of) (NP (NN drug1)))))))))) (CC but) (VP (VBD increased) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS deaths)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (ADJP (RB highly) (JJ lethal)) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 8) (NN mg/kg)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (NP (DT These) (NNS results)) (, ,) (PP (ADVP (RB together)) (IN with) (NP (NP (DT the) (JJ known) (NNS relationships)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (DT the) (JJ immune) (NN response)))))) (, ,) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNS drug2)) (VP (VP (VBP affect) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (JJ septic) (NN shock)))) (PP (IN in) (NP (DT a) (JJ complex) (NN fashion)))) (CC and) (VP (MD may) (VP (VB have) (NP (ADJP (CC either) (ADJP (JJ protective)) (CC or) (ADJP (JJ deleterious))) (NN effect)))))))) (. .)))
(S1 (S (NP (NP (NP (NNS Studies)) (PP (IN on) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NN drug1)))))))) (: :) (NP (NP (NP (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NN respiration)))) (CC and) (NP (NP (NN cell) (NN permeability)) (PP (IN of) (NP (NN Candida) (NNS albicans))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN drug1)) (, ,) (NP (NN drug2)) (, ,)) (VP (VBZ inhibits) (NP (NP (DT the) (NN growth)) (PP (IN of) (NP (NP (JJ several) (NNS species)) (PP (IN of) (NP (NN Candida)))))))) (. .)))
(S1 (S (S (NP (NP (NN Candida) (NNS albicans)) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ pathogenic) (NNS species)))) (, ,)) (VP (VBD was) (ADVP (RB totally)) (VP (VBN inhibited) (PP (IN at) (NP (NP (DT a) (NN concentration)) (PP (IN of) (NP (QP (RB approximately) (CD 10)) (NN mug/ml)))))))) (. .)))
(S1 (S (S (NP (JJ Endogenous) (NN respiration)) (VP (VBD was) (VP (VBN unaffected) (PP (IN by) (NP (NP (DT the) (NN drug)) (PP (IN at) (NP (NP (DT a) (NN concentration)) (ADJP (RB as) (JJ high) (PP (IN as) (NP (CD 100) (NN mug/ml))))))))) (, ,) (SBAR (IN whereas) (S (NP (JJ exogenous) (NN respiration)) (VP (VBD was) (UCP (ADJP (RB markedly) (JJ sensitive)) (CC and) (VP (VBN inhibited) (PP (TO to) (NP (NP (DT an) (NN extent)) (PP (IN of) (NP (CD 85) (NN %)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN permeability)) (PP (IN of) (NP (DT the) (NN cell) (NN membrane)))) (VP (VBD was) (VP (VBN changed) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NP (DT the) (NN leakage)) (PP (IN of) (NP (NP (JJ 260-nm) (JJ absorbing) (NNS materials)) (, ,) (NP (NN amino) (NNS acids)) (, ,) (NP (NNS proteins)) (, ,) (CC and) (NP (JJ inorganic) (NNS cations)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS results)) (ADJP (NP (PRP we)) (JJ present))) (ADVP (RB clearly)) (VP (VBP show) (SBAR (IN that) (S (S (NP (DT the) (NN drug)) (VP (VBZ alters) (NP (DT the) (JJ cellular) (NN permeability)))) (, ,) (CC and) (S (ADVP (RB thus)) (NP (DT the) (JJ exogenous) (NN respiration)) (VP (VBZ becomes) (ADJP (JJ sensitive) (PP (TO to) (NP (DT the) (NN drug)))))))))) (. .)))
(S1 (S (NP (NP (NN Interferon) (NN induction)) (: :) (NP (NP (NN tool)) (PP (IN for) (S (VP (VBG establishing) (NP (NP (NNS interactions)) (PP (IN among) (NP (NNS homopolyribonucleotides)))))))) (. .))))
(S1 (S (S (NP (NP (ADJP (RB Hitherto) (JJ unrecognized)) (NNS interactions)) (PP (IN between) (NP (NP (NNS homopolyribonucleotides)) (CC and) (NP (NNS complexes))))) (ADVP (RB thereof)) (VP (VBP are) (VP (VBN suggested) (PP (IN by) (NP (NP (NN interferon) (NN induction) (NNS data)) (VP (VBN obtained) (PP (IN in) (NP (NP (DT a) (ADJP (RB highly) (JJ sensitive)) (NN assay) (NN system)) (PP (IN of) (NP (NP (JJ primary) (NN rabbit) (NN kidney) (NN cell) (NNS cultures)) (VP (VBN superinduced) (PP (IN by) (NP (JJ metabolic) (NNS inhibitors)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (NP (DT a) (JJ therapeutic) (NN update))) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (PP (IN Since) (NP (NP (PRP$ its) (NN approval)) (PP (IN by) (NP (DT the) (NP (PRP US)) (NP (NP (NN Food)) (CC and) (NP (NN Drug)) (NP (NN Administration))))) (PP (IN in) (NP (NNP March) (CD 1998))))) (, ,) (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (PP (IN by) (NP (NP (NNS millions)) (PP (IN of) (NP (NNS men))))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ erectile) (NN dysfunction))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Recent) (NNS studies)) (CC and) (NP (NN consensus) (NNS reports))) (VP (VBP have) (VP (VBN expanded) (NP (NP (PRP$ our) (NN understanding)) (PP (IN of) (NP (PRP$ its) (NP (NN efficacy)) (, ,) (NP (NN safety)) (, ,) (NP (NNS contraindications)) (, ,) (CC and) (NP (NN drug) (NNS interactions)))))))) (. .)))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (NP (DT This) (NN paper)) (VP (VBZ reviews) (NP (NP (JJ recent) (NNS studies)) (PP (IN of) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (PRP$ its) (JJ adverse) (NNS effects)) (CC and) (NP (NN drug) (NNS interactions))) (, ,) (CC and) (NP (NP (JJ socioeconomic) (NNS factors)) (VP (VBN involved) (PP (IN in) (NP (PRP$ its) (NN use)))))))))) (, ,) (PP (IN with) (NP (NP (DT a) (NN focus)) (PP (IN on) (NP (NP (JJ specific) (NN patient) (NNS populations)) (PRN (-LRB- -LRB-) (NP (NP (NN prostate) (NN cancer)) (, ,) (NP (NN diabetes) (NN mellitus)) (, ,) (NP (JJ ischemic) (NN heart) (NN disease)) (, ,) (NP (JJ spinal) (NN cord) (NN injuries)) (, ,) (NP (JJ neurologic) (NNS disorders))) (-RRB- -RRB-)))))))) (. .))))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (NP (NP (JJ Clinical) (NNS studies)) (, ,) (NP (NN case) (NNS reports)) (, ,) (CC and) (NP (NP (NNS commentaries)) (CC and) (NP (NNS editorials)))) (VP (VBG concerning) (NP (NP (NN drug1)) (VP (VBN published) (PP (IN in) (NP (NP (DT the) (NNP international) (NN literature)) (PP (IN between) (NP (NP (NNP January) (CD 1999)) (CC and) (NP (NNP August) (CD 2000)))))))))) (VP (VBD were) (VP (VBN identified) (PP (IN through) (NP (NP (NNS searches)) (PP (IN of) (NP (NP (NN MEDLINE)) (, ,) (NP (NN PREMEDLINE)) (, ,) (CC and) (NP (NNP International)) (NP (JJ Pharmaceutical) (NN Abstracts)))))) (, ,) (S (VP (VBG using) (NP (DT the) (NNS terms) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (JJ erectile) (NN dysfunction))))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN demonstrated) (NP (NP (NN effectiveness)) (PP (IN in) (NP (NP (NNS men)) (PP (IN with) (NP (NP (JJ erectile) (NN dysfunction)) (VP (VBN associated) (PP (IN with) (NP (NP (NN prostatectomy)) (, ,) (NP (NN radiation) (NN therapy)) (, ,) (NP (NN diabetes) (NN mellitus)) (, ,) (NP (JJ certain) (JJ neurologic) (NNS disorders)) (, ,) (CC and) (NP (NP (NN drug) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LSB-) (NP (NN drug3)) (-RRB- -RSB-)))) (-RRB- -RRB-)))))))))))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ has) (RB not) (VP (VBN been) (ADJP (RB as) (JJ effective) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (JJ sexual) (NN dysfunction))))) (, ,) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NN drug1) (JJ -associated) (JJ sexual) (NN dysfunction))))))))) (. .)))
(S1 (S (S (NP (NP (DT Some) (NNS disorders)) (ADJP (JJ unrelated) (PP (TO to) (NP (NP (JJ sexual) (NN dysfunction)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (JJ esophageal) (NN motility) (NN dysfunction))) (-RRB- -RRB-)))))) (VP (MD may) (ADVP (RB also)) (VP (VB respond) (PP (TO to) (NP (NN drug1)))))) (. .)))
(S1 (S (PP (IN In) (NP (DT the) (JJ general) (NN population))) (, ,) (NP (NN drug1)) (VP (VBZ is) (VP (VBN considered) (S (VP (TO to) (VP (VB have) (NP (DT an) (JJ acceptable) (NN tolerability) (NN profile))))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (ADJP (JJ moderate) (TO to) (JJ severe)) (JJ cardiovascular) (NN disease)) (CC or) (NP (NP (DT those)) (VP (VBG taking) (NP (NN drug1) (NN therapy))))))) (VP (VBP are) (PP (IN at) (NP (NP (VBN increased) (NN risk)) (PP (IN for) (NP (NP (ADJP (ADJP (RB potentially) (JJ serious)) (ADJP (JJ cardiovascular))) (JJ adverse) (NNS effects)) (PP (IN with) (NP (NN drug2) (NN therapy))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NP (NP (DT the) (NN cytochrome) (NN P450) (NN 3A4)) (NN isozyme)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ metabolizes) (NP (NN drug1))))) (, ,)))))))) (VP (MD may) (VP (VBP experience) (NP (NP (VBN increased) (NN drug) (NNS concentrations)) (CC and) (NP (JJ possible) (NN toxicity))) (PP (IN from) (NP (NP (JJ normal) (NNS doses)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT an) (JJ effective) (NN first-line) (NN therapy)) (PP (IN for) (NP (NP (JJ erectile) (NN dysfunction)) (PP (IN in) (NP (NNS men)))))))) (. .))))
(S1 (S (S (NP (DT The) (NN decision) (S (VP (TO to) (VP (VB prescribe) (NP (DT this) (NN agent)))))) (VP (MD should) (VP (VB include) (NP (NP (JJ such) (NNS considerations)) (PP (IN as) (NP (NP (DT the) (JJ cost-risk-benefit) (NN balance)) (, ,) (NP (NN patient) (NN access)) (, ,) (NP (NN drug) (NN distribution) (NNS pathways)) (, ,) (CC and) (NP (NN prescription) (NN drug) (NN coverage)))))))) (. .)))
(S1 (S (NP (NP (NP (NN Tumor) (NN phenotype)) (CC and) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NN progression))))) (PP (IN as) (NP (NP (DT an) (NN expression)) (PP (IN of) (NP (NP (NNS subpopulations)) (PP (IN of) (NP (JJ initiated) (JJ murine) (NNS cells))))))) (. .))))
(S1 (S (S (ADVP (RB Currently)) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN conceived) (SBAR (IN that) (S (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NNS events)) (, ,) (CC or) (NP (NNS hits)) (, ,)))) (VP (VBP are) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNS tumors))) (PP (IN by) (NP (JJ chemical) (NNS agents)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ first) (NN phase)) (PP (IN of) (NP (NP (DT this) (NN sequence)) (, ,) (NP (NN initiation)) (, ,)))) (VP (VBZ is) (VP (VBN considered) (S (VP (TO to) (VP (VB result) (PP (IN from) (NP (QP (IN at) (JJS least) (CD one)) (NN event))) (PP (IN in) (NP (DT the) (JJ genetic) (NN apparatus))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Analyses)) (PP (IN of) (NP (DT this) (NN sequence)))) (, ,) (ADVP (RB however)) (, ,) (ADVP (RB usually)) (VP (VBP give) (NP (JJ little) (NN consideration)) (PP (PP (TO to) (NP (NP (DT the) (NN nature)) (PP (IN of) (NP (DT the) (NN target) (NN cell))))) (CC or) (PP (TO to) (NP (NP (DT the) (NNS characteristics)) (PP (IN of) (NP (DT the) (JJ resultant) (NNS tumors)))))))) (. .)))
(S1 (S (NP (NP (NNP Vesselinovitch) (FW et) (FW al)) (. .))))
(S1 (S (S (PRN (-LRB- -LRB-) (NP (NP (NN Cancer) (NNP Res.)) (, ,) (NP (CD 38)) (: :) (NP (CD 2003-2010)) (, ,) (NP (CD 1978))) (-RRB- -RRB-)) (VP (VBP have) (VP (VBN reported) (SBAR (IN that) (S (NP (NP (DT a) (ADJP (ADJP (JJ single)) (, ,) (ADJP (JJ small))) (NN pulse)) (PP (IN of) (NP (NN carcinogen)))) (VP (MD can) (VP (VB induce) (NP (ADJP (ADJP (JJ early)) (CC and) (ADJP (JJ numerous))) (NN liver) (NNS tumors)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (ADVP (RB neonatally)) (PP (TO to) (NP (NP (NNS mice)) (PP (IN with) (NP (NP (DT a) (JJ genetic) (NN predisposition)) (PP (TO to) (NP (NN hepatotumorigenesis))))))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (, ,) (NP (DT the) (JJ nonpredisposed) (NN strain) (NN C57BL/6N)) (VP (VBD was) (ADVP (RB also)) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (RB highly) (JJ susceptible) (PP (TO to) (NP (NN diethylnitrosamine)))) (PP (IN during) (NP (DT the) (JJ neonatal) (NN period))))))))) (. .)))
(S1 (S (S (NP (NN C57BL/6N)) (VP (VBD demonstrated) (NP (NP (JJ large) (NNS numbers)) (PP (IN of) (NP (NP (CD two)) (PP (IN of) (NP (NP (DT the) (CD three) (NNS types)) (PP (IN of) (NP (NP (NN liver) (NNS tumors)) (VP (VBN seen) (PP (IN in) (NP (NP (NNS livers)) (PP (IN of) (NP (ADJP (RB genetically) (VBN predisposed)) (NNS mice)))))))))))) (, ,) (SBAR (WHNP (NP (CD one)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBD required) (NP (NP (DT the) (JJ additional) (NN stimulus)) (PP (IN of) (NP (NN dietary) (NN drug1))) (PP (IN for) (NP (NN growth)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Tumors)) (PP (IN of) (NP (ADJP (RBR more) (JJ malignant)) (NN phenotype)))) (VP (VBD were) (VP (VBN demonstrated) (PP (ADVP (RB only)) (IN in) (NP (NP (NP (ADJP (RB genetically) (VBN predisposed)) (NNS mice)) (PRN (-LRB- -LRB-) (NP (NN C57BL/6N) (NN X) (NN C3H/HeN) (NN F1)) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (CD one) (NN dose)) (PP (IN of) (NP (NN carcinogen)))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN phenotype)) (PP (IN of) (NP (NP (DT a) (NN tumor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ results) (PP (IN from) (NP (NP (DT a) (NN pulse)) (PP (IN of) (NP (DT a) (JJ chemical) (NN carcinogen))))))))))) (VP (MD may) (VP (VB depend) (PP (IN upon) (NP (DT the) (NN target) (NN cell))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ initiated) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP result) (PP (IN from) (NP (DT this) (NN hit))))))) (VP (MD may) (VP (VB vary) (PP (IN from) (NP (NP (DT those)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP demonstrate) (NP (NP (ADJP (RB very) (JJ little)) (NN progression)) (PP (IN in) (NP (NN cell) (NN type))))) (CC and) (VP (MD may) (CC or) (VP (MD may) (RB not) (VP (VB require) (NP (NP (JJ exogenous) (NN enhancement)) (PP (IN of) (NP (NN growth))) (PP (TO to) (NP (NP (DT those)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB progress) (ADVP (RB very) (RB rapidly)) (PP (TO to) (NP (ADJP (RB fully) (JJ malignant)) (NN behavior))))))))))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ latter)) (VP (MD might) (VP (VB arise) (PP (IN from) (NP (NP (DT a) (NN hit)) (PP (IN in) (NP (DT a) (ADJP (RB genetically) (VBN initiated)) (NN cell))) (, ,) (SBAR (WHNP (NP (DT the) (NN result)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBZ is) (NP (NP (DT a) (ADJP (RBR more) (JJ rapid)) (NN progression)) (PP (IN in) (NP (NN tumor) (NN type)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN drug1))) (PP (IN upon) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (JJ chylomicron-like) (NNS emulsions))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ coronary) (NN artery) (NN disease))))))))) (. .)))
(S1 (S (S (S (NP (JJ Slow) (NN chylomicron) (NN intravascular) (NN catabolism)) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (JJ coronary) (NN artery) (NN disease))))))) (CC and) (S (NP (NP (NN screening)) (PP (IN for) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB speed-up) (NP (DT this) (NN process))))))))) (VP (MD can) (VP (VB be) (ADJP (JJ important)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN upon) (NP (NN chylomicron) (NN metabolism)))) (VP (VBD was) (VP (VBN tested) (PP (IN by) (NP (NP (NN determination)) (PP (IN of) (NP (NP (DT the) (NN plasma) (NNS kinetics)) (PP (IN of) (NP (NP (DT a) (JJ chylomicron-like) (NN emulsion) (NN model)) (PP (IN in) (NP (NP (NP (NP (NP (CD 12) (NNS patients)) (PP (IN with) (NP (JJ coronary) (NN artery) (NN disease)))) (, ,) (NP (JJ aged) (CD 59+/-11) (NNS years)) (, ,)) (PRN (-LRB- -LRB-) (NP (NP (JJ total) (NN cholesterol)) (: :) (NP (CD 240+/-41) (NN mg/dl)) (: ;) (NP (NNS triglycerides)) (: :) (NP (CD 188+/-42) (NN mg/dl))) (-RRB- -RRB-))) (VP (VBN submitted) (PP (TO to) (NP (NP (DT a) (ADJP (ADJP (JJ randomized)) (, ,) (ADJP (JJ crossover)) (, ,) (ADJP (JJ double-blind)) (, ,) (ADJP (JJ placebo-controlled))) (NN study)) (PP (IN with) (NP (NP (NP (NN administration)) (PP (IN of) (NP (NP (CD 1) (NN g)) (PP (IN per) (NP (NN day) (NN drug2)))))) (CC or) (NP (NP (NN placebo)) (PP (IN for) (NP (NN 1-month)))))))))))))))))))) (. .)))
(S1 (S (S (NP (DT A) (JJ 1-month) (NN washout) (NN period)) (VP (VBD was) (VP (VBN inserted) (PP (IN between) (NP (DT the) (NN treatment) (NNS periods)))))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (VBD were) (VP (ADVP (RB intravenously)) (VBN injected) (NP (NP (DT a) (JJ chylomicron-like) (NN emulsion)) (VP (ADVP (RB doubly)) (VBN labeled) (PP (IN with) (NP (NP (JJ 14C-cholesteryl) (NN oleate)) (CC and) (NP (NN 3H-triolein)))) (PP (PP (IN at) (NP (NN baseline))) (CC and) (PP (IN after) (NP (NNS treatments))))))))) (. .)))
(S1 (S (S (PP (IN After) (NP (NN drug1) (NN treatment))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (NP (NN decrease)) (PP (IN of) (NP (NP (JJ total) (NN cholesterol)) (CC and) (NP (NN triglyceride) (NN plasma) (NNS levels))))) (CC and) (NP (NP (DT a) (NN trend)) (S (VP (TO to) (VP (VB increase) (NP (NP (JJ high-density) (NN lipoprotein) (NN cholesterol)) (NN plasma) (NNS levels))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD elicited) (NP (NP (NP (ADJP (CD 62) (NN %)) (NN enhancement)) (PP (IN of) (NP (NN post-) (NN drug2) (JJ lipolytic) (NN activity)))) (CC and) (NP (NP (ADJP (CD 100) (NN %)) (NN increase)) (PP (IN of) (NP (JJ 3H-triglyceride) (JJ fractional) (NN clearance) (NN rate))))) (PP (VBN compared) (PP (IN with) (NP (NN placebo) (NN treatment)))))) (. .)))
(S1 (S (S (NP (JJ 14C-cholesterol) (NN ester) (JJ fractional) (NN clearance) (NN rate)) (VP (VBD was) (ADJP (NP (CD 260) (NN %)) (JJR greater)) (PP (IN after) (NP (NN drug1))) (PP (IN than) (PP (IN after) (NP (NN placebo)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT a) (JJ potent) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (CC both) (NP (NN chylomicron) (NN lipolysis)) (CC and) (NP (JJ remnant) (NN removal))))) (VP (VBD was) (VP (VBN achieved) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (DT this) (NN drug)) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB improve) (NP (NP (DT this) (NN metabolism)) (PP (IN in) (NP (JJ future) (JJ prospective) (NNS studies))))))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Selective) (NN survival)) (PP (IN in) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN of) (NP (FW Pseudomonas) (FW aeruginosa) (NN serotype) (CD O11))) (PP (IN from) (NP (NN drug) (NNS addicts))))) (. .))))
(S1 (S (NP (NP (DT The) (NN growth)) (PP (IN of) (NP (NP (FW Pseudomonas) (FW aeruginosa)) (, ,) (NP (ADVP (RB particularly)) (NP (NN serotype) (NN O11))) (, ,))) (PP (IN in) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))
(S1 (S (S (VP (VBD was) (VP (VBN evaluated) (PP (IN as) (NP (NP (NP (DT a) (JJ possible) (NN explanation)) (PP (IN for) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NP (JJ deep-seated) (NN infection)) (PP (IN with) (NP (DT this) (NN organism)))))))) (CC and) (NP (NP (NN abuse)) (PP (IN of) (NP (DT these) (NNS drugs))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ mean) (NN reduction)) (PP (IN of) (NP (NP (NN growth)) (VP (VBN caused) (PP (IN by) (NP (DT the) (NNS drugs))))))) (VP (VBD was) (ADJP (ADJP (RB 1,000-fold) (JJR greater)) (PP (IN for) (NP (NP (CD 49) (FW Pseudomonas) (NNS strains)) (PP (IN from) (NP (JJ normal) (NNS subjects))))) (PP (IN than) (PP (IN for) (NP (NP (CD 32) (NNS strains)) (PP (IN from) (NP (NP (NN drug) (NNS addicts)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 4.2) (CC vs.) (CD 1.3)) (NNS logs)) (PP (IN of) (NP (NN reduction))) (PP (IN at) (NP (CD 2) (NN hr)))) (, ,) (NP (NP (NN P)) (ADJP (JJR less) (PP (IN than) (NP (NN .0005)))))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ common) (JJ phenotypic) (NN subset)) (PP (IN of) (NP (NP (DT the) (NN serotype) (NN O11) (NNS strains)) (PP (IN from) (NP (NN drug) (NNS addicts)))))) (VP (VBD was) (ADJP (RB especially) (JJ resistant) (PP (TO to) (NP (DT the) (JJ inhibitory) (NNS effects)))))) (. .)))
(S1 (S (S (NP (NP (CD Twelve) (NNS strains)) (PP (IN of) (NP (NP (FW Staphylococcus) (FW aureus)) (PRN (-LRB- -LRB-) (NP (NP (NP (DT a) (JJ frequent) (NN cause)) (PP (IN of) (NP (NN infection))) (PP (PP (IN in) (NP (NN drug1))) (, ,) (CC but) (PP (RB not) (IN in) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))) (, ,) (NP (NNS addicts))) (-RRB- -RRB-))))) (VP (VBD were) (VP (ADVP (RB completely)) (VBN inhibited) (PP (IN by) (NP (DT the) (NN drug) (NN combination)))))) (. .)))
(S1 (S (S (NP (NP (JJ Dose-response) (NNS curves)) (-LRB- -LRB-) (VP (VBN derived) (PP (IN from) (NP (NP (DT the) (NNS results)) (PP (IN of) (S (VP (VBG using) (NP (NP (DT the) (NNS tablets)) (CONJP (RB as) (RB well) (IN as)) (NP (JJ pure) (NNS powders))))))))) (-RRB- -RRB-)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD was) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ inhibitory) (NN activity)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADVP (RB partially)) (VP (VBN antagonized) (PP (IN by) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (DT an) (NN ability)) (PP (IN of) (NP (DT some) (NN P)))))))) (. .)))
(S1 (S (S (NP (FW aeruginosa) (NN serotype) (NN O11)) (VP (VBZ strains) (UCP (, ,) (CONJP (CC but) (RB not)) (NP (NN S))))) (. .)))
(S1 (S (S (ADVP (FW aureus)) (, ,) (S (VP (TO to) (VP (VB survive) (PP (IN in) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (MD may) (VP (VB explain) (PP (IN in) (NP (NN part))) (NP (NP (DT a) (NN shift)) (PP (IN from) (NP (NNS S))))))) (. .)))
(S1 (S (NP (NP (FW aureus)) (PP (TO to) (NP (NN P)))) (. .)))
(S1 (S (NP (NP (FW aeruginosa)) (PP (IN as) (NP (NP (JJ common) (NNS pathogens)) (PP (IN of) (NP (NN drug) (NNS addicts))))) (PP (IN in) (NP (NP (NNS areas)) (SBAR (WHADVP (WRB where)) (S (NP (NP (NN abuse)) (PP (IN of) (NP (NP (DT this) (NN combination)) (PP (IN of) (NP (NNS drugs)))))) (VP (VBZ has) (VP (VBN increased)))))))) (. .)))
(S1 (S (NP (NP (NN Influence)) (PP (IN of) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1))))) (PP (IN on) (NP (NP (NP (NN drug2) (NNS pharmacokinetics)) (CC and) (NP (NN QTc) (NNS intervals))) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))) (. .))))
(S1 (S (NP (NP (NN STUDY) (NN OBJECTIVE)) (: :) (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NP (NNS pharmacokinetics)) (CC and) (NP (JJ cardiovascular) (NN safety))) (PP (IN of) (NP (NN drug2))) (PP (IN at) (NP (NP (JJ steady) (NN state)) (PP (IN in) (NP (JJ healthy) (NNS men))))))))))) (. .))))
(S1 (S (NP (NP (NN DESIGN)) (: :) (NP (ADJP (ADJP (JJ Open-label)) (, ,) (ADJP (JJ three-phase)) (, ,) (ADJP (JJ sequential))) (NN study)) (. .))))
(S1 (S (NP (NP (NN SETTING)) (: :) (NP (JJ Clinical) (NN research) (NN center)) (. .))))
(S1 (S (S (NP (NNS SUBJECTS)) (: :) (NP (CD Twelve) (JJ healthy) (JJ male) (NNS volunteers))) (. .)))
(S1 (S (NP (NP (NN INTERVENTIONS)) (: :) (S (NP (DT Each) (NN subject)) (VP (VBD was) (VP (VBN treated) (PP (VBG according) (PP (TO to) (NP (DT the) (JJ following) (NN sequence))))))) (: :) (NP (NN baseline)) (: ;))))
(S1 (S (NP (NP (NP (NN phase) (CD 1)) (PRN (-LRB- -LRB-) (NP (NNS days) (NP (CD 1-6))) (-RRB- -RRB-))) (: :) (NP (NN drug1) (CD 10) (NN mg) (CD 4) (NN times/day)) (: ;))))
(S1 (S (NP (NP (NN washout)) (PRN (-LRB- -LRB-) (NP (NNS days) (NP (CD 7-13))) (-RRB- -RRB-)) (: ;))))
(S1 (S (NP (NP (NP (NN phase) (CD 2)) (PRN (-LRB- -LRB-) (NP (NNS days) (NP (CD 14-44))) (-RRB- -RRB-))) (: :) (NP (NN drug1) (CD 20) (NN mg/day)) (: ;))))
(S1 (S (NP (NP (CC and) (NP (NP (NN phase) (CD 3)) (PRN (-LRB- -LRB-) (NP (NNS days) (NP (CD 45-52))) (-RRB- -RRB-)))) (: :) (NP (NP (NP (NP (NN drug1) (CD 10) (NN mg) (CD 4)) (ADJP (JJ times/day) (PRN (-LRB- -LRB-) (NP (NNS days) (NP (CD 45-51))) (-RRB- -RRB-)))) (CC plus) (NP (NN drug2) (CD 20) (NN mg/day))) (PRN (-LRB- -LRB-) (NP (NNS days) (NP (CD 45-52))) (-RRB- -RRB-))) (. .))))
(S1 (S (NP (NP (NP (NNS MEASUREMENTS)) (CC and) (NP (JJ MAIN) (NNS RESULTS))) (: :) (S (S (NP (NN Blood) (NNS samples)) (VP (VBD were) (VP (VBN drawn)))) (CC and) (S (NP (NN 12-lead) (NNS electrocardiograms)) (VP (VBN performed) (PP (IN at) (NP (NP (VBN specified) (NN time) (NNS points)) (PP (IN after) (NP (NP (DT the) (JJ last) (NN morning) (NN dose)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NNS phases) (QP (CD 1) (CC and) (CD 3))))))))))) (. .))))
(S1 (S (S (NP (NN Blood) (NNS samples)) (ADVP (RB also)) (VP (VBD were) (VP (VBN taken) (PP (IN before) (NP (NP (NN morning) (NNS doses)) (PP (IN on) (NP (NP (DT the) (QP (CD 3rd) (, ,) (CD 4th) (, ,) (CC and) (CD 5th)) (NNS days)) (PP (IN of) (NP (NNS phases) (QP (CD 1) (CC and) (CD 3))))))))))) (. .)))
(S1 (S (S (NP (NNS Electrocardiograms)) (VP (VBD were) (VP (VBN done) (PP (PP (IN at) (NP (NN baseline))) (CC and) (PP (IN on) (NP (NP (DT the) (JJ last) (NN day)) (PP (IN of) (NP (NP (DT the) (NN washout) (NN period)) (CC and) (NP (NN phase) (CD 2)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1)))) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NN drug2) (NN plasma) (NNS concentrations)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NNS changes)) (PP (IN in) (NP (NP (JJ corrected) (VBG QT) (NNS intervals)) (PP (IN during) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug1))) (UCP (ADVP (RB alone)) (CC or) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (VP (ADVP (RB well)) (VBN tolerated) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (UCP (ADVP (RB alone)) (CC or) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (NN drug1)) (VP (MD can) (VP (VB be) (VP (VBN administered) (ADVP (RB safely)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ low) (JJ therapeutic) (NNS dosages)) (PP (IN of) (NP (NN drug2))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Activity)) (PP (IN of) (NP (NN drug1))) (UCP (ADVP (RB alone)) (CC and) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (PP (IN against) (NP (FW Cryptosporidium) (FW parvum))) (PP (IN in) (NP (NN cell) (NN culture)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (ADJP (FW in) (FW vitro)) (JJ anti-cryptosporidial) (NN activity)) (PP (IN of) (NP (NN drug1))) (UCP (ADVP (RB alone)) (CC and) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))) (VP (VBD was) (VP (VBN investigated)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD showed) (NP (NP (JJ moderate) (NN activity)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD increased) (PP (IN with) (S (VP (VBG increasing) (NP (NN concentration)) (PP (TO to) (NP (NP (ADJP (CD 55.7) (NN %)) (NN suppression)) (PP (IN of) (NP (NN growth))) (PP (IN at) (NP (CD 20) (NN microM)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (PRP$ its) (NN activity)) (VP (VBD was) (VP (VBN enhanced) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBD was) (VP (VBN combined) (PP (IN with) (NP (CC either) (NP (NN drug1)) (CC or) (NP (NN drug2)))) (PP (IN with) (NP (NP (ADJP (CD 90) (NN %)) (NN parasite) (NN reduction)) (PP (IN at) (NP (NP (DT the) (JJS highest) (NN concentration)) (VP (VBN tested))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB be) (ADJP (JJ active)) (PP (IN in) (S (VP (VBG inhibiting) (NP (NN Cryptosporidium) (NN parvum) (NN growth)) (ADVP (FW in) (FW vitro)) (PP (IN upon) (NP (NP (NN combination)) (PP (IN with) (NP (CC either) (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Modification)) (PP (IN of) (NP (NN surface) (NN histidine) (NNS residues)))) (VP (VBZ abolishes) (NP (NP (DT the) (JJ cytotoxic) (NN activity)) (PP (IN of) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ displays) (NP (ADJP (CC both) (ADJP (JJ cytotoxic)) (CC and) (ADJP (JJ enterotoxic))) (NNS activities)))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ has) (ADVP (RB recently)) (VP (VBN been) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ exerts) (NP (PRP$ its) (JJ cytotoxic) (NN effect)) (PP (IN by) (NP (NP (DT the) (NN glucosylation)) (PP (IN of) (NP (NP (DT the) (JJ small) (JJ GTP-binding) (NNS proteins)) (PP (IN of) (NP (DT the) (NN Rho) (NN family)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (PP (IN at) (NP (NN pH) (CD 7.0))) (, ,)) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (ADVP (RB chemically)) (VP (VB modify) (NP (NP (VBN exposed) (NN histidine) (NNS residues)) (PP (IN on) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Modification)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBD abolished) (NP (CC both) (NP (PRP$ its) (JJ cytotoxic) (NN activity)) (CC and) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (DT the) (NN toxin))) (S (VP (TO to) (VP (VB bind) (NP (NN Zn-Sepharose) (NN gel))))))))) (. .)))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (ADJP (-LRB- -LSB-) (-LRB- -LRB-) (CD 14) (-RRB- -RRB-) (NN C) (-RRB- -RSB-) (: -)) (NN drug2)))) (VP (VBD revealed) (NP (NP (ADJP (NN concentration) (JJ dependent)) (NN labelling)) (PP (IN of) (NP (NN histidine) (NNS residues))) (PP (IN on) (NP (DT the) (NN toxin) (NNS molecules)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (MD could) (VP (VB be) (VP (VBN reversed) (PP (IN by) (NP (NN drug2) (NN treatment))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (NP (NP (DT the) (JJ modified) (NN histidine) (NNS residues)) (PP (IN on) (NP (NN drug1)))) (VP (VBP are) (ADJP (JJ critical) (PP (TO to) (NP (PRP$ its) (JJ cytotoxic) (NN activity))))))) (. .)))
(S1 (S (S (NP (NN Histidine) (NN modification)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN glucosyl) (NN transferase) (NN enzyme) (NN activity)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN modification)) (VP (VP (VBD abolished) (NP (NP (DT the) (`` ') (JJ cold) ('' ') (NN binding)) (PP (IN of) (NP (NN toxin))) (PP (TO to) (NP (JJ bovine) (NN thyroglobulin)))) (PP (IN in) (NP (DT an) (NN ELISA)))) (CC and) (VP (VBD reduced) (NP (NN ligand) (NN binding) (NN activity)) (PP (IN in) (NP (DT a) (NN rabbit) (NN erythrocyte) (NN haemagglutination) (NN assay)))))) (. .)))
(S1 (S (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (NN histidine) (NNS residues)) (VP (MD may) (VP (VB be) (ADJP (JJ crucial) (PP (TO to) (NP (NP (DT the) (JJ receptor-binding) (NN activity)) (PP (IN of) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (S (S (NP (NP (VBN Exposed) (NNS histidines)) (PP (IN on) (NP (NN drug1)))) (VP (VBP are) (ADJP (JJ available) (PP (IN for) (NP (NN drug2) (NN chelation)))))) (, ,) (CC and) (S (NP (DT these)) (VP (VBP have) (VP (VBN been) (VP (VBN exploited) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (DT a) (JJ novel) (NN purification) (NN protocol)) (PP (IN for) (NP (NN drug3))))))) (S (VP (VBG using) (NP (NN drug4) (JJ -chelating) (NN chromatography))))))))) (. .)))
(S1 (S (NP (NP (NN Interaction)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (FW vitro))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ minimal) (JJ inhibitory) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (UCP (ADVP (RB alone)) (CC and) (PP (IN in) (NP (NNS combinations))))))) (VP (VBD were) (VP (VBN determined) (PP (IN by) (NP (NP (DT a) (JJ microdilution) (NN method)) (PP (IN for) (NP (CD 163) (ADJP (ADJP (JJ aerobic)) (, ,) (ADJP (JJ facultative)) (, ,) (CC and) (ADJP (JJ anaerobic))) (JJ clinical) (NNS isolates)))))))) (. .)))
(S1 (S (S (NP (NP (DT All) (JJ 77) (NNS strains)) (PP (IN of) (NP (NP (FW Staphylococcus) (FW aureus)) (, ,) (NP (FW Diplococcus) (FW pneumoniae)) (, ,) (NP (FW Streptococcus) (FW pyogenes)) (, ,) (CC and) (NP (JJ anaerobic) (NNS bacteria)))) (-LRB- -LRB-) (PP (IN except) (IN for) (NP (NP (CD three) (NNS strains)) (PP (IN of) (NP (NN Clostridium))))) (-RRB- -RRB-)) (VP (VBD were) (VP (VBN inhibited) (PP (IN by) (NP (NP (CD 1.6) (NN mug) (QP (CC or) (JJR less))) (PP (IN of) (NP (NN drug1))) (PP (IN per) (NP (NN ml)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN drug2))))) (PP (IN within) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (NP (NP (NNS concentrations)) (VP (VBN tested))) (PRN (-LRB- -LRB-) (NP (QP (CD 0.1) (TO to) (CD 100)) (NN mug/ml)) (-RRB- -RRB-))))))))) (: ;)))
(S1 (S (S (PP (IN for) (NP (DT some) (NNS strains))) (NP (NNS combinations)) (VP (VBD were) (ADJP (JJ synergistic)))) (. .)))
(S1 (S (S (NP (NP (NP (NN Sixty-two)) (PRN (-LRB- -LRB-) (NP (CD 94) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (CD 66) (NNS strains)) (PP (IN of) (NP (NP (FW Enterobacteriaceae)) (CC and) (NP (FW Pseudomonas) (FW aeruginosa))))))) (VP (VBD were) (VP (VBN inhibited) (PP (IN by) (NP (NP (CD 6.2) (NN mug) (QP (CC or) (JJR less))) (PP (IN of) (NP (NN drug1))) (PP (IN per) (NP (NN ml)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Combinations)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD were) (ADJP (ADJP (JJ indifferent) (PP (IN for) (NP (CD 29) (NNS strains)))) (CC and) (ADJP (JJ synergistic) (PP (IN for) (NP (CD 33) (NNS strains))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT All) (CD 20) (NNS strains)) (PP (IN of) (NP (NN enterococcus)))) (, ,) (NP (NP (CD three) (NNS strains)) (PP (IN of) (NP (NN Clostridium)))) (, ,) (NP (NP (CD three) (NNS strains)) (PP (IN of) (NP (FW Escherichia) (FW coli)))) (, ,) (CC and) (NP (NP (CD one) (NN strain)) (PP (IN of) (NP (NN Proteus) (NN rettgeri))))) (VP (VBD were) (ADJP (JJ resistant) (PP (TO to) (NP (CC both) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (JJ minimal) (JJ inhibitory) (NN concentration)) (ADJP (JJR greater) (PP (IN than) (NP (CD 3.1) (NN mug/ml))))) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (JJ minimal) (JJ inhibitory) (NN concentration)) (ADJP (JJR greater) (PP (IN than) (NP (CD 6.2) (NN mug/ml))))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Combinations)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD were) (ADJP (ADJP (JJ indifferent) (PP (IN for) (NP (CD 16)))) (CC and) (ADJP (JJ synergistic)) (PP (IN for) (NP (NP (CD 11)) (PP (IN of) (NP (DT the) (JJ resistant) (NNS strains)))))))) (. .)))
(S1 (S (S (PP (IN Except) (IN for) (NP (NN drug1) (JJ -sensitive) (NNS isolates))) (, ,) (NP (NN synergy)) (VP (VBD was) (ADVP (RB usually)) (VP (VBN observed) (ADVP (RB only)) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN of) (NP (NP (CD one)) (CC or) (NP (DT both)) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (RB not) (ADVP (RB readily)) (ADJP (JJ obtainable) (ADVP (FW in) (FW vivo)))))))))))))) (. .)))
(S1 (S (S (NP (NN Antagonism)) (VP (VBD was) (ADVP (RB never)) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (DT the) (JJ common) (NN cold)))) (. .)))
(S1 (S (NP (NP (NN Evaluation)) (PP (IN of) (NP (PRP$ its) (NP (NN efficacy)) (CC and) (NP (NN toxicity)))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBN reviewed) (NP (NP (DT the) (JJ clinical) (NNS data)) (VP (VBG relating) (PP (TO to) (NP (NP (DT the) (NP (NN efficacy)) (CC and) (NP (NN safety))) (PP (IN of) (NP (NP (JJ pharmacologic) (NNS doses)) (PP (IN of) (NP (NN drug1))))) (PP (IN in) (NP (NP (DT the) (NP (NN prevention)) (CC and) (NP (NN treatment))) (PP (IN of) (NP (DT the) (JJ common) (NN cold))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (CD one) (NN study)) (ADVP (RB tentatively)) (VP (VBZ supports) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (JJ such) (NNS doses)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ efficacious)))))))))) (, ,) (S (S (NP (NP (DT a) (JJ second) (NN study)) (PP (IN by) (NP (DT the) (JJ same) (NN group)))) (VP (VBD did) (RB not) (VP (VB confirm) (NP (DT the) (JJ significant) (NNS findings))))) (, ,) (CC and) (S (NP (NP (DT no) (ADJP (ADJP (JJ clear)) (, ,) (ADJP (JJ reproducible))) (NN pattern)) (PP (IN of) (NP (NN efficacy)))) (VP (VBZ has) (VP (VBN emerged) (PP (IN from) (NP (NP (DT the) (NN review)) (PP (IN of) (NP (PDT all) (DT the) (NN evidence)))))))))) (. .)))
(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (EX there)) (VP (VBZ is) (ADVP (RB currently)) (NP (NP (JJ little) (JJ adequate) (NN evidence)) (PP (IN on) (NP (CC either) (DT the) (NP (NN presence)) (CC or) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (JJ serious) (JJ adverse) (NNS reactions)) (PP (TO to) (NP (NP (JJ such) (NNS doses)) (PP (IN of) (NP (NN drug1))))))))))) (, ,) (SBAR (IN although) (S (NP (JJ many) (JJ such) (NNS reactions)) (VP (VBP have) (VP (VBN been) (VP (VBN hypothesized)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ unrestricted) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN for) (NP (DT these) (NNS purposes)))) (VP (MD cannot) (VP (VB be) (VP (VBN advocated) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (DT the) (NN evidence)) (ADJP (RB currently) (JJ available)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (DT a) (NN light/dark) (NN test)) (PP (IN in) (NP (NNS mice)))))) (CC and) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (NN adenosine) (NNS receptors)))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN adenosine) (NN receptor) (NNS antagonists)) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-)))) (, ,))) (PP (IN in) (NP (DT a) (NN light/dark) (NN test)))) (PP (IN in) (NP (NNS mice))))) (. .)))
(S1 (S (S (NP (DT All) (NNS antagonists)) (VP (VBD decreased) (NP (NP (DT the) (NN time) (NN spent)) (PP (IN in) (NP (NP (DT the) (JJ light) (NN zone)) (PP (IN in) (NP (DT this) (NN test))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD suggested) (SBAR (IN that) (S (NP (DT these) (NNS compounds)) (VP (VBP have) (NP (JJ anxiogenic) (NNS effects))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ anxiogenic) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (VP (VBN reduced) (PP (PP (IN by) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (DT an) (JJ A2-selective) (NN agonist)) (, ,))))) (CC but) (PP (RB not) (IN by) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (NP (DT an) (JJ A1-selective) (NN agonist)))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (S (S (NP (NP (DT the) (NN antagonism)) (PP (IN of) (NP (DT the) (NN drug1) (JJ -induced) (JJ anxiogenic) (NNS effects))) (PP (IN by) (NP (NN drug2)))) (VP (VBD was) (ADVP (RB only)) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN time) (NN spent)) (PP (IN in) (NP (DT the) (JJ light) (NN zone)))))))) (, ,) (CC and) (S (NP (NN drug3) (JJ -induced) (JJ anxiogenic) (NNS effects)) (VP (VBD were) (ADVP (RB neither)) (VP (VBN reversed) (PP (PP (IN by) (NP (NN drug4))) (CC nor) (PP (IN by) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (ADVP (RB Finally)) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ notable)) (SBAR (IN that) (S (NP (NP (JJ xanthine-derived) (NN adenosine) (NNS antagonists)) (VP (VBN tested) (ADVP (RB here)))) (ADVP (RB commonly)) (VP (VBD showed) (NP (JJ anxiogenic) (NNS effects)) (PP (IN in) (NP (DT the) (NN light/dark) (NN test))) (PP (IN in) (NP (NNS mice)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN suggested) (SBAR (IN that) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ minor) (NN contribution)) (PP (IN of) (NP (NN adenosine) (NNS receptors))) (PP (TO to) (NP (DT these) (NNS effects)))) (, ,) (SBAR (IN although) (S (NP (ADJP (ADJP (NN drug1) (JJ -induced)) (ADJP (JJ anxiogenic))) (NNS effects)) (VP (VBD were) (VP (VBN antagonized) (PP (IN by) (NP (DT an) (NN A2) (NN receptor) (NN agonist))))))))))))) (. .)))
(S1 (S (NP (NP (NN Restoration)) (PP (IN of) (NP (NP (NN drug1) (NN susceptibility)) (PP (IN in) (NP (NN Enterococcus) (NN faecalis))))) (PP (IN by) (NP (NN antiresistance) (NN determinant) (NN gene) (NN transfer))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD assessed) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN gene) (NN transfer))) (S (VP (TO to) (VP (VB reverse) (NP (NN drug1) (NN resistance)) (PP (IN in) (NP (ADJP (NN class) (NN A) (-LRB- -LRB-) (NN VanA) (-RRB- -RRB-) (JJ glycopeptide-resistant)) (NN Enterococcus) (NN faecalis))))))))) (. .)))
(S1 (S (NP (NP (JJ Recombinant) (NN shuttle) (NNS vectors)) (VP (VBG containing) (NP (DT a) (NN vanH) (NN promoter-vanA) (JJ antisense) (NN gene) (NN cassette)))) (VP (ADVP (RB fully)) (VBD restored) (NP (NN drug1) (NN susceptibility)) (PP (IN through) (NP (NP (NP (DT a) (JJ combined) (JJ transcriptional) (NN activator) (NN binding) (NN domain)) (NN decoy)) (CC and) (NP (NP (JJ inducible) (NN vanA) (JJ antisense) (NN RNA)) (NN effect))))) (. .)))
(S1 (S (NP (NP (NN Induction)) (PP (IN of) (NP (NN apoptosis))) (PP (IN in) (NP (NP (NN breast) (NN cancer) (NNS cells)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (. .))))
(S1 (S (S (NP (NP (CD 1) (, ,) (NN drug1) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-)) (, ,) (NP (NP (DT the) (JJ active) (NN metabolite)) (PP (IN of) (NP (NN drug3)))) (, ,)) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN breast) (NN cancer) (NN cell) (NN growth)))) (ADVP (CC both) (ADVP (FW in) (FW vivo)) (CC and) (ADVP (FW in) (FW vitro))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (NN MCF-7) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (ADJP (CD 100) (NN nM)) (NN drug1))))) (VP (VBP exhibit) (NP (NP (JJ characteristic) (JJ apoptotic) (NN morphology)) (PRN (-LRB- -LRB-) (NP (NP (JJ pyknotic) (NNS nuclei)) (, ,) (NP (NN chromatin) (CC and) (JJ cytoplasmic) (NN condensation)) (, ,) (NP (JJ nuclear) (NN matrix) (NN protein) (NN reorganization))) (-RRB- -RRB-))) (PP (IN within) (NP (CD 48) (NN h))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT the) (NNS experiments)) (VP (VBN reported) (ADVP (RB here))))) (, ,) (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NNS interactions)) (PP (IN between) (NP (NP (NP (NN drug1)) (CC and) (NP (NP (DT the) (NN drug2) (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB also)) (VP (VBZ induces) (NP (NN apoptosis)) (PP (IN in) (NP (NN MCF-7) (NNS cells)))))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (ADVP (RB significantly)) (VP (VBZ potentiates) (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (NP (NN cell) (NN number)) (VP (VBN induced) (PP (IN by) (NP (NP (NN drug2)) (ADVP (RB alone))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Combined) (NN treatment)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ enhances) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NN apoptosis)) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (JJ morphological) (NNS markers)) (SBAR (WHNP (WDT that)) (S (VP (VBP identify) (NP (NP (NN chromatin)) (CC and) (NP (JJ nuclear) (NN matrix) (NN protein) (NN condensation))))))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN selected) (NP (NP (DT a) (NN subclone)) (PP (IN of) (NP (NP (NN MCF-7) (NNS cells)) (ADJP (JJ resistant) (PP (TO to) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN MCF-7D3Res)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS cells)) (VP (VP (VBP express) (NP (DT the) (NN vitamin) (NN D) (NN receptor))) (CC and) (VP (VBP exhibit) (NP (NP (VBG doubling) (NNS times)) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT the) (JJ parental) (NN MCF-7) (NNS cells)) (, ,) (SBAR (WHADVP (RB even) (WRB when)) (S (VP (VBN grown) (PP (IN in) (NP (ADJP (CD 100) (NN mM)) (NN drug1))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN of) (NP (ADJP (CC both) (ADJP (JJ parental)) (CC and) (ADJP (JJ resistant))) (NN MCF-7) (NNS cells))) (PP (IN with) (NP (NN drug1)))) (VP (VBZ induces) (NP (NP (NN apoptosis)) (CC and) (NP (NN clusterin))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP emphasize) (SBAR (IN that) (S (NP (NN apoptosis)) (VP (MD can) (VP (VB be) (VP (VBN induced) (PP (PP (IN in) (NP (NN MCF-7) (NNS cells))) (CC either) (PP (IN by) (NP (NP (NN activation)) (PP (IN of) (NP (NP (NN drug1) (JJ -mediated) (NN signalling)) (CC or) (NP (NP (NN disruption)) (PP (IN of) (NP (NN drug2)))) (NP (JJ -dependent) (NN signalling)))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Cholinergic) (NN role)) (PP (IN in) (NP (NN drug1) (POS 's) (NNS effects))) (PP (IN on) (NP (NP (VBN evoked) (NNS potentials)) (PP (IN in) (NP (NP (JJ visual) (NN cortex)) (PP (IN of) (NP (DT the) (JJ albino) (NN rat))))))) (. .))))
(S1 (S (S (NP (JJ Photic) (VBN evoked) (NNS potentials)) (VP (VBD were) (VP (VBN recorded) (PP (IN from) (NP (NP (DT the) (JJ visual) (NN cortex)) (PP (IN of) (NP (ADJP (RB chronically) (VBN implanted)) (NN albino) (NNS rats)))))))) (. .)))
(S1 (S (SBAR (IN Since) (S (NP (JJ photic) (VBN evoked) (JJ potential) (NNS components)) (VP (VBP are) (NP (NP (NNS representations)) (PP (IN of) (NP (JJ neural) (NNS pathways))) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN activated) (PP (IN during) (NP (JJ photic) (NN stimulation))))))))))) (, ,) (NP (NP (NN study)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (DT these) (NNS components)))))) (VP (MD may) (VP (VB help) (S (VP (TO to) (VP (VB trace) (NP (NP (NNS pathways)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN affected) (PP (IN by) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (VBN evoked) (NNS potentials)) (VP (VBD were) (VP (VBN recorded) (PP (IN at) (NP (NP (QP (CD 5) (, ,) (CD 20) (, ,) (CC and) (CD 40)) (NN min)) (PP (VBG following) (NP (NP (JJ IP) (NNS injections)) (PP (IN of) (NP (NP (NN saline)) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 2.0) (NN g/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 0.6) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 15.0) (NN mg/kg)) (-RRB- -RRB-))))))))) (PP (IN on) (NP (JJ separate) (NNS days))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD depressed) (NP (NP (DT the) (NNS amplitudes)) (PP (IN of) (NP (JJS most) (VBN evoked) (JJ potential) (NNS components))) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NN saline) (NN administration)))))))) (. .)))
(S1 (S (S (NP (NN Component) (NN P2)) (, ,) (ADVP (RB however)) (, ,) (VP (VBD was) (VP (VBN increased) (PP (IN in) (NP (NN amplitude)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB briefly)) (VP (VBD reduced) (NP (NP (DT the) (NN amplitude)) (PP (IN of) (NP (NP (JJ most) (NNS components)) (, ,) (PP (VBG including) (NP (NN P2)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NN drug1)) (VP (VBD increased) (NP (NP (DT the) (NNS amplitudes)) (PP (IN of) (NP (NNS components) (NP (NP (NN P1)) (CC and) (NP (NN P2)))))) (, ,) (SBAR (IN while) (S (VP (VBG decreasing) (NP (NP (NNS components) (NP (NP (NNP N1) (, ,) (NNP N2)) (CC and) (NP (NNP N3)))) (PP (IN for) (NP (NP (VBG varying) (NNS durations)) (PP (IN of) (NP (NN time))))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN pretreatment)) (VP (VBD augmented) (NP (NP (DT the) (JJ depressant) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (DT the) (JJ early) (NNS components) (NP (NP (NN P1)) (CC and) (NP (NN N1)))))) (, ,) (SBAR (IN while) (S (VP (VBG attenuating) (NP (NP (NP (NN drug3) (POS 's)) (NN influence)) (PP (IN on) (NP (NNS components) (NP (NP (NN P2)) (CC and) (NP (NN P3))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NN drug1)))) (ADVP (RB likewise)) (ADVP (RB further)) (VP (VP (VBD reduced) (NP (NP (DT the) (NNS amplitudes)) (PP (IN of) (NP (NNS components) (NP (NP (NN P1)) (CC and) (NP (NN N1))))))) (, ,) (CC and) (VP (VBD produced) (NP (NP (DT a) (JJ similar) (NN effect)) (PP (IN on) (NP (NN component) (NN N3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (UCP (CC either) (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2))))) (, ,))) (VP (VBD produced) (NP (NP (RB approximately) (DT the) (JJ same) (NN degree)) (PP (IN of) (NP (NP (NN enhancement)) (PP (IN of) (NP (NN component) (NN P2)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NN comparison)) (PP (TO to) (NP (NN saline) (NNS values))))) (, ,) (NP (DT all) (CD three) (NNS agents)) (VP (VBD produced) (NP (NP (JJ reliable) (NNS increases)) (PP (IN in) (NP (NP (JJ peak) (NN latency)) (PP (IN for) (NP (NP (JJS most)) (PP (IN of) (NP (DT the) (NNS components)))))))) (, ,) (PP (IN with) (NP (NP (JJ only) (NN N3)) (VP (VBG showing) (NP (DT no) (NNS effects))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ amplitude) (NNS data)) (PP (IN from) (NP (DT this) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NP (NN drug1) (POS 's)) (NN augmentation)) (PP (IN of) (NP (NN component) (NN P2)))) (VP (MD may) (VP (VB result) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (PP (IN from) (NP (NP (NNS alterations)) (PP (IN in) (NP (JJ cholinergic) (NNS functions))))))))))) (. .)))
(S1 (S (S (VP (VBN Increased) (NP (NP (NN hepatotoxicity)) (PP (IN of) (NP (NN drug1)))) (PP (IN by) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (DT the) (NN rat))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB frequently)) (VP (VBN co-administered) (PP (IN with) (NP (NN drug2))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (PP (IN of) (NP (JJ clinical) (NN interest))) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug3))) (PP (IN on) (NP (NP (DT the) (NN hepatotoxicity)) (PP (IN of) (NP (NNS drug4))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (JJ male) (NN Sprague-Dawley) (NNS rats)) (VP (VBN fasted) (PP (IN for) (NP (CD 18) (NN h)))))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PRN (-LRB- -LRB-) (NP (NP (CD 0.1) (NN g/kg)) (, ,) (ADVP (RB i.p.))) (-RRB- -RRB-)))))
(S1 (S (S (IN as) (VP (VBN judged) (PP (IN by) (NP (NP (VBN increased) (NN serum) (NN enzyme) (NNS activities)) (CC and) (NP (NP (VBN increased) (NN incidence)) (PP (IN of) (NP (JJ hepatic) (NN necrosis)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Careful) (NNS observations)) (PP (IN on) (NP (NN hepatotoxicity)))) (VP (VBP are) (VP (VBN suggested) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN prescribed) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (JJ Dual) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NP (ADJP (NN drug2) (JJ -induced)) (NN contraction)) (CC and) (NP (NN norepinephrine) (NN release))) (PP (IN in) (NP (DT the) (JJ guinea-pig) (NN vas) (NNS deferens))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (NP (NN C129H223N3O54)) (, ,) (VP (VBN isolated) (PP (IN from) (NP (NP (JJ marine) (NNS coelenterates)) (PP (IN of) (NP (NN Palythoa) (NN tuberculosa)))))) (, ,)) (VP (VBD caused) (NP (NP (DT a) (JJ first) (JJ rapid) (NN contraction)) (VP (VBN followed) (PP (IN by) (NP (NP (DT the) (JJ slow) (NN phasic) (NN contraction)) (PP (IN of) (NP (JJ guinea-pig) (NN vas) (NNS deferens)))))))) (. .)))
(S1 (S (PP (IN In) (DT the) (NN presence) (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 10) (-LRB- -LRB-) (CD -5) (-RRB- -RRB-) (NN M)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 10) (-LRB- -LRB-) (CD -8) (-RRB- -RRB-) (NN M)) (-RRB- -RRB-))) (VP (VBD failed) (S (VP (TO to) (VP (VB cause) (NP (DT the) (JJ first) (NN contraction)))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (DT the) (JJ second) (NN contraction)) (VP (VBD was) (VP (VBN potentiated)))) (. .)))
(S1 (S (S (PP (IN In) (DT the) (NN presence) (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 10) (-LRB- -LRB-) (CD -6) (-RRB- -RRB-) (NN M)) (-RRB- -RRB-)))) (, ,) (NP (DT the) (JJ second) (NN contraction)) (VP (VBD was) (VP (VBN inhibited) (ADVP (RB selectively))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN applied) (PP (TO to) (NP (DT the) (NN muscle))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2))))))))) (, ,) (NP (NP (ADJP (CC both) (ADJP (JJ first)) (CC and) (ADJP (JJ second))) (JJ contractile) (NNS responses)) (PP (TO to) (NP (NN drug3)))) (VP (VBD were) (VP (VBN abolished)))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NN muscle)) (VP (VBD was) (VP (VBN exposed) (PP (TO to) (NP (DT the) (JJ potassium-depleted) (NN solution))))))) (, ,) (NP (NP (DT the) (JJ first) (JJ contractile) (NN response)) (PP (TO to) (NP (NN drug1)))) (VP (VBD was) (ADVP (RB rather)) (VP (VBN potentiated)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD caused) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NN norepinephrine))) (PP (IN from) (NP (DT the) (NN muscle)))))) (. .)))
(S1 (S (S (NP (NP (NN Exposure)) (PP (IN of) (NP (DT the) (NN muscle))) (PP (TO to) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 10) (-LRB- -LRB-) (CD -5) (-RRB- -RRB-) (NN M)) (-RRB- -RRB-))))) (ADVP (RB markedly)) (VP (VBD increased) (NP (DT the) (JJ drug2) (JJ -induced) (NN release)))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN indicated) (SBAR (IN that) (S (NP (NP (DT the) (ADJP (ADJP (JJ first)) (CC and) (ADJP (JJ second))) (JJ contractile) (NNS responses)) (PP (TO to) (NP (NN drug1)))) (VP (VBP have) (NP (ADJP (RB entirely) (JJ different)) (NNS properties)))))))) (. .)))
(S1 (S (NP (DT The) (JJ second) (NN response)) (VP (VP (VBZ is) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (NN release)) (PP (IN of) (NP (NN norepinephrine))) (PP (IN from) (NP (NNS nerves))))))) (CC and) (VP (VBD was) (VP (VBN potentiated) (PP (IN by) (NP (NN drug1))) (PP (IN through) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (DT the) (NN norepinephrine) (NN release)))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (JJ first) (NN response)) (VP (VP (VBD was) (RB not) (ADJP (JJ due) (PP (PP (TO to) (NP (DT the) (NN norepinephrine) (NN release))) (CC but) (ADVP (RB presumably)) (PP (TO to) (NP (NP (DT a) (JJ direct) (NN action)) (PP (IN on) (NP (JJ smooth) (NN muscle) (NN cell)))))))) (CC and) (VP (VBD was) (VP (VBN inhibited) (PP (IN by) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug1)))))) (VP (VBD was) (VP (VBN discussed) (PP (IN in) (NP (NP (DT the) (NN relation)) (PP (IN with) (NP (NP (NN Na)) (, ,) (NP (NN K-ATPase))))))))) (. .)))
(S1 (S (NP (NP (JJ Analgesic) (NNS effects)) (PP (IN of) (NP (NN drug1))) (. .))))
(S1 (S (NP (DT The) (NN literature)) (VP (VBZ provides) (NP (NP (JJ considerable) (NN evidence)) (VP (VBG indicating) (SBAR (IN that) (S (S (NP (NP (ADJP (JJ several))) (, ,) (CONJP (CC but) (RB not)) (NP (DT all) (JJ drug1)) (, ,)) (VP (VBP are) (ADVP (RB indeed)) (VP (VBN drug2)))) (CC and) (S (NP (DT some)) (VP (VBP are) (VP (VBN drug3) (PP (IN as) (NP (NN well))))))))))) (. .)))
(S1 (S (S (NP (NP (DT Those)) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (NN effectiveness)) (VP (VBZ is) (VP (VBN reported)))))) (VP (VBZ includes) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ proposed) (NNS mechanisms)) (PP (IN of) (NP (NP (JJ analgesic) (NN action)) (PP (IN of) (NP (NN drug1)))))) (VP (VBP are) (VP (VP (VBN reviewed)) (CC and) (VP (VBN discussed))))) (. .)))
(S1 (S (S (NP (DT The) (NN literature)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (QP (JJR more) (IN than) (CD one)) (NN mechanism)) (PP (IN of) (NP (NN action)))) (VP (VBZ exists) (PP (IN for) (NP (PRP them)))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (JJ considerable) (NN evidence)) (VP (VBG suggesting) (SBAR (SBAR (IN that) (S (NP (ADJP (ADJP (JJ histaminergic)) (CC and) (ADJP (JJ serotoninergic))) (JJ central) (NNS pathways)) (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NN nociception))))))) (CC and) (SBAR (IN that) (S (NP (NN drug1) (NNS drugs)) (VP (MD can) (VP (VB modulate) (NP (PRP$ their) (NNS responses))))))))) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN evidence)) (PP (IN for) (NP (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NP (NN norepinephrine)) (CC and) (NP (NN dopamine))))) (CC and) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (PRP them))))))) (VP (VBP are) (ADVP (RBR less) (RB well)) (VP (VBN established)))) (. .)))
(S1 (S (S (ADVP (RB Still)) (NP (JJ other) (NNS pathways)) (VP (VBP have) (VP (VBN been) (VP (VBN proposed))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJR greater) (NN understanding)) (PP (IN of) (NP (JJ pain) (NNS mechanisms)))) (VP (MD will) (VP (VB aid) (PP (IN in) (S (VP (VBG elucidating) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NN analgesia)))))))))) (. .)))
(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NP (NP (JJ voltage-dependent) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NN channel) (NNS subtypes)) (PP (IN in) (NP (JJ bovine) (NN chromaffin) (NNS cells))))) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ previous) (NNS reports))) (NP (PRP we)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBP inhibit) (NP (NP (NP (NP (JJ high) (NN threshold) (JJ voltage-dependent) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NNS channels)) (PP (IN in) (NP (JJ neuronal) (NNS cells)))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT these) (NNS studies)) (VP (VBD did) (RB not) (VP (VB show) (SBAR (IN whether) (S (NP (NP (NN drug1) (JJ -induced) (NN inhibition)) (PP (IN of) (NP (NP (NP (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NNS currents)))) (VP (VBZ discriminates) (PP (IN among) (NP (NP (NP (DT the) (JJ various) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NN channel) (NNS subtypes))))))) (, ,) (SBAR (IN although) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN known) (SBAR (IN that) (S (NP (EX there)) (VP (VBP are) (NP (NP (QP (IN at) (JJS least) (CD five)) (JJ different) (NP (NP (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NN channel) (NNS subtypes)) (PP (IN in) (NP (JJ neuronal) (NNS cells))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NP (JJ high) (NN threshold) (JJ voltage-dependent) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NN channel) (NNS subtypes)))) (S (VP (VBG using) (NP (NP (NP (PRP$ their) (NN drug2) (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN L-type)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN N-type)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN P-type)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ bovine) (NN chromaffin) (NNS cells))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (MD could) (VP (VB observe) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD inhibited) (NP (NP (NP (JJ high) (NN threshold) (JJ voltage-dependent) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NNS currents)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN IC)) (PRN (-LRB- -LRB-) (NP (CD 50)) (-RRB- -RRB-))) (VP (VBD was) (PP (IN about) (NP (CD 120) (NN microgram/ml))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug2) (NN response))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBP are) (ADVP (RB negatively)) (VP (VBN coupled) (PP (TO to) (NP (NP (CD three) (NNS types)) (PP (IN of) (NP (NP (NN calcium) (NNS channels)) (PP (IN in) (NP (JJ bovine) (NN chromaffin) (NN cell))) (, ,) (PP (VBG including) (NP (NP (NP (DT an) (NN drug2) (JJ -sensitive) (-LRB- -LRB-) (NN N-type) (-RRB- -RRB-) (NN channel)) (, ,) (NP (DT an) (NN drug3) (JJ -sensitive) (-LRB- -LRB-) (NN P-type) (-RRB- -RRB-) (NN channel)) (CC and) (NP (NN drug4))) (: /) (NP (NN drug5)) (: /) (NP (ADJP (ADJP (NN drug6) (JJ -resistant)) (PRN (-LRB- -LRB-) (NP (JJ presumptive) (NN Q-type)) (-RRB- -RRB-))) (NN channel)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (JJ selective) (NN regulation)) (PP (IN of) (NP (NP (NP (JJ voltage-dependent) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NNS subtypes))) (PP (IN by) (NP (NN drug1))) (PP (IN in) (NP (JJ bovine) (NN chromaffin) (NN cell)))) (VP (MD could) (VP (VB be) (NP (NP (DT the) (JJ cellular) (NN basis)) (PP (IN of) (NP (NP (JJ antistress) (NNS effects)) (VP (VBN induced) (PP (IN by) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ proposed) (NN mechanism)) (PP (IN for) (NP (NP (DT the) (NN potentiation)) (PP (IN of) (NP (JJ cAMP-mediated) (NN acid) (NN secretion))) (PP (IN by) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (NN Acid) (NN secretion)) (PP (IN in) (NP (VBN isolated) (JJ rabbit) (JJ gastric) (NNS glands)))) (VP (VBD was) (VP (VBN monitored) (PP (IN by) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (-LRB- -LSB-) (PRN (-LRB- -LRB-) (NP (CD 14)) (-RRB- -RRB-)) (NN C) (-RRB- -RSB-) (NN drug1)))))))) (. .)))
(S1 (S (S (NP (NP (NN Stimulation)) (PP (IN of) (NP (DT the) (NNS glands))) (PP (IN with) (NP (NN drug1)))) (ADVP (RB synergistically)) (VP (VBD augmented) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NN dibutyryl) (NN cAMP)))))) (. .)))
(S1 (S (S (NP (DT The) (NN augmentation)) (VP (VBD persisted) (SBAR (RB even) (IN after) (S (NP (NN drug1)) (VP (VP (VBD was) (VP (VBN washed) (PRT (RP out)))) (CC and) (VP (VBD was) (ADJP (JJ resistant) (PP (PP (TO to) (NP (VBN chelated) (NP (NP (JJ extracellular) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))))) (CC and) (PP (TO to) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (CC either) (NP (NN protein) (NN kinase) (NN C)) (CC or) (NP (NN calmodulin) (NN kinase) (CD II)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN at) (NP (CD 10) (NN microM)))) (ADVP (RB preferentially)) (VP (VBD blocked) (NP (NP (NP (DT the) (JJ secretory) (NN effect)) (PP (IN of) (NP (NN drug2)))) (CC and) (NP (NP (PRP$ its) (NN synergism)) (PP (IN with) (NP (NN cAMP))))) (, ,) (SBAR (IN whereas) (S (NP (PRP it)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN histamine-)) (CC or) (NP (JJ cAMP-stimulated) (NN acid) (NN secretion)))) (PP (IN within) (NP (CD 15) (NN min)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD inhibited) (NP (NP (DT the) (JJ drug2) (NP (NP (JJ -stimulated) (JJ intracellular) (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN -LSB-Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-) (-RRB- -RSB-))) (PRN (-LRB- -LRB-) (NP (NN i)) (-RRB- -RRB-))) (-RRB- -RRB-))) (NN increase)) (PP (IN due) (TO to) (NP (NP (NN release)) (PP (IN from) (NP (DT the) (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (NN store)))))))) (. .)))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN of) (NP (DT the) (NNS glands))) (PP (IN with) (NP (NN drug1)))) (VP (VBD redistributed) (NP (NP (NN type) (CD 3) (NN inositol) (NN 1,4,5-trisphosphate) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (JJ major) (NN subtype)) (PP (IN in) (NP (DT the) (JJ parietal) (NN cell)))) (-RRB- -RRB-))) (PP (IN from) (NP (NP (DT the) (NN fraction)) (VP (VBG containing) (NP (NP (NNS membranes)) (PP (IN of) (NP (NP (JJ large) (NN size)) (PP (TO to) (NP (DT the) (JJ microsomal) (NN fraction))))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (NN dissociation)) (PP (IN of) (NP (DT the) (NN store))) (PP (IN from) (NP (DT the) (NN plasma) (NN membrane)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NP (NP (NP (JJ intracellular) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NN release)) (PP (IN by) (NP (JJ cholinergic) (NN stimulation)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (S (VP (VBG determining) (NP (NP (NN synergism)) (PP (IN with) (NP (NN cAMP))) (PP (IN in) (NP (JJ parietal) (NN cell) (NN activation))))))))))) (CC and) (SBAR (IN that) (S (NP (NP (JJ functional) (NN coupling)) (PP (IN between) (NP (NP (NP (NP (DT the) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NN store)) (CC and) (NP (DT the) (NN receptor))))) (VP (VBZ is) (VP (VBN maintained) (PP (IN by) (NP (NN actin) (NNS microfilaments)))))))))) (. .)))
(S1 (S (S (NP (NN Phenytoin) (NN intoxication)) (VP (VBN induced) (PP (IN by) (NP (NN drug1))))) (. .)))
(S1 (S (S (NP (DT A) (NN patient)) (VP (VBD had) (NP (NN phenytoin) (NN intoxication)) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (DT a) (JJ selective) (NN serotonin) (NN reuptake) (NN inhibitor)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN serum) (NN concentration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD increased) (ADVP (RB dramatically)) (PP (IN from) (NP (QP (CD 16.6) (TO to) (CD 49.1)) (NN microg/mL))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN coadministered))))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (JJ daily) (NN dosage)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (JJ other) (NNS drug4))))) (VP (VBD had) (RB not) (VP (VBN changed))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (NP (NN drug1)) (CC and) (NP (NN fluvoxamine)) (NP (NN treatment)))) (, ,) (NP (NP (NN ataxia)) (, ,) (NP (NP (DT a) (JJ typical) (JJ side) (NN effect)) (PP (IN of) (NP (NN drug2)))) (, ,)) (VP (VBD was) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS genotypes)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN 2C19))) (, ,) (NP (NP (DT the) (NNS enzymes)) (ADJP (JJ responsible) (PP (IN for) (NP (NN phenytoin) (NN metabolism))))) (, ,)))) (VP (VBD were) (ADJP (JJ homozygous) (PP (IN for) (NP (NP (DT the) (JJ wild-type) (NNS alleles)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2) (NN *) (NN 1/) (NN *) (CD 1)) (CC and) (NP (NN 2C19) (NN *) (NN 1/) (NN *) (CD 1))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (DT The) (NN interaction)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN inhibition)) (PP (IN of) (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN 2C19)))) (PP (IN by) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (NP (JJ Pharmacokinetic) (NN evaluation)) (PP (IN of) (NP (DT the) (NN drug1) (: -) (NN drug2) (NN interaction))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB raise) (NP (NN serum) (NN drug2) (NNS levels)))))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBD was) (VP (VBN designed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ pharmacokinetic) (NN basis)) (PP (IN of) (NP (DT this) (NN interaction))) (PP (IN in) (NP (CD 10) (JJ normal) (NNS subjects)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ pharmacokinetic) (NNS variables)) (PP (IN for) (NP (NN drug1)))) (VP (VBD were) (VP (VBN determined) (PP (IN after) (NP (NP (DT a) (ADJP (CD 1.0) (NN mg)) (JJ intravenous) (NN dose)) (PP (IN of) (NP (NN drug2))))) (PP (IN in) (NP (DT each) (NN subject))) (, ,) (PP (PP (IN before)) (CC and) (PP (IN after) (NP (NP (JJ oral) (NN drug3)) (, ,) (NP (NP (CD 400) (NN mg)) (ADJP (JJ daily) (PP (IN for) (NP (CD 3) (NNS weeks))))))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (NN drug1) (NN administration))) (, ,) (NP (NP (JJ systemic) (NN clearance)) (PP (IN of) (NP (NN drug2)))) (VP (VBD was) (VP (VBN reduced) (PP (IN from) (NP (NP (QP (CD 234) (CC +/-) (CD 72)) (NN ml/min)) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (CC +/-) (NP (JJ standard) (NN deviation))) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (QP (CD 172) (CC +/-) (CD 33)) (NN ml/min)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJR less) (PP (IN than) (NP (CD 0.01))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBD was) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS reductions)) (PP (IN in) (NP (NP (NP (NP (DT both) (JJ renal) (NN clearance)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (QP (CD 105) (CC +/-) (CD 39) (TO to) (CD 84) (CC +/-) (CD 15)) (NN ml/min))) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ nonrenal) (NN clearance)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (QP (CD 130) (CC +/-) (CD 38) (TO to) (CD 88) (CC +/-) (CD 20)) (NN ml/min))) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN half-life)) (PP (IN of) (NP (NN elimination)))) (VP (VBD was) (ADJP (JJ prolonged)) (PP (IN from) (NP (QP (CD 34) (CC +/-) (CD 13) (TO to) (CD 40) (CC +/-) (CD 16)) (NNS hours))) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJR less) (PP (IN than) (NP (CD 0.05))))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN volume)) (PP (IN of) (NP (NN distribution)))) (VP (VBD was) (RB not) (ADVP (RB significantly)) (VP (VBN changed)))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBD caused) (NP (NP (DT a) (ADJP (CD three-) (TO to) (JJ fivefold)) (NN increase)) (PP (IN in) (NP (NP (NN serum) (NN reverse) (NN triiodothyronine)) (NNS levels)))))) (, ,) (CC but) (S (NP (NP (NNS changes)) (PP (IN in) (NP (NN thyroid) (NN function)))) (VP (VBD were) (RB not) (ADJP (RB quantitatively) (JJ related) (PP (TO to) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NN drug2) (NNS pharmacokinetics))))))))) (. .)))
(S1 (S (S (NP (NP (DT These) (NNS alterations)) (PP (IN in) (NP (NP (NN drug1) (NNS pharmacokinetics)) (VP (VBN produced) (PP (IN by) (NP (NN drug2))))))) (VP (VBP explain) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN serum) (NN drug3) (NN level))) (SBAR (WHNP (WDT that)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (DT this) (NN drug) (NN combination)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB clinically))))))))))))))) (. .)))
(S1 (S (NP (NP (NN Activation)) (PP (IN of) (NP (DT an) (NN effector) (JJ immediate-early) (NN gene) (NN arc))) (PP (IN by) (NP (NN drug1))) (. .))))
(S1 (S (S (SBAR (IN As) (S (NP (NP (JJ immediate-early) (NNS genes)) (PRN (-LRB- -LRB-) (NP (NNS IEGs)) (-RRB- -RRB-))) (VP (VBP are) (VP (VBN thought) (S (VP (TO to) (VP (VB play) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (S (VP (VBG mediating) (NP (JJ stimulus-induced) (JJ neural) (NN plasticity)))))))))))) (, ,) (NP (NP (JJ IEG) (NN response)) (VP (VBN induced) (PP (IN by) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN characterized) (S (VP (TO to) (VP (VB define) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NN gene) (NN expression))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB underlie) (NP (PRP$ its) (ADJP (ADJP (JJ long-lasting)) (ADJP (JJ behavioral))) (NNS effects)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (NN activation)) (PP (IN of) (NP (JJ several) (NN transcription) (NN factor) (NNS IEGs)))) (VP (VBZ has) (VP (VBN been) (VP (VBN described)))))) (, ,) (NP (JJ little)) (VP (VBZ is) (VP (VBN known) (PP (IN about) (NP (NN effector) (NNS IEGs)))))) (. .)))
(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN examined) (SBAR (IN whether) (S (NP (NN drug1) (NN administration)) (VP (VBZ affects) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NP (DT an) (NN effector) (NN IEG) (NN arc)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ activity-regulated)) (, ,) (ADJP (JJ cytoskeleton-associated))) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBZ encodes) (NP (NP (DT a) (NN protein)) (PP (IN with) (NP (NP (NN homology)) (PP (TO to) (NP (NN spectrin))))))))))))))))) (. .)))
(S1 (S (S (VP (VBG Using) (NP (ADJP (FW in) (FW situ)) (NN hybridization)))) (, ,) (NP (PRP we)) (VP (VBD observed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD caused) (NP (NP (DT a) (ADJP (ADJP (JJ rapid)) (CC and) (ADJP (JJ transient))) (JJ dose-dependent) (NN increase)) (PP (IN in) (NP (NP (NN arc) (NN mRNA) (NN level)) (PP (IN in) (NP (DT the) (NP (NP (NN striatum)) (CC and) (NP (NN cortex))))))) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (VP (VBN abolished) (PP (PP (IN by) (NP (NP (NN pretreatment)) (PP (IN with) (NP (DT the) (JJ specific) (NN dopamine) (NN D1) (NN receptor) (NN antagonist) (CD drug2))))) (CC but) (PP (RB not) (IN by) (NP (DT an) (NN drug3) (NN drug4))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD induced) (NP (NN arc) (NN mRNA)) (PP (IN in) (NP (NP (NNS layers) (NP (NP (CD IV)) (CC and) (NP (LS VI) (PP (IN of) (NP (DT the) (NN cortex)))))) (SBAR (WHNP (WDT which) (NN dopamine) (NN receptor)) (S (VP (VBP are) (VP (VBN localized) (PP (TO to)))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN D1) (NNS receptors)) (VP (VBP are) (VP (VBN coupled) (PP (TO to) (NP (NP (NN activation)) (PP (IN of) (NP (NN arc) (NN gene))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (ADJP (ADJP (JJ functional)) (CC or) (ADJP (JJ structural))) (NNS alterations)) (VP (VBG underlying) (NP (NP (JJ neural) (NN plasticity)) (VP (VBN triggered) (PP (IN by) (NP (NN drug1))))))))))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Differential) (NNS actions)) (PP (IN of) (NP (JJ intrathecal) (NN drug1))) (PP (IN on) (S (VP (VBG blocking) (NP (NP (DT the) (NN tail-flick) (NN inhibition)) (VP (VBN induced) (PP (IN by) (NP (NP (NP (JJ intraventricular) (NN drug2)) (CC and) (NP (NN drug3))) (PP (IN in) (NP (NNS rats)))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN proposed) (SBAR (IN that) (S (NP (NP (DT the) (NN drug1)) (VP (VBN applied) (PP (TO to) (NP (JJ supraspinal) (NN brain) (NNS sites))))) (VP (VBD produced) (NP (PRP$ their) (JJ analgesic) (NNS effects)) (PP (IN by) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ different) (NN descending) (NN pain) (JJ inhibitory) (NNS systems))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN blockade)) (PP (IN of) (NP (DT the) (JJ spinal) (JJ endorphinergic) (NN system))) (PP (IN by) (NP (NP (JJ intrathecal) (NN drug1)) (PP (IN on) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NN tail-flick) (NN inhibition))) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intraventricular) (NN drug2)) (CC and) (NP (NN drug3)))))))))) (VP (VBD was) (ADVP (RB then)) (VP (VBN studied)))) (. .)))
(S1 (S (S (NP (NP (JJ Intraventricular) (NN injection)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD produced) (NP (NP (DT an) (NN inhibition)) (PP (IN of) (NP (NP (DT the) (NN tail-flick) (NN response)) (PP (TO to) (NP (DT the) (NN heat) (NN stimulus))) (PP (IN in) (NP (NNS rats)))))))) (. .)))
(S1 (S (S (S (NP (NP (JJ Intrathecal) (NN injection)) (PP (IN of) (NP (NN drug1))) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 0.4) (TO to) (CD 40)) (NNS micrograms)))))) (VP (VBD caused) (NP (NP (DT a) (JJ dose-related) (NN blockade)) (PP (IN of) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NP (DT the) (NN tail-flick) (NN response)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intraventricular) (NN injection)) (PP (IN of) (NP (NN drug2))))))))))))) (, ,) (CC and) (S (NP (NP (DT a) (JJ high) (NN dose)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 40) (NNS micrograms)) (-RRB- -RRB-))))) (ADVP (RB completely)) (VP (VBD blocked) (NP (NP (DT the) (NN tail-flick) (NN inhibition)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intraventricular) (NNS drug4)) (PRN (-LRB- -LRB-) (NP (CD 16) (NNS micrograms)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (JJ intrathecal) (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 12-120) (NNS micrograms)) (-RRB- -RRB-))) (VP (VBD had) (NP (RB only) (DT a) (ADJP (RB very) (JJ weak)) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN tail-flick) (NN inhibition)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intraventricular) (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 40) (NNS micrograms)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Intraventricular) (NN injection)) (PP (IN of) (NP (NN drug1))) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 1.2) (TO to) (CD 12)) (NNS micrograms)))))) (VP (ADVP (RB equally)) (VBD antagonized) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (NP (NP (DT the) (NN tail-flick) (NN inhibition)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intraventricular) (NN drug2)) (CC and) (NP (NN drug3)))))))) (. .)))
(S1 (S (NP (DT The) (NNS results)) (VP (VP (VBP indicate) (SBAR (IN that) (S (NP (DT a) (JJ spinal) (NN drug1) (JJ -sensitive) (NN endorphinergic) (NN system)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (NN drug2)) (CONJP (CC but) (RB not)) (NP (NN drug3) (JJ -induced) (NN tail-flick) (NN inhibition))))))))))) (, ,) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ intraventricular) (NN drug4)) (CC and) (NP (NN drug5))) (VP (VBP elicit) (NP (PRP$ their) (JJ pharmacological) (NNS actions)) (PP (IN via) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ different) (NN descending) (NN pain) (JJ inhibitory) (NNS systems)))))))))) (: ;)))
(S1 (S (S (NP (NP (JJ descending) (NP (NP (NN epsilon)) (CC and) (NP (NN mu))) (NNS systems)) (PP (IN for) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (, ,) (ADVP (RB respectively)) (, ,) (VP (VBP are) (VP (VBN proposed)))) (. .)))
(S1 (S (NP (NP (NP (JJ Pharmacological) (NN treatment)) (PP (IN of) (NP (NN depression)))) (: :) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN drug1)))) (. .))))
(S1 (S (S (NP (NN Depression)) (VP (VBZ is) (VP (VBG reaching) (NP (NP (JJ epidemic) (NNS proportions)) (PP (IN in) (NP (DT the) (NN western) (NN world))))))) (. .)))
(S1 (S (S (NP (ADJP (PP (IN With) (NP (DT each) (JJ successive) (NN generation))) (JJR more)) (NN people)) (VP (VBP are) (VP (VBG becoming) (ADVP (RBR more) (RB severely)) (VP (VBN depressed) (PP (IN at) (NP (DT a) (JJR younger) (NN age))))))) (. .)))
(S1 (S (NP (NP (NN Drug) (NNS interactions)) (: :) (S (ADVP (WRB How)) (VP (TO to) (VP (VB identify) (NP (PRP them))))) (. .))))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN between) (NP (JJ theraputic) (NNS agents)))) (VP (VBP have) (VP (VBN been) (VP (VBN recognized) (SBAR (IN as) (S (NP (NP (ADJP (RB increasingly) (JJ important)) (NNS causes)) (PP (IN of) (NP (NN drug))) (PP (IN at) (NP (PRP$ their) (JJ usual) (VBN recommended) (NN dose)))) (VP (MD may) (, ,) (PP (IN under) (NP (JJ certain) (NNS conditions))) (, ,) (VP (VB produce) (NP (NP (NN toxicity)) (PP (IN of) (NP (JJ life-endangering) (NNS proportions)))))))))))) (. .)))
(S1 (S (SBAR (IN While) (S (NP (NP (DT the) (NN recognition)) (PP (IN of) (NP (NP (NN drug) (NN toxicity)) (VP (VBG resulting) (PP (IN from) (NP (NNS interactions))))))) (VP (VBZ is) (PP (IN of) (NP (NN importance))) (PP (TO to) (NP (DT all) (NNS physciains)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (RB especially) (RB so) (PP (IN for) (NP (DT the) (NN clinician))) (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN welfare)) (PP (IN of) (NP (NP (DT those)) (PP (IN in) (NP (DT the) (NN aerospace) (NN environment))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN paper)) (VP (VBZ attempts) (S (VP (TO to) (VP (VB provide) (NP (NP (DT a) (NN basis)) (PP (IN for) (NP (NP (DT the) (NP (NN understanding)) (CC and) (NP (NNS identifications))) (PP (IN of) (NP (JJ important) (NN drug) (NNS interactions))))))))))) (. .)))
(S1 (S (S (NP (NNS Guidelines)) (VP (VBP are) (VP (VBN provided) (S (VP (TO to) (VP (VBP assist) (NP (NP (DT the) (NN clinician)) (PP (IN in) (NP (NN his) (JJ logical) (NN approach))) (PP (TO to) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (NP (NN drug) (NNS interactions)) (SBAR (WHADVP (WRB when)) (S (NP (JJ serious) (NN drug) (NN toxicity)) (VP (VBZ is) (VP (VBN encountered) (PP (IN in) (NP (DT a) (NN pateint)))))))))))))))))) (. .)))
(S1 (S (ADVP (RB Only)) (PP (IN with) (NP (NP (NN knowledge)) (PP (IN of) (NP (DT the) (NN interaction))))) (SQ (MD can) (NP (DT the) (JJ therapeutic) (NNS regimen)) (VP (VB be) (VP (VBN altered) (ADVP (RB so)) (SBAR (IN as) (S (VP (TO to) (VP (VBP provide) (NP (NP (JJ therapeutic) (NNS levels)) (PP (IN of) (NP (JJ necessary) (NNS drugs)))) (PP (IN while) (S (VP (VBG avoiding) (NP (NN toxicity))))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Changes)) (PP (IN in) (NP (JJ urinary) (NN homocysteine)))) (VP (VBG following) (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (NN administration)) (PP (TO to) (NP (NNS rats)))))) (. .)))
(S1 (S (S (NP (DT The) (JJ present) (NN work)) (VP (VBD involved) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (TO to) (NP (NP (NNS groups)) (PP (IN of) (NP (NNS rats)))))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (NN determination)) (PP (IN of) (NP (NP (DT the) (NN homocysteine) (NN excretion) (NN rate)) (PP (IN in) (NP (NN urine))))))))))) (. .)))
(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN difference)) (VP (VBZ exists) (PP (IN between) (NP (NP (NP (DT the) (JJ excreted) (NNS levels)) (PP (IN of) (NP (NN homocysteine))) (PP (IN in) (NP (NP (DT the) (NN urine)) (PP (IN of) (NP (CC both) (NP (ADJP (JJ control))) (CC and) (NP (JJ drug1) (JJ -treated) (NNS rats))))))) (CC and) (NP (NP (DT the) (NNS levels)) (VP (VBN shown) (PP (IN by) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS implications)) (PP (IN of) (NP (DT these) (NNS results)))) (VP (VBP are) (VP (VBN discussed) (, ,) (PP (ADVP (RB especially)) (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NNS observations)) (SBAR (WHNP (WDT which)) (S (VP (VBP indicate) (SBAR (IN that) (S (NP (NN homocysteine)) (VP (MD may) (VP (VB be) (NP (DT a) (VBG precipitating) (NN factor)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN thrombosis))))))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Also)) (VP (VBN included) (PP (IN in) (NP (DT this) (NN paper))))) (VP (VBZ is) (NP (NP (DT a) (NN study)) (SBAR (WHNP (WDT which)) (S (VP (VBZ confirms) (NP (NP (DT the) (NN identity)) (PP (IN of) (NP (DT the) (NN HPLC) (NN peak)))) (PP (IN as) (S (VP (VBG being) (NP (NN homocysteine)) (PP (IN by) (S (VP (VP (VBG forming) (NP (NP (DT a) (JJ radioactive) (NN derivative)) (PP (IN of) (NP (DT this) (JJ particular) (JJ sulphydryl-containing) (NN amino) (NN acid))))) (, ,) (CC and) (VP (ADVP (RB then)) (VBG analysing) (NP (DT the) (VBG resulting) (NN mixture)) (PP (IN by) (NP (NN TLC))))))))))))))) (. .)))
(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN on) (NP (NP (DT the) (JJ antinociceptive) (NN effect)) (PP (IN of) (NP (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN drug5))) (PP (IN in) (NP (NNS mice))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN on) (NP (NP (JJ antinociceptive) (NN effect)) (PP (IN of) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mg/kg)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-)))))))) (VP (VBD was) (VP (VBN investigated) (PP (IN in) (NP (NP (DT a) (NN mouse) (NN model)) (VP (VBG using) (NP (DT the) (NN tail-flick) (CC and) (NN hot-plate) (NNS tests)))))))) (. .)))
(S1 (S (S (NP (DT All) (NNS drugs)) (VP (VBD were) (VP (VBN injected) (ADVP (RB intraperitoneally))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD were) (VP (VBN administered) (PP (TO to) (NP (NNS mice) (CD 30) (NN min))) (PP (IN before) (S (VP (VBG applying) (NP (DT the) (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (NN Measurement)) (PP (IN of) (NP (NN nociception)))) (VP (VBD was) (VP (VBN performed) (PP (IN within) (NP (NP (CD 2) (NN h)) (PP (IN after) (NP (NN drug1) (NN administration)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (NP (CD 0.25) (NN mg/kg)) (CC and) (NP (CD 2.5) (NN mg/kg))) (VP (VBN injected) (PP (IN with) (NP (NN drug2))))))))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (JJ antinociceptive) (NN effect)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (NN drug1)) (VP (VBD decreased) (NP (NP (DT the) (JJ antinociceptive) (NN effect)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (ADVP (RB only)) (PP (IN in) (NP (DT the) (NN tail-flick) (NN test))) (-RRB- -RRB-))) (CC and) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN used) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 1.25) (NN mg/kg)) (CC and) (NP (CD 2.5) (NN mg/kg)))))))) (VP (VBD decreased) (NP (NP (DT the) (JJ antinociceptive) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (ADVP (RB only)) (PP (IN in) (NP (DT the) (NN tail-flick) (NN test))) (-RRB- -RRB-))) (CC and) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (NN -LSB-The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (JJ renal) (NN excretion)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN in) (NP (NNS dogs))))) (-RRB- -RSB-)) (S (NP (NP (DT The) (JJ intravenous) (NN injection)) (PP (IN of) (NP (NN drug4))) (PP (IN in) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 20) (NN mg/kg)))))) (VP (VBD enhanced) (NP (NP (NN drug5)) (CC and) (NP (NN drug6) (NN excretion))) (PP (IN in) (NP (JJ chronic) (NN canine) (NNS experiments)))))) (. .)))
(S1 (S (S (NP (DT The) (JJR higher) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (NN excretion)) (VP (VBD was) (ADJP (JJ due) (PP (TO to) (NP (PRP$ their) (VBN increased) (JJ renal) (JJ tubular) (NN secretion)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NNS dogs))) (, ,) (NP (NN drug1)) (VP (JJ unchanged) (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NP (DT a) (NN test) (NN agent)) (PP (IN for) (NP (JJ anionic) (NN transport))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Possible) (JJ extrarenal) (NNS mechanisms)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NN drug2)) (CC and) (NP (NN drug3) (NN transport))))))) (VP (VBD were) (ADVP (RB also)) (VP (VBN examined)))) (. .)))
(S1 (S (NP (NP (JJ Differential) (NN regulation)) (PP (IN of) (NP (NN tyrosine) (NN phosphorylation))) (PP (IN in) (NP (NN tumor) (NNS cells))) (PP (IN by) (NP (NP (NN drug1)) (, ,) (NP (DT a) (JJ homodimeric) (NN disintegrin)) (, ,) (CC and) (NP (JJ monomeric) (NNS disintegrins) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))) (. .))))
(S1 (S (S (NP (DT The) (JJ homodimeric) (NN disintegrin) (NN drug1)) (VP (VBD was) (VP (VBN compared) (ADVP (RB directly)) (PP (TO to) (NP (NP (DT the) (JJ monomeric) (NNS disintegrins) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN for) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB affect) (NP (NP (NN protein) (NN tyrosine) (NN phosphorylation)) (PP (IN in) (NP (NN tumor) (NNS cells)))))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBD was) (VP (VBN observed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD had) (NP (DT a) (JJ dramatic) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN tyrosine) (NN phosphorylation) (NN status)) (PP (IN of) (NP (NP (JJ several) (NNS proteins)) (PP (IN in) (NP (NN T24) (JJ human) (NN bladder) (NN cancer) (NNS cells))) (, ,) (PP (VBG including) (NP (NP (JJ robust) (NN induction)) (PP (IN of) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NNS proteins))))) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (CD 120-140) (NN kDa))))))))))))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (ADVP (RB alone)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN in) (NP (NN T24) (NNS cells))))))) (, ,) (CC but) (S (ADVP (RB dose-dependently)) (VP (VBZ inhibits) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2)))) (SBAR (WHADVP (WRB when)) (S (NP (DT both)) (VP (VBP are) (VP (VBN added) (ADVP (RB simultaneously))))))))) (. .)))
(S1 (S (S (PP (IN Among) (NP (NP (DT the) (NNS proteins)) (SBAR (WHNP (WDT that)) (S (VP (VBP undergo) (NP (NN tyrosine) (NN phosphorylation)) (PP (IN in) (NN response) (TO to) (NP (NP (NN drug1) (NN treatment)) (VP (VBZ is) (NP (NN CAS)))))))))) (, ,) (NP (DT a) (ADJP (CD 130) (NN kDa)) (NN adapter) (NN protein)) (VP (VBN involved) (PP (IN in) (NP (NN integrin) (NN signaling))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (ADVP (RB alone))) (VP (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB have) (NP (DT no) (NN effect)) (PP (IN on) (NP (NNS CAS)))))))) (, ,) (CC but) (VP (MD can) (ADVP (RB completely)) (VP (VB block) (NP (NP (NN drug2) (JJ -induced) (NN phosphorylation)) (PP (IN of) (NP (DT this) (NN protein))) (PP (IN in) (NP (NN MDA-MB-435) (NNS cells))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS observations)) (ADVP (RB strongly)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJ homodimeric) (NN structure)) (PP (IN of) (NP (NN drug1)))) (ADVP (RB functionally)) (VP (VBZ distinguishes) (NP (PRP it)) (PP (IN from) (NP (NP (JJ other) (JJ monomeric) (NNS members)) (PP (IN of) (NP (DT the) (NN disintegrin) (NN family)))))))))) (. .)))
(S1 (S (NP (NP (NN Toxicity)) (PP (IN of) (NP (NP (NN cadmium)) (CC and) (NP (NN drug1)))) (PP (TO to) (NP (NP (NN miracidia)) (PP (IN of) (NP (NN Schistosoma) (NNS mansoni))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ specific) (NNS objectives)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD were) (S (VP (TO to) (VP (VB elucidate) (NP (NP (JJ metal) (NN toxicity)) (PP (TO to) (NP (NP (NP (NN hatching)) (, ,) (NP (NN survival)) (CC and) (NP (NN avoidance) (NN behaviour))) (PP (IN of) (NP (NN Schistosoma) (NNS mansoni)))) (NP (NN miracidia))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN toxicity)) (PP (IN of) (NP (NP (NN cadmium)) (, ,) (NP (NN drug1)) (, ,) (CC and) (NP (NN cadmium/zinc) (NNS mixtures)))) (PP (IN at) (NP (NP (NNS concentrations)) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 10000) (TO to) (CD 10)) (NN microg/l))))))) (VP (VBD was) (VP (VBN investigated)))) (. .)))
(S1 (S (S (NP (JJ Metal) (NN mixture) (NN toxicity) (NN investigation)) (VP (VBD was) (VP (VBN undertaken) (PP (IN with) (NP (NP (JJ equal) (NNS concentrations)) (PP (IN of) (NP (DT the) (NNS metals)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN hatching)) (PP (IN of) (NP (NN miracidia))) (PP (IN from) (NP (NNS eggs)))) (VP (VBD was) (VP (VBN inhibited) (PP (IN by) (NP (NP (NNS concentrations)) (PP (IN of) (NP (NP (CD 1000-10000) (NN microg/l)) (PP (IN of) (NP (JJ single) (NNS metals)))))))))) (. .)))
(S1 (S (S (NP (JJ Metal) (NNS mixtures)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug1) (NN hatching))))) (. .)))
(S1 (S (S (NP (NP (NN Survival)) (PP (IN of) (NP (NN miracidia)))) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (S (VP (VBG increasing) (NP (JJ metal) (NN concentration)) (PP (IN except) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN of) (NP (NP (CD 10) (NN microg/l)) (PP (IN for) (NP (NP (JJ single) (JJ metal) (NN toxicity)) (SBAR (WHADVP (WRB where)) (S (NP (NN survival)) (VP (VBD was) (VP (VBN increased) (PP (IN above) (NP (DT the) (NN control)))))))))))))))))))) (. .)))
(S1 (S (S (NP (NN Miracidia)) (VP (VBD demonstrated) (NP (NP (DT a) (JJ rapid) (NN avoidance) (NN behaviour)) (SBAR (WHADVP (WRB when)) (S (ADVP (RB briefly)) (VP (VBN exposed) (PP (TO to) (NP (JJ heavy) (NNS metals))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS mechanisms)) (PP (IN of) (NP (NP (JJ metal) (NN toxicity)) (PP (TO to) (NP (NN miracidia)))))) (VP (VBP are) (ADVP (RB briefly)) (VP (VBN discussed)))) (. .)))
(S1 (S (NP (NP (NN Drug-lab) (NNS interactions)) (: :) (NP (NP (NNS implications)) (PP (IN for) (NP (NN nutrition) (NN support)))) (. .))))
(S1 (S (S (NP (NP (NN drug1) (NN interference)) (PP (IN with) (NP (NN urine) (NN ketone) (NN test))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ important)) (SBAR (IN that) (S (NP (NN health) (NN care) (NNS professionals)) (VP (VB be) (NP (NP (NN aware)) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NNS medications))) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (JJ clinical) (NN laboratory) (NNS tests)))))))))))))) (. .)))
(S1 (S (S (NP (NNS Medications)) (VP (MD can) (VP (VB cause) (NP (ADJP (FW in) (FW vivo)) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (S (NP (NP (DT the) (NP (NN concentration)) (CC or) (NP (NN activity))) (PP (IN of) (NP (DT the) (NN analyte)))) (VP (VBZ is) (VP (VBN altered) (PP (IN before) (NP (DT the) (NN analysis)))))) (CC and) (S (ADVP (RB therefore)) (NP (DT the) (NN assay) (NN result)) (VP (VBZ is) (ADJP (ADJP (JJ true)) (CC and) (ADJP (JJ accurate)))))))))) (. .)))
(S1 (S (S (NP (DT An) (ADJP (FW in) (FW vitro)) (NN effect)) (VP (VBZ occurs) (SBAR (WHADVP (WRB when)) (S (S (NP (DT the) (NN medication)) (VP (VBZ interferes) (PP (IN with) (NP (DT the) (NN assay))))) (, ,) (CC and) (S (NP (DT the) (NN result)) (VP (VP (VBZ is) (NP (NN erroneous))) (CC and) (VP (MD cannot) (VP (VB be) (VP (VBN interpreted)))))))))) (. .)))
(S1 (S (NP (DT This) (NN report)) (VP (VP (VBZ describes) (NP (NP (DT a) (ADJP (RB recently) (VBN identified)) (NN case)) (PP (IN of) (NP (NP (NN interference)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (DT the) (NN urine) (NN test))))) (PP (IN for) (NP (NNS ketones))))) (CC and) (VP (VBZ demonstrates) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (DT a) (JJ thorough) (NN medication) (NN review))) (PP (IN in) (S (VP (VBG evaluating) (NP (JJ abnormal) (NN laboratory) (NNS tests)))))))) (. .)))
(S1 (S (NP (NP (NP (JJ -LSB-Pharmacologic) (NNS interactions)) (PP (IN in) (NP (JJ chronic) (NNS treatments)))) (: :) (NP (NP (JJ corrective) (NNS measures)) (PP (IN for) (NP (NP (PRP$ its) (NN prevention)) (PP (IN in) (NP (NP (DT a) (JJ basic) (NN area)) (PP (IN of) (NP (JJ rural) (NN health) (-RRB- -RSB-) (NNS OBJECTIVES)))))))) (: :) (S (S (VP (TO To) (VP (VB identify) (NP (NP (DT the) (JJ pharmacological) (NNS interactions)) (PP (IN of) (NP (NP (JJ clinical) (NN relevance)) (PRN (-LRB- -LRB-) (NP (NN PICR)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NP (DT the) (NN medication) (NN authorization) (NNS cards)) (PRN (-LRB- -LRB-) (NP (NN MAC)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (DT the)) (ADJP (RB chronically) (JJ ill)))))))))) (CC and) (S (VP (TO to) (VP (VB establish) (NP (NNS strategies)) (S (VP (TO to) (VP (VB minimise) (NP (PRP$ their) (NN appearance))))))))) (. .))))
(S1 (S (NP (NP (NN DESIGN)) (: :) (NP (JJ Cross-sectional) (JJ descriptive) (NN study)) (. .))))
(S1 (S (NP (NP (NN SETTING)) (: :) (NP (JJ Rural) (JJ primary) (NN care) (NN centre)) (. .))))
(S1 (S (NP (NP (NNS PATIENTS)) (: :) (NP (NP (JJ Random) (NN sample)) (PP (IN of) (NP (CD 626) (NN MAC))) (PP (IN out) (IN of) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NN 1306)))))) (. .))))
(S1 (S (NP (NP (NP (NNS MEASUREMENTS)) (CC AND) (NP (JJ MAIN) (NNS RESULTS))) (: :) (S (S (PP (IN In) (NP (NNP December) (CD 1998))) (, ,) (NP (DT the) (NN following)) (VP (VBD was) (VP (VBN gathered) (PP (IN for) (NP (NP (DT every) (NN MAC)) (PP (IN with) (NP (QP (JJR more) (IN than) (CD one)) (NN drug) (NN treatment)))))))) (: :) (S (NP (NP (NN age)) (, ,) (NP (NN sex)) (, ,) (NP (NP (NN number)) (PP (IN of) (NP (NP (NNS drugs)) (, ,) (NP (JJ intrinsic) (NN value)) (, ,) (NP (NP (NNS drugs)) (VP (VBN prescribed))) (, ,) (NP (JJ daily) (NN dose)) (CC and) (NP (NP (JJ pharmacological) (NNS interactions)) (PRN (-LRB- -LRB-) (NP (NN PI)) (-RRB- -RRB-)))))) (, ,)) (VP (VBN classified) (PRN (-LRB- -LRB-) (VP (VBG using) (NP (NP (DT the) (NN scale)) (PP (IN of) (NP (NNP Hansten) (CD 1996))))) (-RRB- -RRB-)) (PP (IN into) (ADJP (ADJP (JJ light)) (CC and) (ADJP (RB clinically) (JJ relevant))))))) (. .))))
(S1 (S (S (NP (JJ Statistical) (NN analysis)) (: :) (NP (NP (NN Mantel-Haenszel)) (PRN (-LRB- -LRB-) (NP (NN alpha) (JJ =) (CD 0.05)) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (NNS Patients) (POS ')) (NN mean) (NN age)) (VP (VBD was) (NP (NP (CD 69.1)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (CC +/-) (NP (CD 1.2))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (NN Mean) (NN number)) (PP (IN of) (NP (NNS drugs))) (PP (IN per) (NP (NN MAC)))) (VP (VBD was) (NP (CD 4) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI) (, ,) (CC +/-) (NP (CD 0.2))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (NN 341) (NN PI) (VBG affecting) (CD 197) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 31.5) (NN %)) (, ,) (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (CC +/-) (NP (CD 3.6))) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN identified)))) (. .)))
(S1 (S (S (NP (NP (CD 24.9) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI) (, ,) (CC +/-) (NP (CD 4.5))) (-RRB- -RRB-))) (VP (VBD were) (NP (NN PICR)) (, ,) (VP (VBN detected) (PP (IN in) (NP (NP (NP (CD 11.7) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI) (, ,) (CC +/-) (NP (CD 2.5))) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN MAC)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN existence)) (PP (IN of) (NP (NN PI)))) (VP (VBD was) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN prescribed)))))) (PP (TO to) (NP (DT each) (NN patient))) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (CD &lt) (: ;) (CD 0.01)) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (CD 26) (NN PI)) (PP (IN with) (NP (NP (NNS drugs)) (PP (IN of) (NP (JJ low) (JJ intrinsic) (NN value))))) (PRN (-LRB- -LRB-) (NP (NP (CD 7.6) (NN %)) (: ;) (NP (CD 95) (NN %) (CD CI)) (, ,) (CC +/-) (NP (CD 2.8))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (NP (CD 74.1) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (CC +/-) (NP (CD 9.3))) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (JJ total) (NN PICR)))) (VP (MD could) (VP (VB be) (VP (VBN avoided) (PP (IN by) (NP (JJ simple) (NNS recommendations))))))) (: ;)))
(S1 (S (S (NP (CC and) (NP (NP (DT the) (VBG remaining) (CD 25.9) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (CC +/-) (NP (CD 9.3))) (-RRB- -RRB-))) (PP (IN by) (NP (NP (NN monitoring)) (CC and) (NP (NP (NN follow-up)) (PP (IN of) (NP (NNS patients)))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ important)) (S (VP (TO to) (VP (VB identify) (NP (NP (DT the) (NNS medications)) (VP (ADVP (RBS most) (RB commonly)) (VBN involved) (PP (IN in) (NP (NP (DT the) (NN PICR)) (SBAR (ADVP (RB so) (RB as)) (S (VP (TO to) (VP (VB establish) (NP (JJ corrective) (NNS measures)) (S (VP (TO to) (VP (VB minimise) (NP (NP (DT the) (NNS risks)) (VP (VBG arising) (PP (IN from) (NP (JJ multiple) (NN medication))))))))))))))))))))) (. .))))
(S1 (S (S (NP (CD Four) (JJ educational) (NNS messages)) (VP (VBP advise) (PP (IN on) (NP (NP (QP (IN over) (CD 60)) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS PICR)) (VP (VBN detected)))))))) (. .)))
(S1 (S (S (NP (NP (NN Neurochemical)) (CC and) (NP (JJ functional) (NNS consequences))) (VP (VBG following) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NN drug3))))) (. .)))
(S1 (S (S (NP (NP (DT The) (ADJP (ADJP (JJ neurochemical)) (CC and) (ADJP (JJ functional))) (NNS consequences)) (VP (VBG following) (NP (NP (NN drug1) (NN administration)) (PP (TO to) (NP (DT the) (NN rat)))))) (VP (VBD were) (VP (VP (VBN evaluated)) (CC and) (VP (VBN compared) (PP (TO to) (NP (JJ similar) (NNS effects))) (PP (VBG following) (NP (NN drug2) (NN administration))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBD was) (VP (VBN observed) (SBAR (IN that) (S (S (NP (NN drug1)) (VP (VBD induced) (NP (NP (JJ long) (NN lasting) (NNS depletions)) (PP (IN of) (NP (NP (JJ striatal) (NN dopamine)) (NNS concentrations)))))) (CC and) (S (NP (DT this) (JJ neurotoxic) (NN effect)) (VP (MD could) (VP (VB be) (VP (VBN prevented) (PP (IN by) (NP (NN drug2) (NN pretreatment)))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN drug1) (JJ -induced) (JJ neuronal) (NN damage)) (VP (VBD produced) (NP (NP (DT a) (NN tolerance)) (PP (TO to) (NP (NP (DT the) (JJ disruptive) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NP (DT a) (NN supersensitivity)) (PP (TO to) (NP (NP (DT the) (JJ disruptive) (NNS effects)) (PP (IN of) (NP (NN drug3))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG responding) (PP (IN in) (NP (DT a) (JJ schedule) (JJ controlled) (NN paradigm)))))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (, ,) (PP (IN like) (NP (NN drug2))) (, ,)) (VP (VBD produced) (NP (NP (NNS depletions)) (PP (IN of) (NP (JJ striatal) (NN dopamine)))))) (CC but) (S (NP (DT these) (NNS actions)) (VP (VBD were) (VP (VBN potentiated) (PP (IN by) (NP (NN drug3) (NN pretreatment))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS observations)) (VP (VBP are) (VP (VBN discussed) (PP (IN in) (NP (NP (NN reference)) (PP (TO to) (NP (NP (JJ possible) (JJ deleterious) (NNS effects)) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN Parkinson) (POS 's)) (NN Disease)))))))))))))) (. .)))
(S1 (S (NP (NP (NNS Responses)) (PP (TO to) (NP (NP (NN drug1)) (PP (IN of) (NP (NP (DT the) (JJ perfused) (NN pancreas)) (PP (IN of) (NP (DT the) (ADJP (RB genetically) (JJ diabetic)) (NN Chinese) (NN hamster))))))) (. .))))
(S1 (S (S (NP (ADJP (ADJP (JJ Nonketotic)) (, ,) (ADJP (RB genetically) (JJ diabetic))) (NN Cinese) (NNS hamsters)) (VP (VBP show) (NP (NP (JJ subnormal) (JJ pancreatic) (NN insulin) (NN release)) (CC and) (NP (NP (JJ impaired) (NN suppression)) (PP (IN of) (NP (NN glucagon))))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NN glucose))))))) (. .)))
(S1 (S (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (JJ pancreatic) (NNS effects)) (PP (IN of) (NP (JJ other) (NNS agents))))))) (, ,) (NP (JJ dynamic) (NN insulin) (CC and) (NN glucagon) (NN release)) (VP (VBD was) (VP (VBN measured) (PP (IN from) (NP (NP (DT the) (ADJP (ADVP (FW in) (FW vitro)) (VBN perfused)) (NNS pancreases)) (PP (IN of) (NP (ADJP (ADJP (JJ normal)) (CC and) (ADJP (JJ diabetic))) (JJ Chinese) (NNS hamsters))))) (PP (IN in) (NN response) (TO to) (NP (NP (JJ various) (NNS combinations)) (PP (IN of) (NP (NP (NN drug1) (-LRB- -LRB-) (CD 20mM) (-RRB- -RRB-)) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 100) (CC or) (CD 150)) (NN mg.)) (PP (IN per) (NP (CD 100) (NN ml.)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mM)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB alone)) (VP (VBD caused) (NP (NP (JJ identical) (NP (NP (NN insulin)) (CC and) (NP (NN glucagon))) (NN release)) (PP (IN in) (NP (NP (NNS diabetics)) (CC and) (NP (NNS normals))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (UCP (ADVP (RB alone)) (CC and) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2))))) (, ,))) (VP (VBD caused) (NP (NP (JJ subnormal) (NN insulin) (NN release)) (CC and) (NP (NP (RBR less) (NN suppression)) (PP (IN of) (NP (NN glucagon) (NN release))))) (PP (IN in) (NP (DT the) (NNS diabectics))) (PP (IN than) (PP (IN in) (NP (DT the) (NNS normals)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))) (, ,)) (VP (VBD caused) (NP (NP (JJ excessive) (NN glucagon) (NN release)) (CONJP (CC but) (RB nearly)) (NP (JJ normal) (NN insulin) (NN release))) (PP (IN in) (NP (DT the) (NNS diabetics))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))) (, ,)) (VP (VBD caused) (NP (NP (NP (JJ excessive) (NN glucagon) (NN release)) (PP (IN in) (NP (DT the) (NNS diabetics)))) (CC and) (NP (JJ undetectable) (NN insulin) (NN release))) (PP (IN in) (NP (CC either) (NP (NNS diabetics)) (CC or) (NP (NNS normals)))))) (. .)))
(S1 (S (S (NP (NP (JJ Pancreatic) (NN content)) (PP (IN after) (NP (NN perfusion)))) (VP (VBD did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NN release))) (PP (IN during) (NP (NN perfusion)))))) (. .)))
(S1 (S (S (NP (NP (NN Infusion)) (PP (IN of) (NP (NN drug1)))) (ADVP (RB alone)) (ADVP (RB markedly)) (VP (VBD decreased) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (JJ extractable) (JJ pancreatic) (NN insulin)) (CC and) (NP (NN glucagon))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (JJ pancreatic) (NN alpha) (NN cell)) (PP (IN of) (NP (DT the) (JJ diabetic) (NN Chinese) (NN hamster)))) (VP (VBZ responds) (ADVP (RB excessively)) (PP (TO to) (NP (NN drug1))) (, ,) (SBAR (IN as) (S (VP (VBZ is) (VP (VBN seen) (PP (IN in) (NP (DT the) (JJ human) (NN diabetic)))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN defect)) (VP (VBZ is) (RB not) (ADJP (JJ related) (PP (TO to) (NP (NP (JJ acute) (NN insulin) (NN release)) (CC or) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (ADVP (RB Further)) (, ,) (NP (DT these) (NNS results)) (VP (VBP confirm) (SBAR (IN that) (S (NP (DT the) (JJ diabetic) (JJ Chinese) (NP (NP (NN hamster) (POS 's) (NN alpha)) (CC and) (NP (NN beta))) (NNS cells)) (VP (VP (VBP respond) (ADVP (RB normally)) (PP (TO to) (NP (NN drug1)))) (, ,) (CC but) (VP (VBP are) (ADJP (RB relatively) (JJ insensitive) (PP (TO to) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (NN Interference)) (PP (IN of) (NP (NN biocytin))) (PP (IN with) (NP (NP (NP (JJ drug1) (JJ -evoked) (NN hyperpolarization)) (CC and) (NP (NN membrane) (NNS properties))) (PP (IN of) (NP (NN rat) (JJ spinal) (NN substantia) (NN gelatinosa) (NNS neurons))))) (. .))))
(S1 (S (PP (IN In) (NP (PRP$ our) (NN laboratory))) (, ,) (NP (NP (JJ preliminary) (ADJP (ADJP (JJ whole-cell)) (, ,) (ADJP (JJ tight))) (NN seal) (NNS recordings)) (PP (IN of) (NP (NP (NN rat) (JJ spinal) (NN substantia) (NN gelatinosa) (NNS neurons)) (PP (VBG including) (NP (NP (NN biocytin)) (PP (IN in) (NP (DT the) (JJ patch) (NN pipette)))))))) (VP (VBD yielded) (NP (NP (DT a) (ADJP (RB significantly) (JJR smaller)) (NN proportion)) (PP (IN of) (NP (NP (NNS neurons)) (VP (VBN hyperpolarized) (PP (IN by) (NP (NN drug1))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS recordings)) (PP (IN without) (NP (NN biocytin))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN biocytin) (NN inclusion))) (PP (IN on) (NP (NP (NN drug1) (NNS responses)) (CC and) (NP (JJ other) (NN membrane) (NNS properties))))) (PP (IN during) (NP (NP (ADJP (ADJP (JJ whole-cell)) (, ,) (ADJP (JJ tight))) (NN seal) (NNS recordings)) (PP (IN of) (NP (DT these) (NNS neurons))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN percentage)) (PP (IN of) (NP (NP (NNS neurons)) (VP (VBN hyperpolarized) (PP (IN by) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3)))))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN reduced)) (SBAR (WHADVP (WRB when)) (S (UCP (ADJP (CD 1) (NN %)) (CC but) (ADVP (RB not)) (VP (VBN &lt))))))) (: ;)))
(S1 (S (S (CC or) (NP (ADJP (CD =0.2) (NN %)) (NN biocytin)) (VP (VBD was) (VP (VBN included) (PP (IN in) (NP (DT the) (JJ recording) (NN pipette))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (NNS neurons)) (VP (VBN recorded) (PP (IN without) (NP (NN biocytin)))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN proportion)) (PP (IN of) (NP (NNS neurons)))) (VP (VBD fired) (NP (JJ spontaneous) (NN action) (NNS potentials)) (PP (IN with) (NP (DT either) (ADJP (QP (CD 0.05-0.2) (CC or) (CD 1)) (NN %)) (NN biocytin))) (PP (VBN compared) (PP (TO to) (NP (DT no) (NN biocytin)))))) (. .)))
(S1 (S (S (NP (NP (JJ Resting) (NN membrane) (NN potential)) (, ,) (NP (NN input) (NN impedance)) (CC and) (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NP (NNS neurons)) (VP (VBG displaying) (NP (JJ transient) (NN outward) (NN rectification))))))) (VP (VBD were) (DT each) (ADVP (RB significantly)) (VP (VBN altered) (PP (IN for) (NP (NP (NNS neurons)) (VP (VBN recorded) (PP (IN with) (NP (NP (CD 1) (NN %)) (CONJP (CC but) (RB not)) (NP (NP (CD 0.05-0.2) (NN %)) (NP (NN biocytin))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (ADJP (RB relatively) (JJ specific)) (NN blockade)) (PP (IN of) (NP (JJ diverse) (NN potassium) (NN channel) (NNS types))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (JJ efficient) (NN labeling)) (VP (MD can) (VP (VB be) (VP (VBN achieved) (PP (IN with) (NP (ADJP (CD 0.1) (NN %)) (NN biocytin))) (PP (IN with) (NP (JJ whole-cell) (NN recording)))))))) (, ,) (NP (JJR higher) (NNS concentrations)) (VP (VBP are) (VP (VBN contraindicated)))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (NP (NP (ADJP (FW in) (FW vitro)) (NN evaluation)) (PP (IN of) (NP (NP (PRP$ its) (NN permeation) (NN enhancing) (NN effect)) (PP (IN on) (NP (NN peptide) (NNS drugs))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-)))) (NNS conjugates))) (PP (IN on) (NP (NP (DT the) (JJ intestinal) (NN permeation)) (PP (IN of) (NP (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ model) (NN peptide) (NNS drugs)) (, ,) (NP (NP (NN drug7)) (CC and) (NP (NN drug8))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (VP (ADVP (RB covalently)) (VBN linked) (PP (TO to) (NP (NN carbodiimide) (JJ activated) (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (JJ Iodometric) (NN titration)) (PP (IN of) (NP (DT the) (NN polymer) (NNS conjugates)))) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (JJ immobilised) (NN drug1)))))))))) (. .)))
(S1 (S (S (NP (NN Permeation) (NNS studies)) (VP (VBD were) (VP (VBN performed) (PP (IN on) (NP (NP (NP (NN guinea) (NN pig)) (JJ small) (JJ intestinal) (NN mucosa)) (VP (VBN mounted) (PP (IN in) (NP (JJ Ussing-type) (NN chamber))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Unmodified) (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN %) (NN m/v)) (-RRB- -RRB-))) (ADVP (RB significantly)) (VP (VBD improved) (NP (NP (NP (DT the) (NN transport) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NP (NN R=) (NN P) (-LRB- -LRB-) (NN app) (-RRB- -RRB-) (NN polymer/) (NN P) (-LRB- -LRB-) (CD app) (-RRB- -RRB-)) (NP (NN control))) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NP (ADJP (QP (CD 1.3) (CC and) (CD 1)) (NN %) (PRN (-LRB- -LRB-) (NP (NN m/v)) (-RRB- -RRB-))) (NN drug3)) (VP (VBN conjugated) (PP (IN with) (S (NP (NN drug4)) (ADVP (RB further)) (VP (VBD enhanced) (NP (DT the) (NN permeation))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN conjugation)) (PP (IN at) (NP (NP (CD 3.6) (, ,) (CD 5.3) (CC and) (CD 7.3) (NN %)) (PRN (-LRB- -LRB-) (NP (NN m/m)) (-RRB- -RRB-))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN R-values)) (PP (IN of) (NP (CD 1.4) (, ,) (CD 1.7) (CC and) (CD 1.8))))) (, ,) (ADVP (RB respectively)))) (. .)))
(S1 (S (S (VP (VBG Decreasing) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (VP (VBG exhibiting) (NP (NP (NP (CD 7.3) (NN %)) (PRN (-LRB- -LRB-) (NP (NN m/m)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ immobilised) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN CMC-Cys7.3)) (-RRB- -RRB-))))) (PP (PP (IN from) (NP (NP (CD 1) (NN %)) (PRN (-LRB- -LRB-) (NP (NN m/v)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD 0.5) (NN %)) (PRN (-LRB- -LRB-) (NP (NN m/v)) (-RRB- -RRB-))))))))))) (VP (VBD decreased) (NP (NP (DT the) (NN R-value)) (PP (IN of) (NP (NN drug3)))) (PP (IN from) (NP (CD 1.8) (TO to) (CD 1.2)))) (. .)))
(S1 (S (S (NP (NP (NP (QP (CD drug1) (IN at) (CD 1)) (NN %)) (PRN (-LRB- -LRB-) (NP (NN m/v)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ free) (NN drug2)))))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN R-value)) (PP (IN of) (NP (NN drug3))) (PP (VBN compared) (PP (TO to) (NP (NP (NN drug4)) (ADVP (RB alone))))))))) (. .)))
(S1 (S (S (NP (NP (NN Formulation)) (PP (IN of) (NP (NP (NN fluorescence) (JJ labelled) (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NP (JJ unconjugated) (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN %) (NN m/v)) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB improve) (NP (DT the) (NN permeation))))) (, ,) (ADVP (RB however)) (S (PP (IN in) (DT the) (NN presence) (IN of) (NP (ADJP (CD 1) (NN %) (PRN (-LRB- -LRB-) (NP (NN m/v)) (-RRB- -RRB-))) (NN drug4) (NN 7.3))) (NP (DT a) (ADJP (RB significantly) (VBN improved)) (NN permeation)) (VP (VBD was) (VP (VBN observed) (PRN (-LRB- -LRB-) (NP (NNP R=) (CD 1.3)) (-RRB- -RRB-))))) (. .)))
(S1 (S (NP (NP (NN Conjugation)) (PP (IN at) (NP (NN drug1))) (PP (IN with) (NP (NN drug2) (NNS moieties)))) (ADVP (RB significantly)) (VP (VBZ improves) (NP (NP (DT the) (JJ intestinal) (NN permeation)) (PP (IN of) (NP (NP (DT the) (JJ hydrophilic) (NN molecule) (NN drug3)) (CC and) (NP (NP (DT the) (NN model) (NN peptide) (NNS drugs)) (NP (NP (NN drug4)) (CC and) (NP (NN drug5))))))) (ADVP (FW in) (FW vitro)) (, ,) (ADVP (RB therefore)) (NP (NP (DT this) (VBN conjugated) (NN system) (NN maybe)) (ADJP (JJ useful) (PP (IN for) (NP (NP (JJ peroral) (NN administration)) (PP (IN of) (NP (NN peptide) (NNS drugs))) (PP (IN in) (NP (DT the) (JJ future)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ low) (NNS temperatures))) (PP (IN on) (NP (NP (NNS microtubules)) (PP (IN in) (NP (NP (DT the) (JJ non-myelinated) (NNS axons)) (PP (IN of) (NP (JJ post-ganglionic) (JJ sympathetic) (NNS nerves))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN temperature) (NNS changes))) (PP (IN on) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS microtubules)) (PP (IN in) (NP (JJ non-myelinated) (NNS axons)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NP (NN cat) (NN inferior) (JJ mesenteric) (JJ ganglion/hypogastric) (NN nerve) (NNS preparations)) (VP (VBN incubated) (PP (IN at) (NP (JJ various) (NNS temperatures))) (PP (IN in) (NP (NP (NN Eagles) (JJ minimal) (JJ essential) (NN tissue) (NN culture) (NN medium)) (ADVP (FW in) (FW vitro))))))))))) (. .)))
(S1 (S (PP (IN At) (NP (CD 37) (NNS degrees) (NN C))) (NP (DT the) (JJ non-myelinated) (NNS axons)) (VP (VBD contained) (NP (CD 28.4) (ADJP (ADJP (JJ plus)) (CC or) (ADJP (JJ minus))) (NP (CD 0.8) (NNP S.E.M.))))))
(S1 (S (S (PRN (-LRB- -LRB-) (NP (CD 54)) (-RRB- -RRB-)) (VP (NNS microtubules) (PP (IN per) (NP (NN axon))))) (. .)))
(S1 (S (PP (IN After) (NP (NP (NN incubation)) (PP (IN at) (NP (CD 0) (NNS degrees) (NN C))) (PP (IN for) (NP (CD 4) (NN h))))) (NP (DT this) (NN number)) (VP (VBP fell) (PP (TO to) (NP (NP (CD 2.3) (JJ plus)) (CC or) (NP (ADJP (JJ minus))) (NP (CD 0.1) (NN S.E.M.)))))))
(S1 (S (S (LST (-LRB- -LRB-) (CD 41) (-RRB- -RRB-)) (CC but) (VP (VBD returned) (PP (TO to) (NP (JJ normal) (NNS levels))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NNS nerves)) (VP (VBD were) (VP (VBN rewarmed))))))) (. .)))
(S1 (S (S (NP (NP (DT This) (NN loss)) (PP (IN of) (NP (NNS microtubules))) (PP (IN on) (S (VP (VBG cooling) (NP (NP (DT the) (NNS nerves)) (CC and) (NP (NP (PRP$ their) (NN reappearance)) (PP (IN on) (NP (NN rewarming))))))))) (VP (VBD was) (NP (DT a) (JJ rapid) (NN process)))) (: ;)))
(S1 (S (S (NP (PRP it)) (VP (VBD was) (ADJP (JJ independent) (PP (PP (IN of) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (DT the) (JJ nueronal) (NN cell) (NN body))))) (CC and) (PP (IN of) (NP (NP (NN protein) (NN synthesis)) (PP (IN within) (NP (DT the) (NN axon))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN preservation)) (PP (IN of) (NP (DT the) (NNS microtubules)))) (VP (VBD was) (VP (VBN improved) (SBAR (WHADVP (WRB when)) (S (NP (NN D2O)) (VP (VBD was) (ADJP (JJ present) (PP (IN in) (NP (DT the) (NN incubation) (NN medium)))))))))) (. .)))
(S1 (S (S (NP (JJ Reformed) (NNS microtubules)) (VP (VBD appeared) (S (VP (TO to) (VP (VB function) (ADVP (RB normally)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (PRP$ their) (JJ possible) (NN role)) (PP (IN in) (NP (NP (DT the) (NN transport)) (PP (IN of) (NP (NN noradrenaline) (NN storage) (NNS vesicles))) (PP (IN along) (NP (DT the) (NNS axons)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN drug1)) (PP (IN for) (NP (JJ urinary) (NN tract) (NNS infections)))) (: :) (NP (DT a) (NN review))) (. .)))
(S1 (S (S (NP (DT The) (NNS drug1)) (VP (VBP are) (NP (NP (DT a) (ADJP (RB rapidly) (VBG growing)) (NN class)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NP (DT a) (JJ broad) (NN spectrum)) (PP (IN of) (NP (NP (NN activity)) (PP (IN against) (NP (ADJP (ADJP (JJ gram-negative)) (CC and) (ADJP (DT some) (JJ gram-positive))) (JJ aerobic) (NNS bacteria)))))))))) (. .)))
(S1 (S (S (NP (NP (DT These) (NNS agents)) (, ,) (PP (VBG including) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))) (, ,)) (VP (VP (VBP have) (VP (VBN been) (ADVP (RB extensively)) (VP (VBN studied)))) (CC and) (VP (VBP have) (VP (VBN demonstrated) (NP (NP (NP (NN efficacy)) (CC and) (NP (NN safety) (NNS profiles))) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NP (JJ other) (JJ traditional) (NNS agents)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ complicated) (CC or) (JJ uncomplicated) (JJ urinary) (NN tract) (NNS infections)) (CC and) (NP (NN prostatitis)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Advantages)) (VP (VBN offered) (PP (IN by) (NP (NP (DT this) (NN class)) (PP (IN of) (NP (NN drug1))))))) (VP (VBP include) (NP (NP (JJ optimal) (NNS pharmacokinetics)) (, ,) (NP (NP (NN effectiveness)) (PP (IN against) (NP (JJ multidrug-resistant) (NNS organisms)))) (, ,) (CC and) (NP (JJ oral) (NN administration))) (SBAR (WHADVP (RB even) (WRB when)) (S (NP (JJ parenteral) (NN drug2)) (VP (VBP are) (ADVP (RB generally)) (VP (VBN used))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS drug1)) (VP (VBP are) (ADVP (RB also)) (VP (ADVP (RB extensively)) (VBN used) (PP (IN in) (NP (JJ urologic) (NN surgery)))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (VP (VBN taken) (PP (NP (CD 1) (NN hour)) (IN before) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))))) (, ,) (NP (NN drug3)) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NN drug4) (NN exposure)) (, ,) (PP (IN despite) (NP (JJ persistent) (VBG buffering) (NNS effects)))))) (. .)))
(S1 (S (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN exposure)) (PP (TO to) (NP (NN drug3)))))))) (, ,) (CC but) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unclear)) (SBAR (WHADVP (WRB how)) (S (ADVP (RB soon)) (PP (IN after) (NP (NN drug4) (NN administration))) (NP (NN drug5)) (VP (MD may) (VP (VB be) (VP (VBN given) (ADVP (RB safely)))))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (NN drug1) (NNS pharmacokinetics)) (CC and) (NP (JJ gastric) (NN pH))) (PP (IN in) (NP (CD 12) (JJ human) (NN immunodeficiency) (JJ virus-positive) (NNS patients))) (PP (IN by) (NP (NP (NN use)) (PP (IN of) (NP (NP (NP (NP (CD 800) (NN mg)) (PP (IN of) (NP (NP (NN drug2)) (ADVP (RB alone))))) (CC versus) (NP (NP (CD 800) (NN mg)) (PP (IN of) (NP (NN drug3))))) (VP (VBN administered) (PP (NP (CD 1) (NN h)) (IN after) (NP (NN drug4) (NN administration))))))))) (. .)))
(S1 (S (S (NP (NN Median) (JJ gastric) (NN pH)) (VP (VBD was) (ADJP (RB significantly) (JJR higher)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN taken) (PP (IN after) (NP (NN drug2) (NN administration))))))))) (: ;)))
(S1 (S (ADVP (RB however)) (, ,) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (NP (DT the) (JJ maximum) (NN concentration)) (PP (IN in) (NP (NN plasma)))) (CC or) (NP (NP (DT the) (NN area)) (PP (IN under) (NP (NP (DT the) (JJ concentration-time) (NN curve)) (PP (IN from) (NP (NN time) (CD zero))) (PP (TO to) (NP (CD 8) (NN h))))))))) (VP (VBD was) (VP (VBN observed))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB be) (VP (VBN taken) (PP (IN with) (NP (NP (DT a) (NN light) (NN meal) (CD 1) (NN h)) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (CD 400) (NN mg)) (PP (IN of) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (S (NP (JJ Progestin-only) (JJ oral) (NN contraception)) (: :) (NP (DT a) (JJ comprehensive) (NN review))) (. .)))
(S1 (S (SBAR (IN In) (NN order) (TO to) (S (VP (VB provide) (NP (NP (NN information)) (PP (IN for) (NP (NP (DT the) (JJ appropriate) (NN package) (NN insert) (NN labeling)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))))) (PP (IN in) (NP (DT the) (NP (PRP US))))))) (, ,) (NP (DT a) (JJ comprehensive) (NN review)) (VP (VBD was) (VP (VBN made) (PP (IN of) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 0.075) (NN mg)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 0.35) (NN mg)) (-RRB- -RRB-))))) (, ,) (PP (IN with) (NP (NP (DT the) (JJ clinical) (NNS differences)) (VP (VBN indicated) (SBAR (WHADVP (WRB where)) (FRAG (JJ applicable)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT this) (NN review)))) (VP (VBD was) (S (VP (TO to) (VP (VBP cite) (NP (NP (JJ primary) (NNS sources)) (PP (IN for) (NP (ADJP (RB virtually) (DT all)) (NN research))) (ADJP (JJ specific) (PP (TO to) (NP (NP (NNS POPs)) (PP (IN since) (NP (NN 1975)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Conclusions)) (CC and) (NP (NP (DT the) (NNS types)) (PP (IN of) (NP (NP (NNS studies)) (SBAR (WHNP (WDT which)) (S (VP (VBP support) (NP (DT these) (NNS conclusions))))))))) (VP (VBP are) (VP (VBN given) (PP (IN for) (NP (DT each) (JJ major) (NN section)))))) (. .)))
(S1 (S (S (NP (DT The) (JJ introductory) (NN chapter)) (VP (VBZ discusses) (NP (NP (DT the) (NP (NNS advantages)) (CC and) (NP (NNS disadvantages))) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (DT the) (NP (NP (NN magnitude)) (CC and) (NP (NN prevalence)))) (PP (IN of) (NP (PRP$ their) (NN use))))))))) (. .)))
(S1 (S (S (NP (JJ Future) (NNS trends)) (VP (VBP are) (ADVP (RB also)) (VP (VBN predicted)))) (. .)))
(S1 (S (S (NP (NN Chapter) (CD 2)) (VP (VBZ considers) (NP (NP (DT the) (NN mode)) (PP (IN of) (NP (NN action)))) (, ,) (S (VP (VBG including) (NP (NN ovulation) (NN prevention)))))) (: ;)))
(S1 (S (NP (NP (NN suppression)) (PP (IN of) (NP (NN midcycle) (NN gonadotropin) (NNS peaks))) (: ;))))
(S1 (S (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ cervical) (NNS mucus)) (, ,) (NP (DT the) (NN endometrium)) (, ,) (CC and) (NP (DT the) (NN fallopian) (NNS tubes)))) (: ;))))
(S1 (S (NP (CC and) (NP (JJ clinical) (NNS implications)) (. .))))
(S1 (S (S (NP (NN Chapter) (CD 3)) (VP (VBZ covers) (NP (NP (NN pharmacology)) (PRN (-LRB- -LRB-) (NP (NP (NNS pharmacokinetics)) (, ,) (NP (NNS pharmacodynamics)) (CC and) (NP (NN potency)) (, ,) (CC and) (NP (JJ clinical) (NNS implications))) (-RRB- -RRB-))))) (. .)))
(S1 (S (NP (DT The) (JJ next) (NN chapter)) (VP (VBZ presents) (NP (NP (NN information)) (PP (IN on) (NP (NP (NP (NN efficacy)) (CC and) (NP (NN pregnancy) (NNS outcomes))) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NN pregnancy) (NNS rates)) (, ,) (NP (NP (NN compliance)) (CC and) (NP (NN efficacy))) (, ,) (NP (JJ ectopic) (NNS pregnancies)) (, ,) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (NP (NNS pregnancies)) (VP (VBN conceived) (PP (IN while) (S (VP (VBG using) (NP (NN drug1))))))))) (, ,) (CC and) (NP (NP (NN fertility)) (PP (VBG following) (NP (NN discontinuation)))))))))))) (. .)))
(S1 (S (NP (NN Chapter) (CD 5)) (VP (VBZ focuses) (PP (IN on) (NP (NP (JJ metabolic) (NNS effects)) (, ,) (ADVP (RB specifically)) (NP (NP (NN lipid) (NN metabolism)) (, ,) (NP (NN carbohydrate) (NN metabolism)) (CC and) (NP (NP (NN diabetes)) (, ,) (NP (NN coagulation) (NNS factors)) (, ,) (CC and) (NP (NN blood) (NN pressure))))))) (. .)))
(S1 (S (S (S (NP (JJ Cardiovascular) (NN disease)) (VP (VBZ is) (VP (VBN considered) (PP (IN in) (NP (DT the) (JJ next) (NN chapter)))))) (, ,) (CC and) (S (NP (NN chapter) (CD 7)) (VP (VBZ presents) (NP (NP (NNS findings)) (PP (IN on) (NP (ADJP (ADJP (JJ endometrial)) (, ,) (ADJP (JJ ovarian)) (, ,) (ADJP (JJ cervical))) (, ,) (NN breast) (, ,) (CC and) (JJ other) (NNS cancers))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN host)) (PP (IN of) (NP (JJ other) (JJ medical) (NNS considerations)))) (VP (VBP are) (VP (VBN discussed) (PP (IN in) (NP (NN chapter) (CD 8))) (, ,) (PP (VBG including) (NP (JJ persistent) (JJ ovarian) (NNS follicles)))))) (: ;)))
(S1 (S (NP (NP (JJ reproductive) (NN tract) (NNS infections)) (: ;))))
(S1 (S (NP (JJ abnormal) (JJ vaginal) (JJ bleeding) (: ;))))
(S1 (S (NP (NP (NN uterine) (NNS fibroids)) (: ;))))
(S1 (S (NP (NP (JJ gestational) (JJ trophoblastic) (NN disease)) (: ;))))
(S1 (S (NP (NP (JJ benign) (NN breast) (NN disease)) (: ;))))
(S1 (S (NP (NP (NNS diseases)) (PP (IN of) (NP (DT the) (NP (NN liver)) (, ,) (NP (NN gallbladder)) (, ,) (CC and) (NP (NN bowel)))) (: ;))))
(S1 (S (NP (NP (JJ endocrine) (NN dysfunction)) (: ;))))
(S1 (S (NP (NN epilepsy) (: ;))))
(S1 (S (NP (NP (NN bone) (NN density)) (: ;))))
(S1 (S (NP (NP (JJ sickle) (NN cell) (NN disease)) (: ;))))
(S1 (S (NP (NP (JJ ocular) (NNS effects)) (: ;))))
(S1 (S (NP (NN surgery) (: ;))))
(S1 (S (S (CC and) (NP (NN overdose))) (. .)))
(S1 (S (S (NP (DT The) (JJ last) (CD 4) (NNS chapters)) (VP (VBP cover) (NP (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (NNS drugs)) (CC and) (NP (NN laboratory) (NNS tests))))) (, ,) (NP (JJ common) (JJ side) (NNS effects)) (, ,) (NP (NN breast) (NN feeding)) (, ,) (CC and) (NP (NP (JJ effective) (NN use)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (NN Information)) (PP (IN on) (NP (NP (NP (NNS precautions)) (CC and) (NP (NNS contraindications)) (, ,) (NP (NNS indications)) (, ,) (NP (NN use) (NNS instructions)) (, ,) (CC and) (NP (NNS instructions))) (PP (IN for) (NP (NP (JJ appropriate) (NNS actions)) (PP (IN after) (S (VP (VBG missing) (NP (DT a) (NN pill)))))))))) (VP (VBZ is) (ADJP (JJ appended)))) (. .)))
(S1 (S (S (NP (NN Hypothermia)) (PP (IN as) (NP (NP (DT an) (NN index)) (PP (IN of) (NP (NP (DT the) (NN drug1) (: -) (NN drug2) (NN reaction)) (PP (IN in) (NP (DT the) (NN rat)))))))) (. .)))
(S1 (S (S (NP (NP (VBN Decreased) (NN core) (NN temperature)) (PP (IN in) (NP (JJ female) (NNS rats)))) (VP (VBD was) (VP (VBN investigated) (PP (IN as) (NP (NP (CD one) (JJ possible) (NN index)) (PP (IN of) (NP (NP (DT the) (NN drug1) (: -) (NN drug2) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN DER)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NN Core) (NN temperature)) (VP (VBD was) (VP (VBN decreased) (PP (IN in) (NP (NNS rats))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (TO to) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NN drug2))) (PP (NP (CD 8) (NNS hours)) (IN before) (NP (DT the) (NN drug3) (NN challenge))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN decrease)) (PP (IN in) (NP (NN temperature)))) (VP (VBD began) (PP (IN within) (NP (NP (CD 20) (NNS minutes)) (PP (IN after) (NP (NN drug1) (NN administration))))) (, ,) (S (VP (VBG reaching) (NP (NP (DT a) (JJ maximal) (NN decrease)) (PP (IN between) (NP (NP (QP (CD 60) (CC and) (CD 120)) (NNS minutes)) (PP (IN post) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN core) (NN temperature)) (VP (VBD returned) (PP (TO to) (NP (JJ normal) (CD 300) (NNS minutes))) (PP (IN after) (NP (NN drug1))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN carotid) (NN cannulation)) (-RRB- -RRB-))) (VP (VBD decreased) (PP (IN along) (PP (IN with) (NP (DT the) (NN core) (NN temperature)))))) (. .)))
(S1 (S (S (NP (JJ Maximal) (NN hypotension)) (VP (VP (VBD was) (VP (VBN found) (PP (NP (CD 120) (NNS minutes)) (IN post) (NP (NN drug1))))) (, ,) (CC and) (VP (VBD returned) (PP (TO to) (NP (JJ normal) (CD 300) (NNS minutes))) (PP (IN after) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NN Heart) (NN rate)) (VP (VP (VBD increased) (ADVP (RB initially))) (CC and) (VP (VBD returned) (PP (TO to) (NP (JJ normal) (CD 40) (NNS minutes))) (PP (IN after) (NP (NN drug1) (NN challenge)))))) (. .)))
(S1 (S (S (NP (NP (JJ Intestinal) (NN absorption)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (DT the) (NN chick))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (VP (VBZ has) (VP (VBN been) (VP (VBN investigated) (PP (IN in) (NP (DT the) (NN chick))) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NP (DT the) (ADJP (FW in) (FW situ)) (VBN ligated) (JJ duodenal) (NN loop)) (NN technique))))))))) (. .)))
(S1 (S (PP (IN By) (NP (DT this) (NN procedure))) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN observed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (ADVP (ADVP (RB rapidly)) (CC and) (ADVP (RB essentially) (RB completely))) (VP (VBN absorbed) (PRN (-LRB- -LRB-) (NP (CD 80-95) (NN %)) (-RRB- -RRB-)) (PP (IN from) (NP (DT the) (NN lumen))) (PP (IN at) (NP (NP (JJ drug2) (NNS concentrations)) (ADJP (QP (RB up) (TO to) (CD 5)) (NN mM))))) (, ,) (S (VP (VBG declining) (PP (TO to) (NP (ADJP (QP (RB about) (CD 50)) (NN %)) (NN absorption))) (PP (IN at) (NP (CD 50) (NN mM)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Transfer)) (PP (IN from) (NP (DT the) (JJ intestinal) (NN lumen))) (PP (TO to) (NP (DT the) (JJ mucosal) (NNS cells))) (PP (IN at) (NP (NP (JJ low) (NN drug1) (NN concentration)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN mM)) (-RRB- -RRB-))))) (VP (VBZ is) (ADJP (JJ rapid)) (, ,) (SBAR (IN while) (S (NP (NP (NN transfer)) (PP (IN from) (NP (DT the) (JJ mucosal) (NNS cells))) (PP (TO to) (NP (DT the) (NN body)))) (VP (VBZ occurs) (ADVP (RBR more) (RB slowly))))))) (. .)))
(S1 (S (S (PP (IN At) (NP (NP (JJ stable) (NN drug1) (NNS concentrations)) (ADJP (JJR greater) (PP (IN than) (NP (CD 1) (NN mM)))))) (, ,) (NP (NP (JJ fractional) (JJ mucosal) (NN cell) (NN accumulation)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ remains) (ADJP (JJ constant)) (, ,) (SBAR (IN while) (S (NP (NP (JJ fractional) (NN transfer)) (PP (TO to) (NP (DT the) (NN body)))) (VP (VBZ declines)))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NP (JJ total) (JJ mucosal) (NN accumulation)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT that)) (VP (VBN transferred) (PP (TO to) (NP (DT the) (NN body)))))) (VP (VBP increase) (PP (IN in) (NP (NP (DT a) (JJ linear) (JJ logarithmic) (NN fashion)) (PP (IN from) (NP (CD 0.05))) (PP (TO to) (NP (ADJP (CD 5) (NN mm)) (NN drug2)))))) (. .)))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (ADVP (RB readily)) (VP (VBZ penetrates) (NP (NP (CC both) (DT the) (ADJP (ADJP (JJ mucosal)) (CC and) (ADJP (JJ serosal))) (NNS surfaces)) (PP (IN of) (NP (DT the) (JJ epithelial) (NN membrane))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP do) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB share) (NP (NP (DT a) (JJ common) (NN transport) (NN pathway)) (PP (IN in) (NP (DT the) (NN duodenum)))))))))) (CC and) (S (NP (DT no) (NN evidence)) (VP (VBD was) (VP (VBN obtained) (PP (IN for) (NP (NP (DT any) (NN interaction)) (PP (IN between) (NP (DT the) (CD two))) (PP (IN at) (NP (DT this) (NN level))))))))) (. .)))
(S1 (S (S (NP (NP (JJ drug1) (NN administration)) (PP (TO to) (NP (JJ rachitic) (NNS chicks)))) (VP (VBD was) (ADJP (JJ effective)) (PP (IN in) (S (ADVP (RB significantly)) (VP (VBG elevating) (NP (NP (JJ duodenal) (NN drug2) (NN absorption)) (, ,) (VP (VBG acting) (ADVP (RB primarily)) (S (VP (TO to) (VP (VB enhance) (NP (JJ serosal) (NN transport)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (NP (NP (DT an) (JJ updated) (NN review)) (PP (IN of) (NP (PRP$ its) (NN use))) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NN schizophrenia)))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (DT a) (NN drug2)) (, ,)) (VP (VBZ is) (NP (NP (DT a) (NN drug3)) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (NP (NP (JJ proven) (NN efficacy)) (PP (IN against) (NP (NP (DT the) (ADJP (ADJP (JJ positive)) (CC and) (ADJP (JJ negative))) (NNS symptoms)) (PP (IN of) (NP (NN schizophrenia)))))))))))) (. .)))
(S1 (S (S (PP (VBN Compared) (PP (IN with) (NP (NN drug1)))) (, ,) (NP (PRP it)) (VP (VBZ has) (NP (NP (JJR greater) (NN affinity)) (PP (IN for) (NP (NN serotonin) (NN 5-HT2A))) (PP (IN than) (PP (IN for) (NP (NN dopamine) (NN D2) (NNS receptors))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (ADJP (ADJP (JJ large)) (, ,) (ADJP (RB well) (VBN controlled))) (NNS trials)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN schizophrenia)) (CC or) (NP (JJ related) (NNS psychoses)))))))) (, ,) (NP (NN drug1) (CD 5) (TO to) (CD 20) (NN mg/day)) (VP (VP (VBD was) (ADJP (RB significantly) (JJ superior) (PP (TO to) (NP (NP (NN drug2) (CD 5) (TO to) (CD 20) (NN mg/day)) (PP (IN in) (NP (NP (JJ overall) (NNS improvements)) (PP (PP (IN in) (NP (NN psychopathology) (JJ rating) (NNS scales))) (CC and) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ depressive) (CC and) (JJ negative) (NNS symptoms)))))))))))) (, ,) (CC and) (VP (VBD was) (ADJP (JJ comparable) (PP (IN in) (NP (NP (NNS effects)) (PP (IN on) (NP (JJ positive) (JJ psychotic) (NNS symptoms)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ 1-year) (NN risk)) (PP (IN of) (NP (NP (NN relapse)) (PRN (-LRB- -LRB-) (NP (NN rehospitalisation)) (-RRB- -RRB-))))) (VP (VBD was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN with) (NP (NN drug1))) (PP (IN than) (PP (IN with) (NP (NN drug2) (NN treatment))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (NP (DT the) (JJ first) (JJ double-blind) (JJ comparative) (NN study)) (PRN (-LRB- -LRB-) (NP (JJ 28-week)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (, ,) (NP (NN drug3) (CD 10) (TO to) (CD 20) (NN mg/day)) (VP (VBD proved) (S (VP (TO to) (VP (VB be) (ADVP (RB significantly)) (ADJP (ADJP (RBR more) (JJ effective)) (PP (IN than) (NP (NN drug4) (CD 4) (TO to) (CD 12) (NN mg/day))) (PP (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ negative) (CC and) (JJ depressive) (NNS symptoms))))) (CC but) (PP (RB not) (IN on) (NP (NP (JJ overall) (NN psychopathology)) (NNS symptoms))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (JJ preliminary) (NNS results)) (PP (IN from) (NP (DT an) (JJ 8-week) (JJ controlled) (NN study)))) (VP (VBD suggested) (NP (NN drug1) (CD 2) (TO to) (CD 6) (NN mg/day)) (VP (VBD was) (ADJP (JJ superior) (PP (TO to) (NP (NN drug2) (CD 5))) (PP (TO to) (NP (NP (CD 20) (NN mg/day)) (PP (IN against) (NP (NP (ADJP (ADJP (JJ positive)) (CC and) (ADJP (JJ anxiety/depressive))) (NNS symptoms)) (PRN (-LRB- -LRB-) (NP (NN p) (CD &lt) (: ;) (CD 0.05)) (-RRB- -RRB-))))))) (, ,) (SBAR (IN although) (S (S (ADJP (JJ consistent) (PP (IN with) (NP (DT the) (JJ first) (NN study))))) (, ,) (NP (DT both) (NNS agents)) (VP (VBD demonstrated) (NP (JJ similar) (NN efficacy)) (PP (IN on) (NP (NP (NNS measures)) (PP (IN of) (NP (JJ overall) (NN psychopathology)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Improvements)) (PP (IN in) (NP (NP (JJ general) (JJ cognitive) (NN function)) (VP (VBN seen) (PP (IN with) (NP (NN drug1) (NN treatment))) (PP (IN in) (NP (NP (DT a) (JJ 1-year) (JJ controlled) (NN study)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ early-phase) (NNS schizophrenia)))))))))) (, ,)) (VP (VBD were) (ADJP (ADJP (RB significantly) (JJR greater)) (PP (IN than) (NP (NP (NNS changes)) (VP (VBN seen) (PP (IN with) (NP (CC either) (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (JJ preliminary) (NNS results)) (PP (IN from) (NP (DT an) (JJ 8-week) (NN trial)))) (VP (VBD showed) (NP (NP (JJ comparable) (JJ cognitive) (NN enhancing) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (NN treatment)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN schizophrenia)) (CC or) (NP (JJ schizoaffective) (NN disorder))))))))) (. .)))
(S1 (S (S (NP (JJ Several) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ has) (NP (NP (NNS benefits)) (PP (IN against) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NP (NN aggression)) (CC and) (NP (NN agitation))))))) (, ,) (SBAR (IN while) (S (NP (JJ other) (NNS studies)) (ADVP (RB strongly)) (VP (VBP support) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ depressive) (NN symptomatology)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RB significantly) (JJR fewer)) (NN extrapyramidal) (NNS symptoms)) (PP (IN than) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN risk)) (PP (IN of) (NP (NN agranulocytosis))))) (SBAR (IN as) (S (VP (VBN seen) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (ADJP (RB clinically) (JJ significant)) (NN hyperprolactinaemia) (SBAR (IN as) (S (VP (VBN seen) (PP (IN with) (NP (NP (NN drug3)) (CC or) (NP (NP (NN prolongation)) (PP (IN of) (NP (DT the) (JJ QT) (NN interval)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ adverse) (NNS effects)) (VP (VBN reported) (PP (IN with) (NP (NN drug1))))) (VP (VBP are) (NP (NP (NN bodyweight) (NN gain)) (, ,) (NP (NN somnolence)) (, ,) (NP (NN dizziness)) (, ,) (NP (NP (JJ anticholinergic) (NNS effects)) (PRN (-LRB- -LRB-) (NP (NP (NN constipation)) (CC and) (NP (NN dry)) (NP (NN mouth))) (-RRB- -RRB-))) (CC and) (NP (JJ transient) (JJ asymptomatic) (NN liver) (NN enzyme) (NNS elevations))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NN comparison)) (PP (IN with) (NP (NN drug1))))) (, ,) (NP (NP (DT the) (JJ adverse) (NNS events)) (VP (VP (VBN reported) (ADVP (RB significantly) (RBR more) (RB frequently)) (PP (IN with) (NP (NN drug2))) (PP (IN in) (NP (NP (ADJP (ADJP (JJ >)) (CC or) (ADJP (JJ =))) (CD 3.5) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBD were) (NP (NP (JJ dry) (NN mouth)) (, ,) (NP (NN bodyweight) (NN gain)) (CC and) (NP (VBN increased) (NN appetite))))))))) (CC and) (VP (VBN compared) (PP (IN with) (NP (NP (NN drug3)) (, ,) (RB only) (NP (NN bodyweight) (NN gain))))))) (VP (VBD occurred) (ADVP (RB significantly) (RBR more) (RB frequently)) (PP (IN with) (NP (NN drug4))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ high) (NN acquisition) (NN cost)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN offset) (PP (IN by) (NP (NP (NNS reductions)) (PP (IN in) (NP (NP (NP (JJ other) (NN treatment) (NNS costs)) (PRN (-LRB- -LRB-) (NP (NP (NN inpatient)) (CC and/or) (NP (JJ outpatient) (NNS services))) (-RRB- -RRB-))) (PP (IN of) (NP (NN schizophrenia)))))))))) (. .)))
(S1 (S (S (NP (JJ Pharmacoeconomic) (NNS analyses)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VP (VBZ does) (RB not) (ADVP (RB significantly)) (VP (VB increase))) (, ,) (CC and) (VP (MD may) (ADVP (RB even)) (VP (VB decrease) (, ,) (NP (NP (DT the) (JJ overall) (JJ direct) (NN treatment) (NNS costs)) (PP (IN of) (NP (NN schizophrenia)))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (PP (VBN Compared) (PP (IN with) (NP (NN drug1)))) (, ,) (NP (NN drug2)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB decrease) (NP (JJ overall) (NN treatment) (NNS costs)) (, ,) (PP (IN despite) (NP (NP (DT the) (ADJP (RB several-fold) (JJR higher)) (JJ daily) (NN acquisition) (NN cost)) (PP (IN of) (NP (DT the) (NN drug)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN treatment)) (VP (VBZ improves) (NP (NP (NN quality)) (PP (IN of) (NP (NN life))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN schizophrenia)) (CC and) (NP (JJ related) (NNS psychoses))))))) (PP (PP (TO to) (NP (NP (DT a) (JJR greater) (NN extent)) (PP (IN than) (NP (NN drug2))))) (, ,) (CC and) (PP (TO to) (NP (NP (RB broadly) (DT the) (JJ same) (NN extent)) (PP (IN as) (NP (NN drug3)))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NN drug1)) (VP (VBD demonstrated) (NP (JJ superior) (JJ antipsychotic) (NN efficacy)) (PP (VBN compared) (PP (IN with) (NP (NN drug2)))) (PP (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ acute) (NN phase) (NN schizophrenia))))) (, ,) (CC and) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (DT some) (NNS patients)) (PP (IN with) (NP (NP (NN first-episode)) (CC or) (NP (JJ treatment-resistant) (NN schizophrenia))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (VBN reduced) (NN risk)) (PP (IN of) (NP (NP (JJ adverse) (NNS events)) (CC and) (NP (JJ therapeutic) (NN superiority)))) (VP (VBN compared) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ negative) (CC and) (JJ depressive) (NNS symptoms))))))) (VP (VBP support) (NP (NP (DT the) (NN choice)) (PP (IN of) (NP (NN drug3)))) (PP (IN as) (NP (NP (DT a) (JJ first-line) (NN option)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NN schizophrenia))) (PP (PP (IN in) (NP (DT the) (JJ acute) (NN phase))) (CC and) (PP (IN for) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NN treatment) (NN response)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Antimicrobial) (NN activity)) (PP (IN of) (NP (NN drug1))) (UCP (ADVP (RB alone)) (CC and) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (DT some) (NNS drug2)))))))) (. .)))
(S1 (S (S (S (NP (NP (JJ Antimicrobial) (NN activity)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (JJ aqueous) (NN extract)) (PP (IN from) (NP (NP (DT the) (NNS carpophores)) (PP (IN of) (NP (NP (NP (NN Ganoderma) (NN lucidum)) (PRN (-LRB- -LRB-) (NP (NN FR)) (-RRB- -RRB-))) (NN KARST)))))) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN tested) (ADVP (FW in) (FW vitro)) (PP (IN against) (NP (ADJP (ADJP (NN Gram) (JJ positive)) (CC and) (ADJP (NN Gram) (JJ negative))) (NNS bacteria))) (PP (IN by) (NP (JJ serial) (NN broth) (NN dilution) (NN method)))))) (, ,) (CC and) (S (NP (DT the) (JJ antimicrobial) (NN activity)) (VP (VBD was) (VP (VBN expressed) (PP (IN by) (NP (NP (JJ minimal) (JJ inhibitory) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN MIC)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (PP (IN Among) (NP (NP (NP (CD fifteen) (NNS species)) (PP (IN of) (NP (NNS bacteria)))) (VP (VBN tested)))) (, ,) (NP (NP (DT the) (JJ antimicrobial) (NN activity)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (NP (NP (DT the) (RBS most) (JJ potent)) (PP (IN against) (NP (JJ Micrococcus) (NNS luteus)))) (PRN (-LRB- -LRB-) (NP (NP (NN MIC)) (, ,) (NP (CD 0.75) (NN mg/ml))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (VP (TO To) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ antimicrobial) (NNS combinations)) (PP (IN of) (NP (NN drug1))))) (PP (IN with) (NP (NP (CD four) (NNS kinds)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6))) (-RRB- -RRB-)))))))))) (, ,) (S (NP (NP (DT the) (JJ fractional) (JJ inhibitory) (NN concentration) (NN index)) (PRN (-LRB- -LRB-) (NP (NN FICI)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN determined) (PP (IN by) (NP (NP (JJ checkerboard) (NN assay)) (PP (IN for) (NP (DT each) (NN strain)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ antimicrobial) (NNS combinations)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (CD four) (NNS drug2)))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ additive) (NN effect)) (PP (IN in) (NP (JJS most) (NNS instances))))) (, ,) (NP (NP (NP (NN synergism)) (PP (IN in) (NP (CD two) (NNS instances)))) (, ,) (CC and) (NP (NP (NN antagonism)) (PP (IN in) (NP (CD two) (NNS instances))))))) (. .)))
(S1 (S (S (NP (NN Synergism)) (VP (VBD was) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN combined) (PP (IN with) (NP (NN drug2))) (PP (IN against) (NP (NP (FW Bacillus) (FW subtilis)) (CC and) (NP (FW Klebsiella) (FW oxytoca))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ protects) (NP (NN mouse) (NN tumour) (CC and) (JJ normal) (NNS tissues)) (PP (IN from) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (JJ oral) (NN drug2))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (DT the) (NN drug1) (NN drug2)) (VP (VBZ is) (VP (VBN given) (ADVP (RB exclusively)) (PP (IN by) (NP (NP (DT the) (JJ oral) (NN route)) (PP (IN in) (NP (NN man))))))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN carried) (PRT (RP out)) (NP (NP (NNS studies)) (PP (IN in) (NP (NNS mice))) (PP (IN on) (NP (NP (DT the) (NP (JJ antitumour) (NN activity)) (, ,) (NP (JJ acute) (NN toxicity)) (CC and) (NP (NNS pharmacokinetics))) (PP (IN of) (NP (NP (JJ oral) (NN drug3)) (, ,) (UCP (CC either) (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (DT the) (NN chemosensitizer) (NN drug4))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (CC both) (NP (NN plasma)) (CC and) (NP (JJ KHT) (NN tumour)))) (NP (NP (DT the) (JJ peak) (NN concentration)) (CC and) (NP (NN &quot))) (: ;) (NP (NN early&quot))) (: ;)))
(S1 (S (S (NP (NP (NN AUC)) (PP (IN for) (NP (JJ total) (NN drug1)))) (VP (VBD were) (ADJP (ADJP (NP (QP (RB about) (CD 1.4-1.5)) (NN fold)) (JJR greater)) (PP (IN for) (NP (DT the) (JJ oral)))))) (S (VP (VBN compared) (PP (TO to) (NP (DT the))) (ADVP (RB i.p.))))))
(S1 (S (NP (NP (NN route)) (. .))))
(S1 (S (S (NP (DT These) (NNS differences)) (VP (VBD were) (VP (VBN reflected) (PP (IN in) (NP (NP (DT the) (ADJP (RB roughly) (RB twofold) (JJR greater)) (JJ antitumour) (NN activity)) (PP (IN for) (NP (DT the) (JJ oral) (NN route)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (JJ acute) (NN toxicity) (NNS tests)) (VP (VBD showed) (SBAR (IN that) (S (NP (JJ oral) (NN drug1)) (VP (VBD was) (NP (NP (CD 1.45) (NNS times)) (ADJP (RBR less) (JJ toxic) (PP (TO to) (NP (JJ normal) (NN tissue))))) (, ,) (SBAR (IN although) (S (NP (DT the) (JJ dose-limiting) (NN organ)) (VP (MD may) (VP (VB be) (ADJP (JJ different) (PP (IN for) (NP (DT the) (CD two) (NNS routes))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD reduced) (NP (NP (DT the) (JJ antitumour) (NN activity)) (PP (IN of) (NP (JJ oral) (NN drug2)))) (PP (IN by) (NP (NP (NP (NN dose) (NN modifying) (NNS factors)) (PRN (-LRB- -LRB-) (NP (NN DMF)) (-RRB- -RRB-))) (PP (IN of) (NP (NN 0.58-0.71))))))) (. .)))
(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (DT the) (JJ acute) (NN toxicity)) (VP (VBD was) (ADVP (RB also)) (VP (VBN diminished) (PP (IN by) (NP (NP (DT a) (NN DMF)) (PP (IN of) (NP (CD 0.74)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (NP (NP (DT a) (JJ complex) (NN effect)) (PP (IN on) (NP (JJ oral) (NN drug2) (NNS pharmacokinetics)))))) (. .)))
(S1 (S (S (NP (DT The) (NP (NP (NN plasma)) (CC and) (NP (NN tumour))) (JJ total) (NN drug1) (NN peak) (NNS concentrations)) (VP (VBD were) (VP (VBN reduced) (PP (IN by) (NP (NP (QP (CD 1.5) (CC and) (CD 1.7)) (NN fold)) (ADVP (RB respectively))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB also)) (VP (VBD reduced) (NP (DT the) (NN &quot)))) (: ;) (NP (NN early&quot)) (: ;)))
(S1 (S (S (NP (NP (NN drug1) (NN AUC)) (, ,) (PP (IN with) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (DT the) (NN reduction)))))) (VP (VBG depending) (PP (IN on) (NP (NP (NP (DT the) (JJ minimum) (JJ effective) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN MEC)) (-RRB- -RRB-))) (VP (VBN chosen)))))) (. .)))
(S1 (S (PP (IN For) (NP (NN example))) (, ,) (NP (DT the) (NN plasma) (NN drug1) (NN AUC)) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (NP (NNS factors)) (PP (IN of) (NP (NP (CD 1.05)) (CC and) (NP (CD 9.6)))))) (PP (IN for) (NP (NP (NN MEC) (NNS values)) (PP (IN of) (NP (QP (CD 1) (CC and) (CD 2)) (NNS micrograms) (NN ml-1))))) (ADVP (RB respectively)))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP propose) (S (NP (DT these) (JJ pharmacokinetic) (NNS changes)) (VP (TO to) (VP (VB be) (NP (NP (DT the) (VBG underlying) (NN mechanism)) (PP (IN for) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (JJ oral) (NN drug1) (NN cytotoxicity))) (PP (IN by) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Clinical) (NNS trials)) (PP (IN of) (NP (JJ such) (NNS combinations)))) (VP (MD should) (VP (VB be) (VP (VBN accompanied) (PP (IN by) (NP (JJ detailed) (JJ pharmacokinetic) (NN evaluation))))))) (. .)))
(S1 (S (NP (NP (JJ Pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (JJ single) (JJ oral) (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (PP (IN in) (NP (JJ healthy) (NNS volunteers))) (. .))))
(S1 (S (NP (NP (NP (NN AIM)) (CC AND) (NP (NN BACKGROUND))) (: :) (S (NP (NP (DT The) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (NN drug2)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4))))) (, ,) (CC and) (NP (DT the) (NN drug3) (NN drug4))))) (VP (VBD was) (VP (VBN studied) (PP (IN in) (NP (CD 18) (JJ healthy) (NNS subjects)))))) (. .))))
(S1 (S (S (NP (JJ Several) (ADJP (RB clinically) (JJ important)) (NNS interactions)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN been) (VP (VBN reported) (PP (PP (IN for) (NP (NP (JJ other) (NNS drug1)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (JJ same) (NN enzyme))))))))) (CC and) (PP (IN for) (NP (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (S (NP (NP (JJ Healthy) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (NP (QP (CD 20) (TO to) (CD 43)) (NNS years)) (JJ old)))))) (VP (VBD participated) (PP (IN in) (NP (NP (DT an) (ADJP (ADJP (JJ open)) (, ,) (ADJP (JJ three-period)) (, ,) (ADJP (JJ randomized)) (, ,) (ADJP (JJ crossover))) (NN study)) (PP (IN of) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT a) (JJ single) (JJ 10-mg) (JJ oral) (NN dose)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (JJ single) (JJ oral) (NN 120-mg) (NN dose)) (PP (IN of) (NP (NN drug2)))))))))))))) (, ,) (CC and) (S (NP (DT the) (CD two) (NNS drugs)) (VP (VBN given) (ADVP (RB together))))) (. .))))
(S1 (S (S (NP (DT The) (CD three) (NN study) (NNS periods)) (VP (VBD were) (VP (VBN separated) (PP (IN by) (NP (DT a) (JJ 21-day) (NN washout) (NN phase)))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (S (NP (NP (NP (DT The) (JJ geometric) (NN mean)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN %) (NN confidence) (NN interval)) (-RRB- -RRB-))) (NP (NP (JJ whole) (NN blood) (NN drug1) (NN area)) (PP (IN under) (NP (DT the) (NN plasma) (NN concentration) (NN time-curve))))) (VP (VBD increased) (NP (NP (CD 60) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 35) (NN %) (CD -90) (NN %)) (-RRB- -RRB-))) (, ,) (PP (IN from) (NP (QP (CD 736) (TO to) (CD 1178)) (NN ng) (NN x) (NN h/mL))))) (, ,) (CC and) (S (NP (NN maximum) (NN concentration)) (VP (VBD increased) (NP (NP (CD 43) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 14) (NN %) (CD -81) (NN %)) (-RRB- -RRB-))) (, ,) (PP (IN from) (NP (QP (CD 67) (TO to) (CD 96)) (NN ng/mL))) (, ,) (PP (IN with) (NP (NN drug2) (NN coadministration))))) (, ,) (IN whereas) (S (NP (NP (DT the) (JJ mean) (NN elimination) (NN half-life)) (PP (IN of) (NP (NN drug3)))) (VP (VBD decreased) (ADVP (RB slightly)) (, ,) (PP (IN from) (NP (QP (CD 79) (TO to) (CD 67)) (NNS hours)))))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Apparent) (JJ oral) (NN clearance)) (CC and) (NP (NN volume))) (PP (IN of) (NP (NP (NN distribution)) (PP (IN of) (NP (NN drug1)))))) (VP (VBD decreased) (PP (IN with) (NP (NP (CD 38) (NN %)) (CC and) (NP (CD 45) (NN %)) (, ,) (ADVP (RB respectively)))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN given) (PP (IN with) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NN plasma) (NN maximum) (NN concentration)) (CC and) (NP (NP (NN area)) (PP (IN under) (NP (NP (DT the) (NN plasma) (NN concentration-time) (NN curve)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3)))))))) (VP (VBD were) (ADJP (JJ unchanged)) (PP (IN after) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug4))))))) (, ,) (CC and) (S (NP (NP (DT no) (NN potentiation)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug5))) (PP (PP (IN on) (NP (ADJP (ADJP (JJ diastolic)) (CC or) (ADJP (JJ systolic))) (NN blood) (NN pressure))) (CC or) (PP (IN on) (NP (DT the) (JJ electrocardiographic) (NNS parameters))))))) (VP (VBD was) (VP (VBN seen))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (JJ Single-dose) (NN drug1) (NN coadministration)) (VP (VBZ leads) (PP (TO to) (NP (JJR higher) (NN drug2) (NN exposure))) (, ,) (ADVP (RB presumably)) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (DT the) (NN first-pass) (NN metabolism)) (PP (IN of) (NP (NN drug3))))))))) (. .))))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (JJ pronounced) (NN intersubject) (NN variability)) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (DT the) (NN drug1) (: -) (NN drug2) (NN interaction)))))))) (, ,) (NP (JJ whole) (NN blood) (NN drug3) (NNS concentrations)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (DT the) (CD two) (NNS drugs)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (DT a) (NN trans-3,4-dimethyl-4-) (-LRB- -LRB-) (NN 3-hydroxyphenyl) (-RRB- -RRB-) (NN piperidine)) (, ,)) (VP (VBZ prevents) (NP (NP (JJ gastrointestinal) (NNS effects)) (PP (IN of) (NP (JJ intravenous) (NN drug2)))) (PP (IN without) (S (VP (VBG affecting) (NP (NN analgesia))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ novel) (NN drug2)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (ADVP (RB selectively)) (VP (VB prevent) (NP (NN drug3) (JJ -induced) (JJ gastrointestinal) (NNS effects)) (PP (IN without) (S (VP (VBG reversing) (NP (NN analgesia)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Gastrointestinal) (NN transit) (NN time)) (PRN (-LRB- -LRB-) (NP (NN lactulose) (NN hydrogen) (NN breath) (NN test)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN measured) (PP (IN in) (NP (NP (CD 14) (NNS volunteers)) (PP (IN with) (NP (NP (ADJP (ADJP (JJ oral)) (CC and) (ADJP (JJ intravenous))) (NN placebo)) (, ,) (NP (NP (NP (JJ oral) (NN placebo)) (CC and) (NP (JJ intravenous) (NN drug1))) (PRN (-LRB- -LRB-) (NP (NP (CD 0.05) (NN mg)) (CC x) (NP (NP (CD kg)) (PRN (-LRB- -LRB-) (NP (CD -1)) (-RRB- -RRB-)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NP (NP (JJ oral) (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN mg)) (-RRB- -RRB-))) (CC and) (NP (JJ intravenous) (NN drug3))) (PRN (-LRB- -LRB-) (NP (NP (CD 0.05) (NN mg)) (CC x) (NP (NP (CD kg)) (PRN (-LRB- -LRB-) (NP (CD -1)) (-RRB- -RRB-)))) (-RRB- -RRB-))))))) (PP (IN in) (NP (NP (DT a) (JJ double) (NN blind)) (, ,) (NP (JJ cross-over) (NN study))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD prolonged) (NP (JJ gastrointestinal) (NN transit) (NN time)) (PP (IN from) (NP (NP (QP (CD 69) (TO to) (CD 103)) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (NN .005)) (-RRB- -RRB-)))))) (: ;)))
(S1 (S (S (NP (NN drug1)) (VP (VBD prolonged) (NP (JJ gastrointestinal) (NN transit) (NN time)) (PP (IN from) (NP (NP (QP (CD 69) (TO to) (CD 103)) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (NN .005)) (-RRB- -RRB-)))))) (: ;) (S (NP (DT this)) (VP (VBD was) (VP (VBN prevented) (PP (IN by) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (CD .004)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (ADVP (RB Postoperatively)) (, ,) (NP (CD 45) (NNS patients)) (VP (VBD were) (VP (ADVP (RB randomly)) (VBN assigned) (PP (IN in) (NP (DT a) (JJ double-blind) (NN fashion))) (S (VP (VP (TO to) (VP (VBP receive) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN mg)) (-RRB- -RRB-))) (CC or) (NP (NP (NP (NN placebo)) (CC and) (NP (JJ intravenous) (NN drug2))) (PRN (-LRB- -LRB-) (NP (CD 0.15) (NN mg/kg)) (-RRB- -RRB-)))))) (CC or) (VP (TO to) (VP (VBP receive) (NP (ADJP (ADJP (JJ oral)) (CC and) (ADJP (JJ intravenous))) (NN placebo))))))))) (. .)))
(S1 (S (S (NP (NP (NN Analgesia)) (CC and) (NP (NN pupil) (NN constriction))) (VP (VBD were) (VP (VBN measured)))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN analgesia)) (CC and) (NP (NN pupil) (NN constriction))) (VP (VP (VBD were) (VP (VBN unaffected) (PP (IN by) (NP (NN drug2))))) (CC and) (VP (VBD differed) (PP (IN from) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NN P) (NN &lt) (: ;) (NN .002)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ prevents) (NP (NP (NN drug2) (JJ -induced) (NNS increases)) (PP (IN in) (NP (JJ gastrointestinal) (NN transit) (NN time)))) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (JJ selective) (JJ peripheral) (NN opioid) (NN anitagonism))))) (PP (IN without) (S (VP (VBG affecting) (NP (JJ central) (NN opioid) (NN analgesia)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN on) (NP (NP (JJ bar-press) (NN behavior)) (PP (IN in) (NP (ADJP (ADJP (JJ normal)) (CC and) (ADJP (RB genetically) (JJ nervous))) (NNS dogs))))))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (PP (IN on) (NP (NP (CD two) (NNS strains)) (PP (IN of) (NP (JJ pointer) (NNS dogs)))))) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT a) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (VP (VBZ facilitates) (NP (NP (NN acquisition)) (PP (IN of) (NP (JJ goal-directed) (NN behavior))) (PP (IN in) (NP (NN &quot)))))))))) (: ;) (FRAG (FRAG (ADVP (RB genetically)) (NP (NN nervous&quot))) (: ;))))
(S1 (S (NP (NP (NNS subjects)) (. .))))
(S1 (S (S (NP (NP (JJ Continued) (NN admistration)) (PP (IN of) (NP (DT the) (NN drug)))) (VP (VBZ is) (VP (VBN required) (S (VP (TO to) (VP (VB maintain) (NP (NN barpress) (NN response)) (PP (IN in) (NP (NP (DT this) (NN strain)) (PP (IN of) (NP (NNS dogs))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (CC either) (NP (NN drug1)) (CC or) (NP (NP (NN drug2)) (, ,) (NP (NP (NNS compounds)) (SBAR (WHNP (WDT which)) (S (VP (VBP inhibit) (NP (NP (JJ neuronal) (NN reuptake)) (PP (IN of) (NP (NN norepinephrine)))))))) (, ,))))) (VP (VBZ disrupts) (NP (NP (DT the) (JJ behavioral) (NN response)) (PP (IN of) (NP (DT the) (ADJP (RB genetically) (JJ nervous)) (NN E-strain) (NNS subjects))) (PP (TO to) (NP (NP (DT a) (ADJP (RB far) (JJR greater)) (NN extent)) (PP (IN than) (NP (DT the) (JJ stable) (NN A-strain) (NNS subjects)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN shown) (SBAR (IN that) (S (PP (IN after) (NP (NP (CD 14) (NNS days)) (PP (IN of) (NP (NP (JJ daily) (NN administration)) (PP (IN of) (NP (NN drug1))))))) (, ,) (NP (NP (NN withdrawal)) (PP (IN of) (NP (DT the) (NN drug)))) (VP (CONJP (RB not) (RB only)) (VP (VBZ re-results) (PP (IN in) (NP (NP (ADJP (RB almost) (JJ complete)) (NN loss)) (PP (IN of) (NP (NN bar-press) (NN response))) (PP (IN in) (NP (DT the) (JJ E-strain) (NNS subjects)))))) (CONJP (CC but) (RB also)) (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (JJ temporary) (NN decrease)) (PP (IN in) (NP (NP (DT the) (VBN acquired) (JJ behavioral) (NN response)) (PP (IN of) (NP (DT the) (JJ stable) (NN A-strain) (NNS subjects)))))))))))))) (. .)))
(S1 (S (S (NP (JJ Therapeutic) (NN drug) (NN monitoring)) (VP (MD can) (VP (VB avoid) (NP (NP (JJ iatrogenic) (NNS alterations)) (VP (VBN caused) (PP (IN by) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN MDP)) (-RRB- -RRB-))) (CC -) (NP (NN drug2) (NN interaction))))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT an) (NN drug2)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (DT a) (JJ wide) (NN variety)) (PP (IN of) (NP (NP (NNS infections)) (VP (VBN caused) (PP (IN by) (NP (JJ gram-negative) (NNS organisms)))))))))))))) (, ,) (CC but) (S (NP (PRP it)) (VP (VBZ is) (ADJP (RB potentially) (JJ toxic) (PP (TO to) (NP (DT the) (NNS kidneys))))))) (. .)))
(S1 (S (S (PP (IN Due) (PP (TO to) (NP (PRP$ its) (NN nephrotoxicity)))) (, ,) (NP (NN drug1)) (VP (MD may) (VP (VB cause) (NP (JJ abnormal) (JJ renal) (NN uptake))) (S (VP (TO to) (VP (VB be) (VP (VBN seen) (PP (IN on) (NP (NN drug2) (NN bone) (NN scintigraphy))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (NP (DT the) (NN drug1)) (PP (IN in) (NP (DT the) (NNS kidneys)))))) (, ,) (PP (IN along) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ renal) (NN retention)))))) (, ,) (VP (VBP tend) (S (VP (TO to) (VP (VB produce) (NP (NP (JJ scintigraphic) (NNS results)) (SBAR (WHNP (WDT that)) (S (ADVP (RB falsely)) (VP (VBP identify) (NP (NP (NNS characteristics)) (ADJP (JJ related) (PP (TO to) (NP (NP (NP (NNS diseases)) (PP (JJ such) (IN as) (NP (JJ renal) (JJ vascular)))) (, ,) (CC or) (NP (JJ urinary) (NN tract) (NN obstruction)) (, ,) (CC and) (NP (JJ even) (JJ renal) (NN cancer))))))))))))))) (. .)))
(S1 (S (S (NP (DT An) (JJ altered) (NN biodistribution)) (VP (MD may) (VP (VB provide) (NP (NP (JJ misleading) (NN information)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (CC either) (VP (VB mask)) (CC or) (VP (VB mimic) (NP (JJ certain) (NN disease) (NNS symptoms))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN method)) (VP (TO to) (VP (VB maximize) (NP (NP (DT the) (JJ therapeutic) (NN benefit)) (PP (IN of) (NP (NN drug1)))) (SBAR (IN while) (S (VP (VBG minimizing) (NP (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN nephrotoxicity)))) (CC and) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (DT a) (JJ hot) (NN kidney))) (PP (IN on) (NP (NN scintigraphy))))))))))) (VP (VBZ is) (ADJP (JJ desirable)))) (. .)))
(S1 (S (S (NP (JJ Serial) (JJ pharmacokinetic) (NN dosing)) (VP (VBZ has) (VP (VBN been) (VP (VBN proposed) (PP (IN as) (NP (NP (DT a) (NN method)) (S (VP (TO to) (VP (VB accomplish) (NP (DT this) (NN goal))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (JJ Therapeutic) (NN drug) (NN monitoring)) (PRN (-LRB- -LRB-) (NP (NN TDM)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug1) (NN therapy)))) (, ,) (CC and) (NP (NP (NN bone) (NN scintigraphy)) (VP (VBG employing) (NP (NN drug2)) (PP (IN as) (NP (DT the) (NN drug3)))))) (VP (VBD was) (VP (VBN carried) (PRT (RP out)) (PP (IN in) (NP (CD 22) (NNS patients)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS data)) (VP (VBN presented) (ADVP (RB here)))) (VP (VBP demonstrate) (SBAR (IN that) (S (PP (IN with) (NP (NP (JJ serial) (JJ pharmacokinetic) (NN dosing)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NP (DT the) (JJ iatrogenic) (NN alteration)) (VP (VBN caused) (PP (IN by) (NP (NN drug2) (NN therapy))))) (VP (MD can) (VP (VB be) (VP (VBN avoided)))))))) (. .)))
(S1 (S (NP (NP (NN Interaction)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (JJ anaesthetised) (NNS horses))) (. .))))
(S1 (S (S (NP (NP (NP (VBN Evoked) (NN hind) (NN limb)) (NP (JJ digital) (NN extensor) (NN tension))) (PRN (-LRB- -LRB-) (NP (NN hoof) (NN twitch)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN maintained) (PP (IN at) (NP (NP (CD 40) (NN %)) (PP (IN of) (NP (NN baseline))))) (PP (IN for) (NP (CD 1) (NN h))) (PP (IN by) (NP (NP (NN drug1) (NN infusion)) (PP (IN in) (NP (NP (CD 7) (NNS horses) (JJ anaesthetised)) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (S (PP (IN After) (NP (CD 1) (NN h))) (, ,) (NP (NN drug1)) (VP (VBD was) (VP (VBN discontinued)))) (CC and) (S (NP (NN hoof) (NN twitch)) (VP (VBD allowed) (S (VP (TO to) (VP (VB recover) (PP (TO to) (NP (CD 75) (NN %))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (ADVP (RB again)) (VP (VBN given) (PP (IN by) (NP (NN infusion)))))) (S (S (VP (TO to) (VP (VB maintain) (NP (NP (ADJP (CD 40) (NN %)) (NN twitch)) (PP (IN for) (NP (DT a) (JJ second) (NN hour))))))) (, ,) (NP (ADJP (QP (RB then) (CD 2)) (NN mg)) (NN drug2) (NN /kg) (NN bwt)) (VP (VBD were) (VP (VBN given) (NP (NN i.v.)))))))
(S1 (S (S (S (NP (NN drug1) (NN infusion)) (VP (VBD was) (VP (VBN continued) (PP (IN for) (NP (DT a) (JJ third) (NN hour)))))) (, ,) (CC and) (S (NP (RB then) (NN hoof) (NN twitch)) (VP (VBD was) (ADVP (RB again)) (VP (VBN allowed) (S (VP (TO to) (VP (VB recover) (ADVP (RB spontaneously)) (PP (TO to) (NP (CD 75) (NN %)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD reduced) (NP (NN twitch) (NN strength)) (PP (IN from) (NP (NP (QP (CD 40) (CC +/-) (CD 1)) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (CC +/-) (NP (NN sem))) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (QP (CD 29) (CC +/-) (CD 4)) (NN %)) (PP (IN within) (NP (NP (QP (CD 7.0) (CC +/-) (CD 1.5)) (NN min)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (CD 0.02)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NN Twitch)) (ADVP (RB gradually)) (VP (VBD returned) (PP (TO to) (NP (JJ pre-) (NN drug1) (NN strength))) (PP (IN over) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (DT the) (JJ next) (NN hour))))))) (. .)))
(S1 (S (S (NP (NP (NN Recovery)) (PP (IN of) (NP (NN hoof) (NN twitch))) (PP (IN from) (NP (QP (CD 50) (NN %) (TO to) (CD 75)) (NN %)))) (VP (VBD took) (NP (NP (NP (QP (CD 7.7) (CC +/-) (CD 0.7)) (NN min)) (PP (IN for) (NP (NP (NN drug1)) (ADVP (RB alone))))) (CC and) (NP (NP (QP (CD 11.5) (CC +/-) (CD 2.7)) (NN min)) (PP (IN for) (NP (NP (NN drug2)) (CC plus) (NP (NN drug3)))))) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (CD 0.03)) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (NN Recovery)) (PP (IN from) (NP (NP (ADJP (CD 50) (NN %)) (NN twitch) (TO to) (CD 75) (NN %)) (VP (VB fade) (NP (NN recovery)))))) (VP (VBD took) (NP (NP (NP (QP (CD 13.8) (CC +/-) (CD 0.8)) (NN min)) (PP (IN for) (NP (NP (NN drug1)) (ADVP (RB alone))))) (CC and) (NP (NP (QP (CD 13.7) (CC +/-) (CD 1.2)) (NN min)) (PP (IN for) (NP (NP (NN drug2)) (CC plus) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (PP (IN At) (NP (NP (ADJP (CD 75) (NN %)) (NN recovery)) (PP (IN of) (NP (VB fade))))) (, ,) (NP (NN hoof) (NN twitch)) (VP (VBD was) (NP (NP (NP (QP (CD 87) (CC +/-) (CD 3)) (NN %)) (PP (IN for) (NP (NP (NN drug1)) (ADVP (RB alone))))) (CC and) (NP (NP (QP (CD 82) (CC +/-) (CD 4)) (NN %)) (PP (IN for) (NP (NP (NN drug2)) (CC plus) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Reversal)) (PP (IN of) (NP (NP (DT the) (NN block)) (PP (IN with) (NP (NN drug1)))))) (CC and) (NP (NP (JJ subsequent) (NN recovery)) (PP (IN of) (NP (NP (DT the) (NNS horses)) (PP (IN from) (NP (NN anaesthesia))))))) (VP (VBD were) (VP (VBN uneventful)))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBD was) (VP (VBN concluded) (SBAR (IN that) (S (, ,) (SBAR (IN although) (S (NP (NN drug1)) (VP (VBD did) (VP (VB augment) (NP (NP (DT the) (JJ neuromuscular) (NN blockade)) (PP (IN of) (NP (NN drug2)))))))) (, ,) (NP (DT the) (NN effect)) (VP (VBD was) (ADJP (JJ minimal)))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (JJ Diagnostic))) (, ,) (NP (NN treatment)) (CC and) (NP (NN aftercare))) (VP (NNS approaches) (PP (TO to) (NP (NN drug1) (NN abuse))))) (. .)))
(S1 (S (S (NP (DT The) (JJ general) (NN public)) (VP (VBZ feels) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (ADJP (RB particularly) (JJ dangerous)) (SBAR (IN because) (S (NP (PRP it)) (VP (VBZ does) (RB not) (VP (VB produce) (NP (NP (DT a) (ADJP (RB well) (VBN defined)) (JJ physical) (NN dependency)) (CC and) (NP (NN abstinence) (NN syndrome)))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN addiction)) (VP (VBZ is) (VP (VBN defined) (PP (IN as) (NP (NP (NN compulsion)) (, ,) (NP (NP (NN loss)) (PP (IN of) (NP (NN control)))) (CC and) (NP (NP (JJ continued) (NN use)) (PP (IN in) (NP (NP (NN spite)) (PP (IN of) (NP (JJ adverse) (NNS consequences)))))))))))) (, ,) (NP (NN drug1) (NN drug) (NN hunger)) (VP (MD can) (VP (VB be) (VP (VBN seen) (PP (IN as) (NP (NP (DT an) (NN agent)) (PP (IN of) (NP (JJ addictive) (NN disease))))))))) (. .)))
(S1 (S (S (NP (NP (NN Withdrawal)) (PP (IN from) (NP (NN drug1) (NN dependence)))) (ADVP (RB usually)) (VP (VBZ involves) (NP (NP (NN depression)) (, ,) (NP (NN anxiety)) (CC and) (NP (NN lethargy))))) (. .)))
(S1 (S (NP (DT These)) (ADVP (RB usually)) (VP (VB clear) (PP (IN within) (NP (DT a) (NN week))) (, ,) (S (VP (VBG leaving) (NP (RB only) (DT the) (NN &quot) (: ;) (NN drug) (NN hunger&quot))))) (: ;)))
(S1 (S (S (VP (TO to) (VP (VB contend) (PP (IN with))))) (. .)))
(S1 (S (S (NP (NN Medication)) (VP (VBZ is) (ADVP (RB rarely)) (VP (VBN needed)))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (NP (DT the) (JJ primary) (NN addiction))))) (, ,) (PP (IN after) (NP (NN withdrawal))) (NP (DT the) (ADJP (RBS most) (JJ effective)) (NN treatment)) (VP (VBZ is) (NP (NP (NN group) (NN therapy)) (PP (IN with) (NP (JJ other) (JJ recovering) (NN cocaine) (NNS abusers)))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VP (VBP incorporate) (NP (NP (DT the) (NNS principles)) (PP (IN of) (NP (NN recovery))))) (CC and) (VP (VBP define) (NP (NP (ADJP (ADJP (JJ positive)) (CC and) (ADJP (JJ constructive))) (NNS alternatives)) (PP (IN in) (S (VP (VBG dealing) (PP (IN with) (NP (NN cocaine) (NN hunger)))))))))) (. .)))
(S1 (S (S (NP (NN Recovery) (NNS programs)) (VP (VP (MD should) (VP (VB be) (ADJP (JJ flexible)))) (CC and) (VP (VB involve) (NP (NP (NN individual)) (CC and) (NP (NN family) (NN education))) (PP (IN on) (NP (NP (NN recovery)) (CC and) (NP (NP (DT the) (NN nature)) (PP (IN of) (NP (JJ addictive) (NN disease))))))))) (. .)))
(S1 (S (S (NP (NP (NN Exercise)) (SBAR (WHNP (WDT that)) (S (VP (VBZ produces) (NP (JJ cardiopulmonary) (NN stimulation)))))) (VP (VBZ is) (NP (NP (DT a) (JJ helpful) (NN means)) (PP (IN of) (S (VP (VBG reducing) (NP (NP (NN drug) (NN hunger)) (CC and) (NP (NN anxiety))) (PP (IN during) (NP (NN recovery) (NN therapy))))))))) (. .)))
(S1 (S (NP (NP (JJ Systemic) (NN drug1)) (. .))))
(S1 (S (S (VP (VBG Understanding) (NP (NP (DT the) (NN breadth)) (PP (IN of) (NP (NP (JJ systemic) (NN drug1)) (ADJP (JJ available) (PP (IN for) (NP (NP (NP (NN use)) (PP (IN by) (NP (DT the) (NN dermatologist)))) (CC and) (NP (NP (PRP$ their) (JJ associated) (NN side-effect) (NNS profiles)) (CC and) (NP (NN drug) (NNS interactions))))))))))) (VP (VBZ allows) (NP (DT the) (NN clinician) (S (VP (TO to) (VP (VB offer) (NP (NP (NNS patients)) (JJ optimal) (NN care)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ cutaneous) (JJ infectious) (NN disease)))))))))) (. .)))
(S1 (S (S (VP (VBN Altered) (NP (NP (NN responsiveness)) (PP (TO to) (NP (NN drug1)))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (JJ organic) (NN lead))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN known) (S (S (VP (TO to) (VP (VB effect) (NP (NP (DT the) (JJ functional) (NN integrity)) (PP (IN of) (NP (DT the) (JJ limbic) (NN system)))) (, ,) (PP (RB particularly) (NP (DT the) (NN hippocampus)))))) (, ,) (CC and) (S (VP (TO to) (VP (VB alter) (NP (NP (NNS behaviors)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN thought) (S (VP (TO to) (VP (VB be) (VP (VBN mediated) (PP (IN through) (NP (JJ limbic) (NN function))))))))))))))))))) (. .)))
(S1 (S (S (NP (NNS Organometals)) (ADVP (RB also)) (VP (VP (VB compromise) (NP (DT the) (JJ limbic) (NN system))) (CC and) (VP (VB result) (PP (IN in) (NP (NP (NNS deficits)) (PP (IN in) (NP (NP (NN learning)) (CC and) (NP (NN memory))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN organoleads))) (VP (VP (VBP are) (ADJP (JJ present) (PP (IN in) (NP (DT the) (NN environment))))) (CC and) (VP (VBP seem) (S (VP (TO to) (VP (VB influence) (NP (JJ limbic) (NN integration))))))))) (, ,) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (DT these) (CD two) (NNS compounds)))) (VP (VBD was) (VP (VBN assessed) (PP (IN in) (NP (DT the) (JJ present) (NN experiment)))))) (. .)))
(S1 (S (S (NP (NP (CD Thirty) (JJ male) (NNS rats)) (PP (IN of) (NP (DT the) (NN Fischer-344) (NN strain)))) (VP (VP (VBD were) (VP (VBN divided) (PP (IN into) (NP (CD three) (JJ equal) (NNS groups))))) (CC and) (VP (VBD were) (VP (VBN given) (NP (NP (NNS injections)) (PP (IN of) (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (QP (CD 8.0) (CC or) (CD 17.0)) (NN mg/kg/ml) (NN SC)) (-RRB- -RRB-))) (CC or) (NP (DT the) (NN saline) (NN vehicle))))))))) (. .)))
(S1 (S (S (ADVP (NP (CD Fourteen) (NNS days)) (RB later)) (, ,) (NP (DT all) (NNS animals)) (VP (VBD were) (VP (VBN challenged) (PP (IN with) (NP (NP (NP (DT a) (JJ single) (JJ hypnotic) (NN dose)) (PP (IN of) (NP (NN drug1)))) (PRN (-LRB- -LRB-) (NP (CD 3.5) (NN g/kg) (NN IP)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (ADJP (CD 20) (NN %)) (NN v/v) (NN solution)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN prepared) (PP (IN in) (NP (NN water))) (PP (IN from) (NP (NP (DT a) (NN stock) (NN solution)) (PP (IN of) (NP (ADJP (CD 95) (NN %)) (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN latency)) (PP (TO to) (NP (NP (NP (NN loss)) (PP (IN of) (NP (DT the) (JJ righting) (NN reflex)))) (CC and) (NP (NP (NN duration)) (PP (IN of) (NP (JJ sleep) (NN time))))))) (VP (VBD were) (VP (VBN recorded) (SBAR (IN while) (S (NP (DT the) (NNS rats)) (VP (VBD were) (VP (VBN kept) (PP (IN in) (NP (JJ sound-attenuating) (NNS chambers)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (JJS highest) (NN dose)) (PP (IN of) (NP (NN drug1))))))) (VP (VBN manifested) (NP (ADJP (RB significantly) (JJR longer)) (NNS latencies)) (S (VP (TO to) (VP (VB lose) (NP (NP (DT the) (NN righting) (NN reflex)) (CC and) (NP (NP (JJR shorter) (NNS durations)) (PP (IN of) (NP (NN sleep))))) (SBAR (IN than) (SINV (VBD did) (NP (NNS controls))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN exposure)) (PP (TO to) (NP (JJ environmental) (NN drug1)))) (VP (MD may) (VP (VBP alter) (NP (NP (DT the) (ADJP (ADJP (JJ biological)) (CC and) (ADJP (JJ behavioral))) (NN responsiveness)) (PP (IN of) (NP (DT an) (NN animal))) (PP (TO to) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (NN Evidence)) (PP (IN for) (NP (NP (NN reduction)) (PP (IN of) (NP (NN drug1) (NN uptake) (NNS sites))) (PP (IN in) (NP (DT the) (JJ failing) (JJ human) (NN heart))))) (. .))))
(S1 (S (NP (NP (NNS OBJECTIVES)) (. .))))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBD investigated) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (JJ neuronal) (NN uptake)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN uptake-1)) (-RRB- -RRB-)))))) (PP (IN in) (NP (JJ human) (NN heart) (NN failure)))) (PP (IN as) (NP (NP (DT a) (JJ local) (NN factor)) (PP (IN for) (S (VP (VBG altering) (NP (NP (NNS concentrations)) (PP (IN of) (NP (NN norepinephrine)))) (PP (IN at) (NP (DT the) (JJ cardiac) (NN myocyte) (NNS membranes)))))))))) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (. .))))
(S1 (S (S (NP (JJ Several) (JJ beta-adrenergic) (NN neuroeffector) (NNS defects)) (VP (VBP occur) (PP (IN in) (NP (NN heart) (NN failure))))) (. .)))
(S1 (S (S (IN Whether) (S (NP (NP (DT an) (NN alteration)) (PP (IN in) (NP (NN drug1) (NN uptake-1)))) (VP (VBZ occurs) (VP (VBZ is) (ADJP (RB still) (JJ unresolved)))))) (. .)))
(S1 (S (NP (NP (NNS METHODS)) (. .))))
(S1 (S (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NN drug1) (NN uptake-1)))) (VP (VBD was) (VP (VBN studied) (PP (IN in) (NP (NP (ADJP (ADJP (RB electrically) (VBN stimulated)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN Hz)) (, ,) (NP (CD 37) (NNS degrees) (NN C)) (-RRB- -RRB-))) (JJ human) (JJ ventricular) (JJ cardiac) (NNS preparations)) (CC and) (NP (VBN isolated) (JJ myocardial) (NNS membranes))))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (. .))))
(S1 (S (S (NP (NP (DT The) (NN effectiveness)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (S (VP (VBG increasing) (NP (NP (DT the) (NN force)) (PP (IN of) (NP (NN contraction)))))))) (VP (VBD was) (VP (VBN decreased) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN heart) (NN failure)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN potency)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN increased) (PP (IN in) (NP (JJ failing) (NNS hearts))) (PRN (-LRB- -LRB-) (NP (JJ New) (NN York) (NN Heart) (NN Association) (JJ functional) (NN class) (CD IV)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (DT the) (NNS concentrations)) (VP (VBG producing) (NP (NP (CD 50) (NN %)) (PP (IN of) (NP (NP (DT the) (JJ maximal) (NN effect)) (PRN (-LRB- -LRB-) (NP (NN EC50)) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN EC50) (NNS values)) (PP (IN for) (NP (NN drug1))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (RB not) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NN drug2) (NN uptake-1))))))) (, ,)) (VP (VBD were) (VP (VBN reduced) (PP (IN in) (NP (NP (NN myocardium)) (PP (IN in) (NP (JJ functional) (NNS classes) (NP (NP (CD II)) (TO to) (NP (CD III) (CC and) (CD IV))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN in) (NP (JJ nonfailing) (NN myocardium))))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (NN uptake) (NNS inhibitors)) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PRN (-LRB- -LRB-) (NP (CD 3) (NN mumol/liter)) (-RRB- -RRB-))) (VP (VBD potentiated) (NP (NP (DT the) (JJ positive) (JJ inotropic) (NNS effects)) (PP (IN of) (NP (NN drug3))) (PP (PP (PP (IN in) (NP (JJ nonfailing) (NN myocardium))) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (CD &lt) (: ;) (CD 0.05)) (-RRB- -RRB-))) (CC but) (PP (RB not) (IN in) (NP (NP (JJ functional) (NN class) (CD IV)) (NN myocardium))))))) (. .)))
(S1 (S (S (NP (NP (NN Radioligand) (NN binding) (NNS experiments)) (VP (VBG using) (NP (DT the) (NN uptake) (NN inhibitor) (NN hydrogen-3) (NN drug1)))) (VP (VBD revealed) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN by) (NP (QP (RB approximately) (CD 30)) (NN %))) (PP (IN in) (NP (NN drug2) (NN uptake-1) (NN carrier) (NN density))) (PP (IN in) (NP (NP (JJ functional) (NNS classes)) (UCP (ADJP (QP (CD II) (TO to) (CD III) (CC and) (CD IV)) (NN myocardium)) (CC versus) (NP (NP (JJ nonfailing) (NN myocardium)) (PRN (-LRB- -LRB-) (NP (NN p) (NN &lt) (: ;) (CD 0.05)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (. .))))
(S1 (S (S (PP (IN In) (NP (JJ human) (NN heart) (NN failure))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ presynaptic) (NN defect)) (PP (IN in) (NP (DT the) (JJ sympathetic) (JJ nervous) (NN system))) (, ,) (VP (VBG leading) (PP (TO to) (NP (VBN reduced) (NN uptake-1) (NN activity))))))) (. .)))
(S1 (S (S (NP (NP (DT This) (NN defect)) (PP (IN in) (NP (DT the) (JJ failing) (NN heart)))) (VP (MD can) (VP (VB be) (VP (VBN mimicked) (PP (IN by) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN uptake) (NN blocking) (NNS agents)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (, ,))) (PP (IN in) (NP (NP (DT the) (JJ nonfailing) (NN heart)) (ADVP (RB only)))))))))) (. .)))
(S1 (S (S (NP (NP (VBN Compromised) (NN drug1) (NN uptake-1)) (PP (IN in) (NP (JJ functional) (NN class) (NN IV)))) (VP (MD cannot) (VP (VB be) (ADVP (RB further)) (VP (VBN increased) (PP (IN by) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ pathophysiologic) (NNS consequences)) (VP (MD could) (VP (VB be) (NP (NP (DT an) (VBN increased) (JJ synaptic) (NN concentration)) (PP (IN of) (NP (NN drug1))) (VP (VBG predisposing) (PP (TO to) (NP (NP (JJ adenylyl) (NN cyclase)) (NN desensitization)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NN drug1) (JJ -induced) (NN vasorelaxation)))) (VP (VBZ differs) (PP (IN in) (NP (NP (DT the) (JJ mesenteric) (NN resistance) (NNS arteries)) (PP (IN of) (NP (ADJP (ADJP (JJ lean)) (CC and) (ADJP (JJ obese))) (NNS rats))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB induce) (NP (NN vasorelaxation))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN mechanism) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (PP (IN of) (NP (NP (JJ drug1) (JJ -induced) (NN vasorelaxation)) (PP (IN in) (NP (NP (NN resistance) (JJ mesenteric) (NNS arteries)) (PP (IN from) (NP (JJ male) (ADJP (ADJP (JJ lean)) (CC and) (ADJP (JJ dietary-induced))) (JJ obese) (NNS rats)))))))))) (. .)))
(S1 (S (S (PP (VBN Compared) (PP (IN with) (NP (JJ lean) (NNS rats)))) (, ,) (NP (NP (NNS arteries)) (PP (IN from) (NP (JJ dietary-obese) (NNS rats)))) (VP (VBD showed) (NP (ADJP (ADJP (JJ significant)) (PRN (-LRB- -LRB-) (NP (NP (NN P&lt)) (: ;) (NP (CD 0.001))) (-RRB- -RRB-))) (JJ endothelial) (NN dysfunction)) (, ,) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (NP (NP (DT a) (NN decrease)) (PRN (-LRB- -LRB-) (NP (CD >20) (NN %)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ maximal) (JJ acetylcholine-induced) (NN vasorelaxation)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 5-35) (NN micromol/l)) (-RRB- -RRB-))) (VP (VBD induced) (NP (NP (JJ concentration-dependent) (NN relaxation)) (PP (IN of) (NP (NP (JJ mesenteric) (NNS arteries)) (VP (VBN preconstricted) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 8) (NN micromol/l)) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 125) (NN mmol/l)) (-RRB- -RRB-))))))))) (PP (IN from) (NP (ADJP (CC both) (ADJP (JJ lean)) (CC and) (ADJP (JJ dietary-obese))) (NNS rats))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))) (, ,) (S (VP (VBG achieving) (NP (NP (DT a) (JJ maximum) (NN relaxation)) (PP (IN of) (NP (CD >95) (NN %)))) (PP (IN at) (NP (NP (DT a) (NN concentration)) (PP (IN of) (NP (CD 35) (NN micromol/l))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (QP (CD 100) (CC and) (CD 300)) (NN micromol/l)) (-RRB- -RRB-))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NP (NNS arteries)) (PP (IN from) (NP (JJ dietary-obese) (NNS rats)))))) (, ,) (S (VP (VBG giving) (NP (JJ superimposed) (JJ concentration-responses) (NNS curves))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (ADVP (RB also)) (ADJP (JJ ineffective)) (PP (IN in) (S (VP (VBG altering) (NP (NP (NN drug2) (NN activity)) (PP (IN in) (NP (NP (NNS arteries)) (PP (IN from) (NP (ADJP (CC both) (ADJP (JJ lean)) (CC and) (ADJP (JJ dietary-obese))) (NNS rats))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ drug1) (JJ -precontracted) (NNS arteries)) (PP (IN from) (NP (JJ dietary-obese) (NNS rats))))) (, ,) (NP (NP (NNS responses)) (PP (TO to) (NP (NN drug2)))) (VP (VBD were) (RB not) (VP (VBN attenuated) (PP (IN by) (NP (JJ endothelial) (NN denudation))) (, ,) (S (VP (VBG indicating) (NP (NP (DT an) (NN action)) (ADJP (JJ independent) (PP (IN of) (NP (DT the) (NN endothelium)))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (S (NP (NP (: :) (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-)) (NP (DT the) (JJ maximal) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (PP (IN on) (NP (NN resistance) (NNS arteries))) (PP (IN from) (NP (ADJP (ADJP (JJ lean)) (CC and) (ADJP (JJ dietary-obese))) (NNS rats)))) (VP (VBP are) (RB not) (VP (VBN effected) (PP (IN by) (NP (JJ endothelial) (NN dysfunction)))))) (, ,) (CC and) (S (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-)) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (PP (PP (IN in) (NP (NP (JJ lean) (NNS animals)) (-LRB- -LRB-) (SBAR (WHADVP (WRB where)) (S (NP (JJ endothelial) (NN function)) (VP (VBZ is) (ADJP (RB not) (JJ impaired))))) (-RRB- -RRB-))) (, ,) (CONJP (CC but) (RB not)) (PP (IN in) (NP (JJ dietary-obese) (NNS rats))) (, ,))))) (VP (VBP are) (VP (VBN mediated) (PP (IN via) (NP (NN NO)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (NP (DT an) (NN IgA-binding) (NN lectin))) (. .)))
(S1 (S (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (IN that) (S (NP (NP (NNS seeds)) (PP (IN of) (NP (NP (FW Artocarpus) (FW integrifolia)) (PRN (-LRB- -LRB-) (NP (NN jackfruit)) (-RRB- -RRB-))))) (VP (VBP contain) (NP (NP (DT a) (NN lectin)) (, ,) (SBAR (WHNP (WDT which)) (S (NP (PRP we)) (VP (VBP call) (NP (NP (NN drug1)) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (NP (NP (CC both) (NP (DT a) (JJ potent) (NN T) (NN cell) (NN mitogen)) (CC and) (NP (NP (DT an) (ADJP (RB apparently) (NN T) (JJ cell-independent)) (NN activator)) (PP (IN of) (NP (JJ human) (NN B) (NNS cells))))) (PP (IN for) (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NNS immunoglobulins))))))))))))))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (DT the) (JJ above) (NNS experiments))) (NP (PRP we)) (VP (VBN noted) (NP (NP (DT a) (JJ massive) (NN precipitation)) (PP (IN in) (NP (NP (NN cell) (NNS cultures)) (VP (VBN stimulated) (PP (IN with) (NP (NP (QP (JJR greater) (IN than) (CC or) (JJ equal) (TO to) (CD 100)) (NNS micrograms)) (PP (IN of) (NP (NN lectin))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN paper))) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (DT the) (NN precipitate)) (VP (VBZ is) (VP (VBN formed) (PP (IN after) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (DT the) (NN serum) (NN protein)) (VP (VBN added) (PP (TO to) (NP (DT the) (NN culture) (NN medium))))))))))))))) (. .)))
(S1 (S (S (ADVP (RBR More) (RB importantly)) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NN IgA)) (VP (VBZ is) (ADVP (RB probably)) (NP (NP (DT the) (JJ major) (NN serum) (NN constituent)) (VP (VBD precipitated) (PP (IN by) (NP (DT the) (NN lectin)))))))) (CC and) (SBAR (IN that) (S (NP (DT no) (NP (NP (NN IgG)) (CC or) (NP (NN IgM)))) (VP (MD can) (VP (VB be) (VP (VBN detected) (PP (IN in) (NP (DT the) (NNS precipitates))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS secretions)) (PP (JJ such) (IN as) (NP (NN colostrum))))) (, ,) (NP (NN IgA)) (VP (VBZ is) (NP (NP (DT the) (JJ only) (NN protein)) (VP (VBD precipitated) (PP (IN by) (NP (NN drug1))))))) (. .)))
(S1 (S (S (PP (IN On) (DT the) (NN basis) (IN of) (NP (DT this) (NN specificity))) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT a) (ADJP (ADJP (JJ simple)) (CC and) (ADJP (JJ reliable))) (NN affinity) (NN chromatography) (NN procedure)) (PP (IN for) (NP (NP (DT the) (NN purification)) (PP (IN of) (NP (DT both) (JJ human) (NN serum) (CC and) (NN colostrum) (NN IgA)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ is) (NP (DT a) (JJ D-Gal) (NN binding) (NN lectin))) (CC and) (VP (MD should) (VP (VB be) (NP (NP (DT a) (JJ useful) (NN tool)) (PP (IN for) (S (VP (VBG studying) (PP (IN of) (NP (NP (NN serum)) (CC and) (NP (JJ secretory) (NN IgA)))))))))))) (. .)))
(S1 (S (NP (NP (NN -LSB-2) (NN epidemics)) (PP (IN of) (NP (JJ arsenical) (NN encephalopathy))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN trypanosomiasis)) (, ,) (NP (NP (NP (NNP Uganda)) (PRN (, ,) (NP (CD 1992-1993)) (-RRB- -RSB-))) (PP (IN Since) (NP (CD 1988)))) (, ,) (NP (NP (DT the) (JJ french) (JJ non-governmental) (NN organisation) (NN M) (NN decins) (NN Sans)) (NP (NNP Fronti) (NNP res)))))))) (VP (VBZ is) (S (VP (VBG running) (NP (NP (DT a) (JJ control) (NN program)) (PP (IN of) (NP (JJ human) (JJ african) (NN trypanosomiasis)))) (PP (IN in) (NP (NP (DT the) (NN district)) (PP (IN of) (NP (NNP Moyo) (, ,) (NNP North-Uganda)))))))) (. .)))
(S1 (S (S (PP (IN Between) (NP (NP (CD 1988)) (CC and) (NP (CD 1993)))) (, ,) (NP (QP (JJR more) (IN than) (CD 7,000)) (NNS patients)) (VP (VBD were) (VP (VP (VBN diagnosed)) (CC and) (VP (VBN treated))))) (. .)))
(S1 (S (S (PP (IN Since) (NP (CD 1988))) (, ,) (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN noted) (SBAR (IN that) (S (NP (NP (NN incidence)) (PP (IN of) (NP (NN drug1) (NN reaction)))) (VP (VBD had) (VP (VBN increased) (ADVP (RB systematically)) (PP (IN between) (NP (NP (NNP June)) (CC and) (NP (NP (NN October)) (PP (IN of) (NP (DT each) (NN year)))))) (, ,) (S (VP (VBG indicating) (NP (JJ strong) (JJ seasonal) (NN variation)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (CD 1992)) (CC and) (NP (CD 1993)))) (, ,) (NP (NP (CD two) (NNS outbreaks)) (PP (IN of) (NP (NP (JJ arsenical) (JJ reactive) (NN encephalopathy)) (PRN (-LRB- -LRB-) (VP (VBP ARE)) (-RRB- -RRB-))))) (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (JJ sleeping) (NN sickness) (NN center)) (PP (IN of) (NP (NNP Adjumani))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN incidence)) (PP (IN of))) (VP (VBP ARE) (ADVP (RB suddenly)) (VP (VBD exceeded) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (VP (VBN treated) (PP (IN by) (NP (NN drug1))) (PP (IN during) (NP (NP (NNP August) (CD 1992)) (CC and) (NP (NNP September) (CD 1993))))))))))) (. .)))
(S1 (S (NP (NP (NP (DT The) (NN onset)) (PP (IN of) (NP (NP (CD 80) (NN %)) (PP (IN of) (NP (DT those) (NN &quot)))))) (: ;) (NP (NN epidemic&quot)) (: ;))))
(S1 (S (S (NP (NNS cases)) (, ,) (VP (VBD occurred) (PP (IN between) (NP (NP (DT the) (JJ 5th) (CC and) (NP (DT the) (JJ 11th) (NN day))) (PP (IN of) (NP (NN treatment))))))) (. .)))
(S1 (S (S (NP (CD Two) (JJ retrospective) (NNS studies)) (VP (VBD were) (VP (VBN conducted) (PP (PP (IN in) (NP (NP (CD 1992)) (PRN (-LRB- -LRB-) (NP (CD 75) (NNS cases)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NP (CD 1993)) (PRN (-LRB- -LRB-) (NP (CD 51) (NNS cases)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (PP (IN Among) (NP (NP (DT the) (NN risk) (NNS factors)) (VP (VBN studied)))) (, ,) (NP (CD two)) (VP (VBP appear) (S (VP (TO to) (VP (VB increase) (NP (DT the) (NN risk) (SBAR (IN of) (S (VP (VBP ARE) (: :) (NP (NP (DT the) (NN prescription)) (PP (IN of) (NP (NN drug1))) (S (VP (TO to) (VP (VB treat) (NP (NP (NN strongyloidiasis)) (PP (IN during) (NP (NP (DT the) (NN drug2) (NP (NN cure)) (CC and) (NP (DT the) (NN bad) (JJ general) (JJ clinical) (NN conditions))) (PP (IN of) (NP (NNS patients))))))))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ exogenous) (NNS co-factors)) (VP (MD could) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (VBP ARE)))))))))))) (. .)))
(S1 (S (S (NP (NNS Recommendations)) (VP (VBD were) (S (S (VP (TO to) (VP (VB avoid) (NP (NP (NN administration)) (PP (IN of) (NP (JJ diffusible) (NN drug1) (NN treatment)))) (PP (IN during) (NP (DT the) (NN cure)))))) (, ,) (CC and) (S (VP (TO to) (VP (VB improve) (NP (NP (DT the) (JJ general) (NNS conditions)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN before) (NP (NP (DT the) (NN cure)) (PP (IN of) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Behavioral) (NNS responses)) (PP (TO to) (NP (JJ repeated) (NN drug1) (NN exposure))) (PP (IN in) (NP (NNS mice)))) (ADVP (RB selectively)) (VP (VBN bred) (PP (IN for) (NP (NP (JJ differential) (NN sensitivity)) (PP (TO to) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NNS Mice)) (PP (IN from) (NP (NP (DT the) (JJ 20th) (NN generation)) (PP (IN of) (NP (NP (CD three) (NNS lines)) (VP (ADVP (RB divergently)) (VBN selected) (PP (IN for) (NP (NP (NN response)) (PP (TO to) (NP (NP (NP (ADJP (NN drug1) (JJ -induced)) (NN sedation) (NNS times) (NN -LSB-long-sedation) (NN time)) (PRN (-LRB- -LRB-) (NP (NN LST)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ short) (NN sedation) (NN time)) (PRN (-LRB- -LRB-) (NP (NN SST)) (-RRB- -RRB-))) (, ,) (CC and) (NP (ADJP (RB randomly) (VBN bred)) (NN control) (-LRB- -LRB-) (NNS RBC) (-RRB- -RRB-)) (-RRB- -RSB-))))))))))) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB study) (NP (JJ drug2) (JJ -induced) (JJ behavioral) (NN sensitization)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS lines)) (VP (VBD showed) (NP (NP (JJ variable) (NNS degrees)) (PP (IN of) (NP (JJ locomotor) (NNS activities)))) (PP (IN in) (NN response) (TO to) (NP (NN drug1))))) (. .)))
(S1 (S (S (PP (IN At) (NP (NP (NP (DT a) (JJ low) (NN drug1) (NN dose)) (CC and) (NP (JJ long) (NN withdrawal) (NN period))) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN mg/kg)) (, ,) (NP (NP (RB twice) (DT a) (NN day)) (PP (IN for) (NP (NP (CD 5) (NNS days)) (VP (VBN followed) (PP (IN by) (NP (DT a) (JJ 14-day) (NN withdrawal)))))))) (-RRB- -RRB-)))) (, ,) (NP (DT the) (JJ LST) (NNS mice)) (VP (VBD showed) (NP (NN tolerance) (NN development)))) (. .)))
(S1 (S (S (PP (IN In) (NN response) (TO to) (NP (NN drug1))) (, ,) (NP (NP (DT the) (JJ locomotor) (NNS activities)) (PP (IN of) (NP (DT the) (NN SST)))) (VP (VBD were) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN from) (NP (DT the) (NNS RBC) (NN group)))))) (. .)))
(S1 (S (PP (IN At) (NP (NP (DT a) (JJR higher) (NN dose)) (CC and) (NP (NP (DT a) (JJR shorter) (NN withdrawal) (NN period)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN mg/kg)) (, ,) (ADJP (JJ daily) (PP (IN for) (NP (NP (CD 7) (NNS days)) (VP (VBN followed) (PP (IN by) (NP (DT a) (JJ 3-day) (NN withdrawal)))))))) (-RRB- -RRB-))))) (, ,) (S (S (NP (DT the) (NN SST) (NNS mice)) (VP (VBD showed) (NP (NP (JJ behavioral) (NN sensitization)) (ADJP (JJ similar) (PP (TO to) (NP (DT the) (NNS RBC) (NNS mice))))))) (, ,) (CC but) (S (NP (DT the) (JJ LST) (NNS mice)) (VP (VBD did) (RB not) (VP (VB develop) (NP (NN sensitization)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ different) (NNS responses)) (PP (IN in) (NP (NP (NN locomotor) (NN activity)) (VP (VBN induced) (PP (IN by) (NP (NN drug1))))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ genetic) (NNS factors)) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG determining) (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (NN response))) (PP (TO to) (NP (DT this) (NN drug))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Dopamine)) (PRN (-LRB- -LRB-) (NP (NN DA)) (-RRB- -RRB-))) (NNS levels)) (VP (VBD did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN in) (NP (CC either) (NP (NP (NN striatum)) (PRN (-LRB- -LRB-) (NP (NN STR)) (-RRB- -RRB-))) (CC or) (NP (NP (NN nucleus) (NNS accumbens)) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-))))) (PP (IN for) (NP (DT the) (NN drug1) (JJ -treated) (NNS animals))) (PP (TO to) (NP (PRP$ their) (JJ corresponding) (JJ saline-treated) (NNS controls)))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (NN affinity)) (PRN (-LRB- -LRB-) (NP (NN Kd)) (-RRB- -RRB-))) (PP (IN of) (NP (NN D2))) (PP (IN in) (NP (DT the) (NN NAC)))) (VP (VBD decreased) (ADVP (RB significantly)) (, ,) (PP (IN without) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN density)) (PRN (-LRB- -LRB-) (NP (NN Bmax)) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NP (DT the) (NN drug1) (JJ -treated) (NN SST) (CC and) (NN RBC) (NNS mice))))) (. .)))
(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (DT the) (NN density)) (PP (IN of) (NP (NP (NP (NN D2) (NN binding) (NNS sites)) (PP (IN in) (NP (DT the) (NN SST)))) (CC and) (NP (DT the) (NNS RBC) (NNS mice)))) (PP (IN in) (NP (DT the) (NN STR)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (NP (JJ drug1) (JJ -treated) (NNS groups)) (PP (IN without) (NP (NP (NN change)) (PP (IN in) (NP (NN Kd))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ LST) (NNS mice)) (VP (VBD did) (RB not) (VP (VB show) (NP (NP (DT any) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NP (NN Kd)) (CC and) (NP (NN Bmax))) (PP (IN in) (NP (CC either) (NP (DT the) (NN STR)) (CC or) (NP (DT the) (NN NAC)))))))))) (. .)))
(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (S (NP (DT these) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (NP (DT the) (NN Kd)) (PP (IN of) (NP (NN D2))) (PP (IN in) (NP (DT the) (NN NAC)))) (CC and) (NP (NP (DT the) (NN Bmax)) (PP (IN of) (NP (NN D2))) (PP (IN in) (NP (DT the) (NN STR))))))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NNS differences)) (PP (IN in) (NP (NP (JJ locomotor) (NNS responses)) (PP (TO to) (NP (NN drug1) (NN exposure))) (PP (IN in) (NP (DT these) (NN mouse) (NNS lines))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (NP (DT the) (ADJP (RB CYP2C9) (VBN catalyzed)) (NN biotransformation)) (PP (IN of) (NP (NN drug2)))))) (. .)))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (NP (PRP$ Our) (NN objective)) (VP (VBD was) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (S (VP (TO to) (VP (VB confirm) (SBAR (IN that) (S (NP (NN drug3)) (VP (VBZ inhibits) (NP (NN CYP2C9)))))))))))))) (. .))))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (DT The) (NN study)) (VP (VBD was) (VP (VBN carried) (PRT (RP out)) (PP (IN as) (NP (NP (DT an) (ADJP (ADJP (JJ open)) (, ,) (ADJP (JJ randomized)) (, ,) (ADJP (JJ crossover))) (NN design)) (PP (IN with) (NP (CD 14) (JJ healthy) (NNS participants)))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN period) (NN A))) (, ,) (NP (DT all) (NNS volunteers)) (VP (VBD took) (NP (NP (CD 500) (NN mg)) (PP (IN of) (NP (NN drug1)))) (ADVP (RB orally)))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN period) (NN B))) (, ,) (NP (DT the) (NNS volunteers)) (VP (VBD were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (CD one)) (PP (IN of) (NP (CD two) (NNS groups)))))))) (. .)))
(S1 (S (S (NP (DT Each) (NN group)) (VP (VBD took) (NP (CC either) (NP (CD 150) (NN mg)) (CC or) (NP (NP (CD 75) (NN mg)) (PP (IN of) (NP (NN drug1)))) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (NP (CD 5) (NNS days)) (PRN (-LRB- -LRB-) (NP (NP (NN day) (CD -3)) (PP (TO to) (NP (NN day) (CD 2)))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS groups)) (ADVP (RB then)) (VP (VBD took) (NP (NP (CD 500) (NN mg)) (PP (IN of) (NP (NN drug1)))) (PP (IN as) (NP (NP (DT a) (JJ single) (NN dose)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 0)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT both) (NNS periods))) (, ,) (NP (NP (NN blood)) (CC and) (NP (NN urine))) (VP (VBD were) (VP (VBN sampled) (PP (IN at) (NP (JJ regular) (NNS intervals)))))) (. .)))
(S1 (S (S (S (NP (NN Plasma)) (VP (VBD was) (VP (VBN analyzed) (PP (IN for) (NP (NN drug1)))))) (, ,) (CC and) (S (NP (NN urine)) (VP (VBD was) (VP (VBN analyzed) (PP (IN for) (NP (NP (NN drug2)) (CC and) (NP (NP (PRP$ its) (CD two) (NNS metabolites)) (, ,) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))))) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NN HPLC))))))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (PP (IN During) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug1))))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN median)) (PP (IN of) (NP (NP (DT the) (JJ total) (NN clearance)) (PP (IN of) (NP (NN drug2)))))))) (, ,) (PP (IN from) (NP (NP (CD 845) (NN mL/h)) (PP (TO to) (NP (CD 688) (NN mL/h))))) (, ,) (PP (IN among) (NP (NP (DT the) (NNS volunteers)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (CD 75) (NN mg/d))))))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT a) (NN reduction)) (SBAR (WHNP (WDT that)) (S (VP (VBD reached) (NP (NN borderline) (JJ statistical) (NN significance)) (PP (IN in) (NP (NP (DT the) (NN group)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (CD 150) (NN mg/d)) (PP (IN of) (NP (NN drug1))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN clearance)) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBD was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN in) (NP (DT both) (NNS groups))) (PRN (-LRB- -LRB-) (PP (FW ie)) (, ,) (PP (PP (IN from) (NP (CD 901) (NN mL/h))) (PP (TO to) (NP (NP (CD 318) (NN mL/h)) (PP (IN in) (NP (NP (DT the) (NN group)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (CD 150) (NN mg)) (PP (IN of) (NP (NN drug3))) (PP (IN per) (NP (NN day))))))))))) (CC and) (PP (IN from) (NP (NP (CD 723) (NN mL/h)) (PP (TO to) (NP (NP (CD 457) (NN mL/h)) (PP (IN in) (NP (NP (DT the) (NN group)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (CD 75) (NN mg)) (PP (IN of) (NP (NN drug4))) (PP (IN per) (NP (NN day)))))))))))))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (S (ADVP (RB Thus)) (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (NN tendency)) (PP (IN toward) (NP (NP (DT a) (ADJP (RBR more) (JJ pronounced)) (NN inhibition)) (PP (IN of) (NP (DT the) (NN 4-hydroxylation)))))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (CD 150) (NN mg/d))) (PP (IN of) (NP (NN drug1))))) (PP (VBN compared) (PP (IN with) (NP (CD 75) (NN mg/d)))))) (, ,) (CC but) (S (NP (DT the) (NN difference)) (VP (VBD was) (RB not) (ADJP (RB statistically) (JJ significant))))) (. .)))
(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ moderate) (NN inhibitor)) (PP (IN of) (NP (NN CYP2C9)))) (ADVP (FW in) (FW vivo)))) (. .))))
(S1 (S (NP (NP (NN Influence)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NN platelet) (NN function)) (CC and) (NP (JJ arachidonic) (NN acid) (NN metabolism)))) (. .))))
(S1 (S (S (NP (JJ Available) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN platelet) (NN function)) (CC and) (NP (JJ arachidonic) (NN acid) (NN metabolism))) (VP (VBP are) (NP (NP (JJ important) (NNS factors)) (PP (IN in) (NP (NP (NP (NN hemostasis)) (CC and) (NP (NN regulation))) (PP (IN of) (NP (JJ vascular) (NN tone))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Plasma) (NN membrane)) (CC and) (NP (NP (JJ intracellular) (NN mobilization)) (PP (IN of) (NP (NN calcium) (NNS ions))))) (VP (VBP are) (ADVP (RB intimately)) (ADJP (JJ related) (PP (TO to) (NP (NP (NP (NN platelet) (NN activation)) (CC and) (NP (NN release))) (PP (IN of) (NP (NN platelet) (NNS contents)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Release)) (PP (IN of) (NP (JJ arachidonic) (NN acid))) (PP (IN from) (NP (NN membrane) (NNS phospholipids)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ subsequent) (NP (NN synthesis)) (CC and) (NP (NN release))) (PP (IN of) (NP (JJ vasoconstrictor) (NN thromboxane) (NN A2))))) (VP (VBP are) (ADVP (RB also)) (VP (VBN regulated) (PP (IN by) (NP (NP (NN movement)) (PP (IN of) (NP (NN calcium) (NNS ions)))))))) (. .)))
(S1 (S (S (NP (NP (NN Adenosine) (CD 3)) (POS ')) (: :) (NP (NP (JJ 5'-cyclic) (NN phosphate)) (PP (IN in) (NP (NN turn)))) (VP (VP (VBZ controls) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (JJ free) (NN calcium) (NNS ions)) (PP (IN in) (NP (NNS platelets))))))) (CC and) (VP (VBZ regulates) (NP (JJ calcium-dependent) (NNS reactions))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (CONJP (JJ such) (IN as)) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4))) (, ,)) (VP (VP (VBP inhibit) (NP (NN platelet) (NN activation)) (ADVP (FW in) (FW vitro))) (, ,) (CC and) (VP (VBP decrease) (NP (NN platelet) (NN adhesion)) (ADVP (RB intravascularly))))) (. .)))
(S1 (S (S (NP (DT These) (NNS agents)) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB decrease) (NP (NP (NN platelet) (NN nucleotide) (NN release)) (CC and) (NP (NN thromboxane) (NN A2) (NN generation)))))))))) (. .)))
(S1 (S (S (NP (DT Some) (JJ preliminary) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (ADVP (RB also)) (VP (VBP increase) (NP (NP (NN generation)) (PP (IN of) (NP (ADJP (ADJP (JJ vasodilator)) (CC and) (ADJP (NN platelet) (JJ antiaggregant))) (NN prostacyclin))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB contribute) (PP (TO to) (NP (NP (NN decrease)) (PP (IN in) (NP (NN platelet) (NN function))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT These) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NN platelet) (NN function)) (CC and) (NP (JJ arachidonic) (NN acid) (NN metabolism))))) (VP (MD could) (VP (VB contribute) (PP (IN in) (NP (NN part))) (PP (TO to) (NP (NP (PRP$ their) (NN efficacy)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ ischemic) (NN heart) (NN disease)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Pharmacology)) (CC and) (NP (NN pharmacotherapy))) (PP (IN of) (NP (JJ cardiovascular) (NNS drugs))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ renal) (NN disease))))))) (. .)))
(S1 (S (S (NP (JJ Cardiovascular) (NN disease)) (VP (VBZ is) (NP (NP (DT a) (JJ common) (NN comorbidity)) (CC and) (NP (NP (DT a) (JJ major) (NN cause)) (PP (IN of) (NP (NN mortality))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ renal) (NN disease))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NNS regimens)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ cardiovascular) (NN disease)))))) (VP (VP (VBP are) (ADVP (RB frequently)) (ADJP (JJ complex))) (CC and) (VP (MD can) (VP (VB be) (ADVP (RB significantly)) (VP (VBN affected) (PP (IN by) (NP (NP (NNS alterations)) (PP (IN in) (NP (JJ renal) (NN function)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ several) (NN cardiovascular) (NNS drugs)) (ADVP (RB directly)) (VP (VBP affect) (NP (NP (JJ renal) (NN function)) (CC and) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ renal) (NN disease))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN article)) (VP (VP (VBZ reviews) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (JJ renal) (NN disease))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (JJ cardiovascular) (NNS drugs))))))) (CC and) (VP (VBZ identifies) (NP (NP (ADJP (RB clinically) (JJ important)) (NNS interactions)) (PP (IN between) (NP (NP (DT these)) (CC and) (NP (NP (JJ other) (NNS drugs)) (VP (ADVP (RB commonly)) (VBN used) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ chronic) (JJ renal) (NN disease))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Several) (NNS classes)) (PP (IN of) (NP (JJ cardiovascular) (NNS drugs)))) (VP (VBP are) (ADVP (RB also)) (VP (VBN discussed) (PP (IN in) (NP (NP (NN relationship)) (PP (TO to) (NP (NP (PRP$ their) (JJ differential) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NP (NN management)) (CC and) (NP (NN progression))) (PP (IN of) (NP (JJ renal) (NN disease)))))))))))) (. .)))
(S1 (S (NP (NP (NN Influence)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN on) (NP (NP (DT the) (NN sensitivity)) (PP (IN of) (NP (NN rat) (JJ thoracic) (NN aorta))) (PP (TO to) (NP (NN drug3))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (PP (IN of) (NP (NP (ADJP (ADJP (JJ low)) (CC and) (ADJP (JJ high))) (NNS doses)) (PP (IN of) (NP (NN drug1))))) (, ,) (CC and) (PP (IN of) (NP (NN drug2)))) (PP (IN on) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NP (NN drug3)) (PP (IN in) (NP (NN rat) (JJ thoracic) (NNS aorta))))))))))))) (. .)))
(S1 (S (NP (NP (NP (CD Two) (NNS weeks)) (PP (IN after) (NP (JJ bilateral) (NN ovariectomy)))) (, ,) (NP (NP (JJ female) (NNS rats)) (VP (VBD received) (NP (DT a) (NN s.c.)))))))
(S1 (S (NP (NP (NN injection)) (PP (IN of) (NP (NP (NP (NN vehicle)) (PRN (-LRB- -LRB-) (NP (NP (NN corn) (NN oil)) (, ,) (NP (CD 0.1) (NN mL/day))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN microg/kg/day) (CC or) (CD 4) (NN mg/kg/day)) (-RRB- -RRB-))) (CC and/or) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg/kg/day)) (-RRB- -RRB-)))) (, ,))) (PP (IN for) (NP (CD eight) (NNS days))) (. .))))
(S1 (S (S (PP (IN On) (NP (DT the) (JJ ninth) (NN day))) (, ,) (S (NP (DT the) (NNS rats)) (VP (VBD were) (VP (VBN sacrificed)))) (CC and) (S (NP (NP (JJ aortic) (NNS rings)) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NN endothelium)))) (, ,)) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB generate) (NP (NP (JJ concentration-response) (NNS curves)) (PP (TO to) (NP (NN drug1))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Aortic) (NNS rings)) (PP (IN with) (NP (JJ intact) (NN endothelium))) (PP (IN from) (NP (DT the) (JJ high-dose) (PRN (-LRB- -LRB-) (NP (CD 4) (NN mg/kg/day)) (-RRB- -RRB-)) (NN drug1) (NN group)))) (VP (VBD were) (ADJP (JJ supersensitive) (PP (TO to) (NP (NN drug2)))) (PP (VBN compared) (PP (TO to) (NP (DT the) (NP (NP (NN vehicle)) (CC or) (NP (ADJP (ADJP (JJ low-dose)) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS microg/kg/day)) (-RRB- -RRB-))) (NN estradiol))) (NNS groups)))) (PRN (-LRB- -LRB-) (S (NP (NN pD2) (NNS values)) (VP (JJ =) (NP (CD 7.86+/-0.09) (, ,) (CD 7.30+/-0.11) (CC and) (CD 7.35+/-0.04)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-)))) (. .)))
(S1 (S (NP (NP (NN Endothelium-intact) (JJ aortic) (NNS rings)) (PP (IN from) (NP (JJ high-) (NN drug1) (NNS rats)))) (VP (VBD were) (ADJP (JJ supersensitive) (PP (TO to) (NP (NN drug2)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (ADJP (ADJP (JJ vehicle-)) (, ,) (ADJP (NP (NP (NN drug3)) (CC -) (NP (ADJP (CC and) (ADJP (JJ drug4)) (CC +) (ADJP (JJ high-))) (NN drug5))) (JJ -treated))) (NNS rats)) (PRN (-LRB- -LRB-) (S (NP (NN pD2) (NNS values)) (VP (JJ =) (NP (NP (CD 7.77+/-0.12)) (, ,) (NP (CD 7.21+/-0.13)) (, ,) (NP (CD 6.93+/-0.04)) (CC and) (NP (CD 7.22+/-0.18))) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN among) (NP (NP (DT the) (NN pD2) (NNS values)) (PP (IN for) (NP (NN drug1))) (PP (IN in) (NP (NP (JJ aortic) (NNS rings)) (PP (IN without) (NP (NN endothelium)))))))))) (. .)))
(S1 (S (S (NP (NP (DT Both)) (PP (IN of) (NP (DT these) (NNS effects)))) (VP (VBD were) (ADJP (JJ endothelium-dependent)))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NNS therapeutics))) (. .))))
(S1 (S (S (NP (NP (CD Two) (JJ different) (NNS types)) (PP (IN of) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug1)))))) (VP (VBP are) (VP (VBN used) (: :) (NP (NP (JJ physiological) (JJ oral) (NN drug2) (NN supplementation)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (RB totally) (JJ atoxic)) (SBAR (IN since) (S (NP (PRP it)) (VP (VBZ palliates) (NP (NN drug3) (NNS deficiencies)) (PP (IN by) (S (ADVP (RB simply)) (VP (VBG normalizing) (NP (NP (DT the) (NP (NN drug4) (NN intake)) (CC and) (NP (JJ pharmacological) (NN drug5) (NN therapy))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB induce) (NP (NN toxicity)) (SBAR (IN since) (S (NP (PRP it)) (VP (VBZ creates) (NP (JJ iatrogenic) (NN drug6) (NN overload))))))))))))))))))))))) (. .)))
(S1 (S (S (NP (ADJP (ADJP (JJ Primary)) (CC and) (ADJP (JJ secondary))) (NN drug1) (NNS deficiencies)) (VP (VBP constitute) (NP (NP (DT the) (JJ sole) (NN indication)) (PP (IN of) (NP (JJ physiological) (JJ oral) (NN drug2) (NN therapy)))))) (. .)))
(S1 (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB therefore)) (ADJP (JJ necessary) (S (VP (VP (TO to) (VP (VB be) (ADJP (RB well) (JJ acquainted) (PP (IN with) (NP (NP (DT the) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ paraclinical))) (NN pattern)) (PP (IN of) (NP (NN drug1) (NN deficit)))))))) (CC and) (VP (TO to) (VP (VB discriminate) (PP (IN between) (NP (NP (NN drug2) (NN deficiency)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT an) (JJ insufficient) (NN drug3) (NN intake)) (SBAR (WHNP (WDT which)) (S (ADVP (RB only)) (VP (VBZ requires) (NP (NP (NP (JJ oral) (JJ physiological) (NN supplementation)) (CC and) (NP (NN drug4) (NN depletion))) (ADJP (JJ related) (PP (TO to) (NP (NP (DT a) (NN dysregulation)) (PP (IN of) (NP (NP (DT the) (JJ control) (NNS mechanisms)) (PP (IN of) (NP (NN drug5) (NN status))))) (SBAR (WHNP (WDT which)) (S (VP (VBZ requires) (NP (NP (ADJP (ADJP (JJR more)) (CC or) (ADJP (RBR less) (JJ specific))) (NN regulation)) (PP (IN of) (NP (PRP$ its) (JJ causal) (NN dysregulation))))))))))))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Physiological) (JJ oral) (NN drug1) (NN load)) (VP (VBZ constitutes) (NP (NP (NP (DT the) (JJS best) (NN tool)) (PP (IN for) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NN drug2) (NN deficiency)))))) (CC and) (NP (NP (DT the) (JJ first) (NN step)) (PP (IN of) (NP (PRP$ its) (NN treatment))))))) (. .)))
(S1 (S (S (NP (NP (JJ Physiological) (JJ oral) (NN drug1) (NN supplementation)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg/day)) (-RRB- -RRB-))) (VP (VP (VBZ is) (ADJP (JJ easy))) (CC and) (VP (MD can) (VP (VB be) (VP (VBN carried) (PRT (RP out)) (PP (PP (IN in) (NP (DT the) (NN diet))) (CC or) (PP (IN with) (NP (NN drug2) (NNS s)))) (, ,) (PP (IN with) (NP (QP (RB practically) (RB only) (CD one)) (NN contra-indication)))))))) (: :) (NP (JJ overt) (JJ renal) (NN failure)) (. .)))
(S1 (S (S (NP (NP (ADJP (ADJP (JJ Specific)) (CC and) (ADJP (JJ aspecific))) (NNS treatments)) (PP (IN of) (NP (NN drug1) (NN depletion)))) (VP (VBP are) (NP (NP (ADJP (NN tricky) (VBG using) (PP (IN for) (NP (NN example)))) (NNS drug2)) (, ,) (NP (NP (JJ pharmacological) (NNS doses)) (PP (IN of) (NP (NN drug3)))) (, ,) (NP (NP (JJ physiological) (NNS doses)) (PP (PP (IN of) (NP (NN drug4))) (CC and) (PP (IN of) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB use) (NP (NP (DT the) (JJ pharmacological) (NNS properties)) (PP (IN of) (NP (JJ induced) (JJ therapeutic) (NN hypermagnesaemia)))))))) (, ,) (S (S (NP (NP (JJ high) (JJ oral) (NNS doses)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (QP (RB >) (CD 10)) (NN mg/kg/day)) (-RRB- -RRB-))))) (VP (VBP are) (ADJP (JJ advisable) (PP (IN for) (NP (JJ chronic) (NNS indications)))))) (CC and) (S (NP (DT the) (JJ parenteral) (NN route)) (VP (VBZ is) (ADJP (JJ suitable) (PP (IN for) (NP (JJ acute) (NNS indications)))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (NP (CD 3) (NNS types)) (PP (IN of) (NP (NP (NNS indications)) (: :) (ADJP (ADJP (JJ specific) (PRN (-LRB- -LRB-) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (DT some) (NNS forms)) (PP (IN of) (NP (NN drug1) (NN deficit))))))) (PP (FW i.e.) (ADJP (JJ acute))) (-RRB- -RRB-))) (, ,) (ADJP (JJ pharmacological) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (PP (IN without) (NP (NP (NNS alterations)) (PP (IN of) (NP (NN drug2) (NN status))))) (-RRB- -RRB-))) (CC and) (ADJP (JJ mixed--pharmacological)))))) (CC and) (NP (NP (CD aetiopathogenic--)) (PRN (-LRB- -LRB-) (PP (IN for) (NP (NP (NN example) (NNS complications)) (PP (IN of) (NP (JJ chronic) (NN alcoholism))))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (JJ Today) (JJ pharmacological) (NN drug1) (NN therapy)) (ADVP (RB mainly)) (VP (VBZ concerns) (NP (DT the) (ADJP (ADJP (JJ obstetrical)) (, ,) (ADJP (JJ cardiological)) (CC and) (ADJP (JJ anaesthesiological))) (NNS fields)))) (. .)))
(S1 (S (S (NP (DT The) (JJ main) (NNS indications)) (VP (VBP are) (NP (NP (NN eclampsia)) (, ,) (NP (NP (DT some) (NNS dysrhythmias)) (PRN (-LRB- -LRB-) (NP (NNS torsades) (NP (NN de) (NN pointe)) (ADVP (RB particularly))) (-RRB- -RRB-))) (CC and) (NP (JJ myocardial) (NN ischaemias))))) (. .)))
(S1 (S (S (CC But) (NP (PRP it)) (VP (VBZ is) (ADVP (RB now)) (ADJP (JJ difficult) (S (VP (TO to) (VP (VB situate) (NP (NP (DT the) (JJ exact) (NN place)) (PP (IN of) (NP (NP (DT the) (JJ pharmacological) (NNS indications)) (PP (IN of) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (NP (NN drug1) (NNS infusions)) (VP (MD can) (ADVP (RB only)) (VP (VB be) (VP (VBN envisaged) (PP (IN in) (NP (NP (JJ intensive) (NN care) (NNS units)) (PP (IN with) (NP (NP (JJ careful) (NN monitoring)) (PP (IN of) (NP (NP (NN pulse)) (, ,) (NP (JJ arterial) (NN pressure)) (, ,) (NP (NN deep) (NN tendon) (NNS reflexes)) (, ,) (NP (NN hourly) (NN diuresis)) (, ,) (NP (NN electrocardiogram)) (CC and) (NP (JJ respiratory) (NNS recordings))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ High) (JJ oral) (NN drug1) (NNS doses)) (PP (IN besides) (NP (PRP$ their) (JJ laxative) (NN action)))) (VP (MD may) (VP (VBP bring) (NP (NP (JJ latent) (NNS complications)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB reduce) (NP (NN lifespan)))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (MD may) (VP (VB remain) (NP (NP (DT some) (NNS indications)) (PP (IN of) (NP (NP (DT the) (ADJP (ADJP (JJ laxative)) (CC and) (ADJP (JJ antacid))) (NNS properties)) (PP (IN of) (NP (JJ non) (JJ soluble) (NN drug1)))))) (, ,) (PP (ADVP (RB particularly)) (IN during) (NP (JJ intermittent) (NN haemodialysis)))))) (. .)))
(S1 (S (S (ADVP (RB Lastly)) (NP (NP (JJ local) (NN use)) (PP (IN of) (NP (NP (DT the) (ADJP (ADJP (JJ mucocutaneous)) (CC and) (ADJP (JJ cytoprotective))) (NNS properties)) (PP (IN of) (NP (NN drug1)))))) (VP (VBZ is) (ADVP (RB still)) (ADJP (JJ valid)) (, ,) (PP (PP (IN in) (NP (NN drug2))) (CC and) (PP (IN for) (NP (NP (NN preservation)) (PP (IN of) (NP (NP (NNS transplants)) (ADVP (RB particularly))))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN upon) (NP (ADJP (NN drug3) (-LRB- -LRB-) (NN drug4) (-RRB- -RRB-) (JJ -induced)) (NN locomotion)))) (CC and) (NP (NP (JJ behavioral) (NNS changes)) (PP (IN in) (NP (NNS mice)))))) (. .)))
(S1 (S (NP (NP (DT The) (JJ behavioral) (NNS changes)) (PP (IN of) (NP (NNS mice))) (VP (VBN induced) (PP (IN by) (NP (NP (ADJP (JJ acute))) (CC and) (NP (ADJP (JJ repeated))))) (ADVP (RB i.p.))))))
(S1 (S (S (NP (NP (NN injection)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN observed) (PP (IN by) (S (VP (VBG measuring) (NP (NP (JJ locomotor) (NN activity)) (CC and) (NP (JJ stereotyped) (NN behavior))))))))) (. .)))
(S1 (S (S (ADVP (RB Then)) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ metabotropic) (NN glutamate) (NN receptor) (-LRB- -LRB-) (NN mGluR) (-RRB- -RRB-) (NNS agonists)) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,))) (PP (IN on) (NP (NP (DT the) (JJ above) (JJ behavioral) (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (NN drug3))))))) (VP (VBD were) (VP (VBN found)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (VP (VBD were) (ADJP (RB very) (JJ strong))) (CC and) (VP (ADVP (RB completely)) (VBD depressed) (NP (DT the) (JJ drug2) (JJ -induced) (NN hyperlocomotion))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (RB not) (ADVP (RB so)) (ADJP (JJ strong)))) (. .)))
(S1 (S (S (NP (NP (JJ Repeated) (NN injection)) (PP (IN of) (NP (NN drug1))) (PP (IN for) (NP (CD 20) (NNS days))) (PP (IN into) (NP (NNS mice)))) (VP (VBD induced) (NP (NP (JJR lower) (NN locomotor) (NN activity)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (ADJP (RB acutely) (VBN injected)) (NNS mice)))))))) (. .)))
(S1 (S (S (NP (DT These) (JJ behavioral) (NNS changes)) (VP (MD may) (VP (VB be) (ADJP (JJ related) (PP (IN with) (NP (NP (DT the) (JJ negative) (NNS symptoms)) (PP (IN of) (NP (NN schizophrenia))))))))) (. .)))
(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB examine) (NP (NP (DT some) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (NN drug1) (JJ -induced) (NN behavioral) (NNS changes)))))))) (, ,) (NP (NP (NN Northern) (NN blot) (NN analysis)) (PP (IN of) (NP (NP (JJ total) (NN RNA)) (PP (IN from) (NP (NP (JJ prefrontal) (JJ cortical) (NNS tissues)) (PP (IN of) (NP (NP (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))))))))) (VP (VBD was) (VP (VBN carried) (PRT (RP out)))) (. .)))
(S1 (S (NP (NP (NN Lack)) (PP (IN of) (NP (NP (DT an) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN disposition)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN in) (NP (JJ HIV-infected) (NNS patients))))))) (. .))))
(S1 (S (S (NP (CD Two) (NNS studies)) (VP (VBD were) (VP (VBN conducted) (PP (IN in) (NP (JJ HIV-infected) (NNS subjects))) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN drug1))) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (NP (DT Both) (NNS studies)) (VP (VBD used) (NP (CD 12) (NNS subjects)))) (. .)))
(S1 (S (NP (DT The) (JJ drug1) (NN study)) (VP (VBD dosed) (NP (NP (NNS subjects)) (PP (IN with) (NP (NP (CD 1200) (NN mg/day)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 7)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (ADVP (RB later)) (VP (VBN changed) (PP (TO to) (NP (ADJP (CD 600) (NN mg/day)) (NN -LSB-n) (JJ =) (CD 5)))) (-RRB- -RSB-) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NP (NNS Days) (NP (CD 8) (TO to) (CD 21))) (PP (IN of) (NP (NP (DT a) (JJ 21-day) (NN course)) (PP (IN of) (NP (CD 100) (NN mg)))))) (, ,) (NP (NP (CD five) (NNS times/day)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (NP (NP (NNS Subjects)) (VP (VBN treated) (PP (IN with) (NP (NP (CD 200) (NN mg)) (PP (IN of) (NP (NN drug1))))) (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (CD 21) (NNS days))))) (VP (VBD received) (NP (NP (NP (CD 1200) (NN mg)) (PP (IN of) (NP (NN drug2)))) (CC or) (NP (NP (DT an) (JJ equivalent) (NN amount)) (PP (IN of) (NP (NN placebo/day))))) (PP (IN for) (NP (NNS Days) (NP (CD 8) (TO to) (CD 21))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN plasma)) (CC and) (NP (NN urine) (NN sampling))) (VP (VBD were) (VP (VBN conducted) (PP (PP (IN on) (NP (NP (NNS Days) (QP (CD 1) (, ,) (CD 7) (, ,) (CC and) (CD 21))) (PP (IN for) (NP (NN drug2))))) (CC and) (PP (IN on) (NP (NP (NNS Days) (CD 7) (CC and) (CD 21)) (PP (IN for) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (JJ Peripheral) (JJ mononuclear) (NNS cells)) (VP (VBD were) (ADVP (RB also)) (VP (VBN collected) (PP (IN for) (NP (NP (NN quantitation)) (PP (IN of) (NP (JJ phosphorylated) (NN drug1)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD had) (NP (DT no) (JJ significant) (NN impact)) (PP (IN on) (NP (NP (DT the) (NP (NN Cmax)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (NN drug2))))) (, ,) (SBAR (IN although) (S (NP (PRP it)) (ADVP (RB significantly)) (VP (VP (VBD decreased) (NP (DT the) (NN drug3) (NN tmax)) (PP (IN by) (NP (CD 44) (NN %)))) (CC and) (VP (VBD increased) (NP (NP (DT the) (JJ intracellular) (NN exposure)) (PP (TO to) (NP (VBN phosphorylated) (NN drug4)))) (PP (IN by) (NP (CD 110) (NN %))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NN drug2) (NNS pharmacokinetics))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (DT these) (NNS studies)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB be) (ADVP (RB safely)) (VP (VBN coadministered) (PP (IN with) (NP (CC both) (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Clinical) (NNS implications)) (PP (IN of) (NP (NP (JJ drug1) (NNS interactions)) (PP (IN with) (NP (CD five)))))) (VP (VBP drug2))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (NP (NN intensity)) (, ,) (NP (NN uniformity)) (CC and) (NP (NN time) (NN course)))) (PP (IN of) (NP (NP (NN drug1) (NN interference)) (PP (IN by) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6))))))) (VP (VBD were) (ADVP (RB systematically)) (VP (VBN investigated) (PP (IN in) (NP (NP (CD 16) (NNS patients)) (VP (VBG receiving) (NP (NN drug7) (NN therapy)))))))) (. .)))
(S1 (S (S (NP (DT Each) (NN subject)) (VP (VP (VBD received) (NP (NP (DT an) (JJ individualized) (JJ fixed) (JJ daily) (NN dose)) (PP (IN of) (NP (NN drug1))))) (CC and) (VP (VBD served) (PP (IN as) (NP (PRP$ his) (JJ own) (ADJP (ADJP (JJ pre-)) (CC and) (ADJP (JJ postsedative))) (NN treatment) (NN control)))))) (. .)))
(S1 (S (S (NP (NN Prothrombin) (NNS times)) (VP (VBD were) (VP (VBN measured) (NP (CD four) (NNS times)) (ADVP (RB weekly)) (PP (IN during) (NP (CD five) (JJ long-term) (NNS experiments)))))) (. .)))
(S1 (S (S (NP (NN Anticoagulant) (NN inhibition)) (VP (VBD was) (VP (VBN observed) (PP (IN during) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (: ;)))
(S1 (S (S (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (JJ significant) (NN change)) (PP (IN in) (NP (NN prothrombin) (NN test) (NNS results)))) (PP (IN during) (NP (NP (DT the) (NNS trials)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NNS drugs)) (PP (IN from) (NP (DT these) (NNS groups)))))) (VP (VBZ is) (VP (VBG decreasing) (PP (VBG according) (PP (TO to) (NP (NP (DT a) (NN survey)) (PP (IN of) (NP (CD 200) (NN hospital) (JJ medical) (NNS records))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP interact) (ADVP (RB pharmacologically)) (PP (IN with) (NP (ADJP (RB orally) (VBN administered)) (NN drug3))))) (, ,) (CC but) (S (NP (DT the) (NN effect)) (VP (VBZ is) (RB not) (ADJP (RB clinically) (JJ significant))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD may) (VP (VB be) (VP (VBN administered) (ADVP (RB safely)) (PP (IN without) (NP (NP (JJ additional) (NN caution)) (PP (IN in) (NP (NN prothrombin) (NN test) (NN monitoring))))) (PP (IN during) (NP (JJ oral) (NN drug3) (NN therapy))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Interaction)) (PP (IN of) (NP (NP (DT the) (NNS constituents)) (PP (IN of) (NP (JJ alcoholic) (NNS beverages))))) (PP (IN in) (NP (NP (DT the) (NN promotion)) (PP (IN of) (NP (NN liver) (NN damage))))))) (. .)))
(S1 (S (S (NP (JJ Little)) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (PP (IN of) (NP (NP (DT the) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NP (DT the) (NN exposure)) (PP (IN of) (NP (DT the) (NN liver))) (PP (TO to) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (PRP$ its) (NNS congeners)) (CC and) (NP (NN drug2)))))))))) (, ,) (S (VP (VBG coexisting) (PP (IN in) (NP (NP (DT the) (NNS contents)) (PP (IN of) (NP (JJ alcoholic) (NNS beverages))))))))))) (. .)))
(S1 (S (S (NP (CD Twenty) (CD four) (JJ male) (NN Wistar) (NNS rats)) (VP (VBD were) (VP (VBN divided) (PP (IN into) (NP (CD four) (NNS groups)))))) (. .)))
(S1 (S (S (NP (NP (CD Two) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NNP SH/DA)) (: ;) (NP (NN SH/FA)) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN submitted) (PP (TO to) (NP (NP (JJ daily) (NN treatment)) (PP (IN with) (NP (NP (JJ synthetic) (JJ hydroalcoholic) (NNS solutions)) (VP (VBG containing) (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (JJR higher) (NN drug3)) (CC and) (NP (NN drug4))) (PP (IN in) (NP (DT the) (JJ same) (NNS proportions)))) (PP (IN as) (NP (NP (DT those)) (VP (VBN found) (PP (IN in) (NP (ADJP (RBS most) (JJ common)) (ADJP (ADJP (JJ distilled)) (CC and) (ADJP (JJ fermented))) (JJ alcoholic) (NNS beverages)))))))))))))) (: ;)))
(S1 (S (S (NP (NP (DT the) (JJ third) (NN group)) (PRN (-LRB- -LRB-) (NP (NN SH/EA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ hydroalcoholic) (NN solution)) (PP (IN of) (NP (NN drug1)))))))) (: ;)))
(S1 (S (S (NP (DT the) (JJ fourth) (NN group)) (VP (VP (VBD served) (PP (IN as) (NP (NN control)))) (CC and) (VP (VBD received) (NP (NP (DT an) (JJ equivalent) (NN volume)) (PP (IN of) (NP (NP (DT an) (JJ isocaloric) (NN solution)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (PDT All) (DT the) (NNS animals)) (VP (VBD were) (VP (VBN killed) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NP (DT the) (JJ 9th) (NN week)) (PP (IN of) (NP (DT the) (NN experiment)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN ratio)) (PP (IN between) (NP (DT the) (NP (NN liver) (NN weight)) (CC and) (NP (NN body) (NN weight))))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (ADJP (JJR lower)) (PP (IN in) (NP (DT the) (JJ treated) (NNS animals))) (PP (IN than) (PP (IN in) (NP (DT the) (JJ control) (NN group))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN histology)) (PP (IN of) (NP (DT the) (NN liver)))) (VP (VBD was) (VP (VBN altered) (PP (IN in) (NP (NP (DT the) (CD three) (NNS groups)) (SBAR (WHNP (WDT which)) (S (VP (VBD were) (VP (VBN submitted) (PP (TO to) (NP (NP (NN treatment)) (PP (IN with) (NP (DT the) (JJ hydroalcoholic) (NNS solutions))))))))))) (, ,) (PP (IN with) (NP (NP (ADJP (ADJP (JJ quantitative)) (CC and) (ADJP (JJ qualitative))) (NNS differences)) (PP (IN between) (NP (DT the) (NNS groups)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN hepatoxicity)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (JJ alcoholic) (NNS beverages)))) (VP (VBZ is) (VP (VBN enhanced) (PP (IN by) (NP (NP (NN interaction)) (PP (IN with) (NP (NP (PRP$ its) (NNS congeners)) (CC and) (NP (NNS drug2)))))))))))) (: ;)))
(S1 (S (S (NP (PRP they)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ alcoholic) (NNS beverages)) (VP (VBP are) (RB not) (ADJP (JJ equivalent)) (PP (IN in) (NP (PRP$ their) (NN potential) (S (VP (TO to) (VP (VB cause) (NP (NN liver) (NN damage)))))))))))) (. .)))
(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1) (NNS prophylaxis))) (. .))))
(S1 (S (S (NP (NP (JJ Successful) (NN prophylaxis)) (PP (IN of) (NP (JJ manic-depressive) (NN disorder)))) (VP (VBZ requires) (ADVP (RBR more) (IN than)) (NP (NP (DT the) (NN prescription)) (PP (IN of) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ administrative) (NNS arrangements)) (PP (IN in) (NP (NP (DT an) (NN area)) (PP (IN of) (NP (NNP Scotland)))))) (VP (VBD were) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (CD 300) (NN %) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NP (NNS admissions)) (PP (IN for) (NP (NN mania)))))))))) (, ,) (SBAR (IN whereas) (S (PP (IN in) (NP (NP (DT an) (NN area)) (PP (IN of) (NP (DT the) (NP (NNP West) (NNP Midlands)))))) (, ,) (NP (DT a) (JJ large) (NN decrease)) (VP (VBD was) (VP (VBN achieved))))))) (. .)))
(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))) (. .))))
(S1 (S (S (NP (DT The) (NNS authors)) (VP (VBD examined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT the) (NP (NP (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NN inhibitor)) (, ,) (NP (NN drug1)) (, ,))) (PP (IN at) (NP (JJ steady) (NN state))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))) (PP (VBG following) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))))))) (. .)))
(S1 (S (S (NP (NP (DT Each) (JJ healthy) (NN subject)) (PRN (-LRB- -LRB-) (NP (NN N) (JJ =) (CD 10)) (-RRB- -RRB-))) (VP (VBD received) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 75) (NN mg)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-))) (CC or) (NP (NP (NN placebo)) (PP (IN for) (NP (NP (CD 11) (NNS days)) (PP (IN in) (NP (DT a) (ADJP (ADJP (JJ double-blind)) (, ,) (ADJP (JJ randomized)) (, ,) (ADJP (JJ balanced)) (, ,) (ADJP (JJ two-period))) (NN crossover) (NN study))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ single) (CD 0.5) (NN mg) (JJ oral) (NN dose)) (PP (IN of) (NP (NN drug1) (NN elixir)))) (VP (VBD was) (VP (VBN administered) (PP (IN on) (NP (NP (DT the) (JJ 7th) (NN day)) (PP (IN of) (NP (DT each) (JJ 11-day) (NN period)))))))) (. .)))
(S1 (S (S (NP (DT Each) (NN treatment) (NN period)) (VP (VBD was) (VP (VBN separated) (PP (IN by) (NP (QP (CD 14) (TO to) (CD 21)) (NNS days)))))) (. .)))
(S1 (S (S (NP (NP (NNS Samples)) (PP (IN for) (NP (NP (NN plasma)) (CC and) (NP (NN urine)) (NP (JJ immunoreactive) (NN drug1) (NNS concentrations))))) (VP (VBD were) (VP (VBN collected) (PP (IN through) (NP (CD 120) (NNS hours))) (PP (VBG following) (NP (DT the) (NN drug2) (NN dose)))))) (. .)))
(S1 (S (S (NP (NP (DT No) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (PP (IN between) (NP (NN treatment) (NNS groups)))) (VP (VBD were) (VP (VBN observed) (PP (IN for) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (VBN calculated) (NN drug1) (JJ pharmacokinetic) (NNS parameters)))))))) (. .)))
(S1 (S (PP (IN For) (NP (NP (NP (NN drug1) (NN AUC)) (PRN (-LRB- -LRB-) (NP (NN 0-infinity)) (-RRB- -RRB-))) (, ,) (NP (NP (NN AUC)) (PRN (-LRB- -LRB-) (NP (NN 0-24)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN Cmax)))) (, ,) (NP (NP (NP (DT the) (JJ geometric) (NN mean) (NNS ratios)) (PRN (-LRB- -LRB-) (NP (NP (CD 90) (NN %)) (ADJP (RB confidence) (JJ interval))) (-RRB- -RRB-))) (PRN (IN for) (-LRB- -LRB-) (NP (NP (NN drug2)) (CC +) (NP (NP (NN drug3) (NN /placebo)) (CC +) (NP (NN drug4)))) (-RRB- -RRB-))) (VP (VBD were) (NP (NP (NP (CD 1.04)) (PRN (-LRB- -LRB-) (NP (CD 0.94)) (, ,) (NP (CD 1.14)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 1.02)) (PRN (-LRB- -LRB-) (NP (CD 0.94)) (, ,) (NP (CD 1.09)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (CD 1.00)) (PRN (-LRB- -LRB-) (NP (CD 0.91)) (, ,) (NP (CD 1.10)) (-RRB- -RRB-)))) (, ,) (ADVP (RB respectively))) (. .)))
(S1 (S (S (NP (DT The) (NN drug1) (NN median) (NN tmax)) (VP (VBD was) (NP (CD 0.5) (NNS hours)) (PP (IN for) (NP (DT both) (NNS treatments))))) (. .)))
(S1 (S (NP (DT The) (JJ harmonic) (NN mean) (NN elimination) (NN half-life)) (VP (VBD was) (NP (QP (CD 45.7) (CC and) (CD 43.4)) (NNS hours)) (PP (IN for) (NP (NP (NP (NN drug1)) (CC +) (NP (NN drug2))) (CC and) (NP (NP (NN placebo)) (CC +) (NP (NN drug3))) (NP (NNS treatments)))) (, ,) (ADVP (RB respectively))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN eliminated) (ADVP (RB renally))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (NP (NN mean)) (PRN (-LRB- -LRB-) (NP (NN SD)) (-RRB- -RRB-))) (JJ cumulative) (JJ urinary) (NN excretion)) (PP (IN of) (NP (JJ immunoreactive) (NN drug1))) (PP (IN after) (NP (NP (JJ concurrent) (NN treatment)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN placebo))))))) (VP (VBD was) (NP (NP (NP (CD 228.2)) (PRN (-LRB- -LRB-) (NP (CC +/-) (CD 30.8)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 235.1)) (PRN (-LRB- -LRB-) (NP (CC +/-) (CD 39.1)) (-RRB- -RRB-))) (NP (CD micrograms/120) (NNS hours))) (, ,) (ADVP (RB respectively)))) (. .)))
(S1 (S (S (S (NP (ADJP (ADJP (JJ Transient)) (CC and) (ADJP (JJ minor))) (JJ adverse) (NNS events)) (VP (VBD occurred) (PP (IN with) (NP (JJ similar) (NN frequency))) (PP (IN on) (NP (NP (NN placebo)) (CC and) (NP (NN drug1)) (NP (NNS treatments)))))) (, ,) (CC and) (S (NP (DT no) (JJ treatment-related) (NN pattern)) (VP (VBD was) (ADJP (JJ apparent))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB influence) (NP (NP (NP (DT the) (NN plasma) (NNS pharmacokinetics)) (CC or) (NP (JJ renal) (NN elimination))) (PP (IN of) (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NN drug3))) (: :) (NP (NP (NN comparison)) (PP (IN of) (NP (NP (JJ antiaddictive) (NN efficacy)) (, ,) (NP (NN toxicity)) (, ,) (CC and) (NP (NP (NNS mechanisms)) (PP (IN of) (NP (NN action))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (DT a) (JJ novel) (NN iboga) (NN alkaloid) (NN congener)) (, ,)) (VP (VBZ is) (VP (VBG being) (VP (VBN developed) (PP (IN as) (NP (NP (DT a) (JJ potential) (NN treatment)) (PP (IN for) (NP (NP (JJ multiple) (NNS forms)) (PP (IN of) (NP (NN drug) (NN abuse))))))))))) (. .)))
(S1 (S (PP (IN Like) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN mg/kg)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBZ decreases) (NP (NP (NP (DT the) (JJ intravenous) (NN self-administration)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))) (CC and) (NP (NP (DT the) (JJ oral) (NN self-administration)) (PP (IN of) (NP (NP (NP (NN drug5)) (CC and) (NP (NN drug6))) (PP (IN in) (NP (NNS rats)))))))) (: ;)))
(S1 (S (S (PP (IN unlike) (NP (NN drug1))) (, ,) (NP (NN drug2)) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (VBG responding)) (PP (IN for) (NP (NP (DT a) (JJ nondrug) (NN reinforcer)) (PRN (-LRB- -LRB-) (NP (NN water)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (CC Both) (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP ameliorate) (NP (NN drug3) (NN withdrawal) (NNS signs)))) (. .)))
(S1 (S (S (NP (CC Both) (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP decrease) (NP (NP (JJ extracellular) (NNS levels)) (PP (IN of) (NP (NN dopamine)))) (PP (IN in) (NP (DT the) (NN nucleus) (NNS accumbens))))) (, ,) (CC but) (S (NP (JJ only) (NN drug3)) (VP (VBZ increases) (NP (NP (JJ extracellular) (NNS levels)) (PP (IN of) (NP (NN serotonin)))) (PP (IN in) (NP (DT the) (NN nucleus) (NNS accumbens))))) (. .)))
(S1 (S (S (NP (CC Both) (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP block) (NP (NP (NN drug3) (JJ -induced) (CC and) (JJ drug4) (JJ -induced) (NN dopamine) (NN release)) (PP (IN in) (NP (DT the) (NN nucleus) (NNS accumbens)))))) (: ;)))
(S1 (S (S (NP (JJ only) (NN drug1)) (VP (VBZ enhances) (NP (NP (NN drug2) (JJ -induced) (NNS increases)) (PP (IN in) (NP (JJ accumbal) (NN dopamine)))))) (. .)))
(S1 (S (S (NP (CC Both) (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP enhance) (NP (NP (DT the) (ADJP (ADJP (JJ locomotor)) (CC and/or) (ADJP (JJ stereotypic))) (NNS effects)) (PP (IN of) (NP (NNS stimulants)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ attenuates))) (, ,) (CC but) (S (NP (NN drug2)) (VP (VBZ potentiates) (, ,) (NP (NP (DT the) (JJ acute) (NN locomotor) (NNS effects)) (PP (IN of) (NP (NN drug3)))))) (: ;)))
(S1 (S (S (NP (DT both) (NNS compounds)) (VP (VBP attenuate) (NP (NP (JJ drug1) (JJ -induced) (NN locomotion)) (PP (IN in) (NP (JJ drug2) (JJ -experienced) (NNS rats)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ produces) (NP (JJ whole) (NN body) (NN tremors))) (CC and) (VP (, ,) (PP (IN at) (NP (NP (JJ high) (NNS doses)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ >)) (CC or) (ADJP (JJ =)) (NP (CD 100) (NN mg/kg))) (-RRB- -RRB-)))) (, ,) (NP (JJ cerebellar) (NN damage))))) (: ;)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB produce) (NP (DT these) (NNS effects))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (CONJP (CC but) (RB not)) (NP (NN drug2)) (, ,)) (VP (VBZ decreases) (NP (NN heart) (NN rate)) (PP (IN at) (NP (JJ high) (NNS doses))))) (. .)))
(S1 (S (SBAR (IN While) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP have) (NP (NP (JJ similar) (NNS affinities)) (PP (IN for) (NP (NP (NN kappa) (NN opioid)) (CC and) (NP (ADVP (RB possibly)) (NP (NN nicotinic) (NNS receptors))))))))) (, ,) (NP (NN drug3)) (VP (VBZ has) (NP (NP (ADJP (RB much) (JJR lower)) (NNS affinities)) (PP (IN than) (NP (NN drug4))) (PP (IN for) (NP (NP (NP (NP (NN NMDA)) (CC and) (NP (NN sigma-2))) (NNS receptors)) (, ,) (NP (NN sodium) (NNS channels)) (, ,) (CC and) (NP (DT the) (JJ 5-HT) (NN transporter)))))) (. .)))
(S1 (S (S (S (NP (CC Both) (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN sequestered) (PP (IN in) (NP (NN fat)))))) (CC and) (S (, ,) (PP (IN like) (NP (NN drug3))) (, ,) (NP (NN drug4)) (ADVP (RB probably)) (VP (VBZ has) (NP (DT an) (JJ active) (NN metabolite))))) (. .)))
(S1 (S (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (VP (VBZ has) (NP (NP (DT a) (JJ narrower) (NN spectrum)) (PP (IN of) (NP (NNS actions))))) (CC and) (VP (MD will) (VP (VB have) (NP (NP (DT a) (ADJP (RB substantially) (JJR greater)) (JJ therapeutic) (NN index)) (PP (IN than) (NP (NN drug2))))))))))) (. .)))
(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NP (JJ coadministered) (NNS drugs)) (CC and) (NP (NN drug1)))) (PP (IN on) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (JJ therapeutic) (NNS drugs))) (PP (TO to) (NP (JJ human) (NN serum))) (PP (IN in) (NP (FW vitro))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ coadministered) (NNS drugs)) (CC and) (NP (NN drug1)))) (PP (IN on) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (JJ therapeutic) (NNS drugs))) (PP (TO to) (NP (JJ human) (NN serum))) (ADVP (FW in) (FW vitro))))) (VP (VBD was) (VP (VBN investigated)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))) (VP (VBD were) (VP (VBN added) (PP (TO to) (NP (JJ pooled) (JJ human) (NN serum))) (PP (IN at) (NP (JJ therapeutic) (NNS concentrations)))))) (. .)))
(S1 (S (S (PP (TO To) (NP (DT each) (NN preparation))) (VP (VBD was) (VP (VBN added) (NP (CD one) (JJ additional) (NN drug)) (PP (IN at) (NP (NP (CD three) (NNS concentrations)) (VP (VBG ranging) (PP (IN from) (ADJP (ADJP (JJ therapeutic)) (TO to) (ADJP (JJ toxic)))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (CD eight) (NN target) (JJ drug/added) (NN drug) (NNS combinations)) (VP (VBD were) (VP (VBN studied) (: :) (NP (NP (NN drug1)) (: /) (NP (NN drug2)))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (, ,) (NP (NN drug3)) (: /) (NP (NN drug4)) (, ,) (NP (NN drug5)) (: /) (NP (NN drug6)) (, ,) (NP (NN drug7)) (: /) (NP (NN drug8)) (, ,) (NP (NN drug9)) (: /) (NP (CD drug10)) (, ,) (NP (CD drug11) (: /) (CD drug12)) (, ,) (CC and) (NP (NN drug13))) (: /) (NP (NN drug14)) (. .))))
(S1 (S (S (NP (NP (NP (DT Each) (NN serum)) (PP (IN without) (NP (DT the) (JJ other) (VBN added) (NN drug)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN serum)) (VP (VBN supplemented) (PP (IN with) (NP (DT the) (JJ other) (NN drug))) (PP (IN at) (NP (DT the) (CD three) (NNS concentrations)))))) (VP (VBD was) (VP (VBN dialyzed) (PP (IN against) (NP (NN phosphate) (NN buffer)))))) (. .)))
(S1 (S (SINV (ADJP (RB Similarly) (VBN dialyzed)) (VP (VBD were) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3)) (, ,) (ADVP (CC both) (ADVP (RB alone)))) (PP (PP (IN at) (NP (NP (JJ therapeutic) (NNS concentrations)) (PP (IN in) (NP (NN serum))))) (CC and) (PP (IN with) (NP (NN drug4))) (PP (IN at) (NP (NP (CD three) (JJ different) (NNS concentrations)) (PP (IN in) (NP (NN serum))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN percentage)) (PP (IN of) (NP (NN drug) (NN binding))) (PP (IN in) (NP (DT each) (NN preparation)))) (VP (VBD was) (VP (VBN calculated)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD diminished) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (JJ human) (NN serum)))) (PP (PP (IN by) (NP (NP (DT a) (JJ net) (NN change)) (PP (IN of) (NP (NP (NP (CD 5.7) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN percentage) (NN increase)) (PP (IN in) (NP (JJ free) (NN drug) (NN fraction) (NN -LSB-FDF)))) (-RRB- -RSB-) (, ,) (NP (CD 11.0) (NN %)) (-RRB- -RRB-))) (PP (IN at) (NP (CD 662) (NN micromol/L))))))) (CC and) (PP (IN by) (NP (NP (DT a) (JJ net) (NN change)) (PP (IN of) (NP (NP (NP (CD 7.1) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN percentage) (NN increase)) (PP (IN in) (NP (NN FDF)))) (, ,) (NP (CD 13.7) (NN %)) (-RRB- -RRB-))) (PP (IN at) (NP (NN 1324) (NN micromol/L)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD decreased) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (NP (DT a) (JJ net) (NN change)) (PP (IN of) (NP (CD 6.8) (NN %))))) (PRN (-LRB- -LRB-) (NP (NP (NN percentage) (NN increase)) (PP (IN in) (NP (NN FDF)))) (, ,) (NP (CD 8.8) (NN %)) (-RRB- -RRB-)) (PP (IN at) (NP (CD 277.5) (NN micromol/L))))) (: ;)))
(S1 (S (S (NP (NN drug1)) (VP (VBD reduced) (NP (PRP it)) (PP (IN by) (NP (NP (DT a) (JJ net) (NN change)) (PP (IN of) (NP (CD 6.6) (NN %))))) (PRN (-LRB- -LRB-) (NP (NP (NN percentage) (NN increase)) (PP (IN in) (NP (NN FDF)))) (, ,) (NP (CD 8.5) (NN %)) (-RRB- -RRB-)) (PP (IN at) (NP (CD 431) (NN micromol/L))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD diminished) (NP (NP (NN binding)) (PP (IN of) (NP (NN drug2))) (PP (IN by) (NP (NP (DT a) (JJ net) (NN change)) (PP (IN of) (NP (NP (NP (CD 9.9) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN percentage) (NN increase)) (PP (IN in) (NP (NN FDF)))) (, ,) (NP (CD 21.2) (NN %)) (-RRB- -RRB-))) (PP (IN at) (NP (CD 1732) (NN micromol/L)))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ significant) (NNS effects)) (VP (VBD were) (VP (VBN noted) (PP (PP (IN with) (NP (JJ other) (NN drug) (NNS combinations))) (CC or) (PP (IN with) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coingestion)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NP (NN drug3)) (PP (IN with) (NP (NN drug4)))) (, ,) (CC and) (NP (NN drug5)))) (PP (IN with) (NP (NN drug6))))) (PP (IN at) (NP (ADJP (ADJP (JJ high)) (TO to) (ADJP (JJ toxic))) (NNS concentrations)))) (VP (VBZ decreases) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (DT the) (NN target) (NN drug)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (VBG resulting) (NN increase)) (PP (IN in) (NP (JJ free) (NN drug) (NN concentration)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (VBN enhanced) (NN drug) (NN effect))) (ADVP (FW in) (FW vivo))))) (. .)))
(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (JJ steady-state) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug2)))))) (VP (VBD was) (VP (VBN evaluated) (PP (IN in) (NP (DT a) (ADJP (ADJP (JJ randomized)) (, ,) (ADJP (JJ double-blind))) (NN study)))))) (. .)))
(S1 (S (S (NP (NP (CD Five) (NNS days)) (PP (IN of) (NP (NN drug1) (NN treatment)))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (JJ steady-state) (JJ pharmacokinetic) (NNS variables)) (PP (IN of) (NP (NN drug2))) (PP (VBN compared) (PP (IN with) (NP (NN placebo)))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ does) (RB not) (VP (VBP necessitate) (NP (DT an) (NN adjustment)) (PP (IN in) (NP (NN drug2) (NN dose))) (S (VP (TO to) (VP (VB maintain) (NP (JJ therapeutic) (NN digoxin) (NNS levels)))))))) (. .)))
(S1 (S (NP (NP (JJ Acid-catalyzed) (NN ethanolysis)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NN anhydrous)) (CC and) (NP (JJ aqueous) (NN drug2) (NNS solutions)))) (. .))))
(S1 (S (S (NP (DT The) (NNS drug1)) (VP (VBP are) (NP (NP (DT a) (NN family)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN taken) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug1)))))) (, ,) (NP (DT a) (JJ pharmacological) (NN interaction)) (VP (MD may) (VP (VB occur) (, ,) (S (VP (VBG potentiating) (NP (NP (NP (DT the) (JJ central) (JJ nervous) (NN system)) (NN depression)) (VP (VBN produced) (PP (IN by) (NP (DT either) (NN drug)))))))))) (. .)))
(S1 (S (PP (IN In) (NN addition) (TO to) (NP (DT this) (JJ pharmacological) (NN interaction))) (, ,) (NP (DT this) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (JJ novel) (JJ chemical) (NN reaction)) (PP (IN between) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (DT a) (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NN drug3))))) (PP (IN under) (NP (NP (JJ acidic) (NNS conditions)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN found) (PP (IN in) (NP (FW vivo))))))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (DT a) (JJ 3-ethoxylated) (NN product)))))) (. .)))
(S1 (S (S (NP (JJ Optimal) (NNS conditions)) (, ,) (NP (NP (NN kinetics)) (, ,) (NP (NN equilibrium)) (, ,) (CC and) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (DT this) (JJ acid-catalyzed) (NN ethanolysis))))) (VP (VBP are) (VP (VBN reported)))) (. .)))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBP raise) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (DT the) (NN ethanolysis) (NN reaction)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (NP (DT the) (NN stomach)) (PP (IN of) (NP (NP (NN people)) (SBAR (WHNP (WP who)) (S (VP (VBD consume) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN on) (NP (DT a) (JJ regular) (NN basis))))))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ acid-catalyzed) (NN drug1) (NN -drug) (NN reaction)) (VP (VP (VBZ is) (NP (DT a) (ADJP (RB relatively) (JJ unexplored)) (NN area))) (CC and) (VP (MD may) (VP (VB alter) (NP (NP (DT the) (JJ pharmacological) (NN action)) (PP (IN of) (NP (DT some) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Inhibitory) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN inositol) (NN 1,4))) (, ,)) (VP (VBD 5-trisphosphate-induced) (NP (NP (NNS responses)) (PP (IN in) (NP (NN rat) (NNS megakaryocytes)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))) (PP (IN on) (NP (ADJP (NN drug3) (-LRB- -LRB-) (NN drug4) (-RRB- -RRB-) (JJ -induced)) (NNS responses)))) (VP (VBD were) (VP (VBN studied) (PP (IN in) (NP (NN rat) (NN bone) (NN marrow) (NNS megakaryocytes))) (PP (IN with) (NP (DT the) (NN patch-clamp) (JJ whole-cell) (NN recording) (NN technique))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN fura-2) (NN microfluorometry)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Internal) (NN application)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN microM)) (-RRB- -RRB-))))) (VP (VP (VBD increased) (NP (NP (JJ intracellular) (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN -LSB-Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-) (-RRB- -RSB-))) (PRN (-LRB- -LRB-) (NP (NN i)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (CC and) (VP (VBD activated) (NP (NP (NP (DT the) (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -dependent)) (NN K)) (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NN current))))) (. .)))
(S1 (S (S (VP (VBG Administering) (NP (NN drug1)) (PP (ADVP (RB together)) (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 100-500) (NN microM)) (-RRB- -RRB-)))))) (VP (VBD inhibited) (NP (NP (ADJP (NN InsP) (-LRB- -LRB-) (CD 3) (-RRB- -RRB-) (JJ -induced)) (NNS responses)) (PRN (-LRB- -LRB-) (NP (CC both) (NP (NP (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (CC and) (NP (JJ current) (NNS responses))) (-RRB- -RRB-))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN fashion)))) (. .)))
(S1 (S (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NNS megakaryocytes))) (PP (IN with) (NP (NP (JJ extracellular) (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN microM)) (-RRB- -RRB-))))) (ADVP (RB also)) (VP (VBD inhibited) (NP (NN drug2) (JJ -induced) (NNS responses)))) (. .)))
(S1 (S (S (NP (NP (ADJP (ADJP (JJ Intracellular)) (CC and) (ADJP (JJ extracellular))) (NN application)) (PP (IN of) (NP (NN drug1)))) (VP (VBD reduced) (NP (NP (JJ ADP-induced) (NNS increases)) (PP (IN in) (NP (NP (NP (NN -LSB-Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-) (-RRB- -RSB-))) (PRN (-LRB- -LRB-) (NP (NN i)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (PP (IN in) (NP (VBN isolated) (JJ single) (JJ pancreatic) (JJ acinar) (NNS cells))) (, ,) (NP (NN drug1)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (JJ drug2) (JJ -induced) (NNS responses))))) (. .)))
(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (S (NP (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN site)) (PP (IN of) (NP (NP (DT the) (JJ inhibitory) (NN action)) (PP (IN of) (NP (NN drug1)))))) (VP (VBZ is) (PP (IN at) (NP (NP (DT the) (NN InsP) (-LRB- -LRB-) (CD 3) (-RRB- -RRB-) (NN receptor)) (, ,) (CC or) (NP (PRP$ its) (ADJP (RB closely) (VBN associated)) (NNS proteins))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ useful) (JJ pharmacological) (NN tool)) (SBAR (WHPP (IN with) (WHNP (WDT which))) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN drug2) (JJ -mediated) (NNS responses)) (PP (IN of) (NP (NNS megakaryocytes))))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Concomitant) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NP (NP (NN drug4) (NN chemotherapy)) (CC plus) (NP (NN drug5) (NN therapy))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ human) (NN immunodeficiency) (JJ virus-related) (, ,) (JJ non-Hodgkin) (NN lymphoma)))))) (. .))))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (DT The) (NP (NN feasibility)) (CC and) (NP (NN efficacy))) (PP (IN of) (NP (NP (JJ concomitant) (NN chemotherapy)) (CC and) (NP (NP (NN drug1) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN HAART)) (-RRB- -RRB-)))))) (VP (VBZ is) (ADVP (RB still)) (ADJP (JJ unknown) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HIV)) (-RRB- -RRB-))) (JJ -related) (NNS malignancies)))))))) (. .))))
(S1 (S (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (NP (NP (NN chemotherapy)) (CC plus) (NP (NN HAART))) (PP (IN on) (NP (NP (DT the) (JJ clinical) (NN course)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (ADJP (JJ HIV-related)) (, ,) (ADJP (JJ systemic))) (, ,) (NP (NP (JJ non-Hodgkin) (NN lymphoma)) (PRN (-LRB- -LRB-) (NP (NN HIV-NHL)) (-RRB- -RRB-))))))))))))))) (, ,) (NP (DT the) (NNS authors)) (VP (VBD compared) (ADVP (RB retrospectively)) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (CD 24) (NNS patients)) (PP (IN with) (NP (NN HIV-NHL))) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NP (NN drug4) (-LRB- -LRB-) (NN CHOP) (-RRB- -RRB-) (NN chemotherapy) (NN regimen)) (CC plus) (NP (NN HAART))))) (PP (IN with) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (CD 80) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NP (NN CHOP) (NN chemotherapy)) (CC or) (NP (NP (DT a) (JJ CHOP-like) (NN regimen)) (PRN (-LRB- -LRB-) (PP (FW i.e.) (, ,) (NP (NP (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8))) (PP (IN with) (NP (NP (NN drug9)) (CC plus) (NP (NN drug10)))))) (-RRB- -RRB-))))) (PP (IN without) (S (VP (VBG receiving) (NP (NN drug11) (NN therapy))))))))))))))))))))) (. .)))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (DT All) (NNS patients)) (VP (VBD were) (VP (VBN enrolled) (PP (IN in) (NP (NP (CD two) (JJ sequential) (NNS trials)) (VP (VBN performed) (PP (IN at) (NP (NP (DT the) (JJ Aviano) (NN Cancer) (NN Center)) (, ,) (NP (NN Italy))))))) (, ,) (PP (IN from) (NP (NP (NNP April) (CD 1988)) (TO to) (NP (NNP December) (CD 1998))))))) (. .))))
(S1 (S (S (NP (NN HAART)) (VP (VBD was) (VP (VBN included) (PP (IN with) (NP (NP (NN combination) (NN therapy)) (PP (IN from) (NP (NNP January) (CD 1997)))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS regimens)) (VP (VBD consisted) (PP (IN of) (NP (NP (CD two) (NN drug2)) (CC and) (NP (CD one) (NN drug3)))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (DT The) (CD two) (NN treatment) (NNS groups)) (VP (VBD were) (ADVP (RB well)) (VP (VBN matched) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (NP (NN patient) (NNS demographics)) (, ,) (NP (NN NHL) (NNS characteristics)) (, ,) (NP (NN HIV) (NN status)) (, ,) (CC and) (NP (NN treatment))) (, ,) (PP (FW i.e.) (, ,) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS cycles)) (CC and) (NP (NN chemotherapy) (NN dose))))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NN response) (NNS rates)) (VP (VBD were) (ADJP (JJ similar) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))))) (. .)))
(S1 (S (S (NP (NP (JJ Severe) (NN anemia)) (PRN (-LRB- -LRB-) (NP (NP (NN Grade) (JJ 3-4)) (PP (VBG according) (PP (TO to) (NP (DT the) (NN World) (NN Health) (NN Organization) (NNS criteria))))) (-RRB- -RRB-))) (VP (VBD was) (ADJP (ADJP (RB significantly) (JJR greater)) (PP (IN in) (NP (NP (DT the) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN CHOP-HAART)) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (NN CHOP)) (ADVP (RB alone))) (PRN (-LRB- -LRB-) (NP (NP (CD 33) (NN %)) (CC vs.) (NP (CD 7) (NN %)) (, ,) (ADVP (RB respectively))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.001)))) (-RRB- -RRB-)))))))))))))))) (. .)))
(S1 (S (S (S (NP (NN Leukopenia)) (VP (VBD was) (ADJP (JJ similar) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))))) (, ,) (CC but) (S (NP (NP (NN colony) (NN stimulating) (NN factor)) (NN support)) (VP (VBD was) (ADJP (ADJP (RB significantly) (JJR greater)) (PP (IN in) (NP (DT the) (JJ CHOP-HAART) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (JJ control) (NN group)))) (PRN (-LRB- -LRB-) (NP (NP (CD 92) (NN %)) (CC vs.) (NP (CD 66) (NN %)) (, ,) (ADVP (RB respectively))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.03)))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (S (NP (NP (CD Seventeen) (NN percent)) (PP (IN of) (NP (JJ CHOP-HAART) (NNS patients)))) (VP (VBD developed) (NP (JJ severe) (JJ autonomic) (NN neurotoxicity)))) (, ,) (IN whereas) (S (NP (NP (NN none)) (PP (IN of) (NP (DT the) (NN CHOP) (NNS patients)))) (VP (VBD developed) (NP (NP (NN neurotoxicity)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (CD 0.002)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (PP (IN At) (NP (JJ similar) (NN median) (NN follow-up))) (, ,) (NP (NP (NP (NP (JJ opportunistic) (NN infection)) (PRN (-LRB- -LRB-) (NP (NN OI)) (-RRB- -RRB-))) (NNS rates)) (CC and) (NP (NN mortality))) (VP (VBD were) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (DT the) (JJ CHOP-HAART) (NNS patients))) (PP (IN than) (PP (IN in) (NP (DT the) (NN CHOP) (NNS patients)))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 18) (NN %)) (CC vs.) (NP (CD 52) (NN %))) (, ,) (ADVP (RB respectively))) (: ;) (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 0.05)))) (: ;) (NP (NP (CC and) (NP (CD 38) (NN %)) (CC vs.) (NP (CD 85) (NN %))) (, ,) (ADVP (RB respectively))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.001)))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (JJ median) (NN survival)) (PP (IN for) (NP (JJ CHOP-HAART) (NNS patients)))) (VP (VBD was) (RB not) (VP (VBN reached)))) (, ,) (IN whereas) (S (NP (NP (DT the) (JJ medial) (NN survival)) (PP (IN of) (NP (NN CHOP) (NNS patients)))) (VP (VBD was) (NP (CD 7) (NNS months)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.03)))) (-RRB- -RRB-))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NN CHOP)) (CC plus) (NP (NN HAART))))) (VP (VP (VBZ is) (ADJP (JJ feasible))) (CC and) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN morbidity)) (PP (IN from) (NP (NN OIs))) (PP (IN in) (NP (JJ HIV-NHL) (NNS patients)))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (JJ careful) (NN attention)) (VP (MD must) (VP (VB be) (VP (VBN directed) (PP (TO to) (NP (NP (NN cross) (NN toxicity)) (CC and) (NP (NP (JJ possible) (JJ pharmacokinetic) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN impact)) (PP (IN of) (NP (NP (DT the) (JJ combined) (NN chemotherapy)) (CC plus) (NP (NN HAART) (NN treatment)))) (PP (IN on) (NP (NN patient) (NN survival)))) (VP (VBZ needs) (S (ADVP (RB urgently)) (VP (TO to) (VP (VB be) (VP (VBN evaluated) (PP (IN in) (NP (JJ prospective) (NNS studies))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (: :) (NP (DT a) (NN drug) (NN interaction))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN drug) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (RB not) (ADVP (RB well)) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN drug2) (NNS requirements)) (PP (IN in) (NP (NP (JJ human) (NNS subjects)) (VP (VBG ingesting) (NP (DT these) (NNS agents)))))) (ADVP (RB simultaneously))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NP (DT an) (ADJP (RB unusually) (JJ high)) (NN maintenance) (NN dose)) (PP (IN of) (NP (NN drug3)))) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN mg)) (PP (IN per) (NP (NN day)))) (-RRB- -RRB-)))))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB produce) (NP (DT a) (JJ therapeutic) (NN effect)))))))) (. .)))
(S1 (S (S (NP (NP (NN Withdrawal)) (PP (IN of) (NP (NN drug1)))) (VP (VBD decreased) (NP (DT the) (NN drug2) (NN requirement)) (PP (IN by) (NP (CD 50) (NN %))))) (. .)))
(S1 (S (S (NP (DT This) (NN effect)) (VP (VP (MD may) (VP (VB be) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN drug1))) (S (VP (TO to) (VP (VB induce) (NP (JJ microsomal) (NNS enzymes)))))))))) (CC and) (, ,) (ADVP (RB thus)) (, ,) (NP (NP (DT the) (NN catabolism)) (PP (IN of) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (JJ drug2) (NN requirement)) (PP (IN of) (NP (PRP$ our) (NN patient)))))) (VP (VP (VBD appeared) (S (VP (TO to) (VP (VB be) (ADJP (JJ maximal) (PP (NP (QP (CD 5) (TO to) (CD 7)) (NNS days)) (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN drug3)))))))))) (CC and) (VP (VBD extended) (NP (NP (DT a) (JJ similar) (NN length)) (PP (IN of) (NP (NN time)))) (PP (IN after) (NP (NN drug4) (NN withdrawal)))))) (. .)))
(S1 (S (S (NP (DT This) (NN interaction)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (ADJP (RB clinically) (JJ significant))))))) (. .)))
(S1 (S (S (VP (VBN Increased) (NP (NP (NN stability)) (PP (IN of) (NP (NN nucleophosmin/B23)))) (PP (IN in) (NP (NP (JJ anti-apoptotic) (NN effect)) (PP (IN of) (NP (NN ras))) (PP (IN during) (NP (NN serum) (NN deprivation))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD obtained) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (VBN increased) (NN stability)) (PP (IN of) (NP (NN nucleophosmin/B23)))) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (JJ antiapoptotic) (NN effect)) (PP (IN of) (NP (NN ras))) (PP (IN during) (NP (NN serum) (NN deprivation)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Nucleophosmin/B23)) (PP (IN in) (NP (ADJP (ADJP (JJ serum-deprived)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 0) (NN %)) (NN serum)) (-RRB- -RRB-))) (NN NIH-3T3) (NNS cells)))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (RB highly) (JJ unstable) (PP (IN with) (NP (NP (DT a) (NN half-life)) (ADJP (JJR less) (PP (IN than) (NP (CD 4) (NN h))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN nucleophosmin/B23)) (PP (IN in) (NP (JJ serum-deprived) (JJ ras-transformed) (-LRB- -LRB-) (NN RAS-3T3) (-RRB- -RRB-) (NNS cells)))) (VP (VBD was) (ADJP (RB as) (JJ stable) (PP (IN as) (NP (NP (DT that)) (PP (IN in) (NP (JJ serum-supplemented) (NN NIH-3T3) (CC or) (NN RAS-3T3) (NNS cells)))))))) (. .)))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN of) (NP (NN RAS-3T3) (NNS cells))) (PP (IN with) (NP (NN nucleophosmin/B23) (JJ antisense) (NN oligomer)))) (ADVP (RB significantly)) (VP (VBD potentiated) (NP (NP (DT the) (NN apoptosis)) (VP (VBN induced) (PP (IN by) (NP (NN serum) (NN deprivation))))))) (. .)))
(S1 (S (S (NP (ADJP (RB Much) (JJR less)) (NN caspase-3) (NN activity)) (VP (VBD was) (VP (VBN noted) (PP (IN in) (NP (NP (DT the) (NN lysate)) (VP (VBN derived) (PP (IN from) (NP (JJ serum-deprived) (NN RAS-3T3) (NNS cells)))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN in) (NP (NP (DT the) (NN lysate)) (PP (IN of) (NP (JJ serum-deprived) (NN NIH-3T3) (NNS cells))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Cell) (JJ permeable) (NN caspase-3) (NN inhibitor)) (VP (VBN added) (PP (IN in) (NP (DT the) (NN medium))))) (VP (VBD blocked) (NP (NP (DT the) (NN decrease)) (PP (IN of) (NP (NP (NP (NN nucleophosmin/B23)) (CC and) (NP (NN apoptosis))) (VP (VBN induced) (PP (IN by) (NP (NP (NN serum) (NN deprivation)) (PP (IN in) (NP (NN NIH-3T3) (NNS cells))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN inhibitor)) (, ,) (PP (IN on) (NP (DT the) (JJ other) (NN hand))) (, ,) (VP (VBD promoted) (NP (NP (JJ significant) (NN decrease)) (PP (IN of) (NP (NN nucleolin/C23))) (PP (IN in) (NP (NN NIH-3T3) (NNS cells)))) (PP (IN during) (NP (NN serum) (NN deprivation))))) (. .)))
(S1 (S (S (PP (IN Unlike) (NP (NN nucleolin/C23))) (, ,) (NP (NP (NN down-regulation)) (PP (IN of) (NP (NN nucleophosmin/B23)))) (VP (VBD was) (ADVP (RB thus)) (RB not) (ADJP (ADJP (JJ proliferation-dependent)) (CC but) (ADJP (ADJP (JJ caspase-3-)) (CC and) (ADJP (JJ apoptosis-dependent)))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP indicate) (NP (NP (JJ important) (NNS relationships)) (PP (IN among) (NP (NP (NN ras)) (, ,) (NP (NN nucleophosmin/B23)) (, ,) (NP (NP (NN activation)) (PP (IN of) (NP (NN caspase-3)))) (, ,) (CC and) (NP (NP (NN induction)) (PP (IN of) (NP (NN apoptosis))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ mammalian) (NN target)) (PP (IN of) (NP (NN drug2) (NN inhibitor)))) (VP (TO to) (VP (VB prevent) (NP (NN kidney) (NN rejection))))) (. .))))
(S1 (S (S (NP (JJ Current) (JJ immunosuppressive) (NNS therapies)) (VP (VP (VBP are) (ADJP (JJ effective))) (CC but) (VP (MD can) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (JJ significant) (JJ adverse) (NNS reactions)))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ works) (ADVP (RB differently)) (PP (IN from) (NP (NP (DT the) (NNS drug2)) (ADJP (RB currently) (JJ available)))))) (, ,) (CC and) (S (PP (IN except) (IN for) (NP (VBN increased) (NN lipid) (NNS levels))) (, ,) (NP (NP (DT the) (JJ adverse) (NN reaction) (NN profile)) (PP (IN of) (NP (NN drug3)))) (VP (VBZ does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB overlap) (PP (TO to) (NP (DT any) (JJ great) (NN extent))) (PP (IN with) (NP (NP (DT that)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug4)) (CC or) (NP (NN drug5)))))))))))))) (. .)))
(S1 (S (SBAR (IN While) (S (NP (JJ additional) (NN research)) (VP (VBZ is) (VP (VBN needed))))) (, ,) (NP (NP (DT the) (JJ initial) (JJ clinical) (NNS data)) (PP (IN in) (NP (NN kidney) (NNS recipients)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (, ,) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))) (, ,) (VP (MD might) (VP (VB have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VP (VB reduce) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NN rejection) (NNS episodes))))) (, ,) (VP (VB permit) (NP (NP (NNS reductions)) (PP (IN in) (NP (NP (NN drug4)) (CC or) (NP (NN drug5) (NN dosage)))))) (, ,) (CC and) (VP (VB permit) (NP (NN steroid) (NN withdrawal))))))) (PRN (-LRB- -LRB-) (NP (NP (NNP Kelly)) (, ,) (NP (CD 1999))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Development)) (CC and) (NP (NN pharmacology))) (PP (IN of) (NP (NN drug1))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN drug2)) (S (VP (TO to) (VP (VB be) (ADJP (JJ approved) (PP (IN for) (NP (JJ clinical) (NN use))))))))) (, ,) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (ADVP (RB extensively)) (PP (IN in) (NP (NP (NNS humans)) (PP (IN since) (NP (CD 1986)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (RB structurally) (JJ distinct) (PP (IN from) (NP (NP (DT the) (JJ other) (ADJP (RB currently) (JJ available)) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))) (-RRB- -RRB-))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (JJ unique) (JJ biopharmaceutical) (NNS properties)) (ADJP (JJ relative) (PP (TO to) (NP (NP (DT the) (JJ other) (NNS agents)) (PP (IN of) (NP (DT this) (NN class)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Absorption)) (PP (IN of) (NP (NN drug1)))) (VP (VP (VBZ is) (ADJP (RB virtually) (JJ complete) (PP (IN across) (NP (NP (DT all) (NNS species)) (, ,) (PP (VBG including) (NP (NN man))) (, ,))))) (CC and) (VP (VBZ is) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN food))))))))) (. .)))
(S1 (S (S (NP (JJ Systemic) (NN exposure)) (VP (VBZ is) (ADJP (JJ limited)) (, ,) (SBAR (IN as) (S (S (NP (NN drug1)) (VP (VBZ is) (ADJP (JJ subject) (PP (TO to) (NP (NN first-pass) (NN metabolism)))))) (, ,) (CC and) (S (NP (NP (DT the) (NN plasma) (NN half-life)) (PP (IN of) (NP (DT the) (NN drug)))) (VP (VBZ is) (NP (QP (RB approximately) (CD 30)) (NNS minutes)))))))) (. .)))
(S1 (S (S (NP (NP (DT Some) (CD 95) (NN %)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dosage)) (PP (IN of) (NP (NN drug1)))))) (VP (VBZ is) (VP (VBN excreted) (PP (IN via) (NP (DT the) (JJ biliary) (NN route))) (, ,) (PP (IN with) (S (NP (NP (QP (JJR less) (IN than) (CD 2)) (NN %)) (PP (IN of) (NP (DT this)))) (VP (VBG being) (NP (DT the) (NN parent) (NN compound)))))))) (. .)))
(S1 (S (S (ADVP (RB Additionally)) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (JJ circulating) (JJ active) (NNS metabolites)) (CC or) (NP (NP (NN accumulation)) (PP (IN during) (NP (JJ chronic) (NN dosing))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN food))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBP have) (VP (VBN demonstrated) (NP (NP (JJ marked) (NNS reductions)) (PP (IN in) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN bioavailability--from) (CD 40) (NN %) (TO to) (CD 60) (NN %))))))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (NP (DT a) (NN comparison)) (PP (IN of) (NP (NN drug1) (NN administration))) (PP (PP (IN with) (NP (DT the) (NN evening) (NN meal))) (CC or) (PP (IN at) (NP (NN bedtime))))) (VP (VBZ has) (VP (VBN revealed) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (NP (NN bioavailability)) (PRN (-LRB- -LRB-) (NP (NP (NN area)) (PP (IN under) (NP (DT the) (NN curve)))) (-RRB- -RRB-))) (PP (IN of) (NP (DT these) (CD two) (NNS regimens))))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (JJ pharmacodynamic) (NN effect)) (PRN (-LRB- -LRB-) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (JJ low-density) (NN lipoprotein) (NN cholesterol)) (NNS levels)))) (-RRB- -RRB-))))) (VP (MD could) (VP (VB be) (VP (VBN ascertained) (PP (IN between) (NP (NP (NN mealtime) (NN dosing)) (CC and) (NP (NN bedtime) (NN dosing)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN assessed) (PP (IN in) (NP (JJ various) (JJ demographic) (NNS groups))))))) (. .)))
(S1 (S (S (PP (JJ Relative) (TO to) (NP (DT the) (JJ general) (NN population))) (, ,) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1)))) (VP (VBP do) (RB not) (VP (VB vary) (PP (IN as) (NP (NP (DT a) (NN function)) (PP (IN of) (NP (CC either) (NP (NN age)) (CC or) (NP (NN gender))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN administration)) (PP (TO to) (NP (DT a) (NN patient) (NN population))) (PP (IN with) (NP (JJ hepatic) (NN insufficiency)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ 2.5-fold) (NN increase)) (PP (IN in) (NP (NP (CC both) (DT the) (NP (NN rate)) (CC and) (NP (NN extent))) (PP (IN of) (NP (NP (NN bioavailability)) (ADJP (JJ relative) (PP (TO to) (NP (NNS controls)))))))))))) (. .)))
(S1 (S (ADVP (RB Also)) (, ,) (SBAR (IN although) (S (NP (NP (JJ minimal) (NNS alterations)) (PP (IN of) (NP (NN drug1) (NN clearance))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ renal) (NN insufficiency)))))) (VP (VBP are) (VP (VBN anticipated) (PP (JJ due) (TO to) (NP (NP (JJ limited) (JJ renal) (NN excretion)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (DT this) (NN patient) (NN group)))) (VP (VBZ is) (ADVP (RB currently)) (VP (VBN underway) (S (VP (TO to) (VP (VB examine) (NP (DT this) (JJ further))))))) (. .)))
(S1 (S (S (NP (NN Interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN with) (NP (NP (NP (NN drug1)) (CC and) (NP (JJ several) (NNS drugs))) (SBAR (WHPP (IN with) (WHNP (WDT which))) (S (NP (PRP it)) (VP (MD might) (VP (VB be) (VP (VBN coadministered)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (DT an) (JJ anionic-binding) (NN resin)) (, ,)) (VP (VBZ has) (NP (DT a) (JJ considerable) (NN effect)) (PP (IN in) (S (VP (VBG lowering) (NP (NP (DT the) (NP (NN rate)) (CC and) (NP (NN extent))) (PP (IN of) (NP (NN drug2) (NN bioavailability))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (DT this) (NN effect)) (VP (VBD was) (VP (VBN noted)) (SBAR (WHADVP (RB even) (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN given) (ADVP (NP (CD 4) (NNS hours)) (RB prior) (PP (TO to) (NP (NN drug2))))))))))) (, ,) (NP (DT this) (NN regimen)) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (VBN diminished) (NN efficacy)))))) (. .)))
(S1 (S (S (ADVP (RB Further)) (, ,) (NP (NP (DT no) (NNS effects)) (PP (IN on) (NP (CC either) (NP (NN drug1) (NNS levels)) (CC or) (NP (NN prothrombin) (NNS times))))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (DT a) (NN study)) (VP (VBG involving) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))))) (. .)))
(S1 (S (ADVP (RB Moreover)) (, ,) (S (S (NP (NP (JJ additional) (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBP have) (RB not) (VP (VBN demonstrated) (NP (NP (DT any) (NN effect)) (PP (IN on) (NP (NN drug3) (NN plasma) (NNS levels))))))) (, ,) (CC and) (S (NP (NP (NN administration)) (PP (TO to) (NP (NP (DT a) (NN patient) (NN population)) (VP (ADVP (RB chronically)) (VBG receiving) (NP (NN drug4)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (NN bioavailability)) (PP (IN of) (NP (NP (NN drug5)) (ADJP (JJ relative) (PP (TO to) (NP (JJ control) (NNS data))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS results)) (VP (VBN generated) (PP (TO to) (NP (NN date))) (PP (IN in) (NP (NP (JJ clinical) (JJ pharmacokinetic) (NNS studies)) (PP (IN with) (NP (NN drug1))))))) (ADVP (RB thus)) (VP (VBP support) (NP (NP (PRP$ its) (NN use)) (PP (IN in) (NP (NP (DT a) (JJ broad) (NN population)) (PP (IN of) (NP (JJ hypercholesterolaemic) (NNS patients)))))))) (. .)))
(S1 (S (NP (NP (JJ Molecular) (NN basis)) (PP (IN for) (NP (NP (DT the) (JJ selective) (NN toxicity)) (PP (IN of) (NP (NN drug1))))) (PP (IN for) (NP (NP (NN yeast)) (CC and) (NP (NN drug2)))) (PP (IN for) (NP (NN animal) (NNS cells))) (. .))))
(S1 (S (PP (IN Among) (NP (DT the) (NN drug1))) (, ,) (NP (JJ many)) (, ,) (PP (IN like) (NP (NN drug2))) (, ,) (NP (NN cannot)) (VP (VB be) (VP (VBN used) (ADVP (RB clinically)) (SBAR (IN because) (S (NP (PRP they)) (VP (VBP are) (ADJP (JJ toxic))))))) (: ;)))
(S1 (S (S (NP (NN drug1)) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ is) (ADJP (JJ useful) (PP (IN in) (NP (NP (NN therapy)) (PP (IN of) (NP (JJ human) (JJ fungal) (NNS infections)))))) (SBAR (IN because) (S (NP (PRP it)) (VP (VBZ is) (ADJP (RBR less) (JJ toxic))))))) (. .)))
(S1 (S (S (NP (CC Both) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT the) (JJ therapeutic) (NN value)) (PP (IN of) (NP (NN drug2))))) (VP (MD can) (VP (VB be) (VP (VBN rationalized) (PP (IN at) (NP (DT the) (ADJP (ADJP (JJ cellular)) (CC and) (ADJP (JJ molecular))) (NN level))) (PP (IN by) (NP (DT the) (JJ following) (NNS observations))))))) (: :) (S (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (NP (DT these) (NNS drug3)) (VP (VBD showed) (NP (NP (JJ differential) (NNS effects)) (PP (IN on) (NP (NNS cells)))))) (: ;)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (ADJP (RBR more) (JJ potent)) (PP (IN in) (NP (VBG lysing) (JJ human) (JJ red) (NN blood) (NNS cells))) (, ,) (SBAR (IN whereas) (S (NP (NN drug2)) (VP (VBD was) (ADJP (RBR more) (JJ potent)) (PP (IN in) (S (VP (VBG inhibiting) (NP (NN yeast) (NN cell) (NN growth)))))))))) (: ;)))
(S1 (S (S (CC and) (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (ADVP (RBR more) (RB efficiently)) (VP (VBN inhibited) (PP (IN by) (NP (NP (VBN added) (NN cholesterol)) (, ,) (NP (NP (DT the) (JJ major) (NN membrane) (NN sterol)) (PP (IN in) (NP (JJ human) (NNS cells))))))))) (, ,) (IN whereas) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2)))) (VP (VBD were) (ADVP (RBR more) (RB efficiently)) (VP (VBN inhibited) (PP (IN by) (NP (NP (NN ergosterol)) (, ,) (NP (NP (DT the) (JJ major) (NN membrane) (NN sterol)) (PP (IN in) (NP (NN yeast))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJS simplest) (NN inference)) (VP (VBZ is) (SBAR (IN that) (S (NP (NP (DT the) (NP (NN toxicity)) (CC and) (NP (NN effectiveness))) (PP (IN of) (NP (NNS polyenes)))) (VP (VBP are) (VP (VBN determined) (PP (IN by) (NP (NP (PRP$ their) (JJ relative) (NNS avidities)) (PP (IN for) (NP (NP (DT the) (JJ predominant) (NN sterol)) (PP (IN in) (NP (NN cell) (NNS membranes))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS -LSB-Hippocampus)) (PP (IN as) (NP (NN interaction) (NNS sites))) (PP (IN between) (NP (JJ cerebral) (NN memory) (NNS systems))) (-RRB- -RSB-) (PP (JJ Most) (IN of) (NP (DT the) (JJ current) (NNS theories)))) (VP (VB assume) (SBAR (IN that) (S (NP (EX there)) (VP (VBP are) (NP (NP (JJ multiple) (NNS forms)) (PP (IN of) (NP (NN memory))) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP are) (VP (VBN supported) (PP (IN by) (NP (JJ separate) (NN brain) (NNS systems))))) (CC and) (VP (VBP have) (NP (JJ different) (NNS characteristics)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Animals) (NNS studies)) (PP (IN on) (NP (DT the) (JJ various) (NN dual-memory) (NNS theories)))) (VP (VBP have) (VP (VBN been) (VP (VBN carried) (PRT (RP out)) (PP (ADVP (RB mainly)) (IN on) (DT the) (NN basis) (IN of) (NP (JJ hippocampal) (NN system) (NN function))))))) (. .)))
(S1 (S (S (ADVP (RB Specifically)) (, ,) (NP (PRP they)) (VP (VBP have) (VP (VBN focused) (PP (IN on) (NP (NP (NNS aspects)) (PP (IN of) (NP (NP (NP (NN learning)) (CC and) (NP (NN memory))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (ADJP (JJ impaired)) (-LRB- -LRB-) (CC vs.) (ADJP (VBN spared)) (-RRB- -RRB-)) (PP (IN by) (NP (NP (NNS lesions)) (PP (IN of) (NP (DT the) (JJ hippocampal) (NN formation))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (VBP are) (NP (NP (JJ several) (NNS instances)) (PP (IN in) (NP (NP (DT the) (JJ animal) (NN literature)) (VP (VBG showing) (SBAR (IN that) (S (NP (JJ hippocampal) (NNS lesions)) (ADVP (RB actually)) (VP (VBD produced) (NP (VBN enhanced) (NP (NP (NN learning)) (CC and) (NP (NN memory))) (NN function))))))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN acquisition)) (PP (IN of) (NP (NP (NNS tasks)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN facilitated) (PP (IN by) (NP (NP (JJ hippocampal) (NNS lesions)) (PRN (-LRB- -LRB-) (CC or) (NP (NN dysfunction)) (-RRB- -RRB-))))))))))) (VP (VBZ is) (ADVP (RB nevertheless)) (VP (VBN associated) (, ,) (PP (IN in) (NP (JJ intact) (NNS subjects))) (, ,) (PP (IN with) (NP (NP (JJ specific) (JJ neurobiological) (NNS alterations)) (PP (IN in) (NP (DT the) (NN hippocampus)))))))) (. .)))
(S1 (S (S (NP (DT This) (NN problem)) (VP (VBZ has) (VP (VBN been) (VP (VBN analysed) (S (VP (VBG using) (NP (NP (NP (CD two) (JJ different) (NNS tasks)) (PP (IN in) (NP (NNS mice)))) (: :) (NP (NP (DT a) (JJ bar-press) (NN conditioning)) (CC and) (NP (DT a) (JJ spatial) (NN discrimination) (NN task)))))))))) (. .)))
(S1 (S (S (NP (NNS Results)) (VP (VBD showed) (SBAR (IN that) (S (, ,) (PP (VBG depending) (PP (IN on) (NP (NP (DT the) (NN task)) (VP (VBN considered))))) (, ,) (NP (DT the) (JJ same) (JJ pharmacological) (NN treatment)) (VP (VBD produced) (NP (CC either) (NP (DT a) (NN facilitation)) (CC or) (NP (NP (DT an) (NN impairment)) (PP (IN of) (NP (NN acquisition)))))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (DT each) (NN task)) (VP (VBD induced) (NP (JJ significant) (NNS alterations)) (PP (PP (IN in) (NP (NP (JJ hippocampal) (NN adenylate) (NN cyclase)) (NN activity))) (CC but) (PP (IN in) (NP (JJ opposite) (NNS directions)))))) (. .)))
(S1 (S (PP (ADVP (RB Together)) (IN with) (NP (JJ previous) (NNS findings))) (, ,) (NP (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (NN hippocampus)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (CC both) (DT the) (JJ so-called) (NN &quot) (: ;) (NN hippocampal-dependent&quot)))))))) (: ;)))
(S1 (S (NP (NP (NN &quot)) (: ;) (NP (NN hippocampal-independent&quot)) (: ;))))
(S1 (S (NP (NP (NNS forms)) (PP (IN of) (NP (NN memory))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN postulated) (SBAR (IN that) (S (NP (NP (DT some)) (PP (IN of) (NP (DT the) (VBN observed) (JJ training-induced) (JJ neurobiological) (NNS alterations)))) (VP (MD might) (VP (VB reflect) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (CD two) (PRN (-LRB- -LRB-) (QP (CC or) (JJR more)) (-RRB- -RRB-)) (VBG competing) (NN memory) (NNS systems))) (PP (IN at) (NP (DT the) (JJ hippocampal) (NN level))))))))))) (. .)))
(S1 (S (ADVP (RB Thus)) (, ,) (PP (IN in) (NN addition) (TO to) (NP (NP (PRP$ its) (JJ proposed) (JJ specific) (NN information) (NN processing) (NNS functions)) (PRN (-LRB- -LRB-) (PP (FW i.e.) (, ,) (NP (NN relational))) (-RRB- -RRB-)))) (, ,) (NP (DT the) (NN hippocampus)) (VP (MD would) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG addressing) (NP (NP (NN information)) (PP (TO to) (NP (NP (DT the) (NN brain) (NN memory) (NN system)) (SBAR (WHNP (WDT that)) (S (, ,) (PP (IN in) (NP (DT a) (JJ given) (NN situation))) (, ,) (VP (VBZ has) (NP (NP (DT the) (JJS best) (JJ adaptive) (NN value.)) (PRN (-LRB- -LRB-) (NP (NP (NN ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))))))))))))))
(S1 (S (S (NP (JJ Behavioral) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (DT the) (NN link)) (PP (IN between) (NP (NP (NN smoking)) (CC and) (NP (NN drinking))))))) (. .)))
(S1 (S (S (NP (JJ Many) (NN people)) (VP (VBP use) (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (, ,) (NP (NP (NNS cigarettes)) (CC and) (NP (JJ other) (NN tobacco) (NNS products))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (DT these) (CD two) (NNS drugs)))) (VP (VBP differ))) (, ,) (CC and) (S (NP (PRP they)) (VP (VBP do) (RB not) (VP (VB act) (PP (IN on) (NP (NP (DT the) (JJ same) (NN target) (NNS sites)) (PP (IN in) (NP (DT the) (NN brain))))) (, ,) (SBAR (IN although) (S (NP (PRP they)) (VP (MD may) (VP (VP (VB share)) (, ,) (CC or) (ADVP (RB partly)) (VP (VBP share) (NP (, ,) (JJ certain) (NNS properties))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN initiation)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2) (NN use))))) (VP (MD may) (VP (VB be) (ADJP (JJ precipitated) (PP (IN by) (NP (NP (JJ similar) (NN personality) (NNS characteristics)) (PP (IN in) (NP (DT the) (NN user))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN impulsivity)) (CC and) (NP (NN sensation) (NN seeking)))))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN dependence)))))) (VP (MD may) (VP (VB be) (ADJP (JJ similar) (PP (IN for) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (JJ certain) (NNS factors)) (, ,) (PP (JJ such) (IN as) (NP (NP (VBG reinforcing) (NN drug) (NNS effects)) (, ,) (NP (JJ conditioning) (NNS processes)) (, ,) (NP (JJ automatic) (NN behavior)) (, ,) (CC and) (NP (NN stress)))) (, ,)) (VP (MD may) (VP (VB influence) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NN dependence)) (PP (IN on) (NP (DT both) (NNS drugs))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS factors)) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (NP (NN tolerance)) (CC and) (NP (NN sensitization))) (PP (TO to) (NP (NP (DT the) (NNS drugs) (POS ')) (NNS actions)))) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN withdrawal) (NNS symptoms)))))) (, ,)) (VP (MD may) (ADVP (RB also)) (VP (VB contribute) (PP (TO to) (NP (NN dependence)))))) (. .)))
(S1 (S (S (NP (DT This) (NN review)) (VP (VBZ discusses) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (DT the) (CD two) (NNS drugs))) (PP (IN on) (NP (NP (JJ certain) (NN brain) (JJ chemical) (PRN (-LRB- -LRB-) (PP (FW i.e.) (, ,) (NP (NN neurotransmitter))) (-RRB- -RRB-)) (NNS systems)) (CC and) (NP (NP (DT the) (NN extent)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT the) (CD two) (NNS drugs)))) (VP (MD may) (VP (VB interact))))))))))) (. .)))
(S1 (S (NP (NP (NN Vancomycin) (NN resistance) (NN reversal)) (PP (IN in) (NP (NN enterococci))) (PP (IN by) (NP (NNS flavonoids))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NP (JJ clinical) (JJ vancomycin-resistant) (NNS strains)) (PP (IN of) (NP (NP (NNS enterococci)) (PRN (-LRB- -LRB-) (NP (NN VRE)) (-RRB- -RRB-))))))) (VP (VBZ is) (NP (NP (DT a) (JJ major) (NN cause)) (PP (IN for) (NP (NN concern)))))) (. .)))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN 3,7-dihydroxyflavone)))) (PP (IN with) (NP (NN drug2)))) (VP (MD may) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB sensitize) (NP (NP (JJ resistant) (NNS strains)) (PP (IN of) (NP (NP (FW Enterococcus) (FW faecalis)) (CC and) (NP (FW Enterococcus) (FW faecium))))) (PP (TO to) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ vancomycin-sensitive) (NNS strains))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Minimum) (JJ inhibitory) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NN MICs)) (-RRB- -RRB-))) (CC and) (NP (JJ viable) (NNS counts))) (VP (VBD were) (VP (VBN determined) (PP (IN in) (NP (NN Iso-sensitest) (CD broth))) (S (VP (VBG using) (NP (DT a) (NN microtitre) (NN method))))))) (. .)))
(S1 (S (NP (NP (NNS MICs)) (PP (IN of) (NP (NN drug1))) (PP (IN against) (NP (NP (CD 67) (NN %)) (PP (IN of) (NP (NP (JJ resistant) (JJ clinical) (NNS isolates)) (CC and) (NP (NP (DT a) (NN type) (NN strain)) (PP (IN of) (NP (NN enterococci))))))))) (VP (VBD were) (VP (VBN lowered) (PP (IN from) (NP (NP (NN >) (CD 250) (NN microg) (NN mL)) (PRN (-LRB- -LRB-) (NP (CD -1)) (-RRB- -RRB-)))) (PP (TO to) (NP (CD 1)))))))
(S1 (S (NP (NP (NP (NP (CD 4) (NN microg) (NN mL)) (PRN (-LRB- -LRB-) (NP (CD -1)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 12.5) (NN microg) (NN mL)) (PRN (-LRB- -LRB-) (NP (CD -1)) (-RRB- -RRB-))) (-RRB- -RRB-))) (CC or) (NP (NP (NN 3,7-dihydroxyflavone)) (PRN (-LRB- -LRB-) (NP (NP (CD 6.25) (NN microg) (NN mL)) (PRN (-LRB- -LRB-) (NP (CD -1)) (-RRB- -RRB-))) (-RRB- -RRB-)))))))) (. .))))
(S1 (S (S (NP (NP (JJ Viable) (NNS counts)) (PP (IN for) (NP (NN type) (NN culture) (NN E))))) (. .)))
(S1 (S (S (NP (NN faecalis) (NN ATCC) (CD 51299)) (VP (VBD showed) (NP (NP (DT the) (NNS flavonoids) (RB alone) (RB significantly) (JJ lowered) (NNS numbers)) (PP (IN of) (NP (NP (NN colony) (VBG forming) (NNS units)) (PRN (-LRB- -LRB-) (NP (NN CFUs)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NN CFUs)) (VP (VBD were) (VP (VBN maintained) (PP (IN at) (NP (NP (JJ low) (NNS levels)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (-LRB- -LRB-) (CD 3) (-RRB- -RRB-) (NN CFU) (NN mL)) (PRN (-LRB- -LRB-) (NP (CD -1)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 24) (NN h))) (PP (IN by) (NP (NN drug1) (NN /flavone) (NNS combinations)))))) (. .)))
(S1 (S (S (NP (NP (DT This) (JJ combinational) (NN action)) (PP (IN in) (S (VP (VBG reversing) (NP (NP (NN vancomycin) (NN resistance)) (PP (IN of) (NP (NN enterococci)))))))) (VP (VP (VBZ highlights) (NP (JJ novel) (NN drug) (NNS targets))) (CC and) (VP (VBZ has) (NP (NP (NN importance)) (PP (IN in) (NP (NP (DT the) (NN design)) (PP (IN of) (NP (NP (JJ new) (JJ therapeutic) (NNS regimes)) (PP (IN against) (NP (JJ resistant) (NNS pathogens))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN Lack)) (PP (IN of) (NP (NN interaction))) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (: :) (NP (NP (NNS pharmacokinetics)) (CC and) (NP (NN drug) (NN disposition))) (. .))))
(S1 (S (S (NP (JJ Previous) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NP (DT the) (JJ oral) (NN bioavailability)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (DT an) (JJ intravenous) (NN drug3)) (PP (JJ such) (IN as) (NP (NN drug4)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT This) (NN decrease)) (PP (IN in) (NP (NN absorption)))) (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (ADJP (NP (NP (CD 36) (NN %)) (CC and) (NP (CD 50) (NN %))) (JJR lower)) (NN AUC)) (PP (IN for) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (, ,) (ADVP (RB respectively)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB cause) (NP (JJ clinical) (NNS failures)))))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS authors)) (VP (VBD investigated) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (DT a) (JJ similar) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (CD Eight) (JJ healthy) (NNS volunteers)) (VP (VBD were) (VP (VBN randomized) (PP (IN in) (NP (DT an) (ADJP (ADJP (JJ open-label)) (, ,) (ADJP (JJ two-way))) (NN crossover) (NN study))) (S (VP (TO to) (VP (VBP receive) (NP (NP (NN drug1)) (, ,) (NP (ADJP (CD 5) (NN mg)) (NN p.o.))))))))))
(S1 (S (NP (NP (NN Q4H)) (, ,) (CC and) (NP (NN drug1)) (, ,) (NP (ADJP (CD 500) (NN mg)) (NN p.o.)))))
(S1 (S (NP (NP (CD 1) (NN hour)) (PP (IN after) (S (VP (VBG starting) (NP (NP (DT the) (NN drug1)) (CC or) (NP (NN drug2) (CD 500) (NN mg) (NN p.o.)))))))))
(S1 (S (ADVP (RB alone)) (. .)))
(S1 (S (S (NP (NN Blood) (NNS samples)) (VP (VBD were) (VP (VBN drawn) (PP (IN at) (NP (QP (CD 0) (, ,) (CD 0.5) (, ,) (CD 1) (, ,) (CD 1.5) (, ,) (CD 2) (, ,) (CD 3) (, ,) (CD 4) (, ,) (CD 6) (, ,) (CD 8) (, ,) (CD 12) (, ,) (CD 18) (, ,) (CC and) (CD 24)) (NNS hours))) (PP (IN for) (NP (NP (NN Cmax)) (, ,) (NP (NN tmax)) (, ,) (CC and) (NP (NN AUC) (NNS determinations))))))) (. .)))
(S1 (S (NP (EX There)) (VP (VBD was) (RB not) (NP (NP (NP (DT a) (JJ significant) (NN difference)) (PRN (-LRB- -LRB-) (NP (NN p) (NN >) (CD 0.05)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NP (NN AUC)) (PRN (-LRB- -LRB-) (QP (QP (CD 48.59) (CC +/-) (CD 8.52) (CC vs.) (CD 49.9)) (CC +/-) (NP (NN 9.93))) (-RRB- -RRB-))) (, ,) (NP (NP (NN Cmax)) (PRN (-LRB- -LRB-) (QP (CD 7.73) (CC +/-) (CD 2.6) (CC vs.) (CD 6.6) (CC +/-) (CD 2.0)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN tmax)) (PRN (-LRB- -LRB-) (QP (CD 1.1) (CC +/-) (CD 0.6) (CC vs.) (CD 1.6) (CC +/-) (CD 1.1)) (-RRB- -RRB-))))) (PP (IN for) (NP (NP (NP (NN drug1)) (CC versus) (NP (NN drug2))) (: /) (NP (NN drug3) (NNS regimens)))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBD was) (VP (VBN concluded) (SBAR (IN that) (S (NP (JJ oral) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (VP (MD can) (VP (VB be) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN without) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (NN AUC)) (, ,) (NP (NN Cmax)) (, ,) (CC or) (NP (NN tmax)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN mode)) (PP (IN of) (NP (NP (JJ toxic) (NN action)) (PP (IN of) (NP (DT the) (NN pesticide) (NN drug1)))))) (: :) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2))) (PP (TO to) (NP (NN drug3))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ biochemical) (NN toxicology)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (JJ known) (NN metabolite)) (PP (IN of) (NP (NP (DT the) (JJ major) (NN ingredient)) (PP (IN of) (NP (NP (DT the) (JJ pesticide) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))))))) (, ,)))) (VP (VBD was) (VP (VBN investigated) (ADVP (ADVP (FW in) (FW vivo)) (CC and) (ADVP (FW in) (FW vitro)))))) (. .)))
(S1 (S (S (NP (NP (NN Rat) (NN kidney) (NNS homogenates)) (VP (VBN supplemented) (PP (IN with) (NP (NP (NN coenzyme) (NN A)) (, ,) (NP (NN ATP)) (, ,) (NP (NN oxaloacetate)) (, ,) (CC and) (NP (NN Mg2+)))))) (VP (VBD converted) (NP (NN drug1)) (PP (TO to) (NP (NN drug2))) (ADVP (FW in) (FW vitro)))) (. .)))
(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN mg) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN body) (NN weight)) (-RRB- -RRB-)))) (PP (TO to) (NP (NNS rats))) (ADVP (FW in) (FW vivo))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN drug2) (NN synthesis)) (PP (IN in) (NP (NP (DT the) (NN kidney)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (VP (VBN preceded) (PP (IN by) (NP (NP (DT an) (NN elevation)) (PP (IN in) (NP (JJ fluoride) (NNS levels)))))) (CC and) (VP (VBN followed) (PP (IN by) (NP (NN citrate) (NN accumulation))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Animals)) (VP (VBN dosed) (PP (IN with) (NP (NN drug1))))) (VP (VBD did) (RB not) (VP (VB display) (NP (NP (DT the) (ADJP (CD 2-3) (NN hour)) (NN lag) (NN phase)) (PP (PP (IN in) (NP (DT either) (NN drug2) (NN synthesis))) (CC or) (PP (IN in) (NP (NP (NP (NP (NN citrate)) (CC and) (NP (NN fluoride))) (NN accumulation)) (ADJP (JJ characteristic) (PP (IN of) (NP (NP (NNS animals)) (VP (VBN dosed) (PP (IN with) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (DT the) (NN conversion)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (NN drug2)) (PP (IN by) (NP (DT an) (JJ NAD+-dependent) (NN oxidation)))))) (VP (VBZ is) (NP (NP (DT the) (JJ rate-limiting) (NN step)) (PP (IN in) (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (NP (DT the) (JJ toxic) (NN product)) (, ,) (NP (NP (NN drug3)) (PP (IN from) (NP (NN drug4)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Prior) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 90) (NN mg) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NP (NN body) (NN weight))) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN shown) (S (VP (VP (TO to) (VP (VB prevent) (NP (NP (DT the) (NN conversion)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN mg) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN body) (NN weight)) (-RRB- -RRB-)))) (PP (TO to) (NP (NN drug3)))) (ADVP (FW in) (FW vivo)))) (CC and) (VP (TO to) (VP (VB eliminate) (NP (NP (DT the) (NN fluoride) (CC and) (NN citrate) (NNS elevations)) (VP (VBN seen) (PP (IN in) (NP (JJ drug4) (JJ -intoxicated) (NNS animals)))))))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN mg) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN body) (NN weight)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (NNS rats)) (ADVP (NP (CD 2) (NNS hours)) (RB prior) (PP (TO to) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (CD 100) (NN mg) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN body) (NN weight)) (-RRB- -RRB-)))))) (VP (VP (VBD was) (ADJP (JJ ineffective) (PP (IN in) (S (VP (VBG preventing) (NP (NN drug3) (NN synthesis))))))) (CC and) (VP (VBD did) (RB not) (VP (VB diminish) (NP (NP (NN fluoride)) (CC or) (NP (NN citrate) (NN accumulation))) (ADVP (FW in) (FW vivo))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (DT the) (ADJP (ADJP (JJ prophylactic)) (CC and) (ADJP (JJ antidotal))) (NNS properties)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN seen) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NN drug2)))))))))) (VP (VBP derive) (PP (IN from) (NP (PRP$ its) (NN capacity) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (JJ NAD+-dependent) (NN oxidation)) (ADJP (JJ responsible) (PP (IN for) (S (VP (VBG converting) (NP (NP (NN drug3)) (PP (TO to) (NP (NN drug4)))) (PP (IN in) (NP (NP (DT the) (VBN committed) (NN step)) (PP (IN of) (NP (DT the) (JJ toxic) (NN pathway)))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (NN drug1) (JJ -induced)) (JJ oxidative) (NN stress)) (PP (IN in) (NP (NP (NN rat) (NN brain)) (CC and) (NP (NN liver))))) (VP (VBZ is) (VP (VBN prevented) (PP (IN by) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))) (. .)))
(S1 (S (S (S (VP (VBG Considering) (SBAR (IN that) (S (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NP (JJ reactive) (NN oxygen) (NNS species)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-))))) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (JJ various) (NNS pesticides)))))))))))) (, ,) (NP (DT this) (NN study)) (VP (VBD was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (NP (JJ oxidative) (NN stress)) (NN induction)) (PP (IN by) (NP (NP (NN drug1)) (, ,) (NP (DT a) (NN drug2))))))))))))) (. .)))
(S1 (S (NP (NP (ADJP (CC Either) (ADJP (JJ single) (PRN (-LRB- -LRB-) (NP (CD 170) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (ADJP (JJ repeated))) (PRN (-LRB- -LRB-) (NP (NP (CD 75) (NN mg/kg)) (PP (IN per) (NP (NN day))) (PP (IN for) (NP (CD 5) (NNS days)))) (-RRB- -RRB-)) (JJ oral) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB produce) (NP (JJ significant) (JJ oxidative) (NN stress)) (PP (IN in) (NP (NP (ADJP (ADJP (JJ cerebral)) (CC and) (ADJP (JJ hepatic))) (NNS tissues)) (PP (IN of) (NP (NNS rats))))) (, ,) (SBAR (IN as) (S (VP (VBD was) (ADJP (JJ evident) (PP (IN by) (NP (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (JJ thiobarbituric) (NN acid) (JJ reactive) (NNS substances)) (PRN (-LRB- -LRB-) (NP (NNS TBARS)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT both) (NNS tissues)))))) (, ,) (CC either) (NP (NP (QP (CD 4) (CC or) (CD 24)) (NN h)) (PP (IN after) (NP (NN treatment))))))))))))))) (. .)))
(S1 (S (S (NP (ADJP (RB Much) (JJR higher)) (NNS changes)) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (NN liver)) (, ,) (VP (VBG increasing) (PP (IN from) (NP (NP (DT a) (NN level)) (PP (IN of) (NP (CD 60) (NN %))))) (PP (IN at) (NP (CD 4) (NN h))) (PP (IN up) (TO to) (NP (NP (QP (RB nearly) (CD 4)) (NNS times)) (NP (NP (DT the) (NN control)) (PP (IN at) (NP (CD 24) (NN h))) (PP (IN for) (NP (JJ single) (NN dose)))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (VBN Reduced) (NNS levels)) (PRN (-LRB- -LRB-) (NP (QP (RB up) (TO to) (CD 20)) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ total) (NN glutathione)) (PRN (-LRB- -LRB-) (NP (JJ total) (NN GSH)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (NN elevation)) (PP (IN of) (NP (NP (VBN conjugated) (NNS dienes)) (PRN (-LRB- -LRB-) (NP (NP (QP (RB approximately) (CD 60)) (NN %)) (PP (IN in) (NP (NN liver)))) (PP (IN by) (NP (NP (JJ single) (NN dose)) (PP (IN at) (NP (CD 4) (NN h))))) (-RRB- -RRB-)))))) (ADVP (RB also)) (VP (VBD indicated) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT an) (JJ oxidative) (NN insult)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Glutathione-S-transferase)) (PRN (-LRB- -LRB-) (NP (NN GST)) (-RRB- -RRB-))) (NN activity)) (, ,) (ADVP (RB however)) (, ,) (VP (VBD did) (RB not) (VP (VB differ) (PP (IN from) (NP (NP (NN control) (NNS values)) (PP (PP (IN for) (NP (DT any) (NN dose))) (CC or) (PP (IN at) (NP (NP (DT any) (NN time) (NN point)) (PP (IN in) (NP (ADJP (ADJP (JJ cerebral)) (CC and) (ADJP (JJ hepatic))) (NNS tissues))))))))))) (. .)))
(S1 (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NNS rats))) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (NN mg/kg)) (, ,) (NP (NN ip))) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 100) (NN mg/kg)) (PP (IN per) (NP (NP (NN day)) (, ,) (NP (NN ig)) (, ,))) (PP (IN for) (NP (CD 3) (NNS days)))) (CC and) (NP (NP (DT a) (NN dose) (IN of) (CD 40) (NN mg/kg)) (PP (IN on) (NP (DT the) (JJ 4th) (NN day))))) (-RRB- -RRB-)))))) (VP (VBD provided) (NP (NP (JJ significant) (NN protection)) (PP (IN against) (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (NP (NNS TBARS) (NNS levels)) (PP (IN in) (NP (ADJP (ADJP (JJ cerebral)) (CC and) (ADJP (JJ hepatic))) (NNS tissues))))) (, ,) (VP (VBN induced) (PP (IN by) (NP (NP (JJ single) (JJ high) (NN dose)) (PP (IN of) (NP (JJ oral) (NN drug3) (NN administration))))) (PP (IN within) (NP (CD 4) (NN h)))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (DT the) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN drug1) (NN exposure)) (PP (IN of) (NP (NNS rats)))) (VP (VBZ results) (PP (IN in) (NP (JJ free) (JJ radical-mediated) (NN tissue) (NN damage))) (, ,) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (NP (JJ elevated) (ADJP (ADJP (JJ cerebral)) (CC and) (ADJP (JJ hepatic))) (NN lipid) (NN peroxidation)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (VBN prevented) (PP (IN by) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Serum) (NN drug1) (NNS levels)) (VP (VBG using) (NP (DT an) (JJ 125I-labelled) (NN antigen)))) (: :) (NP (NP (NP (NN Validation)) (PP (IN of) (NP (NN method)))) (CC and) (NP (NP (NNS observations)) (PP (IN on) (NP (JJ cardiac) (NNS patients)))))) (. .)))
(S1 (S (S (NP (CD 1))) (. .)))
(S1 (S (S (NP (NP (NNS Determinations)) (PP (IN of) (NP (NP (NN serum) (NN drug1) (NNS levels)) (VP (VBG utilizing) (NP (ADJP (RB commercially) (JJ available)) (NNS kits)) (PP (IN with) (NP (DT an) (JJ 125I-labelled) (NN antigen))))))) (VP (VBD were) (UCP (ADJP (JJ precise)) (CC and) (RB not) (ADJP (RB materially) (JJ different) (PP (IN from) (NP (NP (NNS results)) (VP (VBN obtained) (PP (IN with) (NP (DT a) (JJ 3H-labelled) (NN antigen)))))))))) (. .)))
(S1 (S (NP (NP (CD 2)) (. .))))
(S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (JJ approximate) (NP (DT the) (JJ steady) (NN state) (NN level)))))) (, ,) (NP (NN serum) (NN drug1) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN drawn) (PP (CC either) (PP (IN before)) (CC or) (PP (IN at) (NP (QP (JJS least) (CD six)) (NNS hours)))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT an) (JJ oral) (NN tablet))))))))) (. .)))
(S1 (S (NP (NP (CD 3)) (. .))))
(S1 (S (S (NP (ADJP (RB Concomitantly) (VBN given)) (NN drug1)) (VP (VBD did) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (DT a) (NN tablet)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (CD 4))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ digitalized) (NN patient))) (, ,) (NP (NP (JJ slow) (NNS alterations)) (PP (IN in) (NP (NP (NN serum) (NNS levels)) (PP (IN after) (NP (JJ oral) (NN administration)))))) (VP (VBD appeared) (ADVP (RB well)) (VP (VBN correlated) (PP (IN with)) (, ,) (ADVP (IN at) (JJS least)) (, ,) (NP (NP (DT the) (JJ negative) (JJ chronotropic) (NNS effects)) (PP (IN of) (NP (DT the) (NN drug))))))) (. .)))
(S1 (S (NP (NP (CD 5)) (. .))))
(S1 (S (S (NP (NP (JJ Maximal) (NN exercise) (NN testing)) (, ,) (NP (NP (DT a) (NN maneuver)) (VP (ADVP (RB often)) (VBN applied) (PP (TO to) (NP (JJ cardiac) (NNS patients))))) (, ,)) (VP (VBZ does) (RB not) (ADVP (RB significantly)) (VP (VB alter) (NP (DT the) (NN serum) (NN drug1) (NN level))))) (. .)))
(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (JJ drug1) (JJ -induced) (NN diarrhea)) (PP (IN in) (NP (JJ cecectomized) (NNS rats))))) (. .))))
(S1 (S (S (NP (DT The) (ADJP (NN drug1) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-) (JJ -induced)) (NN diarrhea)) (VP (VBD was) (VP (VBN analyzed) (PP (IN in) (NP (NP (JJ cecectomized) (NNS rats)) (VP (VBN prepared) (PP (IN by) (S (VP (VBG resecting) (NP (NP (DT the) (NN cecum)) (CC and) (NP (PRP$ its) (NN vasculature))) (PP (IN without) (S (VP (VBG disturbing) (NP (DT the) (JJ ileocecal) (NN junction)))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.1-1.0) (NN mg/kg)) (, ,) (NP (NN p.o.))) (-RRB- -RRB-)))))
(S1 (S (S (ADVP (RB dose-dependently)) (VP (VP (VBD increased) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN defecation) (NNS episodes))))) (CC and) (VP (VBD induced) (NP (NP (DT a) (ADJP (ADJP (JJ soft)) (CC and) (ADJP (JJ watery))) (NN stool)) (PP (IN in) (NP (JJ cecectomized) (NNS rats))))))) (. .)))
(S1 (S (S (PP (IN At) (NP (CD 0.3) (NN mg/kg))) (, ,) (NP (NP (DT the) (JJ diarrhea-inducing) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (ADJP (RBR more) (JJ pronounced)) (PP (IN in) (NP (NN cecectomized))) (PP (IN than) (PP (IN in) (NP (JJ control) (NNS rats)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN given) (ADVP (RB i.p.))))) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 0.3) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBD induced) (NP (DT a) (JJ watery) (NN stool)) (PP (IN in) (NP (NP (UCP (ADJP (JJ cecectomized)) (CC and) (NP (NN control))) (NNS rats)) (PP (IN with) (NP (DT the) (JJ same) (NN efficacy))))) (, ,) (SBAR (IN although) (S (NP (DT these) (NNS effects)) (VP (VBD were) (ADJP (JJ short-lasting)) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (JJ oral) (NN administration))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 4) (NN ml/kg)) (, ,) (NP (NN p.o.))) (-RRB- -RRB-)))))
(S1 (S (S (ADVP (RB also)) (VP (VP (VBD induced) (NP (NN diarrhea))) (, ,) (CC but) (VP (VBD did) (RB not) (VP (VB produce) (NP (NP (DT a) (JJ watery) (NN stool)) (PP (IN in) (NP (JJ cecectomized) (NNS rats)))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (NNS differences)) (PP (IN between) (NP (NP (ADJP (JJ cecectomized))) (CC and) (NP (ADJP (JJ control))) (NP (NNS rats)))) (PP (PP (IN in) (NP (JJ basal) (JJ small) (JJ intestinal) (NNS transits))) (CC or) (PP (IN in) (NP (ADJP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.3) (NN mg/kg)) (, ,) (NP (NN p.o.))) (-RRB- -RRB-))) (JJ -induced)) (NNS enhancements))))))) (. .)))
(S1 (S (ADVP (RB Moreover)) (, ,) (NP (DT the) (ADJP (ADJP (JJ basal)) (CC and) (ADJP (NN drug1) (JJ -induced))) (JJ jejunal) (JJ net) (NN fluid) (NNS transfers)) (VP (VBD were) (NP (DT the) (JJ same)) (PP (PP (IN in) (NP (JJ cecectomized))) (CC and) (PP (IN in) (NP (NN control) (NNS rats))))) (. .)))
(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (DT the) (VBN enhanced) (NN secretion)) (PP (IN of) (NP (JJ colonic) (NN fluid))) (PP (IN by) (NP (NN drug1))) (, ,) (VP (VBN given) (ADVP (RB intraluminally))) (, ,)) (VP (VBD was) (NP (NP (RB only) (NN half)) (PP (IN of) (NP (NP (DT that)) (PP (IN in) (NP (NN control) (NNS rats)))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (JJ colonic) (JJ transit-enhancing) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (JJ cecectomized) (NNS rats)))) (VP (VBD was) (ADJP (RBR more) (JJ pronounced)) (PP (IN than) (PP (IN in) (NP (JJ control) (NNS rats)))) (PP (PP (IN at) (NP (CD 15))) (CC but) (PP (RB not) (IN at) (NP (NP (CD 30) (NN min)) (PP (IN after) (NP (PRP$ its) (NN administration)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ basal) (JJ colonic) (NN fluid) (NNS contents)) (CC and) (NP (NNS transits))) (VP (VBD were) (NP (DT the) (JJ same)) (PP (PP (IN in) (NP (JJ cecectomized))) (CC and) (PP (IN in) (NP (NN control) (NNS rats)))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 0.1) (CC and) (CD 1.0)) (NN mg/kg)) (, ,) (NP (NN s.c.))) (-RRB- -RRB-)))))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 0.1) (CC and) (CD 1.0)) (NN mg/kg)) (, ,) (NP (NN s.c.))) (-RRB- -RRB-))) (VP (VBD inhibited) (NP (NP (DT the) (ADJP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.3) (NN mg/kg)) (, ,) (NP (NN p.o.))) (-RRB- -RRB-))) (JJ -induced)) (NN diarrhea)) (PP (IN in) (NP (JJ cecectomized) (NNS rats)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 5) (NN mg/kg)) (, ,) (NP (NN s.c.))) (-RRB- -RRB-)))))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 5) (NN mg/kg)) (, ,) (NP (NN s.c.))) (-RRB- -RRB-))) (VP (VP (ADVP (RB completely)) (VBD antagonized) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN drug2))))) (CC and) (VP (ADVP (RB partly)) (VBD antagonized) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ induces) (NP (DT a) (ADJP (RBR more) (JJ pronounced)) (JJ secretory) (NN diarrhea)) (PP (IN in) (NP (NP (VBN cecectomized) (IN than)) (PP (IN in) (NP (NN control) (NNS rats))))) (, ,) (ADVP (RB probably)) (PP (JJ due) (TO to) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NP (DT the) (NN reservoir) (NN function)) (PP (IN of) (NP (DT the) (NN cecum))) (PP (IN in) (NP (DT the) (JJ operated) (NNS animals))))))))))) (. .)))
(S1 (S (S (NP (DT This) (JJ secretory) (NN diarrhea) (NN model)) (VP (VBZ is) (ADJP (JJ suitable) (PP (IN for) (S (VP (VBG evaluating) (NP (NP (DT the) (JJ antidiarrheal) (NN activity)) (PP (IN of) (NP (NNS drugs)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (PP (IN as) (NP (NP (JJ potent) (NN drug2)) (PP (IN of) (NP (JJ glucocorticoid-induced) (NP (NN mouse) (JJ mammary) (NN tumor) (NN virus)) (NN gene) (NN expression)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (ADJP (ADJP (JJ natural)) (CC and) (ADJP (JJ synthetic))) (NN galloyl) (NNS esters))) (PP (IN on) (NP (JJ glucocorticoid-induced) (NN gene) (NN expression)))) (VP (VBD was) (VP (VBN evaluated) (PP (IN by) (S (VP (VBG using) (NP (NP (NN rat) (NN fibroblast) (NN 3Y1) (NNS cells)) (VP (ADVP (RB stably)) (VBN transfected) (PP (IN with) (NP (NP (DT a) (NN luciferase) (NN reporter) (NN gene)) (PP (IN under) (NP (NP (DT the) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT the) (NN mouse) (JJ mammary) (NN tumor) (NN virus) (CD drug1))))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ glucocorticoid-induced) (NN gene) (NN transcription)) (VP (VBD was) (ADVP (RB strongly)) (VP (VBN suppressed) (PP (IN by) (NP (JJ synthetic) (NN alkyl) (NNS esters)))))) (: ;)))
(S1 (S (S (NP (NN drug1)) (VP (VBD showed) (NP (NP (NP (DT the) (ADJP (RBS most) (JJ potent)) (NN inhibition)) (PRN (-LRB- -LRB-) (NP (NP (CD 66) (NN %)) (NP (NN inhibition))) (PP (IN at) (NP (CD 10) (NN microM))) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (ADVP (RB far) (RBR more)) (JJ potent) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (JJ crude) (NNS drug2)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN n-Octyl)) (CC and) (NP (NN n-cetyl) (NN gallate))) (ADVP (RB also)) (VP (VBD showed) (NP (JJ good) (NN inhibition)) (, ,) (SBAR (IN while) (S (NP (NP (JJ gallic) (NN acid)) (NP (PRP itself))) (VP (VBD was) (RB not) (ADVP (RB so)) (ADJP (JJ active))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ hydrophobic) (JJ side) (NN chain)))) (VP (VBZ is) (ADJP (JJ important) (PP (IN for) (NP (DT the) (JJ suppressive) (NN effect))))))))))) (. .)))
(S1 (S (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (ADVP (RB surprisingly)) (, ,) (NP (NP (NN drug1)) (, ,) (NP (PRN (-LRB- -LRB-) (CC -) (-RRB- -RRB-)) (NP (NP (NN -epigallocatechin-3-O-gallate)) (CC and) (NP (NN theasinensin) (NN A)))) (, ,)) (ADVP (RB potently)) (VP (VBD enhanced) (NP (NP (DT the) (NN promoter) (NN activity)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (QP (CD 182) (CC and) (CD 247)) (NN %)) (NN activity)) (PP (IN at) (NP (NP (CD 1) (NN microM)) (, ,) (ADVP (RB respectively))))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN regulation)) (PP (IN of) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (DT the) (JJ glucocorticoid-induced) (NN gene) (NN expression))))) (PP (IN by) (NP (DT the) (JJ antioxidative) (NNS gallates)))) (VP (VBZ is) (PP (IN of) (NP (JJ great) (NN interest))) (PP (IN from) (NP (NP (DT a) (JJ therapeutic) (NN point)) (PP (IN of) (NP (NN view))))))) (. .)))
(S1 (S (S (NP (NP (JJ High-dose) (NN drug1)) (PP (IN with) (NP (NN drug2) (NN protection))))) (. .)))
(S1 (S (S (NP (NN Nephrotoxicity)) (ADVP (RB frequently)) (VP (VBZ limits) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (PP (TO to) (NP (NP (QP (JJR less) (IN than) (CD 120)) (NNS mg/m2)) (PP (IN per) (NP (NN injection))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN neutralizing) (NN agent)) (PP (IN for) (NP (NN drug2))) (SBAR (WHNP (WDT that)) (S (VP (VBZ protects) (PP (IN against) (NP (JJ renal) (NN damage))))))))) (. .)))
(S1 (S (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NN injection)) (PP (IN of) (NP (NN drug1)))) (VP (MD would) (VP (VB permit) (NP (NP (JJR larger) (NNS doses)) (PP (IN of) (NP (NN drug2)))) (S (VP (TO to) (VP (VB be) (VP (VBN administered)))))))))))) (, ,) (NP (NP (DT a) (JJ fixed) (NN 9.9-g/m2) (NN dose)) (PP (IN of) (NP (NN drug3)))) (VP (VBD was) (VP (VBN given) (ADVP (RB intravenously)) (PP (IN over) (NP (CD three) (NNS hours))) (PP (ADVP (RB concurrently)) (IN with) (NP (NP (JJ escalating) (NNS doses)) (PP (IN of) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (IN over) (NP (NP (DT the) (JJ last) (CD two) (NNS hours)) (PP (IN of) (NP (DT the) (NN drug2) (NN infusion)))))))) (. .)))
(S1 (S (S (S (VP (VBG Using) (NP (DT this) (NN technique)))) (, ,) (NP (PRP it)) (VP (VBD was) (ADJP (JJ possible) (S (VP (TO to) (VP (VB escalate) (NP (DT the) (NN drug1) (NN dose)) (PP (TO to) (NP (NN 225) (NNS mg/m2))))))) (SBAR (IN before) (S (NP (JJ dose-limiting) (NNS toxicities)) (VP (VBD were) (VP (VBN encountered))))))) (. .)))
(S1 (S (S (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (NN drug1) (NNS pharmacokinetics)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (CD 202.5) (NNS mg/m2)) (CC plus) (NP (NN drug2))))))))) (PP (TO to) (NP (NP (DT those)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (CD 100) (NNS mg/m2)) (PP (IN without) (NP (NN drug3))))))))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (EX there)) (VP (VBD were) (NP (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN elimination) (NN rate)) (NN constant)))) (, ,) (NP (NP (NN volume)) (PP (IN of) (NP (NN distribution)))) (, ,) (CC or) (NP (NP (JJ total) (NN body) (NN clearance)) (PP (IN of) (NP (NN drug4)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ total) (NN drug) (NN exposure)) (PP (IN for) (NP (DT the) (NN plasma)))) (VP (VBD was) (ADJP (RB approximately) (JJ twofold)) (PP (IN at) (NP (DT the) (JJR higher) (NN drug1) (NN dose))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ permits) (ADVP (IN at) (JJS least)) (NP (NP (NP (DT a) (JJ twofold) (NN increase)) (PP (IN in) (NP (NN dose)))) (CC and) (NP (NP (JJ total) (NN exposure)) (PP (TO to) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NP (NN Interaction)) (PP (IN on) (NP (DT the) (JJ antinociceptive) (NN effect))) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (CC or) (NP (NN drug3)))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN paper)))) (VP (VBD was) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (CC both) (NP (NN drug2)) (CC or) (NP (PRP$ its) (JJ synthetic) (NN analogue) (NN drug3))) (, ,) (CC or) (NP (NN drug4))))) (, ,) (PP (IN on) (NP (NP (DT the) (JJ antinonciceptive) (NN effect)) (PP (IN of) (NP (DT these) (NNS peptides))) (PP (IN in) (NP (NP (NNS mice)) (PP (IN after) (NP (JJ intracisternal) (NN injection)))))))))))) (. .)))
(S1 (S (S (NP (NN Antinociception)) (VP (VBD was) (VP (VBN measured) (PP (IN by) (NP (DT the) (JJ hot-plate) (NN method)))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBD was) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD antagonized) (ADVP (RB evidently)) (NP (NP (DT the) (JJ antinociceptive) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (PRP$ their) (NN analogue))))))))))) (. .)))
(S1 (S (S (PP (IN On) (NP (DT the) (NN contrary))) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD were) (NP (NP (NNS agonists)) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (NN analgesia)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ modulates) (PP (IN in) (NP (DT an) (JJ opposite) (NN way))) (NP (NP (NP (DT the) (NN function)) (PP (IN of) (NP (DT the) (JJ enkephalinergic) (NNS neurons)))) (CC and) (NP (NP (DT the) (JJ central) (NN action)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (VBG emerging) (NNS roles)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NN drug2) (NN therapy))))) (. .)))
(S1 (S (NP (NP (DT The) (NN availability)) (PP (IN of) (NP (NP (JJ potent) (NN drug1) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-) (JJ -based) (NNS regimens)) (PP (IN for) (NP (NN drug3) (NN therapy)))))) (VP (CC and) (VP (VBZ concerns) (S (VP (VBG regarding) (NP (NP (ADJP (NN drug4) (-LRB- -LRB-) (NN drug5) (-RRB- -RRB-) (JJ -related)) (JJ metabolic) (NNS disturbances)) (VP (VBP have) (VP (VBN led) (PP (TO to) (NP (NP (JJ significant) (NNS shifts)) (PP (IN in) (NP (NP (NN treatment) (NNS practices)) (PP (IN in) (NP (NN HIV) (NN infection)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (JJ -based) (NNS regimens)) (VP (MD may) (VP (VB have) (NP (NP (JJ several) (NNS advantages)) (PP (IN over) (NP (NP (JJ drug2) (JJ -based) (NN therapy)) (PP (IN for) (NP (JJ initial) (CC or) (JJ prolonged) (NN therapy))))) (, ,) (PP (VBG including) (NP (NP (ADJP (RBR more) (JJ convenient)) (NN administration) (NNS regimens)) (, ,) (NP (JJR lower) (NN tablet) (NN volume)) (, ,) (NP (JJR fewer) (NN drug) (NNS interactions)) (, ,) (CC and) (NP (NP (JJ central) (JJ nervous) (NN system)) (NN penetration)))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NNS data)) (PP (IN from) (NP (JJ prospective) (JJ clinical) (NNS trials)))) (ADVP (RB currently)) (VP (VBP exist) (S (VP (VBG comparing) (NP (NP (DT the) (CD 3) (JJ approved) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC or) (NP (NN drug3))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (CC Both) (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP have) (VP (VBN been) (VP (VBN compared) (PP (TO to) (NP (NP (JJ triple) (NN therapy)) (PP (IN with) (NP (NP (DT the) (NN drug3) (NN drug4)) (PP (IN over) (NP (CD 48) (NNS weeks))) (PP (IN as) (NP (JJ initial) (NN therapy))))))) (, ,) (PP (IN with) (S (NP (JJ similar) (NNS responses)) (VP (VBG being) (VP (VBN observed) (PP (IN with) (NP (NP (NP (NN drug5) (NNS regimens)) (CC and) (NP (NN superiority))) (VP (VBN observed) (PP (IN with) (NP (NN drug6)))))))))))))) (. .)))
(S1 (S (S (NP (DT A) (JJR smaller) (JJ 24-week) (NN study)) (VP (VBZ has) (VP (VBN suggested) (S (NP (NN drug1)) (VP (MD may) (VP (VB be) (ADJP (JJ superior) (PP (TO to) (NP (DT the) (NN drug2) (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Limited) (JJ comparative) (NNS data)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ high) (JJ viral) (NNS loads))) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (: -) (CC or) (NP (NN drug2)) (NP (JJ -based) (NNS regimens)))))))) (ADVP (RB currently)) (VP (VBP exist))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (NP (NN cohort) (NNS data)) (CC and) (NP (VBN selected) (NN patient) (NNS data))) (PP (IN from) (NP (JJ clinical) (NNS trials)))) (VP (VBP suggest) (NP (NP (JJ comparable) (NN activity)) (PP (TO to) (NP (JJ drug1) (JJ -based) (NNS regimens))) (PP (IN in) (NP (DT these) (NNS patients)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN superiority)) (PP (IN of) (NP (NN drug1))) (PP (IN over) (NP (NN drug2) (JJ -based) (NNS regimens)))) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (JJ comparative) (NNS data))) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ high) (JJ viral) (NNS loads))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (JJ treatment-experienced) (NNS patients))) (, ,) (NP (JJ available) (JJ uncontrolled) (NNS data)) (VP (VBP suggest) (S (NP (DT these) (NNS agents)) (VP (VBP contribute) (PP (TO to) (NP (NP (NN regimen) (NN efficacy)) (PP (IN in) (NP (NN drug1) (NN -na) (NN ve) (, ,) (JJ treatment-experienced) (NNS patients)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN demonstrated) (NP (NP (NN superiority)) (PP (IN over) (NP (NN drug2))) (PP (IN in) (NP (JJ nucleoside-experienced) (NNS patients))))) (, ,) (SBAR (IN although) (S (VP (VBG combining) (S (NP (DT these) (CD 2) (NNS agents)) (VP (MD may) (VP (VB represent) (NP (NP (DT the) (JJS best) (NN approach)) (PP (IN in) (NP (DT these) (NNS circumstances)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN tolerability)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ appears) (ADJP (RB generally) (JJ good) (PP (IN with) (NP (NP (JJ few) (NNS individuals)) (VP (VBG discontinuing) (PP (IN in) (NP (JJ clinical) (NNS studies))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (JJ adverse) (NN drug) (NNS events))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (NP (JJ adverse) (NNS events)) (PP (IN with) (NP (NN drug1)))))) (VP (VP (VBP occur) (PP (IN within) (NP (DT the) (JJ first) (NN month)))) (, ,) (CC and) (VP (VBP are) (ADJP (ADJP (JJ predictable)) (CC and) (ADJP (JJ manageable))) (PP (IN without) (NP (NN therapy) (NN interruption)))))) (. .)))
(S1 (S (NP (NP (NN Suppression)) (PP (IN by) (NP (NN drug1))) (PP (IN of) (NP (NP (NN drug2) (JJ -enhanced) (JJ peritoneal) (NN metastasis)) (PP (IN of) (NP (NP (JJ intestinal) (NNS adenocarcinomas)) (VP (VBN induced) (PP (IN by) (NP (NN drug3))) (PP (IN in) (NP (JJ wistar) (NNS rats)))))))) (. .))))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ combined) (NN administration)) (PP (IN of) (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (DT a) (NN drug4)) (, ,))))) (PP (IN on) (NP (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (JJ peritoneal) (NN metastasis)) (PP (IN of) (NP (NP (JJ intestinal) (NNS adenocarcinomas)) (VP (VBN induced) (PP (IN by) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-)))))))))) (CC and) (NP (NP (DT the) (NN labeling) (NN index)) (PP (IN of) (NP (JJ intestinal) (NNS cancers))))))) (VP (VBD were) (VP (VBN investigated) (PP (IN in) (NP (JJ male) (NN Wistar) (NNS rats)))))) (. .))))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (PP (IN From) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (DT the) (NN experiment))))) (, ,) (NP (NNS rats)) (VP (VBD were) (VP (VBN given) (NP (NP (NP (CD 10) (JJ weekly) (JJ subcutaneous) (NNS injections)) (PP (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 7.4) (NN mg/kg) (NN body) (NN weight)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ subcutaneous) (NNS injections)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN microg/kg) (NN body) (NN weight)) (-RRB- -RRB-))))) (NP (DT every) (JJ other) (NN day)))) (, ,) (CC and) (PP (IN from) (NP (NN week) (CD 16))))) (, ,) (NP (NP (JJ intraperitoneal) (NNS injections)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CC or) (CD 20)) (NN mg/kg) (NN body) (NN weight)) (-RRB- -RRB-))))) (NP (DT every) (JJ other) (NN day))) (PP (IN until) (NP (NP (DT the) (NN end) (NN fo)) (NP (NP (DT the) (NN experiment)) (PP (IN in) (NP (NN week) (CD 45))))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NN drug1)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ intestinal) (NNS tumors)))) (CC and) (NP (NP (NN cancer) (NN metastasis)) (PP (TO to) (NP (DT the) (NN peritoneum))))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (NN drug1)) (VP (VBN administered) (PP (IN at) (NP (DT either) (NN dose))))) (VP (VBD had) (NP (NP (ADJP (JJ little))) (CC or) (NP (DT no) (NN effect))) (PP (PP (IN on) (NP (NP (DT the) (NN enhancement)) (PP (IN of) (NP (JJ intestinal) (NN carcinogenesis))) (PP (IN by) (NP (NN drug2))))) (CC or) (PP (IN on) (NP (NP (DT the) (NN location)) (, ,) (NP (JJ histologic) (NN type)) (, ,) (NP (NP (NN depth)) (PP (IN of) (NP (NP (NN involvement)) (, ,) (NP (NN labeling) (NN index)) (, ,) (NP (JJ apoptotic) (NN index)) (CC or) (NP (NN tumor) (NN vascularity)))) (PP (IN of) (NP (JJ intestinal) (NNS cancers)))))))))) (, ,) (NP (PRP it)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NN cancer) (NN metastasis)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB also)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (JJ lymphatic) (NN invasion)) (PP (IN of) (NP (NP (NN adenocarcinomas)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (VBN enhanced) (PP (IN by) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (NN cancer) (NN metastasis)) (PP (IN through) (NP (NP (NNS actions)) (SBAR (WHNP (WDT that)) (S (VP (VBP do) (RB not) (VP (VB affect) (NP (NP (DT the) (NN growth)) (PP (IN of) (NP (JJ intestinal) (NNS cancers))))))))))))))) (. .))))
(S1 (S (S (NP (NP (JJ -LSB-Dose-time) (NNS effects)) (PP (IN of) (NP (NP (JJ competitive) (NN displacement)) (PP (IN of) (NP (NN drug1))) (PP (IN by) (NP (NN drug2))))) (PP (VBG following) (NP (JJ oral) (CC and) (JJ intravenous) (NN administration))) (-RRB- -RSB-) (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (JJ various) (NNS doses)) (PP (IN of) (NP (NP (NN drug3)) (PP (IN in) (NP (JJ several) (NN dose) (NNS fractions))))))) (PP (IN on) (NP (DT the) (NN extent)))) (CC and) (NP (NP (DT the) (NN time) (NN scale)) (PP (IN of) (NP (NP (NN displacement)) (PP (IN of) (NP (NP (NNS drug4)) (, ,) (PP (IN in) (NP (NP (NN dependence)) (PP (IN on) (NP (NN application) (NN mode))))) (, ,))))))) (VP (VBD was) (VP (VBN studied)))) (. .)))
(S1 (S (S (NP (NP (DT An) (JJ intravenous) (NN dose)) (PP (IN of) (NP (ADJP (CD 50) (NN mg)) (NN drug1)))) (VP (VBD was) (PP (IN in) (NP (NP (NN respect)) (PP (IN of) (NP (NP (JJ competitive) (NN suppression)) (PP (IN of) (NP (NP (NNS organs)) (VP (ADVP (RB actively)) (VBG concentrating) (NP (NN drug2))))))))) (ADJP (RB as) (JJ effective) (PP (IN as) (NP (NP (JJ intravenous) (NP (NP (NP (CD 1000) (NN mg) (JJ ClO-4-)) (ADVP (RB simultaneously))) (CC or) (NP (CD 1000) (NN mg) (QP (RB orally) (CD 30)))) (NN min)) (PP (IN before) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (JJ intravenous) (NN injection)) (PP (IN of) (NP (NN drug1))) (VP (VBN given) (ADVP (RB later)))) (ADVP (RB also)) (VP (VBZ produces) (NP (NP (DT a) (ADJP (ADJP (JJ complete)) (CC and) (ADJP (ADVP (RB immediately)) (VBG beginning))) (NN depletion)) (PP (IN of) (NP (NP (NN drug2)) (VP (ADVP (RB already)) (VBN accumulated) (PP (IN in) (NP (DT the) (NN thyroid))))))) (, ,) (PP (IN within) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (NP (CD 195) (NN min)) (PP (IN after) (NP (NP (NN 99m-TcO-4-injection)) (PP (IN with) (NP (NP (DT a) (JJ corresponding) (NN increase)) (PP (IN in) (NP (NN blood) (NNS levels))))))))))))) (. .)))
(S1 (S (S (NP (CD 20) (NN mg)) (VP (VBP result) (PP (IN in) (NP (NP (JJ incomplete) (NN depletion)) (SBAR (WHNP (WDT which)) (S (VP (VBZ becomes) (ADJP (JJ complete)) (PP (IN after) (NP (DT a) (JJ second) (JJ additional) (NN dose)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ intravenous) (NN application)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ offers) (ADVP (RB advantages)) (PP (IN in) (NP (JJ clinical) (NN use))))) (. .)))
(S1 (S (NP (NP (NP (NNS Combinations)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (: :) (NP (NP (NNS effects)) (PP (IN on) (NP (NP (NN drug) (NN discrimination)) (CC and) (NP (NN behavioral) (NN inhibition)))) (PP (IN in) (NP (NNS rats)))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (VP (VBZ produces) (NP (JJ psychotomimetic) (NNS effects)) (PP (IN in) (NP (NP (NNS humans)) (SBAR (WHNP (WDT that)) (S (VP (VBP resemble) (NP (NN schizophrenia) (NNS symptoms))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT an) (NN effort) (S (VP (TO to) (VP (VB screen) (NP (NP (NNS compounds)) (PP (IN for) (NP (JJ antipsychotic) (NN activity))))))))) (, ,) (NP (JJ preclinical) (NNS researchers)) (VP (VBP have) (VP (VBN investigated) (SBAR (IN whether) (S (NP (DT these) (NNS compounds)) (VP (VBP block) (NP (NP (JJ drug1) (JJ -induced) (NNS behaviors)) (PP (IN in) (NP (NNS animals)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (DT the) (NN drug1) (NN drug2)) (VP (VBD was) (VP (VBN tested) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (DT an) (JJ active) (NN dose)) (PP (IN of) (NP (NP (NP (NN drug3)) (PP (IN in) (NP (JJ two-lever) (NN drug) (NN discrimination)))) (CC and) (NP (JJ mixed) (JJ signalled-unsignalled) (NN differential-reinforcement-of-low-rates) (-LRB- -LRB-) (NN DRL) (-RRB- -RRB-) (NNS procedures))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD produced) (NP (JJ distinctive) (NNS effects)) (PP (IN in) (NP (DT each) (NN task))))) (: :) (S (NP (PRP it)) (VP (VBN substituted) (PP (IN for) (NP (NP (DT the) (JJ training) (NN dose)) (PP (IN in) (NP (NN drug2) (NN discrimination))))))) (CC and) (S (NP (PRP it)) (VP (VBD increased) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS responses)))) (PP (IN with) (NP (NP (ADJP (ADJP (JJ short)) (PRN (-LRB- -LRB-) (NP (NP (NN &lt)) (: ;) (NP (CD 3) (NN s))) (-RRB- -RRB-))) (NN interresponse) (NNS times)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (VBG increasing) (JJ overall) (NN response) (NNS rates)) (PP (IN in) (NP (DT the) (NN DRL) (NN schedule)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Acute) (NN dosing)) (PP (IN with) (NP (NN drug1)))) (VP (VBD failed) (S (VP (TO to) (VP (VB alter) (NP (NP (DT the) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (DT either) (NN procedure)))) (SBAR (WHADVP (RB even) (WRB when)) (S (VP (VBN tested) (PP (RP up) (TO to) (NP (NP (NNS doses)) (SBAR (WHNP (WDT that)) (S (VP (VBD produced) (NP (NP (JJ pharmacological) (NNS effects)) (ADVP (RB alone)))))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ acute) (NN dosing)) (PP (IN with) (NP (NN drug1)))) (VP (MD would) (RB not) (VP (VB affect) (NP (NP (NNS behaviors)) (VP (ADVP (RBS most) (RB closely)) (VBN associated) (PP (IN with) (NP (NN drug2) (NN intoxication))))))))))) (. .)))
(S1 (S (S (ADVP (RB Further)) (, ,) (NP (PRP they)) (VP (VBP bring) (PP (IN into) (NP (NN question))) (NP (NP (DT the) (NN utility)) (PP (IN of) (S (VP (VBG using) (NP (NP (NN drug1) (NN combination) (NNS procedures)) (PP (IN in) (NP (NNS animals)))) (S (VP (TO to) (VP (VB screen) (PP (IN for) (NP (JJ antipsychotic) (NN potential)))))))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (JJ chronic) (NN dosing)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (JJ therapeutic) (NN efficacy)) (PP (IN of) (NP (NN drug1))))))))) (, ,) (NP (JJ future) (NNS studies)) (VP (MD should) (VP (VB focus) (PP (IN on) (NP (NP (NN investigation)) (PP (IN of) (NP (NP (JJ chronic) (NN dosing) (NNS effects)) (PP (IN of) (NP (DT these) (NNS drugs))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (S (VP (JJ -LSB-Multiple) (NP (NP (JJ occupational) (NN exposure)) (PP (TO to) (NP (NNS solvents))))) (-RRB- -RSB-)) (NP (DT This) (NN article)) (VP (VBP review) (NP (NP (NNS papers)) (VP (VBN published) (PP (IN over) (NP (NP (DT the) (JJ last) (CD 20) (NNS years)) (PP (IN on) (NP (NP (JJ multiple) (JJ occupational) (NN exposure)) (PP (TO to) (NP (NNS solvents))))))))))) (. .)))
(S1 (S (S (S (PP (IN At) (NP (NP (NNS low-levels)) (PP (IN of) (NP (NN exposure))))) (NP (NP (DT the) (JJ toxicokinetic) (NNS interferences)) (PP (IN between) (NP (NNS solvents)))) (VP (VBP have) (ADVP (RB generally)) (RB not) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NN man))))))) (CC and) (S (ADVP (RB presumably)) (NP (DT a) (NN threshold) (NN limit)) (VP (VBZ exists)))) (. .)))
(S1 (S (S (ADVP (RB Conversely)) (, ,) (PP (IN at) (NP (NP (NN exposure) (NNS levels)) (ADJP (JJ close) (PP (TO to) (NP (DT the) (NN &quot))))))) (: ;) (NP (NN limit) (NN values&quot)) (: ;)))
(S1 (S (S (S (NP (JJ metabolic) (NN interference)) (VP (VBZ has) (ADVP (RB sometimes)) (VP (VBN been) (VP (VBN observed))))) (CC and) (S (NP (NP (DT the) (NN behaviour)) (PP (IN of) (NP (DT the) (JJ biological) (NNS indicators)))) (VP (VBZ differs) (PP (IN from) (SBAR (WHNP (WP what)) (S (VP (MD would) (VP (VB be) (VP (VBN expected)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Toxicodynamic) (NN interference)) (PP (IN between) (NP (NNS solvents)))) (VP (MD can) (VP (VBP give) (NP (NN rise)) (PP (TO to) (NP (ADJP (ADJP (JJ additive)) (, ,) (ADJP (NN potentiation)) (, ,) (ADJP (JJ synergistic)) (, ,) (ADJP (JJ antagonistic))) (NNS effects)))))) (. .)))
(S1 (S (S (PP (IN For) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (NP (NN &quot)) (: ;) (NP (NN limit) (NN values&quot)) (: ;))))) (, ,) (NP (PRP it)) (VP (VBZ has) (ADVP (RB generally)) (VP (VBN been) (VP (VBN suggested) (PP (IN in) (NP (DT the) (NN literature))) (SBAR (IN that) (S (NP (NP (DT the) (JJ possible) (NNS effects)) (VP (VBG deriving) (PP (IN from) (NP (JJ multiple) (NN exposure))))) (VP (VB be) (VP (VBN considered) (PP (IN as) (NP (JJ additive))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (JJ numerous) (NN potentiation) (NNS effects)) (VP (VBP have) (ADVP (RB frequently)) (VP (VBN been) (VP (VBN reported) (PP (IN for) (NP (NP (JJ combined) (NN exposure)) (PP (TO to) (NP (NP (NNS substances)) (PP (IN of) (NP (JJ widespread) (NN use))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN paper))) (VP (VBZ lists) (PP (IN of) (NP (NP (JJ multiple) (NN exposure)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NP (DT the) (NNS doses)) (PP (IN of) (NP (DT the) (NNS substances)))) (, ,) (NP (NP (DT the) (NNS types)) (PP (IN of) (NP (NNS interferences)))) (CC and) (NP (NP (DT the) (NN behaviour)) (PP (IN of) (NP (DT the) (JJ biological) (NNS levels))))) (VP (VBP have) (VP (VBN been) (VP (VBN drawn) (PRT (RP up)) (CC and) (VP (VBN proposed) (PP (IN as) (NP (NP (DT a) (NN tool)) (PP (IN for) (NP (JJ easy) (NN consultation))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP exert) (NP (JJ additive) (ADJP (ADJP (JJ ocular)) (CC and) (ADJP (JJ renal))) (JJ vasodilator) (NNS effects)) (PP (IN on) (NP (JJ healthy) (NNS humans))))) (. .)))
(S1 (S (NP (NP (NN AIMS/HYPOTHESIS)) (: :) (S (NP (EX There)) (VP (VBZ is) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP cause) (NP (ADJP (ADJP (JJ renal)) (CC and) (ADJP (JJ ocular))) (NN vasodilation)))))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (, ,) (ADVP (RB however)) (, ,) (ADVP (RB currently)) (NP (NP (DT no) (NNS data)) (PP (IN on) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ combined) (NN hyperglycaemia)) (CC and) (NP (NN hyper) (NN drug1) (NN aemia)))) (PP (IN on) (NP (NP (DT the) (ADJP (ADJP (JJ renal)) (CC and) (ADJP (JJ ocular))) (NN blood) (NN flow)) (VP (VBN seen) (PP (IN in) (NP (NP (JJ diabetic) (NNS patients)) (PP (IN on) (NP (NN insulin) (NN therapy))))))))))))) (. .)))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VBD carried) (PRT (RP out)) (NP (CD two) (JJ different) (NN 3-way) (NN crossover) (NNS studies)) (PP (IN in) (NP (NP (JJ healthy) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (DT each)) (, ,) (NP (NN n) (JJ =) (CD 9)) (-RRB- -RRB-)))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NN study) (CD one))) (, ,) (NP (NP (JJ hyperglycaemic) (NNS clamps)) (PRN (-LRB- -LRB-) (NP (NP (CD 5.6) (NN mmol/l)) (, ,) (NP (CD 11.1) (NN mmol/) (CD 1)) (, ,) (NP (CD 16.7) (NN mmol/l))) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN carried) (PRT (RP out)) (PP (IN during) (NP (NP (NP (NP (NN placebo)) (CC or) (NP (NN drug1))) (PRN (-LRB- -LRB-) (NP (NP (NN dose) (CD 1)) (: :) (NP (CD 1) (NN mU/kg/min)) (: ;) (NP (NN dose) (CD 2)) (: :) (NP (CD 2) (NN mU/kg/min))) (-RRB- -RRB-))) (NN infusion)))))) (. .)))
(S1 (S (S (S (NP (DT The) (JJ second) (NN study)) (VP (VBD was) (ADJP (JJ identical)))) (CC but) (S (NP (JJ endogenous) (NN insulin) (NN secretion)) (VP (VBD was) (VP (VBN blocked) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ renal) (NN plasma) (NN flow)) (, ,) (NP (JJ glomerular) (NN filtration) (NN rate)) (CC and) (NP (JJ pulsatile) (JJ choroidal) (NN blood) (NN flow))) (VP (VBD were) (VP (VBN measured) (S (VP (VBG using) (NP (NP (DT the) (NN paraaminohippurate) (NN method)) (, ,) (NP (DT the) (NN inulin) (NN method)) (CC and) (NP (NP (DT a) (NN laser) (JJ interferometric) (NN measurement)) (PP (IN of) (NP (NP (NN fundus) (NN pulsation)) (NN amplitude))))) (, ,) (ADVP (RB respectively))))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NN drug1)) (VP (VBD increased) (NP (NP (JJ renal) (NN plasma) (NN flow)) (CC and) (NP (NP (NN fundus) (NN pulsation)) (NN amplitude)) (CONJP (CC but) (RB not)) (NP (DT the) (JJ glomerular) (NN filtration) (NN rate))))) (. .))))
(S1 (S (S (NP (NN Hyperglycaemia)) (VP (VBD increased) (NP (NP (PDT all) (DT the) (ADJP (ADJP (JJ renal)) (CC and) (ADJP (JJ ocular))) (NNS parameters)) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NP (JJ Haemodynamic) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD were) (ADJP (JJ additive)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VP (VBD was) (VP (VBN co-administered))) (CC but) (VP (ADVP (RB not)) (PP (IN under) (NP (JJ basal) (NNS conditions))))))))) (. .)))
(S1 (S (S (NP (NP (NN CONCLUSIONS/INTERPRETATION)) (: :) (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (MD can) (VP (VB exert) (NP (JJ additive) (NN vasodilator) (NNS properties)) (PP (IN on) (NP (ADJP (ADJP (JJ renal)) (CC and) (ADJP (JJ ocular))) (NN circulation)))))) (. .)))
(S1 (S (S (VP (TO To) (VP (VB find) (PRT (RP out)) (SBAR (IN whether) (S (NP (DT this) (NN observation)) (VP (VBZ is) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (VBN increased) (JJ regional) (NN perfusion)) (PP (IN in) (NP (NP (NN diabetes) (JJ longitudinal) (NNS studies)) (SBAR (IN on) (S (NP (NP (NNS patients)) (PP (IN with) (NP (NN Type) (NN I) (-LRB- -LRB-) (JJ insulin-dependent) (-RRB- -RRB-) (NN diabetes) (NN mellitus)))) (VP (VBP are) (VP (VBN needed)))))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN Interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ antidiuretic) (NN hormone))))) (CC and) (NP (NP (PRP$ its) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN milk) (NN secretion)) (PP (IN by) (NP (NP (NNS alveoli)) (PP (IN of) (NP (NP (DT the) (JJ mammary) (NN gland)) (PP (IN of) (NP (JJ lactating) (NNS rats)))))))))) (. .))))
(S1 (S (S (NP (NP (NN Interaction)) (PP (IN between) (NP (NP (ADJP (ADJP (JJ exogenous)) (CC and) (ADJP (JJ endogenous))) (NN drug1)) (CC and) (NP (NN vasopressin))))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB affect) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN milk) (NN ejection)))) (PP (IN by) (NP (NP (DT the) (NNS alveoli)) (PP (IN of) (NP (DT the) (JJ mammary) (NN gland))) (PP (IN in) (NP (JJ lactating) (NNS rats))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Inhibition)) (CC and) (NP (NN stimulation))) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN milk) (NN ejection))))) (PP (IN by) (NP (NN vasopressin)))) (VP (VBD was) (VP (VBN demonstrated)))) (. .)))
(S1 (S (S (PP (IN On) (DT the) (NN basis) (IN of) (NP (DT the) (NNS principles))) (VBD observed) (NP (NP (DT the) (NNS concentrations)) (VP (NN fo) (NP (DT these) (NNS hormones)))) (VP (VBD were) (VP (VP (VBN investigated) (PP (IN in) (DT the) (NN plasma) (IN of) (NP (NP (NNS dogs)) (VP (VBN deprived) (PP (IN of) (NP (NN water))) (PP (IN for) (NP (CD 3) (NNS days))))))) (CC and) (VP (ADVP (RB then)) (VBN allowed) (PP (TO to) (NP (NN drink))))))) (. .)))
(S1 (S (NP (NP (NP (JJ -LSB-Quantitative) (NN approach)) (PP (TO to) (NP (NP (NN treatment)) (PP (IN with) (NP (JJ incisive) (NN drug1))))) (PP (IN by) (NP (JJ therapeutic) (NN monitoring))) (-RRB- -RSB-)) (: ;) (S (NP (NP (DT The) (NNS problems)) (VP (VBN encountered) (PP (IN during) (NP (NP (DT the) (JJ longterm) (NN treatment)) (PP (IN of) (NP (NP (JJ psychotic) (NNS patients)) (PP (IN with) (NP (NN drug2))))))))) (VP (VBP are) (VP (VBN illustrated) (PP (IN by) (NP (CD six) (JJ typical) (NN case) (NNS reports)))))) (. .))))
(S1 (S (S (NP (NP (DT A) (NN group)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD had) (VP (VBD had) (NP (DT a) (JJ new) (JJ acute) (NN episode)) (PP (IN despite) (NP (ADJP (RB seemingly) (JJ adequate)) (NN treatment)))))))))) (VP (VBD were) (VP (VBN selected)))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT these) (CD six) (NNS cases))) (NP (PRP it)) (VP (VBD was) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (DT the) (NN drug1) (NN dosage)) (VP (VBD was) (ADJP (JJ inappropriate)) (, ,) (S (VP (VBG being) (ADJP (CC either) (ADJP (RB too) (JJ high)) (CC or) (ADJP (RB too) (JJ low))) (SBAR (IN as) (S (VP (VBN judged) (PP (IN from) (NP (DT the) (NN plasma) (NNS concentrations)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Ways)) (PP (IN of) (S (VP (VBG improving) (NP (NP (DT the) (NN adequacy)) (PP (IN of) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ psychotic) (NNS patients))) (PP (IN with) (NP (NN drug1)))))))))) (VP (VBP are) (VP (VBN discussed)))) (. .)))
(S1 (S (S (NP (NP (JJ Longitudinal) (NN assessment)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (ADJP (FW de) (FW novo)) (JJ renal) (NN transplant) (NNS recipients)) (PP (IN over) (NP (DT the) (JJ first) (JJ post-transplant) (NN year)))))) (: :) (NP (NP (NNS pharmacokinetics)) (, ,) (NP (JJ exposure-response) (NNS relationships)) (, ,) (CC and) (NP (NP (NN influence)) (PP (IN on) (NP (NN drug2)))))) (. .)))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (NP (PRP$ Our) (NN objective)) (VP (VBD was) (S (VP (TO to) (VP (VB characterize) (NP (NP (DT the) (JJ steady-state) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (PRN (-LRB- -LRB-) (NP (NP (NNP INN)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN in) (NP (NP (ADJP (FW de) (FW novo)) (NN kidney) (NN allograft) (NNS recipients)) (PP (IN during) (NP (NP (DT the) (JJ first) (NN year)) (PP (IN after) (NP (NN transplantation)))))))))))) (. .))))
(S1 (S (NP (NP (NN METHOD)) (: :) (S (NP (DT This) (NN study)) (VP (VBD was) (NP (NP (DT a) (JJ multicenter) (JJ randomized) (JJ double-blind) (NN study)) (PP (IN of) (NP (NP (CD 101) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB randomly)) (VP (VBN assigned) (VP (VBN 1:1:1) (S (VP (TO to) (VP (VBP receive) (NP (NN drug1) (NNS tablets)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 0.5) (NN mg)) (, ,) (NP (CD 1) (NN mg)) (, ,) (CC or) (NP (NP (CD 2) (NN mg)) (ADJP (RB twice) (JJ daily) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))))))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Blood) (NN sampling)) (PP (IN for) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBD was) (VP (VBN performed) (PP (IN on) (NP (NN day) (CD 1))) (, ,) (PP (PP (IN on) (NP (NNS weeks) (QP (CD 1) (, ,) (CD 2) (, ,) (CD 3) (, ,) (CC and) (CD 4)))) (, ,) (CC and) (PP (IN on) (NP (NNS months) (NP (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (NP (CD 6)) (, ,) (NP (CD 9)) (, ,) (CC and) (NP (CD 12))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1) (NN dose-proportionality)) (CC and) (NP (NN stability))) (PP (IN over) (NP (NN time)))) (VP (VBD were) (VP (VBN assessed) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NP (JJ linear) (NN regression)) (CC and) (NP (NN ANOVA) (NNS models))))))))) (. .)))
(S1 (S (S (NP (NP (JJ drug1) (JJ exposure-response) (NNS relationships)) (PP (IN between) (NP (NP (NP (NN area)) (PP (IN under) (NP (NP (DT the) (NN blood) (NN concentration-time) (NN curve)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))))) (CC and) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NNS platelets)) (, ,) (NP (NNS leukocytes)) (, ,) (CC and) (NP (NNS lipids)))))))) (VP (VBD were) (VP (VBN explored) (PP (IN with) (NP (DT the) (JJ median-effect) (NN model)))))) (. .)))
(S1 (S (S (NP (NP (JJ Potential) (NNS differences)) (PP (IN in) (NP (NP (NP (JJ drug1) (NN dosing)) (CC and) (NP (NNS pharmacokinetics))) (PP (IN at) (NP (NP (JJ different) (NNS levels)) (PP (IN of) (NP (NN drug2) (NN exposure)))))))) (VP (VBD were) (VP (VBN assessed) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NN ANOVA)))))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NN drug1) (JJ steady) (NN state)) (VP (VBD was) (VP (VBN reached) (PP (PP (IN on)) (CC or) (PP (IN before) (NP (NN day) (CD 7)))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ median) (JJ 3-fold) (NN accumulation)) (PP (IN of) (NP (NN drug) (NN exposure))) (PP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN after) (NP (DT the) (JJ first) (JJ postoperative) (NN dose))))))))))) (. .))))
(S1 (S (S (NP (CC Both) (NP (JJ steady-state) (NN maximum) (NN concentration)) (CC and) (NP (NN AUC))) (VP (VBD were) (ADJP (NN dose) (JJ proportional)) (PP (IN over) (NP (DT the) (JJ full) (NN dose) (NN range))) (SBAR (WHADVP (WRB when)) (S (VP (VBN assessed) (PP (PP (IN on) (NP (NN day) (CD 1))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN for) (NP (NP (DT the) (JJ full) (NN duration)) (PP (IN of) (NP (DT the) (NN study))) (PP (IN at) (NP (JJ steady) (NN state))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (NN evidence)) (PP (IN for) (NP (JJ longitudinal) (NN stability)))) (PP (IN in) (NP (NP (NN AUC)) (PP (IN of) (NP (NN drug1))))) (PP (IN during) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (DT the) (NN study))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (JJ interindividual) (JJ pharmacokinetic) (NN variability)) (PP (IN for) (NP (NN AUC)))) (VP (VBD was) (ADJP (NP (CD 85.4) (NN %)) (CC and) (ADJP (JJ intraindividual))))) (, ,) (NP (NN interoccasion) (NN variability)) (VP (VBD was) (NP (CD 40.8) (NN %)))) (. .)))
(S1 (S (S (NP (NP (NP (NN Age)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 17-69) (NNS years))) (-RRB- -RRB-))) (, ,) (NP (NP (NN weight)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 49-106) (NN kg))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN sex)) (PRN (-LRB- -LRB-) (NP (NP (CD 65) (NNS men)) (CC and) (NP (CD 36) (NNS women))) (-RRB- -RRB-)))) (VP (VBD were) (RB not) (NP (NP (JJ significant) (NNS contributors)) (PP (TO to) (NP (NN variability)))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT an) (VBG increasing) (NN incidence)) (PP (IN of) (NP (NP (JJ transient) (NN thrombocytopenia)) (PRN (-LRB- -LRB-) (NP (CC or) (CD =100) (NN x) (CD 10) (-LRB- -LRB-) (CD 9) (-RRB- -RRB-) (NN /L)) (-RRB- -RRB-))))) (PP (IN with) (S (VP (VBG increasing) (NP (NN drug1) (NN AUC))))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD .03)))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NNS doses)) (, ,) (NP (NN trough) (NNS concentrations)) (, ,) (CC and) (NP (NN AUC))) (VP (VBD exhibited) (NP (JJ similar) (JJ temporal) (NNS patterns)) (PP (IN during) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (DT the) (NN study))))) (ADVP (RB regardless) (PP (IN of) (NP (NP (DT the) (VBN co-administered) (NN drug2) (NN dose) (NN level)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (NP (CD .13)) (, ,) (NP (CD .82)) (, ,) (CC and) (NP (CD .76))) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NN drug1)) (VP (VBD exhibited) (NP (ADJP (ADJP (JJ dose-proportional)) (, ,) (ADJP (JJ stable))) (NN exposure)) (PP (IN during) (NP (DT the) (JJ first) (JJ post-transplant) (NN year))))) (. .))))
(S1 (S (S (PP (IN For) (NP (NP (DT a) (JJ 4-fold) (NN range)) (PP (IN of) (NP (JJ drug1) (NNS doses))))) (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (JJ differential) (NNS effects)) (PP (IN on) (NP (NP (JJ drug2) (NN dosing)) (CC or) (NP (NNS pharmacokinetics))))))) (. .)))
(S1 (S (NP (NP (NN Toxicity)) (PP (IN of) (NP (NP (NN cadmium)) (CC and) (NP (NN drug1)))) (PP (TO to) (NP (NP (NP (NN encystment)) (CC and) (NP (ADJP (FW in) (FW vitro)) (NN excystment))) (PP (IN of) (NP (NP (NNP Parorchis) (FW acanthus)) (PRN (-LRB- -LRB-) (NP (NP (NNP Digenea)) (: :) (NP (NNP Philophthalmidae))) (-RRB- -RRB-)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN toxicity)) (PP (IN of) (NP (NP (NN cadmium)) (, ,) (NP (NN drug1)) (CC and) (NP (NN cadmium/zinc) (NNS mixtures)))) (PP (IN at) (NP (NP (NNS concentrations)) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 1000) (TO to) (CD 50000)) (NN microg/l))))))) (VP (VBD were) (VP (VBN investigated) (PP (IN against) (NP (NP (NP (NN cercariae)) (CC and) (NP (NN metacercariae))) (PP (IN of) (NP (NP (FW Parorchis) (FW acanthus)) (VP (VBN obtained) (PP (IN from) (NP (DT the) (NN dog) (NN whelk) (NN Nucella) (NN lapillus))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Cercarial) (NN encystment)) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN of) (NP (CD 25000) (NN microg/l) (QP (CC or) (JJR higher))))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN impaired) (PP (IN by) (NP (DT all) (NN test) (NNS metals)))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (PP (IN at) (NP (JJR lower) (NNS concentrations))) (NP (RB only) (NN drug1)) (VP (VBD demonstrated) (NP (NN toxicity)))) (. .)))
(S1 (S (S (NP (NP (NNS Mixtures)) (PP (IN of) (NP (NP (NN cadmium)) (CC and) (NP (NN drug1))))) (VP (VBD had) (NP (DT a) (JJ synergistic) (NN effect)) (PP (VBN compared) (PP (IN with) (NP (JJ single) (JJ metal) (NN toxicity))) (CC but) (ADVP (RB only)) (PP (IN at) (NP (CD 50000) (NN microg/l)))))) (. .)))
(S1 (S (S (NP (NP (NN Excystment)) (ADVP (FW in) (FW vitro))) (VP (VBD was) (ADVP (RB only) (RB significantly)) (VP (VBN affected) (PP (IN by) (NP (NP (NN cercariae)) (VP (VBN exposed) (PP (TO to) (NP (NN cadmium/zinc) (NNS mixtures))) (PP (IN whilst) (NP (NN encysting))))))))) (. .)))
(S1 (S (S (NP (NP (CD Twenty-four) (NN h) (NNS exposures)) (PP (IN of) (NP (ADJP (RB fully) (VBN formed)) (NNS cysts)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN excystment))) (ADVP (FW in) (FW vitro)))) (. .)))
(S1 (S (S (NP (NP (NNS Effects)) (PP (IN on) (NP (NP (ADJP (FW in) (FW vitro)) (NN excystment) (NNS rates)) (PP (IN over) (NP (DT a) (ADJP (CD 2) (NN h)) (NN period)))))) (VP (VBD demonstrated) (NP (JJ widespread) (NNS effects)) (PP (IN for) (NP (JJ cercariae-exposed) (NN P))))) (. .)))
(S1 (S (NP (NP (NN acanthus)) (. .))))
(S1 (S (S (NP (DT No) (NNS effects)) (VP (VBD were) (ADJP (JJ evident)) (PP (IN on) (NP (NP (JJ excystment) (NNS rates)) (PP (IN of) (NP (JJ cyst-exposed) (NNS parasites))))))) (. .)))
